{"meta":{"query_hash":"ca2496bf98f8","filters":{"venue":"The Lancet Oncology"},"cohort_total":832,"direct_labels_cover":9,"predictions_cover":832,"exported":832,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/ca2496bf98f8","api":"https://metacan.xera.ac/api/v1/cohort?venue=The+Lancet+Oncology"},"results":[{"id":"W1527808522","doi":"10.1016/s1470-2045(15)70198-1","title":"Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":244,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Vismodegib; Basal cell carcinoma; Medicine; Interim analysis; Internal medicine; Adverse effect; Interim; Oncology; Clinical endpoint; Population; Clinical trial; Surgery; Basal cell","score_opus":0.07487761994898005,"score_gpt":0.36777701402804236,"score_spread":0.2928993940790623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1527808522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97105306,0.010215845,0.0017094003,0.0033492476,0.0007813289,0.0022139603,0.0041414048,0.0001664372,0.00636928],"genre_scores_gemma":[0.97925025,0.003561668,0.0027715361,0.0027790514,0.00028194077,0.0019979093,0.0052052187,0.00008623698,0.0040662168],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9987186,0.0006595723,0.000059425915,0.00012774424,0.00010004658,0.00033465592],"domain_scores_gemma":[0.99854773,0.0004346922,0.00023332791,0.00017780012,0.00010065174,0.0005057505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047585657,0.0015472355,0.002517605,0.00031928395,0.0004004211,0.0019926908,0.00065968285,0.0016883493,0.0047362116],"category_scores_gemma":[0.0029984156,0.0004776917,0.0040240604,0.00037479794,0.0008605762,0.002190612,0.0005944482,0.0045484905,0.0010690653],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90505195,0.0040444527,0.00420312,0.0007124312,0.003002345,0.00011086864,0.00015068875,0.0024669087,0.0058387103,0.00056601164,0.0042503616,0.069602065],"study_design_scores_gemma":[0.7672797,0.1900757,0.019827068,0.0003533374,0.0041818316,0.00038365443,0.00024129079,0.00290284,0.0035771558,0.0029391437,0.00812702,0.00011122045],"about_ca_topic_score_codex":0.000664504,"about_ca_topic_score_gemma":0.0027947049,"teacher_disagreement_score":0.0047585657,"about_ca_system_score_codex":0.0013129289,"about_ca_system_score_gemma":0.0014188855,"threshold_uncertainty_score":0.025166035},"labels":[],"label_agreement":null},{"id":"W1534401608","doi":"10.1016/s1470-2045(15)70137-3","title":"Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":134,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Institute for Health and Care Research; Cancer Research UK","keywords":"Medicine; Epirubicin; Docetaxel; Clinical endpoint; Bevacizumab; Breast cancer; Internal medicine; Cyclophosphamide; Chemotherapy; Oncology; Fluorouracil; Neoadjuvant therapy; Mucositis; Phases of clinical research; Clinical trial; Surgery; Cancer","score_opus":0.04623737131073502,"score_gpt":0.36962232590410127,"score_spread":0.32338495459336625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1534401608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865002,0.0056560403,0.0005177726,0.0007951156,0.0004204026,0.0034510526,0.000749016,0.000094735886,0.0018156006],"genre_scores_gemma":[0.987905,0.0025421425,0.0014270269,0.000824194,0.00029986253,0.0040381695,0.0009792943,0.00002183554,0.001962427],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99905664,0.0006055704,0.000049972146,0.00013387416,0.000062410814,0.00009154298],"domain_scores_gemma":[0.99848986,0.00049186207,0.00040015075,0.000083492676,0.00006222099,0.0004723434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002241924,0.0014379197,0.002168017,0.00043916507,0.00036644525,0.0011165529,0.00079541304,0.0017486721,0.0051455735],"category_scores_gemma":[0.0024933596,0.00053441647,0.0015649602,0.000403737,0.0013770722,0.0009495613,0.00040872867,0.003051652,0.0009614739],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97870755,0.005731066,0.00046779498,0.0003875846,0.00033971426,0.000035531215,0.000047836464,0.00033450106,0.0022379644,0.000062877145,0.00045410497,0.011193419],"study_design_scores_gemma":[0.8892051,0.10796842,0.0012206122,0.00003324133,0.00019324229,0.000047642665,0.000013267821,0.00026390504,0.0003694094,0.000111575544,0.00056295603,0.000010661105],"about_ca_topic_score_codex":0.0009450543,"about_ca_topic_score_gemma":0.0028782317,"teacher_disagreement_score":0.0051455735,"about_ca_system_score_codex":0.001446744,"about_ca_system_score_gemma":0.001365448,"threshold_uncertainty_score":0.017213702},"labels":[],"label_agreement":null},{"id":"W1585884249","doi":"10.1016/s1470-2045(15)00130-8","title":"Excessive imaging for breast cancer in Ontario","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Breast cancer; Stage (stratigraphy); Medicine; Breast imaging; Gynecology; Cancer; Medical physics; Mammography; Internal medicine","score_opus":0.20196037369195638,"score_gpt":0.4302839649687756,"score_spread":0.2283235912768192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1585884249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93424,0.0040061357,0.00020551893,0.020789312,0.00017167508,0.0001119467,0.010818268,0.00006131424,0.0295959],"genre_scores_gemma":[0.98956084,0.001974061,0.00016338748,0.0017116601,0.000079445286,0.000024177349,0.0011383265,0.00003100858,0.00531711],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986016,0.00011407845,0.00011697791,0.00010969792,0.0004495498,0.0006080622],"domain_scores_gemma":[0.9938287,0.00044031575,0.0020671356,0.00016213603,0.0015361621,0.001965526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038049414,0.0002271826,0.00040381151,0.0011092272,0.003320335,0.0015259709,0.0011116231,0.0008273192,0.007472174],"category_scores_gemma":[0.0042998553,0.00060418685,0.00069244864,0.0043500685,0.0009165796,0.00052821677,0.0013256996,0.0014919817,0.0003359567],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021176366,0.00005694016,0.96650887,0.00022394596,0.00010416778,0.000976751,0.002820485,0.00020116127,0.000474175,0.0011205288,0.015218286,0.012082776],"study_design_scores_gemma":[0.000026449145,0.000029954179,0.98870265,0.000117997275,0.000065578606,0.0002994688,0.0033156127,0.0001982538,0.00007829474,0.00017173415,0.006969187,0.000024887131],"about_ca_topic_score_codex":0.9936168,"about_ca_topic_score_gemma":0.9980888,"teacher_disagreement_score":0.047483355,"about_ca_system_score_codex":0.047483355,"about_ca_system_score_gemma":0.0756864,"threshold_uncertainty_score":0.34451747},"labels":[],"label_agreement":null},{"id":"W1821272131","doi":"10.1016/s1470-2045(15)00379-4","title":"Developments in paediatric care in Latin America","year":2015,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Latin Americans; Commission; Health care; Political science; Medicine; Economic growth; Business; Economics; Law","score_opus":0.15006815097757562,"score_gpt":0.3906157659402286,"score_spread":0.240547614962653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1821272131","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019929362,0.003029667,0.000020631807,0.98961884,0.006132061,0.0000012245404,0.000013104184,0.0000046218565,0.0009805824],"genre_scores_gemma":[0.0056972043,0.005528472,0.00016026427,0.95686513,0.029648177,0.000014800066,0.000020610187,0.00001879448,0.0020464226],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9944666,0.0019734907,0.00075567083,0.0004844117,0.0010445685,0.0012753702],"domain_scores_gemma":[0.9793174,0.008590999,0.0025728387,0.00036746784,0.0027372215,0.006414118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007138451,0.00057509006,0.0011964343,0.0008130179,0.004460369,0.0062511982,0.0017646822,0.03633776,0.011735527],"category_scores_gemma":[0.031875316,0.0007155103,0.0016414204,0.0011888496,0.006119068,0.005408716,0.0050246385,0.042229157,0.0020594245],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004123857,0.00003980311,0.0035199344,0.0004353483,0.00004030826,0.0034238554,0.0008699526,0.00017987446,0.0002088872,0.014055771,0.9567669,0.020418182],"study_design_scores_gemma":[0.00009659461,0.000036927377,0.0035114158,0.0015924082,0.00004661527,0.0022529918,0.0018157762,0.00018334475,0.00014808879,0.008249523,0.98202837,0.00003790384],"about_ca_topic_score_codex":0.04232198,"about_ca_topic_score_gemma":0.08369321,"teacher_disagreement_score":0.04232198,"about_ca_system_score_codex":0.015745673,"about_ca_system_score_gemma":0.022647532,"threshold_uncertainty_score":0.11424339},"labels":[],"label_agreement":null},{"id":"W1837576367","doi":"10.1016/s1470-2045(15)00229-6","title":"Fewer than three doses of HPV vaccine","year":2015,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Immunogenicity; Vaccination; Scopus; Human papillomavirus; Clinical trial; Cervical cancer; Virology; Oncology; Internal medicine; Immunology; Cancer; MEDLINE; Biology; Immune system","score_opus":0.15748893925231677,"score_gpt":0.41841447650743335,"score_spread":0.2609255372551166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1837576367","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00039802853,0.00091562106,0.00007084817,0.9771633,0.018017307,0.000011715087,0.00006553559,0.000020131487,0.003337488],"genre_scores_gemma":[0.0023668213,0.00055822614,0.00006824635,0.9759352,0.015535129,0.000021502476,0.000030031728,0.0000091257325,0.005475724],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.995272,0.0013163713,0.00062862877,0.0005286179,0.0013156206,0.00093885045],"domain_scores_gemma":[0.9884278,0.007192672,0.00086857006,0.0002960063,0.0010837129,0.0021313063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004307968,0.00086414535,0.0015158412,0.00071873184,0.004424058,0.003842341,0.001948508,0.100302294,0.017664691],"category_scores_gemma":[0.04124892,0.0010830878,0.002105577,0.0006120641,0.0022887515,0.0037378801,0.0022543932,0.053664062,0.009954819],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013374054,0.000059952497,0.00087555376,0.00008848499,0.000033439504,0.001054767,0.00012813904,0.00010139407,0.00029131412,0.0041769533,0.97946584,0.013590432],"study_design_scores_gemma":[0.00033601953,0.00027849426,0.0017797314,0.00059383275,0.00010218719,0.001624889,0.00039049136,0.00046605177,0.00039049415,0.0113127045,0.98265266,0.00007245514],"about_ca_topic_score_codex":0.01186651,"about_ca_topic_score_gemma":0.021321159,"teacher_disagreement_score":0.100302294,"about_ca_system_score_codex":0.005654388,"about_ca_system_score_gemma":0.0075995373,"threshold_uncertainty_score":0.05909431},"labels":[],"label_agreement":null},{"id":"W1850035702","doi":"10.1016/s1470-2045(15)00311-3","title":"Discordance between the results and conclusions of ICON7 – Authors' reply","year":2015,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Cancer Research UK","keywords":"Bevacizumab; Medicine; Ovarian cancer; Chemotherapy; Oncology; Internal medicine; Population; Overall survival; Cancer","score_opus":0.1103282341605306,"score_gpt":0.37946278162361025,"score_spread":0.26913454746307963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1850035702","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020111301,0.0006530292,0.000043260057,0.9700552,0.028092124,0.000008614623,0.000054129967,0.000015951011,0.000876459],"genre_scores_gemma":[0.0018389532,0.00025816605,0.000056252728,0.97313255,0.023271076,0.00002495469,0.000017217348,0.000016663262,0.001384019],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9876243,0.0039839246,0.0017378604,0.0016398065,0.0031645123,0.0018497205],"domain_scores_gemma":[0.96230644,0.022240289,0.0032998808,0.0011301283,0.007117367,0.0039059413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009811355,0.00094921846,0.0025766862,0.0013708248,0.004588655,0.0068959147,0.0035088114,0.10986263,0.0075919423],"category_scores_gemma":[0.091850325,0.001366805,0.0021492387,0.0012230037,0.005631218,0.0041547343,0.0031541877,0.069300756,0.008160339],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008240904,0.000016491398,0.00051705964,0.00007007852,0.000040672447,0.0010535404,0.0002647716,0.00004936549,0.000104172206,0.0016639062,0.99360704,0.00253047],"study_design_scores_gemma":[0.00023964618,0.00009818931,0.0016977786,0.0008327411,0.00017250319,0.002542414,0.0010578687,0.00049091654,0.00076691527,0.013151593,0.97869223,0.00025729413],"about_ca_topic_score_codex":0.0076016015,"about_ca_topic_score_gemma":0.008231437,"teacher_disagreement_score":0.10986263,"about_ca_system_score_codex":0.007887077,"about_ca_system_score_gemma":0.0067189247,"threshold_uncertainty_score":0.05722505},"labels":[],"label_agreement":null},{"id":"W1935362880","doi":"10.1016/s1470-2045(15)00223-5","title":"Global cancer surgery: delivering safe, affordable, and timely cancer surgery","year":2015,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":685,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Centre for Global Health Research; St. Michael's Hospital","funders":"","keywords":"Medicine; Cancer; Cancer surgery; Global health; Surgery; Public health; Nursing; Internal medicine","score_opus":0.17122752256125046,"score_gpt":0.4991732710837786,"score_spread":0.32794574852252817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1935362880","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000035528905,0.99651283,0.00009612219,0.0017333382,0.0005307377,0.0000030108781,0.000016470482,0.0000069593834,0.0010650477],"genre_scores_gemma":[0.00039510292,0.99787235,0.00011096835,0.00076505507,0.00044345664,0.0000028417,0.00001663155,0.0000014522983,0.00039207138],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99957794,0.00008112788,0.000044737404,0.000042891137,0.00020769944,0.000045635257],"domain_scores_gemma":[0.9987936,0.00064494176,0.00018991946,0.000023932573,0.00024380397,0.000103799364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011569473,0.00088114676,0.0011995181,0.0018365033,0.00028048095,0.0012960155,0.0008968901,0.0015562789,0.0060235932],"category_scores_gemma":[0.002011616,0.00023471384,0.0004945844,0.0025368023,0.00073151314,0.002028585,0.0012029982,0.0025266176,0.0022307911],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033441505,0.000029682089,0.00013989645,0.012783938,0.00007127781,0.000058206228,0.000038363225,0.00028975002,0.00035217122,0.0062775263,0.07735696,0.9025688],"study_design_scores_gemma":[0.000013343781,0.00003373358,0.00048980024,0.0051305494,0.000060197955,0.00029712077,0.000056105207,0.000061672596,0.00010697828,0.0027896124,0.99094754,0.000013309719],"about_ca_topic_score_codex":0.0020386297,"about_ca_topic_score_gemma":0.005874883,"teacher_disagreement_score":0.0060235932,"about_ca_system_score_codex":0.001337124,"about_ca_system_score_gemma":0.002415921,"threshold_uncertainty_score":0.0201509},"labels":[],"label_agreement":null},{"id":"W1936755136","doi":"10.1016/s1470-2045(15)00205-3","title":"The expanding role of primary care in cancer control","year":2015,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":544,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; University of Manitoba; University of Toronto; Ontario Institute for Cancer Research","funders":"Cancer Research UK; Public Health Wales; National Institute for Health and Care Research; Betsi Cadwaladr University Health Board","keywords":"Primary care; Cancer; Primary (astronomy); Control (management); Primary cancer; Medicine; Family medicine; Computer science; Internal medicine; Artificial intelligence","score_opus":0.22097489652309535,"score_gpt":0.47503436473613914,"score_spread":0.2540594682130438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1936755136","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000023070083,0.9981444,0.00003727804,0.0010556906,0.00035117942,0.0000016842358,0.000013166654,0.0000028686889,0.0003707765],"genre_scores_gemma":[0.0005674968,0.9976465,0.000085879874,0.0010608451,0.00051406765,0.000003639493,0.00001075849,0.000001151955,0.00010952676],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99850345,0.00052687945,0.00017713304,0.00018098274,0.0004837353,0.00012786004],"domain_scores_gemma":[0.9928294,0.005487731,0.00060353044,0.00009726163,0.00076506584,0.00021707772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036723558,0.0010563864,0.0031741397,0.003075867,0.0004339886,0.002029027,0.0012909521,0.0026401947,0.0074745473],"category_scores_gemma":[0.007164959,0.00043832755,0.0015855333,0.004909509,0.0012793976,0.002593598,0.0014438074,0.0036092796,0.0012168306],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000094048715,0.00004994423,0.00034343865,0.07505528,0.0004650714,0.00009348411,0.00010154041,0.0004085863,0.0002127304,0.009171672,0.049696006,0.8643082],"study_design_scores_gemma":[0.00011685744,0.00015528174,0.0029254842,0.051522937,0.0009512591,0.00045976182,0.00021681706,0.00017175342,0.00013708964,0.006764874,0.93653464,0.000043311087],"about_ca_topic_score_codex":0.007610035,"about_ca_topic_score_gemma":0.013335001,"teacher_disagreement_score":0.007610035,"about_ca_system_score_codex":0.002887617,"about_ca_system_score_gemma":0.0050135013,"threshold_uncertainty_score":0.025004804},"labels":[],"label_agreement":null},{"id":"W1948945226","doi":"10.1016/s1470-2045(15)00002-9","title":"Breast cancer risk in women with PALB2 mutations in different populations","year":2015,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Cancer Research UK","keywords":"Breast cancer; PALB2; Medicine; Context (archaeology); Population; Cancer; Oncology; Odds ratio; Incidence (geometry); Scopus; Gynecology; Internal medicine; Demography; Germline mutation; MEDLINE; Genetics; Mutation; Biology; Environmental health","score_opus":0.03538884622093482,"score_gpt":0.3258172434171433,"score_spread":0.2904283971962085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1948945226","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12098952,0.0133078545,0.0004380324,0.838478,0.011241388,0.000028523938,0.0016440894,0.00005643992,0.013816032],"genre_scores_gemma":[0.5245115,0.0070007723,0.00045082424,0.4246624,0.037175752,0.00006859845,0.0006415943,0.000036255457,0.005452251],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99932253,0.00024217309,0.00005457733,0.00011944261,0.000111665904,0.00014971248],"domain_scores_gemma":[0.99854785,0.00068952405,0.0001517625,0.00007384945,0.00017642458,0.0003605927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079488644,0.00023542183,0.0006618737,0.0004717573,0.0007955661,0.00079346553,0.00050120364,0.0060707107,0.0024425038],"category_scores_gemma":[0.006084546,0.00030086466,0.0006059856,0.00091575284,0.0006175369,0.0006186291,0.00052851037,0.004435546,0.00065302686],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002647437,0.00021641023,0.5190388,0.00030623897,0.00064694945,0.011323973,0.0010323818,0.0006260805,0.0022125533,0.0034275346,0.38457015,0.073951505],"study_design_scores_gemma":[0.001366601,0.0009085736,0.75385684,0.0008428037,0.0010186752,0.030272484,0.0034980916,0.003030451,0.0011461736,0.026023382,0.17776857,0.00026737194],"about_ca_topic_score_codex":0.009214331,"about_ca_topic_score_gemma":0.014507062,"teacher_disagreement_score":0.009214331,"about_ca_system_score_codex":0.001306847,"about_ca_system_score_gemma":0.00045827575,"threshold_uncertainty_score":0.018321395},"labels":[],"label_agreement":null},{"id":"W1950224348","doi":"10.1016/s1470-2045(15)00035-2","title":"Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Nausea and vomiting management","field":"Medicine","cited_by":141,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Nausea; Vomiting; Medicine; NK1 receptor antagonist; Chemotherapy; Chemotherapy-induced nausea and vomiting; Dexamethasone; Granisetron; Internal medicine; Placebo; Gastroenterology; Anesthesia; Antiemetic; Receptor","score_opus":0.08553834392799094,"score_gpt":0.40894196704447805,"score_spread":0.3234036231164871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1950224348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98364234,0.0105614085,0.0006802638,0.0005229557,0.0003832707,0.0023048783,0.00049471983,0.00012941599,0.0012807286],"genre_scores_gemma":[0.99011177,0.0047195572,0.0011677186,0.00052700075,0.00030499705,0.0013973968,0.0004610209,0.0000290231,0.0012816009],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99887806,0.000639595,0.00010079764,0.00017465104,0.0000837833,0.00012296594],"domain_scores_gemma":[0.9979534,0.00080809125,0.0005828361,0.00018620693,0.000099538775,0.0003698667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027984148,0.0014256394,0.004109816,0.0006451824,0.0004770999,0.0011302566,0.0013004378,0.0021671846,0.0034217755],"category_scores_gemma":[0.0036056906,0.0009414878,0.0029023548,0.00050837256,0.0018027134,0.0014522811,0.00042054796,0.003410015,0.0006705975],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96652305,0.0041716755,0.00050879427,0.0011431975,0.0014726237,0.000036860347,0.00008817201,0.00028475007,0.0030608831,0.000072635885,0.00032638165,0.022310963],"study_design_scores_gemma":[0.9236608,0.07282045,0.0015988987,0.000046176356,0.00071550556,0.00003696872,0.000018328754,0.00022761534,0.00047104107,0.00008644809,0.0002983721,0.00001939365],"about_ca_topic_score_codex":0.0009227542,"about_ca_topic_score_gemma":0.0016404877,"teacher_disagreement_score":0.004109816,"about_ca_system_score_codex":0.0007531127,"about_ca_system_score_gemma":0.0012318809,"threshold_uncertainty_score":0.014799595},"labels":[],"label_agreement":null},{"id":"W1964525628","doi":"10.1016/s1470-2045(14)70181-0","title":"When is downstream pathway inhibition important?","year":2014,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Pertuzumab; Trastuzumab; Medicine; Lapatinib; Oncology; Internal medicine; Trastuzumab emtansine; Breast cancer; Vinorelbine; Taxane; Cancer; Everolimus; Metastatic breast cancer; Context (archaeology); Neratinib; Clinical trial; Chemotherapy","score_opus":0.0997091515519647,"score_gpt":0.3847506483452985,"score_spread":0.2850414967933338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964525628","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007943455,0.0016414983,0.000036175592,0.9866219,0.010423416,0.000003980619,0.000020587186,0.00000853379,0.0011644408],"genre_scores_gemma":[0.0012344081,0.0016582106,0.00009462766,0.9610264,0.033406544,0.000018911964,0.000015673546,0.000010386152,0.0025348586],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99225813,0.0023544133,0.0008437982,0.00092430675,0.002357008,0.0012623497],"domain_scores_gemma":[0.97755367,0.013860117,0.0014243674,0.00053687405,0.0026417577,0.003983085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0073482855,0.0012126068,0.0028850646,0.001054028,0.0046167825,0.0069784317,0.002567769,0.098251395,0.0116196405],"category_scores_gemma":[0.048997115,0.0013088619,0.0024326053,0.0010123686,0.006551615,0.006961702,0.0036419753,0.09040751,0.008794937],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000092174894,0.000033393437,0.00031916203,0.00007746338,0.000028819522,0.000627305,0.00005634468,0.000068014204,0.00014882014,0.004614852,0.98035973,0.013573898],"study_design_scores_gemma":[0.00047769796,0.00015570292,0.0007102182,0.0007589353,0.00009147394,0.001244214,0.00032123073,0.0004081492,0.00036201667,0.031776432,0.9635894,0.00010440367],"about_ca_topic_score_codex":0.004120746,"about_ca_topic_score_gemma":0.009374036,"teacher_disagreement_score":0.098251395,"about_ca_system_score_codex":0.0071864147,"about_ca_system_score_gemma":0.007167242,"threshold_uncertainty_score":0.05214131},"labels":[],"label_agreement":null},{"id":"W1966238809","doi":"10.1016/s1470-2045(03)01117-3","title":"Isolated limb perfusion with melphalan in the treatment of malignant melanoma of the extremities: a systematic review of randomised controlled trials","year":2003,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Melphalan; Melanoma; Perfusion; Limb perfusion; Randomized controlled trial; Clinical trial; Surgery; Chemotherapy; Internal medicine; Oncology","score_opus":0.086090373439733,"score_gpt":0.3647785349593234,"score_spread":0.2786881615195904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966238809","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0040127942,0.99478585,0.00019614128,0.00013338999,0.00016740047,0.00030095153,0.00016685408,0.00001073158,0.00022596294],"genre_scores_gemma":[0.05176931,0.94600815,0.000805221,0.00047795338,0.00011533669,0.0004291304,0.00015009436,0.000008201868,0.00023666793],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9975883,0.0011188552,0.0006644663,0.00026046197,0.0002696335,0.0000984455],"domain_scores_gemma":[0.9930565,0.0049364497,0.0014713833,0.000107179774,0.0002860999,0.00014246053],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.004599451,0.001299451,0.010443386,0.0017687787,0.00035643353,0.0014269562,0.0014447428,0.0014650829,0.0040941276],"category_scores_gemma":[0.01234584,0.0006789568,0.0072355275,0.0025850378,0.0008446738,0.0011110351,0.00077744416,0.0015512583,0.00023079789],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017397573,0.00010444686,0.00060952874,0.8455931,0.05590321,0.00012796109,0.00013086187,0.00041240396,0.0005531041,0.00020232324,0.0015392697,0.07742624],"study_design_scores_gemma":[0.066443644,0.007872355,0.009980873,0.31134093,0.57753825,0.00070897397,0.0004445156,0.00047767648,0.0009891266,0.0010906702,0.022961285,0.00015174497],"about_ca_topic_score_codex":0.0051607154,"about_ca_topic_score_gemma":0.013832191,"teacher_disagreement_score":0.99540055,"about_ca_system_score_codex":0.0019196476,"about_ca_system_score_gemma":0.0024083012,"threshold_uncertainty_score":0.024324536},"labels":[],"label_agreement":null},{"id":"W1966436678","doi":"10.1016/s1470-2045(07)70084-0","title":"Scoring systems: predictive accuracy through specificity","year":2007,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cardiac, Anesthesia and Surgical Outcomes","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Scoring system; Colorectal cancer; Predictive value; Outcome (game theory); Predictive value of tests; Predictive modelling; Surgery; Intensive care medicine; Cancer; Internal medicine; Machine learning; Computer science","score_opus":0.10220063095012856,"score_gpt":0.3693338189685991,"score_spread":0.2671331880184706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966436678","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018956789,0.003969075,0.0008569584,0.9844578,0.006199758,0.0000088944225,0.00008664425,0.000029593866,0.0024957021],"genre_scores_gemma":[0.07004313,0.0064641475,0.006037209,0.83209,0.08031041,0.00012734623,0.00017543606,0.00009136114,0.0046609626],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9881974,0.0069250357,0.001218826,0.00082160125,0.0023423107,0.0004948743],"domain_scores_gemma":[0.85821897,0.11998841,0.002772821,0.0021772739,0.014721441,0.0021210613],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.023665711,0.00075839466,0.0022195124,0.0014460841,0.0017862541,0.004061275,0.0020898478,0.021105668,0.004191634],"category_scores_gemma":[0.1369533,0.00087649276,0.0010547995,0.0013491618,0.0054854597,0.004652431,0.0016815292,0.027568057,0.003665932],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035986296,0.00005691986,0.01432293,0.00015035596,0.00010358787,0.0008127623,0.00027536237,0.00027417796,0.0002435712,0.011909356,0.8851558,0.08633536],"study_design_scores_gemma":[0.0017629407,0.000557572,0.03675166,0.003183271,0.000776217,0.011601608,0.0020987634,0.01689627,0.0019233371,0.2801113,0.64372885,0.0006081724],"about_ca_topic_score_codex":0.004652848,"about_ca_topic_score_gemma":0.011039039,"teacher_disagreement_score":0.023665711,"about_ca_system_score_codex":0.0034431329,"about_ca_system_score_gemma":0.0027310695,"threshold_uncertainty_score":0.12515771},"labels":[],"label_agreement":null},{"id":"W1967485936","doi":"10.1016/s1470-2045(13)70083-4","title":"The Fluorspar Mines of Newfoundland","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Geological and Geochemical Analysis","field":"Earth and Planetary Sciences","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Environmental science","score_opus":0.02556321535008661,"score_gpt":0.2405836253936181,"score_spread":0.2150204100435315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967485936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92944366,0.0046346434,0.0007341492,0.016727071,0.00018385878,0.000053970263,0.019432941,0.000044301047,0.028745461],"genre_scores_gemma":[0.9385704,0.0025543827,0.00085350807,0.0019992464,0.00006162242,0.00003285319,0.0037121682,0.000031579602,0.05218421],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99944216,0.000056721714,0.000021719376,0.000062634084,0.00010535704,0.0003114519],"domain_scores_gemma":[0.99811506,0.00021860417,0.0005816406,0.0001127794,0.0005566937,0.00041527324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003872625,0.00021144138,0.0002781654,0.0012547976,0.0022509936,0.0014187564,0.0005432229,0.0004945245,0.0052401912],"category_scores_gemma":[0.0017565079,0.00032305744,0.00024461778,0.0021704165,0.00073045323,0.00070817734,0.0015565812,0.0008642022,0.00033451832],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034662962,0.00006460509,0.8496523,0.00024015106,0.00022817722,0.0033253345,0.003431661,0.0012672583,0.0016371633,0.0030958424,0.06759648,0.069114305],"study_design_scores_gemma":[0.000012909925,0.000027176886,0.95466894,0.00011230749,0.000039551942,0.0005068165,0.0070001567,0.00028174632,0.0003494925,0.00026543828,0.0367136,0.00002186942],"about_ca_topic_score_codex":0.952429,"about_ca_topic_score_gemma":0.99276567,"teacher_disagreement_score":0.047571003,"about_ca_system_score_codex":0.010311093,"about_ca_system_score_gemma":0.015766777,"threshold_uncertainty_score":0.09570229},"labels":[],"label_agreement":null},{"id":"W1967732005","doi":"10.1016/s1470-2045(05)01748-1","title":"Complementary treatment: who cares how it works, as long as it does?","year":2005,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Complementary and Alternative Medicine Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Victoria Park","funders":"","keywords":"Argument (complex analysis); Reflection (computer programming); Welfare; Epistemology; Psychology; Medical education; Medicine; Philosophy; Political science; Law; Computer science","score_opus":0.10152416960418124,"score_gpt":0.41804095446159356,"score_spread":0.3165167848574123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967732005","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002201751,0.63067704,0.00035330397,0.35159776,0.0046728863,0.000026645064,0.0000718139,0.000005478222,0.010393267],"genre_scores_gemma":[0.09865928,0.6468501,0.0030305223,0.2306185,0.01664436,0.00020378016,0.0001086959,0.00003419143,0.0038505923],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9852519,0.009588322,0.00068587996,0.00065519125,0.003185572,0.0006330903],"domain_scores_gemma":[0.95163834,0.035708614,0.0035540152,0.0017361321,0.004911656,0.0024513106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0197947,0.0005838355,0.0034116053,0.0015727489,0.0026240242,0.0070534283,0.0019001025,0.010207363,0.0087177325],"category_scores_gemma":[0.05465828,0.000446552,0.0010368767,0.003182299,0.011469624,0.012825693,0.0023009016,0.007835088,0.0014160129],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013672188,0.00065760134,0.0062792753,0.0266539,0.0021251969,0.00024056007,0.004855317,0.00018187473,0.00061233714,0.0978339,0.17771958,0.6814732],"study_design_scores_gemma":[0.0022038969,0.0010927465,0.025389202,0.11179649,0.0032890432,0.001218474,0.023804387,0.00041768045,0.0005813205,0.24107066,0.58878446,0.0003515914],"about_ca_topic_score_codex":0.019168843,"about_ca_topic_score_gemma":0.041201405,"teacher_disagreement_score":0.0197947,"about_ca_system_score_codex":0.006301082,"about_ca_system_score_gemma":0.017039966,"threshold_uncertainty_score":0.104685664},"labels":[],"label_agreement":null},{"id":"W1968735621","doi":"10.1016/s1470-2045(15)70027-6","title":"Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":122,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Pharmaceuticals; Takeda Oncology; GlaxoSmithKline; Public Health Agency; Astellas Pharma Canada; Novartis; Exelixis; Ministry of Education, Culture, Sports, Science and Technology; Bayer; Bristol-Myers Squibb; AstraZeneca; Pfizer","keywords":"Medicine; Prednisone; Prostate cancer; Abiraterone acetate; Internal medicine; Placebo; Clinical endpoint; Enzalutamide; Androgen deprivation therapy; Clinical trial; Population; Oncology; Cancer; Surgery; Urology; Pathology; Androgen receptor","score_opus":0.09142640043602607,"score_gpt":0.3987588878018678,"score_spread":0.30733248736584173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968735621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97161597,0.0179873,0.00085317495,0.0010180528,0.0011651991,0.0031354213,0.0011305739,0.0002728274,0.002821403],"genre_scores_gemma":[0.9807349,0.008119461,0.0013623369,0.001340281,0.0006135402,0.0020985117,0.000865289,0.000027091597,0.00483858],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.999519,0.00023515892,0.000032205084,0.0000941565,0.000034225326,0.000085365704],"domain_scores_gemma":[0.999471,0.00016451982,0.00012600298,0.000038817998,0.000032000684,0.00016762361],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012866436,0.002062779,0.0036496732,0.0005442221,0.00042748614,0.0010220503,0.0010524156,0.0019357097,0.0074600363],"category_scores_gemma":[0.0014299033,0.0007440449,0.0023168635,0.00047466625,0.0013654792,0.0011371803,0.00044695952,0.0028713564,0.0010592716],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9847847,0.0020072185,0.00023553139,0.0011991046,0.00094346347,0.00003204215,0.000032041993,0.00020523205,0.0012442173,0.000057049878,0.00042616372,0.008833216],"study_design_scores_gemma":[0.9729249,0.025145898,0.00075904274,0.000037592203,0.00045544605,0.000019154953,0.0000137525785,0.00014083243,0.00013538261,0.00006900398,0.00028744093,0.000011639903],"about_ca_topic_score_codex":0.0013015666,"about_ca_topic_score_gemma":0.0030752544,"teacher_disagreement_score":0.0074600363,"about_ca_system_score_codex":0.0006249567,"about_ca_system_score_gemma":0.0008788041,"threshold_uncertainty_score":0.024956286},"labels":[],"label_agreement":null},{"id":"W1968899146","doi":"10.1016/s1470-2045(14)71207-0","title":"Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2007,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute","keywords":"Carboplatin; Medicine; Cetuximab; Paclitaxel; Oncology; Radiation therapy; Stage (stratigraphy); Internal medicine; Lung cancer; Chemotherapy; Nuclear medicine; Cancer; Cisplatin; Colorectal cancer","score_opus":0.04436868744910295,"score_gpt":0.3865590085254279,"score_spread":0.34219032107632497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968899146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99346066,0.001831272,0.00047541386,0.00039168587,0.00048651532,0.0016965951,0.0004967764,0.00007939267,0.0010817563],"genre_scores_gemma":[0.9901779,0.0019015935,0.0014522469,0.00069162773,0.00046518722,0.0019526414,0.00064595346,0.000051851897,0.0026609714],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988537,0.0006356026,0.000057746936,0.00018845983,0.000071670926,0.00019282162],"domain_scores_gemma":[0.99861455,0.00042506502,0.0003106182,0.0001522663,0.000051317664,0.0004462044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002420452,0.0023777448,0.004434626,0.0008018501,0.00044951806,0.0013624694,0.0019517359,0.0021217251,0.00782836],"category_scores_gemma":[0.0019562384,0.0012951992,0.0039916583,0.0008980073,0.002358561,0.0014782035,0.000722323,0.004676122,0.001286695],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9835292,0.005657401,0.00027839307,0.00024709062,0.0005630598,0.000013523814,0.000045662204,0.00055494264,0.0011407902,0.00005828778,0.0002876708,0.007624083],"study_design_scores_gemma":[0.9130501,0.08463964,0.0010066401,0.000015923288,0.00034846723,0.000017666602,0.000022269363,0.00032016195,0.00023950226,0.00010782947,0.00021896037,0.0000127382655],"about_ca_topic_score_codex":0.002749619,"about_ca_topic_score_gemma":0.0044386955,"teacher_disagreement_score":0.00782836,"about_ca_system_score_codex":0.0016853269,"about_ca_system_score_gemma":0.0019446568,"threshold_uncertainty_score":0.026188433},"labels":[],"label_agreement":null},{"id":"W1970668319","doi":"10.1016/s1470-2045(09)70078-6","title":"Breast-tissue composition and other risk factors for breast cancer in young women: a cross-sectional study","year":2009,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Digital Radiography and Breast Imaging","field":"Medicine","cited_by":184,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; Health Sciences Centre; Sunnybrook Health Science Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Breast cancer; Mammography; Menstrual cycle; Gynecology; Cross-sectional study; Obstetrics; Follicular phase; Breast density; Risk factors for breast cancer; Breast development; Hormone; Cancer; Physiology; Internal medicine; Pathology","score_opus":0.024450156422956518,"score_gpt":0.3550274863330137,"score_spread":0.33057732991005717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970668319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992785,0.00021209668,0.00004558019,0.000039542298,0.000008342608,0.000009545201,0.00019983632,0.0000020260786,0.00020448967],"genre_scores_gemma":[0.9988403,0.00025425694,0.00008626172,0.00009623447,0.000014269452,0.000017019991,0.0002559336,0.0000026837497,0.000433083],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995466,0.00013873992,0.000047324862,0.00008866196,0.00007776365,0.000100837395],"domain_scores_gemma":[0.99837923,0.00030793383,0.00044349916,0.00014987616,0.00018454116,0.000534957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009014021,0.0004386981,0.0006305646,0.0008217695,0.0008936295,0.000864682,0.0004045488,0.0011961163,0.001873941],"category_scores_gemma":[0.0021890753,0.0014383189,0.0008104684,0.0014209029,0.00047141066,0.000957449,0.0005711069,0.0012742633,0.0006409324],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001196201,0.00013317647,0.99866605,0.000008576075,0.00007039691,0.00008766612,0.00022553194,0.000006895119,0.00029720008,0.00000602156,0.000035374847,0.00034357063],"study_design_scores_gemma":[0.000008413372,0.00030800657,0.9987179,0.000004676895,0.000053027485,0.00021334381,0.00053384656,0.00002417471,0.000038622788,0.000008287288,0.00008558785,0.000004117556],"about_ca_topic_score_codex":0.010578771,"about_ca_topic_score_gemma":0.013696569,"teacher_disagreement_score":0.010578771,"about_ca_system_score_codex":0.00038468116,"about_ca_system_score_gemma":0.00047246582,"threshold_uncertainty_score":0.02103442},"labels":[],"label_agreement":null},{"id":"W1971159432","doi":"10.1016/s1470-2045(14)70375-4","title":"Outcomes and endpoints in trials of cancer treatment: the past, present, and future","year":2014,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":218,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Surrogate endpoint; Clinical endpoint; Clinical trial; Intensive care medicine; Quality of life (healthcare); Medicine; Endpoint Determination; Overall survival; Cancer; Disease; Oncology; Internal medicine; Nursing","score_opus":0.7857781232112138,"score_gpt":0.682581246318719,"score_spread":0.1031968768924948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971159432","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007789589,0.9966108,0.0011008752,0.0018164399,0.00020212097,0.000014873399,0.000020639256,0.000008172319,0.00014818105],"genre_scores_gemma":[0.004952701,0.9888466,0.0033112639,0.0016771652,0.0009672673,0.00010618572,0.00003588017,0.0000129942055,0.00008990344],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9612128,0.031030154,0.0027319381,0.0009997876,0.003739061,0.0002862293],"domain_scores_gemma":[0.80789953,0.17972295,0.007018483,0.0019541844,0.0027818887,0.00062291324],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.056831103,0.0013639008,0.009130762,0.0032627736,0.00031299636,0.003718439,0.0029067225,0.0031670898,0.00262355],"category_scores_gemma":[0.09888586,0.0007707444,0.003048864,0.005472087,0.0038698635,0.0041476833,0.0019322655,0.0063720453,0.0005750308],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068763515,0.000055424312,0.0006322184,0.10029654,0.003002917,0.000033443903,0.00016490373,0.0015841246,0.00012282943,0.02906918,0.010067456,0.8542833],"study_design_scores_gemma":[0.003136754,0.001222958,0.0052158544,0.20560832,0.010889871,0.000965228,0.00058595906,0.0053205513,0.00073171605,0.3865942,0.3794491,0.0002794725],"about_ca_topic_score_codex":0.0018052119,"about_ca_topic_score_gemma":0.0032082333,"teacher_disagreement_score":0.9431689,"about_ca_system_score_codex":0.0022654925,"about_ca_system_score_gemma":0.007084789,"threshold_uncertainty_score":0.30055523},"labels":[],"label_agreement":null},{"id":"W1972912578","doi":"10.1016/s1470-2045(13)70184-0","title":"Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":287,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Aflibercept; Docetaxel; Medicine; Prednisone; Prostate cancer; Placebo; Clinical endpoint; Internal medicine; Oncology; Chemotherapy; Surgery; Cancer; Bevacizumab; Urology; Randomized controlled trial; Pathology","score_opus":0.12222259731709838,"score_gpt":0.4218269267105545,"score_spread":0.2996043293934561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972912578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9614772,0.017699122,0.0016725598,0.0015712882,0.0026623078,0.008583874,0.0021287312,0.00044727442,0.0037576114],"genre_scores_gemma":[0.9755798,0.0067224246,0.0020510792,0.0014550809,0.0012073789,0.0057619014,0.0011764914,0.000058908165,0.005986817],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99904007,0.0004885334,0.000065048705,0.00020145201,0.000053868825,0.00015107942],"domain_scores_gemma":[0.9988783,0.00037288523,0.00022249704,0.00010047385,0.000059582286,0.00036627834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022623483,0.0028018968,0.005385211,0.0008093007,0.0007231168,0.0016405509,0.0015090649,0.0033250453,0.0110271815],"category_scores_gemma":[0.0022057844,0.0012774355,0.003845067,0.0007054812,0.002168837,0.0017408179,0.0006348106,0.004536364,0.0017959601],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9921038,0.0015299565,0.000080099024,0.00049630256,0.00051875855,0.000015930784,0.00002453,0.00012758022,0.0005145626,0.000048018115,0.00030714876,0.004233276],"study_design_scores_gemma":[0.9833272,0.015912697,0.00020358557,0.00001759981,0.00018021569,0.000010225583,0.000007323536,0.00008718144,0.000053093936,0.000047611844,0.00014690285,0.0000064753244],"about_ca_topic_score_codex":0.0018272905,"about_ca_topic_score_gemma":0.003259204,"teacher_disagreement_score":0.0110271815,"about_ca_system_score_codex":0.0008698911,"about_ca_system_score_gemma":0.0011754055,"threshold_uncertainty_score":0.036889613},"labels":[],"label_agreement":null},{"id":"W1975647972","doi":"10.1016/s1470-2045(14)70081-6","title":"The value of randomised trials for prostate cancer management","year":2014,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Management of prostate cancer; Value (mathematics); MEDLINE; Randomized controlled trial; Oncology; Cancer; Gynecology; Medical physics; Internal medicine; Statistics","score_opus":0.10652173638972241,"score_gpt":0.3987593430601752,"score_spread":0.2922376066704528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975647972","genre_codex":"review","genre_gemma":"commentary","domain_codex":"methods","domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0076026632,0.5979454,0.13317354,0.08638415,0.09914289,0.045391627,0.0059993705,0.0013905183,0.022969805],"genre_scores_gemma":[0.30199257,0.09988808,0.23840727,0.12488281,0.024153411,0.19908313,0.0039918134,0.00095903943,0.0066419574],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.27755347,0.6650468,0.023525216,0.015557027,0.016708665,0.0016088132],"domain_scores_gemma":[0.31867146,0.6022501,0.025667073,0.04176757,0.009162851,0.0024809951],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.37473553,0.004319876,0.020203557,0.007228294,0.002192925,0.010899176,0.00637867,0.015252267,0.026206102],"category_scores_gemma":[0.61985934,0.0021334137,0.013305508,0.0068211798,0.008940079,0.014652153,0.005584343,0.012694051,0.0045034587],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08334539,0.0011526735,0.0058191908,0.20278448,0.13605022,0.00086528744,0.0013605433,0.008865486,0.0005695579,0.16806766,0.08366349,0.30745617],"study_design_scores_gemma":[0.1272614,0.0074025174,0.0031573426,0.10683988,0.025712522,0.00047860653,0.0005655839,0.012758861,0.00065749185,0.59885967,0.115806535,0.00049953605],"about_ca_topic_score_codex":0.0023846985,"about_ca_topic_score_gemma":0.0018839309,"teacher_disagreement_score":0.37473553,"about_ca_system_score_codex":0.0078636715,"about_ca_system_score_gemma":0.008679025,"threshold_uncertainty_score":0.77106243},"labels":[],"label_agreement":null},{"id":"W1976250589","doi":"10.1016/s1470-2045(13)70026-3","title":"Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":166,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Amgen","keywords":"Exemestane; Fulvestrant; Postmenopausal women; Medicine; Oncology; Breast cancer; Hormone receptor; Internal medicine; Aromatase inhibitor; Cancer; Gynecology; Aromatase; Estrogen receptor","score_opus":0.03208678168695916,"score_gpt":0.32787530743548443,"score_spread":0.29578852574852527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976250589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9693717,0.013261671,0.0013133076,0.0018257637,0.0020780999,0.005754285,0.0024431476,0.00037559576,0.0035765714],"genre_scores_gemma":[0.9700524,0.007866484,0.002071764,0.0019374642,0.0008267664,0.006783455,0.0019225223,0.000064472406,0.00847457],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994752,0.00025180506,0.000028691393,0.0001104014,0.000036448204,0.00009741978],"domain_scores_gemma":[0.9994543,0.00017727468,0.0001067723,0.000057141933,0.000026615113,0.0001779076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017241045,0.002781524,0.0035691964,0.00061515253,0.0004143183,0.0011165721,0.0009638003,0.0021747344,0.009069094],"category_scores_gemma":[0.0018505052,0.0010361543,0.0023346806,0.00057539163,0.0015546897,0.0014996114,0.00054918753,0.0038490358,0.0015449336],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98682284,0.0014683395,0.00017645162,0.0005771697,0.00058631663,0.000022488013,0.000032348755,0.00022996517,0.0013905247,0.00007946928,0.0005995542,0.008014568],"study_design_scores_gemma":[0.9862917,0.012660316,0.00028826974,0.00001374833,0.00016098378,0.000012844548,0.000008652897,0.000111659836,0.00010268679,0.00008008436,0.0002627651,0.00000634817],"about_ca_topic_score_codex":0.0013296441,"about_ca_topic_score_gemma":0.0030193368,"teacher_disagreement_score":0.009069094,"about_ca_system_score_codex":0.0008604758,"about_ca_system_score_gemma":0.00094132585,"threshold_uncertainty_score":0.030339122},"labels":[],"label_agreement":null},{"id":"W1976585485","doi":"10.1016/s1470-2045(11)70037-7","title":"Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne; Centre hospitalier universitaire de Québec","funders":"","keywords":"Bevacizumab; Metastatic breast cancer; Medicine; Paclitaxel; Placebo; HER2 negative; Oncology; Breast cancer; Internal medicine; Open label; Double blind; Cancer; Clinical trial; Chemotherapy; Pathology; Alternative medicine","score_opus":0.24401072602498708,"score_gpt":0.47205516413850956,"score_spread":0.22804443811352249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976585485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97667515,0.0113213435,0.0011760346,0.0009045581,0.0012991669,0.003980356,0.0013272351,0.00030691744,0.0030093708],"genre_scores_gemma":[0.9749536,0.008418277,0.0022906645,0.0014772521,0.0009983232,0.004017677,0.0015297756,0.00005594459,0.0062585226],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993544,0.00031655212,0.000035085817,0.00011196016,0.000065777946,0.00011620473],"domain_scores_gemma":[0.99935263,0.00019150006,0.0001157262,0.000045852143,0.000046214544,0.00024811135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015855038,0.0023750055,0.0044601043,0.0007854956,0.00041236627,0.0009562743,0.0012371641,0.0021743288,0.0064401827],"category_scores_gemma":[0.0016173397,0.0011988247,0.0016824276,0.00063681573,0.0015061143,0.0014294058,0.0004132828,0.0033001818,0.001160062],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97458726,0.007023655,0.00015897206,0.0006663162,0.00057864643,0.000024991637,0.000025715974,0.00020064604,0.0031975782,0.00007445806,0.0005787234,0.012882941],"study_design_scores_gemma":[0.945169,0.053065203,0.0005397508,0.000018857945,0.00025700068,0.000020631207,0.000009667522,0.00022438008,0.0002869657,0.000052689815,0.00034391793,0.000011956025],"about_ca_topic_score_codex":0.0014794666,"about_ca_topic_score_gemma":0.0037568999,"teacher_disagreement_score":0.0064401827,"about_ca_system_score_codex":0.0008891764,"about_ca_system_score_gemma":0.001083182,"threshold_uncertainty_score":0.021544576},"labels":[],"label_agreement":null},{"id":"W1977580610","doi":"10.1016/s1470-2045(10)70296-5","title":"A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":148,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"National Cancer Institute","keywords":"Bladder cancer; NODAL; Oncology; Medicine; Internal medicine; Cancer","score_opus":0.09256945034448312,"score_gpt":0.3755695150153489,"score_spread":0.2830000646708658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977580610","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2866466,0.001724322,0.6929146,0.004357007,0.00042827372,0.00049640896,0.002957525,0.0006446393,0.009830584],"genre_scores_gemma":[0.8411949,0.0013191897,0.14338088,0.0008611612,0.00018135253,0.0009933485,0.002193555,0.00028679188,0.009588801],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99886763,0.00064586854,0.000038436316,0.00019800411,0.00015595669,0.000094043105],"domain_scores_gemma":[0.9968651,0.0018668959,0.00026053566,0.00026525627,0.00056599174,0.0001762726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005444904,0.00093889976,0.00087680004,0.0012419666,0.0005387646,0.0013407117,0.0017404915,0.0007039369,0.0057732984],"category_scores_gemma":[0.006847399,0.0003479044,0.0013153671,0.0008683892,0.0011468377,0.0012418034,0.00080621964,0.0011826854,0.0015255895],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036732138,0.0010348994,0.3048895,0.0002843769,0.0011035132,0.0007653138,0.000930858,0.20675342,0.021436436,0.16976292,0.009991572,0.27937403],"study_design_scores_gemma":[0.00052832114,0.0020546454,0.050302204,0.000118309654,0.0008899157,0.00093877374,0.00034233526,0.75602454,0.0030903593,0.17162296,0.013962631,0.00012492748],"about_ca_topic_score_codex":0.007407343,"about_ca_topic_score_gemma":0.0059474907,"teacher_disagreement_score":0.007407343,"about_ca_system_score_codex":0.0013128902,"about_ca_system_score_gemma":0.0020861023,"threshold_uncertainty_score":0.02879572},"labels":[],"label_agreement":null},{"id":"W1981283022","doi":"10.1016/s1470-2045(14)70121-4","title":"The need to expand global access to radiotherapy","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Computer science; Business","score_opus":0.03977384840597784,"score_gpt":0.4564466225348249,"score_spread":0.416672774128847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981283022","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021767626,0.047610115,0.0022418224,0.8937699,0.013560408,0.000028777744,0.0006518981,0.00041247837,0.0395479],"genre_scores_gemma":[0.08106727,0.118534714,0.0069835936,0.6797136,0.068897866,0.0002188345,0.0016977278,0.0006915565,0.042194802],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99624985,0.0013906651,0.00022279262,0.00037687278,0.0007929259,0.0009668086],"domain_scores_gemma":[0.9747464,0.010296075,0.0020442042,0.0018113202,0.0032552409,0.007846815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008420328,0.0009121521,0.0015529763,0.0021724643,0.0013724027,0.0061903703,0.0020505425,0.012318747,0.13097656],"category_scores_gemma":[0.026058853,0.00055476354,0.0020408167,0.0020652558,0.0051907813,0.016748056,0.010988513,0.012330112,0.017328978],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002825382,0.00011735581,0.0021298956,0.0024498107,0.00011757133,0.00031447088,0.00050675886,0.0011052719,0.00094304024,0.079543345,0.70486027,0.2076297],"study_design_scores_gemma":[0.00008746,0.0000870344,0.0027063077,0.000969344,0.00004003004,0.0005024923,0.00058442284,0.00017613119,0.00014681168,0.039567225,0.9550925,0.00004023258],"about_ca_topic_score_codex":0.004142021,"about_ca_topic_score_gemma":0.00588627,"teacher_disagreement_score":0.13097656,"about_ca_system_score_codex":0.0043149684,"about_ca_system_score_gemma":0.00955776,"threshold_uncertainty_score":0.43816024},"labels":[],"label_agreement":null},{"id":"W1982314007","doi":"10.1016/s1470-2045(06)70622-2","title":"Use of antidepressants and risk of colorectal cancer: a nested case-control study","year":2006,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer, Stress, Anesthesia, and Immune Response","field":"Medicine","cited_by":140,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Health; McGill University; Jewish General Hospital","funders":"National Cancer Institute","keywords":"Colorectal cancer; Medicine; Internal medicine; Incidence (geometry); Cancer registry; Cancer; Population; Rate ratio; Oncology; Confidence interval; Environmental health","score_opus":0.034354148197534434,"score_gpt":0.3183250091567965,"score_spread":0.28397086095926205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982314007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987232,0.00048050247,0.0002632055,0.000047754293,0.000022051108,0.000037288526,0.00021885379,0.0000042977304,0.00020291653],"genre_scores_gemma":[0.9989146,0.000168014,0.00032764484,0.000066050845,0.000024714374,0.000036129044,0.00022036234,0.0000037528819,0.0002386815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99840707,0.0007239992,0.000110855144,0.00042446255,0.00017666485,0.00015711114],"domain_scores_gemma":[0.99726117,0.00078592956,0.000604658,0.00067072286,0.00024779854,0.00042975496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014677137,0.00069235725,0.0011342819,0.00047596748,0.0010009034,0.0008780416,0.0007438613,0.0010490448,0.0013901533],"category_scores_gemma":[0.0035219556,0.0012705965,0.0014856417,0.0007404538,0.0007726847,0.0004493499,0.0004934246,0.0010360739,0.00029963604],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015008133,0.0020473064,0.9655025,0.00016671918,0.0036843503,0.0011204333,0.0010279135,0.00017870296,0.008070001,0.00016811269,0.0005544659,0.0024714854],"study_design_scores_gemma":[0.001992005,0.0036876686,0.9873563,0.00004044017,0.0026431626,0.001690787,0.00052238826,0.00087351317,0.00039957656,0.00012258631,0.00062996586,0.00004162024],"about_ca_topic_score_codex":0.013148487,"about_ca_topic_score_gemma":0.015235029,"teacher_disagreement_score":0.013148487,"about_ca_system_score_codex":0.00057288667,"about_ca_system_score_gemma":0.00063742267,"threshold_uncertainty_score":0.026143909},"labels":[],"label_agreement":null},{"id":"W1984251852","doi":"10.1016/s1470-2045(14)70018-x","title":"Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology","year":2014,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":235,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Geriatric oncology; Prostate cancer; Task force; Multidisciplinary approach; Geriatrics; Cancer; Family medicine; Internal medicine; Gerontology; Physical therapy; Psychiatry","score_opus":0.092242447733692,"score_gpt":0.4246081119954325,"score_spread":0.3323656642617405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984251852","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024105114,0.986808,0.0004557356,0.009407677,0.0017219879,0.000079624595,0.00035182227,0.0000245731,0.00090960553],"genre_scores_gemma":[0.0014824362,0.989484,0.0021812639,0.0051298463,0.00068034185,0.00011031292,0.0005279837,0.000007688427,0.0003960741],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980494,0.00042476252,0.0005896889,0.00013887206,0.0006679572,0.00012936328],"domain_scores_gemma":[0.9954122,0.001407769,0.0010600658,0.00006964607,0.0017172896,0.00033317253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060000056,0.0015591519,0.0035420104,0.0042125103,0.0005509447,0.0017638097,0.0027912639,0.0026811808,0.0019664837],"category_scores_gemma":[0.007940939,0.00054508954,0.0033822062,0.003558853,0.0006106584,0.0017502634,0.0018323411,0.004129059,0.0010151371],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023497365,0.00011612687,0.0017225271,0.042885203,0.0009501633,0.00018351075,0.00017511971,0.0006075364,0.0004639098,0.0015193191,0.1492702,0.80187136],"study_design_scores_gemma":[0.00048479412,0.00026972193,0.010026759,0.11674895,0.004351603,0.0010687872,0.00044880385,0.00046497578,0.0005305745,0.0030776914,0.86241215,0.00011534065],"about_ca_topic_score_codex":0.013690579,"about_ca_topic_score_gemma":0.02300274,"teacher_disagreement_score":0.013690579,"about_ca_system_score_codex":0.0026772679,"about_ca_system_score_gemma":0.009467438,"threshold_uncertainty_score":0.031731486},"labels":[],"label_agreement":null},{"id":"W1984729575","doi":"10.1016/s1470-2045(09)70295-5","title":"Should a biopsy be recommended to confirm metastatic disease in women with breast cancer?","year":2009,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Breast cancer; Metastatic breast cancer; Progesterone receptor; Oncology; Concordance; Biopsy; Internal medicine; Hormone receptor; Cancer; Estrogen receptor; Gynecology","score_opus":0.16106710979578487,"score_gpt":0.44171524985814115,"score_spread":0.2806481400623563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984729575","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00045532934,0.0012331615,0.000052089108,0.9870582,0.009679939,0.0000057632074,0.00003350835,0.000008891497,0.0014730205],"genre_scores_gemma":[0.006453504,0.0017430153,0.0003536272,0.9399488,0.049486667,0.000023819126,0.000052439198,0.0000147533165,0.0019233256],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99662244,0.0009929239,0.0005783185,0.00041408732,0.0008472602,0.00054500584],"domain_scores_gemma":[0.98445964,0.00775876,0.0013198227,0.0005100499,0.0030279113,0.0029239007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034842587,0.0006678607,0.0017311604,0.0010819115,0.0029639418,0.0027230682,0.0018787438,0.069111705,0.007823258],"category_scores_gemma":[0.041614905,0.000938839,0.0015079301,0.00096168736,0.0029055758,0.003999754,0.0013361011,0.04473715,0.006122105],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016870392,0.00004756448,0.0058266167,0.00014310781,0.000048361453,0.0038625367,0.00014053364,0.00012446307,0.00039053863,0.0019744497,0.96401954,0.023253614],"study_design_scores_gemma":[0.00072755123,0.0003486421,0.014020167,0.0022164276,0.00024580336,0.02114407,0.0017147792,0.0014156586,0.00065015914,0.025498934,0.931805,0.00021284012],"about_ca_topic_score_codex":0.0095914705,"about_ca_topic_score_gemma":0.020992137,"teacher_disagreement_score":0.069111705,"about_ca_system_score_codex":0.004665304,"about_ca_system_score_gemma":0.004175543,"threshold_uncertainty_score":0.0338493},"labels":[],"label_agreement":null},{"id":"W1987942446","doi":"10.1016/s1470-2045(12)70127-4","title":"Screening of symptomatic women for ovarian cancer – Authors' reply","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Ovarian cancer; Gynecology; Oncology; Internal medicine; Cancer","score_opus":0.08046158177394504,"score_gpt":0.38738397600514635,"score_spread":0.3069223942312013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987942446","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042066796,0.0017676317,0.000049095568,0.95329684,0.043922115,0.000009124584,0.00012673746,0.0000123992,0.00039532685],"genre_scores_gemma":[0.0038010387,0.0014837412,0.00014019787,0.94012547,0.052459437,0.00004010593,0.000073876196,0.000015286108,0.0018608822],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99672556,0.00097466615,0.00069897796,0.00054530066,0.0006473639,0.0004081491],"domain_scores_gemma":[0.9660778,0.02171812,0.0019755694,0.00082392327,0.0066174646,0.0027870797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044155857,0.00078764715,0.0015625256,0.0015458873,0.002197436,0.0024513693,0.001960505,0.03604384,0.0064439373],"category_scores_gemma":[0.04305947,0.000972046,0.0014414322,0.00094275567,0.0019789273,0.0031615607,0.0020162477,0.031609338,0.0030857068],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000097378696,0.000036981022,0.0025361252,0.00020524148,0.000053690303,0.00083284156,0.00020217591,0.000054162876,0.00013731458,0.0005502519,0.9885365,0.0067573558],"study_design_scores_gemma":[0.0005571011,0.00025580023,0.013314585,0.0012494733,0.00036682776,0.004401102,0.002256506,0.00053043896,0.00079032726,0.005749035,0.9701994,0.00032934514],"about_ca_topic_score_codex":0.005178273,"about_ca_topic_score_gemma":0.005819201,"teacher_disagreement_score":0.03604384,"about_ca_system_score_codex":0.002044488,"about_ca_system_score_gemma":0.0032458568,"threshold_uncertainty_score":0.023352146},"labels":[],"label_agreement":null},{"id":"W1990879009","doi":"10.1016/s1470-2045(08)70210-9","title":"A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China","year":2008,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":474,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Colposcopy; Endocervical curettage; Cervical intraepithelial neoplasia; Medicine; Gynecology; Cervical cancer; Obstetrics; Population; Cross-sectional study; Cancer; Internal medicine; Pathology","score_opus":0.32577779341712393,"score_gpt":0.5356799611736501,"score_spread":0.2099021677565262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990879009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9997079,0.00006496864,0.000043714164,0.000025292677,0.0000027212866,0.000008399148,0.000047544498,0.0000015627181,0.00009779502],"genre_scores_gemma":[0.999741,0.000035210902,0.00006713607,0.000019929612,0.0000033290069,0.000005383158,0.00005800874,0.0000011636137,0.00006870928],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99847895,0.0004214607,0.00019633828,0.00036435202,0.00030073422,0.00023801971],"domain_scores_gemma":[0.99542564,0.0012167825,0.0012684371,0.00042692703,0.0009267627,0.0007355058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024348835,0.0005487587,0.0006699223,0.0015737518,0.0013333992,0.0010822244,0.00096127286,0.00086076243,0.00066375744],"category_scores_gemma":[0.006291971,0.0009198481,0.0005831079,0.0022794052,0.0011185335,0.0010557384,0.0006811526,0.00088656606,0.00015263788],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003387351,0.000036294594,0.9989611,0.000004298713,0.000018001894,0.00003541007,0.0002595131,0.000017506387,0.00016747645,0.0000064041224,0.000015296,0.00044491678],"study_design_scores_gemma":[0.0000081812,0.00014252416,0.9989021,0.0000022940858,0.000035756857,0.00010642071,0.00044662537,0.00021191775,0.000078042445,0.00001456976,0.00004653954,0.0000050400126],"about_ca_topic_score_codex":0.053852934,"about_ca_topic_score_gemma":0.037421413,"teacher_disagreement_score":0.053852934,"about_ca_system_score_codex":0.0013839126,"about_ca_system_score_gemma":0.0017784009,"threshold_uncertainty_score":0.10707897},"labels":[],"label_agreement":null},{"id":"W1993929185","doi":"10.1016/s1470-2045(12)70511-9","title":"ChIPing away at breast cancer","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Genomics and Chromatin Dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research","funders":"","keywords":"Enhancer; Chromatin immunoprecipitation; Chromatin; Biology; Human genome; Gene; Computational biology; Promoter; Genetics; Epigenetics; Transcription factor; Regulation of gene expression; Gene expression; Genome","score_opus":0.019497571234393885,"score_gpt":0.29595339947435284,"score_spread":0.27645582823995896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993929185","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.029009376,0.5388425,0.004567787,0.35669607,0.020704443,0.00002891194,0.0019144986,0.0006694976,0.047566965],"genre_scores_gemma":[0.5085578,0.23365684,0.0027527316,0.16065338,0.022957703,0.00006256506,0.0010263193,0.00032629634,0.070006356],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99941933,0.000102620856,0.000022388018,0.00012139793,0.00020596417,0.00012823619],"domain_scores_gemma":[0.9986563,0.00045883513,0.00014161301,0.00013433337,0.00024402096,0.00036485522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011047227,0.00044210025,0.00074912654,0.0007959988,0.00092424644,0.0018864853,0.00064921915,0.0029037155,0.013661166],"category_scores_gemma":[0.002964655,0.00047335977,0.0003084789,0.00072240154,0.0015905238,0.002205709,0.001485472,0.0042438274,0.003904083],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006986929,0.00009064762,0.009268889,0.0014622016,0.00024052686,0.0006302059,0.0006569756,0.00084717385,0.026687762,0.09758226,0.50130326,0.36053136],"study_design_scores_gemma":[0.00012397493,0.00016783806,0.02507427,0.0007182913,0.00022765886,0.0014031718,0.001270059,0.00073035463,0.012325051,0.17814805,0.77972215,0.0000891644],"about_ca_topic_score_codex":0.001836401,"about_ca_topic_score_gemma":0.0038202438,"teacher_disagreement_score":0.013661166,"about_ca_system_score_codex":0.0015402649,"about_ca_system_score_gemma":0.0009760718,"threshold_uncertainty_score":0.045701206},"labels":[],"label_agreement":null},{"id":"W1997212925","doi":"10.1016/s1470-2045(14)70115-9","title":"The growing burden of cancer in India: epidemiology and social context","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":445,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Indian Council of Medical Research","keywords":"Epidemiology; Quarter (Canadian coin); Context (archaeology); Demography; Incidence (geometry); Cancer; Population; Medicine; Environmental health; Geography; Sociology; Pathology","score_opus":0.12824508697313297,"score_gpt":0.42863037410366706,"score_spread":0.3003852871305341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997212925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85676163,0.057961673,0.0005716784,0.058565985,0.0006880225,0.00004027622,0.003993119,0.000080353144,0.021337334],"genre_scores_gemma":[0.97899264,0.01795422,0.0001653034,0.0012677944,0.0006981207,0.000011183382,0.0003782119,0.000012226387,0.0005202269],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987679,0.0004897537,0.00007987634,0.000105141975,0.00018356873,0.00037370925],"domain_scores_gemma":[0.9966127,0.0010301521,0.0013513163,0.00016577222,0.00030686823,0.0005331639],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074856996,0.00023907748,0.00041358886,0.003075858,0.0009031843,0.0026657917,0.0006102226,0.00087611907,0.0037886451],"category_scores_gemma":[0.0032814466,0.000339361,0.00051559537,0.008442186,0.0016928609,0.0015896374,0.002174877,0.0016491713,0.00032008247],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016462652,0.00010112395,0.95056903,0.0007698525,0.00029522792,0.0007052184,0.002789918,0.00039887786,0.00050362933,0.0050143558,0.0062157074,0.032472324],"study_design_scores_gemma":[0.000005240031,0.00007050457,0.98361105,0.00021565819,0.00011519794,0.0007466995,0.0076164654,0.00013763491,0.00009952699,0.002005822,0.0053408835,0.00003535452],"about_ca_topic_score_codex":0.043171197,"about_ca_topic_score_gemma":0.069528,"teacher_disagreement_score":0.043171197,"about_ca_system_score_codex":0.0020182242,"about_ca_system_score_gemma":0.0035400535,"threshold_uncertainty_score":0.08583981},"labels":[],"label_agreement":null},{"id":"W1998119861","doi":"10.1016/s1470-2045(00)00192-3","title":"Cervical-cancer screening beyond the year 2000","year":2001,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Cervical cancer; Medicine; Cervical cancer screening; Human papillomavirus; Cytology; Cancer screening; Disease; Cancer; Cervical screening; Gynecology; Obstetrics; Oncology; Internal medicine; Pathology","score_opus":0.1133289028550536,"score_gpt":0.4230474455792471,"score_spread":0.3097185427241935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998119861","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1921791,0.18043411,0.0026400092,0.42194635,0.02349857,0.00022258279,0.020315237,0.00047358783,0.15829054],"genre_scores_gemma":[0.70119596,0.1045064,0.0019056054,0.113304004,0.0077936472,0.00016691854,0.011115256,0.000073261544,0.05993895],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989195,0.00017469493,0.000062767045,0.00013270661,0.00021899557,0.0004914202],"domain_scores_gemma":[0.99508697,0.0011003236,0.0006762558,0.00011703024,0.0010292835,0.001990145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017159136,0.0003461074,0.00047701556,0.0014246542,0.0006570112,0.0013091579,0.0004975954,0.0043576234,0.008259141],"category_scores_gemma":[0.011114459,0.00022451652,0.0005363837,0.0015589404,0.00046165075,0.0025052405,0.0011347384,0.002509148,0.00069951016],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035146647,0.0006840367,0.10759569,0.003185438,0.00014628467,0.0014750814,0.0014688066,0.0014012271,0.003623926,0.02157674,0.30416846,0.5511597],"study_design_scores_gemma":[0.00020406737,0.0006983048,0.3565771,0.005515508,0.0003455676,0.0016678557,0.00093852455,0.00082808314,0.0015615212,0.0052204817,0.6263611,0.00008186499],"about_ca_topic_score_codex":0.06643014,"about_ca_topic_score_gemma":0.11655478,"teacher_disagreement_score":0.06643014,"about_ca_system_score_codex":0.0035498822,"about_ca_system_score_gemma":0.008659147,"threshold_uncertainty_score":0.13208699},"labels":[],"label_agreement":null},{"id":"W1999442391","doi":"10.1016/s1470-2045(08)70177-3","title":"Part II: Milestones in personalised medicine—trastuzumab","year":2008,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Trastuzumab; Oncology; Medicine; Imatinib; Breast cancer; Internal medicine; Oncogene; Cancer; Ovarian cancer; Cancer research; Bioinformatics; Myeloid leukemia; Biology; Cell cycle","score_opus":0.269792299096941,"score_gpt":0.452685699643005,"score_spread":0.18289340054606396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999442391","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00177736,0.56318533,0.003193898,0.3442625,0.052733015,0.00012550295,0.00017975237,0.00011051213,0.03443211],"genre_scores_gemma":[0.04742504,0.53036,0.004825184,0.23580687,0.10803721,0.00037749202,0.00039956483,0.00019579957,0.0725729],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967849,0.0012246709,0.00023903733,0.00031293381,0.0009333546,0.0005049815],"domain_scores_gemma":[0.9933216,0.0037105482,0.0005965672,0.00047818976,0.00093270803,0.00096032594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0071514207,0.0012229885,0.0010328916,0.0012670622,0.0007365068,0.0049234307,0.0013141788,0.008739082,0.007877147],"category_scores_gemma":[0.011498368,0.00053398265,0.0007269702,0.001286483,0.003935893,0.006552847,0.0025639797,0.008978892,0.0033092347],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022277846,0.00011988795,0.00030119455,0.0012679234,0.0000457741,0.00017385234,0.0002418371,0.0006793644,0.0014038387,0.09344388,0.6751105,0.22698914],"study_design_scores_gemma":[0.00007652391,0.0001510077,0.0014269709,0.0013599019,0.000025176882,0.00040462622,0.000121873665,0.00034639763,0.0008741585,0.034931757,0.96024996,0.00003158599],"about_ca_topic_score_codex":0.0018486232,"about_ca_topic_score_gemma":0.002532695,"teacher_disagreement_score":0.008739082,"about_ca_system_score_codex":0.005217556,"about_ca_system_score_gemma":0.004135242,"threshold_uncertainty_score":0.03785616},"labels":[],"label_agreement":null},{"id":"W2002431108","doi":"10.1016/s1470-2045(11)70103-6","title":"Sentinel nodes in colorectal cancer: cul-de-sac or clarion call?","year":2011,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Lumpectomy; Breast cancer; Axillary Lymph Node Dissection; Sentinel node; Mastectomy; Lymph node; Dissection (medical); Sentinel lymph node; Surgery; General surgery; Cancer; Internal medicine","score_opus":0.044321614251565174,"score_gpt":0.3242253386356955,"score_spread":0.27990372438413036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002431108","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019369766,0.005751814,0.00007107658,0.9794941,0.013600898,0.0000044931553,0.000031721243,0.00000977282,0.0008424152],"genre_scores_gemma":[0.0033176523,0.0044064713,0.00027381716,0.92116123,0.06849506,0.000026911106,0.000036759346,0.000012485787,0.002269539],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9935435,0.003000583,0.0007828802,0.0005959384,0.001456698,0.000620349],"domain_scores_gemma":[0.9645264,0.025002733,0.002087388,0.0013111215,0.0031400425,0.003932325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010272776,0.00091700756,0.0028498417,0.00078391633,0.0023436954,0.0033963057,0.0029340128,0.05789462,0.007769445],"category_scores_gemma":[0.03725868,0.0010593211,0.0014144778,0.0008827194,0.0056521473,0.007213615,0.0022454294,0.04558001,0.0046661613],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026297677,0.000044865978,0.0011202694,0.0001860326,0.000058834215,0.0007168438,0.00008208155,0.0000727667,0.00021291431,0.003714919,0.9741034,0.019424096],"study_design_scores_gemma":[0.0008843464,0.00025671505,0.0030911113,0.0010950553,0.00020131085,0.002384846,0.000760525,0.0006373384,0.0003636449,0.03386645,0.95629823,0.00016054523],"about_ca_topic_score_codex":0.0034915993,"about_ca_topic_score_gemma":0.010292599,"teacher_disagreement_score":0.05789462,"about_ca_system_score_codex":0.003437024,"about_ca_system_score_gemma":0.00451873,"threshold_uncertainty_score":0.054328263},"labels":[],"label_agreement":null},{"id":"W2002566754","doi":"10.1016/s1470-2045(07)70002-5","title":"Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy","year":2007,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":202,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Center for Research Resources; National Institutes of Health","keywords":"Medicine; Cystectomy; Survivin; Bladder cancer; Hazard ratio; Oncology; Internal medicine; Apoptosis; Cancer; Univariate analysis; Urology; Gastroenterology; Pathology; Multivariate analysis; Confidence interval; Biology","score_opus":0.08985829872637918,"score_gpt":0.37150324276310487,"score_spread":0.2816449440367257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002566754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868035,0.009787721,0.00094206614,0.0004119114,0.00015293254,0.000035118406,0.00045468943,0.000030043608,0.0013819942],"genre_scores_gemma":[0.99738103,0.0008704286,0.00078648777,0.00007034631,0.00011892327,0.00002126716,0.00029667956,0.000003712702,0.0004511284],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990127,0.00038881594,0.000094159084,0.00015079287,0.0002615091,0.000091952534],"domain_scores_gemma":[0.9956518,0.0020362115,0.00088418415,0.00022836184,0.0008445132,0.00035500867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017245354,0.00046578282,0.0016871756,0.0015774589,0.00030656852,0.001280151,0.00050510257,0.00086457486,0.000761312],"category_scores_gemma":[0.0056450395,0.00033620917,0.00065709976,0.0011275847,0.00028565055,0.0007443027,0.00036531253,0.00093279197,0.00024963848],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046576755,0.00019449189,0.9409268,0.00010448316,0.0007562025,0.000101902144,0.000057920282,0.0011285316,0.0052436795,0.000054219523,0.0004251338,0.04634905],"study_design_scores_gemma":[0.00036662637,0.004857279,0.96659684,0.000072605275,0.0018427881,0.0010256944,0.00019452244,0.01337252,0.009105631,0.0005529751,0.0019292621,0.000083242914],"about_ca_topic_score_codex":0.001040492,"about_ca_topic_score_gemma":0.0021781083,"teacher_disagreement_score":0.0017245354,"about_ca_system_score_codex":0.00049720303,"about_ca_system_score_gemma":0.00047589332,"threshold_uncertainty_score":0.009120345},"labels":[],"label_agreement":null},{"id":"W2003747306","doi":"10.1016/s1470-2045(14)70409-7","title":"Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group","year":2015,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Heart Failure Treatment and Management","field":"Medicine","cited_by":563,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children; SickKids Foundation","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute","keywords":"Medicine; Asymptomatic; Guideline; Heart failure; Cardiomyopathy; Intensive care medicine; Population; Psychological intervention; Cancer; Pediatrics; Cardiology; Internal medicine; Environmental health; Psychiatry; Pathology","score_opus":0.07668287512611396,"score_gpt":0.4013047604394293,"score_spread":0.3246218853133154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003747306","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017240032,0.9026975,0.005248775,0.06421196,0.006202066,0.0015833701,0.008924703,0.00024537015,0.009162296],"genre_scores_gemma":[0.012217656,0.884349,0.031987,0.05080477,0.0015827342,0.0024801688,0.012875117,0.00010779848,0.0035957769],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99490213,0.0014196233,0.0015511113,0.0003290648,0.0015090238,0.0002891275],"domain_scores_gemma":[0.9908279,0.002840787,0.0018782758,0.00020418914,0.0036943918,0.00055437704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011121966,0.0012504493,0.003581337,0.0034026722,0.00064596714,0.0018843182,0.0045282533,0.003687476,0.0028481907],"category_scores_gemma":[0.017204607,0.00086101104,0.0062262383,0.0029517077,0.000684903,0.0015157618,0.0019215076,0.005956711,0.0012562763],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040195193,0.00021482666,0.003972416,0.056519408,0.0023705615,0.0002393618,0.00039272048,0.0016131602,0.0012037997,0.0059726457,0.3391393,0.58795977],"study_design_scores_gemma":[0.0011206253,0.00021541279,0.016995315,0.14065368,0.008168536,0.00052092946,0.00044679345,0.0007330152,0.00088978827,0.005208582,0.82489866,0.00014860228],"about_ca_topic_score_codex":0.03228699,"about_ca_topic_score_gemma":0.04792612,"teacher_disagreement_score":0.03228699,"about_ca_system_score_codex":0.0035222168,"about_ca_system_score_gemma":0.0168679,"threshold_uncertainty_score":0.06419814},"labels":[],"label_agreement":null},{"id":"W2005205748","doi":"10.1016/s1470-2045(14)71106-4","title":"Stereotactic radiosurgery alone for brain metastases","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"Elekta; Medtronic","keywords":"Radiosurgery; Medicine; Radiation therapy; Adjuvant radiotherapy; Stereotactic radiation therapy; Melanoma; Whole brain radiotherapy; Adjuvant; Radiology; Brain metastasis; Medical physics; Oncology; Internal medicine; Cancer; Metastasis","score_opus":0.1652645879779496,"score_gpt":0.39626723882358356,"score_spread":0.23100265084563396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005205748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6195618,0.10221833,0.015077246,0.014360214,0.0065811733,0.00065405905,0.0052554295,0.001985567,0.23430616],"genre_scores_gemma":[0.9414532,0.030956132,0.0048686336,0.0027712795,0.0025425765,0.00013555346,0.0021334493,0.0002453194,0.014893964],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9998903,0.000010210041,0.0000075200014,0.00002066801,0.000036409656,0.00003493214],"domain_scores_gemma":[0.9999045,0.000021681544,0.000017398133,0.000021705975,0.000009389035,0.000025301972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019160479,0.00034888185,0.0007162539,0.00075980957,0.0002783877,0.00035939043,0.0005065174,0.00052416674,0.006496832],"category_scores_gemma":[0.00044884734,0.00016697678,0.0009224337,0.00066443434,0.00031944562,0.00051444,0.0003563963,0.000631464,0.0022059912],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057309014,0.00059068395,0.006983861,0.0018971424,0.0012969202,0.0035107767,0.0001333796,0.0027625472,0.049988575,0.0035741103,0.05687796,0.86665314],"study_design_scores_gemma":[0.007780888,0.025189817,0.43841738,0.0011256476,0.004630861,0.074649215,0.00050554797,0.005376706,0.05691755,0.038560413,0.3465592,0.00028672058],"about_ca_topic_score_codex":0.0035184163,"about_ca_topic_score_gemma":0.011448331,"teacher_disagreement_score":0.006496832,"about_ca_system_score_codex":0.00053862005,"about_ca_system_score_gemma":0.0008620142,"threshold_uncertainty_score":0.021734},"labels":[],"label_agreement":null},{"id":"W2005967211","doi":"10.1016/s1470-2045(08)70007-x","title":"Does Canadian research investment relate to cancer burden?","year":2008,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Institute of Cancer Research; Canadian Institutes of Health Research","funders":"","keywords":"Medicine; Cancer; Investment (military); MEDLINE; Internal medicine","score_opus":0.16088777916785127,"score_gpt":0.43653804374463645,"score_spread":0.2756502645767852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005967211","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"incentives","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":"incentives","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002928172,0.0021044188,0.000009033004,0.9916357,0.0035981648,0.0000025460736,0.00008525855,0.000003658128,0.0022683865],"genre_scores_gemma":[0.012802816,0.0061026732,0.0001150033,0.9607293,0.012919094,0.000021479329,0.00012869935,0.000024453459,0.0071564484],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9904613,0.0017052531,0.0010266759,0.00050348404,0.0039042644,0.002399036],"domain_scores_gemma":[0.9421109,0.021028692,0.0039003082,0.00086228846,0.016536528,0.0155613],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008371067,0.0005296728,0.0014076808,0.0016918281,0.006583569,0.006092522,0.0027333184,0.04032043,0.017639589],"category_scores_gemma":[0.072136596,0.0007885972,0.0013568352,0.003123512,0.005645256,0.0037578675,0.0027137399,0.03206958,0.002613126],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005922213,0.000014259825,0.0033146078,0.00014988179,0.00004642444,0.00029697033,0.00021895884,0.0000600723,0.000038307997,0.00632813,0.97805756,0.01141555],"study_design_scores_gemma":[0.00030638964,0.00006999141,0.013312648,0.0016851729,0.0001939587,0.00066332135,0.0022295117,0.00028270145,0.00013332925,0.011684575,0.96929115,0.00014720278],"about_ca_topic_score_codex":0.7309851,"about_ca_topic_score_gemma":0.86017346,"teacher_disagreement_score":0.99162894,"about_ca_system_score_codex":0.043489523,"about_ca_system_score_gemma":0.09205268,"threshold_uncertainty_score":0.5411984},"labels":[],"label_agreement":null},{"id":"W2008171713","doi":"10.1016/s1470-2045(06)70615-5","title":"Diffuse brainstem glioma in children: critical review of clinical trials","year":2006,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":639,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Clinical trial; Brainstem; Radiation therapy; Glioma; Overall survival; Consistency (knowledge bases); Intensive care medicine; Oncology; Internal medicine","score_opus":0.364698182033378,"score_gpt":0.5608016764064655,"score_spread":0.1961034943730875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008171713","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001487902,0.9993592,0.000034064346,0.00020925968,0.00008079545,0.000025658808,0.00004474357,0.0000024904484,0.000095104486],"genre_scores_gemma":[0.0022373986,0.99670815,0.00028786375,0.0005343566,0.000086884844,0.00003770413,0.000047500896,0.0000022254912,0.00005791047],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9982576,0.0006106192,0.00057888264,0.00015909597,0.00031634432,0.000077584824],"domain_scores_gemma":[0.98909074,0.008003218,0.0017702158,0.00015335617,0.00080761255,0.00017495963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005600354,0.0011547501,0.0076887645,0.0022767922,0.00024662734,0.0017983621,0.002110704,0.0015516683,0.0028167123],"category_scores_gemma":[0.012864546,0.0006187856,0.0032378202,0.003368786,0.00054919824,0.0013415962,0.00077638804,0.0014858341,0.0003440685],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027582815,0.00007157432,0.0007390475,0.48003662,0.010400982,0.0002665386,0.0001447969,0.00062647753,0.00079367694,0.00086050015,0.022790594,0.48051092],"study_design_scores_gemma":[0.004659256,0.002037302,0.0077589946,0.46202657,0.08991326,0.001926926,0.00042670988,0.00035016882,0.00094063976,0.0024768617,0.42733926,0.00014406398],"about_ca_topic_score_codex":0.0026708585,"about_ca_topic_score_gemma":0.011030172,"teacher_disagreement_score":0.0076887645,"about_ca_system_score_codex":0.0019468765,"about_ca_system_score_gemma":0.004030366,"threshold_uncertainty_score":0.029617846},"labels":[],"label_agreement":null},{"id":"W2008814726","doi":"10.1016/s1470-2045(03)01017-9","title":"Clinical-practice guidelines in Europe: time for European co-operation for cancer guidelines","year":2003,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Regional Laboratory Medicine Program","funders":"","keywords":"Cancer; Medicine; Clinical Practice; Scopus; Cancer survival; Family medicine; MEDLINE; Demography; Political science; Internal medicine; Sociology; Law","score_opus":0.5479520958621692,"score_gpt":0.6384755372412064,"score_spread":0.09052344137903723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008814726","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002221616,0.020141698,0.006135336,0.94294465,0.017469266,0.00025066413,0.00018953557,0.00017984203,0.010467398],"genre_scores_gemma":[0.09393475,0.02635324,0.13042904,0.7140092,0.013708211,0.0014372219,0.0019437341,0.00060009677,0.017584518],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.8173027,0.095962115,0.03152757,0.0060546095,0.033160917,0.01599207],"domain_scores_gemma":[0.48274413,0.18345669,0.029088145,0.023706522,0.20244122,0.07856329],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.2505823,0.0014221253,0.0031557577,0.0044306805,0.004868988,0.01924916,0.009454349,0.049331382,0.013717507],"category_scores_gemma":[0.3338169,0.0016611116,0.0044000396,0.0062376754,0.007339581,0.014257138,0.01273299,0.043044418,0.0030814179],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020855191,0.00084452645,0.004154131,0.0020338835,0.00042122012,0.0008045796,0.00326698,0.0013997981,0.0006836537,0.120439515,0.65256256,0.21318054],"study_design_scores_gemma":[0.0005092977,0.00031495088,0.015584919,0.013421165,0.00026236623,0.00065684796,0.0058125197,0.0014217265,0.00060537696,0.051797077,0.90936345,0.0002502494],"about_ca_topic_score_codex":0.029659556,"about_ca_topic_score_gemma":0.031298738,"teacher_disagreement_score":0.74941766,"about_ca_system_score_codex":0.018092368,"about_ca_system_score_gemma":0.13631323,"threshold_uncertainty_score":0.9241654},"labels":[],"label_agreement":null},{"id":"W2008823106","doi":"10.1016/s1470-2045(08)70041-x","title":"Trials in palliative treatment—have the goal posts been moved?","year":2008,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Gemcitabine; Oncology; Internal medicine; Pancreatic cancer; Clinical trial; Cancer; Kidney cancer; Renal cell carcinoma; Temsirolimus; Clinical endpoint; Cabozantinib; Cosmesis; Quality of life (healthcare); Surgery; Discovery and development of mTOR inhibitors","score_opus":0.2596304731499695,"score_gpt":0.46816843483746245,"score_spread":0.20853796168749295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008823106","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008147887,0.0038327063,0.00009286102,0.9834456,0.011744729,0.000009243201,0.000025862306,0.000009589316,0.00075797824],"genre_scores_gemma":[0.0016864523,0.0019613386,0.00032992032,0.95786774,0.037161615,0.000045537792,0.000022989829,0.000018024215,0.0009064079],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.95060045,0.030577907,0.0056612645,0.0033726755,0.007573745,0.0022139142],"domain_scores_gemma":[0.7716631,0.17740431,0.010143686,0.005171509,0.014855358,0.020761993],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.067941405,0.001675368,0.006157239,0.0013379692,0.0053585847,0.011383733,0.0063567148,0.097032994,0.01447369],"category_scores_gemma":[0.19494383,0.0015964258,0.0032288083,0.002177013,0.015796693,0.022291346,0.006200017,0.086250916,0.0088281],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048318127,0.00006543714,0.00046064565,0.00056390814,0.00014447357,0.0004721984,0.00015680243,0.0001518799,0.00016351276,0.0139604565,0.96336395,0.02001362],"study_design_scores_gemma":[0.0020762638,0.00027764725,0.00067784917,0.0021461847,0.00018194006,0.00061583286,0.0005037806,0.00058584404,0.00020463504,0.083348915,0.9092265,0.00015462359],"about_ca_topic_score_codex":0.0033285047,"about_ca_topic_score_gemma":0.007363305,"teacher_disagreement_score":0.9320586,"about_ca_system_score_codex":0.010320834,"about_ca_system_score_gemma":0.010766549,"threshold_uncertainty_score":0.35931277},"labels":[],"label_agreement":null},{"id":"W2009643025","doi":"10.1016/s1470-2045(08)70224-9","title":"Cancer inquiry unveils Canada's troubled health system","year":2008,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Commission; Breast cancer; Immunohistochemistry; Medicine; Cancer; Gynecology; Pathology; Political science; Internal medicine; Law","score_opus":0.6561342398067538,"score_gpt":0.6042411413789155,"score_spread":0.05189309842783829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009643025","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014737544,0.0035880862,0.00017273444,0.98196125,0.0021004467,0.000015368909,0.000065365566,0.000017228685,0.010605852],"genre_scores_gemma":[0.09475388,0.0052479054,0.0008267018,0.8650486,0.0031355955,0.00007350488,0.00009152081,0.00008673556,0.030735554],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.94652426,0.013444586,0.0013316286,0.0027897481,0.020671237,0.015238489],"domain_scores_gemma":[0.81592673,0.07179583,0.0042308467,0.0045324415,0.03774444,0.0657696],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.040517617,0.00071051397,0.0015855333,0.0026582794,0.034971904,0.029549448,0.005586337,0.038220655,0.011839372],"category_scores_gemma":[0.095788285,0.0010131182,0.001369107,0.003946998,0.054524906,0.0077999677,0.01265726,0.04392481,0.0011483545],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000083974715,0.000036419897,0.0023669293,0.0001733403,0.000062280815,0.0003041385,0.004867311,0.000331514,0.00014817466,0.3398579,0.6335265,0.01824142],"study_design_scores_gemma":[0.00015312502,0.000046395788,0.0036538907,0.0006509299,0.00009044808,0.00013050159,0.008719989,0.00027827546,0.00016084319,0.09981186,0.8861547,0.00014905001],"about_ca_topic_score_codex":0.96670324,"about_ca_topic_score_gemma":0.9806033,"teacher_disagreement_score":0.9594824,"about_ca_system_score_codex":0.17163321,"about_ca_system_score_gemma":0.5892581,"threshold_uncertainty_score":0.9607881},"labels":[],"label_agreement":null},{"id":"W2012710514","doi":"10.1016/s1470-2045(09)70114-7","title":"The Brief Pain Inventory: revealing the effect of cancer pain","year":2009,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; McGill Pain Questionnaire; Cancer pain; Visual analogue scale; Physical therapy; Alternative medicine","score_opus":0.0261271755007328,"score_gpt":0.34406071249484954,"score_spread":0.31793353699411675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012710514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95124376,0.012319502,0.0040340773,0.0016131453,0.00059813424,0.0018528054,0.008237636,0.00014968986,0.019951176],"genre_scores_gemma":[0.9683452,0.008309229,0.010445011,0.0011765617,0.00040014333,0.0018968129,0.004044335,0.000036534588,0.0053461185],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984195,0.0005801414,0.00021290453,0.0000823954,0.0005879492,0.000116996525],"domain_scores_gemma":[0.99634594,0.0015108275,0.0012364575,0.0001246144,0.0004255001,0.0003566932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001762967,0.0006558004,0.0010880583,0.0011536006,0.00032908397,0.0006189142,0.0004710392,0.0004982748,0.0026367125],"category_scores_gemma":[0.006916148,0.00029648238,0.0009789505,0.0010833467,0.00029881872,0.0006234795,0.0006639776,0.0014873799,0.00049229193],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046247966,0.0018635476,0.7671515,0.0015460518,0.0014968893,0.00035491548,0.0011217856,0.0014584565,0.007662213,0.0006160552,0.010333281,0.20177056],"study_design_scores_gemma":[0.00017544498,0.001459692,0.99459946,0.00007692795,0.00017329468,0.00026182018,0.0002481953,0.00060401484,0.0004657878,0.00018675807,0.001709907,0.00003871535],"about_ca_topic_score_codex":0.0039344467,"about_ca_topic_score_gemma":0.008061976,"teacher_disagreement_score":0.0039344467,"about_ca_system_score_codex":0.0005825179,"about_ca_system_score_gemma":0.00073610403,"threshold_uncertainty_score":0.009323597},"labels":[],"label_agreement":null},{"id":"W2013614225","doi":"10.1016/s1470-2045(13)70308-5","title":"Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group","year":2013,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":143,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; London Health Sciences Centre; Ontario Institute for Cancer Research; Queen's University","funders":"American Academy of Clinical Neuropsychology; Breast Cancer Research Foundation","keywords":"Neurocognitive; Quality of life (healthcare); Clinical trial; Medicine; Clinical study design; Reliability (semiconductor); Independence (probability theory); Medical physics; Oncology; Intensive care medicine; Psychology; Physical therapy; Internal medicine; Cognition; Psychiatry; Nursing","score_opus":0.6563948950622244,"score_gpt":0.5635441045459594,"score_spread":0.09285079051626499,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013614225","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005305097,0.9986563,0.00006365703,0.0009091783,0.00011283302,0.000015747195,0.00002628614,0.0000027941062,0.00016026151],"genre_scores_gemma":[0.0011547646,0.9973757,0.00027354152,0.00083854306,0.00019356803,0.000043643056,0.000041934945,0.00000313297,0.0000751378],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99237543,0.0037280961,0.0015849539,0.0004326645,0.0016722283,0.00020659811],"domain_scores_gemma":[0.95646864,0.036723293,0.0032416768,0.00037214012,0.0028440442,0.00035016838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02049389,0.0009116734,0.0057137064,0.0024160163,0.00035224948,0.002714744,0.0018868274,0.002340747,0.0027957747],"category_scores_gemma":[0.037108727,0.0005769325,0.0028091285,0.0036616223,0.0010046024,0.0028267656,0.0013783829,0.0032357897,0.0007077863],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033066992,0.000032416734,0.00027776134,0.09368289,0.0013978925,0.00008726964,0.00012073915,0.0004199713,0.00040858812,0.0030241278,0.031794153,0.8684234],"study_design_scores_gemma":[0.00073531765,0.000736008,0.0040466934,0.17830372,0.007635528,0.0017361178,0.00040119688,0.00062852394,0.0007760923,0.010945272,0.7939251,0.00013048778],"about_ca_topic_score_codex":0.0030364518,"about_ca_topic_score_gemma":0.008086934,"teacher_disagreement_score":0.02049389,"about_ca_system_score_codex":0.0025980226,"about_ca_system_score_gemma":0.005416943,"threshold_uncertainty_score":0.10838336},"labels":[],"label_agreement":null},{"id":"W2013905542","doi":"10.1016/s1470-2045(12)70561-2","title":"The conundrum of clinical trials in adult germ-cell tumours","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Germ cell tumors; Clinical trial; Etoposide; Chemotherapy; Oncology; Testicular cancer; Cancer; Malignancy; Internal medicine; Bleomycin","score_opus":0.22170314846267947,"score_gpt":0.5119216264592878,"score_spread":0.2902184779966084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013905542","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006322035,0.54185045,0.008561794,0.38720483,0.040433448,0.0019216008,0.001517756,0.00016623415,0.01202192],"genre_scores_gemma":[0.20946018,0.26099876,0.037533194,0.40643513,0.0658963,0.010353592,0.001605896,0.0004679714,0.007248923],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.830677,0.13916004,0.01675545,0.0046332604,0.007225785,0.0015485504],"domain_scores_gemma":[0.55321044,0.39256847,0.020331083,0.011591038,0.01484136,0.007457643],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.21109423,0.0013875233,0.013727535,0.0015686181,0.0022041302,0.00786266,0.003561663,0.012191256,0.010319144],"category_scores_gemma":[0.32063657,0.00145553,0.007155654,0.00273533,0.010124484,0.014537642,0.003761529,0.023077328,0.002538042],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.066782475,0.0009163192,0.0038496447,0.06346675,0.0145407645,0.0003731757,0.0011891536,0.0028292963,0.0020828762,0.101434425,0.18569587,0.5568392],"study_design_scores_gemma":[0.097330205,0.013667655,0.0047652572,0.054490615,0.00872861,0.0007084648,0.0008512538,0.0023590375,0.0011127864,0.23398852,0.58164054,0.0003570861],"about_ca_topic_score_codex":0.001766505,"about_ca_topic_score_gemma":0.004059222,"teacher_disagreement_score":0.21109423,"about_ca_system_score_codex":0.0051071034,"about_ca_system_score_gemma":0.0076660234,"threshold_uncertainty_score":0.9728613},"labels":[],"label_agreement":null},{"id":"W2014633297","doi":"10.1016/s1470-2045(14)70203-7","title":"VeriStrat validated in patients with non-small-cell lung cancer","year":2014,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Gefitinib; Medicine; Oncology; Internal medicine; Lung cancer; Clinical Oncology; Chemotherapy; Targeted therapy; Tyrosine-kinase inhibitor; Cancer; Epidermal growth factor receptor; Cancer research","score_opus":0.021411344125403336,"score_gpt":0.33752057463548435,"score_spread":0.316109230510081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014633297","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.020589573,0.007865693,0.0005158778,0.9348288,0.016186593,0.00003236133,0.0011466214,0.0001351824,0.018699167],"genre_scores_gemma":[0.21908572,0.004678889,0.0016873325,0.7296237,0.031134536,0.00008747795,0.0012509297,0.000086191656,0.012365252],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9980422,0.000532724,0.00022393563,0.00027944878,0.0005586082,0.00036301385],"domain_scores_gemma":[0.9933143,0.0045424225,0.00038893305,0.0002682148,0.0008592659,0.0006267828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015858081,0.00038477726,0.001068406,0.0005226937,0.0011301737,0.0019174836,0.00085574127,0.01187062,0.0039620968],"category_scores_gemma":[0.01880014,0.00032948455,0.0007221761,0.0007435983,0.0010015911,0.0013395746,0.00048604034,0.008677524,0.0018765285],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009997793,0.00016134174,0.089983284,0.0002710643,0.000171147,0.015055634,0.00025657046,0.0007891554,0.0033650743,0.005777578,0.76982534,0.11334394],"study_design_scores_gemma":[0.0019744285,0.001859655,0.083448716,0.0023432008,0.001111113,0.048125762,0.0013935661,0.010586346,0.012560696,0.04189007,0.7944498,0.00025661735],"about_ca_topic_score_codex":0.0054746876,"about_ca_topic_score_gemma":0.009343638,"teacher_disagreement_score":0.01187062,"about_ca_system_score_codex":0.002453279,"about_ca_system_score_gemma":0.0016222247,"threshold_uncertainty_score":0.017799914},"labels":[],"label_agreement":null},{"id":"W2016863751","doi":"10.1016/s1470-2045(14)71185-4","title":"Skeletal muscle anabolism in patients with advanced cancer","year":2014,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Wasting; Cachexia; Myostatin; Sarcopenia; Cancer; Skeletal muscle; Adipose tissue; Weight loss; Internal medicine; Population; Anabolism; Oncology; Obesity","score_opus":0.041392163077914546,"score_gpt":0.3623387152181815,"score_spread":0.32094655214026696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016863751","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019943456,0.0054578064,0.00006723715,0.97530466,0.012647488,0.000010629081,0.00007526642,0.00001899012,0.0044236802],"genre_scores_gemma":[0.028212553,0.007595395,0.00026441968,0.85160714,0.10651571,0.00005412214,0.00012678879,0.000018507404,0.0056054387],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99904424,0.0002986417,0.00014362943,0.000089486115,0.00025284,0.00017115254],"domain_scores_gemma":[0.9965522,0.0016773667,0.00036084067,0.000083713625,0.000517416,0.00080857665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010552403,0.00038361383,0.001195819,0.0006283092,0.0018898075,0.0015060747,0.00066376565,0.017786952,0.005516903],"category_scores_gemma":[0.015022176,0.0003969182,0.00092261564,0.000847884,0.0013878755,0.0013066118,0.00097482227,0.016809966,0.0023516326],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029708314,0.00010252048,0.0127162365,0.00021260651,0.000071411014,0.0048504598,0.00012683733,0.00012226572,0.0003208763,0.0016898812,0.92657185,0.052917987],"study_design_scores_gemma":[0.001740167,0.0009856541,0.040929325,0.0024248164,0.00052530726,0.027641732,0.001103576,0.0015900688,0.0006959038,0.020358525,0.90186226,0.00014266068],"about_ca_topic_score_codex":0.005340246,"about_ca_topic_score_gemma":0.012694504,"teacher_disagreement_score":0.017786952,"about_ca_system_score_codex":0.002565369,"about_ca_system_score_gemma":0.0027964343,"threshold_uncertainty_score":0.01861316},"labels":[],"label_agreement":null},{"id":"W2017402841","doi":"10.1016/s1470-2045(10)70021-8","title":"Male hypogonadism associated with advanced cancer: a systematic review","year":2010,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Hormonal and reproductive studies","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Concordia University; McGill University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Cachexia; Wasting; Androgen deficiency; Testosterone (patch); Cancer; Sarcopenia; Internal medicine; Epidemiology; Androgen deprivation therapy; Androgen; Quality of life (healthcare); Oncology; Prostate cancer; Endocrinology; Hormone","score_opus":0.08823081872278844,"score_gpt":0.4098366423465363,"score_spread":0.32160582362374784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017402841","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007051206,0.9987986,0.000036068534,0.000094743424,0.00006881604,0.00004905942,0.0001552029,0.0000028570391,0.00008943271],"genre_scores_gemma":[0.017564394,0.9815482,0.00020823073,0.00038816477,0.00006497661,0.00007050541,0.00007788802,0.0000025765075,0.00007511198],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9980215,0.00068467547,0.0006513884,0.00024947498,0.00029969277,0.00009331228],"domain_scores_gemma":[0.990375,0.0065797125,0.0022892682,0.00013541518,0.0004652135,0.00015551997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032169183,0.0011420969,0.007238672,0.004251639,0.0003531806,0.001602745,0.0011452433,0.0016299954,0.0054971287],"category_scores_gemma":[0.014760832,0.0010587409,0.006067843,0.006579812,0.00065371057,0.0012351378,0.0012675184,0.0011665074,0.00024477227],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005138608,0.000025276642,0.0023017381,0.916032,0.041702874,0.0001649691,0.00011937103,0.0001430874,0.00014046511,0.00013319544,0.00234803,0.036375172],"study_design_scores_gemma":[0.0014909334,0.00052603445,0.018251816,0.44324225,0.5074376,0.0009597278,0.00042117844,0.00013481006,0.0002185293,0.000412271,0.026812792,0.00009206601],"about_ca_topic_score_codex":0.011189136,"about_ca_topic_score_gemma":0.03889541,"teacher_disagreement_score":0.011189136,"about_ca_system_score_codex":0.0018063413,"about_ca_system_score_gemma":0.004374976,"threshold_uncertainty_score":0.02224803},"labels":[],"label_agreement":null},{"id":"W2018508414","doi":"10.1016/s1470-2045(11)70265-0","title":"Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":195,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pyrogenesis (Canada); Royal Victoria Hospital; Princess Margaret Cancer Centre","funders":"National Center for Research Resources; National Institutes of Health; National Cancer Institute; Celgene","keywords":"Medicine; Internal medicine; Adverse effect; Neutropenia; Cohort; Population; Lymphoma; Refractory (planetary science); Surgery; Gastroenterology; Toxicity","score_opus":0.21118876763172023,"score_gpt":0.4264847079896755,"score_spread":0.2152959403579553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018508414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881813,0.0056649055,0.0006304225,0.00088919594,0.00037955472,0.0011558249,0.0010463604,0.00016632664,0.0018860595],"genre_scores_gemma":[0.98586607,0.004319644,0.0014588924,0.0014127474,0.00023517938,0.0014498334,0.0014746942,0.00003443352,0.0037484325],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997341,0.00011216784,0.000010032797,0.000045966335,0.00002006218,0.00007767758],"domain_scores_gemma":[0.9995353,0.000107319174,0.000058631955,0.0000423472,0.000019370886,0.0002370196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010619067,0.0015475573,0.0029022484,0.00036335707,0.00030545288,0.0009586324,0.0007594111,0.0011834556,0.0049182475],"category_scores_gemma":[0.00074525946,0.0005004701,0.0012507365,0.0003964325,0.0009953011,0.001211322,0.00030111198,0.0028962812,0.0009793418],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90978736,0.007534442,0.001510152,0.0009186737,0.0014790876,0.00014774347,0.000121984245,0.0012784839,0.0069353203,0.00031252424,0.002548162,0.067426056],"study_design_scores_gemma":[0.9279597,0.065929405,0.0028528534,0.000039924667,0.0003667775,0.00012361063,0.000044389923,0.0006406646,0.0005365884,0.0003396093,0.0011455929,0.000020779202],"about_ca_topic_score_codex":0.000837512,"about_ca_topic_score_gemma":0.0032678607,"teacher_disagreement_score":0.0049182475,"about_ca_system_score_codex":0.0007559716,"about_ca_system_score_gemma":0.00082431285,"threshold_uncertainty_score":0.016453207},"labels":[],"label_agreement":null},{"id":"W2018625819","doi":"10.1016/s1470-2045(02)00903-8","title":"Antisense therapy for cancer—the time of truth","year":2002,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"DNA and Nucleic Acid Chemistry","field":"Biochemistry, Genetics and Molecular Biology","cited_by":168,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital","funders":"Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; National Foundation for Cancer Research","keywords":"Oligonucleotide; Antisense therapy; Computational biology; Gene; Genetic enhancement; Biology; Functional genomics; RNA; DNA; Chemistry; Cancer research; Genomics; Genome; Genetics; Locked nucleic acid","score_opus":0.06778498299737551,"score_gpt":0.37312699938485633,"score_spread":0.3053420163874808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018625819","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000476974,0.99361694,0.00018977556,0.0032196546,0.0019023573,0.000002035614,0.000005107849,0.0000072127013,0.0010092288],"genre_scores_gemma":[0.0010992714,0.9897522,0.00038631415,0.004671881,0.0021656677,0.000008582904,0.000012543015,0.0000044740264,0.0018991344],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994537,0.00016275154,0.00004512664,0.00006894982,0.00022593746,0.000043566888],"domain_scores_gemma":[0.9988759,0.0007522184,0.000065503744,0.000031622872,0.00019131164,0.00008332844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025243845,0.0013170632,0.0021367671,0.0014524838,0.0006315151,0.0020390423,0.0011989898,0.0038014306,0.0028947764],"category_scores_gemma":[0.002157268,0.00036487344,0.0004385773,0.0016397951,0.0025331865,0.0035831786,0.000990916,0.0063797543,0.001998437],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025125113,0.000100940146,0.00014156672,0.0041025598,0.00007184708,0.0003460997,0.0001960992,0.00048131077,0.0021637876,0.032906998,0.2265731,0.7326645],"study_design_scores_gemma":[0.000040445768,0.000054469394,0.00011153587,0.00088481343,0.000019865307,0.00042190598,0.00008143742,0.00005798016,0.00018066217,0.007020747,0.99111485,0.000011208324],"about_ca_topic_score_codex":0.0014960719,"about_ca_topic_score_gemma":0.0037942918,"teacher_disagreement_score":0.0038014306,"about_ca_system_score_codex":0.0015278194,"about_ca_system_score_gemma":0.0014761968,"threshold_uncertainty_score":0.013350427},"labels":[],"label_agreement":null},{"id":"W2018748803","doi":"10.1016/s1470-2045(12)70221-8","title":"Canadian cuts overshadow good news on cancer statistics","year":2012,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer; Colorectal cancer; Prostate cancer; Breast cancer; Lung cancer; Demography; Gerontology; Oncology; Internal medicine","score_opus":0.1593767799649948,"score_gpt":0.4008904376809729,"score_spread":0.24151365771597808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018748803","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010874633,0.001584048,0.000031958836,0.97031254,0.025424683,0.000009853402,0.00016320181,0.00003050403,0.0023344173],"genre_scores_gemma":[0.0013868465,0.0011034936,0.0000966927,0.96874267,0.017499821,0.000017284687,0.00007737193,0.000045006305,0.011030875],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98156977,0.0023274468,0.0014822622,0.0011738739,0.009520688,0.0039259414],"domain_scores_gemma":[0.9541895,0.013643452,0.002139934,0.0009429,0.015063734,0.014020592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011368599,0.0019839667,0.002306796,0.0031528207,0.015436663,0.010311341,0.0040836865,0.09559798,0.02615715],"category_scores_gemma":[0.07027724,0.0019871811,0.003638966,0.004045869,0.007987492,0.005360977,0.005036011,0.08136747,0.008642883],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017195507,0.000004273856,0.00010174578,0.000031333766,0.000009211188,0.0000722524,0.00004659639,0.000016623204,0.000017712597,0.00086648617,0.99682,0.0019966897],"study_design_scores_gemma":[0.00013465699,0.000023693437,0.0016034497,0.00035149782,0.00005938391,0.00013175335,0.00039201212,0.00011974494,0.000077180615,0.0028576583,0.9941664,0.000082422725],"about_ca_topic_score_codex":0.7561552,"about_ca_topic_score_gemma":0.8697673,"teacher_disagreement_score":0.2438448,"about_ca_system_score_codex":0.06183582,"about_ca_system_score_gemma":0.097961396,"threshold_uncertainty_score":0.49056166},"labels":[],"label_agreement":null},{"id":"W2022412505","doi":"10.1016/s1470-2045(11)70008-0","title":"Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Spinal Fractures and Fixation Techniques","field":"Medicine","cited_by":521,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Randomized controlled trial; Clinical endpoint; Surgery; Vertebral compression fracture; Balloon; Percutaneous","score_opus":0.02882977539405042,"score_gpt":0.33857593388888635,"score_spread":0.30974615849483594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022412505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9670553,0.018581528,0.0011727248,0.0015054673,0.002821041,0.0056944927,0.001189755,0.0001543906,0.0018253127],"genre_scores_gemma":[0.9837462,0.005348504,0.0014254965,0.0010902355,0.0011454269,0.004240328,0.0005544062,0.000021147638,0.002428312],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982218,0.0009298665,0.0001691525,0.00031239333,0.00012234479,0.00024449284],"domain_scores_gemma":[0.9978097,0.0009505365,0.00053040363,0.00017400115,0.00011752439,0.0004178125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002407251,0.0024524643,0.00661512,0.0006737213,0.0008437897,0.0017659435,0.0017101575,0.0038618206,0.009196531],"category_scores_gemma":[0.0051214886,0.0013177866,0.0045951284,0.00092222105,0.0021222825,0.0016306536,0.00094859645,0.0043215603,0.0011211401],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9930298,0.0012530512,0.00022482163,0.0008875313,0.0012784523,0.000020888609,0.00003348671,0.000088393084,0.00028449213,0.000042162035,0.0002040273,0.0026528803],"study_design_scores_gemma":[0.98394024,0.014204888,0.00064605306,0.000053114167,0.00077376416,0.000013069398,0.00001782568,0.0001184426,0.000045018165,0.000064134605,0.00011415178,0.000009247506],"about_ca_topic_score_codex":0.0034244042,"about_ca_topic_score_gemma":0.0047435495,"teacher_disagreement_score":0.009196531,"about_ca_system_score_codex":0.0013693157,"about_ca_system_score_gemma":0.001458595,"threshold_uncertainty_score":0.030765414},"labels":[],"label_agreement":null},{"id":"W2024903800","doi":"10.1016/s1470-2045(13)70383-8","title":"Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":226,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Trastuzumab; Medicine; Clinical endpoint; Breast cancer; Internal medicine; Population; Surgery; Oncology; Clinical trial; Cancer","score_opus":0.11089225089377973,"score_gpt":0.41324273047037563,"score_spread":0.3023504795765959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024903800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98987204,0.0025997988,0.0010327556,0.0005287073,0.0007452136,0.0025241792,0.00076232443,0.00006713687,0.001867988],"genre_scores_gemma":[0.9926318,0.0012255267,0.0010367789,0.00067359593,0.0005382432,0.0017169195,0.000435056,0.000020186315,0.00172197],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979176,0.0012656789,0.00013545736,0.00031848773,0.000114606286,0.00024817552],"domain_scores_gemma":[0.9967957,0.0017068097,0.0005475562,0.00030336785,0.00010691495,0.00053962006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026598233,0.0019248748,0.0039978814,0.00040950323,0.00044961987,0.0013220657,0.0010179641,0.002410488,0.013324238],"category_scores_gemma":[0.00397851,0.0010420182,0.0031741625,0.0005573138,0.0021013562,0.002009904,0.00071234856,0.004056325,0.0015722727],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.99081403,0.0026198141,0.00026243427,0.00021544578,0.0002863348,0.000016356546,0.00003070487,0.000118063326,0.0005112535,0.00005812192,0.00014490924,0.0049226005],"study_design_scores_gemma":[0.91384566,0.08357419,0.0009955157,0.00002920196,0.00044782038,0.000018309218,0.000030340805,0.00037156077,0.00015245342,0.00019511086,0.00031655488,0.00002328463],"about_ca_topic_score_codex":0.000899806,"about_ca_topic_score_gemma":0.0012121635,"teacher_disagreement_score":0.013324238,"about_ca_system_score_codex":0.0010280135,"about_ca_system_score_gemma":0.00094568846,"threshold_uncertainty_score":0.044574022},"labels":[],"label_agreement":null},{"id":"W2026650308","doi":"10.1016/s1470-2045(03)00984-7","title":"A model for decision making for the use of radiotherapy in lung cancer","year":2003,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cancer Care Ontario","keywords":"Radiation therapy; Lung cancer; Medicine; Medical physics; Radiation treatment planning; Cancer; Intensive care medicine; Oncology; Internal medicine","score_opus":0.30230056246561,"score_gpt":0.5166585408664045,"score_spread":0.2143579784007945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026650308","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0058178846,0.493233,0.40969747,0.052048627,0.0018848095,0.00041805816,0.0014668631,0.00028882994,0.035144445],"genre_scores_gemma":[0.21673867,0.51690483,0.24544372,0.008199392,0.0015928949,0.0012837056,0.0010534006,0.00006316095,0.008720215],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9958488,0.0028065944,0.00025680175,0.00030665868,0.00063028827,0.00015094738],"domain_scores_gemma":[0.9887061,0.010091627,0.0005019583,0.00011871963,0.0004561478,0.00012538026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0063822456,0.0022112348,0.0031974777,0.002343266,0.000722374,0.004225606,0.004047393,0.0047876816,0.00593576],"category_scores_gemma":[0.013870071,0.00073568814,0.002561038,0.0030377123,0.0022130453,0.0036977825,0.0011787051,0.0042824703,0.0014398017],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002610476,0.00020286454,0.0014229472,0.007593013,0.0012250531,0.00067012873,0.0004068525,0.2635707,0.00024995612,0.40946913,0.023604034,0.29132432],"study_design_scores_gemma":[0.00018580373,0.00016209258,0.0006858966,0.0052543622,0.0006985029,0.00080719544,0.00023239669,0.097272135,0.00020286438,0.79791665,0.096460685,0.000121442376],"about_ca_topic_score_codex":0.0130194,"about_ca_topic_score_gemma":0.015355763,"teacher_disagreement_score":0.0130194,"about_ca_system_score_codex":0.0064163636,"about_ca_system_score_gemma":0.0066336584,"threshold_uncertainty_score":0.046554208},"labels":[],"label_agreement":null},{"id":"W2029032030","doi":"10.1016/s1470-2045(14)71198-2","title":"Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":162,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Juravinski Cancer Centre; Hôtel-Dieu de Québec; Centre hospitalier universitaire de Québec","funders":"Amgen","keywords":"Medicine; Panitumumab; Chemoradiotherapy; Internal medicine; Clinical endpoint; Head and neck squamous-cell carcinoma; Oncology; Cetuximab; Mucositis; Head and neck cancer; Radiation therapy; Surgery; Clinical trial; Cancer; Colorectal cancer","score_opus":0.07095194315395562,"score_gpt":0.3716621512149996,"score_spread":0.300710208061044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029032030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98552346,0.0077096224,0.00038546012,0.0007513614,0.0007966817,0.0017921134,0.0008255837,0.00012287068,0.002092919],"genre_scores_gemma":[0.9844824,0.005521739,0.0008797024,0.0011232032,0.0004415961,0.0019583483,0.0012866661,0.000029933579,0.004276496],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99954885,0.00020031957,0.000025066765,0.0001110195,0.000028819302,0.000085898675],"domain_scores_gemma":[0.99947995,0.00013271587,0.00011326604,0.000057765512,0.000031033265,0.00018526173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013123408,0.0020320457,0.0031500629,0.0004262877,0.0004392446,0.0010450338,0.001093882,0.0018289152,0.0069192667],"category_scores_gemma":[0.0012757666,0.00075744744,0.002852639,0.000512624,0.0013394289,0.0012461375,0.0004482705,0.0037584978,0.0012261915],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9692755,0.0054632234,0.0007212525,0.0011590804,0.0016756393,0.000043997105,0.000097072385,0.0005589981,0.002709813,0.000120964636,0.0010929318,0.017081559],"study_design_scores_gemma":[0.93908626,0.057274956,0.0017128021,0.0000399917,0.00068372104,0.000031324384,0.00004221175,0.00024000973,0.00026299924,0.00008387621,0.00052782154,0.000014096605],"about_ca_topic_score_codex":0.0023575332,"about_ca_topic_score_gemma":0.0058581,"teacher_disagreement_score":0.0069192667,"about_ca_system_score_codex":0.0010530169,"about_ca_system_score_gemma":0.0010185689,"threshold_uncertainty_score":0.023147225},"labels":[],"label_agreement":null},{"id":"W2029982246","doi":"10.1016/s1470-2045(13)70101-3","title":"Vertebral compression fracture after stereotactic body radiotherapy for spinal metastases","year":2013,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":191,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; Princess Margaret Cancer Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"University of Toronto; Canadian Association of Radiation Oncology","keywords":"Medicine; Vertebral compression fracture; Myelopathy; Radiosurgery; Adverse effect; Spinal cord compression; Vertebral body; Complication; Radiation therapy; Radiology; Spinal fracture; Surgery; Internal medicine; Spinal cord","score_opus":0.1175536820902281,"score_gpt":0.444949903591429,"score_spread":0.3273962215012009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029982246","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000051895175,0.9994343,0.000024957108,0.000109144436,0.00008784466,0.0000017735567,0.000008723019,0.0000019028174,0.0002794977],"genre_scores_gemma":[0.00080200343,0.99849284,0.00007245142,0.0002167121,0.00016498982,0.00000261157,0.000018494828,9.562657e-7,0.0002288829],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99973565,0.00004107185,0.00004328155,0.00004232912,0.000116941344,0.00002075052],"domain_scores_gemma":[0.9994923,0.00028342215,0.00010414683,0.0000074055797,0.00009267942,0.000020057747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005800956,0.0007297154,0.0018702192,0.0022318761,0.00024000519,0.0008877233,0.0010682838,0.0012151946,0.0036758294],"category_scores_gemma":[0.0015022262,0.00030305283,0.00074494595,0.0022168485,0.00053853664,0.0006792348,0.00049972365,0.0012725203,0.00091477536],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009949025,0.000035482157,0.00025705545,0.035328757,0.0003064238,0.0002613825,0.000036338766,0.00030109854,0.0005086893,0.0009528611,0.029719722,0.9321927],"study_design_scores_gemma":[0.00021473228,0.00029991136,0.0046302024,0.034308344,0.0016150463,0.006820629,0.00018449957,0.00024208431,0.0005008751,0.0024819747,0.9486328,0.00006886583],"about_ca_topic_score_codex":0.0048479764,"about_ca_topic_score_gemma":0.011932988,"teacher_disagreement_score":0.0048479764,"about_ca_system_score_codex":0.00077579793,"about_ca_system_score_gemma":0.0012831385,"threshold_uncertainty_score":0.012296855},"labels":[],"label_agreement":null},{"id":"W2031320118","doi":"10.1016/s1470-2045(14)71113-1","title":"RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":270,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"National Institute of General Medical Sciences; National Cancer Institute; National Institutes of Health; Prostate Cancer Foundation; Doris Duke Charitable Foundation; Howard Hughes Medical Institute; U.S. Department of Defense","keywords":"Prostate cancer; Oncology; Prostatectomy; Medicine; Cohort; Internal medicine; Tumor progression; Multivariate analysis; Prostate-specific antigen; Cancer","score_opus":0.02743596481291197,"score_gpt":0.35465089479141604,"score_spread":0.32721492997850404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031320118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99149656,0.0013557327,0.0016179938,0.0002959079,0.000023627896,0.00003887817,0.0044493177,0.0000933486,0.0006285615],"genre_scores_gemma":[0.9902126,0.00066075166,0.0026694578,0.00033929254,0.00003774086,0.000061148734,0.0049678413,0.00005278872,0.0009983156],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99955386,0.000067577865,0.000021305688,0.00015212708,0.0001153529,0.000089690715],"domain_scores_gemma":[0.9993765,0.00016695465,0.00017365935,0.000093117116,0.00010344427,0.000086338165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006377423,0.000370929,0.00050799066,0.00080329477,0.00048911246,0.0012084927,0.00044709523,0.00057350815,0.0014538912],"category_scores_gemma":[0.00094923703,0.0003319862,0.00049868535,0.0010350321,0.00040739946,0.00037696783,0.00065131724,0.0008539806,0.0004575632],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002695913,0.00055066874,0.56540227,0.00045322784,0.001886061,0.00057212723,0.00048947934,0.0029358384,0.35657448,0.00054834347,0.005865361,0.062026255],"study_design_scores_gemma":[0.0001208611,0.00087520847,0.9246281,0.000051593124,0.0013691896,0.001769665,0.00075589604,0.004914815,0.05707489,0.0007794145,0.0075619384,0.00009843194],"about_ca_topic_score_codex":0.0017834175,"about_ca_topic_score_gemma":0.0046178014,"teacher_disagreement_score":0.0017834175,"about_ca_system_score_codex":0.00044400964,"about_ca_system_score_gemma":0.00050286803,"threshold_uncertainty_score":0.0048636794},"labels":[],"label_agreement":null},{"id":"W2031365500","doi":"10.1016/s1470-2045(15)70002-1","title":"Putting palliative care on the global health agenda","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Hospice Palliative Care Association","funders":"","keywords":"Palliative care; Nursing; Political science; Medicine","score_opus":0.7447579008297739,"score_gpt":0.5591897808951655,"score_spread":0.18556811993460842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031365500","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006709787,0.0409492,0.0008998253,0.948377,0.0045849923,0.0000075901007,0.00012728864,0.000017126657,0.0043660398],"genre_scores_gemma":[0.13179953,0.19527805,0.0047630267,0.59797746,0.0650631,0.00019901294,0.00049956376,0.00015862747,0.0042616026],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9787089,0.015405901,0.0009280975,0.0005748768,0.0029528118,0.0014293825],"domain_scores_gemma":[0.86754,0.103789344,0.0055885594,0.0033013057,0.01026055,0.009520178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.045890052,0.0012741084,0.0029621401,0.0040067066,0.0017812771,0.013157269,0.002193788,0.021470776,0.016827904],"category_scores_gemma":[0.12338537,0.0007168951,0.0014238621,0.0045189406,0.015965495,0.024765834,0.0108213015,0.026869312,0.001910546],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041207866,0.00020505284,0.002238102,0.0030463727,0.00046925474,0.00028685213,0.0008906355,0.0046655615,0.00024329133,0.4828316,0.34819576,0.15651536],"study_design_scores_gemma":[0.00017324564,0.000106228545,0.0019186845,0.0052050534,0.00012073809,0.00008586061,0.0017303264,0.0008981315,0.00009566465,0.7641877,0.2253965,0.00008184918],"about_ca_topic_score_codex":0.0047264555,"about_ca_topic_score_gemma":0.006190745,"teacher_disagreement_score":0.045890052,"about_ca_system_score_codex":0.008783417,"about_ca_system_score_gemma":0.014914424,"threshold_uncertainty_score":0.24269265},"labels":[],"label_agreement":null},{"id":"W2032391990","doi":"10.1016/s1470-2045(03)01197-5","title":"Autonomic dysreflexia associated with intramedullary astrocytoma of the spinal cord","year":2003,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Spinal Cord Injury Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University Health Network; Toronto Western Hospital; University of Toronto","funders":"Heart and Stroke Foundation of Canada; Christopher and Dana Reeve Foundation","keywords":"Autonomic dysreflexia; Medicine; Spinal cord; Spinal cord injury; Autonomic nervous system; Anesthesia; Internal medicine; Heart rate; Blood pressure","score_opus":0.08996694803334179,"score_gpt":0.4137380897802274,"score_spread":0.3237711417468856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032391990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98315465,0.002146738,0.00084388256,0.0006158511,0.00011368587,0.000043480588,0.00008552308,0.00009148254,0.01290467],"genre_scores_gemma":[0.9989951,0.0003171026,0.00007751001,0.00012369304,0.000094842435,0.0000030646856,0.000021457738,0.0000047806548,0.0003625655],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9998202,0.000027117432,0.000018590461,0.000027500426,0.00003561284,0.00007098505],"domain_scores_gemma":[0.99926,0.00024042497,0.00024400228,0.00006478156,0.000053589196,0.00013716206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013220085,0.00047171995,0.00055897894,0.00087988033,0.0005321737,0.00046294235,0.00041893925,0.00078564946,0.0018732882],"category_scores_gemma":[0.0023434756,0.00022932865,0.0003077472,0.0008505924,0.00086371024,0.00034828036,0.000346994,0.0011071375,0.00032190268],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010884961,0.00015915779,0.16970973,0.00017360266,0.00017273531,0.7924066,0.0002678153,0.0005826538,0.010654685,0.00046755304,0.0011446277,0.023172379],"study_design_scores_gemma":[0.00008152082,0.00048610134,0.40472463,0.00003123682,0.0001526444,0.5906547,0.00022042992,0.00068962405,0.0016304436,0.0005510378,0.00074923487,0.00002836636],"about_ca_topic_score_codex":0.0045829657,"about_ca_topic_score_gemma":0.0048065446,"teacher_disagreement_score":0.0045829657,"about_ca_system_score_codex":0.00064188516,"about_ca_system_score_gemma":0.0004975665,"threshold_uncertainty_score":0.0091125965},"labels":[],"label_agreement":null},{"id":"W2032741873","doi":"10.1016/s1470-2045(00)00139-x","title":"Canadian researchers uncover vital new clues in cancer","year":2000,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Granzyme B; Cytotoxic T cell; Granzyme; Perforin; Programmed cell death; Biology; Immune system; Cancer cell; Receptor; Apoptosis; Cancer; Cancer research; Immunology; Cell biology; T cell; CD8; Biochemistry","score_opus":0.0746943148202789,"score_gpt":0.4036168362799058,"score_spread":0.3289225214596269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032741873","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0039468245,0.11755941,0.00092472305,0.8066229,0.015944347,0.000035018435,0.0012188175,0.0001570079,0.053590935],"genre_scores_gemma":[0.17247328,0.34461927,0.004576343,0.30285713,0.020995673,0.000079519195,0.0012968841,0.0002791228,0.15282269],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966208,0.00053527975,0.0000781812,0.00021624412,0.0015897052,0.0009598114],"domain_scores_gemma":[0.9923528,0.0013775015,0.0003488477,0.00035879275,0.0032963147,0.0022656613],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0059049693,0.00086973445,0.0011325931,0.0031809306,0.0060641402,0.0087365545,0.0015589183,0.006576846,0.022952367],"category_scores_gemma":[0.012800481,0.0005112769,0.00060179894,0.0052560805,0.012340231,0.0053767944,0.003306152,0.009558416,0.0028341447],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002861994,0.000030906118,0.0028349003,0.00044821858,0.000083596744,0.00024797992,0.0017159074,0.0002177257,0.0010046229,0.14888775,0.77629846,0.06794373],"study_design_scores_gemma":[0.00007416116,0.000020388894,0.0017884128,0.00021152354,0.000048990714,0.000058070756,0.0022471633,0.000069078815,0.00033334497,0.043695282,0.9514178,0.0000357926],"about_ca_topic_score_codex":0.78517836,"about_ca_topic_score_gemma":0.8928121,"teacher_disagreement_score":0.21482164,"about_ca_system_score_codex":0.05289929,"about_ca_system_score_gemma":0.077388234,"threshold_uncertainty_score":0.4321735},"labels":[],"label_agreement":null},{"id":"W2033816200","doi":"10.1016/s1470-2045(14)71135-0","title":"Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":544,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Université Laval; Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Olaparib; Medicine; Carboplatin; Tolerability; Internal medicine; Regimen; Ovarian cancer; Chemotherapy; Oncology; Paclitaxel; Response Evaluation Criteria in Solid Tumors; Clinical endpoint; Phases of clinical research; Urology; Cancer; Randomized controlled trial; Cisplatin; Adverse effect","score_opus":0.05582660886094198,"score_gpt":0.39046445905146526,"score_spread":0.3346378501905233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033816200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.968951,0.013628698,0.0013206685,0.0026461221,0.0016944318,0.005184971,0.002715407,0.000235226,0.0036234905],"genre_scores_gemma":[0.9733208,0.0075897407,0.0020598753,0.0027415152,0.0007644061,0.00547319,0.0023514095,0.00006268117,0.005636385],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991542,0.00048345223,0.000045179593,0.00015285722,0.000043658503,0.000120629185],"domain_scores_gemma":[0.9988759,0.00040143306,0.00022040194,0.000112806294,0.000040539064,0.00034895155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018077339,0.0022290344,0.0035807837,0.0004732449,0.00042982795,0.0015525358,0.0009897881,0.0020670532,0.009320953],"category_scores_gemma":[0.0025944295,0.00097555167,0.0025731714,0.0006235606,0.0016814331,0.0016206068,0.00079749484,0.004317354,0.0013770105],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98095244,0.0021254313,0.00038422903,0.0007354862,0.0010103681,0.000045175577,0.000049897008,0.0004041727,0.0009703272,0.00009539831,0.0008562115,0.012370852],"study_design_scores_gemma":[0.9768296,0.021174766,0.00057643873,0.000032842298,0.00038476207,0.00003119622,0.000016871925,0.0001563369,0.00009491893,0.00015409141,0.00053777086,0.000010458328],"about_ca_topic_score_codex":0.0010752621,"about_ca_topic_score_gemma":0.0021027606,"teacher_disagreement_score":0.009320953,"about_ca_system_score_codex":0.0010629831,"about_ca_system_score_gemma":0.0011390531,"threshold_uncertainty_score":0.031181693},"labels":[],"label_agreement":null},{"id":"W20378407","doi":"10.1016/s1470-2045(10)70058-9","title":"Synthèse des portraits socioéconomiques des territoires de CLE de l’île de Montréal : CLE de Rosemont–Petite-Patrie.","year":2009,"lang":"fr","type":"article","venue":"The Lancet Oncology","topic":"French Urban and Social Studies","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Art; Humanities; Political science","score_opus":0.06041559281854616,"score_gpt":0.3113909747832302,"score_spread":0.25097538196468405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W20378407","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1461507,0.49207747,0.008068761,0.06770386,0.004089472,0.00021940222,0.030129787,0.0002936125,0.25126705],"genre_scores_gemma":[0.8277776,0.08896455,0.006949269,0.0024513528,0.0007607992,0.00021770483,0.0057811886,0.00027741317,0.06682013],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9991924,0.00027206514,0.00002993894,0.00010928788,0.00024585015,0.00015053102],"domain_scores_gemma":[0.9976833,0.00093139545,0.00021518861,0.00017324049,0.0008231239,0.0001737435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017798032,0.00054353545,0.0004921155,0.0069603017,0.0034967528,0.0028127506,0.0010706654,0.00069611357,0.019229766],"category_scores_gemma":[0.006244661,0.00034198456,0.00042144532,0.012460422,0.0031555553,0.0016999203,0.0013414411,0.0013251051,0.000648364],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019667928,0.000038434882,0.025942238,0.0019859783,0.00033344515,0.001742118,0.14882262,0.0018766348,0.000979048,0.16575345,0.35779575,0.29453358],"study_design_scores_gemma":[0.0000125981815,0.000012420099,0.11115979,0.0027272569,0.000081107864,0.00028769692,0.031651076,0.00021432407,0.00035066323,0.0043350738,0.8491056,0.00006242202],"about_ca_topic_score_codex":0.93555635,"about_ca_topic_score_gemma":0.97715396,"teacher_disagreement_score":0.06444365,"about_ca_system_score_codex":0.0267504,"about_ca_system_score_gemma":0.018243207,"threshold_uncertainty_score":0.19408864},"labels":[],"label_agreement":null},{"id":"W2038407564","doi":"10.1016/s1470-2045(14)70246-3","title":"Made-to-measure medicine: BRCA and gynaecological cancer","year":2014,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Scopus; Genetic testing; Test (biology); Medicine; Breast cancer; Family medicine; Cancer; Bioinformatics; Library science; MEDLINE; Political science; Biology; Computer science; Internal medicine; Law","score_opus":0.05327035473538556,"score_gpt":0.34340143654642424,"score_spread":0.2901310818110387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038407564","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015868268,0.00196382,0.00004163319,0.9808414,0.015511823,0.000005780931,0.00001463976,0.0000071051895,0.0014550125],"genre_scores_gemma":[0.00260926,0.0018707844,0.000098051256,0.93157506,0.05753938,0.000024758116,0.0000111790205,0.000010081668,0.006261439],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964929,0.0011996995,0.00030444007,0.0004137645,0.0010485027,0.0005407536],"domain_scores_gemma":[0.9908992,0.0055032205,0.00056980416,0.00028005286,0.00078649126,0.0019611747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033226095,0.0012152628,0.0017584565,0.00082259567,0.004984568,0.0044728387,0.0021496825,0.089217596,0.0095036365],"category_scores_gemma":[0.03042925,0.0012813031,0.0014470326,0.0007397943,0.00550877,0.005733665,0.0028520229,0.068078645,0.0043574846],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006266372,0.000045367113,0.00058137835,0.0000619778,0.000024095647,0.0015375882,0.000110671295,0.00006934832,0.0001314743,0.005766324,0.9817005,0.009908531],"study_design_scores_gemma":[0.00028772024,0.00018030436,0.0019273979,0.0006045043,0.000072839124,0.0037093896,0.0005810446,0.00072515965,0.0002701686,0.032300644,0.9592346,0.00010634275],"about_ca_topic_score_codex":0.0064376234,"about_ca_topic_score_gemma":0.012086786,"teacher_disagreement_score":0.089217596,"about_ca_system_score_codex":0.0056306254,"about_ca_system_score_gemma":0.0048095654,"threshold_uncertainty_score":0.040853262},"labels":[],"label_agreement":null},{"id":"W2040267226","doi":"10.1016/s1470-2045(01)00438-7","title":"Stop teaching breast self-examination, say Canadian experts","year":2001,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Breast self-examination; Task force; Harm; Medicine; Suspect; Family medicine; Task (project management); Advice (programming); Modality (human–computer interaction); Medical advice; Psychology; Medical education; Nursing; Breast cancer; Management; Social psychology; Political science; Criminology","score_opus":0.08041438990951585,"score_gpt":0.371436560841335,"score_spread":0.29102217093181915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040267226","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003110813,0.002532469,0.000091922666,0.9764033,0.0167745,0.000014214434,0.00011756101,0.000047194517,0.0037078059],"genre_scores_gemma":[0.0024608863,0.0025401874,0.0004270394,0.9643061,0.011002616,0.000034092915,0.00008613477,0.000033699125,0.019109225],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954922,0.00045890166,0.00032886892,0.00044343126,0.0020241588,0.0012523768],"domain_scores_gemma":[0.9695011,0.0031689852,0.0011226422,0.00049938407,0.013895978,0.011811947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048926966,0.0010000998,0.0012073779,0.0013847201,0.0069974875,0.0037893814,0.0025147675,0.037489887,0.029241534],"category_scores_gemma":[0.028159125,0.0006975739,0.001758227,0.0014623759,0.003337584,0.003846461,0.0015760453,0.030438192,0.011513678],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003939082,0.00003869146,0.0012730418,0.00008147277,0.0000129767,0.000086824395,0.000108497065,0.000023080935,0.00011024906,0.0003811361,0.99041474,0.007429969],"study_design_scores_gemma":[0.00018332232,0.00006462463,0.0057298606,0.00064993714,0.00008895808,0.00024942178,0.0026774586,0.00011186515,0.00012350429,0.0019295597,0.98806375,0.0001277713],"about_ca_topic_score_codex":0.56572986,"about_ca_topic_score_gemma":0.7606363,"teacher_disagreement_score":0.43427014,"about_ca_system_score_codex":0.012520154,"about_ca_system_score_gemma":0.046049673,"threshold_uncertainty_score":0.8736553},"labels":[],"label_agreement":null},{"id":"W2040879959","doi":"10.1016/s1470-2045(05)70304-1","title":"Neuroblastoma screening in Canada","year":2005,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Neuroblastoma; Medicine; Environmental health; Biology; Genetics","score_opus":0.051705001077346234,"score_gpt":0.3386298162075189,"score_spread":0.2869248151301727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040879959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.68443525,0.025830915,0.0006555389,0.13260433,0.0018619404,0.00056995644,0.03750202,0.0002209059,0.116319105],"genre_scores_gemma":[0.92344993,0.013730916,0.0008930022,0.021028461,0.00027309376,0.00013759964,0.005058517,0.0000802777,0.03534813],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980698,0.00010835896,0.000092053524,0.00016223785,0.0005151833,0.001052334],"domain_scores_gemma":[0.9963303,0.0001692145,0.0003069785,0.000040313313,0.0013546569,0.0017983755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005321747,0.00027405305,0.00050742755,0.0017069498,0.003912857,0.0019092407,0.001286621,0.001446655,0.008792372],"category_scores_gemma":[0.0028389532,0.0005130495,0.0007806122,0.00540173,0.0007381144,0.0005055315,0.0013205009,0.002053939,0.000561112],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040942404,0.00022942264,0.7883909,0.00046852007,0.00020796164,0.0032891638,0.0018299324,0.0010936368,0.0007322844,0.0064891316,0.13249858,0.064361036],"study_design_scores_gemma":[0.00018698243,0.00010738102,0.9248583,0.00063779345,0.00020911703,0.0015258034,0.0064971973,0.0011317489,0.00034746123,0.00075874344,0.06365511,0.000084375366],"about_ca_topic_score_codex":0.99802065,"about_ca_topic_score_gemma":0.99916315,"teacher_disagreement_score":0.07810345,"about_ca_system_score_codex":0.07810345,"about_ca_system_score_gemma":0.17163597,"threshold_uncertainty_score":0.5666829},"labels":[],"label_agreement":null},{"id":"W2041265397","doi":"10.1016/s1470-2045(11)70153-x","title":"Effect of dignity therapy on distress and end-of-life experience in terminally ill patients: a randomised controlled trial","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Patient Dignity and Privacy","field":"Medicine","cited_by":769,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Winnipeg Regional Health Authority; University of Manitoba; CancerCare Manitoba","funders":"National Cancer Institute; Canadian Institutes of Health Research; Canada Research Chairs; Memorial Sloan-Kettering Cancer Center","keywords":"Dignity; Palliative care; Medicine; Quality of life (healthcare); Distress; End-of-life care; Hospital Anxiety and Depression Scale; Randomized controlled trial; Anxiety; Psychiatry; Nursing; Clinical psychology","score_opus":0.09930062075559846,"score_gpt":0.37275175737684946,"score_spread":0.273451136621251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041265397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9605828,0.018263737,0.0012575662,0.0024377485,0.002884433,0.009769959,0.0012703674,0.0001271414,0.0034063098],"genre_scores_gemma":[0.9772892,0.0058413385,0.00172956,0.0013867557,0.0009971577,0.009228209,0.0005137038,0.00001701847,0.0029969837],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977428,0.001329636,0.00018420395,0.00036541617,0.00011696674,0.00026107335],"domain_scores_gemma":[0.99641514,0.0017922568,0.0007058336,0.00022996566,0.00013395931,0.00072282495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028051508,0.002346298,0.0053032106,0.00068458286,0.0009994274,0.0017924844,0.0015667045,0.0050067175,0.01323336],"category_scores_gemma":[0.006228,0.0011589874,0.0041204644,0.00080340693,0.0030204856,0.0020215425,0.0010035521,0.0053957775,0.0010214492],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9917286,0.0023810281,0.00021758421,0.0011138307,0.00093820173,0.000027797336,0.000047336613,0.00008816039,0.00025416393,0.00008406141,0.00022183103,0.0028973322],"study_design_scores_gemma":[0.97813696,0.020354642,0.00037692356,0.00007305505,0.0006097151,0.000007755922,0.000023156248,0.000083183375,0.00004771461,0.00010948189,0.00016707166,0.0000104353885],"about_ca_topic_score_codex":0.0022821452,"about_ca_topic_score_gemma":0.0028415287,"teacher_disagreement_score":0.01323336,"about_ca_system_score_codex":0.0016582105,"about_ca_system_score_gemma":0.001631409,"threshold_uncertainty_score":0.04427004},"labels":[],"label_agreement":null},{"id":"W2042528112","doi":"10.1016/s1470-2045(09)70031-2","title":"Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction","year":2009,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":305,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Exercise intolerance; Cancer; Cancer treatment; Exercise therapy; Cancer therapy; Intensive care medicine; Internal medicine; Randomized controlled trial","score_opus":0.03157482436770046,"score_gpt":0.33837824389223403,"score_spread":0.30680341952453355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042528112","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000045802575,0.9987503,0.00007555473,0.00042469415,0.0002539096,0.0000019001285,0.00000802772,0.0000032637042,0.00043657908],"genre_scores_gemma":[0.00039643506,0.99856865,0.000097052245,0.0002492761,0.00029724877,0.0000040081286,0.000012363708,8.451076e-7,0.00037407893],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999819,0.000034641336,0.000020893161,0.00003472704,0.000070295675,0.00002051165],"domain_scores_gemma":[0.9995509,0.0002603576,0.00004789077,0.000012413578,0.00009266602,0.000035667243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007851787,0.0010911303,0.0027701922,0.0014375917,0.00032771454,0.0011958407,0.0012565234,0.002093363,0.00348971],"category_scores_gemma":[0.0008810083,0.00030057968,0.0005943859,0.0020428689,0.00084736873,0.0013089173,0.00079396326,0.0028359366,0.0020525586],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014147014,0.00009929443,0.00022658128,0.006996792,0.000121981524,0.00023377995,0.000031017324,0.00046717262,0.000956947,0.003951161,0.046027075,0.9407468],"study_design_scores_gemma":[0.000081638165,0.00013646223,0.0015131369,0.002816201,0.00015160191,0.0013136691,0.00008409623,0.00015459761,0.00030043098,0.00436068,0.9890569,0.000030590025],"about_ca_topic_score_codex":0.0018541391,"about_ca_topic_score_gemma":0.0036912619,"teacher_disagreement_score":0.00348971,"about_ca_system_score_codex":0.0008592223,"about_ca_system_score_gemma":0.0009320314,"threshold_uncertainty_score":0.011674225},"labels":[],"label_agreement":null},{"id":"W2042844054","doi":"10.1016/s1470-2045(15)70157-9","title":"Targeting the microenvironment in ovarian cancer","year":2015,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ovarian cancer; Cancer; Tumor microenvironment; Cancer research; Oncology; Medicine; Biology; Computational biology; Internal medicine","score_opus":0.059247390125151386,"score_gpt":0.3343081014540412,"score_spread":0.2750607113288898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042844054","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022161889,0.0039347974,0.00006397103,0.9750494,0.018994456,0.0000081058315,0.000026210277,0.00001202427,0.0016894505],"genre_scores_gemma":[0.0048164474,0.004307978,0.00014967867,0.908172,0.07760584,0.000031980868,0.000020722928,0.000011704715,0.0048836414],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972548,0.0011054736,0.00026048342,0.00020989618,0.00083843624,0.00033093122],"domain_scores_gemma":[0.99369437,0.0040307287,0.0004592149,0.00014065525,0.0007202334,0.0009547027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029020084,0.0006718737,0.0014036489,0.0005882296,0.0022344794,0.0032085716,0.0011790178,0.03543379,0.004843768],"category_scores_gemma":[0.01994013,0.0006055185,0.0011145528,0.00038599607,0.0025065849,0.003250912,0.0021528485,0.03280082,0.0033354736],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000108639266,0.000059113307,0.0005555388,0.00011486385,0.00002292545,0.0009506891,0.00008773519,0.00010728289,0.0002249929,0.003567339,0.9722096,0.021991372],"study_design_scores_gemma":[0.00033371465,0.00018279813,0.0010025997,0.000537657,0.00006235761,0.0011948058,0.00027516537,0.000695291,0.0003360364,0.015494729,0.97982633,0.000058363417],"about_ca_topic_score_codex":0.0028242818,"about_ca_topic_score_gemma":0.0062568793,"teacher_disagreement_score":0.03543379,"about_ca_system_score_codex":0.003452229,"about_ca_system_score_gemma":0.00311813,"threshold_uncertainty_score":0.02504778},"labels":[],"label_agreement":null},{"id":"W2043541016","doi":"10.1016/s1470-2045(11)70222-4","title":"The tubal hypothesis of ovarian cancer: caution needed","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Ovarian cancer; Medicine; Breast cancer; Oncology; Gynecology; Germline mutation; Internal medicine; Hazard ratio; Ovarian carcinoma; Cancer; BRCA mutation; Family history; Mutation; Obstetrics; Genetics; Biology; Gene; Confidence interval","score_opus":0.06706038960577423,"score_gpt":0.3148672844619313,"score_spread":0.24780689485615706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043541016","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014584528,0.052684665,0.0049132663,0.9005192,0.033389818,0.00003107223,0.00013342281,0.00011194472,0.006758184],"genre_scores_gemma":[0.047642034,0.04187836,0.008617562,0.7373242,0.1558137,0.00013410002,0.00009259305,0.00015721511,0.008340193],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9941602,0.0027495397,0.0007668523,0.0007848131,0.0013373311,0.00020125607],"domain_scores_gemma":[0.96403193,0.025088307,0.0013562776,0.0034646017,0.0046110596,0.0014477387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.022314142,0.00096890365,0.0038001502,0.0019502094,0.0021196837,0.0042228145,0.006644181,0.017245857,0.004093799],"category_scores_gemma":[0.066517256,0.0006460869,0.0015145937,0.00089927803,0.016963977,0.01015119,0.0033847431,0.04676059,0.0038715987],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007405039,0.00012432558,0.0042273114,0.001927786,0.0008679436,0.0046779895,0.0023292082,0.0006191678,0.00088846864,0.19673435,0.70086116,0.086001724],"study_design_scores_gemma":[0.00041303042,0.0001145795,0.0023442272,0.0021072377,0.00026751639,0.0042477953,0.0021236534,0.0013494837,0.0004397772,0.5559653,0.43039736,0.00023002826],"about_ca_topic_score_codex":0.005077213,"about_ca_topic_score_gemma":0.0059666233,"teacher_disagreement_score":0.022314142,"about_ca_system_score_codex":0.0018119169,"about_ca_system_score_gemma":0.0029540956,"threshold_uncertainty_score":0.118009865},"labels":[],"label_agreement":null},{"id":"W2044083199","doi":"10.1016/s1470-2045(12)70013-x","title":"Don't pick the loser: lessons from the GeparQuinto trial","year":2012,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Taxane; Trastuzumab; Medicine; Lapatinib; Anthracycline; Oncology; Internal medicine; Epirubicin; Breast cancer; Docetaxel; Regimen; Chemotherapy; Cancer","score_opus":0.253008395605485,"score_gpt":0.4743445344544751,"score_spread":0.22133613884899012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044083199","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00051255635,0.005063939,0.000087044005,0.98548895,0.0058998787,0.0000055656515,0.00009509946,0.000018463566,0.002828588],"genre_scores_gemma":[0.0053825937,0.0026418425,0.00017836374,0.9670282,0.0222916,0.000026814296,0.000048880567,0.00003937257,0.002362207],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99134094,0.0045416523,0.0004899017,0.0007898267,0.0018855081,0.00095226767],"domain_scores_gemma":[0.9677844,0.02360709,0.0013636053,0.00079801097,0.0017437278,0.0047032074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014094451,0.0008941776,0.002455975,0.00055392843,0.0028398419,0.005291401,0.0027218706,0.049273107,0.0111227],"category_scores_gemma":[0.054657906,0.0005548034,0.0016271732,0.0008802049,0.004214437,0.0056715184,0.002494539,0.043905117,0.006522017],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007226285,0.00006323713,0.00069186446,0.00015951073,0.000109554545,0.0007649545,0.000114820505,0.00014938686,0.00021488579,0.0077659846,0.9527448,0.03649842],"study_design_scores_gemma":[0.003309497,0.0004470926,0.0020543667,0.0012706963,0.000283452,0.0014210443,0.00039986696,0.00064298895,0.0004556256,0.060008485,0.9295627,0.00014416747],"about_ca_topic_score_codex":0.004068155,"about_ca_topic_score_gemma":0.009738334,"teacher_disagreement_score":0.049273107,"about_ca_system_score_codex":0.0040450566,"about_ca_system_score_gemma":0.0046373163,"threshold_uncertainty_score":0.07453948},"labels":[],"label_agreement":null},{"id":"W2044168781","doi":"10.1016/s1470-2045(13)70019-6","title":"IGF-1R inhibition: right direction, wrong pathway?","year":2013,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Breast cancer; Medicine; Cancer research; Fulvestrant; Tamoxifen; Cancer; Internal medicine; Oncology","score_opus":0.03881329493364188,"score_gpt":0.28422666119629947,"score_spread":0.24541336626265758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044168781","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009805312,0.0038198442,0.00006502249,0.98723084,0.007515556,0.0000032816392,0.000023257517,0.000011785875,0.0012322895],"genre_scores_gemma":[0.003237971,0.0050609177,0.00027222553,0.9531306,0.035565905,0.000023563254,0.000021830347,0.000018426526,0.0026686527],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958423,0.001717835,0.000399009,0.00040889648,0.0011272915,0.00050462084],"domain_scores_gemma":[0.9922841,0.0050464356,0.0004038074,0.00016358623,0.0009834531,0.0011185547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043489616,0.00094551593,0.0019728267,0.0006843917,0.0021825545,0.0037878049,0.0019136482,0.035726473,0.009364552],"category_scores_gemma":[0.02162757,0.0005411859,0.0014649894,0.000592114,0.0039684493,0.005063449,0.001798905,0.044839744,0.0062732366],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017316994,0.00005386722,0.00044443068,0.00013803995,0.000040178198,0.0014417211,0.000050711693,0.00012458934,0.00021691356,0.0069933166,0.9581138,0.032209273],"study_design_scores_gemma":[0.0006598889,0.00015989246,0.0007094254,0.00067854655,0.000066225395,0.0024578539,0.00039234277,0.0005226707,0.0004035536,0.03887541,0.9549856,0.00008862158],"about_ca_topic_score_codex":0.0038181015,"about_ca_topic_score_gemma":0.008473357,"teacher_disagreement_score":0.035726473,"about_ca_system_score_codex":0.00567083,"about_ca_system_score_gemma":0.0038038818,"threshold_uncertainty_score":0.041144967},"labels":[],"label_agreement":null},{"id":"W2044764573","doi":"10.1016/s1470-2045(02)00845-8","title":"Thyroid cancer in a child born after the Chernobyl disaster","year":2002,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Radiation Dose and Imaging","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Alberta; University of Alberta Hospital","funders":"","keywords":"Thyroid cancer; Chernobyl Nuclear Accident; Thyroid; Scopus; Medicine; Thyroid carcinoma; Incidence (geometry); Radioactive iodine; Pediatrics; Nuclear medicine; Internal medicine; Environmental health; MEDLINE; Physics; Chemistry","score_opus":0.03298809204586942,"score_gpt":0.32030675737812425,"score_spread":0.2873186653322548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044764573","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28874686,0.004459219,0.0006006529,0.6700254,0.016272772,0.00010632814,0.0003576966,0.00009293742,0.019338079],"genre_scores_gemma":[0.69987977,0.0075249285,0.00087887316,0.24907385,0.022825722,0.000065419306,0.00019019439,0.00012466106,0.019436514],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99931276,0.00016779522,0.00006145112,0.00011897783,0.0000980964,0.00024090358],"domain_scores_gemma":[0.99836165,0.0007376066,0.00022584238,0.0000644695,0.00017591775,0.00043443483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007245899,0.00074227544,0.0010330805,0.00061222253,0.004419343,0.001439102,0.0013163283,0.018087061,0.0025375711],"category_scores_gemma":[0.0062537817,0.0007992556,0.0011637721,0.0007419933,0.0016695673,0.0014732274,0.000817551,0.013016147,0.0005427462],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003297689,0.00021689337,0.027722046,0.00012719863,0.000073975905,0.891024,0.002753249,0.0003301218,0.0011025306,0.0020100328,0.06882893,0.0054812077],"study_design_scores_gemma":[0.00027683566,0.0016444382,0.053283222,0.00054303743,0.00043204593,0.8299679,0.015415975,0.002321135,0.0019520975,0.006179696,0.0877928,0.0001906916],"about_ca_topic_score_codex":0.03909229,"about_ca_topic_score_gemma":0.04564519,"teacher_disagreement_score":0.03909229,"about_ca_system_score_codex":0.005090082,"about_ca_system_score_gemma":0.0021545917,"threshold_uncertainty_score":0.07772952},"labels":[],"label_agreement":null},{"id":"W2044834268","doi":"10.1016/s1470-2045(11)70084-5","title":"Genetic variants associated with breast-cancer risk","year":2011,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital","funders":"","keywords":"CHEK2; Breast cancer; Genome-wide association study; Penetrance; Odds ratio; Cancer; Medicine; Oncology; Scopus; Genetics; Biology; Mutation; Internal medicine; Single-nucleotide polymorphism; MEDLINE; Germline mutation; Gene; Genotype; Phenotype","score_opus":0.02555895387443447,"score_gpt":0.2861538338174263,"score_spread":0.26059487994299185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044834268","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004025558,0.005819771,0.00029257897,0.96330255,0.020343453,0.000012796288,0.00023638741,0.000036259346,0.005930666],"genre_scores_gemma":[0.07747813,0.010253868,0.0009664035,0.72067344,0.17452283,0.000085014195,0.00027839933,0.00004579061,0.015696097],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9987299,0.000535092,0.00011085441,0.0001415685,0.00032064674,0.0001619638],"domain_scores_gemma":[0.9966582,0.0023139194,0.0001930486,0.00013557327,0.00037117454,0.00032802176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013624616,0.0007188188,0.0012256987,0.00065287686,0.001142431,0.0012793166,0.0007472026,0.018455742,0.0035187756],"category_scores_gemma":[0.012411019,0.0005748834,0.0007699919,0.00063986523,0.0010786174,0.0012261841,0.00063995033,0.013104771,0.0016978211],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005372222,0.00008958964,0.013583649,0.00014657495,0.00014088865,0.0101192435,0.00016335609,0.00033811695,0.0010396739,0.0052092383,0.93231565,0.036316816],"study_design_scores_gemma":[0.0014299981,0.0005240085,0.04627073,0.0010417958,0.0008498755,0.03778556,0.0009508111,0.00735634,0.0018388869,0.05162354,0.8500739,0.00025458023],"about_ca_topic_score_codex":0.0028712512,"about_ca_topic_score_gemma":0.005061775,"teacher_disagreement_score":0.018455742,"about_ca_system_score_codex":0.0012680726,"about_ca_system_score_gemma":0.0006680243,"threshold_uncertainty_score":0.0117715},"labels":[],"label_agreement":null},{"id":"W2045950562","doi":"10.1016/s1470-2045(09)70087-7","title":"Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study","year":2009,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Institute for Health and Care Research; GlaxoSmithKline","keywords":"Medicine; Lapatinib; Internal medicine; Breast cancer; Response Evaluation Criteria in Solid Tumors; Oncology; Inflammatory breast cancer; Trastuzumab; Anthracycline; Cohort; Progressive disease; Metastatic breast cancer; Cancer; Refractory (planetary science); Taxane; Gastroenterology; Chemotherapy","score_opus":0.0591464160017507,"score_gpt":0.4011642093019165,"score_spread":0.3420177933001658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045950562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975005,0.0011188827,0.00009838455,0.00012926475,0.000021897675,0.000076945704,0.00035295213,0.000020432826,0.00068076566],"genre_scores_gemma":[0.99547774,0.0013127666,0.0003544387,0.00026873153,0.00007269053,0.0001222589,0.0015419279,0.00001438351,0.0008351294],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996965,0.00013760409,0.000015876794,0.000044599656,0.000036296697,0.00006917875],"domain_scores_gemma":[0.99957114,0.000090515125,0.000079848396,0.000051327792,0.000018563685,0.0001885319],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011293982,0.000983396,0.0019991058,0.0002305441,0.00023828982,0.0007972957,0.0005682329,0.0005301456,0.0011797638],"category_scores_gemma":[0.0005742859,0.00034876348,0.0011056246,0.00038696357,0.0004792193,0.00086787844,0.00028058497,0.0018122861,0.00033835066],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.727372,0.012132927,0.05953685,0.00042208025,0.002668259,0.0007472242,0.00025023936,0.0048317057,0.027765915,0.00018109179,0.003481392,0.16061038],"study_design_scores_gemma":[0.43912265,0.27737248,0.26301,0.0000892429,0.0032507083,0.0017192139,0.00029850908,0.0056219506,0.004550726,0.0005632799,0.004271751,0.00012948533],"about_ca_topic_score_codex":0.0010169797,"about_ca_topic_score_gemma":0.0035486526,"teacher_disagreement_score":0.0019991058,"about_ca_system_score_codex":0.00071795995,"about_ca_system_score_gemma":0.0006449171,"threshold_uncertainty_score":0.005972922},"labels":[],"label_agreement":null},{"id":"W2046583400","doi":"10.1016/s1470-2045(02)00676-9","title":"Trastuzumab: hopes and realities","year":2002,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":169,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Mary's Hospital; McGill University; Montreal General Hospital; Royal Victoria Hospital","funders":"","keywords":"Trastuzumab; Political science; Medicine; Internal medicine; Breast cancer; Cancer","score_opus":0.39974076953613047,"score_gpt":0.5236081176257247,"score_spread":0.12386734808959421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046583400","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000031787506,0.9962121,0.00003260367,0.0026416583,0.0007671164,9.52395e-7,0.000006374403,0.0000031077145,0.00030433078],"genre_scores_gemma":[0.0005398067,0.9945387,0.00011421584,0.0029493673,0.0012994685,0.000004275448,0.00001163112,0.0000018022561,0.000540706],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991872,0.00022531202,0.00010135107,0.00009169334,0.00031993014,0.00007454808],"domain_scores_gemma":[0.9962136,0.0026050135,0.00031637444,0.00006247869,0.00058642577,0.0002160486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037124008,0.0015890495,0.0032295543,0.0026843615,0.00068601256,0.003803036,0.0013503953,0.0045688064,0.0039141304],"category_scores_gemma":[0.00609621,0.0004721887,0.00077206385,0.004458551,0.0019775643,0.0062743784,0.0015461242,0.0053235656,0.0016717615],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040806836,0.000070395385,0.00030969185,0.016926873,0.00026370454,0.0003223329,0.00019566996,0.00065132725,0.0007321369,0.019927533,0.19955036,0.760642],"study_design_scores_gemma":[0.00010584294,0.000058243022,0.0004153933,0.007174137,0.00016552824,0.00048441126,0.00019853219,0.00013946852,0.000084733074,0.00855489,0.9825921,0.000026740265],"about_ca_topic_score_codex":0.0023864238,"about_ca_topic_score_gemma":0.007519853,"teacher_disagreement_score":0.0045688064,"about_ca_system_score_codex":0.0028807714,"about_ca_system_score_gemma":0.0030210556,"threshold_uncertainty_score":0.020901501},"labels":[],"label_agreement":null},{"id":"W2046984143","doi":"10.1016/s1470-2045(10)70204-7","title":"Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial","year":2010,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":447,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; Centre Hospitalier Universitaire Sainte-Justine; McMaster University","funders":"National Institutes of Health; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute of Allergy and Infectious Diseases; Eunice Kennedy Shriver National Institute of Child Health and Human Development; University of Miami","keywords":"Dexrazoxane; Medicine; Doxorubicin; Anthracycline; Chemotherapy; Internal medicine; Surgery; Cancer; Breast cancer","score_opus":0.01014617022172221,"score_gpt":0.29535533113951923,"score_spread":0.285209160917797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046984143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99398863,0.003940104,0.0002740198,0.0004070951,0.00020216923,0.00053864135,0.0002906266,0.000022049262,0.0003367539],"genre_scores_gemma":[0.99474347,0.0022252994,0.00058005215,0.00035869118,0.00019315019,0.00068700215,0.0005012661,0.000011589564,0.0006994592],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980724,0.0012613826,0.00012381564,0.00023761441,0.00010450772,0.00020022997],"domain_scores_gemma":[0.99711657,0.0009538595,0.0007790366,0.000345672,0.00014602389,0.00065890624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029273194,0.0016299224,0.0034074832,0.00031864838,0.00044840772,0.0012212866,0.0009637127,0.0020585996,0.0024854194],"category_scores_gemma":[0.0039609154,0.0006976148,0.0023951316,0.000547316,0.0016982525,0.0012244018,0.00065989,0.0038739664,0.0005632167],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9844876,0.0020560948,0.0025349509,0.00027807924,0.0012974727,0.0000395007,0.00007898608,0.00022869879,0.0017080236,0.000046796806,0.00017893275,0.007064932],"study_design_scores_gemma":[0.8728017,0.11490263,0.009203601,0.000052897663,0.0014736057,0.00007644153,0.00006942566,0.0002490177,0.00052224955,0.0001080821,0.00051450136,0.000025913492],"about_ca_topic_score_codex":0.0016063268,"about_ca_topic_score_gemma":0.0028411082,"teacher_disagreement_score":0.0034074832,"about_ca_system_score_codex":0.0011566983,"about_ca_system_score_gemma":0.0012146137,"threshold_uncertainty_score":0.015481353},"labels":[],"label_agreement":null},{"id":"W2048434417","doi":"10.1016/s1470-2045(11)70185-1","title":"Dignity therapy for patients who are terminally ill","year":2011,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Patient Dignity and Privacy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Grey Nuns Community Hospital","funders":"","keywords":"Dignity; Terminally ill; Distress; Psychosocial; Meaning (existential); Psychological intervention; Death with dignity; Psychotherapist; Medicine; Life review; Depression (economics); Psychology; Palliative care; Intensive care medicine; Psychiatry; Nursing; Alternative medicine","score_opus":0.1579440727531785,"score_gpt":0.35930289649930053,"score_spread":0.20135882374612202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048434417","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005617021,0.0019113104,0.00004623038,0.9878825,0.0050271484,0.000005081495,0.000011301994,0.00000615271,0.0045486772],"genre_scores_gemma":[0.007999216,0.002153571,0.00012412088,0.9700697,0.011795712,0.000020828116,0.000014101289,0.000010607154,0.007812086],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997479,0.00088342023,0.00024414674,0.00021466496,0.0005324156,0.00064630865],"domain_scores_gemma":[0.9909134,0.004815563,0.0008816084,0.00023041223,0.0006061194,0.0025530045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027987529,0.00046766538,0.0010656021,0.0004041408,0.0065763127,0.0036228832,0.0012983921,0.06997202,0.010100685],"category_scores_gemma":[0.025365632,0.00064211484,0.0011585039,0.0005475957,0.004420382,0.0036518432,0.0031722437,0.05642653,0.0036257622],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000112081565,0.00005180516,0.0016006993,0.00015826804,0.000035228666,0.0054785167,0.0008109474,0.00014808404,0.00032451027,0.013714708,0.9540805,0.023484703],"study_design_scores_gemma":[0.00019530642,0.00015969871,0.0015963758,0.0009662036,0.00005879348,0.0071663526,0.0011860448,0.00028721523,0.00027640502,0.021917405,0.9661292,0.00006107903],"about_ca_topic_score_codex":0.0054154717,"about_ca_topic_score_gemma":0.01850309,"teacher_disagreement_score":0.06997202,"about_ca_system_score_codex":0.004673817,"about_ca_system_score_gemma":0.006587353,"threshold_uncertainty_score":0.03391111},"labels":[],"label_agreement":null},{"id":"W2050126505","doi":"10.1016/s1470-2045(06)70983-4","title":"Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study","year":2006,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":244,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McGill University; Coalition for Research in Women's Health; Hôtel-Dieu de Montréal; Lunenfeld-Tanenbaum Research Institute","funders":"National Cancer Institute; Canadian Breast Cancer Research Alliance; Breast Cancer Alliance; Cancer Research Institute","keywords":"Ovarian cancer; BRCA mutation; Medicine; Gynecology; Odds ratio; Breast cancer; Tubal ligation; Family history; Cancer; Population; Oncology; Obstetrics; Case-control study; Internal medicine; Family planning; Environmental health","score_opus":0.04654725572640173,"score_gpt":0.3675856329846427,"score_spread":0.32103837725824097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050126505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99850047,0.0005932005,0.00017785394,0.000039204067,0.00002009602,0.000047223377,0.00023752076,0.000006065062,0.00037829968],"genre_scores_gemma":[0.9983499,0.0003357288,0.00018891384,0.00005365289,0.00004686468,0.000065223714,0.0003351723,0.000006171409,0.00061821606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998357,0.00058898196,0.0001592202,0.00045853472,0.000215205,0.00022102668],"domain_scores_gemma":[0.9963217,0.0015914941,0.0006925306,0.0007504105,0.00021408123,0.00042990505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018047815,0.0010660341,0.0012847296,0.0017336633,0.0018842474,0.0012238037,0.0013798474,0.0021655385,0.00439748],"category_scores_gemma":[0.0058445833,0.0019579327,0.00146596,0.0019347997,0.0013960659,0.0009457803,0.0007494397,0.0014984502,0.00051592843],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006635214,0.0024359974,0.98006594,0.00012601311,0.0010760392,0.0025168778,0.001044915,0.00008146724,0.0023644986,0.00024443888,0.0003917103,0.0030167673],"study_design_scores_gemma":[0.00069699215,0.002814649,0.9909078,0.00002205349,0.00082594337,0.0029526947,0.00055280986,0.00027632545,0.00024224866,0.00011406135,0.000558986,0.00003553519],"about_ca_topic_score_codex":0.009482161,"about_ca_topic_score_gemma":0.006524947,"teacher_disagreement_score":0.009482161,"about_ca_system_score_codex":0.00064110715,"about_ca_system_score_gemma":0.00052095106,"threshold_uncertainty_score":0.018853962},"labels":[],"label_agreement":null},{"id":"W2050315067","doi":"10.1016/s1470-2045(09)70126-3","title":"Concurrent hormone and radiation therapy in patients with breast cancer: how does chemotherapy affect treatment?","year":2009,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Breast cancer; Medicine; Radiation therapy; Antiestrogen; Tamoxifen; Oncology; Internal medicine; Cancer; Hormonal therapy; Chemotherapy; Hormone therapy; Adjuvant; Gynecology","score_opus":0.007894214839771763,"score_gpt":0.25809263601925636,"score_spread":0.2501984211794846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050315067","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002557364,0.010593613,0.00011905948,0.9714361,0.012241153,0.000009030274,0.00004956416,0.000011741316,0.0029823803],"genre_scores_gemma":[0.03911558,0.014135113,0.00051190663,0.84293133,0.099417076,0.000045072407,0.000065985485,0.000023755703,0.0037542488],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998178,0.0008449531,0.00025507747,0.00015451944,0.0003924457,0.00017502352],"domain_scores_gemma":[0.99351305,0.0045522833,0.00043654325,0.00014615397,0.0005326222,0.00081942463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002548423,0.00032484657,0.0015366077,0.00042930956,0.0011363784,0.001427413,0.00084805815,0.01857521,0.0034795299],"category_scores_gemma":[0.020233052,0.0004264212,0.0010417049,0.00077948347,0.0013176096,0.0018502102,0.0007048965,0.014582572,0.0016173727],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017207332,0.00023696337,0.01892712,0.00043363005,0.00027123615,0.007215443,0.00020583143,0.00058656663,0.0009512621,0.0061153425,0.8292457,0.13409013],"study_design_scores_gemma":[0.002634418,0.001264573,0.032357708,0.0011935547,0.00069477037,0.017506966,0.0007497379,0.0025020416,0.0011739383,0.03195266,0.90778846,0.00018124426],"about_ca_topic_score_codex":0.0035693403,"about_ca_topic_score_gemma":0.010443839,"teacher_disagreement_score":0.01857521,"about_ca_system_score_codex":0.0032260965,"about_ca_system_score_gemma":0.0022165428,"threshold_uncertainty_score":0.023407102},"labels":[],"label_agreement":null},{"id":"W2050352131","doi":"10.1016/s1470-2045(14)70127-5","title":"Complications of prostate cancer treatment – Author's reply","year":2014,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Scopus; Prostate cancer; Prostatectomy; Population; Cancer; MEDLINE; Cohort; Gynecology; Oncology; Internal medicine","score_opus":0.09472766165938883,"score_gpt":0.3868066538992569,"score_spread":0.29207899223986805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050352131","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010034119,0.0008232628,0.000023575052,0.9805561,0.017691411,0.000003668606,0.000033755572,0.0000070209717,0.00076091225],"genre_scores_gemma":[0.0011475722,0.0006395216,0.000048812344,0.9702387,0.025316661,0.000017684022,0.00001760453,0.000009743141,0.0025637625],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9937552,0.00194523,0.0008139824,0.0006913689,0.0018346035,0.0009596641],"domain_scores_gemma":[0.9806287,0.011206181,0.0022602216,0.0004705675,0.0026802185,0.0027541476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052807657,0.0009158197,0.002215053,0.0013337383,0.0046283384,0.005931173,0.002641801,0.08809542,0.0079916],"category_scores_gemma":[0.050234314,0.0014534924,0.0022769645,0.0012395751,0.0040029767,0.0048997574,0.0037541722,0.06960414,0.0047924686],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046178775,0.000020574029,0.000542138,0.000052955893,0.000031197796,0.0007538645,0.00010140016,0.000063213534,0.00004737515,0.0015739629,0.9928087,0.0039583426],"study_design_scores_gemma":[0.00017298169,0.00010093532,0.0019976753,0.00060988794,0.00009445975,0.0016911556,0.00067377294,0.00035294387,0.00015523881,0.007885825,0.9861034,0.00016161491],"about_ca_topic_score_codex":0.009698212,"about_ca_topic_score_gemma":0.013649784,"teacher_disagreement_score":0.08809542,"about_ca_system_score_codex":0.0062823063,"about_ca_system_score_gemma":0.008137134,"threshold_uncertainty_score":0.04558146},"labels":[],"label_agreement":null},{"id":"W2050629268","doi":"10.1016/s1470-2045(05)70424-1","title":"Selection of adjuvant chemotherapy for treatment of node-positive breast cancer","year":2005,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":134,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; University of Ottawa; University of Alberta; Santé Montérégie; Université de Sherbrooke; Memorial University of Newfoundland; BC Cancer Agency; University of Toronto; Hôpital du Saint-Sacrement; Sunnybrook Health Science Centre","funders":"","keywords":"Epirubicin; Anthracycline; Regimen; Medicine; Internal medicine; Docetaxel; Cyclophosphamide; Oncology; Breast cancer; Taxane; Doxorubicin; Chemotherapy; Cancer","score_opus":0.048863306834817946,"score_gpt":0.39525919132361115,"score_spread":0.3463958844887932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050629268","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001379564,0.9989648,0.00009580736,0.00029454086,0.00011867434,0.000002362866,0.000010458357,0.0000023975776,0.00037307406],"genre_scores_gemma":[0.0015867987,0.9973316,0.00023322651,0.0003523436,0.00019656299,0.0000053293547,0.000026910402,0.0000013250741,0.00026588986],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997365,0.000086441454,0.000037312802,0.000049246228,0.000073466574,0.00001705708],"domain_scores_gemma":[0.9989618,0.00072201237,0.00013968111,0.000018761628,0.00012670933,0.000030967643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011945827,0.0005854643,0.0018444159,0.0010160146,0.00015189595,0.0006833809,0.0009434952,0.0008249532,0.002150197],"category_scores_gemma":[0.0019292496,0.00022121213,0.00039145976,0.0017368525,0.00046179202,0.0005170861,0.000301505,0.0013095869,0.00079358614],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021313675,0.000050929346,0.0004675588,0.00668083,0.00012747335,0.000117201576,0.000014571005,0.00033729873,0.000633364,0.0012179831,0.016026968,0.97411263],"study_design_scores_gemma":[0.00035154165,0.0004853026,0.0075237826,0.010819807,0.00096304587,0.0031221577,0.000112050046,0.00036925756,0.001475656,0.0048788856,0.96984667,0.000051882886],"about_ca_topic_score_codex":0.0016029509,"about_ca_topic_score_gemma":0.0037171233,"teacher_disagreement_score":0.002150197,"about_ca_system_score_codex":0.00079946284,"about_ca_system_score_gemma":0.00083004666,"threshold_uncertainty_score":0.007193148},"labels":[],"label_agreement":null},{"id":"W2050701036","doi":"10.1016/s1470-2045(13)70446-7","title":"Surgery versus SABR for NSCLC","year":2013,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"SABR volatility model; Radiation therapy; Medicine; Lung cancer; Stage (stratigraphy); Ablative case; Surgery; Oncology","score_opus":0.12285970875660586,"score_gpt":0.37818727135757757,"score_spread":0.2553275626009717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050701036","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00034044293,0.0019712148,0.00004789301,0.98004764,0.0136799365,0.000007826278,0.000041112176,0.000010546042,0.0038534105],"genre_scores_gemma":[0.004690591,0.0014989597,0.00006832532,0.94755805,0.039695412,0.000018614692,0.000026901496,0.000013897767,0.0064292112],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965669,0.00091714785,0.00040774877,0.0003645352,0.0009321098,0.000811631],"domain_scores_gemma":[0.99196965,0.004543066,0.000609386,0.00017164755,0.00079380977,0.001912528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032875596,0.0006130435,0.001425127,0.0007727012,0.0036294714,0.0041316347,0.001538027,0.07157162,0.011337391],"category_scores_gemma":[0.028704785,0.000650508,0.001780749,0.00085013063,0.0029361716,0.002501392,0.0021226762,0.042852882,0.00703601],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021079925,0.00003936857,0.0008404545,0.00008482195,0.000038211005,0.0011115544,0.00009087726,0.00016546137,0.00023738256,0.0058315326,0.97235614,0.018993398],"study_design_scores_gemma":[0.00048046344,0.00021037729,0.002186882,0.00077120546,0.00012289785,0.0022804954,0.0004209061,0.00077223877,0.0005214396,0.029254774,0.9628755,0.00010290636],"about_ca_topic_score_codex":0.011245251,"about_ca_topic_score_gemma":0.027849589,"teacher_disagreement_score":0.07157162,"about_ca_system_score_codex":0.0071386714,"about_ca_system_score_gemma":0.0074751796,"threshold_uncertainty_score":0.051794887},"labels":[],"label_agreement":null},{"id":"W2052968703","doi":"10.1016/s1470-2045(11)70128-0","title":"Abandonment of treatment for childhood cancer: position statement of a SIOP PODC Working Group","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":261,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stollery Children's Hospital; Hospital for Sick Children","funders":"","keywords":"Scopus; Medicine; Abandonment (legal); Cancer; Family medicine; Pediatrics; MEDLINE; Internal medicine; Political science","score_opus":0.10395944798347974,"score_gpt":0.37270104627841205,"score_spread":0.2687415982949323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052968703","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012001565,0.01083927,0.00012697419,0.95985395,0.023969162,0.00002837831,0.00067411596,0.000014338044,0.0032937035],"genre_scores_gemma":[0.01807,0.020367429,0.0013366872,0.9044769,0.041187122,0.00022646868,0.0018236001,0.00016608859,0.012345718],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98180616,0.0032040859,0.002590757,0.0013483319,0.007538415,0.0035121369],"domain_scores_gemma":[0.89880604,0.041155417,0.012163685,0.002592981,0.011227973,0.03405396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03328882,0.0011076444,0.0018693223,0.0012528087,0.0034192675,0.0063032894,0.0054055587,0.038780343,0.005625481],"category_scores_gemma":[0.07713706,0.00092727627,0.002827087,0.0024842636,0.00504322,0.0042974898,0.008167354,0.032926187,0.001617861],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000148104,0.00004715112,0.0047184946,0.00048642798,0.000120955294,0.00019008553,0.00045893653,0.00019674498,0.00028741252,0.0069164573,0.96036506,0.026064154],"study_design_scores_gemma":[0.00019392569,0.00008703733,0.008255816,0.0019365292,0.00018152926,0.0002461336,0.0007152702,0.00015073104,0.00065742567,0.0033891678,0.9841127,0.00007371512],"about_ca_topic_score_codex":0.04423865,"about_ca_topic_score_gemma":0.07302512,"teacher_disagreement_score":0.04423865,"about_ca_system_score_codex":0.010000183,"about_ca_system_score_gemma":0.082083024,"threshold_uncertainty_score":0.17605025},"labels":[],"label_agreement":null},{"id":"W2054340543","doi":"10.1016/s1470-2045(13)70473-x","title":"Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Pemetrexed; Docetaxel; Cetuximab; Medicine; Oncology; Internal medicine; Open label; Lung cancer; Chemotherapy; Clinical trial; Cancer; Colorectal cancer; Cisplatin","score_opus":0.07556084289108853,"score_gpt":0.44264760369058054,"score_spread":0.367086760799492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054340543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852137,0.006587468,0.00060336106,0.0007993578,0.00082824874,0.002545603,0.0010173041,0.000100868485,0.002304013],"genre_scores_gemma":[0.9867932,0.003925177,0.00090178556,0.00084222876,0.00029679562,0.0016410546,0.0010021937,0.00002658213,0.004570905],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.999281,0.00034405984,0.000040385185,0.00015283142,0.00004887022,0.00013295875],"domain_scores_gemma":[0.99928015,0.00023643607,0.0001292098,0.000059855873,0.000036611847,0.00025778124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017212606,0.0020513837,0.0035418791,0.00039546753,0.00045006498,0.0013025742,0.0009969344,0.0019380159,0.0061578783],"category_scores_gemma":[0.0016408064,0.0008185702,0.0026654685,0.00048390668,0.0014641896,0.001522365,0.0004678542,0.0043831333,0.0011997186],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9805462,0.0029453728,0.00035712897,0.00066460355,0.0011736763,0.0000431675,0.00006577401,0.00050547766,0.0012889452,0.00013161598,0.00070817355,0.011569881],"study_design_scores_gemma":[0.95729274,0.04005419,0.0010122535,0.000034936904,0.000505078,0.000028496615,0.000024657746,0.00027118952,0.00017736974,0.00013388979,0.00045068914,0.000014431964],"about_ca_topic_score_codex":0.0021473363,"about_ca_topic_score_gemma":0.0047712605,"teacher_disagreement_score":0.0061578783,"about_ca_system_score_codex":0.001127093,"about_ca_system_score_gemma":0.0010255494,"threshold_uncertainty_score":0.02060014},"labels":[],"label_agreement":null},{"id":"W2055235037","doi":"10.1016/s1470-2045(13)70411-x","title":"Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":386,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Jewish General Hospital; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"GlaxoSmithKline","keywords":"Medicine; Lapatinib; Trastuzumab; Breast cancer; Internal medicine; Clinical endpoint; Neoadjuvant therapy; Oncology; Population; Pertuzumab; Cyclophosphamide; Chemotherapy; Surgery; Clinical trial; Cancer","score_opus":0.18881223491172663,"score_gpt":0.5311267806640083,"score_spread":0.3423145457522817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055235037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94517523,0.0059107,0.0024976595,0.0027175054,0.0015644614,0.027366683,0.005631763,0.0005317992,0.008604182],"genre_scores_gemma":[0.93205345,0.004234921,0.005419084,0.0034954364,0.0006994734,0.037912846,0.004591351,0.00012980014,0.0114637185],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99866354,0.00080989726,0.000059445305,0.00017827291,0.00007525535,0.00021368242],"domain_scores_gemma":[0.9986437,0.00037212597,0.00024558112,0.00013117035,0.000058187004,0.0005492497],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029027532,0.003012743,0.0034662588,0.0005485357,0.0006642403,0.0016182269,0.0012148017,0.0026382843,0.01573076],"category_scores_gemma":[0.0027742933,0.0011239573,0.0029714718,0.0006260817,0.0021110415,0.001891475,0.0008813391,0.005380075,0.0026269173],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9881521,0.0025604384,0.00015912876,0.00040016908,0.00038142182,0.000018289069,0.0000370339,0.00031367215,0.0008986545,0.00008954766,0.00088542904,0.006104088],"study_design_scores_gemma":[0.9770733,0.021685317,0.0003179987,0.000021340313,0.00012735515,0.000013334738,0.000010169137,0.0001528336,0.00009225088,0.00013733601,0.00036003435,0.0000087557],"about_ca_topic_score_codex":0.0016455866,"about_ca_topic_score_gemma":0.0035874883,"teacher_disagreement_score":0.01573076,"about_ca_system_score_codex":0.0015047853,"about_ca_system_score_gemma":0.0023893644,"threshold_uncertainty_score":0.052624643},"labels":[],"label_agreement":null},{"id":"W2055346449","doi":"10.1016/s1470-2045(14)71205-7","title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1354,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Janssen Research and Development","keywords":"Abiraterone acetate; Prednisone; Medicine; Prostate cancer; Placebo; Internal medicine; Oncology; Castration; Urology; Abiraterone; Enzalutamide; Cancer; Androgen deprivation therapy; Hormone; Androgen receptor; Pathology","score_opus":0.15890906001276825,"score_gpt":0.4258998720708133,"score_spread":0.2669908120580451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055346449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98826724,0.006663199,0.0005371831,0.0004613051,0.0005479255,0.0014020638,0.0007098213,0.000171577,0.0012395817],"genre_scores_gemma":[0.9910575,0.003549463,0.00070685224,0.00045906773,0.00049362547,0.00086547225,0.0005327034,0.000027932361,0.0023074185],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99912935,0.00052224763,0.00006140306,0.00011524367,0.0000640947,0.00010763036],"domain_scores_gemma":[0.9985648,0.00053997774,0.00029237726,0.00012403041,0.00006622555,0.00041269706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023034995,0.0019199006,0.0036688903,0.0007445123,0.00046924056,0.001227529,0.0010520964,0.0017756162,0.0047854036],"category_scores_gemma":[0.002228218,0.00085091504,0.0027147415,0.0006246045,0.0016021156,0.0011655699,0.00045037392,0.0030896906,0.0009849538],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98920363,0.00209019,0.00017145892,0.0003082028,0.00050664024,0.0000152984,0.00003347394,0.00020044106,0.0011967429,0.00002815476,0.00016425745,0.0060814805],"study_design_scores_gemma":[0.925648,0.071688466,0.0012341065,0.000022306067,0.00050839235,0.000023027509,0.000025644125,0.00025710455,0.0002659917,0.00011311569,0.00019844188,0.000015383444],"about_ca_topic_score_codex":0.0019231507,"about_ca_topic_score_gemma":0.0037109903,"teacher_disagreement_score":0.0047854036,"about_ca_system_score_codex":0.0007269862,"about_ca_system_score_gemma":0.0011026085,"threshold_uncertainty_score":0.016008735},"labels":[],"label_agreement":null},{"id":"W2055827929","doi":"10.1016/s1470-2045(12)70391-1","title":"Conditional survival of patients with metastatic renal-cell carcinoma","year":2012,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Sunitinib; Renal cell carcinoma; Oncology; Sorafenib; Internal medicine; Context (archaeology); Population; Clear cell renal cell carcinoma; Carcinoma; Kidney cancer; Targeted therapy; Cancer","score_opus":0.056122131624055105,"score_gpt":0.2929632004744176,"score_spread":0.2368410688503625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055827929","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012524445,0.0031955063,0.00014938999,0.969606,0.0045351232,0.0000058812393,0.00039554085,0.000023736342,0.009564447],"genre_scores_gemma":[0.2285066,0.0046845432,0.00032126444,0.7169112,0.038122497,0.00003742509,0.0007093015,0.000032749133,0.01067451],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99945146,0.00021639925,0.000035801335,0.0000584538,0.00009662821,0.00014127142],"domain_scores_gemma":[0.99732095,0.0014701324,0.00018985423,0.00008270288,0.00022482665,0.000711559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009793531,0.00017291846,0.00061318954,0.0001892511,0.0009681502,0.00094424747,0.00046821003,0.006739526,0.003829883],"category_scores_gemma":[0.008541261,0.0001527245,0.00045894005,0.0003778657,0.00072815106,0.000835138,0.0006089749,0.007473493,0.0012358886],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013496882,0.000120014956,0.044388182,0.00013237134,0.000108620494,0.0033603588,0.00018093587,0.0007330671,0.0011363557,0.009794751,0.8538823,0.0848134],"study_design_scores_gemma":[0.0014928698,0.0011575788,0.14613168,0.0007291654,0.0005915109,0.014405268,0.0010329547,0.004280776,0.0016864741,0.07624194,0.75208104,0.00016884808],"about_ca_topic_score_codex":0.0051186685,"about_ca_topic_score_gemma":0.01563338,"teacher_disagreement_score":0.006739526,"about_ca_system_score_codex":0.0019231783,"about_ca_system_score_gemma":0.0017662713,"threshold_uncertainty_score":0.013953686},"labels":[],"label_agreement":null},{"id":"W2057136886","doi":"10.1016/s1470-2045(07)70352-2","title":"Onto solid footing","year":2007,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Patient Dignity and Privacy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Computer science; Environmental science","score_opus":0.2004752038912596,"score_gpt":0.424780362219567,"score_spread":0.22430515832830739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057136886","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023058133,0.001146118,0.00018634547,0.949919,0.030119736,0.000012006924,0.000022983697,0.000030584124,0.018332735],"genre_scores_gemma":[0.0026271644,0.00032186756,0.000104093866,0.96112865,0.008848519,0.00001836525,0.000010424054,0.000025444742,0.026915416],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9875547,0.0033099067,0.0006138348,0.0016828453,0.003983006,0.0028557165],"domain_scores_gemma":[0.9808115,0.009792771,0.00071685965,0.0011465403,0.002817776,0.004714582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008331806,0.0009374704,0.0016880054,0.0010007237,0.015113649,0.015554479,0.0027278182,0.097825244,0.03948837],"category_scores_gemma":[0.05946468,0.0009881915,0.0016270555,0.0005455472,0.014226111,0.009588925,0.010536764,0.10139151,0.018433059],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013946844,0.000009272155,0.000067351684,0.000018582097,0.0000064812475,0.0002951957,0.00025632305,0.00002037511,0.00004974943,0.01882022,0.97662884,0.00381357],"study_design_scores_gemma":[0.000026599233,0.000019645016,0.0001803018,0.00020055297,0.00001013272,0.00024466918,0.0009593275,0.00009110529,0.00007123261,0.027554026,0.9706132,0.000029213432],"about_ca_topic_score_codex":0.014227474,"about_ca_topic_score_gemma":0.027339522,"teacher_disagreement_score":0.097825244,"about_ca_system_score_codex":0.0063564316,"about_ca_system_score_gemma":0.011988641,"threshold_uncertainty_score":0.13210177},"labels":[],"label_agreement":null},{"id":"W2059624809","doi":"10.1016/s1470-2045(07)70384-4","title":"Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3","year":2007,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":558,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Cancer Institute","keywords":"Temozolomide; Medicine; Radiation therapy; Oncology; Internal medicine; Population; Nomogram; Clinical trial; Cancer","score_opus":0.030776179021699386,"score_gpt":0.3178752894288564,"score_spread":0.287099110407157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059624809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94070446,0.018924098,0.011123472,0.0030360748,0.00069970405,0.000575784,0.01665481,0.00033409486,0.007947449],"genre_scores_gemma":[0.9866361,0.0017053207,0.0035893517,0.00022120649,0.0002181903,0.00023497822,0.006561941,0.000043301105,0.0007895297],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978619,0.0016235008,0.00011646731,0.00012081372,0.00019751728,0.00007983784],"domain_scores_gemma":[0.99213374,0.005362794,0.0011666496,0.00057617517,0.00035001524,0.0004106459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069524157,0.0007579373,0.0014798611,0.0017253261,0.0002984224,0.0009392532,0.00067258964,0.00065625494,0.0023980218],"category_scores_gemma":[0.017848555,0.00020070006,0.001599411,0.0014205214,0.00025972593,0.0008134348,0.0005778064,0.0011462267,0.00068459794],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038720146,0.00042583563,0.6882338,0.0008167819,0.0052765235,0.00018289662,0.00014316839,0.021669487,0.0007065204,0.001648773,0.0312681,0.21090806],"study_design_scores_gemma":[0.012321147,0.0069856886,0.77096236,0.0006022608,0.008114925,0.0010398952,0.00041067094,0.16110502,0.001336464,0.010233226,0.026679454,0.00020893886],"about_ca_topic_score_codex":0.001779543,"about_ca_topic_score_gemma":0.0033886656,"teacher_disagreement_score":0.0069524157,"about_ca_system_score_codex":0.00054601254,"about_ca_system_score_gemma":0.0006927117,"threshold_uncertainty_score":0.036768377},"labels":[],"label_agreement":null},{"id":"W2060209146","doi":"10.1016/s1470-2045(04)01712-7","title":"See-and-treat strategy for diagnosis and management of cervical squamous intraepithelial lesions","year":2005,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Colposcopy; Referral; Cervical cancer; Biopsy; Squamous intraepithelial lesion; Cervical intraepithelial neoplasia; Cancer; Surgery; Radiology; Internal medicine; Family medicine","score_opus":0.25136549489886695,"score_gpt":0.48961594857555507,"score_spread":0.23825045367668812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060209146","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014193729,0.9957437,0.000472809,0.0012699192,0.00044204417,0.00002799494,0.000054221025,0.000017674396,0.0018297434],"genre_scores_gemma":[0.0015964535,0.9945597,0.0010611933,0.0013423482,0.0003530862,0.000030173782,0.00008222683,0.0000031789589,0.00097152294],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99970144,0.00008091274,0.000038737217,0.000049747352,0.000105180654,0.000023919127],"domain_scores_gemma":[0.99951434,0.0003030064,0.00008330111,0.000009620133,0.00006410539,0.00002566054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086419436,0.00088809774,0.0022294014,0.001970706,0.00028319214,0.00072965526,0.001529214,0.0014057993,0.0065636556],"category_scores_gemma":[0.0015171249,0.00023551006,0.0012901254,0.0012658541,0.0003588912,0.0010498016,0.00048184925,0.0017788488,0.0021735355],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000072768096,0.000059876817,0.00019146845,0.015872482,0.00026211247,0.00018099608,0.000027766788,0.00044845816,0.0003791969,0.0018884691,0.037044585,0.9435718],"study_design_scores_gemma":[0.0003015641,0.00037453425,0.00325363,0.029523358,0.0016680212,0.002979063,0.00015203621,0.00040788084,0.00053555187,0.0052780835,0.9554756,0.00005062079],"about_ca_topic_score_codex":0.0025655876,"about_ca_topic_score_gemma":0.008712229,"teacher_disagreement_score":0.0065636556,"about_ca_system_score_codex":0.0010668595,"about_ca_system_score_gemma":0.0014166266,"threshold_uncertainty_score":0.021957636},"labels":[],"label_agreement":null},{"id":"W2063944010","doi":"10.1016/s1470-2045(07)70409-6","title":"Venous thromboembolism in cervical cancer","year":2008,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Venous thromboembolism; Medicine; Cervical cancer; Cancer; Oncology; Internal medicine; Thrombosis","score_opus":0.12888677164208906,"score_gpt":0.42827921194673413,"score_spread":0.29939244030464507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063944010","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003725774,0.9989631,0.000026740378,0.00031125598,0.00023301816,0.0000035202313,0.000013204401,0.0000026381083,0.000409141],"genre_scores_gemma":[0.00049778895,0.99860376,0.0000640462,0.00029880882,0.00020657021,0.000004894637,0.000015572848,6.2139844e-7,0.0003080495],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99969995,0.00006497631,0.000060609415,0.000038594495,0.00011330935,0.00002247222],"domain_scores_gemma":[0.99904686,0.0005340369,0.00020293215,0.000015548736,0.00015319102,0.000047470938],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007228198,0.00070015277,0.0020863684,0.0031389182,0.00025366014,0.0011073695,0.00066029327,0.0011692151,0.00472541],"category_scores_gemma":[0.0021914283,0.00035628674,0.0006203951,0.004048814,0.00041972013,0.0010994012,0.00060128694,0.0013027497,0.0011960246],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007083126,0.000030391771,0.00029451677,0.041178297,0.00020217955,0.00016515395,0.00004487781,0.00023822414,0.0002842417,0.0009215049,0.056144416,0.90042543],"study_design_scores_gemma":[0.00012274979,0.00015111906,0.0024163343,0.032494314,0.0010606194,0.001952232,0.000119087475,0.00014744268,0.00020380219,0.0012353373,0.96007234,0.000024636687],"about_ca_topic_score_codex":0.004504577,"about_ca_topic_score_gemma":0.011217703,"teacher_disagreement_score":0.00472541,"about_ca_system_score_codex":0.0011295656,"about_ca_system_score_gemma":0.0023207257,"threshold_uncertainty_score":0.015808046},"labels":[],"label_agreement":null},{"id":"W2064047759","doi":"10.1016/s1470-2045(10)70297-7","title":"Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute","funders":"Genentech","keywords":"Medicine; Breast cancer; Internal medicine; Discontinuation; Trastuzumab; Oncology; Human Epidermal Growth Factor Receptor 2; Clinical trial; Cancer","score_opus":0.1137773007743218,"score_gpt":0.37204568943079974,"score_spread":0.25826838865647794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064047759","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006514391,0.092991844,0.0007081883,0.8743296,0.019760827,0.000014096206,0.0002958645,0.00005957617,0.0053254925],"genre_scores_gemma":[0.22208169,0.17871623,0.0025888656,0.4758249,0.10541094,0.000055107383,0.0005970495,0.00015019106,0.014575035],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9968274,0.0012350758,0.00047675325,0.00031099338,0.00090758776,0.00024209196],"domain_scores_gemma":[0.9769364,0.011481493,0.0014897807,0.0013407348,0.006356281,0.002395315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039607272,0.00067269476,0.0015081356,0.0013762022,0.0008785005,0.0023070988,0.00087111536,0.0065810527,0.0025590896],"category_scores_gemma":[0.046506446,0.00064318976,0.00070763426,0.0009402722,0.0018264358,0.003645005,0.0013611595,0.010216468,0.001332664],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006772232,0.00007447608,0.021609867,0.00030503815,0.00014114313,0.0015628687,0.00034064337,0.00020022983,0.0005408439,0.0043350756,0.76667327,0.20353922],"study_design_scores_gemma":[0.0009574108,0.00094242545,0.060414895,0.0070728716,0.0006810332,0.020228786,0.0039173714,0.0031323493,0.0018981744,0.05531602,0.844834,0.00060464675],"about_ca_topic_score_codex":0.0037527531,"about_ca_topic_score_gemma":0.0049707447,"teacher_disagreement_score":0.0065810527,"about_ca_system_score_codex":0.0013057585,"about_ca_system_score_gemma":0.0020382002,"threshold_uncertainty_score":0.020946562},"labels":[],"label_agreement":null},{"id":"W2064892114","doi":"10.1016/s1470-2045(07)70046-3","title":"Use of warfarin and risk of urogenital cancer: a population-based, nested case-control study","year":2007,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Jewish General Hospital","funders":"","keywords":"Medicine; Warfarin; Genitourinary system; Cancer registry; Incidence (geometry); Cancer; Population; Prostate cancer; Internal medicine; Nested case-control study; Confounding; Gynecology; Odds ratio","score_opus":0.02995590776402292,"score_gpt":0.3157091838420222,"score_spread":0.2857532760779993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064892114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988985,0.00024768163,0.0003283753,0.000037552578,0.000016273663,0.000027834118,0.00023240458,0.0000064749443,0.0002049528],"genre_scores_gemma":[0.99891317,0.000110254536,0.00034961465,0.000056257057,0.000021097243,0.000025067671,0.00027377746,0.000006401575,0.00024430637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997894,0.000846738,0.00015768033,0.00064550736,0.00028306423,0.0001728981],"domain_scores_gemma":[0.9970812,0.0007700092,0.00052384596,0.00081854535,0.00033479717,0.0004715799],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021715672,0.0009427318,0.0014597144,0.0007970796,0.001489411,0.0013437138,0.001038639,0.0014607238,0.001469578],"category_scores_gemma":[0.0038483085,0.0018429601,0.0019388702,0.0014208711,0.001210999,0.00076769135,0.0006784154,0.0015322545,0.000429015],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006699414,0.0015189493,0.9775398,0.0000775749,0.0032715462,0.00096753676,0.0011143446,0.00017874168,0.0064448435,0.00015121527,0.00039789302,0.0016381834],"study_design_scores_gemma":[0.0011459895,0.002231627,0.98992413,0.000021677932,0.0022151908,0.0019242325,0.00056081463,0.000956332,0.0003646747,0.00011747691,0.00049641536,0.000041382347],"about_ca_topic_score_codex":0.013825109,"about_ca_topic_score_gemma":0.013345902,"teacher_disagreement_score":0.013825109,"about_ca_system_score_codex":0.00068560767,"about_ca_system_score_gemma":0.0006920004,"threshold_uncertainty_score":0.027489305},"labels":[],"label_agreement":null},{"id":"W2065116344","doi":"10.1016/s1470-2045(11)70421-1","title":"Chemotherapy for colorectal cancer","year":2012,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Bevacizumab; Medicine; Oxaliplatin; Chemotherapy; Colorectal cancer; Oncology; Internal medicine; Clinical trial; Cancer; Randomized controlled trial; Surgery","score_opus":0.06792156756469317,"score_gpt":0.3798708501176678,"score_spread":0.3119492825529746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065116344","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029923406,0.006815891,0.0000440881,0.9631235,0.02536904,0.000019881503,0.000094912146,0.0000146866805,0.004218855],"genre_scores_gemma":[0.0021951715,0.0031788424,0.00009111141,0.9400075,0.044580974,0.000054232813,0.00005271872,0.000011322762,0.009828099],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953577,0.0017702611,0.00061654544,0.00046112027,0.0011969445,0.0005974338],"domain_scores_gemma":[0.98641706,0.008005701,0.0013627289,0.00044364532,0.0012640918,0.0025067192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044791237,0.0008733498,0.0018081494,0.0011811329,0.0029739097,0.0027079645,0.0013354816,0.042737693,0.012166262],"category_scores_gemma":[0.026803833,0.0008983348,0.0016631783,0.0010420003,0.0021059096,0.0026584298,0.0022859732,0.031016197,0.0058930824],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012130042,0.00002286321,0.00039616003,0.0001506279,0.000029241572,0.0003558168,0.000044270244,0.000043024484,0.00010729591,0.0018534096,0.9809869,0.015888993],"study_design_scores_gemma":[0.00032407223,0.00015021597,0.0018868932,0.00080452295,0.00009166768,0.00080020115,0.00009436662,0.00020357255,0.00017326925,0.0048875636,0.9905415,0.000042141666],"about_ca_topic_score_codex":0.0067484756,"about_ca_topic_score_gemma":0.026178645,"teacher_disagreement_score":0.042737693,"about_ca_system_score_codex":0.00498966,"about_ca_system_score_gemma":0.0047476618,"threshold_uncertainty_score":0.040700197},"labels":[],"label_agreement":null},{"id":"W2065624579","doi":"10.1016/s1470-2045(09)70039-7","title":"Accessing unfunded cancer drugs in publicly funded hospitals","year":2009,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Cancer Care Ontario","funders":"","keywords":"Nice; Excellence; Medicine; Health care; Psychological intervention; Irinotecan; Public health; Cancer drugs; Cancer; Family medicine; Colorectal cancer; Actuarial science; Business; Nursing; Political science; Economic growth; Economics","score_opus":0.4789897163383777,"score_gpt":0.49689069406148134,"score_spread":0.017900977723103617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065624579","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0041715386,0.00075107685,0.00007987184,0.9902508,0.0016463391,0.000010576835,0.00020110479,0.0000073722317,0.0028812937],"genre_scores_gemma":[0.055301875,0.0011680657,0.00025395557,0.9284213,0.010221524,0.000056314166,0.00015340747,0.000024058629,0.0043995194],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9876199,0.0065719676,0.0013484653,0.0006289171,0.0013637714,0.0024669028],"domain_scores_gemma":[0.9101146,0.065813795,0.008050006,0.0013599998,0.0042935344,0.01036799],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012535101,0.00027768922,0.0010622153,0.0006031791,0.0029543554,0.0051542097,0.0012571495,0.034588493,0.0072421688],"category_scores_gemma":[0.084853046,0.0006249064,0.0011042678,0.0012524519,0.0025351932,0.004039148,0.002494609,0.020849193,0.0011371971],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050595624,0.00013508959,0.021873595,0.00017256585,0.0000860514,0.0012765455,0.0005626445,0.00042000547,0.00021926497,0.014480165,0.9377057,0.02256237],"study_design_scores_gemma":[0.0018134044,0.0006167645,0.09821772,0.003611347,0.0005830789,0.002932017,0.0058693625,0.007875072,0.0016987793,0.06700758,0.80936563,0.00040914663],"about_ca_topic_score_codex":0.047109567,"about_ca_topic_score_gemma":0.121522516,"teacher_disagreement_score":0.047109567,"about_ca_system_score_codex":0.0095892465,"about_ca_system_score_gemma":0.011770391,"threshold_uncertainty_score":0.093670726},"labels":[],"label_agreement":null},{"id":"W2069649975","doi":"10.1016/s1470-2045(14)70035-x","title":"Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Sunnybrook Health Science Centre; University of Toronto","funders":"National Cancer Institute; Canadian Institutes of Health Research; Avon Foundation for Women","keywords":"Anastrozole; Exemestane; Medicine; Aromatase inhibitor; Breast cancer; Bone mineral; Internal medicine; Aromatase; Oncology; Cancer; Osteoporosis; Gynecology","score_opus":0.01923397270228526,"score_gpt":0.32154278623470234,"score_spread":0.30230881353241706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069649975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95578927,0.032691836,0.0007164956,0.00251323,0.0013606051,0.0018298583,0.0017141913,0.00014193232,0.0032426368],"genre_scores_gemma":[0.9849166,0.007184983,0.0008510173,0.0010661177,0.0007181472,0.0011570402,0.0008003135,0.000025072302,0.0032806122],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99856013,0.0009692965,0.00011557963,0.00013431968,0.0000971053,0.00012356702],"domain_scores_gemma":[0.9974764,0.0014949335,0.00044074346,0.00016290194,0.00012473126,0.00030022775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002550956,0.001274367,0.0036764701,0.00043065666,0.0003219208,0.0011601968,0.0007832712,0.0020037976,0.008003622],"category_scores_gemma":[0.005884842,0.00058931694,0.004331463,0.00043119848,0.00085536373,0.0008342186,0.0005309236,0.003952166,0.0010164856],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98632485,0.0008258986,0.00028538017,0.0012134807,0.002320339,0.000025129733,0.00002842192,0.00016996634,0.00072054734,0.00006298935,0.0004414214,0.007581687],"study_design_scores_gemma":[0.9586244,0.033441164,0.001980725,0.00015923503,0.0044020996,0.000032939985,0.00003066379,0.0002629584,0.00027831347,0.00015994548,0.00061123044,0.00001634161],"about_ca_topic_score_codex":0.002356688,"about_ca_topic_score_gemma":0.0036303906,"teacher_disagreement_score":0.008003622,"about_ca_system_score_codex":0.00080499664,"about_ca_system_score_gemma":0.0010346432,"threshold_uncertainty_score":0.026774764},"labels":[],"label_agreement":null},{"id":"W2070825440","doi":"10.1016/s1470-2045(15)70122-1","title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":1255,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation","funders":"National Cancer Institute; Bristol-Myers Squibb","keywords":"Ipilimumab; Placebo; Medicine; Adjuvant; Oncology; Melanoma; Internal medicine; Stage (stratigraphy); Resection; Surgery; Cancer; Immunotherapy; Cancer research; Pathology","score_opus":0.11659487388885283,"score_gpt":0.37045905221319325,"score_spread":0.25386417832434044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070825440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97715056,0.008274632,0.0014338223,0.001128884,0.0017563556,0.005426227,0.0013852915,0.00032602882,0.0031182112],"genre_scores_gemma":[0.9768289,0.0043785586,0.0017633848,0.001475357,0.000984208,0.006050042,0.001085358,0.00006190748,0.007372298],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99929225,0.0003288153,0.000035085075,0.00014509748,0.000040174094,0.00015853865],"domain_scores_gemma":[0.99916875,0.00026026927,0.00018139477,0.000068829926,0.00003944203,0.00028135563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019930226,0.0025413781,0.0048265806,0.00059332943,0.0005385854,0.0014358726,0.0012383969,0.0024376044,0.008890889],"category_scores_gemma":[0.0015857582,0.00105985,0.0027224724,0.00053087756,0.0017156107,0.0014533147,0.000577355,0.0043278965,0.0018386153],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9904242,0.002206098,0.00007775342,0.00033858465,0.00032373454,0.000011463547,0.000020333395,0.00015112925,0.0009082681,0.000049722727,0.00037007025,0.0051186006],"study_design_scores_gemma":[0.9674887,0.031340428,0.00035319466,0.000020110141,0.00020040557,0.000009773281,0.000009053897,0.00016930085,0.00011971137,0.00008295406,0.0001968338,0.000009428751],"about_ca_topic_score_codex":0.0014411625,"about_ca_topic_score_gemma":0.0023007877,"teacher_disagreement_score":0.008890889,"about_ca_system_score_codex":0.0009609409,"about_ca_system_score_gemma":0.0011919809,"threshold_uncertainty_score":0.029743016},"labels":[],"label_agreement":null},{"id":"W2073681230","doi":"10.1016/s1470-2045(11)70146-2","title":"Combination therapy in metastatic renal cell carcinoma","year":2011,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"","keywords":"Temsirolimus; Medicine; Bevacizumab; Sunitinib; Renal cell carcinoma; Oncology; Internal medicine; Toxicity; Combination therapy; Discovery and development of mTOR inhibitors; Chemotherapy; PI3K/AKT/mTOR pathway","score_opus":0.10222718322988199,"score_gpt":0.3187340458167887,"score_spread":0.2165068625869067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073681230","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012103225,0.0069729397,0.00014392802,0.9660035,0.016054358,0.000017408276,0.00006927589,0.000020425097,0.009507869],"genre_scores_gemma":[0.019513182,0.008382812,0.00043938126,0.8806138,0.06634548,0.000080928876,0.00009905945,0.000028877663,0.024496531],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985251,0.00050211407,0.00014427918,0.00012674068,0.00049678393,0.00020504605],"domain_scores_gemma":[0.99741614,0.0015652956,0.00024834406,0.000062975625,0.0002821952,0.00042498598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016499552,0.00058031816,0.0012677363,0.0005698259,0.0022522607,0.0022255902,0.0009230302,0.0294996,0.005617455],"category_scores_gemma":[0.0083054,0.00047297415,0.0011426111,0.0006312648,0.0014064902,0.0020136386,0.0013035137,0.021280378,0.002957453],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021597213,0.000055871147,0.0011014079,0.00012792167,0.000040509978,0.0037882696,0.00008346121,0.00039893662,0.0003639107,0.004100722,0.95408833,0.035634633],"study_design_scores_gemma":[0.00043433066,0.00027215926,0.0019134678,0.00042633695,0.000085389656,0.005688541,0.00016165644,0.0013122819,0.00041784032,0.009049497,0.98019135,0.000047182246],"about_ca_topic_score_codex":0.0035473749,"about_ca_topic_score_gemma":0.015260162,"teacher_disagreement_score":0.0294996,"about_ca_system_score_codex":0.004236324,"about_ca_system_score_gemma":0.00201213,"threshold_uncertainty_score":0.030736864},"labels":[],"label_agreement":null},{"id":"W2083185084","doi":"10.1016/s1470-2045(14)71111-8","title":"PSA test not recommended by Canadian Task Force","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Overdiagnosis; Task force; False positive paradox; Test (biology); Prostate cancer; Medicine; Task (project management); Prostate-specific antigen; Cancer; Computer science; Internal medicine; Political science; Artificial intelligence; Management; Economics; Biology","score_opus":0.03295197470442415,"score_gpt":0.31397679413694224,"score_spread":0.2810248194325181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083185084","genre_codex":"other","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006788622,0.024362352,0.002514163,0.36255336,0.04299479,0.0012556486,0.06503755,0.0008295907,0.49366388],"genre_scores_gemma":[0.14097337,0.029194882,0.010235592,0.4712411,0.012074371,0.0011284213,0.053479716,0.0008688991,0.28080374],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.990189,0.0007719251,0.0006967642,0.000649104,0.005305232,0.002388049],"domain_scores_gemma":[0.9570491,0.0041405787,0.0016212737,0.0012862881,0.030962296,0.0049403734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0063191773,0.0008926755,0.0012213936,0.0041527264,0.0050283684,0.0024755546,0.0038835853,0.0077376245,0.034144823],"category_scores_gemma":[0.04344654,0.0007799537,0.002561364,0.0038448095,0.0015320939,0.0013803133,0.0011323818,0.006282319,0.0069873794],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000061353574,0.00001747158,0.0026418765,0.00026481508,0.000034417313,0.000073822404,0.00003804472,0.000072875075,0.00010537566,0.0016921865,0.9803012,0.0146964975],"study_design_scores_gemma":[0.00038843646,0.00007573619,0.033949193,0.0029144865,0.000251873,0.00038115602,0.00025098916,0.00034879273,0.00052079617,0.0028694097,0.9579316,0.00011745588],"about_ca_topic_score_codex":0.9157352,"about_ca_topic_score_gemma":0.95529026,"teacher_disagreement_score":0.9799048,"about_ca_system_score_codex":0.02009524,"about_ca_system_score_gemma":0.14969394,"threshold_uncertainty_score":0.1695221},"labels":[],"label_agreement":null},{"id":"W2084148280","doi":"10.1016/s1470-2045(11)70330-8","title":"Prostate cancer therapy: finding the right balance","year":2011,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Androgen suppression; Prostate cancer; Androgen; Oncology; Internal medicine; Randomized controlled trial; Cancer; Radiation therapy; Disease; Hormone","score_opus":0.0704486714911461,"score_gpt":0.345523327705107,"score_spread":0.27507465621396093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084148280","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006792112,0.00095984584,0.000030450023,0.9901722,0.007541594,0.0000036888457,0.000014584048,0.0000056865806,0.0012040101],"genre_scores_gemma":[0.0012890731,0.0010554604,0.00010806986,0.97212493,0.020316511,0.000015439151,0.000013320172,0.00001030527,0.0050668186],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9911152,0.0032252371,0.0008519561,0.0007613582,0.002641463,0.0014046789],"domain_scores_gemma":[0.9878407,0.0059842975,0.0008364403,0.00026445033,0.0019519944,0.003122053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060564945,0.0012323986,0.0021640346,0.00096517045,0.006772692,0.0072103543,0.0022879776,0.109396964,0.010714248],"category_scores_gemma":[0.03190546,0.0011481888,0.0018030901,0.0009505579,0.005226179,0.008503428,0.0037617986,0.0894513,0.008117395],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006329869,0.00003803617,0.00030150806,0.000056363217,0.000016344777,0.00048888,0.000104501516,0.000064168395,0.00010615032,0.0036508113,0.98651576,0.008594033],"study_design_scores_gemma":[0.00017232448,0.000098856966,0.0008714024,0.00048454915,0.000040514406,0.0009955714,0.00059110334,0.00043345074,0.00013478156,0.014568539,0.98152715,0.000081786115],"about_ca_topic_score_codex":0.012248599,"about_ca_topic_score_gemma":0.029752212,"teacher_disagreement_score":0.109396964,"about_ca_system_score_codex":0.008594171,"about_ca_system_score_gemma":0.0100915115,"threshold_uncertainty_score":0.06235534},"labels":[],"label_agreement":null},{"id":"W2087433133","doi":"10.1016/s1470-2045(14)70090-7","title":"Complications of prostate cancer treatment","year":2014,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Canadian Association of Nurses in Oncology; University of British Columbia","funders":"","keywords":"Prostate cancer; Medicine; Prostate; Cancer; Oncology; Internal medicine","score_opus":0.0864906108586704,"score_gpt":0.37815624116704516,"score_spread":0.2916656303083748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087433133","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023764298,0.0014968393,0.0000311414,0.9824133,0.01145431,0.0000057913667,0.000035918507,0.000008053378,0.0043169265],"genre_scores_gemma":[0.002544069,0.0016155455,0.00006418678,0.95383906,0.034757115,0.000018069402,0.00003395858,0.000009886279,0.0071181147],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939213,0.001976227,0.0006661028,0.000473925,0.0018717626,0.0010905957],"domain_scores_gemma":[0.9868472,0.0059519005,0.0014120403,0.0003552544,0.0017983495,0.0036352233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036606446,0.0007302291,0.0015748738,0.0010626379,0.0054729898,0.004987113,0.001985919,0.068484575,0.013086886],"category_scores_gemma":[0.039481036,0.00092517416,0.002189545,0.0011967215,0.003151562,0.0035634197,0.003289729,0.05035318,0.005855107],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058932135,0.000040613428,0.0010437452,0.000060426126,0.00002829815,0.0013319037,0.000086898755,0.00008097731,0.00006655379,0.0030131026,0.9793427,0.014845877],"study_design_scores_gemma":[0.00020364729,0.00013748041,0.0032696996,0.00087919226,0.00008039929,0.0027955808,0.00041331063,0.0004228643,0.00012757553,0.010840555,0.98072815,0.00010158393],"about_ca_topic_score_codex":0.0147480285,"about_ca_topic_score_gemma":0.038646374,"teacher_disagreement_score":0.068484575,"about_ca_system_score_codex":0.0073675932,"about_ca_system_score_gemma":0.010032889,"threshold_uncertainty_score":0.05345589},"labels":[],"label_agreement":null},{"id":"W2087748477","doi":"10.1016/s1470-2045(14)70363-8","title":"Role of bisphosphonates in non-metastatic prostate cancer","year":2014,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Zoledronic acid; Prostate cancer; Medicine; Denosumab; Oncology; Androgen deprivation therapy; Internal medicine; Cancer; Radiation therapy; Cabozantinib; Osteonecrosis of the jaw; Osteoporosis; Bisphosphonate","score_opus":0.032227840651259984,"score_gpt":0.3558734122866907,"score_spread":0.32364557163543073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087748477","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019682464,0.005314387,0.000036498175,0.97948724,0.012071485,0.000004826646,0.000027901351,0.00000779162,0.00285301],"genre_scores_gemma":[0.0042589665,0.006029179,0.000118193995,0.9031527,0.08116117,0.000020876334,0.000026264368,0.000013026802,0.005219519],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966595,0.0012951219,0.00035468605,0.00025466998,0.0010504642,0.00038558885],"domain_scores_gemma":[0.9915291,0.005355778,0.00065516995,0.00019035004,0.0010117502,0.0012577602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031019212,0.000650931,0.0017361679,0.0008324716,0.002643465,0.00312373,0.0015192855,0.042917382,0.008196255],"category_scores_gemma":[0.024717005,0.00071485667,0.0014558419,0.0007190888,0.0032188226,0.0033426017,0.0017146611,0.036545273,0.0038657703],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019023586,0.0000701546,0.0008318272,0.00017005714,0.000040293045,0.0016850694,0.00006787935,0.00015018944,0.00021576643,0.0047464473,0.9646582,0.027173879],"study_design_scores_gemma":[0.0004083887,0.00016773748,0.0013661232,0.0006804794,0.0000838288,0.002552707,0.00019868891,0.00048561688,0.00021166872,0.013056846,0.9807342,0.00005368928],"about_ca_topic_score_codex":0.006395214,"about_ca_topic_score_gemma":0.0149896275,"teacher_disagreement_score":0.042917382,"about_ca_system_score_codex":0.00498479,"about_ca_system_score_gemma":0.004886581,"threshold_uncertainty_score":0.036167383},"labels":[],"label_agreement":null},{"id":"W2088382500","doi":"10.1016/s1470-2045(12)70167-5","title":"Polyglutamine diseases and the risk of cancer","year":2012,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Genetic Neurodegenerative Diseases","field":"Neuroscience","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Child and Family Research Institute","funders":"","keywords":"Cancer; Medicine; Internal medicine","score_opus":0.048379976375082324,"score_gpt":0.3252523891109662,"score_spread":0.27687241273588387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088382500","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006498971,0.004450318,0.00010163236,0.9719597,0.020265087,0.000008082212,0.00010148707,0.000028520099,0.002435266],"genre_scores_gemma":[0.011573309,0.004714384,0.000269981,0.8645414,0.11034036,0.000044428474,0.00007293955,0.000021954711,0.008421224],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99860746,0.00059065764,0.00013071804,0.00015715993,0.00037942984,0.00013463988],"domain_scores_gemma":[0.9951127,0.0032389096,0.00027921025,0.00016788272,0.0006628967,0.00053843367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021141404,0.0007835721,0.0016711736,0.00056815904,0.0020220561,0.0016617728,0.0013358275,0.034593176,0.0044724736],"category_scores_gemma":[0.015477999,0.0006124793,0.0010171162,0.00055281474,0.0015797256,0.0021367243,0.00080688135,0.025810258,0.003725386],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027717988,0.000087016546,0.0018106194,0.00010769977,0.00006601423,0.0014003603,0.000079099606,0.00009628272,0.00028474708,0.0024597114,0.97313875,0.020192493],"study_design_scores_gemma":[0.0007168777,0.00039417768,0.0088717425,0.0006715119,0.00030611464,0.003850335,0.0005170239,0.0020447902,0.00066246756,0.024990322,0.95680654,0.00016806799],"about_ca_topic_score_codex":0.00614709,"about_ca_topic_score_gemma":0.012275743,"teacher_disagreement_score":0.034593176,"about_ca_system_score_codex":0.001835549,"about_ca_system_score_gemma":0.0016557423,"threshold_uncertainty_score":0.014961898},"labels":[],"label_agreement":null},{"id":"W2090708746","doi":"10.1016/s1470-2045(12)70532-6","title":"Status of radiotherapy resources in Africa: an International Atomic Energy Agency analysis","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":297,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Pace; Radiation oncology; Agency (philosophy); Radiation therapy; Brachytherapy; Atomic energy; Business; Medicine; Economic growth; Geography; Surgery; Economics","score_opus":0.03439045985104002,"score_gpt":0.3853314686181866,"score_spread":0.3509410087671466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090708746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9392885,0.02111333,0.000489167,0.0068929642,0.00007843094,0.00006833865,0.008822842,0.000013065418,0.023233369],"genre_scores_gemma":[0.98743963,0.009955072,0.00029540568,0.00022736537,0.000034524088,0.00003779995,0.00088598544,0.000013672908,0.0011106586],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991856,0.00021468638,0.000052294163,0.000046765897,0.0001431693,0.0003574554],"domain_scores_gemma":[0.9975223,0.0007072874,0.0010510057,0.00007240791,0.00044270876,0.00020433147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010601771,0.0005238116,0.0004370173,0.003657896,0.0006471314,0.0016151337,0.00048405366,0.00044556826,0.0032096638],"category_scores_gemma":[0.0049666073,0.00031750454,0.00052709016,0.014802623,0.000580233,0.0015413917,0.0014457708,0.00054351316,0.00018378651],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007870755,0.00012025085,0.83079165,0.0023331088,0.0011959353,0.0020454044,0.005501706,0.0062956614,0.0015995997,0.02319091,0.011229156,0.114909604],"study_design_scores_gemma":[0.00002622059,0.000120969984,0.932483,0.0011547898,0.00054198387,0.00070983375,0.01374043,0.000989727,0.0008990511,0.0024096158,0.046888165,0.000036214275],"about_ca_topic_score_codex":0.04870565,"about_ca_topic_score_gemma":0.06633483,"teacher_disagreement_score":0.04870565,"about_ca_system_score_codex":0.0026850293,"about_ca_system_score_gemma":0.0030994492,"threshold_uncertainty_score":0.096844256},"labels":[],"label_agreement":null},{"id":"W2091061603","doi":"10.1016/s1470-2045(03)01163-x","title":"Breast cancer trial with erythropoietin terminated unexpectedly","year":2003,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":472,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Erythropoietin; Epoetin alfa; Cancer; Radiation therapy; Oncology; Internal medicine; Anemia; Hemoglobin; Clinical trial","score_opus":0.03356449566456138,"score_gpt":0.34192028979714534,"score_spread":0.30835579413258396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091061603","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.350244,0.052846976,0.009872267,0.3943776,0.05953795,0.004942373,0.040299706,0.0013855458,0.08649361],"genre_scores_gemma":[0.72279614,0.008402632,0.00310344,0.18605107,0.014595186,0.0037319146,0.0105473045,0.00030069865,0.050471663],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99778146,0.0013676808,0.00010449142,0.00020129477,0.00025814807,0.0002870938],"domain_scores_gemma":[0.9907539,0.0058096345,0.00085218454,0.0005113351,0.00042204425,0.0016510397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069786464,0.00058547436,0.0018906469,0.00030245908,0.00060241326,0.0014954084,0.0006115763,0.0038226785,0.008693371],"category_scores_gemma":[0.015686389,0.0002916335,0.0018346327,0.00035049455,0.00063675625,0.0009081851,0.00058178935,0.007631455,0.0024510312],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.62108314,0.0014061203,0.0062406776,0.0015092606,0.0025166806,0.00075057184,0.00009860507,0.000936186,0.005494374,0.006124964,0.19302318,0.16081634],"study_design_scores_gemma":[0.5071437,0.05760645,0.02273895,0.0006774714,0.0053584916,0.0013726793,0.00010872154,0.003276536,0.012198394,0.02914865,0.36027005,0.0000999643],"about_ca_topic_score_codex":0.0006167532,"about_ca_topic_score_gemma":0.0017871413,"teacher_disagreement_score":0.008693371,"about_ca_system_score_codex":0.001440851,"about_ca_system_score_gemma":0.001902591,"threshold_uncertainty_score":0.036907077},"labels":[],"label_agreement":null},{"id":"W2093711999","doi":"10.1016/s1470-2045(11)70331-x","title":"Radiogenomics: associations in all the wrong places?","year":2011,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Effects of Radiation Exposure","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Radiogenomics; Scopus; Medicine; Radiation therapy; Single-nucleotide polymorphism; SNP; Prospective cohort study; Bioinformatics; Oncology; MEDLINE; Internal medicine; Genetics; Biology; Gene; Genotype","score_opus":0.08418806426636781,"score_gpt":0.3442430314413792,"score_spread":0.26005496717501136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093711999","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016065926,0.0015621693,0.00008538074,0.9920204,0.0056321933,0.0000017127188,0.00003424644,0.000009610026,0.00049371744],"genre_scores_gemma":[0.0037013988,0.0029427232,0.00028943017,0.94204706,0.049338326,0.00001446403,0.000039470175,0.000019562722,0.00160751],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9924624,0.0035150961,0.0009801604,0.00081749866,0.0016717387,0.00055302173],"domain_scores_gemma":[0.95569074,0.034345068,0.0021092515,0.0010325677,0.003961754,0.0028606944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010027899,0.0011064939,0.0030607863,0.0010622106,0.0035357368,0.0043046353,0.002566708,0.06327736,0.007168338],"category_scores_gemma":[0.057997495,0.001144003,0.0015805735,0.0011498821,0.004404088,0.007968758,0.0029989448,0.054382864,0.00527766],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012252748,0.00004344558,0.0023097992,0.00015533657,0.00009123923,0.0015157391,0.00017250692,0.00009711865,0.00020441168,0.0033168236,0.97180283,0.0201682],"study_design_scores_gemma":[0.0004748493,0.00015583621,0.004681752,0.0013681581,0.00029016272,0.0055647595,0.0013825921,0.000967638,0.0004159847,0.058835786,0.92564255,0.00021989613],"about_ca_topic_score_codex":0.0073395767,"about_ca_topic_score_gemma":0.014558088,"teacher_disagreement_score":0.06327736,"about_ca_system_score_codex":0.003486001,"about_ca_system_score_gemma":0.0041568005,"threshold_uncertainty_score":0.053033233},"labels":[],"label_agreement":null},{"id":"W2095826876","doi":"10.1016/s1470-2045(09)70334-1","title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study","year":2009,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1187,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Ipilimumab; Adverse effect; Clinical endpoint; Internal medicine; Melanoma; Clinical trial; Intention-to-treat analysis; Phases of clinical research; Randomized controlled trial; Gastroenterology; Surgery; Immunotherapy; Cancer","score_opus":0.03300815461349548,"score_gpt":0.35211559063508846,"score_spread":0.31910743602159297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095826876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99297875,0.0021404517,0.00048054158,0.00041783717,0.00031175348,0.0019050158,0.000596108,0.000075427575,0.001094116],"genre_scores_gemma":[0.98782533,0.0024285342,0.0012799156,0.0011952303,0.00055664586,0.0027285435,0.0010140688,0.000036000354,0.0029357285],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99920815,0.0003692177,0.000044440334,0.00016633538,0.000056931196,0.00015499475],"domain_scores_gemma":[0.99900764,0.00024823958,0.00019496688,0.00011754201,0.00005947424,0.00037220033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002016576,0.0023109633,0.0049621747,0.0006056585,0.0005166639,0.0013380967,0.0010525003,0.002441659,0.0056446004],"category_scores_gemma":[0.0016566995,0.0012408557,0.0018339377,0.00075720024,0.0014695744,0.0017123456,0.00057798566,0.003744387,0.0014444554],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9740831,0.008385796,0.00077235897,0.0003182663,0.00059088354,0.000033801218,0.00005913021,0.00032392546,0.0050980626,0.000038189533,0.00040285845,0.009893635],"study_design_scores_gemma":[0.90699214,0.089117706,0.0026323001,0.000012616034,0.00035451548,0.000022786524,0.000016400878,0.00021748208,0.0002554864,0.000056411176,0.00030605728,0.000016048858],"about_ca_topic_score_codex":0.000879898,"about_ca_topic_score_gemma":0.0013896556,"teacher_disagreement_score":0.0056446004,"about_ca_system_score_codex":0.00077520113,"about_ca_system_score_gemma":0.0010923867,"threshold_uncertainty_score":0.01888305},"labels":[],"label_agreement":null},{"id":"W2096367061","doi":"10.1016/s1470-2045(14)70440-1","title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":788,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; Hôpital Maisonneuve-Rosemont; Université de Montréal","funders":"Novartis Pharmaceuticals Corporation; Celgene; Amgen","keywords":"Panobinostat; Bortezomib; Medicine; Dexamethasone; Multiple myeloma; Placebo; Clinical endpoint; Internal medicine; Oncology; Clinical trial; Pathology","score_opus":0.044164886168599204,"score_gpt":0.3379999064510631,"score_spread":0.2938350202824639,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096367061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843789,0.006728339,0.0006546141,0.0012581351,0.0013575638,0.0028517605,0.0010371892,0.00015720488,0.0015763373],"genre_scores_gemma":[0.9816191,0.004670794,0.0015359408,0.0015207722,0.00086868845,0.0033924314,0.0012071374,0.00004199996,0.005143092],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99930644,0.00033696173,0.000038335842,0.00015301997,0.00003933867,0.00012588891],"domain_scores_gemma":[0.9990452,0.0002477147,0.00020821468,0.000070754584,0.000050729373,0.000377413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018088579,0.0029800648,0.005549759,0.000599483,0.0006367566,0.0014591514,0.0013404697,0.002235497,0.008686832],"category_scores_gemma":[0.0016622712,0.0011522274,0.0030907274,0.0007481135,0.0021481202,0.0016298952,0.0007115466,0.0044329404,0.0015794106],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.99318826,0.0013408557,0.0001245124,0.00026490598,0.00043361788,0.000013660015,0.000022791772,0.00015479379,0.00082943897,0.0000432641,0.00020848622,0.0033753728],"study_design_scores_gemma":[0.97186273,0.02689808,0.00047356306,0.000014954381,0.00023048793,0.000011787163,0.000013612561,0.00014108914,0.000093207644,0.00008340112,0.00016876034,0.000008304907],"about_ca_topic_score_codex":0.0019304428,"about_ca_topic_score_gemma":0.0035191004,"teacher_disagreement_score":0.008686832,"about_ca_system_score_codex":0.0011520688,"about_ca_system_score_gemma":0.00135202,"threshold_uncertainty_score":0.029060364},"labels":[],"label_agreement":null},{"id":"W2096615679","doi":"10.1016/s1470-2045(11)70406-5","title":"Phase 2 trial design in neuro-oncology revisited: a report from the RANO group","year":2012,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; Western University","funders":"","keywords":"Medicine; Bevacizumab; Clinical trial; Temozolomide; Clinical study design; Discontinuation; Oncology; Population; Glioma; Drug development; Medical physics; Internal medicine; Intensive care medicine; Drug; Pharmacology; Chemotherapy; Cancer research","score_opus":0.2338715737795336,"score_gpt":0.450051414387947,"score_spread":0.2161798406084134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096615679","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03889878,0.8936708,0.0126930475,0.02858871,0.009503644,0.004867044,0.0033311048,0.00028990323,0.008156916],"genre_scores_gemma":[0.29917568,0.54576015,0.047291677,0.06850715,0.005174007,0.017838228,0.0037888875,0.00059669727,0.011867481],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.987911,0.009589608,0.0007441289,0.0007100023,0.00079674984,0.000248483],"domain_scores_gemma":[0.9684446,0.026185507,0.0021003848,0.0010961941,0.0016112643,0.00056207407],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.034018584,0.0012851971,0.006410226,0.00056178763,0.00032381414,0.0027936352,0.0017069742,0.002821809,0.00434251],"category_scores_gemma":[0.04226941,0.00048919336,0.0051357406,0.0011291665,0.0008000386,0.0018818697,0.00089688937,0.0066332184,0.0008123484],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14204265,0.0010884762,0.0024675808,0.038345672,0.019716127,0.00026790585,0.0005018964,0.0031533057,0.0028058037,0.008167493,0.062408514,0.7190346],"study_design_scores_gemma":[0.39425334,0.040576592,0.015055262,0.037827857,0.06159271,0.0014736719,0.00042382898,0.0059552947,0.0049573197,0.021229427,0.41618735,0.00046738845],"about_ca_topic_score_codex":0.0014422099,"about_ca_topic_score_gemma":0.003727266,"teacher_disagreement_score":0.9659814,"about_ca_system_score_codex":0.002209995,"about_ca_system_score_gemma":0.003708745,"threshold_uncertainty_score":0.17990965},"labels":[],"label_agreement":null},{"id":"W2098276344","doi":"10.1016/s1470-2045(13)70335-8","title":"Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":436,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Institute for Health and Care Research","keywords":"Medicine; Bevacizumab; Breast cancer; Internal medicine; Oncology; Anthracycline; Clinical endpoint; Taxane; Chemotherapy; Population; Triple-negative breast cancer; Ixabepilone; Cancer; Surgery; Randomized controlled trial; Metastatic breast cancer","score_opus":0.030516842716199154,"score_gpt":0.3359500223103854,"score_spread":0.30543317959418625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098276344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9794688,0.010482977,0.00062373275,0.0017067809,0.00049807975,0.0014020897,0.0013365501,0.000121584766,0.0043593277],"genre_scores_gemma":[0.9795701,0.0053934287,0.0018674731,0.0023426374,0.0004247083,0.0020842818,0.0023001418,0.00004986158,0.005967357],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99935526,0.00038305434,0.000020692598,0.00008734304,0.000050226772,0.00010340095],"domain_scores_gemma":[0.9990808,0.00030059196,0.00018488562,0.0000816347,0.000046310666,0.0003058554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018357001,0.0010520467,0.0021668547,0.0002476422,0.00032590373,0.00093795743,0.0006860237,0.0013779248,0.004912582],"category_scores_gemma":[0.0020590003,0.00035915512,0.0014625842,0.000311488,0.00064848136,0.0007473347,0.00038795275,0.0027180044,0.00081464136],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9573738,0.0031502862,0.0008764521,0.0006912744,0.0017716575,0.00004759689,0.00007250424,0.0005365253,0.0033475715,0.00017349688,0.0023523397,0.029606557],"study_design_scores_gemma":[0.9485826,0.044387016,0.0034113096,0.000058472357,0.0009808559,0.000057663136,0.000029687335,0.00029077625,0.00032181642,0.00022438186,0.0016382971,0.000017055188],"about_ca_topic_score_codex":0.0020862562,"about_ca_topic_score_gemma":0.0056758495,"teacher_disagreement_score":0.004912582,"about_ca_system_score_codex":0.0009257782,"about_ca_system_score_gemma":0.0008497613,"threshold_uncertainty_score":0.016434252},"labels":[],"label_agreement":null},{"id":"W2098494491","doi":"10.1016/s1470-2045(14)70508-x","title":"Knowledge, attitudes, and behaviours towards cancer screening in indigenous populations: a systematic review","year":2014,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Government of Northwest Territories; University of Alberta","funders":"H2020 European Research Council; Alberta Innovates - Health Solutions","keywords":"Indigenous; Traditional knowledge; Cancer; Psychology; Geography; Medicine; Biology; Ecology","score_opus":0.16485263619804466,"score_gpt":0.46993107081090646,"score_spread":0.30507843461286177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098494491","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004031252,0.995175,0.00007213097,0.00017836895,0.000054434124,0.00010614979,0.00024134768,0.0000030974643,0.00013805702],"genre_scores_gemma":[0.03653601,0.96227366,0.00038827563,0.00037174328,0.00004791405,0.00016792289,0.00012858566,0.0000018674929,0.00008396485],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99637944,0.0011472526,0.001251651,0.00033697078,0.0007270251,0.00015769662],"domain_scores_gemma":[0.98638725,0.009622597,0.0025769619,0.0001776845,0.0010013158,0.0002342507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005950265,0.0009427547,0.005687678,0.003934811,0.00052723737,0.0015097463,0.0011706421,0.0015077672,0.0021522667],"category_scores_gemma":[0.028377743,0.000872134,0.0058456557,0.005188221,0.00073885865,0.0014312773,0.0015043456,0.0012712756,0.00013139176],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034943596,0.00004894758,0.008306428,0.89395964,0.035792693,0.00011959226,0.00067604816,0.00008798565,0.00015086523,0.00012747088,0.0012200131,0.05916077],"study_design_scores_gemma":[0.0005577308,0.0003745711,0.048387107,0.60882837,0.32579577,0.00062533625,0.0013433188,0.00010805224,0.00018185131,0.0003796224,0.013325323,0.000092846014],"about_ca_topic_score_codex":0.02308628,"about_ca_topic_score_gemma":0.07317644,"teacher_disagreement_score":0.02308628,"about_ca_system_score_codex":0.0020572373,"about_ca_system_score_gemma":0.0075466987,"threshold_uncertainty_score":0.045903802},"labels":[],"label_agreement":null},{"id":"W2098499757","doi":"10.1016/s1470-2045(12)70509-0","title":"Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":526,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Genentech","keywords":"Bevacizumab; Medicine; Oxaliplatin; Capecitabine; Colorectal cancer; Clinical endpoint; Internal medicine; Bolus (digestion); Chemotherapy; Fluorouracil; Surgery; Gastroenterology; Phases of clinical research; Randomized controlled trial; Cancer","score_opus":0.0801800099192156,"score_gpt":0.4280330432983145,"score_spread":0.3478530333790989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098499757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9432797,0.031412065,0.0023456584,0.002718192,0.003260269,0.009275374,0.0029631348,0.00031128447,0.0044342303],"genre_scores_gemma":[0.96257716,0.012749058,0.004153533,0.0024792335,0.0010992528,0.008784409,0.0019083933,0.00006873673,0.0061802557],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988494,0.0006590186,0.00008446281,0.00018629646,0.00007324775,0.0001476133],"domain_scores_gemma":[0.99868804,0.00044801942,0.00032955114,0.00011098717,0.0000823954,0.0003409984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027602187,0.002157807,0.0039185667,0.00050362427,0.0005314476,0.0014595975,0.0011211972,0.0023494062,0.008428083],"category_scores_gemma":[0.0030011924,0.0009565841,0.0035449907,0.00069570175,0.00142556,0.0014015336,0.0005844925,0.0037216132,0.0010396978],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9898084,0.0011192393,0.0001356768,0.001080007,0.0011911258,0.000019913863,0.000029457262,0.00018574149,0.00076868676,0.00009322778,0.0005442261,0.0050242743],"study_design_scores_gemma":[0.9853923,0.012980627,0.00029598395,0.00004618052,0.000654464,0.0000116786805,0.000008563386,0.0001054143,0.00007378584,0.00008727526,0.0003367915,0.0000069794805],"about_ca_topic_score_codex":0.0020697145,"about_ca_topic_score_gemma":0.0042335186,"teacher_disagreement_score":0.008428083,"about_ca_system_score_codex":0.0010934783,"about_ca_system_score_gemma":0.0014110323,"threshold_uncertainty_score":0.028194785},"labels":[],"label_agreement":null},{"id":"W2098898117","doi":"10.1016/s1470-2045(11)70231-5","title":"HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data","year":2011,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":193,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; St. Michael's Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"Amis de l'Institut Bordet; Cancer Research UK; Strategiske Forskningsråd","keywords":"Anthracycline; Internal medicine; Oncology; Medicine; Breast cancer; Hazard ratio; Cyclophosphamide; Adjuvant; Chemotherapy; Methotrexate; Cancer; Confidence interval","score_opus":0.43518734685932126,"score_gpt":0.5262071644404532,"score_spread":0.09101981758113198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098898117","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20203827,0.7808526,0.00932365,0.0010718098,0.00094815285,0.00027204957,0.004114072,0.0002528568,0.0011265136],"genre_scores_gemma":[0.95407075,0.038918708,0.003185535,0.0006974616,0.0003677763,0.0003065203,0.0019082384,0.00011565677,0.0004291809],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9761741,0.01698446,0.0019791368,0.0030978115,0.0013168838,0.00044768813],"domain_scores_gemma":[0.9548918,0.035458785,0.0044231773,0.003609851,0.0009612907,0.0006550666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.030305972,0.0028846902,0.0127013065,0.0034343335,0.00048540282,0.003233368,0.0020187814,0.0020335615,0.0018976515],"category_scores_gemma":[0.02930318,0.0015123377,0.052683648,0.004300284,0.0007341506,0.0013450711,0.0015243647,0.002431186,0.00026704324],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067331353,0.000018432065,0.025855238,0.0053939205,0.95589894,0.000074345924,0.00002168986,0.002271237,0.00033257186,0.00006923718,0.0002576333,0.0030735654],"study_design_scores_gemma":[0.00083275494,0.00041156227,0.017533902,0.00053369126,0.97781664,0.00009251046,0.000019968778,0.0014797284,0.00022466636,0.0002821871,0.0007489272,0.000023422472],"about_ca_topic_score_codex":0.0039240387,"about_ca_topic_score_gemma":0.0046259225,"teacher_disagreement_score":0.030305972,"about_ca_system_score_codex":0.001252795,"about_ca_system_score_gemma":0.00096980605,"threshold_uncertainty_score":0.16027516},"labels":[],"label_agreement":null},{"id":"W2099777151","doi":"10.1016/s1470-2045(08)70235-3","title":"Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis","year":2008,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":425,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institutes of Health","keywords":"Prostate cancer; Medicine; Body mass index; Overweight; Hazard ratio; Proportional hazards model; Internal medicine; Cancer; Prostate; Oncology; Gynecology; Confidence interval","score_opus":0.03654156562712102,"score_gpt":0.3206869880629975,"score_spread":0.2841454224358765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099777151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998355,0.00079762505,0.00013167944,0.00007812581,0.00001993496,0.000004577779,0.0003889828,0.000006400652,0.000217601],"genre_scores_gemma":[0.9987239,0.00018734322,0.000064645435,0.000038669088,0.00005317213,0.0000057078587,0.00061399955,0.000003190711,0.00030931892],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995098,0.0001556267,0.00003470829,0.00010807977,0.00006370378,0.00012805886],"domain_scores_gemma":[0.9975932,0.00073659123,0.000502364,0.00039182178,0.00015182114,0.00062418816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018123086,0.0007626859,0.0010142539,0.0008373321,0.0006781836,0.00095503323,0.00091890333,0.0012920136,0.0016331731],"category_scores_gemma":[0.0023301945,0.0007660091,0.0030397158,0.0010816787,0.0006717949,0.0010851899,0.0007575842,0.0017610873,0.0002553015],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004627174,0.00014395594,0.9910362,0.000019022973,0.0010216244,0.00015958544,0.000043271706,0.00039369988,0.00037975365,0.000031103515,0.00016166811,0.0019829473],"study_design_scores_gemma":[0.00009425065,0.0006559181,0.9970009,0.00000524137,0.0006989594,0.00023657401,0.00008984031,0.0009342266,0.00008027545,0.00006397359,0.00012371363,0.000016144128],"about_ca_topic_score_codex":0.006658736,"about_ca_topic_score_gemma":0.007214599,"teacher_disagreement_score":0.006658736,"about_ca_system_score_codex":0.00048817092,"about_ca_system_score_gemma":0.0007939621,"threshold_uncertainty_score":0.01323992},"labels":[],"label_agreement":null},{"id":"W2100175209","doi":"10.1016/s1470-2045(09)70067-1","title":"The price function of toxicity","year":2009,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Transparency (behavior); Toxicity; Scrutiny; Valuation (finance); Value (mathematics); Economics; Function (biology); Payment; Business; Medicine; Computer science; Computer security; Finance; Law; Biology","score_opus":0.41469738112595195,"score_gpt":0.46161273388584745,"score_spread":0.0469153527598955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100175209","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1348059,0.046002846,0.5108515,0.121675886,0.004267302,0.00023117375,0.0031777194,0.0009295252,0.17805815],"genre_scores_gemma":[0.89134914,0.012465864,0.011450055,0.00341341,0.003356747,0.00013243432,0.00063264335,0.00025938312,0.07694031],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99705195,0.0013658678,0.00013976858,0.00037231192,0.00074800855,0.00032208313],"domain_scores_gemma":[0.97425973,0.019740265,0.0019354789,0.0016799335,0.0017813488,0.0006032381],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0074082683,0.0012202959,0.00224475,0.002045247,0.0005894408,0.0057192515,0.0017539916,0.006057542,0.016466437],"category_scores_gemma":[0.0620469,0.0012540341,0.0015930057,0.0021331883,0.0035100603,0.010684495,0.0012554037,0.0076398305,0.002352155],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021246757,0.00009593026,0.0031257784,0.00030945882,0.00015654592,0.00039511803,0.00020115123,0.044897918,0.0005638995,0.8808146,0.02204004,0.047187064],"study_design_scores_gemma":[0.000093564406,0.0000711628,0.0027389852,0.000104004626,0.00007565848,0.00051766884,0.0000950779,0.08957517,0.00022778178,0.8941511,0.012291018,0.00005867783],"about_ca_topic_score_codex":0.0035225765,"about_ca_topic_score_gemma":0.0019254963,"teacher_disagreement_score":0.016466437,"about_ca_system_score_codex":0.0035601216,"about_ca_system_score_gemma":0.0013390707,"threshold_uncertainty_score":0.05508572},"labels":[],"label_agreement":null},{"id":"W2101027485","doi":"10.1016/s1470-2045(13)70181-5","title":"Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":433,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"Amgen","keywords":"Medicine; Panitumumab; Fluorouracil; Cetuximab; Internal medicine; Oncology; Clinical endpoint; Radiation therapy; Clinical trial; Surgery; Chemotherapy; Colorectal cancer; Cancer","score_opus":0.08315162691552298,"score_gpt":0.3725965093969344,"score_spread":0.2894448824814114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101027485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885433,0.005283731,0.000393787,0.00061739766,0.00058086106,0.0021364538,0.0006219345,0.00007026767,0.0017523197],"genre_scores_gemma":[0.98952043,0.0036486492,0.00083809835,0.0007222241,0.0001966624,0.0016930075,0.00074767275,0.000017431226,0.0026158425],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994684,0.0002576747,0.000029698349,0.00011253484,0.000034391865,0.00009736302],"domain_scores_gemma":[0.9993717,0.00019159362,0.00010461055,0.000054425956,0.000040168245,0.0002375116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013699464,0.0019425757,0.00312087,0.00043853337,0.00048901665,0.0011063162,0.0010435574,0.0016740025,0.005717893],"category_scores_gemma":[0.0015395222,0.00084028457,0.0029160813,0.0005787837,0.0014283818,0.0013542436,0.0005412932,0.0036030177,0.00086105365],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97766393,0.002835407,0.000611215,0.00076861156,0.0011665454,0.000059610153,0.00008163577,0.00057377556,0.0016885581,0.0001109606,0.00072119315,0.013718569],"study_design_scores_gemma":[0.9549079,0.04227045,0.0012110311,0.000037956914,0.0005678119,0.000034563098,0.000033483797,0.0002497285,0.0001820249,0.00010027638,0.00039194716,0.000012890098],"about_ca_topic_score_codex":0.0037024373,"about_ca_topic_score_gemma":0.008158729,"teacher_disagreement_score":0.005717893,"about_ca_system_score_codex":0.0014001396,"about_ca_system_score_gemma":0.0013458636,"threshold_uncertainty_score":0.019128263},"labels":[],"label_agreement":null},{"id":"W2101058247","doi":"10.1016/s1470-2045(08)70107-4","title":"Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial","year":2008,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":522,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Oncolytic virus; Refractory (planetary science); Medicine; Oncology; Cancer; Liver cancer; Phases of clinical research; Cancer research; Internal medicine; Virology; Clinical trial; Biology","score_opus":0.1005350859476827,"score_gpt":0.3687444118071548,"score_spread":0.2682093258594721,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101058247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916409,0.0035232943,0.000604749,0.0006144359,0.00020431342,0.0008415833,0.0003982099,0.00008565852,0.0020869235],"genre_scores_gemma":[0.98810464,0.0043630553,0.0009940515,0.0007454106,0.00014909847,0.0011002595,0.0010936563,0.00003031142,0.0034194742],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9998246,0.00007087484,0.000008842992,0.000027441443,0.000017821543,0.000050377417],"domain_scores_gemma":[0.99969447,0.00007774786,0.000044340733,0.000027581615,0.000014134801,0.00014170347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008624023,0.0011423653,0.001744271,0.00029431639,0.0003126656,0.00085225684,0.0005793165,0.0010986113,0.0031091177],"category_scores_gemma":[0.0005973576,0.0003002331,0.0012275951,0.00033868468,0.000722204,0.0006607953,0.00022297756,0.0021746971,0.00048474074],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6432379,0.037258416,0.0047566155,0.0020549998,0.0021892975,0.00048282187,0.00047963366,0.004730583,0.06786945,0.001251266,0.0049033845,0.23078567],"study_design_scores_gemma":[0.5556335,0.42163852,0.0077856868,0.00009725145,0.0007351535,0.00039662755,0.00014103387,0.0020542133,0.0069364686,0.00059494196,0.0039491155,0.000037491198],"about_ca_topic_score_codex":0.0007595935,"about_ca_topic_score_gemma":0.0013763123,"teacher_disagreement_score":0.0031091177,"about_ca_system_score_codex":0.0005524892,"about_ca_system_score_gemma":0.00073715416,"threshold_uncertainty_score":0.01040107},"labels":[],"label_agreement":null},{"id":"W2101095958","doi":"10.1016/s1470-2045(15)00244-2","title":"Consensus on the management of intracranial germ-cell tumours","year":2015,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Delphi Technique in Research","field":"Social Sciences","cited_by":249,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Chugai Pharmaceutical; Children's Cancer and Leukaemia Group","keywords":"Multidisciplinary approach; Delphi method; Delphi; Medicine; Consensus conference; Germ cell; Germ cell tumors; Political science; Internal medicine; Chemotherapy; Computer science","score_opus":0.4008159004287329,"score_gpt":0.5433592322362883,"score_spread":0.14254333180755546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101095958","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000550707,0.99538136,0.00017256771,0.0034390122,0.00046400126,0.00000913059,0.00002096485,0.00000222372,0.00045570414],"genre_scores_gemma":[0.0016891297,0.994728,0.0005330616,0.002373954,0.00040198612,0.00002801096,0.000053593318,0.0000023417617,0.0001899827],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9941156,0.002445751,0.0013466573,0.00040687696,0.0014227714,0.00026240502],"domain_scores_gemma":[0.9868465,0.009775333,0.0011888164,0.00017183418,0.0017242802,0.00029325442],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01295939,0.0010633239,0.0036942165,0.0045793233,0.0006495171,0.0026068874,0.0027598212,0.0037601318,0.0042785946],"category_scores_gemma":[0.026260734,0.00047846348,0.002227015,0.0039541167,0.0017298532,0.0028809276,0.0024621836,0.003971025,0.0009139442],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011515798,0.000025317562,0.00023657068,0.102866665,0.0005738297,0.00019468833,0.00029336484,0.00047381467,0.00020898864,0.0086561665,0.040972885,0.8453825],"study_design_scores_gemma":[0.00013785149,0.00009075074,0.0013797691,0.25560263,0.0016628422,0.0011805258,0.00075503375,0.00018596122,0.0002845558,0.01575179,0.7229047,0.00006367253],"about_ca_topic_score_codex":0.0039263614,"about_ca_topic_score_gemma":0.006541889,"teacher_disagreement_score":0.01295939,"about_ca_system_score_codex":0.0030074297,"about_ca_system_score_gemma":0.008688906,"threshold_uncertainty_score":0.06853664},"labels":[],"label_agreement":null},{"id":"W2101922439","doi":"10.1016/s1470-2045(14)70379-1","title":"Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":1019,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Merck KGaA","keywords":"Temozolomide; Medicine; Chemoradiotherapy; Internal medicine; Oncology; Clinical endpoint; Phases of clinical research; Progression-free survival; Clinical trial; Chemotherapy","score_opus":0.045915261996500485,"score_gpt":0.37465635131886754,"score_spread":0.32874108932236706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101922439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9814263,0.009244174,0.0006676135,0.0013827232,0.0011235544,0.0017499392,0.0015482384,0.00019364915,0.0026637544],"genre_scores_gemma":[0.98209363,0.005045438,0.0013713641,0.001981345,0.00059692684,0.0020484969,0.0026110914,0.000042681255,0.0042089988],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99963653,0.00015789876,0.000015354984,0.00007779164,0.000026502254,0.000085992935],"domain_scores_gemma":[0.99956673,0.000104769555,0.00008374877,0.000035378398,0.000028699358,0.00018067562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011302894,0.0017824874,0.003503492,0.0005193014,0.00037902722,0.0011010105,0.0010910981,0.0018313366,0.0052018836],"category_scores_gemma":[0.0011142594,0.00062504935,0.002240949,0.00056501175,0.001162942,0.0013259244,0.000421594,0.003533505,0.001176138],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9714835,0.00326861,0.00065404904,0.000798471,0.0014165444,0.00004641497,0.000048633192,0.0004560852,0.0018587577,0.00016648302,0.0020312977,0.017771175],"study_design_scores_gemma":[0.94868845,0.047106355,0.0019766658,0.000048238155,0.0006028507,0.00003279429,0.00003386041,0.0003469911,0.00019632491,0.0002028264,0.00074562954,0.000018921472],"about_ca_topic_score_codex":0.0020503688,"about_ca_topic_score_gemma":0.0056021735,"teacher_disagreement_score":0.0052018836,"about_ca_system_score_codex":0.0010469282,"about_ca_system_score_gemma":0.00097616337,"threshold_uncertainty_score":0.017401993},"labels":[],"label_agreement":null},{"id":"W2102195694","doi":"10.1016/s1470-2045(14)70244-x","title":"Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":305,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal","funders":"University of Arizona Cancer Center; Amgen","keywords":"Medicine; Placebo; Clinical endpoint; Internal medicine; Population; Progression-free survival; Randomized controlled trial; Oncology; Phases of clinical research; Adverse effect; Clinical trial; Surgery; Chemotherapy; Pathology","score_opus":0.05990155337821918,"score_gpt":0.3706850085049904,"score_spread":0.31078345512677125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102195694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9719648,0.012981132,0.0013004891,0.0017668923,0.0017819301,0.0045665787,0.0022219222,0.00037062063,0.0030457245],"genre_scores_gemma":[0.97114885,0.0073740245,0.0022123277,0.0024874236,0.0008762668,0.0064776936,0.002100004,0.000080229445,0.0072431793],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994487,0.00026312983,0.000029059935,0.0000980613,0.000037852104,0.00012312058],"domain_scores_gemma":[0.9992403,0.0002114766,0.0001633038,0.000072916715,0.000042297255,0.00026969347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017143773,0.0019990013,0.0039367643,0.00043638077,0.00044552475,0.0011931026,0.00100362,0.002246747,0.0077241748],"category_scores_gemma":[0.0018194608,0.0007350305,0.002488927,0.00045250688,0.0013028986,0.001324336,0.0004701555,0.0036216355,0.0013841842],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9823806,0.0017752828,0.00021776758,0.0007285426,0.00090085174,0.00003071462,0.000035926358,0.00024035604,0.0019295347,0.000111687914,0.0010486252,0.010600142],"study_design_scores_gemma":[0.9814198,0.017201979,0.00046484757,0.000023709077,0.00019836625,0.000019373829,0.000009382154,0.0001106445,0.0001131727,0.00008886118,0.00034068443,0.000009205285],"about_ca_topic_score_codex":0.0010192906,"about_ca_topic_score_gemma":0.0021516618,"teacher_disagreement_score":0.0077241748,"about_ca_system_score_codex":0.00072424236,"about_ca_system_score_gemma":0.0009560065,"threshold_uncertainty_score":0.025839925},"labels":[],"label_agreement":null},{"id":"W2102306754","doi":"10.1016/s1470-2045(15)00086-8","title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":867,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôtel-Dieu de Québec; Centre hospitalier universitaire de Québec; University of British Columbia; Princess Margaret Cancer Centre","funders":"Wellbeing of Women; Medical Research Council; National Institute for Health and Care Research","keywords":"Bevacizumab; Medicine; Ovarian cancer; Oncology; Chemotherapy; Internal medicine; Cancer","score_opus":0.08231778117429578,"score_gpt":0.3864691238198101,"score_spread":0.3041513426455143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102306754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95978576,0.018541247,0.00085210556,0.00214637,0.0011772701,0.0088432245,0.0019671859,0.00015695939,0.00652995],"genre_scores_gemma":[0.96429074,0.008201845,0.0025812313,0.0035284578,0.00075796526,0.013167914,0.003490759,0.000053347623,0.003927726],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980716,0.0013565567,0.00008798345,0.00018490983,0.00012540749,0.00017363086],"domain_scores_gemma":[0.99794465,0.0006938228,0.00046063363,0.00014813972,0.00013949366,0.0006132607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043968344,0.0011693503,0.002482879,0.0004468417,0.00037874168,0.0010392442,0.00085769675,0.0019502122,0.006218831],"category_scores_gemma":[0.0039034956,0.00037130367,0.0021880807,0.0006223628,0.0012847572,0.0009139499,0.0005185429,0.0026908733,0.0005720584],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97847474,0.002221991,0.00046038945,0.0007370201,0.00072485366,0.000024619792,0.00003913183,0.0002554287,0.00063706026,0.00012539705,0.0013223157,0.014977022],"study_design_scores_gemma":[0.9673102,0.030140296,0.00093987974,0.00006442015,0.00045164267,0.000018620003,0.000014106763,0.00017017245,0.00007628852,0.000119064585,0.00068752875,0.000007729086],"about_ca_topic_score_codex":0.0017918214,"about_ca_topic_score_gemma":0.004783748,"teacher_disagreement_score":0.006218831,"about_ca_system_score_codex":0.0015105947,"about_ca_system_score_gemma":0.002103308,"threshold_uncertainty_score":0.023253024},"labels":[],"label_agreement":null},{"id":"W2103251300","doi":"10.1016/s1470-2045(13)70110-4","title":"Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":253,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Hospital for Sick Children; Ontario Institute for Cancer Research; University Health Network; University of Toronto; SickKids Foundation","funders":"Canadian Institutes of Health Research; Terry Fox Foundation","keywords":"Methylation; Malignancy; CpG site; Cohort; DNA methylation; Biomarker; Oncology; Medicine; Pyrosequencing; Cancer; Internal medicine; Pathology; Biology; Cancer research; Gene; Genetics; Gene expression","score_opus":0.017512960069337925,"score_gpt":0.3098881122709735,"score_spread":0.29237515220163557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103251300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99648994,0.0019215702,0.0005220626,0.00024228457,0.000005910431,0.0000067158353,0.00025592034,0.000007614045,0.0005479393],"genre_scores_gemma":[0.99797565,0.0010231234,0.0006071032,0.000049029844,0.000016041084,0.0000036335032,0.00014614663,0.0000056104404,0.00017352561],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996586,0.00011513812,0.000014486076,0.00008966325,0.00005881011,0.000063229985],"domain_scores_gemma":[0.9992829,0.00033408587,0.00018918508,0.00007378529,0.000053043772,0.00006710575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007663074,0.0003390856,0.00048281823,0.0006094368,0.00030256266,0.00047403458,0.00034692817,0.00032500766,0.0012730138],"category_scores_gemma":[0.0014096408,0.00018999257,0.00062506844,0.0010569799,0.00040915987,0.00025088043,0.0005792152,0.00056376937,0.00009898381],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035641433,0.00019307858,0.8723193,0.00024403463,0.003107293,0.0008193171,0.0013121074,0.00176304,0.04205264,0.001093081,0.0005961049,0.07293596],"study_design_scores_gemma":[0.0000782728,0.00040851053,0.9905676,0.00003706252,0.0013373101,0.0010223766,0.00042341463,0.001169295,0.002950022,0.00080626353,0.0011819839,0.000017836583],"about_ca_topic_score_codex":0.008811021,"about_ca_topic_score_gemma":0.01007102,"teacher_disagreement_score":0.008811021,"about_ca_system_score_codex":0.0005052819,"about_ca_system_score_gemma":0.00059974444,"threshold_uncertainty_score":0.017519474},"labels":[],"label_agreement":null},{"id":"W2104985658","doi":"10.1016/s1470-2045(06)70624-6","title":"Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study","year":2006,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":108,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; McGill University; Université de Montréal; Hôtel-Dieu de Montréal; Coalition for Research in Women's Health; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Breast cancer; Mammography; BRCA mutation; Obstetrics; Gynecology; Oophorectomy; Odds ratio; Oncology; Cancer; Internal medicine; Surgery; Hysterectomy","score_opus":0.01136395743167024,"score_gpt":0.2930139361479605,"score_spread":0.2816499787162903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104985658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99883646,0.00052926794,0.00013280686,0.000034896122,0.000015950758,0.000023683117,0.00015318739,0.000008108405,0.0002656141],"genre_scores_gemma":[0.99874216,0.00023419202,0.0001638703,0.000038781178,0.00003544042,0.000032337008,0.00022443745,0.000007172976,0.00052165455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978148,0.0008317894,0.00022153999,0.0006107187,0.00026014572,0.0002611041],"domain_scores_gemma":[0.9944824,0.0023743568,0.0009714025,0.0010156845,0.00037283465,0.00078330067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002432885,0.0015376938,0.0017735495,0.002525046,0.001879039,0.0017420058,0.0017600558,0.0029873406,0.004638419],"category_scores_gemma":[0.0076221917,0.0028362668,0.0017303918,0.0024704847,0.001641961,0.0011776766,0.00090706383,0.0018766882,0.00064327504],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012923066,0.0024421804,0.97452515,0.00010719274,0.00156404,0.0020372942,0.0009927336,0.0001224809,0.0025316468,0.00019944742,0.0003156034,0.0022392024],"study_design_scores_gemma":[0.0009127262,0.0032597855,0.9891879,0.00002164217,0.0012637095,0.003158013,0.000654192,0.00062407367,0.00031709086,0.00015434169,0.0003965273,0.00004992406],"about_ca_topic_score_codex":0.011581626,"about_ca_topic_score_gemma":0.0066366633,"teacher_disagreement_score":0.011581626,"about_ca_system_score_codex":0.0008085053,"about_ca_system_score_gemma":0.0005634468,"threshold_uncertainty_score":0.023028433},"labels":[],"label_agreement":null},{"id":"W2105263683","doi":"10.1016/s1470-2045(10)70104-2","title":"Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in early stage vulvar cancer: results from GROINSS-V, a multicentre observational study","year":2010,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":263,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Sentinel node; Vulvar cancer; Lymphadenectomy; Metastasis; Stage (stratigraphy); Cancer; Oncology; Surgery; Radiology; Internal medicine; Breast cancer","score_opus":0.11081995486043818,"score_gpt":0.37555933868468816,"score_spread":0.26473938382425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105263683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976311,0.0006783899,0.000068195826,0.00005307906,0.000011464403,0.000013620783,0.0014125154,0.0000034413715,0.00012825431],"genre_scores_gemma":[0.99807006,0.0002520722,0.000087781584,0.000050984345,0.000022024775,0.00002170814,0.0013267415,0.0000054960155,0.00016314305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99825174,0.00086582784,0.00013927373,0.00035499275,0.00016719896,0.00022099452],"domain_scores_gemma":[0.9938245,0.0021633152,0.0018490049,0.0008377236,0.00037369394,0.0009518647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023061947,0.00090285344,0.0010324508,0.00082044874,0.00058794854,0.0012328271,0.0014312862,0.0014919392,0.0016869226],"category_scores_gemma":[0.007235788,0.0008913517,0.00265777,0.0022039267,0.0006746205,0.00081851834,0.0010315705,0.0013005692,0.00033750787],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031658923,0.00013387945,0.9937983,0.000055475375,0.0010231244,0.00009847994,0.00015994036,0.0001528138,0.00027562308,0.000027528617,0.0002670228,0.0008418685],"study_design_scores_gemma":[0.00033377635,0.0004525164,0.9976528,0.000020258147,0.0007025685,0.00013839903,0.00025789754,0.00016965724,0.00005326307,0.000034331224,0.0001670894,0.000017476508],"about_ca_topic_score_codex":0.02259205,"about_ca_topic_score_gemma":0.022719657,"teacher_disagreement_score":0.02259205,"about_ca_system_score_codex":0.00078444235,"about_ca_system_score_gemma":0.0008761253,"threshold_uncertainty_score":0.0449211},"labels":[],"label_agreement":null},{"id":"W2106285196","doi":"10.1016/s1470-2045(10)70223-0","title":"External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study","year":2010,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":944,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Mount Sinai Hospital; Princess Margaret Cancer Centre","funders":"Ligue Contre le Cancer; AstraZeneca; American Society for Radiation Oncology","keywords":"Medicine; Goserelin; Androgen suppression; Prostate cancer; Clinical endpoint; Urology; Cyproterone acetate; Radiation therapy; Androgen; Prostate; Antiandrogen; Internal medicine; Androgen deprivation therapy; Randomized controlled trial; Medroxyprogesterone acetate; Cancer; Surgery; Hormone","score_opus":0.034388300340051865,"score_gpt":0.3603229668372296,"score_spread":0.3259346664971777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106285196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99005836,0.005205099,0.0006440997,0.00045701565,0.0005119981,0.0007573515,0.0010158843,0.000057221205,0.001292994],"genre_scores_gemma":[0.9906289,0.0030311083,0.0005831242,0.00070258183,0.00050476624,0.0007270939,0.0010590904,0.00004650978,0.0027167895],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99608934,0.002486961,0.0002086713,0.00048318657,0.00021717118,0.0005146693],"domain_scores_gemma":[0.9962443,0.0016757916,0.000674123,0.0005817298,0.00015022795,0.0006739296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005687158,0.0025483053,0.006014866,0.0005898451,0.0006539442,0.001756462,0.0017469117,0.0033898496,0.0062070163],"category_scores_gemma":[0.0042275107,0.0012985844,0.0066520884,0.0009218547,0.0027881928,0.0020343338,0.0011352191,0.004807021,0.0010613423],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.99360037,0.0013807993,0.00047140697,0.00019439856,0.0011314361,0.000020367559,0.000027137932,0.00017348454,0.000561777,0.000031085707,0.0001231993,0.0022846616],"study_design_scores_gemma":[0.9420749,0.04884421,0.0055494597,0.000048489084,0.0025644181,0.000034074255,0.00004260794,0.00015742335,0.00021720194,0.00014115914,0.0002985069,0.000027464557],"about_ca_topic_score_codex":0.0043283156,"about_ca_topic_score_gemma":0.0049435175,"teacher_disagreement_score":0.0062070163,"about_ca_system_score_codex":0.0016820695,"about_ca_system_score_gemma":0.0014511048,"threshold_uncertainty_score":0.030076921},"labels":[],"label_agreement":null},{"id":"W2108275065","doi":"10.1016/s1470-2045(05)70394-6","title":"Chemotherapy-induced anaemia during adjuvant treatment for breast cancer: development of a prediction model","year":2005,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Logistic regression; Chemotherapy; Receiver operating characteristic; Internal medicine; Area under the curve; Oncology; Sample size determination; Cancer; Surgery; Statistics","score_opus":0.05331006828365456,"score_gpt":0.35086283400032575,"score_spread":0.2975527657166712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108275065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6863642,0.0016767784,0.30152056,0.0038464689,0.0002823275,0.00040350127,0.00225523,0.00097912,0.0026717538],"genre_scores_gemma":[0.96728444,0.000471021,0.029205069,0.00013708198,0.00013459106,0.0002031774,0.0015863748,0.00002884635,0.0009493867],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99936825,0.00030176202,0.000061175786,0.00013325892,0.000073238574,0.00006220486],"domain_scores_gemma":[0.9909656,0.0075972965,0.00048663144,0.00016120399,0.00057064474,0.00021860939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046163835,0.0009286741,0.0011130574,0.0011795239,0.0003975728,0.0014045743,0.0011156156,0.0009744954,0.0009507703],"category_scores_gemma":[0.009923208,0.0004353848,0.00087398494,0.000611874,0.000258287,0.0006864936,0.0006043717,0.0016440268,0.00029831176],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009320302,0.00071261014,0.1982876,0.000117971045,0.0007042751,0.00029351274,0.00013325982,0.6773572,0.0005170763,0.0027923507,0.0047515933,0.11340047],"study_design_scores_gemma":[0.000023925108,0.00005418188,0.0038255814,0.000008110035,0.00008160111,0.000031876498,0.0000092659975,0.9950513,0.00006578053,0.0007166507,0.00012522358,0.0000064479523],"about_ca_topic_score_codex":0.012596302,"about_ca_topic_score_gemma":0.00828009,"teacher_disagreement_score":0.012596302,"about_ca_system_score_codex":0.0008211574,"about_ca_system_score_gemma":0.0013271658,"threshold_uncertainty_score":0.025045991},"labels":[],"label_agreement":null},{"id":"W2108319301","doi":"10.1016/s1470-2045(10)70256-4","title":"Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China","year":2010,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":160,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Fogarty International Center","keywords":"Colposcopy; Medicine; Cervical cancer; Squamous intraepithelial lesion; Cervix; Population; Cervical intraepithelial neoplasia; Gynecology; Biopsy; Cytology; Cancer; Obstetrics; Oncology; Internal medicine; Pathology","score_opus":0.12761277244206512,"score_gpt":0.41634827178975076,"score_spread":0.2887354993476856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108319301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97909355,0.018219726,0.0009990339,0.00007515335,0.000055015997,0.000070165166,0.0010993602,0.000025449779,0.00036259828],"genre_scores_gemma":[0.9978668,0.00088678487,0.0002564211,0.000044951856,0.00002564061,0.00003545139,0.0008134325,0.00001246442,0.00005801977],"study_design_codex":"observational","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9785364,0.012090652,0.0027667796,0.0036785842,0.0019245282,0.0010030742],"domain_scores_gemma":[0.9762788,0.011359363,0.0044860574,0.004613972,0.0025075409,0.0007542956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.021164373,0.0024652188,0.006227445,0.005023135,0.0010189838,0.003020846,0.0015915328,0.0018283153,0.0007633174],"category_scores_gemma":[0.023878269,0.0016608657,0.0124305785,0.0065127667,0.0014691176,0.0014570056,0.002194572,0.000786645,0.00014948734],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043798885,0.000045315377,0.8859909,0.00055685925,0.10200751,0.00017588735,0.00036259647,0.00065415737,0.0005377402,0.000035396984,0.00017165717,0.0050820946],"study_design_scores_gemma":[0.00045548266,0.00076280953,0.90099746,0.000097974094,0.09511114,0.00025057961,0.00033984106,0.0010283743,0.0003742204,0.00011636043,0.00039650878,0.000069121525],"about_ca_topic_score_codex":0.0144315865,"about_ca_topic_score_gemma":0.015245866,"teacher_disagreement_score":0.021164373,"about_ca_system_score_codex":0.0015012745,"about_ca_system_score_gemma":0.0017224418,"threshold_uncertainty_score":0.11192924},"labels":[],"label_agreement":null},{"id":"W2108765055","doi":"10.1016/s1470-2045(15)00034-0","title":"Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Nausea and vomiting management","field":"Medicine","cited_by":151,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Anthracycline; Nausea; Vomiting; Chemotherapy; Cyclophosphamide; Chemotherapy-induced nausea and vomiting; Randomized controlled trial; Palonosetron; Cancer; Internal medicine; Oncology; Antiemetic; Breast cancer","score_opus":0.07038524306020998,"score_gpt":0.3918463014891096,"score_spread":0.3214610584288996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108765055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99137574,0.004010561,0.00040147416,0.00048193306,0.00034899448,0.0017098024,0.0004737323,0.00009959079,0.0010981101],"genre_scores_gemma":[0.99275315,0.0020702898,0.00090030587,0.00059520203,0.00033963984,0.0013125108,0.00049775693,0.000025636931,0.0015056387],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99913377,0.0004910784,0.00006140111,0.00014474736,0.000051293246,0.000117675176],"domain_scores_gemma":[0.99840933,0.0005552688,0.0004067013,0.00015058658,0.000062674466,0.00041542223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021789996,0.001434842,0.0036199084,0.00050712127,0.00047085492,0.0010862966,0.0012378613,0.0021066312,0.004698749],"category_scores_gemma":[0.0026941793,0.00077434804,0.0024798622,0.00042088484,0.0017200003,0.0012411966,0.00047085108,0.003621562,0.00087253057],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98157805,0.0034453734,0.00038328848,0.0004568537,0.0007125814,0.000028264372,0.000052205138,0.0001863882,0.0020681617,0.000055727898,0.0002566859,0.010776381],"study_design_scores_gemma":[0.93841964,0.059246052,0.0011708885,0.000023271654,0.00035442627,0.000023198641,0.00001299835,0.00020465713,0.00027168496,0.000071546514,0.0001886093,0.000013026508],"about_ca_topic_score_codex":0.00094103353,"about_ca_topic_score_gemma":0.0015829222,"teacher_disagreement_score":0.004698749,"about_ca_system_score_codex":0.00068005867,"about_ca_system_score_gemma":0.0011899531,"threshold_uncertainty_score":0.015718877},"labels":[],"label_agreement":null},{"id":"W2109063533","doi":"10.1016/s1470-2045(05)70390-9","title":"Mammographic breast density as an intermediate phenotype for breast cancer","year":2005,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Digital Radiography and Breast Imaging","field":"Medicine","cited_by":630,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Hospital for Sick Children; University of Toronto; Ontario Institute for Cancer Research","funders":"Medical Research Council; Canada Research Chairs; National Breast Cancer Foundation","keywords":"Breast cancer; Breast density; Mammography; MAMMOGRAPHIC DENSITY; Breast tissue; Medicine; Risk factors for breast cancer; Oncology; Cancer; Internal medicine","score_opus":0.06242076777872589,"score_gpt":0.4033152415651653,"score_spread":0.3408944737864394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109063533","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020796686,0.99833965,0.000096262316,0.00038250393,0.00020558122,0.000003415869,0.000034942994,0.0000051104516,0.00072448316],"genre_scores_gemma":[0.0034911663,0.99489945,0.0003053292,0.00043402024,0.00030214028,0.000008025532,0.000080431666,0.0000012501379,0.00047814814],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99972945,0.000051226565,0.000049984435,0.0000530267,0.00009887702,0.00001748495],"domain_scores_gemma":[0.9990068,0.0005693555,0.00015998952,0.000019854142,0.00020231765,0.000041732812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000688549,0.0006887131,0.0022113947,0.0020875013,0.00014446676,0.0007576138,0.0006537535,0.00076799537,0.0022028899],"category_scores_gemma":[0.002242584,0.0002597299,0.00043750516,0.0023270505,0.00048335653,0.00069292955,0.00039640057,0.00094422133,0.0007817932],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015641865,0.000029089178,0.002465789,0.012789716,0.0001632257,0.00033464027,0.000026605796,0.00022869743,0.00038985605,0.0013984715,0.034855068,0.9471625],"study_design_scores_gemma":[0.00018533746,0.00031812862,0.026524266,0.024097482,0.0023185483,0.012392266,0.00027111254,0.0004937887,0.00070946896,0.0043455604,0.92826146,0.00008251718],"about_ca_topic_score_codex":0.002796812,"about_ca_topic_score_gemma":0.005499207,"teacher_disagreement_score":0.002796812,"about_ca_system_score_codex":0.00059588224,"about_ca_system_score_gemma":0.0009833899,"threshold_uncertainty_score":0.007369399},"labels":[],"label_agreement":null},{"id":"W2109575571","doi":"10.1016/s1470-2045(06)70576-9","title":"Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors","year":2006,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":539,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Hospital for Sick Children; University of British Columbia; Canadian College of Naturopathic Medicine; University of Toronto; McMaster University","funders":"Sick Kids Foundation","keywords":"Clinical trial; Medicine; Protocol (science); Systematic review; Alternative medicine; Meta-analysis; Placebo; Family medicine; Patient participation; MEDLINE; Internal medicine; Pathology","score_opus":0.8673190754124493,"score_gpt":0.7341545071881482,"score_spread":0.13316456822430112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109575571","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04670129,0.9454357,0.002943487,0.0021545303,0.00041492976,0.0010655607,0.0006182884,0.000029490304,0.0006367941],"genre_scores_gemma":[0.79160416,0.1939713,0.007207431,0.0027714316,0.0004698992,0.0031045547,0.00055694045,0.00004563774,0.0002686052],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.7472197,0.1855226,0.047579166,0.0062143244,0.011613198,0.0018510359],"domain_scores_gemma":[0.42676604,0.5027709,0.051862452,0.010094888,0.006607736,0.0018979891],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.13124797,0.0015114385,0.009296692,0.0026817764,0.0008125737,0.0028850152,0.0017998719,0.0032867503,0.0020900685],"category_scores_gemma":[0.35492745,0.0015831023,0.020054586,0.005034554,0.0016375108,0.0028617175,0.0025266525,0.003563892,0.00013476859],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009713461,0.00013009865,0.055517517,0.20655839,0.6807,0.00019628766,0.0012347619,0.00046852042,0.00020093884,0.0005038522,0.0015051067,0.043271117],"study_design_scores_gemma":[0.005324716,0.0014369044,0.043289334,0.042546794,0.89902645,0.0004405742,0.0007165615,0.00045666727,0.00041212564,0.0013784576,0.0048644026,0.00010713899],"about_ca_topic_score_codex":0.0026030056,"about_ca_topic_score_gemma":0.0072919866,"teacher_disagreement_score":0.868752,"about_ca_system_score_codex":0.0028391937,"about_ca_system_score_gemma":0.00603838,"threshold_uncertainty_score":0.69411385},"labels":[],"label_agreement":null},{"id":"W2109611268","doi":"10.1016/s1470-2045(15)00201-6","title":"Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":157,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"National Cancer Institute; Sunesis","keywords":"Cytarabine; Medicine; Refractory (planetary science); Placebo; Myeloid leukaemia; Double blind; Internal medicine; Chemotherapy; Physics","score_opus":0.09009627044355988,"score_gpt":0.38511582346662937,"score_spread":0.2950195530230695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109611268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99265164,0.0031396677,0.00045391603,0.00037309603,0.00041471267,0.0014315121,0.0005121714,0.00010059466,0.0009226614],"genre_scores_gemma":[0.9911873,0.0023254312,0.0009037509,0.0005976124,0.00036314217,0.0014083082,0.0006171274,0.000025956302,0.0025715283],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993393,0.00038666523,0.000033457167,0.0000964603,0.000035247303,0.00010884988],"domain_scores_gemma":[0.9990314,0.00032736268,0.00019466829,0.00007268862,0.000046504745,0.00032738672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016532093,0.0016662102,0.0036775847,0.00045503912,0.0003935827,0.0010803986,0.0009549537,0.0015935298,0.004700141],"category_scores_gemma":[0.0014837416,0.00063371944,0.0020897903,0.00046558966,0.0012659795,0.0011023686,0.0004305733,0.0028180506,0.0009105904],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9873232,0.002721478,0.00023868999,0.00030926746,0.00044021566,0.000016603213,0.00003706171,0.00018648375,0.0017072277,0.00004772616,0.00022608391,0.006746019],"study_design_scores_gemma":[0.93193895,0.06599829,0.0010806711,0.000015867823,0.00023366904,0.00001722569,0.00001952094,0.00018863115,0.0001938872,0.00007660189,0.0002255091,0.000011263965],"about_ca_topic_score_codex":0.0011401676,"about_ca_topic_score_gemma":0.002453462,"teacher_disagreement_score":0.004700141,"about_ca_system_score_codex":0.00063002034,"about_ca_system_score_gemma":0.0009386914,"threshold_uncertainty_score":0.015723586},"labels":[],"label_agreement":null},{"id":"W2109847618","doi":"10.1016/s1470-2045(04)01468-8","title":"Environmental, genetic, and molecular features of prostate cancer","year":2004,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Prostate cancer; Carcinogenesis; Cancer; Disease; Prostate; Oncology; Androgen; Medicine; Stage (stratigraphy); Internal medicine; Cancer research; Biology; Hormone","score_opus":0.052135824976632876,"score_gpt":0.40191947715364446,"score_spread":0.3497836521770116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109847618","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000057592086,0.99901223,0.00006979851,0.00020180752,0.00013130889,0.000001730349,0.0000115853545,0.000003516029,0.0005103242],"genre_scores_gemma":[0.0003460607,0.99900776,0.000087923654,0.00013040517,0.00014053979,0.0000017765569,0.0000174913,4.6438893e-7,0.00026758754],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997478,0.00005504433,0.000026418771,0.0000438033,0.00010624795,0.000020661202],"domain_scores_gemma":[0.9995468,0.00025333054,0.00006660817,0.000013737902,0.00009086388,0.000028553195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007213827,0.0011354305,0.0023605297,0.0021282476,0.00026094663,0.000843383,0.0012079754,0.0011081694,0.0025898977],"category_scores_gemma":[0.00088687876,0.00035570914,0.00055443944,0.0034829394,0.0006512971,0.0010003042,0.00056882063,0.0016150114,0.0013375902],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010577593,0.000059915885,0.0009171055,0.013917409,0.00024981625,0.0005169394,0.000044881937,0.00049423514,0.001166504,0.003007534,0.04100615,0.9385137],"study_design_scores_gemma":[0.00003367157,0.00006139841,0.0044656224,0.005239486,0.000369729,0.0035052074,0.000105797684,0.000073157804,0.00034006892,0.0027771187,0.9829994,0.000029316374],"about_ca_topic_score_codex":0.0031289954,"about_ca_topic_score_gemma":0.007266378,"teacher_disagreement_score":0.0031289954,"about_ca_system_score_codex":0.0008256371,"about_ca_system_score_gemma":0.0012547361,"threshold_uncertainty_score":0.008664131},"labels":[],"label_agreement":null},{"id":"W2111285159","doi":"10.1016/s1470-2045(11)70141-3","title":"Delivering affordable cancer care in high-income countries","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":714,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Institute for Health and Care Research; King's College London; King's College Hospital NHS Foundation Trust; Department of Health and Social Care; Conquer Cancer Foundation","keywords":"Medicine; Health care; Cancer; Concordance; Modalities; Health technology; Public economics; Economic growth; Economics","score_opus":0.05469430517267371,"score_gpt":0.2706740393965379,"score_spread":0.21597973422386418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111285159","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.306165,0.09691954,0.01946163,0.5247277,0.0037773345,0.00023094875,0.0057822266,0.00011362959,0.04282196],"genre_scores_gemma":[0.97375035,0.017988337,0.0015090528,0.0031444882,0.0008693636,0.00008799575,0.0007182377,0.000014913813,0.0019172651],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961808,0.0026602438,0.000108366454,0.00012008487,0.00029209038,0.0006383218],"domain_scores_gemma":[0.9851732,0.009809341,0.002356069,0.0002989193,0.0009863721,0.0013760297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0054987087,0.00037185184,0.00073987606,0.0013097984,0.00054478936,0.0034584124,0.0006036386,0.0023151734,0.0048256665],"category_scores_gemma":[0.029332926,0.00039397838,0.0005529939,0.003943483,0.0012349507,0.002730676,0.0016264918,0.0026845387,0.0002357644],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006726216,0.00039026502,0.15723494,0.0018306485,0.0009628852,0.0009749669,0.00069408474,0.22986588,0.00025172078,0.40832087,0.11859071,0.080210395],"study_design_scores_gemma":[0.0006631168,0.0006825362,0.20876119,0.0036148936,0.0007562769,0.00059466384,0.006171357,0.18745753,0.0006672831,0.4852957,0.10512276,0.00021273777],"about_ca_topic_score_codex":0.037383363,"about_ca_topic_score_gemma":0.030220944,"teacher_disagreement_score":0.037383363,"about_ca_system_score_codex":0.005183395,"about_ca_system_score_gemma":0.0059793494,"threshold_uncertainty_score":0.07433158},"labels":[],"label_agreement":null},{"id":"W2111404068","doi":"10.1016/s1470-2045(14)70012-9","title":"Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":978,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Medical Research Council; National Health and Medical Research Council; National Cancer Institute; National Institutes of Health; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Genentech; F. Hoffmann-La Roche","keywords":"Vemurafenib; Dacarbazine; Medicine; Internal medicine; Melanoma; Population; Oncology; Progression-free survival; Metastatic melanoma; Chemotherapy; Cancer research; Cancer","score_opus":0.0286159142605539,"score_gpt":0.3339014764236995,"score_spread":0.3052855621631456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111404068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99167293,0.0047524567,0.0004626338,0.00040933606,0.00019128175,0.00046462347,0.000985936,0.00008585576,0.00097488693],"genre_scores_gemma":[0.99372286,0.0015021666,0.0004907216,0.00062032195,0.00023301839,0.0006096335,0.0013580752,0.00003562452,0.0014275884],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99872833,0.0006131897,0.00006362491,0.00016202425,0.00012748309,0.0003054112],"domain_scores_gemma":[0.9979856,0.0005695259,0.00049975276,0.0002264808,0.00013192705,0.0005866196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003949154,0.0018262627,0.0036587354,0.00041765007,0.00046277163,0.0018103584,0.0011022305,0.0020356025,0.0035823206],"category_scores_gemma":[0.0029276935,0.00085706316,0.003841465,0.0004780108,0.001255677,0.0021236553,0.0004808018,0.004416535,0.0011533354],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95676416,0.003857563,0.0020382584,0.00048029487,0.0018548663,0.000079259764,0.00008827834,0.0008627842,0.005060294,0.00008658344,0.0011240011,0.027703583],"study_design_scores_gemma":[0.8063305,0.16647942,0.020687902,0.00007640621,0.0016794241,0.00022631006,0.000078332196,0.0009554772,0.0013807025,0.0004578911,0.0015756332,0.00007200619],"about_ca_topic_score_codex":0.0009440455,"about_ca_topic_score_gemma":0.0015214767,"teacher_disagreement_score":0.003949154,"about_ca_system_score_codex":0.0013212564,"about_ca_system_score_gemma":0.00095832883,"threshold_uncertainty_score":0.020885348},"labels":[],"label_agreement":null},{"id":"W2111498373","doi":"10.1016/s1470-2045(14)70265-7","title":"Risk of late effects of treatment in children newly diagnosed with standard-risk acute lymphoblastic leukaemia: a report from the Childhood Cancer Survivor Study cohort","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":141,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University of Toronto; Hospital for Sick Children; University of Alberta","funders":"National Cancer Institute; Swiss Cancer Research Foundation; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung","keywords":"Medicine; Pediatrics; Cohort; Cohort study; Epidemiology; Cancer; Incidence (geometry); Population; Internal medicine","score_opus":0.008375098535697043,"score_gpt":0.2933682577099663,"score_spread":0.2849931591742692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111498373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99581367,0.00077291176,0.00008142023,0.00023097867,0.000018577286,0.000006115083,0.0026047777,0.000008427941,0.00046319855],"genre_scores_gemma":[0.99674714,0.00070591393,0.000058287907,0.00006695315,0.00002532579,0.000009655014,0.0019552382,0.0000089466885,0.00042248936],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996245,0.00007977745,0.00003082472,0.00009268212,0.000059161986,0.0001130588],"domain_scores_gemma":[0.99820673,0.00026439465,0.00078866456,0.00019914661,0.00012531447,0.00041573262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056216394,0.00030366716,0.00051469135,0.00062302686,0.0004265013,0.0008738425,0.0005161316,0.0005253672,0.0012609955],"category_scores_gemma":[0.0020859712,0.00046011704,0.0009838777,0.0013315876,0.00024023595,0.0005423209,0.00057534606,0.0013345827,0.0001463319],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025128163,0.000023374258,0.998095,0.000007495869,0.000117391064,0.000115013085,0.00008428238,0.00004466353,0.00015558153,0.00003167711,0.00030710865,0.00076726225],"study_design_scores_gemma":[0.00001533669,0.00004622,0.99899894,0.000004650552,0.00007900025,0.00028689855,0.00016954189,0.00005955494,0.000046928522,0.000019690127,0.00026822032,0.0000050517283],"about_ca_topic_score_codex":0.042162113,"about_ca_topic_score_gemma":0.036447894,"teacher_disagreement_score":0.042162113,"about_ca_system_score_codex":0.0007083994,"about_ca_system_score_gemma":0.0007533887,"threshold_uncertainty_score":0.0838334},"labels":[],"label_agreement":null},{"id":"W2112121482","doi":"10.1016/s1470-2045(15)70076-8","title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2666,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"National Institutes of Health; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; GlaxoSmithKline; Bristol-Myers Squibb","keywords":"Open label; Medicine; Nivolumab; Oncology; Chemotherapy; Internal medicine; Ipilimumab; Randomized controlled trial; Immunotherapy; Cancer","score_opus":0.05803676378711036,"score_gpt":0.3752254400827541,"score_spread":0.31718867629564373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112121482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98952943,0.0044731926,0.00039847923,0.00081000867,0.00069251814,0.0015418069,0.00074645126,0.000087651715,0.0017204642],"genre_scores_gemma":[0.99119157,0.001974671,0.0007296998,0.0010883083,0.00027391434,0.0012449845,0.00075344584,0.000020945083,0.0027225094],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995334,0.00026611396,0.000020989912,0.000078550154,0.000024656329,0.00007625762],"domain_scores_gemma":[0.99938,0.00021676547,0.000115918476,0.000045029727,0.000033593133,0.00020870022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012879738,0.0011813781,0.0022642163,0.00028739803,0.00030476056,0.0010523495,0.000757686,0.0015757873,0.004668729],"category_scores_gemma":[0.0015151903,0.0005328783,0.0023230752,0.000304987,0.00090184924,0.001014309,0.00035630816,0.0031850303,0.0007976077],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9747882,0.0032320234,0.00074504246,0.00061800337,0.0011503777,0.000036861387,0.000054894193,0.000455368,0.0017181828,0.00011385672,0.00091118476,0.016176045],"study_design_scores_gemma":[0.94338536,0.052963622,0.001582022,0.000041719624,0.0005183443,0.000027963963,0.000027678476,0.0004429325,0.00024139883,0.00018817163,0.00056664547,0.00001417169],"about_ca_topic_score_codex":0.0012458029,"about_ca_topic_score_gemma":0.00323372,"teacher_disagreement_score":0.004668729,"about_ca_system_score_codex":0.00087498233,"about_ca_system_score_gemma":0.0007385144,"threshold_uncertainty_score":0.015618503},"labels":[],"label_agreement":null},{"id":"W2113057788","doi":"10.1016/s1470-2045(14)70380-8","title":"Outcomes and endpoints in cancer trials: bridging the divide","year":2014,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":91,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Medical Research Council; National Institutes of Health; Cancer Research UK","keywords":"Clinical endpoint; Medicine; Clinical trial; Psychological intervention; Intensive care medicine; Bridging (networking); Cancer; Disease; Clinical study design; Modalities; Randomized controlled trial; Computer science; Internal medicine; Nursing","score_opus":0.14362320288141806,"score_gpt":0.4459898483730344,"score_spread":0.30236664549161635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113057788","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000033745953,0.99733907,0.00020233986,0.0019483094,0.00026371673,0.0000045992447,0.000017097804,0.000004351733,0.00018667195],"genre_scores_gemma":[0.0016389906,0.9915092,0.0006950942,0.003992873,0.0019094794,0.00004247907,0.000041731168,0.000008070868,0.0001621589],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9883187,0.0066089374,0.0013508319,0.00095949695,0.0024712747,0.00029065783],"domain_scores_gemma":[0.91215104,0.080697805,0.0029154385,0.000751838,0.0026994054,0.00078452437],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.027892817,0.001952179,0.010381581,0.0029244828,0.00048097208,0.004829857,0.0036082717,0.0059003644,0.004037813],"category_scores_gemma":[0.05652139,0.0008274832,0.0025850898,0.0045553376,0.0034720302,0.0049494063,0.002993802,0.009624576,0.0010333635],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007800724,0.00007525127,0.0006390267,0.029437527,0.0011070227,0.00009667118,0.000113843176,0.0009252906,0.0001873482,0.019168831,0.035857093,0.911612],"study_design_scores_gemma":[0.001201754,0.0006143956,0.005321965,0.0973145,0.0031105992,0.0011393279,0.00036364593,0.0014078189,0.00034601506,0.12922366,0.7597219,0.00023459554],"about_ca_topic_score_codex":0.0018067437,"about_ca_topic_score_gemma":0.0032966998,"teacher_disagreement_score":0.9721072,"about_ca_system_score_codex":0.0043683616,"about_ca_system_score_gemma":0.005028063,"threshold_uncertainty_score":0.14751303},"labels":[],"label_agreement":null},{"id":"W2113322173","doi":"10.1016/s1470-2045(12)70559-4","title":"External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1029,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Health Sciences Centre; Western University; Sunnybrook Health Science Centre; University of Calgary","funders":"National Cancer Institute","keywords":"Renal cell carcinoma; Medicine; Prognostic model; Population; Oncology; Database; Internal medicine; Computer science; Overall survival; Environmental health","score_opus":0.08719604319912287,"score_gpt":0.3307886472917002,"score_spread":0.24359260409257733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113322173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869731,0.00031790946,0.0080557875,0.00022134306,0.000105885316,0.0002295457,0.0033093838,0.000072706694,0.00071439816],"genre_scores_gemma":[0.9882224,0.00009748443,0.0021914195,0.00011236,0.00006727705,0.00027633904,0.008614427,0.00010884636,0.00030946024],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9667055,0.026072722,0.0010599709,0.0036878735,0.0018061104,0.0006677452],"domain_scores_gemma":[0.87611413,0.086844735,0.0053047785,0.021577183,0.008752376,0.001406803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.07331189,0.0020979592,0.0018615216,0.0014587278,0.00146698,0.0024683233,0.004223462,0.002224792,0.0029017846],"category_scores_gemma":[0.10414292,0.0007127037,0.0043195435,0.0018338854,0.0021625988,0.0022951816,0.0030126427,0.0038543493,0.0013627964],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027473405,0.0033384652,0.90779895,0.00029564317,0.012361768,0.00037425334,0.0014298701,0.018387478,0.0009831417,0.0011393392,0.0076362356,0.018781474],"study_design_scores_gemma":[0.0079163965,0.009058295,0.8277296,0.00027566336,0.010603331,0.0013923527,0.0016918345,0.12752515,0.001459352,0.004743157,0.0073257275,0.0002791523],"about_ca_topic_score_codex":0.0049086697,"about_ca_topic_score_gemma":0.0034381626,"teacher_disagreement_score":0.07331189,"about_ca_system_score_codex":0.0012027399,"about_ca_system_score_gemma":0.0016604664,"threshold_uncertainty_score":0.38771498},"labels":[],"label_agreement":null},{"id":"W2113344831","doi":"10.1016/s1470-2045(09)70314-6","title":"Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial","year":2009,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1405,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Genomic Health; U.S. Department of Health and Human Services","keywords":"Tamoxifen; Medicine; Internal medicine; Breast cancer; Oncology; Hazard ratio; Proportional hazards model; Anthracycline; Chemotherapy; Cyclophosphamide; Retrospective cohort study; Gynecology; Cancer; Confidence interval","score_opus":0.008274236675616017,"score_gpt":0.2673977770089922,"score_spread":0.2591235403333762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113344831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99471825,0.004161738,0.00014070339,0.00014924743,0.00010561206,0.00010952548,0.0002479025,0.000006384371,0.0003606377],"genre_scores_gemma":[0.9983563,0.00074191636,0.00013780086,0.0001047716,0.000092403934,0.000070124246,0.00028981714,0.000003950733,0.0002029217],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99641126,0.0024078311,0.00031573605,0.00044383004,0.00022210144,0.00019919187],"domain_scores_gemma":[0.9907137,0.005222095,0.002052582,0.0010019201,0.00028758595,0.0007219974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004676948,0.0010501532,0.0022283676,0.00039520237,0.0003892712,0.0012848201,0.0008254644,0.0016445256,0.0019103723],"category_scores_gemma":[0.010217037,0.0006771284,0.0029170811,0.0008909213,0.001542758,0.0010417154,0.0005543203,0.0017576823,0.0003112508],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9223838,0.0005018896,0.060476515,0.00035872226,0.005683722,0.00007068371,0.00011955967,0.00052018394,0.0013071707,0.00009258886,0.00019100771,0.008294235],"study_design_scores_gemma":[0.5032617,0.13601023,0.3158547,0.00031403737,0.034126665,0.00059810287,0.00033612037,0.0032794988,0.002177735,0.0013654631,0.0024480661,0.00022769379],"about_ca_topic_score_codex":0.0012476073,"about_ca_topic_score_gemma":0.001500675,"teacher_disagreement_score":0.004676948,"about_ca_system_score_codex":0.0007740223,"about_ca_system_score_gemma":0.0007611713,"threshold_uncertainty_score":0.024734378},"labels":[],"label_agreement":null},{"id":"W2113721264","doi":"10.1016/s1470-2045(09)70279-7","title":"Eradication of a disease: how we cured asymptomatic prostate cancer","year":2000,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Asymptomatic; Prostate cancer; Disease; Medicine; Cancer; Prostate; Oncology; Internal medicine","score_opus":0.031400975568474994,"score_gpt":0.3364240071741232,"score_spread":0.3050230316056482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113721264","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0060128383,0.42217824,0.005486196,0.53106713,0.019397292,0.000020760343,0.0000931387,0.00017032566,0.01557409],"genre_scores_gemma":[0.22545056,0.38439646,0.00735484,0.29415566,0.058678135,0.00008456934,0.00022444718,0.0002481983,0.02940714],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99840987,0.0006932865,0.00010278907,0.00015220024,0.00041637532,0.00022542507],"domain_scores_gemma":[0.9953868,0.0024526569,0.0003433491,0.00030935652,0.0007070117,0.0008008303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040376307,0.0005336794,0.0009204276,0.0006301423,0.0011505598,0.0025674505,0.000697447,0.0043891137,0.006022685],"category_scores_gemma":[0.011414093,0.00025385464,0.0006765011,0.00038834498,0.004106662,0.005464043,0.0017949477,0.009638994,0.00158363],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044590305,0.00036704598,0.0036742303,0.002053679,0.0002257533,0.00064131606,0.0011220115,0.00059215113,0.0026635244,0.061859265,0.27862167,0.64773333],"study_design_scores_gemma":[0.00020855118,0.00048562026,0.0036320721,0.0015331336,0.00017786348,0.0015540915,0.0010552786,0.00030273633,0.00097521255,0.07278359,0.9172094,0.00008260856],"about_ca_topic_score_codex":0.0022066578,"about_ca_topic_score_gemma":0.004335784,"teacher_disagreement_score":0.006022685,"about_ca_system_score_codex":0.0013769154,"about_ca_system_score_gemma":0.0023126812,"threshold_uncertainty_score":0.021353304},"labels":[],"label_agreement":null},{"id":"W2115081639","doi":"10.1016/s1470-2045(14)70376-6","title":"Evidence-based care for trilateral retinoblastoma","year":2014,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children","funders":"","keywords":"Retinoblastoma; Scopus; Medicine; Pediatrics; Clinical trial; Epidemiology; Incidence (geometry); Family medicine; MEDLINE; Pathology; Political science","score_opus":0.10890512585081343,"score_gpt":0.37147253368953076,"score_spread":0.26256740783871735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115081639","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001643087,0.0031969072,0.00007226912,0.98739505,0.006860552,0.000005890229,0.000029529472,0.000007108497,0.0022684974],"genre_scores_gemma":[0.006343051,0.0038816265,0.00034269056,0.9440076,0.042795703,0.00003343426,0.000049354614,0.000013523899,0.002533062],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9920535,0.0034942515,0.0012494333,0.00041817778,0.0019768067,0.0008079082],"domain_scores_gemma":[0.96390957,0.02568325,0.0022183536,0.0007318177,0.004227732,0.003229157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007282056,0.000502811,0.0014993222,0.0013475529,0.0027231756,0.0036843682,0.0024245393,0.050747268,0.010074187],"category_scores_gemma":[0.072292686,0.00068023853,0.0020267593,0.00094837503,0.0032817367,0.004285961,0.0029538062,0.03985693,0.003573418],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016643325,0.00006595699,0.0010041945,0.00035933097,0.00007813591,0.001293581,0.00009405102,0.0001984768,0.00015928845,0.008748075,0.95083576,0.03699671],"study_design_scores_gemma":[0.0012926372,0.00019316074,0.0030961416,0.0051044775,0.00028903378,0.0035093233,0.00045877666,0.000992931,0.0004332349,0.05973861,0.92476314,0.00012850639],"about_ca_topic_score_codex":0.011048772,"about_ca_topic_score_gemma":0.028866515,"teacher_disagreement_score":0.050747268,"about_ca_system_score_codex":0.008025982,"about_ca_system_score_gemma":0.009396486,"threshold_uncertainty_score":0.058232903},"labels":[],"label_agreement":null},{"id":"W2115528152","doi":"10.1016/s1470-2045(15)00038-8","title":"Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":281,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Astex Pharmaceuticals; National Cancer Institute; Stand Up To Cancer; Entertainment Industry Foundation","keywords":"Tolerability; Medicine; Decitabine; International Prognostic Scoring System; Internal medicine; Hypomethylating agent; Myelodysplastic syndromes; Adverse effect; Neutropenia; Febrile neutropenia; Oncology; Pharmacology; Gastroenterology; Bone marrow; Toxicity; Biology; DNA methylation","score_opus":0.029835544640734405,"score_gpt":0.33339687282781183,"score_spread":0.30356132818707743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115528152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969983,0.0012406564,0.00020036635,0.00018910426,0.000072949035,0.0005001877,0.0003474432,0.00003956122,0.00041149717],"genre_scores_gemma":[0.99601704,0.0009268173,0.0005557384,0.00042340223,0.00006724582,0.00049519574,0.00063611806,0.000016184773,0.0008622517],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994271,0.00031097827,0.000029258244,0.000087078166,0.000047095455,0.00009850278],"domain_scores_gemma":[0.99929273,0.00015856307,0.00017359878,0.00006282907,0.000038630867,0.000273705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013292334,0.0014876818,0.002448973,0.00033324637,0.0002516468,0.0008581243,0.0006926499,0.0014108449,0.0025689197],"category_scores_gemma":[0.0012427913,0.0007943091,0.0013966378,0.00042121075,0.0012276886,0.00092592946,0.00034531593,0.0027774996,0.00068117335],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94525915,0.008773699,0.0020674837,0.00045380957,0.00095236156,0.00007044453,0.000115148694,0.0010413622,0.011785527,0.000093251416,0.0008807216,0.028507072],"study_design_scores_gemma":[0.7916769,0.19762856,0.0072727404,0.000021600285,0.00047508467,0.00010251977,0.000044191544,0.0007021996,0.0012013454,0.00013874975,0.00070537254,0.000030895895],"about_ca_topic_score_codex":0.0009983268,"about_ca_topic_score_gemma":0.0021366237,"teacher_disagreement_score":0.0025689197,"about_ca_system_score_codex":0.0010547633,"about_ca_system_score_gemma":0.0009415738,"threshold_uncertainty_score":0.008593917},"labels":[],"label_agreement":null},{"id":"W2116183806","doi":"10.1016/s1470-2045(12)70567-3","title":"Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":137,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia; McMaster University","funders":"Medical Research Council; National Institute for Health and Care Research","keywords":"Bevacizumab; Medicine; Ovarian cancer; Carboplatin; Clinical endpoint; Quality of life (healthcare); Internal medicine; Randomized controlled trial; Oncology; Chemotherapy; Endometrial cancer; Gynecologic oncology; Cancer; Clinical trial; Surgery","score_opus":0.07110357242492646,"score_gpt":0.4109774263119079,"score_spread":0.33987385388698144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116183806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95837826,0.027524007,0.0009041155,0.002112294,0.0013026784,0.0022790388,0.003231543,0.00009495425,0.0041731014],"genre_scores_gemma":[0.9856742,0.0047368133,0.0010788146,0.0017626547,0.00043243094,0.0018955693,0.0026118385,0.00002487335,0.0017828882],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987804,0.00072082423,0.00009127335,0.00016969616,0.00008366701,0.00015399713],"domain_scores_gemma":[0.998623,0.00046605564,0.0003872469,0.000113716465,0.000084699575,0.0003252932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020677557,0.0013694318,0.003279741,0.00038657626,0.00035265996,0.0011151513,0.00071021373,0.0016024443,0.00474068],"category_scores_gemma":[0.0027867998,0.0004233911,0.004352667,0.0005541774,0.00087086105,0.001001418,0.0007559431,0.0032723306,0.00044117513],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9810193,0.0007294446,0.000983607,0.0010186641,0.0045804246,0.000015570042,0.00002569711,0.00048379638,0.00055764447,0.0001510342,0.0012864693,0.009148326],"study_design_scores_gemma":[0.97274965,0.017053686,0.004548398,0.00016096522,0.0038239413,0.000024419294,0.000027281367,0.0003134616,0.00013250364,0.00038565946,0.00076092326,0.000019008012],"about_ca_topic_score_codex":0.00278387,"about_ca_topic_score_gemma":0.0064473934,"teacher_disagreement_score":0.00474068,"about_ca_system_score_codex":0.0016299706,"about_ca_system_score_gemma":0.0011440804,"threshold_uncertainty_score":0.015859187},"labels":[],"label_agreement":null},{"id":"W2116799256","doi":"10.1016/s1470-2045(10)70265-5","title":"Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study","year":2010,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":293,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Lynch syndrome; Endometrial cancer; Colorectal cancer; Cohort; Oncology; Medicine; Internal medicine; Gynecology; Cancer; DNA mismatch repair","score_opus":0.015752714071996615,"score_gpt":0.31767708056204846,"score_spread":0.30192436649005183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116799256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99909675,0.0002027881,0.00008177994,0.00003615383,0.000009205404,0.000006727005,0.00030755592,0.000003891617,0.00025522462],"genre_scores_gemma":[0.9991636,0.00012876434,0.00006733274,0.000021998665,0.00001129508,0.000007940952,0.00019849278,0.0000039006695,0.000396641],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993782,0.0001383155,0.00004975437,0.00022376863,0.00007557742,0.0001343687],"domain_scores_gemma":[0.9984894,0.00021719592,0.00037475766,0.0003615345,0.00014005887,0.00041703563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006812795,0.00067305,0.0007069838,0.00081709656,0.0010049802,0.00097298785,0.00074371987,0.0011772172,0.0025590372],"category_scores_gemma":[0.001986178,0.0012829448,0.0013455849,0.0012169239,0.00041328598,0.0007722468,0.0007026507,0.0013944049,0.00036149457],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011658303,0.00012279654,0.9948704,0.000010768223,0.0005749642,0.0004926424,0.0001971292,0.000054577544,0.0016235196,0.000040249553,0.00015576277,0.0006914866],"study_design_scores_gemma":[0.00006944476,0.00038823157,0.9972458,0.000006136114,0.00035424953,0.0010567968,0.00027486324,0.00019946291,0.00013187037,0.000035959776,0.0002219951,0.000015319634],"about_ca_topic_score_codex":0.014762031,"about_ca_topic_score_gemma":0.012322659,"teacher_disagreement_score":0.014762031,"about_ca_system_score_codex":0.00037984853,"about_ca_system_score_gemma":0.00047286635,"threshold_uncertainty_score":0.029352248},"labels":[],"label_agreement":null},{"id":"W2117355364","doi":"10.1016/s1470-2045(15)00216-8","title":"Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":121,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"","keywords":"Medicine; Bevacizumab; Erlotinib; Internal medicine; Colorectal cancer; Maintenance therapy; Oncology; Clinical endpoint; Progression-free survival; Chemotherapy; Cancer; Randomized controlled trial; Surgery; Epidermal growth factor receptor","score_opus":0.12324925473229352,"score_gpt":0.4226656086118182,"score_spread":0.29941635387952464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117355364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807093,0.0086843725,0.0007504553,0.0014673016,0.0008795494,0.0022157023,0.0016878919,0.00020684929,0.0033985828],"genre_scores_gemma":[0.98349124,0.0037580272,0.0016063919,0.0017667547,0.00045017563,0.0019969516,0.0019962206,0.00004307623,0.004891191],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994784,0.00024172281,0.000029869469,0.000103562415,0.000037552993,0.0001088804],"domain_scores_gemma":[0.99942446,0.00015339909,0.0001200474,0.000049762606,0.00003146166,0.00022089489],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018098026,0.0015164597,0.0027169436,0.00035965742,0.0003228176,0.0010590213,0.0008967966,0.0017654444,0.0072600036],"category_scores_gemma":[0.0014127917,0.0006406808,0.0024717117,0.00036225663,0.0011598964,0.0013533618,0.00049977173,0.0035395927,0.0011475688],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97471094,0.002361741,0.00040713116,0.0006841407,0.0010241227,0.00002620253,0.000051221352,0.00044601853,0.0017795056,0.00014880719,0.001351931,0.017008176],"study_design_scores_gemma":[0.9591064,0.038062766,0.0009322424,0.00003665795,0.00041338464,0.00003163919,0.000021593918,0.00035773157,0.0002115269,0.0001838307,0.000628241,0.000014068393],"about_ca_topic_score_codex":0.0015505967,"about_ca_topic_score_gemma":0.00407691,"teacher_disagreement_score":0.0072600036,"about_ca_system_score_codex":0.0010136584,"about_ca_system_score_gemma":0.0009345208,"threshold_uncertainty_score":0.024287105},"labels":[],"label_agreement":null},{"id":"W2117964602","doi":"10.1016/s1470-2045(11)70214-5","title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1113,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Juravinski Cancer Centre; Vancouver General Hospital; Hôtel-Dieu de Montréal; Centre Hospitalier de l’Université de Montréal; Université de Montréal; BC Cancer Agency; Princess Margaret Cancer Centre; Jewish General Hospital","funders":"AstraZeneca","keywords":"Medicine; Olaparib; Internal medicine; Tolerability; Breast cancer; Ovarian cancer; Oncology; BRCA mutation; PARP inhibitor; Clinical endpoint; Triple-negative breast cancer; Adverse effect; Response Evaluation Criteria in Solid Tumors; Cancer; Serous fluid; Phases of clinical research; Clinical trial","score_opus":0.11106092244593813,"score_gpt":0.3838345029660907,"score_spread":0.27277358052015255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117964602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927713,0.004122259,0.00036865348,0.00040767773,0.00021143678,0.0006877633,0.0006363013,0.00004401532,0.00075038814],"genre_scores_gemma":[0.99299496,0.0028098517,0.00059075764,0.0007372315,0.00022372488,0.0007170221,0.00085054134,0.000015861073,0.0010600706],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9992493,0.00040141633,0.00005028744,0.00012836757,0.000058592766,0.00011205689],"domain_scores_gemma":[0.99905723,0.00034675162,0.0002043744,0.00009641634,0.000042521715,0.0002526743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001518688,0.0016462597,0.0031190193,0.00036780146,0.0003383737,0.0013093108,0.0006725653,0.0015159062,0.0029478706],"category_scores_gemma":[0.0020018867,0.00070278096,0.0023912294,0.0005405281,0.0010747269,0.0013397378,0.00048014367,0.0026804963,0.000673212],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96886796,0.0034474134,0.0029097262,0.0006636194,0.001586037,0.00011283471,0.00008157673,0.00047869972,0.0026183503,0.00006752579,0.000528466,0.018637802],"study_design_scores_gemma":[0.9204349,0.06985808,0.0066982666,0.000036937967,0.0011007419,0.00013369939,0.00005471263,0.00047840245,0.00028729686,0.00017774121,0.0007094108,0.000029872679],"about_ca_topic_score_codex":0.0007898663,"about_ca_topic_score_gemma":0.0013857973,"teacher_disagreement_score":0.0031190193,"about_ca_system_score_codex":0.000652259,"about_ca_system_score_gemma":0.000742389,"threshold_uncertainty_score":0.0098615885},"labels":[],"label_agreement":null},{"id":"W2117969937","doi":"10.1016/s1470-2045(14)70471-1","title":"HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis","year":2014,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":729,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"Instituto de Salud Carlos III; European Commission","keywords":"Meta-analysis; Medicine; Head and neck cancer; Oncology; Larynx; Head and neck squamous-cell carcinoma; Cancer; Carcinogenesis; Internal medicine; Genotype; HPV infection; Cervical cancer; Pathology; Biology; Gene; Surgery; Genetics","score_opus":0.1688515908043484,"score_gpt":0.4355661928634556,"score_spread":0.26671460205910724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117969937","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004230522,0.9947344,0.00025155797,0.00009390295,0.000109641165,0.00009419103,0.00036367998,0.00001241539,0.00010965905],"genre_scores_gemma":[0.16084673,0.83449155,0.0018232194,0.000902145,0.0002228379,0.0005253556,0.00066526985,0.000024973195,0.0004979242],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9951468,0.0018122708,0.0015915893,0.00069833756,0.0005211551,0.00022993353],"domain_scores_gemma":[0.991353,0.0060703373,0.001454231,0.00034031962,0.0006408607,0.00014133095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0073360032,0.0027785115,0.015996652,0.003913013,0.0005909745,0.0024400847,0.0019858123,0.0021348535,0.0033031115],"category_scores_gemma":[0.021931494,0.0019624375,0.031512912,0.0061084777,0.00071335875,0.0016616912,0.0017713095,0.0017637147,0.00037165976],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017066337,0.000024944557,0.005564246,0.3438174,0.63676786,0.00012635192,0.00009607573,0.00027913792,0.00026610977,0.000083876934,0.0006635443,0.010603783],"study_design_scores_gemma":[0.0004488786,0.00010946312,0.0033091372,0.011658682,0.9829868,0.00007843431,0.000049280916,0.00005742186,0.00006860448,0.00009660455,0.0011171602,0.000019469362],"about_ca_topic_score_codex":0.011765938,"about_ca_topic_score_gemma":0.032520782,"teacher_disagreement_score":0.015996652,"about_ca_system_score_codex":0.0020834713,"about_ca_system_score_gemma":0.0030026569,"threshold_uncertainty_score":0.03879696},"labels":[],"label_agreement":null},{"id":"W2118779298","doi":"10.1016/s1470-2045(15)70081-1","title":"Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Adrenal and Paraganglionic Tumors","field":"Medicine","cited_by":333,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Université de Montréal; University of Colorado Denver; Leids Universitair Medisch Centrum; Centre Léon Bérard; Università degli Studi di Padova; Università Cattolica del Sacro Cuore; Erasmus Medisch Centrum; Astellas Pharma; University of Miami","keywords":"Medicine; Tolerability; Adrenocortical carcinoma; Clinical endpoint; Placebo; Internal medicine; Population; Oncology; Carcinoma; Clinical trial; Adverse effect; Surgery; Pathology","score_opus":0.1504030667974675,"score_gpt":0.41161209600715803,"score_spread":0.2612090292096905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118779298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9765667,0.00990353,0.0014686859,0.0010646997,0.0014352017,0.0049632867,0.0014473344,0.00035235088,0.0027982555],"genre_scores_gemma":[0.98070747,0.0053069317,0.0019342845,0.0014716216,0.00069131097,0.0035276688,0.00082492875,0.00006149811,0.0054743215],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99937433,0.00031354156,0.000041183634,0.00011499172,0.00004400302,0.000111950634],"domain_scores_gemma":[0.9992446,0.0002202897,0.00015170178,0.000061571634,0.000043681655,0.0002781034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016763111,0.0021431677,0.004563405,0.0005916063,0.0005166117,0.001241312,0.0010599928,0.0021070442,0.00875298],"category_scores_gemma":[0.001500169,0.0011918707,0.0026051088,0.00055356504,0.0019104513,0.0015370095,0.00052072323,0.0038633086,0.00160451],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9881207,0.002244478,0.00011734254,0.00048133387,0.00048629014,0.000014929346,0.000028756822,0.0001659829,0.0017408411,0.00005422618,0.00030725411,0.006237888],"study_design_scores_gemma":[0.96709174,0.031556744,0.000423924,0.000017743865,0.00024249971,0.000013023664,0.000013582694,0.0001699905,0.00014672177,0.00008077286,0.00023156084,0.000011630409],"about_ca_topic_score_codex":0.0014827105,"about_ca_topic_score_gemma":0.0028486876,"teacher_disagreement_score":0.00875298,"about_ca_system_score_codex":0.0008462657,"about_ca_system_score_gemma":0.0011380478,"threshold_uncertainty_score":0.029281616},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W2120100820","doi":"10.1016/s1470-2045(11)70303-5","title":"Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":357,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Bevacizumab; Nasopharyngeal carcinoma; Medicine; Oncology; Internal medicine; Radiation therapy; Chemotherapy","score_opus":0.1398796454562106,"score_gpt":0.3966526387327276,"score_spread":0.25677299327651704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120100820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98777467,0.004870742,0.0005336834,0.0008351558,0.0006316408,0.00197943,0.0010680169,0.00013502435,0.0021716421],"genre_scores_gemma":[0.9867669,0.0031407748,0.0020827032,0.0012237575,0.0003039838,0.0017414378,0.0016113624,0.00003725612,0.0030918648],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99920386,0.00040109883,0.00004550087,0.00015217245,0.000063092164,0.0001342528],"domain_scores_gemma":[0.9992021,0.00017383913,0.00015749903,0.0000757491,0.000050146995,0.0003407135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025545706,0.0017439837,0.0029291778,0.00057234796,0.00038687672,0.001269006,0.0013940631,0.0015478042,0.0055566086],"category_scores_gemma":[0.0015777069,0.0007231179,0.0029476634,0.00059380324,0.001127712,0.0013558664,0.0005761602,0.0038984686,0.0011338773],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9273925,0.013748911,0.0010936782,0.0008164458,0.002641027,0.00004641419,0.000117637894,0.0016461789,0.0039507914,0.00022963295,0.0024443474,0.045872457],"study_design_scores_gemma":[0.87675834,0.116604574,0.0026635863,0.00005232098,0.0009674131,0.000057304154,0.000034161498,0.000625987,0.000725039,0.00017210793,0.0013170952,0.000022054008],"about_ca_topic_score_codex":0.0026178453,"about_ca_topic_score_gemma":0.006840191,"teacher_disagreement_score":0.0055566086,"about_ca_system_score_codex":0.0015720318,"about_ca_system_score_gemma":0.0017854593,"threshold_uncertainty_score":0.018588722},"labels":[],"label_agreement":null},{"id":"W2120639027","doi":"10.1016/s1470-2045(12)70525-9","title":"Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":223,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Translational Research in Oncology; Hôpital du Saint-Sacrement; Essar Steel Algoma (Canada); Dr. H. Bliss Murphy Cancer Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Docetaxel; Hazard ratio; Anthracycline; Cyclophosphamide; Clinical endpoint; Taxane; Cancer; Chemotherapy; Oncology; Surgery; Randomized controlled trial; Confidence interval","score_opus":0.018305453951353627,"score_gpt":0.3107389978638279,"score_spread":0.2924335439124743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120639027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9804253,0.009745165,0.00040345904,0.0014015156,0.0003759266,0.00085725763,0.0034210426,0.000068383044,0.003301921],"genre_scores_gemma":[0.9806451,0.0047755865,0.0006426718,0.0016299572,0.00030355607,0.001212448,0.0059680776,0.000052733238,0.0047698813],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9985159,0.0008935784,0.000056522927,0.00017751372,0.00011127324,0.00024518793],"domain_scores_gemma":[0.99781907,0.00066344056,0.00055598485,0.00025232698,0.000105779756,0.0006034192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041512023,0.0016921882,0.002873711,0.00033732515,0.00051383453,0.0013842752,0.0010016899,0.0019037286,0.005127554],"category_scores_gemma":[0.003188108,0.00060643366,0.0025701479,0.00069061946,0.0009328448,0.0013389144,0.0005827103,0.004066231,0.0010594078],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9665903,0.002773359,0.0023138693,0.00041957817,0.0019224223,0.000035621284,0.00007647027,0.001120432,0.0014360347,0.00013113845,0.00247066,0.020710178],"study_design_scores_gemma":[0.86749536,0.09460334,0.027384818,0.00017194646,0.004001463,0.00014915735,0.00010911107,0.0008500508,0.000760705,0.0007502238,0.0036704552,0.00005339592],"about_ca_topic_score_codex":0.003676947,"about_ca_topic_score_gemma":0.0087141935,"teacher_disagreement_score":0.005127554,"about_ca_system_score_codex":0.0018038977,"about_ca_system_score_gemma":0.0016948639,"threshold_uncertainty_score":0.02195388},"labels":[],"label_agreement":null},{"id":"W2120711586","doi":"10.1016/s1470-2045(14)70005-1","title":"Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Rituximab; Follicular lymphoma; Clinical endpoint; Internal medicine; International Prognostic Index; Vincristine; Regimen; Prednisone; Cyclophosphamide; Population; Lymphoma; Oncology; Gastroenterology; Surgery; Randomized controlled trial; Chemotherapy","score_opus":0.025716597926266682,"score_gpt":0.35121340322397865,"score_spread":0.32549680529771197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120711586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99558157,0.00183765,0.0004532336,0.00020268626,0.000070474794,0.0006572868,0.00044875845,0.00006333577,0.0006850196],"genre_scores_gemma":[0.9958847,0.00085262203,0.0006709811,0.00035191464,0.000104001076,0.00068009895,0.0005482895,0.000037391677,0.0008700167],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978042,0.0014890274,0.000076505305,0.00024098536,0.00016221742,0.00022704597],"domain_scores_gemma":[0.99746406,0.00082873733,0.00070435076,0.00036657447,0.00012853219,0.0005076612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032191242,0.0014778128,0.0029985656,0.00047775044,0.00045202015,0.0015633352,0.0010418901,0.0017694,0.004119496],"category_scores_gemma":[0.003192653,0.0010429011,0.0031012,0.000590707,0.0017147117,0.0015209805,0.00045540073,0.0033880603,0.0009254382],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96949065,0.0036835172,0.0017523014,0.00024014898,0.0014261565,0.000041225278,0.00011259442,0.00081191247,0.004416205,0.00008409057,0.0004689507,0.017472161],"study_design_scores_gemma":[0.8498524,0.13767166,0.008428077,0.000028249533,0.0011630906,0.00009555245,0.00004017577,0.0007657461,0.000919327,0.00024208556,0.0007528652,0.000040856812],"about_ca_topic_score_codex":0.0014125891,"about_ca_topic_score_gemma":0.0019496137,"teacher_disagreement_score":0.004119496,"about_ca_system_score_codex":0.0016972965,"about_ca_system_score_gemma":0.0016925966,"threshold_uncertainty_score":0.017024577},"labels":[],"label_agreement":null},{"id":"W2120901491","doi":"10.1016/s1470-2045(12)70346-7","title":"Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":588,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Canadian Cancer Society Research Institute; Cancer Research UK; Chugai Pharmaceutical; Cancer Research Institute","keywords":"Medicine; Ifosfamide; Soft tissue sarcoma; Chemotherapy; Hazard ratio; Surgery; Radiation therapy; Clinical endpoint; Sarcoma; Internal medicine; Neutropenia; Doxorubicin; Randomized controlled trial; Oncology; Soft tissue; Etoposide; Confidence interval; Pathology","score_opus":0.03809641802320107,"score_gpt":0.34358341347774546,"score_spread":0.3054869954545444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120901491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96541405,0.018953742,0.0014384151,0.0016546997,0.0018691001,0.005720349,0.0018135516,0.00021557746,0.0029205873],"genre_scores_gemma":[0.97510296,0.007242459,0.0021200394,0.0017149522,0.0007259252,0.0060587674,0.0014048814,0.000044839948,0.0055851713],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9986314,0.00081981247,0.00008277775,0.0002222709,0.000069802176,0.0001739761],"domain_scores_gemma":[0.99893886,0.0003444168,0.0002697003,0.00010445092,0.000052486674,0.00028999842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029108787,0.0024456147,0.0045661004,0.0005338893,0.00043168478,0.0014271261,0.0011893802,0.0023413706,0.008425163],"category_scores_gemma":[0.002791049,0.0010513444,0.0034206635,0.00068928563,0.0016044863,0.0014690757,0.0008655397,0.0038016762,0.0012663256],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.99175996,0.00092874904,0.00020102672,0.0007912539,0.0010488735,0.000019789657,0.000026657492,0.00024657947,0.00057433697,0.0000666545,0.00036588375,0.003970203],"study_design_scores_gemma":[0.9869779,0.0110958945,0.0005258891,0.000051434683,0.0007527666,0.000011796865,0.000010603149,0.00013527514,0.00006907821,0.0000811443,0.000280479,0.000007799513],"about_ca_topic_score_codex":0.0023389182,"about_ca_topic_score_gemma":0.0040127644,"teacher_disagreement_score":0.008425163,"about_ca_system_score_codex":0.0014133138,"about_ca_system_score_gemma":0.0013504133,"threshold_uncertainty_score":0.02818501},"labels":[],"label_agreement":null},{"id":"W2121847974","doi":"10.1016/s1470-2045(15)70127-0","title":"Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":955,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Bevacizumab; FOLFIRI; Ramucirumab; Medicine; Oxaliplatin; Oncology; Internal medicine; Colorectal cancer; Second-line therapy; Placebo; Chemotherapy; Overall survival; Cancer; Pathology","score_opus":0.09086894514201639,"score_gpt":0.35377839830773355,"score_spread":0.2629094531657172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121847974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99200565,0.0046829735,0.0002975839,0.0003582068,0.00044433802,0.0008280145,0.00030149342,0.00010186233,0.0009798459],"genre_scores_gemma":[0.9942497,0.001778046,0.00066625973,0.00043806096,0.00034941855,0.00063690095,0.00037410672,0.000016091979,0.0014913558],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991757,0.0004282208,0.00005232747,0.00014624857,0.00004481807,0.00015268814],"domain_scores_gemma":[0.9991936,0.00022450142,0.0001944329,0.0000759707,0.000046904286,0.00026458965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002070412,0.0020388463,0.0048300195,0.00060308655,0.0004173464,0.0013176887,0.0010879583,0.0018637665,0.0031936439],"category_scores_gemma":[0.0016959525,0.0010070768,0.0029575091,0.00047035338,0.001025974,0.0015458305,0.00042151383,0.0037107768,0.0007649325],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98198503,0.0041301786,0.00039762235,0.0003377922,0.0007898417,0.000028549248,0.00004986785,0.00022833681,0.0018151344,0.00003342692,0.00024899494,0.009955158],"study_design_scores_gemma":[0.86007774,0.13540234,0.0023752837,0.000026918491,0.0007393245,0.000040866988,0.000032240918,0.0004282811,0.00047301743,0.00006676002,0.00031472245,0.000022576836],"about_ca_topic_score_codex":0.0011428904,"about_ca_topic_score_gemma":0.002649689,"teacher_disagreement_score":0.0048300195,"about_ca_system_score_codex":0.00093410903,"about_ca_system_score_gemma":0.0009033749,"threshold_uncertainty_score":0.010949492},"labels":[],"label_agreement":null},{"id":"W2122019520","doi":"10.1016/s1470-2045(05)70434-4","title":"Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium","year":2005,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":380,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Institute of Environmental Health Sciences; National Cancer Institute; National Institutes of Health","keywords":"Lymphoma; Odds ratio; Single-nucleotide polymorphism; Follicular lymphoma; Genotype; Allele; Medicine; Immunology; Diffuse large B-cell lymphoma; Internal medicine; Oncology; Biology; Genetics; Gene","score_opus":0.018200695965837014,"score_gpt":0.29873375294802484,"score_spread":0.28053305698218783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122019520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99608994,0.00035563024,0.000326265,0.00045291532,0.0000304538,0.000025272044,0.0016266821,0.000009640903,0.0010833528],"genre_scores_gemma":[0.9979898,0.00018117935,0.00022167439,0.00015619575,0.000047392452,0.000024492263,0.0010292211,0.0000102764,0.0003398563],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997547,0.0011731851,0.00016096249,0.00042981908,0.00038617535,0.00030285883],"domain_scores_gemma":[0.9950453,0.0019508653,0.0008236722,0.000568226,0.0007798331,0.0008320885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026877325,0.00072549784,0.00051850535,0.0010276806,0.0009464374,0.001181624,0.0008207928,0.0011991692,0.0018416055],"category_scores_gemma":[0.0058112475,0.00037378742,0.00079529296,0.0022941662,0.00065476587,0.00033814769,0.0008633836,0.0009280506,0.00021820462],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013628368,0.00008853123,0.9903397,0.000023753622,0.00044434186,0.0016043141,0.00059217535,0.00017890095,0.001575693,0.00011599704,0.0009242052,0.0027496999],"study_design_scores_gemma":[0.00017242056,0.00017072135,0.99468344,0.000020199275,0.0004569074,0.0018204165,0.0007681217,0.00020075993,0.00056813424,0.000107541055,0.0010091296,0.000022190658],"about_ca_topic_score_codex":0.02503551,"about_ca_topic_score_gemma":0.012005195,"teacher_disagreement_score":0.02503551,"about_ca_system_score_codex":0.00055536424,"about_ca_system_score_gemma":0.00063621,"threshold_uncertainty_score":0.049779534},"labels":[],"label_agreement":null},{"id":"W2122040419","doi":"10.1016/s1470-2045(02)00875-6","title":"Hormonal risk factors for breast cancer: identification, chemoprevention, and other intervention strategies","year":2002,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Breast cancer; Tamoxifen; Medicine; Tolerability; Psychological intervention; Clinical trial; Family history; Oncology; Cancer; Gynecology; Internal medicine; Adverse effect","score_opus":0.11875684668306657,"score_gpt":0.4330071391026873,"score_spread":0.3142502924196207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122040419","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000031103646,0.9994393,0.000050734383,0.00024997094,0.00007455644,0.000002097104,0.0000066224497,0.0000015961655,0.00014397057],"genre_scores_gemma":[0.00025126353,0.99928975,0.000098701945,0.00016441282,0.00009115232,0.0000038463136,0.0000073936008,3.1413165e-7,0.00009312991],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9994535,0.00014071168,0.00006210814,0.000086326865,0.00021980415,0.00003755743],"domain_scores_gemma":[0.9983954,0.0011457944,0.00015163966,0.00003348044,0.00021599482,0.00005767873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019075922,0.0016145065,0.0047336253,0.002536274,0.00033292308,0.0012499517,0.0012629391,0.0019677682,0.0033537499],"category_scores_gemma":[0.0025268965,0.00044827542,0.0011735942,0.0034673708,0.0008232512,0.0012757508,0.00071272993,0.0020485744,0.0014940689],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020493777,0.00011171533,0.00055231544,0.026936892,0.00048340135,0.00019911308,0.000050632756,0.0003985261,0.0005109184,0.0023909332,0.022288159,0.9458725],"study_design_scores_gemma":[0.00029227175,0.00036580616,0.006789712,0.03022498,0.0020404938,0.0033709642,0.00037925912,0.00026744886,0.0006618047,0.006854096,0.9486731,0.000080051606],"about_ca_topic_score_codex":0.0042123464,"about_ca_topic_score_gemma":0.008674883,"teacher_disagreement_score":0.0047336253,"about_ca_system_score_codex":0.0012044458,"about_ca_system_score_gemma":0.002258971,"threshold_uncertainty_score":0.011219382},"labels":[],"label_agreement":null},{"id":"W2123591186","doi":"10.1016/s1470-2045(11)70336-9","title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2358,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"","keywords":"Pertuzumab; Trastuzumab; Docetaxel; Medicine; Internal medicine; Clinical endpoint; Breast cancer; Oncology; Population; Chemotherapy; Clinical trial; Cancer","score_opus":0.06039123479763487,"score_gpt":0.3881995916148677,"score_spread":0.32780835681723286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123591186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950448,0.0018324394,0.0002065504,0.000617025,0.00020457101,0.000618451,0.0004117519,0.000040048148,0.0010243286],"genre_scores_gemma":[0.9911761,0.0015872855,0.0006657872,0.00089476357,0.00032557914,0.0013366247,0.0010836257,0.000023794619,0.0029064915],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993394,0.0003898284,0.00002745304,0.000104374085,0.000042910557,0.000096056945],"domain_scores_gemma":[0.99897814,0.00033716246,0.00019516164,0.000086987435,0.000039816106,0.0003627707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017531526,0.0017814697,0.0022799398,0.0003637272,0.00033057507,0.0009581393,0.00083788,0.0020711462,0.005738767],"category_scores_gemma":[0.0021602632,0.0008675606,0.0015842317,0.00037449776,0.0015818909,0.0015237862,0.00050987164,0.0031336856,0.0010143699],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9806631,0.003770045,0.0006735985,0.00017910359,0.00036971908,0.000027587683,0.000055384262,0.00031061727,0.0025330395,0.00006034163,0.0003911775,0.010966199],"study_design_scores_gemma":[0.875684,0.119945124,0.0023486847,0.000018444402,0.0003468345,0.00005716455,0.000030920037,0.0003720478,0.0004540383,0.00018646457,0.00053929747,0.000017002996],"about_ca_topic_score_codex":0.00070918293,"about_ca_topic_score_gemma":0.0016115828,"teacher_disagreement_score":0.005738767,"about_ca_system_score_codex":0.0010717179,"about_ca_system_score_gemma":0.0009633532,"threshold_uncertainty_score":0.01919806},"labels":[],"label_agreement":null},{"id":"W2124385271","doi":"10.1016/s1470-2045(13)70067-6","title":"Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label, randomised controlled trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":176,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Imiquimod; Medicine; Open label; Men who have sex with men; Fluorouracil; Human immunodeficiency virus (HIV); Intraepithelial neoplasia; Randomized controlled trial; Gynecology; Internal medicine; Dermatology; Family medicine; Chemotherapy; Cancer","score_opus":0.06802685372697216,"score_gpt":0.4116889270562707,"score_spread":0.34366207332929855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124385271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95551527,0.025886765,0.0014392062,0.001217232,0.0033008496,0.0077622924,0.0012694029,0.00018764487,0.0034212403],"genre_scores_gemma":[0.97703063,0.008432756,0.0019959125,0.0009505883,0.0011256953,0.0055854046,0.00063044386,0.000025255782,0.0042233625],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99857366,0.0007487495,0.00012992491,0.00026281874,0.000119218756,0.00016558074],"domain_scores_gemma":[0.99855286,0.00070590375,0.0002948586,0.00009584789,0.00009216168,0.00025842994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021697269,0.0024778577,0.006471824,0.0008034632,0.0006651078,0.001666783,0.0017573569,0.0034939009,0.008559298],"category_scores_gemma":[0.003694713,0.001331892,0.003722987,0.00072004955,0.0019812654,0.001841282,0.000643325,0.0035979745,0.0010427852],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.99195015,0.0011748149,0.000106226216,0.0009877426,0.0009111325,0.000020037089,0.000030261825,0.00010315444,0.00050424424,0.000058114587,0.00017160161,0.0039826515],"study_design_scores_gemma":[0.9818071,0.016681075,0.00033605905,0.00005431881,0.000602242,0.000010380094,0.000017383421,0.00016602212,0.000076891854,0.00006614946,0.0001724116,0.000009857008],"about_ca_topic_score_codex":0.0031320283,"about_ca_topic_score_gemma":0.0046909973,"teacher_disagreement_score":0.008559298,"about_ca_system_score_codex":0.0014156395,"about_ca_system_score_gemma":0.0012621533,"threshold_uncertainty_score":0.028633654},"labels":[],"label_agreement":null},{"id":"W2125620887","doi":"10.1016/s1470-2045(11)70033-x","title":"Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":611,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Trastuzumab; Medicine; Internal medicine; Interim analysis; Breast cancer; Oncology; Clinical endpoint; Population; Adjuvant; Surgery; Clinical trial; Hazard ratio; Cancer; Confidence interval","score_opus":0.0317431920055709,"score_gpt":0.327746268557953,"score_spread":0.2960030765523821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125620887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98250455,0.010841863,0.00056459854,0.0009606966,0.0013364499,0.0016900096,0.00085122697,0.00007874102,0.0011718496],"genre_scores_gemma":[0.98910576,0.003408131,0.0005484837,0.000983514,0.0006963568,0.0016645148,0.0010664796,0.00001954929,0.0025071357],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973013,0.0014150047,0.00019053539,0.00043545742,0.00015022465,0.000507383],"domain_scores_gemma":[0.9969304,0.0010331678,0.0008012664,0.00037073263,0.00020876524,0.0006556513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004106796,0.002524831,0.006905101,0.0006524436,0.00082866644,0.0019649186,0.0016061983,0.0042994106,0.0056308396],"category_scores_gemma":[0.0052081896,0.0012261156,0.006060629,0.0009387553,0.0020167774,0.0023832142,0.0008949673,0.005769826,0.0009304335],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.99391717,0.0012141968,0.00047785105,0.0002282359,0.0010697274,0.000021136946,0.000027919054,0.00011644916,0.00027824735,0.00002247117,0.00016622659,0.0024604504],"study_design_scores_gemma":[0.9484632,0.04538711,0.0033381346,0.0000619971,0.0019064692,0.000022428461,0.000032222717,0.00020810393,0.00013779974,0.00010673369,0.00031434535,0.000021368165],"about_ca_topic_score_codex":0.003359125,"about_ca_topic_score_gemma":0.0039498075,"teacher_disagreement_score":0.006905101,"about_ca_system_score_codex":0.0018690652,"about_ca_system_score_gemma":0.0016235914,"threshold_uncertainty_score":0.021719038},"labels":[],"label_agreement":null},{"id":"W2125681453","doi":"10.1016/s1470-2045(11)70404-1","title":"Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Endometriosis Research and Treatment","field":"Medicine","cited_by":932,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency","funders":"Medical Research and Materiel Command; U.S. Public Health Service; University of South China; American University of Sharjah; Bundesministerium für Bildung und Forschung; Lon V. Smith Foundation; National Cancer Institute; Seventh Framework Programme; University College London; National Institute of Allergy and Infectious Diseases; Medical Research Council; Roswell Park Alliance Foundation, Roswell Park Cancer Institute; Deutsches Krebsforschungszentrum; National Health and Medical Research Council; State of Connecticut Department of Public Health; California Breast Cancer Research Program; Kræftens Bekæmpelse; California Department of Public Health; Oak Foundation; Cancer Council Tasmania; National Institutes of Health; Ovarian Cancer Research Fund","keywords":"Endometriosis; Ovarian cancer; Medicine; Serous fluid; Odds ratio; Oncology; Internal medicine; Case-control study; Logistic regression; Clear cell; Cancer; Gynecology; Carcinoma","score_opus":0.0728237132127975,"score_gpt":0.3976482121092373,"score_spread":0.3248244988964398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125681453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5792038,0.39639974,0.015560661,0.0003437569,0.0003930094,0.0008076978,0.005707767,0.0001923194,0.0013912937],"genre_scores_gemma":[0.96890444,0.023456274,0.0039883787,0.00015491982,0.00016993289,0.00062723266,0.0024780114,0.000039887527,0.00018093747],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9688413,0.017711647,0.0061662276,0.0043322872,0.002419402,0.00052911387],"domain_scores_gemma":[0.9381047,0.037425723,0.0133357225,0.0068753674,0.0035966246,0.0006618912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.027245117,0.0016002838,0.005890535,0.007144223,0.000503336,0.0025077763,0.0012492423,0.0014532655,0.001353858],"category_scores_gemma":[0.056280322,0.0014846821,0.014588322,0.006486828,0.0005701393,0.00079801097,0.0013986236,0.0007608015,0.00015292238],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006433782,0.000058936585,0.4736264,0.0061335545,0.5013986,0.00036357788,0.00012487099,0.0010517299,0.0008410133,0.00011106458,0.00056965393,0.009286831],"study_design_scores_gemma":[0.0011983968,0.0009107233,0.47701228,0.0014766034,0.5139161,0.0008968227,0.00016605509,0.0019230486,0.0003790682,0.00044686708,0.0015876489,0.00008638658],"about_ca_topic_score_codex":0.003956313,"about_ca_topic_score_gemma":0.0041260896,"teacher_disagreement_score":0.027245117,"about_ca_system_score_codex":0.0006739724,"about_ca_system_score_gemma":0.00069837377,"threshold_uncertainty_score":0.14408767},"labels":[],"label_agreement":null},{"id":"W2125690417","doi":"10.1016/s1470-2045(00)00256-4","title":"Role of nitric oxide in carcinogenesis and tumour progression","year":2001,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Nitric Oxide and Endothelin Effects","field":"Medicine","cited_by":572,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"American Society for Investigative Pathology","keywords":"Cytostasis; Cancer research; Nitric oxide; Carcinogenesis; DNA damage; Mutation; Nitric oxide synthase; Carcinogen; Biology; Inflammation; Apoptosis; Chemistry; Cancer; Immunology; DNA; Biochemistry; Genetics; Gene; In vitro; Endocrinology; Cytotoxicity","score_opus":0.06680968871380165,"score_gpt":0.3968322013162112,"score_spread":0.33002251260240956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125690417","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006872717,0.9984909,0.00008143447,0.0003685905,0.00045113257,0.0000024444194,0.0000060841558,0.0000029001687,0.0005276981],"genre_scores_gemma":[0.00051208487,0.9980921,0.000110604786,0.00021799271,0.0005347167,0.0000036089846,0.000008366154,5.6706546e-7,0.0005199829],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99977213,0.000043563276,0.00002784449,0.000034765773,0.00010202035,0.000019664778],"domain_scores_gemma":[0.9993285,0.00040485596,0.00008422975,0.000018171162,0.000119020675,0.000045314697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011517912,0.00095794536,0.0019620387,0.0014661191,0.00034428475,0.0010708403,0.00093121437,0.0017275121,0.0030595472],"category_scores_gemma":[0.001084854,0.00029722022,0.00040261514,0.0020090884,0.0008462205,0.0017060426,0.0007802619,0.0021448815,0.001398916],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024165721,0.000091865775,0.00028335513,0.0128953075,0.00013365156,0.00044315954,0.00007429329,0.00054839684,0.0026828137,0.0042588436,0.0423557,0.93599105],"study_design_scores_gemma":[0.00007685544,0.00014662684,0.0011993893,0.0028922753,0.00016580554,0.001227846,0.00010231929,0.00011263594,0.00050859543,0.0042648003,0.9892785,0.000024293808],"about_ca_topic_score_codex":0.0013359351,"about_ca_topic_score_gemma":0.002926981,"teacher_disagreement_score":0.0030595472,"about_ca_system_score_codex":0.00072907936,"about_ca_system_score_gemma":0.001190207,"threshold_uncertainty_score":0.01023519},"labels":[],"label_agreement":null},{"id":"W2126357214","doi":"10.1016/s1470-2045(12)70226-7","title":"Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":194,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; BC Cancer Agency","funders":"National Cancer Institute; U.S. Public Health Service","keywords":"Medicine; Breast cancer; Hazard ratio; Placebo; Internal medicine; Clinical endpoint; Oncology; Adjuvant; Adjuvant therapy; Cancer; Randomized controlled trial; Confidence interval; Surgery; Gastroenterology; Pathology","score_opus":0.07326399201664018,"score_gpt":0.42403138067342394,"score_spread":0.35076738865678375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126357214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88884413,0.026280664,0.0039373212,0.0040842528,0.004035508,0.05626523,0.00836818,0.0006898749,0.0074947486],"genre_scores_gemma":[0.9111591,0.01036816,0.006325164,0.004179957,0.0014635881,0.04976013,0.0035236278,0.00010469777,0.013115609],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99810386,0.0011258519,0.00013184671,0.00025636613,0.00011618267,0.0002659387],"domain_scores_gemma":[0.9987437,0.00037623305,0.00035087575,0.00011143489,0.00010107844,0.00031674386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00292681,0.0036122494,0.005907825,0.00087690237,0.00085670315,0.0017176609,0.001592807,0.00419161,0.0136760995],"category_scores_gemma":[0.0044887043,0.0013613163,0.003414833,0.00085679867,0.0019551895,0.0014636416,0.0008990746,0.0035125613,0.0023414565],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.99388427,0.0007506675,0.000091275106,0.0010065587,0.00057026383,0.000014983283,0.000024045183,0.00009474676,0.0006361167,0.00006694963,0.00047123508,0.002388814],"study_design_scores_gemma":[0.9935503,0.0054655033,0.00020834712,0.000037345602,0.00030666633,0.000007619494,0.00000716974,0.00005446298,0.000047237998,0.000064897526,0.0002434828,0.0000069696193],"about_ca_topic_score_codex":0.0034664795,"about_ca_topic_score_gemma":0.0064700614,"teacher_disagreement_score":0.0136760995,"about_ca_system_score_codex":0.0017342642,"about_ca_system_score_gemma":0.002123737,"threshold_uncertainty_score":0.045751154},"labels":[],"label_agreement":null},{"id":"W2126863660","doi":"10.1016/s1470-2045(08)70336-x","title":"Effects of comorbidity on screening and early diagnosis of cancer in elderly people","year":2008,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Comorbidity; Life expectancy; Medicine; Cancer; Cancer screening; Population; Gerontology; Clinical trial; MEDLINE; Psychiatry; Environmental health; Internal medicine","score_opus":0.15260097971444953,"score_gpt":0.43551549771047127,"score_spread":0.28291451799602174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126863660","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028822976,0.9993612,0.0000129248065,0.00010755927,0.000053189367,0.0000018377398,0.000023171522,0.0000011410328,0.00015083743],"genre_scores_gemma":[0.0031225001,0.9965371,0.00005079445,0.00012699829,0.000084256266,0.000002931178,0.000021413762,3.5718662e-7,0.000053629272],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99963105,0.00010342298,0.00007354343,0.000045404904,0.0001225929,0.000023968041],"domain_scores_gemma":[0.9980003,0.0013822607,0.0003983799,0.000018037174,0.00014671526,0.00005420395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007885972,0.000521114,0.002447031,0.0016284155,0.00013054578,0.00058601314,0.00057590567,0.0007195426,0.001950603],"category_scores_gemma":[0.0032965653,0.00027676122,0.0013367592,0.0023671384,0.000226394,0.00043682838,0.00042252985,0.0007025452,0.00019997914],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004525601,0.00007417325,0.0054101837,0.102472074,0.0036095122,0.00023445381,0.00007594728,0.00043178748,0.000305526,0.00072729355,0.0137764895,0.8724299],"study_design_scores_gemma":[0.0010610053,0.0015960678,0.17691156,0.18004315,0.046691872,0.0066651404,0.0006272726,0.00094341935,0.0011124947,0.0051565766,0.5790079,0.00018341717],"about_ca_topic_score_codex":0.006424078,"about_ca_topic_score_gemma":0.015182881,"teacher_disagreement_score":0.006424078,"about_ca_system_score_codex":0.00066395226,"about_ca_system_score_gemma":0.0011035248,"threshold_uncertainty_score":0.012773335},"labels":[],"label_agreement":null},{"id":"W2127018518","doi":"10.1016/s1470-2045(15)70128-2","title":"Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":335,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Jewish General Hospital","funders":"Genentech","keywords":"Medicine; Internal medicine; Tolerability; Brentuximab vedotin; Rituximab; Antibody-drug conjugate; Oncology; Refractory (planetary science); Lymphoma; Phases of clinical research; Adverse effect; Clinical trial; Antibody; Immunology; Monoclonal antibody; Hodgkin lymphoma","score_opus":0.036975464534527845,"score_gpt":0.3523724593174217,"score_spread":0.3153969947828939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127018518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972179,0.0016811335,0.00013017996,0.00008694255,0.000030036226,0.00018531777,0.00020345335,0.000016482965,0.00044841153],"genre_scores_gemma":[0.9970252,0.0012209731,0.00017349664,0.0001714943,0.000050453866,0.00018232038,0.00042941957,0.000012566676,0.00073400943],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999622,0.00018083559,0.000017151751,0.00006807265,0.000042239306,0.00006978019],"domain_scores_gemma":[0.99939144,0.00017241933,0.00014759132,0.000057066674,0.00002939693,0.00020208195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001058445,0.0008171954,0.0014853481,0.00031351062,0.00023447115,0.0009967886,0.0006406475,0.0009847456,0.0015377486],"category_scores_gemma":[0.000905818,0.00042012264,0.00093697227,0.00030125558,0.0008794629,0.0007891159,0.00022142989,0.00184855,0.00042804496],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7530681,0.03418594,0.010220025,0.00085765414,0.0017696221,0.00039099847,0.00034200665,0.0030746392,0.05451124,0.00035442752,0.0018775866,0.13934779],"study_design_scores_gemma":[0.40011376,0.56277865,0.024539689,0.000051619678,0.0009065569,0.0006459692,0.00009955259,0.0016337448,0.0056681284,0.0003602722,0.0031572913,0.00004474709],"about_ca_topic_score_codex":0.0006323617,"about_ca_topic_score_gemma":0.0010118348,"teacher_disagreement_score":0.0015377486,"about_ca_system_score_codex":0.0008975232,"about_ca_system_score_gemma":0.0006194409,"threshold_uncertainty_score":0.006512046},"labels":[],"label_agreement":null},{"id":"W2127385754","doi":"10.1016/s1470-2045(14)70030-0","title":"Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":263,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; BC Cancer Agency","funders":"National Cancer Institute; Novartis Pharmaceuticals Corporation","keywords":"Sorafenib; Open label; Renal cell carcinoma; Medicine; Oncology; Internal medicine; Second line treatment; Hepatocellular carcinoma; Clinical trial; Overall survival","score_opus":0.1290889388003442,"score_gpt":0.3833123518399601,"score_spread":0.25422341303961593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127385754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799304,0.0067813178,0.0013695608,0.0017588569,0.0015389328,0.0037451012,0.0016785266,0.00022135844,0.002975877],"genre_scores_gemma":[0.98531175,0.00296966,0.0013243078,0.0013613694,0.00051711337,0.0030105193,0.0013468447,0.00004545191,0.0041130343],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.999244,0.0003709061,0.000040902367,0.00013778206,0.00005217074,0.00015429403],"domain_scores_gemma":[0.9988432,0.0003792354,0.00022445481,0.00009812289,0.00006642899,0.00038858468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019242998,0.0026594326,0.004053774,0.00048022767,0.00056361867,0.001696412,0.0011121745,0.0023465892,0.00850352],"category_scores_gemma":[0.0024010947,0.0008994743,0.0036321243,0.0004791198,0.0015281279,0.0020175462,0.0005787122,0.0049583474,0.0015730709],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9876293,0.0020441993,0.00019971214,0.00041465048,0.0008909221,0.000026740281,0.000040031206,0.00033443674,0.0007669191,0.00009605258,0.0006069865,0.006950078],"study_design_scores_gemma":[0.9775279,0.02080747,0.00042229035,0.00002369189,0.00028243248,0.000023366436,0.000018586206,0.0003140643,0.00011967033,0.00016701077,0.000281639,0.000011782135],"about_ca_topic_score_codex":0.0013354506,"about_ca_topic_score_gemma":0.0029292013,"teacher_disagreement_score":0.00850352,"about_ca_system_score_codex":0.0012092268,"about_ca_system_score_gemma":0.0011589288,"threshold_uncertainty_score":0.028447151},"labels":[],"label_agreement":null},{"id":"W2127424726","doi":"10.1016/s1470-2045(08)70153-0","title":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study","year":2008,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":3195,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Sarcopenic obesity; Sarcopenia; Obesity; Body mass index; Internal medicine; Geriatric oncology; Population; Hazard ratio; Cancer; Gastroenterology; Confidence interval","score_opus":0.09781448145996925,"score_gpt":0.4135071674502254,"score_spread":0.3156926859902562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127424726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99929774,0.00016915212,0.000036672667,0.000049244056,0.0000061173655,0.0000075417947,0.0001674289,0.0000016428199,0.00026458869],"genre_scores_gemma":[0.9995609,0.000089462745,0.0000305025,0.00004031056,0.00001527969,0.000007953289,0.00016026186,0.0000012029587,0.00009417051],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994567,0.00017059731,0.00006586742,0.00013705959,0.00008536087,0.00008448402],"domain_scores_gemma":[0.9988588,0.00016360835,0.00041196554,0.00010993608,0.00013330128,0.00032237155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006734703,0.00047016106,0.00054995256,0.000956442,0.0008104928,0.0011151339,0.00043846667,0.0013349971,0.0014385579],"category_scores_gemma":[0.0020401515,0.0007699945,0.00080681406,0.0015169147,0.0006430795,0.0010521625,0.0006567073,0.0012137792,0.00032925312],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014472222,0.0000689121,0.99912506,0.0000047197905,0.000060185936,0.000053425825,0.000063396175,0.000009529729,0.00014472664,0.0000070395795,0.00003264535,0.00028559295],"study_design_scores_gemma":[0.000010138367,0.00014043917,0.9993174,0.0000017608297,0.000032873755,0.00019093351,0.00020551034,0.000038562364,0.000010798895,0.000010564576,0.000037458496,0.0000036077856],"about_ca_topic_score_codex":0.004004496,"about_ca_topic_score_gemma":0.0041825576,"teacher_disagreement_score":0.004004496,"about_ca_system_score_codex":0.00031782466,"about_ca_system_score_gemma":0.00027996956,"threshold_uncertainty_score":0.007962406},"labels":[],"label_agreement":null},{"id":"W2128083415","doi":"10.1016/s1470-2045(13)70510-2","title":"Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":526,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Juravinski Cancer Centre; Institut universitaire de cardiologie et de pneumologie de Québec; Alberta Cancer Foundation","funders":"Merck KGaA","keywords":"Medicine; Placebo; Chemoradiotherapy; Clinical endpoint; Internal medicine; Population; Lung cancer; Surgery; Phases of clinical research; Hazard ratio; Cancer; Clinical trial; Oncology; Confidence interval; Pathology","score_opus":0.08993665752350942,"score_gpt":0.43539217495574034,"score_spread":0.3454555174322309,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128083415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9718168,0.010312694,0.0014355275,0.00092845404,0.0014176887,0.007302948,0.002374579,0.00047375885,0.0039375545],"genre_scores_gemma":[0.97366387,0.004668603,0.0019359929,0.0014185596,0.0006481945,0.008136789,0.001596551,0.000057476238,0.007873814],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99949634,0.00023193084,0.000027778176,0.00009432945,0.0000375193,0.0001121479],"domain_scores_gemma":[0.999411,0.0001719724,0.00011372189,0.000049009323,0.000029642997,0.00022456504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015215714,0.0022295944,0.0037449861,0.0005758571,0.0005005682,0.0012386605,0.0011021502,0.002458773,0.009692902],"category_scores_gemma":[0.0012174004,0.00087281235,0.0025027762,0.0005107832,0.0015845055,0.0014866684,0.0005187819,0.0037057225,0.0021010912],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9881495,0.0021792653,0.000109468005,0.0004953792,0.00041480424,0.00002211364,0.000028946224,0.00015929263,0.0012967812,0.00007125848,0.00057703274,0.006496032],"study_design_scores_gemma":[0.97386485,0.025077527,0.00029823597,0.000022083843,0.00016213016,0.000010496915,0.000011222885,0.00011127761,0.00014212508,0.000061654035,0.00022990549,0.00000848329],"about_ca_topic_score_codex":0.0011544912,"about_ca_topic_score_gemma":0.0025902092,"teacher_disagreement_score":0.009692902,"about_ca_system_score_codex":0.00070273376,"about_ca_system_score_gemma":0.0010006231,"threshold_uncertainty_score":0.032426},"labels":[],"label_agreement":null},{"id":"W2128628205","doi":"10.1016/s1470-2045(13)70479-0","title":"Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":231,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Bristol-Myers Squibb (Canada)","funders":"National Cancer Institute","keywords":"Medicine; Dasatinib; Docetaxel; Prostate cancer; Internal medicine; Oncology; Clinical endpoint; Placebo; Chemotherapy; Cancer; Urology; Clinical trial; Tyrosine kinase; Pathology","score_opus":0.13220226536863128,"score_gpt":0.4325167925736302,"score_spread":0.3003145272049989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128628205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96269906,0.01760709,0.0014101027,0.0017851038,0.0024034535,0.007362301,0.0022819494,0.00037956398,0.004071461],"genre_scores_gemma":[0.9773746,0.0069366302,0.0015399042,0.0014886042,0.0007075183,0.004495009,0.0011387144,0.000055832854,0.0062632575],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9990671,0.00048448594,0.00006295306,0.00018972307,0.000049707207,0.0001460022],"domain_scores_gemma":[0.9990526,0.0003215491,0.00018527401,0.00008392198,0.000052743548,0.00030380953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019973866,0.0025982365,0.005155811,0.0005656238,0.0006697873,0.0014569854,0.0012091611,0.0023275842,0.011169169],"category_scores_gemma":[0.002344853,0.0012260935,0.0032729637,0.0005813091,0.0019963288,0.0018784656,0.0006334881,0.0043488354,0.0018318526],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9889548,0.0014113354,0.00012473595,0.00071157044,0.0008301171,0.000021907535,0.00004283944,0.00021886287,0.0006853657,0.00008919374,0.000551714,0.0063577606],"study_design_scores_gemma":[0.98157436,0.017352099,0.00026274723,0.000020103067,0.00022483418,0.0000143538255,0.000016933694,0.00009272951,0.00007268496,0.00009506207,0.00026317508,0.0000110174215],"about_ca_topic_score_codex":0.0015464518,"about_ca_topic_score_gemma":0.0038947356,"teacher_disagreement_score":0.011169169,"about_ca_system_score_codex":0.00084974425,"about_ca_system_score_gemma":0.0011189684,"threshold_uncertainty_score":0.037364602},"labels":[],"label_agreement":null},{"id":"W2128694012","doi":"10.1016/s1470-2045(08)70231-6","title":"Cancer patterns in Inuit populations","year":2008,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Urological Disorders and Treatments","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Circumpolar star; Life expectancy; Epidemiology; Cancer; Demography; Medicine; Biology; Population; Environmental health; Pathology; Internal medicine","score_opus":0.297517825632857,"score_gpt":0.48077680248405485,"score_spread":0.18325897685119785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128694012","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014823248,0.9971163,0.000030794596,0.00038618757,0.00011229497,0.000005264286,0.00018183797,0.0000037362463,0.0006812655],"genre_scores_gemma":[0.005353568,0.99390984,0.000088983434,0.00019223739,0.000062242485,0.000004764677,0.00011031919,8.383338e-7,0.00027717373],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998449,0.00002577677,0.00003095632,0.000031242227,0.00004886787,0.000018200451],"domain_scores_gemma":[0.99961424,0.00016807059,0.000109422785,0.000006609323,0.00008226884,0.00001941425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041896058,0.00044638896,0.0010620833,0.0027765515,0.00020851416,0.000702774,0.00052712485,0.0005042429,0.002189321],"category_scores_gemma":[0.0012646718,0.00023230044,0.00054606976,0.005632559,0.00024060914,0.0007582237,0.00049323036,0.0005179086,0.00022868671],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011853113,0.000042059837,0.013044134,0.03353247,0.0005167006,0.0002643071,0.00036770478,0.00026853257,0.00034289254,0.00091475074,0.021876844,0.928711],"study_design_scores_gemma":[0.00007922748,0.00029741006,0.22532625,0.07298579,0.0036178203,0.0046542133,0.0022270186,0.00036555366,0.00073023664,0.0017020174,0.68791646,0.000098035176],"about_ca_topic_score_codex":0.04312161,"about_ca_topic_score_gemma":0.10257296,"teacher_disagreement_score":0.95687836,"about_ca_system_score_codex":0.0011651536,"about_ca_system_score_gemma":0.0018845568,"threshold_uncertainty_score":0.08574122},"labels":[],"label_agreement":null},{"id":"W2128967557","doi":"10.1016/s1470-2045(00)00019-x","title":"Repopulation of tumour cells between cycles of chemotherapy: a neglected factor","year":2000,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Effects of Radiation Exposure","field":"Medicine","cited_by":153,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Repopulation; Clonogenic assay; Chemotherapy; Cancer research; Biology; Radiation therapy; Cell; Immunology; Oncology; Medicine; Internal medicine; Stem cell; Cell biology; Haematopoiesis; Genetics","score_opus":0.08015071912839168,"score_gpt":0.40092475537340433,"score_spread":0.32077403624501266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128967557","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014431596,0.9990073,0.0000757282,0.0001893939,0.00013656514,0.0000020759371,0.000006727275,0.0000033745891,0.00043456285],"genre_scores_gemma":[0.0015441009,0.9975145,0.000091198446,0.00022887571,0.00017340244,0.000004787995,0.000013521405,0.0000018437233,0.00042782188],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99959713,0.00011380601,0.00004638098,0.00007485828,0.00012881923,0.000038993727],"domain_scores_gemma":[0.9989524,0.000690898,0.00015542173,0.00003932601,0.00012823498,0.00003368939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009595316,0.00091394596,0.0034800526,0.0009794739,0.00025653787,0.0014141802,0.0012027777,0.0016496951,0.0035163239],"category_scores_gemma":[0.0012534276,0.0002795087,0.00076338946,0.001543675,0.0008696636,0.0013624422,0.0006577132,0.0015343444,0.0016181074],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019996079,0.000045464836,0.00035904188,0.016374486,0.0001753997,0.00031591734,0.00012148608,0.00036474428,0.003153976,0.0024919768,0.015051544,0.961346],"study_design_scores_gemma":[0.00008267283,0.00041164737,0.00397615,0.007201736,0.00043434862,0.004226856,0.0003068787,0.0001103245,0.0026017448,0.003026656,0.97758615,0.000034901404],"about_ca_topic_score_codex":0.0011836152,"about_ca_topic_score_gemma":0.0020313738,"teacher_disagreement_score":0.0035163239,"about_ca_system_score_codex":0.0008291285,"about_ca_system_score_gemma":0.00095075084,"threshold_uncertainty_score":0.011763275},"labels":[],"label_agreement":null},{"id":"W2129298960","doi":"10.1016/s1470-2045(15)70142-7","title":"Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":164,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital","funders":"Narodowe Centrum Nauki","keywords":"Medicine; Breast cancer; PALB2; Hazard ratio; Internal medicine; Odds ratio; Cancer; Oncology; Prospective cohort study; Gynecology; Mutation; Confidence interval; Germline mutation; Genetics","score_opus":0.029255847640818716,"score_gpt":0.37145603228828383,"score_spread":0.3422001846474651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129298960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965576,0.00064612774,0.00011807457,0.0001448567,0.000024197414,0.000012824558,0.0021011312,0.000008384075,0.00038680932],"genre_scores_gemma":[0.99705803,0.00033756677,0.000083474144,0.00007689192,0.000025863057,0.000018507146,0.001991887,0.000007002261,0.00040066027],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991449,0.0001700037,0.00008753277,0.00030420002,0.00009317628,0.00020016452],"domain_scores_gemma":[0.998035,0.00025107418,0.00066221325,0.00038615175,0.00020177361,0.000463753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010026853,0.000617333,0.00078649214,0.0010318761,0.00082315825,0.0012353519,0.0009428939,0.0010641499,0.002419278],"category_scores_gemma":[0.0026254784,0.0010038055,0.0016821497,0.002495575,0.0004658805,0.001156533,0.0013189607,0.0017549086,0.00056122115],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045647545,0.00004040191,0.9978109,0.000010578851,0.00035988152,0.00017094059,0.000050445495,0.0000385763,0.00022484339,0.000025533856,0.0002459597,0.00056546595],"study_design_scores_gemma":[0.00003908526,0.00013981892,0.9984666,0.00000809076,0.00021312015,0.00044128075,0.000231731,0.00011477546,0.000044707827,0.000048145015,0.00023887817,0.000013667573],"about_ca_topic_score_codex":0.008932604,"about_ca_topic_score_gemma":0.008975341,"teacher_disagreement_score":0.008932604,"about_ca_system_score_codex":0.0005833663,"about_ca_system_score_gemma":0.00058726163,"threshold_uncertainty_score":0.01776117},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"agree"},{"id":"W2129306198","doi":"10.1016/s1470-2045(01)00617-9","title":"Persistent human papillomavirus infection and cervical neoplasia","year":2002,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":256,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Carcinogenesis; Cervical intraepithelial neoplasia; Biology; Cervical cancer; Genotype; HPV infection; Cancer research; Loss of heterozygosity; Oncogene; Tumor suppressor gene; Telomerase; Intraepithelial neoplasia; Cancer; Gene; Immunology; Genetics; Allele; Cell cycle","score_opus":0.246386251105243,"score_gpt":0.4686531876521851,"score_spread":0.2222669365469421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129306198","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002458545,0.9989895,0.000014635866,0.00023798614,0.0003356696,0.0000031591183,0.000011388569,0.0000018032588,0.00038110788],"genre_scores_gemma":[0.0003144633,0.99879897,0.00004443688,0.0002489748,0.00017642586,0.000004862984,0.000011777679,4.1652603e-7,0.00039962467],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99959725,0.00008410165,0.0000670247,0.000051508065,0.00017056178,0.000029658418],"domain_scores_gemma":[0.99911374,0.0004595876,0.00017925534,0.00001951134,0.00017696449,0.000050906074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009948394,0.0010383823,0.0025576393,0.0035352814,0.00037825838,0.0014919911,0.0008304363,0.0017727815,0.0064227995],"category_scores_gemma":[0.0021968568,0.0004224668,0.000619683,0.0061709685,0.00058876106,0.0016574402,0.00085463346,0.0015205548,0.0016932123],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013717671,0.000037476788,0.00025536082,0.06134576,0.00021423664,0.0002926682,0.00010562172,0.00024356777,0.0005185645,0.002190502,0.08530613,0.84935284],"study_design_scores_gemma":[0.00006178739,0.00009154691,0.0011185622,0.01947363,0.0006111955,0.0011533671,0.00015204184,0.000036914433,0.0001111185,0.001189768,0.9759862,0.000013903309],"about_ca_topic_score_codex":0.005412465,"about_ca_topic_score_gemma":0.011720611,"teacher_disagreement_score":0.0064227995,"about_ca_system_score_codex":0.0015476348,"about_ca_system_score_gemma":0.0034972148,"threshold_uncertainty_score":0.021486342},"labels":[],"label_agreement":null},{"id":"W2129559903","doi":"10.1016/s1470-2045(13)70311-5","title":"Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group","year":2013,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Queen's University; London Health Sciences Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Clinical trial; Medicine; Clinical study design; Oncology; Intensive care medicine; Population; Schedule; Disease; Medical physics; Internal medicine; Computer science","score_opus":0.4126715099977182,"score_gpt":0.5398693156544768,"score_spread":0.12719780565675864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129559903","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000044886616,0.9978916,0.00008804639,0.0015500969,0.00017774549,0.000015703039,0.000024198123,0.0000032584264,0.00020449994],"genre_scores_gemma":[0.0009463868,0.99653375,0.00030736523,0.0015993147,0.0003856446,0.00004520853,0.00003900576,0.000003817929,0.00013941005],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99412054,0.003010902,0.0010498377,0.00041487368,0.0012242667,0.00017952229],"domain_scores_gemma":[0.96453756,0.030596089,0.0020044574,0.00032716035,0.0022356913,0.00029906444],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.018492956,0.0008773283,0.005180094,0.0018109564,0.000334824,0.0025871093,0.0017072828,0.00254835,0.0027514165],"category_scores_gemma":[0.026900357,0.0006174551,0.0022662997,0.0026072927,0.0011233542,0.0033943164,0.0013015541,0.004181398,0.0009179823],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031625543,0.000034752138,0.00022056722,0.052445225,0.0007510372,0.00009547251,0.00012374966,0.00042402514,0.00044034026,0.0048069586,0.04529725,0.8950443],"study_design_scores_gemma":[0.0004424693,0.00047724904,0.0020556669,0.06812702,0.0027247814,0.0013681977,0.00023513983,0.0004039944,0.00048733587,0.009347697,0.91424435,0.00008599569],"about_ca_topic_score_codex":0.0025122399,"about_ca_topic_score_gemma":0.007067673,"teacher_disagreement_score":0.98150706,"about_ca_system_score_codex":0.0027511402,"about_ca_system_score_gemma":0.0048389323,"threshold_uncertainty_score":0.09780127},"labels":[],"label_agreement":null},{"id":"W2129978807","doi":"10.1016/s1470-2045(15)00199-0","title":"Dexamethasone in the prophylaxis of radiation-induced pain flare after palliative radiotherapy for bone metastases: a double-blind, randomised placebo-controlled, phase 3 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":171,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Ottawa; Princess Margaret Cancer Centre; University of Calgary; Kingston General Hospital; Ottawa Hospital; CancerCare Manitoba; Centre Hospitalier de l’Université de Montréal; Juravinski Hospital; Hôpital Maisonneuve-Rosemont; Sunnybrook Health Science Centre; Centre Hospitalier Universitaire de Sherbrooke; Cancer Care Ontario; Ontario Institute for Cancer Research; Grand River Hospital; Queen's University; McMaster University","funders":"","keywords":"Medicine; Placebo; Dexamethasone; Analgesic; Radiation therapy; Clinical endpoint; Palliative care; Randomized controlled trial; Anesthesia; Surgery; Internal medicine","score_opus":0.13037721851186684,"score_gpt":0.41523441587961,"score_spread":0.2848571973677432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129978807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95952654,0.024235062,0.0015241369,0.0012229037,0.0023403284,0.00724236,0.0011434079,0.00026961137,0.0024956015],"genre_scores_gemma":[0.9783039,0.008746781,0.0017769249,0.001276805,0.0010522271,0.0046870504,0.0005134749,0.000038498336,0.0036043315],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.999186,0.00042690244,0.000058628288,0.00014310532,0.000060077546,0.00012531044],"domain_scores_gemma":[0.99890435,0.00045055323,0.00020674712,0.00007959053,0.000055676708,0.00030302722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014769462,0.0018177874,0.00550348,0.00058370864,0.0005865507,0.0011844143,0.0013501843,0.0029155796,0.007282139],"category_scores_gemma":[0.002274183,0.00075423566,0.0022838057,0.00062435336,0.0018165126,0.0010031626,0.0004920972,0.0038669545,0.0011012523],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9877029,0.0023822791,0.000111331196,0.00080836396,0.00055553403,0.000022680424,0.000031363434,0.00013806889,0.0012344648,0.00006861035,0.00028904006,0.006655467],"study_design_scores_gemma":[0.96858793,0.030340709,0.00033239336,0.000035310917,0.00018230936,0.00001194395,0.000010602381,0.0001108851,0.00012307902,0.000062487845,0.00019293149,0.000009491758],"about_ca_topic_score_codex":0.0013750145,"about_ca_topic_score_gemma":0.0024505148,"teacher_disagreement_score":0.007282139,"about_ca_system_score_codex":0.00071359094,"about_ca_system_score_gemma":0.0010902622,"threshold_uncertainty_score":0.024361193},"labels":[],"label_agreement":null},{"id":"W2131133701","doi":"10.1016/s1470-2045(11)70363-1","title":"Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":281,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Key Research and Development Program of China; Vrije Universiteit Brussel; Fonds Wetenschappelijk Onderzoek","keywords":"Medicine; Pediatrics; Neurocognitive; Bayley Scales of Infant Development; Child Behavior Checklist; Gestational age; Intelligence quotient; Pregnancy; Observational study; Cognition; Internal medicine; Psychiatry; Psychomotor learning","score_opus":0.09336844782096625,"score_gpt":0.3987549622373315,"score_spread":0.3053865144163652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131133701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997993,0.0006027722,0.00007127001,0.000072313625,0.000016520873,0.000012641746,0.0010574367,0.0000027661386,0.00017130491],"genre_scores_gemma":[0.9970342,0.00072926725,0.00016286202,0.000109060245,0.00003613305,0.00004050625,0.0016321334,0.0000045467996,0.00025141324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99887544,0.00027214567,0.0001597689,0.00028263178,0.00013495616,0.00027506961],"domain_scores_gemma":[0.99479103,0.00090490695,0.0025285818,0.0005616547,0.0003804469,0.0008334979],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011216081,0.00082844496,0.0010538268,0.00095994986,0.0010896698,0.0010272738,0.0009248261,0.0015160973,0.0011515175],"category_scores_gemma":[0.00429282,0.0011639228,0.0022799454,0.002930558,0.0006169475,0.0011595202,0.0010929477,0.002532012,0.0003052357],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037618537,0.00015642284,0.99794644,0.000034351087,0.0004021877,0.0001570854,0.00018733239,0.000024077332,0.000118881915,0.00001664621,0.000119589546,0.0004608636],"study_design_scores_gemma":[0.000034985493,0.00026567365,0.9985574,0.000019058596,0.00027022668,0.00023203758,0.0003576172,0.00004295949,0.00004052328,0.000016086522,0.00015290278,0.000010633332],"about_ca_topic_score_codex":0.047808133,"about_ca_topic_score_gemma":0.04297362,"teacher_disagreement_score":0.047808133,"about_ca_system_score_codex":0.0010041858,"about_ca_system_score_gemma":0.0012208022,"threshold_uncertainty_score":0.09505975},"labels":[],"label_agreement":null},{"id":"W2131145274","doi":"10.1016/s1470-2045(15)00232-6","title":"Cancer incidence in indigenous people in Australia, New Zealand, Canada, and the USA: a comparative population-based study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Blue Quills First Nations College; University of Alberta; Ministry of Health","funders":"World Health Organization","keywords":"Indigenous; Demography; Cancer registry; Population; Geography; Medicine; Life expectancy; Incidence (geometry); Population health; Cancer incidence; Ethnic group; Socioeconomics; Environmental health; Political science; Ecology; Sociology; Biology","score_opus":0.19749027479980646,"score_gpt":0.4351334547109858,"score_spread":0.23764317991117934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131145274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99870837,0.00027065238,0.00002487034,0.000040815234,0.000004497876,0.000018149361,0.00047721507,0.0000019226254,0.00045342368],"genre_scores_gemma":[0.9987679,0.0004074745,0.00005450232,0.000048530597,0.000008646404,0.000018941562,0.00046083823,0.0000020764178,0.00023107257],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99921644,0.00014785636,0.000068130816,0.00015813342,0.00018422744,0.00022514164],"domain_scores_gemma":[0.99892443,0.00009527821,0.00026284135,0.00007735463,0.0003233892,0.00031668277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068596815,0.00044822332,0.0007378398,0.002217032,0.0015554716,0.0010412525,0.0010007075,0.0008325418,0.0010371716],"category_scores_gemma":[0.0019638548,0.0005171766,0.0010215805,0.0052173454,0.000965519,0.00089541683,0.0011103511,0.00096702366,0.00020510191],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017291316,0.0001053317,0.9953908,0.00004811999,0.00021819824,0.00014583011,0.0019980832,0.000030268398,0.00020269476,0.00002837688,0.0001670199,0.0014923009],"study_design_scores_gemma":[0.0000044603,0.000044422988,0.9984257,0.0000076089277,0.000050733324,0.000056956207,0.0012814756,0.00002085229,0.000009845756,0.000005779449,0.00008723517,0.000004957659],"about_ca_topic_score_codex":0.7695227,"about_ca_topic_score_gemma":0.7871776,"teacher_disagreement_score":0.23047727,"about_ca_system_score_codex":0.0045088036,"about_ca_system_score_gemma":0.002607568,"threshold_uncertainty_score":0.46366918},"labels":[],"label_agreement":null},{"id":"W2131719808","doi":"10.1016/s1470-2045(10)70207-2","title":"Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial","year":2010,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1919,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital; Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute","keywords":"Medicine; Axillary Lymph Node Dissection; Sentinel lymph node; Breast cancer; Lumpectomy; Mastectomy; Surgery; Axilla; Sentinel node; Lymph node; Clinical endpoint; Randomized controlled trial; Cancer; Internal medicine","score_opus":0.02129551545244373,"score_gpt":0.32099030728354333,"score_spread":0.2996947918310996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131719808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98883086,0.006781208,0.00025910145,0.0012752434,0.00039863677,0.00024066621,0.0007607854,0.000046999627,0.0014065106],"genre_scores_gemma":[0.993024,0.002863829,0.00037369633,0.00076340523,0.00023260461,0.00025093966,0.00060107745,0.000017100534,0.0018734143],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9992173,0.00053173513,0.00003491289,0.000098115095,0.000043871747,0.000074075855],"domain_scores_gemma":[0.99875605,0.0005536634,0.00025852252,0.000101307625,0.000042303374,0.00028821462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021926498,0.001884886,0.0020695028,0.0002630978,0.00021604847,0.0008429307,0.0007569106,0.0012340988,0.0045799427],"category_scores_gemma":[0.0022631192,0.00044755297,0.0025478145,0.000369845,0.001229752,0.0011381361,0.00048930367,0.002830077,0.0006756822],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98319614,0.0009414871,0.0011255618,0.00042699653,0.0011056125,0.000022158849,0.000042261454,0.00044569274,0.0011836409,0.00006236927,0.0006035135,0.010844489],"study_design_scores_gemma":[0.91299736,0.06693444,0.014450412,0.00010936393,0.00249199,0.00008164519,0.000106473606,0.0007057821,0.0005693958,0.0006749534,0.00084738166,0.000030788142],"about_ca_topic_score_codex":0.0017246905,"about_ca_topic_score_gemma":0.003992388,"teacher_disagreement_score":0.0045799427,"about_ca_system_score_codex":0.0008482582,"about_ca_system_score_gemma":0.00089598354,"threshold_uncertainty_score":0.015321374},"labels":[],"label_agreement":null},{"id":"W2132870547","doi":"10.1016/s1470-2045(14)71173-8","title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1580,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Boehringer Ingelheim","keywords":"Medicine; Afatinib; Pemetrexed; Lung cancer; Internal medicine; Adenocarcinoma; Lung; Gemcitabine; Chemotherapy; Population; Gastroenterology; Oncology; Cisplatin; Surgery; Gefitinib; Epidermal growth factor receptor; Cancer","score_opus":0.17100506631650386,"score_gpt":0.4951860196022361,"score_spread":0.32418095328573227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132870547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9690295,0.024018057,0.0010313498,0.0011272299,0.00047519544,0.0012362023,0.0012807286,0.00009717297,0.0017045793],"genre_scores_gemma":[0.98856086,0.005931124,0.0012049706,0.0007764235,0.00018882769,0.00089312036,0.001192931,0.00003383774,0.0012178902],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974962,0.0017337262,0.00016822097,0.0002662136,0.00013782311,0.00019776903],"domain_scores_gemma":[0.99692756,0.0014673958,0.00076431717,0.0002675264,0.00011562343,0.0004575949],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052793077,0.0015184806,0.003908913,0.00051587704,0.0003292905,0.0013470536,0.001205662,0.0018266626,0.0036621145],"category_scores_gemma":[0.005747153,0.0005550613,0.006175588,0.0007252072,0.001506886,0.0020819718,0.0006306953,0.004067939,0.0005296491],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96329945,0.0011498082,0.0010066007,0.00145248,0.004647218,0.000033513395,0.000077803656,0.0012407658,0.001405236,0.00015213051,0.0007252824,0.024809727],"study_design_scores_gemma":[0.93406856,0.05596494,0.003807032,0.000114332084,0.0032694135,0.00011085631,0.0000555375,0.0006776191,0.00036828616,0.00059808063,0.00092551956,0.000039910177],"about_ca_topic_score_codex":0.0010169394,"about_ca_topic_score_gemma":0.0029566556,"teacher_disagreement_score":0.0052793077,"about_ca_system_score_codex":0.0013363373,"about_ca_system_score_gemma":0.0008760226,"threshold_uncertainty_score":0.027919948},"labels":[],"label_agreement":null},{"id":"W2133367407","doi":"10.1016/s1470-2045(01)00489-2","title":"Current and future developments in the use of temozolomide for the treatment of brain tumours","year":2001,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":248,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Cancer Research Society; American Association for Cancer Research","keywords":"Temozolomide; Medicine; Glioma; Concomitant; Oncology; Chemotherapy; Radiation therapy; Drug; Clinical trial; Dacarbazine; Internal medicine; Phases of clinical research; Brain tumor; Pharmacology; Pathology; Cancer research","score_opus":0.22527878642532184,"score_gpt":0.43536852915759616,"score_spread":0.21008974273227432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133367407","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009616843,0.99844414,0.00013887134,0.0004923222,0.00018802055,0.0000036487409,0.0000094632105,0.00000778173,0.0006195682],"genre_scores_gemma":[0.00038470599,0.99856514,0.0002533249,0.00023055969,0.00023879037,0.0000035346904,0.000016868535,0.0000011160489,0.0003059703],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99962497,0.00007345313,0.000060047907,0.000057129673,0.00015305443,0.000031371575],"domain_scores_gemma":[0.9986798,0.0007611921,0.0001596738,0.000027407148,0.0002668067,0.00010511164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018735013,0.0010460414,0.002228692,0.002226783,0.00034048661,0.0014555403,0.001514689,0.0016676568,0.0049713342],"category_scores_gemma":[0.0015821251,0.0003139569,0.0007054896,0.0034529916,0.0008223495,0.0021211002,0.00059653714,0.0023843085,0.0024944297],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019826158,0.00009204847,0.00016586478,0.009114707,0.00008058611,0.00024768896,0.000046601872,0.00043781666,0.0012352819,0.0018611102,0.022348573,0.96417147],"study_design_scores_gemma":[0.00012049394,0.00032808076,0.0017890886,0.0030918736,0.00024402665,0.0023611018,0.00010896232,0.00019682471,0.00051934604,0.0020196158,0.9891846,0.000036034802],"about_ca_topic_score_codex":0.0027967282,"about_ca_topic_score_gemma":0.007760458,"teacher_disagreement_score":0.0049713342,"about_ca_system_score_codex":0.0010100775,"about_ca_system_score_gemma":0.001722431,"threshold_uncertainty_score":0.016630769},"labels":[],"label_agreement":null},{"id":"W2133427336","doi":"10.1016/s1470-2045(03)01322-6","title":"Management of Wilms' tumour: current practice and future goals","year":2003,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":197,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Alberta","funders":"","keywords":"Wilms tumour; Radiation therapy; Medicine; Wilms' tumor; Intensive care medicine; Childhood cancer; Quality of life (healthcare); Chemotherapy; Cancer; Pediatrics; Surgery; Internal medicine; Nursing","score_opus":0.03233062085068108,"score_gpt":0.3780878001615636,"score_spread":0.34575717931088257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133427336","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010251951,0.9958248,0.0003997737,0.0024018036,0.00058564206,0.0000037069972,0.0000089315,0.000010663642,0.00066219666],"genre_scores_gemma":[0.0012671896,0.99421245,0.00080444146,0.0013331533,0.0019325017,0.00000999,0.000026738247,0.0000039986244,0.00040961968],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993272,0.00018145987,0.00009282579,0.00009870761,0.0002359613,0.00006383426],"domain_scores_gemma":[0.99798715,0.0010726781,0.00021079545,0.00004793287,0.00047167356,0.00020965569],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032248576,0.0013389061,0.0026698464,0.0018242535,0.0004575433,0.002106138,0.0021611452,0.0032223694,0.002838821],"category_scores_gemma":[0.0030659388,0.00035509942,0.0009036909,0.0019633034,0.0015307122,0.0031131094,0.0009183379,0.004502018,0.0017821616],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023436587,0.00009828783,0.00066208426,0.0071163564,0.00010846102,0.0007338375,0.00006803228,0.0011284994,0.0006502884,0.0047015385,0.046682633,0.93781555],"study_design_scores_gemma":[0.00017231,0.00033858142,0.0028266585,0.008863168,0.0003137829,0.0059815687,0.00034453714,0.0005697306,0.00030747236,0.009408207,0.9708046,0.00006943639],"about_ca_topic_score_codex":0.0018912147,"about_ca_topic_score_gemma":0.004262701,"teacher_disagreement_score":0.0032248576,"about_ca_system_score_codex":0.0015946052,"about_ca_system_score_gemma":0.0019606918,"threshold_uncertainty_score":0.017054915},"labels":[],"label_agreement":null},{"id":"W2133436228","doi":"10.1016/s1470-2045(02)00788-x","title":"Nucleoside analogues and nucleobases in cancer treatment","year":2002,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Biochemical and Molecular Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":606,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Nucleoside; Nucleobase; Purine; Nucleoside analogue; Cytotoxicity; Nucleoside transporter; Pyrimidine; Biochemistry; Cancer cell; Chemistry; Biology; Cancer; Pharmacology; Enzyme; Transporter; In vitro; DNA; Gene; Genetics","score_opus":0.16611701688756003,"score_gpt":0.43807110515966147,"score_spread":0.27195408827210144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133436228","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007870231,0.9971855,0.00016532691,0.00039814424,0.0006924469,0.0000048659895,0.000009202895,0.000006620813,0.0014591719],"genre_scores_gemma":[0.00081296504,0.9961056,0.00035181548,0.00040306177,0.0005785833,0.0000117298005,0.000020031424,0.0000024210706,0.0017137225],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99972993,0.0000700312,0.000027073898,0.000035044584,0.000114521456,0.000023354925],"domain_scores_gemma":[0.9995919,0.00023936346,0.000048824673,0.000014404988,0.00007946581,0.000026007016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011223541,0.0011828279,0.001726358,0.0016251574,0.0004116238,0.0010000932,0.0012232058,0.0017141257,0.005181625],"category_scores_gemma":[0.0011083342,0.00036757553,0.0004115061,0.0025876001,0.0008792694,0.0013984644,0.0006153426,0.0025225303,0.0031639887],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022025233,0.00009479649,0.00009824446,0.005763846,0.00006362387,0.0003150181,0.00003962657,0.00060218375,0.0018580122,0.006694642,0.067746736,0.9165029],"study_design_scores_gemma":[0.00005941871,0.00008733386,0.00020843543,0.0008083179,0.00005393558,0.00079959823,0.00002643457,0.00007471756,0.00047256582,0.0019555045,0.99544466,0.000009071472],"about_ca_topic_score_codex":0.0013965094,"about_ca_topic_score_gemma":0.0034593726,"teacher_disagreement_score":0.005181625,"about_ca_system_score_codex":0.0010645316,"about_ca_system_score_gemma":0.0009970351,"threshold_uncertainty_score":0.017334223},"labels":[],"label_agreement":null},{"id":"W2134021845","doi":"10.1016/s1470-2045(11)70338-2","title":"Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":151,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame; Université de Montréal; Juravinski Cancer Centre; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Aflibercept; Paracentesis; Ascites; Placebo; Surgery; Population; Clinical endpoint; Internal medicine; Ovarian cancer; Chemotherapy; Bevacizumab; Gastroenterology; Randomized controlled trial; Cancer","score_opus":0.06439106428427824,"score_gpt":0.35626371206261853,"score_spread":0.2918726477783403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134021845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97713894,0.012037302,0.0014460075,0.00082396367,0.0012228005,0.0040236497,0.0009805203,0.0002261686,0.0021006304],"genre_scores_gemma":[0.98254514,0.006265044,0.0018999083,0.001184702,0.00094972807,0.003346694,0.00074915326,0.00003357776,0.0030260445],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995394,0.0002054629,0.000036659923,0.00008317332,0.000044604298,0.00009071515],"domain_scores_gemma":[0.99927527,0.00022967298,0.00016855652,0.000056106343,0.00004408821,0.00022630185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011553399,0.0016452592,0.004619831,0.00058529666,0.00034720494,0.0010524362,0.00089669245,0.0023328275,0.0049618115],"category_scores_gemma":[0.001684965,0.0008783022,0.0016641343,0.00062231947,0.0013389584,0.001145897,0.00038741555,0.0028240439,0.0008669527],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.970099,0.0049199127,0.00031478415,0.0011203593,0.00069075415,0.000045758978,0.000045723948,0.00021288721,0.0031523707,0.0000754543,0.0005802959,0.018742776],"study_design_scores_gemma":[0.963476,0.03498632,0.0006118148,0.000020274128,0.00018331852,0.000021060478,0.000009360542,0.0001572181,0.00019429883,0.000040962368,0.00029033748,0.000009004255],"about_ca_topic_score_codex":0.00079027447,"about_ca_topic_score_gemma":0.0013325987,"teacher_disagreement_score":0.0049618115,"about_ca_system_score_codex":0.000486999,"about_ca_system_score_gemma":0.00081076234,"threshold_uncertainty_score":0.01659894},"labels":[],"label_agreement":null},{"id":"W2135359531","doi":"10.1016/s1470-2045(05)70093-0","title":"Cardiac tumours: diagnosis and management","year":2005,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cardiac tumors and thrombi","field":"Medicine","cited_by":841,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Intracardiac injection; Autopsy; Chemotherapy; Constitutional symptoms; Radiation therapy; Radiology; Incidence (geometry); Disease; Surgery; Internal medicine","score_opus":0.09777482929734728,"score_gpt":0.41384492416532465,"score_spread":0.3160700948679774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135359531","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000041777534,0.99805933,0.00007735459,0.0005491111,0.0005024296,0.0000038049452,0.000012642551,0.000006658516,0.0007469057],"genre_scores_gemma":[0.00056005217,0.9971927,0.00014476143,0.0005990158,0.00084325013,0.0000055503574,0.00002685387,0.0000014833304,0.0006262867],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996581,0.00006106818,0.000055846347,0.000048490358,0.0001465795,0.000029838651],"domain_scores_gemma":[0.9988789,0.00054200087,0.00025830982,0.000026901946,0.0002181762,0.00007576318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008776092,0.0010982178,0.0025954107,0.0031141469,0.00027330965,0.0012307785,0.000967373,0.0018663175,0.004052213],"category_scores_gemma":[0.0021556243,0.0004007098,0.0005578636,0.003105118,0.0006298591,0.0014114348,0.000734987,0.0021263033,0.0024106312],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007000904,0.0000329123,0.00017892392,0.010381893,0.0000923818,0.00020688822,0.000031634492,0.00045773038,0.00037181735,0.0011629513,0.088137075,0.8988758],"study_design_scores_gemma":[0.00006885475,0.00010321575,0.0011090905,0.009532906,0.00032851833,0.0018036917,0.000073364106,0.00013227129,0.00013681118,0.0014664792,0.9852207,0.000024147112],"about_ca_topic_score_codex":0.0024707844,"about_ca_topic_score_gemma":0.0068089925,"teacher_disagreement_score":0.004052213,"about_ca_system_score_codex":0.0012048475,"about_ca_system_score_gemma":0.0017587804,"threshold_uncertainty_score":0.013556004},"labels":[],"label_agreement":null},{"id":"W2135655084","doi":"10.1016/s1470-2045(11)70378-3","title":"A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":80,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Breast Cancer Research Foundation","keywords":"Breast cancer; Medicine; Clinical trial; Neoadjuvant therapy; Clinical endpoint; Medical physics; Surrogate endpoint; Population; Oncology; Cancer; Intensive care medicine; Internal medicine","score_opus":0.18231508853691675,"score_gpt":0.481869523507254,"score_spread":0.29955443497033724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135655084","genre_codex":"methods","genre_gemma":"methods","domain_codex":"methods","domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004623156,0.07058845,0.57879287,0.28889653,0.03630745,0.009370548,0.0023420004,0.0012587936,0.007820281],"genre_scores_gemma":[0.054575294,0.012815163,0.7208661,0.14791924,0.016099744,0.043337755,0.002046022,0.000890573,0.001450158],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.1724366,0.56863207,0.19588439,0.015343256,0.043624815,0.0040788166],"domain_scores_gemma":[0.14994131,0.65921557,0.059860278,0.064628005,0.059077315,0.00727745],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.73998845,0.007517768,0.034780536,0.017828621,0.011493199,0.041916743,0.0260196,0.03947384,0.0022700096],"category_scores_gemma":[0.7879192,0.0071611037,0.023653764,0.021297378,0.055555433,0.029115966,0.026825218,0.09518324,0.0027821602],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003762398,0.00033864228,0.0049795024,0.023666957,0.0056102113,0.00049694587,0.008735628,0.004455627,0.001416227,0.7055547,0.10638289,0.13460033],"study_design_scores_gemma":[0.0035740484,0.0016039272,0.0037332512,0.039883316,0.0053996616,0.00084467896,0.0029546914,0.007304317,0.0020094716,0.82476354,0.106961,0.00096812623],"about_ca_topic_score_codex":0.0025766261,"about_ca_topic_score_gemma":0.002795267,"teacher_disagreement_score":0.26001155,"about_ca_system_score_codex":0.019059358,"about_ca_system_score_gemma":0.04034243,"threshold_uncertainty_score":0.32064056},"labels":[],"label_agreement":null},{"id":"W2135671488","doi":"10.1016/s1470-2045(11)70287-x","title":"Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":507,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; University of Alberta","funders":"GlaxoSmithKline","keywords":"Medicine; Vaccine efficacy; Cohort; Serostatus; Cervical cancer; Vaccine trial; Vaccination; Adjuvant; HPV infection; Internal medicine; Oncology; Immunology; Cancer; Virus; Viral load","score_opus":0.09181201552947253,"score_gpt":0.4050317562153602,"score_spread":0.31321974068588765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135671488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99315226,0.003430663,0.0004706238,0.0003265719,0.00031341932,0.0008301084,0.00042047174,0.000086659704,0.0009691137],"genre_scores_gemma":[0.99444205,0.0012450515,0.0008014559,0.00030081253,0.00026997313,0.00086521095,0.0004973774,0.000022212922,0.0015559471],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970816,0.0018806037,0.00016303326,0.0004351438,0.00015107416,0.00028854067],"domain_scores_gemma":[0.99766195,0.0008611934,0.0005805643,0.0003854295,0.00013692833,0.00037391682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043910313,0.0022547708,0.005613573,0.00050301326,0.00034786394,0.0014141735,0.0016858972,0.0024629964,0.004062203],"category_scores_gemma":[0.0048395316,0.0010612549,0.004300774,0.0005118664,0.0016133739,0.0016525523,0.00075578364,0.0037285339,0.00074261613],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9906838,0.0008489668,0.0003819429,0.0003328944,0.0013961083,0.00001851687,0.000027624046,0.00028260463,0.0010257986,0.000048424132,0.0001292811,0.0048239953],"study_design_scores_gemma":[0.916817,0.07591497,0.0032248895,0.00004502497,0.0023513234,0.000040628365,0.000018991333,0.0005582165,0.0005759418,0.00016613318,0.00026971684,0.000017107848],"about_ca_topic_score_codex":0.0012892424,"about_ca_topic_score_gemma":0.0012139567,"teacher_disagreement_score":0.005613573,"about_ca_system_score_codex":0.0010296018,"about_ca_system_score_gemma":0.0012745266,"threshold_uncertainty_score":0.023222268},"labels":[],"label_agreement":null},{"id":"W2136344041","doi":"10.1016/s1470-2045(14)70063-4","title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":1174,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Montreal General Hospital","funders":"Universität Duisburg-Essen; Aarhus Universitet; Universität zu Köln; Universitair Medisch Centrum Groningen; University College London; National Institute for Health and Care Research; Universitaire Ziekenhuizen Leuven, KU Leuven; Canadian Cancer Society Research Institute; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; EORTC Charitable Trust; Aarhus Universitetshospital; Cancer Research UK; Amgen","keywords":"Ifosfamide; Doxorubicin; Soft tissue sarcoma; Medicine; Sarcoma; Oncology; Soft tissue; Chemotherapy; Internal medicine; Surgery; Pathology; Cisplatin","score_opus":0.11187372635953846,"score_gpt":0.4083463554134927,"score_spread":0.2964726290539542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136344041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9761396,0.00885469,0.001482109,0.0013997495,0.0015786699,0.005374189,0.0016936477,0.00021931405,0.0032580069],"genre_scores_gemma":[0.97718424,0.0053487215,0.0022210295,0.0015935093,0.0006497792,0.0054750536,0.0014131463,0.000059720733,0.006054933],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993131,0.0003291171,0.000036799815,0.00015296976,0.000037564838,0.00013048122],"domain_scores_gemma":[0.9989028,0.00037370552,0.00023105486,0.00009176801,0.00004988579,0.00035084432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018132421,0.0024524282,0.0043988284,0.00050337106,0.0004450027,0.0014399162,0.0013239596,0.0019703638,0.010721306],"category_scores_gemma":[0.0020560455,0.0008570228,0.0031014227,0.0005484429,0.0016351949,0.0015194165,0.0005883435,0.0048084813,0.0015863713],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9905619,0.001807534,0.00012452969,0.00042821802,0.0006539993,0.000017885128,0.000031231415,0.00027744955,0.0008447748,0.000070181806,0.0003692692,0.0048130634],"study_design_scores_gemma":[0.981092,0.017619843,0.0003802006,0.000025294315,0.00031241178,0.000011504036,0.0000106104635,0.00015198301,0.00008165729,0.00008992244,0.00021602646,0.000008595401],"about_ca_topic_score_codex":0.0020952139,"about_ca_topic_score_gemma":0.004038118,"teacher_disagreement_score":0.010721306,"about_ca_system_score_codex":0.0014782872,"about_ca_system_score_gemma":0.0012460069,"threshold_uncertainty_score":0.03586632},"labels":[],"label_agreement":null},{"id":"W2136541422","doi":"10.1016/s1470-2045(13)70380-2","title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":799,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; Vancouver General Hospital","funders":"Celgene","keywords":"Pomalidomide; Dexamethasone; Medicine; Lenalidomide; Refractory (planetary science); Internal medicine; Multiple myeloma; Clinical endpoint; Bortezomib; Population; Thalidomide; Progressive disease; Clinical trial; Phases of clinical research; Oncology; Gastroenterology; Chemotherapy","score_opus":0.08314179518883183,"score_gpt":0.37908462025288053,"score_spread":0.2959428250640487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136541422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98008746,0.006784879,0.0007802942,0.0020233432,0.0012668053,0.0035950092,0.0021603273,0.00023823629,0.0030635367],"genre_scores_gemma":[0.9847719,0.0029362417,0.0017256872,0.0019317954,0.0006236575,0.002858542,0.0012962339,0.000045264365,0.0038106046],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9992623,0.00038593804,0.000039204726,0.0001441617,0.000048153197,0.00012035298],"domain_scores_gemma":[0.9989422,0.0003529156,0.0002095811,0.00008147049,0.000036598663,0.00037731655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021514394,0.0027226254,0.0037624547,0.0005222539,0.00054075534,0.0017316287,0.0017639449,0.0023826747,0.009994194],"category_scores_gemma":[0.002124199,0.000897209,0.0037311988,0.0007176638,0.0020660777,0.0017446756,0.00077940396,0.005390675,0.0016201447],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9886956,0.0022670336,0.0002116398,0.00031735163,0.0006636717,0.00002119473,0.000039023806,0.00024810495,0.00078690215,0.000090408554,0.0006345232,0.0060245884],"study_design_scores_gemma":[0.9786839,0.019912075,0.00046138134,0.000018674587,0.0002260165,0.000016885053,0.000014410826,0.00017779786,0.000089898866,0.00016140968,0.00022811243,0.000009437439],"about_ca_topic_score_codex":0.0022651292,"about_ca_topic_score_gemma":0.0039787423,"teacher_disagreement_score":0.009994194,"about_ca_system_score_codex":0.0016140568,"about_ca_system_score_gemma":0.0014377957,"threshold_uncertainty_score":0.033433855},"labels":[],"label_agreement":null},{"id":"W2137043950","doi":"10.1016/s1470-2045(15)00006-6","title":"Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":434,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"AstraZeneca; Eli Lilly and Company","keywords":"Afatinib; Erlotinib; Medicine; Clinical endpoint; Internal medicine; Lung cancer; Erlotinib Hydrochloride; Oncology; Population; Randomized controlled trial; Surgery; Cancer; Epidermal growth factor receptor","score_opus":0.06509205628352367,"score_gpt":0.4127227631918144,"score_spread":0.34763070690829073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137043950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795583,0.0083962465,0.000806301,0.0014906018,0.0014774456,0.003311779,0.0017074447,0.00023384632,0.0030180858],"genre_scores_gemma":[0.98339224,0.0035166047,0.0012709211,0.001407937,0.0005916456,0.003289349,0.0014449918,0.00004142492,0.0050450005],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99924195,0.00034417977,0.000048149508,0.00016375151,0.000047533034,0.00015454169],"domain_scores_gemma":[0.99909437,0.00025981493,0.000182455,0.00007812211,0.00006246873,0.00032277431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018071024,0.0026809142,0.0046715857,0.0004890463,0.0005336893,0.0018419771,0.0013919325,0.0028329836,0.009406119],"category_scores_gemma":[0.0020921265,0.00088645297,0.0042878394,0.00046029556,0.0014354289,0.0022956587,0.0005452673,0.0053245835,0.0018829922],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98300856,0.002986166,0.0002770238,0.00060872245,0.001040368,0.00004006912,0.00004522492,0.00038276048,0.0011967901,0.00009982295,0.0007862083,0.009528244],"study_design_scores_gemma":[0.96893746,0.029227162,0.0005182039,0.000026041314,0.00033721633,0.000033667682,0.000020287553,0.0002791283,0.00011319353,0.00014779264,0.00034535772,0.000014505457],"about_ca_topic_score_codex":0.0012977676,"about_ca_topic_score_gemma":0.0031166894,"teacher_disagreement_score":0.009406119,"about_ca_system_score_codex":0.0011576375,"about_ca_system_score_gemma":0.0010233875,"threshold_uncertainty_score":0.031466603},"labels":[],"label_agreement":null},{"id":"W2137508065","doi":"10.1016/s1470-2045(11)70004-3","title":"Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":396,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Gemcitabine; Medicine; Placebo; Axitinib; Internal medicine; Oncology; Double blind; Ursodeoxycholic acid; Pancreatic cancer; Chemotherapy; Cancer","score_opus":0.13174673638970355,"score_gpt":0.39103431325916943,"score_spread":0.2592875768694659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137508065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9793155,0.0073594,0.0010762493,0.0010022103,0.0014090915,0.0054551517,0.0016086859,0.00023847082,0.0025352512],"genre_scores_gemma":[0.9767825,0.0053491136,0.0020539672,0.0015636171,0.0010516192,0.00664866,0.0012099572,0.00006785443,0.0052727386],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988422,0.0006381825,0.00008148323,0.00021354339,0.00005999757,0.0001646096],"domain_scores_gemma":[0.99857855,0.0004731753,0.00028884408,0.00015062345,0.00007458955,0.00043421172],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024522964,0.0029276211,0.006980904,0.0008009826,0.00076012744,0.0016643497,0.0014505128,0.0027782882,0.011076291],"category_scores_gemma":[0.0021070172,0.001491055,0.0041290517,0.00092721405,0.0023234598,0.0019296318,0.0007936255,0.0048355535,0.0017310173],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9933617,0.0019852323,0.00008259512,0.0002642996,0.00037994861,0.000010425118,0.000017254282,0.00011840529,0.0006037866,0.00002313732,0.00016091358,0.0029921536],"study_design_scores_gemma":[0.9706363,0.028426548,0.0003085764,0.0000105382005,0.0002303721,0.0000075677854,0.000007797439,0.00009587891,0.00008044739,0.000053377324,0.000135991,0.000006578531],"about_ca_topic_score_codex":0.0013762153,"about_ca_topic_score_gemma":0.0025600756,"teacher_disagreement_score":0.011076291,"about_ca_system_score_codex":0.0012298673,"about_ca_system_score_gemma":0.0015583846,"threshold_uncertainty_score":0.037053943},"labels":[],"label_agreement":null},{"id":"W2137616140","doi":"10.1016/s1470-2045(14)71160-x","title":"Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":387,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"National Cancer Institute; Canadian Cancer Society Research Institute; Eli Lilly and Company","keywords":"Cystectomy; Urothelial carcinoma; Medicine; Urology; Open label; Chemotherapy; Carcinoma; Oncology; Urothelial cancer; Bladder cancer; Randomized controlled trial; Internal medicine; Cancer","score_opus":0.051772857023881236,"score_gpt":0.35889775882615577,"score_spread":0.30712490180227453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137616140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920018,0.0038777865,0.00035991138,0.0005024078,0.0005578886,0.000790597,0.00046445942,0.00007838634,0.001366742],"genre_scores_gemma":[0.9937941,0.0015318252,0.0005725656,0.000556762,0.0002927088,0.00059836725,0.00046500735,0.00001546142,0.0021732023],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994505,0.00027814665,0.000025747293,0.00012806017,0.000023845896,0.000093717725],"domain_scores_gemma":[0.99899775,0.00034990892,0.00017457538,0.000078650155,0.000033844917,0.00036534842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012154869,0.0014497816,0.0030412958,0.00033852117,0.00042299044,0.00096481695,0.0010922181,0.0017391904,0.006730531],"category_scores_gemma":[0.0015144461,0.00057318294,0.00207371,0.000363173,0.001343703,0.0012486273,0.00047088682,0.0039209533,0.00087033137],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9855192,0.002863229,0.00036099702,0.00034398912,0.00037534063,0.00002132306,0.00005081287,0.00033849108,0.00074769545,0.000059154125,0.00030903312,0.0090107955],"study_design_scores_gemma":[0.8715537,0.123824425,0.0025889648,0.000059729013,0.000490972,0.000035109995,0.000041207455,0.00045772898,0.00027225207,0.00024022565,0.00041544752,0.000020173897],"about_ca_topic_score_codex":0.0018930301,"about_ca_topic_score_gemma":0.0038095561,"teacher_disagreement_score":0.006730531,"about_ca_system_score_codex":0.0008578819,"about_ca_system_score_gemma":0.0010316239,"threshold_uncertainty_score":0.022515833},"labels":[],"label_agreement":null},{"id":"W2137935883","doi":"10.1016/s1470-2045(09)70262-1","title":"Ki67 in breast cancer: prognostic and predictive potential","year":2010,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1226,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Breast cancer; Oncology; Medicine; Pathological; Oestrogen receptor; Internal medicine; Predictive marker; Cancer; Human Epidermal Growth Factor Receptor 2; Gynecology; Progesterone receptor; Bioinformatics; Estrogen receptor; Biology","score_opus":0.0245620792448499,"score_gpt":0.3433855665218097,"score_spread":0.3188234872769598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137935883","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000049808554,0.9992231,0.0000475784,0.00030858585,0.00011756623,0.0000011566817,0.000013023955,0.0000023814168,0.000236703],"genre_scores_gemma":[0.0006937692,0.99840206,0.00012362738,0.00023581549,0.00028952767,0.0000027457738,0.00002140687,0.0000010797315,0.00023006501],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99972385,0.00005084659,0.000036610152,0.000057506782,0.00010766359,0.000023565088],"domain_scores_gemma":[0.99879384,0.0007148323,0.00013795136,0.000031634117,0.00026571905,0.000055871547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014945007,0.0010817256,0.0021373213,0.0018536883,0.00019013138,0.0010937117,0.001099297,0.0012710625,0.0016784024],"category_scores_gemma":[0.0018528688,0.00040689047,0.0004615137,0.002785826,0.0008149496,0.0010856444,0.0005631297,0.0022212174,0.0013610661],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019209762,0.000040152263,0.0006675625,0.007151485,0.00015822753,0.00012514893,0.000021660606,0.0003394879,0.00070128916,0.0018519994,0.03427138,0.95447946],"study_design_scores_gemma":[0.000139488,0.0001883193,0.0056406884,0.006174122,0.00063646084,0.0019687298,0.000117496296,0.00029283634,0.00077848136,0.0058176485,0.97818494,0.00006077766],"about_ca_topic_score_codex":0.0029165098,"about_ca_topic_score_gemma":0.0056569977,"teacher_disagreement_score":0.0029165098,"about_ca_system_score_codex":0.000995784,"about_ca_system_score_gemma":0.0012923318,"threshold_uncertainty_score":0.007903755},"labels":[],"label_agreement":null},{"id":"W2138156952","doi":"10.1016/s1470-2045(13)70556-4","title":"Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":298,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; McMaster University; Juravinski Hospital; Queen's University; Sunnybrook Health Science Centre; Centre Hospitalier Universitaire de Sherbrooke; University of Calgary; University of Toronto","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Medicine; Randomized controlled trial; Oncology; Internal medicine; Physical therapy; Nuclear medicine","score_opus":0.06335275486606788,"score_gpt":0.35184966037814175,"score_spread":0.28849690551207385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138156952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96192354,0.022641832,0.0025437158,0.0016382659,0.0024225533,0.004339902,0.0010980989,0.00026946003,0.0031226578],"genre_scores_gemma":[0.98024356,0.0052212556,0.002753523,0.0016683583,0.0010967809,0.004237431,0.00050314015,0.000054214932,0.0042217276],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998334,0.0008627702,0.00012396555,0.00036620322,0.00012646399,0.00018657219],"domain_scores_gemma":[0.99757105,0.0011981165,0.00051084225,0.0002585923,0.00008743006,0.00037394126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026761554,0.002723314,0.006852638,0.00058220455,0.00061936973,0.0014089195,0.001675739,0.0036310218,0.012027771],"category_scores_gemma":[0.004289185,0.0010369311,0.004311545,0.0006564729,0.0019874214,0.0017156008,0.0006860495,0.0047495794,0.0015124882],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.99071735,0.0012673085,0.00010698812,0.00072664197,0.0012949107,0.000021635113,0.000028000963,0.0001893167,0.0007419042,0.00008338324,0.00024089804,0.0045816414],"study_design_scores_gemma":[0.9825927,0.015606165,0.0003943026,0.000057151676,0.0007166595,0.000020222851,0.0000113808865,0.00017456638,0.000076236654,0.0001883427,0.00014996527,0.000012344439],"about_ca_topic_score_codex":0.0012984538,"about_ca_topic_score_gemma":0.0022410846,"teacher_disagreement_score":0.012027771,"about_ca_system_score_codex":0.001006403,"about_ca_system_score_gemma":0.0009717668,"threshold_uncertainty_score":0.04023689},"labels":[],"label_agreement":null},{"id":"W2138256570","doi":"10.1016/s1470-2045(08)70028-7","title":"Cancer registration in developing countries: luxury or necessity?","year":2008,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":164,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Pediatric Oncology Group of Ontario","keywords":"Developing country; Cancer; Developed country; Low and middle income countries; Business; Health care; Population; Environmental health; Economic growth; Medicine; Economics","score_opus":0.3596719865317487,"score_gpt":0.5027934480522409,"score_spread":0.1431214615204922,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138256570","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000032008087,0.9953074,0.000049004444,0.0032797093,0.00081373635,0.000002413013,0.000026522837,0.0000066766947,0.00048261503],"genre_scores_gemma":[0.00048176086,0.9971591,0.00011620739,0.0014595967,0.00049990066,0.000004046898,0.000025687088,0.0000021833503,0.00025151978],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987494,0.00038270088,0.00025952366,0.00012640674,0.00037623124,0.00010566372],"domain_scores_gemma":[0.9955722,0.0024773018,0.0007464455,0.00010935534,0.00084942183,0.0002453229],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004391948,0.0011423804,0.0042279623,0.0042039165,0.00047178043,0.0031407184,0.0017299553,0.00289248,0.0062581636],"category_scores_gemma":[0.0070602377,0.00063645747,0.0010055725,0.008935399,0.0018397841,0.0049581337,0.0017092419,0.003880622,0.002068732],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000065093634,0.000026097678,0.00039521165,0.027160397,0.00017360886,0.00011700072,0.00013721913,0.00017428103,0.00014351151,0.004595713,0.1452536,0.8217583],"study_design_scores_gemma":[0.000045629375,0.000056786295,0.0017974841,0.029372187,0.0003336491,0.0007395224,0.0005150257,0.00007864577,0.00006857853,0.003087877,0.9638732,0.000031346764],"about_ca_topic_score_codex":0.007782395,"about_ca_topic_score_gemma":0.017423633,"teacher_disagreement_score":0.007782395,"about_ca_system_score_codex":0.0021219654,"about_ca_system_score_gemma":0.0075183944,"threshold_uncertainty_score":0.023227155},"labels":[],"label_agreement":null},{"id":"W2138662170","doi":"10.1016/s1470-2045(13)70107-4","title":"Subsequent neoplasms of the CNS among survivors of childhood cancer: a systematic review","year":2013,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":121,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute","keywords":"Medicine; Cancer; Radiation therapy; Population; Childhood cancer; Incidence (geometry); Pediatrics; Internal medicine; Oncology; Environmental health","score_opus":0.06366249309083598,"score_gpt":0.3630867245911064,"score_spread":0.2994242315002704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138662170","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015419786,0.9979857,0.00003266732,0.00005639027,0.00004058607,0.000027635278,0.00021372625,0.0000017879067,0.00009948819],"genre_scores_gemma":[0.016128596,0.9833688,0.00010038949,0.0001559044,0.000028893617,0.000034684545,0.00012558443,0.0000012288451,0.00005591269],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99904066,0.000209895,0.0003579476,0.00014771592,0.00017775342,0.00006583309],"domain_scores_gemma":[0.99646074,0.0021921557,0.00094816304,0.000047895945,0.00026573116,0.00008535835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011683762,0.0008266526,0.0037665179,0.0032708114,0.00029207065,0.0010561569,0.0009112734,0.0011202391,0.0026810176],"category_scores_gemma":[0.007822355,0.0005931465,0.0052282833,0.004897491,0.0004200019,0.0010121473,0.0009249948,0.0009051175,0.00018411942],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004726644,0.000028175215,0.0062207645,0.89557153,0.034405537,0.00028843663,0.00020005504,0.0002346774,0.00030284422,0.00017369914,0.0025100159,0.059591573],"study_design_scores_gemma":[0.00062052906,0.00044085138,0.04227216,0.5535597,0.36534593,0.0017677725,0.00077863556,0.00011860784,0.0003899266,0.00046187922,0.034133,0.00011096693],"about_ca_topic_score_codex":0.017100995,"about_ca_topic_score_gemma":0.054195244,"teacher_disagreement_score":0.017100995,"about_ca_system_score_codex":0.0015040297,"about_ca_system_score_gemma":0.003751717,"threshold_uncertainty_score":0.0340029},"labels":[],"label_agreement":null},{"id":"W2138746991","doi":"10.1016/s1470-2045(13)70449-2","title":"Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":404,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Montreal Children's Hospital; BC Children's Hospital; University of Toronto; SickKids Foundation","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Cancer Institute; Canadian Institutes of Health Research; National Center for Advancing Translational Sciences; Pediatric Brain Tumor Foundation","keywords":"Medulloblastoma; Medicine; Cancer research","score_opus":0.05283324484993569,"score_gpt":0.40220487391839227,"score_spread":0.3493716290684566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138746991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963819,0.0011119342,0.00052773976,0.00017480823,0.0000075088674,0.00001556234,0.0010796927,0.000024248955,0.0006766394],"genre_scores_gemma":[0.9981489,0.00020076582,0.00032359947,0.000035266145,0.000012912428,0.000007864011,0.0010775535,0.000018322933,0.00017470123],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991762,0.00016138967,0.00008574235,0.0002348441,0.00015345037,0.00018840925],"domain_scores_gemma":[0.9986841,0.0003513328,0.00044465793,0.0001777366,0.00018765761,0.00015457538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010610775,0.0003388087,0.0011233649,0.0022242968,0.00045474336,0.0010678656,0.0007383853,0.0005296438,0.0017360738],"category_scores_gemma":[0.0028826268,0.00030851155,0.0013938427,0.002166935,0.0003419707,0.0010566269,0.0011343299,0.0005837796,0.00046121902],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00086214306,0.000031648106,0.9746595,0.000039092087,0.0006593865,0.00014994376,0.00019603112,0.00044930016,0.003381232,0.000109891254,0.00047964047,0.018982153],"study_design_scores_gemma":[0.000021138892,0.00018864892,0.9948698,0.000014578277,0.0006063543,0.0006708633,0.00043276226,0.0013905576,0.00044437306,0.00045663884,0.00089052523,0.0000137305815],"about_ca_topic_score_codex":0.005597919,"about_ca_topic_score_gemma":0.011306317,"teacher_disagreement_score":0.005597919,"about_ca_system_score_codex":0.0006317394,"about_ca_system_score_gemma":0.000707374,"threshold_uncertainty_score":0.011130691},"labels":[],"label_agreement":null},{"id":"W2138809580","doi":"10.1016/s1470-2045(12)70473-4","title":"Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":280,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Abiraterone acetate; Prednisone; Prostate cancer; Medicine; Placebo; Oncology; Castration; Internal medicine; Pain control; Enzalutamide; Cancer; Hormone; Androgen deprivation therapy; Surgery; Pathology; Alternative medicine","score_opus":0.04245628526734094,"score_gpt":0.342165039565691,"score_spread":0.2997087542983501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138809580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850626,0.010201164,0.0002937733,0.0007133904,0.00054471206,0.00047182973,0.00082872453,0.00007450604,0.0018092766],"genre_scores_gemma":[0.9953759,0.0021945464,0.00029914445,0.00023095618,0.0003678592,0.00023879278,0.0004038381,0.000009370734,0.0008795812],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9977423,0.0014464603,0.0002069423,0.0002483751,0.00014180383,0.00021415701],"domain_scores_gemma":[0.9966445,0.0018111872,0.00064411527,0.00025892735,0.00009486766,0.000546556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003049645,0.0019571185,0.0047397553,0.00056953623,0.00041989362,0.0012951344,0.0009885507,0.0016934994,0.0057684286],"category_scores_gemma":[0.005564627,0.00075397623,0.004285853,0.00064313126,0.0017254378,0.0013298532,0.0006950195,0.0037318533,0.00071944797],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9921389,0.00047634082,0.00040653156,0.00036495418,0.0011999597,0.000017074459,0.000026911253,0.0002842819,0.00029877908,0.00004312735,0.00011825988,0.004624821],"study_design_scores_gemma":[0.93545777,0.05578936,0.0047379117,0.00008064356,0.0023234196,0.000055877743,0.000054736644,0.0005699214,0.00018935873,0.0003633062,0.00034961413,0.000028024759],"about_ca_topic_score_codex":0.0025596605,"about_ca_topic_score_gemma":0.0050601303,"teacher_disagreement_score":0.0057684286,"about_ca_system_score_codex":0.0010805946,"about_ca_system_score_gemma":0.0013374813,"threshold_uncertainty_score":0.019297302},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W2140075859","doi":"10.1016/s1470-2045(13)70158-x","title":"Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data","year":2013,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":245,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Surrogate endpoint; Radiation therapy; Lung cancer; Clinical endpoint; Internal medicine; Oncology; Clinical trial; Chemotherapy; Randomized controlled trial; Meta-analysis; Survival analysis; Cancer; Surgery","score_opus":0.4131700831971058,"score_gpt":0.5358208102113513,"score_spread":0.12265072701424551,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140075859","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07250052,0.875731,0.041055426,0.0020407902,0.0016967186,0.0010780125,0.0042264624,0.00042630103,0.0012448699],"genre_scores_gemma":[0.9250333,0.048016023,0.017274784,0.0019881153,0.00072750397,0.0020033882,0.003935326,0.00038983213,0.00063178013],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.7643266,0.191384,0.021770021,0.012374628,0.008984871,0.0011599185],"domain_scores_gemma":[0.64395803,0.29086164,0.024304213,0.03251364,0.0073092543,0.0010532534],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.21516009,0.004253175,0.019263046,0.006186642,0.00053367176,0.005903307,0.0031907188,0.0027112118,0.0018065933],"category_scores_gemma":[0.2688362,0.0020981668,0.07435464,0.0084288595,0.0013916132,0.0033562642,0.0025423283,0.0049222256,0.00038737993],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035171025,0.000013640752,0.012571514,0.014209774,0.9604222,0.0001043712,0.000068259396,0.0024837854,0.00018964849,0.00026643887,0.0006112259,0.005542024],"study_design_scores_gemma":[0.0019310781,0.0005209257,0.016734546,0.0026356124,0.9699809,0.00020254169,0.000052363026,0.0029549666,0.0003380197,0.0020505842,0.002520963,0.00007744874],"about_ca_topic_score_codex":0.0024229656,"about_ca_topic_score_gemma":0.0034504218,"teacher_disagreement_score":0.7848399,"about_ca_system_score_codex":0.0024784848,"about_ca_system_score_gemma":0.001991248,"threshold_uncertainty_score":0.96784735},"labels":[],"label_agreement":null},{"id":"W2140116071","doi":"10.1016/s1470-2045(14)71222-7","title":"The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":375,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Queen Elizabeth II Health Sciences Centre; University of British Columbia; Sunnybrook Health Science Centre; Dalhousie University; University of Toronto; University Health Network; BC Cancer Agency; Princess Margaret Cancer Centre; University of Calgary","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Renal cell carcinoma; Medicine; Oncology; Internal medicine; Population based study; Epidemiology","score_opus":0.05650128386318062,"score_gpt":0.29932592221088883,"score_spread":0.2428246383477082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140116071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942755,0.00095145474,0.00048653048,0.00035280304,0.00005378988,0.00002951397,0.0032433465,0.000016735215,0.00059029745],"genre_scores_gemma":[0.997045,0.00020321137,0.00018095897,0.00006111657,0.000041211257,0.000033263696,0.0022760225,0.0000100348325,0.00014922177],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976392,0.0010672912,0.00018480468,0.000575632,0.00028912604,0.00024400643],"domain_scores_gemma":[0.9940692,0.0022332354,0.0016948148,0.0009145378,0.00049795257,0.00059031625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036395367,0.0007334631,0.0014587325,0.001062649,0.0005785203,0.0020529814,0.001457222,0.0011214147,0.002047056],"category_scores_gemma":[0.012841611,0.00049110915,0.0028529696,0.0027084642,0.000464383,0.0022873974,0.0014161916,0.0023736842,0.0003503973],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019296458,0.00010592116,0.992916,0.000037220776,0.0017291534,0.000060511295,0.00007371283,0.00039407104,0.00008051674,0.00010475565,0.0008746592,0.0016937942],"study_design_scores_gemma":[0.0003635029,0.0006015795,0.9876815,0.00003920225,0.0024090044,0.00048992445,0.0004562134,0.0064749946,0.00009538842,0.00046768493,0.0008759785,0.000044916764],"about_ca_topic_score_codex":0.0065787216,"about_ca_topic_score_gemma":0.0061288457,"teacher_disagreement_score":0.0065787216,"about_ca_system_score_codex":0.0009488197,"about_ca_system_score_gemma":0.0008518208,"threshold_uncertainty_score":0.01924795},"labels":[],"label_agreement":null},{"id":"W2140258972","doi":"10.1016/s1470-2045(08)70295-x","title":"Cancer patterns in Inuit populations","year":2008,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; MEDLINE","score_opus":0.08490454540519131,"score_gpt":0.3684336520764244,"score_spread":0.2835291066712331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140258972","genre_codex":"empirical","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6090828,0.0032928882,0.0002619305,0.3656665,0.0022540449,0.00004889797,0.0026800956,0.000040553383,0.016672164],"genre_scores_gemma":[0.8553136,0.0030702555,0.0003655241,0.127768,0.003016342,0.00006132524,0.0006928062,0.000028487222,0.009683643],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995989,0.00013394184,0.00006424087,0.000051414903,0.000057898367,0.000093639435],"domain_scores_gemma":[0.99846965,0.0004892834,0.00035401146,0.00006412462,0.00034248887,0.00028053176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005099042,0.000120870725,0.0002700486,0.00058796175,0.001039219,0.0007817645,0.0005239852,0.002689636,0.0025704938],"category_scores_gemma":[0.003288105,0.00023249765,0.00023403986,0.0013664092,0.0003800727,0.0008432789,0.00048970256,0.0019177938,0.00046520063],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002827342,0.00014164449,0.817917,0.00020568074,0.00008237865,0.0044246097,0.0046224752,0.00012610358,0.0010932945,0.0012489357,0.14065933,0.029195799],"study_design_scores_gemma":[0.00006855642,0.00023801769,0.9184036,0.00035830445,0.00008824067,0.0058273016,0.013350635,0.00081460486,0.00044136873,0.0017338101,0.058612093,0.000063472566],"about_ca_topic_score_codex":0.070050105,"about_ca_topic_score_gemma":0.16390543,"teacher_disagreement_score":0.9299499,"about_ca_system_score_codex":0.0012295868,"about_ca_system_score_gemma":0.0006934445,"threshold_uncertainty_score":0.13928479},"labels":[],"label_agreement":null},{"id":"W2140324582","doi":"10.1016/s1470-2045(13)70606-5","title":"Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":223,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto; University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Institute for Clinical Evaluative Sciences","keywords":"Medicine; Cumulative incidence; Prostate cancer; Prostatectomy; Erectile dysfunction; Incidence (geometry); Urinary incontinence; Cancer registry; Cohort; Radiation therapy; Population; Complication; Comorbidity; Retrospective cohort study; Surgery; Cancer; Internal medicine","score_opus":0.03113809499732038,"score_gpt":0.3560763615609574,"score_spread":0.324938266563637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140324582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976059,0.00046665408,0.00014348092,0.000081054975,0.000024593766,0.000020096139,0.0012715252,0.000010027598,0.00037662446],"genre_scores_gemma":[0.9982406,0.00028174,0.000093453884,0.00006383117,0.000028193825,0.000019101162,0.0009052024,0.0000082275865,0.00035961525],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99843925,0.00036002422,0.00015946431,0.000554494,0.0002043575,0.00028241216],"domain_scores_gemma":[0.9970355,0.00034945834,0.00093513343,0.00079270935,0.00033788008,0.0005492781],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016497234,0.0007308533,0.0009436215,0.001217426,0.001075966,0.0016771395,0.0013539805,0.0019384034,0.002520278],"category_scores_gemma":[0.0033672445,0.0016978928,0.0036168138,0.0024382747,0.00065658905,0.0017224991,0.0011143289,0.0023723475,0.00052600936],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062505255,0.00012810943,0.997141,0.000013837824,0.0008466152,0.00011715511,0.00010851871,0.000040857452,0.00028671668,0.00001881601,0.00016294612,0.0005103635],"study_design_scores_gemma":[0.000033442328,0.00022903144,0.99885607,0.0000051539105,0.00025186807,0.00021490004,0.00016628772,0.00008821676,0.00003015307,0.000017805283,0.00009503938,0.000011986023],"about_ca_topic_score_codex":0.02113231,"about_ca_topic_score_gemma":0.019734923,"teacher_disagreement_score":0.02113231,"about_ca_system_score_codex":0.0007420725,"about_ca_system_score_gemma":0.00080328406,"threshold_uncertainty_score":0.042018652},"labels":[],"label_agreement":null},{"id":"W2140587309","doi":"10.1016/s1470-2045(12)70490-4","title":"Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Liver physiology and pathology","field":"Medicine","cited_by":550,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Vancouver General Hospital","funders":"","keywords":"Medicine; Placebo; Clinical endpoint; Internal medicine; Hepatocellular carcinoma; Sorafenib; Population; Neutropenia; Performance status; Randomized controlled trial; Surgery; Oncology; Cancer; Chemotherapy; Pathology","score_opus":0.0695716841107646,"score_gpt":0.374972235833241,"score_spread":0.30540055172247643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140587309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97744226,0.010614498,0.0011612384,0.0010347364,0.0015504395,0.00405509,0.0016573964,0.00020757316,0.002276786],"genre_scores_gemma":[0.9750404,0.008121771,0.0018827643,0.0016294774,0.0010141159,0.0046229656,0.0017490296,0.000065779444,0.0058736056],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994205,0.00030104796,0.000033013188,0.00009684663,0.00003805227,0.00011063292],"domain_scores_gemma":[0.9992181,0.00023386473,0.00015329782,0.00008160218,0.000054108543,0.00025901632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014714039,0.0022370461,0.00454516,0.000454267,0.00040231048,0.0011600057,0.0009083105,0.0021212576,0.008329206],"category_scores_gemma":[0.0017775256,0.0009815547,0.0022511885,0.00046872286,0.0012810737,0.0012152026,0.00038772827,0.0029511184,0.0014835931],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98753476,0.0020497425,0.00015742847,0.00060844043,0.00073332555,0.000031641346,0.000026113463,0.00014086961,0.0020349533,0.000049649254,0.00043705053,0.0061959643],"study_design_scores_gemma":[0.9684559,0.030035816,0.0005630013,0.000019638816,0.00026531247,0.000023087541,0.000012613931,0.00011146134,0.00016238887,0.000052570733,0.00028843235,0.000009744214],"about_ca_topic_score_codex":0.0012085825,"about_ca_topic_score_gemma":0.002220711,"teacher_disagreement_score":0.008329206,"about_ca_system_score_codex":0.0009144717,"about_ca_system_score_gemma":0.0009631311,"threshold_uncertainty_score":0.02786398},"labels":[],"label_agreement":null},{"id":"W2140859993","doi":"10.1016/s1470-2045(05)70432-0","title":"Health-related quality of life in patients with glioblastoma: a randomised controlled trial","year":2005,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":329,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Queen's University; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Quality of life (healthcare); Temozolomide; Radiation therapy; Clinical endpoint; Randomized controlled trial; Internal medicine; Cancer; Clinical trial; Physical therapy; Oncology","score_opus":0.03270685746671431,"score_gpt":0.3344756783315177,"score_spread":0.3017688208648034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140859993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9609477,0.023303108,0.0010362024,0.0028097937,0.0025042535,0.005445554,0.0017530104,0.00013113444,0.0020693112],"genre_scores_gemma":[0.98138887,0.007039015,0.0010408224,0.0015522301,0.0007727609,0.0057139015,0.0008602227,0.000016035618,0.0016160855],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979012,0.0011554628,0.00020293465,0.00033090802,0.00011643747,0.00029307406],"domain_scores_gemma":[0.99784863,0.0007452547,0.00062842015,0.00016278146,0.0001147448,0.0005001523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025093667,0.0022666943,0.00577949,0.0007486976,0.00072986074,0.0015793894,0.0012755747,0.0036854409,0.008176115],"category_scores_gemma":[0.004811828,0.0011056056,0.005432114,0.0011915257,0.0021652386,0.0018824885,0.0010064936,0.004994473,0.00090580113],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9903376,0.0014463706,0.0004424362,0.0011962228,0.0017869767,0.000028320466,0.00003386566,0.000133702,0.00030497674,0.00007301169,0.00039054616,0.0038258985],"study_design_scores_gemma":[0.98261213,0.014743974,0.0008980537,0.000076611694,0.0011591604,0.000012689539,0.00002098692,0.000098110904,0.000043351458,0.00013096914,0.00019183553,0.000012077408],"about_ca_topic_score_codex":0.003085063,"about_ca_topic_score_gemma":0.0040355525,"teacher_disagreement_score":0.008176115,"about_ca_system_score_codex":0.0016874501,"about_ca_system_score_gemma":0.0018894991,"threshold_uncertainty_score":0.027351856},"labels":[],"label_agreement":null},{"id":"W2141046618","doi":"10.1016/s1470-2045(04)01596-7","title":"Assessment of therapeutic response in patients with metastatic bone disease","year":2004,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Osteoclast; Bone resorption; Disease; Bone disease; Osteoporosis; Oncology; Resorption; Internal medicine; Pathology","score_opus":0.0991501852052402,"score_gpt":0.45508676674341525,"score_spread":0.35593658153817503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141046618","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00031797233,0.9987179,0.00011791676,0.00032464784,0.00010557448,0.000007636398,0.000030431353,0.0000046839164,0.00037327094],"genre_scores_gemma":[0.007978155,0.9899402,0.0006571517,0.00071575324,0.00029250534,0.00003077361,0.00008574115,0.0000025297402,0.00029704193],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989309,0.00037724353,0.00020490024,0.00013753361,0.00031330678,0.00003607496],"domain_scores_gemma":[0.99733955,0.001964979,0.00040852051,0.000032036576,0.00022056719,0.00003433684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020547914,0.0007906307,0.004396926,0.001534031,0.00011546416,0.00088218215,0.0010900326,0.0010255235,0.0016440488],"category_scores_gemma":[0.005053356,0.0002733185,0.0011306701,0.0015316716,0.00054044696,0.000621301,0.00042637714,0.0016232304,0.00041100878],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006185317,0.000049378257,0.0014834289,0.023911813,0.0006118706,0.0001232522,0.00004092087,0.0003929601,0.00047556378,0.0007444516,0.010621782,0.9609261],"study_design_scores_gemma":[0.0024833865,0.0031799325,0.0519313,0.08729737,0.012277785,0.008678587,0.00058512145,0.0020138668,0.0029979167,0.0073842597,0.8209555,0.00021501145],"about_ca_topic_score_codex":0.0021183477,"about_ca_topic_score_gemma":0.0048453314,"teacher_disagreement_score":0.004396926,"about_ca_system_score_codex":0.00077656156,"about_ca_system_score_gemma":0.0010087054,"threshold_uncertainty_score":0.01086694},"labels":[],"label_agreement":null},{"id":"W2142148449","doi":"10.1016/s1470-2045(09)70155-x","title":"Molecular predictive and prognostic markers in non-small-cell lung cancer","year":2009,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":215,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Lung cancer; Oncology; Targeted therapy; Internal medicine; Adjuvant; Chemotherapy; Cancer; Adjuvant chemotherapy; Intensive care medicine","score_opus":0.028587391361870357,"score_gpt":0.3983639984049767,"score_spread":0.36977660704310633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142148449","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006849993,0.99884546,0.00009754279,0.000423978,0.00016756568,0.0000024616422,0.000017712335,0.000004601946,0.00037220525],"genre_scores_gemma":[0.0009457303,0.9977385,0.00020783291,0.00036013208,0.00030749536,0.000004671828,0.00003237925,0.000001124081,0.0004022435],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997036,0.000054007258,0.000045476067,0.000052432064,0.00011997768,0.000024382478],"domain_scores_gemma":[0.9990466,0.00061196124,0.00013894732,0.000022847331,0.00014617655,0.00003346862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012424754,0.00086795905,0.0023845546,0.001732378,0.00017852322,0.0010270228,0.0011518258,0.0012578837,0.002295993],"category_scores_gemma":[0.0020053345,0.00042438286,0.0007373407,0.0019109007,0.00055674015,0.0011528521,0.00045571147,0.0023328764,0.0012906153],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000107431704,0.00004534275,0.00044570374,0.0068832133,0.00020289606,0.00014601447,0.000020895799,0.0004677039,0.0006483473,0.0023817078,0.034419786,0.95423084],"study_design_scores_gemma":[0.000113958435,0.00018885775,0.0033159498,0.0055263825,0.00077048264,0.0019909057,0.000056202476,0.00042308666,0.0007323788,0.00433978,0.98249763,0.000044373915],"about_ca_topic_score_codex":0.0015048004,"about_ca_topic_score_gemma":0.0029076845,"teacher_disagreement_score":0.0023845546,"about_ca_system_score_codex":0.00085794774,"about_ca_system_score_gemma":0.0010868841,"threshold_uncertainty_score":0.007680893},"labels":[],"label_agreement":null},{"id":"W2142226415","doi":"10.1016/s1470-2045(15)70064-1","title":"Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":285,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Fudan University; Natural Science Foundation of Shanghai; Eli Lilly and Company","keywords":"Gemcitabine; Medicine; Internal medicine; Regimen; Metastatic breast cancer; Oncology; Breast cancer; Clinical endpoint; Triple-negative breast cancer; Chemotherapy; Cisplatin; Paclitaxel; Cancer; Clinical trial","score_opus":0.2756851049856489,"score_gpt":0.49839696780858883,"score_spread":0.22271186282293992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142226415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98182124,0.0048006643,0.000905894,0.0015699506,0.001227346,0.004604789,0.0019140557,0.00027977588,0.0028764415],"genre_scores_gemma":[0.97481185,0.004792084,0.002424568,0.0024057995,0.0007384035,0.004599624,0.0026507329,0.00009041167,0.007486457],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9992957,0.00038095555,0.000029320316,0.00013021604,0.00005485043,0.0001089997],"domain_scores_gemma":[0.9989209,0.0003070927,0.00019424215,0.000076963915,0.000050093742,0.00045073498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020517674,0.0028346868,0.003940663,0.0006249475,0.0005353145,0.001610868,0.0015759473,0.0025588218,0.011354465],"category_scores_gemma":[0.002216277,0.00094534026,0.0032366293,0.0006771371,0.0016800866,0.0017337062,0.00074642967,0.0062591685,0.0020656234],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9859081,0.0030749259,0.00017683985,0.00035942293,0.00053880725,0.000023278446,0.00003660754,0.0003592541,0.00096629624,0.00008915281,0.0008997852,0.007567499],"study_design_scores_gemma":[0.9672455,0.031331606,0.00046823942,0.000022331773,0.00019798681,0.000017786539,0.000012469266,0.00022205235,0.0001097116,0.000111718735,0.00025012202,0.000010498182],"about_ca_topic_score_codex":0.0020151879,"about_ca_topic_score_gemma":0.0049694763,"teacher_disagreement_score":0.011354465,"about_ca_system_score_codex":0.0014232477,"about_ca_system_score_gemma":0.0016914239,"threshold_uncertainty_score":0.03798449},"labels":[],"label_agreement":null},{"id":"W2142466432","doi":"10.1016/s1470-2045(12)70560-0","title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":740,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; National Cancer Institute; Institut National Du Cancer; Sanofi; Roche; Bayer; AstraZeneca; Unicancer; Novartis; Pfizer; Amgen","keywords":"Medicine; Docetaxel; Androgen deprivation therapy; Prostate cancer; Internal medicine; Oncology; Estramustine; Clinical endpoint; Chemotherapy; Goserelin; Prostate-specific antigen; Urology; Cancer; Randomized controlled trial","score_opus":0.14905012062048997,"score_gpt":0.44504975400106633,"score_spread":0.29599963338057633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142466432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856737,0.005377793,0.00058348925,0.0008482774,0.0008020346,0.0030494581,0.0013203078,0.00023455992,0.0021103069],"genre_scores_gemma":[0.9866,0.0029619823,0.0013213186,0.0012921223,0.00044110746,0.002445033,0.0012543012,0.000046961577,0.0036371832],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99924314,0.00037600208,0.000035086832,0.00013935623,0.000048480444,0.00015792425],"domain_scores_gemma":[0.9991553,0.00023278623,0.00015008394,0.000059548638,0.000031702446,0.00037058524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021192883,0.002524046,0.0036077644,0.00068722275,0.000526716,0.0012887162,0.0011405629,0.0021733514,0.009512435],"category_scores_gemma":[0.0017395258,0.00087482564,0.0033054072,0.0005762538,0.0020772992,0.0017346242,0.0006494942,0.0045937286,0.0013862837],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97686654,0.004649007,0.00035830392,0.0005284484,0.00084704766,0.00002639747,0.000070643975,0.00043924854,0.0009569621,0.00014039762,0.0009761236,0.014140793],"study_design_scores_gemma":[0.9344261,0.06328947,0.00093909964,0.000029130691,0.00031759773,0.000029635492,0.00002616176,0.0002846013,0.00013420261,0.00016831525,0.00033834518,0.000017269835],"about_ca_topic_score_codex":0.002728285,"about_ca_topic_score_gemma":0.0067339707,"teacher_disagreement_score":0.009512435,"about_ca_system_score_codex":0.0011291739,"about_ca_system_score_gemma":0.0013324489,"threshold_uncertainty_score":0.031822205},"labels":[],"label_agreement":null},{"id":"W2142875113","doi":"10.1016/s1470-2045(07)70278-4","title":"Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial","year":2007,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1078,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Saint John Regional Hospital; Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute","keywords":"Medicine; Axillary Lymph Node Dissection; Sentinel lymph node; Breast cancer; Surgery; Lymph node; Stage (stratigraphy); Randomized controlled trial; Dissection (medical); Cancer; Internal medicine","score_opus":0.02027302097998062,"score_gpt":0.33800450789262054,"score_spread":0.3177314869126399,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142875113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919127,0.004886359,0.00026111442,0.00065599376,0.00025097266,0.000201577,0.0006152699,0.000021408694,0.0011945862],"genre_scores_gemma":[0.99449944,0.0018466301,0.00036058054,0.00056299893,0.0002767785,0.00027593278,0.0010777839,0.0000153702,0.001084404],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9986928,0.0008348118,0.000072532086,0.00016294248,0.00010044868,0.00013644822],"domain_scores_gemma":[0.99796826,0.0007564154,0.0005707132,0.00020030077,0.00006841419,0.00043588434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030574503,0.0016347364,0.0021209952,0.00029779715,0.00023915863,0.0009847939,0.0008784705,0.0014708702,0.0022769007],"category_scores_gemma":[0.0028848478,0.0005212603,0.0026014624,0.0004446047,0.0013723484,0.0012924623,0.0005732704,0.0025741349,0.00039896523],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9760429,0.0013726492,0.005290538,0.00031512903,0.0016940444,0.000029720703,0.000044397897,0.0009838087,0.0011666232,0.000114188355,0.00059968827,0.012346294],"study_design_scores_gemma":[0.80234694,0.13275759,0.056319665,0.00012599667,0.003442004,0.00014334964,0.0001496964,0.0013511947,0.00094418426,0.0010950702,0.0012549014,0.000069454676],"about_ca_topic_score_codex":0.0012006006,"about_ca_topic_score_gemma":0.002453427,"teacher_disagreement_score":0.0030574503,"about_ca_system_score_codex":0.0010928097,"about_ca_system_score_gemma":0.0011111484,"threshold_uncertainty_score":0.016169548},"labels":[],"label_agreement":null},{"id":"W2144143639","doi":"10.1016/s1470-2045(15)70114-2","title":"Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":182,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill Genome Centre; McGill University; London Health Sciences Centre; Vancouver General Hospital; Children’s Health Research Institute; Children's Hospital of Eastern Ontario; Ottawa Hospital; Centre Hospitalier Universitaire Sainte-Justine; University of Alberta; University of Ottawa; University of British Columbia; Alberta Hospital Edmonton; University of Calgary; Hospital for Sick Children; Western University; McGill University and Génome Québec Innovation Centre; University of Toronto; University of Alberta Hospital; Montreal Children's Hospital; Children's & Women's Health Centre of British Columbia; Alberta Children's Hospital; SickKids Foundation; McMaster University; Université de Montréal","funders":"National Cancer Institute; Genome Canada","keywords":"Biology; Atypical teratoid rhabdoid tumor; Immunohistochemistry; Pathology; Chemotherapy; Cancer research; Oncology; Medicine; Genetics","score_opus":0.030455597976323034,"score_gpt":0.3249774823903661,"score_spread":0.2945218844140431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144143639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99294233,0.0030839043,0.0010308024,0.0003222672,0.000011507015,0.000024607505,0.001007699,0.000028231081,0.0015486237],"genre_scores_gemma":[0.9960756,0.0012684454,0.0013166559,0.000065996355,0.00003339465,0.000021094025,0.0010045687,0.000022122715,0.00019208866],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994661,0.00009954383,0.000048673206,0.00011044294,0.0001319012,0.00014326097],"domain_scores_gemma":[0.9989681,0.00033892834,0.00036341837,0.000089624475,0.000101348465,0.00013852178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073916285,0.00043159816,0.000684654,0.0022757656,0.00038179313,0.0010746666,0.00066456,0.0005226217,0.0012206255],"category_scores_gemma":[0.0018506972,0.00035258647,0.0006463998,0.0018675028,0.0006110773,0.00068557105,0.0010632135,0.00057796476,0.0003685717],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045116723,0.000017900229,0.96534824,0.00006524413,0.00013388644,0.0020578492,0.00024594995,0.00093459466,0.0122206295,0.000642817,0.0006761058,0.017205581],"study_design_scores_gemma":[0.000023976467,0.00012298806,0.9735841,0.000041910236,0.00024345439,0.016510852,0.0010230475,0.00094218715,0.0026417826,0.0014155961,0.0034263358,0.000023843959],"about_ca_topic_score_codex":0.0014859665,"about_ca_topic_score_gemma":0.0020821958,"teacher_disagreement_score":0.0022757656,"about_ca_system_score_codex":0.0005637967,"about_ca_system_score_gemma":0.00069494,"threshold_uncertainty_score":0.004090667},"labels":[],"label_agreement":null},{"id":"W2144921015","doi":"10.1016/s1470-2045(15)00363-0","title":"Intravenous pegylated asparaginase versus intramuscular native Escherichia coli l-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":240,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine; McMaster University","funders":"National Cancer Institute; Dana-Farber Cancer Institute; Enzon Pharmaceuticals","keywords":"Medicine; Asparaginase; Internal medicine; Gastroenterology; Pediatrics; Surgery; Leukemia; Lymphoblastic Leukemia","score_opus":0.07495321031302048,"score_gpt":0.38566004730027914,"score_spread":0.31070683698725865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144921015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831312,0.006576048,0.0008208137,0.0011775772,0.00081811135,0.002820435,0.0015798485,0.0002521976,0.0028236753],"genre_scores_gemma":[0.981482,0.0050747064,0.0016413913,0.0016062948,0.00034820172,0.0031134142,0.0017034222,0.00004829316,0.004982235],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995433,0.00023714766,0.000018569704,0.00007420695,0.000030693125,0.00009600326],"domain_scores_gemma":[0.9991887,0.00027653357,0.0001347771,0.00006130898,0.00002758815,0.00031098563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013228643,0.0018078123,0.0029034214,0.00042775375,0.00028062938,0.0012494898,0.00127358,0.001874808,0.008497488],"category_scores_gemma":[0.0016904395,0.0006879544,0.0018683482,0.00052458834,0.0013620089,0.0010799689,0.0004276571,0.004412461,0.0013372202],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.972063,0.0037415188,0.00035372487,0.00057271856,0.00059449975,0.000053403914,0.00006346506,0.00043352175,0.0019124239,0.0001934801,0.0010975284,0.018920692],"study_design_scores_gemma":[0.9634199,0.034821313,0.00057947094,0.000022366525,0.00017005004,0.000030396088,0.000021526916,0.00019998019,0.00019052003,0.00011853124,0.00041778045,0.000008088777],"about_ca_topic_score_codex":0.0022550058,"about_ca_topic_score_gemma":0.0037568538,"teacher_disagreement_score":0.008497488,"about_ca_system_score_codex":0.0014199506,"about_ca_system_score_gemma":0.0013834336,"threshold_uncertainty_score":0.028426886},"labels":[],"label_agreement":null},{"id":"W2145118120","doi":"10.1016/s1470-2045(13)70162-1","title":"Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":138,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Princess Margaret Cancer Centre; Ottawa Regional Cancer Foundation; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"Celgene","keywords":"Medicine; Tolerability; Response Evaluation Criteria in Solid Tumors; Internal medicine; Regimen; Metastatic Urothelial Carcinoma; Paclitaxel; Clinical endpoint; Adverse effect; Gastroenterology; Progressive disease; Refractory (planetary science); Phases of clinical research; Oncology; Progression-free survival; Chemotherapy; Bladder cancer; Cancer; Clinical trial; Urothelial carcinoma","score_opus":0.10664524640324281,"score_gpt":0.38548825514371515,"score_spread":0.27884300874047235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145118120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99493223,0.001507549,0.00075034297,0.0003027326,0.0001709521,0.0012394057,0.0003456769,0.00009173368,0.0006594425],"genre_scores_gemma":[0.9908394,0.0020157488,0.0015397281,0.0008169654,0.00018694437,0.0012413854,0.0009439334,0.00009016292,0.002325738],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994184,0.00022645517,0.000019318626,0.00014242413,0.00007335661,0.00012008468],"domain_scores_gemma":[0.9993616,0.000103239705,0.00014386466,0.00007424938,0.000062902705,0.00025416774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017266227,0.0019836116,0.003127064,0.00057561405,0.00054751005,0.0016334412,0.0010920974,0.0022849925,0.0025352538],"category_scores_gemma":[0.0010685247,0.00078441104,0.0021271997,0.0006090492,0.0010971365,0.0012364932,0.00047149314,0.0029658757,0.0007589972],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74090797,0.08450559,0.003457671,0.00141421,0.005179639,0.00026154815,0.0005257309,0.0037363996,0.07392616,0.00019879866,0.0039374,0.081948854],"study_design_scores_gemma":[0.5533999,0.42741004,0.008903581,0.000037646423,0.0014356489,0.00018564834,0.000092042406,0.0014235761,0.005072762,0.00012787747,0.0018482779,0.000062916995],"about_ca_topic_score_codex":0.002123736,"about_ca_topic_score_gemma":0.0036006693,"teacher_disagreement_score":0.003127064,"about_ca_system_score_codex":0.0015060782,"about_ca_system_score_gemma":0.0016141406,"threshold_uncertainty_score":0.010927379},"labels":[],"label_agreement":null},{"id":"W2145140579","doi":"10.1016/s1470-2045(06)70904-4","title":"Image-guided radiotherapy: rationale, benefits, and limitations","year":2006,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":335,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"University of Texas MD Anderson Cancer Center","keywords":"Radiation therapy; Medical physics; Computer science; Medicine; Radiology","score_opus":0.10250541464930628,"score_gpt":0.39277465590586425,"score_spread":0.29026924125655795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145140579","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000038621052,0.9989446,0.00013457504,0.0004002776,0.00010026352,0.0000026859095,0.000005762832,0.0000028363609,0.0003703264],"genre_scores_gemma":[0.00050589605,0.9983041,0.00040104755,0.00033231638,0.00022797768,0.0000067849646,0.00000988368,0.0000019265688,0.00021001269],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99925965,0.0001746931,0.00009718722,0.00013328128,0.00029401478,0.00004113604],"domain_scores_gemma":[0.99708647,0.0019254748,0.00026969254,0.00007959834,0.0005603422,0.000078408324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035011102,0.0014388566,0.003223123,0.0025579287,0.00040894773,0.0022702096,0.0025528118,0.0030855485,0.0030297788],"category_scores_gemma":[0.0030975535,0.0006226253,0.0011213986,0.0029870109,0.002415874,0.0026532928,0.001008186,0.0042656474,0.0021431076],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015947978,0.000076054275,0.0002774253,0.014077049,0.0001531695,0.00019121775,0.00006792844,0.0005605262,0.0009200518,0.0072859074,0.016977167,0.95925397],"study_design_scores_gemma":[0.00011218401,0.00019188185,0.0016429061,0.010202054,0.00039821913,0.003196121,0.00015553106,0.0003122172,0.0009042562,0.008581153,0.9742313,0.000072252486],"about_ca_topic_score_codex":0.002521724,"about_ca_topic_score_gemma":0.0047295005,"teacher_disagreement_score":0.0035011102,"about_ca_system_score_codex":0.0016552836,"about_ca_system_score_gemma":0.0025386624,"threshold_uncertainty_score":0.018515885},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"systematic_review","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W2145280166","doi":"10.1016/s1470-2045(10)70218-7","title":"Definition and classification of cancer cachexia: an international consensus","year":2011,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":5631,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Cachexia; Consensus conference; Cancer cachexia; Cancer; Intensive care medicine; Medicine; Political science; Internal medicine","score_opus":0.5331106926091742,"score_gpt":0.5308219039922553,"score_spread":0.0022887886169189464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145280166","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002255396,0.99031675,0.0014040687,0.0060668667,0.0012136789,0.000039682098,0.000113694216,0.00001963848,0.0006000685],"genre_scores_gemma":[0.002703414,0.984923,0.0067369775,0.0035601088,0.0011322298,0.00010103799,0.00040190367,0.000015633206,0.0004256159],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965842,0.00064486417,0.0011869434,0.0005660689,0.00081871054,0.00019922738],"domain_scores_gemma":[0.99433005,0.0025176718,0.00079683657,0.00013891817,0.0019496526,0.000266926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011754783,0.0026581858,0.008540676,0.00924838,0.0011409976,0.0049069887,0.006006633,0.0036561256,0.0018785576],"category_scores_gemma":[0.009812346,0.0009586032,0.005048321,0.007842866,0.0036085236,0.0061803893,0.0030750087,0.008123886,0.0011689822],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030229517,0.00012293809,0.0027157573,0.046635658,0.0007975172,0.00028398787,0.0005176272,0.0010367591,0.0008161219,0.016214963,0.08680451,0.84375197],"study_design_scores_gemma":[0.000301459,0.0002904092,0.008711164,0.09314352,0.002935563,0.0032768426,0.0015008203,0.001355226,0.0008372687,0.024893459,0.8624625,0.00029180094],"about_ca_topic_score_codex":0.011164915,"about_ca_topic_score_gemma":0.01202487,"teacher_disagreement_score":0.011754783,"about_ca_system_score_codex":0.0056105764,"about_ca_system_score_gemma":0.013988973,"threshold_uncertainty_score":0.062165976},"labels":[],"label_agreement":null},{"id":"W2145376545","doi":"10.1016/s1470-2045(15)70057-4","title":"Response assessment criteria for brain metastases: proposal from the RANO group","year":2015,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":1088,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Queen's University; London Health Sciences Centre; Ontario Institute for Cancer Research","funders":"Breast Cancer Research Foundation","keywords":"Group (periodic table); Computer science; Medicine; Medical physics; Psychology; Physics","score_opus":0.2039613437360562,"score_gpt":0.5016602951475275,"score_spread":0.2976989514114713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145376545","genre_codex":"review","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00062241824,0.9772564,0.0028836073,0.013962745,0.0020646208,0.00052632566,0.0005911437,0.000051119005,0.0020415685],"genre_scores_gemma":[0.02215049,0.9080924,0.027523117,0.029686755,0.0034621407,0.003914141,0.0022300954,0.00011013157,0.0028307445],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9933129,0.003075184,0.0016455087,0.00047842483,0.0011974243,0.00029067785],"domain_scores_gemma":[0.9860663,0.009570378,0.0013266496,0.0002492268,0.002494764,0.00029270584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.021086235,0.0015783753,0.007723272,0.0033044696,0.0005276484,0.002593846,0.004500144,0.0034576303,0.0025362764],"category_scores_gemma":[0.02187469,0.00052289426,0.006902266,0.0025058566,0.0014606905,0.002436247,0.0022172492,0.0076510925,0.0013275607],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019073029,0.0001239964,0.0012877752,0.06265285,0.0023765774,0.00016248967,0.00031170552,0.0014664803,0.0009376156,0.014824132,0.08362829,0.8303208],"study_design_scores_gemma":[0.004314798,0.0010179821,0.010279284,0.11966095,0.011448827,0.0012939235,0.00037232882,0.0020341487,0.0012577589,0.02336602,0.82464,0.00031414826],"about_ca_topic_score_codex":0.0057530417,"about_ca_topic_score_gemma":0.00777157,"teacher_disagreement_score":0.021086235,"about_ca_system_score_codex":0.0051333564,"about_ca_system_score_gemma":0.0068375967,"threshold_uncertainty_score":0.111516},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"methods","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":["metaresearch"],"domain":"methods","study_design":"theoretical_or_conceptual","genre":"methods","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"split"},{"id":"W2145426305","doi":"10.1016/s1470-2045(05)70101-7","title":"Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial","year":2005,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":1580,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Placebo; Medicine; Double blind; Virus-like particle; Human papillomavirus; Internal medicine; Virology; Recombinant DNA; Alternative medicine; Pathology; Biology","score_opus":0.08610090242738114,"score_gpt":0.4192445002258663,"score_spread":0.3331435977984851,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145426305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848704,0.005328064,0.0009079545,0.0008576173,0.0008837725,0.0041491855,0.0013833138,0.00016388045,0.0014557374],"genre_scores_gemma":[0.9806105,0.004229221,0.0016478571,0.0015974046,0.000608083,0.0055230395,0.0011147889,0.000039463735,0.0046295687],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99933076,0.00031371092,0.000039230003,0.00013186045,0.000056357057,0.00012817177],"domain_scores_gemma":[0.9989561,0.00031703126,0.00018708518,0.000087194574,0.00005765699,0.0003949361],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019906624,0.002064291,0.0047305776,0.0006136573,0.0006151417,0.0010204765,0.0011177443,0.0029719693,0.0068957317],"category_scores_gemma":[0.0021114072,0.0011698656,0.0017437722,0.0005469611,0.0016524469,0.0011348525,0.00050451286,0.0029018938,0.0012617242],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9855924,0.003977913,0.00028752876,0.00038535203,0.00038301776,0.00002724765,0.00006317265,0.000106749794,0.0018154087,0.000055938734,0.00041394195,0.0068912865],"study_design_scores_gemma":[0.96372384,0.034938175,0.00069464644,0.000015064754,0.00016092273,0.000012532776,0.000012781536,0.000063619744,0.00012899331,0.000052660995,0.00019005995,0.000006591152],"about_ca_topic_score_codex":0.0018239678,"about_ca_topic_score_gemma":0.00254031,"teacher_disagreement_score":0.0068957317,"about_ca_system_score_codex":0.0008741328,"about_ca_system_score_gemma":0.001393702,"threshold_uncertainty_score":0.023068488},"labels":[],"label_agreement":null},{"id":"W2145434047","doi":"10.1016/s1470-2045(14)70417-6","title":"Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McMaster University","funders":"Janssen Research and Development; National Cancer Institute","keywords":"Abiraterone acetate; Prostate cancer; Medicine; Oncology; Chemotherapy; Protocol (science); Internal medicine; Castration; Abiraterone; Cancer; Urology; Androgen deprivation therapy; Alternative medicine; Hormone; Pathology; Androgen receptor","score_opus":0.1270490815713082,"score_gpt":0.4639079775581205,"score_spread":0.3368588959868123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145434047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9536738,0.0049329293,0.003362726,0.001533367,0.00080629025,0.02386014,0.006936393,0.00035807653,0.0045363843],"genre_scores_gemma":[0.96218306,0.00178898,0.004429607,0.0012111333,0.0004026956,0.02166787,0.004033878,0.000080636564,0.004202167],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9938154,0.0047345106,0.000327972,0.00039896628,0.0003176005,0.0004055862],"domain_scores_gemma":[0.9952095,0.0018094886,0.0011334004,0.00079820835,0.00027896994,0.0007704957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0080260895,0.0029186544,0.0033177903,0.00047185217,0.00079992804,0.0022165878,0.001333295,0.0019144352,0.008526463],"category_scores_gemma":[0.008967087,0.00093127834,0.0032831049,0.0007690181,0.0017837418,0.0016418985,0.00095114956,0.0041207736,0.0017087653],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9874834,0.0015247654,0.00053235,0.00045965106,0.001460034,0.00002153652,0.000083779596,0.00032265758,0.00068508973,0.000083466504,0.0007172161,0.006626046],"study_design_scores_gemma":[0.98069155,0.015546142,0.0018912995,0.000038977298,0.000673319,0.000024233888,0.00002783126,0.00021298863,0.00013755921,0.0002334351,0.0005046116,0.000018054701],"about_ca_topic_score_codex":0.0024612374,"about_ca_topic_score_gemma":0.0055889627,"teacher_disagreement_score":0.008526463,"about_ca_system_score_codex":0.0016157359,"about_ca_system_score_gemma":0.0029629346,"threshold_uncertainty_score":0.042446554},"labels":[],"label_agreement":null},{"id":"W2145453495","doi":"10.1016/s1470-2045(11)70235-2","title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":811,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Rituximab; CHOP; Diffuse large B-cell lymphoma; Open label; Internal medicine; Oncology; Lymphoma; Chemotherapy; Clinical trial","score_opus":0.046055733105281375,"score_gpt":0.3159028828759636,"score_spread":0.2698471497706822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145453495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99252856,0.004895339,0.00032487253,0.000458095,0.00037701402,0.00035784338,0.00039188526,0.000038875307,0.0006276066],"genre_scores_gemma":[0.9926704,0.0028309708,0.00062285847,0.0008419169,0.0005528779,0.00067491725,0.0007451498,0.000022842454,0.0010381755],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988551,0.0006225673,0.00006545742,0.00018946333,0.00005960807,0.00020768863],"domain_scores_gemma":[0.99824834,0.0006306572,0.00031933555,0.0001787196,0.00006540118,0.0005575706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002294641,0.0016647587,0.00493609,0.00048161848,0.00049600995,0.001331024,0.00094843784,0.002236882,0.0028621913],"category_scores_gemma":[0.0023593262,0.00074226374,0.0030086478,0.0006555851,0.0017116993,0.002347727,0.0006424586,0.0036857424,0.00067670876],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9847788,0.0024484447,0.0010418644,0.00023116812,0.00086029514,0.000034732922,0.000055818302,0.00024766283,0.00086261844,0.000049970447,0.0002707159,0.009118],"study_design_scores_gemma":[0.9089932,0.083207004,0.005755995,0.0000392332,0.0008779301,0.000053502055,0.000043921293,0.00031672345,0.0002081712,0.00015809183,0.00032522966,0.000021014142],"about_ca_topic_score_codex":0.0013820943,"about_ca_topic_score_gemma":0.0021152776,"teacher_disagreement_score":0.00493609,"about_ca_system_score_codex":0.0010952199,"about_ca_system_score_gemma":0.0009447747,"threshold_uncertainty_score":0.0121353865},"labels":[],"label_agreement":null},{"id":"W2145665617","doi":"10.1016/s1470-2045(10)70245-x","title":"Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review","year":2010,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Salivary Gland Tumors Diagnosis and Treatment","field":"Medicine","cited_by":395,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Adenoid cystic carcinoma; Chemotherapy; Asymptomatic; Clinical trial; Oncology; Regimen; Internal medicine; Radiation therapy; Disease; Natural history; Cancer; Carcinoma","score_opus":0.11250866762771078,"score_gpt":0.39742384113460155,"score_spread":0.2849151735068908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145665617","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00039549253,0.99930847,0.000035582972,0.000047743917,0.00003549286,0.00002317401,0.00004379098,0.0000017206843,0.000108452674],"genre_scores_gemma":[0.006067607,0.9934643,0.00015305831,0.00015848946,0.000032346175,0.000027772523,0.00004051107,0.000001137372,0.000054633932],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.999191,0.0002750264,0.0002453174,0.00009559473,0.00015394954,0.000039159113],"domain_scores_gemma":[0.99717927,0.001967538,0.00056567416,0.00003152502,0.0001931186,0.00006274745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015312574,0.00080856466,0.0051390287,0.0022109644,0.00027437042,0.0009687902,0.0010633356,0.0010000789,0.0031398837],"category_scores_gemma":[0.0051121237,0.00043161423,0.00388112,0.0031251514,0.00044048385,0.0009469972,0.00059213967,0.0008184357,0.0002169671],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008605406,0.000053658783,0.00082422956,0.78157115,0.013407861,0.00018228863,0.000110581255,0.00039538366,0.00040921135,0.00024932637,0.004305985,0.19762984],"study_design_scores_gemma":[0.0023837336,0.0015932719,0.01216248,0.7001802,0.19726998,0.0016570108,0.0005045834,0.00042672415,0.0007455962,0.00080278143,0.08215695,0.00011675684],"about_ca_topic_score_codex":0.005641296,"about_ca_topic_score_gemma":0.018180327,"teacher_disagreement_score":0.005641296,"about_ca_system_score_codex":0.0012033794,"about_ca_system_score_gemma":0.0022577227,"threshold_uncertainty_score":0.011216879},"labels":[],"label_agreement":null},{"id":"W2146102224","doi":"10.1016/s1470-2045(02)00930-0","title":"The role of systemic chemotherapy in the management of muscle-invasive bladder cancer","year":2002,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Chemotherapy; Bladder cancer; Gemcitabine; Cystectomy; Oncology; Context (archaeology); Transitional cell carcinoma; Vinblastine; Internal medicine; Cisplatin; Clinical trial; Cancer; Surgery","score_opus":0.06863531054331733,"score_gpt":0.3817276324511727,"score_spread":0.31309232190785535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146102224","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008581741,0.99906033,0.00007030379,0.0002502203,0.00009789203,0.0000022918664,0.000005480308,0.0000023462146,0.00042535132],"genre_scores_gemma":[0.00060847355,0.9987607,0.00012873021,0.000190262,0.00011245023,0.0000029772411,0.000009153012,6.450579e-7,0.0001867032],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997526,0.000072329436,0.000034102883,0.00004352335,0.000081251856,0.00001614353],"domain_scores_gemma":[0.9992694,0.00048108175,0.00010115777,0.000014394808,0.00010489203,0.0000290024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094420824,0.00069413247,0.0022484022,0.0014448061,0.0002581927,0.00085964287,0.00094172056,0.0010500441,0.0029058729],"category_scores_gemma":[0.0010107082,0.0002225027,0.00070108986,0.0022360778,0.00058558874,0.0010799628,0.00045328788,0.0018590948,0.0009704494],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014062405,0.000058618367,0.00016698276,0.012361611,0.00013645606,0.00021609978,0.000032596396,0.00046916856,0.00071379787,0.0013859111,0.013664357,0.97065365],"study_design_scores_gemma":[0.00017077106,0.00042557178,0.002952461,0.010582536,0.00063976337,0.003159922,0.00010518392,0.0003181685,0.0006953002,0.002216489,0.97869396,0.00003988864],"about_ca_topic_score_codex":0.0020773485,"about_ca_topic_score_gemma":0.0058987113,"teacher_disagreement_score":0.0029058729,"about_ca_system_score_codex":0.00068026705,"about_ca_system_score_gemma":0.001103446,"threshold_uncertainty_score":0.0097211},"labels":[],"label_agreement":null},{"id":"W2146561872","doi":"10.1016/s1470-2045(07)70280-2","title":"COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial","year":2007,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Cancer Institute; Pennsylvania Department of Health","keywords":"Medicine; Proportional hazards model; Prostate cancer; Radiation therapy; Oncology; Hazard ratio; Androgen deprivation therapy; Internal medicine; Immunohistochemistry; Multivariate analysis; Cancer; Metastasis; Prostate; Survival analysis; Cohort; Confidence interval","score_opus":0.12963120339120784,"score_gpt":0.4283932411821041,"score_spread":0.2987620377908963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146561872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911423,0.004822876,0.00020712033,0.00041904429,0.000063282154,0.00004307434,0.0026092776,0.000019763287,0.00067327573],"genre_scores_gemma":[0.9953307,0.0010540447,0.00015056887,0.00014321718,0.000119017124,0.00005159286,0.002644119,0.000012987072,0.00049370434],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9976592,0.0016619732,0.00009480978,0.00023630144,0.00017583574,0.00017199117],"domain_scores_gemma":[0.9947166,0.002564847,0.0013500104,0.0007383963,0.00016975455,0.00046036777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036096037,0.0011987272,0.0024565356,0.00024570894,0.000268637,0.0011755588,0.00079680316,0.0006582324,0.002244781],"category_scores_gemma":[0.0054623694,0.00046119,0.0023656907,0.000853103,0.00054860394,0.0006095573,0.0004839572,0.0020543272,0.00038001602],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6584864,0.0010588976,0.26870707,0.0012885886,0.03185677,0.00047420416,0.00019957974,0.0028326572,0.006159722,0.00035900174,0.0054252488,0.02315179],"study_design_scores_gemma":[0.12365223,0.02198289,0.8026941,0.00018871197,0.03792909,0.0009266327,0.0002451752,0.003945435,0.0022478781,0.0009358065,0.0051115085,0.00014066305],"about_ca_topic_score_codex":0.0017431463,"about_ca_topic_score_gemma":0.003208834,"teacher_disagreement_score":0.0036096037,"about_ca_system_score_codex":0.0003787549,"about_ca_system_score_gemma":0.0007098893,"threshold_uncertainty_score":0.01908958},"labels":[],"label_agreement":null},{"id":"W2146701863","doi":"10.1016/s1470-2045(13)70501-1","title":"Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":270,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Brentuximab vedotin; ABVD; Medicine; Dacarbazine; Internal medicine; Vinblastine; Oncology; Bleomycin; Phases of clinical research; Lymphoma; Surgery; Chemotherapy; CD30; Vincristine; Cyclophosphamide","score_opus":0.05715420935216558,"score_gpt":0.35931487641307147,"score_spread":0.3021606670609059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146701863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99527514,0.0022872789,0.00033080575,0.0002852929,0.00012721568,0.0004581418,0.0004142864,0.00004798614,0.0007738405],"genre_scores_gemma":[0.9931331,0.0024334963,0.0009126168,0.0006930373,0.0001710844,0.00050812843,0.00079593324,0.000025205583,0.00132749],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99947196,0.00024413133,0.000022643264,0.0000875352,0.000052566797,0.0001212361],"domain_scores_gemma":[0.9991571,0.00021159879,0.00014309531,0.00008141888,0.000037852536,0.00036894597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015089393,0.0014388594,0.0024404514,0.00051214633,0.00036122932,0.0014759621,0.00084980665,0.0010858425,0.0021363196],"category_scores_gemma":[0.0011067864,0.0007188171,0.0014531666,0.00051507243,0.0011376272,0.001416599,0.0003426358,0.0039743003,0.00065958756],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78938985,0.05256401,0.007913586,0.0009404066,0.0024827076,0.00021483617,0.0004117153,0.0033747116,0.015979122,0.00034706344,0.0024922038,0.1238899],"study_design_scores_gemma":[0.66977894,0.31130326,0.0129294535,0.00004999443,0.00077475247,0.00018362926,0.00009987273,0.00131095,0.0013216478,0.00029875038,0.0019060936,0.000042689928],"about_ca_topic_score_codex":0.0010764417,"about_ca_topic_score_gemma":0.0024246017,"teacher_disagreement_score":0.0024404514,"about_ca_system_score_codex":0.000992362,"about_ca_system_score_gemma":0.00087488483,"threshold_uncertainty_score":0.007980108},"labels":[],"label_agreement":null},{"id":"W2147387301","doi":"10.1016/s1470-2045(11)70057-2","title":"Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas","year":2011,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":645,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Oncology; Medicine; Outcome (game theory); Internal medicine; Medical physics; Mathematics","score_opus":0.22363914146036262,"score_gpt":0.49018725007671715,"score_spread":0.26654810861635453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147387301","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021383348,0.9964084,0.00018587911,0.0004814868,0.00013021231,0.00021194949,0.00015726761,0.000011474424,0.0002750232],"genre_scores_gemma":[0.03644518,0.9584238,0.0017351574,0.0018301747,0.00017006708,0.00068920804,0.0003250643,0.000018763063,0.00036263926],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99647564,0.0020225965,0.0006731815,0.00027585347,0.00040055756,0.00015222051],"domain_scores_gemma":[0.9903155,0.0073909196,0.0014177626,0.00020304842,0.00051623065,0.00015652791],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011564308,0.0011106456,0.007998237,0.0012709869,0.00021524374,0.0014661506,0.0014368793,0.0012917047,0.0020463297],"category_scores_gemma":[0.01614894,0.00047265415,0.0057910695,0.0016141159,0.00060368894,0.0012122899,0.0011080159,0.0024404398,0.0002415633],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014051408,0.00016392217,0.0013381677,0.2902447,0.021557998,0.0001275358,0.00029766606,0.0011451293,0.0011604944,0.0012629478,0.010888364,0.6577616],"study_design_scores_gemma":[0.056712814,0.015782457,0.034653425,0.32305214,0.19243741,0.0016863949,0.0008836385,0.0018375203,0.003512963,0.00684339,0.3622279,0.000370002],"about_ca_topic_score_codex":0.00275585,"about_ca_topic_score_gemma":0.006268197,"teacher_disagreement_score":0.011564308,"about_ca_system_score_codex":0.0024326872,"about_ca_system_score_gemma":0.0024898837,"threshold_uncertainty_score":0.061158657},"labels":[],"label_agreement":null},{"id":"W2148004875","doi":"10.1016/s1470-2045(11)70058-4","title":"Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma","year":2011,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":149,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; University of Calgary; Alberta Health Services","funders":"Canadian Institutes of Health Research","keywords":"Ovary; Mucinous Tumor; Mucinous carcinoma; Mucin; Pathology; Adenocarcinoma; Carcinoma; Rectum; Medicine; Biology; Cancer; Internal medicine; Pancreas","score_opus":0.13044719982098338,"score_gpt":0.35886265752626,"score_spread":0.22841545770527663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148004875","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000252776,0.99914634,0.00003035995,0.00042544474,0.00016373974,7.119923e-7,0.0000035422063,0.0000017311474,0.00020283434],"genre_scores_gemma":[0.00039819142,0.99861467,0.00008102829,0.0004319941,0.00027937395,0.0000012109318,0.000008053988,6.000106e-7,0.00018483252],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996841,0.00006973649,0.000043449247,0.000042616703,0.00013242257,0.000027646402],"domain_scores_gemma":[0.9992126,0.00045097174,0.0001351674,0.000016133901,0.00013096588,0.000054132972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008277218,0.00076593173,0.0023741077,0.0024157865,0.00026990828,0.0013651587,0.0009704156,0.0016705499,0.0021280553],"category_scores_gemma":[0.0014466337,0.0003435673,0.0005220825,0.0028780592,0.0009218187,0.0022311055,0.0008699951,0.0024305799,0.00093914935],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008625733,0.00003277389,0.00033456474,0.019519588,0.00016369185,0.00059909123,0.0000648931,0.00024039607,0.00091889343,0.0041968264,0.06798297,0.90586],"study_design_scores_gemma":[0.0000498005,0.000049186146,0.0011278379,0.008693952,0.00026462608,0.004735505,0.0001595389,0.0000840553,0.00019831888,0.0032509516,0.9813529,0.00003316321],"about_ca_topic_score_codex":0.0021459605,"about_ca_topic_score_gemma":0.005016469,"teacher_disagreement_score":0.0024157865,"about_ca_system_score_codex":0.0009416999,"about_ca_system_score_gemma":0.0015413278,"threshold_uncertainty_score":0.0071190596},"labels":[],"label_agreement":null},{"id":"W2148413869","doi":"10.1016/s1470-2045(08)70148-7","title":"Role of the cerebellum in the neurocognitive sequelae of treatment of tumours of the posterior fossa: an update","year":2008,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"","keywords":"Neurocognitive; Cerebellum; Cognition; Psychology; Neuroscience; Population; Neuroimaging; Posterior fossa; Medicine; Surgery","score_opus":0.08011164677112421,"score_gpt":0.3728488131099985,"score_spread":0.2927371663388743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148413869","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008505721,0.9989146,0.000074352036,0.0003315696,0.0002039887,0.0000021927283,0.000012851384,0.0000041708013,0.0003713469],"genre_scores_gemma":[0.00043034548,0.99869484,0.00013725951,0.00022536237,0.00031120714,0.0000023406415,0.00001700371,9.439854e-7,0.0001806818],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99973136,0.000047137022,0.00005611894,0.000042397376,0.00009896589,0.000024051233],"domain_scores_gemma":[0.99888843,0.00070748135,0.00014644123,0.000018914277,0.0001938696,0.000044811895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010778193,0.0011273619,0.0028635603,0.0023669705,0.00025960957,0.0016366169,0.0014355623,0.0020405245,0.0026771226],"category_scores_gemma":[0.0015564235,0.00032549974,0.00091617275,0.002601455,0.0006823995,0.0016414854,0.0006676634,0.0019467893,0.0013543551],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009873603,0.00004988951,0.0003707601,0.015698815,0.00016278525,0.000704753,0.00005507492,0.0004296455,0.0006276897,0.0014695767,0.03270397,0.9476284],"study_design_scores_gemma":[0.00007948423,0.0001727441,0.0021279177,0.008570461,0.0006236052,0.005025453,0.0001172128,0.00022092728,0.00037262516,0.0014563003,0.98118776,0.000045451914],"about_ca_topic_score_codex":0.004521567,"about_ca_topic_score_gemma":0.010209107,"teacher_disagreement_score":0.004521567,"about_ca_system_score_codex":0.00099316,"about_ca_system_score_gemma":0.002048236,"threshold_uncertainty_score":0.008990526},"labels":[],"label_agreement":null},{"id":"W2149654081","doi":"10.1016/s1470-2045(14)70472-3","title":"Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University; University of Ottawa; Jewish General Hospital; Regional Municipality of Durham; Princess Margaret Cancer Centre; BC Cancer Agency; Queen's University; Juravinski Cancer Centre","funders":"Cancer Care Ontario; Cancer Research Institute","keywords":"Medicine; Internal medicine; Erlotinib; Gefitinib; Placebo; Lung cancer; Population; Performance status; Oncology; Cancer; Adverse effect; Clinical trial; Surgery; Epidermal growth factor receptor; Pathology","score_opus":0.044423323650779334,"score_gpt":0.3947671100906369,"score_spread":0.3503437864398576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149654081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97192377,0.0119763,0.0009219437,0.0012626667,0.0015034301,0.005325057,0.00229263,0.0003340836,0.004460102],"genre_scores_gemma":[0.98117447,0.004474293,0.0014874226,0.001340127,0.0006082395,0.0036538339,0.0013726734,0.00003543949,0.0058534644],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994723,0.00027832334,0.000034793753,0.00010266751,0.00003512521,0.00007673413],"domain_scores_gemma":[0.9993237,0.00022251772,0.00016036784,0.000048641778,0.000042111405,0.0002027777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001463087,0.0022512623,0.0036672594,0.0004331279,0.0004826896,0.0010464047,0.00086826883,0.0025054263,0.009001911],"category_scores_gemma":[0.0018126863,0.0007570307,0.0021411302,0.0004434321,0.0011492656,0.0012530216,0.00041327137,0.0030171818,0.0013772753],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.99005157,0.0014170352,0.00012998017,0.000466189,0.00044280983,0.000019004616,0.000022083406,0.00018023617,0.0010406836,0.000058034566,0.00061447755,0.0055578547],"study_design_scores_gemma":[0.9752041,0.023467498,0.00042625226,0.000026158672,0.00016083087,0.000016250762,0.000008644636,0.00018021412,0.00012674666,0.000091569294,0.00028380743,0.000007996468],"about_ca_topic_score_codex":0.00096054,"about_ca_topic_score_gemma":0.0018552823,"teacher_disagreement_score":0.009001911,"about_ca_system_score_codex":0.00068056537,"about_ca_system_score_gemma":0.00084651937,"threshold_uncertainty_score":0.030114412},"labels":[],"label_agreement":null},{"id":"W2150203804","doi":"10.1016/s1470-2045(15)00285-5","title":"Global Task Force on Radiotherapy for Cancer Control","year":2015,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Task force; Radiation therapy; Control (management); Task (project management); Computer science; Medicine; Political science; Engineering; Internal medicine; Artificial intelligence; Systems engineering; Public administration","score_opus":0.04132175517005908,"score_gpt":0.4265265278868563,"score_spread":0.3852047727167972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150203804","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001056013,0.002930244,0.00016350095,0.91852903,0.07302323,0.000042183976,0.00032332525,0.00003256301,0.004850404],"genre_scores_gemma":[0.0012408751,0.0021965166,0.00023934501,0.93409944,0.049954228,0.00016027266,0.00017525774,0.00005587558,0.011878198],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9875072,0.002897899,0.0015133747,0.0010956229,0.00469077,0.0022950745],"domain_scores_gemma":[0.97598755,0.011622657,0.002343897,0.0009680583,0.0050405576,0.004037256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011835798,0.0021874416,0.003652957,0.0018642676,0.006139931,0.0068239383,0.00347698,0.103673495,0.014265952],"category_scores_gemma":[0.061957125,0.0022858297,0.004234136,0.002039708,0.0051325522,0.005611348,0.0056884657,0.07744616,0.0124889575],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032142798,0.0000127838275,0.00018103316,0.00006330823,0.000018572742,0.00015103126,0.000050838746,0.00005582612,0.000053577285,0.002295258,0.9923718,0.0047138236],"study_design_scores_gemma":[0.00012044798,0.000036148078,0.0007415781,0.0006367902,0.00006267319,0.00019023128,0.00009023693,0.00020548831,0.00015950223,0.0058134906,0.991891,0.00005231236],"about_ca_topic_score_codex":0.02219695,"about_ca_topic_score_gemma":0.041905466,"teacher_disagreement_score":0.103673495,"about_ca_system_score_codex":0.010124217,"about_ca_system_score_gemma":0.021273658,"threshold_uncertainty_score":0.073456705},"labels":[],"label_agreement":null},{"id":"W2151730005","doi":"10.1016/s1470-2045(09)70311-0","title":"Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival","year":2009,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":1974,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Regional Laboratory Medicine Program","funders":"","keywords":"Medicine; Cetuximab; Head and neck cancer; Clinical endpoint; Radiation therapy; Rash; Internal medicine; Oncology; Head and neck squamous-cell carcinoma; Randomized controlled trial; Surgery; Cancer; Colorectal cancer","score_opus":0.154146220113929,"score_gpt":0.43423469870752923,"score_spread":0.2800884785936002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151730005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98294234,0.013066154,0.00030647375,0.0005603518,0.0002764815,0.0005708669,0.0012234472,0.000028778644,0.0010248999],"genre_scores_gemma":[0.99087256,0.0044072536,0.00037986934,0.00062021666,0.00021633437,0.00045550882,0.0016061452,0.000020046611,0.0014221537],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997216,0.0018264262,0.00021114238,0.00030496327,0.00019501628,0.0002465538],"domain_scores_gemma":[0.9962902,0.0016964491,0.0009820875,0.00038673118,0.00015736178,0.00048712787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006451491,0.0014153766,0.0030094162,0.0005018892,0.0005995316,0.0012553678,0.0012435303,0.0020329056,0.0045014555],"category_scores_gemma":[0.005237443,0.0007539579,0.005175913,0.00090161856,0.0013885755,0.0013754567,0.0007166547,0.003562228,0.00054761936],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9767371,0.0016407048,0.003604219,0.00082177285,0.0058568823,0.000030021285,0.00006291617,0.0006629151,0.0012631087,0.0000621075,0.0004899695,0.008768307],"study_design_scores_gemma":[0.8330896,0.112853706,0.038041797,0.0001831875,0.012404837,0.00015231044,0.000107441505,0.00059141376,0.0008497033,0.00034517195,0.0013187022,0.00006207904],"about_ca_topic_score_codex":0.0040679523,"about_ca_topic_score_gemma":0.00948139,"teacher_disagreement_score":0.006451491,"about_ca_system_score_codex":0.0015484521,"about_ca_system_score_gemma":0.0013805993,"threshold_uncertainty_score":0.03411913},"labels":[],"label_agreement":null},{"id":"W2152162065","doi":"10.1016/s1470-2045(15)00169-2","title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":613,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"BC Cancer Agency; Canadian Institutes of Health Research; H. Lundbeck A/S; University of British Columbia; Celgene; Terry Fox Research Institute; Genome British Columbia; Dr. Mildred Scheel Stiftung für Krebsforschung; Michael Smith Health Research BC; Amgen; Alfred Benzon Foundation; Genome Canada; Deutsche Krebshilfe","keywords":"Medicine; Rituximab; Follicular lymphoma; Internal medicine; Oncology; Population; Vincristine; Prednisone; International Prognostic Index; Cyclophosphamide; Lymphoma; Surgery; Chemotherapy","score_opus":0.06967241767753558,"score_gpt":0.3970410134681473,"score_spread":0.3273685957906117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152162065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99846673,0.00054771145,0.00020853872,0.00004766078,0.000011261763,0.000030436382,0.00043584866,0.0000060902494,0.00024563202],"genre_scores_gemma":[0.9992009,0.00008339729,0.00015728391,0.00002522364,0.000014499341,0.000019859002,0.0004403875,0.000004681581,0.000053767344],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934929,0.0036541447,0.0005925043,0.0012365172,0.00055014994,0.0004737691],"domain_scores_gemma":[0.9869174,0.004310552,0.0048235715,0.0024379042,0.0008522806,0.00065847114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005691822,0.00046385676,0.0009022412,0.0008982127,0.00055869395,0.001694717,0.0010052511,0.00084954227,0.0013991052],"category_scores_gemma":[0.0123073105,0.00054032926,0.0014830332,0.0025199675,0.00097216776,0.0012297232,0.0007704433,0.00095188065,0.0002736413],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051716072,0.0000943513,0.9907755,0.000029338784,0.0010822843,0.00007398687,0.000086429485,0.00013626475,0.0005346678,0.00006483105,0.00012751031,0.0018231109],"study_design_scores_gemma":[0.0006016202,0.0014057757,0.9941434,0.000019393996,0.0016364263,0.00034737348,0.0001613426,0.00055283954,0.00054768636,0.000121214216,0.00044517883,0.000017834172],"about_ca_topic_score_codex":0.0016235621,"about_ca_topic_score_gemma":0.0020050881,"teacher_disagreement_score":0.005691822,"about_ca_system_score_codex":0.00066782505,"about_ca_system_score_gemma":0.000707319,"threshold_uncertainty_score":0.030101597},"labels":[],"label_agreement":null},{"id":"W2152261493","doi":"10.1016/s1470-2045(06)70579-4","title":"Proteins with whey-acidic-protein motifs and cancer","year":2006,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Animal Genetics and Reproduction","field":"Biochemistry, Genetics and Molecular Biology","cited_by":200,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Canadian Institutes of Health Research","keywords":"Gene; Biology; Carcinogenesis; Cancer; Cancer research; Computational biology; Genetics","score_opus":0.04870910941863724,"score_gpt":0.3448152108010417,"score_spread":0.29610610138240445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152261493","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008725345,0.99722075,0.00017066867,0.0007428804,0.00075934536,0.0000027966805,0.000010134863,0.0000083511295,0.0009978075],"genre_scores_gemma":[0.00089801406,0.99532974,0.00027724428,0.0005608749,0.00064529316,0.0000085391475,0.00003017092,0.000002034335,0.0022481764],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998666,0.000022074879,0.000013655473,0.000019798987,0.00006012432,0.000017721026],"domain_scores_gemma":[0.9997652,0.0001095195,0.000031890657,0.000008889453,0.00005808521,0.000026395508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007176853,0.00096201495,0.0010944881,0.0010465542,0.00028003711,0.0008777982,0.0008567803,0.0016572003,0.0028665233],"category_scores_gemma":[0.0006069503,0.00032067744,0.00025908908,0.0014981177,0.00084569975,0.0011480406,0.00060430635,0.0020322565,0.0027418896],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018561723,0.00008162786,0.00019466419,0.004390513,0.00006277898,0.00035116062,0.000035566085,0.00037257018,0.0033557182,0.008359773,0.14207904,0.84053093],"study_design_scores_gemma":[0.000032252326,0.00003788641,0.00028062484,0.00037536374,0.000030594365,0.00073802564,0.000023496204,0.000045863988,0.0005795214,0.0013658738,0.99648404,0.0000064215687],"about_ca_topic_score_codex":0.0010100896,"about_ca_topic_score_gemma":0.002546568,"teacher_disagreement_score":0.0028665233,"about_ca_system_score_codex":0.0009518802,"about_ca_system_score_gemma":0.0006746809,"threshold_uncertainty_score":0.009589493},"labels":[],"label_agreement":null},{"id":"W2152280560","doi":"10.1016/s1470-2045(12)70237-1","title":"Radiotherapy for head and neck tumours in 2012 and beyond: conformal, tailored, and adaptive?","year":2012,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Radiation therapy; Head and neck; Head and neck cancer; Medical physics; Parotid gland; Radiology; Nuclear medicine; Pathology; Surgery","score_opus":0.1385623288787938,"score_gpt":0.4182639424880143,"score_spread":0.2797016136092205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152280560","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010511567,0.9993298,0.000026544198,0.0002807582,0.000059783997,0.000002202654,0.000007013411,7.456299e-7,0.00018811125],"genre_scores_gemma":[0.001745135,0.9975077,0.000111036185,0.0004148308,0.000099061166,0.000004985402,0.000011194446,0.0000010056253,0.00010505659],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994973,0.0002205159,0.00006863111,0.000072886105,0.000104943676,0.00003567564],"domain_scores_gemma":[0.9990792,0.0007117654,0.00010532641,0.000024641506,0.00006041273,0.000018740657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022232367,0.00053876743,0.0027329326,0.0007745152,0.00014334788,0.0009990133,0.0011955884,0.0011087852,0.0036696347],"category_scores_gemma":[0.0031960448,0.00026841296,0.0011690876,0.0017457537,0.000620388,0.001292972,0.000602957,0.0015349239,0.0004618581],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045723803,0.000048063368,0.00031155866,0.049893294,0.0008961318,0.00004590847,0.0000709889,0.00058914005,0.00037909398,0.0043501533,0.009776819,0.9331816],"study_design_scores_gemma":[0.0011334148,0.0010394751,0.00664596,0.07471249,0.0056803804,0.0014584805,0.00040468012,0.00032670968,0.00074869295,0.009924466,0.8978283,0.00009693848],"about_ca_topic_score_codex":0.0031571172,"about_ca_topic_score_gemma":0.007372732,"teacher_disagreement_score":0.0036696347,"about_ca_system_score_codex":0.0011121437,"about_ca_system_score_gemma":0.0012907825,"threshold_uncertainty_score":0.012276173},"labels":[],"label_agreement":null},{"id":"W2152283335","doi":"10.1016/s1470-2045(07)70216-4","title":"CYP3A4/5 and pharmacogenetics in patients with sarcoma – Authors' reply","year":2007,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of British Columbia; Vancouver Coastal Health Research Institute; Princess Margaret Cancer Centre; BC Cancer Agency; SickKids Foundation; University of Toronto; Mount Sinai Hospital; Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Oncology; Medicine; Breast cancer; Docetaxel; CYP3A4; Internal medicine; Pharmacogenetics; Cancer; Scopus; Osteosarcoma; Sarcoma; Cancer research; Pathology; MEDLINE; Biology; Genotype; Cytochrome P450; Genetics","score_opus":0.022248374246121406,"score_gpt":0.30564249019674405,"score_spread":0.28339411595062264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152283335","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011037923,0.0021073339,0.000073764546,0.97301,0.022343373,0.000008096674,0.00009348808,0.000015579473,0.0012445584],"genre_scores_gemma":[0.0152722765,0.0018150101,0.00019081563,0.91357505,0.063799925,0.0000420784,0.00008660596,0.000020788444,0.005197387],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99857676,0.0005426454,0.00016111392,0.000188249,0.000325989,0.00020536919],"domain_scores_gemma":[0.9950193,0.0033279767,0.00037971564,0.0001676924,0.0005792562,0.00052613067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019032303,0.00052214216,0.0015144078,0.0006590168,0.0014747363,0.0015720302,0.001242892,0.03287379,0.0045225867],"category_scores_gemma":[0.013625782,0.00061821326,0.0009394241,0.000624157,0.001556754,0.0016866326,0.0009145841,0.021655444,0.0024407185],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017815143,0.000037621023,0.0029044894,0.000078022036,0.00006380216,0.0035356616,0.0001397007,0.0001434291,0.0002199287,0.0013878775,0.9827946,0.008516838],"study_design_scores_gemma":[0.0007873249,0.00036688583,0.0088797035,0.0004511398,0.00028398825,0.012341158,0.0010733817,0.0017390965,0.0010448466,0.012296974,0.96054184,0.00019369142],"about_ca_topic_score_codex":0.0025303988,"about_ca_topic_score_gemma":0.0037206535,"teacher_disagreement_score":0.03287379,"about_ca_system_score_codex":0.0018671225,"about_ca_system_score_gemma":0.0014409408,"threshold_uncertainty_score":0.015129566},"labels":[],"label_agreement":null},{"id":"W2152643817","doi":"10.1016/s1470-2045(04)01565-7","title":"Molecular therapy in pancreatic adenocarcinoma","year":2004,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Pancreatic cancer; Radiation therapy; Immunotherapy; Disease; Targeted therapy; Adenocarcinoma; Oncology; Cancer; Chemotherapy; Genetic enhancement; Internal medicine; Gene","score_opus":0.15541389936879954,"score_gpt":0.45313519882315073,"score_spread":0.2977212994543512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152643817","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000672697,0.9983758,0.000054090935,0.00036480266,0.00032800474,0.000004036155,0.000008317095,0.0000049035916,0.00079284736],"genre_scores_gemma":[0.0006796191,0.99753606,0.000100866804,0.00053127884,0.00031424785,0.000006088316,0.000017424076,0.0000010382876,0.0008134332],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99982685,0.000044113473,0.000022110009,0.000028210929,0.00005934407,0.000019309206],"domain_scores_gemma":[0.99972266,0.00014950942,0.000053622192,0.00000984095,0.0000435863,0.000020679348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007327505,0.00086443685,0.0018727294,0.0020353235,0.000255275,0.0010569164,0.0007025269,0.0011789319,0.0042339913],"category_scores_gemma":[0.00075622095,0.00031099987,0.0005562302,0.0021493982,0.0005247001,0.0012200745,0.00065250735,0.0020612394,0.0018903348],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017226681,0.000064948705,0.00012956082,0.01193814,0.00012432254,0.00029241457,0.000035871297,0.0005426978,0.0011774073,0.0027085184,0.061249316,0.9215646],"study_design_scores_gemma":[0.00011037788,0.00014908811,0.00050143275,0.003232972,0.00021019258,0.0010679632,0.000031559346,0.00009531888,0.0003364748,0.0011249495,0.99312687,0.000012750776],"about_ca_topic_score_codex":0.0012799461,"about_ca_topic_score_gemma":0.0034833597,"teacher_disagreement_score":0.0042339913,"about_ca_system_score_codex":0.0008942445,"about_ca_system_score_gemma":0.00089662225,"threshold_uncertainty_score":0.01416409},"labels":[],"label_agreement":null},{"id":"W2152905269","doi":"10.1016/s1470-2045(12)70087-6","title":"Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":953,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Afatinib; Medicine; Erlotinib; Gefitinib; Internal medicine; Clinical endpoint; Hazard ratio; Placebo; Lung cancer; Oncology; Performance status; Chemotherapy; Adenocarcinoma; Randomized controlled trial; Surgery; Cancer; Epidermal growth factor receptor; Confidence interval; Pathology","score_opus":0.03765453655497886,"score_gpt":0.40357536614862405,"score_spread":0.3659208295936452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152905269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97388184,0.012842078,0.000881224,0.0024468245,0.0021755286,0.0029259713,0.0014434957,0.00025423363,0.0031488098],"genre_scores_gemma":[0.98842585,0.0030687468,0.00078282756,0.0012430613,0.0006336986,0.0017410176,0.00067073636,0.000024757323,0.0034093435],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99906784,0.00045071702,0.000078651465,0.00019424237,0.000044375996,0.00016419958],"domain_scores_gemma":[0.9990797,0.00030852304,0.0001829571,0.00007266788,0.000052606134,0.00030345467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019709058,0.0023897088,0.0052743447,0.00057483086,0.0005625978,0.0014669073,0.0010675066,0.0031785984,0.008294312],"category_scores_gemma":[0.0024679054,0.00081166485,0.0040363367,0.0005327513,0.0017645218,0.00217747,0.00058610225,0.0043950332,0.001597802],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9891192,0.0011897313,0.00020880182,0.0005034719,0.0008368677,0.000031295567,0.000033357992,0.00020823548,0.0008754985,0.00008423895,0.00046163297,0.006447704],"study_design_scores_gemma":[0.97409785,0.024236066,0.00044432087,0.000022773995,0.0003513021,0.000026966494,0.000018352268,0.00019262613,0.000117884374,0.00019450235,0.0002853753,0.000012110332],"about_ca_topic_score_codex":0.00095866754,"about_ca_topic_score_gemma":0.0017824348,"teacher_disagreement_score":0.008294312,"about_ca_system_score_codex":0.00085115066,"about_ca_system_score_gemma":0.0008813021,"threshold_uncertainty_score":0.027747273},"labels":[],"label_agreement":null},{"id":"W2152969899","doi":"10.1016/s1470-2045(13)70589-8","title":"Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":206,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; U.S. Public Health Service; U.S. Department of Health and Human Services","keywords":"Medicine; Breast cancer; Chemotherapy; Hazard ratio; Lumpectomy; Internal medicine; Mastectomy; Oncology; Cancer; Clinical endpoint; Surgery; Randomized controlled trial; Confidence interval","score_opus":0.027297002398603727,"score_gpt":0.3294643913437202,"score_spread":0.30216738894511647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152969899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.952325,0.027351983,0.0012475854,0.004205771,0.0027319428,0.0045154463,0.0019352369,0.00016032587,0.0055268053],"genre_scores_gemma":[0.97582936,0.00882623,0.0011417868,0.0032493551,0.0007175513,0.003517194,0.00093371613,0.000026125837,0.0057587377],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99903595,0.00061971555,0.000059905884,0.00012459017,0.000041044004,0.0001187531],"domain_scores_gemma":[0.9986243,0.0005819748,0.00029682877,0.00013691318,0.00005068789,0.00030935855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016477932,0.0012857002,0.002968762,0.00031785286,0.0003959387,0.0008624685,0.00080273085,0.0022251445,0.0116241155],"category_scores_gemma":[0.0028166173,0.0005308826,0.0027669957,0.0005475779,0.0012436723,0.0010836419,0.000653203,0.003169225,0.0010994185],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98768425,0.00079036166,0.00038443258,0.0009904171,0.0014905785,0.000031567706,0.000027735798,0.00022459346,0.0004788844,0.000140947,0.00064127514,0.007114938],"study_design_scores_gemma":[0.98313046,0.013597546,0.0010045995,0.00009870797,0.0011829097,0.000023701301,0.00002341423,0.000092042814,0.00007190787,0.00019544386,0.00056949345,0.0000096608765],"about_ca_topic_score_codex":0.0017882574,"about_ca_topic_score_gemma":0.0033050603,"teacher_disagreement_score":0.0116241155,"about_ca_system_score_codex":0.00080952985,"about_ca_system_score_gemma":0.00083223445,"threshold_uncertainty_score":0.038886607},"labels":[],"label_agreement":null},{"id":"W2153954237","doi":"10.1016/s1470-2045(13)70253-5","title":"Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":432,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency; University of Toronto; University of Calgary","funders":"National Institutes of Health; Cancer Research UK; National Cancer Institute; Kræftens Bekæmpelse","keywords":"Ovarian cancer; Ovarian tissue cryopreservation; Oncology; Hormone receptor; Internal medicine; Medicine; Gynecology; Biology; Cancer research; Cancer; Breast cancer; Fertility; Fertility preservation","score_opus":0.05828470196006116,"score_gpt":0.37146549834479403,"score_spread":0.3131807963847329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153954237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950121,0.00020229,0.00017434979,0.00034388545,0.00001212894,0.000057466117,0.0037459917,0.000008691118,0.00044320343],"genre_scores_gemma":[0.9906881,0.00019236495,0.00034667423,0.0002024738,0.000041942203,0.00010914104,0.0076491376,0.000029577137,0.0007405417],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970697,0.0016217107,0.00013941617,0.00050941145,0.00030434623,0.00035534677],"domain_scores_gemma":[0.9934465,0.0013963713,0.0013549626,0.0019066457,0.00063843076,0.0012570242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042141387,0.0007042519,0.0010816343,0.0007923963,0.001260059,0.0015053054,0.0012709033,0.00080988096,0.0018610777],"category_scores_gemma":[0.006156483,0.0007125832,0.0013929133,0.0028010642,0.0009826294,0.00072661525,0.0022828456,0.0016105521,0.0004401783],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006544981,0.00041367623,0.97774965,0.00006603271,0.002209148,0.0006877792,0.0006969103,0.0002282009,0.0029776297,0.00022438397,0.004182736,0.0040188646],"study_design_scores_gemma":[0.0010213279,0.00033234007,0.9934052,0.000019215802,0.0012104909,0.00063682266,0.00089196564,0.00029038542,0.0003603728,0.00008322768,0.0017166742,0.00003197966],"about_ca_topic_score_codex":0.03335663,"about_ca_topic_score_gemma":0.048172712,"teacher_disagreement_score":0.03335663,"about_ca_system_score_codex":0.0014291641,"about_ca_system_score_gemma":0.0022439854,"threshold_uncertainty_score":0.06632495},"labels":[],"label_agreement":null},{"id":"W2154350319","doi":"10.1016/s1470-2045(01)00456-9","title":"Depression in cancer patients","year":2001,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":268,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Depression (economics); Cancer; Epidemiology; Medicine; Psychiatry; Intensive care medicine; Internal medicine","score_opus":0.12533192905507254,"score_gpt":0.44481256621605314,"score_spread":0.31948063716098063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154350319","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003045131,0.9981341,0.000028523284,0.0006725601,0.0002872429,0.000009966533,0.00003682225,0.0000025298596,0.0005236817],"genre_scores_gemma":[0.0036279508,0.99461246,0.000081894505,0.0009588579,0.00022719121,0.000019455287,0.000049784114,6.7669333e-7,0.00042170257],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996947,0.00010132917,0.000058469363,0.000037457452,0.000087326975,0.000020680054],"domain_scores_gemma":[0.99933976,0.0003171872,0.00019312088,0.0000151961885,0.00008951856,0.00004520376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008008212,0.0005961276,0.0016891571,0.0010571787,0.0001914229,0.0008202583,0.0006165457,0.0007867826,0.0032353573],"category_scores_gemma":[0.002192469,0.0002482476,0.0007041774,0.002150849,0.00021016406,0.0005796225,0.0005985416,0.0009986917,0.0005348292],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026364514,0.00007567758,0.0016145688,0.03221303,0.0006550413,0.00010962624,0.0000663934,0.00009750444,0.0002004454,0.00040985752,0.049360003,0.9149342],"study_design_scores_gemma":[0.00140531,0.0011326524,0.048606157,0.07837296,0.007054196,0.00427859,0.0005662471,0.0003629579,0.00047164195,0.0025051308,0.85515934,0.00008472186],"about_ca_topic_score_codex":0.0035858387,"about_ca_topic_score_gemma":0.0124838315,"teacher_disagreement_score":0.0035858387,"about_ca_system_score_codex":0.000566181,"about_ca_system_score_gemma":0.0013335954,"threshold_uncertainty_score":0.010823369},"labels":[],"label_agreement":null},{"id":"W2154581953","doi":"10.1016/s1470-2045(10)70151-0","title":"Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study","year":2010,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":268,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Bevacizumab; Internal medicine; Adverse effect; Lung cancer; Clinical endpoint; Population; Chemotherapy; Surgery; Oncology; Phases of clinical research; Incidence (geometry); Clinical trial","score_opus":0.022379649479756486,"score_gpt":0.3924690575272414,"score_spread":0.3700894080474849,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154581953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99464595,0.0027706665,0.0001766946,0.00026979734,0.00008129295,0.00040769274,0.0006878214,0.000059462265,0.0009006084],"genre_scores_gemma":[0.9940601,0.0017046639,0.0004165649,0.0004115137,0.00012621054,0.0004962546,0.001293344,0.000030092775,0.001461271],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99945813,0.00023918746,0.000020910134,0.000089893976,0.00007006419,0.00012180483],"domain_scores_gemma":[0.99915266,0.00018303328,0.00020920306,0.000067025634,0.000055992718,0.00033211295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001633054,0.0014235862,0.002657847,0.000602782,0.0004271733,0.001177478,0.0010746942,0.0016751512,0.0022506625],"category_scores_gemma":[0.0011411824,0.0006107029,0.0020701569,0.00041726526,0.0009977681,0.0010099232,0.00027455806,0.0038148165,0.00068554527],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.79579824,0.035121433,0.009279622,0.0007663373,0.002559907,0.00021611001,0.00016413587,0.0025273762,0.030150933,0.00017595141,0.0034129266,0.11982707],"study_design_scores_gemma":[0.5082783,0.4501913,0.03027873,0.00006168517,0.0015302815,0.0003629957,0.000061009498,0.0018428792,0.0049766046,0.00024800494,0.0021067054,0.00006140122],"about_ca_topic_score_codex":0.001434512,"about_ca_topic_score_gemma":0.0032680847,"teacher_disagreement_score":0.002657847,"about_ca_system_score_codex":0.0017379995,"about_ca_system_score_gemma":0.0012681658,"threshold_uncertainty_score":0.012610137},"labels":[],"label_agreement":null},{"id":"W2154582201","doi":"10.1016/s1470-2045(11)70389-8","title":"Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bone health and osteoporosis research","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Juravinski Cancer Centre; University of Toronto; University Health Network; Queen's University; McMaster University; Women's College Hospital","funders":"Canadian Institutes of Health Research","keywords":"Exemestane; Medicine; Postmenopausal women; Breast cancer; Oncology; Cancer; Primary prevention; Randomized controlled trial; Internal medicine; Gynecology; Aromatase; Disease","score_opus":0.027134062633625323,"score_gpt":0.3490563849927078,"score_spread":0.32192232235908247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154582201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836015,0.009699944,0.0005078754,0.00047032879,0.00025373156,0.0013969198,0.00250934,0.00008646427,0.0014739281],"genre_scores_gemma":[0.99256814,0.0020308192,0.0007019547,0.00039943613,0.00026020972,0.0017302515,0.0012895388,0.000009574748,0.0010100772],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.999348,0.00036934056,0.00004404158,0.000093726616,0.000071852206,0.00007297717],"domain_scores_gemma":[0.9993311,0.00021158197,0.0001829916,0.00010383938,0.000055478846,0.00011495385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001253637,0.0013270382,0.0032423015,0.0003696453,0.00040186377,0.00076084817,0.0006750215,0.0016044795,0.003688368],"category_scores_gemma":[0.0023883178,0.0006202024,0.0026258894,0.00045141648,0.00078702293,0.00049380946,0.00062448665,0.0015626112,0.00047778737],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98244077,0.0009849309,0.0028325203,0.0013057418,0.003763613,0.000047541213,0.00008991263,0.00023547304,0.0012961725,0.000100485064,0.00080906635,0.0060937805],"study_design_scores_gemma":[0.95490116,0.022246005,0.014731631,0.00013882999,0.005991387,0.0000643716,0.00004604644,0.00036867606,0.00031787745,0.0003414968,0.0008308881,0.000021672573],"about_ca_topic_score_codex":0.0031139452,"about_ca_topic_score_gemma":0.004444304,"teacher_disagreement_score":0.003688368,"about_ca_system_score_codex":0.00055994594,"about_ca_system_score_gemma":0.0006554205,"threshold_uncertainty_score":0.012338817},"labels":[],"label_agreement":null},{"id":"W2155440695","doi":"10.1016/s1470-2045(05)70255-2","title":"Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials","year":2005,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":230,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University of Toronto; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Associazione Italiana per la Ricerca sul Cancro","keywords":"Vinorelbine; Medicine; Gemcitabine; Neutropenia; Internal medicine; Chemotherapy; Hazard ratio; Lung cancer; Clinical endpoint; Surgery; Oncology; Clinical trial; Cisplatin; Confidence interval","score_opus":0.09235030140493503,"score_gpt":0.4565041393492671,"score_spread":0.3641538379443321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155440695","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.031355392,0.9654647,0.0007555536,0.00023495908,0.00028712608,0.0006067524,0.0006889925,0.000032405263,0.0005741002],"genre_scores_gemma":[0.35754108,0.63603884,0.0021860707,0.00092580385,0.00026435126,0.0011324162,0.00094850647,0.00003289724,0.0009300383],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9957064,0.0024632993,0.0008974535,0.00040844202,0.00034899663,0.00017550711],"domain_scores_gemma":[0.9941771,0.004186987,0.0011052997,0.00017711798,0.00021199945,0.00014152922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069531593,0.0017506127,0.011339102,0.0015784882,0.00026464072,0.0017010317,0.0011616445,0.0016377206,0.0028774668],"category_scores_gemma":[0.011689389,0.0007990429,0.01495446,0.002185519,0.00060256396,0.000991325,0.0008314672,0.0019555683,0.00018712803],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13573156,0.00016369585,0.0030338268,0.27041936,0.52182317,0.00019545956,0.00015390302,0.0020976723,0.0010016782,0.0003670561,0.0019926077,0.06301995],"study_design_scores_gemma":[0.08892406,0.0049093966,0.008685377,0.013805441,0.8755562,0.000281783,0.00013655014,0.0005113099,0.0004477576,0.0008695555,0.005788474,0.00008404712],"about_ca_topic_score_codex":0.0026344215,"about_ca_topic_score_gemma":0.0065216646,"teacher_disagreement_score":0.011339102,"about_ca_system_score_codex":0.0018419728,"about_ca_system_score_gemma":0.0015047365,"threshold_uncertainty_score":0.03677231},"labels":[],"label_agreement":null},{"id":"W2155487288","doi":"10.1016/s1470-2045(09)70187-1","title":"TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies","year":2009,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":158,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thunder Bay Regional Research Institute","funders":"National Cancer Institute; Deutsche Forschungsgemeinschaft","keywords":"Genotype; Heterozygote advantage; Cervical cancer; Allele; Odds ratio; Arginine; Genetics; Biology; Genetic epidemiology; Epidemiology; Allele frequency; Internal medicine; Cancer; Medicine; Gene","score_opus":0.12895856000093608,"score_gpt":0.3991768301553864,"score_spread":0.2702182701544503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155487288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70821804,0.27638245,0.0037200497,0.0002113832,0.00017823861,0.00041326,0.00961567,0.000106597014,0.0011543767],"genre_scores_gemma":[0.97876245,0.016216543,0.0013483919,0.00015319772,0.00009015593,0.00029313835,0.002843828,0.000054284385,0.00023788743],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98279804,0.008941644,0.003245467,0.003098072,0.0012725623,0.00064422796],"domain_scores_gemma":[0.9769216,0.015303688,0.0040585054,0.0023117578,0.0010628382,0.0003417431],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.011882618,0.0020369338,0.007881075,0.0054675527,0.0006750324,0.0023441403,0.0010707715,0.0017839082,0.0026726706],"category_scores_gemma":[0.020405104,0.0017457181,0.019284453,0.007702711,0.000620388,0.0012834411,0.001862891,0.00087818713,0.00036386334],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020421118,0.000051823667,0.1658601,0.0073763947,0.79216266,0.00049957656,0.00019673152,0.0009962915,0.00233879,0.00006127151,0.00062110845,0.0094141895],"study_design_scores_gemma":[0.0021206357,0.000793507,0.16304888,0.0007055528,0.8306887,0.00041614482,0.00019104479,0.00035592067,0.00049511134,0.00017517316,0.0009465542,0.0000626816],"about_ca_topic_score_codex":0.0038478095,"about_ca_topic_score_gemma":0.0070095942,"teacher_disagreement_score":0.99211895,"about_ca_system_score_codex":0.0007716722,"about_ca_system_score_gemma":0.00070641533,"threshold_uncertainty_score":0.06284207},"labels":[],"label_agreement":null},{"id":"W2156667572","doi":"10.1016/s1470-2045(02)00775-1","title":"Impact of the Human Genome Project on the clinical management of sporadic cancers","year":2002,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Gene expression and cancer classification","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"American Society of Clinical Oncology; European Society for Medical Oncology; Cancer Research Society; American Association for Cancer Research","keywords":"DNA microarray; Human genome; Computational biology; Cancer; Molecular pathology; Breast cancer; Gene; Genome; Biology; Molecular diagnostics; Function (biology); DNA sequencing; Bioinformatics; Gene expression; Genetics","score_opus":0.24435742766123925,"score_gpt":0.48726423163551086,"score_spread":0.2429068039742716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156667572","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012857142,0.9938018,0.00023666877,0.0040073856,0.0009749883,0.000003878642,0.000029520002,0.000009979115,0.00080727524],"genre_scores_gemma":[0.0010681963,0.9953225,0.00037633796,0.0018067867,0.0010085063,0.0000056328813,0.00004047695,0.0000027852677,0.00036880528],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991842,0.0002504139,0.000093292685,0.00011131915,0.00030659357,0.00005425842],"domain_scores_gemma":[0.9953216,0.0030494821,0.00025720606,0.00008362349,0.0010567728,0.00023128634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036762531,0.0009170408,0.002454974,0.002087589,0.00035809152,0.0014250157,0.0013035801,0.0023063505,0.0024211637],"category_scores_gemma":[0.00534012,0.00027274113,0.0006794834,0.0032714116,0.0011265879,0.0014767859,0.00084117707,0.002855737,0.0011945468],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002139494,0.0000496751,0.00052657124,0.0044687134,0.00012078645,0.00026836238,0.000042464417,0.000707438,0.00046446998,0.0046360902,0.077532545,0.9109689],"study_design_scores_gemma":[0.000114300055,0.00014301031,0.0031426898,0.0039877333,0.00024848798,0.0012258204,0.00009084759,0.00024372409,0.00028538535,0.005053422,0.98542506,0.00003949829],"about_ca_topic_score_codex":0.005350141,"about_ca_topic_score_gemma":0.00921619,"teacher_disagreement_score":0.005350141,"about_ca_system_score_codex":0.0019889115,"about_ca_system_score_gemma":0.0025807263,"threshold_uncertainty_score":0.019442081},"labels":[],"label_agreement":null},{"id":"W2158179945","doi":"10.1016/s1470-2045(03)01137-9","title":"Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer","year":2003,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":281,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University; University Health Network; University of Toronto","funders":"Cancer Research Society; American Association for Cancer Research","keywords":"Erlotinib; Gefitinib; Cetuximab; Epidermal growth factor receptor; Medicine; Lung cancer; Amphiregulin; Cancer research; Epidermal growth factor; Tyrosine kinase; Cancer; Carcinogenesis; Trastuzumab; Oncology; Receptor; Internal medicine; Colorectal cancer; Breast cancer","score_opus":0.39172005433816587,"score_gpt":0.5739504872546254,"score_spread":0.18223043291645952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158179945","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004716542,0.99932003,0.00005771426,0.00013754886,0.00015167113,0.0000053647364,0.000017415792,0.0000053588356,0.00025768828],"genre_scores_gemma":[0.00023900547,0.99904066,0.00016061883,0.00021115121,0.000100892816,0.000005061541,0.000025945295,9.353182e-7,0.0002156656],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996449,0.00006148045,0.00006578351,0.000057333968,0.00014339185,0.000027158792],"domain_scores_gemma":[0.9992262,0.0004164919,0.00011855074,0.000014608303,0.00016776293,0.0000564644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010755084,0.0013391139,0.0038057612,0.003485259,0.00026332392,0.001321201,0.0013837051,0.001503761,0.003245525],"category_scores_gemma":[0.00126512,0.00035735863,0.0009522502,0.004961019,0.00047969006,0.0016331279,0.0005940362,0.001866665,0.0015335513],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026745233,0.000092680966,0.00014551869,0.040974498,0.0002793859,0.00026088135,0.000050737926,0.0003677433,0.0015989777,0.0014728556,0.06305405,0.89143527],"study_design_scores_gemma":[0.00019223952,0.0002791893,0.0011981896,0.013436478,0.000812893,0.001614105,0.000108762724,0.00014231133,0.00041565357,0.0012787783,0.9804834,0.00003798066],"about_ca_topic_score_codex":0.0020737515,"about_ca_topic_score_gemma":0.0059457175,"teacher_disagreement_score":0.0038057612,"about_ca_system_score_codex":0.0009511952,"about_ca_system_score_gemma":0.0016443095,"threshold_uncertainty_score":0.010857403},"labels":[],"label_agreement":null},{"id":"W2158681922","doi":"10.1016/s1470-2045(09)70025-7","title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","year":2009,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":7801,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Ontario Institute for Cancer Research; Queen's University; Hôpital Notre-Dame; Western University; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Temozolomide; Radiation therapy; Concomitant; Internal medicine; Hazard ratio; Clinical endpoint; Oncology; Adjuvant; Cancer; Clinical trial; Surgery; Confidence interval","score_opus":0.021054825445956833,"score_gpt":0.3383414721996334,"score_spread":0.31728664675367657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158681922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99224746,0.004427704,0.00036757733,0.00048925524,0.00040442645,0.0005020599,0.00068666687,0.00005053058,0.0008243803],"genre_scores_gemma":[0.99423176,0.0018659211,0.0005625941,0.00042461808,0.00034602752,0.00058195874,0.00079975615,0.000030342077,0.0011568925],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99785113,0.0013742446,0.00011248655,0.00031970322,0.00009521106,0.00024728393],"domain_scores_gemma":[0.9975873,0.0009102363,0.0005417529,0.00026333475,0.000087839006,0.0006094055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040769684,0.002527892,0.0053505623,0.00049526914,0.00050026574,0.0015966577,0.0016261456,0.0020578953,0.003669279],"category_scores_gemma":[0.0036751165,0.0009223823,0.0047149444,0.0007719201,0.0019015191,0.001957721,0.0008116091,0.005524458,0.00080074184],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9924138,0.0010977478,0.00046366762,0.00016044805,0.0014152188,0.000014687098,0.000025964118,0.00033006744,0.0005525629,0.000041878135,0.00021587021,0.0032681231],"study_design_scores_gemma":[0.88673395,0.10129905,0.006197281,0.00006220468,0.0037206637,0.00005468048,0.000048373728,0.00066030456,0.0004005383,0.00034160542,0.00044291068,0.000038377177],"about_ca_topic_score_codex":0.0023883178,"about_ca_topic_score_gemma":0.0048624333,"teacher_disagreement_score":0.0053505623,"about_ca_system_score_codex":0.0017327738,"about_ca_system_score_gemma":0.0015976112,"threshold_uncertainty_score":0.021561325},"labels":[],"label_agreement":null},{"id":"W2158872144","doi":"10.1016/s1470-2045(14)71021-6","title":"Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":351,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Genome British Columbia; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Centre for Addiction and Mental Health; Ontario Institute for Cancer Research","funders":"Cancer Research UK Cambridge Institute, University of Cambridge; NIHR Cambridge Biomedical Research Centre; Canadian Institutes of Health Research; Ontario Institute for Cancer Research; Wellcome Trust; Hutchison Whampoa Limited; National Institute for Health and Care Research; Cancer Research UK; University of Cambridge; Academy of Medical Sciences; Prostate Cancer Canada; Government of Ontario; National Institutes of Health; Movember Foundation","keywords":"Medicine; Prostate cancer; Prostatectomy; Hazard ratio; Oncology; Cohort; Biochemical recurrence; Internal medicine; Radiation therapy; Retrospective cohort study; Clinical endpoint; Cancer; Prostate; Proportional hazards model; Clinical trial; Confidence interval","score_opus":0.02177070498801827,"score_gpt":0.3035306737901098,"score_spread":0.28175996880209153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158872144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991685,0.00015642215,0.000191572,0.000011639043,0.0000032200653,0.000013352961,0.00032627487,0.0000040793852,0.00012490616],"genre_scores_gemma":[0.99937123,0.000053458356,0.00013859948,0.000007929245,0.000004376344,0.000010466423,0.00033911617,0.0000031372751,0.000071694245],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99929,0.00015991571,0.000053594642,0.00028617374,0.00012059531,0.00008970844],"domain_scores_gemma":[0.99814606,0.000244814,0.00055153953,0.00060385524,0.00016588578,0.00028795042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013474687,0.0003475268,0.00038821538,0.0006576183,0.00051491807,0.0007665641,0.00061850087,0.00043964866,0.0011368456],"category_scores_gemma":[0.0021609375,0.00044294476,0.0007022712,0.0008118345,0.00040751213,0.00037025596,0.0005576589,0.0006525736,0.00020972747],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001988856,0.0000151631875,0.9986141,0.0000037864286,0.00010753074,0.000050952283,0.000050853203,0.000050594837,0.0002685405,0.000011077915,0.00005394135,0.00057465327],"study_design_scores_gemma":[0.000015172593,0.00013801432,0.99872094,0.0000033794663,0.00010808348,0.00032216663,0.00008301262,0.00035917672,0.00008774313,0.000018619923,0.00013708192,0.000006722468],"about_ca_topic_score_codex":0.01149296,"about_ca_topic_score_gemma":0.014109294,"teacher_disagreement_score":0.01149296,"about_ca_system_score_codex":0.0005324122,"about_ca_system_score_gemma":0.00058352173,"threshold_uncertainty_score":0.022852123},"labels":[],"label_agreement":null},{"id":"W2160120519","doi":"10.1016/s1470-2045(09)70162-7","title":"Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial","year":2009,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":591,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Sunitinib; Medicine; Discontinuation; Renal cell carcinoma; Expanded access; Internal medicine; Adverse effect; Population; Clinical trial; Oncology","score_opus":0.12229784488383882,"score_gpt":0.39522004052956183,"score_spread":0.272922195645723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160120519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909917,0.0047551673,0.00033607974,0.0006962419,0.00021055376,0.00039748932,0.000664455,0.00006692855,0.001881446],"genre_scores_gemma":[0.99628973,0.00093441753,0.00028022437,0.0004392923,0.00023461408,0.00023246906,0.0004700722,0.000013647586,0.0011056442],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99872655,0.0007917355,0.00005169005,0.00017190544,0.00010473192,0.00015340501],"domain_scores_gemma":[0.99808997,0.0007109274,0.00036439905,0.00021821668,0.00010211977,0.000514339],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025995132,0.0013207644,0.0032656451,0.00032098975,0.00044577004,0.0011059284,0.00057426293,0.0015615522,0.0047760084],"category_scores_gemma":[0.0028647687,0.00044209685,0.0023355025,0.0004023318,0.0010650108,0.0015931862,0.00039984897,0.0036340335,0.0006802801],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9628132,0.0030696513,0.002119022,0.0005209397,0.0023746116,0.00012809054,0.000074801326,0.0010863324,0.0018170275,0.00017387417,0.0013138957,0.024508676],"study_design_scores_gemma":[0.8871802,0.09571004,0.010328556,0.00007455588,0.00213748,0.00024016673,0.000048328613,0.0011282408,0.0009340238,0.0006271311,0.0015490965,0.000042179665],"about_ca_topic_score_codex":0.000692887,"about_ca_topic_score_gemma":0.001285131,"teacher_disagreement_score":0.0047760084,"about_ca_system_score_codex":0.0010183045,"about_ca_system_score_gemma":0.00074429665,"threshold_uncertainty_score":0.015977323},"labels":[],"label_agreement":null},{"id":"W2160305510","doi":"10.1016/s1470-2045(06)70664-7","title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","year":2006,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2085,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Rituximab; CHOP; Internal medicine; Vincristine; International Prognostic Index; Chemotherapy; Clinical endpoint; Diffuse large B-cell lymphoma; Lymphoma; Oncology; Prednisone; Surgery; Cyclophosphamide; Gastroenterology; Randomized controlled trial","score_opus":0.011568933367359015,"score_gpt":0.2673967495049783,"score_spread":0.2558278161376193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160305510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9734899,0.016305061,0.0009057404,0.0016238877,0.0022415356,0.0025376282,0.0009747397,0.00013201381,0.0017895494],"genre_scores_gemma":[0.98286706,0.005885602,0.0015448936,0.001689177,0.0010353297,0.0036154515,0.0007649083,0.000030669573,0.0025668496],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99904186,0.00052276894,0.00007230869,0.00017940353,0.000047276433,0.00013636242],"domain_scores_gemma":[0.99873763,0.00045559867,0.00027162067,0.000099029254,0.00005832054,0.00037789927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019566137,0.0020488775,0.0057671545,0.0005161345,0.0005202626,0.0013395114,0.0010945617,0.002777662,0.005985349],"category_scores_gemma":[0.0028001785,0.0009257178,0.0033448094,0.0006558938,0.0014913105,0.0019414473,0.0007132071,0.004460687,0.0010431281],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9932991,0.0008971936,0.00021095868,0.00041195622,0.0007702112,0.0000180658,0.000024747553,0.00009774666,0.00043768785,0.00005639039,0.00023995819,0.0035359622],"study_design_scores_gemma":[0.97590125,0.02206898,0.0007324062,0.000041575866,0.00065054174,0.000018669964,0.000018652949,0.00012916498,0.00008238579,0.00012078222,0.0002261576,0.000009492495],"about_ca_topic_score_codex":0.001480267,"about_ca_topic_score_gemma":0.002120411,"teacher_disagreement_score":0.005985349,"about_ca_system_score_codex":0.0010276209,"about_ca_system_score_gemma":0.000977688,"threshold_uncertainty_score":0.020022988},"labels":[],"label_agreement":null},{"id":"W2161689638","doi":"10.1016/s1470-2045(11)70175-9","title":"Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":1028,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Hepatocellular carcinoma; Liver transplantation; Transplantation; Consensus conference; Listing (finance); Donation; Family medicine; Internal medicine; Political science; Law","score_opus":0.3238269917420179,"score_gpt":0.3579941574896356,"score_spread":0.03416716574761769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161689638","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0034233227,0.18828076,0.011023313,0.74460256,0.033212293,0.002032617,0.0030410008,0.00028056643,0.014103553],"genre_scores_gemma":[0.07209703,0.36216488,0.17470916,0.3265628,0.019774726,0.009039726,0.01787584,0.00054604554,0.017229754],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9746713,0.008184456,0.007735594,0.0012535792,0.006718817,0.0014363402],"domain_scores_gemma":[0.93760026,0.020272588,0.009296869,0.0012333062,0.024563612,0.0070333993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.06249036,0.0020678442,0.0043887408,0.0052801715,0.0023954131,0.0059360084,0.008308311,0.012579434,0.004109369],"category_scores_gemma":[0.061700292,0.001592133,0.006992016,0.005252562,0.002161393,0.003536241,0.0057686255,0.021609772,0.0024537258],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048647838,0.00039309656,0.008645077,0.016477909,0.0018251343,0.0005289914,0.0015325395,0.0018502667,0.0007698703,0.006017952,0.6793438,0.28212896],"study_design_scores_gemma":[0.0024405767,0.00030239834,0.02059841,0.089408316,0.0062639876,0.00092003646,0.0035696365,0.0016891279,0.0012277692,0.012683765,0.8605329,0.00036313353],"about_ca_topic_score_codex":0.022421662,"about_ca_topic_score_gemma":0.027299382,"teacher_disagreement_score":0.06249036,"about_ca_system_score_codex":0.010077777,"about_ca_system_score_gemma":0.037508786,"threshold_uncertainty_score":0.33048457},"labels":[],"label_agreement":null},{"id":"W2162139554","doi":"10.1016/s1470-2045(13)70045-7","title":"Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":418,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Ontario Institute for Cancer Research; University Health Network; University of Toronto; Princess Margaret Cancer Centre; Toronto Western Hospital; Hospital for Sick Children; University of British Columbia; Impact","funders":"National Cancer Institute; Canadian Institutes of Health Research; Vrije Universiteit Amsterdam","keywords":"Retinoblastoma; Biology; Gene; Cancer research; Allele; Mutation; Oncogene; Genetics; Cell cycle","score_opus":0.08976245876623609,"score_gpt":0.41596714531929263,"score_spread":0.32620468655305657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162139554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981608,0.00080706796,0.00033465022,0.000014149018,0.0000018645088,0.000016068634,0.00012250427,0.000012396444,0.00053051056],"genre_scores_gemma":[0.99853444,0.0003127163,0.0005480167,0.00000931974,0.0000061727624,0.000010959868,0.0003227011,0.000007806877,0.00024786516],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99961996,0.000045569857,0.000050687548,0.00013378407,0.00009409204,0.000055910506],"domain_scores_gemma":[0.9990496,0.00032970565,0.0002828968,0.00007534147,0.00013313387,0.00012933518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048747082,0.0002483468,0.0003166865,0.00124051,0.0002589061,0.00034613826,0.00025810508,0.0002814332,0.0014321158],"category_scores_gemma":[0.0014281465,0.00016642586,0.00012872976,0.00053469895,0.00058424385,0.00023872555,0.0002726005,0.00019832182,0.00046942933],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013716822,0.00011231751,0.7673787,0.00026548246,0.000058148435,0.007209357,0.0004221297,0.00019222125,0.19937994,0.00010557866,0.00017056108,0.023333902],"study_design_scores_gemma":[0.000031539574,0.00061716133,0.91165024,0.000019016252,0.00007084834,0.06263412,0.00022714993,0.00037108018,0.022787537,0.00007590884,0.001504722,0.000010668942],"about_ca_topic_score_codex":0.0007322476,"about_ca_topic_score_gemma":0.00068720937,"teacher_disagreement_score":0.0014321158,"about_ca_system_score_codex":0.00024359675,"about_ca_system_score_gemma":0.00015327713,"threshold_uncertainty_score":0.004790902},"labels":[],"label_agreement":null},{"id":"W2162327900","doi":"10.1016/s1470-2045(13)70037-8","title":"Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Refractory (planetary science); Internal medicine; Clinical endpoint; Dosing; Regimen; Intention-to-treat analysis; Surgery; Complete remission; Clinical trial; Gastroenterology; Chemotherapy","score_opus":0.05924214384470794,"score_gpt":0.3954304370345984,"score_spread":0.33618829318989046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162327900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99531823,0.0012053351,0.00035327527,0.0002906002,0.0002946941,0.0011651927,0.0005403723,0.000060536455,0.0007716694],"genre_scores_gemma":[0.9894957,0.0016901011,0.001196833,0.0008454742,0.00046197523,0.0025521931,0.0008759575,0.000030312147,0.0028516324],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9992974,0.00033222217,0.000040859835,0.00012944921,0.00004533719,0.00015465186],"domain_scores_gemma":[0.9987263,0.00035828847,0.00020558025,0.00013423702,0.000053188942,0.00052237266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013454856,0.0019738192,0.0041693375,0.0007127934,0.0004457722,0.0014848433,0.0010942906,0.002311236,0.007550889],"category_scores_gemma":[0.0023027556,0.0009658861,0.0020149634,0.00048741463,0.0015010216,0.002143941,0.0006577559,0.0037374364,0.0011992125],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98132485,0.007752597,0.00032993418,0.00016918295,0.00032166275,0.000025945319,0.000060790324,0.00022777347,0.001108854,0.00006050767,0.00022191774,0.00839598],"study_design_scores_gemma":[0.907783,0.089970455,0.0012178906,0.000011286,0.000169912,0.000020315632,0.000032248627,0.00021433157,0.0001519221,0.000089989415,0.00031985526,0.000018875618],"about_ca_topic_score_codex":0.0010446083,"about_ca_topic_score_gemma":0.0017129994,"teacher_disagreement_score":0.007550889,"about_ca_system_score_codex":0.00083228,"about_ca_system_score_gemma":0.0009158699,"threshold_uncertainty_score":0.02526027},"labels":[],"label_agreement":null},{"id":"W2162479847","doi":"10.1016/s1470-2045(05)70210-2","title":"Time to reconsider subcutaneous mastectomy for breast-cancer prevention?","year":2005,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Coalition for Research in Women's Health; Sunnybrook Health Science Centre; University of Toronto; Women's College Hospital","funders":"","keywords":"Medicine; Prophylactic Mastectomy; Breast cancer; Prophylactic Surgery; Tamoxifen; Mastectomy; Oophorectomy; Genetic testing; BRCA mutation; Gynecology; Cancer; Oncology; Lifetime risk; Internal medicine; Surgery; Hysterectomy","score_opus":0.0669606223564708,"score_gpt":0.4100729233009038,"score_spread":0.343112300944433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162479847","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020443684,0.9849615,0.00023954941,0.010292433,0.0025318782,0.0000040679806,0.0000218871,0.000015535634,0.0017285711],"genre_scores_gemma":[0.0032937701,0.97572917,0.00096258754,0.011487626,0.0058348044,0.000015992997,0.00005096232,0.000008476144,0.002616643],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996853,0.00009876343,0.000033399592,0.000044194596,0.000101097045,0.000037340116],"domain_scores_gemma":[0.9991636,0.0005328046,0.00007225753,0.000030510102,0.00013396514,0.000066833345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017150939,0.00067673455,0.0020401243,0.0007528738,0.0003383247,0.0011219574,0.0012869855,0.0027474065,0.0074841003],"category_scores_gemma":[0.0022211804,0.00027226,0.00061628246,0.00089329673,0.0009963157,0.0022932105,0.0006068821,0.005551791,0.003012707],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003200346,0.000090675894,0.00048683494,0.0038535197,0.000114455645,0.0005077108,0.00006198154,0.00054088054,0.00074973603,0.009222513,0.1535839,0.83046776],"study_design_scores_gemma":[0.0002567284,0.00018374795,0.0015966669,0.0038756656,0.00013046566,0.0022731123,0.0001827961,0.00016524618,0.00017285754,0.00886991,0.9822667,0.000025988975],"about_ca_topic_score_codex":0.0016648704,"about_ca_topic_score_gemma":0.0052437093,"teacher_disagreement_score":0.0074841003,"about_ca_system_score_codex":0.0007754545,"about_ca_system_score_gemma":0.0009882578,"threshold_uncertainty_score":0.025036812},"labels":[],"label_agreement":null},{"id":"W2162556132","doi":"10.1016/s1470-2045(09)70178-0","title":"Total mesometrial resection for cancer of the cervix: the future surgical procedure, or oblivion?","year":2009,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre","funders":"","keywords":"Medicine; Cervical cancer; Cervix; Surgical resection; Compartment (ship); Resection; Cancer; Stage (stratigraphy); Adjuvant therapy; Surgery; Gynecology; Internal medicine","score_opus":0.06776605957267769,"score_gpt":0.3822829355227033,"score_spread":0.31451687595002564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162556132","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005540293,0.0041071083,0.00006743193,0.98383015,0.009165595,0.0000049370415,0.00002841047,0.000006856437,0.002235522],"genre_scores_gemma":[0.00892104,0.006136024,0.00023253253,0.9372731,0.040673114,0.000018818931,0.00003775112,0.000010724422,0.0066969376],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980211,0.0006297859,0.00026075548,0.00019447532,0.0005639084,0.00032984777],"domain_scores_gemma":[0.9967462,0.0019422485,0.00027899144,0.00008630577,0.00038158163,0.000564688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019731985,0.00044859754,0.0011309044,0.00038645134,0.0017837385,0.0016953674,0.0009977478,0.036929935,0.0049730875],"category_scores_gemma":[0.011204188,0.00044456252,0.00091014494,0.0004429568,0.002456379,0.002921056,0.0011967045,0.025580565,0.003358351],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028442245,0.00007019449,0.001710685,0.00020784416,0.00003184598,0.0035484806,0.00015516,0.00018899879,0.0006074902,0.009012682,0.9479724,0.036209736],"study_design_scores_gemma":[0.00037555172,0.0002895618,0.0025081409,0.0006283471,0.00006235021,0.006809923,0.0006009262,0.00058345846,0.00039456566,0.019080294,0.96858525,0.00008166686],"about_ca_topic_score_codex":0.0042563532,"about_ca_topic_score_gemma":0.014596981,"teacher_disagreement_score":0.036929935,"about_ca_system_score_codex":0.0031813402,"about_ca_system_score_gemma":0.0037248058,"threshold_uncertainty_score":0.023082316},"labels":[],"label_agreement":null},{"id":"W2162854541","doi":"10.1016/s1470-2045(12)70508-9","title":"Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":131,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"GlaxoSmithKline","keywords":"Lapatinib; Adjuvant; Medicine; Oncology; Breast cancer; Stage (stratigraphy); Internal medicine; Cancer; Trastuzumab; Gynecology","score_opus":0.07012591633160038,"score_gpt":0.43312643149354113,"score_spread":0.36300051516194076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162854541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95913774,0.020096423,0.0019428473,0.0026215762,0.0019432893,0.0074808206,0.0026425682,0.00027387176,0.0038608573],"genre_scores_gemma":[0.9673303,0.00968612,0.0023906399,0.002575814,0.0007502039,0.008140087,0.0020969398,0.000050215353,0.006979674],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.999361,0.0003558768,0.000034994184,0.00009983806,0.000042789783,0.0001055787],"domain_scores_gemma":[0.99921477,0.00027563295,0.0001655318,0.000067321926,0.000039195835,0.00023748925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018723283,0.0021679755,0.0034869122,0.00038949357,0.0004191054,0.0010726741,0.0008170012,0.001900314,0.007975633],"category_scores_gemma":[0.0024712097,0.000786708,0.0024967184,0.0005387787,0.0011856203,0.0013050615,0.0005826303,0.0035621317,0.0010075258],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9880747,0.0012454968,0.00026228864,0.00077348226,0.0008150333,0.000030126752,0.00003136061,0.00021294369,0.0010067513,0.00006274172,0.0005896451,0.006895386],"study_design_scores_gemma":[0.98677737,0.0118145645,0.0004396388,0.000027001592,0.00033453037,0.000016379154,0.000010934065,0.00011021972,0.00006606536,0.00009110779,0.0003056446,0.000006497784],"about_ca_topic_score_codex":0.0016016108,"about_ca_topic_score_gemma":0.00402389,"teacher_disagreement_score":0.007975633,"about_ca_system_score_codex":0.0009549427,"about_ca_system_score_gemma":0.0011867152,"threshold_uncertainty_score":0.026681185},"labels":[],"label_agreement":null},{"id":"W2162901058","doi":"10.1016/s1470-2045(15)00051-0","title":"Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":306,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Translational Research in Oncology","funders":"Novartis Pharmaceuticals Corporation","keywords":"Everolimus; Medicine; Trastuzumab; Internal medicine; Metastatic breast cancer; Breast cancer; Oncology; Response Evaluation Criteria in Solid Tumors; Paclitaxel; Placebo; Cancer; Clinical trial; Phases of clinical research; Pathology","score_opus":0.10727531899554954,"score_gpt":0.43749981331845356,"score_spread":0.330224494322904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162901058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9781843,0.011226097,0.0007166324,0.0015883205,0.0012177222,0.0022852768,0.0013957007,0.0002465476,0.003139379],"genre_scores_gemma":[0.9726847,0.0082117,0.002129836,0.0024638402,0.00087045354,0.0030329402,0.002453577,0.00007356295,0.008079429],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994649,0.0002756144,0.000027391314,0.00010529244,0.000034586257,0.000092205235],"domain_scores_gemma":[0.9993445,0.0001718508,0.00013589591,0.00005718069,0.000028686301,0.00026172973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019550147,0.0021100321,0.0037827003,0.0005106498,0.00040134403,0.0015340217,0.001366138,0.0019992858,0.006876017],"category_scores_gemma":[0.0015189389,0.0008662059,0.0023180775,0.0004941671,0.0013851395,0.0017728758,0.0005771789,0.004396446,0.0014680171],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97877675,0.004434233,0.00035243787,0.0006142916,0.0011357868,0.00003248284,0.000052898005,0.0004422448,0.0015282435,0.00010366671,0.0010137712,0.011513311],"study_design_scores_gemma":[0.9610267,0.03674922,0.0008138993,0.000028126427,0.00035929267,0.00002726593,0.000015471225,0.00024205058,0.00016025399,0.00009573939,0.0004689654,0.000012984082],"about_ca_topic_score_codex":0.0011607822,"about_ca_topic_score_gemma":0.0031211518,"teacher_disagreement_score":0.006876017,"about_ca_system_score_codex":0.00092975167,"about_ca_system_score_gemma":0.0010454779,"threshold_uncertainty_score":0.023002565},"labels":[],"label_agreement":null},{"id":"W2163398618","doi":"10.1016/s1470-2045(13)70007-x","title":"New policies to address the global burden of childhood cancers","year":2013,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":122,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; McMaster University","funders":"","keywords":"Medicine; Remuneration; Government (linguistics); Global health; Economic growth; Millennium Development Goals; Public health; Health care; Health policy; Childhood cancer; Public relations; Cancer; Nursing; Developing country; Political science; Business; Finance","score_opus":0.1133052629903105,"score_gpt":0.4391050741731601,"score_spread":0.32579981118284956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163398618","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005093021,0.99454415,0.00006085163,0.0039543384,0.000624436,0.0000031914335,0.00002533685,0.0000055212645,0.0007312444],"genre_scores_gemma":[0.00061030436,0.99726236,0.000117057454,0.0014685101,0.0003230963,0.000005322661,0.000024054745,0.0000015349025,0.00018780374],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99926883,0.00021815086,0.00008069574,0.00006985773,0.00025571103,0.000106730295],"domain_scores_gemma":[0.9973838,0.0015958342,0.00030000927,0.000044612898,0.00049053,0.00018524221],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002430262,0.0011147255,0.0017842216,0.0018996431,0.00040448128,0.0014883633,0.0012639163,0.0023127364,0.0065386207],"category_scores_gemma":[0.0050652875,0.00031653862,0.0011613707,0.0029063013,0.0009768691,0.002445174,0.0017102773,0.0044830698,0.0011378764],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006292742,0.000054153068,0.0003707922,0.02957612,0.00029622696,0.000098346056,0.00012482169,0.0007257076,0.00033174802,0.016695121,0.09937517,0.85228884],"study_design_scores_gemma":[0.000038847582,0.000047961308,0.0016621809,0.033034835,0.0003207822,0.00027815366,0.00026186524,0.000082745566,0.000116529474,0.0059848987,0.95814615,0.000024977075],"about_ca_topic_score_codex":0.0071048397,"about_ca_topic_score_gemma":0.01251707,"teacher_disagreement_score":0.0071048397,"about_ca_system_score_codex":0.0030261313,"about_ca_system_score_gemma":0.0074954787,"threshold_uncertainty_score":0.021956205},"labels":[],"label_agreement":null},{"id":"W2163524004","doi":"10.1016/s1470-2045(08)70195-5","title":"Cardiorespiratory exercise testing in clinical oncology research: systematic review and practice recommendations","year":2008,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cardiovascular and exercise physiology","field":"Medicine","cited_by":223,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"Lance Armstrong Foundation","keywords":"Medicine; Cardiorespiratory fitness; Internal medicine; Oncology; MEDLINE; Clinical Practice; Test (biology); Clinical trial; Physical therapy","score_opus":0.6042289766429304,"score_gpt":0.5878831163428533,"score_spread":0.01634586030007712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163524004","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028040784,0.98916316,0.0005851647,0.007586494,0.0013474174,0.0003797167,0.00025223847,0.000024046403,0.00038146685],"genre_scores_gemma":[0.009285249,0.97368515,0.0073536197,0.007106735,0.001074305,0.0007938634,0.000278037,0.000017080189,0.00040602876],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9712819,0.012787461,0.008922881,0.0020585724,0.004320197,0.0006290242],"domain_scores_gemma":[0.86217856,0.099523045,0.018967444,0.001762796,0.015565435,0.0020026558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.05702315,0.0027006161,0.016457675,0.0089699775,0.00090807775,0.005643966,0.0055164476,0.005875067,0.0067192586],"category_scores_gemma":[0.13157183,0.0024688905,0.008313966,0.007701537,0.0020421944,0.0051439335,0.0035745504,0.0046623005,0.0010567785],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083402963,0.00008777983,0.0017304898,0.6790907,0.02562381,0.00022034431,0.00040023914,0.0004526668,0.00032417406,0.0013301421,0.03950443,0.25040123],"study_design_scores_gemma":[0.0031425594,0.00030741494,0.0047784643,0.8217238,0.09747414,0.00032082148,0.0005787539,0.0005946912,0.00029574733,0.0042900415,0.06636513,0.00012838675],"about_ca_topic_score_codex":0.017092405,"about_ca_topic_score_gemma":0.06581611,"teacher_disagreement_score":0.05702315,"about_ca_system_score_codex":0.0072032684,"about_ca_system_score_gemma":0.026481142,"threshold_uncertainty_score":0.30157083},"labels":[],"label_agreement":null},{"id":"W2163563579","doi":"10.1016/s1470-2045(14)70051-8","title":"Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":292,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Vemurafenib; Rash; Adverse effect; Internal medicine; Nausea; Clinical endpoint; Population; Dacarbazine; Expanded access; Interim analysis; Dermatology; Surgery; Oncology; Gastroenterology; Clinical trial; Metastatic melanoma; Chemotherapy; Cancer","score_opus":0.03517410555670822,"score_gpt":0.3139019102081614,"score_spread":0.2787278046514532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163563579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99446577,0.0032750648,0.00045629122,0.00026175205,0.00008114633,0.00021216701,0.0005488306,0.000032200944,0.0006670152],"genre_scores_gemma":[0.996393,0.0012186145,0.00036934932,0.00037200665,0.00013812412,0.00020627338,0.0006499981,0.000013971505,0.0006385967],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99919933,0.00040439868,0.000046614347,0.00014577371,0.00009404312,0.00010985155],"domain_scores_gemma":[0.9986965,0.00040651576,0.00037984783,0.00014155958,0.00009365274,0.00028182488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016478985,0.0012129662,0.0021350547,0.00023225395,0.0002774341,0.0012590404,0.0004963301,0.0011959592,0.0018338977],"category_scores_gemma":[0.002178786,0.00050480897,0.0022827706,0.0003805183,0.0007063817,0.0012460188,0.00033423209,0.002149305,0.00040505064],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.905978,0.005380731,0.015581419,0.0011987718,0.0058677755,0.0002744225,0.00017370413,0.001510097,0.011504664,0.00023806977,0.0016623174,0.05063002],"study_design_scores_gemma":[0.68890005,0.21032266,0.082126245,0.00017177021,0.006042107,0.0010046916,0.00020485536,0.0027433508,0.0026178206,0.0009312122,0.0047943173,0.00014083342],"about_ca_topic_score_codex":0.00040361233,"about_ca_topic_score_gemma":0.0008681738,"teacher_disagreement_score":0.0021350547,"about_ca_system_score_codex":0.0007314818,"about_ca_system_score_gemma":0.0006434712,"threshold_uncertainty_score":0.0087150335},"labels":[],"label_agreement":null},{"id":"W2163925767","doi":"10.1016/s1470-2045(05)70242-4","title":"Hernias and Ewing's sarcoma family of tumours: a pooled analysis and meta-analysis","year":2005,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Hernia repair and management","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute; University of Queensland","keywords":"Ewing's sarcoma; Sarcoma; Medicine; Meta-analysis; Odds ratio; Umbilical hernia; Family history; Hernia; Logistic regression; Oncology; Internal medicine; Surgery; Pathology","score_opus":0.18935566732405995,"score_gpt":0.4266113620291372,"score_spread":0.23725569470507724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163925767","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021497728,0.97536874,0.001280541,0.00016483388,0.00025981912,0.000099340396,0.00096502755,0.000041348412,0.0003227404],"genre_scores_gemma":[0.49995917,0.4928489,0.0034985668,0.00063364056,0.00046974423,0.00041529315,0.0011981864,0.000049923103,0.0009264839],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9960031,0.0022895026,0.0006228225,0.0005910474,0.0003317813,0.00016171735],"domain_scores_gemma":[0.99068636,0.0070245513,0.0013166337,0.00041025595,0.00043481187,0.00012734813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0070060315,0.0023051284,0.012139648,0.0025414277,0.00032358733,0.0015756486,0.0014091609,0.0016192094,0.0034679228],"category_scores_gemma":[0.013953401,0.0012926913,0.027190428,0.0040098685,0.00035498178,0.0011682888,0.0009310219,0.001382538,0.0002755031],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064937477,0.000025713303,0.006161469,0.062022142,0.91058457,0.0001854024,0.000052694,0.0008680637,0.0002970457,0.00010858306,0.00086951855,0.012331122],"study_design_scores_gemma":[0.0011523516,0.00023120931,0.0054091974,0.0014777174,0.9900002,0.00012608296,0.00002877201,0.00019973522,0.00008167107,0.00016141444,0.001110941,0.000020810367],"about_ca_topic_score_codex":0.0043847486,"about_ca_topic_score_gemma":0.011629737,"teacher_disagreement_score":0.012139648,"about_ca_system_score_codex":0.0010110794,"about_ca_system_score_gemma":0.0010700919,"threshold_uncertainty_score":0.037051916},"labels":[],"label_agreement":null},{"id":"W2164327861","doi":"10.1016/s1470-2045(07)70169-9","title":"Opportunities for improving the therapeutic ratio for patients with sarcoma","year":2007,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":143,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of British Columbia; Vancouver Coastal Health Research Institute; Princess Margaret Cancer Centre; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; SickKids Foundation; University of Toronto","funders":"National Cancer Institute; Michael Smith Health Research BC; University of Toronto; Canadian Institutes of Health Research; Terry Fox Foundation; Canada Research Chairs","keywords":"Medicine; Sarcoma; Dermatofibrosarcoma protuberans; Imatinib; Synovial sarcoma; Fibromatosis; Radiation therapy; Oncology; Pazopanib; Cancer research; Imatinib mesylate; Bone Sarcoma; Bioinformatics; Pathology; Internal medicine; Cancer; Biology; Sunitinib","score_opus":0.27773844185431484,"score_gpt":0.41716269453241417,"score_spread":0.13942425267809933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164327861","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000059539394,0.99797744,0.00008781932,0.0007630388,0.00023990763,0.0000020317457,0.000009401536,0.000004873231,0.0008559172],"genre_scores_gemma":[0.0008050234,0.99742645,0.00020889263,0.0007092105,0.00044197147,0.000005627373,0.000021346199,0.0000017709053,0.00037965758],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99967086,0.00009977848,0.00003876508,0.000050617477,0.000109422515,0.00003060817],"domain_scores_gemma":[0.99924767,0.00049876707,0.0000950556,0.000014118571,0.000103606166,0.000040746472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010303158,0.0008765382,0.0024681403,0.0018014112,0.00029789738,0.0010360739,0.001057826,0.0015065703,0.0074469843],"category_scores_gemma":[0.00153421,0.00022032406,0.0007802678,0.0017907004,0.0006572357,0.0014457013,0.0007480518,0.0028740647,0.002707989],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010871338,0.000057564215,0.00020736888,0.010149043,0.0001576785,0.00019676871,0.000025644138,0.00039407035,0.00061815046,0.0042534037,0.04202333,0.9418083],"study_design_scores_gemma":[0.00012561821,0.00016642456,0.0016672744,0.0069812764,0.0002906762,0.0025586104,0.00010255418,0.00013865446,0.00034194507,0.0062351692,0.9813603,0.00003149925],"about_ca_topic_score_codex":0.0010461172,"about_ca_topic_score_gemma":0.0029103996,"teacher_disagreement_score":0.0074469843,"about_ca_system_score_codex":0.0009600039,"about_ca_system_score_gemma":0.00094909634,"threshold_uncertainty_score":0.024912596},"labels":[],"label_agreement":null},{"id":"W2164437838","doi":"10.1016/s1470-2045(15)00222-3","title":"Expanding global access to radiotherapy","year":2015,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":1085,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Princess Margaret Cancer Centre; University of Toronto; Queen's University; University Health Network","funders":"World Health Organization","keywords":"Radiation therapy; Low and middle income countries; Middle income; Developed country; Developing country; Medicine; Business; Economic growth; Economics; Environmental health; Demographic economics; Surgery; Population","score_opus":0.20159668286846,"score_gpt":0.5736985221372256,"score_spread":0.3721018392687656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164437838","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004728938,0.996394,0.00006781156,0.0013907548,0.00037629734,0.0000025701534,0.000021481144,0.000006206674,0.0016935858],"genre_scores_gemma":[0.0007006713,0.9968939,0.00009385979,0.0011887206,0.0005219226,0.0000036419221,0.000028932902,0.000002160887,0.00056618516],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99961287,0.00011105881,0.000046075787,0.000045202836,0.00012472906,0.000060063907],"domain_scores_gemma":[0.99911684,0.0004900163,0.0001515524,0.000022793265,0.00013773117,0.00008114166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001105178,0.00081319374,0.0012527352,0.0020904248,0.00027450387,0.0013454611,0.0007167008,0.0015261299,0.013840414],"category_scores_gemma":[0.0024363839,0.000292456,0.0005921436,0.002454098,0.00076745765,0.0025351646,0.0018278116,0.0023184305,0.0023987484],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000068506146,0.00002549854,0.00018629148,0.020341301,0.00009076887,0.00011868189,0.00007045255,0.00037693494,0.00038663897,0.008182505,0.08853053,0.88162184],"study_design_scores_gemma":[0.000025038551,0.000028418812,0.0005202968,0.007717678,0.00008572773,0.00041125555,0.00007052356,0.000050881106,0.00008030397,0.003074763,0.9879246,0.0000104890605],"about_ca_topic_score_codex":0.0022069982,"about_ca_topic_score_gemma":0.0059932265,"teacher_disagreement_score":0.013840414,"about_ca_system_score_codex":0.0015012238,"about_ca_system_score_gemma":0.0023850775,"threshold_uncertainty_score":0.04630077},"labels":[],"label_agreement":null},{"id":"W2164777416","doi":"10.1016/s1470-2045(15)00041-8","title":"Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":152,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute","keywords":"Medicine; Docetaxel; Bevacizumab; Capecitabine; Clinical endpoint; Neoadjuvant therapy; Internal medicine; Oncology; Breast cancer; Gemcitabine; Cyclophosphamide; Taxane; Chemotherapy; Surgery; Cancer; Clinical trial; Colorectal cancer","score_opus":0.0375631773273734,"score_gpt":0.35795323757138886,"score_spread":0.32039006024401545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164777416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9682482,0.016621392,0.001242397,0.001792444,0.0012770147,0.00452741,0.002789955,0.00014455814,0.0033566335],"genre_scores_gemma":[0.97831887,0.006028701,0.0019262146,0.001628101,0.00073740084,0.0056407587,0.002037963,0.000041503743,0.0036404333],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99809176,0.0012161483,0.00013150544,0.00023739004,0.00011141165,0.00021189854],"domain_scores_gemma":[0.9978683,0.00073820417,0.0006458183,0.00016101141,0.0001438733,0.00044285515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035895193,0.0025779943,0.003755362,0.00046672617,0.0005339933,0.0014890756,0.0009408954,0.002150185,0.0056769233],"category_scores_gemma":[0.0039524944,0.0007767011,0.0036745036,0.0006501814,0.0013319415,0.0014141634,0.00065030006,0.0042130346,0.00106074],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9905212,0.0011214828,0.0004039701,0.00066901534,0.001978412,0.000015170586,0.000022567148,0.00016088848,0.0006079902,0.000055399905,0.0004796116,0.0039643007],"study_design_scores_gemma":[0.9703648,0.024794081,0.0015580084,0.00007264016,0.0020955328,0.000020958585,0.000020084392,0.00018814865,0.00018008657,0.00019378377,0.00049734785,0.000014463941],"about_ca_topic_score_codex":0.0019648278,"about_ca_topic_score_gemma":0.004099059,"teacher_disagreement_score":0.0056769233,"about_ca_system_score_codex":0.0014104351,"about_ca_system_score_gemma":0.0014108919,"threshold_uncertainty_score":0.018991232},"labels":[],"label_agreement":null},{"id":"W2165413853","doi":"10.1016/s1470-2045(12)70425-4","title":"Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies","year":2012,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":1159,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Child Health and Human Development; National Cancer Institute; Norwegian Institute of Public Health; University of California, San Francisco; University of North Carolina at Chapel Hill; Instituto Nacional De Salud Pública; Institut Gustave-Roussy; Wuhan University; Syddansk Universitet; Universidad de Costa Rica; Universitetet i Bergen; Odense Universitetshospital; Memorial Sloan-Kettering Cancer Center; Università degli Studi di Padova; Universiteit Maastricht; Imperial College London; World Health Organization; University of Southern California; University College London; Cancer Research UK; London School of Hygiene and Tropical Medicine; Loma Linda University; University of Otago; Shanghai Institute Of Planned Parenthood Research; Deutsches Krebsforschungszentrum; University of Pittsburgh; National and Kapodistrian University of Athens; Karolinska Institutet; Universidad de Chile; Institut National de la Santé et de la Recherche Médicale; University of Minnesota; Università degli Studi di Milano; University of Pennsylvania; Vanderbilt University; University of Toronto; National University of Singapore; Kaiser Permanente","keywords":"Menarche; Breast cancer; Epidemiology; Menopause; Medicine; Obstetrics; Gynecology; Cancer; Demography; Internal medicine; Sociology","score_opus":0.5872332569421976,"score_gpt":0.511669772123417,"score_spread":0.07556348481878061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165413853","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21096326,0.7722677,0.0074127894,0.0006906976,0.0006769511,0.0005566858,0.006083709,0.00022096663,0.0011271753],"genre_scores_gemma":[0.92596626,0.06410598,0.0043868693,0.0005967336,0.00018240075,0.0009828974,0.0030230377,0.00008978564,0.0006660048],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9887422,0.0070658266,0.0018475893,0.0013066782,0.0007228936,0.00031492685],"domain_scores_gemma":[0.98625726,0.009747004,0.0016599474,0.0013119098,0.00072936865,0.00029448635],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.015590643,0.0023015714,0.009554827,0.0029771805,0.0008322337,0.0026672804,0.0017562605,0.0019950524,0.0029650214],"category_scores_gemma":[0.023721667,0.0023542475,0.03142408,0.0051562297,0.00061733095,0.0010243049,0.0015935486,0.0021117346,0.00034230406],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005908571,0.000027042019,0.030133052,0.010624257,0.94899875,0.00015323401,0.000051566934,0.0006528268,0.00033794146,0.0000656281,0.00038868142,0.0026583234],"study_design_scores_gemma":[0.0014165752,0.00028035726,0.016027763,0.0008493398,0.97963333,0.0001382627,0.000041698102,0.00035053067,0.00014205348,0.00016388221,0.00093743106,0.000018730783],"about_ca_topic_score_codex":0.007448373,"about_ca_topic_score_gemma":0.0089721605,"teacher_disagreement_score":0.9904452,"about_ca_system_score_codex":0.0008809793,"about_ca_system_score_gemma":0.0013970741,"threshold_uncertainty_score":0.08245218},"labels":[],"label_agreement":null},{"id":"W2165693726","doi":"10.1016/s1470-2045(08)70179-7","title":"Cancer survival in five continents: a worldwide population-based study (CONCORD)","year":2008,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":1469,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; National Institute for Health and Care Research; Cancer Research UK","keywords":"Relative survival; Medicine; Demography; Cancer; Population; Cancer registry; Breast cancer; Prostate cancer; Colorectal cancer; Survival rate; Survival analysis; Gerontology; Oncology; Internal medicine; Environmental health","score_opus":0.18474573467920447,"score_gpt":0.42316363617726677,"score_spread":0.2384179014980623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165693726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935742,0.00090686214,0.0001274636,0.00018616299,0.000012793617,0.000059360595,0.0040263776,0.000008607211,0.0010982183],"genre_scores_gemma":[0.9907217,0.0008385222,0.00034734554,0.00026322764,0.000029939876,0.00009507326,0.007268043,0.000011942902,0.00042411566],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992023,0.00017053487,0.00008498982,0.00025627745,0.00011835101,0.00016750443],"domain_scores_gemma":[0.99862325,0.00011507528,0.000453336,0.00020501438,0.00030697393,0.00029633436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014055042,0.00050200406,0.0005561172,0.0022577,0.0011012402,0.0010552926,0.0008320759,0.00087885105,0.0008895327],"category_scores_gemma":[0.0015831807,0.00030782406,0.00075630244,0.0045396704,0.0005498577,0.0008544262,0.0017466389,0.000736097,0.00030633563],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001008515,0.000034618613,0.9958099,0.00003248903,0.0001268363,0.00015902343,0.00031881867,0.000053725744,0.00007614624,0.000051274754,0.00085810764,0.0023781897],"study_design_scores_gemma":[0.000008513559,0.00002938185,0.99869496,0.000026087017,0.000037480066,0.00012251081,0.0002316967,0.00006608603,0.000018390812,0.000012016203,0.00074806594,0.000004855425],"about_ca_topic_score_codex":0.13073628,"about_ca_topic_score_gemma":0.15986563,"teacher_disagreement_score":0.13073628,"about_ca_system_score_codex":0.0017118157,"about_ca_system_score_gemma":0.0015022383,"threshold_uncertainty_score":0.25995064},"labels":[],"label_agreement":null},{"id":"W2165854883","doi":"10.1016/s1470-2045(11)70119-x","title":"Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":415,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Population Health Research Institute; McMaster University; University of Toronto; Hospital for Sick Children","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Cancer Research Institute","keywords":"Asymptomatic; Medicine; Observational study; Asymptomatic carrier; Germline mutation; Internal medicine; Prospective cohort study; Cancer; Mutation; Pediatrics; Oncology; Genetics; Biology","score_opus":0.06143933199466351,"score_gpt":0.32017331968553014,"score_spread":0.25873398769086664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165854883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99909973,0.0003491934,0.000059692138,0.000031867577,0.0000041031417,0.000006752594,0.00027495855,0.0000023962602,0.00017142801],"genre_scores_gemma":[0.9991841,0.0001743201,0.000047366204,0.000030830746,0.000010257063,0.000007363568,0.00044937618,0.000002796447,0.000093586656],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990238,0.00024590126,0.00012464677,0.00029903144,0.0001184631,0.00018808809],"domain_scores_gemma":[0.99605966,0.00077035266,0.0016891196,0.0005684037,0.00031522574,0.0005973337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000996161,0.0008004267,0.0010672942,0.0011637965,0.0010200007,0.0013906135,0.0009045515,0.0013451679,0.0018545381],"category_scores_gemma":[0.004419343,0.0011575839,0.0013611101,0.002736558,0.0008235831,0.0013989826,0.0007787889,0.0015143292,0.00040092703],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056265504,0.00009189336,0.9979937,0.0000084002895,0.00016184873,0.0003068173,0.00007942317,0.000031169457,0.0002859099,0.000019719524,0.000050877716,0.00040753523],"study_design_scores_gemma":[0.000093315095,0.00042589864,0.99663264,0.000014195151,0.00029549722,0.0016284449,0.00035416477,0.0002045232,0.0000970095,0.00007417504,0.00016098974,0.00001913784],"about_ca_topic_score_codex":0.0112609435,"about_ca_topic_score_gemma":0.007446043,"teacher_disagreement_score":0.0112609435,"about_ca_system_score_codex":0.0007688635,"about_ca_system_score_gemma":0.0007829089,"threshold_uncertainty_score":0.022390842},"labels":[],"label_agreement":null},{"id":"W2166326729","doi":"10.1016/s1470-2045(12)70257-7","title":"Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: an integrative genomic analysis","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":174,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Hospital for Sick Children; Alberta Children's Hospital; SickKids Foundation; University of Toronto","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; Canadian Institutes of Health Research; Brain Tumour Charity; National Cancer Institute; Cancer Research UK; Brain Tumour Research; Cancer Research Institute","keywords":"Biology; Immunohistochemistry; Internal medicine; Oncology; Lineage markers; Pathology; Bioinformatics; Gene; Medicine; Genetics; Immunology; Phenotype","score_opus":0.025722737562476183,"score_gpt":0.3212109845479067,"score_spread":0.2954882469854305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166326729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948702,0.0020738798,0.00083576434,0.0002485246,0.0000056771,0.0000067672772,0.0010889699,0.0000135394275,0.0008567054],"genre_scores_gemma":[0.99813795,0.00046558722,0.0004950675,0.000040536164,0.000009420821,0.00000492086,0.00061800017,0.000008314122,0.00022011186],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996537,0.000085557425,0.000017414979,0.00010662934,0.000057265945,0.000079361576],"domain_scores_gemma":[0.9992512,0.00039133432,0.00018882255,0.000058211022,0.000055172986,0.000055338507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057753496,0.00037716678,0.00052768784,0.0013830437,0.00040241212,0.0007910195,0.00045452965,0.0003041313,0.0017569796],"category_scores_gemma":[0.0013449232,0.00017714212,0.00086180517,0.0018534448,0.00042214736,0.0003407888,0.00072937785,0.0005175245,0.00014580374],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012361557,0.000084443855,0.9158641,0.0001410767,0.0018490828,0.0006904906,0.0006221633,0.002818931,0.02241397,0.0012574582,0.000727532,0.052294485],"study_design_scores_gemma":[0.000020688223,0.00013876052,0.9930587,0.000020901849,0.0010138436,0.0005700295,0.000325069,0.001279823,0.0013449921,0.0009634595,0.0012516198,0.0000121466555],"about_ca_topic_score_codex":0.006231436,"about_ca_topic_score_gemma":0.007554259,"teacher_disagreement_score":0.006231436,"about_ca_system_score_codex":0.00055606844,"about_ca_system_score_gemma":0.0005222012,"threshold_uncertainty_score":0.0123903155},"labels":[],"label_agreement":null},{"id":"W2166656480","doi":"10.1016/s1470-2045(09)70230-x","title":"Management of HER2-positive breast cancer in Asia: consensus statement from the Asian Oncology Summit 2009","year":2009,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Summit; Statement (logic); Breast cancer; Oncology; Internal medicine; Medicine; Political science; Cancer; Geography; Cartography; Law","score_opus":0.12434831521486477,"score_gpt":0.48312958374674864,"score_spread":0.35878126853188386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166656480","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009136263,0.99164516,0.00009120237,0.0070401365,0.00067829224,0.000008146875,0.000036459223,0.000003901049,0.00040527814],"genre_scores_gemma":[0.0008508025,0.9950311,0.00031087795,0.0030423084,0.00042625467,0.000013921132,0.000055640896,0.0000017058424,0.00026728702],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99937266,0.00014655192,0.00014619401,0.000053863485,0.00020043406,0.00008037048],"domain_scores_gemma":[0.9986979,0.00048520925,0.00025722716,0.000018154085,0.00042902053,0.00011237873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036118424,0.0008215765,0.0022699859,0.001439211,0.00031347026,0.0013611161,0.00152047,0.0021411749,0.0018654853],"category_scores_gemma":[0.002942351,0.00032904226,0.0014215796,0.0017859167,0.0005116257,0.001693268,0.001199625,0.0032462534,0.000683689],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020615848,0.00007083982,0.00062949397,0.028118491,0.00029766458,0.0002485959,0.00008652336,0.0005908599,0.00049784157,0.0017233436,0.16144665,0.8060837],"study_design_scores_gemma":[0.00021903364,0.00019714373,0.0040796725,0.052989315,0.0010507115,0.0013095328,0.0003505957,0.00021945704,0.00049219537,0.0022557506,0.93678874,0.00004781897],"about_ca_topic_score_codex":0.0067386418,"about_ca_topic_score_gemma":0.019245915,"teacher_disagreement_score":0.0067386418,"about_ca_system_score_codex":0.0024275144,"about_ca_system_score_gemma":0.00666523,"threshold_uncertainty_score":0.0191015},"labels":[],"label_agreement":null},{"id":"W2166678252","doi":"10.1016/s1470-2045(11)70286-8","title":"Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":703,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; University of Alberta","funders":"GlaxoSmithKline","keywords":"Medicine; Cervical cancer; Vaccine efficacy; Cervical intraepithelial neoplasia; Serostatus; Clinical endpoint; Surrogate endpoint; Clinical trial; Randomized controlled trial; Internal medicine; Gynecology; Vaccination; Oncology; Cancer; Immunology; Viral load; Human immunodeficiency virus (HIV)","score_opus":0.1649345748730365,"score_gpt":0.39859530325464876,"score_spread":0.23366072838161225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166678252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98626155,0.0059273676,0.0011517062,0.0006590107,0.00052497943,0.0017315989,0.0012435503,0.00020129805,0.0022989803],"genre_scores_gemma":[0.98917145,0.0018939959,0.0013989111,0.00055366405,0.00041912936,0.0020451683,0.0011044304,0.000046400888,0.003366876],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965593,0.0023695808,0.00015478981,0.0004644886,0.00015162071,0.00030020357],"domain_scores_gemma":[0.99774075,0.000865572,0.00056209014,0.0003798424,0.00013675369,0.00031501424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004519078,0.0027055882,0.0064665554,0.00050136517,0.00035711785,0.0015810815,0.0018438287,0.0025453945,0.005301769],"category_scores_gemma":[0.0050786245,0.0010668916,0.004866011,0.0005223685,0.001713953,0.0019182565,0.0007785725,0.0041063554,0.001068774],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.991995,0.00046564505,0.00026663975,0.000374499,0.0013293448,0.000016326576,0.000021496686,0.00029526209,0.0006845058,0.000050910297,0.00018639909,0.0043140925],"study_design_scores_gemma":[0.95166004,0.042351082,0.0023023079,0.00004344767,0.0021424328,0.00003340229,0.000015402033,0.0005491232,0.00036134198,0.00021205573,0.00031143642,0.000018024703],"about_ca_topic_score_codex":0.0011208699,"about_ca_topic_score_gemma":0.0011660001,"teacher_disagreement_score":0.0064665554,"about_ca_system_score_codex":0.0009862027,"about_ca_system_score_gemma":0.0012267616,"threshold_uncertainty_score":0.023899436},"labels":[],"label_agreement":null},{"id":"W2167195670","doi":"10.1016/s1470-2045(15)00027-3","title":"Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":380,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Terry Fox Foundation","keywords":"Medicine; Metformin; Gemcitabine; Erlotinib; Clinical endpoint; Pancreatic cancer; Placebo; Internal medicine; Population; Cancer; Clinical trial; Oncology; Surgery; Insulin","score_opus":0.040079280554151754,"score_gpt":0.34324842754807783,"score_spread":0.30316914699392605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167195670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9682276,0.016774042,0.0010795349,0.0019090673,0.0022790486,0.0052236537,0.0016320182,0.00022331148,0.0026517303],"genre_scores_gemma":[0.96978295,0.01128398,0.00214285,0.0032888101,0.0013290942,0.0050204643,0.0015221951,0.000049962287,0.0055795307],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99936706,0.00030678188,0.000047600184,0.00013803327,0.000040813225,0.00009956796],"domain_scores_gemma":[0.9992029,0.00023170779,0.00017043467,0.00006521224,0.000053965075,0.00027580795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017573871,0.0025678913,0.005019926,0.0006241442,0.00059821765,0.0015634863,0.0010510144,0.0034095708,0.008482893],"category_scores_gemma":[0.0021921666,0.0010961159,0.0027999457,0.0006052433,0.0013122569,0.0018151583,0.0006017737,0.0034998762,0.0012285706],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.99072754,0.0019558063,0.00021515001,0.00068170053,0.0008868504,0.00002541071,0.000022247394,0.000104789055,0.00078416197,0.00004427242,0.0004006523,0.0041514835],"study_design_scores_gemma":[0.9876552,0.011155145,0.00046698592,0.000024378753,0.0002926624,0.000010009982,0.000010172127,0.00007948013,0.000057140976,0.00005284117,0.00018845529,0.000007526122],"about_ca_topic_score_codex":0.0010756222,"about_ca_topic_score_gemma":0.0021006824,"teacher_disagreement_score":0.008482893,"about_ca_system_score_codex":0.000743705,"about_ca_system_score_gemma":0.0009992503,"threshold_uncertainty_score":0.028378129},"labels":[],"label_agreement":null},{"id":"W2167355583","doi":"10.1016/s1470-2045(11)70150-4","title":"Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Rituximab; Medicine; Bortezomib; Follicular lymphoma; Internal medicine; Clinical endpoint; Lymphoma; Oncology; Clinical trial; Surgery; Multiple myeloma","score_opus":0.05732662351427194,"score_gpt":0.3184787071032654,"score_spread":0.2611520835889935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167355583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9780207,0.011514353,0.00077808386,0.0017030503,0.0013808772,0.0027044425,0.0010769692,0.00014236114,0.0026791566],"genre_scores_gemma":[0.98506063,0.004012084,0.0010862974,0.0017543033,0.00067539315,0.0029375844,0.0009591434,0.000035860794,0.0034786342],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99896336,0.0005627242,0.00005849628,0.00019191719,0.000052973588,0.0001705258],"domain_scores_gemma":[0.9986442,0.000518722,0.0002580674,0.000124329,0.00006139841,0.00039322593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023661724,0.0024884073,0.005234942,0.00051888084,0.0006671046,0.0018078905,0.0014654645,0.0026730709,0.0077243866],"category_scores_gemma":[0.0025805433,0.0010954802,0.0035618676,0.00064664223,0.0019325616,0.0018559562,0.0007381995,0.004581795,0.0017666909],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.992157,0.0011917872,0.00023344577,0.00036089387,0.00081345753,0.000029509562,0.000044085296,0.00017138077,0.0006737982,0.00006210393,0.00033997174,0.003922535],"study_design_scores_gemma":[0.97959775,0.018908158,0.00052059354,0.000023442724,0.0003548952,0.00002232015,0.000020684778,0.0001285437,0.0000621774,0.0001339798,0.00021846783,0.0000090471685],"about_ca_topic_score_codex":0.0019392447,"about_ca_topic_score_gemma":0.002726546,"teacher_disagreement_score":0.0077243866,"about_ca_system_score_codex":0.0013863635,"about_ca_system_score_gemma":0.0011325468,"threshold_uncertainty_score":0.02584058},"labels":[],"label_agreement":null},{"id":"W2168108459","doi":"10.1016/s1470-2045(12)70379-0","title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1387,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; BC Cancer Agency","funders":"Janssen Research and Development; UCLH Biomedical Research Centre","keywords":"Abiraterone acetate; Medicine; Placebo; Prednisone; Prostate cancer; Clinical endpoint; Interim analysis; Internal medicine; Enzalutamide; Docetaxel; Population; Oncology; Androgen deprivation therapy; Clinical trial; Cancer; Androgen receptor; Pathology","score_opus":0.18733768892073796,"score_gpt":0.45450891352613365,"score_spread":0.26717122460539566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168108459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97999865,0.012128477,0.0009932175,0.0005739984,0.000557118,0.0015590823,0.001577385,0.00022404765,0.0023880189],"genre_scores_gemma":[0.9889075,0.0048626703,0.0008173855,0.00059308874,0.00046813439,0.0009306689,0.0010552811,0.000040037896,0.0023252293],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998769,0.00078411575,0.00007981049,0.00011749072,0.0001205775,0.00012903413],"domain_scores_gemma":[0.9981489,0.00070567743,0.00039279618,0.00022370406,0.00009717358,0.00043174153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026639933,0.0019000798,0.0035374828,0.0006525494,0.00046705815,0.0012281155,0.0008827086,0.0015884556,0.00469738],"category_scores_gemma":[0.0025728154,0.0006595561,0.0031528927,0.00068702106,0.0015254886,0.00097474095,0.00041441253,0.002915118,0.00089741027],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98699003,0.0012024611,0.00032989454,0.0004444844,0.0009753189,0.000022727083,0.00003316144,0.00026449718,0.0015087809,0.0000430531,0.0003145562,0.00787115],"study_design_scores_gemma":[0.9526424,0.041863225,0.0030659703,0.0000340606,0.0011137744,0.000047274752,0.000023845621,0.00028234738,0.00027631017,0.00017497991,0.0004522688,0.000023643408],"about_ca_topic_score_codex":0.0020082032,"about_ca_topic_score_gemma":0.0042277896,"teacher_disagreement_score":0.00469738,"about_ca_system_score_codex":0.00073872914,"about_ca_system_score_gemma":0.0012451974,"threshold_uncertainty_score":0.015714288},"labels":[],"label_agreement":null},{"id":"W2168579528","doi":"10.1016/s1470-2045(13)70154-2","title":"Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":654,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Institutes of Health; Institute of Cancer Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; F. Hoffmann-La Roche","keywords":"Capecitabine; Medicine; Bevacizumab; Internal medicine; Irinotecan; Colorectal cancer; Hazard ratio; Clinical endpoint; Oxaliplatin; Adverse effect; Oncology; Population; Cancer; Randomized controlled trial; Chemotherapy; Surgery; Confidence interval","score_opus":0.06574882485102473,"score_gpt":0.37486971767816896,"score_spread":0.3091208928271442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168579528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98942626,0.005305968,0.0003718802,0.0006938377,0.0005516729,0.0013734273,0.0006956541,0.00006273994,0.0015186262],"genre_scores_gemma":[0.98808974,0.0034163976,0.0010989112,0.0009799361,0.0004954064,0.0015349931,0.0009638966,0.00001792814,0.0034026792],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995677,0.00022397823,0.0000259264,0.00008095763,0.000026171514,0.00007515049],"domain_scores_gemma":[0.99911743,0.0003064544,0.00018110008,0.000049768863,0.00004017986,0.00030502334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015270697,0.0017379789,0.0026249802,0.0003919885,0.0003949429,0.0009971159,0.0006356621,0.0015387557,0.0065054065],"category_scores_gemma":[0.001790587,0.0006149008,0.0021884963,0.0003968919,0.0010144535,0.0012653255,0.0004075591,0.0027719948,0.0007569253],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9835082,0.002509728,0.0004421093,0.00040454362,0.0007200863,0.000032745495,0.00005028089,0.0002631286,0.0012779224,0.00007914792,0.0005701993,0.01014191],"study_design_scores_gemma":[0.93835044,0.058606137,0.00163392,0.000031009382,0.00036978803,0.000031047173,0.000025526655,0.00027485145,0.00014302212,0.00011390251,0.00040803928,0.0000122026795],"about_ca_topic_score_codex":0.0016185058,"about_ca_topic_score_gemma":0.0042225253,"teacher_disagreement_score":0.0065054065,"about_ca_system_score_codex":0.00085502194,"about_ca_system_score_gemma":0.0007828015,"threshold_uncertainty_score":0.021762729},"labels":[],"label_agreement":null},{"id":"W2168794802","doi":"10.1016/s1470-2045(12)70285-1","title":"Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Alberta; University of British Columbia; Health Sciences Centre; Western University; University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Renal cell carcinoma; Oncology; Targeted therapy; Internal medicine; Population; Cancer","score_opus":0.04824841459005484,"score_gpt":0.2997648199313557,"score_spread":0.2515164053413008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168794802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99899215,0.00024541977,0.0000780996,0.000052456096,0.000008265785,0.0000049605287,0.0003432756,0.000003835946,0.0002716609],"genre_scores_gemma":[0.999323,0.00009091348,0.000018694243,0.000030683404,0.000016035463,0.000005867658,0.0004084598,0.0000024035253,0.0001039165],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993299,0.00020781907,0.000046631994,0.00022455561,0.000060799583,0.00013034276],"domain_scores_gemma":[0.99874,0.00028225782,0.00044325762,0.00015382342,0.00008772121,0.00029292234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008225071,0.00043790007,0.0008421194,0.0004980723,0.0005497589,0.0009221173,0.0004950235,0.0010293444,0.0019397562],"category_scores_gemma":[0.0021790804,0.00044772812,0.0015653946,0.0011040374,0.0005466072,0.0010789159,0.0005889166,0.0013775727,0.0002914045],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003194709,0.00018895803,0.99300224,0.000023194372,0.0008840349,0.00017192721,0.000100951715,0.0002174062,0.0006324242,0.00006120608,0.00019839568,0.0013244504],"study_design_scores_gemma":[0.00013044772,0.0009390807,0.9971328,0.000004780169,0.0004629221,0.0003270404,0.00017456515,0.00040087526,0.000066741086,0.00010821439,0.00023450446,0.00001797479],"about_ca_topic_score_codex":0.0037881057,"about_ca_topic_score_gemma":0.0028512352,"teacher_disagreement_score":0.0037881057,"about_ca_system_score_codex":0.00047267057,"about_ca_system_score_gemma":0.00038846972,"threshold_uncertainty_score":0.0075321198},"labels":[],"label_agreement":null},{"id":"W2169012257","doi":"10.1016/s1470-2045(15)70056-2","title":"Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":220,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Medical Association; University of Alberta","funders":"Merck","keywords":"Vorinostat; Tolerability; Medicine; Internal medicine; Placebo; Population; Oncology; Adverse effect; Surgery; Histone deacetylase; Pathology","score_opus":0.03588223247442272,"score_gpt":0.360391855471871,"score_spread":0.3245096229974483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169012257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9808108,0.010811737,0.00061954034,0.0009363683,0.0011113336,0.0019128637,0.0012669165,0.00016747182,0.0023629875],"genre_scores_gemma":[0.98221177,0.0076141725,0.0009533281,0.001164594,0.00044063746,0.0014812958,0.0014961798,0.000026274703,0.0046118097],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99973315,0.00012027749,0.000020396446,0.000052785923,0.000020624713,0.000052774598],"domain_scores_gemma":[0.999613,0.00009920002,0.00008304637,0.00002805413,0.000028714978,0.0001480391],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096639694,0.0015379603,0.0027533036,0.00032038713,0.00031815574,0.0009527721,0.0008051973,0.0014239087,0.0053411],"category_scores_gemma":[0.0010857333,0.0006381445,0.0021787756,0.00047509602,0.0008772443,0.0010125408,0.00032794333,0.0026893867,0.00078459637],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96300185,0.003191147,0.00072987657,0.0014673622,0.0018794122,0.00006746033,0.00006359579,0.00040399397,0.0051338393,0.00014450261,0.001291464,0.022625497],"study_design_scores_gemma":[0.94987047,0.04648554,0.0015265951,0.000042608794,0.00057566963,0.000039091265,0.000031002313,0.0002672889,0.00032931508,0.00012378216,0.00069398887,0.000014703483],"about_ca_topic_score_codex":0.0012902815,"about_ca_topic_score_gemma":0.0029604775,"teacher_disagreement_score":0.0053411,"about_ca_system_score_codex":0.00064026116,"about_ca_system_score_gemma":0.000663341,"threshold_uncertainty_score":0.017867804},"labels":[],"label_agreement":null},{"id":"W2169429264","doi":"10.1016/s1470-2045(11)70333-3","title":"Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":154,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GDI Integrated Facility Services (Canada); Université de Montréal; McGill University Health Centre","funders":"Biotechnology and Biological Sciences Research Council; Canadian Institutes of Health Research; Fondation Cancer","keywords":"Dove; Ovarian cancer; Prospective cohort study; Medicine; Gynecology; Oncology; Cancer; Internal medicine; Political science","score_opus":0.07418821961832656,"score_gpt":0.3901691244541551,"score_spread":0.3159809048358285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169429264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950971,0.00031588846,0.00020723073,0.00049665105,0.00002192715,0.00037668773,0.0023165066,0.000009616425,0.0011583925],"genre_scores_gemma":[0.99372745,0.00051166967,0.00091852347,0.0002566646,0.000024739555,0.0005791743,0.0030384704,0.000012752039,0.00093047397],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99838114,0.00089818856,0.000121043275,0.0001955479,0.0002448978,0.00015910322],"domain_scores_gemma":[0.9925902,0.003212398,0.0014721706,0.0007566498,0.0010412154,0.0009272984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027402225,0.0005743226,0.0007825505,0.00032405593,0.00062515005,0.00095245126,0.0008855391,0.00093675614,0.0020132086],"category_scores_gemma":[0.011142132,0.00052187603,0.00079938554,0.00096338254,0.00072903803,0.0008526979,0.0018819056,0.00087622425,0.0005335494],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008038699,0.001326467,0.96675307,0.00024148074,0.00015628937,0.0003570883,0.001622249,0.00014381406,0.0007220251,0.00007789695,0.0018439315,0.018717038],"study_design_scores_gemma":[0.001307599,0.002386694,0.9923268,0.00005282968,0.0001258939,0.00022413731,0.0019305645,0.00016830696,0.00016211456,0.00011186763,0.0011824297,0.000020776783],"about_ca_topic_score_codex":0.024860328,"about_ca_topic_score_gemma":0.030344877,"teacher_disagreement_score":0.024860328,"about_ca_system_score_codex":0.000811514,"about_ca_system_score_gemma":0.0023135298,"threshold_uncertainty_score":0.049431264},"labels":[],"label_agreement":null},{"id":"W2171655986","doi":"10.1016/s1470-2045(11)70117-6","title":"Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Breast cancer; Clinical trial; Protocol (science); Neoadjuvant therapy; Biopsy; Cancer; Blood collection; Oncology; Internal medicine; Medical physics; Surgery; Pathology; Alternative medicine; Emergency medicine","score_opus":0.1882908449813799,"score_gpt":0.41782961570556126,"score_spread":0.22953877072418136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171655986","genre_codex":"methods","genre_gemma":"protocol","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024618244,0.019255918,0.46168327,0.3115272,0.056003846,0.06702124,0.012184161,0.004337369,0.043368705],"genre_scores_gemma":[0.052967418,0.004569117,0.7012658,0.15962768,0.014218848,0.045837738,0.008817007,0.0012718618,0.011424551],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.61237884,0.24189232,0.08241828,0.014344219,0.03733508,0.011631191],"domain_scores_gemma":[0.2061369,0.3572507,0.09311762,0.15257621,0.15630229,0.03461622],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.5881908,0.002483245,0.005832922,0.010453892,0.0028956297,0.018263448,0.012157141,0.015931183,0.007949229],"category_scores_gemma":[0.5791826,0.006520602,0.008112061,0.010925434,0.008248153,0.013727335,0.013516577,0.025155794,0.0069695422],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015707744,0.0013353723,0.023216793,0.005801207,0.001333604,0.0009179792,0.0024771048,0.009457354,0.013158767,0.09197261,0.4175886,0.41703296],"study_design_scores_gemma":[0.01342339,0.008671442,0.0961014,0.010067082,0.0027123066,0.0017190222,0.0016003158,0.0101248985,0.019566515,0.057467766,0.7772331,0.0013127382],"about_ca_topic_score_codex":0.004935001,"about_ca_topic_score_gemma":0.007539405,"teacher_disagreement_score":0.4118092,"about_ca_system_score_codex":0.0072346954,"about_ca_system_score_gemma":0.047832202,"threshold_uncertainty_score":0.5078341},"labels":[],"label_agreement":null},{"id":"W2173158856","doi":"10.1016/s1470-2045(15)00197-7","title":"Classification of treatment-related mortality in children with cancer: a systematic assessment","year":2015,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; SickKids Foundation; London Health Sciences Centre; Pediatric Oncology Group; Hospital for Sick Children","funders":"National Institute for Health and Care Research","keywords":"Medicine; Systematic review; Cancer; Intensive care medicine; MEDLINE; Internal medicine; Political science","score_opus":0.1856014357122295,"score_gpt":0.477525115467459,"score_spread":0.2919236797552295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2173158856","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0038132928,0.994399,0.00020092352,0.00020457241,0.000096919364,0.00008950575,0.0010400356,0.000008345912,0.0001474229],"genre_scores_gemma":[0.11254797,0.88325906,0.0016138905,0.0006783366,0.00010943727,0.00030978658,0.0013584626,0.000012067922,0.00011102092],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9937395,0.0017877101,0.00260693,0.0006858246,0.0009849834,0.00019507992],"domain_scores_gemma":[0.9861355,0.008936237,0.0034559604,0.00029256646,0.00097442017,0.00020528592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006834132,0.0012549225,0.0061522042,0.0075188107,0.00036107024,0.0015395677,0.001351359,0.0010148474,0.0019127048],"category_scores_gemma":[0.025992936,0.0008710867,0.01653634,0.0071544885,0.0006172009,0.001370159,0.0018312617,0.0016888316,0.00013679756],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067510986,0.000045262936,0.05134275,0.6327991,0.19504714,0.000073488896,0.00046238693,0.0005468922,0.00017933876,0.00054598774,0.004002221,0.11428032],"study_design_scores_gemma":[0.0008963711,0.00036423557,0.09164461,0.3619061,0.52265507,0.00046593905,0.0007544963,0.00059391954,0.00023047383,0.001011722,0.019326728,0.00015031683],"about_ca_topic_score_codex":0.019614525,"about_ca_topic_score_gemma":0.05961896,"teacher_disagreement_score":0.019614525,"about_ca_system_score_codex":0.0030790998,"about_ca_system_score_gemma":0.0047725555,"threshold_uncertainty_score":0.03900069},"labels":[],"label_agreement":null},{"id":"W2185514522","doi":"10.1016/s1470-2045(15)00364-2","title":"Hypofractionation for prostate cancer and PROs","year":2015,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; Prostate; Oncology; Cancer; MEDLINE; Medical physics; General surgery; Internal medicine","score_opus":0.08919415730930157,"score_gpt":0.38333831448689665,"score_spread":0.29414415717759507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2185514522","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.65584266,0.30894125,0.003481093,0.0038395692,0.0013057959,0.001487749,0.006928419,0.00023448913,0.017938973],"genre_scores_gemma":[0.9829076,0.0088665215,0.0009663703,0.0016314158,0.00031260305,0.0009835291,0.002630167,0.000029378956,0.0016724212],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979347,0.0012569271,0.00018762665,0.00018744922,0.00033204042,0.00010130911],"domain_scores_gemma":[0.9987363,0.00051612285,0.00048797217,0.00012380129,0.000053984233,0.00008182141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031718882,0.0005189001,0.0010807455,0.00061105896,0.00021168886,0.00074367307,0.00033539903,0.00066484674,0.0060160663],"category_scores_gemma":[0.003289593,0.00013896449,0.0032651038,0.00087900175,0.00039447838,0.00067710935,0.0006282955,0.0015154702,0.00040805052],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36276665,0.0018310396,0.018660488,0.014421898,0.023011563,0.00009807932,0.00029933263,0.0064211483,0.0039290455,0.0030714397,0.010660018,0.55482936],"study_design_scores_gemma":[0.27593642,0.16557184,0.3788187,0.006271807,0.030942472,0.001854841,0.00026308442,0.005357868,0.006832751,0.019203385,0.1085628,0.00038397167],"about_ca_topic_score_codex":0.00033287582,"about_ca_topic_score_gemma":0.0007380068,"teacher_disagreement_score":0.0060160663,"about_ca_system_score_codex":0.0005984985,"about_ca_system_score_gemma":0.00046941126,"threshold_uncertainty_score":0.020125806},"labels":[],"label_agreement":null},{"id":"W2185554757","doi":"10.1016/s1470-2045(15)00166-7","title":"Response assessment after stereotactic body radiotherapy for spinal metastasis: a report from the SPIne response assessment in Neuro-Oncology (SPINO) group","year":2015,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":249,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Sunnybrook Health Science Centre; University of British Columbia; University of Toronto; University Health Network; Centre hospitalier universitaire de Québec; Toronto Western Hospital; Université Laval","funders":"Genentech; Elekta; Novartis; Sigma-Tau Pharmaceuticals; Varian Medical Systems; Spectrum Pharmaceuticals; Merck","keywords":"Medicine; Modalities; Radiosurgery; Clinical trial; Radiation oncology; Medical physics; Oncology; Radiation therapy; Radiology; Internal medicine","score_opus":0.13831410719411144,"score_gpt":0.489116862030939,"score_spread":0.35080275483682755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2185554757","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019555178,0.99933165,0.000036446934,0.00017960882,0.00006674923,0.000009368017,0.00002781187,0.000002093425,0.00015070887],"genre_scores_gemma":[0.0024851535,0.99648476,0.00020870795,0.00052405614,0.00007510305,0.000017383498,0.00007311939,0.000002395273,0.00012939163],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99935406,0.00016390535,0.00015439124,0.0000833386,0.00020375739,0.000040522824],"domain_scores_gemma":[0.998009,0.0013862225,0.0002366351,0.000026578653,0.00029679673,0.000044730357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027055189,0.0005423871,0.002373089,0.0014380901,0.00015208102,0.0009614446,0.0009954894,0.00094280863,0.0013327758],"category_scores_gemma":[0.0039113443,0.00024988115,0.0015703398,0.0015979481,0.0003372136,0.0007803184,0.00061832345,0.0016606349,0.00034412445],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041450837,0.00005679791,0.0006505268,0.044324446,0.00086241803,0.00013067875,0.000090230045,0.00031415868,0.0005477823,0.00052761735,0.018468112,0.9336127],"study_design_scores_gemma":[0.0011824917,0.0012433223,0.019048419,0.083153725,0.009290951,0.0040241196,0.00038245213,0.00043841242,0.0014480855,0.0014905396,0.878133,0.00016454098],"about_ca_topic_score_codex":0.0033918559,"about_ca_topic_score_gemma":0.007991249,"teacher_disagreement_score":0.0033918559,"about_ca_system_score_codex":0.0011156593,"about_ca_system_score_gemma":0.0015316942,"threshold_uncertainty_score":0.014308274},"labels":[],"label_agreement":null},{"id":"W2190659314","doi":"10.1016/s1470-2045(15)00480-5","title":"Limited screening with versus without 18F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Daiichi Sankyo Europe; Daiichi-Sankyo; Agence Nationale de la Recherche","keywords":"Medicine; Occult; Venous thromboembolism; Open label; Radiology; Malignancy; Randomized controlled trial; Fluorodeoxyglucose; Positron emission tomography; Internal medicine; Pathology; Thrombosis; Alternative medicine","score_opus":0.17560773969901336,"score_gpt":0.40355915050439,"score_spread":0.22795141080537665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2190659314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95114964,0.01895552,0.0029379292,0.0023292478,0.0045812144,0.013637736,0.002209598,0.00031347026,0.003885589],"genre_scores_gemma":[0.972281,0.0056584734,0.0030025672,0.0017977945,0.0018999887,0.010150891,0.0011539971,0.000048853788,0.004006417],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99752,0.0012810675,0.00021664513,0.0005250876,0.00015193022,0.0003052105],"domain_scores_gemma":[0.99636626,0.001807171,0.00059216755,0.00037527515,0.00020244498,0.00065664214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034369295,0.0035387992,0.007923861,0.0007964867,0.0009582412,0.002218806,0.0019179463,0.0056710537,0.015036647],"category_scores_gemma":[0.0060532023,0.0019308976,0.0050135083,0.00089470134,0.004396801,0.0031478968,0.0011863422,0.005715747,0.002445916],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9945807,0.0016997743,0.00009491593,0.0005035686,0.0005694163,0.000016058697,0.000023046432,0.000076410375,0.00027485532,0.00004035643,0.00014029151,0.0019806419],"study_design_scores_gemma":[0.9778106,0.020713015,0.00031343004,0.0000593098,0.0005476398,0.000012706064,0.000015126458,0.00011646255,0.000063696796,0.00013710189,0.00019913327,0.000011812549],"about_ca_topic_score_codex":0.0024772473,"about_ca_topic_score_gemma":0.0029244535,"teacher_disagreement_score":0.015036647,"about_ca_system_score_codex":0.0016629497,"about_ca_system_score_gemma":0.0014702779,"threshold_uncertainty_score":0.050302565},"labels":[],"label_agreement":null},{"id":"W2191219754","doi":"10.1016/s1470-2045(15)00465-9","title":"Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":410,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; McMaster University; Juravinski Cancer Centre","funders":"Janssen Research and Development","keywords":"Bendamustine; Medicine; Rituximab; Ibrutinib; Internal medicine; Chronic lymphocytic leukemia; Placebo; Oncology; Gastroenterology; Lymphoma; Leukemia; Pathology","score_opus":0.13129195784477976,"score_gpt":0.38503411858453745,"score_spread":0.2537421607397577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2191219754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848744,0.007065066,0.00073392724,0.00054917653,0.0010442387,0.00275928,0.00082935044,0.00018104195,0.001963501],"genre_scores_gemma":[0.98194087,0.0043854397,0.0015955664,0.001064877,0.00094579486,0.004092555,0.00096821034,0.000057532958,0.0049491194],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9989029,0.00055417727,0.00007125409,0.00020549662,0.00008288716,0.0001832764],"domain_scores_gemma":[0.9988299,0.0004020565,0.00022298393,0.00010508955,0.000067043926,0.00037285528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024106782,0.0028024951,0.0055225487,0.00085335504,0.00061886024,0.001625436,0.0018469917,0.0030357116,0.007239156],"category_scores_gemma":[0.0021961555,0.0015533431,0.0031137057,0.0006803245,0.0021958484,0.0018729782,0.0006992289,0.003790539,0.0017122722],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9921428,0.0025016668,0.000086607295,0.00025129723,0.0005324208,0.000011648281,0.00002072702,0.00010905995,0.001175599,0.000029352133,0.00013096482,0.0030077158],"study_design_scores_gemma":[0.9634883,0.0353038,0.00038904036,0.00001514474,0.00031211894,0.000008384292,0.000010660991,0.000120401564,0.00013510813,0.000050259332,0.00015751709,0.000009410374],"about_ca_topic_score_codex":0.0021127216,"about_ca_topic_score_gemma":0.0028149744,"teacher_disagreement_score":0.007239156,"about_ca_system_score_codex":0.0012113907,"about_ca_system_score_gemma":0.0011367108,"threshold_uncertainty_score":0.024217427},"labels":[],"label_agreement":null},{"id":"W2193716145","doi":"10.1016/s1470-2045(15)00464-7","title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":849,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; London Health Sciences Centre","funders":"Cilag; Onyx Pharmaceuticals; Amgen; Takeda Oncology; Spectrum Pharmaceuticals; Array BioPharma; Janssen Pharmaceuticals; Genentech; Celgene; Sanofi; Bristol-Myers Squibb; Chugai Pharmaceutical","keywords":"Carfilzomib; Medicine; Bortezomib; Dexamethasone; Multiple myeloma; Clinical endpoint; Internal medicine; Refractory (planetary science); Population; Tolerability; Interim analysis; Oncology; Surgery; Clinical trial; Adverse effect","score_opus":0.17996979241503736,"score_gpt":0.430217007053223,"score_spread":0.25024721463818567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2193716145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892279,0.004348198,0.0004488696,0.00088045304,0.00067278254,0.0019954327,0.0008623562,0.000081595135,0.001482406],"genre_scores_gemma":[0.9889577,0.0025445116,0.0011376797,0.0012563895,0.0007229033,0.0020253512,0.000939247,0.000021930258,0.0023943163],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988343,0.00066135015,0.000059042766,0.00017587403,0.00007716618,0.00019228058],"domain_scores_gemma":[0.99816716,0.00069435884,0.00033360496,0.00015310504,0.00008640549,0.00056530867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002791215,0.0021768906,0.0038977636,0.00055641227,0.0005658571,0.001540889,0.0011485503,0.0025316651,0.0068981065],"category_scores_gemma":[0.0025631408,0.0010149828,0.0031298762,0.0007061108,0.0020490394,0.0017518998,0.00067799015,0.0037336797,0.0010603444],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.99085253,0.0028341517,0.00024592923,0.00019657232,0.00047557103,0.000013955911,0.000029407036,0.00016691851,0.0008068974,0.000049132585,0.0002442997,0.0040847603],"study_design_scores_gemma":[0.94524914,0.052878458,0.00091797754,0.0000141865585,0.00029355666,0.000014389819,0.000019546762,0.00015087385,0.000098910576,0.000079053105,0.00027237853,0.000011548504],"about_ca_topic_score_codex":0.0021137302,"about_ca_topic_score_gemma":0.0037859143,"teacher_disagreement_score":0.0068981065,"about_ca_system_score_codex":0.0013081328,"about_ca_system_score_gemma":0.0013525467,"threshold_uncertainty_score":0.023076475},"labels":[],"label_agreement":null},{"id":"W2197280774","doi":"10.1016/s1470-2045(15)00250-8","title":"Fatigue and mortality: from description to action","year":2015,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Scopus; Lung cancer; Cancer; Quality of life (healthcare); Observational study; Internal medicine; Oncology; Family medicine; MEDLINE","score_opus":0.2718236066418764,"score_gpt":0.4084351184512572,"score_spread":0.1366115118093808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2197280774","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000074775824,0.0021573475,0.000024779263,0.9825575,0.014559404,0.0000032582057,0.0000178756,0.0000057758725,0.00059936376],"genre_scores_gemma":[0.0015457298,0.0020269628,0.00006992421,0.92055947,0.073881514,0.000021138725,0.000016035137,0.000010471265,0.0018689067],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9914613,0.0033512288,0.0012661023,0.0007872805,0.0021835186,0.00095066364],"domain_scores_gemma":[0.96493816,0.021063268,0.0028221507,0.00086911616,0.004825107,0.0054821814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0077547743,0.0012667303,0.0026548642,0.0014632341,0.0053048884,0.0071814805,0.0026065328,0.07360134,0.008959293],"category_scores_gemma":[0.07193918,0.0012803405,0.001978951,0.001246194,0.0066189757,0.009066062,0.0058242013,0.07253201,0.004857761],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035331617,0.00002171526,0.0003418237,0.000121200836,0.000020646914,0.00034171744,0.00018007278,0.000024554689,0.000045291257,0.0022802802,0.9881594,0.008427863],"study_design_scores_gemma":[0.0003958704,0.00014860339,0.0023143995,0.0031138272,0.00012286789,0.0015996572,0.001549285,0.00052493,0.0001743687,0.028463677,0.9614306,0.00016197987],"about_ca_topic_score_codex":0.010532678,"about_ca_topic_score_gemma":0.015141269,"teacher_disagreement_score":0.07360134,"about_ca_system_score_codex":0.007948891,"about_ca_system_score_gemma":0.010804777,"threshold_uncertainty_score":0.057673514},"labels":[],"label_agreement":null},{"id":"W2203645865","doi":"10.1016/s1470-2045(15)00029-7","title":"Metformin for pancreatic cancer","year":2015,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Metformin; Medicine; Pancreatic cancer; Diabetes mellitus; Internal medicine; Gemcitabine; Type 2 diabetes; Cancer; Oncology; Erlotinib; Placebo; Pharmacology; Endocrinology; Pathology","score_opus":0.06869754596636672,"score_gpt":0.3532410433157031,"score_spread":0.28454349734933637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2203645865","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003579644,0.011955737,0.000108771936,0.9363754,0.046730395,0.000014730301,0.0000598859,0.000027348558,0.0043697003],"genre_scores_gemma":[0.0041892873,0.007506604,0.00017231063,0.8631599,0.115390934,0.000037925332,0.000039071117,0.00001552912,0.009488512],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99800044,0.000569215,0.00019994001,0.0002408774,0.000746956,0.000242603],"domain_scores_gemma":[0.9963665,0.0019787822,0.00025677556,0.00015108161,0.00037396123,0.0008728915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034231513,0.0008466581,0.0012829248,0.0009059073,0.0021765656,0.002506994,0.001091046,0.02083698,0.0061508873],"category_scores_gemma":[0.015629051,0.0005105817,0.0011553311,0.0004596762,0.0022218577,0.0027641945,0.0018965238,0.02601682,0.0039018276],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015487924,0.00006118648,0.00039794322,0.000099261204,0.000033922537,0.0007275425,0.000036208807,0.000081909515,0.00015959491,0.0052831853,0.9595246,0.033439733],"study_design_scores_gemma":[0.00046729422,0.0002084609,0.0014729891,0.00059799483,0.00007196785,0.0010187555,0.00012948211,0.00040353122,0.0002280145,0.015939983,0.9794082,0.00005332236],"about_ca_topic_score_codex":0.002841619,"about_ca_topic_score_gemma":0.0076198503,"teacher_disagreement_score":0.02083698,"about_ca_system_score_codex":0.0027782447,"about_ca_system_score_gemma":0.0024970567,"threshold_uncertainty_score":0.020576835},"labels":[],"label_agreement":null},{"id":"W2209448786","doi":"10.1016/s1470-2045(15)00462-3","title":"Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":363,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; University of British Columbia; Princess Margaret Cancer Centre; Vancouver General Hospital; BC Children's Hospital; Université Laval; Hôpital de l'Enfant-Jésus; Child and Family Research Institute; BC Cancer Agency; Hôtel-Dieu de Québec; CancerCare Manitoba; Capital District Health Authority; University of Toronto; Dalhousie University; Royal Victoria Hospital; Centre hospitalier universitaire de Québec; McMaster University; Hôpital Maisonneuve-Rosemont; Juravinski Hospital","funders":"Canadian Institutes of Health Research; National Institutes of Health","keywords":"Anti-thymocyte globulin; Medicine; Transplantation; Internal medicine; Graft-versus-host disease; Clinical endpoint; Gastroenterology; Globulin; Immunosuppression; Randomized controlled trial; Surgery","score_opus":0.06285534341132204,"score_gpt":0.3304848937193195,"score_spread":0.26762955030799745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2209448786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901239,0.004523174,0.0006175733,0.00070589216,0.0008141689,0.0015203195,0.00047730107,0.00010148544,0.001116152],"genre_scores_gemma":[0.991026,0.0024531235,0.0010507355,0.0009330344,0.00050573365,0.0015383856,0.00054746214,0.000023103463,0.001922344],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993831,0.00035081757,0.000028080383,0.0001112042,0.000024814077,0.00010196344],"domain_scores_gemma":[0.99915147,0.00032715575,0.00013804721,0.00007182862,0.00003274752,0.00027879176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001369763,0.0021896763,0.004375491,0.00037294618,0.0004585257,0.0012578394,0.0010548306,0.0023038448,0.0065027755],"category_scores_gemma":[0.0015422549,0.0006572188,0.0024962435,0.0005371435,0.0019798384,0.0014856608,0.00043628656,0.0041012634,0.0011758326],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98914415,0.0026432434,0.00019205088,0.0003096228,0.00037674102,0.000021900592,0.000034495766,0.00018802186,0.001320435,0.000053939075,0.00025896807,0.0054564853],"study_design_scores_gemma":[0.9358319,0.06261359,0.0006005756,0.000022714872,0.00022183025,0.000017112841,0.000020029564,0.00017859768,0.00016103887,0.000118497934,0.00020241454,0.000011798692],"about_ca_topic_score_codex":0.00083818584,"about_ca_topic_score_gemma":0.0017177999,"teacher_disagreement_score":0.0065027755,"about_ca_system_score_codex":0.0008006739,"about_ca_system_score_gemma":0.0009449205,"threshold_uncertainty_score":0.021753967},"labels":[],"label_agreement":null},{"id":"W2210363578","doi":"10.1016/s1470-2045(15)00381-2","title":"Postmarket policy considerations for biosimilar oncology drugs","year":2015,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":64,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Biosimilar; Context (archaeology); Authorization; Business; Marketing authorization; Competition (biology); Interchangeability; Medicine","score_opus":0.240915421907452,"score_gpt":0.4804593703366855,"score_spread":0.23954394842923352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2210363578","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017908803,0.9925143,0.00023748266,0.0036907177,0.000721455,0.000009119585,0.0000277187,0.000008987854,0.002611201],"genre_scores_gemma":[0.0028885894,0.9865254,0.000607359,0.0065262197,0.0014246482,0.000021926828,0.000064944805,0.0000074701234,0.0019335214],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984158,0.0004500452,0.00018140126,0.00017218021,0.0006499358,0.0001305665],"domain_scores_gemma":[0.99344903,0.004713455,0.00083623675,0.00010406013,0.00073439674,0.00016281834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004882905,0.00069538254,0.001463682,0.0020017829,0.00038622023,0.0027309423,0.0013929058,0.0052344846,0.0073915613],"category_scores_gemma":[0.0081880335,0.00034859212,0.00090401206,0.0018427381,0.00143901,0.002631872,0.0011547002,0.0043775584,0.0016132663],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001431396,0.000069672504,0.0001655719,0.008523597,0.0000860623,0.0003246133,0.00007965764,0.00038576475,0.0009921512,0.01613659,0.07351649,0.8995767],"study_design_scores_gemma":[0.00004805081,0.000082517116,0.0005336658,0.0062924903,0.00008250468,0.00073220755,0.000057969188,0.000087594744,0.0003428819,0.0059429416,0.98577905,0.000018163948],"about_ca_topic_score_codex":0.001522731,"about_ca_topic_score_gemma":0.0031802487,"teacher_disagreement_score":0.0073915613,"about_ca_system_score_codex":0.0022649902,"about_ca_system_score_gemma":0.003228319,"threshold_uncertainty_score":0.025823534},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"split"},{"id":"W2219463573","doi":"10.1016/s1470-2045(15)00554-9","title":"TIME for a successful cancer vaccine in NSCLC?","year":2015,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Pembrolizumab; Nivolumab; Docetaxel; Oncology; Lung cancer; Internal medicine; Clinical trial; Chemotherapy; Clinical endpoint; Cancer; Immunotherapy; Phases of clinical research","score_opus":0.055105661926996514,"score_gpt":0.3677829949587555,"score_spread":0.312677333031759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2219463573","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016422855,0.003803453,0.000081897444,0.9830283,0.011801407,0.000004893896,0.000026442303,0.000014227422,0.0010752837],"genre_scores_gemma":[0.0037273776,0.0024647494,0.0002032669,0.9496841,0.04079262,0.000029265255,0.000032127315,0.000014696575,0.0030517222],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99463505,0.0020378155,0.00062708696,0.0004896884,0.001368727,0.0008415799],"domain_scores_gemma":[0.98647505,0.008514474,0.0010336881,0.0003830655,0.0011990478,0.0023947658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0072621587,0.0008354162,0.0021018183,0.00065097597,0.0030036604,0.004828008,0.0016130812,0.057629764,0.010012941],"category_scores_gemma":[0.040861223,0.00072285044,0.001769806,0.0003683643,0.004026289,0.007505091,0.003349021,0.043723788,0.006944584],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016834796,0.000066213586,0.0006004864,0.0001483532,0.000034726716,0.0010353172,0.00009781058,0.0001489905,0.0003086566,0.008712373,0.9604088,0.028269947],"study_design_scores_gemma":[0.00034828886,0.0002493858,0.0006109679,0.0006131104,0.000061697894,0.0012628403,0.00033838558,0.0004905699,0.00029604736,0.032085992,0.9635757,0.0000669225],"about_ca_topic_score_codex":0.0027363654,"about_ca_topic_score_gemma":0.0059860474,"teacher_disagreement_score":0.057629764,"about_ca_system_score_codex":0.005125508,"about_ca_system_score_gemma":0.005423367,"threshold_uncertainty_score":0.03840643},"labels":[],"label_agreement":null},{"id":"W2233483325","doi":"10.1016/s1470-2045(15)00515-x","title":"Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":424,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Cancer Research UK; North Carolina GlaxoSmithKline Foundation; Novartis; Celgene; Bayer Corporation; Bristol-Myers Squibb; AstraZeneca; F. Hoffmann-La Roche; Astellas Pharma US; Pfizer; Durham University; Abbott Laboratories","keywords":"Sunitinib; Everolimus; Renal cell carcinoma; Medicine; Oncology; Open label; Internal medicine; Phases of clinical research; Clinical trial","score_opus":0.0994465300835262,"score_gpt":0.3632002380958994,"score_spread":0.2637537080123732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2233483325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859844,0.0072200983,0.0005960468,0.0009879906,0.0007735297,0.0015535819,0.00092749804,0.00010731805,0.0018495907],"genre_scores_gemma":[0.98805773,0.0031752686,0.0011189898,0.0010445113,0.00034927906,0.0014508663,0.0009872894,0.000025432591,0.0037907322],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99924374,0.00044302168,0.00004059594,0.00012167051,0.00004644149,0.00010454321],"domain_scores_gemma":[0.99930537,0.00021211595,0.00016064408,0.000056159424,0.000041124746,0.0002245017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019465615,0.0020780514,0.0033360077,0.00034491188,0.0003973328,0.0011936363,0.0007601101,0.0018034307,0.006318668],"category_scores_gemma":[0.0016685273,0.00072369695,0.002631261,0.00037092916,0.0010740423,0.0017187798,0.00048129383,0.0033206993,0.000961675],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98289895,0.002083391,0.00043077132,0.0006372192,0.0013305901,0.00003720132,0.000050029783,0.00050061976,0.0012330717,0.00010877125,0.00070962874,0.009979674],"study_design_scores_gemma":[0.95542765,0.04112717,0.001337926,0.00003415839,0.0005628953,0.00004510026,0.000028640336,0.00034947135,0.00020139168,0.00020589386,0.0006641513,0.000015575684],"about_ca_topic_score_codex":0.00091775146,"about_ca_topic_score_gemma":0.002806541,"teacher_disagreement_score":0.006318668,"about_ca_system_score_codex":0.0008113768,"about_ca_system_score_gemma":0.0008268665,"threshold_uncertainty_score":0.021138012},"labels":[],"label_agreement":null},{"id":"W2239698670","doi":"10.1016/s1470-2045(15)00518-5","title":"Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":283,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"Sanofi; Amgen","keywords":"Enzalutamide; Bicalutamide; Prostate cancer; Medicine; Oncology; Internal medicine; Androgen receptor; Cancer","score_opus":0.09227178365285235,"score_gpt":0.4254760336601119,"score_spread":0.3332042500072595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2239698670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941498,0.0021141095,0.0004142474,0.00030981153,0.00025825505,0.0011210892,0.0004879451,0.00009276095,0.0010520631],"genre_scores_gemma":[0.99279046,0.0015902583,0.0008323331,0.00051059906,0.00031915843,0.0013063673,0.0005447905,0.00003482729,0.0020711713],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99924785,0.00045051583,0.000040330382,0.00011056064,0.00004931176,0.000101338184],"domain_scores_gemma":[0.9990578,0.00027799944,0.0001954898,0.00009132212,0.000050607425,0.00032680389],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013320271,0.0019052321,0.0034777133,0.0006213564,0.0004034202,0.0010501707,0.0010670343,0.0017106078,0.005916852],"category_scores_gemma":[0.0020168503,0.0010329413,0.0016281713,0.0005559211,0.0016569179,0.0015531753,0.0004530268,0.002906377,0.0009587913],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98673046,0.0036569587,0.00021363678,0.00020773042,0.0003599389,0.000014225042,0.0000298196,0.00021919017,0.0018774578,0.000036392015,0.00018175489,0.006472397],"study_design_scores_gemma":[0.9085338,0.0891855,0.0009856952,0.000011792688,0.00026375704,0.000019330999,0.000016308695,0.0002568471,0.00037142288,0.00007373756,0.00026622755,0.00001562574],"about_ca_topic_score_codex":0.0010085078,"about_ca_topic_score_gemma":0.001921472,"teacher_disagreement_score":0.005916852,"about_ca_system_score_codex":0.0007719028,"about_ca_system_score_gemma":0.0009095767,"threshold_uncertainty_score":0.019793868},"labels":[],"label_agreement":null},{"id":"W2243880855","doi":"10.1016/s1470-2045(15)00582-3","title":"Chemotherapy-induced vomiting in children: some progress, more questions","year":2016,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Nausea and vomiting management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Vomiting; Chemotherapy; Chemotherapy-induced nausea and vomiting; MEDLINE; Pediatrics; General surgery; Internal medicine; Antiemetic","score_opus":0.03916238553065602,"score_gpt":0.35188558386436525,"score_spread":0.3127231983337092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2243880855","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00036301743,0.012867042,0.000041792275,0.9757606,0.009822324,0.0000031693032,0.00003177209,0.000008957561,0.0011013325],"genre_scores_gemma":[0.005194315,0.026204946,0.0002509124,0.8523784,0.113961406,0.000016008931,0.00005134891,0.000025869344,0.001916725],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99728763,0.00094274344,0.00053641625,0.00026159862,0.00067968277,0.0002919663],"domain_scores_gemma":[0.98575956,0.0076994943,0.0018921942,0.0002917454,0.002220025,0.002137002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030286007,0.0006203709,0.0016686536,0.0006327396,0.0014484505,0.0032239077,0.0010835326,0.022086186,0.00518353],"category_scores_gemma":[0.02341735,0.0005748533,0.0012784306,0.0008288737,0.0030345786,0.0046688328,0.0015930108,0.030634936,0.002376866],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000088343746,0.00004307218,0.002606783,0.0004891323,0.00004645073,0.0029419383,0.0002550642,0.000120501834,0.00018983742,0.0034761801,0.94692564,0.04281701],"study_design_scores_gemma":[0.0003255229,0.000167129,0.0042972164,0.0033820183,0.00010007758,0.009819213,0.0012559685,0.00028706293,0.00016899007,0.011318791,0.96879464,0.000083372055],"about_ca_topic_score_codex":0.00668584,"about_ca_topic_score_gemma":0.013598834,"teacher_disagreement_score":0.022086186,"about_ca_system_score_codex":0.004438653,"about_ca_system_score_gemma":0.003911718,"threshold_uncertainty_score":0.032204807},"labels":[],"label_agreement":null},{"id":"W2261388716","doi":"10.1016/s1470-2045(16)00029-2","title":"Prophylactic dexamethasone for radiation-induced bone-pain flare – Authors' reply","year":2016,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Ottawa; Princess Margaret Cancer Centre; University of Calgary; Kingston General Hospital; Centre Hospitalier de l’Université de Montréal; Juravinski Hospital; Hôpital Maisonneuve-Rosemont; Cancer Care Ontario; Ontario Institute for Cancer Research; Grand River Hospital; Queen's University; McMaster University; Centre Hospitalier Universitaire de Sherbrooke; Sunnybrook Health Science Centre; Ottawa Hospital; CancerCare Manitoba; Health Sciences Centre","funders":"","keywords":"Medicine; Placebo; Dexamethasone; Internal medicine; Gastroenterology; Alternative medicine; Pathology","score_opus":0.07930828486497739,"score_gpt":0.36456867781310165,"score_spread":0.2852603929481243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2261388716","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00034437014,0.0024513076,0.000056244044,0.9729888,0.02304219,0.0000070514516,0.00005228915,0.000014500176,0.00104323],"genre_scores_gemma":[0.005306124,0.001877272,0.00013964597,0.93194693,0.05789566,0.000027704053,0.000034117802,0.000020572752,0.002751992],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997624,0.00080599915,0.000392287,0.00026420903,0.00061712466,0.00029640933],"domain_scores_gemma":[0.9921761,0.0047733756,0.0007633407,0.00022646162,0.0012325963,0.00082818285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024434566,0.0005676751,0.0016854329,0.00080619537,0.0017987774,0.00271008,0.0015371982,0.039753318,0.0052072653],"category_scores_gemma":[0.025750235,0.00067505846,0.0011485564,0.00068431254,0.0024047443,0.0029587073,0.0014217244,0.032734785,0.003765401],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012556995,0.000039610357,0.0011791849,0.000112639005,0.000044802946,0.0029953867,0.00015097191,0.0001220752,0.00017729087,0.0016227344,0.9838934,0.009536352],"study_design_scores_gemma":[0.0003494527,0.00014815129,0.002069603,0.00061832875,0.00009788114,0.0061857677,0.0006070589,0.00047329356,0.00045101688,0.007899086,0.98094213,0.0001582969],"about_ca_topic_score_codex":0.003198782,"about_ca_topic_score_gemma":0.004915758,"teacher_disagreement_score":0.039753318,"about_ca_system_score_codex":0.0028847393,"about_ca_system_score_gemma":0.0024467295,"threshold_uncertainty_score":0.02093041},"labels":[],"label_agreement":null},{"id":"W2264000214","doi":"10.1016/s1470-2045(15)00551-3","title":"Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":565,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Puma Biotechnology","keywords":"Neratinib; Medicine; Trastuzumab; Internal medicine; Breast cancer; Oncology; Placebo; Regimen; Cancer; Metastatic breast cancer; Adjuvant therapy; Gynecology; Pathology","score_opus":0.04734896813518842,"score_gpt":0.3900358492526455,"score_spread":0.3426868811174571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2264000214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791494,0.010992751,0.00096666114,0.0012506078,0.0011406696,0.0025635539,0.0013146811,0.00021694183,0.0024047075],"genre_scores_gemma":[0.98270345,0.005118908,0.0013781518,0.0015176336,0.00049584755,0.002419985,0.001422882,0.000038989267,0.0049041323],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99937063,0.00031253492,0.000044272252,0.00012025807,0.000039786042,0.000112471374],"domain_scores_gemma":[0.9993926,0.00016833359,0.00013912622,0.00006395531,0.000037288766,0.00019861764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018887212,0.0020481923,0.00392972,0.0003642701,0.0003985617,0.0011900319,0.0010400326,0.001955599,0.006115931],"category_scores_gemma":[0.0018132239,0.0006418989,0.0023980525,0.00044734016,0.0012236095,0.0017342477,0.0004992737,0.003699146,0.0011609243],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9839544,0.0018076351,0.00029833263,0.00080582465,0.001067818,0.000038660364,0.0000430554,0.00028335248,0.0014581569,0.00010842072,0.0007803575,0.0093540205],"study_design_scores_gemma":[0.9789948,0.019079393,0.0006909075,0.000024659625,0.0003318458,0.000030575793,0.00001609167,0.00015665682,0.00014823796,0.00012111759,0.00039453217,0.000011227585],"about_ca_topic_score_codex":0.0006303002,"about_ca_topic_score_gemma":0.0017768398,"teacher_disagreement_score":0.006115931,"about_ca_system_score_codex":0.00066215766,"about_ca_system_score_gemma":0.00074724463,"threshold_uncertainty_score":0.02045989},"labels":[],"label_agreement":null},{"id":"W2267333092","doi":"10.1016/s1470-2045(15)00386-1","title":"Rare cancers: a sea of opportunity","year":2016,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Queen's University; BC Cancer Agency","funders":"Institute of Cancer Research; Institut National Du Cancer","keywords":"Cancer; Histogenesis; Context (archaeology); Pathognomonic; Medicine; Bioinformatics; Biology; Oncology; Pathology; Internal medicine; Disease","score_opus":0.23402373160054568,"score_gpt":0.44630697736033387,"score_spread":0.21228324575978819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2267333092","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003407823,0.9957891,0.000051675037,0.0024163094,0.0011092335,0.0000018678825,0.00001396498,0.000006172186,0.0005776473],"genre_scores_gemma":[0.0006362411,0.99409384,0.0001665775,0.0024729862,0.0020216145,0.0000036193562,0.000026811913,0.0000031258996,0.00057504984],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99927515,0.00017919968,0.000090728194,0.00007756265,0.00029956774,0.00007777464],"domain_scores_gemma":[0.99710447,0.0018433039,0.0002825949,0.000057229183,0.0005054966,0.00020692227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001724758,0.0008548786,0.0023559052,0.0031225113,0.00051787583,0.0029146636,0.0010722833,0.0029887196,0.0075513823],"category_scores_gemma":[0.0033513058,0.00037112777,0.00086336886,0.0027298164,0.0011425458,0.004740527,0.0017026836,0.004052407,0.001985338],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009685063,0.000040611805,0.00023862717,0.019962808,0.0001348183,0.00027335918,0.00014496814,0.00028932487,0.00047253628,0.0073633716,0.18406017,0.7869225],"study_design_scores_gemma":[0.00002233515,0.000033886525,0.00035459493,0.009408334,0.000096840326,0.00065652886,0.0001581509,0.000056025023,0.000044841992,0.003213092,0.98593765,0.000017662578],"about_ca_topic_score_codex":0.0018088967,"about_ca_topic_score_gemma":0.005669599,"teacher_disagreement_score":0.0075513823,"about_ca_system_score_codex":0.0016158959,"about_ca_system_score_gemma":0.0028551342,"threshold_uncertainty_score":0.025261879},"labels":[],"label_agreement":null},{"id":"W2280894559","doi":"10.1016/s1470-2045(15)00560-4","title":"Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":741,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Cleveland Clinic; Memorial Sloan-Kettering Cancer Center","keywords":"Medicine; Oncology; Cancer; Cohort; Stage (stratigraphy); Internal medicine; Hazard ratio; Proportional hazards model; Confidence interval","score_opus":0.04022950691569897,"score_gpt":0.3569615610435162,"score_spread":0.3167320541278172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2280894559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99424237,0.00040005532,0.0018536276,0.00011763984,0.00011874082,0.00058271585,0.0022286784,0.000012730353,0.0004434256],"genre_scores_gemma":[0.98951447,0.00018792856,0.0033084669,0.00012159538,0.0000547647,0.0009359839,0.005209187,0.00004660532,0.00062102213],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99082714,0.0044206623,0.0007798952,0.0017530714,0.0011129288,0.0011063823],"domain_scores_gemma":[0.9889352,0.0017947684,0.0019662923,0.0033733633,0.0030215282,0.00090884324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02315683,0.0018638036,0.0016068522,0.0012766393,0.0022291362,0.0026928752,0.0024245924,0.0021595366,0.0016713955],"category_scores_gemma":[0.021864736,0.0017638248,0.00321716,0.0021615217,0.0013009302,0.002257177,0.0033220726,0.002126869,0.00084648066],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044837766,0.0006369654,0.9823141,0.0000891446,0.0015598318,0.00010483657,0.0014885857,0.00024943706,0.0015758867,0.00021574202,0.0018094297,0.0054721422],"study_design_scores_gemma":[0.0013646021,0.0026577548,0.9887636,0.00008223273,0.0019333502,0.00028989566,0.0013511578,0.0008845734,0.0004886397,0.00018192819,0.0019211984,0.000081169645],"about_ca_topic_score_codex":0.023429122,"about_ca_topic_score_gemma":0.026456902,"teacher_disagreement_score":0.023429122,"about_ca_system_score_codex":0.0019503679,"about_ca_system_score_gemma":0.0034010122,"threshold_uncertainty_score":0.122466505},"labels":[],"label_agreement":null},{"id":"W2289763126","doi":"10.1016/s1470-2045(16)00023-1","title":"DCIS and invasive interval breast cancer","year":2016,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital","funders":"","keywords":"Medicine; Breast cancer; Ductal carcinoma; Cancer; Incidence (geometry); Oncology; Population; Retrospective cohort study; Cohort; Cancer registry; Internal medicine; Gynecology","score_opus":0.13369203461183,"score_gpt":0.39356853282843784,"score_spread":0.25987649821660785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2289763126","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002723374,0.0022474169,0.00002580405,0.9744407,0.020194065,0.000007825733,0.00006098451,0.000007604421,0.002743284],"genre_scores_gemma":[0.0035308644,0.0031064497,0.00006503655,0.9053076,0.078573175,0.000029423949,0.000045809233,0.000015342503,0.009326342],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997638,0.00062736974,0.00033576068,0.0002248383,0.0007348516,0.00043925713],"domain_scores_gemma":[0.9927705,0.0037628973,0.0009368928,0.0002180304,0.0008332651,0.0014784429],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023605938,0.0007796799,0.0012909595,0.00079785555,0.0034453312,0.003970427,0.0012522282,0.059072975,0.011157401],"category_scores_gemma":[0.028567214,0.0009202137,0.0014904134,0.00076223945,0.0025413297,0.0033710315,0.002708033,0.040662948,0.006645742],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000066800036,0.000025762281,0.00089264516,0.00007839094,0.000016916181,0.0010442504,0.00011287423,0.00005341639,0.00011194094,0.002849184,0.9832091,0.011538843],"study_design_scores_gemma":[0.00029194396,0.00010058982,0.002086068,0.0010702866,0.00007655726,0.0024343112,0.00046682195,0.00042110292,0.00025381273,0.011599861,0.9811389,0.00005970274],"about_ca_topic_score_codex":0.008356082,"about_ca_topic_score_gemma":0.015418586,"teacher_disagreement_score":0.059072975,"about_ca_system_score_codex":0.0038940478,"about_ca_system_score_gemma":0.005417457,"threshold_uncertainty_score":0.037325203},"labels":[],"label_agreement":null},{"id":"W2290950904","doi":"10.1016/s1470-2045(15)00613-0","title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1822,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Calgary","funders":"University of California, Los Angeles; Novartis; Daiichi-Sankyo; Pfizer; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline; U.S. Department of Defense","keywords":"Fulvestrant; Palbociclib; Metastatic breast cancer; Medicine; Placebo; Internal medicine; Oncology; Gynecology; Cancer; Breast cancer; Estrogen receptor","score_opus":0.12359904773172471,"score_gpt":0.4149209742192354,"score_spread":0.2913219264875107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2290950904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96918833,0.015386181,0.0019289071,0.0013150548,0.0017637903,0.0052053626,0.0020144836,0.00038843352,0.0028094675],"genre_scores_gemma":[0.98280245,0.0047452096,0.0019505544,0.001082356,0.00057029084,0.0037429347,0.0010405343,0.00005032662,0.0040152743],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99908376,0.0005325862,0.00005834198,0.00014251421,0.000051089253,0.00013162624],"domain_scores_gemma":[0.9990283,0.00037945874,0.00022796539,0.000091095106,0.00005873504,0.00021442484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025164187,0.002579488,0.0039699217,0.00059877406,0.00040525262,0.0012918826,0.0013570673,0.0019182485,0.008257579],"category_scores_gemma":[0.0027156337,0.0007694033,0.0038398525,0.00054864626,0.0013872015,0.0015943432,0.0005516667,0.00348331,0.0012097498],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9918806,0.0006768257,0.00008925319,0.00055793836,0.00083202485,0.000013152308,0.000021360422,0.00017009344,0.0007900264,0.00005625146,0.00026299123,0.0046494394],"study_design_scores_gemma":[0.98492765,0.013717166,0.00039250616,0.000024932166,0.00037051147,0.000010632287,0.000010455836,0.00016692365,0.000099490986,0.00009213231,0.00017939214,0.000008164335],"about_ca_topic_score_codex":0.0016523502,"about_ca_topic_score_gemma":0.0035371666,"teacher_disagreement_score":0.008257579,"about_ca_system_score_codex":0.0010710766,"about_ca_system_score_gemma":0.0010294974,"threshold_uncertainty_score":0.027624309},"labels":[],"label_agreement":null},{"id":"W2295354328","doi":"10.1016/s1470-2045(15)00614-2","title":"Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":470,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Ignyta; National Institutes of Health; University of Washington; Astex Pharmaceuticals; Eli Lilly and Company; Novartis Institutes for BioMedical Research; Ariad Pharmaceuticals; Genentech; Pfizer; Novartis Pharmaceuticals Corporation; Chugai Pharmaceutical; Servier; Universität Heidelberg","keywords":"Ceritinib; Crizotinib; Medicine; ALK inhibitor; Internal medicine; Anaplastic lymphoma kinase; Lung cancer; Oncology; Tyrosine-kinase inhibitor; Clinical trial; Cancer","score_opus":0.04046967010096525,"score_gpt":0.3862219429664884,"score_spread":0.3457522728655231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2295354328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9529435,0.038313244,0.00056018564,0.0013099273,0.00042224827,0.00042727287,0.0025981409,0.00016897889,0.0032565976],"genre_scores_gemma":[0.9885972,0.0055918144,0.0004890693,0.0008191311,0.00029173377,0.00017563076,0.0028889137,0.00003508889,0.0011116086],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9991541,0.0003807857,0.000064313725,0.00015684217,0.00011861467,0.00012527418],"domain_scores_gemma":[0.9983461,0.00056480046,0.0005948362,0.00010566418,0.00012257506,0.00026603878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030310508,0.0012265478,0.0029630149,0.00035390237,0.0003035282,0.001207069,0.00070814835,0.0013097491,0.0021920875],"category_scores_gemma":[0.0026456057,0.00036694552,0.0030561206,0.00043505747,0.0007380106,0.0017154132,0.00030555538,0.0030541862,0.00046063334],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7273095,0.0032017275,0.015962938,0.0039080107,0.010209536,0.00018501005,0.00022227135,0.004605023,0.010206178,0.000412207,0.010447518,0.21333002],"study_design_scores_gemma":[0.67352337,0.18957686,0.1005252,0.00044973395,0.011144124,0.0012781182,0.00018576597,0.0029281287,0.0048646997,0.0014169976,0.01392567,0.00018136458],"about_ca_topic_score_codex":0.0006678578,"about_ca_topic_score_gemma":0.0024562983,"teacher_disagreement_score":0.0030310508,"about_ca_system_score_codex":0.0011141245,"about_ca_system_score_gemma":0.00067333394,"threshold_uncertainty_score":0.016029894},"labels":[],"label_agreement":null},{"id":"W2295672901","doi":"10.1016/s1470-2045(15)00581-1","title":"Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":369,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University of Toronto; University of Calgary; McGill University; Centre Hospitalier Universitaire Sainte-Justine; Hospital for Sick Children","funders":"National Institute of Neurological Disorders and Stroke; National Institutes of Health; Deutsche Kinderkrebsstiftung; Hospital for Sick Children; Brain Tumour Foundation of Canada; St. Baldrick's Foundation; Dr. Mildred Scheel Stiftung für Krebsforschung; National Cancer Institute; University of Toronto; Canadian Institutes of Health Research; Pediatric Brain Tumor Foundation; Terry Fox Research Institute; Magyar Tudományos Akadémia; Alex's Lemonade Stand Foundation for Childhood Cancer; Merck; CURE Childhood Cancer; American Cancer Society","keywords":"Medulloblastoma; Medicine; Subgroup analysis; Radiation therapy; Oncology; Chemoradiotherapy; Internal medicine; Retrospective cohort study; Surgery; Confidence interval; Pathology","score_opus":0.02245403311570908,"score_gpt":0.34877826364288894,"score_spread":0.32632423052717985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2295672901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998075,0.00063660135,0.00027446522,0.00005398802,0.000010853974,0.0000053467975,0.00061445404,0.0000067967594,0.00032256494],"genre_scores_gemma":[0.9992367,0.000088449895,0.000095757154,0.000011219679,0.000010222954,0.0000026856958,0.00045505122,0.0000051422426,0.00009481988],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992894,0.00012782397,0.00006938714,0.0002487934,0.0000921175,0.0001724925],"domain_scores_gemma":[0.9986343,0.00025713377,0.00049289124,0.00029395436,0.00012313903,0.00019866499],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010675453,0.00041411747,0.00061619293,0.0008412336,0.0004196125,0.0008230979,0.0006374543,0.00042414726,0.0010708306],"category_scores_gemma":[0.0022057532,0.00042430963,0.001254061,0.0012262891,0.0004895852,0.0010003062,0.0007153398,0.00067296537,0.0002443765],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008446983,0.000016690507,0.9940222,0.000013214942,0.0005530569,0.00014208892,0.00006945562,0.00029710875,0.001147031,0.00006100966,0.00015960226,0.002673836],"study_design_scores_gemma":[0.0000118828775,0.00011807131,0.99657094,0.000007384772,0.00059279834,0.0005954128,0.00016977024,0.0008950697,0.00031100822,0.0001937327,0.0005214814,0.000012325626],"about_ca_topic_score_codex":0.0050851633,"about_ca_topic_score_gemma":0.011407826,"teacher_disagreement_score":0.0050851633,"about_ca_system_score_codex":0.00054106314,"about_ca_system_score_gemma":0.0006285656,"threshold_uncertainty_score":0.010111153},"labels":[],"label_agreement":null},{"id":"W2312262713","doi":"10.1016/s1470-2045(16)00010-3","title":"Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":478,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Mount Sinai Hospital","funders":"","keywords":"Nomogram; Soft tissue; Medicine; Resection; Retrospective cohort study; Surgical resection; Overall survival; Soft tissue sarcoma; Radiology; Pathology; Surgery; Oncology","score_opus":0.02897161080700858,"score_gpt":0.32198575573604044,"score_spread":0.2930141449290319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2312262713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958994,0.00028753528,0.0016766883,0.000025785226,0.000027902715,0.00013827773,0.0012743183,0.0000128317415,0.00065720786],"genre_scores_gemma":[0.9961635,0.00009199693,0.0008337393,0.000018747061,0.00001554515,0.00012809764,0.0025498131,0.00001568238,0.00018284211],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99464923,0.0020586338,0.00087798276,0.001068321,0.000914241,0.00043164933],"domain_scores_gemma":[0.97513926,0.011056288,0.0046054292,0.0051825065,0.0033047744,0.00071183464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014083153,0.0009167534,0.00097551075,0.0022684012,0.0006363283,0.001810803,0.001263019,0.0009757729,0.0011991468],"category_scores_gemma":[0.02347943,0.00063961494,0.0015648693,0.0019571315,0.0014207866,0.001225749,0.001926598,0.0009483475,0.00061908265],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074937055,0.0000895928,0.99431396,0.000037727983,0.00032988863,0.000068989015,0.00025768706,0.0003538412,0.00031023228,0.00006685471,0.00017520302,0.0032466163],"study_design_scores_gemma":[0.00013452026,0.0005988922,0.99240994,0.000035719666,0.0005364364,0.00055563945,0.00045002924,0.002657179,0.00066022866,0.00011224582,0.0018242123,0.000024907751],"about_ca_topic_score_codex":0.0019429058,"about_ca_topic_score_gemma":0.0022162474,"teacher_disagreement_score":0.014083153,"about_ca_system_score_codex":0.0008990699,"about_ca_system_score_gemma":0.0008917443,"threshold_uncertainty_score":0.0744797},"labels":[],"label_agreement":null},{"id":"W2319418820","doi":"10.1016/s1470-2045(16)00117-0","title":"Targeted therapy in BRAF-mutated lung adenocarcinoma","year":2016,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Adenocarcinoma; Targeted therapy; Cancer research; Lung; Oncology; Medicine; Adenocarcinoma of the lung; Internal medicine; Cancer","score_opus":0.031531213826955166,"score_gpt":0.2888015405649193,"score_spread":0.25727032673796413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2319418820","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003187043,0.020671422,0.0002708564,0.9419796,0.026915956,0.000027016667,0.00008193852,0.000044874378,0.0068211844],"genre_scores_gemma":[0.06270695,0.027549885,0.00094887684,0.7284988,0.15918942,0.00012401922,0.00012964632,0.000044246906,0.020808175],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994307,0.00015335134,0.00006311594,0.000057209072,0.00019084263,0.000104710656],"domain_scores_gemma":[0.9989203,0.0005874822,0.00009303716,0.00004944551,0.00010847426,0.00024129427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086625,0.00044996952,0.0009830203,0.0003981565,0.0009180103,0.0013947502,0.00067064253,0.013831344,0.0030617833],"category_scores_gemma":[0.0050768903,0.00038221432,0.0007884661,0.00025680044,0.0011817028,0.0013415572,0.00079574354,0.013373502,0.0018047609],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005825447,0.00015981754,0.0020293135,0.00027932596,0.00006274064,0.013044979,0.00009280499,0.00057850574,0.0024084907,0.007936031,0.8940492,0.07877627],"study_design_scores_gemma":[0.0010487004,0.00060228806,0.002684065,0.0004948405,0.00012883211,0.016368976,0.00016972348,0.0023914026,0.0021929212,0.03107492,0.9427843,0.000059137627],"about_ca_topic_score_codex":0.0010097125,"about_ca_topic_score_gemma":0.0031435995,"teacher_disagreement_score":0.013831344,"about_ca_system_score_codex":0.002125118,"about_ca_system_score_gemma":0.0009018913,"threshold_uncertainty_score":0.0154188275},"labels":[],"label_agreement":null},{"id":"W2326502592","doi":"10.1016/s1470-2045(15)00539-2","title":"Paediatric cancer stage in population-based cancer registries: the Toronto consensus principles and guidelines","year":2016,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Pediatric Oncology Group; Princess Margaret Cancer Centre; Hospital for Sick Children; University of Toronto","funders":"National Cancer Institute; Medical Research Council; Hospital for Sick Children; World Health Organization","keywords":"Medicine; Stage (stratigraphy); Population; Cancer; Incidence (geometry); Delphi method; Family medicine; Environmental health; Internal medicine; Computer science","score_opus":0.222017052685827,"score_gpt":0.47752872812394814,"score_spread":0.25551167543812114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2326502592","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011652468,0.9176073,0.010597406,0.054590795,0.0042129736,0.0013680614,0.005530669,0.00018059343,0.004746928],"genre_scores_gemma":[0.022711622,0.87553394,0.070357494,0.013552686,0.0024080258,0.0036540935,0.009605578,0.0001252472,0.0020513718],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.96535504,0.010893191,0.014571914,0.001902242,0.006373071,0.00090451544],"domain_scores_gemma":[0.94138974,0.02769065,0.010187045,0.001980843,0.01674981,0.0020017743],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.06696902,0.0020423343,0.007107367,0.012083445,0.0018749312,0.007170541,0.009780744,0.0052225776,0.0022083616],"category_scores_gemma":[0.088078626,0.0022316673,0.007290102,0.012849822,0.0028195907,0.00502237,0.0059640193,0.009141077,0.0009431361],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000291954,0.00012946044,0.017702824,0.09416912,0.0027827008,0.0003326914,0.0024637699,0.0026739505,0.00034911442,0.0235186,0.2360783,0.61950755],"study_design_scores_gemma":[0.000463174,0.00011995347,0.028314989,0.355654,0.0052180085,0.000888818,0.0015984464,0.0018644155,0.0006992602,0.01381925,0.59111154,0.00024816318],"about_ca_topic_score_codex":0.10279418,"about_ca_topic_score_gemma":0.15650563,"teacher_disagreement_score":0.93303096,"about_ca_system_score_codex":0.017912798,"about_ca_system_score_gemma":0.061770137,"threshold_uncertainty_score":0.35417026},"labels":[],"label_agreement":null},{"id":"W2329267790","doi":"10.1016/s1470-2045(16)00037-1","title":"Wernicke-Korsakoff syndrome in patients with cancer: a systematic review","year":2016,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Alcoholism and Thiamine Deficiency","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Disease; Pediatrics; Ataxia; Cancer; Psychiatry; Intensive care medicine; Internal medicine","score_opus":0.05493484664456953,"score_gpt":0.3811513260763749,"score_spread":0.3262164794318054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2329267790","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008210864,0.9986482,0.000025984791,0.000111538524,0.000063828986,0.000038264625,0.00018885589,0.000002474326,0.000099811],"genre_scores_gemma":[0.01636077,0.982757,0.00017262234,0.0003901341,0.00005284271,0.000060944567,0.00012495692,0.0000017746768,0.000079084435],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9987544,0.00030717856,0.00052834675,0.00015046044,0.00018706187,0.00007251505],"domain_scores_gemma":[0.99606305,0.002405957,0.0010877125,0.00006194505,0.00028905054,0.000092375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017163336,0.0009611053,0.005333516,0.004374255,0.00032193153,0.001192167,0.00096316915,0.0013260482,0.0038614115],"category_scores_gemma":[0.008570704,0.00071469723,0.005158608,0.005653694,0.00048098722,0.0011757296,0.0011457491,0.0009704355,0.00019732701],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004979671,0.000025319869,0.0029834423,0.9154684,0.02887954,0.00019576999,0.00015075796,0.00013277623,0.00024756708,0.00019231183,0.0034449259,0.047781195],"study_design_scores_gemma":[0.0012800765,0.00044429168,0.018877711,0.56775326,0.3659742,0.0012775103,0.0005732141,0.0001229627,0.00026135307,0.0005310241,0.042801447,0.00010295713],"about_ca_topic_score_codex":0.009409371,"about_ca_topic_score_gemma":0.033347268,"teacher_disagreement_score":0.009409371,"about_ca_system_score_codex":0.0014528669,"about_ca_system_score_gemma":0.0032977029,"threshold_uncertainty_score":0.018709183},"labels":[],"label_agreement":null},{"id":"W2332223853","doi":"10.1016/s1470-2045(15)00545-8","title":"Paediatric extracranial germ-cell tumours","year":2016,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; SickKids Foundation","funders":"Sparks; Cancer Research UK; Teenage Cancer Trust","keywords":"Germ cell; Medicine; Germ cell tumors; Risk stratification; Disease; Clinical trial; Oncology; Pediatrics; Pathology; Intensive care medicine; Internal medicine; Chemotherapy; Biology","score_opus":0.07173120171155324,"score_gpt":0.396332931647973,"score_spread":0.3246017299364198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2332223853","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000050159542,0.9986298,0.000028642613,0.00021458168,0.00023591766,0.000003582555,0.000024331353,0.000003588601,0.00080944406],"genre_scores_gemma":[0.000569342,0.99840397,0.00007956106,0.0002750355,0.000178479,0.0000036022984,0.000026699552,0.0000010156699,0.0004623291],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9997687,0.000042589345,0.00004506602,0.000029786137,0.000089092035,0.000024710678],"domain_scores_gemma":[0.99946505,0.0002851947,0.00012818069,0.000010755819,0.00007637138,0.00003438873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054465304,0.0007403966,0.0016643441,0.0024236655,0.00020033658,0.0010155728,0.00054967037,0.0008436679,0.006820424],"category_scores_gemma":[0.0012159166,0.0002836504,0.0005306939,0.0027709366,0.00038835386,0.0009484216,0.00078440394,0.0013043166,0.0015431606],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008306752,0.000024599622,0.00015760561,0.049463764,0.00020622426,0.00019218713,0.000057076828,0.0002983519,0.00054736674,0.0017238891,0.0495768,0.8976691],"study_design_scores_gemma":[0.000059893744,0.000053575066,0.0007381914,0.017605767,0.0004804446,0.0010777579,0.00006639301,0.0000505582,0.00014773208,0.0009936559,0.9787113,0.00001470835],"about_ca_topic_score_codex":0.0017612535,"about_ca_topic_score_gemma":0.0062179323,"teacher_disagreement_score":0.006820424,"about_ca_system_score_codex":0.0007483752,"about_ca_system_score_gemma":0.0015255292,"threshold_uncertainty_score":0.022816539},"labels":[],"label_agreement":null},{"id":"W2339311613","doi":"10.1016/s1470-2045(16)30033-x","title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1175,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Ottawa Hospital; McGill University","funders":"European Society for Medical Oncology; Boehringer Ingelheim","keywords":"Afatinib; Gefitinib; Medicine; Internal medicine; Lung cancer; Oncology; Population; Clinical endpoint; Randomized controlled trial; Epidermal growth factor receptor; Cancer","score_opus":0.04042620639566981,"score_gpt":0.40655069506489666,"score_spread":0.36612448866922687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339311613","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96809185,0.01771316,0.0010352914,0.0019780924,0.0021078875,0.003588949,0.0018488057,0.00030641208,0.0033295297],"genre_scores_gemma":[0.98380476,0.0052752355,0.0013179653,0.0014185098,0.0007005581,0.0025380421,0.001333908,0.000037804602,0.0035732617],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9989942,0.0005000847,0.00006712015,0.00020233305,0.00006572564,0.00017050975],"domain_scores_gemma":[0.99902225,0.00032731125,0.00019810049,0.00007016165,0.00007132019,0.00031090924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020212317,0.002557346,0.0056998343,0.0005523631,0.0004880276,0.0016789034,0.0014008757,0.003170215,0.007954195],"category_scores_gemma":[0.0024755816,0.0009701212,0.004581523,0.0004957592,0.0016494942,0.0022148476,0.0005165339,0.0047641336,0.0015219107],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9862153,0.0016576076,0.00025819265,0.00085981766,0.0012947195,0.000031391253,0.000035166995,0.0002842268,0.00083227304,0.00008889875,0.0007185132,0.007723949],"study_design_scores_gemma":[0.97646904,0.021755628,0.00045577358,0.000027858649,0.0004760611,0.000027496246,0.00001652364,0.00025595186,0.00009660816,0.00011076096,0.00029539692,0.000012913744],"about_ca_topic_score_codex":0.0012627869,"about_ca_topic_score_gemma":0.002909564,"teacher_disagreement_score":0.007954195,"about_ca_system_score_codex":0.0011140534,"about_ca_system_score_gemma":0.0011178831,"threshold_uncertainty_score":0.02660948},"labels":[],"label_agreement":null},{"id":"W2339943063","doi":"10.1016/s1470-2045(16)00080-2","title":"Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":259,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Princess Margaret Cancer Centre","funders":"Ariad Pharmaceuticals","keywords":"Ponatinib; Medicine; Imatinib; Internal medicine; Myeloid leukemia; Imatinib mesylate; Oncology; Clinical trial; Clinical endpoint; Nilotinib","score_opus":0.14917091176216268,"score_gpt":0.447745619994161,"score_spread":0.29857470823199833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339943063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9653817,0.01982013,0.0015826933,0.002511382,0.0013680209,0.0031592962,0.0016897814,0.00019526067,0.004291773],"genre_scores_gemma":[0.9821748,0.0070730434,0.0015878926,0.0017395221,0.00039271888,0.00249522,0.0013281753,0.000037003996,0.00317158],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9990864,0.00048328712,0.00006130119,0.00016060306,0.00006709012,0.000141354],"domain_scores_gemma":[0.9989629,0.00033734334,0.00023407406,0.000082694976,0.00005226845,0.0003306522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019462623,0.002114022,0.0037001814,0.00034245534,0.00042121296,0.0013985158,0.00094617234,0.0017420788,0.0065793702],"category_scores_gemma":[0.0026138644,0.00055398996,0.0028329152,0.0004846224,0.0014242445,0.0021765935,0.00065150874,0.00427088,0.001120925],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9686752,0.0016585459,0.00048045404,0.0012849256,0.0021072698,0.000067627254,0.00008095389,0.00059913367,0.001656066,0.00028033552,0.0013890656,0.02172039],"study_design_scores_gemma":[0.97763056,0.018884402,0.0010251142,0.00004778013,0.0005819194,0.0000823647,0.000033657427,0.00026803772,0.000143987,0.0003769967,0.0009069225,0.000018268885],"about_ca_topic_score_codex":0.00080792035,"about_ca_topic_score_gemma":0.0023186754,"teacher_disagreement_score":0.0065793702,"about_ca_system_score_codex":0.0009884142,"about_ca_system_score_gemma":0.0010526583,"threshold_uncertainty_score":0.022010207},"labels":[],"label_agreement":null},{"id":"W2344407614","doi":"10.1016/s1470-2045(16)00152-2","title":"Under-reporting of harm in clinical trials","year":2016,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Pharmacovigilance and Adverse Drug Reactions","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":112,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Queen's University","funders":"","keywords":"Medicine; Observational study; Harm; Clinical trial; Tolerability; Pharmacovigilance; Intensive care medicine; Clinical Practice; Adverse effect; Family medicine; Pharmacology; Internal medicine","score_opus":0.8462647241493233,"score_gpt":0.7183082145743631,"score_spread":0.1279565095749602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2344407614","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009868374,0.98857224,0.0035455122,0.003685222,0.0007672046,0.00012712875,0.00041103957,0.000050429047,0.0018543286],"genre_scores_gemma":[0.06464254,0.90603435,0.011864804,0.012416766,0.0029722978,0.00043891216,0.0007221582,0.00005675995,0.0008514127],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.8094066,0.10828016,0.038533524,0.009212241,0.0332978,0.0012696941],"domain_scores_gemma":[0.37696105,0.5245117,0.076052345,0.010262705,0.01100694,0.0012053498],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.1400078,0.0012703683,0.0070471726,0.005202515,0.0004133961,0.0051074666,0.0041254745,0.005778745,0.0053016134],"category_scores_gemma":[0.33441362,0.0012733035,0.006227079,0.005604328,0.0034984332,0.0051997844,0.003420426,0.0045379666,0.000581717],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011626893,0.00007233509,0.0061649345,0.15887582,0.011059545,0.00039230342,0.0005628994,0.0010947859,0.0004993375,0.008394855,0.015709518,0.796011],"study_design_scores_gemma":[0.002484423,0.0016934332,0.03643125,0.41820005,0.04856718,0.0071466994,0.0010780161,0.0033594917,0.0034781403,0.06820541,0.40894452,0.00041134685],"about_ca_topic_score_codex":0.0010573878,"about_ca_topic_score_gemma":0.0015399833,"teacher_disagreement_score":0.8599922,"about_ca_system_score_codex":0.002390679,"about_ca_system_score_gemma":0.0054025245,"threshold_uncertainty_score":0.74044085},"labels":[],"label_agreement":null},{"id":"W2344504503","doi":"10.1016/s1470-2045(16)00156-x","title":"Proton beam therapy for medulloblastoma","year":2016,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Radiation Therapy and Dosimetry","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Medulloblastoma; Proton therapy; Proton; Beam (structure); Medicine; Physics; Nuclear physics; Optics; Cancer research","score_opus":0.06182798544108919,"score_gpt":0.3657506457445373,"score_spread":0.3039226603034481,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2344504503","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007500922,0.0040050456,0.000115268056,0.9742241,0.016661739,0.00000990736,0.00005313652,0.000022503686,0.0041582054],"genre_scores_gemma":[0.018491488,0.00707714,0.00036698143,0.8867023,0.07198136,0.000035714114,0.00008596113,0.00006080694,0.015198285],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984439,0.0003869076,0.00020877813,0.0001477074,0.0005660859,0.00024669545],"domain_scores_gemma":[0.99695253,0.0016394758,0.00032967696,0.00012279293,0.000359932,0.00059552176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018638835,0.00050117524,0.0010303834,0.00064984715,0.0030172234,0.002235044,0.0012243167,0.03842926,0.005264497],"category_scores_gemma":[0.016361449,0.00065634656,0.0013093905,0.00061973266,0.002088826,0.0022884358,0.001997457,0.029020699,0.0028619205],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001242124,0.00003390271,0.0013681059,0.00014271152,0.00004752368,0.00871334,0.0002287197,0.0004406367,0.0005553547,0.006076433,0.9565049,0.025764165],"study_design_scores_gemma":[0.00021793434,0.00016780717,0.0024310572,0.00076204585,0.000111210225,0.013668315,0.000363764,0.0011462886,0.00087271136,0.027856827,0.9523336,0.00006838747],"about_ca_topic_score_codex":0.008138527,"about_ca_topic_score_gemma":0.022893617,"teacher_disagreement_score":0.03842926,"about_ca_system_score_codex":0.00563967,"about_ca_system_score_gemma":0.003837165,"threshold_uncertainty_score":0.040918887},"labels":[],"label_agreement":null},{"id":"W2346524736","doi":"10.1016/s1470-2045(16)00107-8","title":"Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":217,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Ottawa Hospital; Health Sciences Centre; University of Toronto","funders":"National Medical Research Council; Cancer Council Victoria; National Health and Medical Research Council; American Society for Radiation Oncology","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Radiation therapy; Population; Hormonal therapy; Internal medicine; Randomized controlled trial; Prostate-specific antigen; Cancer; Oncology","score_opus":0.03918470300119959,"score_gpt":0.34027947658870444,"score_spread":0.30109477358750486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2346524736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98310006,0.007338112,0.0009021204,0.0009622961,0.0012586331,0.002795877,0.00092252897,0.00020908691,0.0025112368],"genre_scores_gemma":[0.98796576,0.0026522619,0.0017042821,0.0011585322,0.0006478004,0.0022895774,0.000627398,0.000039109967,0.0029152867],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99914956,0.00045915967,0.00005365251,0.00015972057,0.000051236173,0.00012679286],"domain_scores_gemma":[0.99875295,0.00040286142,0.00031342162,0.000093379414,0.000044327582,0.0003930858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018507353,0.001723589,0.0028801647,0.0004806432,0.00041615774,0.0013679992,0.0010423576,0.0019343182,0.007649301],"category_scores_gemma":[0.002259674,0.00073702465,0.0024219896,0.0005561938,0.0010556228,0.0011833891,0.00049182103,0.003893887,0.0012001764],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98566324,0.0020547675,0.00032164415,0.00030436192,0.00048720132,0.00001009727,0.00003351522,0.00028649287,0.0009065609,0.0000601453,0.00038659482,0.00948544],"study_design_scores_gemma":[0.9516457,0.046611607,0.00075130345,0.000022518057,0.00021577161,0.000016599659,0.000012707121,0.00017521043,0.00011452629,0.00014721013,0.00027528347,0.000011544472],"about_ca_topic_score_codex":0.0012883303,"about_ca_topic_score_gemma":0.0027713715,"teacher_disagreement_score":0.007649301,"about_ca_system_score_codex":0.00084281026,"about_ca_system_score_gemma":0.0013343387,"threshold_uncertainty_score":0.025589466},"labels":[],"label_agreement":null},{"id":"W2379981061","doi":"10.1016/s1470-2045(16)00163-7","title":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":874,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"European Society for Medical Oncology","keywords":"Pertuzumab; Docetaxel; Medicine; Trastuzumab; Clinical endpoint; Epirubicin; Internal medicine; Breast cancer; Oncology; Neoadjuvant therapy; Surgery; Cancer; Clinical trial","score_opus":0.0391025579184239,"score_gpt":0.3926124320995352,"score_spread":0.35350987418111135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2379981061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99222213,0.0035468948,0.00046633522,0.0007316092,0.00051818654,0.0006323385,0.0006910554,0.000049381288,0.0011420498],"genre_scores_gemma":[0.9907951,0.001767138,0.000780492,0.000913752,0.00049577036,0.00094259536,0.0015741265,0.000031088384,0.002699999],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983248,0.0009992654,0.000073903466,0.00024582463,0.000091569396,0.0002647072],"domain_scores_gemma":[0.99780744,0.00069550634,0.00047322855,0.00022217268,0.0001142158,0.0006875664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038641982,0.0024674477,0.0034245197,0.0004077828,0.00042402415,0.0017303795,0.0011310611,0.0022413384,0.005341908],"category_scores_gemma":[0.0032710726,0.000933811,0.003972881,0.00047073534,0.0015729235,0.002107309,0.0007905553,0.0044127037,0.0011001937],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9913191,0.0016959856,0.0006614439,0.00017325534,0.0010796571,0.00002540676,0.00003991152,0.00032268406,0.00089299824,0.00005777186,0.00028495514,0.0034467527],"study_design_scores_gemma":[0.91559786,0.07646539,0.0044145132,0.000040791492,0.0016781597,0.00004913462,0.000056607136,0.0006028629,0.00025456032,0.00023622661,0.0005730079,0.000030928146],"about_ca_topic_score_codex":0.0013393245,"about_ca_topic_score_gemma":0.0026891618,"teacher_disagreement_score":0.005341908,"about_ca_system_score_codex":0.0015213889,"about_ca_system_score_gemma":0.0011934959,"threshold_uncertainty_score":0.020436108},"labels":[],"label_agreement":null},{"id":"W2413013962","doi":"10.1016/s1470-2045(16)30240-6","title":"Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis","year":2016,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":180,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; McMaster University; University of British Columbia","funders":"H2020 European Research Council; National Center for Advancing Translational Sciences; Johns Hopkins University; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute for Health and Care Research; National Institute of Neurological Disorders and Stroke; Medical Research Council; University of Texas MD Anderson Cancer Center; National Cancer Institute; Academy of Medical Sciences; Cancer Research UK; Francis Crick Institute; European Commission","keywords":"Adenocarcinoma; Genome-wide association study; Barrett's oesophagus; Single-nucleotide polymorphism; Genetic association; SNP; Biology; Internal medicine; Medicine; Genetics; Cancer; Gene; Genotype","score_opus":0.21109433644482933,"score_gpt":0.4567632876625054,"score_spread":0.24566895121767607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2413013962","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17237534,0.80616724,0.007374968,0.001717105,0.000725614,0.00016578713,0.0100056995,0.0002803427,0.00118789],"genre_scores_gemma":[0.9202891,0.06895847,0.0037575152,0.00094312837,0.0003581685,0.00026705893,0.004858597,0.00013763005,0.00043041422],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9882315,0.005895396,0.0016156267,0.002675705,0.0009756488,0.0006061915],"domain_scores_gemma":[0.9785331,0.015436934,0.001880834,0.0025056666,0.0010850027,0.00055848627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014215708,0.0023022878,0.008386245,0.005032213,0.0011444123,0.003362107,0.0018551464,0.002013791,0.0032967597],"category_scores_gemma":[0.019087827,0.0011925072,0.03569839,0.009909804,0.00064360804,0.0011741656,0.001949533,0.0024228804,0.0003523247],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003221307,0.000030868992,0.15228276,0.012206216,0.8188926,0.0004563699,0.00008689028,0.0016930475,0.0011871697,0.00018677913,0.0013160172,0.008439914],"study_design_scores_gemma":[0.0003591985,0.00020417715,0.11659375,0.0014256195,0.87646264,0.00038886612,0.00009875312,0.0012470225,0.00029831438,0.00055105967,0.00232705,0.000043604778],"about_ca_topic_score_codex":0.007451194,"about_ca_topic_score_gemma":0.011841789,"teacher_disagreement_score":0.014215708,"about_ca_system_score_codex":0.0010272778,"about_ca_system_score_gemma":0.0013397136,"threshold_uncertainty_score":0.07518077},"labels":[],"label_agreement":null},{"id":"W2415950182","doi":"10.1016/s1470-2045(16)30107-3","title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":939,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Exelixis; Memorial Sloan-Kettering Cancer Center","keywords":"Cabozantinib; Everolimus; Meteor (satellite); Renal cell carcinoma; Medicine; Open label; Oncology; Internal medicine; Clinical trial; Astronomy; Physics","score_opus":0.16141156173900909,"score_gpt":0.39215930367378826,"score_spread":0.23074774193477918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2415950182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828363,0.011360413,0.0004693202,0.0009550922,0.00045551755,0.0009866429,0.0009803876,0.00010967456,0.0018467226],"genre_scores_gemma":[0.988308,0.0046743276,0.0012920542,0.0009627148,0.00036962374,0.0009688183,0.001132164,0.000030954357,0.0022614242],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99956113,0.00022963944,0.000030779407,0.00006766051,0.00003706295,0.00007375658],"domain_scores_gemma":[0.9992099,0.00026143953,0.00017228627,0.000070708425,0.00004596511,0.00023971965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001338416,0.0011743171,0.0029187459,0.00023940389,0.00037075084,0.0010361118,0.0006039088,0.0011914603,0.0041788216],"category_scores_gemma":[0.001689906,0.00041561917,0.0021364854,0.0003142216,0.0007752244,0.0009912787,0.00034443132,0.0024998721,0.00065375236],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97734785,0.0012294506,0.00046753147,0.00062589813,0.0011611698,0.00004483953,0.000041608757,0.0003314476,0.001707844,0.00010149848,0.00084334594,0.016097613],"study_design_scores_gemma":[0.9617875,0.033705074,0.0020275225,0.00004394703,0.00067398563,0.00007396973,0.00002775458,0.00025534222,0.00030070462,0.00024502244,0.00084306154,0.000016142512],"about_ca_topic_score_codex":0.0011775049,"about_ca_topic_score_gemma":0.003142987,"teacher_disagreement_score":0.0041788216,"about_ca_system_score_codex":0.0007498886,"about_ca_system_score_gemma":0.00081652915,"threshold_uncertainty_score":0.013979554},"labels":[],"label_agreement":null},{"id":"W2418044106","doi":"10.1016/s1470-2045(16)00103-0","title":"The five Rs of chemotherapy","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Radiation Therapy and Dosimetry","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Radiation therapy; Radiosensitivity; Repopulation; Medicine; Radioresistance; Chemotherapy; Cancer research; Population; Cancer; Nuclear medicine; Oncology; Surgery; Stem cell; Internal medicine; Biology; Genetics","score_opus":0.027345301404987747,"score_gpt":0.34289696466038505,"score_spread":0.3155516632553973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2418044106","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005862781,0.21067879,0.011593036,0.5540843,0.028269365,0.00005702151,0.00033196373,0.00023740424,0.1888854],"genre_scores_gemma":[0.43977594,0.1844207,0.008218898,0.20382294,0.04873577,0.00025827598,0.00043843646,0.00044599743,0.11388315],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9904792,0.004910431,0.00051904167,0.0007738272,0.0025067173,0.00081083097],"domain_scores_gemma":[0.97782546,0.011731308,0.0014541451,0.0042399494,0.0027239884,0.00202514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0132278055,0.00075738644,0.0008962854,0.0018664036,0.0014924712,0.007261385,0.0016433641,0.005339393,0.01276823],"category_scores_gemma":[0.03751512,0.00055733346,0.0011412541,0.001277764,0.018412407,0.011002762,0.005232665,0.01308858,0.0027343181],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001864407,0.00003549755,0.00080666324,0.0002742069,0.000073928444,0.00010269735,0.00047812727,0.000677556,0.000246101,0.75935745,0.095329024,0.14243238],"study_design_scores_gemma":[0.000040911993,0.00010090082,0.00088005123,0.00047707174,0.000041319596,0.00024739842,0.0005273055,0.00029119567,0.00033053718,0.34532017,0.6517003,0.000042815136],"about_ca_topic_score_codex":0.003726041,"about_ca_topic_score_gemma":0.0037930645,"teacher_disagreement_score":0.0132278055,"about_ca_system_score_codex":0.0058387453,"about_ca_system_score_gemma":0.006762422,"threshold_uncertainty_score":0.06995618},"labels":[],"label_agreement":null},{"id":"W2461640426","doi":"10.1016/s1470-2045(16)30155-3","title":"Reducing radiation doses for breast tomosynthesis?","year":2016,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Digital Radiography and Breast Imaging","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre","funders":"","keywords":"Tomosynthesis; Medicine; Mammography; Digital Breast Tomosynthesis; Digital mammography; Breast cancer; Breast imaging; Medical physics; Nuclear medicine; Radiology; Breast cancer screening; Cancer; Internal medicine","score_opus":0.03716022325636447,"score_gpt":0.31847475284541304,"score_spread":0.28131452958904857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2461640426","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015459298,0.0033018386,0.00007613089,0.98901784,0.0055116755,0.0000032518788,0.000016302141,0.000011657115,0.0019066768],"genre_scores_gemma":[0.004075806,0.004082587,0.0004303179,0.9476743,0.039113797,0.000018325512,0.000027751357,0.000035452405,0.004541677],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99574983,0.0016104383,0.00050115987,0.00036361144,0.0013153922,0.00045960472],"domain_scores_gemma":[0.98339105,0.010287687,0.001415704,0.0005935749,0.0021323129,0.0021797318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057867994,0.00066165865,0.0011526424,0.0007206842,0.0017842182,0.0034265774,0.0017794153,0.049326,0.01770563],"category_scores_gemma":[0.046777923,0.00078803685,0.0015059493,0.0006384456,0.003075839,0.0046462873,0.0028624812,0.039081227,0.007989098],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002002117,0.00007760566,0.00092365645,0.00025610958,0.000049126727,0.0008433243,0.0001335273,0.00023989363,0.0005895159,0.008762965,0.92946523,0.058458798],"study_design_scores_gemma":[0.00019519315,0.00009333015,0.0008782783,0.0006031882,0.000050527302,0.001287751,0.00023195194,0.00022712137,0.0002845406,0.020687982,0.9754193,0.000040848856],"about_ca_topic_score_codex":0.0050435164,"about_ca_topic_score_gemma":0.013474701,"teacher_disagreement_score":0.049326,"about_ca_system_score_codex":0.0041739587,"about_ca_system_score_gemma":0.005919812,"threshold_uncertainty_score":0.05923122},"labels":[],"label_agreement":null},{"id":"W2462276505","doi":"10.1016/s1470-2045(16)30095-x","title":"Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":165,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Dalhousie University","funders":"Research for Patient Benefit Programme; North Bristol NHS Trust; Marie Curie; National Institute for Health and Care Research","keywords":"Medicine; Radiation therapy; Mesothelioma; Surgery; Randomized controlled trial; Incidence (geometry); Pleural disease; Adverse effect; Odds ratio; Clinical endpoint; Intention-to-treat analysis; Population; Internal medicine; Lung; Respiratory disease","score_opus":0.041873360183480306,"score_gpt":0.38633625637563057,"score_spread":0.34446289619215026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2462276505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9629021,0.014388942,0.0013746729,0.0010987686,0.0012945868,0.015901191,0.0011478212,0.0001382231,0.0017537588],"genre_scores_gemma":[0.96902937,0.0043962137,0.0035210534,0.0014155871,0.0008090996,0.018536638,0.00054033904,0.000021605227,0.0017302026],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979577,0.0013482863,0.00018604514,0.00024032903,0.00010798739,0.00015961222],"domain_scores_gemma":[0.9971656,0.0011777084,0.0008266181,0.00024039652,0.000125524,0.0004641338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00442373,0.0014741963,0.0031094577,0.0004493118,0.0004332939,0.0011059289,0.000938108,0.002506815,0.0061223693],"category_scores_gemma":[0.005646597,0.00058333547,0.0031307407,0.0005206361,0.0014605973,0.0009919599,0.00051137025,0.0023274545,0.0007050215],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9873849,0.0022331767,0.00037341774,0.0013242571,0.0008184766,0.00002440185,0.00005097329,0.00016716176,0.00083460414,0.00006993037,0.0002713601,0.0064471806],"study_design_scores_gemma":[0.95499367,0.043178204,0.0007113568,0.00008206862,0.0003928594,0.000020533167,0.000011659093,0.00011492284,0.00011604964,0.00008985144,0.00028090697,0.000007993011],"about_ca_topic_score_codex":0.00074803724,"about_ca_topic_score_gemma":0.0014405883,"teacher_disagreement_score":0.0061223693,"about_ca_system_score_codex":0.00079907215,"about_ca_system_score_gemma":0.0016956304,"threshold_uncertainty_score":0.02339518},"labels":[],"label_agreement":null},{"id":"W2464046943","doi":"10.1016/s1470-2045(16)30034-1","title":"Phosphenes in patients receiving radiotherapy","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean","funders":"","keywords":"Phosphene; Medicine; Radiation therapy; Ophthalmology; Retina; Neuroscience; Psychology; Stimulation; Surgery; Internal medicine","score_opus":0.026839031987170196,"score_gpt":0.327159132281375,"score_spread":0.3003201002942048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2464046943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82977486,0.12811674,0.00024990944,0.007426181,0.0004971034,0.000058491176,0.0021510972,0.000040428575,0.031685285],"genre_scores_gemma":[0.97010225,0.024519041,0.00019461072,0.0017406628,0.0003781701,0.000022813623,0.0010483104,0.0000064676706,0.0019877458],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997789,0.000052924494,0.000031288346,0.000027555654,0.000055002125,0.0000543619],"domain_scores_gemma":[0.99935967,0.00020042401,0.0002788352,0.000019183035,0.00004835205,0.00009344862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019293978,0.00012973111,0.00045149136,0.0003436435,0.0002962363,0.00069277507,0.00018852942,0.0005514914,0.0034576845],"category_scores_gemma":[0.0021581755,0.00012538665,0.0006232422,0.0010539999,0.00015711728,0.00040528743,0.0002348103,0.0012114616,0.00028649467],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068229856,0.00034659877,0.83924973,0.0011502561,0.0006724252,0.0020190475,0.00020394786,0.00019910754,0.0014751365,0.0008703473,0.0070220707,0.1399684],"study_design_scores_gemma":[0.0006471141,0.0017789464,0.96606445,0.0006476629,0.0013798374,0.006502909,0.00076598296,0.00026010355,0.0007052173,0.0017579811,0.019446092,0.000043701846],"about_ca_topic_score_codex":0.003933251,"about_ca_topic_score_gemma":0.0040933266,"teacher_disagreement_score":0.003933251,"about_ca_system_score_codex":0.00048762886,"about_ca_system_score_gemma":0.0006435234,"threshold_uncertainty_score":0.011567116},"labels":[],"label_agreement":null},{"id":"W2464196345","doi":"10.1016/s1470-2045(16)30065-1","title":"Prophylactic cranial irradiation for patients with lung cancer","year":2016,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prophylactic cranial irradiation; Neurocognitive; Brain metastasis; Lung cancer; Incidence (geometry); Oncology; Quality of life (healthcare); Internal medicine; Cancer; Lung; Radiation therapy; Surgery; Metastasis","score_opus":0.08109539761877588,"score_gpt":0.47817937414475764,"score_spread":0.39708397652598176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2464196345","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010590221,0.9994068,0.000011369589,0.00013888108,0.000064300235,0.0000044642698,0.0000228389,0.0000013940657,0.00024419342],"genre_scores_gemma":[0.0022827727,0.99714845,0.000056670335,0.00030258714,0.00008897472,0.00000853993,0.00002339382,8.088509e-7,0.00008781945],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9994074,0.00022484668,0.00014557745,0.000070241076,0.000117886586,0.000034042056],"domain_scores_gemma":[0.9979742,0.0015440393,0.00033406224,0.000030882933,0.00008015583,0.0000365917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013869512,0.00063829985,0.0018693267,0.0017632339,0.00015292778,0.0006917208,0.0007443637,0.0008539029,0.0059572784],"category_scores_gemma":[0.0051036277,0.00027762385,0.0013380877,0.0022440688,0.00044907007,0.0005383796,0.00053251575,0.0012053078,0.00035585463],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006626602,0.000040557486,0.0005175093,0.26779103,0.0028860099,0.000114573384,0.00006126399,0.00027348817,0.00045371125,0.0011463367,0.021078743,0.70497423],"study_design_scores_gemma":[0.0019581083,0.0009710177,0.010670714,0.30807173,0.03572915,0.0019444318,0.00028961615,0.00013647803,0.0010143864,0.002994958,0.6361484,0.000071010254],"about_ca_topic_score_codex":0.0034361929,"about_ca_topic_score_gemma":0.009348689,"teacher_disagreement_score":0.0059572784,"about_ca_system_score_codex":0.0011001608,"about_ca_system_score_gemma":0.0018680362,"threshold_uncertainty_score":0.019929051},"labels":[],"label_agreement":null},{"id":"W2468311487","doi":"10.1016/s1470-2045(16)30120-6","title":"Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":177,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Université de Sherbrooke","funders":"Canadian Cancer Society Research Institute; KWF Kankerbestrijding; Agenzia Italiana del Farmaco, Ministero della Salute; National Health and Medical Research Council; Cancer Research UK","keywords":"Medicine; Endometrial cancer; Chemoradiotherapy; Adjuvant; Oncology; Radiation therapy; Quality of life (healthcare); Open label; Internal medicine; Cancer; Clinical trial; Gynecology","score_opus":0.10892158562130659,"score_gpt":0.4203140416483053,"score_spread":0.3113924560269987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2468311487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98221946,0.0064081335,0.000790525,0.0009381,0.00038498442,0.006244473,0.0012568522,0.00009108315,0.0016662756],"genre_scores_gemma":[0.9767989,0.0029794998,0.002754662,0.0014014198,0.00047934172,0.0123979235,0.00125471,0.000028318447,0.0019052519],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981127,0.0014085169,0.00007973752,0.00017528166,0.00009437799,0.00012946848],"domain_scores_gemma":[0.99764353,0.000945786,0.0006329858,0.00017226457,0.00010070418,0.00050468114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004353531,0.0017827742,0.002696329,0.00043418742,0.00042595342,0.0009973575,0.0010969735,0.0021830893,0.006832081],"category_scores_gemma":[0.0040046195,0.00049136457,0.0031683922,0.0006092475,0.0014615887,0.0010196704,0.0006252799,0.0037538798,0.00063453865],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9851295,0.0038157015,0.00041242028,0.0005346573,0.00057024154,0.000029151986,0.00002810088,0.00037555685,0.0008268541,0.00006018966,0.000378502,0.007839169],"study_design_scores_gemma":[0.9317816,0.06594434,0.0009948702,0.000036125384,0.00032740404,0.000036182617,0.000010015788,0.00028220832,0.0001573237,0.00012320693,0.00029846135,0.000008240579],"about_ca_topic_score_codex":0.00059573003,"about_ca_topic_score_gemma":0.0011676791,"teacher_disagreement_score":0.006832081,"about_ca_system_score_codex":0.000996732,"about_ca_system_score_gemma":0.0013870358,"threshold_uncertainty_score":0.023023963},"labels":[],"label_agreement":null},{"id":"W2469109222","doi":"10.1016/s1470-2045(16)30097-3","title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":343,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of British Columbia; BC Cancer Agency","funders":"Genentech; F. Hoffmann-La Roche; Gilead Sciences","keywords":"Bendamustine; Obinutuzumab; Medicine; Rituximab; Internal medicine; Neutropenia; Population; Oncology; Surgery; Lymphoma; Chemotherapy","score_opus":0.055703202204740475,"score_gpt":0.36469524390968916,"score_spread":0.3089920417049487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2469109222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98956686,0.0052675796,0.00043917683,0.0007176099,0.0005830528,0.0014293422,0.0005370013,0.00006769078,0.0013916261],"genre_scores_gemma":[0.99109066,0.002613374,0.0008796647,0.00084164395,0.0003160876,0.0012925683,0.00069712015,0.000021095819,0.002247837],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994585,0.0002670453,0.000027079095,0.000097966535,0.000031534768,0.000117834395],"domain_scores_gemma":[0.99922884,0.00021114247,0.00016354243,0.00005398233,0.0000358311,0.00030659],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014736258,0.0020021067,0.0030427796,0.00039202347,0.00042571838,0.0014044463,0.0009566858,0.0016543446,0.00439697],"category_scores_gemma":[0.0015639873,0.000730012,0.0019451262,0.0004718283,0.0014463245,0.001485061,0.0005351857,0.0032811875,0.0008719712],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9847696,0.0027192675,0.00040596703,0.0004005253,0.00069978606,0.000031606865,0.000062278734,0.0002901805,0.001676845,0.000082916165,0.0003700308,0.008491029],"study_design_scores_gemma":[0.9582516,0.039347008,0.0010361134,0.000030105568,0.0003116592,0.000029083829,0.000028205015,0.00021703208,0.00019503171,0.00017286582,0.00036891742,0.000012411005],"about_ca_topic_score_codex":0.0011890382,"about_ca_topic_score_gemma":0.0026409482,"teacher_disagreement_score":0.00439697,"about_ca_system_score_codex":0.0010850205,"about_ca_system_score_gemma":0.00091240153,"threshold_uncertainty_score":0.014709353},"labels":[],"label_agreement":null},{"id":"W2480841917","doi":"10.1016/s1470-2045(16)30249-2","title":"Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":526,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Princess Margaret Cancer Centre; Hospital for Sick Children; University of Toronto","funders":"Foundation of Hope for Research and Treatment of Mental Illness; Hope Foundation","keywords":"Medicine; Asymptomatic; Observational study; Prospective cohort study; Colonoscopy; Pediatrics; Cancer; Colorectal cancer; Internal medicine","score_opus":0.03202712947594968,"score_gpt":0.3102890552416203,"score_spread":0.27826192576567066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2480841917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989717,0.0004248472,0.00005709294,0.00003935971,0.000006211584,0.0000055378955,0.00035663458,0.0000023337846,0.00013639641],"genre_scores_gemma":[0.9986872,0.00022973689,0.000053891516,0.00003398302,0.000012112594,0.0000072319535,0.00084847887,0.0000030504962,0.00012417308],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989518,0.00022267198,0.00013362656,0.00033580422,0.0001175305,0.0002386055],"domain_scores_gemma":[0.9966208,0.0006049028,0.001358623,0.0004813713,0.0004040658,0.0005301881],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013393997,0.0006698106,0.0010407016,0.0010889268,0.0010447861,0.0015783012,0.0008063798,0.0012306296,0.001172875],"category_scores_gemma":[0.0039608628,0.00091036694,0.0015422822,0.0020930097,0.0006297328,0.0015080436,0.00096909015,0.0015860858,0.00035396073],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052181777,0.0000990528,0.9978249,0.000009774091,0.00020431726,0.00028720405,0.00011001874,0.00003139714,0.00024271352,0.000015703998,0.00008432662,0.00056878524],"study_design_scores_gemma":[0.00004070245,0.00025711936,0.9979976,0.000011964843,0.00022633863,0.00071259786,0.00036356732,0.0001204421,0.000052753116,0.00003696882,0.0001658263,0.000014093648],"about_ca_topic_score_codex":0.014312644,"about_ca_topic_score_gemma":0.008508475,"teacher_disagreement_score":0.014312644,"about_ca_system_score_codex":0.0007677546,"about_ca_system_score_gemma":0.0007168285,"threshold_uncertainty_score":0.028458714},"labels":[],"label_agreement":null},{"id":"W2483834070","doi":"10.1016/s1470-2045(16)30173-5","title":"Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":291,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Cilag; Johnson and Johnson","keywords":"Medicine; Prostate cancer; Concomitant; Clinical trial; Lymph node; Asymptomatic; Radium-223; Cancer; Internal medicine; Oncology; Surgery; Bone metastasis","score_opus":0.16484752784240742,"score_gpt":0.44727528475559597,"score_spread":0.28242775691318855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2483834070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860243,0.00797617,0.00056156545,0.00082371925,0.0002960526,0.000881754,0.00083971897,0.00015104935,0.002445575],"genre_scores_gemma":[0.9872121,0.0048241974,0.0013451066,0.0010400902,0.00031964015,0.0009860791,0.0013957182,0.00006659062,0.0028104791],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994349,0.00029278809,0.00002703552,0.000099150006,0.000046816076,0.000099297715],"domain_scores_gemma":[0.9993143,0.00014027073,0.00016337339,0.00006996145,0.000031154676,0.00028091721],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013439935,0.0018699702,0.0031612646,0.00042740608,0.00045602373,0.0015836654,0.00085291895,0.0015545445,0.0042288117],"category_scores_gemma":[0.001213578,0.00073738326,0.0026366762,0.00066004635,0.0011686967,0.0011791454,0.00051913067,0.004168437,0.00104252],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9260575,0.009361817,0.0017446429,0.00068799476,0.0024920253,0.00007585686,0.00010808375,0.0010898478,0.005553288,0.0001683958,0.0018357525,0.050824676],"study_design_scores_gemma":[0.8657936,0.1234729,0.005502321,0.00006160268,0.0013200362,0.00018026469,0.000048022313,0.0008322475,0.0008063712,0.00027937893,0.0016604204,0.0000428343],"about_ca_topic_score_codex":0.0009527212,"about_ca_topic_score_gemma":0.0023705573,"teacher_disagreement_score":0.0042288117,"about_ca_system_score_codex":0.0007669565,"about_ca_system_score_gemma":0.001273138,"threshold_uncertainty_score":0.014146745},"labels":[],"label_agreement":null},{"id":"W2486629951","doi":"10.1016/s1470-2045(16)30206-6","title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","year":2016,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2995,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Multiple myeloma; Minimal residual disease; Medicine; Bone marrow; Myeloma protein; Clinical trial; Disease; Oncology; Monoclonal; Internal medicine; Monoclonal antibody; Immunology; Antibody","score_opus":0.18498453553729838,"score_gpt":0.47315065993772726,"score_spread":0.2881661244004289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2486629951","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005837761,0.9829705,0.0028382938,0.006184016,0.0013561684,0.001054248,0.0009768977,0.00007742318,0.0039587156],"genre_scores_gemma":[0.027458044,0.9124593,0.035216626,0.010911441,0.002228097,0.0044198777,0.0046103797,0.00007560513,0.002620622],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98938763,0.0038577118,0.0035280457,0.00047653238,0.0023749284,0.00037513158],"domain_scores_gemma":[0.981818,0.011401893,0.0028916197,0.00030347425,0.003216306,0.00036872088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020359622,0.0016718347,0.008345437,0.005463595,0.0008364171,0.003302782,0.0044076582,0.0027010492,0.0035273265],"category_scores_gemma":[0.031162597,0.00070316513,0.0066370717,0.0039924756,0.0017303044,0.001842911,0.0024070677,0.004147543,0.0012784128],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011089746,0.000134728,0.004589734,0.12692188,0.0035627335,0.0002381485,0.00041970253,0.0010850895,0.0007080137,0.0076931375,0.10166837,0.7518695],"study_design_scores_gemma":[0.002085608,0.00068307307,0.025395235,0.2171715,0.014105326,0.0023688339,0.0006840591,0.0017706106,0.0012996806,0.018826185,0.715267,0.00034277272],"about_ca_topic_score_codex":0.008423733,"about_ca_topic_score_gemma":0.013061568,"teacher_disagreement_score":0.020359622,"about_ca_system_score_codex":0.004842759,"about_ca_system_score_gemma":0.01080067,"threshold_uncertainty_score":0.10767323},"labels":[],"label_agreement":null},{"id":"W2498753998","doi":"10.1016/s1470-2045(16)30215-7","title":"Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin's lymphoma: an analysis from the St Jude Lifetime Cohort Study","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":179,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute","keywords":"Hodgkin lymphoma; Medicine; Cohort; Young adult; Pediatrics; Lymphoma; Gerontology; Cohort study; Demography; Internal medicine; Sociology","score_opus":0.025987212733697945,"score_gpt":0.2994177467544547,"score_spread":0.2734305340207568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2498753998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983304,0.00034648133,0.00005777462,0.000047650497,0.0000051992497,0.0000040439777,0.0010495558,0.0000021537605,0.000156716],"genre_scores_gemma":[0.998212,0.00035525212,0.0000543346,0.000027496282,0.000011376906,0.0000062172276,0.0011602319,0.0000026979671,0.00017042938],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997037,0.00006136434,0.000035927427,0.00008525431,0.0000444561,0.00006935225],"domain_scores_gemma":[0.99923885,0.0000772031,0.00026792067,0.00012663836,0.00008114616,0.00020825386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005081657,0.00026350096,0.00037554814,0.000703317,0.000386413,0.00061635714,0.00044759354,0.00052213075,0.0009587142],"category_scores_gemma":[0.0010900883,0.0004218571,0.000909812,0.0012292988,0.00018072646,0.00044818252,0.0007428352,0.00079497544,0.00016340798],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009385411,0.00001408242,0.99883956,0.0000045375855,0.00013062278,0.000059643025,0.000047613958,0.00003312787,0.00009913688,0.00001340113,0.00009682542,0.0005675752],"study_design_scores_gemma":[0.000003941219,0.000026892454,0.9995468,0.0000035200585,0.000049820268,0.00009074335,0.00010188789,0.00006471869,0.000011989979,0.0000068341533,0.000090662725,0.0000021661524],"about_ca_topic_score_codex":0.024432538,"about_ca_topic_score_gemma":0.033307232,"teacher_disagreement_score":0.024432538,"about_ca_system_score_codex":0.0003768814,"about_ca_system_score_gemma":0.00041306205,"threshold_uncertainty_score":0.048580647},"labels":[],"label_agreement":null},{"id":"W2504623699","doi":"10.1016/s1470-2045(16)30167-x","title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":924,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto","funders":"NIHR Oxford Biomedical Research Centre; National Institutes of Health; National Cancer Institute; National Institute for Health and Care Research; Bristol-Myers Squibb","keywords":"Brentuximab vedotin; Medicine; Nivolumab; Internal medicine; Oncology; Autologous stem-cell transplantation; Clinical endpoint; Transplantation; Lymphoma; Surgery; Clinical trial; Hodgkin lymphoma; Immunotherapy; Cancer","score_opus":0.033560026239753946,"score_gpt":0.3124283474722595,"score_spread":0.27886832123250554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2504623699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99385744,0.0031930385,0.0003813083,0.00041020705,0.00025106716,0.0006552062,0.00040315723,0.0000668402,0.0007818109],"genre_scores_gemma":[0.9944713,0.0013539001,0.0007964328,0.000636385,0.00012397501,0.00065306143,0.00063848926,0.000020508805,0.0013059546],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9993876,0.00031209644,0.000023511175,0.00010103486,0.00004079352,0.00013497399],"domain_scores_gemma":[0.9993986,0.00013151736,0.00008807069,0.00006753799,0.00003684324,0.00027750345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002077141,0.0017797218,0.0026722676,0.00033652873,0.00042151142,0.0013609818,0.0008265986,0.0013909142,0.0023616753],"category_scores_gemma":[0.0011091385,0.0005628341,0.0019835136,0.00033746412,0.0012154394,0.0014967866,0.0004482677,0.0030425075,0.0008402747],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9302389,0.0067252447,0.0025376666,0.0005300156,0.0022393828,0.000089998,0.00013047001,0.0013073414,0.0044490616,0.00018082143,0.0013211861,0.05025004],"study_design_scores_gemma":[0.8980363,0.09297341,0.004916655,0.000047286816,0.0008084361,0.00011797541,0.00006824098,0.00080639665,0.00066960626,0.00039205645,0.0011285584,0.000035088804],"about_ca_topic_score_codex":0.00091316557,"about_ca_topic_score_gemma":0.0026858258,"teacher_disagreement_score":0.0026722676,"about_ca_system_score_codex":0.0013201036,"about_ca_system_score_gemma":0.0011363449,"threshold_uncertainty_score":0.010985136},"labels":[],"label_agreement":null},{"id":"W2505666614","doi":"10.1016/s1470-2045(16)30313-8","title":"Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":498,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary; Queen's University; University of Toronto; BC Cancer Agency","funders":"National Health and Medical Research Council; National Institute for Health and Care Research; Canadian Cancer Society Research Institute; Medical Research Council; National Cancer Institute; Krebsliga Schweiz; Cancer Research UK","keywords":"Temozolomide; Medicine; Glioma; Internal medicine; Radiation therapy; Chemotherapy; Oncology; Oligodendroglioma; Surgery; Gastroenterology; Astrocytoma","score_opus":0.05562643958390778,"score_gpt":0.38883921043138453,"score_spread":0.33321277084747675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2505666614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99377537,0.0018572751,0.00042967766,0.000397602,0.00027388294,0.0015183301,0.0006493445,0.000057699886,0.0010408066],"genre_scores_gemma":[0.9879038,0.0029182986,0.0012908442,0.0008775923,0.00038677914,0.0024892315,0.00094972923,0.00004246198,0.0031412854],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99938166,0.00038127255,0.000025872081,0.00007804925,0.000037122125,0.00009602528],"domain_scores_gemma":[0.9992151,0.0002535734,0.00016163272,0.00007206024,0.00003219259,0.00026541244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017653754,0.0016647055,0.0025832006,0.00050149683,0.00031934027,0.00095451524,0.0009076499,0.0014673698,0.0050109923],"category_scores_gemma":[0.0013042805,0.0006124355,0.0017081358,0.00060849276,0.0013512579,0.0009985442,0.00041726785,0.002799067,0.00095165253],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9734677,0.008468039,0.00039826293,0.0004031672,0.0006103595,0.00002683014,0.000068442496,0.00044240107,0.0024003512,0.000106307096,0.00075606717,0.012852033],"study_design_scores_gemma":[0.89322174,0.10290423,0.00200013,0.000025085048,0.0003919625,0.000026745738,0.000034119304,0.00036648198,0.0003312144,0.00016368492,0.00051665585,0.000017830389],"about_ca_topic_score_codex":0.001833134,"about_ca_topic_score_gemma":0.0036070154,"teacher_disagreement_score":0.0050109923,"about_ca_system_score_codex":0.00095240853,"about_ca_system_score_gemma":0.0012139435,"threshold_uncertainty_score":0.016763449},"labels":[],"label_agreement":null},{"id":"W2513951655","doi":"10.1016/s1470-2045(16)30214-5","title":"Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":541,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Dalhousie University","funders":"Medical Research Council; Deutsche Krebshilfe; Fonds Wetenschappelijk Onderzoek; Fonds De La Recherche Scientifique - FNRS; Bundesministerium für Bildung und Forschung; Norges Forskningsråd; Cancer Research UK; Academy of Finland; ZonMw; Deutsche Forschungsgemeinschaft; European Science Foundation; European Commission; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; National Cancer Institute; Sundhed og Sygdom, Det Frie Forskningsråd","keywords":"Osteosarcoma; Open label; Medicine; Chemotherapy; Oncology; Randomized controlled trial; Internal medicine; Pathology","score_opus":0.07297720028559644,"score_gpt":0.40048151067345056,"score_spread":0.3275043103878541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2513951655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9730924,0.017174117,0.00089716143,0.0010286551,0.0011379839,0.0040740124,0.0006002015,0.00009601351,0.0018994872],"genre_scores_gemma":[0.98389536,0.005321449,0.0016662367,0.0012536651,0.0007298392,0.0049999994,0.00053594663,0.000017979582,0.0015793947],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9985965,0.00091590435,0.00011209396,0.00018832112,0.00007322698,0.0001139313],"domain_scores_gemma":[0.9982992,0.00064009416,0.0005651457,0.00009777286,0.000084138344,0.00031362238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003219133,0.0014819828,0.003553132,0.00041584088,0.0003122176,0.001141917,0.00090702536,0.0018344903,0.005338868],"category_scores_gemma":[0.0035295447,0.00059086387,0.0026301863,0.0004888503,0.0010618105,0.0011628689,0.00050596945,0.0022334252,0.00047492151],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.99024206,0.0012796632,0.00030230885,0.0009461803,0.00074268883,0.000014333755,0.000022240583,0.00012259977,0.00061057025,0.000057830955,0.00017781857,0.0054816003],"study_design_scores_gemma":[0.96510583,0.032871015,0.00079717103,0.00006355029,0.00049283274,0.000014630051,0.000012529724,0.00016851416,0.00009693404,0.00008128508,0.00028787355,0.0000078125295],"about_ca_topic_score_codex":0.00056998094,"about_ca_topic_score_gemma":0.0013120183,"teacher_disagreement_score":0.005338868,"about_ca_system_score_codex":0.00068639836,"about_ca_system_score_gemma":0.0009509049,"threshold_uncertainty_score":0.017860353},"labels":[],"label_agreement":null},{"id":"W2514454733","doi":"10.1016/s1470-2045(16)30321-7","title":"EANO guidelines for the diagnosis and treatment of meningiomas","year":2016,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Meningioma and schwannoma management","field":"Medicine","cited_by":858,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute for Health and Care Research; CMC Microsystems; Merck KGaA; Boehringer Ingelheim; Roche; GlaxoSmithKline","keywords":"Medicine; Radiosurgery; Meningioma; Radiation therapy; Grading (engineering); Radiology","score_opus":0.4616444835712515,"score_gpt":0.5002393630257916,"score_spread":0.038594879454540154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2514454733","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000861368,0.99000007,0.00044129594,0.0036718645,0.0015885404,0.000051201136,0.00033799728,0.00004223012,0.0037806332],"genre_scores_gemma":[0.000643446,0.9911129,0.00170224,0.0031617985,0.00069467584,0.00007371992,0.0005242491,0.000010679311,0.0020763602],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986895,0.00026230307,0.00038233688,0.000108896806,0.0004511504,0.00010601348],"domain_scores_gemma":[0.9973007,0.0010188242,0.00061713596,0.000058451184,0.000852539,0.00015237676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017554656,0.0013264233,0.0020849938,0.005509211,0.00048251986,0.0016061012,0.0023311756,0.002837021,0.0074754492],"category_scores_gemma":[0.0048268945,0.00043531798,0.002218504,0.0031086048,0.00066796376,0.0013998916,0.0012826829,0.0028537363,0.0044480865],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012672013,0.00007404311,0.0002979209,0.029733196,0.00023598001,0.00024109692,0.00007375079,0.00046300874,0.0005835556,0.0035169523,0.19555923,0.7690945],"study_design_scores_gemma":[0.000062324645,0.000051428993,0.0008948994,0.0325359,0.000374105,0.00064809975,0.000049007853,0.0000686787,0.00013748826,0.002549279,0.96260417,0.000024692072],"about_ca_topic_score_codex":0.008218605,"about_ca_topic_score_gemma":0.017696103,"teacher_disagreement_score":0.008218605,"about_ca_system_score_codex":0.001964108,"about_ca_system_score_gemma":0.0063159177,"threshold_uncertainty_score":0.025007844},"labels":[],"label_agreement":null},{"id":"W2526176932","doi":"10.1016/s1470-2045(16)30305-9","title":"Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":133,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto","funders":"National Health and Medical Research Council; Medical Research Council; National Institute for Health and Care Research; Canadian Cancer Society Research Institute; European Organisation for Research and Treatment of Cancer; National Cancer Institute; Krebsliga Schweiz; Cancer Research UK","keywords":"Temozolomide; Medicine; Radiation therapy; Internal medicine; Glioma; Oligodendroglioma; Clinical endpoint; Quality of life (healthcare); Chemotherapy; Oncology; Randomized controlled trial; Surgery; Astrocytoma","score_opus":0.06117070943676122,"score_gpt":0.38973305534424574,"score_spread":0.3285623459074845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2526176932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969524,0.0010496391,0.00012354444,0.00021332748,0.00007338078,0.00064780616,0.00051103055,0.000015088778,0.000413802],"genre_scores_gemma":[0.99502665,0.00090985355,0.00038987317,0.00058688346,0.00015203744,0.0011674449,0.0011056424,0.000006992561,0.00065460714],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99932516,0.00040182294,0.00003250471,0.00008272757,0.000047930396,0.00010994273],"domain_scores_gemma":[0.99903107,0.00020671776,0.00022467265,0.0000915093,0.00005967386,0.0003863278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017468135,0.001781556,0.0021551698,0.0004120621,0.0004274845,0.00091168255,0.0007378257,0.0014578694,0.0026408213],"category_scores_gemma":[0.0012813343,0.00050929387,0.0025186446,0.0006391981,0.0011000512,0.0008711934,0.0005846892,0.0027327647,0.00058122596],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96198356,0.013297025,0.0064787655,0.00044532894,0.0018082736,0.00005317306,0.000121686135,0.00033369756,0.0017310112,0.000072842566,0.0009433114,0.01273137],"study_design_scores_gemma":[0.840197,0.13056964,0.02658667,0.000040543182,0.0011099281,0.000059440175,0.00009047239,0.000351531,0.0002648795,0.0001549968,0.00054285047,0.000031918815],"about_ca_topic_score_codex":0.0021303368,"about_ca_topic_score_gemma":0.0037826824,"teacher_disagreement_score":0.0026408213,"about_ca_system_score_codex":0.0008959468,"about_ca_system_score_gemma":0.00106485,"threshold_uncertainty_score":0.0092381835},"labels":[],"label_agreement":null},{"id":"W2529469085","doi":"10.1016/s1470-2045(16)30369-2","title":"International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer","year":2016,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":347,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McGill University","funders":"Institut National Du Cancer","keywords":"Medicine; Intensive care medicine; Venous thromboembolism; Cancer; Venous thrombosis; Thrombosis; Grading (engineering); Major bleeding; Internal medicine","score_opus":0.2379228769798971,"score_gpt":0.5208992725229508,"score_spread":0.28297639554305365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2529469085","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021376883,0.96268135,0.0023132171,0.021165231,0.0039306167,0.00058825186,0.001072958,0.0001353691,0.007899249],"genre_scores_gemma":[0.0019490889,0.9644933,0.015435606,0.011446748,0.0012613689,0.0009052127,0.0015615731,0.000040107938,0.0029070461],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9935313,0.0018459456,0.0023893733,0.00031882778,0.0016959005,0.00021868787],"domain_scores_gemma":[0.98105687,0.00904655,0.0036984903,0.00033500692,0.0053168084,0.0005463583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0072527765,0.0014638278,0.004342454,0.006067892,0.000880059,0.002416005,0.0042788847,0.0057381415,0.009541168],"category_scores_gemma":[0.022169705,0.0008577961,0.0045901975,0.005802667,0.0011720994,0.00174587,0.0016744043,0.005495463,0.0041106753],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018333511,0.00013724685,0.00047052282,0.063650616,0.00060374103,0.00023673793,0.000258821,0.00054781453,0.00049948326,0.005017941,0.27194273,0.65645105],"study_design_scores_gemma":[0.0004439188,0.00013467096,0.0022216358,0.12593116,0.0019154217,0.00072974793,0.00016662123,0.00029041804,0.00024139753,0.0052141296,0.8626344,0.00007650245],"about_ca_topic_score_codex":0.013824056,"about_ca_topic_score_gemma":0.023701722,"teacher_disagreement_score":0.013824056,"about_ca_system_score_codex":0.0032772212,"about_ca_system_score_gemma":0.015067836,"threshold_uncertainty_score":0.03835684},"labels":[],"label_agreement":null},{"id":"W2530874255","doi":"10.1016/s1470-2045(16)30491-0","title":"Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":216,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"Evans Medical Foundation; A. Alfred Taubman Medical Research Institute; Patient-Centered Outcomes Research Institute; V Foundation for Cancer Research; Prostate Cancer Foundation","keywords":"Medicine; Radiation therapy; Prostatectomy; Retrospective cohort study; Cohort; Prostate cancer; Androgen deprivation therapy; Oncology; Internal medicine; Clinical endpoint; Metastasis; Surgery; Cancer; Clinical trial","score_opus":0.028402166999602674,"score_gpt":0.33383297628999814,"score_spread":0.30543080929039546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2530874255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997147,0.00025492386,0.0015403508,0.00002389868,0.00001603339,0.000037292044,0.0006299728,0.000008210848,0.00034231224],"genre_scores_gemma":[0.99791783,0.00006298735,0.0008588849,0.000026104604,0.00001592644,0.000042449574,0.00084090896,0.000011459751,0.00022344952],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99735487,0.0008715379,0.0002750037,0.00074343145,0.0005013241,0.00025381055],"domain_scores_gemma":[0.9956989,0.0013432591,0.0010377337,0.0011917097,0.0005337315,0.00019462993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037246428,0.00035302303,0.0005900416,0.0013027262,0.00058173505,0.0009137226,0.0007686865,0.00049734523,0.0013194726],"category_scores_gemma":[0.0065295766,0.00036766243,0.00076051435,0.0015364878,0.0006293212,0.00047938744,0.0007170902,0.00043342944,0.00044969426],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012942048,0.00012294212,0.98791504,0.000020075951,0.00045357118,0.00010297397,0.00012543856,0.00037240074,0.003396829,0.00008715026,0.0001877814,0.005921695],"study_design_scores_gemma":[0.00008461034,0.0008339858,0.99203146,0.000008766647,0.0004731365,0.0006387486,0.00018371124,0.0015564882,0.0023575565,0.00015231708,0.0016643123,0.000015037083],"about_ca_topic_score_codex":0.0022568216,"about_ca_topic_score_gemma":0.002193572,"teacher_disagreement_score":0.0037246428,"about_ca_system_score_codex":0.000420485,"about_ca_system_score_gemma":0.00056752795,"threshold_uncertainty_score":0.019698083},"labels":[],"label_agreement":null},{"id":"W2534459715","doi":"10.1016/s1470-2045(16)30510-1","title":"Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards","year":2016,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":198,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada; University of British Columbia","funders":"Boehringer Ingelheim","keywords":"Clinical trial; Medicine; Quality of life (healthcare); Cancer; Quality (philosophy); Health care; Family medicine; Nursing","score_opus":0.7267668108285595,"score_gpt":0.577075975979053,"score_spread":0.14969083484950652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2534459715","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005373665,0.9726281,0.009945443,0.013686527,0.0013932922,0.00026827372,0.00063207984,0.000043150143,0.000865719],"genre_scores_gemma":[0.023856165,0.90966463,0.04339175,0.015739664,0.003581168,0.0017282668,0.0015011189,0.00015247225,0.00038476993],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.7462429,0.1942934,0.027638214,0.0055447407,0.024892464,0.0013882621],"domain_scores_gemma":[0.30090833,0.63819414,0.026643889,0.018112337,0.015132185,0.0010090241],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.29445475,0.0021303887,0.017453905,0.006726894,0.000591877,0.008827465,0.0064790514,0.006264325,0.003072272],"category_scores_gemma":[0.47807664,0.001317057,0.0109562855,0.010338155,0.005413995,0.009121978,0.004984601,0.015224682,0.00094507326],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008100711,0.000104140156,0.0045133666,0.14345711,0.019300992,0.00008510776,0.0005527401,0.0024287538,0.00037210571,0.033424824,0.024383623,0.7705672],"study_design_scores_gemma":[0.0018685353,0.00086930965,0.024335189,0.37229133,0.024965432,0.0005255216,0.0010221279,0.0031583267,0.0012486308,0.23666178,0.332702,0.00035175946],"about_ca_topic_score_codex":0.0033551224,"about_ca_topic_score_gemma":0.004867385,"teacher_disagreement_score":0.70554525,"about_ca_system_score_codex":0.0062160264,"about_ca_system_score_gemma":0.015721496,"threshold_uncertainty_score":0.8700629},"labels":[],"label_agreement":null},{"id":"W2536396512","doi":"10.1016/s1470-2045(16)30508-3","title":"Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":643,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; University of Ottawa; Ottawa Hospital","funders":"National Cancer Institute; AstraZeneca","keywords":"Osimertinib; Lung cancer; Medicine; Open label; Cancer; Oncology; Internal medicine; Adenocarcinoma; Clinical trial","score_opus":0.06472232217388303,"score_gpt":0.4461270129553907,"score_spread":0.3814046907815077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2536396512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926468,0.0020592983,0.00044382326,0.0003657614,0.00019555366,0.0013655291,0.0012018089,0.00009996919,0.0016214111],"genre_scores_gemma":[0.9861974,0.0026077966,0.0011604474,0.0009731709,0.00022356647,0.0017063238,0.002605241,0.0000539532,0.0044719605],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99958533,0.00015348977,0.000016993245,0.00008059953,0.00004155089,0.00012191284],"domain_scores_gemma":[0.999603,0.000056718993,0.000075170705,0.000041827185,0.000027591428,0.00019565618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016348012,0.0026092576,0.0026324687,0.00039796394,0.00044279319,0.0014661708,0.00078586396,0.0015261902,0.0038198754],"category_scores_gemma":[0.00071924645,0.00079655193,0.0021392584,0.0004988929,0.0011148572,0.0015983689,0.0003868459,0.0032093755,0.0011235381],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8969789,0.020548955,0.0035845258,0.0008601741,0.002161158,0.00017086657,0.00019087356,0.0018313337,0.017529842,0.00024696777,0.0033933432,0.05250306],"study_design_scores_gemma":[0.81895286,0.16772616,0.008059401,0.00002950567,0.00074825186,0.00018034916,0.000074948264,0.0009234325,0.0011260284,0.00025614258,0.0018809319,0.000041999247],"about_ca_topic_score_codex":0.0012829748,"about_ca_topic_score_gemma":0.004790141,"teacher_disagreement_score":0.0038198754,"about_ca_system_score_codex":0.0010923388,"about_ca_system_score_gemma":0.0011813454,"threshold_uncertainty_score":0.012778759},"labels":[],"label_agreement":null},{"id":"W2536769127","doi":"10.1016/s1470-2045(16)30532-0","title":"Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1086,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center","keywords":"Medicine; Oncology; Maintenance therapy; Clinical endpoint; Internal medicine; Systemic therapy; Radiation therapy; Lung cancer; Performance status; Progression-free survival; Targeted therapy; Chemotherapy; Cancer; Randomized controlled trial","score_opus":0.0456415097933536,"score_gpt":0.37584147898149683,"score_spread":0.3301999691881432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2536769127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920008,0.0032913391,0.0004318644,0.0003609992,0.00043443995,0.0017833471,0.000579542,0.0000763659,0.0010412559],"genre_scores_gemma":[0.99045277,0.002039376,0.00094608124,0.0005734758,0.0003589086,0.0022859373,0.0007793574,0.00002561087,0.002538429],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99928385,0.00033402533,0.000035715944,0.00016664267,0.000048222853,0.00013150752],"domain_scores_gemma":[0.99903286,0.00030374643,0.00020013368,0.000087008964,0.000054498792,0.00032177192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015868782,0.0018714275,0.0042942977,0.00049964484,0.00041665908,0.001034762,0.0013317442,0.0016751655,0.006299231],"category_scores_gemma":[0.0014945613,0.00063479604,0.0024205016,0.0005964703,0.0015726874,0.0013557599,0.0005622909,0.0035364458,0.00096254953],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9845746,0.0042037037,0.00032321826,0.00041937895,0.0005371881,0.00001625559,0.000043532968,0.00022222985,0.0012604763,0.00003880723,0.0002809825,0.008079618],"study_design_scores_gemma":[0.9265781,0.070575394,0.0017466628,0.00002345888,0.00038285842,0.000013946182,0.000024211602,0.0002334634,0.00015541265,0.000066402936,0.0001899326,0.000010184695],"about_ca_topic_score_codex":0.0019519086,"about_ca_topic_score_gemma":0.00452255,"teacher_disagreement_score":0.006299231,"about_ca_system_score_codex":0.0011289153,"about_ca_system_score_gemma":0.001024631,"threshold_uncertainty_score":0.021073043},"labels":[],"label_agreement":null},{"id":"W2539908888","doi":"10.1016/s1470-2045(16)30525-3","title":"Biochemical and imaging surveillance in Li-Fraumeni syndrome – Authors’ reply","year":2016,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Observational study; Medicine; Li–Fraumeni syndrome; Germline mutation; Internal medicine; Mutation; Genetics; Biology","score_opus":0.02532850457482967,"score_gpt":0.30306148105869074,"score_spread":0.2777329764838611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2539908888","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00034097958,0.0016824434,0.000048968297,0.9789342,0.018183107,0.0000049159175,0.00005245466,0.0000129037335,0.0007399163],"genre_scores_gemma":[0.005818989,0.0016069142,0.00015766476,0.9286348,0.06121288,0.00002786281,0.000045383076,0.000019972274,0.0024756305],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99759716,0.00081756344,0.00037915082,0.00032878708,0.0005322007,0.0003451335],"domain_scores_gemma":[0.98900837,0.006846254,0.0008557834,0.000345259,0.0016186526,0.0013256264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028903189,0.00063026807,0.0018171767,0.0009098913,0.0020155215,0.003113241,0.0015127064,0.047716647,0.00483559],"category_scores_gemma":[0.030114485,0.0008205403,0.0010879486,0.00072082056,0.002653278,0.003629842,0.0018482212,0.03915317,0.0037000757],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000082150036,0.000027195638,0.0019200026,0.0000775942,0.00003504259,0.0036790366,0.00017274132,0.00009547573,0.00017312857,0.0016042084,0.98498964,0.0071437443],"study_design_scores_gemma":[0.00033465392,0.00015954417,0.003171833,0.00073100324,0.00012078958,0.011642495,0.0010396639,0.000864445,0.0005211399,0.014758197,0.9664247,0.00023152013],"about_ca_topic_score_codex":0.002830841,"about_ca_topic_score_gemma":0.0039615342,"teacher_disagreement_score":0.047716647,"about_ca_system_score_codex":0.0023390828,"about_ca_system_score_gemma":0.0024529358,"threshold_uncertainty_score":0.01697129},"labels":[],"label_agreement":null},{"id":"W2547090839","doi":"10.1016/s1470-2045(16)30522-8","title":"Sarcoma and germ-line DICER1 mutations","year":2016,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; Jewish General Hospital","funders":"","keywords":"Sarcoma; Genetics; Biology; Proband; Cancer; Germline; Population; Gene; Mutation; Medicine; Pathology","score_opus":0.07094434047944337,"score_gpt":0.3597795450764759,"score_spread":0.28883520459703255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2547090839","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011345664,0.002084597,0.00009835981,0.9766366,0.014317002,0.000011098368,0.000084615516,0.0000136868,0.005619428],"genre_scores_gemma":[0.02706968,0.0050335852,0.0004696292,0.8741732,0.070655,0.000048563918,0.00011473924,0.000037060767,0.022398451],"study_design_codex":"not_applicable","study_design_gemma":"case_report","domain_scores_codex":[0.9985954,0.00043297233,0.00017003047,0.00014603182,0.000415634,0.0002400319],"domain_scores_gemma":[0.9977786,0.0011913547,0.00023181306,0.000080784914,0.000257652,0.00045985432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015826426,0.0006456579,0.0010539548,0.0005060589,0.00231161,0.00241619,0.00075165473,0.028551003,0.0055502327],"category_scores_gemma":[0.014980281,0.00057138375,0.0010021272,0.0005101006,0.0019447764,0.0020998907,0.0013287802,0.020941302,0.003312459],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015405823,0.00006402974,0.0025501763,0.000095460266,0.000041033465,0.016203564,0.00020068545,0.00026698655,0.00053320086,0.008096059,0.94910914,0.022685608],"study_design_scores_gemma":[0.00049599196,0.00019722737,0.00247768,0.00066753966,0.00011266059,0.031166855,0.00056027644,0.0017557816,0.00092171394,0.037633628,0.92392004,0.00009061101],"about_ca_topic_score_codex":0.003621868,"about_ca_topic_score_gemma":0.0078847855,"teacher_disagreement_score":0.028551003,"about_ca_system_score_codex":0.0029165307,"about_ca_system_score_gemma":0.0026075519,"threshold_uncertainty_score":0.02116102},"labels":[],"label_agreement":null},{"id":"W2548570873","doi":"10.1016/s1470-2045(16)30312-6","title":"21st century pharmacovigilance: efforts, roles, and responsibilities","year":2016,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":80,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Pharmacovigilance; Biosimilar; Medicine; Agency (philosophy); Patient safety; Under-reporting; Business; Adverse effect; Pharmacology; Health care; Political science","score_opus":0.08451045535989471,"score_gpt":0.4112558686540705,"score_spread":0.3267454132941758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2548570873","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006561048,0.9910603,0.00019986008,0.006923101,0.0007144362,0.0000035304106,0.000009274253,0.000011385311,0.0010125823],"genre_scores_gemma":[0.0010842147,0.9925087,0.0004603065,0.0041519925,0.0011261196,0.000007633154,0.00001974429,0.000004678726,0.00063655863],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975986,0.00067113986,0.00028446753,0.00020255664,0.0010465501,0.00019667843],"domain_scores_gemma":[0.9920101,0.004216774,0.0012185308,0.00017886977,0.0016366823,0.000739022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0079027405,0.0009894765,0.0014052725,0.002580428,0.00054370874,0.0035339647,0.0017151143,0.003982372,0.0041108723],"category_scores_gemma":[0.009035177,0.0003539852,0.00067518937,0.003338476,0.0021721686,0.004073516,0.002366884,0.0047673425,0.0016663839],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005930313,0.000036963804,0.0002792268,0.0072833267,0.00007629182,0.00014532908,0.0001817967,0.00019573515,0.00030874973,0.013284457,0.06185645,0.9162925],"study_design_scores_gemma":[0.000020639238,0.00004044633,0.00045206578,0.0070308857,0.000054762884,0.0006060563,0.00013507606,0.00006122387,0.00013292054,0.0070013944,0.9844432,0.0000213982],"about_ca_topic_score_codex":0.002067483,"about_ca_topic_score_gemma":0.0040367143,"teacher_disagreement_score":0.0079027405,"about_ca_system_score_codex":0.0031656136,"about_ca_system_score_gemma":0.007964145,"threshold_uncertainty_score":0.04179418},"labels":[],"label_agreement":null},{"id":"W2557127686","doi":"10.1016/s1470-2045(16)30579-4","title":"A common global risk stratification system for hepatoblastoma","year":2016,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Hepatoblastoma; Risk stratification; Medicine; Stratification (seeds); Oncology; Internal medicine","score_opus":0.05063985268760364,"score_gpt":0.34817495926777675,"score_spread":0.2975351065801731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557127686","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004873007,0.0008424115,0.00026138645,0.9880719,0.008958815,0.000009501264,0.00008565453,0.00001337355,0.001269551],"genre_scores_gemma":[0.01646614,0.0021304837,0.0018334549,0.8999593,0.07492902,0.00009957328,0.0002363509,0.000049199825,0.0042964206],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99210256,0.0039708754,0.0013005959,0.0005109892,0.0014222782,0.00069274806],"domain_scores_gemma":[0.9768506,0.012851722,0.0014684518,0.00101211,0.0053029666,0.0025141353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009241121,0.00060888985,0.0016307794,0.0011930503,0.0027483108,0.0030288934,0.0011846647,0.023027478,0.0036686829],"category_scores_gemma":[0.05342245,0.0007523449,0.0017506434,0.0010137646,0.0025754538,0.0029042691,0.0026795121,0.029247448,0.0030288787],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000116624746,0.00004382643,0.0067148986,0.00008753052,0.00005611856,0.0010797244,0.00024002962,0.00017738112,0.00024386999,0.006294134,0.9555208,0.029425064],"study_design_scores_gemma":[0.00068801595,0.00026335628,0.016965609,0.0022553152,0.00031658378,0.0044639697,0.001250471,0.0032890665,0.00069975894,0.056887943,0.9126801,0.00023980552],"about_ca_topic_score_codex":0.010069989,"about_ca_topic_score_gemma":0.019004177,"teacher_disagreement_score":0.023027478,"about_ca_system_score_codex":0.004803047,"about_ca_system_score_gemma":0.0052356543,"threshold_uncertainty_score":0.048872292},"labels":[],"label_agreement":null},{"id":"W2557305032","doi":"10.1016/s1470-2045(16)30625-8","title":"Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Hearing, Cochlea, Tinnitus, Genetics","field":"Neuroscience","cited_by":257,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; McMaster University","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Sodium thiosulfate; Clinical endpoint; Cisplatin; Hearing loss; Regimen; Ototoxicity; Phases of clinical research; Confidence interval; Randomized controlled trial; Clinical trial; Internal medicine; Audiology; Chemotherapy","score_opus":0.14479622522191735,"score_gpt":0.39017761747898005,"score_spread":0.2453813922570627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557305032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837901,0.0093736835,0.0007158804,0.0009948086,0.000838942,0.0018702974,0.00085847423,0.00016561661,0.0013922019],"genre_scores_gemma":[0.98891675,0.0037943644,0.0011008698,0.0008722677,0.00038084068,0.001891377,0.0006700156,0.000028819293,0.0023445725],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9992065,0.00041795947,0.000050928862,0.00015691787,0.000048489717,0.00011922425],"domain_scores_gemma":[0.9986191,0.00049964956,0.00029247848,0.00010054151,0.000080903636,0.00040724283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016540895,0.0019808137,0.0043256306,0.00048052456,0.0005040884,0.0012304268,0.0012359858,0.002525206,0.0058271596],"category_scores_gemma":[0.0024905102,0.00069742335,0.0031809835,0.0005106722,0.0015340567,0.0013601934,0.00046642747,0.004394439,0.0011043593],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.982202,0.002341618,0.0003139732,0.00067944516,0.0010690335,0.000032332173,0.000051415296,0.00028937703,0.0010801449,0.00008238393,0.0005440545,0.011314252],"study_design_scores_gemma":[0.94226223,0.055335365,0.000999851,0.00004683779,0.00048453236,0.000025466015,0.00002347633,0.00023135461,0.00016364764,0.00012036886,0.00029148703,0.000015341615],"about_ca_topic_score_codex":0.0019383286,"about_ca_topic_score_gemma":0.0035779148,"teacher_disagreement_score":0.0058271596,"about_ca_system_score_codex":0.0010354557,"about_ca_system_score_gemma":0.0011410154,"threshold_uncertainty_score":0.019493759},"labels":[],"label_agreement":null},{"id":"W2557666746","doi":"10.1016/s1470-2045(16)30559-9","title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1200,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; University Health Network","funders":"Cancer Research UK; Clovis Oncology; Ovarian Cancer Research Fund; Stand Up To Cancer; Healthway; U.S. Department of Defense; National Ovarian Cancer Coalition; Ovarian Cancer Research Fund Alliance; American Association for Cancer Research","keywords":"Open label; Oncology; Medicine; Internal medicine; Ovarian carcinoma; Platinum; Ovarian cancer; Clinical trial; Cancer; Chemistry","score_opus":0.14688348836785434,"score_gpt":0.4311228869311657,"score_spread":0.2842393985633114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557666746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9757085,0.011728101,0.0009870726,0.0015532306,0.00048801748,0.0017679653,0.0026821797,0.00040649046,0.004678438],"genre_scores_gemma":[0.9743536,0.005971343,0.0022364801,0.0025356903,0.0004154857,0.0020538145,0.0053938073,0.00010870216,0.006931029],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995245,0.00021131696,0.000015661932,0.00009241849,0.0000408014,0.00011545142],"domain_scores_gemma":[0.9993293,0.00015564935,0.00011067073,0.00007922612,0.000034427143,0.00029076132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019095333,0.0016096431,0.0025508702,0.00039159055,0.0003098634,0.0012379363,0.0010141946,0.0016248695,0.00538216],"category_scores_gemma":[0.0013358772,0.0004909491,0.0017668197,0.000427501,0.000804156,0.0013361285,0.0004292531,0.0046223584,0.0014362186],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7911469,0.020085823,0.002915731,0.00203434,0.0030611344,0.0002713131,0.00023718055,0.0031981897,0.0140079735,0.00063232187,0.011042366,0.15136668],"study_design_scores_gemma":[0.8638442,0.121653296,0.005008267,0.00007965576,0.00073780835,0.0003404723,0.00006198061,0.0015676589,0.001767188,0.0004324607,0.0044571324,0.000049803013],"about_ca_topic_score_codex":0.00079094345,"about_ca_topic_score_gemma":0.0024567905,"teacher_disagreement_score":0.00538216,"about_ca_system_score_codex":0.00081229926,"about_ca_system_score_gemma":0.0008818129,"threshold_uncertainty_score":0.018005073},"labels":[],"label_agreement":null},{"id":"W2558422895","doi":"10.1016/s1470-2045(16)30630-1","title":"Reducing cisplatin ototoxicity in children: some hope and many questions","year":2016,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children; SickKids Foundation","funders":"","keywords":"Ototoxicity; Medicine; Cisplatin; Amifostine; Etoposide; Hearing loss; Oncology; Audiology; Internal medicine; Chemotherapy","score_opus":0.0319433415984729,"score_gpt":0.3228738333002321,"score_spread":0.2909304917017592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2558422895","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020231481,0.004814106,0.00004772701,0.98682505,0.007281562,0.0000022070324,0.000020141239,0.000007894075,0.00079893565],"genre_scores_gemma":[0.004302082,0.008868076,0.00033417088,0.9162328,0.067425475,0.000015788646,0.00003357587,0.000021684245,0.0027662106],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99688643,0.0011126857,0.00048406923,0.00029413108,0.0008871603,0.00033563064],"domain_scores_gemma":[0.9856689,0.008131825,0.0010518401,0.0003137959,0.0026667006,0.0021669494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036397027,0.00069383223,0.0018186002,0.00052808964,0.0019274188,0.0032072498,0.0015541295,0.037239652,0.006251269],"category_scores_gemma":[0.028083919,0.00050550234,0.0013176816,0.0005194873,0.0035015014,0.005138514,0.001966668,0.039389715,0.003988745],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017717852,0.00007340796,0.0014420277,0.0002739203,0.000061937026,0.0022091847,0.0001559049,0.00027007918,0.00039229958,0.0049677086,0.9432533,0.04672307],"study_design_scores_gemma":[0.00038268726,0.00021623686,0.0014938297,0.0009765787,0.000072224866,0.0031999974,0.0005248573,0.00041922086,0.0003118218,0.019881263,0.9724334,0.00008796176],"about_ca_topic_score_codex":0.0052468074,"about_ca_topic_score_gemma":0.012827751,"teacher_disagreement_score":0.037239652,"about_ca_system_score_codex":0.0043535354,"about_ca_system_score_gemma":0.0039965673,"threshold_uncertainty_score":0.031587303},"labels":[],"label_agreement":null},{"id":"W2558674288","doi":"10.1016/s1470-2045(16)30572-1","title":"Relevance of randomised controlled trials in oncology","year":2016,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":117,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Queen's University; CancerCare Manitoba; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Randomized controlled trial; Relevance (law); Medicine; Clinical trial; Medical physics; Intensive care medicine; Surrogate endpoint; Clinical significance; Alternative medicine; MEDLINE; Physical therapy; Internal medicine; Pathology","score_opus":0.19916237634647957,"score_gpt":0.4003345978127974,"score_spread":0.20117222146631783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2558674288","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012747369,0.99360645,0.0006725622,0.003297498,0.0013752384,0.00017189668,0.0001593824,0.00001123946,0.00057826773],"genre_scores_gemma":[0.020222545,0.95556307,0.004049748,0.014652965,0.0036526779,0.0009956282,0.00024499695,0.000044663404,0.00057375536],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.8740092,0.08987437,0.018696247,0.005737691,0.010435584,0.0012469633],"domain_scores_gemma":[0.4408744,0.5263234,0.02045154,0.0050568134,0.006119231,0.0011746638],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.11755195,0.0020791653,0.019900035,0.004903444,0.0007475526,0.007971967,0.004917972,0.010904889,0.017011086],"category_scores_gemma":[0.4063568,0.0017020595,0.009835315,0.0068381927,0.004357224,0.007925368,0.0027146887,0.010841461,0.0013220531],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003988352,0.000100112375,0.00070782553,0.7105439,0.025326911,0.00017626054,0.0001857412,0.0013297207,0.00020014141,0.01792218,0.01827238,0.22124648],"study_design_scores_gemma":[0.013572318,0.0011168445,0.003363928,0.6609275,0.063061126,0.0005908284,0.0003518113,0.0013081253,0.0003703641,0.08478552,0.17038053,0.00017112639],"about_ca_topic_score_codex":0.005710535,"about_ca_topic_score_gemma":0.008275115,"teacher_disagreement_score":0.8824481,"about_ca_system_score_codex":0.0074862367,"about_ca_system_score_gemma":0.014850214,"threshold_uncertainty_score":0.6216816},"labels":[],"label_agreement":null},{"id":"W2558685144","doi":"10.1016/s1470-2045(16)30577-0","title":"Referral criteria for outpatient specialty palliative cancer care: an international consensus","year":2016,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":307,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; National Institutes of Health; Multinational Association of Supportive Care in Cancer","keywords":"Medicine; Referral; Palliative care; Specialty; Family medicine; Ambulatory care; Health care; Nursing","score_opus":0.5375981897176354,"score_gpt":0.594040011233374,"score_spread":0.05644182151573862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2558685144","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013441072,0.96468616,0.0028259014,0.022237597,0.003499123,0.00038300478,0.0007283485,0.000053008036,0.0042428277],"genre_scores_gemma":[0.028373951,0.90556675,0.03045233,0.026291963,0.0025853617,0.0012388269,0.003526359,0.000119536155,0.0018448934],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9883521,0.0026843562,0.0049589183,0.0012754723,0.0021988978,0.0005302136],"domain_scores_gemma":[0.9763273,0.011958173,0.0030729554,0.00044084265,0.0072075105,0.0009932073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.023009952,0.0014878801,0.0067142732,0.0072482186,0.0018074929,0.005977448,0.0069717243,0.0053143096,0.0054648696],"category_scores_gemma":[0.036145948,0.0009976884,0.0064192736,0.006513273,0.0023508663,0.004318381,0.003687569,0.006784859,0.0018864017],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046539464,0.00023230616,0.009595425,0.09917316,0.001749154,0.00046431756,0.00128358,0.0010359387,0.00095208106,0.011083824,0.17605448,0.69791037],"study_design_scores_gemma":[0.000989645,0.000237211,0.022635004,0.3484085,0.0067882254,0.0024042227,0.0031568257,0.0015556803,0.0009148335,0.009223125,0.6032765,0.0004101399],"about_ca_topic_score_codex":0.014275197,"about_ca_topic_score_gemma":0.037440706,"teacher_disagreement_score":0.023009952,"about_ca_system_score_codex":0.00796024,"about_ca_system_score_gemma":0.022859167,"threshold_uncertainty_score":0.12168974},"labels":[],"label_agreement":null},{"id":"W2559562829","doi":"10.1016/s1470-2045(16)30558-7","title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":254,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Polycythaemia; Ruxolitinib; Internal medicine; Polycythemia vera; Clinical endpoint; Myeloproliferative neoplasm; Randomized controlled trial; Pediatrics; Myelofibrosis","score_opus":0.16147605963586667,"score_gpt":0.4526537947164275,"score_spread":0.2911777350805609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559562829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860633,0.006751657,0.0007612024,0.0008693578,0.00039162516,0.0019573034,0.0011705116,0.0001499274,0.0018850581],"genre_scores_gemma":[0.9870705,0.0038534591,0.0011954417,0.0014038915,0.00041180602,0.0018137401,0.0013981289,0.000036804642,0.002816307],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993255,0.00036361735,0.000031941636,0.00009116262,0.000046368863,0.00014140538],"domain_scores_gemma":[0.99910057,0.00031246987,0.000176302,0.000087207096,0.000049618408,0.00027378913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023122698,0.0015918873,0.0032395597,0.00039857902,0.00035952116,0.001397597,0.0008866294,0.0021207137,0.0055371807],"category_scores_gemma":[0.0014783836,0.00064517563,0.0023786838,0.00037916977,0.0010358144,0.0013791755,0.00036069372,0.0035841765,0.0011574737],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9488465,0.008582726,0.0008555109,0.00093797763,0.0012277503,0.0001142161,0.00009142387,0.0006447326,0.0052233255,0.00017182632,0.0014866579,0.031817324],"study_design_scores_gemma":[0.93930954,0.057221245,0.0017575239,0.000033490862,0.00027512506,0.000074609685,0.000023299212,0.00032526028,0.00026619158,0.00012129997,0.00057424605,0.00001827805],"about_ca_topic_score_codex":0.0007998637,"about_ca_topic_score_gemma":0.0015865074,"teacher_disagreement_score":0.0055371807,"about_ca_system_score_codex":0.0006711083,"about_ca_system_score_gemma":0.0006846146,"threshold_uncertainty_score":0.018523693},"labels":[],"label_agreement":null},{"id":"W2560704457","doi":"10.1016/s1470-2045(16)30624-6","title":"Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":961,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital; Princess Margaret Cancer Centre; Juravinski Cancer Centre; University of Toronto; McMaster University","funders":"National Cancer Institute; University of Oxford","keywords":"Nivolumab; Ipilimumab; Medicine; Tolerability; Internal medicine; Lung cancer; Oncology; Cancer; Surgery; Adverse effect; Immunotherapy","score_opus":0.08906368332496893,"score_gpt":0.43502498492940195,"score_spread":0.345961301604433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560704457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947753,0.002128334,0.00030725065,0.00020281337,0.0001569618,0.0006818435,0.0009991815,0.00006421207,0.0006840279],"genre_scores_gemma":[0.993687,0.0014070673,0.00086525426,0.00058879075,0.00020652283,0.0005838005,0.0015847468,0.000033202414,0.0010436346],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99871814,0.00074433227,0.000051330913,0.00024408796,0.000104975734,0.00013711512],"domain_scores_gemma":[0.99843484,0.0005133307,0.00031888843,0.00022284006,0.00010383701,0.00040627364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037340685,0.0019811569,0.002731945,0.0004913421,0.00052907615,0.0016761626,0.0010584056,0.0016724373,0.0027638266],"category_scores_gemma":[0.0025518395,0.0009486742,0.0029499414,0.00056313135,0.0011108144,0.0017820445,0.00045084066,0.0029186488,0.00083672436],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9481148,0.014280093,0.00541743,0.00054151745,0.0036870046,0.00006380218,0.00009134047,0.0009180941,0.0036940244,0.000060505976,0.0010081253,0.022123236],"study_design_scores_gemma":[0.7826654,0.18659699,0.02123707,0.000058282843,0.0054047205,0.000148791,0.000109588414,0.0013691853,0.0011434185,0.00016664961,0.0010327483,0.000067261804],"about_ca_topic_score_codex":0.0016349108,"about_ca_topic_score_gemma":0.003121032,"teacher_disagreement_score":0.0037340685,"about_ca_system_score_codex":0.0012197166,"about_ca_system_score_gemma":0.0011750393,"threshold_uncertainty_score":0.019747853},"labels":[],"label_agreement":null},{"id":"W2560708148","doi":"10.1016/s1470-2045(16)30632-5","title":"Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":236,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Royal Victoria Regional Health Centre; Royal Victoria Hospital; Dalhousie University","funders":"Pharmacyclics","keywords":"Rituximab; Medicine; Ibrutinib; Internal medicine; Population; Waldenstrom macroglobulinemia; Oncology; Lymphoma; Leukemia; Chronic lymphocytic leukemia","score_opus":0.10975313428633213,"score_gpt":0.454956165901559,"score_spread":0.3452030316152269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560708148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9598201,0.030809838,0.00051158643,0.0014326378,0.00044859448,0.0009370641,0.0016465047,0.00012740017,0.0042661997],"genre_scores_gemma":[0.98236614,0.008863734,0.001095034,0.0019726013,0.00033787853,0.00074422336,0.0027102313,0.00003159866,0.0018786263],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9992636,0.00034078714,0.00004153205,0.000108244974,0.00007417996,0.00017158894],"domain_scores_gemma":[0.99924916,0.00023135374,0.0001901716,0.00007371247,0.000050158975,0.00020544714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030922706,0.0011726387,0.0021072347,0.00037435675,0.0003538103,0.0015600474,0.0008498051,0.0013133972,0.0022969216],"category_scores_gemma":[0.0016681746,0.00046282497,0.0023524906,0.0004735132,0.00087581563,0.0013031755,0.0004639483,0.0033008438,0.0007175041],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84136546,0.0044455454,0.0067435857,0.0021807533,0.006531575,0.00015570827,0.0003621824,0.0014951637,0.008476986,0.00043102412,0.0053885523,0.12242351],"study_design_scores_gemma":[0.92505574,0.050185606,0.013087955,0.00022755159,0.0031458023,0.0002211829,0.00013416598,0.00069785485,0.0010415066,0.00039946567,0.0057543335,0.000048700073],"about_ca_topic_score_codex":0.0010591869,"about_ca_topic_score_gemma":0.0037484716,"teacher_disagreement_score":0.0030922706,"about_ca_system_score_codex":0.001078582,"about_ca_system_score_gemma":0.00083521806,"threshold_uncertainty_score":0.016353726},"labels":[],"label_agreement":null},{"id":"W2562329111","doi":"10.1016/s1470-2045(16)30652-0","title":"Access to essential medicines for children with cancer: a joint SIOP-CCI position statement","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; McMaster University; University of Toronto","funders":"","keywords":"Medicine; Position statement; Statement (logic); Joint (building); Position (finance); Position paper; MEDLINE; Cancer; Oncology; Family medicine; Internal medicine; Pathology; Law","score_opus":0.12794439905631794,"score_gpt":0.4782464798019758,"score_spread":0.3503020807456579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2562329111","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00044404107,0.0070005152,0.00021765567,0.97386044,0.013458697,0.000045612578,0.00077359023,0.00001788478,0.0041815084],"genre_scores_gemma":[0.011369789,0.016117096,0.0036689795,0.91754115,0.039556693,0.00041322727,0.0012751953,0.00010344692,0.009954406],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.95553845,0.00815824,0.006303234,0.0023894815,0.020876797,0.0067338],"domain_scores_gemma":[0.7173297,0.13894103,0.029344069,0.006868838,0.034253635,0.07326285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.051323984,0.0014868907,0.002546844,0.0030873825,0.0035503933,0.009804376,0.0048330436,0.062010672,0.010807749],"category_scores_gemma":[0.16571276,0.0016653918,0.0037235585,0.004533112,0.0051415646,0.006601382,0.012564019,0.041050933,0.0030223757],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011773139,0.00010162891,0.0023722842,0.00081261195,0.00017388191,0.00019095953,0.00028466346,0.00015765111,0.00038124714,0.014324226,0.95642143,0.02466152],"study_design_scores_gemma":[0.00031213195,0.00012434853,0.0067690643,0.0041607176,0.00031268908,0.0003334935,0.00031686111,0.00021435478,0.00072719174,0.006656751,0.9799477,0.0001247042],"about_ca_topic_score_codex":0.03228167,"about_ca_topic_score_gemma":0.049937468,"teacher_disagreement_score":0.062010672,"about_ca_system_score_codex":0.010116344,"about_ca_system_score_gemma":0.10334261,"threshold_uncertainty_score":0.27143037},"labels":[],"label_agreement":null},{"id":"W2566177347","doi":"10.1016/s1470-2045(16)30641-6","title":"Can modelling of PSA dynamics accelerate drug development for prostate cancer?","year":2016,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Docetaxel; Oncology; Cancer; Retrospective cohort study; Clinical trial; Internal medicine; Mitoxantrone; Prednisone; Gynecology; Chemotherapy","score_opus":0.12021579097227539,"score_gpt":0.37582139221186084,"score_spread":0.2556056012395854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566177347","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00044196818,0.003548408,0.0010639292,0.9831685,0.009985153,0.000006424852,0.0000915575,0.000060644183,0.0016334285],"genre_scores_gemma":[0.05434946,0.02593794,0.0051468927,0.80796474,0.094478205,0.00011281235,0.00022729945,0.00018554754,0.011597241],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976509,0.0011991514,0.0001968368,0.00016589538,0.0006099729,0.00017724987],"domain_scores_gemma":[0.97761416,0.01780392,0.0010658224,0.0007486742,0.0016996795,0.0010678394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005285171,0.0006725371,0.0014275808,0.0003458701,0.0007693776,0.0024487565,0.0017490326,0.01868608,0.008742586],"category_scores_gemma":[0.047282778,0.0006205956,0.0017311588,0.00034736702,0.0015835622,0.004696789,0.0015966424,0.02134799,0.0050695543],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005172569,0.00011784365,0.0018985678,0.00045291078,0.00015407323,0.00071961473,0.0001010891,0.009272605,0.00042948933,0.027864605,0.85562146,0.10285041],"study_design_scores_gemma":[0.0008086287,0.00030464944,0.0007145525,0.0005921021,0.00013908908,0.0007317484,0.00015728186,0.02297736,0.0008656791,0.14671355,0.8258837,0.000111560585],"about_ca_topic_score_codex":0.0043212995,"about_ca_topic_score_gemma":0.005482854,"teacher_disagreement_score":0.01868608,"about_ca_system_score_codex":0.0020878958,"about_ca_system_score_gemma":0.00309747,"threshold_uncertainty_score":0.029246926},"labels":[],"label_agreement":null},{"id":"W2582286477","doi":"10.1016/s1470-2045(17)30064-5","title":"Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":219,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Internal medicine; Placebo; Regimen; Clinical endpoint; Oncology; Chemotherapy; Phases of clinical research; Response Evaluation Criteria in Solid Tumors; Clinical trial; Head and neck squamous-cell carcinoma; Paclitaxel; Surgery; Head and neck cancer; Radiation therapy; Pathology","score_opus":0.04651944937229081,"score_gpt":0.3421933897887764,"score_spread":0.2956739404164856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2582286477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.976694,0.010884378,0.0006499724,0.001438285,0.0010653262,0.0035701247,0.0018134159,0.00035824798,0.0035262657],"genre_scores_gemma":[0.97525907,0.00765157,0.0010819935,0.0021054458,0.0006160412,0.003702737,0.002326809,0.000045770532,0.007210467],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996648,0.000139995,0.000019453413,0.00006647983,0.000022457398,0.00008689254],"domain_scores_gemma":[0.9996081,0.00010058677,0.00009466046,0.000029228426,0.00002531969,0.00014219235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010320457,0.0019224873,0.0034644722,0.00043962328,0.00034736848,0.0010224915,0.0010122369,0.0018430831,0.008304142],"category_scores_gemma":[0.0010102773,0.0007865697,0.0016987716,0.00045334623,0.0009067303,0.0012248374,0.0004006999,0.0035537162,0.0014518953],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9661994,0.0039405474,0.00046909525,0.0012253366,0.0010916551,0.000045960132,0.00003870582,0.000433428,0.0025006388,0.00011361886,0.0016570552,0.022284567],"study_design_scores_gemma":[0.97046494,0.027488975,0.0008424941,0.000026312064,0.00028127455,0.00002512154,0.000013121343,0.00022731173,0.00016133011,0.00007259931,0.0003861485,0.000010236352],"about_ca_topic_score_codex":0.0009957517,"about_ca_topic_score_gemma":0.0029801584,"teacher_disagreement_score":0.008304142,"about_ca_system_score_codex":0.0007616713,"about_ca_system_score_gemma":0.0008190743,"threshold_uncertainty_score":0.027780175},"labels":[],"label_agreement":null},{"id":"W2583378635","doi":"10.1016/s1470-2045(17)30041-4","title":"Advancing access and equity: the vision of a new generation in cancer control","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Health and Surgery","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"International agency; Cancer; Cancer incidence; Cancer prevention; Disease; Incidence (geometry); Medicine; Mortality rate; Internal medicine","score_opus":0.13593512422011397,"score_gpt":0.5034144697509542,"score_spread":0.36747934553084016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2583378635","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015333298,0.055568468,0.0037167785,0.9168589,0.00712317,0.000019057046,0.00013030494,0.000069563,0.014980573],"genre_scores_gemma":[0.35885105,0.116994694,0.009630546,0.42532024,0.07486041,0.00030240862,0.00036135665,0.00022810094,0.013451296],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.98258257,0.008771575,0.00057928474,0.0011798812,0.0039315685,0.0029550653],"domain_scores_gemma":[0.94262105,0.035983358,0.0026932096,0.0036782522,0.0040380135,0.010986067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.041700553,0.0010591495,0.002531635,0.0022833636,0.0032375986,0.012279109,0.003002484,0.017631013,0.022682514],"category_scores_gemma":[0.049738076,0.000582627,0.0015287269,0.0020682388,0.030233286,0.03990199,0.01710328,0.021236913,0.002229939],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016608064,0.00011656272,0.0010630875,0.000740673,0.00010019934,0.00012796564,0.0014407068,0.00075010024,0.00023599711,0.7587878,0.13946073,0.097009964],"study_design_scores_gemma":[0.00008274921,0.00008085068,0.00073286926,0.0007484671,0.000033110464,0.0000851633,0.0012227611,0.00038458477,0.0001229803,0.7957225,0.20073909,0.0000450082],"about_ca_topic_score_codex":0.0039223838,"about_ca_topic_score_gemma":0.0042012124,"teacher_disagreement_score":0.041700553,"about_ca_system_score_codex":0.0090912385,"about_ca_system_score_gemma":0.022216884,"threshold_uncertainty_score":0.22053623},"labels":[],"label_agreement":null},{"id":"W2583641997","doi":"10.1016/s1470-2045(17)30003-7","title":"Adjuvant ipilimumab for stage III melanoma: the patient voice","year":2017,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Ipilimumab; Medicine; Internal medicine; Melanoma; Discontinuation; Placebo; Adverse effect; Oncology; Adjuvant; Adjuvant therapy; Hazard ratio; Cancer; Gastroenterology; Immunotherapy; Pathology; Cancer research","score_opus":0.06020058253608758,"score_gpt":0.3461598513023324,"score_spread":0.28595926876624483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2583641997","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012398743,0.0034843641,0.000093051865,0.98177737,0.0103626195,0.0000058935,0.000032128253,0.000013621159,0.0029911306],"genre_scores_gemma":[0.024993433,0.0061320905,0.00030577698,0.87700087,0.08331022,0.00002480933,0.0000562961,0.0000313727,0.008145151],"study_design_codex":"not_applicable","study_design_gemma":"qualitative","domain_scores_codex":[0.9988605,0.00039599463,0.00010834504,0.00010598321,0.00031648134,0.00021266588],"domain_scores_gemma":[0.9971687,0.0017135215,0.0002271445,0.00007699747,0.00026386188,0.0005497146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015888868,0.00044517065,0.0010122475,0.0003416792,0.001624841,0.002203761,0.0006860894,0.020209726,0.003813128],"category_scores_gemma":[0.010902086,0.00033470112,0.00070682715,0.0002949872,0.0015568584,0.0025960577,0.0011652181,0.019416783,0.0028234774],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026558508,0.000073131254,0.001677263,0.00012021355,0.0000320503,0.011432133,0.0001998669,0.00021837873,0.00080889533,0.0066031828,0.93052125,0.04804809],"study_design_scores_gemma":[0.0005239109,0.00038546344,0.0018254921,0.0006325007,0.000079747755,0.02200399,0.00065281,0.001391895,0.0006799296,0.034716625,0.93702924,0.00007850015],"about_ca_topic_score_codex":0.0009750931,"about_ca_topic_score_gemma":0.002896625,"teacher_disagreement_score":0.020209726,"about_ca_system_score_codex":0.002296111,"about_ca_system_score_gemma":0.0017151901,"threshold_uncertainty_score":0.016659498},"labels":[],"label_agreement":null},{"id":"W2587429794","doi":"10.1016/s1470-2045(17)30072-4","title":"Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":206,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Merck Sharp and Dohme; Bristol-Myers Squibb","keywords":"Vismodegib; Medicine; Basal cell carcinoma; Regimen; Placebo; Internal medicine; Population; Dosing; Basal Cell Nevus Syndrome; Oncology; Urology; Pathology; Basal cell","score_opus":0.0508492730864267,"score_gpt":0.339065832435165,"score_spread":0.28821655934873835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587429794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98477846,0.00514671,0.00090788543,0.0010283167,0.0007790999,0.0034096017,0.0011955526,0.00019628594,0.0025580076],"genre_scores_gemma":[0.9778476,0.0037248193,0.0022204982,0.0019660068,0.00052940426,0.0055383425,0.0015543802,0.00005591274,0.006563004],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99945885,0.00020563061,0.000030336127,0.00013460747,0.00004056226,0.00013003303],"domain_scores_gemma":[0.99930274,0.00017017523,0.0001263996,0.00008592365,0.0000360312,0.00027879086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014393678,0.0023193946,0.0038615786,0.00058212,0.00049935625,0.0013167979,0.0010737395,0.0022634387,0.009724824],"category_scores_gemma":[0.0015748657,0.0009370971,0.00240291,0.0004934542,0.001347703,0.0018330319,0.0005808926,0.0044366918,0.0016096812],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97316676,0.0045746886,0.0003389173,0.00044359404,0.0007844961,0.000022618417,0.00004883063,0.0003555324,0.0021668863,0.00011332811,0.00070986076,0.017274607],"study_design_scores_gemma":[0.959994,0.038157523,0.0007318112,0.000021897065,0.00020639587,0.000018707005,0.000017251741,0.00017610489,0.00016926267,0.00013034751,0.00036395044,0.000012629216],"about_ca_topic_score_codex":0.0010646005,"about_ca_topic_score_gemma":0.0026444974,"teacher_disagreement_score":0.009724824,"about_ca_system_score_codex":0.0010480384,"about_ca_system_score_gemma":0.00089723937,"threshold_uncertainty_score":0.03253281},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W2589695286","doi":"10.1016/s1470-2045(17)30085-2","title":"Predicting outcomes after a positive interim FDG-PET scan in advanced Hodgkin's lymphoma","year":2017,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lymphoma; Rituximab; Oncology; Stage (stratigraphy); Internal medicine; Interim; Classical Hodgkin lymphoma; Follicular lymphoma; Hodgkin lymphoma; Progression-free survival; Positron emission tomography; Nuclear medicine; Overall survival","score_opus":0.033576701464211094,"score_gpt":0.3488544561523942,"score_spread":0.3152777546881831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589695286","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20196109,0.012608936,0.00080397335,0.74908096,0.012753722,0.000049774775,0.0006383645,0.00009453695,0.022008596],"genre_scores_gemma":[0.796849,0.006394964,0.0011158409,0.14855048,0.04198552,0.000058971345,0.0005564862,0.000043931115,0.004444729],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992675,0.00026523173,0.00010882193,0.00006352935,0.000117196214,0.00017762091],"domain_scores_gemma":[0.9946871,0.003049118,0.00045330432,0.00015852481,0.0007017828,0.0009501707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011588042,0.00023226968,0.0007485653,0.00062004727,0.0007854881,0.0016116819,0.0006501104,0.0049849986,0.0017936801],"category_scores_gemma":[0.014813969,0.00028067676,0.0003801666,0.0006367742,0.0007159956,0.0010758922,0.00054208055,0.0059537585,0.0011033182],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014811283,0.0003724861,0.5726868,0.00019827341,0.00012474817,0.024675649,0.0004798592,0.0008231571,0.0012147636,0.0018442345,0.25281513,0.1432838],"study_design_scores_gemma":[0.001422852,0.0024815998,0.5466906,0.002390049,0.0009892907,0.11723033,0.0062518977,0.016256912,0.003089809,0.057362124,0.24552143,0.00031317765],"about_ca_topic_score_codex":0.0026520048,"about_ca_topic_score_gemma":0.005316659,"teacher_disagreement_score":0.0049849986,"about_ca_system_score_codex":0.0014853304,"about_ca_system_score_gemma":0.0011487971,"threshold_uncertainty_score":0.010776877},"labels":[],"label_agreement":null},{"id":"W2591745019","doi":"10.1016/s1470-2045(17)30121-3","title":"The drama of prostate cancer diagnostics","year":2017,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Prostate; Biopsy; Cancer; Population; Prostate biopsy; Gynecology; Prostate-specific antigen; Management of prostate cancer; Radiology; Oncology; Internal medicine","score_opus":0.05375259614490459,"score_gpt":0.36606365046757433,"score_spread":0.31231105432266976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591745019","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009051926,0.0022859336,0.000022708158,0.98133284,0.014229261,0.000003985453,0.000017007755,0.0000077233435,0.002010002],"genre_scores_gemma":[0.0016573861,0.0018770033,0.0000489411,0.9542872,0.03676789,0.000015197189,0.000013896842,0.000020356965,0.0053121876],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9906963,0.003044652,0.00066471257,0.00080647325,0.003245415,0.001542555],"domain_scores_gemma":[0.9818001,0.010006664,0.0012784683,0.00050758425,0.0023158086,0.0040913173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006660105,0.0012740939,0.0018114108,0.0011736808,0.008607801,0.010012016,0.0027088881,0.10035377,0.011179654],"category_scores_gemma":[0.04449678,0.0012912325,0.0015078291,0.0011237534,0.00932845,0.009175057,0.0054202788,0.09063715,0.008047316],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002547028,0.00001825656,0.00021132155,0.00003978574,0.000009908215,0.0005484367,0.0001741569,0.000031259082,0.00006852406,0.004917369,0.9887814,0.005174086],"study_design_scores_gemma":[0.00006655411,0.0000408415,0.0003779111,0.00039009066,0.000019032172,0.0005955423,0.00066255295,0.00017684877,0.000109901026,0.011461024,0.98604333,0.000056328914],"about_ca_topic_score_codex":0.010316779,"about_ca_topic_score_gemma":0.017482106,"teacher_disagreement_score":0.10035377,"about_ca_system_score_codex":0.007848359,"about_ca_system_score_gemma":0.011671995,"threshold_uncertainty_score":0.056944072},"labels":[],"label_agreement":null},{"id":"W2592144107","doi":"10.1016/s1470-2045(17)30074-8","title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","year":2017,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2408,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Cancer Institute","keywords":"Guideline; Clinical trial; Medicine; Medical physics; Response Evaluation Criteria in Solid Tumors; Immunotherapy; Cancer; Intensive care medicine; Oncology; Internal medicine; Pathology","score_opus":0.8623875272759276,"score_gpt":0.6325735133841923,"score_spread":0.22981401389173528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592144107","genre_codex":"review","genre_gemma":"methods","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012527788,0.74755543,0.057526477,0.07057121,0.01607583,0.03137224,0.025041262,0.0035367352,0.047068026],"genre_scores_gemma":[0.020661077,0.2780234,0.3852513,0.12689143,0.008644222,0.12166509,0.032473773,0.002347013,0.024042666],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.85930276,0.07368834,0.045725472,0.002145861,0.016818704,0.0023188915],"domain_scores_gemma":[0.77332234,0.15772963,0.027705664,0.0065300986,0.03186608,0.002846226],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.13499095,0.0034404588,0.012529419,0.009299776,0.0020774277,0.009136073,0.008366374,0.009820137,0.02228388],"category_scores_gemma":[0.22507001,0.002080813,0.016960138,0.0077632135,0.0035620385,0.004254583,0.008199942,0.013167339,0.01493832],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026053865,0.0001503663,0.0013361662,0.1290278,0.0030587234,0.0001754469,0.00068696693,0.0009350352,0.00093742897,0.014504577,0.34429568,0.5022865],"study_design_scores_gemma":[0.0028309727,0.00042738867,0.003979693,0.15188205,0.00449629,0.00047928345,0.00029058426,0.00063317537,0.0010766198,0.0261819,0.80751586,0.00020611021],"about_ca_topic_score_codex":0.0041073556,"about_ca_topic_score_gemma":0.008364408,"teacher_disagreement_score":0.86500907,"about_ca_system_score_codex":0.006520491,"about_ca_system_score_gemma":0.019400688,"threshold_uncertainty_score":0.7139089},"labels":[],"label_agreement":null},{"id":"W2593722738","doi":"10.1016/s1470-2045(17)30168-7","title":"Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Regional Municipality of Durham; Hamilton Health Sciences; Juravinski Cancer Centre; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Docetaxel; Medicine; Prostate cancer; Prednisone; Clusterin; Internal medicine; Clinical endpoint; Oncology; Population; Enzalutamide; Randomized controlled trial; Chemotherapy; Cancer","score_opus":0.0888808162791997,"score_gpt":0.4204282111513942,"score_spread":0.33154739487219453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593722738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787612,0.010372563,0.0006159428,0.0013816169,0.00079056236,0.001990516,0.0016123927,0.00021306421,0.004262119],"genre_scores_gemma":[0.98203605,0.0049858275,0.0013882606,0.0017520905,0.00047829055,0.0015739134,0.0020050588,0.000046058754,0.0057342974],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995437,0.00021731912,0.000018635066,0.000086674954,0.000040234743,0.00009339509],"domain_scores_gemma":[0.9994448,0.00012508473,0.000117278956,0.000041467705,0.000030888474,0.0002405832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001161213,0.0017660914,0.0026568184,0.00041217016,0.00048705164,0.0013000706,0.0010353181,0.0014613284,0.00758072],"category_scores_gemma":[0.0011272851,0.00063716114,0.0022619222,0.0004734561,0.0011611488,0.0011809511,0.000547752,0.0045624715,0.0013069137],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.962276,0.0050209435,0.0007181237,0.0012712044,0.0019426394,0.000054221116,0.000107847714,0.000924061,0.0019095772,0.0003118407,0.0028896686,0.022573907],"study_design_scores_gemma":[0.95560944,0.040799186,0.0013565235,0.00005119429,0.0005147297,0.000047771005,0.000039892555,0.00034469867,0.0001668573,0.00020931388,0.0008420782,0.00001839721],"about_ca_topic_score_codex":0.002086828,"about_ca_topic_score_gemma":0.00671372,"teacher_disagreement_score":0.00758072,"about_ca_system_score_codex":0.0009822068,"about_ca_system_score_gemma":0.0012052268,"threshold_uncertainty_score":0.025360048},"labels":[],"label_agreement":null},{"id":"W2594529508","doi":"10.1016/s1470-2045(17)30180-8","title":"Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":491,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Dacarbazine; Medicine; Neuroblastoma RAS viral oncogene homolog; Hazard ratio; Melanoma; Internal medicine; Clinical endpoint; Population; Adverse effect; Oncology; Progression-free survival; Randomized controlled trial; Vemurafenib; Cancer; Confidence interval; Chemotherapy; Metastatic melanoma; Cancer research; Colorectal cancer","score_opus":0.05756250214883237,"score_gpt":0.3665577832550817,"score_spread":0.30899528110624935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594529508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868499,0.0062151756,0.00054206024,0.0012367037,0.0006123555,0.0013237024,0.0009218091,0.00008536401,0.0022130667],"genre_scores_gemma":[0.9869363,0.003728971,0.00093712483,0.0012893764,0.00028644953,0.0013224629,0.0011487555,0.000028760838,0.0043218345],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996853,0.00014974098,0.000012967834,0.000054089203,0.00002190712,0.00007601962],"domain_scores_gemma":[0.99958855,0.000094968214,0.000085553074,0.000029691724,0.000021922388,0.00017931231],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010900913,0.0015662229,0.002195093,0.00025783526,0.00033874618,0.0010490093,0.00062124594,0.0011643438,0.0052768295],"category_scores_gemma":[0.0010288924,0.00050826935,0.0017016674,0.00033562168,0.00085117744,0.0011798054,0.00043051218,0.0031542596,0.0008562604],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9669834,0.0030715838,0.00077327417,0.00065932365,0.0011657494,0.000051694107,0.000079425896,0.0007177944,0.003389788,0.00016771349,0.0012903878,0.021649847],"study_design_scores_gemma":[0.942104,0.05258199,0.0024016201,0.000052156433,0.0004144834,0.00006822674,0.000046827154,0.00048566784,0.0003248769,0.00037472678,0.0011260752,0.000019225577],"about_ca_topic_score_codex":0.0010510575,"about_ca_topic_score_gemma":0.0033707332,"teacher_disagreement_score":0.0052768295,"about_ca_system_score_codex":0.00087501865,"about_ca_system_score_gemma":0.00068036275,"threshold_uncertainty_score":0.01765275},"labels":[],"label_agreement":null},{"id":"W2603276734","doi":"10.1016/s1470-2045(17)30162-6","title":"Stereotactic body radiotherapy for patients with hepatocellular carcinoma and intermediate grade cirrhosis","year":2017,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Hepatocellular carcinoma; Medicine; Cirrhosis; Liver transplantation; Milan criteria; Internal medicine; Liver function; Gastroenterology; Oncology; Transplantation","score_opus":0.07017228260266349,"score_gpt":0.29543840819648487,"score_spread":0.22526612559382136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603276734","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009853924,0.0059949425,0.00013201551,0.962705,0.010672586,0.000018063622,0.000116762894,0.000021163758,0.010485536],"genre_scores_gemma":[0.22439973,0.011622319,0.0005670611,0.6542374,0.09620688,0.00007484004,0.00032990126,0.00004583946,0.0125160115],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9995546,0.00013358127,0.00005334598,0.000039612565,0.00009696979,0.00012189514],"domain_scores_gemma":[0.9985386,0.0006320826,0.00018913308,0.00005685812,0.00017227858,0.0004110215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057535816,0.00023950594,0.00070919277,0.0004471673,0.0015419965,0.0010079474,0.00049079425,0.00971848,0.0036217715],"category_scores_gemma":[0.008289031,0.00027103702,0.000652875,0.0006287028,0.0010068656,0.0011191762,0.0006467504,0.008514886,0.0013421375],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057553576,0.00014298988,0.047456313,0.00028319206,0.00014246814,0.04986439,0.000355698,0.0005578085,0.0009681432,0.0051861587,0.8220857,0.07238158],"study_design_scores_gemma":[0.0015327451,0.0009944288,0.093298875,0.0020139161,0.0006147902,0.18751594,0.0027255793,0.0041577662,0.0016505937,0.04474872,0.6605097,0.00023690374],"about_ca_topic_score_codex":0.0046501923,"about_ca_topic_score_gemma":0.010958559,"teacher_disagreement_score":0.00971848,"about_ca_system_score_codex":0.002803832,"about_ca_system_score_gemma":0.0022915353,"threshold_uncertainty_score":0.020343304},"labels":[],"label_agreement":null},{"id":"W2610443697","doi":"10.1016/s1470-2045(17)30259-0","title":"Widening the gap: additional concerns with crowdfunding in health care","year":2017,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University","funders":"","keywords":"Health care; Population; Medicine; Public relations; Service (business); Population ageing; Political science; Business; Economic growth; Marketing; Environmental health; Law; Economics","score_opus":0.11710791013667125,"score_gpt":0.3282794166360063,"score_spread":0.21117150649933503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2610443697","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000108134256,0.00067881896,0.000055850447,0.99490935,0.0035589386,0.0000025993274,0.00002075449,0.0000050190724,0.0006605732],"genre_scores_gemma":[0.0033881478,0.0009900032,0.0001616476,0.9561571,0.037911557,0.00002375618,0.00001691065,0.000029817535,0.0013209968],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9776244,0.009832273,0.0019067412,0.001882376,0.005670069,0.0030841304],"domain_scores_gemma":[0.8534867,0.108146295,0.005883985,0.0032904714,0.0117263235,0.017466057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.028232982,0.0008513275,0.0025862653,0.0013781368,0.006434333,0.011237168,0.0041805804,0.109378934,0.018047974],"category_scores_gemma":[0.15686347,0.0009805186,0.0025913503,0.0018916936,0.011950666,0.017543286,0.008982334,0.085519426,0.00529359],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039060757,0.000025929732,0.00043354862,0.00008102373,0.000022225224,0.00041594933,0.00026570813,0.00011141891,0.000053023017,0.017072067,0.9714527,0.010027396],"study_design_scores_gemma":[0.00020729357,0.000051548246,0.0009943726,0.00087097834,0.000044797256,0.0006728441,0.0012993005,0.0007034199,0.0001519373,0.087630674,0.9072299,0.00014287284],"about_ca_topic_score_codex":0.013824998,"about_ca_topic_score_gemma":0.026492443,"teacher_disagreement_score":0.109378934,"about_ca_system_score_codex":0.009230121,"about_ca_system_score_gemma":0.020902261,"threshold_uncertainty_score":0.14931202},"labels":[],"label_agreement":null},{"id":"W2610700401","doi":"10.1016/s1470-2045(17)30266-8","title":"Engaging specialist oncologists in the assessment of oncology drugs in Canada","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Agency for Drugs and Technologies in Health; Sunnybrook Health Science Centre; Health Sciences Centre; University of Alberta; McMaster University","funders":"","keywords":"Medicine; Oncology; Clinical Oncology; Internal medicine; Family medicine; Cancer drugs; Cancer","score_opus":0.5078851034052443,"score_gpt":0.5233580489296832,"score_spread":0.015472945524438897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2610700401","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24772434,0.055627435,0.0016523164,0.6183387,0.0015606147,0.0005322,0.0043087797,0.00009052941,0.07016505],"genre_scores_gemma":[0.95047057,0.016110152,0.002476307,0.024734892,0.0006003607,0.00008897655,0.0008007684,0.0000466846,0.0046712216],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9820816,0.0082947295,0.00107524,0.0005262406,0.004225278,0.0037969067],"domain_scores_gemma":[0.87097317,0.0545749,0.0081662955,0.0010045303,0.035802394,0.029478759],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015246094,0.0003475689,0.0009098029,0.0027426016,0.003582329,0.0062708175,0.001664914,0.003893589,0.006599443],"category_scores_gemma":[0.1156179,0.000503125,0.00070479646,0.0066215913,0.0029063565,0.0017464535,0.0026042021,0.0044408096,0.00035627655],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0029178862,0.0006818344,0.286171,0.004301365,0.0012293197,0.0015607005,0.0065477365,0.020982035,0.00074931467,0.030378828,0.34653008,0.29795],"study_design_scores_gemma":[0.0018164177,0.00082065834,0.60552114,0.00734142,0.0013231012,0.00101582,0.02546534,0.03202584,0.0012972286,0.0284228,0.29431504,0.0006350655],"about_ca_topic_score_codex":0.9798933,"about_ca_topic_score_gemma":0.9910343,"teacher_disagreement_score":0.86141956,"about_ca_system_score_codex":0.13858047,"about_ca_system_score_gemma":0.25278136,"threshold_uncertainty_score":0.9991245},"labels":[],"label_agreement":null},{"id":"W2610966285","doi":"10.1016/s1470-2045(17)30263-2","title":"Genomic biomarkers for precision radiation medicine","year":2017,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Institute of Cancer Research; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"","keywords":"Radiation therapy; Precision medicine; Medical physics; Medicine; Personalized medicine; Bioinformatics; Internal medicine; Pathology; Biology","score_opus":0.037809324979623235,"score_gpt":0.3356601559436628,"score_spread":0.2978508309640395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2610966285","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014070982,0.0030033402,0.00015633732,0.9799383,0.015101894,0.0000060697457,0.000032166634,0.000015866444,0.0016052442],"genre_scores_gemma":[0.0042208834,0.0032364985,0.0003675302,0.9033728,0.084459625,0.00003929256,0.00003995166,0.000023287734,0.0042400816],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947803,0.0020919447,0.00041648978,0.00051676406,0.0016638815,0.0005305906],"domain_scores_gemma":[0.9757971,0.017460449,0.0010981852,0.0009906782,0.0023911474,0.0022623756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064990213,0.0009669008,0.0016822305,0.0009812495,0.0030805669,0.0047768815,0.0017343169,0.056574874,0.0071624154],"category_scores_gemma":[0.044218898,0.00089060643,0.0011325054,0.00069061754,0.0069457884,0.0058621666,0.0037525175,0.05462675,0.0051497687],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005326558,0.000026570042,0.00051878975,0.00006505846,0.000019271234,0.00082522404,0.00008737992,0.00009302094,0.00019224692,0.012219276,0.968524,0.017375998],"study_design_scores_gemma":[0.00021286483,0.00008952355,0.0006426383,0.00039064916,0.000044991408,0.0016370781,0.00029944553,0.0006917953,0.00043158833,0.088674806,0.9068205,0.00006408866],"about_ca_topic_score_codex":0.0020802568,"about_ca_topic_score_gemma":0.0030493683,"teacher_disagreement_score":0.056574874,"about_ca_system_score_codex":0.003857884,"about_ca_system_score_gemma":0.0040437886,"threshold_uncertainty_score":0.03437054},"labels":[],"label_agreement":null},{"id":"W2616596696","doi":"10.1016/s1470-2045(17)30312-1","title":"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":656,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute; Genentech; GlaxoSmithKline","keywords":"Medicine; Lapatinib; Capecitabine; Trastuzumab emtansine; Taxane; Trastuzumab; Internal medicine; Oncology; Breast cancer; Interim analysis; Metastatic breast cancer; Pertuzumab; Population; Cancer; Clinical trial; Colorectal cancer","score_opus":0.1471450445887598,"score_gpt":0.43954737622099455,"score_spread":0.2924023316322347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2616596696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990703,0.0060637635,0.00035097948,0.00024350714,0.0001497291,0.0007176925,0.0007722963,0.000031173546,0.0009678557],"genre_scores_gemma":[0.99451315,0.0017415995,0.00055072014,0.0004577847,0.00017700998,0.0005268799,0.0011319157,0.000013474192,0.0008875315],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977018,0.0015729631,0.0001561477,0.0002551998,0.000118115146,0.0001957784],"domain_scores_gemma":[0.99703646,0.0016806226,0.00072133105,0.00019548667,0.0000796403,0.00028649936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004610684,0.0012671184,0.002465228,0.0005863075,0.0002453,0.00096660596,0.0006505223,0.0010355938,0.0032818816],"category_scores_gemma":[0.0045578745,0.00047188456,0.0035997014,0.0005857389,0.0008437314,0.0013039613,0.00046042592,0.0020685084,0.00040459388],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9762517,0.0015410244,0.0022000263,0.00044985517,0.0030451878,0.00003522774,0.00006083401,0.0005912848,0.001098493,0.00005551014,0.00029394196,0.014376831],"study_design_scores_gemma":[0.80685806,0.15891135,0.02463636,0.0001409268,0.0056475573,0.0001451757,0.00009211671,0.0013227618,0.00070148543,0.00034906776,0.0011421633,0.000052913718],"about_ca_topic_score_codex":0.0005156995,"about_ca_topic_score_gemma":0.0017198699,"teacher_disagreement_score":0.004610684,"about_ca_system_score_codex":0.0010620094,"about_ca_system_score_gemma":0.0005846418,"threshold_uncertainty_score":0.024383962},"labels":[],"label_agreement":null},{"id":"W2619858681","doi":"10.1016/s1470-2045(17)30376-5","title":"Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":539,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Ottawa Hospital","funders":"National Cancer Institute; Novartis Pharmaceuticals Corporation","keywords":"Fulvestrant; Medicine; Breast cancer; Placebo; Internal medicine; Metastatic breast cancer; Oncology; Cancer; Aromatase inhibitor; Estrogen receptor; Tamoxifen; Pathology","score_opus":0.04915608166519876,"score_gpt":0.3711958041582476,"score_spread":0.32203972249304885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2619858681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97550166,0.012113037,0.000992659,0.0015613226,0.0011187427,0.0036069455,0.0017449718,0.00033763924,0.0030230205],"genre_scores_gemma":[0.97785246,0.006156651,0.0015115079,0.0018694827,0.0005746017,0.00414543,0.0013862905,0.000040689927,0.006462969],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996481,0.00015774812,0.00002094329,0.00006986252,0.000025551295,0.00007778238],"domain_scores_gemma":[0.999571,0.00013309364,0.00009511076,0.000033144923,0.000024316689,0.00014330813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012805491,0.0020428398,0.0029228106,0.0004707551,0.00035220096,0.0009777867,0.0009705348,0.0018623599,0.008628648],"category_scores_gemma":[0.001340508,0.00065016985,0.0019698846,0.00041708292,0.0010413978,0.0012454565,0.00040860754,0.0029009997,0.001329108],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9805977,0.0025571852,0.00017070198,0.0007089162,0.0006843523,0.000021854517,0.00002822723,0.0002672507,0.0021078489,0.000109049506,0.00074851164,0.011998495],"study_design_scores_gemma":[0.9660429,0.03232917,0.00053293904,0.000024404988,0.00023321329,0.000018691835,0.000013990141,0.00019726637,0.00017470583,0.000107891494,0.00031532938,0.000009560312],"about_ca_topic_score_codex":0.0008646791,"about_ca_topic_score_gemma":0.0020671594,"teacher_disagreement_score":0.008628648,"about_ca_system_score_codex":0.00068614166,"about_ca_system_score_gemma":0.0007091346,"threshold_uncertainty_score":0.028865635},"labels":[],"label_agreement":null},{"id":"W2620608626","doi":"10.1016/s1470-2045(17)30423-0","title":"Measuring value and benefit—a matter of perspective","year":2017,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; McMaster University","funders":"","keywords":"Scopus; Medicine; Psychological intervention; Medical prescription; Health care; Alternative medicine; Prescription drug; Family medicine; MEDLINE; Library science; Political science; Pharmacology; Computer science; Nursing; Law; Pathology","score_opus":0.09881712241165262,"score_gpt":0.2869346739451015,"score_spread":0.1881175515334489,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2620608626","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001421492,0.009061442,0.00037040946,0.98444563,0.005002603,0.0000031756565,0.000034476572,0.0000050551407,0.00093501265],"genre_scores_gemma":[0.018141737,0.021822434,0.0013397994,0.81007344,0.1470293,0.000044051743,0.000048296733,0.000056249297,0.0014446792],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.96302176,0.022079583,0.003169306,0.0028970162,0.007640902,0.0011914552],"domain_scores_gemma":[0.72253937,0.238278,0.0072872657,0.0059941327,0.020179,0.0057222894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.047659382,0.0011013178,0.003431353,0.002510649,0.0021425844,0.012283991,0.004301254,0.033651553,0.0064306515],"category_scores_gemma":[0.2504836,0.00097093766,0.0013712863,0.0028781933,0.018017402,0.020352978,0.0042491523,0.059179313,0.003258817],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021842353,0.00011071542,0.0017955169,0.00057888095,0.00020975599,0.00047430268,0.00032324405,0.00083963387,0.00022094113,0.17673303,0.73182625,0.08666932],"study_design_scores_gemma":[0.00021905285,0.000086908214,0.0012490203,0.0020514734,0.00008569296,0.0006769545,0.00085725985,0.0013036389,0.00026822195,0.6158017,0.3772467,0.00015337703],"about_ca_topic_score_codex":0.006454502,"about_ca_topic_score_gemma":0.008502105,"teacher_disagreement_score":0.047659382,"about_ca_system_score_codex":0.0107585015,"about_ca_system_score_gemma":0.0070618293,"threshold_uncertainty_score":0.25204992},"labels":[],"label_agreement":null},{"id":"W2620651944","doi":"10.1016/s1470-2045(17)30429-1","title":"Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":775,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Bristol-Myers Squibb","keywords":"Dabrafenib; Trametinib; Medicine; Melanoma; Asymptomatic; Clinical endpoint; Oncology; MEK inhibitor; Internal medicine; Brain metastasis; Phases of clinical research; Clinical trial; Metastatic melanoma; Cancer; Metastasis; Vemurafenib; Cancer research; Biology; MAPK/ERK pathway","score_opus":0.06803476530507808,"score_gpt":0.3693754023310494,"score_spread":0.3013406370259713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2620651944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98666346,0.006475767,0.0005005918,0.0011807433,0.00038114883,0.0011706512,0.0015595811,0.00013062042,0.0019373157],"genre_scores_gemma":[0.9860643,0.004207412,0.0011384309,0.001179339,0.0002566124,0.0012121841,0.0022400622,0.000036401205,0.003665228],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9997092,0.00012243155,0.000011925414,0.000051701205,0.000020822563,0.00008385973],"domain_scores_gemma":[0.9996464,0.000062201,0.0000697324,0.000027226337,0.00002484214,0.000169678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010738944,0.0019305135,0.0020839733,0.00030135585,0.0003264059,0.0012321703,0.00062587706,0.0012774707,0.004048687],"category_scores_gemma":[0.0008114746,0.00055796595,0.0017528656,0.00038390647,0.0006614232,0.0011905857,0.00030460255,0.0028703695,0.0009952836],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9135118,0.005962158,0.0020982695,0.0010371037,0.0023846233,0.00013881607,0.00013288867,0.001422704,0.008270795,0.00028523142,0.004287895,0.060467727],"study_design_scores_gemma":[0.9286817,0.06172111,0.004618043,0.000048546168,0.00072482636,0.00019447955,0.00006409946,0.0008643386,0.0006746161,0.00036208585,0.0020109245,0.00003526246],"about_ca_topic_score_codex":0.0013672966,"about_ca_topic_score_gemma":0.004532118,"teacher_disagreement_score":0.004048687,"about_ca_system_score_codex":0.001021348,"about_ca_system_score_gemma":0.0008634322,"threshold_uncertainty_score":0.013544142},"labels":[],"label_agreement":null},{"id":"W2620810773","doi":"10.1016/s1470-2045(17)30325-x","title":"Improving childhood cancer care in Latin America and the Caribbean: a PAHO Childhood Cancer Working Group position statement","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Scopus; Global health; Medicine; Cancer; Childhood cancer; Family medicine; Political science; MEDLINE; Public health; Internal medicine; Nursing","score_opus":0.03539205654018276,"score_gpt":0.354677557437213,"score_spread":0.3192855008970303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2620810773","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0028217384,0.03984964,0.00018935675,0.9355149,0.008828792,0.0000720318,0.0014528778,0.00002157367,0.011249112],"genre_scores_gemma":[0.09440234,0.28997985,0.00999075,0.5399003,0.026685154,0.0013902237,0.006639756,0.0002408431,0.03077083],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99495006,0.0012792819,0.00052518677,0.00021876865,0.0014505021,0.0015762554],"domain_scores_gemma":[0.97268784,0.0058331075,0.0030345977,0.0005317359,0.0045177317,0.013394886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017789837,0.001016923,0.0008993547,0.001645719,0.0023908596,0.005238998,0.0025371609,0.007533956,0.0056892727],"category_scores_gemma":[0.02352567,0.00046586982,0.001311819,0.0031564285,0.001962966,0.0030588966,0.008131679,0.008816349,0.00097545027],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010237343,0.00015340325,0.021762634,0.0020839784,0.00025186012,0.0002420134,0.0024771113,0.00036400586,0.0005882143,0.009065027,0.81178385,0.15112557],"study_design_scores_gemma":[0.0001488381,0.00009502138,0.03323628,0.007507558,0.0002756876,0.00017699639,0.0051213456,0.00011801784,0.00051697885,0.0041102064,0.94862133,0.0000716602],"about_ca_topic_score_codex":0.09562707,"about_ca_topic_score_gemma":0.15286203,"teacher_disagreement_score":0.09562707,"about_ca_system_score_codex":0.006479607,"about_ca_system_score_gemma":0.064734764,"threshold_uncertainty_score":0.1901409},"labels":[],"label_agreement":null},{"id":"W2621250710","doi":"10.1016/s1470-2045(17)30415-1","title":"Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":147,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Princess Margaret Cancer Centre; Kingston General Hospital; University of Toronto","funders":"","keywords":"Medicine; Breast cancer; Colorectal cancer; Clinical trial; Cancer; Cohort; Internal medicine; Oncology; Pancreatic cancer; Cost effectiveness; Randomized controlled trial; Retrospective cohort study","score_opus":0.03926225781668552,"score_gpt":0.3084167639594485,"score_spread":0.269154506142763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621250710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957755,0.00044999196,0.00014276341,0.00040808256,0.000026724716,0.000025968648,0.0027430216,0.000002854638,0.00042518938],"genre_scores_gemma":[0.99708885,0.00019613001,0.00013527182,0.000114597846,0.000023842971,0.000025801328,0.0020480063,0.0000068176532,0.00036068415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99777263,0.00084292097,0.00023519936,0.00038675332,0.0002859289,0.00047661224],"domain_scores_gemma":[0.9893482,0.0029729733,0.0045899916,0.0012047847,0.00079315464,0.0010909946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037443726,0.0003523852,0.00059412053,0.00073934917,0.00061581685,0.002085353,0.0009840445,0.0010704069,0.00357029],"category_scores_gemma":[0.016271818,0.0006308342,0.0020500908,0.0023259085,0.0004362516,0.0018547454,0.001490368,0.0024640206,0.00063949544],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011361288,0.00021725925,0.9947301,0.00001851682,0.0004267046,0.000046966252,0.00016380753,0.00021046246,0.000048100297,0.0002814124,0.00073256047,0.0019879218],"study_design_scores_gemma":[0.00010890509,0.0005950109,0.9945851,0.000054489712,0.00046972642,0.00021208909,0.00092947803,0.0013864115,0.000059937145,0.0003311949,0.0012388668,0.00002889608],"about_ca_topic_score_codex":0.02859418,"about_ca_topic_score_gemma":0.022178628,"teacher_disagreement_score":0.02859418,"about_ca_system_score_codex":0.0017206159,"about_ca_system_score_gemma":0.0015362414,"threshold_uncertainty_score":0.05685544},"labels":[],"label_agreement":null},{"id":"W2621656000","doi":"10.1016/s1470-2045(17)30404-7","title":"Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"Eisai; National Institute for Health and Care Research; Cancer Research UK; University College London; Les Laboratories Pierre Fabre; AstraZeneca; Celgene; Genomic Health; Research England; Pfizer; Amgen","keywords":"Epirubicin; Medicine; Capecitabine; Cyclophosphamide; Breast cancer; Internal medicine; Fluorouracil; Gastroenterology; Chemotherapy; Cancer; Surgery; Colorectal cancer","score_opus":0.08496628285504446,"score_gpt":0.4261559906783022,"score_spread":0.34118970782325775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621656000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870459,0.0052602966,0.00060129666,0.0005872534,0.0008835126,0.0035646397,0.0005664066,0.00008562714,0.0014050794],"genre_scores_gemma":[0.9889643,0.0020842878,0.0012982931,0.0006802054,0.0006963462,0.0039275377,0.00053835876,0.00001978115,0.0017907614],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977464,0.0016025297,0.00011982321,0.0002326547,0.000091851485,0.00020674332],"domain_scores_gemma":[0.99780613,0.00064838683,0.0006719318,0.00018129377,0.000103729086,0.00058847957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038725093,0.0019791366,0.003458608,0.0005287835,0.0004512706,0.0012384716,0.0009918573,0.0019392337,0.0048993784],"category_scores_gemma":[0.003742989,0.0007166806,0.002241446,0.0005898002,0.0015187286,0.0012375643,0.00047521718,0.0028440848,0.0006406485],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9934149,0.0018881755,0.00016094767,0.00019950478,0.0002632461,0.0000141638075,0.000016895223,0.00013221292,0.0005495438,0.00003827016,0.00018176589,0.003140323],"study_design_scores_gemma":[0.939499,0.058730833,0.00077413773,0.00002105088,0.00026542638,0.000019892292,0.000008635129,0.00023257076,0.0001534504,0.000070823546,0.00021557252,0.000008636513],"about_ca_topic_score_codex":0.0014107171,"about_ca_topic_score_gemma":0.0026864838,"teacher_disagreement_score":0.0048993784,"about_ca_system_score_codex":0.0010157799,"about_ca_system_score_gemma":0.001258033,"threshold_uncertainty_score":0.020480037},"labels":[],"label_agreement":null},{"id":"W2623725180","doi":"10.1016/s1470-2045(17)30339-x","title":"Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":580,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Ignyta; Shionogi; AstraZeneca; Associazione Italiana per la Ricerca sul Cancro; Astellas Pharma; Eli Lilly and Company","keywords":"Ceritinib; Crizotinib; Medicine; Anaplastic lymphoma kinase; Lung cancer; ALK inhibitor; Internal medicine; Chemotherapy; Oncology; Docetaxel; Pemetrexed; Gastroenterology; Cisplatin","score_opus":0.04534884463340635,"score_gpt":0.4133336191056075,"score_spread":0.3679847744722012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2623725180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98353,0.009738078,0.0004327325,0.0009686682,0.000851319,0.0014712069,0.00069462584,0.0001700895,0.002143346],"genre_scores_gemma":[0.99095356,0.0030996073,0.00057576835,0.0008770536,0.000386421,0.00094599195,0.0008338797,0.000021982545,0.0023057521],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993143,0.0003324719,0.00003958903,0.00013615306,0.000041478186,0.00013607324],"domain_scores_gemma":[0.99919254,0.00023004129,0.00020157137,0.00005166625,0.00003853104,0.00028572557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016402206,0.0018727026,0.0042387387,0.00043477555,0.0003839147,0.0011728995,0.00089001725,0.0019893895,0.004940008],"category_scores_gemma":[0.001681598,0.0006425027,0.00272164,0.0004682957,0.0013120108,0.0015063098,0.00040769434,0.0037815913,0.0009418449],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9805162,0.0021267524,0.00053262344,0.0006082037,0.0011106078,0.000042203897,0.0000427969,0.0005551003,0.0014627832,0.000097895565,0.000703813,0.012200939],"study_design_scores_gemma":[0.93345976,0.06254014,0.0017729922,0.000034817156,0.00057390815,0.000051176296,0.000026864285,0.0005379058,0.0002601848,0.00014807335,0.0005772979,0.000017047421],"about_ca_topic_score_codex":0.001600024,"about_ca_topic_score_gemma":0.004244637,"teacher_disagreement_score":0.004940008,"about_ca_system_score_codex":0.0012507429,"about_ca_system_score_gemma":0.0010486125,"threshold_uncertainty_score":0.016525984},"labels":[],"label_agreement":null},{"id":"W2653632515","doi":"10.1016/s1470-2045(17)30381-9","title":"Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":306,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute","keywords":"Doxorubicin; Medicine; Open label; Soft tissue sarcoma; Sarcoma; Oncology; Phases of clinical research; Internal medicine; Chemotherapy; Soft tissue; Clinical trial; Radiology; Pathology","score_opus":0.18838234775149656,"score_gpt":0.4786800370415504,"score_spread":0.29029768929005384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2653632515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865427,0.0052917786,0.0006534471,0.0010035994,0.00065829087,0.0014611374,0.0010178189,0.00015501144,0.0032162967],"genre_scores_gemma":[0.98441386,0.0037859967,0.0012996728,0.0011983763,0.0003472995,0.0017641521,0.0014706561,0.000046150068,0.005673893],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99958056,0.00022036965,0.000018405823,0.000089503075,0.000021777392,0.00006944351],"domain_scores_gemma":[0.9993948,0.00017748775,0.00011885762,0.00003846797,0.000024064055,0.00024630598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012969984,0.0016394835,0.0024282988,0.00044043764,0.00029165714,0.0009649359,0.0008127468,0.001453849,0.007928702],"category_scores_gemma":[0.001160713,0.00051409047,0.0016354081,0.00037687313,0.0010479924,0.0012038791,0.00045240318,0.0032203805,0.0013685426],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9679709,0.0035105369,0.00034426482,0.0006827469,0.0006979692,0.0000345348,0.000060120325,0.0006754703,0.0029293504,0.00019396014,0.0012027018,0.02169744],"study_design_scores_gemma":[0.92797875,0.06885027,0.001124881,0.000050573464,0.0002888276,0.000039004706,0.000027075239,0.0004677446,0.0003029807,0.00021683537,0.0006371116,0.000015804206],"about_ca_topic_score_codex":0.0010266271,"about_ca_topic_score_gemma":0.0028293033,"teacher_disagreement_score":0.007928702,"about_ca_system_score_codex":0.0008681654,"about_ca_system_score_gemma":0.0007736141,"threshold_uncertainty_score":0.026524127},"labels":[],"label_agreement":null},{"id":"W2699278758","doi":"10.1016/s1470-2045(17)30318-2","title":"Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":570,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa","funders":"Cancer Research UK","keywords":"Medicine; Chemoradiotherapy; Regimen; Lung cancer; Radiation therapy; Etoposide; Chemotherapy regimen; Internal medicine; Clinical endpoint; Performance status; Surgery; Randomized controlled trial; Chemotherapy; Oncology","score_opus":0.15045437894064043,"score_gpt":0.4667886956623838,"score_spread":0.3163343167217434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2699278758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893889,0.004037239,0.0003663499,0.00044314034,0.00046952907,0.0033402652,0.0005375364,0.00007573357,0.0013412861],"genre_scores_gemma":[0.9895141,0.0018969954,0.0014591776,0.0009714154,0.0006527884,0.0034336848,0.0007231755,0.00001764096,0.0013309874],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9989623,0.0006384385,0.000075300835,0.0001578901,0.00007827629,0.0000878474],"domain_scores_gemma":[0.99788517,0.0008202411,0.00042498962,0.00021280113,0.000108454384,0.0005483037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031139276,0.0013896815,0.0031303687,0.00038968615,0.00048124083,0.0013488805,0.0009515673,0.0017724548,0.005799573],"category_scores_gemma":[0.0027137154,0.0005236519,0.0021801444,0.00048078803,0.0013714547,0.0011619759,0.00046680466,0.002600453,0.0006987046],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98446566,0.004498863,0.00035016888,0.00047964673,0.0003965735,0.000022118418,0.00003935832,0.00024208808,0.0010706111,0.00006696398,0.00029934486,0.008068545],"study_design_scores_gemma":[0.95023423,0.048242465,0.0006466585,0.00002007706,0.00016234751,0.000021955258,0.000008952817,0.00022291893,0.00011812294,0.0000682442,0.00024675392,0.0000072291473],"about_ca_topic_score_codex":0.00057205895,"about_ca_topic_score_gemma":0.0011772789,"teacher_disagreement_score":0.005799573,"about_ca_system_score_codex":0.0007437277,"about_ca_system_score_gemma":0.0011108234,"threshold_uncertainty_score":0.01940149},"labels":[],"label_agreement":null},{"id":"W2724863835","doi":"10.1016/s1470-2045(17)30448-5","title":"Radiosurgery for resected brain metastases—a new standard of care?","year":2017,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Radiosurgery; Medicine; Neurocognitive; Randomized controlled trial; Radiation therapy; Brain tumor; Brain metastasis; Nuclear medicine; Internal medicine; Cognition; Cancer; Metastasis; Pathology; Psychiatry","score_opus":0.08474161213672306,"score_gpt":0.38636621793527054,"score_spread":0.3016246057985475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2724863835","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022630337,0.0068807728,0.00019084499,0.98087597,0.009892772,0.0000039273436,0.000026941356,0.000016951239,0.0018855513],"genre_scores_gemma":[0.006642668,0.012068206,0.0005264273,0.88036114,0.0971332,0.000028792227,0.00007537627,0.000030295965,0.00313397],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996323,0.0011222494,0.0005272196,0.00032866065,0.0012116457,0.00048723354],"domain_scores_gemma":[0.9918134,0.004274006,0.00078152446,0.00032287362,0.0013126747,0.0014955816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004132671,0.00068566087,0.0017326312,0.0010458794,0.0017574382,0.0033680447,0.002082491,0.032182693,0.0067417864],"category_scores_gemma":[0.022627933,0.0005848282,0.0013225223,0.00084594445,0.004099353,0.0066399775,0.0025399716,0.040273994,0.0044252174],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017002074,0.00006184869,0.0008969389,0.00023621458,0.000047124166,0.0022941695,0.000097612356,0.0004087409,0.0004191772,0.013679952,0.91257775,0.06911045],"study_design_scores_gemma":[0.00037206954,0.00021241937,0.0010302977,0.0012408294,0.00008645222,0.0058157914,0.00038639075,0.00093328435,0.00039115388,0.061143257,0.9282653,0.0001228052],"about_ca_topic_score_codex":0.0030486768,"about_ca_topic_score_gemma":0.010940392,"teacher_disagreement_score":0.032182693,"about_ca_system_score_codex":0.0048644664,"about_ca_system_score_gemma":0.0046517244,"threshold_uncertainty_score":0.035294354},"labels":[],"label_agreement":null},{"id":"W2726395676","doi":"10.1016/s1470-2045(17)30438-2","title":"The TNM classification of malignant tumours—towards common understanding and reasonable expectations","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":286,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; National Institutes of Health; World Health Organization","keywords":"CLARITY; Profiling (computer programming); Disease; Medicine; Cancer; Pathology; Internal medicine; Computer science; Biology","score_opus":0.1075127998060665,"score_gpt":0.3980224307440145,"score_spread":0.290509630937948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2726395676","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.028502708,0.06781501,0.21700588,0.6653729,0.0068231933,0.00020357785,0.0011313802,0.00033702908,0.012808258],"genre_scores_gemma":[0.68319,0.032987487,0.14829305,0.10621598,0.024749847,0.0007541793,0.001999178,0.00030990475,0.0015003799],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.93808776,0.04004102,0.005934168,0.0038904995,0.010928337,0.0011180952],"domain_scores_gemma":[0.8594582,0.09075154,0.012712505,0.009433892,0.022528332,0.005115545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.11052611,0.0014082681,0.003423532,0.0063945977,0.0019121899,0.0115584,0.0076805213,0.006581171,0.0012527257],"category_scores_gemma":[0.2463646,0.0010967123,0.0017377671,0.0022869566,0.01637884,0.016829703,0.0061985333,0.018215206,0.0009281625],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011321378,0.00034489238,0.039876215,0.0021502506,0.00098864,0.0007084174,0.0047868253,0.015485763,0.0016109603,0.510782,0.10719696,0.31493697],"study_design_scores_gemma":[0.000056922116,0.00013924955,0.0046553393,0.001301923,0.000083365674,0.00036868211,0.001206757,0.013007379,0.00025018398,0.9606457,0.01818046,0.00010408919],"about_ca_topic_score_codex":0.0063762614,"about_ca_topic_score_gemma":0.004365067,"teacher_disagreement_score":0.11052611,"about_ca_system_score_codex":0.008284234,"about_ca_system_score_gemma":0.0079772705,"threshold_uncertainty_score":0.58452487},"labels":[],"label_agreement":null},{"id":"W2726463501","doi":"10.1016/s1470-2045(17)30441-2","title":"Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":1192,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame; Juravinski Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Radiosurgery; Brain metastasis; Radiation therapy; Clinical endpoint; Randomized controlled trial; Surgery; Metastasis; Internal medicine; Cancer","score_opus":0.08135849473403658,"score_gpt":0.40909258631001555,"score_spread":0.327734091575979,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2726463501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98375386,0.006725391,0.000896632,0.0009343649,0.0010614484,0.0028022623,0.0012145286,0.00019364581,0.0024179784],"genre_scores_gemma":[0.9814525,0.0045982134,0.0017064749,0.0014798015,0.0005578807,0.003582129,0.0014720915,0.00006137749,0.005089514],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993395,0.0003483911,0.00003518451,0.000121097786,0.00005653568,0.00009929042],"domain_scores_gemma":[0.9993112,0.00020665507,0.00018360345,0.00006563017,0.000042032396,0.00019093377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014503897,0.0021912719,0.003377866,0.00036836043,0.00046710693,0.0010934315,0.0011620125,0.0017599034,0.006652825],"category_scores_gemma":[0.001509394,0.0005646629,0.0029166858,0.00053546525,0.0014486236,0.00095769484,0.0004384178,0.0037994264,0.0013138514],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9850204,0.0019457191,0.00020033371,0.0006218129,0.0010670926,0.000017771372,0.000034576733,0.0002811853,0.001049467,0.000095745425,0.0008881849,0.008777719],"study_design_scores_gemma":[0.9567367,0.040655624,0.0010091674,0.00004178341,0.0005714501,0.000021809075,0.000019545836,0.0002687736,0.00017060048,0.00014072319,0.00035002892,0.000013814481],"about_ca_topic_score_codex":0.0028798427,"about_ca_topic_score_gemma":0.005705737,"teacher_disagreement_score":0.006652825,"about_ca_system_score_codex":0.0010089854,"about_ca_system_score_gemma":0.0012554403,"threshold_uncertainty_score":0.022255957},"labels":[],"label_agreement":null},{"id":"W2729284305","doi":"10.1016/s1470-2045(17)30445-x","title":"Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":503,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Consumers, Health, Agriculture and Food Executive Agency; Queen's University; Queen's University Belfast; European Commission","keywords":"Relative survival; Medicine; Incidence (geometry); European union; Cancer registry; Population; Demography; Cancer; Referral; Pediatrics; Internal medicine; Family medicine; Environmental health","score_opus":0.0724263099790792,"score_gpt":0.3657372715329165,"score_spread":0.2933109615538373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2729284305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99520856,0.0010754459,0.00010439466,0.00014008931,0.000016010386,0.00001804892,0.0028758433,0.0000057835555,0.0005558071],"genre_scores_gemma":[0.9961054,0.0006523438,0.0000961697,0.00014001352,0.00004431569,0.000032303626,0.0027021032,0.000011624827,0.00021575604],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99761933,0.0008560361,0.0003288044,0.000623314,0.0002544664,0.00031802172],"domain_scores_gemma":[0.9950706,0.00078683265,0.0025878928,0.00041552528,0.00052752096,0.0006116821],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018000477,0.00045058117,0.0009139024,0.0015318342,0.0004381646,0.0022942657,0.00084615924,0.0011502627,0.0019406999],"category_scores_gemma":[0.007108181,0.00053770136,0.0018776156,0.0049544084,0.0005932062,0.001748162,0.00176266,0.0010561057,0.00026685695],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006749344,0.00013342129,0.99478394,0.00006149416,0.0008291177,0.00008504926,0.0002642679,0.00023579843,0.00007560687,0.00009802338,0.00075341243,0.0020049347],"study_design_scores_gemma":[0.00008930471,0.0001518141,0.99794656,0.000038225488,0.00029643162,0.00016366153,0.0004741859,0.00015673645,0.000023309749,0.000061947525,0.00058525696,0.000012542007],"about_ca_topic_score_codex":0.01931911,"about_ca_topic_score_gemma":0.016852401,"teacher_disagreement_score":0.01931911,"about_ca_system_score_codex":0.0014841286,"about_ca_system_score_gemma":0.000944886,"threshold_uncertainty_score":0.038413346},"labels":[],"label_agreement":null},{"id":"W2737389832","doi":"10.1016/s1470-2045(17)30469-2","title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1863,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"European Society for Medical Oncology","keywords":"Olaparib; Medicine; BRCA mutation; Ovarian cancer; Internal medicine; Oncology; Placebo; PARP inhibitor; Clinical endpoint; Population; Randomized controlled trial; Cancer; Pathology","score_opus":0.05211112076256093,"score_gpt":0.3733703096465478,"score_spread":0.3212591888839869,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2737389832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9747771,0.015216589,0.0009407399,0.0010651483,0.00081308483,0.0026248079,0.0015055167,0.00029818702,0.0027587512],"genre_scores_gemma":[0.9829664,0.0063035414,0.0014325499,0.0014842099,0.0005121696,0.0020324674,0.0014577636,0.00004359632,0.0037671893],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995677,0.00021068196,0.00003058339,0.00009420187,0.00003203859,0.000064747204],"domain_scores_gemma":[0.99928975,0.00023324203,0.00013509252,0.000058439662,0.000035031993,0.0002484407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012394559,0.0015763583,0.0038570154,0.00046925954,0.00040527963,0.0012034831,0.0010507451,0.0020721043,0.005457962],"category_scores_gemma":[0.0014614968,0.0007361307,0.0016208884,0.0005165866,0.0011833366,0.001447535,0.00039672907,0.0033056715,0.0011277217],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97665817,0.0024044453,0.00034547425,0.00075086916,0.00060950354,0.00004274384,0.000044690234,0.0002192743,0.0020600418,0.00007428463,0.00070835656,0.016082117],"study_design_scores_gemma":[0.96598125,0.0317253,0.0009189216,0.00003299423,0.00021719593,0.00003794597,0.000016753864,0.00026656513,0.0002026142,0.00011473726,0.00047224687,0.000013459026],"about_ca_topic_score_codex":0.00063647627,"about_ca_topic_score_gemma":0.0013005176,"teacher_disagreement_score":0.005457962,"about_ca_system_score_codex":0.00049138354,"about_ca_system_score_gemma":0.0006703214,"threshold_uncertainty_score":0.01825869},"labels":[],"label_agreement":null},{"id":"W2739585441","doi":"10.1016/s1470-2045(17)30426-6","title":"Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Ottawa Hospital; Health Sciences Centre","funders":"Cancer Council Victoria","keywords":"Androgen deprivation therapy; Medicine; Prostate cancer; Quality of life (healthcare); Asymptomatic; Clinical endpoint; Internal medicine; Randomized controlled trial; Cancer; Pediatrics; Oncology","score_opus":0.0682546867180194,"score_gpt":0.3932217866723322,"score_spread":0.32496709995431283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2739585441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98746026,0.0061891847,0.0004469547,0.0008957078,0.0006810921,0.0015257028,0.0011205294,0.00009332088,0.0015872864],"genre_scores_gemma":[0.99256104,0.001510211,0.0007511914,0.00072411227,0.00038668865,0.0016760067,0.0006483674,0.000016381073,0.0017260059],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99914575,0.0004895188,0.000043346532,0.00014460534,0.000040160696,0.00013661363],"domain_scores_gemma":[0.99884605,0.00039254155,0.00026498616,0.000087092805,0.0000498978,0.00035944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001808251,0.0015653746,0.002589586,0.00035589127,0.00043187125,0.0013545635,0.0010734699,0.0019115446,0.0073039876],"category_scores_gemma":[0.0021218937,0.0005375837,0.0031781965,0.00041857138,0.0014257962,0.0010458659,0.0006400211,0.0046105087,0.0008235784],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98892736,0.0017929107,0.00032892262,0.0003766232,0.0005390641,0.000011942289,0.000031392738,0.00018954482,0.00057514507,0.00004687006,0.00035555317,0.006824675],"study_design_scores_gemma":[0.9476127,0.04978603,0.0015191224,0.000032517633,0.0003487731,0.000019782392,0.000019371773,0.00017865332,0.00012254236,0.0001340624,0.00021542513,0.000011062627],"about_ca_topic_score_codex":0.0016325496,"about_ca_topic_score_gemma":0.002734317,"teacher_disagreement_score":0.0073039876,"about_ca_system_score_codex":0.00092356466,"about_ca_system_score_gemma":0.0010694162,"threshold_uncertainty_score":0.024434268},"labels":[],"label_agreement":null},{"id":"W2740402187","doi":"10.1016/s1470-2045(17)30458-8","title":"Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis","year":2017,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":339,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Toronto; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Institut National Du Cancer","keywords":"Meta-analysis; Radiation therapy; Medicine; Head and neck; Oncology; Head and neck cancer; Internal medicine; Surgery","score_opus":0.2827684759502197,"score_gpt":0.5024295914096837,"score_spread":0.21966111545946398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2740402187","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0036222653,0.9947187,0.00043298156,0.00017569675,0.00024596098,0.00003217015,0.00049443234,0.000018629667,0.00025913477],"genre_scores_gemma":[0.23321936,0.758437,0.0021932279,0.0028143453,0.0007823944,0.00017839753,0.0012854487,0.000100591315,0.0009892952],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99545974,0.0018499291,0.0012003384,0.0007487416,0.000528618,0.00021254683],"domain_scores_gemma":[0.99298143,0.0048562605,0.0011490219,0.0004901283,0.00041662907,0.00010649152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007866008,0.0023377067,0.009492485,0.0020635603,0.00036335966,0.002187067,0.0017373164,0.0019279189,0.005012871],"category_scores_gemma":[0.017943801,0.0012554115,0.032271553,0.0036376037,0.00045278025,0.0017033125,0.0014845917,0.0025973113,0.00055360567],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039206413,0.000023606919,0.0092075085,0.12645233,0.8273879,0.00011669507,0.000076498894,0.00062492664,0.00039634778,0.000217127,0.0017616422,0.02981482],"study_design_scores_gemma":[0.00060736475,0.0001248998,0.005854807,0.0053996784,0.98454267,0.00007637046,0.000027841628,0.00008205506,0.000082538216,0.00026475877,0.0029170266,0.000020024105],"about_ca_topic_score_codex":0.00812313,"about_ca_topic_score_gemma":0.019260079,"teacher_disagreement_score":0.009492485,"about_ca_system_score_codex":0.0012839057,"about_ca_system_score_gemma":0.0014602469,"threshold_uncertainty_score":0.04159993},"labels":[],"label_agreement":null},{"id":"W2740545693","doi":"10.1016/s1470-2045(17)30573-9","title":"Androgen deprivation in prostate cancer: first do no harm","year":2017,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Prostatectomy; Oncology; Radiation therapy; Cancer; Internal medicine; Prostate-specific antigen; Gynecology","score_opus":0.07795646313435715,"score_gpt":0.3914052653661275,"score_spread":0.31344880223177035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2740545693","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000087754765,0.0033855715,0.00003399749,0.98197776,0.01279661,0.000004032179,0.000021348742,0.000007986082,0.0016848883],"genre_scores_gemma":[0.0015536608,0.0024894658,0.00004807507,0.9454505,0.046837658,0.000015108663,0.000015954656,0.00001277873,0.0035768908],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9930541,0.0023947118,0.00070689333,0.00058043515,0.002282528,0.0009813409],"domain_scores_gemma":[0.9819354,0.011711779,0.001336263,0.0004871924,0.0017817826,0.0027475005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055400017,0.0011353272,0.0025220562,0.00092464016,0.004697913,0.005401113,0.0021612563,0.09185823,0.011356108],"category_scores_gemma":[0.039174024,0.0010109546,0.0019072826,0.0009120366,0.0067863604,0.007001945,0.004033357,0.077533066,0.009079904],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006470479,0.000027358778,0.00030068564,0.000099582154,0.000029723684,0.00056722586,0.000088339984,0.000055442466,0.00010318461,0.0066192877,0.97837573,0.013668868],"study_design_scores_gemma":[0.0002936751,0.000110726025,0.00057090144,0.00075267593,0.000066127745,0.0014146173,0.00029654408,0.0002722033,0.00019852263,0.030074984,0.965872,0.000077148026],"about_ca_topic_score_codex":0.0055744564,"about_ca_topic_score_gemma":0.009983947,"teacher_disagreement_score":0.09185823,"about_ca_system_score_codex":0.0065480373,"about_ca_system_score_gemma":0.008338037,"threshold_uncertainty_score":0.04750949},"labels":[],"label_agreement":null},{"id":"W2745668487","doi":"10.1016/s1470-2045(17)30576-4","title":"Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":154,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Astex Pharmaceuticals","keywords":"Medicine; Myeloid leukaemia; Internal medicine","score_opus":0.05811141162999822,"score_gpt":0.3966105076241037,"score_spread":0.3384990959941055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2745668487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98521614,0.008417782,0.00042248986,0.001100646,0.0004327313,0.0012845221,0.001173316,0.00013095391,0.001821435],"genre_scores_gemma":[0.98359805,0.0060588922,0.0015197715,0.0018517778,0.00021952782,0.0015750282,0.0022599753,0.00004056985,0.0028763807],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995203,0.00026728652,0.00002326059,0.00007131704,0.00003362943,0.00008428867],"domain_scores_gemma":[0.9995184,0.00012304218,0.000104543826,0.000036815833,0.000027338234,0.00018999566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013119446,0.0013472307,0.0025135488,0.00026989132,0.0002491306,0.00085050374,0.00064292166,0.0012723368,0.0036072158],"category_scores_gemma":[0.0013319004,0.00049388385,0.0012655986,0.00041515505,0.00093474175,0.0008644303,0.00038576356,0.0028449069,0.00080582366],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93530506,0.0036176587,0.00137829,0.0013467888,0.001579586,0.000094004965,0.00011798288,0.00074602757,0.0072184727,0.00020864229,0.003211299,0.045176305],"study_design_scores_gemma":[0.9509523,0.043020386,0.0030607644,0.000044699293,0.0004656301,0.00009335431,0.00003097127,0.00027628097,0.00045543886,0.00021166657,0.0013707371,0.000017769367],"about_ca_topic_score_codex":0.0011752223,"about_ca_topic_score_gemma":0.0036263983,"teacher_disagreement_score":0.0036072158,"about_ca_system_score_codex":0.000902816,"about_ca_system_score_gemma":0.0009461579,"threshold_uncertainty_score":0.012067318},"labels":[],"label_agreement":null},{"id":"W2748154165","doi":"10.1016/s1470-2045(17)30471-0","title":"Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Clinical endpoint; Everolimus; Placebo; Discontinuation; Quality of life (healthcare); Internal medicine; Adverse effect; Clinical trial; Surgery; Pathology","score_opus":0.09983468570026899,"score_gpt":0.4149173118146561,"score_spread":0.3150826261143871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2748154165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98676527,0.008113433,0.00048525183,0.00068259466,0.0007227335,0.0014018583,0.00057383237,0.000099054494,0.0011559515],"genre_scores_gemma":[0.9913145,0.0024187085,0.0007876877,0.0007278778,0.00048005013,0.0016650329,0.0005799225,0.000018710882,0.0020075322],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99925596,0.00040544997,0.000054403616,0.00013056461,0.000039752274,0.00011377671],"domain_scores_gemma":[0.9992495,0.00025970588,0.00018556803,0.000054243857,0.000044038916,0.00020679628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017719917,0.0020885407,0.004036881,0.00043946825,0.00046099356,0.0011188692,0.0008660318,0.0024645422,0.0055451556],"category_scores_gemma":[0.0016549093,0.0007504273,0.0029761232,0.00038642573,0.0014700386,0.0013712099,0.000517149,0.0036838062,0.0007976917],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9919796,0.0015188433,0.00021960789,0.00035885934,0.0005994772,0.000016995451,0.000024458233,0.00013425859,0.0011586762,0.000033167755,0.00017257649,0.003783638],"study_design_scores_gemma":[0.945623,0.051609688,0.0013973926,0.00002731384,0.0005064345,0.00002206035,0.000018398167,0.00021492728,0.00024263827,0.000094921335,0.00023081433,0.000012509122],"about_ca_topic_score_codex":0.00062623207,"about_ca_topic_score_gemma":0.0011140455,"teacher_disagreement_score":0.0055451556,"about_ca_system_score_codex":0.0005374953,"about_ca_system_score_gemma":0.0005558274,"threshold_uncertainty_score":0.018550456},"labels":[],"label_agreement":null},{"id":"W2749746182","doi":"10.1016/s1470-2045(17)30578-8","title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":401,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"Onyx Pharmaceuticals; Amgen","keywords":"Carfilzomib; Bortezomib; Medicine; Interim analysis; Multiple myeloma; Dexamethasone; Proteasome inhibitor; Tolerability; Internal medicine; Refractory (planetary science); Clinical trial; Oncology; Surgery; Adverse effect","score_opus":0.2558644524284098,"score_gpt":0.49781809117761694,"score_spread":0.2419536387492071,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2749746182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9785696,0.009795321,0.0010359294,0.0021088042,0.00053098693,0.0013060047,0.0025158804,0.00019735887,0.003940165],"genre_scores_gemma":[0.9845829,0.002605586,0.0017325756,0.002363971,0.00051744195,0.0014383767,0.0039549354,0.00005435163,0.0027499082],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99756926,0.0016145145,0.000088401124,0.00025212744,0.0001506803,0.0003250287],"domain_scores_gemma":[0.9967631,0.0014076658,0.00056719116,0.00031445385,0.00016017978,0.0007874204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060888957,0.0017251931,0.0033970498,0.00044380315,0.00050872087,0.0019320457,0.0009740735,0.0023279386,0.004439439],"category_scores_gemma":[0.004041462,0.00054103375,0.003664887,0.00054236635,0.0018924241,0.0021285221,0.0007580503,0.0040239473,0.0009426304],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97709036,0.0015723124,0.00092809665,0.0002429051,0.0012752223,0.000035648543,0.000056323264,0.00058125873,0.0011319155,0.00016690706,0.0013084173,0.015610537],"study_design_scores_gemma":[0.926241,0.06332015,0.005706734,0.000056212193,0.0014244557,0.00008076489,0.000048231796,0.0006408431,0.00043678161,0.0005712516,0.0014401531,0.00003347176],"about_ca_topic_score_codex":0.0012465804,"about_ca_topic_score_gemma":0.0031344187,"teacher_disagreement_score":0.0060888957,"about_ca_system_score_codex":0.0013156809,"about_ca_system_score_gemma":0.0014187079,"threshold_uncertainty_score":0.03220153},"labels":[],"label_agreement":null},{"id":"W2749747068","doi":"10.1016/s1470-2045(17)30517-x","title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1113,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Foothills Medical Centre; University of Calgary; Sunnybrook Health Science Centre; Juravinski Cancer Centre","funders":"Celldex Therapeutics","keywords":"Temozolomide; Medicine; Internal medicine; Clinical endpoint; Oncology; Progression-free survival; Phases of clinical research; Clinical trial; Chemotherapy; Surgery","score_opus":0.053021347482432236,"score_gpt":0.37165072096852086,"score_spread":0.3186293734860886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2749747068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98436224,0.006408061,0.0008136383,0.00096043164,0.0008516316,0.002494646,0.0010128954,0.00018247608,0.00291418],"genre_scores_gemma":[0.98452526,0.003833538,0.0014433932,0.0011831297,0.00037797648,0.002827035,0.0011126635,0.000039568044,0.004657405],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99948525,0.00026568605,0.000023974193,0.00009241874,0.00003180156,0.00010085602],"domain_scores_gemma":[0.99952316,0.00012004781,0.000108553904,0.000042378684,0.00003118562,0.00017464586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013636884,0.0019079736,0.0024510126,0.0003810292,0.00036483412,0.0010562696,0.000880116,0.0015786624,0.005076693],"category_scores_gemma":[0.0013135193,0.0006673981,0.0019825583,0.00041441803,0.0011469879,0.0014104372,0.00041486786,0.0035057617,0.0009995507],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97801983,0.0023856938,0.00034208456,0.0005581848,0.0011449277,0.00003449463,0.00006025329,0.0003747041,0.0017793558,0.00016679775,0.0011938689,0.013939784],"study_design_scores_gemma":[0.9692444,0.028115097,0.0009651184,0.000030276957,0.0003424995,0.000028976867,0.00002319058,0.00025050197,0.0002093895,0.00021263884,0.0005641372,0.000013763912],"about_ca_topic_score_codex":0.001616977,"about_ca_topic_score_gemma":0.0037688406,"teacher_disagreement_score":0.005076693,"about_ca_system_score_codex":0.00096733426,"about_ca_system_score_gemma":0.0010743022,"threshold_uncertainty_score":0.01698327},"labels":[],"label_agreement":null},{"id":"W2752964876","doi":"10.1016/s1470-2045(17)30459-x","title":"Radiotherapy for the treatment of malignant pleural mesothelioma","year":2017,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Extrapleural Pneumonectomy; Radiation therapy; Medicine; Mesothelioma; Decortication; Pleural disease; Oncology; Radiology; Pneumonectomy; Internal medicine; Lung; Respiratory disease; Lung cancer; Pathology","score_opus":0.27779452603899,"score_gpt":0.48394010614513727,"score_spread":0.20614558010614725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2752964876","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000036161495,0.99958295,0.000022339384,0.000063916945,0.000083382976,0.0000020184539,0.0000067836663,0.0000015298698,0.00020089997],"genre_scores_gemma":[0.00043379905,0.9991062,0.000055809236,0.00012818625,0.00009852217,0.0000024488336,0.000013007139,7.040853e-7,0.00016121226],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99975306,0.000055274395,0.00004172227,0.000042180713,0.00008680968,0.000021039703],"domain_scores_gemma":[0.99956805,0.00027448704,0.000070332135,0.0000099675635,0.000060010887,0.000017151677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063192425,0.0006794604,0.0018046577,0.0016808537,0.0002075759,0.0007296664,0.0010189867,0.0010573186,0.0032285554],"category_scores_gemma":[0.0011426465,0.00025325295,0.00092055433,0.001523922,0.00040201456,0.0006790141,0.00057018606,0.0016057487,0.0010018727],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011973248,0.0000462898,0.00011351547,0.045071475,0.00035996785,0.0001495536,0.000038936523,0.0003601505,0.00091283553,0.0010295195,0.02219696,0.9296009],"study_design_scores_gemma":[0.00017064354,0.00028332,0.0018435358,0.02638089,0.0013792549,0.0023193916,0.000097414464,0.00014277369,0.00068885833,0.00166111,0.9649872,0.000045583714],"about_ca_topic_score_codex":0.002015229,"about_ca_topic_score_gemma":0.0038335086,"teacher_disagreement_score":0.0032285554,"about_ca_system_score_codex":0.00050205283,"about_ca_system_score_gemma":0.0008420135,"threshold_uncertainty_score":0.01080054},"labels":[],"label_agreement":null},{"id":"W2753659610","doi":"10.1016/s1470-2045(17)30582-x","title":"Definition and recommendations for advance care planning: an international consensus supported by the European Association for Palliative Care","year":2017,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1382,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Japanese Association of Cardiac Rehabilitation; L'Oreal USA","keywords":"Advance care planning; Delphi method; Delphi; Pooling; Palliative care; Health care; Process (computing); Adaptation (eye); Medicine; Nursing; Process management; Psychology; Medical education; Political science; Computer science; Business","score_opus":0.5513145969617606,"score_gpt":0.5722748071410236,"score_spread":0.020960210179263083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2753659610","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022657732,0.9561637,0.0034437156,0.034227,0.0022386233,0.00020419738,0.00035467744,0.000033841232,0.0031077024],"genre_scores_gemma":[0.0046306904,0.9615718,0.02019449,0.010800591,0.0008725619,0.00047163767,0.0007320084,0.000031114138,0.000695204],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9893469,0.0041140127,0.0026653975,0.0007964293,0.0025748664,0.00050236133],"domain_scores_gemma":[0.9713723,0.019131688,0.0027247546,0.0005752358,0.005245254,0.00095068774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.032108765,0.002100014,0.004192872,0.008640088,0.0015225867,0.0072711683,0.0065446324,0.006311915,0.005341832],"category_scores_gemma":[0.040156092,0.0011074925,0.0035696763,0.009512223,0.0037400988,0.0068680993,0.00658033,0.011894152,0.0020281572],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013794718,0.00011929353,0.0009236317,0.076307744,0.00039604044,0.0002656097,0.001755146,0.0015586099,0.0002440274,0.05993371,0.1091059,0.74925244],"study_design_scores_gemma":[0.00011726456,0.000067297064,0.0013398791,0.15774651,0.0007128804,0.00075453136,0.0013178068,0.00044205954,0.0002556642,0.025484527,0.8116594,0.000102087506],"about_ca_topic_score_codex":0.010564755,"about_ca_topic_score_gemma":0.014995198,"teacher_disagreement_score":0.032108765,"about_ca_system_score_codex":0.00884549,"about_ca_system_score_gemma":0.038453035,"threshold_uncertainty_score":0.1698094},"labels":[],"label_agreement":null},{"id":"W2758277690","doi":"10.1016/s1470-2045(17)30703-9","title":"SRS versus WBRT for resected brain metastases – Authors' reply","year":2017,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Radiosurgery; Medicine; Whole brain radiotherapy; Radiation therapy; Stereotactic radiotherapy; Nuclear medicine; Surgery; Internal medicine; Brain metastasis; Metastasis; Cancer","score_opus":0.17450924352181243,"score_gpt":0.43067172043897917,"score_spread":0.25616247691716676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2758277690","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019822986,0.0013715413,0.00003202925,0.9808647,0.016554149,0.0000051916536,0.00004221245,0.000008656061,0.000923256],"genre_scores_gemma":[0.0026992282,0.0009948318,0.00006531693,0.9611258,0.032536272,0.000025262936,0.000026351976,0.000016199192,0.0025107753],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996487,0.0011613128,0.0004445946,0.00043475346,0.0009130304,0.0005592688],"domain_scores_gemma":[0.98654884,0.009195741,0.00093066716,0.00026819756,0.0019121434,0.0011444291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037223077,0.00063349935,0.0017711695,0.00083372626,0.0029169468,0.003974,0.0020499073,0.05813347,0.00900014],"category_scores_gemma":[0.03682523,0.00076465186,0.0013264752,0.0008468243,0.0034166963,0.0033417377,0.00234345,0.046627544,0.0061146906],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011630343,0.000015534713,0.0004634036,0.00006748976,0.000029464109,0.0007019405,0.000115107294,0.000086229964,0.000099988836,0.001984891,0.989894,0.006425664],"study_design_scores_gemma":[0.000371018,0.0001129556,0.0010572707,0.00046886917,0.00011401885,0.0016273397,0.00063416426,0.00037731417,0.00039084337,0.015878454,0.9788518,0.00011594468],"about_ca_topic_score_codex":0.004730315,"about_ca_topic_score_gemma":0.0075543984,"teacher_disagreement_score":0.05813347,"about_ca_system_score_codex":0.0050974456,"about_ca_system_score_gemma":0.00452866,"threshold_uncertainty_score":0.03698474},"labels":[],"label_agreement":null},{"id":"W2758552192","doi":"10.1016/s1470-2045(17)30566-1","title":"Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Liver physiology and pathology","field":"Medicine","cited_by":343,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"National Institutes of Health; National Cancer Institute; National Institute for Health and Care Research; Amgen","keywords":"Medicine; Capecitabine; Epirubicin; Internal medicine; Placebo; Clinical endpoint; Gastroenterology; Phases of clinical research; Cancer; Chemotherapy; Performance status; Oncology; Surgery; Clinical trial; Pathology; Breast cancer; Colorectal cancer","score_opus":0.09008277766277609,"score_gpt":0.4101330386963679,"score_spread":0.3200502610335918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2758552192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97861755,0.012872286,0.0006844792,0.00088014104,0.00093463407,0.0027481138,0.0009457788,0.00024702496,0.0020700078],"genre_scores_gemma":[0.9815186,0.006642965,0.001413998,0.0012348722,0.0005183949,0.002871351,0.0012880506,0.00004430924,0.0044675167],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995327,0.00022316362,0.000026967864,0.00009889489,0.000028690993,0.00008967453],"domain_scores_gemma":[0.99949014,0.00013398501,0.00011224115,0.00004491969,0.000029862158,0.00018881964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001655918,0.0022136897,0.0036763882,0.00038984165,0.00037199297,0.001082689,0.0011795773,0.0017800819,0.0048817075],"category_scores_gemma":[0.001469303,0.00081435655,0.0023602939,0.0004347998,0.0011005858,0.0012350678,0.00039130883,0.0038633414,0.0011700857],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9748161,0.0029137593,0.00029646244,0.0011195266,0.0010594501,0.000045028562,0.000054493812,0.00039192988,0.0029231303,0.000093629,0.00097189686,0.015314639],"study_design_scores_gemma":[0.95911527,0.038583048,0.0008092553,0.000030652613,0.00041327812,0.000034737273,0.000013182771,0.00025068916,0.0002587236,0.00007410463,0.0004040953,0.00001299635],"about_ca_topic_score_codex":0.0011494074,"about_ca_topic_score_gemma":0.003032968,"teacher_disagreement_score":0.0048817075,"about_ca_system_score_codex":0.0008636621,"about_ca_system_score_gemma":0.0009138197,"threshold_uncertainty_score":0.016330957},"labels":[],"label_agreement":null},{"id":"W2761190519","doi":"10.1016/s1470-2045(17)30600-9","title":"Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":158,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Seed Growers' Association","keywords":"Anastrozole; Medicine; Tamoxifen; Aromatase inhibitor; Internal medicine; Breast cancer; Clinical endpoint; Oncology; Adjuvant therapy; Clinical trial; Gynecology; Cancer","score_opus":0.05707933250787036,"score_gpt":0.3853302614165258,"score_spread":0.3282509289086555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761190519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9612658,0.016214183,0.001439665,0.0033160944,0.0017527574,0.0033585993,0.005685103,0.00026151794,0.0067062792],"genre_scores_gemma":[0.9644161,0.0072487635,0.0022764353,0.0036636584,0.0008713972,0.0038942148,0.004825376,0.00007361469,0.012730473],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99940836,0.0002879936,0.00003042969,0.00010046525,0.000044665703,0.00012813015],"domain_scores_gemma":[0.9987463,0.00041786578,0.00020404869,0.00013709637,0.000050418876,0.00044427908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020024725,0.0017650661,0.0035243158,0.0004157866,0.0004299464,0.0011695576,0.00080999976,0.0016758627,0.01197893],"category_scores_gemma":[0.0020776205,0.0005919873,0.00282142,0.0004990803,0.0012905624,0.0015657285,0.0006537311,0.0039732167,0.0015655033],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9773013,0.0018523998,0.00040211095,0.00058426283,0.0009274537,0.00003919943,0.000045214794,0.00048101283,0.001237233,0.00015231206,0.0018500905,0.015127326],"study_design_scores_gemma":[0.9657128,0.030437099,0.0012343993,0.000042297066,0.0004829413,0.000048558155,0.000020629755,0.00015358662,0.00017613279,0.00034803088,0.0013309491,0.00001259508],"about_ca_topic_score_codex":0.0011782949,"about_ca_topic_score_gemma":0.0035386933,"teacher_disagreement_score":0.01197893,"about_ca_system_score_codex":0.00082551234,"about_ca_system_score_gemma":0.0011344866,"threshold_uncertainty_score":0.040073514},"labels":[],"label_agreement":null},{"id":"W2761538670","doi":"10.1016/s1470-2045(17)30787-8","title":"Extended adjuvant therapy: the role of subset analyses","year":2017,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; University of Toronto","funders":"","keywords":"Anastrozole; Medicine; Aromatase inhibitor; Tamoxifen; Adjuvant; Aromatase; Oncology; Clinical endpoint; Internal medicine; Breast cancer; Adjuvant therapy; Letrozole; Exemestane; Clinical trial; Gynecology; Cancer","score_opus":0.04827145982047389,"score_gpt":0.358169260865085,"score_spread":0.3098978010446111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761538670","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0037903788,0.03797037,0.0031382826,0.93395466,0.0151667055,0.000051086758,0.00027609945,0.000048205322,0.005604168],"genre_scores_gemma":[0.051946178,0.03990425,0.0061399257,0.70835435,0.18836391,0.00018828761,0.00028495322,0.00009685148,0.004721265],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970196,0.0016962896,0.00031479824,0.00033614735,0.00046797257,0.0001651516],"domain_scores_gemma":[0.96767825,0.026611848,0.0010159693,0.0015062008,0.0017709889,0.0014167945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007821686,0.0004801949,0.0019517981,0.00049610686,0.0006640532,0.0021795968,0.0014141902,0.006473609,0.0034005872],"category_scores_gemma":[0.025818352,0.0004205588,0.0008675456,0.00064142863,0.0016094722,0.003526244,0.0011247944,0.017312933,0.0012278511],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001332898,0.00015359414,0.01027931,0.0004209632,0.00021121754,0.0026584466,0.00018735373,0.001493658,0.0013837945,0.019979471,0.5586593,0.40323997],"study_design_scores_gemma":[0.0012161502,0.0007577981,0.008882425,0.0016109191,0.00041182654,0.008954861,0.00038645658,0.0060874154,0.0010556709,0.20191374,0.7685816,0.0001411812],"about_ca_topic_score_codex":0.0008452688,"about_ca_topic_score_gemma":0.002893718,"teacher_disagreement_score":0.007821686,"about_ca_system_score_codex":0.001676508,"about_ca_system_score_gemma":0.001284398,"threshold_uncertainty_score":0.041365504},"labels":[],"label_agreement":null},{"id":"W2762323160","doi":"10.1016/s1470-2045(17)30605-8","title":"Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; Centre Hospitalier de l’Université de Montréal; Juravinski Cancer Centre","funders":"","keywords":"Cabazitaxel; Docetaxel; Medicine; Prostate cancer; Enzalutamide; Mitoxantrone; Prednisone; Oncology; Internal medicine; Chemotherapy; Cancer; Urology; Androgen deprivation therapy; Androgen receptor","score_opus":0.0842271304700907,"score_gpt":0.3939221756151177,"score_spread":0.309695045145027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762323160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98800045,0.0051507326,0.0003213628,0.0009263475,0.00047443915,0.0011307603,0.00098477,0.00017415316,0.0028368947],"genre_scores_gemma":[0.98767483,0.0031068458,0.00076852244,0.0008700249,0.00028138165,0.0007963828,0.0014319054,0.000037311773,0.005032699],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99963117,0.00016275141,0.000014610823,0.00007615482,0.000026045393,0.000089167406],"domain_scores_gemma":[0.9994229,0.00013331069,0.00011676993,0.0000321878,0.000024649558,0.00027017167],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001230976,0.0018164702,0.0022784348,0.00045467113,0.00038568102,0.0014243915,0.0010780817,0.0014539722,0.00793036],"category_scores_gemma":[0.0010189314,0.0006922593,0.0019252672,0.00051341567,0.001376937,0.0013062877,0.00043915457,0.004040842,0.0011042278],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9674328,0.0049516894,0.0006529224,0.00069951446,0.0012132236,0.000046231755,0.000097433614,0.0007102958,0.0028748456,0.00022088141,0.0018233738,0.019276679],"study_design_scores_gemma":[0.9295324,0.06598884,0.0021272548,0.00004028555,0.00049917336,0.000058996884,0.000052863335,0.00041113156,0.0003008986,0.00019163871,0.00077482336,0.00002167195],"about_ca_topic_score_codex":0.0028886374,"about_ca_topic_score_gemma":0.008676261,"teacher_disagreement_score":0.00793036,"about_ca_system_score_codex":0.0011859541,"about_ca_system_score_gemma":0.0011961807,"threshold_uncertainty_score":0.02652973},"labels":[],"label_agreement":null},{"id":"W2765335987","doi":"10.1016/s1470-2045(17)30597-1","title":"Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":219,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; Queen's University; Vancouver General Hospital; University of Calgary; Ottawa Hospital; University Health Network; Dalhousie University; St. Joseph’s Healthcare Hamilton; Institut universitaire de cardiologie et de pneumologie de Québec; Juravinski Cancer Centre; Memorial University of Newfoundland; BC Cancer Agency; Brock University","funders":"Partenariat Canadien Contre Le Cancer; Terry Fox Research Institute; Pancreatic Cancer Action Network","keywords":"Medicine; Lung cancer; National Lung Screening Trial; Lung cancer screening; Cancer; Internal medicine; Body mass index; Family history; Prospective cohort study; Incidence (geometry); Oncology","score_opus":0.09311705415612477,"score_gpt":0.39621573381541525,"score_spread":0.3030986796592905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765335987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858167,0.0024066917,0.0024210229,0.0006263552,0.00013134892,0.0025299955,0.004879283,0.00004970668,0.0011388785],"genre_scores_gemma":[0.98570627,0.00096583046,0.004666862,0.00058888143,0.00010762164,0.0023885912,0.004343245,0.0000302626,0.0012024837],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9928387,0.0035420519,0.00037974695,0.0011174185,0.0013079329,0.00081410614],"domain_scores_gemma":[0.9933402,0.0015493571,0.0013783014,0.0014266773,0.0013785874,0.0009268121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011792843,0.002930366,0.002444562,0.0006421755,0.0038344883,0.0013218442,0.003926753,0.002856807,0.002693179],"category_scores_gemma":[0.019323992,0.0015427779,0.004151851,0.001909051,0.001328274,0.0010717849,0.001677939,0.0025084813,0.00045151115],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07290781,0.004829752,0.86133856,0.0016602923,0.017539276,0.0006579477,0.002108716,0.0016342547,0.0014391671,0.0017320106,0.008696795,0.025455436],"study_design_scores_gemma":[0.020477695,0.009344702,0.93981254,0.00043463154,0.013332992,0.0007846015,0.0012941586,0.004782099,0.00043876035,0.0016828725,0.007243535,0.00037136284],"about_ca_topic_score_codex":0.6977629,"about_ca_topic_score_gemma":0.6970337,"teacher_disagreement_score":0.3022371,"about_ca_system_score_codex":0.008810138,"about_ca_system_score_gemma":0.016591785,"threshold_uncertainty_score":0.608034},"labels":[],"label_agreement":null},{"id":"W2766668723","doi":"10.1016/s1470-2045(17)30698-8","title":"Future cancer research priorities in the USA: a Lancet Oncology Commission","year":2017,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":210,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; SickKids Foundation; Hospital for Sick Children","funders":"National Cancer Institute","keywords":"Commission; Cancer prevention; Cancer; Medicine; Political science; Public relations; Business; Internal medicine","score_opus":0.45080538052915314,"score_gpt":0.639479793813089,"score_spread":0.1886744132839358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766668723","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"incentives","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"incentives","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006255819,0.87527734,0.000079289006,0.10545482,0.017492708,0.0000059385375,0.0000543978,0.000014189486,0.0015587128],"genre_scores_gemma":[0.0016747027,0.9136473,0.00033552703,0.06921799,0.012491894,0.000019064526,0.00008307562,0.000012845566,0.0025175991],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99771357,0.00062507426,0.00024786152,0.00018478816,0.0008912491,0.0003375573],"domain_scores_gemma":[0.98898774,0.0051487745,0.0007878098,0.00015256405,0.0029517494,0.0019713999],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007174025,0.0010556872,0.0024840178,0.0022631502,0.0012025669,0.0055293753,0.0014307057,0.008882507,0.009124999],"category_scores_gemma":[0.012850185,0.0005306463,0.001306595,0.0034722628,0.0017236335,0.0071311793,0.0033172104,0.011073262,0.0028075448],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010966834,0.000038384478,0.00015786232,0.005876055,0.00008393893,0.00016585566,0.00013360064,0.00014864653,0.00018237442,0.012028125,0.7451174,0.23595807],"study_design_scores_gemma":[0.00003461626,0.000019299034,0.00021699698,0.0055772658,0.000058385616,0.00014825791,0.00019522883,0.000032311385,0.00003486667,0.0053417003,0.98832315,0.000018010682],"about_ca_topic_score_codex":0.006240886,"about_ca_topic_score_gemma":0.01738626,"teacher_disagreement_score":0.992826,"about_ca_system_score_codex":0.0066974494,"about_ca_system_score_gemma":0.025797695,"threshold_uncertainty_score":0.04859358},"labels":[],"label_agreement":null},{"id":"W2766848342","doi":"10.1016/s1470-2045(17)30677-0","title":"Cancer incidence and mortality among young adults aged 20–39 years worldwide in 2012: a population-based study","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":587,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"European Commission; World Health Organization","keywords":"Life expectancy; Cancer; Demography; Medicine; Young adult; Socioeconomic status; Population; Incidence (geometry); Disease; Human Development Index; Cancer registry; Gerontology; Environmental health; Pathology; Human development (humanity); Internal medicine","score_opus":0.054312270788177595,"score_gpt":0.3959895759348087,"score_spread":0.34167730514663114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766848342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98155814,0.0019455311,0.0002933184,0.00018262696,0.000026686994,0.00013131039,0.013912554,0.000016492166,0.0019333977],"genre_scores_gemma":[0.9881648,0.0016577455,0.00037545702,0.00023410107,0.000061128754,0.00017298509,0.008783978,0.0000061361125,0.0005436414],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999617,0.00006169947,0.00007649723,0.00009467973,0.00009679272,0.000053330587],"domain_scores_gemma":[0.9994091,0.00004310966,0.00023196102,0.000039095707,0.00015996268,0.0001168102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068159157,0.00025590466,0.00042916657,0.0013581571,0.0004233852,0.0005817145,0.00034671836,0.00039502897,0.0011233664],"category_scores_gemma":[0.0011036193,0.00029163325,0.00057528797,0.002497584,0.00019142053,0.0007558535,0.000554319,0.00047988878,0.0006087068],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025334442,0.000027837948,0.9978877,0.000044650893,0.000043157397,0.00004623018,0.00012126958,0.000015175426,0.00006397025,0.000011630254,0.00043733598,0.001275768],"study_design_scores_gemma":[0.0000031210727,0.000037757763,0.9988354,0.000022948245,0.000036234625,0.00013622778,0.0002467592,0.00003291507,0.000017156195,0.0000074410796,0.0006209259,0.0000031026284],"about_ca_topic_score_codex":0.01562985,"about_ca_topic_score_gemma":0.022614498,"teacher_disagreement_score":0.01562985,"about_ca_system_score_codex":0.00050846394,"about_ca_system_score_gemma":0.0007164471,"threshold_uncertainty_score":0.031077743},"labels":[],"label_agreement":null},{"id":"W2767266730","doi":"10.1016/s1470-2045(17)30700-3","title":"Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis","year":2017,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":345,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer; Universiteit van Amsterdam; Medical Research Council; Genesis Research Trust; British Society for Colposcopy and Cervical Pathology","keywords":"Medicine; Cervical intraepithelial neoplasia; Meta-analysis; Cervical cancer; MEDLINE; Surgery; Oncology; Internal medicine; Cancer","score_opus":0.44142660882086193,"score_gpt":0.5322687875650057,"score_spread":0.0908421787441438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767266730","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007131251,0.99163646,0.0003550204,0.00012133616,0.0001370698,0.0001195779,0.00031365835,0.000013187463,0.00017240463],"genre_scores_gemma":[0.37373617,0.62046343,0.00220878,0.0015337873,0.00032192483,0.0004872063,0.00070479733,0.000035909834,0.0005079491],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9949443,0.0019717421,0.001576662,0.0007697334,0.0005024838,0.00023506983],"domain_scores_gemma":[0.9872614,0.0090884045,0.002264792,0.0005172474,0.0006464606,0.00022166588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006926213,0.0020680802,0.0134967845,0.002771208,0.00051956257,0.0024139096,0.0018559174,0.0023147573,0.004239944],"category_scores_gemma":[0.022561414,0.0014956867,0.031357307,0.0037856605,0.00072483753,0.0017681447,0.0015389228,0.0023899216,0.0003474445],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025455025,0.000040190596,0.010512153,0.23155801,0.74341494,0.00012995403,0.00010898505,0.00034507026,0.00020543573,0.00008085645,0.000490353,0.01056854],"study_design_scores_gemma":[0.0004892263,0.00016130247,0.00421304,0.00864255,0.9853973,0.00006558321,0.000049480786,0.00009280497,0.00004719891,0.00010212997,0.0007194364,0.000019908462],"about_ca_topic_score_codex":0.008545191,"about_ca_topic_score_gemma":0.025162164,"teacher_disagreement_score":0.0134967845,"about_ca_system_score_codex":0.0018085463,"about_ca_system_score_gemma":0.0026468541,"threshold_uncertainty_score":0.036629736},"labels":[],"label_agreement":null},{"id":"W2767287110","doi":"10.1016/s1470-2045(17)30690-3","title":"Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":349,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Quality of life (healthcare); Lung cancer; Discontinuation; Response Evaluation Criteria in Solid Tumors; Oncology; Clinical endpoint; Cancer; Clinical trial; Chemotherapy; Progressive disease; Immunotherapy; Nursing","score_opus":0.18616216440643962,"score_gpt":0.4962273689759054,"score_spread":0.3100652045694658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767287110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862618,0.0060022254,0.0005784631,0.001033579,0.0005801879,0.0019488009,0.0014362391,0.000092759714,0.0020659803],"genre_scores_gemma":[0.991738,0.0014693119,0.0008388167,0.00080440775,0.00029129675,0.0017991565,0.001137007,0.0000224855,0.0018995208],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988801,0.0006370055,0.000060292958,0.00020239406,0.00006844733,0.00015183154],"domain_scores_gemma":[0.99889743,0.00039500557,0.00028221594,0.00008815774,0.000057762358,0.0002793574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002855164,0.002138372,0.0029570772,0.00039100475,0.0005104243,0.0014741324,0.0010847315,0.0023765347,0.0075668995],"category_scores_gemma":[0.002402119,0.0007630228,0.0032211656,0.0003854364,0.0013815252,0.001746939,0.00065391057,0.0045065526,0.0010959024],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9865046,0.0020731355,0.00035188402,0.00042814587,0.0009869047,0.000019082432,0.000030082094,0.0002735856,0.0014661149,0.000058037363,0.00044405932,0.007364279],"study_design_scores_gemma":[0.9549946,0.04149203,0.0017428152,0.000033402506,0.000682871,0.000025176532,0.000017839253,0.0002574092,0.00026968768,0.00015245944,0.00031884646,0.00001283899],"about_ca_topic_score_codex":0.00081899035,"about_ca_topic_score_gemma":0.0012571897,"teacher_disagreement_score":0.0075668995,"about_ca_system_score_codex":0.0012500534,"about_ca_system_score_gemma":0.0007485439,"threshold_uncertainty_score":0.025313795},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"agree"},{"id":"W2767470081","doi":"10.1016/s1470-2045(17)30691-5","title":"Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":172,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre","funders":"National Cancer Institute; National Institutes of Health; American College of Radiology Imaging Network","keywords":"Medicine; Bevacizumab; Docetaxel; Internal medicine; Gemcitabine; Vinorelbine; Oncology; Pemetrexed; Lung cancer; Chemotherapy; Regimen; Cancer; Chemotherapy regimen; Surgery; Cisplatin","score_opus":0.057940193869425914,"score_gpt":0.41199314246569974,"score_spread":0.35405294859627384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767470081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98714185,0.0059636277,0.0006648148,0.0007282292,0.0006551322,0.0018804029,0.0007763664,0.00010331727,0.002086295],"genre_scores_gemma":[0.9887855,0.0027560417,0.0011225395,0.0015367165,0.00027712347,0.0015818151,0.001285513,0.000021447171,0.0026333749],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994469,0.00027044164,0.000034518354,0.00011214567,0.0000329769,0.00010289741],"domain_scores_gemma":[0.99947685,0.0001418155,0.000131005,0.000036235393,0.000027827718,0.00018614098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014160561,0.0014078947,0.0025226008,0.00033755324,0.00028283487,0.0010473112,0.0008022449,0.0015949429,0.005139026],"category_scores_gemma":[0.001328753,0.0005592041,0.0023247579,0.0003563625,0.0009971524,0.0011638408,0.00046087158,0.002765257,0.0009173274],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.968218,0.0032956032,0.0007667741,0.00093488133,0.0014534894,0.00003708807,0.0000744562,0.00063451397,0.0025090368,0.0001890396,0.0012391816,0.020647865],"study_design_scores_gemma":[0.9351425,0.06024386,0.002173927,0.00006491536,0.00072951685,0.000034142224,0.000032585383,0.00045860183,0.0002222106,0.00019335306,0.0006880793,0.000016358526],"about_ca_topic_score_codex":0.0015687624,"about_ca_topic_score_gemma":0.0041181073,"teacher_disagreement_score":0.005139026,"about_ca_system_score_codex":0.0009800097,"about_ca_system_score_gemma":0.00088144076,"threshold_uncertainty_score":0.017191768},"labels":[],"label_agreement":null},{"id":"W2768649895","doi":"10.1016/s1470-2045(17)30716-7","title":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":529,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; McGill University","funders":"Johnson and Johnson; F. Hoffmann-La Roche; Eli Lilly and Company","keywords":"Pertuzumab; Medicine; Trastuzumab; Trastuzumab emtansine; Docetaxel; Oncology; Internal medicine; Breast cancer; Carboplatin; Regimen; Neoadjuvant therapy; Metastatic breast cancer; Cancer; Chemotherapy","score_opus":0.09179359523436297,"score_gpt":0.4422125994061898,"score_spread":0.3504190041718268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768649895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868058,0.0028077904,0.0005574957,0.00070151663,0.00046057484,0.0063402047,0.00057315204,0.00007408715,0.0016795353],"genre_scores_gemma":[0.98126596,0.0017666381,0.0025453821,0.0012684839,0.0004835172,0.009640353,0.000724344,0.00002018453,0.0022852556],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984067,0.001050591,0.000091020454,0.00019017061,0.000076545,0.00018502114],"domain_scores_gemma":[0.9982352,0.00053670886,0.00038062292,0.00014757122,0.00009002868,0.0006096984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035026232,0.0012701488,0.0025950589,0.0003341782,0.00052848516,0.0009900918,0.0008576257,0.0017002448,0.004709816],"category_scores_gemma":[0.002653496,0.00064938684,0.0018163812,0.00037603677,0.001364842,0.0013132753,0.0005947174,0.0023016646,0.0006645056],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98607475,0.0048883785,0.00031489722,0.00025641816,0.00025322137,0.00002070734,0.000053018786,0.0002452843,0.0013727287,0.00006182354,0.0003446593,0.0061140847],"study_design_scores_gemma":[0.92932355,0.06873528,0.0008405058,0.000022160179,0.00015935501,0.000024671817,0.000013645605,0.00020331902,0.00016714234,0.00009870732,0.00039988765,0.000011723668],"about_ca_topic_score_codex":0.00075084006,"about_ca_topic_score_gemma":0.0022693705,"teacher_disagreement_score":0.004709816,"about_ca_system_score_codex":0.00094509125,"about_ca_system_score_gemma":0.0019190265,"threshold_uncertainty_score":0.018523872},"labels":[],"label_agreement":null},{"id":"W2768980003","doi":"10.1016/s1470-2045(17)30717-9","title":"Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":589,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; BC Cancer Agency","funders":"National Institute for Health and Care Research; Puma Biotechnology","keywords":"Medicine; Neratinib; Trastuzumab; Internal medicine; Breast cancer; Oncology; Clinical endpoint; Placebo; Regimen; Metastatic breast cancer; Adverse effect; Cancer; Clinical trial; Pathology","score_opus":0.09916280515671266,"score_gpt":0.4624950642930083,"score_spread":0.36333225913629563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768980003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97624683,0.015154864,0.0012905045,0.0010499799,0.001055766,0.0017069249,0.0014288902,0.00019241255,0.001873843],"genre_scores_gemma":[0.9867225,0.0046344716,0.0011193507,0.0010664297,0.0004391076,0.0013979733,0.0014365155,0.00004223547,0.0031412926],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99864286,0.0007343357,0.000086980384,0.00022966668,0.000083605635,0.00022251568],"domain_scores_gemma":[0.99850625,0.0004913181,0.0003563138,0.00017337284,0.000091421025,0.00038134604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036568134,0.0022078059,0.0050506205,0.00046603687,0.00045831114,0.0015948701,0.0012633096,0.0022854123,0.0051443605],"category_scores_gemma":[0.0030249518,0.00069535634,0.004394197,0.0005563044,0.0014974716,0.002510563,0.0005829897,0.004596834,0.0010390492],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98885286,0.0011325472,0.00031085775,0.00051276863,0.0015207169,0.000029232688,0.000031368585,0.00030426262,0.0007890726,0.00007557468,0.0004000105,0.006040598],"study_design_scores_gemma":[0.97229385,0.024257781,0.0013884794,0.000041238152,0.0009188283,0.000037094644,0.000025082454,0.00028438968,0.00018833025,0.00017509617,0.0003718367,0.000018033785],"about_ca_topic_score_codex":0.0009790853,"about_ca_topic_score_gemma":0.0022011623,"teacher_disagreement_score":0.0051443605,"about_ca_system_score_codex":0.0009729541,"about_ca_system_score_gemma":0.0008754494,"threshold_uncertainty_score":0.019339323},"labels":[],"label_agreement":null},{"id":"W2772259112","doi":"10.1016/s1470-2045(17)30856-2","title":"Go, no-go decision making for phase 3 clinical trials: ACT IV revisited – Authors' reply","year":2017,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Foothills Medical Centre; University of Calgary; Sunnybrook Health Science Centre; Juravinski Cancer Centre","funders":"Novartis; Actelion Pharmaceuticals; Roche; Merck; Bristol-Myers Squibb","keywords":"Go/no go; Phase (matter); Clinical decision making; Medicine; Psychology; Intensive care medicine; Economics; Operations management; Chemistry","score_opus":0.8258981385330232,"score_gpt":0.7328234551869758,"score_spread":0.0930746833460474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2772259112","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008077814,0.00035158865,0.000055114753,0.993792,0.005277125,0.0000048679317,0.000025176907,0.00000773193,0.00040566217],"genre_scores_gemma":[0.0009678557,0.00016308446,0.00011473408,0.9901731,0.008027687,0.000022512644,0.000009006547,0.000010345693,0.00051161955],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.96187454,0.017543573,0.005842415,0.0037452336,0.0075024096,0.003491924],"domain_scores_gemma":[0.82424754,0.13952987,0.007473953,0.0035788533,0.015509943,0.0096598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.04044344,0.00090146094,0.003318385,0.0013794183,0.0068173753,0.009642532,0.005446319,0.14814697,0.0075156763],"category_scores_gemma":[0.18418594,0.0020388267,0.0027057761,0.0019685952,0.014629982,0.008961233,0.0050881943,0.12620908,0.00689792],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000089383255,0.000022776401,0.00043150535,0.00010045519,0.000050295588,0.00046433666,0.00041901664,0.00008098797,0.000094675954,0.007860845,0.98526233,0.0051233373],"study_design_scores_gemma":[0.00058121624,0.000092149945,0.001198046,0.0010969413,0.00017068158,0.0010607269,0.0011607276,0.0006194185,0.00040481414,0.051833782,0.9414776,0.0003038503],"about_ca_topic_score_codex":0.009701685,"about_ca_topic_score_gemma":0.014089841,"teacher_disagreement_score":0.14814697,"about_ca_system_score_codex":0.010254378,"about_ca_system_score_gemma":0.02034959,"threshold_uncertainty_score":0.21388787},"labels":[],"label_agreement":null},{"id":"W2775223042","doi":"10.1016/s1470-2045(17)30612-5","title":"An integrated multidisciplinary algorithm for the management of spinal metastases: an International Spine Oncology Consortium report","year":2017,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":355,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Multidisciplinary approach; Radiosurgery; Spinal cord; Metastasis; Vertebral column; Spinal column; Radiology; Cancer; Medical physics; Radiation therapy; Surgery; Internal medicine","score_opus":0.2200781386489042,"score_gpt":0.5176297738599871,"score_spread":0.2975516352110829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2775223042","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008550236,0.99065757,0.0015241376,0.0038886196,0.0006186875,0.00008152221,0.00010634478,0.000022536355,0.0022454823],"genre_scores_gemma":[0.011180737,0.9752999,0.009268108,0.002543724,0.00057660707,0.00009096499,0.00039631818,0.000008926467,0.0006348288],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993874,0.00014411254,0.0001107046,0.00008504806,0.00022406579,0.00004862929],"domain_scores_gemma":[0.9989434,0.00038293883,0.00013853473,0.000021577263,0.00044414072,0.00006938111],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020236224,0.0006375293,0.001121059,0.0016713452,0.00028399084,0.0011457665,0.0013364034,0.00087159657,0.0017267928],"category_scores_gemma":[0.0034042217,0.00021997686,0.0013774945,0.0015005443,0.0002939465,0.0010376222,0.0008173629,0.0021630318,0.00048615763],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009396331,0.000065206266,0.0012355668,0.007529726,0.00034131217,0.00010845384,0.00005012691,0.0011479242,0.00022651217,0.002054376,0.025841614,0.9613053],"study_design_scores_gemma":[0.0006182345,0.00065122085,0.024996167,0.08459419,0.005018844,0.004584942,0.00041959554,0.0040443917,0.0008578442,0.0076849232,0.86636484,0.00016477537],"about_ca_topic_score_codex":0.006663857,"about_ca_topic_score_gemma":0.017071286,"teacher_disagreement_score":0.006663857,"about_ca_system_score_codex":0.0021130352,"about_ca_system_score_gemma":0.004406859,"threshold_uncertainty_score":0.015331149},"labels":[],"label_agreement":null},{"id":"W2776537462","doi":"10.1016/s1470-2045(17)30693-9","title":"Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group","year":2017,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Queen's University","funders":"Bayer Fund; Roche; Teva Pharmaceutical Industries; Karyopharm Therapeutics; Novartis; Dietmar Hopp Stiftung; AbbVie; Merck; GlaxoSmithKline; Pfizer; Boehringer Ingelheim; Siemens USA; AstraZeneca; National Institutes of Health; Medtronic","keywords":"Medicine; Clinical trial; Systemic therapy; Oncology; Guideline; Internal medicine; Efficacy; Regimen; Surrogate endpoint; Clinical study design; Intensive care medicine; Drug; Cancer; Pharmacology; Pathology; Breast cancer","score_opus":0.3621266698721051,"score_gpt":0.5249072376343089,"score_spread":0.1627805677622038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2776537462","genre_codex":"review","genre_gemma":"methods","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012991601,0.9795659,0.0030127019,0.007201543,0.0018498453,0.0023531122,0.0010181468,0.00011043792,0.0035890704],"genre_scores_gemma":[0.036099806,0.9058117,0.021106841,0.019667765,0.002113812,0.008582818,0.0022257604,0.00012909439,0.004262448],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9938513,0.003887733,0.0011232607,0.00032766306,0.00064471643,0.00016521044],"domain_scores_gemma":[0.98732287,0.009583142,0.0018032463,0.00024819514,0.0007609397,0.00028166038],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013982016,0.001047667,0.0050130826,0.0010061163,0.00025609555,0.002218769,0.0019847173,0.0028852923,0.0054121697],"category_scores_gemma":[0.020009037,0.00043924482,0.004814322,0.00097612845,0.00052123447,0.0011883157,0.0007478526,0.004347407,0.0013484977],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008050811,0.00020990842,0.00058558444,0.12825471,0.0062552495,0.000115470495,0.00015384244,0.001400565,0.0014723662,0.004755218,0.068768494,0.7799778],"study_design_scores_gemma":[0.053676296,0.004099626,0.005562593,0.17498176,0.02808354,0.0006927488,0.00020091362,0.0026868053,0.0018404694,0.02019445,0.7077919,0.00018888112],"about_ca_topic_score_codex":0.0013159761,"about_ca_topic_score_gemma":0.0039284076,"teacher_disagreement_score":0.986018,"about_ca_system_score_codex":0.0014914888,"about_ca_system_score_gemma":0.0027588173,"threshold_uncertainty_score":0.07394481},"labels":[],"label_agreement":null},{"id":"W2776736524","doi":"10.1016/s1470-2045(17)30912-9","title":"Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1–2 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency","funders":"National Center for Advancing Translational Sciences; BC Cancer Agency; University of British Columbia","keywords":"Brentuximab vedotin; Medicine; Bendamustine; Anaplastic large-cell lymphoma; Internal medicine; Oncology; Regimen; Lymphoma; Chemotherapy; Chemotherapy regimen; Refractory (planetary science); Surgery; CD30; Rituximab","score_opus":0.15133620773205653,"score_gpt":0.43123620369396665,"score_spread":0.2798999959619101,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2776736524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862596,0.008106565,0.0005725109,0.0008403604,0.00042650008,0.00067075546,0.00078173,0.00010514217,0.0022368773],"genre_scores_gemma":[0.98968494,0.0035566324,0.0011626811,0.0011658383,0.00019568997,0.00066682184,0.0014064425,0.00003235612,0.002128596],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994729,0.0002465311,0.000018917117,0.0000956135,0.000036456673,0.00012955668],"domain_scores_gemma":[0.9994449,0.00011204185,0.000097813034,0.00004607046,0.00002479749,0.0002744111],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001675136,0.0015926363,0.002372834,0.0003349533,0.00030795997,0.0011137319,0.0008935844,0.0010706577,0.0028845295],"category_scores_gemma":[0.0010007881,0.0004998644,0.0014267524,0.0003917033,0.0010876822,0.0014308147,0.00048812904,0.0037639292,0.0007200863],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92080426,0.005897897,0.0014383806,0.0009851408,0.0019687489,0.000107258464,0.00016014985,0.0021642293,0.00762769,0.0003366504,0.0029070403,0.055602595],"study_design_scores_gemma":[0.9203438,0.07137642,0.0041299486,0.000060248392,0.0005560597,0.00012861623,0.00005142091,0.0007095345,0.00065124984,0.00037443684,0.0015903546,0.000027982911],"about_ca_topic_score_codex":0.0008614464,"about_ca_topic_score_gemma":0.0022551934,"teacher_disagreement_score":0.0028845295,"about_ca_system_score_codex":0.0010054178,"about_ca_system_score_gemma":0.00080792117,"threshold_uncertainty_score":0.009649754},"labels":[],"label_agreement":null},{"id":"W2778244968","doi":"10.1016/s1470-2045(17)30915-4","title":"Complications during minimal invasive thoracic surgery: are new surgeons prepared?","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Thoracotomy; Cardiothoracic surgery; Surgery; Robotic surgery; Open surgery; General surgery; Lung cancer","score_opus":0.11012324832517882,"score_gpt":0.39920204456266895,"score_spread":0.2890787962374901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2778244968","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015765635,0.24329104,0.0008526168,0.70615405,0.023872087,0.000035663317,0.0003611529,0.00007006773,0.00959775],"genre_scores_gemma":[0.1719771,0.4437938,0.0027675189,0.24936843,0.12717304,0.0001267654,0.00082681613,0.00014840657,0.0038181855],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99152464,0.00303131,0.001391064,0.00074662187,0.0022167577,0.0010895972],"domain_scores_gemma":[0.912727,0.03733706,0.02211302,0.0024074535,0.013589205,0.011826397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010805063,0.00059125596,0.0018909465,0.0015656956,0.0021366107,0.008423099,0.0016936694,0.01047549,0.009295032],"category_scores_gemma":[0.08994175,0.00079483044,0.0016720345,0.002051865,0.0034387738,0.0104549825,0.0024849735,0.015142336,0.0020517479],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014206077,0.00043688263,0.06481226,0.0035183388,0.00059508806,0.0018269925,0.0019808407,0.00092802156,0.0005346576,0.008801297,0.33983606,0.5753089],"study_design_scores_gemma":[0.0011341755,0.0026370508,0.2500549,0.03285245,0.0016692771,0.015029863,0.029373238,0.0011780716,0.0008573613,0.0888563,0.57529765,0.001059662],"about_ca_topic_score_codex":0.0046543856,"about_ca_topic_score_gemma":0.009311983,"teacher_disagreement_score":0.010805063,"about_ca_system_score_codex":0.0028707162,"about_ca_system_score_gemma":0.007859718,"threshold_uncertainty_score":0.05714327},"labels":[],"label_agreement":null},{"id":"W2780407194","doi":"10.1016/s1470-2045(17)30692-7","title":"Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group","year":2017,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"AbbVie; Novartis; Roche; Merck; GlaxoSmithKline","keywords":"Clinical trial; Clinical endpoint; Medicine; Context (archaeology); Guideline; Clinical study design; Oncology; Surrogate endpoint; Medical physics; Internal medicine; Intensive care medicine; Pathology","score_opus":0.45547192864289415,"score_gpt":0.5629153715408106,"score_spread":0.10744344289791646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2780407194","genre_codex":"review","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018038256,0.92025214,0.018364998,0.022520352,0.007595863,0.017362792,0.004210969,0.00046145174,0.0074277106],"genre_scores_gemma":[0.053843196,0.680729,0.12147391,0.04977366,0.0062684715,0.07015319,0.007121687,0.00066131295,0.009975624],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9526669,0.03525712,0.0067684324,0.0014722265,0.0033055292,0.00052984763],"domain_scores_gemma":[0.9314771,0.054746475,0.0072891903,0.0017451057,0.0037501364,0.0009920221],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.056784395,0.0018722106,0.008587685,0.001727781,0.00055448205,0.0045235874,0.0035899743,0.005514473,0.008307681],"category_scores_gemma":[0.08150981,0.00096988823,0.0094131585,0.001836311,0.0012471427,0.0019618752,0.0015133446,0.008244125,0.002938508],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016066894,0.00026907265,0.00089069107,0.1748441,0.013293965,0.0001415127,0.00031444686,0.0019498678,0.0016446112,0.0089779245,0.112405725,0.66920125],"study_design_scores_gemma":[0.08717053,0.0036540742,0.00589847,0.21812826,0.04179478,0.0005921068,0.00023451433,0.0040929723,0.0021079988,0.03866321,0.59734416,0.0003190038],"about_ca_topic_score_codex":0.0020192408,"about_ca_topic_score_gemma":0.005488621,"teacher_disagreement_score":0.056784395,"about_ca_system_score_codex":0.0028307443,"about_ca_system_score_gemma":0.0065228236,"threshold_uncertainty_score":0.30030817},"labels":[],"label_agreement":null},{"id":"W2785671534","doi":"10.1016/s1470-2045(17)30899-9","title":"Chromatin organisation and cancer prognosis: a pan-cancer study","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Genomics and Chromatin Dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Norges Forskningsråd; Universitetet i Oslo; National Institute for Health and Care Research; Institute of Genetics; Helse Sør-Øst RHF; NIHR Bristol Biomedical Research Centre; National Institutes of Health; Cancer Research UK; Wellcome Trust","keywords":"Cancer; Chromatin; Oncology; Colorectal cancer; Hazard ratio; Stage (stratigraphy); Medicine; Internal medicine; Cohort; Cancer research; Biology; Gene; Genetics","score_opus":0.02451727799611411,"score_gpt":0.32319909924616175,"score_spread":0.29868182125004766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2785671534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99448663,0.0040019024,0.000307833,0.00010505293,0.000010536291,0.000018092747,0.0004919871,0.000012240788,0.00056559907],"genre_scores_gemma":[0.9987625,0.00053138804,0.00010942531,0.00003394904,0.000021862093,0.000009430069,0.00041277503,0.0000037936786,0.000114868286],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995371,0.00014817374,0.000023659984,0.00019654522,0.000037156766,0.000057286743],"domain_scores_gemma":[0.9985305,0.00033928035,0.00041772253,0.0002986422,0.00010908162,0.0003048186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011173546,0.00041644648,0.00064862106,0.00068831677,0.00041292523,0.00072478846,0.00033994467,0.0005126787,0.0026225857],"category_scores_gemma":[0.0016711345,0.00024675435,0.0005883177,0.0013448629,0.000573325,0.00045562937,0.00085906056,0.00054614525,0.00023867753],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003149267,0.0000650072,0.9828621,0.00010571161,0.0010273454,0.00012677906,0.00010101155,0.00018860342,0.0018359827,0.00009127418,0.0003425391,0.010104365],"study_design_scores_gemma":[0.00013232054,0.0005712506,0.9960115,0.000021539043,0.0007048156,0.00059148174,0.0000729774,0.00031234976,0.00022792576,0.0001394823,0.0012059694,0.000008333393],"about_ca_topic_score_codex":0.0018309646,"about_ca_topic_score_gemma":0.0025749588,"teacher_disagreement_score":0.0026225857,"about_ca_system_score_codex":0.00040942032,"about_ca_system_score_gemma":0.00037397386,"threshold_uncertainty_score":0.0087733865},"labels":[],"label_agreement":null},{"id":"W2787010973","doi":"10.1016/s1470-2045(18)30032-9","title":"Young adults: a unique group in cancer epidemiological research – Authors' reply","year":2018,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"World Health Organization","keywords":"Scopus; Cancer; Incidence (geometry); Demography; Medicine; International agency; Epidemiology; Population; Cancer registry; Young adult; Gerontology; MEDLINE; Pathology; Environmental health; Internal medicine; Political science","score_opus":0.2359367407698882,"score_gpt":0.4880265055722506,"score_spread":0.2520897648023624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2787010973","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024400144,0.0008922585,0.000021906539,0.9801909,0.018329814,0.000004339367,0.000030778778,0.000006597394,0.00027948315],"genre_scores_gemma":[0.002254303,0.00097209594,0.00006615117,0.9603394,0.03496098,0.00004089834,0.000022746408,0.000010574289,0.0013328445],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9931322,0.0024311114,0.0010592403,0.000899562,0.0016038874,0.0008741208],"domain_scores_gemma":[0.95457363,0.02871618,0.003515694,0.0013084369,0.0061677555,0.0057183076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007497583,0.00067268615,0.0019629989,0.0010126652,0.004480474,0.0042294683,0.0021652395,0.05398028,0.0054706396],"category_scores_gemma":[0.068982676,0.0012284208,0.0011074281,0.0010222713,0.0042654546,0.005713734,0.004530354,0.049423162,0.003915889],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019910598,0.000014526217,0.0015002651,0.000086975626,0.000020839381,0.0007858174,0.0004924942,0.00001989194,0.0000589796,0.0010479889,0.9910467,0.00490558],"study_design_scores_gemma":[0.00012804272,0.0000831937,0.0029475102,0.0008342116,0.000074463554,0.0029798308,0.0035512247,0.00014578173,0.00019829508,0.005938392,0.9830073,0.00011170514],"about_ca_topic_score_codex":0.004162835,"about_ca_topic_score_gemma":0.0066519463,"teacher_disagreement_score":0.05398028,"about_ca_system_score_codex":0.0032958544,"about_ca_system_score_gemma":0.0068317926,"threshold_uncertainty_score":0.039651453},"labels":[],"label_agreement":null},{"id":"W2787725515","doi":"10.1016/s1470-2045(18)30079-2","title":"Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":623,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Hôpital Notre-Dame; Université de Sherbrooke","funders":"Agenzia Italiana del Farmaco, Ministero della Salute; National Health and Medical Research Council; Cancer Research UK; Cancer Australia; Strong; Cancer Research Institute","keywords":"Medicine; Endometrial cancer; Radiation therapy; Chemoradiotherapy; Carboplatin; Internal medicine; Oncology; Lymphadenectomy; Clinical endpoint; Clinical trial; Surgery; Gynecology; Cancer; Chemotherapy; Cisplatin","score_opus":0.11775227188093922,"score_gpt":0.43636421173025913,"score_spread":0.3186119398493199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2787725515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9646283,0.014682202,0.0016782191,0.0020169236,0.000794551,0.009069654,0.0034548647,0.00015405029,0.0035212908],"genre_scores_gemma":[0.96415716,0.006366942,0.0053449413,0.0026848938,0.0006662664,0.01277046,0.0038767122,0.000051920684,0.0040806346],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987232,0.0009687902,0.000056365083,0.00009625733,0.00006581242,0.00008956663],"domain_scores_gemma":[0.9983669,0.0006539075,0.000423925,0.00014686592,0.00009558004,0.00031286248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004249917,0.0011200706,0.0015380358,0.00026930758,0.0003112155,0.0009205512,0.00068668264,0.0012234463,0.0056898333],"category_scores_gemma":[0.004318621,0.00032765488,0.0027233127,0.00039710785,0.00067753735,0.0007874689,0.0005037318,0.0024768102,0.0006202928],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9695164,0.0033658398,0.0009940005,0.0010094458,0.0016755229,0.000047536956,0.000057305362,0.0004689421,0.0010739772,0.00013095081,0.0016371254,0.020023033],"study_design_scores_gemma":[0.9456088,0.048624437,0.0024953953,0.000107130036,0.001002071,0.00006812925,0.000023098228,0.00033126326,0.00025297064,0.00024810896,0.0012231385,0.000015554146],"about_ca_topic_score_codex":0.0005404243,"about_ca_topic_score_gemma":0.0015729346,"teacher_disagreement_score":0.0056898333,"about_ca_system_score_codex":0.00059285545,"about_ca_system_score_gemma":0.0011223155,"threshold_uncertainty_score":0.022475958},"labels":[],"label_agreement":null},{"id":"W2788428060","doi":"10.1016/s1470-2045(18)30076-7","title":"Cancer groundshot: going global before going to the moon","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Commission; Political science; Cancer; Global health; European commission; Pandemic; Public relations; European union; Public administration; Health care; Medicine; Economic growth; Coronavirus disease 2019 (COVID-19); Business; Law; Economics; International trade; Internal medicine","score_opus":0.06443721358206132,"score_gpt":0.3251231178188614,"score_spread":0.26068590423680005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2788428060","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008074447,0.044218864,0.0004000934,0.8292063,0.09885815,0.00003098842,0.0020630094,0.00031789416,0.02409725],"genre_scores_gemma":[0.037910614,0.07511436,0.002089535,0.62511766,0.11870955,0.00017449803,0.0036468594,0.0012223502,0.13601461],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979202,0.0006903592,0.00010810059,0.00014302657,0.0006787771,0.00045953464],"domain_scores_gemma":[0.98759043,0.003868501,0.0006250274,0.00075742154,0.0029933956,0.004165173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039244634,0.0009604087,0.0010204351,0.0020252785,0.0023343673,0.008858661,0.0012952337,0.009748114,0.09265534],"category_scores_gemma":[0.020101026,0.00046916204,0.0012236551,0.002518448,0.0033376748,0.010227603,0.005431735,0.01217794,0.016621104],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058924557,0.000015899157,0.00020886546,0.00018455053,0.000015878246,0.00004656793,0.00006241939,0.000054513563,0.000045404493,0.005051458,0.97521496,0.019040486],"study_design_scores_gemma":[0.0000347809,0.000033095213,0.0012516279,0.0007503993,0.000027570668,0.000080222104,0.000639458,0.0000503071,0.0000731071,0.012179946,0.9848498,0.00002954498],"about_ca_topic_score_codex":0.03026765,"about_ca_topic_score_gemma":0.04415332,"teacher_disagreement_score":0.09265534,"about_ca_system_score_codex":0.004709515,"about_ca_system_score_gemma":0.009397885,"threshold_uncertainty_score":0.309963},"labels":[],"label_agreement":null},{"id":"W2789626795","doi":"10.1016/s1470-2045(18)30143-8","title":"Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Musculoskeletal synovial abnormalities and treatments","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer","keywords":"Pigmented villonodular synovitis; Medicine; Nilotinib; Clinical endpoint; Internal medicine; Synovitis; Surgery; Progressive disease; Adverse effect; Oncology; Dermatology; Clinical trial; Tyrosine kinase; Rheumatoid arthritis; Disease; Receptor","score_opus":0.10193185493969692,"score_gpt":0.41602375562944066,"score_spread":0.31409190068974374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789626795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97501975,0.017280962,0.0009779115,0.0012048827,0.0004947845,0.0012336274,0.0009969319,0.00016128518,0.0026297714],"genre_scores_gemma":[0.98813677,0.004597649,0.0010721581,0.001167824,0.0001901895,0.0011250697,0.0010878583,0.00002458714,0.002597834],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995389,0.00022213664,0.00002215205,0.00008174492,0.000032918,0.00010220376],"domain_scores_gemma":[0.999506,0.00011754301,0.00009269323,0.000035030385,0.0000371549,0.00021149975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013356279,0.0015953226,0.0025307694,0.00030598245,0.00033679607,0.0013324922,0.0006909855,0.0011925226,0.0039363215],"category_scores_gemma":[0.0010509132,0.00035849356,0.0018214337,0.00030620425,0.00093215937,0.0012833677,0.00042336766,0.0024550555,0.0010134744],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8887856,0.007939882,0.0017019936,0.0027032902,0.002822505,0.00022713428,0.00017559796,0.0017201825,0.01095723,0.00042046478,0.0035477078,0.07899846],"study_design_scores_gemma":[0.8893014,0.102583006,0.0028587116,0.00011562759,0.0007826019,0.00024512396,0.000094981944,0.00089937955,0.0007053329,0.0004545545,0.001919519,0.000039722698],"about_ca_topic_score_codex":0.0005824929,"about_ca_topic_score_gemma":0.0019468118,"teacher_disagreement_score":0.0039363215,"about_ca_system_score_codex":0.0008467956,"about_ca_system_score_gemma":0.0008692113,"threshold_uncertainty_score":0.013168275},"labels":[],"label_agreement":null},{"id":"W2791290180","doi":"10.1016/s1470-2045(18)30144-x","title":"Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":576,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Cancer Institute; Kite Pharma; EMD Serono; MacroGenics; Sanofi; GlaxoSmithKline; Amgen; Pfizer; Genentech; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Durvalumab; Medicine; Internal medicine; Oncology; Lung cancer; Anaplastic lymphoma kinase; Response Evaluation Criteria in Solid Tumors; Cohort; Progressive disease; Cancer; Nivolumab; Anaplastic large-cell lymphoma; Immunotherapy; Chemotherapy; Lymphoma; Malignant pleural effusion","score_opus":0.13285510740048945,"score_gpt":0.45235716903037204,"score_spread":0.3195020616298826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791290180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909525,0.0035762268,0.00038527197,0.00050820265,0.00024815177,0.000830494,0.0010545594,0.00007084117,0.0023738556],"genre_scores_gemma":[0.9851638,0.0037164374,0.0014318867,0.0014498938,0.00021816285,0.0009695391,0.0026884503,0.0000349836,0.004326887],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99971193,0.00008291371,0.000014416999,0.0000613707,0.000037169502,0.0000921119],"domain_scores_gemma":[0.99951625,0.000078599616,0.000081378574,0.00004314431,0.00003952874,0.0002410248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010811316,0.0009442519,0.0017553956,0.00026261213,0.0003035236,0.0008855027,0.00067153375,0.00082300836,0.003398377],"category_scores_gemma":[0.00067117007,0.00035840215,0.0015523334,0.00022959382,0.00063260546,0.0009517419,0.00036083194,0.0026804172,0.00092367106],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.793402,0.03050738,0.007406117,0.0011567848,0.0019904647,0.00015659981,0.00020982366,0.0013709455,0.014756302,0.0005039061,0.0056297868,0.14290972],"study_design_scores_gemma":[0.75648105,0.22145079,0.012059329,0.000079316786,0.0012670236,0.00025422286,0.00011196793,0.0017938728,0.0016840589,0.00037416696,0.004398647,0.00004542434],"about_ca_topic_score_codex":0.0019271227,"about_ca_topic_score_gemma":0.00724331,"teacher_disagreement_score":0.003398377,"about_ca_system_score_codex":0.0009321598,"about_ca_system_score_gemma":0.0011629974,"threshold_uncertainty_score":0.0113687515},"labels":[],"label_agreement":null},{"id":"W2791813598","doi":"10.1016/s1470-2045(18)30110-4","title":"Vulvar field resection: innovative procedure or same old?","year":2018,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Resection; MEDLINE; Surgery; Medical physics","score_opus":0.09205123661033167,"score_gpt":0.3879892835994605,"score_spread":0.29593804698912884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791813598","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019797313,0.0035525819,0.000050462953,0.9852637,0.009197458,0.0000030170343,0.000019686562,0.000008442428,0.0017066612],"genre_scores_gemma":[0.0051290733,0.0053322935,0.00020327406,0.9186421,0.066271536,0.000015450692,0.000031433432,0.000017274933,0.00435753],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971397,0.0009531378,0.0003453976,0.00037380608,0.00070994307,0.0004779678],"domain_scores_gemma":[0.99422497,0.0031909433,0.0004571332,0.00017076297,0.0007767133,0.0011795772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029598665,0.00057895936,0.0013170269,0.00080060144,0.0024303694,0.0032683748,0.001378658,0.046244137,0.012436774],"category_scores_gemma":[0.019813884,0.00050861394,0.0009227124,0.0005974262,0.0035781786,0.006566825,0.001896533,0.035214845,0.0055473857],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010335578,0.00005728336,0.0011808296,0.00015694374,0.000023394441,0.0033636522,0.00015108916,0.00008674352,0.00025652745,0.0084701795,0.95436645,0.031783566],"study_design_scores_gemma":[0.00025462935,0.00013261888,0.0008899158,0.0006756078,0.00004186711,0.006870843,0.0008207242,0.00032286913,0.00017212282,0.02680098,0.9629414,0.000076495526],"about_ca_topic_score_codex":0.002913796,"about_ca_topic_score_gemma":0.00667393,"teacher_disagreement_score":0.046244137,"about_ca_system_score_codex":0.0033546584,"about_ca_system_score_gemma":0.0035687692,"threshold_uncertainty_score":0.041605175},"labels":[],"label_agreement":null},{"id":"W2794642699","doi":"10.1016/s1470-2045(18)30162-1","title":"Genetic testing for young women with breast cancer","year":2018,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; Women's College Hospital; University of Toronto","funders":"","keywords":"Breast cancer; Genetic testing; Oncology; Medicine; Cancer; Internal medicine","score_opus":0.03221763229642136,"score_gpt":0.31213406249182885,"score_spread":0.27991643019540746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794642699","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012043967,0.0035370504,0.00010120654,0.9755224,0.015147546,0.000012757356,0.00006145071,0.000022595352,0.0043906854],"genre_scores_gemma":[0.01787716,0.006102924,0.0003417436,0.8904797,0.07507593,0.00005339329,0.00008120196,0.000024333258,0.009963563],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99856406,0.00048342292,0.00014057882,0.00014978388,0.0004015859,0.00026057655],"domain_scores_gemma":[0.9946097,0.0033415812,0.0003329338,0.00015237949,0.00050674967,0.0010566849],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001382232,0.0006237428,0.0008565227,0.00078715157,0.001964149,0.0013802969,0.0009893464,0.030859625,0.006142122],"category_scores_gemma":[0.017646827,0.0006071493,0.0007314417,0.00043799842,0.0015039315,0.0017784407,0.001045359,0.01962936,0.002648685],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000121181176,0.00007763704,0.0052726497,0.00009331233,0.000027085009,0.010160716,0.00018367832,0.00009152216,0.00048349335,0.0030034531,0.94918483,0.03130048],"study_design_scores_gemma":[0.00045855902,0.00039482294,0.0093005365,0.001375273,0.00013869823,0.023159895,0.0007507952,0.0010586728,0.00078458246,0.016711505,0.94577235,0.000094425806],"about_ca_topic_score_codex":0.0043465276,"about_ca_topic_score_gemma":0.0073217037,"teacher_disagreement_score":0.030859625,"about_ca_system_score_codex":0.0020080274,"about_ca_system_score_gemma":0.001963038,"threshold_uncertainty_score":0.02054739},"labels":[],"label_agreement":null},{"id":"W2794658314","doi":"10.1016/s1470-2045(18)30203-1","title":"Slogans and donor pages of cancer centres: do they convey discordant messages?","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Corporate Identity and Reputation","field":"Business, Management and Accounting","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Advertising; Cancer; Identity (music); Brand names; Business; Internal medicine; Aesthetics","score_opus":0.04159577411960745,"score_gpt":0.3019653635248387,"score_spread":0.26036958940523125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794658314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4202131,0.010842404,0.0028616139,0.3768167,0.006339176,0.000042671563,0.0006554442,0.000102312224,0.18212664],"genre_scores_gemma":[0.9781245,0.001794969,0.0003780614,0.012692035,0.0011628958,0.000020199177,0.00010077019,0.000065115506,0.005661503],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.9749834,0.019283466,0.0008371718,0.0006261086,0.0029157088,0.0013542002],"domain_scores_gemma":[0.9023353,0.055756662,0.019205404,0.0062130485,0.009197662,0.007291843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016541598,0.00028357902,0.0005116696,0.0026853955,0.0043766685,0.014179003,0.0010333852,0.004515752,0.012530221],"category_scores_gemma":[0.1417671,0.00040823416,0.0002248966,0.0030938424,0.008753759,0.009760565,0.006874962,0.0050141932,0.0018716619],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013816166,0.00017840773,0.1494001,0.0010022911,0.00034753865,0.0013986847,0.22329159,0.00037175475,0.00057289033,0.19984756,0.20854156,0.21366598],"study_design_scores_gemma":[0.00023815094,0.00033530357,0.08232867,0.003322714,0.000330063,0.0022541014,0.31657577,0.00090901775,0.0013764532,0.11812321,0.47388163,0.00032500256],"about_ca_topic_score_codex":0.0033093197,"about_ca_topic_score_gemma":0.004564991,"teacher_disagreement_score":0.016541598,"about_ca_system_score_codex":0.0023865087,"about_ca_system_score_gemma":0.0029967742,"threshold_uncertainty_score":0.08748138},"labels":[],"label_agreement":null},{"id":"W2795355542","doi":"10.1016/s1470-2045(17)30609-5","title":"Periosteal aneurysmal bone cyst","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bone Tumor Diagnosis and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Neurovascular bundle; Medicine; Presentation (obstetrics); Surgery; Aneurysmal bone cyst; Range of motion; Swelling; Radiology; Pathology","score_opus":0.05811514374355914,"score_gpt":0.361509540922831,"score_spread":0.30339439717927186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795355542","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.102078825,0.43785948,0.005270055,0.27368,0.030968815,0.00010439617,0.0013354811,0.00035891458,0.14834407],"genre_scores_gemma":[0.6769951,0.17779323,0.0040871147,0.04650562,0.061475206,0.000056364242,0.0006911228,0.00010223274,0.032294005],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.99967027,0.000051586358,0.000030758645,0.000046906975,0.00011990596,0.00008064659],"domain_scores_gemma":[0.9976732,0.0010963153,0.0004612256,0.00018124162,0.00020163335,0.00038638595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004922248,0.00018404148,0.00056016725,0.00089333375,0.0006790108,0.0010551864,0.00041625436,0.0017686707,0.0055634845],"category_scores_gemma":[0.00329854,0.0002147376,0.00028902196,0.00095146627,0.0018958271,0.0008672924,0.0005914781,0.00299402,0.0014215892],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014353418,0.0002009619,0.015930045,0.0028339291,0.00042109305,0.13645075,0.0002990193,0.0007749667,0.0055020703,0.081424944,0.30337554,0.4513514],"study_design_scores_gemma":[0.00062298076,0.00029574105,0.01759571,0.0011708795,0.00030452845,0.49425754,0.0005257473,0.0004891992,0.00232174,0.042849302,0.43948773,0.000078804245],"about_ca_topic_score_codex":0.0011090523,"about_ca_topic_score_gemma":0.0019038571,"teacher_disagreement_score":0.0055634845,"about_ca_system_score_codex":0.0010843019,"about_ca_system_score_gemma":0.0018426715,"threshold_uncertainty_score":0.01861173},"labels":[],"label_agreement":null},{"id":"W2795488377","doi":"10.1016/s1470-2045(18)30146-3","title":"Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Liver physiology and pathology","field":"Medicine","cited_by":349,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Daiichi-Sankyo; ArQule","keywords":"Medicine; Placebo; Sorafenib; Internal medicine; Hepatocellular carcinoma; Clinical endpoint; Population; Gastroenterology; Cirrhosis; Adverse effect; Intention-to-treat analysis; Phases of clinical research; Clinical trial; Surgery; Pathology","score_opus":0.07760832321810575,"score_gpt":0.3859511444927207,"score_spread":0.308342821274615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795488377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9639395,0.026206749,0.0013265224,0.0010440197,0.0010023913,0.002554157,0.001769563,0.00021589002,0.0019412598],"genre_scores_gemma":[0.981756,0.00934457,0.0017354266,0.0011860935,0.00045876604,0.0014352445,0.0016587034,0.000050288858,0.0023749238],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993711,0.00033730347,0.000046407124,0.00008375929,0.000045297013,0.00011611914],"domain_scores_gemma":[0.9992735,0.00023370246,0.00014708789,0.000070009446,0.00006135244,0.00021429386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018679376,0.0014468107,0.0035983745,0.00034545964,0.0003437811,0.0012531774,0.0007678154,0.0015477785,0.004440847],"category_scores_gemma":[0.0016217498,0.0006579878,0.0032512024,0.0003980381,0.0008241161,0.0010778548,0.00030466384,0.0027689475,0.0008904613],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96785975,0.0012158616,0.0005356604,0.0014325497,0.0027651067,0.000059543087,0.00005182931,0.00027441297,0.003954833,0.00008716482,0.0007819323,0.020981312],"study_design_scores_gemma":[0.9602156,0.034513034,0.002243071,0.00007093959,0.001342022,0.000060892562,0.000026826132,0.00019623284,0.00045122835,0.00011126314,0.0007490267,0.000019772842],"about_ca_topic_score_codex":0.0011363763,"about_ca_topic_score_gemma":0.003359194,"teacher_disagreement_score":0.004440847,"about_ca_system_score_codex":0.0008949303,"about_ca_system_score_gemma":0.00092655426,"threshold_uncertainty_score":0.0148561},"labels":[],"label_agreement":null},{"id":"W2799371667","doi":"10.1016/s1470-2045(18)30097-4","title":"Incorporating the patient experience into regulatory decision making in the USA, Europe, and Canada","year":2018,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":199,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Canada","funders":"","keywords":"Medicine; Identification (biology); Process (computing); Quality of life (healthcare); Health care; MEDLINE; Quality (philosophy); Regulatory focus theory; Nursing; Economic growth","score_opus":0.07301386959545315,"score_gpt":0.3813628747180579,"score_spread":0.30834900512260477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799371667","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00071820157,0.9864389,0.000098618846,0.009464366,0.0003150703,0.000014854499,0.0000657972,0.0000029723449,0.0028812971],"genre_scores_gemma":[0.01823114,0.9765387,0.00028710577,0.0041182716,0.00018708699,0.000019761746,0.00006081679,0.0000054613206,0.00055163674],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9932634,0.002299399,0.00053002994,0.00033406354,0.002829167,0.00074393855],"domain_scores_gemma":[0.97807133,0.012815256,0.0013289094,0.00024887474,0.0063334387,0.0012021094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015580554,0.0005809092,0.002174311,0.0028557735,0.0019179992,0.006715956,0.002680996,0.0033863264,0.0030824156],"category_scores_gemma":[0.031308882,0.0003067457,0.0010704956,0.005597612,0.0037229357,0.0018946967,0.0021577617,0.0040320833,0.00021531948],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023542387,0.00007810239,0.0037762956,0.03432997,0.0006902804,0.00026853578,0.0030555048,0.0016575832,0.00013544988,0.035920165,0.06456023,0.8552925],"study_design_scores_gemma":[0.000094381474,0.00007375596,0.011207196,0.09750664,0.00091320375,0.0003302784,0.0035261763,0.00031270724,0.0003190802,0.009915338,0.87564254,0.00015880713],"about_ca_topic_score_codex":0.7806992,"about_ca_topic_score_gemma":0.89287996,"teacher_disagreement_score":0.95980406,"about_ca_system_score_codex":0.04019596,"about_ca_system_score_gemma":0.13797235,"threshold_uncertainty_score":0.44118458},"labels":[],"label_agreement":null},{"id":"W2799574682","doi":"10.1016/s1470-2045(18)30242-0","title":"Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":394,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency; University of Calgary; McGill University; University of Toronto; Toronto General Hospital; University Health Network; Hospital for Sick Children","funders":"National Heart, Lung, and Blood Institute; Strategic Research Council; Canadian Institutes of Health Research; Brain Tumour Research; National Cancer Institute; Fondation de l'Hôpital de Montréal pour enfants; BC Cancer Foundation; Lékařská fakulta, Masarykova univerzita; Eunice Kennedy Shriver National Institute of Child Health and Human Development; Masarykova Univerzita; Nationales Centrum für Tumorerkrankungen Heidelberg; Göteborgs Universitet; Universitetet i Oslo; Karolinska Institutet; Terry Fox Research Institute; Cancerfonden; Universität Zürich; Bundesministerium für Bildung und Forschung; Norges Forskningsråd; Semmelweis Egyetem; Bundesamt für Gesundheit; Pediatric Brain Tumor Foundation; Deutsche Krebshilfe; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Broad Institute; Forskningsrådet om Hälsa, Arbetsliv och Välfärd; Universidad Nacional Autónoma de México; Pediatric Oncology Group of Ontario; FH Foundation; Instituto Mexicano del Seguro Social; Colorado State University; Barncancerfonden; Ontario Institute for Cancer Research; University of Miami; European Molecular Biology Organization; University of Bern; Ministerstvo Zdravotnictví Ceské Republiky; Rockefeller University; Massachusetts Institute of Technology; Universität Basel; National Institutes of Health; Children's Hospital Foundation; John D. and Catherine T. MacArthur Foundation; Genome Canada; Garron Family Cancer Centre; European Commission; Sontag Foundation; Hospital for Sick Children; Genome British Columbia; Strategiske Forskningsråd; Cancer Research UK; World Health Organization; Deutsche Kinderkrebsstiftung; University of Chicago; University of California; Vetenskapsrådet; European Research Council; V Foundation for Cancer Research; Government of Ontario; Alexander and Margaret Stewart Trust; Deutsches Krebsforschungszentrum","keywords":"Medulloblastoma; Genetic predisposition; Retrospective cohort study; Medicine; Prospective cohort study; Cohort; Clinical trial; Oncology; Pediatrics; Internal medicine; Pathology","score_opus":0.03558688702811941,"score_gpt":0.3766558975379356,"score_spread":0.3410690105098162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799574682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99862695,0.00029725645,0.00026294985,0.000035155732,0.000006739718,0.00009535708,0.0004336482,0.000005821748,0.00023601015],"genre_scores_gemma":[0.9984326,0.000108774875,0.00033534013,0.000045523022,0.0000121085695,0.00011696882,0.0008340262,0.000009342218,0.000105193314],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960484,0.0018171036,0.00040234296,0.0010630458,0.0003801522,0.0002890146],"domain_scores_gemma":[0.99198216,0.0017978282,0.0028384111,0.0018670671,0.00059552136,0.00091894733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0056225737,0.00059077545,0.0006952765,0.00096782466,0.0008680968,0.0010533922,0.0008856543,0.0007068534,0.0028373934],"category_scores_gemma":[0.009197021,0.00047381435,0.0009381889,0.0013468458,0.0012170144,0.0008903362,0.0011961744,0.0007302211,0.0006612801],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038023652,0.00023631012,0.99263835,0.000038443508,0.00043126915,0.0002641666,0.00022913686,0.00006288495,0.00046869347,0.000076152064,0.0002099564,0.0015422491],"study_design_scores_gemma":[0.0006810782,0.0028813276,0.99232155,0.000037665886,0.0006630796,0.0015810967,0.00030158626,0.00040524258,0.00024163006,0.00014542163,0.00071631477,0.000024210001],"about_ca_topic_score_codex":0.0022926072,"about_ca_topic_score_gemma":0.0024904998,"teacher_disagreement_score":0.0056225737,"about_ca_system_score_codex":0.0007017182,"about_ca_system_score_gemma":0.00093234057,"threshold_uncertainty_score":0.029735386},"labels":[],"label_agreement":null},{"id":"W2799848443","doi":"10.1016/s1470-2045(18)30096-2","title":"Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology","year":2018,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Radiation oncology; Guideline; Radiation therapy; Medicine; Precision oncology; Medical physics; Oncology; Internal medicine; Cancer; Pathology","score_opus":0.047103449275449474,"score_gpt":0.4542423468226427,"score_spread":0.40713889754719323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799848443","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011209157,0.994354,0.00041457257,0.0026200893,0.0006809316,0.000051841864,0.00018490861,0.000022538447,0.0015590405],"genre_scores_gemma":[0.0009625261,0.99156123,0.0016373964,0.0036941848,0.0003726503,0.000099410034,0.00036324278,0.000008161785,0.0013012096],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993319,0.00013582461,0.00017692802,0.000066758854,0.00024162032,0.000046952133],"domain_scores_gemma":[0.9990688,0.000465015,0.00017717115,0.000021342477,0.00022936771,0.000038222515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018512442,0.001029774,0.0022774236,0.002325573,0.00034261568,0.001219594,0.0016292793,0.0026207366,0.0025462892],"category_scores_gemma":[0.0020154677,0.00045317732,0.0020931622,0.0015466852,0.00048564002,0.0011525913,0.0008293628,0.003537098,0.0015964197],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001769654,0.00008539553,0.00029327613,0.032918915,0.00037303395,0.00015363793,0.00006182107,0.00070623524,0.0013690923,0.0034830342,0.16359651,0.7967821],"study_design_scores_gemma":[0.00017120589,0.00010723778,0.00085749204,0.015855914,0.0006225271,0.0006752478,0.00003129285,0.00017799811,0.00044357884,0.0016736507,0.9793545,0.000029356346],"about_ca_topic_score_codex":0.004642661,"about_ca_topic_score_gemma":0.013366174,"teacher_disagreement_score":0.004642661,"about_ca_system_score_codex":0.001487975,"about_ca_system_score_gemma":0.0036781193,"threshold_uncertainty_score":0.0107960105},"labels":[],"label_agreement":null},{"id":"W2802450491","doi":"10.1016/s1470-2045(18)30287-0","title":"Body-mass index and metastatic melanoma outcomes","year":2018,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Melanoma; Body mass index; Incidence (geometry); Oncology; Internal medicine; Population; Obesity; Cancer research; Environmental health","score_opus":0.05080202648312223,"score_gpt":0.3475610063345605,"score_spread":0.2967589798514383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802450491","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014643817,0.002537623,0.000038440765,0.9763985,0.014578432,0.000007199671,0.00029951363,0.000015065756,0.004660833],"genre_scores_gemma":[0.03771624,0.005280187,0.00020709193,0.80473715,0.13813597,0.00008853593,0.00049519294,0.00003324685,0.013306355],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9982992,0.0006196058,0.00019954416,0.0001648342,0.00048166543,0.00023515949],"domain_scores_gemma":[0.9914886,0.0049798787,0.0007601139,0.00026331688,0.0012555744,0.0012525505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022674925,0.00036943922,0.000928104,0.00067371235,0.0016141428,0.0017281651,0.00086995406,0.016900813,0.010008027],"category_scores_gemma":[0.028360354,0.0004140277,0.0007269297,0.00077011005,0.0009771009,0.0016564928,0.001062153,0.014912071,0.004057391],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017651496,0.000049255934,0.0073900046,0.000059641483,0.00003139314,0.00062364194,0.000065931716,0.00006144533,0.00005041737,0.0013649376,0.9709839,0.019142851],"study_design_scores_gemma":[0.0009757902,0.0002341614,0.025512889,0.0013012211,0.00025950986,0.0027633812,0.00085528364,0.0014954093,0.00033304223,0.022502327,0.9436567,0.00011024763],"about_ca_topic_score_codex":0.007912586,"about_ca_topic_score_gemma":0.015752893,"teacher_disagreement_score":0.016900813,"about_ca_system_score_codex":0.0022040883,"about_ca_system_score_gemma":0.0027819949,"threshold_uncertainty_score":0.033480227},"labels":[],"label_agreement":null},{"id":"W2803437699","doi":"10.1016/s1470-2045(18)30270-5","title":"Does a patient's sex predict the efficacy of cancer immunotherapy?","year":2018,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Immunotherapy; Cancer; Lung cancer; Cancer immunotherapy; Pembrolizumab; Oncology; Internal medicine; Melanoma; Meta-analysis; Scopus; Nivolumab; Clinical trial; MEDLINE; Cancer research","score_opus":0.027200920113298246,"score_gpt":0.329764280774798,"score_spread":0.3025633606614998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803437699","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016509813,0.0040208898,0.0000760554,0.98276526,0.009517159,0.0000041732296,0.00010938826,0.000013621348,0.0018425336],"genre_scores_gemma":[0.044758398,0.008415338,0.0003497112,0.8172517,0.12514403,0.000035835496,0.00016199476,0.000031394775,0.0038517294],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967451,0.0015579956,0.0004440609,0.00031500796,0.0006456989,0.0002921143],"domain_scores_gemma":[0.9776499,0.017172916,0.0013289734,0.0005033609,0.0018903452,0.001454461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004503407,0.00050560833,0.0021728964,0.00079565065,0.0016092736,0.002358416,0.0013648727,0.02060919,0.0050849654],"category_scores_gemma":[0.04586281,0.0005539963,0.0009887522,0.0008775248,0.0019570477,0.0030501105,0.00081026537,0.025065841,0.0039065266],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006611562,0.00015598578,0.03429763,0.000236632,0.0002000034,0.003230067,0.00033652096,0.00025386157,0.00032199893,0.0070002307,0.8604633,0.09284242],"study_design_scores_gemma":[0.000950948,0.00077578955,0.022961196,0.0014732236,0.00045156697,0.010686372,0.0019428922,0.0027805087,0.0008606552,0.05413633,0.9027379,0.00024267528],"about_ca_topic_score_codex":0.004094302,"about_ca_topic_score_gemma":0.00614232,"teacher_disagreement_score":0.02060919,"about_ca_system_score_codex":0.002481101,"about_ca_system_score_gemma":0.0021860506,"threshold_uncertainty_score":0.023816586},"labels":[],"label_agreement":null},{"id":"W2804105316","doi":"10.1016/s1470-2045(18)30292-4","title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1011,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"Astex Pharmaceuticals; Novartis","keywords":"Medicine; Breast cancer; Oncology; Internal medicine; Hormone receptor; Endocrine system; Hormone therapy; Gynecology; Cancer; Hormone","score_opus":0.03244725651231038,"score_gpt":0.37153790821677674,"score_spread":0.33909065170446634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804105316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95043695,0.025393587,0.0008993712,0.003009056,0.0017531788,0.005027988,0.004235759,0.00034200377,0.008901997],"genre_scores_gemma":[0.95332146,0.013191916,0.001962294,0.0044017215,0.0009019407,0.006029165,0.0050592287,0.00007789171,0.015054438],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99963737,0.00018019966,0.000014738054,0.000057187404,0.000027356486,0.000083046565],"domain_scores_gemma":[0.9995239,0.00013691254,0.00007237974,0.000045675548,0.000027899529,0.00019332473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012809302,0.0015209733,0.0022492209,0.00036478284,0.00035014673,0.0010139806,0.00090132613,0.0017113701,0.0108109405],"category_scores_gemma":[0.0013879455,0.00057250814,0.0024183793,0.00038094784,0.0009553131,0.00086100155,0.0005038374,0.0032520383,0.0019523668],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96384025,0.0031437844,0.0006164248,0.001054655,0.0017329352,0.000064096865,0.000060900737,0.0004692136,0.002447357,0.00022481833,0.0030855532,0.023259992],"study_design_scores_gemma":[0.9682809,0.028046459,0.0012077024,0.00004412474,0.0005235228,0.000043117223,0.000026512353,0.0001890975,0.00012375195,0.00019580618,0.0013068567,0.000012190675],"about_ca_topic_score_codex":0.0018723247,"about_ca_topic_score_gemma":0.0066781677,"teacher_disagreement_score":0.0108109405,"about_ca_system_score_codex":0.00085751945,"about_ca_system_score_gemma":0.001091216,"threshold_uncertainty_score":0.03616619},"labels":[],"label_agreement":null},{"id":"W2805341297","doi":"10.1016/s1470-2045(18)30354-1","title":"Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":206,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"Amgen","keywords":"Carfilzomib; Medicine; Dosing; Refractory (planetary science); Interim analysis; Interim; Multiple myeloma; Lenalidomide; Internal medicine; Oncology; Clinical trial; Materials science","score_opus":0.05709115066878615,"score_gpt":0.3817391800709356,"score_spread":0.32464802940214943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805341297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898935,0.005066142,0.0006079135,0.0007278746,0.00050593994,0.0007346991,0.0008109496,0.0001604679,0.001492507],"genre_scores_gemma":[0.99153155,0.001653812,0.0013718784,0.0009575949,0.00039494497,0.0010303099,0.00084801804,0.000043820546,0.0021680275],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99879944,0.00068836287,0.00006435695,0.00013912149,0.000099853634,0.0002087107],"domain_scores_gemma":[0.99833894,0.0006304285,0.0003859972,0.00022400734,0.00008142207,0.00033924018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031234794,0.0013344683,0.004096191,0.00037696387,0.00046991376,0.0012925527,0.000916494,0.0017977358,0.003422091],"category_scores_gemma":[0.0025960032,0.0006298813,0.0033254388,0.00048617407,0.00085542985,0.0012244636,0.00040906356,0.003517363,0.00084871094],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97081685,0.002662667,0.00064043904,0.00029538586,0.0012592294,0.00002971431,0.00005069318,0.0005646241,0.002403648,0.0000704859,0.0008135338,0.02039276],"study_design_scores_gemma":[0.8788586,0.10894119,0.0077446382,0.000048254748,0.0018163809,0.00005792989,0.00003199052,0.0007711348,0.0007086393,0.00031609318,0.00066927454,0.00003586091],"about_ca_topic_score_codex":0.0010016613,"about_ca_topic_score_gemma":0.0017976108,"teacher_disagreement_score":0.004096191,"about_ca_system_score_codex":0.0006649018,"about_ca_system_score_gemma":0.0008171915,"threshold_uncertainty_score":0.016518712},"labels":[],"label_agreement":null},{"id":"W2805592007","doi":"10.1016/s1470-2045(18)30351-6","title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":2536,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Merck","keywords":"Medicine; Pembrolizumab; Sorafenib; Internal medicine; Clinical endpoint; Hepatocellular carcinoma; Adverse effect; Response Evaluation Criteria in Solid Tumors; Population; Oncology; Discontinuation; Clinical trial; Phases of clinical research; Surgery; Cancer; Immunotherapy","score_opus":0.07727556601902094,"score_gpt":0.32807063219425886,"score_spread":0.25079506617523795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805592007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98911846,0.0055787046,0.00040315994,0.0010744475,0.0004009969,0.0009968645,0.00071388826,0.00008079356,0.001632569],"genre_scores_gemma":[0.99028045,0.003511319,0.0006454292,0.0008940428,0.00026638887,0.0010899272,0.0011936667,0.00001531314,0.0021034176],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995603,0.00022493362,0.000023776345,0.00007346441,0.000027570683,0.00008988533],"domain_scores_gemma":[0.99947315,0.0001330187,0.00012142091,0.000041620504,0.000028677903,0.00020212428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001511291,0.0013948599,0.0023344639,0.00031596725,0.00032437587,0.0011143141,0.00047545825,0.0011850648,0.004731635],"category_scores_gemma":[0.0013088787,0.0005465918,0.0020605715,0.0003549094,0.0008036386,0.001359865,0.00040643822,0.0026781238,0.00094811304],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9538386,0.0044476446,0.0016850231,0.0009179621,0.0019667752,0.00008088331,0.00007590077,0.00070101075,0.003433473,0.00014785361,0.001385393,0.0313194],"study_design_scores_gemma":[0.92330164,0.06913009,0.0043279347,0.00005568074,0.0008719969,0.00008503078,0.000042011434,0.00047156072,0.0004260052,0.0002279034,0.0010395055,0.00002079215],"about_ca_topic_score_codex":0.0008567562,"about_ca_topic_score_gemma":0.0017759604,"teacher_disagreement_score":0.004731635,"about_ca_system_score_codex":0.00072993,"about_ca_system_score_gemma":0.00076447334,"threshold_uncertainty_score":0.015828848},"labels":[],"label_agreement":null},{"id":"W2806421431","doi":"10.1016/s1470-2045(18)30365-6","title":"Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":409,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Olaparib; Medicine; Prostate cancer; Internal medicine; Oncology; Enzalutamide; PARP inhibitor; Placebo; Clinical endpoint; Docetaxel; Population; Androgen deprivation therapy; Clinical trial; Cancer; Androgen receptor; Pathology","score_opus":0.063617209979282,"score_gpt":0.3828651709096185,"score_spread":0.3192479609303365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806421431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96539557,0.018270269,0.0017132323,0.0016234571,0.0020317603,0.004752944,0.0020751564,0.00044717832,0.0036904565],"genre_scores_gemma":[0.977715,0.008448423,0.0018830774,0.0016028178,0.0010451868,0.0036127856,0.0012910765,0.000060050228,0.0043414207],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99911886,0.00045644134,0.000062419946,0.00017317539,0.00006788763,0.00012125384],"domain_scores_gemma":[0.9989157,0.0003442929,0.00022566256,0.00009658277,0.000057103844,0.0003606038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017046268,0.002834331,0.004322777,0.0007609331,0.0005928594,0.0017334208,0.0010792727,0.0022991507,0.007596233],"category_scores_gemma":[0.0026893215,0.0011269437,0.0022621977,0.0006874701,0.0019072163,0.0018239757,0.00062361115,0.004013986,0.0015281454],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9874094,0.0017568998,0.00016019089,0.00067247543,0.000618156,0.000025691623,0.000039709856,0.00019045049,0.0009691683,0.000061735176,0.00039926814,0.007696804],"study_design_scores_gemma":[0.97975326,0.018960001,0.000327811,0.000025454372,0.0002226549,0.000021861933,0.000014120834,0.00014300148,0.00010228377,0.00010339298,0.00031438537,0.000011865933],"about_ca_topic_score_codex":0.0011997924,"about_ca_topic_score_gemma":0.0021857042,"teacher_disagreement_score":0.007596233,"about_ca_system_score_codex":0.00077360414,"about_ca_system_score_gemma":0.0011951443,"threshold_uncertainty_score":0.025411904},"labels":[],"label_agreement":null},{"id":"W2810571299","doi":"10.1016/s1470-2045(18)30427-3","title":"How economic sanctions compromise cancer care in Iran","year":2018,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Compromise; Sanctions; Economic sanctions; Political science; Medicine; Business; Law","score_opus":0.05767427401511837,"score_gpt":0.41220277876244277,"score_spread":0.3545285047473244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810571299","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010138865,0.00094162574,0.000016170323,0.9919299,0.0037351074,0.0000023044015,0.000013884312,0.000002525241,0.0023446039],"genre_scores_gemma":[0.02529974,0.0016096835,0.000059203932,0.953461,0.0150065115,0.000016051643,0.000016215998,0.000016262647,0.0045153773],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99559504,0.0016048836,0.00024059335,0.00025094714,0.0008992284,0.0014092824],"domain_scores_gemma":[0.99109507,0.0048136557,0.0008111185,0.00021206542,0.0012743879,0.0017937435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057516997,0.00034639478,0.0006969841,0.00062148133,0.0061555025,0.0044854134,0.0012591868,0.04278072,0.006344156],"category_scores_gemma":[0.035778068,0.0004063726,0.0009916056,0.0008660433,0.0045356387,0.002889768,0.0026607406,0.03323371,0.0018062477],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000698231,0.00003445199,0.002879511,0.00008038368,0.000053084685,0.0016368155,0.0010212301,0.00018541579,0.000103803606,0.017894918,0.9620375,0.014003088],"study_design_scores_gemma":[0.00020740328,0.0000640114,0.0028295082,0.00039966326,0.00007585856,0.0012528375,0.0042106993,0.00031585078,0.00023785913,0.030749258,0.9595809,0.000076140954],"about_ca_topic_score_codex":0.02602514,"about_ca_topic_score_gemma":0.04605718,"teacher_disagreement_score":0.04278072,"about_ca_system_score_codex":0.01003261,"about_ca_system_score_gemma":0.0119204065,"threshold_uncertainty_score":0.07279199},"labels":[],"label_agreement":null},{"id":"W2883673963","doi":"10.1016/s1470-2045(18)30343-7","title":"Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":137,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Cancer Institute; AstraZeneca","keywords":"Medicine; Internal medicine; Olaparib; Tolerability; Quality of life (healthcare); Placebo; Clinical endpoint; Oncology; Ovarian cancer; Adverse effect; Nausea; Progression-free survival; Randomized controlled trial; Cancer; Chemotherapy; Surgery","score_opus":0.028783105922643652,"score_gpt":0.3335244201553895,"score_spread":0.30474131423274586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883673963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99140537,0.0062580355,0.00016844567,0.00039080696,0.00020411571,0.00045710753,0.00042607755,0.000026276288,0.00066385494],"genre_scores_gemma":[0.9957722,0.0016950642,0.00029999847,0.00034735515,0.00019159038,0.0005763735,0.00045122032,0.0000057099624,0.0006606104],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99940825,0.0003126075,0.000044825545,0.00010680811,0.000036624224,0.00009093884],"domain_scores_gemma":[0.99911803,0.0002924352,0.00026395495,0.00006111324,0.00003407854,0.00023038902],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011239493,0.0012918063,0.0024702824,0.00028322157,0.0003233406,0.0010360419,0.00067662046,0.0014945086,0.00338369],"category_scores_gemma":[0.0016420457,0.00048517963,0.0026668252,0.0004205295,0.00091307773,0.0008550114,0.00046419137,0.002920856,0.00035468783],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97967935,0.0022681889,0.0017277653,0.0006352472,0.0016993808,0.000028471597,0.00004132641,0.00034805824,0.00090849726,0.00005265468,0.0002959845,0.012315148],"study_design_scores_gemma":[0.8965965,0.087249205,0.012068681,0.00010457121,0.0020937962,0.000053205535,0.000050636103,0.00060115603,0.00034779706,0.000253713,0.0005502886,0.000030377882],"about_ca_topic_score_codex":0.0009107839,"about_ca_topic_score_gemma":0.001455144,"teacher_disagreement_score":0.00338369,"about_ca_system_score_codex":0.0007743041,"about_ca_system_score_gemma":0.00060614996,"threshold_uncertainty_score":0.011319578},"labels":[],"label_agreement":null},{"id":"W2884001607","doi":"10.1016/s1470-2045(18)30333-4","title":"Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal; University Health Network","funders":"","keywords":"Nova (rocket); Placebo; Double blind; Medicine; Quality of life (healthcare); Oncology; Gynecology; Ovarian cancer; Internal medicine; Cancer; Alternative medicine; Pathology; Nursing","score_opus":0.14681145589951522,"score_gpt":0.4253526568431366,"score_spread":0.2785412009436214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884001607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97474766,0.018756347,0.000620008,0.00080334424,0.0008624348,0.0016285394,0.0009766769,0.000113636765,0.0014913607],"genre_scores_gemma":[0.98952895,0.0047177956,0.0008900227,0.00075089117,0.0005097387,0.0015526084,0.00073591765,0.000017226419,0.0012968497],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9989373,0.0006064875,0.000094534626,0.00018480145,0.00006634548,0.00011047255],"domain_scores_gemma":[0.99881244,0.0004334668,0.00038157305,0.000084528496,0.00005056504,0.00023735875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001930427,0.0017311554,0.004359964,0.00043944415,0.00038177127,0.0012261507,0.0010244899,0.0018107651,0.0051022186],"category_scores_gemma":[0.0024734843,0.000822754,0.003561925,0.00050581974,0.0014887431,0.0011263046,0.0005850906,0.0033255336,0.00057800993],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9872343,0.0012519445,0.0005093189,0.0009549389,0.0013913917,0.00001648926,0.000028171718,0.00015321278,0.0006474242,0.00003352488,0.000227083,0.007552096],"study_design_scores_gemma":[0.96739,0.029060803,0.0019153132,0.00004971501,0.00087189383,0.000021314567,0.000017112876,0.00021757015,0.00012282272,0.00009480818,0.00022590191,0.0000127271815],"about_ca_topic_score_codex":0.0009113073,"about_ca_topic_score_gemma":0.0013338254,"teacher_disagreement_score":0.0051022186,"about_ca_system_score_codex":0.00077057065,"about_ca_system_score_gemma":0.00069932686,"threshold_uncertainty_score":0.017068624},"labels":[],"label_agreement":null},{"id":"W2886412900","doi":"10.1016/s1470-2045(18)30425-x","title":"A roadmap for restoring trust in Big Data","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Medical Research Council","keywords":"Big data; Public relations; Human services; Political science; Corporate governance; Exploit; Medicine; Business; Computer science; Computer security; Law","score_opus":0.9121562296899259,"score_gpt":0.688809364006139,"score_spread":0.22334686568378692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886412900","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011347496,0.005134144,0.0122940205,0.9671399,0.004992439,0.000065287844,0.00012038866,0.00022075117,0.008898224],"genre_scores_gemma":[0.25260445,0.018992908,0.08603481,0.59693307,0.024331557,0.0011940652,0.000795799,0.00093388045,0.018179463],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.8947746,0.07339666,0.0043319603,0.004377908,0.014040224,0.009078507],"domain_scores_gemma":[0.41838524,0.39097148,0.0148427915,0.053666506,0.057498135,0.06463588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.17329885,0.0011752313,0.0021836627,0.0033130823,0.009040133,0.030407479,0.0054678116,0.03134345,0.03237454],"category_scores_gemma":[0.36229527,0.001272373,0.002912786,0.0036868453,0.035257965,0.059948582,0.024718333,0.044686995,0.0067532337],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016925382,0.0002044067,0.0018990996,0.00083069183,0.00019261986,0.00043765036,0.0033205769,0.0012564263,0.00030707064,0.65286976,0.2877311,0.050781418],"study_design_scores_gemma":[0.000116537194,0.000067262976,0.00084375485,0.0012885561,0.000043844884,0.00017674883,0.0027948823,0.0010248356,0.00023135202,0.7537107,0.2396032,0.00009824109],"about_ca_topic_score_codex":0.0080949785,"about_ca_topic_score_gemma":0.008734883,"teacher_disagreement_score":0.17329885,"about_ca_system_score_codex":0.011957154,"about_ca_system_score_gemma":0.08204582,"threshold_uncertainty_score":0.9165029},"labels":[],"label_agreement":null},{"id":"W2887665498","doi":"10.1016/s1470-2045(18)30364-4","title":"Biological material collection to advance translational research and treatment of children with CNS tumours: position paper from the SIOPE Brain Tumour Group","year":2018,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Brain Tumour Charity; Rosetrees Trust; Cancer Research UK","keywords":"Biobank; Translational research; Medicine; Childhood cancer; Biorepository; Medical diagnosis; Disease; Data collection; Cancer; Bioinformatics; Intensive care medicine; Medical physics; Pathology; Internal medicine; Biology","score_opus":0.11314543967697425,"score_gpt":0.40792931324774995,"score_spread":0.2947838735707757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887665498","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029306603,0.96814984,0.00080281985,0.014062462,0.0071345605,0.00021581654,0.0011703931,0.00007229603,0.008098668],"genre_scores_gemma":[0.0022233238,0.98162705,0.0022730397,0.0055972207,0.0021674877,0.00020334912,0.0014374825,0.000033282748,0.004437766],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981475,0.00058252265,0.0002511717,0.00012698062,0.0007183008,0.00017345158],"domain_scores_gemma":[0.9934495,0.0036662577,0.0007747642,0.0003128438,0.0014096345,0.00038698793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006707884,0.00068187097,0.001491699,0.0022008345,0.0003852702,0.0023570836,0.0014277779,0.002329462,0.011377457],"category_scores_gemma":[0.010860715,0.00029807267,0.001447284,0.0017579442,0.0009905187,0.0019074107,0.0020971817,0.0029070047,0.004725906],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016960544,0.000048455197,0.00021862192,0.01846687,0.00013669676,0.00014792981,0.000088257555,0.00013190003,0.0008529977,0.00739397,0.23115435,0.7411903],"study_design_scores_gemma":[0.000071073875,0.000046510144,0.00059196044,0.008747115,0.00009036482,0.00019430711,0.00003499478,0.000017100454,0.00046373444,0.0011642955,0.98856795,0.000010593082],"about_ca_topic_score_codex":0.0038934278,"about_ca_topic_score_gemma":0.005218613,"teacher_disagreement_score":0.011377457,"about_ca_system_score_codex":0.001767453,"about_ca_system_score_gemma":0.010054495,"threshold_uncertainty_score":0.03806138},"labels":[],"label_agreement":null},{"id":"W2887875384","doi":"10.1016/s1470-2045(18)30449-2","title":"CCR4-targeted therapy in cutaneous T-cell lymphoma","year":2018,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Mycosis fungoides; CCR4; Medicine; Cutaneous T-cell lymphoma; Lymphoma; Vorinostat; T cell; Bexarotene; Cancer research; Immunology; Chemokine receptor; Chemokine; Biology; Inflammation; Immune system","score_opus":0.06080439211977353,"score_gpt":0.35552555913635736,"score_spread":0.29472116701658385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887875384","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002003716,0.019364044,0.00021051425,0.94127893,0.02696944,0.000018911696,0.000073028794,0.000049786544,0.010031664],"genre_scores_gemma":[0.05029032,0.020392224,0.00065355946,0.77108335,0.13675304,0.00009085087,0.00012698883,0.000045532237,0.020564165],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99924374,0.00027000348,0.000075867356,0.000064260195,0.00020695469,0.00013917939],"domain_scores_gemma":[0.99826294,0.001084808,0.00011505175,0.000058362577,0.00020666698,0.00027210277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010094787,0.00040023605,0.0008234363,0.00042697747,0.0010083743,0.001400261,0.0007126324,0.0129810795,0.005704352],"category_scores_gemma":[0.005892373,0.000268046,0.0005594549,0.00027459234,0.0011132265,0.0014205681,0.0006211033,0.011710905,0.0030822763],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021322446,0.0000873035,0.0011830099,0.00020997258,0.000034496763,0.006446612,0.00007194757,0.0002716151,0.00090743805,0.006073432,0.91877854,0.06572242],"study_design_scores_gemma":[0.0005775313,0.0002583025,0.001097055,0.00040586723,0.00006942231,0.007833207,0.00012048575,0.0009961161,0.00078486063,0.011198704,0.9766302,0.000028313016],"about_ca_topic_score_codex":0.001054012,"about_ca_topic_score_gemma":0.0027333756,"teacher_disagreement_score":0.0129810795,"about_ca_system_score_codex":0.0021276807,"about_ca_system_score_gemma":0.00096903526,"threshold_uncertainty_score":0.019082904},"labels":[],"label_agreement":null},{"id":"W2888567495","doi":"10.1016/s1470-2045(18)30448-0","title":"Near-infrared fluorescence for detection of sentinel lymph nodes in women with cervical and uterine cancers (FILM): a randomised, phase 3, multicentre, non-inferiority trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":344,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Sunnybrook Health Science Centre; Hôtel-Dieu de Québec","funders":"National Cancer Institute; National Institutes of Health","keywords":"Indocyanine green; Medicine; Lymph; Sentinel lymph node; Surgery; Lymph node; Cervical cancer; Surgical margin; Radiology; Cancer; Pathology; Internal medicine; Breast cancer; Resection","score_opus":0.02975133024637914,"score_gpt":0.3510060640054008,"score_spread":0.32125473375902164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888567495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97834307,0.012242945,0.0009399623,0.0011330522,0.0009928028,0.002951242,0.0008485387,0.00010556841,0.0024427907],"genre_scores_gemma":[0.9813965,0.00585556,0.0019967789,0.0016761011,0.0005454045,0.003416394,0.0007434718,0.000029718767,0.004339986],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99943286,0.00032857351,0.000025096935,0.0000965542,0.00003829542,0.00007861285],"domain_scores_gemma":[0.9993517,0.00028620745,0.00014307925,0.00005774191,0.000029170062,0.00013207401],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016870727,0.0014233257,0.0019989926,0.00027333622,0.000321318,0.0009509166,0.0006800813,0.0018825971,0.007643808],"category_scores_gemma":[0.0020402826,0.00054554257,0.0022905434,0.0003029243,0.0011484447,0.00091245817,0.00040568245,0.0026669556,0.00086229754],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9750337,0.0018661642,0.00044634944,0.0010502946,0.0010882188,0.000039932074,0.00007215231,0.00028716703,0.0028211728,0.00013932055,0.0008018789,0.016353564],"study_design_scores_gemma":[0.9551398,0.041995134,0.00110516,0.00005576617,0.00055440154,0.000040029543,0.000032148142,0.00016308029,0.00022115049,0.00020065474,0.00048035776,0.000012372554],"about_ca_topic_score_codex":0.0010979186,"about_ca_topic_score_gemma":0.0023861614,"teacher_disagreement_score":0.007643808,"about_ca_system_score_codex":0.00063857675,"about_ca_system_score_gemma":0.00066337833,"threshold_uncertainty_score":0.025571108},"labels":[],"label_agreement":null},{"id":"W2888793209","doi":"10.1016/s1470-2045(18)30418-2","title":"Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review","year":2018,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"European Organisation for Research and Treatment of Cancer; Boehringer Ingelheim","keywords":"Medicine; Breast cancer; Randomized controlled trial; Sample size determination; MEDLINE; Systematic review; Clinical trial; Quality of life (healthcare); Meta-analysis; Missing data; Data quality; Medical physics; Alternative medicine; Cancer; Family medicine; Internal medicine; Pathology; Statistics","score_opus":0.23198629264013598,"score_gpt":0.520737163619044,"score_spread":0.288750870978908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888793209","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022829722,0.9934487,0.0018008313,0.00032958144,0.00035007525,0.0009441041,0.0005680456,0.000040699873,0.00023497606],"genre_scores_gemma":[0.17622039,0.8033565,0.011359986,0.0024797232,0.0006218899,0.00441259,0.0011274295,0.00008696822,0.00033449152],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.8665941,0.08638501,0.03244791,0.0050641196,0.008460786,0.0010481563],"domain_scores_gemma":[0.7074474,0.25406593,0.028538086,0.0046332385,0.0046425336,0.00067281205],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.06682053,0.0022933849,0.021515166,0.005532003,0.0005499424,0.004316151,0.003583291,0.0032854665,0.0058817435],"category_scores_gemma":[0.2556437,0.0017994548,0.027940411,0.005645358,0.0022970133,0.0038021076,0.0023719324,0.00455068,0.00033192165],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002416867,0.000027337528,0.0013067989,0.7758487,0.19534607,0.000052447143,0.00012500936,0.00036544452,0.0001307235,0.00046094085,0.0010137802,0.022905916],"study_design_scores_gemma":[0.0074560186,0.0008586838,0.005874962,0.21764477,0.7537889,0.00021006819,0.00022939248,0.0006583845,0.00029326932,0.0030512393,0.0098174205,0.00011688499],"about_ca_topic_score_codex":0.0031535325,"about_ca_topic_score_gemma":0.007822714,"teacher_disagreement_score":0.9331795,"about_ca_system_score_codex":0.004111337,"about_ca_system_score_gemma":0.007115379,"threshold_uncertainty_score":0.35338497},"labels":[],"label_agreement":null},{"id":"W2891576771","doi":"10.1016/s1470-2045(18)30456-x","title":"Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Placebo; Clinical endpoint; Internal medicine; Prostate-specific antigen; Oncology; Randomized controlled trial; Urology; Cancer; Pathology","score_opus":0.046862068757382316,"score_gpt":0.4188538237009971,"score_spread":0.3719917549436148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891576771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98281235,0.012874201,0.00037015285,0.0007601754,0.00041776386,0.00058148976,0.00068130763,0.00008230598,0.00142024],"genre_scores_gemma":[0.9949104,0.0027866769,0.00031674042,0.00043610207,0.0002139189,0.00027089872,0.00043002056,0.000013084602,0.00062216504],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991511,0.0005486643,0.000055457742,0.00011311524,0.000054181335,0.0000773617],"domain_scores_gemma":[0.9989374,0.00041445982,0.00027207352,0.00008721797,0.00005249786,0.0002362459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013253399,0.0013942657,0.0031761182,0.00033235198,0.00031122795,0.0008339186,0.00086880097,0.0011919263,0.0032285],"category_scores_gemma":[0.0022149158,0.0004706947,0.003006682,0.00042771667,0.0012142592,0.0009988672,0.00034609222,0.003271379,0.0004541189],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97839236,0.0010648023,0.0008322676,0.00081318314,0.0030066797,0.00004283636,0.00003674153,0.00029068865,0.0013999338,0.00007315558,0.00044382675,0.013603478],"study_design_scores_gemma":[0.9445254,0.04680493,0.0051752264,0.00005363737,0.0019636413,0.00007354869,0.000035512643,0.0003606898,0.00033568707,0.00023201627,0.00041672122,0.000023010152],"about_ca_topic_score_codex":0.0012207917,"about_ca_topic_score_gemma":0.002522229,"teacher_disagreement_score":0.0032285,"about_ca_system_score_codex":0.00068177254,"about_ca_system_score_gemma":0.00063942483,"threshold_uncertainty_score":0.010800362},"labels":[],"label_agreement":null},{"id":"W2895886892","doi":"10.1016/s1470-2045(18)30588-6","title":"Pelvic radiotherapy in prostate cancer: an unresolved question","year":2018,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Prostate cancer; Radiation therapy; Medicine; Prostate; Cancer; Oncology; Radiology; Internal medicine","score_opus":0.04924383599259098,"score_gpt":0.38039663500597126,"score_spread":0.3311527990133803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895886892","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000067310684,0.0038147178,0.00002069612,0.98620033,0.008883504,0.0000014009686,0.000013279349,0.000003971768,0.0009947544],"genre_scores_gemma":[0.0027355503,0.006655646,0.00009502067,0.9008483,0.08694214,0.00001262388,0.000025636124,0.000016878817,0.002668149],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942622,0.002515327,0.00061844004,0.00044020146,0.0014489132,0.00071482285],"domain_scores_gemma":[0.98212,0.011571091,0.0011235544,0.00043876495,0.0024199462,0.0023265805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006544149,0.0006387274,0.0017957381,0.0009104888,0.0037025216,0.0044023613,0.0020153967,0.067157455,0.011379146],"category_scores_gemma":[0.041255914,0.00076360913,0.0011447547,0.0009362285,0.004783639,0.0072650956,0.0033765035,0.05139683,0.0068086735],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041037507,0.000020852722,0.000321327,0.0001146013,0.000014074996,0.0005218374,0.00010445639,0.000051228,0.000059804446,0.005374068,0.9754699,0.01790685],"study_design_scores_gemma":[0.00011791423,0.000055347195,0.0005364363,0.0007223786,0.000026320333,0.0010424344,0.00034329004,0.00012567104,0.00006717205,0.01613055,0.98079497,0.00003758256],"about_ca_topic_score_codex":0.004599117,"about_ca_topic_score_gemma":0.008659528,"teacher_disagreement_score":0.067157455,"about_ca_system_score_codex":0.0049389387,"about_ca_system_score_gemma":0.0068053915,"threshold_uncertainty_score":0.038067043},"labels":[],"label_agreement":null},{"id":"W2896015079","doi":"10.1016/s1470-2045(18)30415-7","title":"Integration of oncology and palliative care: a Lancet Oncology Commission","year":2018,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":834,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Italfarmaco; Ipsen; European Society for Medical Oncology; Helsinn; Marie Curie; GW Pharmaceuticals; Les Laboratories Pierre Fabre; National Institute for Health and Care Research; Teva Pharmaceutical Industries; European Commission; Amgen; Pfizer; Merck","keywords":"Palliative care; Medicine; Multidisciplinary approach; Oncology; Health care; Commission; Quality of life (healthcare); Nursing; End-of-life care; Family medicine; Internal medicine","score_opus":0.464774379592267,"score_gpt":0.5651483393700169,"score_spread":0.10037395977774988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896015079","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021346528,0.086137384,0.0004728276,0.79725707,0.10744353,0.00009077017,0.00005723498,0.00004660303,0.008281266],"genre_scores_gemma":[0.01492845,0.06858756,0.0038250813,0.7866119,0.052251037,0.00040936127,0.00022316267,0.00025542112,0.07290802],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.95376813,0.014342661,0.003637131,0.0033571722,0.019668812,0.005226073],"domain_scores_gemma":[0.91712624,0.03727291,0.003849426,0.0053841686,0.011878073,0.024489183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.051991638,0.0016965582,0.0027650136,0.0019122408,0.003991611,0.018457046,0.0056671645,0.043520935,0.007219655],"category_scores_gemma":[0.079420656,0.0015292168,0.0024794433,0.0026398583,0.0094300695,0.01317019,0.008595236,0.033508632,0.0034142875],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000048867783,0.000036101672,0.00008922485,0.0005776777,0.000025776671,0.00021120175,0.0005115357,0.00018549754,0.00012089542,0.0354135,0.9314924,0.03128719],"study_design_scores_gemma":[0.00004823096,0.000025690228,0.00013149112,0.0007730009,0.000011126345,0.000108771645,0.00015132473,0.00005203961,0.00004678148,0.0074781193,0.991154,0.000019444558],"about_ca_topic_score_codex":0.014231433,"about_ca_topic_score_gemma":0.020037642,"teacher_disagreement_score":0.051991638,"about_ca_system_score_codex":0.022353055,"about_ca_system_score_gemma":0.06485381,"threshold_uncertainty_score":0.27496135},"labels":[],"label_agreement":null},{"id":"W2896458230","doi":"10.1016/s1470-2045(18)30618-1","title":"Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":159,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre; University of Alberta","funders":"National Health and Medical Research Council; AstraZeneca Australia; Siemens; National Health Research Institutes; Engineering and Physical Sciences Research Council; National Institute for Health and Care Research; F. Hoffmann-La Roche","keywords":"Obinutuzumab; Medicine; Follicular lymphoma; Vincristine; Bendamustine; Rituximab; Internal medicine; Prednisone; Clinical endpoint; CHOP; Oncology; Cyclophosphamide; Surgery; Lymphoma; Gastroenterology; Randomized controlled trial; Chemotherapy","score_opus":0.03272674167592464,"score_gpt":0.3595032829152931,"score_spread":0.32677654123936845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896458230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951309,0.0023241148,0.00032099755,0.0003336758,0.00016511235,0.0003455572,0.0006649292,0.00003614016,0.00067859684],"genre_scores_gemma":[0.9975957,0.0003377472,0.00022963753,0.00022389863,0.00017014657,0.000282449,0.00071213697,0.000014054854,0.00043420715],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99672204,0.0022766818,0.00011864731,0.0004394494,0.00012792964,0.00031520502],"domain_scores_gemma":[0.9932909,0.0034277176,0.0014599578,0.00075475435,0.00020018882,0.00086643914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051493556,0.001803751,0.0028078891,0.00037399863,0.00044776572,0.0017133068,0.0013710584,0.0021462138,0.003600921],"category_scores_gemma":[0.0063419975,0.0005873213,0.003721088,0.00049175095,0.0016033525,0.0018010519,0.0008798925,0.0033333628,0.00063405174],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98371583,0.00096001057,0.0060479967,0.00020090413,0.0022791934,0.000020753516,0.00003371026,0.0004913056,0.0008724364,0.000045597975,0.0002613438,0.0050709397],"study_design_scores_gemma":[0.7483249,0.16124424,0.07260579,0.00013032247,0.010594192,0.00015764072,0.00010466173,0.0026323264,0.0017750589,0.0011670766,0.0011678806,0.00009596261],"about_ca_topic_score_codex":0.00090155756,"about_ca_topic_score_gemma":0.0011916516,"teacher_disagreement_score":0.0051493556,"about_ca_system_score_codex":0.0012751896,"about_ca_system_score_gemma":0.00078046194,"threshold_uncertainty_score":0.027232707},"labels":[],"label_agreement":null},{"id":"W2896600825","doi":"10.1016/s1470-2045(18)30700-9","title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1409,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Ipilimumab; Nivolumab; Medicine; Internal medicine; Oncology; Immunotherapy; Cancer","score_opus":0.059457284228469,"score_gpt":0.3855917897477813,"score_spread":0.3261345055193123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896600825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869451,0.0068831956,0.00048628027,0.00091624423,0.0006652562,0.0012422204,0.000955089,0.0000996176,0.0018070254],"genre_scores_gemma":[0.9902418,0.0023804917,0.0010532179,0.0009745004,0.00042359624,0.001079814,0.0011076445,0.00003522572,0.0027037538],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9989017,0.0006663247,0.00004806115,0.00017359141,0.000062597595,0.00014755882],"domain_scores_gemma":[0.9986687,0.0005035638,0.00028440004,0.000115154064,0.000058135825,0.00037012648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030028366,0.0017438518,0.002991277,0.00039398795,0.00038771355,0.001412676,0.0011700351,0.002018235,0.0046667545],"category_scores_gemma":[0.002533619,0.00066520285,0.0035648255,0.00036726624,0.0012313658,0.0015406535,0.0006387323,0.004321244,0.001026548],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98412746,0.0019452458,0.00055670814,0.00037549806,0.0014890712,0.000021009706,0.000039563376,0.0003567301,0.001150996,0.000071940165,0.0006418975,0.0092238095],"study_design_scores_gemma":[0.9468643,0.048308425,0.0024986642,0.000044031003,0.0010523336,0.000027997767,0.000027940363,0.00036102303,0.00022940975,0.00017617861,0.0003915267,0.000018190509],"about_ca_topic_score_codex":0.0014261323,"about_ca_topic_score_gemma":0.0028500776,"teacher_disagreement_score":0.0046667545,"about_ca_system_score_codex":0.0011093905,"about_ca_system_score_gemma":0.0008640326,"threshold_uncertainty_score":0.015880704},"labels":[],"label_agreement":null},{"id":"W2897382264","doi":"10.1016/s1470-2045(18)30586-2","title":"The effect of postmastectomy radiotherapy on patient-reported outcomes","year":2018,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences","funders":"","keywords":"Medicine; Breast cancer; Radiation therapy; Mastectomy; Axillary Lymph Node Dissection; Oncology; Lymph node; Cancer; Axillary lymph nodes; Disease; Internal medicine; Sentinel lymph node","score_opus":0.015034009161065233,"score_gpt":0.30716272129331373,"score_spread":0.2921287121322485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897382264","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11193406,0.21703088,0.0003899454,0.6305446,0.017158348,0.00006873578,0.006933596,0.000037084093,0.015902855],"genre_scores_gemma":[0.65151185,0.05871331,0.00074626016,0.25172842,0.030163113,0.00023042168,0.0024699771,0.00004553341,0.0043911478],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9893349,0.0069157556,0.001101329,0.00068975694,0.0013938444,0.0005644889],"domain_scores_gemma":[0.9211933,0.063857295,0.006976167,0.0023808167,0.0034871807,0.0021051893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012048812,0.00028415388,0.0013797652,0.00066287303,0.00052001193,0.0015068615,0.0013428964,0.0041558887,0.006213826],"category_scores_gemma":[0.07958665,0.0003172041,0.0023665302,0.001911441,0.0008738934,0.0011409286,0.0010240191,0.0044464204,0.0009578878],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028752048,0.00046281161,0.3715388,0.0065071373,0.013734701,0.0014503071,0.00049352256,0.0012478753,0.00081697374,0.00400531,0.2844636,0.28652686],"study_design_scores_gemma":[0.008184484,0.005634397,0.74609375,0.0060723573,0.017648924,0.0020461748,0.00107514,0.0010211219,0.0012321293,0.013820143,0.19687515,0.00029626835],"about_ca_topic_score_codex":0.006069186,"about_ca_topic_score_gemma":0.012761704,"teacher_disagreement_score":0.012048812,"about_ca_system_score_codex":0.0021348484,"about_ca_system_score_gemma":0.0017848611,"threshold_uncertainty_score":0.06372094},"labels":[],"label_agreement":null},{"id":"W2897867911","doi":"10.1016/s1470-2045(18)30589-8","title":"Towards improving accuracy, effectiveness, and efficiency in breast cancer screening","year":2018,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Digital Radiography and Breast Imaging","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Breast cancer; Medicine; Breast cancer screening; Cancer; Medical physics; Computer science; Oncology; Internal medicine; Mammography","score_opus":0.02638061643442126,"score_gpt":0.3265582997418236,"score_spread":0.30017768330740235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897867911","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000223798,0.0024415117,0.00019893714,0.99281937,0.00319572,0.000004656279,0.000022859178,0.000015024162,0.001078102],"genre_scores_gemma":[0.007900253,0.0040634256,0.0011872533,0.93682474,0.048121437,0.00003246428,0.00004146443,0.000037428425,0.0017915617],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.972388,0.011505039,0.00328881,0.0017063586,0.0096755875,0.0014362158],"domain_scores_gemma":[0.7792692,0.17347533,0.007913563,0.003729519,0.02848274,0.007129682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.026449379,0.0006904201,0.002011098,0.0015085592,0.0020423662,0.005337408,0.0026779782,0.04720163,0.010179464],"category_scores_gemma":[0.20724115,0.00080797344,0.0012585326,0.0013416089,0.005500396,0.009066087,0.0033013066,0.047295336,0.007767475],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002428895,0.00012598226,0.0034675812,0.00035693354,0.00006993656,0.0006000415,0.00023203748,0.0002459425,0.00040523626,0.014216607,0.87830615,0.101730734],"study_design_scores_gemma":[0.0005885357,0.00043419658,0.006126165,0.0020808806,0.00017301134,0.0026598147,0.0008404428,0.0018078748,0.0009370105,0.067119494,0.9170689,0.00016370733],"about_ca_topic_score_codex":0.00512724,"about_ca_topic_score_gemma":0.007710762,"teacher_disagreement_score":0.04720163,"about_ca_system_score_codex":0.007797126,"about_ca_system_score_gemma":0.007600638,"threshold_uncertainty_score":0.13987935},"labels":[],"label_agreement":null},{"id":"W2899334087","doi":"10.1016/s1470-2045(18)30536-9","title":"Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated women: a modelling study","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; Canadian Cancer Society; Centre hospitalier universitaire de Québec; Université de Montréal; University of British Columbia; McGill University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Cervical cancer; Demography; Incidence (geometry); Population; Cancer; Cervical screening; Gynecology; Cancer registry; Obstetrics; Internal medicine; Environmental health","score_opus":0.07594709274700287,"score_gpt":0.3951939684561794,"score_spread":0.31924687570917654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899334087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903508,0.0006902364,0.0041048285,0.0005257814,0.000021733673,0.000103321516,0.0018573387,0.000043035918,0.002302837],"genre_scores_gemma":[0.99505687,0.000502884,0.001392662,0.0000793737,0.000013422239,0.000086231754,0.0011800892,0.000015301526,0.0016731814],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99929523,0.00025634188,0.000028324213,0.00012872554,0.000056126675,0.0002351841],"domain_scores_gemma":[0.99375856,0.0040770555,0.0008306572,0.0003545393,0.000538446,0.00044080438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002696197,0.00093534443,0.0009661802,0.0014008525,0.00094491564,0.001265463,0.0024717823,0.001919252,0.0043527107],"category_scores_gemma":[0.009701295,0.0005989533,0.0026559138,0.001398936,0.0006485769,0.00077766425,0.00087716396,0.0014792617,0.0005447746],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001877709,0.0014165238,0.4668382,0.00028073622,0.0011933076,0.00146206,0.0016863359,0.4973942,0.00057161355,0.00814185,0.004602636,0.014534749],"study_design_scores_gemma":[0.00034849113,0.0006773431,0.09042001,0.00016388045,0.00079726684,0.0005196684,0.0009682737,0.8984261,0.00017324236,0.0049007456,0.0024929598,0.00011197674],"about_ca_topic_score_codex":0.3822893,"about_ca_topic_score_gemma":0.22362842,"teacher_disagreement_score":0.3822893,"about_ca_system_score_codex":0.00499883,"about_ca_system_score_gemma":0.0033363458,"threshold_uncertainty_score":0.76012826},"labels":[],"label_agreement":null},{"id":"W2899388060","doi":"10.1016/s1470-2045(18)30751-4","title":"The silent victims of the US embargo against Iran","year":2018,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Ethics and Legal Issues in Pediatric Healthcare","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Counterfeit; Ask price; Family medicine; Medicine; Psychology; Traditional medicine; Political science; Business; Law","score_opus":0.08276957762902769,"score_gpt":0.3919243443804915,"score_spread":0.3091547667514638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899388060","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009830889,0.0015646253,0.000021428918,0.9872394,0.005424229,0.0000033397712,0.0000110792,0.000004982836,0.004747845],"genre_scores_gemma":[0.01583274,0.0011955192,0.00005953815,0.96376836,0.01073118,0.000012962952,0.000006825799,0.00002364105,0.008369179],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99454814,0.0019291246,0.00033247945,0.00043229363,0.0012008655,0.0015570393],"domain_scores_gemma":[0.987463,0.007045069,0.0011572415,0.00037072416,0.0016088143,0.002355124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0062524746,0.0006582839,0.00114964,0.00070426805,0.010700494,0.007039389,0.0019690364,0.077015,0.007697781],"category_scores_gemma":[0.04091665,0.0007200042,0.001128008,0.0006155631,0.009089116,0.0059287413,0.0039727055,0.061886106,0.0028137246],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029634395,0.000028517386,0.0010749752,0.000052628126,0.000026749703,0.0039005424,0.004369067,0.000041838248,0.00014809216,0.023879983,0.9594653,0.0069825877],"study_design_scores_gemma":[0.00004458613,0.000026782605,0.0010167508,0.0004331305,0.000038020222,0.002125908,0.006564653,0.000089437,0.00027340514,0.017538643,0.97178936,0.000059362654],"about_ca_topic_score_codex":0.018182255,"about_ca_topic_score_gemma":0.023881987,"teacher_disagreement_score":0.077015,"about_ca_system_score_codex":0.0069754687,"about_ca_system_score_gemma":0.011024717,"threshold_uncertainty_score":0.05061084},"labels":[],"label_agreement":null},{"id":"W2899472327","doi":"10.1016/s1470-2045(18)30754-x","title":"Developing cancer care institutions for the developing world","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Health and Surgery","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Developing country; Cancer; Business; Political science; Medicine; Economic growth; Economics; Internal medicine","score_opus":0.22709938437415975,"score_gpt":0.47520720641394265,"score_spread":0.2481078220397829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899472327","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025386421,0.034907356,0.0034153634,0.8178474,0.006198889,0.00032326084,0.002703765,0.0002054008,0.109012246],"genre_scores_gemma":[0.611531,0.126644,0.024632825,0.15154243,0.006708211,0.00091743196,0.0044591106,0.00038775284,0.07317718],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99788755,0.00079095596,0.0001055197,0.00011071402,0.00027959497,0.0008257032],"domain_scores_gemma":[0.9819973,0.0028508606,0.003281843,0.000853521,0.002798976,0.008217407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034714788,0.000584042,0.00043755668,0.0010781741,0.0037261806,0.00697683,0.0010094835,0.0026740003,0.044031095],"category_scores_gemma":[0.015941676,0.00025076492,0.0006695147,0.0035977142,0.0022620857,0.0047575226,0.0060473643,0.005512499,0.0031026085],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033642346,0.00026309805,0.07924663,0.002502791,0.00026018778,0.00094679487,0.0025698268,0.0010024343,0.0020993156,0.19256029,0.48070207,0.23751013],"study_design_scores_gemma":[0.00021855698,0.00019711637,0.057718553,0.0031278313,0.00018982982,0.00076355785,0.013115176,0.00039207592,0.0012304547,0.034407537,0.88855636,0.00008296436],"about_ca_topic_score_codex":0.025911892,"about_ca_topic_score_gemma":0.06574476,"teacher_disagreement_score":0.044031095,"about_ca_system_score_codex":0.01059201,"about_ca_system_score_gemma":0.047549073,"threshold_uncertainty_score":0.14729863},"labels":[],"label_agreement":null},{"id":"W2900298813","doi":"10.1016/s1470-2045(18)30566-7","title":"Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":306,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; Medical Research Council; Wellbeing of Women; Mauritius Research Council; Cancer Research UK","keywords":"Debulking; Medicine; Stage (stratigraphy); Chemotherapy; Oncology; Clinical trial; Randomized controlled trial; Surgery; Ovarian cancer; Internal medicine; Gynecologic oncology; Cancer","score_opus":0.1755971065629348,"score_gpt":0.4055934884821742,"score_spread":0.22999638191923938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900298813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.71490204,0.27261084,0.0026169922,0.00096402015,0.00070154626,0.00034009176,0.00482789,0.00011145315,0.0029249892],"genre_scores_gemma":[0.98106027,0.014782512,0.0007369405,0.00045548036,0.00024166149,0.00016675284,0.0019276012,0.000037589143,0.0005912889],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9933002,0.0050985864,0.0005780271,0.00054545887,0.00025482156,0.00022281575],"domain_scores_gemma":[0.9930681,0.0044498346,0.0014843196,0.00062566786,0.00015592785,0.00021615946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008949937,0.0012084967,0.0054983823,0.00084630755,0.00019967029,0.0014663977,0.0006374561,0.0010379431,0.0019015445],"category_scores_gemma":[0.013786552,0.00059507374,0.011625858,0.0012670206,0.00049342855,0.0011087371,0.0009722724,0.0017668557,0.00021943975],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42497358,0.00022663259,0.034310598,0.011007874,0.46790352,0.00015614045,0.00016113307,0.006302487,0.001672543,0.00040096932,0.0025256306,0.05035891],"study_design_scores_gemma":[0.09293619,0.015720725,0.12843679,0.0017648332,0.74603605,0.00038112453,0.00025416142,0.003846968,0.0012565774,0.0028340374,0.0063549685,0.00017752424],"about_ca_topic_score_codex":0.0017581391,"about_ca_topic_score_gemma":0.0053110314,"teacher_disagreement_score":0.008949937,"about_ca_system_score_codex":0.00075856014,"about_ca_system_score_gemma":0.00059974275,"threshold_uncertainty_score":0.047332346},"labels":[],"label_agreement":null},{"id":"W2900348927","doi":"10.1016/s1470-2045(18)30537-0","title":"Temporal patterns in the risk of chronic health conditions in survivors of childhood cancer diagnosed 1970–99: a report from the Childhood Cancer Survivor Study cohort","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":259,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute; National Institutes of Health; American Lebanese Syrian Associated Charities","keywords":"Medicine; Cumulative incidence; Cancer; Incidence (geometry); Hazard ratio; Cohort; Pediatrics; Retrospective cohort study; Proportional hazards model; Internal medicine; Pediatric cancer; Cohort study; Confidence interval","score_opus":0.044148029212780694,"score_gpt":0.39117160089673203,"score_spread":0.3470235716839513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900348927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99427235,0.0004180092,0.000061184684,0.000100070276,0.0000089088035,0.000005758981,0.0044877543,0.0000068124273,0.0006392278],"genre_scores_gemma":[0.99555075,0.0004270283,0.000044085034,0.0000238402,0.000008528793,0.000008957973,0.0035947855,0.000003827667,0.0003382624],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99977726,0.000026352815,0.00003020037,0.000054777043,0.00003355387,0.000077803925],"domain_scores_gemma":[0.99917847,0.00009030526,0.00035525236,0.00008221815,0.00012965171,0.00016410866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038325085,0.00015837354,0.00023932722,0.0013256354,0.0004886795,0.0006574437,0.00029090373,0.0003933136,0.0015605764],"category_scores_gemma":[0.0013533282,0.00033381043,0.00053902477,0.002530133,0.00024693675,0.000519492,0.0007120608,0.00057174603,0.00021064574],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008888197,0.000014960418,0.99841547,0.000008557937,0.0000635666,0.000058473343,0.00020589685,0.000044293214,0.00018290034,0.000022530416,0.00015971971,0.0007347148],"study_design_scores_gemma":[0.0000013930023,0.000010455243,0.9995097,0.0000027649264,0.000013315206,0.000055002572,0.00023548213,0.000020046184,0.000017339446,0.0000052944283,0.00012718425,0.000002110067],"about_ca_topic_score_codex":0.111900575,"about_ca_topic_score_gemma":0.119613014,"teacher_disagreement_score":0.111900575,"about_ca_system_score_codex":0.0005654874,"about_ca_system_score_gemma":0.0006595439,"threshold_uncertainty_score":0.22249848},"labels":[],"label_agreement":null},{"id":"W2900592090","doi":"10.1016/s1470-2045(18)30711-3","title":"Radiosurgery and risk of intracranial malignancies: more research needed","year":2018,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Pediatric Oncology Group; University Health Network; University of Toronto","funders":"","keywords":"Radiosurgery; Medicine; Radiation therapy; Malignancy; Cohort; Retrospective cohort study; Radiology; Surgery; Internal medicine","score_opus":0.09148683743019372,"score_gpt":0.3818851779728545,"score_spread":0.2903983405426608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900592090","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002444873,0.0104841525,0.00007396355,0.97459066,0.013053302,0.000003210343,0.00007770209,0.000016437167,0.0014561302],"genre_scores_gemma":[0.005263352,0.019579984,0.00037076633,0.7712759,0.2009317,0.000021968068,0.00014490356,0.000030683204,0.0023807292],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962204,0.0012726567,0.0005739608,0.00039827116,0.0011622745,0.000372473],"domain_scores_gemma":[0.96658987,0.022137305,0.0025284989,0.0008264451,0.004862873,0.0030549923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044456352,0.0007121812,0.0026423426,0.0010834438,0.0016496134,0.003964994,0.0024658064,0.034881864,0.01341978],"category_scores_gemma":[0.035901815,0.0006191461,0.0017953423,0.0011477885,0.0028878408,0.0066996543,0.0019485108,0.034681674,0.0064070956],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015044096,0.00008571909,0.0018245619,0.00032508638,0.000098662254,0.00066190585,0.00009271918,0.00012816154,0.00017973362,0.003963966,0.93975383,0.052735128],"study_design_scores_gemma":[0.00038737882,0.00015530977,0.0038801087,0.0019504643,0.00020402296,0.0016178726,0.0009528368,0.00037696984,0.0001782098,0.0414205,0.94872904,0.0001472568],"about_ca_topic_score_codex":0.007606816,"about_ca_topic_score_gemma":0.015132455,"teacher_disagreement_score":0.034881864,"about_ca_system_score_codex":0.003599951,"about_ca_system_score_gemma":0.0052514006,"threshold_uncertainty_score":0.044893622},"labels":[],"label_agreement":null},{"id":"W2900820241","doi":"10.1016/s1470-2045(18)30659-4","title":"Risk of radiation-associated intracranial malignancy after stereotactic radiosurgery: a retrospective, multicentre, cohort study","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":123,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; London Health Sciences Centre; Western University","funders":"","keywords":"Radiosurgery; Medicine; Malignancy; Cohort; Incidence (geometry); Population; Retrospective cohort study; Radiology; Radiation therapy; Surgery; Internal medicine","score_opus":0.016536977888361205,"score_gpt":0.3076291367489019,"score_spread":0.2910921588605407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900820241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99895763,0.0002893497,0.0001238938,0.000025897458,0.00000833791,0.000010484815,0.00037983846,0.000004344453,0.00020019153],"genre_scores_gemma":[0.9992773,0.00014066997,0.000075205935,0.000025821219,0.000011102263,0.000008612907,0.000369225,0.0000058371174,0.000086203225],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990607,0.00016310654,0.000086679596,0.00042714903,0.00010564225,0.000156736],"domain_scores_gemma":[0.99828255,0.00022466065,0.0006427634,0.00045376038,0.0001435343,0.00025273734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000754621,0.0005365456,0.00073860097,0.0007578701,0.0007377987,0.0011315811,0.0007484344,0.0007688158,0.0014613179],"category_scores_gemma":[0.0022520465,0.0008990874,0.0015363488,0.0015830126,0.00060054153,0.0009358663,0.00068698736,0.0011334539,0.0003167088],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078983133,0.0000648321,0.9965437,0.0000151016775,0.00057268504,0.00024035429,0.00015721444,0.00006773687,0.00067281764,0.00003503485,0.00014404191,0.00069659646],"study_design_scores_gemma":[0.000051999825,0.00031449695,0.9976406,0.000007817731,0.00035642085,0.0008401231,0.0002697225,0.00018828841,0.00009150463,0.000043534536,0.00017970598,0.000015732543],"about_ca_topic_score_codex":0.0101949945,"about_ca_topic_score_gemma":0.008192291,"teacher_disagreement_score":0.0101949945,"about_ca_system_score_codex":0.0006226232,"about_ca_system_score_gemma":0.0005810194,"threshold_uncertainty_score":0.020271301},"labels":[],"label_agreement":null},{"id":"W2901760736","doi":"10.1016/s1470-2045(18)30576-x","title":"Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":244,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Princess Margaret Cancer Centre","funders":"UCLH Biomedical Research Centre; National Cancer Institute; Cancer Research UK; National Institutes of Health; National Institute for Health and Care Research; GlaxoSmithKline; American Society of Hematology","keywords":"Conjugate; Antibody-drug conjugate; Multiple myeloma; Medicine; Refractory (planetary science); Antibody; Cancer research; Drug; Oncology; Antigen; Internal medicine; Pharmacology; Immunology; Monoclonal antibody; Materials science","score_opus":0.0496385688750652,"score_gpt":0.38452979460518505,"score_spread":0.33489122573011987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901760736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906944,0.0028161223,0.000418411,0.0010929459,0.0002125696,0.0013913142,0.00091919577,0.00019073671,0.0022642447],"genre_scores_gemma":[0.984697,0.0031581658,0.0015879823,0.001852355,0.00016584028,0.0017363154,0.0023425901,0.000071434166,0.0043883417],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995448,0.00015461212,0.000020566702,0.00008485031,0.000060702736,0.00013447009],"domain_scores_gemma":[0.99945885,0.00008662958,0.00009805424,0.00005179652,0.000027114871,0.00027751146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015997979,0.0017230879,0.002638297,0.000529692,0.00039610348,0.0014286933,0.0010395091,0.0018223277,0.0044908356],"category_scores_gemma":[0.00097478565,0.000587056,0.001994254,0.0004839556,0.0010679648,0.0011255951,0.0006647808,0.0054622577,0.001443494],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.63245463,0.05207065,0.0033864412,0.0017626676,0.0031920404,0.00044261105,0.0005247932,0.0052881213,0.048359577,0.0014397906,0.015410327,0.2356684],"study_design_scores_gemma":[0.74661696,0.23914821,0.004521256,0.000063447755,0.0005461592,0.00030449693,0.000051538795,0.001373452,0.0035067876,0.0005250233,0.0032990868,0.000043728145],"about_ca_topic_score_codex":0.0010648967,"about_ca_topic_score_gemma":0.0021809423,"teacher_disagreement_score":0.0044908356,"about_ca_system_score_codex":0.0013145555,"about_ca_system_score_gemma":0.001217865,"threshold_uncertainty_score":0.015023291},"labels":[],"label_agreement":null},{"id":"W2902516639","doi":"10.1016/s1470-2045(18)30663-6","title":"Competing risks of extended adjuvant aromatase inhibitors","year":2018,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Letrozole; Medicine; Tamoxifen; Breast cancer; Aromatase inhibitor; Oncology; Internal medicine; Aromatase; Adjuvant therapy; Adjuvant; Gynecology; Placebo; Cancer; Randomized controlled trial; Anastrozole; Alternative medicine; Pathology","score_opus":0.0460646919073738,"score_gpt":0.3401484784589049,"score_spread":0.2940837865515311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902516639","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0028753069,0.011002942,0.00047903522,0.96756214,0.007730079,0.000006147661,0.00026117248,0.000018095348,0.010065016],"genre_scores_gemma":[0.10691727,0.013690213,0.00054460525,0.7241989,0.1450842,0.000044407603,0.00027226185,0.00004652968,0.009201615],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99714214,0.0014978512,0.00016477448,0.00022296792,0.00061159173,0.00036066334],"domain_scores_gemma":[0.98300606,0.013293012,0.0010114227,0.00042755288,0.000702324,0.0015597283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036625967,0.0002817336,0.00092481414,0.00029775742,0.0007667033,0.0016686806,0.00096291373,0.016381437,0.010531799],"category_scores_gemma":[0.026457373,0.00030796614,0.00095458387,0.0004431506,0.0013940552,0.0014229687,0.0009876672,0.015159463,0.0023317582],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014240731,0.000102919155,0.006489083,0.00030484286,0.0002703585,0.0049875076,0.000116694886,0.0012892524,0.0005218975,0.043735042,0.8499513,0.09080707],"study_design_scores_gemma":[0.0016049714,0.00046910215,0.0071382886,0.0007100945,0.00037045174,0.013845426,0.00036829629,0.0049369927,0.0007079254,0.1785814,0.7911301,0.0001370179],"about_ca_topic_score_codex":0.0019712388,"about_ca_topic_score_gemma":0.00473507,"teacher_disagreement_score":0.016381437,"about_ca_system_score_codex":0.0020236347,"about_ca_system_score_gemma":0.0015425568,"threshold_uncertainty_score":0.035232425},"labels":[],"label_agreement":null},{"id":"W2902706178","doi":"10.1016/s1470-2045(18)30788-5","title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":548,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Obinutuzumab; Ibrutinib; Chlorambucil; Medicine; Oncology; Internal medicine; Open label; Chronic lymphocytic leukemia; Venetoclax; Clinical trial; Leukemia; Chemotherapy; Cyclophosphamide","score_opus":0.16909667303358808,"score_gpt":0.4438783636128727,"score_spread":0.2747816905792846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902706178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98162353,0.011008086,0.0005463747,0.0008068221,0.000812888,0.0015660608,0.0010066183,0.00016103986,0.0024686754],"genre_scores_gemma":[0.98632556,0.0042217495,0.0012310569,0.0011778775,0.0004564673,0.0017756685,0.0012909119,0.000041895404,0.0034788207],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994247,0.00028451902,0.000022604458,0.00010148979,0.00003808169,0.0001285815],"domain_scores_gemma":[0.99916685,0.00025575177,0.00016439919,0.0000689516,0.00003927579,0.0003047369],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014623975,0.0019795792,0.003468333,0.00037792692,0.00040692653,0.0015512634,0.0011660524,0.0016551298,0.0057307626],"category_scores_gemma":[0.0017334934,0.0007009432,0.002485326,0.00045000896,0.0012536097,0.001186293,0.0005754878,0.0036432839,0.0011724065],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98181564,0.0018031668,0.00031574766,0.0005681472,0.0010146339,0.000028660279,0.000059169583,0.00035775726,0.0015219633,0.000096036405,0.0006775176,0.011741506],"study_design_scores_gemma":[0.967922,0.029434174,0.0010113441,0.00004505476,0.0004501471,0.00003096125,0.000025003057,0.00022079992,0.00016688723,0.00012301338,0.00055755296,0.000013132531],"about_ca_topic_score_codex":0.0018547289,"about_ca_topic_score_gemma":0.0039540115,"teacher_disagreement_score":0.0057307626,"about_ca_system_score_codex":0.001186784,"about_ca_system_score_gemma":0.00089558447,"threshold_uncertainty_score":0.019171238},"labels":[],"label_agreement":null},{"id":"W2902844274","doi":"10.1016/s1470-2045(18)30621-1","title":"Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":163,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Korea Health Industry Development Institute; Ministry of Health and Welfare; National Cancer Institute; U.S. Department of Health and Human Services; National Institutes of Health; U.S. Public Health Service; Novartis Pharmaceuticals Corporation","keywords":"Medicine; Letrozole; Aromatase inhibitor; Internal medicine; Breast cancer; Tamoxifen; Placebo; Oncology; Clinical endpoint; Interim analysis; Cancer; Gynecology; Randomized controlled trial","score_opus":0.04278072334570308,"score_gpt":0.3548242458836685,"score_spread":0.3120435225379654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902844274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9784828,0.0105135115,0.0007746568,0.001397356,0.0009512787,0.002963178,0.001564493,0.00030503617,0.0030478465],"genre_scores_gemma":[0.981152,0.0058832737,0.0011078808,0.0015643729,0.0005081419,0.0024521183,0.0014021704,0.000041748808,0.0058884914],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99956614,0.00020711131,0.000023735658,0.00008093389,0.000037142083,0.000084897125],"domain_scores_gemma":[0.99946886,0.00015610727,0.00009036545,0.000048506983,0.000027779715,0.00020851943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001225187,0.0017524117,0.0032669615,0.0005575927,0.00044722017,0.0009807321,0.0008304901,0.002532772,0.0063507296],"category_scores_gemma":[0.0014214856,0.00071825454,0.0016262053,0.00048720324,0.0013033176,0.0011416102,0.00035896344,0.00306537,0.0012598214],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9845852,0.0021663806,0.00020354164,0.00041859414,0.0005492672,0.000028904484,0.000034244396,0.00015978604,0.0019244297,0.00006302269,0.0005732295,0.009293291],"study_design_scores_gemma":[0.96144086,0.03634481,0.0008059439,0.000021038431,0.00029692793,0.000019806874,0.000016672793,0.00013688813,0.00025134254,0.0001080379,0.0005470462,0.0000106060525],"about_ca_topic_score_codex":0.0011174333,"about_ca_topic_score_gemma":0.0026507226,"teacher_disagreement_score":0.0063507296,"about_ca_system_score_codex":0.00064958615,"about_ca_system_score_gemma":0.00086333917,"threshold_uncertainty_score":0.0212453},"labels":[],"label_agreement":null},{"id":"W2903247006","doi":"10.1016/s1470-2045(18)30830-1","title":"National cancer control plans","year":2018,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Scopus; Cancer; Medicine; Nice; Family medicine; Quarter (Canadian coin); Primary care; MEDLINE; Political science; Computer science; Geography; Internal medicine","score_opus":0.18148294881658775,"score_gpt":0.4288465343402003,"score_spread":0.24736358552361257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903247006","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002863633,0.0022427312,0.00017182658,0.868693,0.049215835,0.00017750764,0.0018573791,0.00016796615,0.07718738],"genre_scores_gemma":[0.0014405472,0.0013151201,0.00030421253,0.8259247,0.011264101,0.0004462694,0.0008440683,0.0001069665,0.15835403],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98957086,0.0013136589,0.00076844473,0.0011080615,0.004770129,0.0024689066],"domain_scores_gemma":[0.9832548,0.0052544773,0.0008291738,0.0010132723,0.004802674,0.004845607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006647694,0.0014159644,0.0019910205,0.0020589826,0.00763571,0.00757103,0.0040734867,0.0651739,0.089225516],"category_scores_gemma":[0.051958308,0.0020133166,0.0022435703,0.0021085818,0.0025651567,0.004972153,0.005351679,0.042410105,0.04620905],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012972253,0.000013433473,0.00009136661,0.000021741473,0.0000026865462,0.00003454494,0.000016696049,0.000015661662,0.000019277719,0.0017062206,0.994745,0.0033203347],"study_design_scores_gemma":[0.000051726067,0.000011810278,0.0004239598,0.00015374881,0.00000882196,0.0000445674,0.000039551083,0.000044825374,0.00004467843,0.0013744934,0.99778914,0.0000125752495],"about_ca_topic_score_codex":0.08511013,"about_ca_topic_score_gemma":0.14964049,"teacher_disagreement_score":0.089225516,"about_ca_system_score_codex":0.012666548,"about_ca_system_score_gemma":0.050803337,"threshold_uncertainty_score":0.2984891},"labels":[],"label_agreement":null},{"id":"W2907304754","doi":"10.1016/s1470-2045(18)30950-1","title":"Patients' crowdfunding campaigns for alternative cancer treatments","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"FinTech, Crowdfunding, Digital Finance","field":"Business, Management and Accounting","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Simon Fraser University","funders":"","keywords":"Medicine; Alternative medicine; Adverse effect; Popularity; Cancer; Cancer survival; Cancer treatment; Cancer therapy; Intensive care medicine; Internal medicine; Pathology","score_opus":0.052118109488045856,"score_gpt":0.3145241346615955,"score_spread":0.26240602517354966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907304754","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08745863,0.010260501,0.00067514635,0.8004464,0.0049655335,0.00011686132,0.0011015739,0.00014966202,0.094825685],"genre_scores_gemma":[0.7979366,0.006059096,0.000673465,0.16412981,0.014028109,0.00012453985,0.00048395983,0.00008358499,0.016480777],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.98775256,0.0076467735,0.0004382696,0.00046793564,0.0023274359,0.0013670695],"domain_scores_gemma":[0.8898353,0.073267095,0.018301392,0.0028329797,0.0039950446,0.0117681315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013417521,0.00028272488,0.00043634934,0.001282571,0.003036751,0.005608802,0.0006180424,0.005680154,0.024615243],"category_scores_gemma":[0.09482169,0.00031423778,0.0006515373,0.0015321617,0.0026398746,0.0028629848,0.0042708092,0.007144071,0.0016922003],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077006174,0.00026085545,0.03186559,0.0003835336,0.00024604812,0.0003612504,0.0041416083,0.00045759472,0.00035562887,0.027121738,0.76684284,0.16719323],"study_design_scores_gemma":[0.0005830395,0.0006343421,0.04880813,0.0011187714,0.0002426119,0.0006071915,0.008365386,0.0011214967,0.000741621,0.018343853,0.91930586,0.00012765024],"about_ca_topic_score_codex":0.0035502748,"about_ca_topic_score_gemma":0.0057097934,"teacher_disagreement_score":0.024615243,"about_ca_system_score_codex":0.0032267512,"about_ca_system_score_gemma":0.004430851,"threshold_uncertainty_score":0.08234626},"labels":[],"label_agreement":null},{"id":"W2911465702","doi":"10.1016/s1470-2045(18)30898-2","title":"Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Astellas Foundation for Research on Metabolic Disorders; Cancer Research UK; Ironwood Pharmaceuticals, Incorporated; Pfizer","keywords":"Enzalutamide; Medicine; Prostate cancer; Clinical endpoint; Placebo; Quality of life (healthcare); Internal medicine; Discontinuation; Oncology; Prostate-specific antigen; Clinical trial; Visual analogue scale; Cancer; Physical therapy; Pathology; Nursing","score_opus":0.07290594750234178,"score_gpt":0.41209821916643674,"score_spread":0.33919227166409494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911465702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95644665,0.028406156,0.0010250404,0.0012541345,0.0012927429,0.003881731,0.0036210779,0.00026184236,0.0038106705],"genre_scores_gemma":[0.98031116,0.007086429,0.001647827,0.0012785356,0.0007146338,0.0035317559,0.0017206733,0.00003994259,0.0036690126],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987717,0.00081710186,0.00006981717,0.00015660611,0.0000614089,0.00012330183],"domain_scores_gemma":[0.9987375,0.00044623358,0.0003734047,0.000091642825,0.000084428226,0.00026679388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026331185,0.0022031048,0.0042507867,0.0005031164,0.00054338604,0.001031771,0.0010038596,0.0023973489,0.007145677],"category_scores_gemma":[0.0026017285,0.00071297307,0.0036723574,0.00043841678,0.0013000737,0.001204428,0.0006517718,0.003613171,0.0009467085],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98820263,0.0010086978,0.00033843546,0.0012453968,0.0016153539,0.00002140499,0.00004084951,0.00022260693,0.000586395,0.000063624015,0.0005558843,0.0060987878],"study_design_scores_gemma":[0.97218496,0.023947924,0.0019540759,0.00007476397,0.00086506666,0.000020483081,0.00002196902,0.00017380888,0.00013282857,0.00012617772,0.00048170926,0.000016306289],"about_ca_topic_score_codex":0.0016569644,"about_ca_topic_score_gemma":0.0030178372,"teacher_disagreement_score":0.007145677,"about_ca_system_score_codex":0.0007425025,"about_ca_system_score_gemma":0.000902561,"threshold_uncertainty_score":0.023904681},"labels":[],"label_agreement":null},{"id":"W2911475883","doi":"10.1016/s1470-2045(19)30012-9","title":"Limitations of simulation models for cervical cancer screening – Authors' reply","year":2019,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Cervical cancer; Incidence (geometry); Cervix; Cancer; Demography; Cohort; Cervical screening; Disease; Gynecology; Oncology; Internal medicine","score_opus":0.43574307576817817,"score_gpt":0.46450395424091767,"score_spread":0.028760878472739504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911475883","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015481802,0.00044339467,0.00015088491,0.9845359,0.014140396,0.000006000153,0.000112781905,0.000024279194,0.00043152084],"genre_scores_gemma":[0.0046106866,0.0008599208,0.00044869352,0.97096133,0.020965204,0.000095253614,0.0000638522,0.000060871276,0.0019341521],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9902552,0.005727078,0.0011425593,0.00068879453,0.0016176094,0.000568798],"domain_scores_gemma":[0.86147636,0.11636772,0.0035331992,0.0025961378,0.012440586,0.003586071],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01408539,0.0007521707,0.0017441896,0.001110862,0.0023081342,0.0042368467,0.0027369643,0.042274777,0.010608062],"category_scores_gemma":[0.1488015,0.0010950973,0.0021703772,0.0008608986,0.0031582115,0.0049758963,0.002809719,0.04148973,0.0053399447],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001258372,0.000022146736,0.0005380916,0.00012259849,0.00004724781,0.00029807616,0.00017696172,0.0006684423,0.00003469535,0.0032373474,0.9905566,0.0041718725],"study_design_scores_gemma":[0.0006142741,0.0001091529,0.0010235748,0.0013859525,0.00016658343,0.0007003084,0.000970358,0.0049989833,0.00038645638,0.04397263,0.9453878,0.0002839723],"about_ca_topic_score_codex":0.013897367,"about_ca_topic_score_gemma":0.012308789,"teacher_disagreement_score":0.042274777,"about_ca_system_score_codex":0.0039109057,"about_ca_system_score_gemma":0.006442676,"threshold_uncertainty_score":0.07449156},"labels":[],"label_agreement":null},{"id":"W2911490798","doi":"10.1016/s1470-2045(18)30860-x","title":"Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":397,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Bayer Fund","keywords":"Abiraterone acetate; Medicine; Prostate cancer; Prednisone; Abiraterone; Placebo; Urology; Radium-223; Internal medicine; Castration; Prednisolone; Oncology; Cancer; Androgen deprivation therapy; Bone metastasis; Hormone; Alternative medicine; Pathology","score_opus":0.047407643392600944,"score_gpt":0.3646799658367788,"score_spread":0.31727232244417786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911490798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97770566,0.010935809,0.00083338143,0.0010478746,0.0012936451,0.0036270916,0.0011052977,0.0003558393,0.0030953393],"genre_scores_gemma":[0.98334277,0.0054979566,0.0011388783,0.0013391855,0.0007629613,0.0024822897,0.0008993053,0.000052104537,0.0044844975],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9992124,0.0004191219,0.000048516184,0.00013409399,0.000057865545,0.0001280116],"domain_scores_gemma":[0.9990096,0.00031768685,0.00020064806,0.000088284265,0.00004988675,0.00033377032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017312373,0.0023471923,0.004361997,0.0007180825,0.0006199728,0.0014527715,0.0011433003,0.002672298,0.0071424004],"category_scores_gemma":[0.0018839488,0.001052142,0.0031341324,0.0007285172,0.0018983497,0.0010689574,0.00053078594,0.004554801,0.0016793789],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9882812,0.0021244928,0.0001566475,0.0004028087,0.0007680286,0.000020829522,0.000035242276,0.00016533633,0.0011638263,0.000044398905,0.0003526625,0.006484545],"study_design_scores_gemma":[0.9670097,0.031514525,0.0005379196,0.000018399902,0.00032397977,0.000018070054,0.000010849432,0.00010849262,0.00014356893,0.00006235759,0.00024228335,0.000010008921],"about_ca_topic_score_codex":0.0020130484,"about_ca_topic_score_gemma":0.0037714536,"teacher_disagreement_score":0.0071424004,"about_ca_system_score_codex":0.00072495214,"about_ca_system_score_gemma":0.0014620612,"threshold_uncertainty_score":0.023893714},"labels":[],"label_agreement":null},{"id":"W2912630069","doi":"10.1016/s1470-2045(18)30863-5","title":"Quality of life in men with prostate cancer","year":2019,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Prostate cancer; Quality of life (healthcare); Prostate; Medicine; Cancer; Oncology; Gerontology; Internal medicine; Nursing","score_opus":0.06595235535805974,"score_gpt":0.37068719479208645,"score_spread":0.3047348394340267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912630069","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023566608,0.0025340442,0.00002040581,0.98118156,0.0105934,0.000007503894,0.00014215485,0.000006248022,0.0031580748],"genre_scores_gemma":[0.03822288,0.0037795445,0.000084659514,0.91817856,0.03138598,0.000079871075,0.0002029033,0.000017333496,0.008048328],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997054,0.0013493965,0.00027937206,0.00016652583,0.00057750323,0.00057330425],"domain_scores_gemma":[0.9930353,0.0030786362,0.0006734843,0.00016479356,0.00090465526,0.002143225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023432248,0.00035635845,0.0009075414,0.0006525239,0.0029721938,0.002363812,0.0008614201,0.019002048,0.0062209503],"category_scores_gemma":[0.020130133,0.0003755261,0.0009038407,0.0010298088,0.0017473408,0.0019726877,0.0016446703,0.0172179,0.0020183348],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027685464,0.00010935209,0.014534569,0.00020168784,0.00005564981,0.0012298691,0.0005058874,0.0000746732,0.0001288179,0.0016592968,0.94538945,0.035833932],"study_design_scores_gemma":[0.0010006303,0.0007070936,0.09751659,0.002840284,0.0002884108,0.004390388,0.0063934065,0.0010851867,0.00026664027,0.014425342,0.8708627,0.00022328977],"about_ca_topic_score_codex":0.019643197,"about_ca_topic_score_gemma":0.03511833,"teacher_disagreement_score":0.019643197,"about_ca_system_score_codex":0.003493483,"about_ca_system_score_gemma":0.004260909,"threshold_uncertainty_score":0.03905773},"labels":[],"label_agreement":null},{"id":"W2913336223","doi":"10.1016/s1470-2045(18)30897-0","title":"Essential TNM: a registry tool to reduce gaps in cancer staging information","year":2019,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Centre International de Recherche sur le Cancer; World Health Organization","keywords":"Medicine; Cancer; Cancer registry; Stage (stratigraphy); Population; Oncology; Disease; Prostate cancer; Internal medicine; Gynecology; Environmental health","score_opus":0.19966496151969765,"score_gpt":0.4846025077963191,"score_spread":0.28493754627662143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913336223","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012330933,0.9587091,0.005098648,0.01429666,0.0037627926,0.0003202909,0.008053172,0.00036540857,0.008160668],"genre_scores_gemma":[0.017672803,0.94595045,0.016064325,0.006751714,0.0018298862,0.00055520394,0.008562183,0.00007987136,0.0025335604],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971963,0.000977359,0.0006055933,0.00021011158,0.00086531753,0.00014540702],"domain_scores_gemma":[0.9912177,0.004483706,0.0016095884,0.0004023269,0.0018987367,0.00038790453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00828488,0.00087304116,0.0021171132,0.0069067557,0.0002986521,0.0016343046,0.00223913,0.0010262633,0.010381278],"category_scores_gemma":[0.024627114,0.00048460814,0.0022296314,0.006404267,0.00041953372,0.002759791,0.0027148165,0.0023374099,0.0017871957],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000114486706,0.00004402841,0.0020685666,0.02790862,0.00087829033,0.000031011314,0.00010281645,0.00035786533,0.0000697053,0.0055845263,0.10792739,0.8549127],"study_design_scores_gemma":[0.00048182733,0.00018265113,0.014635933,0.11127502,0.004631513,0.00042182728,0.00046575305,0.0011414487,0.00032421428,0.009816093,0.85654163,0.00008217913],"about_ca_topic_score_codex":0.010477364,"about_ca_topic_score_gemma":0.0101558,"teacher_disagreement_score":0.010477364,"about_ca_system_score_codex":0.0021429963,"about_ca_system_score_gemma":0.008685986,"threshold_uncertainty_score":0.043815196},"labels":[],"label_agreement":null},{"id":"W2914004109","doi":"10.1016/s1470-2045(18)30779-4","title":"Endpoint selection in HER2-positive early breast cancer","year":2019,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Surrogate endpoint; Breast cancer; Clinical endpoint; Oncology; Internal medicine; Clinical trial; Cancer; Disease; Trastuzumab; Stage (stratigraphy)","score_opus":0.016734888017355624,"score_gpt":0.29623716129831196,"score_spread":0.27950227328095634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914004109","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008454066,0.01981422,0.0022459165,0.91798276,0.040098645,0.0001379862,0.0010952755,0.00006595858,0.010105115],"genre_scores_gemma":[0.056249972,0.00873111,0.0022944426,0.8343183,0.09003964,0.00078407174,0.00059558713,0.00008699811,0.0068998416],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9670433,0.026767986,0.0019165706,0.00079296314,0.0026424532,0.0008368079],"domain_scores_gemma":[0.9076432,0.08037496,0.0025998657,0.0027347987,0.0034317211,0.003215509],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.038725756,0.00069357606,0.002604046,0.0007443378,0.0011069751,0.0028060419,0.001859439,0.011724306,0.003233511],"category_scores_gemma":[0.08899519,0.00050234364,0.0013123858,0.001303127,0.0017182415,0.0017445891,0.0012542509,0.0135094635,0.0017602015],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010921825,0.00034897766,0.01759034,0.00072179287,0.00030018095,0.0016541788,0.00026441686,0.00049343257,0.0008780416,0.011415827,0.7961997,0.15921126],"study_design_scores_gemma":[0.010166011,0.0039359657,0.042058375,0.0027970998,0.0011022269,0.0038585735,0.0005494658,0.004520867,0.0038061205,0.14606982,0.78086996,0.000265507],"about_ca_topic_score_codex":0.0018124162,"about_ca_topic_score_gemma":0.003827995,"teacher_disagreement_score":0.038725756,"about_ca_system_score_codex":0.002617589,"about_ca_system_score_gemma":0.0026038624,"threshold_uncertainty_score":0.20480376},"labels":[],"label_agreement":null},{"id":"W2914106356","doi":"10.1016/s1470-2045(18)30953-7","title":"CHISELing a path forward in the treatment of early-stage non-small-cell lung cancer","year":2019,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Clinical trial; Randomized controlled trial; SABR volatility model; Radiation therapy; Stage (stratigraphy); Lung cancer; Internal medicine","score_opus":0.038591505470496876,"score_gpt":0.3427920122693942,"score_spread":0.3042005067988973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914106356","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008688904,0.0029098536,0.000042506235,0.97899413,0.016471434,0.0000045395795,0.000021941309,0.000009757311,0.0014589346],"genre_scores_gemma":[0.0022696515,0.0030726455,0.00013342578,0.9259684,0.063419044,0.000018874074,0.000022361977,0.000016743588,0.005078806],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9929771,0.0025882805,0.0005593595,0.00048736352,0.002505985,0.0008820664],"domain_scores_gemma":[0.98337793,0.00969258,0.0009247635,0.0003405982,0.0024764223,0.0031876771],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055691404,0.00090998714,0.0021698426,0.0011546649,0.0044032955,0.0057619754,0.0017561434,0.058136374,0.010168372],"category_scores_gemma":[0.030375173,0.00074125297,0.0017533813,0.00084042794,0.0053644744,0.0075169965,0.0028875002,0.057493974,0.0073188357],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009656594,0.000031054235,0.00024997853,0.00009146604,0.000015463078,0.00048739364,0.000083707564,0.000056466575,0.0001600183,0.0036419928,0.9842089,0.010877047],"study_design_scores_gemma":[0.00026358274,0.000118958196,0.0008215822,0.0006228335,0.00003844028,0.00079920114,0.00034969428,0.00036349328,0.00016320168,0.015283263,0.9811008,0.00007486504],"about_ca_topic_score_codex":0.009224994,"about_ca_topic_score_gemma":0.020675197,"teacher_disagreement_score":0.058136374,"about_ca_system_score_codex":0.0076061646,"about_ca_system_score_gemma":0.007474536,"threshold_uncertainty_score":0.055186868},"labels":[],"label_agreement":null},{"id":"W2914512849","doi":"10.1016/s1470-2045(18)30939-2","title":"Conservative management of adnexal masses","year":2019,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Adnexal mass; Scopus; Malignancy; Ovarian cancer; Gynecology; MEDLINE; Cancer; Pathology; Internal medicine","score_opus":0.09741370730472958,"score_gpt":0.3681989465383599,"score_spread":0.2707852392336303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914512849","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010145574,0.004942456,0.00009749258,0.9671398,0.019297846,0.000010110227,0.000036485806,0.00001688267,0.007444417],"genre_scores_gemma":[0.019608857,0.0055542584,0.00032775514,0.8348234,0.124906056,0.000042385855,0.0000644947,0.000030452791,0.014642385],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99863917,0.0004237322,0.00014490285,0.00011558967,0.00040742583,0.00026923115],"domain_scores_gemma":[0.99602026,0.0022681607,0.0003373016,0.00012386074,0.0004817162,0.00076869596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012873998,0.00046446818,0.00073863904,0.0010736944,0.0026833555,0.0022348887,0.0009043442,0.028831981,0.005675831],"category_scores_gemma":[0.016083688,0.000588572,0.0008641466,0.0006394376,0.0022378678,0.002115939,0.0013039575,0.023930728,0.0029937937],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001111849,0.00005688623,0.0021390766,0.00014427913,0.00002282995,0.017769694,0.00016506654,0.00015073373,0.00037576296,0.003541704,0.95225114,0.023271583],"study_design_scores_gemma":[0.00030852755,0.00014579052,0.0051531624,0.0013930739,0.00005424283,0.035218783,0.0005127548,0.00078257575,0.00038814286,0.016144121,0.93982077,0.00007803909],"about_ca_topic_score_codex":0.005509321,"about_ca_topic_score_gemma":0.013144588,"teacher_disagreement_score":0.028831981,"about_ca_system_score_codex":0.0038289952,"about_ca_system_score_gemma":0.0028107453,"threshold_uncertainty_score":0.027781487},"labels":[],"label_agreement":null},{"id":"W2916014925","doi":"10.1016/s1470-2045(18)30902-1","title":"10-year performance of four models of breast cancer risk: a validation study","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":171,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Public Health Ontario; University of Toronto; Lunenfeld-Tanenbaum Research Institute","funders":"National Center for Advancing Translational Sciences; National Health and Medical Research Council; National Cancer Institute; National Medical Research Council; NSW Ministry of Health; National Breast Cancer Foundation","keywords":"Breast cancer; Medicine; Cohort; Family history; Cancer; Oncology; Ovarian cancer; Cohort study; Prospective cohort study; Gynecology; Internal medicine","score_opus":0.031200918139862987,"score_gpt":0.31178036523778446,"score_spread":0.2805794470979215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916014925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873634,0.0013274639,0.0051118657,0.00052069424,0.00012945342,0.00008988895,0.0045219054,0.00021516116,0.00072014076],"genre_scores_gemma":[0.98727024,0.0003026254,0.0020833474,0.0001079147,0.000043996577,0.000086111475,0.00884331,0.00012283189,0.0011396455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.992605,0.0051603764,0.00028031168,0.001160575,0.00042678966,0.0003669769],"domain_scores_gemma":[0.9167237,0.067379646,0.0032690854,0.007815087,0.002946102,0.0018663484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.043948956,0.002667359,0.002324216,0.001530004,0.0008159928,0.0018836664,0.0038170025,0.0033078354,0.0025079325],"category_scores_gemma":[0.032018863,0.00094596465,0.005050841,0.00074211846,0.001706109,0.0017677695,0.0016347434,0.0035411168,0.0011623738],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044982284,0.004760918,0.4562034,0.00045581083,0.014970377,0.0006759099,0.0006555656,0.42423138,0.0015749736,0.00083584536,0.011354179,0.039299328],"study_design_scores_gemma":[0.003324385,0.013067799,0.2177463,0.00016533738,0.0049902857,0.0008288555,0.00041391974,0.7516351,0.002407668,0.0023634378,0.0027449243,0.00031202153],"about_ca_topic_score_codex":0.019535009,"about_ca_topic_score_gemma":0.009856327,"teacher_disagreement_score":0.043948956,"about_ca_system_score_codex":0.002415527,"about_ca_system_score_gemma":0.0020032914,"threshold_uncertainty_score":0.23242712},"labels":[],"label_agreement":null},{"id":"W2916100539","doi":"10.1016/s1470-2045(18)30907-0","title":"Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":175,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital; University of Calgary","funders":"Janssen Pharmaceuticals; National Cancer Institute; Takeda Pharmaceuticals U.S.A.; Sanofi Genzyme; Genentech; National Institutes of Health; European Society for Medical Oncology; Eisai; Bayer Fund; Clovis Oncology; Active Biotech; Ipsen Biopharmaceuticals; Bavarian Nordic; Novartis; AbbVie; Exelixis; Sanofi; Merck; GlaxoSmithKline; Roche; Astellas Pharma US; Pfizer; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim","keywords":"Cabozantinib; Medicine; Renal cell carcinoma; Retrospective cohort study; Oncology; Cohort; Internal medicine; Urology","score_opus":0.01779356237453034,"score_gpt":0.2916839099226428,"score_spread":0.2738903475481125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916100539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955081,0.0027698237,0.00014113064,0.00008673762,0.00003050261,0.0000246456,0.0010063372,0.000007037667,0.00042563642],"genre_scores_gemma":[0.9980714,0.00069317076,0.000104396255,0.00008118937,0.000030664207,0.000018302946,0.00077658176,0.0000063543016,0.00021793475],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990621,0.00020779073,0.00009767399,0.00034913945,0.00012216481,0.00016106451],"domain_scores_gemma":[0.9984218,0.00022471343,0.0006590274,0.00032497683,0.00015263115,0.00021690819],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008530888,0.0006310032,0.0010959739,0.0005134301,0.0005348335,0.0012783519,0.0006054317,0.0008070063,0.0019409427],"category_scores_gemma":[0.002069749,0.0006871707,0.0014575585,0.0015611248,0.0004326387,0.0006833369,0.00050244253,0.0010372453,0.00037641748],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013342451,0.00024859063,0.97468966,0.00019668456,0.0036515982,0.000689282,0.0001773237,0.00014502651,0.0019838423,0.0001470748,0.00095359155,0.0037749696],"study_design_scores_gemma":[0.001100148,0.0013986184,0.9910591,0.00004273799,0.0024245533,0.0016031837,0.00031089006,0.00034808606,0.00021437886,0.00010795222,0.0013537329,0.000036581616],"about_ca_topic_score_codex":0.008400933,"about_ca_topic_score_gemma":0.0087028025,"teacher_disagreement_score":0.008400933,"about_ca_system_score_codex":0.0008321092,"about_ca_system_score_gemma":0.0006557679,"threshold_uncertainty_score":0.016704082},"labels":[],"label_agreement":null},{"id":"W2916231496","doi":"10.1016/s1470-2045(18)30941-0","title":"Adolescents and young adults with cancer and the risk of subsequent primary neoplasms: not just big children","year":2019,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Medicine; Young adult; Cancer; Pediatrics; MEDLINE; Childhood cancer; Family medicine; Oncology; Gerontology; Internal medicine","score_opus":0.02894674781683117,"score_gpt":0.2941405866666177,"score_spread":0.26519383884978653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916231496","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47327462,0.39779255,0.00064266945,0.07430283,0.002271238,0.00011590588,0.023581883,0.00005835066,0.02795996],"genre_scores_gemma":[0.79679835,0.18400347,0.0007215283,0.0053479834,0.0016637065,0.00013785042,0.0075050048,0.000043440934,0.0037786097],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996635,0.000085887965,0.000033852164,0.000056419227,0.00010158891,0.000058899586],"domain_scores_gemma":[0.99768806,0.00062382495,0.00081070035,0.00007067504,0.0002809765,0.0005259103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055636826,0.00019063405,0.00043343662,0.0008064393,0.00038100957,0.0009471036,0.00027029123,0.0005276298,0.006080605],"category_scores_gemma":[0.0051154546,0.00021859506,0.0005552735,0.0015940928,0.00023648664,0.0012995779,0.00082713756,0.0015966911,0.0006838578],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029383323,0.0000635853,0.8587321,0.0013046974,0.00041804303,0.00042720244,0.0011870143,0.00007342028,0.0000938254,0.0012369757,0.04006396,0.09610532],"study_design_scores_gemma":[0.00002686821,0.000093629584,0.95478106,0.0027377885,0.00030966746,0.001198393,0.0021665487,0.00005573916,0.00006361874,0.0014759763,0.037067693,0.00002303213],"about_ca_topic_score_codex":0.011293989,"about_ca_topic_score_gemma":0.01453922,"teacher_disagreement_score":0.011293989,"about_ca_system_score_codex":0.00042749124,"about_ca_system_score_gemma":0.0009918285,"threshold_uncertainty_score":0.022456467},"labels":[],"label_agreement":null},{"id":"W2917351544","doi":"10.1016/s1470-2045(19)30072-5","title":"Global elimination of cervical cancer as a public health problem","year":2019,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":123,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Cervical cancer; Medicine; Vaccination; Cervical screening; Public health; Human papillomavirus; Epidemiology; Cancer; Disease; Action (physics); Global health; Family medicine; Gynecology; Oncology; Immunology; Internal medicine; Pathology","score_opus":0.15353283899402628,"score_gpt":0.45725399017779955,"score_spread":0.3037211511837733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2917351544","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011041991,0.0014325195,0.00003334604,0.97493964,0.021176832,0.000007129568,0.000043238007,0.000011870478,0.002244965],"genre_scores_gemma":[0.0012126389,0.0010792521,0.00009407867,0.9586838,0.031096615,0.000024229657,0.00002718561,0.000017237495,0.007764883],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9932448,0.002137134,0.00057329464,0.00054562016,0.0021133397,0.0013857789],"domain_scores_gemma":[0.98424965,0.007864922,0.0010594098,0.00043252352,0.0027835572,0.0036099975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0059604556,0.0011770698,0.0018147194,0.0012189077,0.0059660464,0.0064765536,0.0021395953,0.09220528,0.016568298],"category_scores_gemma":[0.03157937,0.0011921581,0.0019522179,0.0010983183,0.005024364,0.0065514687,0.0041624336,0.05183696,0.010077416],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046627756,0.000031495416,0.00024657024,0.0001067326,0.000013208891,0.00030855634,0.00010962953,0.000030489688,0.00016693726,0.0028044826,0.98985773,0.0062774704],"study_design_scores_gemma":[0.00013646328,0.00006399181,0.001067385,0.0004820252,0.000038776845,0.00033547892,0.00047056304,0.0001669666,0.00018870781,0.008620977,0.98837703,0.000051553397],"about_ca_topic_score_codex":0.020048,"about_ca_topic_score_gemma":0.028483352,"teacher_disagreement_score":0.09220528,"about_ca_system_score_codex":0.0064752186,"about_ca_system_score_gemma":0.015599683,"threshold_uncertainty_score":0.05542648},"labels":[],"label_agreement":null},{"id":"W2921728285","doi":"10.1016/s1470-2045(19)30092-0","title":"Choosing Wisely India: ten low-value or harmful practices that should be avoided in cancer care","year":2019,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Healthcare cost, quality, practices","field":"Health Professions","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University of Toronto","funders":"","keywords":"Specialty; Best practice; Concordance; Multidisciplinary approach; Medicine; Health care; Private sector; Palliative care; Family medicine; Nursing; Public relations; Medical education; Political science","score_opus":0.9202317752949634,"score_gpt":0.6991229596263484,"score_spread":0.22110881566861496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921728285","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030736666,0.9943711,0.000037879374,0.0045247846,0.00024567556,0.0000054955635,0.000040727482,0.0000032141907,0.00046378237],"genre_scores_gemma":[0.008665011,0.98643076,0.0003340452,0.0039731376,0.00035052004,0.000015243925,0.00003559569,0.000003673835,0.0001919675],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99704933,0.0011093359,0.0005675278,0.00014377758,0.00091658434,0.00021333621],"domain_scores_gemma":[0.99235475,0.005259866,0.0013642526,0.00010748756,0.00065198325,0.00026172976],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004427117,0.000589742,0.002364018,0.0025317674,0.00048773948,0.0024578986,0.0012325434,0.0018888167,0.0046308893],"category_scores_gemma":[0.012345957,0.0003792108,0.0018510169,0.0046376376,0.0015029794,0.0018407702,0.0014123834,0.0043366896,0.00041673103],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027966395,0.00009315239,0.001667021,0.12173202,0.002290452,0.000066561835,0.00036863942,0.00021432845,0.000107077954,0.005765163,0.031135099,0.8362807],"study_design_scores_gemma":[0.00081026444,0.0004802542,0.026413783,0.40688026,0.012236058,0.000681186,0.0023478267,0.00031148264,0.0003000467,0.01614884,0.53325623,0.00013376583],"about_ca_topic_score_codex":0.024315162,"about_ca_topic_score_gemma":0.067519575,"teacher_disagreement_score":0.99557287,"about_ca_system_score_codex":0.0048600226,"about_ca_system_score_gemma":0.009650632,"threshold_uncertainty_score":0.048347235},"labels":[],"label_agreement":null},{"id":"W2921993687","doi":"10.1016/s1470-2045(19)30094-4","title":"Should we expand the carbon ion footprint of prostate cancer?","year":2019,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Radiation Therapy and Dosimetry","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Footprint; Carbon footprint; Oncology; Cancer; Internal medicine; Oceanography; Greenhouse gas; Archaeology; Geology","score_opus":0.08110415414711854,"score_gpt":0.3652762029762045,"score_spread":0.284172048829086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921993687","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011072629,0.0036265717,0.000051601688,0.97837037,0.01693454,0.0000025570196,0.000019313411,0.000012426131,0.0008719412],"genre_scores_gemma":[0.0018433419,0.0027481066,0.00012826647,0.94066143,0.052007623,0.000011780348,0.000015872933,0.000020373573,0.0025631348],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939029,0.0020079368,0.00055762916,0.0006142233,0.002109389,0.0008080484],"domain_scores_gemma":[0.9766335,0.015103581,0.0012042653,0.0009489857,0.0028817842,0.0032278548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0067303837,0.0009768128,0.0019380214,0.0008772772,0.0044319634,0.0044667493,0.0022744038,0.066553004,0.011047595],"category_scores_gemma":[0.039157424,0.0009147915,0.0017303152,0.0007466054,0.0070796153,0.008566775,0.004802222,0.05815768,0.0062922123],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000077303754,0.000035440742,0.00029005323,0.0001289407,0.000025840674,0.0005848869,0.0001349094,0.00006467107,0.00023861516,0.0055083414,0.97630024,0.016610907],"study_design_scores_gemma":[0.000088100474,0.000059595848,0.00046073436,0.00027112412,0.00002700335,0.00069877337,0.00038212957,0.000106687425,0.00018600868,0.029740006,0.9679242,0.000055592525],"about_ca_topic_score_codex":0.008361945,"about_ca_topic_score_gemma":0.01249097,"teacher_disagreement_score":0.066553004,"about_ca_system_score_codex":0.004846458,"about_ca_system_score_gemma":0.0072598048,"threshold_uncertainty_score":0.03695792},"labels":[],"label_agreement":null},{"id":"W2935020610","doi":"10.1016/s1470-2045(19)30141-x","title":"Interactive architecture—UV protection unfolding above you!","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Impact of Light on Environment and Health","field":"Environmental Science","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Metropolitan University","funders":"","keywords":"Noon; Sunlight; Architecture; Ultraviolet; Environmental science; Computer science; Meteorology; Visual arts; Art; Atmospheric sciences; Geography; Physics; Optics","score_opus":0.027879197004789857,"score_gpt":0.2988077342344727,"score_spread":0.27092853722968285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2935020610","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0055693164,0.07041065,0.02509698,0.5382882,0.054441735,0.000078388744,0.0009136348,0.0056263283,0.29957473],"genre_scores_gemma":[0.16854884,0.06838504,0.026464941,0.16960178,0.03677734,0.00031867845,0.0010741053,0.003993422,0.5248359],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99874395,0.00046919208,0.000022098364,0.00011467877,0.00045251517,0.00019750041],"domain_scores_gemma":[0.99707425,0.0010754875,0.00012477364,0.00042300587,0.00056606217,0.00073639303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024674651,0.0007961619,0.00035652186,0.00056894857,0.0023305812,0.0045307064,0.0012659717,0.0048578945,0.1040797],"category_scores_gemma":[0.0062703625,0.00045613432,0.0007766663,0.0004393369,0.0029981039,0.006978997,0.0050199637,0.006994053,0.022151576],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007122277,0.000056870562,0.00048767804,0.00027325246,0.000028341861,0.00007581884,0.0007318929,0.00023703299,0.0012223478,0.033951264,0.8539059,0.10895839],"study_design_scores_gemma":[0.000009732674,0.000021404056,0.0003145027,0.00012197518,0.00000849794,0.00006102468,0.00039664214,0.000047183028,0.00029455387,0.01790988,0.98080057,0.000014101984],"about_ca_topic_score_codex":0.0040867478,"about_ca_topic_score_gemma":0.007578392,"teacher_disagreement_score":0.1040797,"about_ca_system_score_codex":0.0010888277,"about_ca_system_score_gemma":0.0014816286,"threshold_uncertainty_score":0.34818125},"labels":[],"label_agreement":null},{"id":"W2935541805","doi":"10.1016/s1470-2045(19)30029-4","title":"Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":537,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Ovarian cancer; BRCA mutation; Oncology; Progressive disease; Chemotherapy; Progression-free survival; Population; Phases of clinical research; Carboplatin; Combination therapy; Surgery; Gastroenterology; Cancer; Cisplatin","score_opus":0.24555150791936622,"score_gpt":0.4816545343169153,"score_spread":0.23610302639754907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2935541805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.976484,0.008809147,0.0014427457,0.0019182164,0.00071948307,0.0030051025,0.0035901873,0.00030801372,0.003723062],"genre_scores_gemma":[0.9720392,0.005386302,0.004150069,0.0028339117,0.00045261323,0.0034729016,0.0049735964,0.00009775107,0.0065937163],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995617,0.00021982753,0.000018005556,0.00009277234,0.000029294102,0.00007836062],"domain_scores_gemma":[0.9992812,0.00015262434,0.00013215377,0.00007870827,0.00003446132,0.00032091493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019285906,0.001705872,0.0023935167,0.00031012553,0.00032833626,0.001262568,0.0009598502,0.001285685,0.0064732437],"category_scores_gemma":[0.0013511158,0.0005693685,0.0021066612,0.00032327126,0.0009864734,0.0013335275,0.00052116986,0.0042416314,0.0014545767],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90271527,0.011895074,0.0016008005,0.0012990423,0.0019303844,0.00011513378,0.00013246179,0.0014866226,0.008514596,0.00041523585,0.005288338,0.06460706],"study_design_scores_gemma":[0.9092796,0.08368403,0.0026886195,0.00004545389,0.0003594084,0.00017876271,0.00003254648,0.00075215386,0.00046093052,0.00037771737,0.002113242,0.000027512498],"about_ca_topic_score_codex":0.000469753,"about_ca_topic_score_gemma":0.0017633581,"teacher_disagreement_score":0.0064732437,"about_ca_system_score_codex":0.0007561734,"about_ca_system_score_gemma":0.0010697024,"threshold_uncertainty_score":0.021655142},"labels":[],"label_agreement":null},{"id":"W2938589827","doi":"10.1016/s1470-2045(19)30082-8","title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":813,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Janssen Research and Development","keywords":"Abiraterone acetate; Prostate cancer; Medicine; Prednisone; Internal medicine; Oncology; Androgen deprivation therapy; Urology; Cancer","score_opus":0.06476036434540433,"score_gpt":0.3773706945959527,"score_spread":0.31261033025054835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2938589827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98371696,0.011394551,0.00045784112,0.00050905504,0.0004484061,0.00092560303,0.0006950522,0.00011151628,0.001741001],"genre_scores_gemma":[0.98984164,0.005156499,0.0006561044,0.00056791876,0.00034391365,0.0007355726,0.0006968052,0.000020155429,0.0019813923],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994543,0.00032914255,0.000033836302,0.000068986636,0.000039556267,0.00007410247],"domain_scores_gemma":[0.9990938,0.0002809541,0.00022052128,0.00008350064,0.000038685477,0.00028251242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014686937,0.0012362254,0.0020214682,0.00038980503,0.0003551341,0.0009629949,0.0005290363,0.00084214145,0.003742973],"category_scores_gemma":[0.0016011671,0.00040911697,0.0022352226,0.0004374228,0.0010232647,0.00073761656,0.00039843522,0.0022060303,0.0005929218],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9792814,0.001270543,0.0006878549,0.00048207332,0.001102096,0.00002597704,0.000062925654,0.00047468345,0.0012980986,0.00006537744,0.0004347101,0.014814146],"study_design_scores_gemma":[0.9536874,0.041861266,0.0027071293,0.000034062927,0.0006007713,0.000045992958,0.00003226268,0.00023410762,0.00017057992,0.00016733007,0.00044482586,0.000014310692],"about_ca_topic_score_codex":0.0019489771,"about_ca_topic_score_gemma":0.00528966,"teacher_disagreement_score":0.003742973,"about_ca_system_score_codex":0.00061222544,"about_ca_system_score_gemma":0.0011387115,"threshold_uncertainty_score":0.012521446},"labels":[],"label_agreement":null},{"id":"W2940012666","doi":"10.1016/s1470-2045(19)30155-x","title":"Importance of early treatment in metastatic prostate cancer: a question of life or death","year":2019,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Abiraterone acetate; Medicine; Prostate cancer; Prednisone; Oncology; Docetaxel; Cancer; Internal medicine; Prostate; Androgen deprivation therapy","score_opus":0.10795924696837893,"score_gpt":0.4141552426201033,"score_spread":0.30619599565172434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2940012666","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000082373204,0.0017510969,0.00001622597,0.986772,0.0105039,0.0000018753731,0.000015787475,0.0000025901384,0.0008542124],"genre_scores_gemma":[0.0025545948,0.0016698419,0.00004812652,0.93566674,0.057389617,0.0000136370945,0.000014289371,0.000012875326,0.0026303492],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99134237,0.003865177,0.0008297375,0.00068901305,0.0019817713,0.0012920671],"domain_scores_gemma":[0.9651108,0.023557117,0.0021085765,0.0006833469,0.003326824,0.005213362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008157039,0.0008648876,0.0023564703,0.0008461689,0.005820633,0.006301551,0.0020499495,0.08567206,0.008341819],"category_scores_gemma":[0.059430167,0.00091613823,0.0013816502,0.001154847,0.0072753513,0.0074516023,0.0030924676,0.07410318,0.005042308],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001162948,0.00002426751,0.00036139475,0.000110601606,0.000024265799,0.00040938504,0.00015368316,0.000038083097,0.00009112749,0.006412165,0.9833229,0.008935692],"study_design_scores_gemma":[0.00038434012,0.00012776082,0.0015603272,0.0012612861,0.00008253784,0.0013158823,0.00083676,0.00038945384,0.00018421083,0.030815907,0.96290433,0.00013720716],"about_ca_topic_score_codex":0.009760657,"about_ca_topic_score_gemma":0.015791912,"teacher_disagreement_score":0.08567206,"about_ca_system_score_codex":0.008282005,"about_ca_system_score_gemma":0.009953448,"threshold_uncertainty_score":0.060090423},"labels":[],"label_agreement":null},{"id":"W2942308489","doi":"10.1016/s1470-2045(19)30100-7","title":"Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Musculoskeletal synovial abnormalities and treatments","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"Daiichi Sankyo Europe","keywords":"Medicine; Retrospective cohort study; Cohort; Surgery; Giant Cell Tumors; Univariate analysis; Proportional hazards model; Sarcoma; Multivariate analysis; Internal medicine; Giant cell; Pathology","score_opus":0.01609272539954112,"score_gpt":0.3045513844286504,"score_spread":0.2884586590291093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2942308489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99908566,0.00024929745,0.000067264584,0.00002208521,0.000005980312,0.000004452866,0.00034304286,0.000001820328,0.00022042362],"genre_scores_gemma":[0.99915445,0.00016922338,0.000036933856,0.00001814805,0.000010006136,0.0000056508798,0.0005329018,0.0000028711868,0.000069814494],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99938834,0.00008128177,0.00007293183,0.00022960457,0.000081550876,0.0001462493],"domain_scores_gemma":[0.99869055,0.00014391143,0.0005316341,0.0001986023,0.00011426599,0.00032101685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005757786,0.00046520217,0.0005234176,0.0008872959,0.0005790697,0.00096331513,0.0005179684,0.00053564063,0.0014330633],"category_scores_gemma":[0.0016517964,0.000505678,0.0008086228,0.0015920177,0.00056548446,0.0010473477,0.0008864546,0.00076994824,0.0002648038],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025493233,0.00003304392,0.9981572,0.000011850689,0.00015124347,0.00020977421,0.00010313584,0.00004060032,0.00031899443,0.000036481775,0.000098965655,0.00058377633],"study_design_scores_gemma":[0.000016780974,0.00013523214,0.9977112,0.0000084164,0.00009563777,0.0010942678,0.0005393088,0.00010324068,0.00004597682,0.00005033051,0.00018854954,0.000011093747],"about_ca_topic_score_codex":0.0030811995,"about_ca_topic_score_gemma":0.0034399095,"teacher_disagreement_score":0.0030811995,"about_ca_system_score_codex":0.00041687125,"about_ca_system_score_gemma":0.00037533822,"threshold_uncertainty_score":0.006126523},"labels":[],"label_agreement":null},{"id":"W2943536090","doi":"10.1016/s1470-2045(19)30247-5","title":"Do not use robotic surgery in oncology patients when conventional surgical approaches are equally effective – Authors' reply","year":2019,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cardiac, Anesthesia and Surgical Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Robotic surgery; Health care; General surgery; Cancer surgery; Population; Quality of life (healthcare); Surgery; Cancer; Nursing; Internal medicine","score_opus":0.13210549576522035,"score_gpt":0.3289182035455605,"score_spread":0.19681270778034016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943536090","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013157121,0.00059536326,0.00002050454,0.9858235,0.012832387,0.0000027317778,0.00003330209,0.0000069954654,0.0005535941],"genre_scores_gemma":[0.0013717565,0.00038065048,0.00003691814,0.97896016,0.01791944,0.000013782862,0.000015339147,0.0000090458,0.0012927653],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940294,0.001523591,0.0008975481,0.0008311435,0.0015939269,0.0011245081],"domain_scores_gemma":[0.96810514,0.01967956,0.0024824634,0.00075655815,0.0044408524,0.004535457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004975306,0.00074603787,0.001868769,0.00095591496,0.004407227,0.005926632,0.0021814725,0.09222592,0.009560673],"category_scores_gemma":[0.053771555,0.0011432334,0.0015598558,0.0010046302,0.0042978064,0.0044189594,0.00297307,0.07125068,0.007896992],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043713037,0.00001611521,0.00073051645,0.000061020346,0.0000314169,0.00047929687,0.0001556611,0.000043021173,0.000076974975,0.0016141674,0.9925403,0.004207717],"study_design_scores_gemma":[0.000318943,0.00010934085,0.0020171155,0.0008112279,0.0001100368,0.0015377026,0.0011728111,0.00030038998,0.00030321899,0.012840846,0.98026454,0.00021384678],"about_ca_topic_score_codex":0.0077643925,"about_ca_topic_score_gemma":0.011865492,"teacher_disagreement_score":0.09222592,"about_ca_system_score_codex":0.0052985814,"about_ca_system_score_gemma":0.007408927,"threshold_uncertainty_score":0.0384441},"labels":[],"label_agreement":null},{"id":"W2943864790","doi":"10.1016/s1470-2045(19)30178-0","title":"Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":86,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"Cilag; Genentech; F. Hoffmann-La Roche; Roche; Merck; Amgen","keywords":"Medicine; Clinical endpoint; Ovarian cancer; Carboplatin; Population; Progression-free survival; Internal medicine; Placebo; Oncology; Phases of clinical research; Clinical trial; Gynecology; Cancer; Chemotherapy; Pathology","score_opus":0.08349518990222415,"score_gpt":0.400998555831424,"score_spread":0.31750336592919987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943864790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9649707,0.013456082,0.0015835419,0.0019744867,0.0024602923,0.006429267,0.002900956,0.0006362028,0.0055884863],"genre_scores_gemma":[0.967496,0.0075299945,0.002101418,0.0021383483,0.0008434879,0.005870429,0.0022079034,0.000113300215,0.011699223],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99952316,0.00022771492,0.000026692314,0.00009394441,0.00002926463,0.000099177676],"domain_scores_gemma":[0.9993795,0.00018752343,0.0001076029,0.000053037875,0.000032424865,0.00023988499],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001547844,0.0020864755,0.0041774944,0.0005882981,0.00043294523,0.0011965801,0.0010844287,0.0022760276,0.010956678],"category_scores_gemma":[0.00138998,0.00088056433,0.0022305823,0.0005368801,0.0013525158,0.0014209902,0.00043829266,0.004158676,0.0019027367],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98469955,0.0020348444,0.00011091849,0.00052930077,0.0005375861,0.00001856468,0.00002398339,0.00020124181,0.0015112633,0.00009507559,0.0007114279,0.009526301],"study_design_scores_gemma":[0.9744145,0.024146214,0.0003697206,0.000020974823,0.00018934351,0.000016923032,0.000011038154,0.00019265403,0.0001623303,0.000111469184,0.00035574404,0.000009158083],"about_ca_topic_score_codex":0.0012860971,"about_ca_topic_score_gemma":0.0025879634,"teacher_disagreement_score":0.010956678,"about_ca_system_score_codex":0.0007000647,"about_ca_system_score_gemma":0.0009185396,"threshold_uncertainty_score":0.036653757},"labels":[],"label_agreement":null},{"id":"W2945852816","doi":"10.1016/s1470-2045(19)30152-4","title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":385,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"Celgene","keywords":"Pomalidomide; Lenalidomide; Dexamethasone; Bortezomib; Medicine; Refractory (planetary science); Multiple myeloma; Open label; Oncology; Internal medicine; Thalidomide; Randomized controlled trial; Biology","score_opus":0.07880100858038529,"score_gpt":0.38267076028817626,"score_spread":0.30386975170779096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945852816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97997737,0.009331343,0.0005360901,0.0016222581,0.00083957857,0.0033155126,0.0014423914,0.00013721241,0.0027982162],"genre_scores_gemma":[0.983526,0.004263879,0.0016908132,0.00215909,0.0005745372,0.0029946184,0.0014857377,0.000027023447,0.0032784634],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993759,0.00033515156,0.000031621177,0.000113166156,0.000042016403,0.00010215601],"domain_scores_gemma":[0.99929893,0.00021140874,0.00014024103,0.000047876416,0.000027525095,0.00027402714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018334909,0.0017814662,0.0027955968,0.00040595827,0.0004369658,0.0013822634,0.0009696438,0.0018876151,0.0062773013],"category_scores_gemma":[0.0015304113,0.0006735656,0.002951838,0.00047186343,0.0013212595,0.0012094658,0.0006448421,0.003593403,0.0009329004],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97921693,0.0031824913,0.0005138399,0.00046741153,0.0010852766,0.000032885535,0.000055098804,0.0003095558,0.0013860976,0.000116287636,0.00084554276,0.012788695],"study_design_scores_gemma":[0.9766568,0.021420533,0.0008578377,0.000023777498,0.00024033211,0.00002112015,0.00001478372,0.00014800685,0.00008884243,0.0001363646,0.00038287663,0.000008723901],"about_ca_topic_score_codex":0.0015277512,"about_ca_topic_score_gemma":0.0036813358,"teacher_disagreement_score":0.0062773013,"about_ca_system_score_codex":0.0011745245,"about_ca_system_score_gemma":0.0012781194,"threshold_uncertainty_score":0.02099961},"labels":[],"label_agreement":null},{"id":"W2946386783","doi":"10.1016/s1470-2045(19)30167-6","title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1681,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"F. Hoffmann-La Roche","keywords":"Carboplatin; Medicine; Paclitaxel; Atezolizumab; Chemotherapy; Oncology; Nab-paclitaxel; Open label; Internal medicine; Lung cancer; Cisplatin; Cancer; Randomized controlled trial; Nivolumab; Immunotherapy","score_opus":0.048483638906467647,"score_gpt":0.3745263839184664,"score_spread":0.3260427450119987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946386783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893066,0.0044560614,0.0004360082,0.00074390456,0.000680422,0.0013918598,0.00090428855,0.0001335074,0.0019473513],"genre_scores_gemma":[0.98900396,0.0023552272,0.001054181,0.0009492929,0.00040537165,0.0014570635,0.0012246424,0.000035989724,0.0035143506],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99946696,0.00027131452,0.000027218362,0.00010785787,0.000040125975,0.000086558364],"domain_scores_gemma":[0.99933845,0.00022090958,0.00014401235,0.000048241356,0.000034681958,0.00021366947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014360688,0.0016541138,0.0032554592,0.00043238245,0.00029727322,0.001330272,0.001050701,0.0017185163,0.0053882333],"category_scores_gemma":[0.0016007754,0.0006528576,0.0026659032,0.00041102737,0.0010950639,0.0013098713,0.0005818301,0.0042621084,0.0010043785],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9768663,0.0037323122,0.00047543654,0.00059312425,0.0010774918,0.000023491697,0.00005103008,0.00038888137,0.0019427822,0.00010402494,0.0008094474,0.013935591],"study_design_scores_gemma":[0.9091512,0.0872168,0.001623417,0.000036470527,0.00058541883,0.00003762478,0.000025800482,0.00044912365,0.00025901303,0.00013561745,0.0004628479,0.000016576192],"about_ca_topic_score_codex":0.0011281536,"about_ca_topic_score_gemma":0.002456475,"teacher_disagreement_score":0.0053882333,"about_ca_system_score_codex":0.00083654537,"about_ca_system_score_gemma":0.0008349705,"threshold_uncertainty_score":0.018025398},"labels":[],"label_agreement":null},{"id":"W2946486395","doi":"10.1016/s1470-2045(19)30091-9","title":"Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":139,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Open label; Medicine; Internal medicine; Oncology; Lymphoma; Brentuximab vedotin; Phases of clinical research; Diffuse large B-cell lymphoma; Clinical trial; Hodgkin lymphoma","score_opus":0.018808620936235258,"score_gpt":0.3208220799402624,"score_spread":0.30201345900402715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946486395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99220204,0.0043070605,0.00040950876,0.00039361176,0.00029465053,0.00063725136,0.0003895428,0.000045207544,0.001321119],"genre_scores_gemma":[0.9915217,0.0028221156,0.0007172885,0.00069511053,0.0003230404,0.00084201194,0.0008409527,0.000021771388,0.002215986],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9992999,0.00036518823,0.000030974345,0.000115830284,0.00005743746,0.0001306583],"domain_scores_gemma":[0.99925,0.00023212921,0.00014916676,0.000071740404,0.00003848456,0.00025847007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001500247,0.0014593835,0.002703515,0.00045512128,0.00034452573,0.0013764631,0.00073411694,0.0013300793,0.0035705261],"category_scores_gemma":[0.0012264947,0.00068020937,0.0018470092,0.0005205872,0.0014168303,0.0015207916,0.00041031698,0.002758782,0.0008616868],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9453376,0.01055984,0.0017812526,0.0006191278,0.0014411581,0.00007819936,0.00010090433,0.0007257048,0.0046672355,0.00014615933,0.00073464477,0.033808272],"study_design_scores_gemma":[0.81263393,0.17834596,0.005537906,0.00004292755,0.0006025816,0.00010329731,0.00005073536,0.00057081867,0.00047533732,0.0002062211,0.0014021429,0.000028134427],"about_ca_topic_score_codex":0.00089111016,"about_ca_topic_score_gemma":0.0016796396,"teacher_disagreement_score":0.0035705261,"about_ca_system_score_codex":0.0009659841,"about_ca_system_score_gemma":0.00078218186,"threshold_uncertainty_score":0.011944592},"labels":[],"label_agreement":null},{"id":"W2947615258","doi":"10.1016/s1470-2045(19)30304-3","title":"Selumetinib in paediatric low-grade glioma: a new era?","year":2019,"lang":"it","type":"letter","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; SickKids Foundation; University of Toronto","funders":"","keywords":"Selumetinib; Medicine; Glioma; Family medicine; Internal medicine; Cancer research; Cancer","score_opus":0.03938761532343604,"score_gpt":0.31674450708439383,"score_spread":0.2773568917609578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947615258","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003656507,0.011402722,0.00007772445,0.9729968,0.013232803,0.000003496131,0.00004612858,0.0000148789695,0.001859819],"genre_scores_gemma":[0.010722528,0.021781407,0.00036642078,0.8145598,0.14843093,0.000026650714,0.00007129122,0.000038212536,0.004002683],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99774396,0.00071298087,0.00032360337,0.00024998022,0.0006564693,0.00031307156],"domain_scores_gemma":[0.992031,0.0042876294,0.00068038213,0.0001851792,0.0013060515,0.0015097817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021646267,0.00068651483,0.0019199547,0.00079663587,0.0015445895,0.003744764,0.0011170119,0.023868412,0.0060877446],"category_scores_gemma":[0.017896581,0.0004277503,0.0012161215,0.0007457941,0.0025654605,0.0050658253,0.0011742897,0.024547989,0.0042187697],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017943006,0.000039389288,0.0011850948,0.00028423104,0.00004217986,0.0045089982,0.00011876683,0.00023333188,0.00027546356,0.0064547593,0.94283336,0.043844983],"study_design_scores_gemma":[0.00036387506,0.00016361203,0.0013715721,0.0012807389,0.000083769984,0.008567074,0.00042886694,0.000652884,0.0002780757,0.023079002,0.96363807,0.00009242211],"about_ca_topic_score_codex":0.00387239,"about_ca_topic_score_gemma":0.008006747,"teacher_disagreement_score":0.023868412,"about_ca_system_score_codex":0.0043588793,"about_ca_system_score_gemma":0.0032670177,"threshold_uncertainty_score":0.031625986},"labels":[],"label_agreement":null},{"id":"W2947820602","doi":"10.1016/s1470-2045(19)30308-0","title":"Scale-up of radiotherapy for cervical cancer in the era of human papillomavirus vaccination in low-income and middle-income countries: a model-based analysis of need and economic impact","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Commonwealth Fund","keywords":"Cervical cancer; Low and middle income countries; Human papillomavirus; Scale (ratio); Radiation therapy; Medicine; Socioeconomics; Economics; Economic growth; Developing country; Cancer; Geography; Internal medicine","score_opus":0.020819552417263503,"score_gpt":0.3930930907106677,"score_spread":0.3722735382934042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947820602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857107,0.0022025923,0.002583096,0.00344593,0.000116587646,0.0002574374,0.0014388727,0.00005544172,0.004189325],"genre_scores_gemma":[0.9985483,0.00026573407,0.00042652144,0.00008662053,0.0000105207855,0.00004718175,0.00031161762,0.0000058191968,0.00029773777],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9977598,0.0013140561,0.000080449805,0.00017374108,0.00015119668,0.0005208364],"domain_scores_gemma":[0.99192727,0.005948921,0.0006349834,0.00026247997,0.0005387464,0.0006876178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058436776,0.0007738863,0.0012615786,0.0008490491,0.00061661593,0.0023042175,0.0013980344,0.0016446445,0.0045235464],"category_scores_gemma":[0.01792154,0.00056631997,0.0025905753,0.0013155155,0.00072433345,0.0021217463,0.0017653116,0.0018441711,0.00020474844],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004241998,0.0009922684,0.10096184,0.00050699525,0.0014589957,0.00063216675,0.00017315985,0.8573704,0.0005188522,0.0065126587,0.0032084167,0.023422306],"study_design_scores_gemma":[0.0015714793,0.0039440147,0.20354243,0.00026570875,0.0021918933,0.00025874827,0.0019827818,0.7648477,0.00078274234,0.016743489,0.003732836,0.00013622768],"about_ca_topic_score_codex":0.039993968,"about_ca_topic_score_gemma":0.029073207,"teacher_disagreement_score":0.039993968,"about_ca_system_score_codex":0.00515229,"about_ca_system_score_gemma":0.003628844,"threshold_uncertainty_score":0.07952237},"labels":[],"label_agreement":null},{"id":"W2947985696","doi":"10.1016/s1470-2045(19)30322-5","title":"India's new health scheme: what does it mean for cancer care?","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Healthcare Systems and Reforms","field":"Economics, Econometrics and Finance","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Government (linguistics); Health care; Medicine; Economic growth; Population; Scheme (mathematics); Environmental health; Economics","score_opus":0.07996591785183273,"score_gpt":0.3536374365807042,"score_spread":0.27367151872887147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947985696","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013384064,0.010339834,0.0004350242,0.9521048,0.005974953,0.000024396028,0.0014780128,0.00009738534,0.016161531],"genre_scores_gemma":[0.58859277,0.019425305,0.0017962005,0.34922045,0.016131785,0.00012821321,0.0014037148,0.0002109915,0.023090469],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99264866,0.0024070505,0.00029397826,0.00041612776,0.0018578562,0.0023764204],"domain_scores_gemma":[0.9794006,0.009028026,0.0019777727,0.0012585954,0.0032708945,0.0050641987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007924899,0.0006268426,0.00094246154,0.0017730345,0.0018309479,0.009835005,0.002412211,0.007107205,0.014625548],"category_scores_gemma":[0.025460178,0.00041164362,0.0013174898,0.004435761,0.0078665,0.006772246,0.003497404,0.010239136,0.0016917702],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068388827,0.00019643485,0.017783884,0.001514348,0.00031631853,0.0005936479,0.0016957483,0.0018991933,0.00046061006,0.46195033,0.42735022,0.08555534],"study_design_scores_gemma":[0.0006198644,0.00049455283,0.106883794,0.0019886678,0.000584892,0.0007785842,0.0047476687,0.0018937746,0.0008767376,0.11807051,0.76262164,0.00043920946],"about_ca_topic_score_codex":0.106644675,"about_ca_topic_score_gemma":0.111113444,"teacher_disagreement_score":0.106644675,"about_ca_system_score_codex":0.019182228,"about_ca_system_score_gemma":0.035369415,"threshold_uncertainty_score":0.21204787},"labels":[],"label_agreement":null},{"id":"W2948900598","doi":"10.1016/s1470-2045(19)30150-0","title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":479,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"Daiichi-Sankyo; Incyte; National Cancer Institute; National Cancer Research Institute; Celgene","keywords":"Medicine; Cytarabine; Internal medicine; Chemotherapy; Salvage therapy; Chemotherapy regimen; Febrile neutropenia; Etoposide; Surgery; Mitoxantrone; Fludarabine; Phases of clinical research; Transplantation; Refractory (planetary science); Oncology; Gastroenterology; Neutropenia; Cyclophosphamide","score_opus":0.09386240084003972,"score_gpt":0.4315224040450322,"score_spread":0.3376600032049925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948900598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985232,0.0066207917,0.000733291,0.0010552433,0.0007052656,0.0020251176,0.0011314482,0.00018938589,0.0023074993],"genre_scores_gemma":[0.98718613,0.003321127,0.0012471734,0.0013629599,0.00024789583,0.0018840298,0.00105481,0.00002653536,0.0036693888],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99963343,0.00018134262,0.000016665637,0.00007199333,0.000024158526,0.00007238954],"domain_scores_gemma":[0.99959403,0.000113364134,0.00009459435,0.000031135827,0.000024369714,0.0001424125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010590082,0.0012070657,0.0027271917,0.0002535818,0.00032706038,0.00090480014,0.0007667676,0.0012314814,0.0057819923],"category_scores_gemma":[0.0011598096,0.000377981,0.0017315157,0.00031414675,0.0008797466,0.0009274637,0.00036318492,0.0026058906,0.0008699097],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9562276,0.0029779125,0.0005035018,0.0012093273,0.0014265279,0.000054903925,0.00006516155,0.0007814037,0.0030505862,0.00033175581,0.0025108939,0.030860335],"study_design_scores_gemma":[0.96009266,0.03559123,0.0017469251,0.000047262158,0.0005341834,0.000047520727,0.000024393805,0.00054454966,0.00022885863,0.00030342996,0.00082123803,0.000017726048],"about_ca_topic_score_codex":0.0012764923,"about_ca_topic_score_gemma":0.0037511988,"teacher_disagreement_score":0.0057819923,"about_ca_system_score_codex":0.00083541346,"about_ca_system_score_gemma":0.0007548274,"threshold_uncertainty_score":0.01934266},"labels":[],"label_agreement":null},{"id":"W2954737844","doi":"10.1016/s1470-2045(19)30299-2","title":"Leptomeningeal metastasis of classical Hodgkin lymphoma in a patient with malignant posterior reversible encephalopathy syndrome","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Neurological Complications and Syndromes","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Western University","funders":"","keywords":"Medicine; Posterior reversible encephalopathy syndrome; Dacarbazine; Encephalopathy; Fluid-attenuated inversion recovery; Hypertensive encephalopathy; Hyperintensity; Pathology; Surgery; Radiology; Chemotherapy; Internal medicine; Magnetic resonance imaging; Blood pressure","score_opus":0.03330577865551398,"score_gpt":0.2916589347096551,"score_spread":0.2583531560541411,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954737844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9660004,0.0033406354,0.0011848365,0.005771932,0.0003125134,0.0001836173,0.0005520676,0.00018040805,0.022473656],"genre_scores_gemma":[0.9966311,0.0008107479,0.00030561627,0.00065848907,0.0006645917,0.000011901684,0.00010476445,0.000016905127,0.0007958465],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99961674,0.000041889998,0.00004549476,0.000074450014,0.000053008993,0.00016839846],"domain_scores_gemma":[0.9981055,0.00068912696,0.00030145948,0.00014786195,0.00015114581,0.0006048388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029030585,0.001632719,0.0010678605,0.0022651237,0.0023459988,0.0017921858,0.001448154,0.004528471,0.0044872384],"category_scores_gemma":[0.0039205714,0.0010029208,0.0008971821,0.0017368896,0.0018588558,0.0019332662,0.0012286877,0.002801665,0.001071909],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008010547,0.00002097613,0.007922698,0.000018612074,0.000009049675,0.9907087,0.000058749898,0.000052292475,0.00026887597,0.00007797711,0.00020183122,0.00058003486],"study_design_scores_gemma":[0.000039657054,0.00012846118,0.016568793,0.000017628281,0.00004171152,0.98183066,0.00019460425,0.0003495845,0.00028455624,0.00022129943,0.00030572247,0.00001743918],"about_ca_topic_score_codex":0.0061799884,"about_ca_topic_score_gemma":0.0061083967,"teacher_disagreement_score":0.0061799884,"about_ca_system_score_codex":0.0017196096,"about_ca_system_score_gemma":0.0014078692,"threshold_uncertainty_score":0.015011311},"labels":[],"label_agreement":null},{"id":"W2956873218","doi":"10.1016/s1470-2045(19)30338-9","title":"The fragility of phase 3 trials supporting FDA-approved anticancer medicines: a retrospective analysis","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":73,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Thunder Bay Regional Health Sciences Centre; NOSM University","funders":"","keywords":"Medicine; Fragility; Statistical significance; Confidence interval; Clinical trial; Randomized controlled trial; Sample size determination; Internal medicine; Statistics","score_opus":0.5921369313792776,"score_gpt":0.6538412243340906,"score_spread":0.061704292954813056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956873218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8475879,0.07468209,0.04635255,0.005077421,0.00033911964,0.0009818579,0.016584808,0.00023369995,0.008160618],"genre_scores_gemma":[0.99161655,0.0016856465,0.0026568037,0.0006405361,0.00013936462,0.00020027398,0.0026509876,0.00007670338,0.00033305865],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.89113533,0.063700244,0.020316863,0.010239692,0.012076046,0.0025317548],"domain_scores_gemma":[0.40824282,0.40592057,0.13304098,0.04170053,0.007937046,0.0031580706],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.10729605,0.00063210586,0.0018056589,0.004767422,0.0009803254,0.0030785042,0.0016440807,0.0014729355,0.00570929],"category_scores_gemma":[0.3097383,0.0011126027,0.0054651913,0.006642088,0.0023953232,0.0033098953,0.0027647873,0.0027638478,0.0007843385],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010515539,0.00007640935,0.91136956,0.0013249507,0.017442007,0.00049947994,0.00068497146,0.004420295,0.00045516918,0.006283551,0.005115406,0.04181271],"study_design_scores_gemma":[0.0011072461,0.003414081,0.8776,0.0022121968,0.030377071,0.006239103,0.0013073636,0.016935607,0.0017604989,0.025814533,0.032928094,0.00030420968],"about_ca_topic_score_codex":0.0012466338,"about_ca_topic_score_gemma":0.0015881192,"teacher_disagreement_score":0.89270395,"about_ca_system_score_codex":0.0014698447,"about_ca_system_score_gemma":0.001630871,"threshold_uncertainty_score":0.56744254},"labels":[],"label_agreement":null},{"id":"W2959633209","doi":"10.1016/s1470-2045(19)30459-0","title":"Improving affordability of new Essential Cancer Medicines","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Public Health Ontario","funders":"","keywords":"Essential medicines; Business; Access to medicines; Investment (military); Workforce; Quality (philosophy); Low and middle income countries; Supply chain; Cancer drugs; Medicine; Health care; Cancer; Economic growth; Developing country; Marketing; Nursing; Public health; Political science; Economics","score_opus":0.08620239956862087,"score_gpt":0.3603103379768915,"score_spread":0.27410793840827063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2959633209","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46374246,0.075600386,0.12855268,0.14869656,0.002316124,0.000464956,0.013000378,0.0010989152,0.1665276],"genre_scores_gemma":[0.98758405,0.0048977314,0.0037261306,0.0008792939,0.0006998802,0.00004148771,0.00050230714,0.00006094944,0.0016080175],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9918853,0.003876333,0.00061097107,0.00050877564,0.0023146167,0.0008040874],"domain_scores_gemma":[0.9594335,0.029821519,0.0056300713,0.0019204831,0.001746803,0.0014476328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01109365,0.00060706603,0.0016818574,0.0022483594,0.00034523263,0.0035369971,0.0012200512,0.0022381297,0.013463804],"category_scores_gemma":[0.06134503,0.00056147255,0.0016279512,0.0022611315,0.0015545904,0.0075159995,0.0026273846,0.0033709912,0.00039919425],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024232084,0.0006892977,0.026730403,0.0028661774,0.0014808666,0.00039577845,0.00036483168,0.18077639,0.0018658675,0.52861917,0.023170605,0.23061746],"study_design_scores_gemma":[0.00074875186,0.0008603853,0.017363338,0.00054833613,0.0006705089,0.00026000966,0.00029434913,0.06546369,0.0015830968,0.8561922,0.055933654,0.00008168423],"about_ca_topic_score_codex":0.009848745,"about_ca_topic_score_gemma":0.0054766377,"teacher_disagreement_score":0.013463804,"about_ca_system_score_codex":0.004488423,"about_ca_system_score_gemma":0.005360931,"threshold_uncertainty_score":0.058669508},"labels":[],"label_agreement":null},{"id":"W2963015093","doi":"10.1016/s1470-2045(19)30395-x","title":"Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":456,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Hôpital Notre-Dame; Université de Sherbrooke","funders":"National Health and Medical Research Council; Canadian Cancer Society Research Institute; KWF Kankerbestrijding; Strong; European SocieTy for Radiotherapy and Oncology; Agenzia Italiana del Farmaco, Ministero della Salute; National Cancer Research Institute; Cancer Australia; Cancer Research UK; Merck","keywords":"Medicine; Endometrial cancer; Radiation therapy; Chemoradiotherapy; Clinical endpoint; Carboplatin; Oncology; Internal medicine; Lymphadenectomy; Post-hoc analysis; Gynecology; Surgery; Clinical trial; Cancer; Chemotherapy; Cisplatin","score_opus":0.03306297968360868,"score_gpt":0.3534208534692313,"score_spread":0.32035787378562264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2963015093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850175,0.006142969,0.0016422357,0.0005463199,0.00035592605,0.0038527988,0.0012283331,0.000060538794,0.0011534248],"genre_scores_gemma":[0.9875163,0.0013387322,0.0024023065,0.000519846,0.00023659365,0.0056191846,0.0010731932,0.000023278157,0.001270536],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.991355,0.0072557367,0.00041892563,0.00044059774,0.00023401485,0.00029568796],"domain_scores_gemma":[0.9920912,0.0041913977,0.0019521909,0.0009440975,0.00025901437,0.0005621366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012550266,0.0012830396,0.0022839447,0.00039035763,0.00030044184,0.001003424,0.0008047202,0.0011387939,0.0037374184],"category_scores_gemma":[0.013621105,0.00041221397,0.0064223553,0.000578713,0.00090094784,0.0010520142,0.0007477497,0.002156209,0.00036668655],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97776353,0.0011768012,0.0029887587,0.0006334278,0.0069553014,0.00003831749,0.00005730224,0.00062745635,0.0006265143,0.00009697167,0.0003909256,0.008644678],"study_design_scores_gemma":[0.87060905,0.09826156,0.01491523,0.00018493488,0.01064065,0.00011892245,0.000077828605,0.002135123,0.00066162134,0.0009978253,0.0013425101,0.000054740987],"about_ca_topic_score_codex":0.00053245254,"about_ca_topic_score_gemma":0.0013634203,"teacher_disagreement_score":0.012550266,"about_ca_system_score_codex":0.0008055039,"about_ca_system_score_gemma":0.0012490418,"threshold_uncertainty_score":0.06637293},"labels":[],"label_agreement":null},{"id":"W2963476376","doi":"10.1016/s1470-2045(19)30388-2","title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1153,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre","funders":"Merck Sharp and Dohme; Les Laboratories Pierre Fabre; Merck; Meso Scale Diagnostics; Roche; British Microcirculation Society; Amgen","keywords":"Ipilimumab; Pembrolizumab; Post-hoc analysis; Open label; Medicine; Post hoc; Oncology; Internal medicine; Clinical trial; Immunotherapy; Cancer","score_opus":0.04835099458072202,"score_gpt":0.3901170919169451,"score_spread":0.3417660973362231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2963476376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98569065,0.0064193616,0.00093402056,0.0006387478,0.0006134927,0.0019806072,0.00128399,0.00014112578,0.002297976],"genre_scores_gemma":[0.9859838,0.0035910995,0.0016509072,0.0010948082,0.0005304482,0.001894575,0.0013756588,0.000046229492,0.003832437],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9989416,0.0006013688,0.000049600338,0.00016296768,0.00006922303,0.00017520301],"domain_scores_gemma":[0.9987789,0.00046682393,0.0002785528,0.00010169753,0.000062087944,0.00031195127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031352546,0.001882151,0.0033978585,0.00045866362,0.00042530525,0.0013817574,0.0011203208,0.0016581875,0.0059066014],"category_scores_gemma":[0.002167792,0.00071571313,0.0028102468,0.00045171348,0.0012786783,0.001980364,0.0005299829,0.0042504277,0.001205747],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.983634,0.0027275102,0.00021080847,0.00042166942,0.0007545332,0.000018675055,0.000030582098,0.00030893006,0.0015736377,0.00005016556,0.0003689955,0.0099004945],"study_design_scores_gemma":[0.93446904,0.061830744,0.0019313211,0.00003358276,0.00057314144,0.000022401215,0.00002399324,0.00032095987,0.00030593833,0.00010959986,0.00036447367,0.000014881057],"about_ca_topic_score_codex":0.001196962,"about_ca_topic_score_gemma":0.0020862094,"teacher_disagreement_score":0.0059066014,"about_ca_system_score_codex":0.00087786803,"about_ca_system_score_gemma":0.0008404616,"threshold_uncertainty_score":0.019759595},"labels":[],"label_agreement":null},{"id":"W2965073418","doi":"10.1016/s1470-2045(19)30516-9","title":"Advancing cancer care and prevention in the Caribbean: a survey of strategies for the region","year":2019,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"World Health Organization; National Institutes of Health; AES Corporation; AbbVie; John Templeton Foundation; Foundation for the National Institutes of Health","keywords":"Specialty; Caribbean region; Palliative care; Medicine; Health care; Cancer prevention; Healthcare system; Public health; Caribbean island; Developing country; Business; Family medicine; Cancer; Economic growth; Nursing; Political science; Latin Americans","score_opus":0.3874149358166617,"score_gpt":0.5140616115443222,"score_spread":0.12664667572766047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965073418","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000104777886,0.9960491,0.000026247635,0.003090061,0.0001650626,0.00000638039,0.00003974611,0.0000026071543,0.0005159695],"genre_scores_gemma":[0.00068249996,0.99839884,0.000085771215,0.00065361726,0.000077365774,0.0000058678074,0.000016748334,9.132771e-7,0.000078491306],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990054,0.0002721673,0.00017930462,0.000080361475,0.00032307138,0.00013973117],"domain_scores_gemma":[0.995862,0.0018706945,0.00062874885,0.00005310878,0.001101945,0.0004834777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031662756,0.000807357,0.0016512963,0.0035382088,0.0005778706,0.0027862513,0.0009686877,0.0015473261,0.0037357234],"category_scores_gemma":[0.0069869757,0.00035237646,0.0010929367,0.0077318787,0.00075428747,0.00180589,0.0014357591,0.0023326844,0.0004835307],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014549433,0.00006484192,0.0016050048,0.07647945,0.00040703392,0.0001097475,0.0005316599,0.00033643097,0.00036047644,0.006823186,0.050376832,0.86275995],"study_design_scores_gemma":[0.00006363965,0.00009990015,0.009206402,0.12220972,0.00095582235,0.00033822478,0.0016109265,0.00018820072,0.00014225578,0.0030376625,0.862098,0.00004927028],"about_ca_topic_score_codex":0.057562284,"about_ca_topic_score_gemma":0.13691983,"teacher_disagreement_score":0.057562284,"about_ca_system_score_codex":0.005127211,"about_ca_system_score_gemma":0.020781724,"threshold_uncertainty_score":0.11445451},"labels":[],"label_agreement":null},{"id":"W2965089489","doi":"10.1016/s1470-2045(19)30171-8","title":"Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy","year":2019,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":204,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"European Research Council; Weill Cornell Medical College; Genentech; Labex Immuno-Oncology; European Research Area Network on Cardiovascular Diseases; PharmaMar; Institut Universitaire de France; Chancellerie des Universités de Paris; Cancéropôle Ile de France; Ligue Contre le Cancer; Fondation pour la Recherche Médicale; Fondation pour la recherche juridique; U.S. Department of Defense; European Commission; Institut National de la Santé et de la Recherche Médicale; Bayer HealthCare; Servier; AstraZeneca; Institut National Du Cancer; Fondation Leducq; Agence Nationale de la Recherche; E-Rare; Bristol-Myers Squibb; Direction Générale de l’offre de Soins; Association pour la Recherche sur le Cancer; Seerave Foundation","keywords":"Radioimmunotherapy; Immunotherapy; Medicine; Radiation therapy; Toxicity; Oncology; Internal medicine; Cancer; Immunology; Monoclonal antibody; Antibody","score_opus":0.15012238987139914,"score_gpt":0.43593377494448915,"score_spread":0.28581138507309,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965089489","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000066460954,0.99930096,0.00006877846,0.00014556735,0.00008662226,0.000004281667,0.000008120287,0.0000029411103,0.00031622197],"genre_scores_gemma":[0.0007628324,0.99850476,0.00014559584,0.00023854627,0.000105432024,0.000007892718,0.0000148351055,0.0000011951183,0.00021894975],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99959487,0.00011501545,0.00005893791,0.00005246307,0.00013932408,0.000039344734],"domain_scores_gemma":[0.9992976,0.00047960374,0.000104835686,0.000014031408,0.00008403107,0.00001990731],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011957063,0.0010220099,0.0023703126,0.0015851755,0.00014605046,0.0011467586,0.0010728627,0.0012953257,0.0033402452],"category_scores_gemma":[0.0017346456,0.0003150396,0.00079154735,0.0014945007,0.0004493356,0.00095189334,0.0006401858,0.0020598175,0.0009931447],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021510197,0.000062757004,0.000086628694,0.038261224,0.00028036293,0.000071420276,0.000033696837,0.0006664991,0.0011802076,0.0035029745,0.014640157,0.9409989],"study_design_scores_gemma":[0.00023038601,0.00032689536,0.0012993357,0.02045529,0.0009619436,0.0007943569,0.000051030107,0.00029121994,0.0010255767,0.0043411967,0.9701812,0.000041534095],"about_ca_topic_score_codex":0.00117442,"about_ca_topic_score_gemma":0.0022032703,"teacher_disagreement_score":0.0033402452,"about_ca_system_score_codex":0.00084354606,"about_ca_system_score_gemma":0.0010117476,"threshold_uncertainty_score":0.011174202},"labels":[],"label_agreement":null},{"id":"W2967350775","doi":"10.1016/s1470-2045(19)30413-9","title":"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":780,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Calgary","funders":"Cilag; Foundation Medicine; Pharmacyclics; EMD Serono; Genentech; Astellas Pharma; Eisai; Jounce Therapeutics; Acceleron; Chugai Pharmaceutical; Horizon Pharma; National Cancer Institute; Intuitive Surgical; Gilead Sciences; Calithera Biosciences; Celldex Therapeutics; Ipsen; Array BioPharma; Center for Outcomes Research and Evaluation, Yale School of Medicine; Bayer HealthCare; Society of Memorial Sloan Kettering; Exelixis; Sanofi; Bristol-Myers Squibb; Ono Pharmaceutical; Eli Lilly and Company; EUSA Pharma; AstraZeneca; Memorial Sloan-Kettering Cancer Center; GlaxoSmithKline; Agilent Technologies; Amgen; Pfizer","keywords":"Nivolumab; Sunitinib; Ipilimumab; Medicine; Renal cell carcinoma; Internal medicine; Oncology; Carcinoma; First line; Randomized controlled trial; Clinical trial; Immunotherapy; Cancer","score_opus":0.06296786444902643,"score_gpt":0.34241897178061087,"score_spread":0.27945110733158446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967350775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899594,0.004669338,0.00044597877,0.00034732136,0.00031974015,0.0025405702,0.0007597005,0.000075939235,0.00088198093],"genre_scores_gemma":[0.9931463,0.0012207556,0.00078251946,0.00043813934,0.0003032302,0.0025979257,0.0006970653,0.000014211183,0.000799932],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997306,0.0018448478,0.00018515499,0.0002952221,0.0001567331,0.00021218005],"domain_scores_gemma":[0.9968003,0.0010254645,0.0009890953,0.00032710508,0.00019229553,0.0006657275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0059462725,0.0011808674,0.0031236098,0.00044804794,0.00054794387,0.0011987288,0.00093346275,0.0015678612,0.0040743267],"category_scores_gemma":[0.0048811976,0.00051232794,0.0034043463,0.0005074871,0.0009977539,0.0011086077,0.0004852888,0.0024998577,0.0005774807],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9870651,0.0023882485,0.00079887325,0.00033590462,0.000957919,0.000024041441,0.00003849289,0.00022675605,0.0010752347,0.000031747444,0.00025190614,0.006805859],"study_design_scores_gemma":[0.9307785,0.06342169,0.00391834,0.000031460582,0.00078296656,0.00003866232,0.0000132133855,0.00027825325,0.0002820796,0.00011673996,0.00032341754,0.000014692304],"about_ca_topic_score_codex":0.0007385971,"about_ca_topic_score_gemma":0.0018329726,"teacher_disagreement_score":0.0059462725,"about_ca_system_score_codex":0.0010922431,"about_ca_system_score_gemma":0.0013953649,"threshold_uncertainty_score":0.03144729},"labels":[],"label_agreement":null},{"id":"W2967398918","doi":"10.1016/s1470-2045(19)30407-3","title":"Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":365,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Bristol-Myers Squibb; Ono Pharmaceutical; European Society for Medical Oncology; Cancer Research Society; American Association for Cancer Research","keywords":"Nivolumab; Medicine; Docetaxel; Lung cancer; Internal medicine; Oncology; Clinical trial; Survival analysis; Cancer; Progressive disease; Chemotherapy; Immunotherapy","score_opus":0.011169927419285955,"score_gpt":0.26970985525713,"score_spread":0.258539927837844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967398918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.842942,0.139849,0.003329445,0.00043593106,0.0009528509,0.00020780563,0.009822551,0.00016721842,0.002293296],"genre_scores_gemma":[0.9829947,0.008695923,0.0007431147,0.0004633594,0.00041835217,0.00015505018,0.005398121,0.000057626567,0.0010737571],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9959566,0.0016356036,0.00050284015,0.0011628668,0.00035305577,0.00038902843],"domain_scores_gemma":[0.99763966,0.0009409439,0.0006132604,0.00035252035,0.00029589655,0.0001577418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051575354,0.0021367213,0.0060255257,0.0016209579,0.00032098364,0.0018084594,0.001270487,0.0014891792,0.0017089668],"category_scores_gemma":[0.0050887205,0.0010668737,0.02551352,0.0019546053,0.0003789555,0.0013853012,0.0013167966,0.0015432907,0.00037683416],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09401312,0.00015946096,0.186668,0.004875177,0.6811141,0.0002792383,0.000093908515,0.004516753,0.0018511465,0.00015605922,0.002769675,0.0235034],"study_design_scores_gemma":[0.009521678,0.004877861,0.3944926,0.0006006867,0.5796785,0.0003817773,0.00023471445,0.004608321,0.00065379275,0.00056016387,0.0042250413,0.00016482707],"about_ca_topic_score_codex":0.007430982,"about_ca_topic_score_gemma":0.014485632,"teacher_disagreement_score":0.007430982,"about_ca_system_score_codex":0.0011534403,"about_ca_system_score_gemma":0.000798647,"threshold_uncertainty_score":0.02727598},"labels":[],"label_agreement":null},{"id":"W2967453129","doi":"10.1016/s1470-2045(19)30410-3","title":"Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":462,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; University of Ottawa; University Health Network; University of Toronto; McGill University; University of British Columbia; Western University","funders":"Canadian Cancer Society Research Institute; University of Texas MD Anderson Cancer Center; Cancer Research Institute; Eisai; Canadian Cancer Society; Ontario Institute for Cancer Research","keywords":"Transoral robotic surgery; Medicine; Neck dissection; Radiation therapy; Basal cell; Dissection (medical); Open label; Randomized controlled trial; Surgery; Oncology; Radiology; Carcinoma; Internal medicine","score_opus":0.11332656014311564,"score_gpt":0.3992188345265018,"score_spread":0.28589227438338616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967453129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9612736,0.019739643,0.0016655045,0.0013606908,0.0026405514,0.00688653,0.0020955706,0.00023466264,0.0041031973],"genre_scores_gemma":[0.96371037,0.010589112,0.0026310566,0.0017951456,0.0010039533,0.009566676,0.0013153483,0.00005786064,0.009330538],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9989635,0.0005956353,0.00006525577,0.00018796323,0.000055267203,0.00013246728],"domain_scores_gemma":[0.99902296,0.00044199487,0.00020722393,0.00009766568,0.000047803802,0.00018240315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022997328,0.002886125,0.004413552,0.0004061553,0.00046250215,0.001441886,0.0014084143,0.0025275273,0.01211929],"category_scores_gemma":[0.0027144486,0.0009379775,0.004037303,0.0005273203,0.0015067568,0.0017094493,0.00062643056,0.004112118,0.001766184],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98870856,0.001325868,0.00012665844,0.0010782048,0.0010689645,0.000019628686,0.000045050732,0.00019800349,0.0005738608,0.00008382045,0.0003756289,0.0063956403],"study_design_scores_gemma":[0.9726572,0.025518173,0.00033876154,0.00006043714,0.00066415186,0.000019197461,0.000023472528,0.00014505212,0.00009646709,0.00013062904,0.00033396145,0.000012498141],"about_ca_topic_score_codex":0.0017056932,"about_ca_topic_score_gemma":0.0033223978,"teacher_disagreement_score":0.01211929,"about_ca_system_score_codex":0.0009476999,"about_ca_system_score_gemma":0.001097299,"threshold_uncertainty_score":0.04054308},"labels":[],"label_agreement":null},{"id":"W2970380239","doi":"10.1016/s1470-2045(18)30858-1","title":"Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium","year":2019,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Hearing, Cochlea, Tinnitus, Genetics","field":"Neuroscience","cited_by":143,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster Children's Hospital; Hospital for Sick Children; University of British Columbia; McMaster University; BC Children's Hospital","funders":"National Cancer Institute; Cancer Research UK","keywords":"Ototoxicity; Guideline; Harmonization; Medicine; Hearing loss; Multidisciplinary approach; Tinnitus; Family medicine; Psychiatry; Audiology; Surgery; Chemotherapy; Pathology","score_opus":0.06916719563057598,"score_gpt":0.3792822199720031,"score_spread":0.3101150243414271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970380239","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000867128,0.943875,0.0036846353,0.037642967,0.003968686,0.000629141,0.0033088855,0.00020308889,0.005820476],"genre_scores_gemma":[0.0043916116,0.9474094,0.014063649,0.024542268,0.0008303494,0.0008741275,0.0047530616,0.00004772121,0.0030877905],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9973132,0.00078543776,0.000658209,0.0002244697,0.00083450973,0.00018421229],"domain_scores_gemma":[0.99412197,0.0017653778,0.00073636335,0.00013210328,0.0028797241,0.00036437402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008090369,0.0011674534,0.0031064898,0.002723103,0.0005680015,0.0015336608,0.0041530337,0.0036847845,0.0029102322],"category_scores_gemma":[0.009031236,0.0005639989,0.004276381,0.002139682,0.0006231335,0.0015049514,0.0016641881,0.005047313,0.0014734778],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002630428,0.00016816125,0.0016483893,0.030507514,0.0007667596,0.00021737043,0.0001887823,0.0012952657,0.0013209007,0.0048746765,0.27104095,0.6877082],"study_design_scores_gemma":[0.0003870085,0.0001881561,0.0058987616,0.062285386,0.0025270395,0.0005428943,0.00025582567,0.00043340935,0.0005447734,0.0040849983,0.9227687,0.0000830009],"about_ca_topic_score_codex":0.019783415,"about_ca_topic_score_gemma":0.036733113,"teacher_disagreement_score":0.019783415,"about_ca_system_score_codex":0.0027580722,"about_ca_system_score_gemma":0.013186158,"threshold_uncertainty_score":0.04278642},"labels":[],"label_agreement":null},{"id":"W2971424022","doi":"10.1016/s1470-2045(19)30535-2","title":"Barriers to treatment for patients with breast cancer in Kenya","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Incidence (geometry); Breast cancer; Disease; Quarter (Canadian coin); Population; Health care; Cancer; Demography; Internal medicine; Environmental health; Economic growth","score_opus":0.05031095409804269,"score_gpt":0.3685023787750488,"score_spread":0.3181914246770061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971424022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85428786,0.010611412,0.0001336307,0.10660559,0.00035484388,0.00012675802,0.0011126833,0.000012310762,0.026754923],"genre_scores_gemma":[0.9857384,0.005616953,0.00016469859,0.0064767087,0.00008600591,0.00007957334,0.00020468142,0.000011057757,0.001621932],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99845433,0.00058195426,0.00009189107,0.00004695745,0.00009678216,0.00072807923],"domain_scores_gemma":[0.99588984,0.00096565404,0.001255573,0.00004139175,0.00016743096,0.0016801184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082567014,0.00014911321,0.00028838476,0.0003649418,0.002206049,0.001494559,0.0007121833,0.0009723253,0.009186329],"category_scores_gemma":[0.007252787,0.00031741225,0.0004613204,0.00088950054,0.0007221864,0.0010052808,0.0017565665,0.002536298,0.00035722615],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038983778,0.00073715596,0.8991017,0.0011196294,0.00020825559,0.0014520813,0.012496886,0.00021795006,0.0005838367,0.0055069556,0.032533128,0.04565263],"study_design_scores_gemma":[0.0001636911,0.00034887446,0.9154523,0.0027330795,0.00022353658,0.0012844274,0.052306026,0.00032622638,0.00020246046,0.0017758278,0.025107855,0.00007570324],"about_ca_topic_score_codex":0.12493352,"about_ca_topic_score_gemma":0.23208314,"teacher_disagreement_score":0.12493352,"about_ca_system_score_codex":0.0034778735,"about_ca_system_score_gemma":0.010083645,"threshold_uncertainty_score":0.24841261},"labels":[],"label_agreement":null},{"id":"W2972019042","doi":"10.1016/s1470-2045(19)30336-5","title":"2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","year":2019,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":658,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McGill University","funders":"University of North Carolina at Chapel Hill; Trakya Üniversitesi; National Institutes of Health; Universidad de Granada; Universidad de la República Uruguay; University of Southern California; Universidad de Navarra; University of Rochester; Memorial Sloan-Kettering Cancer Center; Universidad Nacional Autónoma de México; Mahidol University; Foundation for the National Institutes of Health","keywords":"Medicine; Thrombosis; Intensive care medicine; Clinical trial; Venous thrombosis; Grading (engineering); Cancer; Venous thromboembolism; Low molecular weight heparin; Clinical Practice; Family medicine; Surgery; Internal medicine","score_opus":0.23019862109672373,"score_gpt":0.5194032340421533,"score_spread":0.28920461294542954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972019042","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000058199585,0.9886574,0.00041246787,0.005226354,0.0023933565,0.00011768249,0.0005129446,0.000043856293,0.002577595],"genre_scores_gemma":[0.0006090646,0.9897411,0.0019989521,0.004565047,0.0008180979,0.00018152874,0.00076037185,0.000013326735,0.0013125386],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99750596,0.00060178933,0.0007619539,0.00016596177,0.0008266558,0.00013769229],"domain_scores_gemma":[0.9932371,0.002926946,0.0015782261,0.000121661076,0.00183325,0.00030286078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004291171,0.0013997343,0.0037607232,0.006103613,0.0004580419,0.0018627146,0.0027013987,0.0036660433,0.010028898],"category_scores_gemma":[0.009909842,0.0006039652,0.0032048693,0.0053066323,0.0006724419,0.0012437116,0.0013580532,0.004126599,0.004761263],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000167389,0.00008606683,0.00021034345,0.07157654,0.0005126768,0.000098449,0.00007230446,0.00037852812,0.0005012832,0.0031859644,0.21078323,0.7124272],"study_design_scores_gemma":[0.0002552851,0.00012385736,0.0014251795,0.10724857,0.0016625127,0.00031433982,0.00006733886,0.00016901562,0.0001490632,0.0024404654,0.8861021,0.00004224742],"about_ca_topic_score_codex":0.010588687,"about_ca_topic_score_gemma":0.01772346,"teacher_disagreement_score":0.010588687,"about_ca_system_score_codex":0.003074665,"about_ca_system_score_gemma":0.010512645,"threshold_uncertainty_score":0.033550024},"labels":[],"label_agreement":null},{"id":"W2972165994","doi":"10.1016/s1470-2045(19)30489-9","title":"MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc)","year":2019,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; Public Health Ontario; University of Toronto","funders":"","keywords":"Mammography; Medicine; Breast cancer; Cancer; Gynecology; Obstetrics; Breast cancer screening; Mammography screening; Oncology; Internal medicine","score_opus":0.023814572005953417,"score_gpt":0.30582374074023805,"score_spread":0.2820091687342846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972165994","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011861195,0.003476405,0.0000405927,0.9753838,0.015322748,0.000019892654,0.00012464536,0.000013822645,0.0044319704],"genre_scores_gemma":[0.009162972,0.0022916433,0.00014839484,0.9248769,0.056509,0.000056695644,0.000064657565,0.000019980014,0.0068697683],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983688,0.0005216585,0.00019400836,0.0002452238,0.00033014116,0.00034017902],"domain_scores_gemma":[0.9906094,0.006183327,0.0007052169,0.00018254232,0.00075095874,0.0015685932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002728646,0.0006201131,0.0011063763,0.0010018832,0.0024406267,0.002674743,0.0011284718,0.044752266,0.01139979],"category_scores_gemma":[0.023504166,0.0008145059,0.0010414827,0.00084721006,0.0014337137,0.0017403922,0.0010108723,0.02117591,0.004277861],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006348667,0.00007317037,0.002919767,0.00015532564,0.000053206182,0.0025763193,0.00008890785,0.00009904379,0.0003793689,0.0024267547,0.9680632,0.022530105],"study_design_scores_gemma":[0.0015083465,0.00066384,0.011874541,0.0017959329,0.00034893263,0.007546204,0.0005403686,0.0014742912,0.0009166671,0.014137743,0.9590457,0.00014730328],"about_ca_topic_score_codex":0.010581486,"about_ca_topic_score_gemma":0.024851613,"teacher_disagreement_score":0.044752266,"about_ca_system_score_codex":0.004909024,"about_ca_system_score_gemma":0.0037788262,"threshold_uncertainty_score":0.038136065},"labels":[],"label_agreement":null},{"id":"W2973153606","doi":"10.1016/s1470-2045(19)30456-5","title":"Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":1052,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Nova Scotia Health Authority; Government of New Brunswick; Canadian Partnership Against Cancer; Dr. H. Bliss Murphy Cancer Centre; Saskatchewan Cancer Agency; CancerCare Manitoba; Cancer Care Ontario; Alberta Health Services","funders":"Department of Health, Government of Western Australia; Public Health Agency; Cancer Council Victoria; Partenariat Canadien Contre Le Cancer; Cancer Society of New Zealand; Cancer Institute NSW; Kreftforeningen; Cancer Research UK; World Health Organization; Cancer Focus Northern Ireland; Northern Ireland Environment Agency; Kræftens Bekæmpelse; Scottish Government","keywords":"Medicine; Cancer; Population; Colorectal cancer; Incidence (geometry); Demography; Cancer registry; Lung cancer; Stomach cancer; Environmental health; Oncology; Internal medicine","score_opus":0.12235468485963746,"score_gpt":0.43464199303880136,"score_spread":0.3122873081791639,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2973153606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773357,0.0006140939,0.00020405701,0.00014598758,0.000027029539,0.000044497676,0.020691032,0.000022086424,0.0009155817],"genre_scores_gemma":[0.97608703,0.0004822168,0.00021419046,0.0000962796,0.000026213009,0.00011255141,0.022406664,0.000015749712,0.00055927614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985569,0.00036619965,0.00023124044,0.00033843843,0.00020502188,0.00030215026],"domain_scores_gemma":[0.9979844,0.0002258938,0.00072425266,0.0002333331,0.0004626834,0.0003693762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020941792,0.0008462726,0.0008439911,0.0025303408,0.00063994696,0.0016704242,0.001184122,0.0009875355,0.0011458572],"category_scores_gemma":[0.002885601,0.00084565516,0.001660585,0.007244592,0.0006704179,0.0012589085,0.0020534925,0.0013545449,0.0005627917],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021719043,0.000045529196,0.99649125,0.0000356874,0.00031036505,0.0000573949,0.00024393213,0.0001575924,0.000065968205,0.000036923757,0.0010471949,0.0012911194],"study_design_scores_gemma":[0.00001945246,0.00005685143,0.99859065,0.000014480305,0.00013827572,0.00006804582,0.0004899844,0.00008220215,0.00003305389,0.000010860017,0.0004871443,0.000008962543],"about_ca_topic_score_codex":0.09152083,"about_ca_topic_score_gemma":0.07997507,"teacher_disagreement_score":0.09152083,"about_ca_system_score_codex":0.0015010658,"about_ca_system_score_gemma":0.0015189615,"threshold_uncertainty_score":0.18197626},"labels":[],"label_agreement":null},{"id":"W2973514824","doi":"10.1016/s1470-2045(19)30569-8","title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":536,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Institute for Health and Care Research; Institute of Cancer Research; Metropolitan Museum of Art; Cancer Research UK; Manchester Biomedical Research Centre; Accuray; Cilag; NIHR Bristol Biomedical Research Centre; National Health Insurance Service; Royal Marsden NHS Foundation Trust","keywords":"Medicine; Radiation therapy; Prostate cancer; Dose fractionation; Clinical endpoint; Androgen deprivation therapy; Prostate; Internal medicine; Randomized controlled trial; Oncology; Urology; Cancer","score_opus":0.06750216261748353,"score_gpt":0.43494058957700754,"score_spread":0.367438426959524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2973514824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9584841,0.016942263,0.002127172,0.0017526883,0.0010717751,0.010934372,0.0021817533,0.0002395802,0.006266269],"genre_scores_gemma":[0.9650199,0.0076473784,0.003579431,0.0027385177,0.0010992215,0.014328391,0.0020175509,0.00006785929,0.0035017624],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99615014,0.002874596,0.00020386951,0.0003163609,0.00022622882,0.00022878074],"domain_scores_gemma":[0.9957345,0.0015258843,0.0012627955,0.000399238,0.00023605528,0.00084159995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069716778,0.001960338,0.0035535626,0.0005274362,0.00048137107,0.0015089572,0.0014027716,0.002623036,0.009881525],"category_scores_gemma":[0.006938993,0.0006314896,0.0035647324,0.0008474039,0.0018891861,0.001608778,0.0007627699,0.0034812996,0.0011089673],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98485696,0.0029952438,0.0001942629,0.00079897617,0.00074482645,0.00001624531,0.000044578614,0.00020028118,0.0014228349,0.00009753407,0.0005505015,0.008077751],"study_design_scores_gemma":[0.95831835,0.040004276,0.0005532128,0.000049976254,0.00034096173,0.00001599015,0.000008898018,0.000108434375,0.00013779174,0.000101556994,0.000351757,0.000008695344],"about_ca_topic_score_codex":0.00061732775,"about_ca_topic_score_gemma":0.0011810187,"teacher_disagreement_score":0.009881525,"about_ca_system_score_codex":0.0009606059,"about_ca_system_score_gemma":0.0018343383,"threshold_uncertainty_score":0.03687018},"labels":[],"label_agreement":null},{"id":"W2977514272","doi":"10.1016/s1470-2045(19)30580-7","title":"A critique of the fragility index – Authors' reply","year":2019,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; NOSM University; Princess Margaret Cancer Centre; Thunder Bay Regional Health Sciences Centre","funders":"","keywords":"Fragility; Scopus; Medicine; Confidence interval; Meta-analysis; Statistical significance; Index (typography); MEDLINE; Internal medicine; Computer science; Political science","score_opus":0.39568517824955574,"score_gpt":0.47117584875158947,"score_spread":0.07549067050203373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977514272","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006127826,0.0006467977,0.000052217696,0.98531485,0.013581337,0.0000028286693,0.00003869352,0.0000073855404,0.0002945893],"genre_scores_gemma":[0.0010497218,0.00034115606,0.00009470724,0.9659988,0.03172024,0.000020997066,0.000014519394,0.000022258111,0.00073766266],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9793736,0.007316148,0.0034281085,0.0028010937,0.0054555694,0.0016255245],"domain_scores_gemma":[0.8787672,0.09165831,0.0060720714,0.0032502958,0.015285624,0.004966554],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.022598816,0.0011449754,0.0033791664,0.0027224116,0.004670517,0.009504706,0.0047456548,0.09889605,0.006709794],"category_scores_gemma":[0.15876965,0.0017166719,0.0024097369,0.0025776154,0.011478078,0.008772609,0.0051534884,0.09123791,0.0066321786],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044183776,0.000011669736,0.00031541794,0.00006829202,0.00003421396,0.0001844159,0.00016575263,0.0000445876,0.000038731323,0.005669275,0.9902255,0.0031979762],"study_design_scores_gemma":[0.00030066166,0.000050421437,0.0015962949,0.0013045259,0.0001240867,0.00068479567,0.0008797786,0.0005588843,0.00028791677,0.047394674,0.9465551,0.00026282313],"about_ca_topic_score_codex":0.010213093,"about_ca_topic_score_gemma":0.011538048,"teacher_disagreement_score":0.9774012,"about_ca_system_score_codex":0.0074530914,"about_ca_system_score_gemma":0.0078003625,"threshold_uncertainty_score":0.11951542},"labels":[],"label_agreement":null},{"id":"W2978525767","doi":"10.1016/s1470-2045(19)30394-8","title":"Access to radiotherapy among circumpolar Inuit populations","year":2019,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Circumpolar star; Indigenous; Referral; Radiation therapy; Geography; Population; Epidemiology; Medicine; Environmental health; Oceanography; Family medicine; Ecology; Pathology; Biology; Surgery","score_opus":0.22781396163676448,"score_gpt":0.5406879605641577,"score_spread":0.3128739989273932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978525767","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008980962,0.9985775,0.000017370685,0.0005792474,0.00011687674,0.000001346018,0.0000236356,0.000001164756,0.0005930879],"genre_scores_gemma":[0.0009865682,0.99824095,0.000031273546,0.0003558767,0.00017629012,0.0000028380418,0.000017690038,5.808394e-7,0.00018799772],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99982005,0.00005172943,0.000027101243,0.000031668067,0.00004329759,0.000026262016],"domain_scores_gemma":[0.9992447,0.0005138426,0.000110498746,0.000009963683,0.000079941456,0.000041110878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067706744,0.0003931119,0.00088525855,0.0011365543,0.00020784602,0.00081553694,0.00043807295,0.000762465,0.0061364546],"category_scores_gemma":[0.0023038776,0.00018997102,0.00038305108,0.0019320853,0.00040339556,0.00084304466,0.00067872263,0.0011762001,0.00042245252],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009336206,0.000026404668,0.0008966661,0.03694994,0.00020019825,0.00008474632,0.00017057576,0.00022857168,0.00018625433,0.0037658315,0.033207573,0.92418987],"study_design_scores_gemma":[0.000039760285,0.00010374162,0.0068080956,0.049235586,0.0008157748,0.00066672557,0.00040959026,0.00009744035,0.00013670644,0.0031663966,0.9384933,0.000026962025],"about_ca_topic_score_codex":0.0145417545,"about_ca_topic_score_gemma":0.031368125,"teacher_disagreement_score":0.98545825,"about_ca_system_score_codex":0.0012260221,"about_ca_system_score_gemma":0.0021833386,"threshold_uncertainty_score":0.028914213},"labels":[],"label_agreement":null},{"id":"W2979269615","doi":"10.1016/s1470-2045(19)30583-2","title":"A critique of the fragility index","year":2019,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Fragility; Clinical trial; Oncology; Food and drug administration; Alternative medicine; Clinical Oncology; Internal medicine; Pharmacology; Cancer; Pathology","score_opus":0.6148560317831308,"score_gpt":0.6006552477939483,"score_spread":0.014200783989182453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979269615","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000068478876,0.0024330555,0.00091428816,0.9857538,0.009624022,0.000007391086,0.00004950293,0.000022484526,0.0011269922],"genre_scores_gemma":[0.0027384183,0.0011804308,0.001545812,0.9376237,0.055488102,0.00010203464,0.00002158326,0.00007467221,0.0012252438],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.88147223,0.06862938,0.012648687,0.008406347,0.026554633,0.002288689],"domain_scores_gemma":[0.38927224,0.55060226,0.010606416,0.01111871,0.03249254,0.005907792],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.114854865,0.0017006132,0.0055800234,0.0044836765,0.00511207,0.012358667,0.007235715,0.069311805,0.008201587],"category_scores_gemma":[0.46639755,0.002071001,0.0030648108,0.004033514,0.030669041,0.012332203,0.0059571792,0.11201737,0.007651607],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016884944,0.000027999211,0.00048102313,0.0002722802,0.000121314086,0.00020403758,0.0003042132,0.0002491336,0.00007109637,0.08576549,0.88900495,0.023329535],"study_design_scores_gemma":[0.0007039589,0.00008438694,0.0010741075,0.0025225705,0.00021025621,0.00055398094,0.00027959535,0.0023229416,0.00029463344,0.38968122,0.60198826,0.00028409573],"about_ca_topic_score_codex":0.011851171,"about_ca_topic_score_gemma":0.012416017,"teacher_disagreement_score":0.8851451,"about_ca_system_score_codex":0.011403262,"about_ca_system_score_gemma":0.012226403,"threshold_uncertainty_score":0.6074178},"labels":[],"label_agreement":null},{"id":"W2979548369","doi":"10.1016/s1470-2045(19)30493-0","title":"Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"National Cancer Institute; Novartis","keywords":"Medicine; Refractory (planetary science); Quality of life (healthcare); Young adult; Pediatrics; Oncology; Internal medicine; Biology","score_opus":0.03486376564826552,"score_gpt":0.34536738574798603,"score_spread":0.3105036200997205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979548369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99590355,0.0022145638,0.00010285736,0.0003407612,0.00006118217,0.0002475122,0.0006440788,0.000031248375,0.00045420855],"genre_scores_gemma":[0.9945673,0.0015877344,0.00034122434,0.0005831297,0.000093011484,0.0008419272,0.001159238,0.000011688677,0.00081477256],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99950874,0.00024594017,0.000020697,0.00008651296,0.00003426792,0.00010371411],"domain_scores_gemma":[0.9993278,0.00012473833,0.00018368215,0.00003536265,0.00002598346,0.00030248336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009309913,0.0013794682,0.002090033,0.0002568455,0.0002544386,0.0010084978,0.00064269867,0.001198532,0.0023196219],"category_scores_gemma":[0.000870003,0.0003348789,0.0019523723,0.0003899472,0.0010609905,0.0007895973,0.0005760089,0.0030796912,0.00045622938],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91516566,0.010222602,0.012708868,0.00093064393,0.003507338,0.00018810562,0.0002521569,0.0011765956,0.0040281494,0.0002341597,0.002437134,0.049148545],"study_design_scores_gemma":[0.7866395,0.16103023,0.04670837,0.00009702931,0.0015208968,0.0002698981,0.00015467092,0.00081708166,0.00079843035,0.0002634039,0.0016559765,0.00004447459],"about_ca_topic_score_codex":0.0011101412,"about_ca_topic_score_gemma":0.002393512,"teacher_disagreement_score":0.0023196219,"about_ca_system_score_codex":0.0009107757,"about_ca_system_score_gemma":0.00083749404,"threshold_uncertainty_score":0.0077599287},"labels":[],"label_agreement":null},{"id":"W2982460038","doi":"10.1016/s1470-2045(19)30653-9","title":"Sparing of swallowing-related organs in radiotherapy for oropharyngeal squamous cell carcinoma–Authors’ reply","year":2019,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Swallowing; Radiation therapy; Dysphagia; Cancer; Quality of life (healthcare); Surgery; Internal medicine","score_opus":0.047700985395617304,"score_gpt":0.3288354211786673,"score_spread":0.28113443578305003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982460038","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00037213866,0.0019737785,0.00002049084,0.9751667,0.021410288,0.000005332483,0.00010985819,0.000006713803,0.0009346602],"genre_scores_gemma":[0.0033663309,0.001496025,0.00005624641,0.95664155,0.035661995,0.000036899823,0.000053049665,0.000015653317,0.0026722755],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996729,0.0012486344,0.00046493267,0.0003703214,0.00066489313,0.00052219705],"domain_scores_gemma":[0.9856047,0.010354764,0.0010299542,0.0003164467,0.0014274972,0.001266544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040311622,0.0005229598,0.0016783417,0.0007032704,0.0023223867,0.0025814443,0.0014002203,0.03805827,0.008455776],"category_scores_gemma":[0.027467724,0.00068652857,0.0011464757,0.0010402397,0.002229796,0.0028847354,0.001865781,0.025773967,0.0041298494],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023316064,0.00002252212,0.0008740627,0.0001798385,0.00004401063,0.0004974222,0.00012838292,0.000063231746,0.00012899766,0.0010781733,0.98938423,0.007365841],"study_design_scores_gemma":[0.0005481877,0.0002251594,0.002918098,0.0006642601,0.00017424159,0.0012593584,0.0005793891,0.00018880694,0.00043568562,0.007426396,0.98546183,0.000118589116],"about_ca_topic_score_codex":0.005640218,"about_ca_topic_score_gemma":0.009530206,"teacher_disagreement_score":0.03805827,"about_ca_system_score_codex":0.0034791597,"about_ca_system_score_gemma":0.004554317,"threshold_uncertainty_score":0.02828741},"labels":[],"label_agreement":null},{"id":"W2982569177","doi":"10.1016/s1470-2045(19)30404-8","title":"Core elements of national cancer control plans: a tool to support plan development and review","year":2019,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Kingston General Hospital","funders":"World Health Organization","keywords":"Checklist; Process (computing); Core (optical fiber); Plan (archaeology); Control (management); Process management; Quality (philosophy); Critical appraisal; Population; Business; Computer science; Management science; Medicine; Engineering; Geography; Psychology; Environmental health; Alternative medicine","score_opus":0.47981905966532695,"score_gpt":0.5123818453119852,"score_spread":0.03256278564665821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982569177","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010657778,0.87772286,0.022549342,0.051622175,0.0053408584,0.0040625082,0.009660071,0.0015837763,0.026392685],"genre_scores_gemma":[0.015139962,0.8099622,0.14866482,0.009263971,0.0011503119,0.004002942,0.008260979,0.0002195597,0.0033352217],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98441064,0.005462903,0.0034121026,0.0005252758,0.005866233,0.00032279763],"domain_scores_gemma":[0.9486492,0.031870104,0.0067248736,0.001897356,0.009309706,0.0015487325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.031353626,0.0020019189,0.0033624903,0.014240468,0.00072647474,0.0059358366,0.0033603115,0.0023134449,0.009532358],"category_scores_gemma":[0.07370053,0.0016784782,0.0029467638,0.011404675,0.0009885653,0.00584422,0.00413613,0.004542777,0.0018187353],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000083846346,0.00006390585,0.0006631018,0.07584687,0.0009105989,0.00005394315,0.00044884105,0.0021022006,0.00020245656,0.021959806,0.13922355,0.7584408],"study_design_scores_gemma":[0.00011411264,0.000055955123,0.0015421155,0.13953793,0.0017694654,0.00009601177,0.00036557644,0.0011457975,0.00030239378,0.010801254,0.84421915,0.000050275852],"about_ca_topic_score_codex":0.018310588,"about_ca_topic_score_gemma":0.02507366,"teacher_disagreement_score":0.031353626,"about_ca_system_score_codex":0.011290873,"about_ca_system_score_gemma":0.039019242,"threshold_uncertainty_score":0.16581577},"labels":[],"label_agreement":null},{"id":"W2982581267","doi":"10.1016/s1470-2045(19)30625-4","title":"Navigating prostate cancer control in Nigeria","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Queen's University","funders":"","keywords":"Nigerians; Prostate cancer; Medicine; Cancer; Demography; Population; Gynecology; Environmental health; Internal medicine; Political science; Sociology","score_opus":0.06358863863930656,"score_gpt":0.4129022455259878,"score_spread":0.3493136068866812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982581267","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3592517,0.08299906,0.0009233462,0.46632388,0.004031203,0.00012072713,0.0004809783,0.000038065864,0.0858311],"genre_scores_gemma":[0.9174341,0.053989332,0.0009816788,0.01951712,0.00052790646,0.000065026834,0.00014002998,0.000016209631,0.007328704],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993794,0.00019877171,0.00003168392,0.000029942315,0.000054017964,0.0003062148],"domain_scores_gemma":[0.9990355,0.00017891578,0.00015444715,0.000015829359,0.000104402374,0.0005108443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00099481,0.0001969926,0.00023556015,0.00045369685,0.0013065309,0.0019073772,0.00037320793,0.001349068,0.0035515842],"category_scores_gemma":[0.0023393745,0.00019390654,0.00016183179,0.0006443448,0.00072287326,0.0015119683,0.002026658,0.002291944,0.00022304688],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005670846,0.0012187656,0.32003444,0.0072310567,0.00024414397,0.0036182257,0.0312713,0.0017104577,0.0031242725,0.10836226,0.07473836,0.4478796],"study_design_scores_gemma":[0.00024835952,0.0008791357,0.35909212,0.017112246,0.00048338846,0.0024072176,0.17181778,0.0015667479,0.0017250357,0.051229496,0.39324722,0.00019118756],"about_ca_topic_score_codex":0.050083626,"about_ca_topic_score_gemma":0.09202226,"teacher_disagreement_score":0.050083626,"about_ca_system_score_codex":0.0020400758,"about_ca_system_score_gemma":0.015956052,"threshold_uncertainty_score":0.09958422},"labels":[],"label_agreement":null},{"id":"W2982865643","doi":"10.1016/s1470-2045(19)30668-0","title":"Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; Roche; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Docetaxel; Medicine; Ramucirumab; Clinical endpoint; Internal medicine; Metastatic Urothelial Carcinoma; Population; Oncology; Placebo; Progression-free survival; Surgery; Clinical trial; Chemotherapy; Cancer; Urothelial carcinoma; Bladder cancer; Pathology","score_opus":0.0584573287324271,"score_gpt":0.3466840245943807,"score_spread":0.2882266958619536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982865643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9792252,0.0143369725,0.00047029526,0.00069918385,0.00074095756,0.0011511032,0.00090552587,0.00020002038,0.0022708564],"genre_scores_gemma":[0.9896986,0.003836627,0.00086163887,0.00078909245,0.0004103939,0.0008093255,0.00078706664,0.000029693301,0.0027776493],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99912196,0.0005007223,0.000048994498,0.00017155694,0.000044394612,0.00011241529],"domain_scores_gemma":[0.99914217,0.00030409126,0.00022684882,0.000076670316,0.000043139145,0.00020698161],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002131508,0.0016422268,0.0036116762,0.00047083246,0.00037462558,0.0012446329,0.001003829,0.001474178,0.0041656387],"category_scores_gemma":[0.0018751507,0.000682618,0.003049377,0.00043057412,0.0010156971,0.0013863808,0.0004177307,0.0035194897,0.00091845606],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97644037,0.001893479,0.0004973907,0.0005987034,0.0013948716,0.000028060796,0.0000545056,0.00043393593,0.0011213492,0.000062548395,0.00053828297,0.016936406],"study_design_scores_gemma":[0.9247552,0.06950711,0.0030120597,0.000055591947,0.0011346339,0.000048273334,0.000029364488,0.00044263326,0.0002857479,0.00015856257,0.0005450921,0.00002576528],"about_ca_topic_score_codex":0.0012110561,"about_ca_topic_score_gemma":0.003032632,"teacher_disagreement_score":0.0041656387,"about_ca_system_score_codex":0.00084695214,"about_ca_system_score_gemma":0.000701279,"threshold_uncertainty_score":0.013935506},"labels":[],"label_agreement":null},{"id":"W2984712394","doi":"10.1016/s1470-2045(19)30688-6","title":"Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":352,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Spinal Cord Injury BC; Kelowna General Hospital","funders":"","keywords":"Enzalutamide; Abiraterone acetate; Prostate cancer; Medicine; Prednisone; Open label; Oncology; Internal medicine; Abiraterone; Randomized controlled trial; Crossover study; Docetaxel; Cancer; Androgen deprivation therapy; Placebo; Androgen receptor; Pathology","score_opus":0.12050590991124985,"score_gpt":0.4350927641428153,"score_spread":0.3145868542315654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2984712394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898157,0.003940713,0.0009792644,0.0005337127,0.0006981921,0.001990191,0.00045687184,0.00015073939,0.0014345618],"genre_scores_gemma":[0.991276,0.0019140051,0.0016894338,0.00057407015,0.00036284822,0.0019368837,0.00041450546,0.000035871788,0.0017964483],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988152,0.0006589665,0.00007059649,0.00022763979,0.000076975506,0.00015068961],"domain_scores_gemma":[0.9986369,0.00046570046,0.0002789284,0.00012078377,0.00006922079,0.00042846895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021519053,0.0026468188,0.0040013823,0.0005902,0.00045136717,0.0014595016,0.0009810934,0.0017672689,0.0067112115],"category_scores_gemma":[0.0026802528,0.0011083442,0.0019511925,0.00049862737,0.0018055178,0.0017481836,0.00059421454,0.0038784733,0.0011797936],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9886137,0.0025254306,0.00013885809,0.00020877078,0.0004987487,0.000010907315,0.000041565832,0.00042234035,0.0006984394,0.00006650492,0.00019706975,0.006577728],"study_design_scores_gemma":[0.9604628,0.037827283,0.0005112762,0.000021708887,0.0002525234,0.000014949027,0.000015522783,0.00038425284,0.00010895939,0.0001857445,0.00020038386,0.0000145061695],"about_ca_topic_score_codex":0.0016632599,"about_ca_topic_score_gemma":0.0025253524,"teacher_disagreement_score":0.0067112115,"about_ca_system_score_codex":0.0011119784,"about_ca_system_score_gemma":0.0014045835,"threshold_uncertainty_score":0.022451222},"labels":[],"label_agreement":null},{"id":"W2989816903","doi":"10.1016/s1470-2045(19)30736-3","title":"The incomplete story of complete mesocolic excision","year":2019,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Mesorectum; Total mesorectal excision; Colorectal cancer; Lymph node; Surgery; Population; Cancer; Wide local excision; General surgery; Internal medicine","score_opus":0.11227423577646004,"score_gpt":0.36813596403465226,"score_spread":0.2558617282581922,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989816903","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00034645724,0.0029190113,0.00003568454,0.9807428,0.013447789,0.0000029107703,0.000025331825,0.0000042007246,0.0024758114],"genre_scores_gemma":[0.0066729398,0.0032065946,0.000096228476,0.93089956,0.05312601,0.000014611668,0.000023723776,0.00002002175,0.005940316],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968148,0.001346004,0.00025715577,0.00033236534,0.0007337223,0.00051588996],"domain_scores_gemma":[0.9896744,0.006934705,0.00060781196,0.00030183085,0.00091953407,0.0015616716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004176895,0.00060856354,0.0010301273,0.0006550414,0.0039921566,0.0044574146,0.0011416967,0.050352495,0.005591669],"category_scores_gemma":[0.029698672,0.00077906274,0.0008444263,0.00071246707,0.0043867556,0.004888156,0.0022240502,0.049595516,0.0031874944],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012575823,0.000022247577,0.0006428486,0.0000848093,0.000026285974,0.003836719,0.00025932712,0.000099921184,0.000172285,0.00885876,0.9749434,0.010927618],"study_design_scores_gemma":[0.00012806071,0.0000693014,0.0011595873,0.0006670272,0.00004010819,0.00366731,0.0006868103,0.000318037,0.00017263956,0.020430561,0.9725778,0.00008268427],"about_ca_topic_score_codex":0.008137565,"about_ca_topic_score_gemma":0.015963428,"teacher_disagreement_score":0.050352495,"about_ca_system_score_codex":0.006292615,"about_ca_system_score_gemma":0.0046190815,"threshold_uncertainty_score":0.045656323},"labels":[],"label_agreement":null},{"id":"W2989894179","doi":"10.1016/s1470-2045(19)30684-9","title":"Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":644,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Prostate Cancer UK; Public Health Agency; Division of Research, Evaluation, and Communication; Prostate Cancer Foundation; Movember Foundation; AstraZeneca; Medical Research Council; Institute of Cancer Research; Cancer Research UK; Royal Marsden NHS Foundation Trust; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; U.S. Department of Veterans Affairs","keywords":"Olaparib; Medicine; Prostate cancer; Open label; Oncology; Internal medicine; Urology; Cancer; Randomized controlled trial; Gene; Biology; Poly ADP ribose polymerase; Genetics","score_opus":0.06985848620486315,"score_gpt":0.3983035503391584,"score_spread":0.3284450641342952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989894179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832085,0.0056051207,0.0006719131,0.0009921258,0.0005001617,0.0057345326,0.001514823,0.00013942791,0.0016333975],"genre_scores_gemma":[0.9812966,0.0034077424,0.0020060318,0.0015043941,0.00063397514,0.00696894,0.0015512452,0.000029537572,0.0026014827],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9992126,0.00048719303,0.00003331491,0.00010598367,0.000054771437,0.00010597215],"domain_scores_gemma":[0.999079,0.00021701268,0.00021937129,0.000067900204,0.000054098327,0.0003626388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002433076,0.0019357365,0.0023306513,0.000448206,0.00039382104,0.0013365237,0.0009130043,0.0018516955,0.005822424],"category_scores_gemma":[0.0018584046,0.00064249075,0.0013827546,0.00053748663,0.0008918139,0.0011488458,0.00054364686,0.0025127658,0.00080924947],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9717975,0.0050552343,0.00071920076,0.00079027785,0.000506382,0.00010115796,0.00006477086,0.00042253896,0.0034944576,0.00010727312,0.0010200075,0.015921228],"study_design_scores_gemma":[0.9483895,0.049443208,0.0009809063,0.000021902108,0.00012927612,0.000069349655,0.000011378951,0.00020933774,0.00017202273,0.00009408886,0.00046814882,0.000010929149],"about_ca_topic_score_codex":0.0005856806,"about_ca_topic_score_gemma":0.0011956857,"teacher_disagreement_score":0.005822424,"about_ca_system_score_codex":0.0006454837,"about_ca_system_score_gemma":0.0012698342,"threshold_uncertainty_score":0.019477963},"labels":[],"label_agreement":null},{"id":"W2990013460","doi":"10.1016/s1470-2045(19)30744-2","title":"Multiplicity in oncology randomised controlled trials: a threat to medical evidence?","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Health and Medical Research Impacts","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Laura and John Arnold Foundation","keywords":"Observational study; Medicine; Randomized controlled trial; Clinical trial; Alternative medicine; Confounding; Evidence-based medicine; MEDLINE; Grading (engineering); Family medicine; Internal medicine; Pathology","score_opus":0.4347278422398513,"score_gpt":0.5693328463959209,"score_spread":0.13460500415606957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990013460","genre_codex":"review","genre_gemma":"empirical","domain_codex":"methods","domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"methods","domain_consensus":"methods","prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00495954,0.51542294,0.059365038,0.3465483,0.05900351,0.001860301,0.0011927052,0.0006827667,0.010964935],"genre_scores_gemma":[0.24070965,0.11299622,0.1810877,0.33286205,0.11818528,0.0077794474,0.001191491,0.0010440036,0.004144198],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.14463392,0.68649685,0.082428254,0.028327426,0.055201847,0.0029116722],"domain_scores_gemma":[0.020758487,0.92398655,0.021386806,0.022851737,0.008625286,0.002391222],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.7271052,0.0045601553,0.037845552,0.011979416,0.006156845,0.021225061,0.014384424,0.030693147,0.019829545],"category_scores_gemma":[0.8878962,0.0070507475,0.021464758,0.015126032,0.03830694,0.041500855,0.016184792,0.044379935,0.0035984635],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035812806,0.0005539059,0.0142419925,0.106824815,0.08570408,0.0010950537,0.004688076,0.0038807627,0.0011180168,0.25211987,0.11934483,0.37461576],"study_design_scores_gemma":[0.025288323,0.0033255524,0.007697693,0.04824817,0.02648208,0.001671273,0.0010875191,0.0061235228,0.00061055686,0.7286877,0.1498736,0.00090388017],"about_ca_topic_score_codex":0.0073322235,"about_ca_topic_score_gemma":0.011718998,"teacher_disagreement_score":0.2728948,"about_ca_system_score_codex":0.016570332,"about_ca_system_score_gemma":0.020199612,"threshold_uncertainty_score":0.33652794},"labels":[],"label_agreement":null},{"id":"W2990422537","doi":"10.1016/s1470-2045(19)30656-4","title":"Prognostic value of patient-reported outcomes from international randomised clinical trials on cancer: a systematic review","year":2019,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Rigour; Medicine; Systematic review; Clinical trial; Quality of life (healthcare); MEDLINE; Intensive care medicine; Internal medicine","score_opus":0.32166189865803924,"score_gpt":0.5304250247647438,"score_spread":0.2087631261067046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990422537","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035810352,0.994395,0.00043272052,0.00025743686,0.00025759454,0.00029314595,0.00052890717,0.000020489755,0.00023355702],"genre_scores_gemma":[0.17955674,0.81409365,0.002021459,0.0017096531,0.00042186186,0.0010351056,0.00086721726,0.000042734784,0.00025162948],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9702889,0.014818563,0.008915085,0.002410236,0.0029908137,0.00057642977],"domain_scores_gemma":[0.88269556,0.09739176,0.014818994,0.002184762,0.0022059379,0.0007029342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.025006713,0.0020426665,0.01629458,0.004005116,0.00044742442,0.0037243885,0.002551825,0.0029653048,0.00474014],"category_scores_gemma":[0.120621726,0.0015087452,0.016596828,0.005179219,0.0017064633,0.0031787206,0.0025583252,0.0038650853,0.00036851395],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037510314,0.000029360293,0.0044442,0.6805206,0.2851121,0.0000793454,0.00015508934,0.00038201307,0.00016024178,0.00039689697,0.0014313657,0.023537772],"study_design_scores_gemma":[0.0056595565,0.000491943,0.010449088,0.13899636,0.836546,0.00018785628,0.0001763276,0.00030627308,0.00016378569,0.0012284308,0.005706026,0.00008836915],"about_ca_topic_score_codex":0.0037962077,"about_ca_topic_score_gemma":0.009550531,"teacher_disagreement_score":0.025006713,"about_ca_system_score_codex":0.0030275038,"about_ca_system_score_gemma":0.004513997,"threshold_uncertainty_score":0.13224971},"labels":[],"label_agreement":null},{"id":"W2990762362","doi":"10.1016/s1470-2045(19)30750-8","title":"2019 international clinical practice guidelines for the treatment of venous thromboembolism – Authors' reply","year":2019,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McMaster University","funders":"","keywords":"Medicine; Venous thromboembolism; Thrombosis; Intensive care medicine; Clinical Practice; Venous thrombosis; Cancer; Low molecular weight heparin; Fondaparinux; Internal medicine; Family medicine","score_opus":0.21854719688498989,"score_gpt":0.497356358120722,"score_spread":0.2788091612357321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990762362","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000059419537,0.00077827496,0.00005153226,0.96612877,0.031970117,0.000006944135,0.00007463968,0.00001553224,0.00091479946],"genre_scores_gemma":[0.0009428225,0.0005380741,0.00012392995,0.9542807,0.04120329,0.00003661738,0.00004578697,0.000021782527,0.0028071213],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9908296,0.0029005723,0.0015763582,0.0008523033,0.0025965823,0.0012445594],"domain_scores_gemma":[0.9633283,0.020535631,0.0037785936,0.0009384768,0.0070347046,0.0043842844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006491771,0.0010488484,0.0025066398,0.0020283512,0.0037974163,0.0069327136,0.0023885975,0.08661522,0.0108859055],"category_scores_gemma":[0.058978267,0.0012922586,0.0018338532,0.0016869484,0.0046774847,0.0042598424,0.0027327088,0.05590698,0.013688037],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003183645,0.000012891876,0.00019269288,0.000051820065,0.000010850594,0.00022473873,0.00007100614,0.000024714507,0.000037854057,0.0008527595,0.99589044,0.0025984491],"study_design_scores_gemma":[0.00016168896,0.00004068624,0.0009780396,0.0006925211,0.00005468195,0.00057757495,0.00034538738,0.0002849301,0.00016808872,0.005772666,0.99081707,0.0001067954],"about_ca_topic_score_codex":0.008800097,"about_ca_topic_score_gemma":0.012832414,"teacher_disagreement_score":0.08661522,"about_ca_system_score_codex":0.006836632,"about_ca_system_score_gemma":0.0077916826,"threshold_uncertainty_score":0.04960352},"labels":[],"label_agreement":null},{"id":"W2990772450","doi":"10.1016/s1470-2045(19)30673-4","title":"Sebaceous carcinoma: evidence-based clinical practice guidelines","year":2019,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":205,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute","keywords":"Medicine; Radiation therapy; Sebaceous carcinoma; Carcinoma; Biopsy; Lymph node; Eyelid; Physical examination; Dermatology; Medical diagnosis; Surgery; Radiology; Pathology","score_opus":0.6629900588417426,"score_gpt":0.6042140844306624,"score_spread":0.05877597441108018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990772450","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000092173126,0.99332905,0.0005651875,0.0036239605,0.0010570997,0.0003211916,0.0003862532,0.000037353777,0.0005878043],"genre_scores_gemma":[0.0024460438,0.9845499,0.006067755,0.004696191,0.00061778055,0.0005941724,0.00047615505,0.000022993896,0.00052911235],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.98176515,0.0056822044,0.008240114,0.0012050117,0.0027164489,0.00039113226],"domain_scores_gemma":[0.9423615,0.040240657,0.009171198,0.000917994,0.006322414,0.0009863264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.022325072,0.0026817955,0.0129767675,0.010409052,0.0011575845,0.006228841,0.0067551564,0.0059572584,0.010541782],"category_scores_gemma":[0.06494641,0.0017667338,0.011060388,0.008645776,0.0018956115,0.0039587263,0.0035119955,0.005688372,0.0022663968],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005948018,0.00007492843,0.0005324705,0.6479021,0.007371343,0.00016707898,0.00019282516,0.00070377294,0.0004091991,0.002541462,0.058823153,0.2806869],"study_design_scores_gemma":[0.0010890089,0.00013936176,0.0015809229,0.7834273,0.024594681,0.000283409,0.00021609754,0.00033614525,0.00029562847,0.005825916,0.18210869,0.00010290317],"about_ca_topic_score_codex":0.016355725,"about_ca_topic_score_gemma":0.03155177,"teacher_disagreement_score":0.022325072,"about_ca_system_score_codex":0.006666553,"about_ca_system_score_gemma":0.018629907,"threshold_uncertainty_score":0.11806768},"labels":[],"label_agreement":null},{"id":"W2990849834","doi":"10.1016/s1470-2045(19)30693-x","title":"Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1–2 study","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":169,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"School of Medicine, Stanford University; Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino; Penn State Health Children's Hospital; F. Hoffmann-La Roche; Pfizer","keywords":"Atezolizumab; Medicine; Adverse effect; Internal medicine; Clinical trial; Population; Phases of clinical research; Lymphoma; Clinical endpoint; Incidence (geometry); Surgery; Pediatrics; Cancer; Immunotherapy","score_opus":0.012094129770249843,"score_gpt":0.3121682710117557,"score_spread":0.3000741412415059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990849834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951199,0.0032981555,0.000080569116,0.00017811466,0.00006856527,0.00034681705,0.0005461927,0.0000071202794,0.00035458052],"genre_scores_gemma":[0.99257445,0.002830928,0.0005533153,0.0008369022,0.0001852381,0.0007265902,0.0015272498,0.000008924125,0.0007563024],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994271,0.00026474486,0.00004312232,0.000103732054,0.0000502061,0.00011122809],"domain_scores_gemma":[0.9988016,0.00025633624,0.00038102182,0.00008510495,0.000064849475,0.00041100863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018396159,0.0010291752,0.0016927836,0.00021848046,0.0003454267,0.0008403675,0.00055977545,0.0010382546,0.0014243326],"category_scores_gemma":[0.0018327405,0.000533145,0.0018502797,0.0004090881,0.00074567535,0.0007447781,0.00057030754,0.0017585208,0.000270241],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7445364,0.01630235,0.15122364,0.0021509032,0.009757082,0.0007248293,0.00064232456,0.00073826645,0.0077482085,0.00025815197,0.0034099142,0.06250799],"study_design_scores_gemma":[0.5882654,0.15428947,0.24507792,0.00017038132,0.0051788087,0.0008584514,0.0003347152,0.00036066736,0.0007629075,0.000150468,0.0044940603,0.000056777335],"about_ca_topic_score_codex":0.0014092106,"about_ca_topic_score_gemma":0.003938674,"teacher_disagreement_score":0.0018396159,"about_ca_system_score_codex":0.00075175863,"about_ca_system_score_gemma":0.0009846461,"threshold_uncertainty_score":0.009728968},"labels":[],"label_agreement":null},{"id":"W2992921938","doi":"10.1016/s1470-2045(19)30671-0","title":"Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":343,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Merck Sharp and Dohme; Merck","keywords":"Medicine; Pembrolizumab; Tolerability; Interim analysis; Refractory (planetary science); Internal medicine; Oncology; Cohort; Response Evaluation Criteria in Solid Tumors; Adverse effect; Clinical trial; Phases of clinical research; Cancer; Surgery; Immunotherapy","score_opus":0.0939061329066039,"score_gpt":0.4336228266562593,"score_spread":0.3397166937496554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2992921938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98641413,0.007891785,0.0006269087,0.0009931063,0.0001879722,0.00074680813,0.0013039074,0.000051382314,0.001784002],"genre_scores_gemma":[0.98465836,0.0057893763,0.0025152005,0.0014381605,0.00018133032,0.0012878384,0.0027123513,0.000025906746,0.0013914008],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99916923,0.00049330527,0.00004758976,0.00011121477,0.000053498396,0.00012510654],"domain_scores_gemma":[0.9988686,0.0002948194,0.00036347294,0.00010731286,0.00005139959,0.00031444684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028783605,0.00090865366,0.0018389323,0.00022006707,0.00031159195,0.0009808214,0.00064505235,0.00096778135,0.0022698],"category_scores_gemma":[0.0020193271,0.00037592152,0.0019114008,0.0003524594,0.0006984283,0.0010826719,0.00046848189,0.003680033,0.00050041627],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.800874,0.010795554,0.011926511,0.0014851909,0.0048534316,0.0004983143,0.00033632797,0.0032487698,0.010619214,0.00068395934,0.0054764803,0.14920235],"study_design_scores_gemma":[0.75146013,0.19588381,0.033955507,0.000318246,0.002509187,0.0008766676,0.00014239928,0.0014279938,0.0038999382,0.0006741689,0.008799914,0.000052108237],"about_ca_topic_score_codex":0.00084194005,"about_ca_topic_score_gemma":0.002530241,"teacher_disagreement_score":0.0028783605,"about_ca_system_score_codex":0.0009996869,"about_ca_system_score_gemma":0.0017380095,"threshold_uncertainty_score":0.015222371},"labels":[],"label_agreement":null},{"id":"W2995934717","doi":"10.1016/s1470-2045(19)30788-0","title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":796,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"UCLH Biomedical Research Centre; National Institute for Health and Care Research; Seattle Genetics; GlaxoSmithKline; U.S. Department of Veterans Affairs","keywords":"Medicine; Internal medicine; Refractory (planetary science); Population; Multiple myeloma; Discontinuation; Toxicity; Phases of clinical research; Gastroenterology; Oncology; Surgery","score_opus":0.13348396835885917,"score_gpt":0.452415809330682,"score_spread":0.3189318409718228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995934717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98787874,0.00406339,0.00097006327,0.0009456806,0.0005690603,0.0025129355,0.0010757117,0.00018390833,0.0018004997],"genre_scores_gemma":[0.9764891,0.0042107874,0.0032013976,0.001702612,0.00053111924,0.005516571,0.0016890416,0.00006607998,0.0065931054],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9992618,0.0003848498,0.000030209712,0.0001174856,0.00006294978,0.00014274802],"domain_scores_gemma":[0.9993443,0.00018862436,0.00012010097,0.000077763034,0.000034520668,0.0002346971],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023445394,0.0021663515,0.0035009123,0.0005138098,0.00039508147,0.0012861082,0.001241801,0.002006968,0.00758782],"category_scores_gemma":[0.0014765209,0.0009757181,0.0021262174,0.00038486402,0.0013619115,0.001905129,0.00061791996,0.0034974506,0.0016192448],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9611711,0.010676241,0.0003975401,0.0006136991,0.0008162075,0.00004371824,0.00006628364,0.00048592873,0.004158867,0.00023261878,0.0010032556,0.020334648],"study_design_scores_gemma":[0.944246,0.053388473,0.00072160066,0.000016418831,0.00020681226,0.000039188675,0.000017980938,0.00030552162,0.0002520701,0.0001775332,0.0006126759,0.000015834245],"about_ca_topic_score_codex":0.0008629506,"about_ca_topic_score_gemma":0.001635019,"teacher_disagreement_score":0.00758782,"about_ca_system_score_codex":0.0010055887,"about_ca_system_score_gemma":0.0010376426,"threshold_uncertainty_score":0.02538377},"labels":[],"label_agreement":null},{"id":"W2999399991","doi":"10.1016/s1470-2045(19)30738-7","title":"Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":615,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; University Health Network","funders":"EIT Health; European Research Council; Walter Ahlströmin Säätiö; KAUTE-Säätiö; Syöpäjärjestöt; Forskningsrådet om Hälsa, Arbetsliv och Välfärd; Vetenskapsrådet; Emil Aaltosen Säätiö; Orionin Tutkimussäätiö; Tekniikan Edistämissäätiö; Tampereen Yliopisto; Tampereen Teknillinen Yliopisto; Cancerfonden; Academy of Finland","keywords":"Medicine; Grading (engineering); Prostate cancer; Concordance; Prostate; Receiver operating characteristic; Population; Biopsy; Radiology; Pathology; Cancer; Internal medicine","score_opus":0.1147713191908764,"score_gpt":0.39265864242285775,"score_spread":0.27788732323198134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999399991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975715,0.000630318,0.000864116,0.00012595051,0.000018445842,0.000045630826,0.00019032619,0.000009474472,0.000544211],"genre_scores_gemma":[0.99857306,0.00028280957,0.00055427087,0.000060091617,0.00002473622,0.00002454873,0.00023576932,0.0000043330215,0.0002403094],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99600756,0.002682742,0.00016557252,0.0004482546,0.00056500244,0.00013089886],"domain_scores_gemma":[0.9831593,0.0125701325,0.0014438966,0.001345895,0.0010924845,0.0003882937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0066132657,0.0005521002,0.000541592,0.0013199162,0.0005780975,0.0013198992,0.001067857,0.0011353245,0.0013056303],"category_scores_gemma":[0.033154324,0.00039902038,0.001210238,0.0009193548,0.0011176282,0.0010117394,0.0007919831,0.0011903311,0.00032812034],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004073799,0.0020166463,0.9597245,0.00014296742,0.0016410612,0.00018157634,0.00067718764,0.0011486401,0.00056520716,0.00023841643,0.0007812071,0.028808884],"study_design_scores_gemma":[0.000369535,0.005314212,0.97869384,0.000049873164,0.0014179964,0.0012480188,0.0011535102,0.00931101,0.00049289945,0.0009229102,0.00097363634,0.000052612497],"about_ca_topic_score_codex":0.004228354,"about_ca_topic_score_gemma":0.0032793821,"teacher_disagreement_score":0.0066132657,"about_ca_system_score_codex":0.00055539445,"about_ca_system_score_gemma":0.0005127806,"threshold_uncertainty_score":0.034974754},"labels":[],"label_agreement":null},{"id":"W3003402209","doi":"10.1016/s1470-2045(19)30790-9","title":"International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium","year":2020,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":306,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada; University of British Columbia","funders":"Health Canada; Genentech; National Cancer Institute; National Institutes of Health; European Organisation for Research and Treatment of Cancer; U.S. Food and Drug Administration; National Institute for Health and Care Research; Boehringer Ingelheim","keywords":"Terminology; Medicine; Quality of life (healthcare); Missing data; Alternative medicine; Randomized controlled trial; Quality (philosophy); MEDLINE; Clinical trial; Management science; Medical physics; Family medicine; Medical education; Computer science; Nursing; Political science; Pathology; Engineering","score_opus":0.7358815487013696,"score_gpt":0.6023151836046768,"score_spread":0.13356636509669273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003402209","genre_codex":"methods","genre_gemma":"methods","domain_codex":"methods","domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":"methods","domain_consensus":"methods","prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018544123,0.2691221,0.41643068,0.059840865,0.027804242,0.1607426,0.040039238,0.0072212634,0.016944563],"genre_scores_gemma":[0.011610647,0.054822702,0.6414284,0.017523246,0.0031501949,0.24624272,0.018457647,0.0019326502,0.004831847],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.35319266,0.44026932,0.14793566,0.009949644,0.045103222,0.003549572],"domain_scores_gemma":[0.34547192,0.41781312,0.06794954,0.056875527,0.10597548,0.005914459],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.47667763,0.005685775,0.02773636,0.018743655,0.003478882,0.018692268,0.019315965,0.021658156,0.012705356],"category_scores_gemma":[0.56857127,0.0061959582,0.04772579,0.024155615,0.009845439,0.0053091627,0.008326647,0.037012704,0.010171554],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0128777465,0.00047767276,0.0028374533,0.28246185,0.031661525,0.00039717066,0.002156119,0.005333403,0.0019016162,0.05984395,0.31890306,0.2811485],"study_design_scores_gemma":[0.027175495,0.0013849413,0.0153529355,0.2697365,0.042935982,0.0009866187,0.00078188017,0.009121668,0.0037255592,0.09589168,0.53204834,0.0008583729],"about_ca_topic_score_codex":0.008746373,"about_ca_topic_score_gemma":0.009263859,"teacher_disagreement_score":0.52332234,"about_ca_system_score_codex":0.0148067195,"about_ca_system_score_gemma":0.042673804,"threshold_uncertainty_score":0.6453496},"labels":[],"label_agreement":null},{"id":"W3004211670","doi":"10.1016/s1470-2045(19)30859-9","title":"Targeting MET in EGFR resistance in non-small-cell lung cancer—ready for daily practice?","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca Schweiz; Takeda Pharmaceutical Company; Roche; Merck Sharp and Dohme; Bristol-Myers Squibb","keywords":"Afatinib; Osimertinib; Medicine; Gefitinib; Erlotinib; Lung cancer; T790M; Cancer research; Tyrosine kinase; Oncology; Resistance mutation; Internal medicine; Cancer; Epidermal growth factor receptor; Biology; Receptor; Genetics","score_opus":0.046250517288371484,"score_gpt":0.4013117916393306,"score_spread":0.35506127435095913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004211670","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012529951,0.0032617622,0.000070493545,0.98196906,0.0125066005,0.0000065875897,0.000036609534,0.00001907766,0.0020045734],"genre_scores_gemma":[0.002254993,0.00297092,0.00023821878,0.9345622,0.05433921,0.000031807365,0.00003720371,0.00001947996,0.005546015],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954319,0.0014386259,0.0005028862,0.00039756787,0.0015684336,0.0006606151],"domain_scores_gemma":[0.9873053,0.0063205753,0.00085559476,0.0003090077,0.0016805673,0.0035289025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046194457,0.0009518498,0.002003235,0.00086375925,0.0027920336,0.0053322306,0.0018546529,0.05422024,0.012086165],"category_scores_gemma":[0.023843596,0.00071846135,0.0015384605,0.0007334603,0.003434895,0.006544031,0.0024191525,0.036989603,0.008887134],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009077639,0.00004201933,0.00025196528,0.000077841105,0.000015984659,0.0005245561,0.00004603843,0.00007774304,0.00017281371,0.0031268254,0.9776285,0.017944949],"study_design_scores_gemma":[0.00027693034,0.00014402872,0.0006198817,0.0004751108,0.000035274184,0.0009123075,0.0002434887,0.0005881975,0.00014785148,0.019014979,0.9774793,0.00006260318],"about_ca_topic_score_codex":0.0045658625,"about_ca_topic_score_gemma":0.011958258,"teacher_disagreement_score":0.05422024,"about_ca_system_score_codex":0.00497519,"about_ca_system_score_gemma":0.0059214258,"threshold_uncertainty_score":0.040432215},"labels":[],"label_agreement":null},{"id":"W3004892473","doi":"10.1016/s1470-2045(20)30076-0","title":"Advancing the systemic therapy of lung cancer: quality or quantity?","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Pfizer Canada; Merck Sharp and Dohme; Bristol-Myers Squibb Canada; Roche; AstraZeneca","keywords":"Pembrolizumab; Pemetrexed; Medicine; Lung cancer; Oncology; Internal medicine; Chemotherapy; Placebo; Cancer; Immunotherapy; Pathology; Alternative medicine","score_opus":0.09466019374412431,"score_gpt":0.41580427094612077,"score_spread":0.32114407720199645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004892473","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000047108348,0.0030788379,0.000058556987,0.9875432,0.00847399,0.0000033581823,0.00002000305,0.000007765708,0.000767191],"genre_scores_gemma":[0.0012288506,0.0026771924,0.0001960624,0.94144666,0.052431382,0.000017687922,0.00001813446,0.000014862103,0.0019691952],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9851206,0.0057600103,0.0015669737,0.001097955,0.0052823466,0.0011722109],"domain_scores_gemma":[0.9369451,0.042942118,0.0033048769,0.0013024535,0.007556596,0.007948966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017086485,0.0011330276,0.003286886,0.0012764296,0.003992494,0.008539162,0.0032077986,0.073514834,0.011195929],"category_scores_gemma":[0.06868775,0.0010038945,0.0017221589,0.0013570279,0.008205133,0.01157463,0.0041413778,0.0647549,0.008938723],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000119367585,0.000049086048,0.00027013887,0.00016182917,0.000029025969,0.00028345216,0.00007349116,0.00007408896,0.00018681928,0.0085182935,0.96596974,0.024264632],"study_design_scores_gemma":[0.00032395558,0.00009932843,0.00057960936,0.0006136078,0.00004484035,0.00051858375,0.00032100873,0.0005003521,0.00016887812,0.040969092,0.9557736,0.00008721699],"about_ca_topic_score_codex":0.0065478394,"about_ca_topic_score_gemma":0.014814623,"teacher_disagreement_score":0.073514834,"about_ca_system_score_codex":0.008444845,"about_ca_system_score_gemma":0.012285084,"threshold_uncertainty_score":0.090363085},"labels":[],"label_agreement":null},{"id":"W3005292744","doi":"10.1016/s1470-2045(19)30801-0","title":"Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":213,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Hôpital Charles-Le Moyne","funders":"Merck Sharp and Dohme; Eli Lilly and Company","keywords":"Pemetrexed; Medicine; Pembrolizumab; Lung cancer; Carboplatin; Internal medicine; Placebo; Response Evaluation Criteria in Solid Tumors; Oncology; Cancer; Surgery; Progressive disease; Chemotherapy; Cisplatin; Pathology; Immunotherapy","score_opus":0.040831192833675936,"score_gpt":0.33795517121566354,"score_spread":0.2971239783819876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005292744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849556,0.009493056,0.0003841189,0.00054585456,0.0005576774,0.001477844,0.0009227821,0.000079423,0.0015835149],"genre_scores_gemma":[0.9913017,0.002942515,0.0005651652,0.00071570015,0.00039583296,0.0016645471,0.0007605075,0.00001461619,0.0016394034],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99933416,0.000342127,0.000046305053,0.00012974565,0.000044117267,0.00010350867],"domain_scores_gemma":[0.9991447,0.0002750294,0.0002638082,0.000053990858,0.000047567904,0.00021499002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016670886,0.001614727,0.0032803486,0.0003706902,0.00044737515,0.0010844789,0.0009615719,0.0021831766,0.0053325268],"category_scores_gemma":[0.0019244162,0.0006223862,0.0029582714,0.00038977436,0.0008937739,0.0011960486,0.0004322176,0.0037888847,0.0008332466],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98591125,0.0023155361,0.0005000466,0.0007566639,0.0012279595,0.000028211423,0.000033671946,0.00018046366,0.0014211072,0.00004240771,0.0004007421,0.007181965],"study_design_scores_gemma":[0.9396598,0.055030655,0.0032958977,0.00004979161,0.0009328985,0.00003168747,0.00002116642,0.00023381268,0.00028755446,0.00009577761,0.00034464194,0.000016317968],"about_ca_topic_score_codex":0.0008979715,"about_ca_topic_score_gemma":0.0016559716,"teacher_disagreement_score":0.0053325268,"about_ca_system_score_codex":0.00075435895,"about_ca_system_score_gemma":0.00065485295,"threshold_uncertainty_score":0.017839074},"labels":[],"label_agreement":null},{"id":"W3005639301","doi":"10.1016/s1470-2045(19)30800-9","title":"Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":373,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University of Toronto; Hospital for Sick Children","funders":"National Cancer Institute; National Institutes of Health; American Lebanese Syrian Associated Charities","keywords":"Medicine; Hazard ratio; Cancer; Pediatrics; Young adult; Retrospective cohort study; Common Terminology Criteria for Adverse Events; Proportional hazards model; Survivorship curve; Cohort; Population; Cohort study; Gerontology; Internal medicine; Confidence interval","score_opus":0.04938348953489941,"score_gpt":0.37836495008373433,"score_spread":0.3289814605488349,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005639301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99744344,0.00042802343,0.00006569645,0.0000536717,0.000011356648,0.000009596183,0.001829267,0.000002197052,0.00015669582],"genre_scores_gemma":[0.99687386,0.00037579806,0.00006671816,0.000036587033,0.000011191334,0.000015085704,0.0023270955,0.0000034971983,0.0002901296],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994436,0.000117370895,0.000076325116,0.0001318219,0.00008126548,0.00014956007],"domain_scores_gemma":[0.9983411,0.00018300657,0.00059866987,0.00023925303,0.000224474,0.0004135925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001099782,0.00045659178,0.0005758173,0.0011311113,0.0008131643,0.0012187446,0.0006777792,0.0006405703,0.0010852478],"category_scores_gemma":[0.0023568606,0.000659946,0.0012889096,0.0023496118,0.0003224986,0.0008271526,0.0010606243,0.0011970885,0.0002321105],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000081798134,0.000020366817,0.9990752,0.0000067986866,0.00013994539,0.00005175225,0.00010740622,0.00001635072,0.00007509893,0.0000123507425,0.00010974848,0.00030326348],"study_design_scores_gemma":[0.000005898997,0.00003942333,0.9992655,0.0000062304757,0.00007333,0.0000924216,0.00032401897,0.00003355125,0.000021195368,0.000006349121,0.00012808008,0.0000040291784],"about_ca_topic_score_codex":0.054046202,"about_ca_topic_score_gemma":0.07142584,"teacher_disagreement_score":0.054046202,"about_ca_system_score_codex":0.00062037585,"about_ca_system_score_gemma":0.00094634766,"threshold_uncertainty_score":0.10746324},"labels":[],"label_agreement":null},{"id":"W3006303699","doi":"10.1016/s1470-2045(19)30818-6","title":"Predicting acute ovarian failure in female survivors of childhood cancer: a cohort study in the Childhood Cancer Survivor Study (CCSS) and the St Jude Lifetime Cohort (SJLIFE)","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Alberta","funders":"Canadian Institutes of Health Research; National Institutes of Health; National Cancer Institute; Novo Nordisk; American Lebanese Syrian Associated Charities","keywords":"Childhood cancer; Cohort; Medicine; Ovarian cancer; Cohort study; Oncology; Cancer; Internal medicine","score_opus":0.031038659193574215,"score_gpt":0.3388556691149781,"score_spread":0.3078170099214039,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006303699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970651,0.0005288884,0.000038498645,0.000278186,0.000025824396,0.000011536022,0.0016663128,0.0000023811351,0.0003833307],"genre_scores_gemma":[0.9976144,0.0004022951,0.00007042459,0.00008269045,0.000025185393,0.000014040849,0.0013766353,0.0000026671223,0.00041157848],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996006,0.000119003926,0.00003189508,0.00008362175,0.00006449032,0.000100355865],"domain_scores_gemma":[0.9984018,0.0002503947,0.00059060246,0.00018370176,0.00017104135,0.000402438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095645705,0.000303931,0.00036265247,0.000520787,0.0004795328,0.0009207469,0.00046911265,0.00062601245,0.0014012253],"category_scores_gemma":[0.0034038366,0.00036760917,0.0008618967,0.0011788124,0.00022700612,0.0004891141,0.00070620637,0.0011091733,0.00017740327],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000072000796,0.000016107324,0.99899,0.0000037426603,0.00007166424,0.000021684098,0.00004194966,0.0000151034765,0.000055467208,0.000011391725,0.00018129642,0.0005196871],"study_design_scores_gemma":[0.000011157331,0.000032503627,0.99954623,0.000005079004,0.00003656688,0.000047993606,0.00011399768,0.000040790885,0.000015085419,0.000008940245,0.00013915251,0.0000024830733],"about_ca_topic_score_codex":0.040221553,"about_ca_topic_score_gemma":0.05790993,"teacher_disagreement_score":0.040221553,"about_ca_system_score_codex":0.00042715576,"about_ca_system_score_gemma":0.0007740655,"threshold_uncertainty_score":0.07997483},"labels":[],"label_agreement":null},{"id":"W3009369214","doi":"10.1016/s1470-2045(19)30855-1","title":"Definitive radiotherapy with image-guided adaptive brachytherapy for primary vaginal cancer","year":2020,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Merck Sharp and Dohme; European SocieTy for Radiotherapy and Oncology; Takeda Pharmaceutical Company; Roche","keywords":"Brachytherapy; Medicine; Cervical cancer; Radiation therapy; External beam radiotherapy; Radiology; Cancer; Vaginal cancer; Cervix; Internal medicine","score_opus":0.15849496485545733,"score_gpt":0.43546477191865146,"score_spread":0.27696980706319413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009369214","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000098766446,0.99928313,0.00006634427,0.00004804508,0.000057296387,0.000004447681,0.000014453923,0.000003143434,0.0004244092],"genre_scores_gemma":[0.0011998045,0.9980805,0.00012991624,0.00016189908,0.00005096023,0.0000061026117,0.000029127927,0.0000021084531,0.00033972503],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999838,0.000042806823,0.000022274935,0.00003240211,0.000051217572,0.000013235375],"domain_scores_gemma":[0.9997782,0.00015619521,0.00003259589,0.0000065985787,0.000018960018,0.0000075384587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005043201,0.00059513754,0.0015796894,0.00091699226,0.00012886328,0.00067041087,0.00091038557,0.00067075854,0.0047023497],"category_scores_gemma":[0.00087512034,0.0002777983,0.00092039513,0.0010814953,0.0003222939,0.00048752892,0.0004126437,0.001212649,0.000856766],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021983366,0.000035371275,0.00009363624,0.04808495,0.0003878504,0.000071687005,0.000034259287,0.0005340959,0.0010489522,0.0010632809,0.013164001,0.9352622],"study_design_scores_gemma":[0.0004715991,0.00066385797,0.0032867694,0.03329908,0.00257702,0.002463552,0.00011509858,0.00034332377,0.001270907,0.0024362674,0.9530023,0.00007031099],"about_ca_topic_score_codex":0.0021358938,"about_ca_topic_score_gemma":0.004283131,"teacher_disagreement_score":0.0047023497,"about_ca_system_score_codex":0.0005437723,"about_ca_system_score_gemma":0.0007552951,"threshold_uncertainty_score":0.015730977},"labels":[],"label_agreement":null},{"id":"W3009777504","doi":"10.1016/s1470-2045(20)30092-9","title":"Statistical significance and clinical evidence – Authors' reply","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Observational study; Medicine; Confounding; Bonferroni correction; Clinical trial; Randomized controlled trial; Publication bias; Alternative medicine; Medical physics; Family medicine; Meta-analysis; Internal medicine; Statistics; Pathology","score_opus":0.8081831323988989,"score_gpt":0.6434700718790197,"score_spread":0.16471306051987922,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009777504","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005348314,0.0007973914,0.000081503145,0.9720088,0.026570078,0.000011007574,0.0000597066,0.000013433209,0.0004045954],"genre_scores_gemma":[0.0005886037,0.00028430435,0.00014759295,0.96073836,0.037242655,0.000049878865,0.000017805782,0.000018671832,0.00091212953],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9616611,0.015275289,0.007046016,0.0043344502,0.009031583,0.0026515832],"domain_scores_gemma":[0.7411412,0.20696706,0.010829638,0.0061348137,0.023313561,0.011613764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03792154,0.0013995178,0.0053450987,0.0029996661,0.0061346344,0.010976704,0.004964251,0.14008594,0.009856057],"category_scores_gemma":[0.2525188,0.0028486876,0.0033061064,0.0032296835,0.012127965,0.008077652,0.0059786043,0.11830668,0.0089769615],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008273663,0.000013277814,0.0003046651,0.000102629085,0.00005045237,0.00023201518,0.000114852766,0.000046443674,0.000044809036,0.0031153257,0.992269,0.0036237147],"study_design_scores_gemma":[0.0006828669,0.0000836895,0.0013719868,0.0017043488,0.00023749264,0.0008816809,0.00052774855,0.0006639647,0.00024397469,0.04005332,0.9533082,0.00024065789],"about_ca_topic_score_codex":0.00809257,"about_ca_topic_score_gemma":0.010480399,"teacher_disagreement_score":0.14008594,"about_ca_system_score_codex":0.008425844,"about_ca_system_score_gemma":0.014783852,"threshold_uncertainty_score":0.20055062},"labels":[],"label_agreement":null},{"id":"W3009834583","doi":"10.1016/s1470-2045(20)30077-2","title":"Anti-PD-1 shows promise against advanced paediatric Hodgkin lymphoma","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Pembrolizumab; Medicine; Refractory (planetary science); Interim; Lymphoma; Clinical trial; Internal medicine; Oncology; Interim analysis; Cancer; Immunotherapy","score_opus":0.03841565935122185,"score_gpt":0.30755215407944975,"score_spread":0.26913649472822787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009834583","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00092510745,0.00735077,0.00013015485,0.9615103,0.024943938,0.000011988957,0.00008341103,0.00002830333,0.00501596],"genre_scores_gemma":[0.0130801955,0.0067496463,0.00037840172,0.9003513,0.06725063,0.00004881679,0.000091699934,0.000030525207,0.012018812],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99862874,0.0004458851,0.00015741316,0.00013355583,0.0004034857,0.00023098926],"domain_scores_gemma":[0.9957743,0.002526353,0.00029840093,0.00009225932,0.0005041463,0.00080445793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019119395,0.0005650869,0.0009964976,0.00044087096,0.0013589362,0.0022922833,0.00072864944,0.021988334,0.0055712853],"category_scores_gemma":[0.011027608,0.00041515112,0.00094199966,0.00034848796,0.0018832484,0.0019910159,0.0011015172,0.018385367,0.003598354],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018512248,0.000042512278,0.0009837949,0.0001322713,0.000029208424,0.0030492502,0.00007517261,0.00020751647,0.00041901993,0.0056129727,0.95166403,0.037599057],"study_design_scores_gemma":[0.00038283737,0.0002330354,0.0012620369,0.00032291707,0.00004487625,0.003672865,0.00011841451,0.0005210517,0.00047484122,0.012011691,0.98092455,0.000030874162],"about_ca_topic_score_codex":0.0025466562,"about_ca_topic_score_gemma":0.00565788,"teacher_disagreement_score":0.021988334,"about_ca_system_score_codex":0.0031409154,"about_ca_system_score_gemma":0.0023660834,"threshold_uncertainty_score":0.022789001},"labels":[],"label_agreement":null},{"id":"W3011900353","doi":"10.1016/s1470-2045(20)30085-1","title":"Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; McMaster University","funders":"National Health and Medical Research Council; European Organisation for Research and Treatment of Cancer; Canadian Cancer Society; KWF Kankerbestrijding; Breast Cancer Now; Susan G. Komen for the Cure","keywords":"Ductal carcinoma; Medicine; Radiation therapy; Randomized controlled trial; Quality of life (healthcare); Oncology; Adjuvant therapy; Breast cancer; In situ; Internal medicine; Cancer; Nursing","score_opus":0.03920554261291111,"score_gpt":0.32529996260174476,"score_spread":0.28609441998883367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011900353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98547655,0.008202868,0.0003330887,0.0009922276,0.0003841515,0.0012958229,0.0013541613,0.00008388567,0.0018773524],"genre_scores_gemma":[0.98717785,0.0034147345,0.0008364978,0.0015311163,0.00039542557,0.0027563868,0.0019479842,0.000025965383,0.0019140855],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988391,0.00079784053,0.000044957953,0.00010967254,0.0000704861,0.00013790879],"domain_scores_gemma":[0.9988267,0.00041178515,0.0003035442,0.00010111672,0.00005372871,0.00030314643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025536632,0.0013761728,0.0022551848,0.00037244664,0.00038497263,0.00091931364,0.0010096572,0.0017351063,0.0047274623],"category_scores_gemma":[0.0018642712,0.00040048867,0.0035523963,0.00043115203,0.0012672481,0.00088413275,0.00058232306,0.0035367664,0.00066340074],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9781764,0.002922862,0.0011503359,0.0006218331,0.0017470852,0.000023635774,0.000046185814,0.00031496756,0.0010131976,0.00008828914,0.00107566,0.012819402],"study_design_scores_gemma":[0.9138174,0.0761724,0.0073423497,0.00009114168,0.0011772697,0.00004601083,0.00003986305,0.00025671104,0.00027444324,0.00023776692,0.00052687724,0.000017893644],"about_ca_topic_score_codex":0.00161249,"about_ca_topic_score_gemma":0.0024787006,"teacher_disagreement_score":0.0047274623,"about_ca_system_score_codex":0.0010315389,"about_ca_system_score_gemma":0.00096696196,"threshold_uncertainty_score":0.0158149},"labels":[],"label_agreement":null},{"id":"W3013503990","doi":"10.1016/s1470-2045(20)30022-x","title":"Sustainable care for children with cancer: a Lancet Oncology Commission","year":2020,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":346,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Waterloo; University of Toronto; Hospital for Sick Children","funders":"National Institute for Health and Care Research; CHILDREN with CANCER UK; World Health Organization","keywords":"Psychological intervention; Referral; Medicine; Productivity; Global health; Health care; Scale (ratio); Cancer; Environmental health; Economic growth; Family medicine; Economics; Geography; Nursing","score_opus":0.09321128440859124,"score_gpt":0.43797778461338216,"score_spread":0.34476650020479094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013503990","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000053334792,0.92698133,0.00006887767,0.058349937,0.012652539,0.000016640346,0.00007367084,0.000015449714,0.001788131],"genre_scores_gemma":[0.0019514384,0.94207245,0.00038707856,0.04738286,0.0053637363,0.000073579155,0.00009969529,0.000015372896,0.002653756],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972621,0.0008252306,0.00030701957,0.00018128932,0.0010596464,0.00036463368],"domain_scores_gemma":[0.9913039,0.004488678,0.00086196995,0.0001814326,0.0017599362,0.001404077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0076500396,0.0012218347,0.002356458,0.0020824377,0.0008558644,0.0034674332,0.0013185398,0.0071242983,0.0071172663],"category_scores_gemma":[0.014591037,0.0006952215,0.0014497401,0.003364249,0.0016101527,0.0045960075,0.0042061927,0.011998823,0.0016132739],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000067872614,0.000029813484,0.000118264856,0.013459675,0.00015595977,0.00008025327,0.00018090337,0.00017109125,0.00012599654,0.014953241,0.6688169,0.30183998],"study_design_scores_gemma":[0.000053399566,0.000027601613,0.0002866141,0.015025255,0.000094836185,0.00007270975,0.000106007275,0.000021950404,0.000026068066,0.0029288188,0.98134273,0.000013961816],"about_ca_topic_score_codex":0.011195137,"about_ca_topic_score_gemma":0.02766877,"teacher_disagreement_score":0.011195137,"about_ca_system_score_codex":0.0091268355,"about_ca_system_score_gemma":0.026291044,"threshold_uncertainty_score":0.066220164},"labels":[],"label_agreement":null},{"id":"W3013709580","doi":"10.1016/s1470-2045(20)30094-2","title":"Childhood cancer care: closing equity gaps on the ground","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Scopus; Commission; Psychological intervention; Cancer; Family medicine; Health care; Population; Equity (law); MEDLINE; Nursing; Political science; Environmental health; Internal medicine; Law","score_opus":0.11966734661634615,"score_gpt":0.3994078636176031,"score_spread":0.27974051700125696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013709580","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016806168,0.0009444184,0.00001884523,0.99456066,0.0034587488,0.0000018853236,0.00001650981,0.00000368707,0.0008271663],"genre_scores_gemma":[0.0044559482,0.0015954929,0.00011759468,0.97241795,0.018588776,0.000025588917,0.000030031706,0.000015492216,0.0027531218],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99038845,0.0031743818,0.0006021988,0.00068414846,0.0027148402,0.0024359156],"domain_scores_gemma":[0.9536097,0.023371514,0.0022406771,0.00080367207,0.0036670677,0.016307367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011015623,0.00071026786,0.0016373144,0.0008906374,0.006774447,0.007814184,0.002660447,0.06370639,0.018519564],"category_scores_gemma":[0.047964808,0.0008351042,0.0015200265,0.0011563721,0.010092639,0.011628778,0.007919005,0.05894979,0.0034965568],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004348489,0.000032118962,0.000765486,0.000111873465,0.000014935252,0.0004202409,0.000454898,0.00007368936,0.00011836324,0.016024929,0.9685565,0.013383488],"study_design_scores_gemma":[0.00017638007,0.00007353352,0.002414988,0.0011464279,0.000037940532,0.0008486234,0.003105958,0.00032314076,0.0001673113,0.04135869,0.9502651,0.000081894286],"about_ca_topic_score_codex":0.023435162,"about_ca_topic_score_gemma":0.03943301,"teacher_disagreement_score":0.06370639,"about_ca_system_score_codex":0.012481028,"about_ca_system_score_gemma":0.02786545,"threshold_uncertainty_score":0.09055668},"labels":[],"label_agreement":null},{"id":"W3020482066","doi":"10.1016/s1470-2045(20)30112-1","title":"Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":261,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Eisai; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Trastuzumab; Fulvestrant; Internal medicine; Breast cancer; Oncology; Metastatic breast cancer; Cancer; Chemotherapy; Tamoxifen","score_opus":0.053427430914663586,"score_gpt":0.3829554564653619,"score_spread":0.3295280255506983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3020482066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98449314,0.0056745633,0.00051071635,0.0012279404,0.0009813972,0.0021293345,0.0013321922,0.0001567001,0.0034941041],"genre_scores_gemma":[0.9799712,0.004053375,0.0012708553,0.0014196073,0.00066438963,0.0024026884,0.0016661866,0.000043464635,0.008508307],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995666,0.00021459255,0.000019147414,0.000083943785,0.000030432157,0.00008529547],"domain_scores_gemma":[0.9994572,0.00017216807,0.00010618557,0.000047341393,0.00002858322,0.00018854115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013074751,0.0020014322,0.0025751058,0.00050000264,0.00029594556,0.001105097,0.0010245206,0.0016350299,0.009329692],"category_scores_gemma":[0.0016238163,0.00066715834,0.0018523723,0.00039195898,0.0011593717,0.0013265894,0.0005296693,0.0031887947,0.0014229029],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9797411,0.0039174072,0.0002775886,0.0004910358,0.00064792373,0.000026186875,0.000043960037,0.00034403263,0.0015982707,0.00013837132,0.00079361926,0.011980489],"study_design_scores_gemma":[0.9608486,0.03676104,0.0008255835,0.000025307298,0.00029973226,0.000025196638,0.000021554313,0.0002713848,0.00018046878,0.00018311436,0.0005461358,0.000011757721],"about_ca_topic_score_codex":0.0012709148,"about_ca_topic_score_gemma":0.0036588176,"teacher_disagreement_score":0.009329692,"about_ca_system_score_codex":0.0009588978,"about_ca_system_score_gemma":0.0008701767,"threshold_uncertainty_score":0.031210959},"labels":[],"label_agreement":null},{"id":"W3023738757","doi":"10.1016/s1470-2045(20)30061-9","title":"Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":127,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University Health Network; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Manchester Biomedical Research Centre; Clovis Oncology; Memorial Sloan-Kettering Cancer Center; Stand Up To Cancer; Entertainment Industry Foundation; V Foundation for Cancer Research; University College London; American Association for Cancer Research","keywords":"Placebo; Medicine; Oncology; Internal medicine; Ovarian carcinoma; Ovarian cancer; Cancer; Alternative medicine; Pathology","score_opus":0.04068493652222073,"score_gpt":0.3485534876066515,"score_spread":0.3078685510844308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3023738757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9291712,0.058006357,0.0009543865,0.0019263515,0.00083483075,0.0010858926,0.0029326985,0.00031345006,0.004774773],"genre_scores_gemma":[0.9796586,0.0110798,0.0009448361,0.0021314335,0.000499759,0.0007190498,0.0025389018,0.000040799856,0.0023868582],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99935704,0.00033029186,0.000040687908,0.00009829797,0.000074249394,0.00009942823],"domain_scores_gemma":[0.99898666,0.00036033598,0.00031564324,0.00008264357,0.00006246253,0.00019223822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019776584,0.0009584237,0.0021795377,0.00029337537,0.00026171005,0.0009819462,0.0007281136,0.0013081919,0.0036806085],"category_scores_gemma":[0.0022115516,0.00031679613,0.0025935143,0.00051388616,0.0006391366,0.0009019218,0.00031757753,0.0036167556,0.0006652802],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87676674,0.0021975115,0.003786667,0.0026642038,0.0076855137,0.00012269644,0.000089416324,0.000965005,0.0039240024,0.00028647706,0.0041950652,0.09731663],"study_design_scores_gemma":[0.9097472,0.062090367,0.01682545,0.00021373907,0.004136251,0.00027139572,0.000054284268,0.00080069766,0.00088083715,0.00057433825,0.004354632,0.000050742652],"about_ca_topic_score_codex":0.0008553112,"about_ca_topic_score_gemma":0.0028417122,"teacher_disagreement_score":0.0036806085,"about_ca_system_score_codex":0.0005946794,"about_ca_system_score_gemma":0.00056332943,"threshold_uncertainty_score":0.012312889},"labels":[],"label_agreement":null},{"id":"W3033009715","doi":"10.1016/s1470-2045(20)30166-2","title":"Response assessment in diffuse intrinsic pontine glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group","year":2020,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Glioma; Clinical trial; Oncology; Internal medicine; Medical physics","score_opus":0.0919955913500505,"score_gpt":0.412632248934347,"score_spread":0.3206366575842965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033009715","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001700702,0.9944073,0.00040608464,0.0035507553,0.0004635238,0.0001267664,0.00021279283,0.000022680371,0.0006400912],"genre_scores_gemma":[0.0027180172,0.9895635,0.0028014374,0.0035018101,0.00032181508,0.00030322626,0.00041077269,0.000014626214,0.0003649144],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965842,0.001365731,0.00091348874,0.00028976853,0.00069014303,0.00015676105],"domain_scores_gemma":[0.98942715,0.0069630123,0.0015945372,0.00014297402,0.0015924545,0.00027987827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0138287945,0.0011250258,0.005572194,0.0028434803,0.00034231774,0.0021842157,0.0028849603,0.0026002047,0.0033585986],"category_scores_gemma":[0.016071023,0.0005417376,0.005591404,0.0023289875,0.0006456815,0.0017440908,0.0015136567,0.0049646967,0.0011626142],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054830854,0.00006897399,0.0005076105,0.0799441,0.0013760695,0.00006587811,0.00010615769,0.0006987691,0.00039022355,0.0019053648,0.03414065,0.88024795],"study_design_scores_gemma":[0.001774382,0.00073529006,0.005257661,0.2791235,0.010714877,0.00074604346,0.00024193127,0.0009655211,0.0007359607,0.0057442454,0.6938406,0.00011996128],"about_ca_topic_score_codex":0.0060072592,"about_ca_topic_score_gemma":0.012192134,"teacher_disagreement_score":0.0138287945,"about_ca_system_score_codex":0.0036733714,"about_ca_system_score_gemma":0.006736654,"threshold_uncertainty_score":0.07313454},"labels":[],"label_agreement":null},{"id":"W3033099933","doi":"10.1016/s1470-2045(20)30081-4","title":"Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy (LACC): a secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; National Institutes of Health; Medtronic; Gateway Foundation; Roche; AstraZeneca; University of Texas MD Anderson Cancer Center; V Foundation for Cancer Research","keywords":"Medicine; Cervical cancer; Clinical endpoint; Quality of life (healthcare); Hysterectomy; Population; Surgery; Randomized controlled trial; Radical Hysterectomy; Cancer; Internal medicine","score_opus":0.1497248583454132,"score_gpt":0.4317359927658011,"score_spread":0.28201113442038794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033099933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819312,0.010053108,0.00050727656,0.0011507542,0.0007490686,0.0019904368,0.0016069947,0.000045154287,0.001966106],"genre_scores_gemma":[0.99221474,0.0017206952,0.0005676215,0.0009518708,0.00045612932,0.0020764663,0.000965611,0.000010479439,0.0010363753],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981832,0.0011860298,0.00011340403,0.00023063092,0.00009061367,0.00019600011],"domain_scores_gemma":[0.9967866,0.0013617006,0.0008615422,0.00021441185,0.00016498646,0.0006109161],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032250783,0.0015799294,0.0028239703,0.00038685088,0.00055613555,0.0014936607,0.00082527014,0.0023852298,0.005907699],"category_scores_gemma":[0.0048561315,0.00044220794,0.0044288887,0.00051543495,0.0012900401,0.0011492824,0.0006968218,0.0038048627,0.0006113485],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9877287,0.0016147178,0.0009936581,0.0006528773,0.0019464216,0.0000182068,0.00003794717,0.0001913429,0.0004700961,0.000058337315,0.0003536642,0.0059339697],"study_design_scores_gemma":[0.91299915,0.07692612,0.0063375416,0.00009948245,0.0020283496,0.000037616734,0.000050316932,0.00041066014,0.00025346986,0.00035763698,0.0004735418,0.000026158856],"about_ca_topic_score_codex":0.0011659975,"about_ca_topic_score_gemma":0.0017701397,"teacher_disagreement_score":0.005907699,"about_ca_system_score_codex":0.0012372296,"about_ca_system_score_gemma":0.0011206463,"threshold_uncertainty_score":0.019763172},"labels":[],"label_agreement":null},{"id":"W3033224838","doi":"10.1016/s1470-2045(20)30283-7","title":"Knowing your tumour?","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Pancreatic cancer; Medicine; Oncology; Internal medicine; Precision medicine; Profiling (computer programming); Overall survival; Clinical trial; Cancer; Pathology","score_opus":0.1608465594569304,"score_gpt":0.41732075858220313,"score_spread":0.2564741991252727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033224838","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013094425,0.002292971,0.000029347073,0.9697711,0.023225196,0.000007343173,0.00002103516,0.0000106712905,0.004511406],"genre_scores_gemma":[0.0014443373,0.0013247193,0.000051601102,0.95589244,0.025496982,0.000020525382,0.00002045406,0.000017559289,0.015731407],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948945,0.001134617,0.00045203776,0.00058935414,0.00161228,0.0013173441],"domain_scores_gemma":[0.98695207,0.0043489253,0.00066991034,0.00043845017,0.0014565832,0.006134082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053064334,0.001141701,0.0019042696,0.0012275536,0.010267085,0.009120305,0.0022487117,0.100011654,0.024799762],"category_scores_gemma":[0.031782947,0.0013954093,0.0016774508,0.0009823893,0.006889492,0.007674324,0.0063699293,0.073166855,0.015607373],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019564233,0.000010898122,0.0002163069,0.000033196262,0.00000850844,0.00073075533,0.000113943555,0.000018735847,0.000057774847,0.0030635966,0.99132127,0.0044055814],"study_design_scores_gemma":[0.000064055464,0.000041144645,0.00052119355,0.00040459153,0.000022515023,0.0017980663,0.0007779515,0.00009586033,0.00008622038,0.013457619,0.9826791,0.00005168161],"about_ca_topic_score_codex":0.01015383,"about_ca_topic_score_gemma":0.023508111,"teacher_disagreement_score":0.100011654,"about_ca_system_score_codex":0.0063973563,"about_ca_system_score_gemma":0.011919732,"threshold_uncertainty_score":0.08296347},"labels":[],"label_agreement":null},{"id":"W3033356285","doi":"10.1016/s1470-2045(20)30275-8","title":"Developing anti-CD19 antibody-based combinations in lymphoma","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Blinatumomab; Antibody-drug conjugate; Medicine; Lymphoma; Refractory (planetary science); Antibody; CD19; Cancer research; Internal medicine; Oncology; Immunology; Monoclonal antibody; Biology","score_opus":0.11330106448099528,"score_gpt":0.40981677696904834,"score_spread":0.2965157124880531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033356285","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009794325,0.006614527,0.000362172,0.9700721,0.015946113,0.000026514017,0.00005847156,0.00003349002,0.005907136],"genre_scores_gemma":[0.013082841,0.005288651,0.00079378544,0.9188402,0.05029854,0.00009618576,0.000058350855,0.00004105327,0.011500309],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977702,0.0008035,0.00020503704,0.00021596623,0.0007012153,0.00030417572],"domain_scores_gemma":[0.994426,0.003921155,0.00026070423,0.00009480122,0.00051408,0.00078320655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003377866,0.00069553003,0.0011423575,0.00055035716,0.001702503,0.0027871232,0.0011596747,0.027826423,0.005917399],"category_scores_gemma":[0.01220105,0.000571491,0.000985966,0.00046831023,0.0021186338,0.003507058,0.0013625952,0.021763358,0.0042324294],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003377724,0.00010775282,0.0009580989,0.0001487894,0.000039027273,0.002393538,0.00012248516,0.00032125454,0.0009814431,0.007140832,0.9348008,0.052648213],"study_design_scores_gemma":[0.0005450504,0.0002871385,0.0006794274,0.00021164333,0.000053115993,0.0020469802,0.00018737368,0.0010153465,0.000680881,0.018295586,0.975963,0.000034328525],"about_ca_topic_score_codex":0.0023297144,"about_ca_topic_score_gemma":0.0062635476,"teacher_disagreement_score":0.027826423,"about_ca_system_score_codex":0.0033023972,"about_ca_system_score_gemma":0.0020879414,"threshold_uncertainty_score":0.02396065},"labels":[],"label_agreement":null},{"id":"W3033591069","doi":"10.1016/s1470-2045(20)30064-4","title":"Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group","year":2020,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":234,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Expert opinion; Clinical trial; Oncology; Glioma; MEDLINE; Intensive care medicine; Medical physics; Pediatrics; Internal medicine","score_opus":0.09717844553045905,"score_gpt":0.41825016120089087,"score_spread":0.3210717156704318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033591069","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019471372,0.9928508,0.00055913057,0.0045961384,0.000519998,0.00017235076,0.00031379636,0.00003223861,0.0007609122],"genre_scores_gemma":[0.0030874433,0.9870073,0.0042329617,0.0038736097,0.0003140665,0.00045521013,0.0006207733,0.000019949988,0.00038863436],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9951565,0.0020054658,0.0013700218,0.00035601843,0.00090860954,0.00020334708],"domain_scores_gemma":[0.9854277,0.009484359,0.0023494596,0.00020210812,0.0021307035,0.0004056394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017607763,0.0012213605,0.005884401,0.0033704978,0.0003738824,0.0024840825,0.0031412004,0.0026743426,0.0034471995],"category_scores_gemma":[0.020437425,0.0006186878,0.006278756,0.0028193921,0.0007250575,0.0018698517,0.0018234086,0.005305432,0.0013323119],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005573687,0.00006954204,0.0006114026,0.08885476,0.0014240477,0.00006572771,0.00012558616,0.00069660123,0.00038063453,0.0019850538,0.03582098,0.8694083],"study_design_scores_gemma":[0.0015332939,0.0006520449,0.005603878,0.32464927,0.0100474,0.0007045024,0.0002509713,0.00091510674,0.0007760687,0.0055562393,0.64918745,0.00012385049],"about_ca_topic_score_codex":0.0066741486,"about_ca_topic_score_gemma":0.01287027,"teacher_disagreement_score":0.017607763,"about_ca_system_score_codex":0.004267827,"about_ca_system_score_gemma":0.008313644,"threshold_uncertainty_score":0.09311986},"labels":[],"label_agreement":null},{"id":"W3034965161","doi":"10.1016/s1470-2045(20)30314-4","title":"COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":624,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Foundation Medicine; Merck Sharp and Dohme; Bristol-Myers Squibb Canada; Grifols; PharmaMar; Otsuka Pharmaceutical; Eisai; Institut National de la Santé et de la Recherche Médicale; G1 Therapeutics; Clovis Oncology; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Takeda Pharmaceutical Company; AbbVie; Samsung; Bristol-Myers Squibb; European Respiratory Society; Merck; Spectrum Pharmaceuticals; Bayer; Gilead Sciences; Celgene; Novartis; Exelixis; Sanofi; Roche Italia; GlaxoSmithKline; Pfizer; Incyte; Stanford University; Amgen; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Lung cancer; Internal medicine; Cohort; Cancer registry; Pneumonia; Odds ratio; Population; Cancer; Comorbidity; Stage (stratigraphy)","score_opus":0.10391562650031756,"score_gpt":0.43023762820529216,"score_spread":0.3263220017049746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034965161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98604834,0.0016686658,0.0002861817,0.0004710736,0.000097018055,0.00004137503,0.009550187,0.000012159178,0.0018249949],"genre_scores_gemma":[0.9909705,0.0010044484,0.00030152453,0.00021592784,0.000090879585,0.000050200393,0.0068409336,0.000017577013,0.0005081484],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987644,0.00027837243,0.00013108828,0.00034056007,0.00017609466,0.00030948667],"domain_scores_gemma":[0.99636465,0.00041099958,0.0017336889,0.00067626836,0.00028799762,0.0005264739],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016764913,0.00047176424,0.00054125034,0.00067067577,0.0006582651,0.0020065887,0.00069896074,0.00074570096,0.0025969197],"category_scores_gemma":[0.005127362,0.0005181373,0.0011770491,0.0026878398,0.00038196624,0.0011680407,0.0015704818,0.0018067162,0.0005564767],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006133499,0.000048487957,0.99566406,0.000026483754,0.000354526,0.000076984,0.000070882175,0.000041886942,0.00013324611,0.00011893273,0.0010997183,0.001751467],"study_design_scores_gemma":[0.00015495451,0.00023379254,0.9958905,0.000055907447,0.00051135843,0.00038086445,0.0004796183,0.00016882845,0.00010198164,0.00015596325,0.001844185,0.000021948945],"about_ca_topic_score_codex":0.008112606,"about_ca_topic_score_gemma":0.010678906,"teacher_disagreement_score":0.008112606,"about_ca_system_score_codex":0.00062651804,"about_ca_system_score_gemma":0.0007064766,"threshold_uncertainty_score":0.016130805},"labels":[],"label_agreement":null},{"id":"W3035153803","doi":"10.1016/s1470-2045(20)30334-x","title":"Recommendations for head and neck surgical oncology practice in a setting of acute severe resource constraint during the COVID-19 pandemic: an international consensus","year":2020,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Rehabilitation Institute; University of Toronto; University Health Network; Institute for Work & Health; Western University","funders":"National Cancer Institute; Tata Memorial Centre; European Organisation for Research and Treatment of Cancer; National Cancer Centre of Singapore; National Institute for Health and Care Research; National Cancer Research Institute; American College of Radiology Imaging Network","keywords":"Medicine; Pandemic; Context (archaeology); Head and neck cancer; Delphi method; Surgical oncology; Health care; Coronavirus disease 2019 (COVID-19); Intensive care medicine; Radiation therapy; Oncology; Internal medicine; Disease; Infectious disease (medical specialty); Political science","score_opus":0.304603782948215,"score_gpt":0.5523475790488261,"score_spread":0.24774379610061115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035153803","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020473596,0.85525674,0.0013694719,0.1314292,0.006198724,0.00027388576,0.0006301001,0.000061624734,0.004575622],"genre_scores_gemma":[0.0025598041,0.95042413,0.0075489716,0.034586523,0.0017141837,0.00048967864,0.0005464529,0.000025240664,0.0021050381],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942392,0.0022940934,0.0013590952,0.0004557909,0.0012122387,0.00043954817],"domain_scores_gemma":[0.97991234,0.009587712,0.0019337286,0.00030336945,0.006766561,0.0014962731],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016386207,0.001417898,0.0036834546,0.0039578914,0.0012007132,0.004901783,0.005036474,0.008366734,0.012727458],"category_scores_gemma":[0.038282014,0.000879271,0.004402879,0.0029061865,0.0014034951,0.005219472,0.0043066465,0.009575937,0.0038552883],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011576867,0.00013788075,0.0007527581,0.06957991,0.0005512238,0.00019186144,0.00058639987,0.00084172556,0.0002171581,0.01160696,0.2943308,0.6210875],"study_design_scores_gemma":[0.0001779814,0.00006872313,0.0013670152,0.22618298,0.0008042132,0.00018152363,0.00094214187,0.00019732128,0.00010774209,0.0089136595,0.7609773,0.00007930241],"about_ca_topic_score_codex":0.022093197,"about_ca_topic_score_gemma":0.044512507,"teacher_disagreement_score":0.022093197,"about_ca_system_score_codex":0.005844586,"about_ca_system_score_gemma":0.041914932,"threshold_uncertainty_score":0.08665961},"labels":[],"label_agreement":null},{"id":"W3037235771","doi":"10.1016/s1470-2045(20)30340-5","title":"New approaches to cancer care in a COVID-19 world","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Dalhousie University; St. Michael's Hospital; University of Manitoba; Vancouver General Hospital; CancerCare Manitoba; McMaster University; Canadian Partnership Against Cancer","funders":"Partenariat Canadien Contre Le Cancer; Cancer Research UK; Dalhousie University; McMaster University; Royal Marsden NHS Foundation Trust; Rigshospitalet","keywords":"Scopus; Cancer; Medicine; Health care; Coronavirus disease 2019 (COVID-19); Global health; Pandemic; Population; World population; Lung cancer; Family medicine; Collateral damage; Political science; MEDLINE; Public health; Environmental health; Psychology; Disease; Oncology; Nursing; Pathology; Internal medicine","score_opus":0.45795988683759603,"score_gpt":0.4721732708355843,"score_spread":0.014213383997988271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037235771","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000080123624,0.0014180131,0.00004011417,0.98204184,0.014828762,0.0000048332845,0.00001840279,0.0000076010974,0.001560345],"genre_scores_gemma":[0.0013605094,0.0011291013,0.00012647748,0.97172886,0.022838179,0.000026287002,0.000019019453,0.000018073531,0.0027534254],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.97105646,0.00848424,0.0024999366,0.0018542905,0.009588192,0.006516889],"domain_scores_gemma":[0.9093307,0.038308956,0.004705297,0.0022938347,0.009089031,0.036272075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.024417471,0.0016500698,0.0027098581,0.0019439621,0.015012675,0.021027155,0.0046548937,0.14339523,0.037840344],"category_scores_gemma":[0.08777368,0.0020426298,0.0037323977,0.0018835901,0.0212514,0.022710063,0.018887723,0.111321025,0.011237909],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032016258,0.00003562833,0.00026060466,0.0001053384,0.000018173776,0.0004153682,0.00021032058,0.000060607625,0.00009566989,0.013110002,0.9801051,0.0055512195],"study_design_scores_gemma":[0.00010648445,0.000048865244,0.00051195855,0.00046409408,0.000024064371,0.00046121667,0.001060994,0.00018946062,0.00009117353,0.025757477,0.97120124,0.00008302149],"about_ca_topic_score_codex":0.021881599,"about_ca_topic_score_gemma":0.04470747,"teacher_disagreement_score":0.14339523,"about_ca_system_score_codex":0.01990716,"about_ca_system_score_gemma":0.042416833,"threshold_uncertainty_score":0.14443725},"labels":[],"label_agreement":null},{"id":"W3037987551","doi":"10.1016/s1470-2045(20)30335-1","title":"Moving gastrointestinal stromal tumours towards truly personalised precision therapy","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Novartis Pharmaceuticals Canada","keywords":"PDGFRA; Imatinib; Medicine; Stromal cell; Cancer research; GiST; Stromal tumor; Regorafenib; Tyrosine kinase; Tyrosine-kinase inhibitor; Oncology; Targeted therapy; Cancer; Internal medicine; Bioinformatics; Biology; Colorectal cancer; Receptor","score_opus":0.10470251152651992,"score_gpt":0.3630308298079164,"score_spread":0.25832831828139646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037987551","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014653296,0.004858284,0.00011353531,0.96579194,0.026377313,0.00000792702,0.000028542107,0.000017478484,0.0026583334],"genre_scores_gemma":[0.003527139,0.0027932066,0.00026166602,0.9115914,0.07456293,0.00003240425,0.000028028406,0.00002722491,0.0071759266],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.993555,0.0019725412,0.0005496166,0.00057279505,0.0025216676,0.0008284421],"domain_scores_gemma":[0.9815803,0.011953083,0.001087232,0.00056668086,0.0018719239,0.0029406992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0061510443,0.000917241,0.0018697325,0.00083300564,0.0034228924,0.0067237117,0.0015064906,0.07833044,0.010601933],"category_scores_gemma":[0.030751314,0.0009883186,0.001473724,0.0007485913,0.0062651564,0.006625673,0.0040278477,0.053760286,0.008555668],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000078478886,0.000022015269,0.00017582337,0.0001234485,0.000019516672,0.00088277686,0.000112608745,0.000098724515,0.00029862902,0.007781078,0.9771274,0.013279593],"study_design_scores_gemma":[0.00020558147,0.00008596825,0.00028226292,0.0002858883,0.000025019095,0.0011390101,0.0001969008,0.00036603594,0.00020262618,0.028277574,0.96889114,0.000041904495],"about_ca_topic_score_codex":0.0028062302,"about_ca_topic_score_gemma":0.0061048083,"teacher_disagreement_score":0.07833044,"about_ca_system_score_codex":0.0057173134,"about_ca_system_score_gemma":0.0049485066,"threshold_uncertainty_score":0.04148215},"labels":[],"label_agreement":null},{"id":"W3042132061","doi":"10.1016/s1470-2045(20)30326-0","title":"Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":190,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McMaster University; Juravinski Cancer Centre","funders":"Merck Sharp and Dohme; MacroGenics","keywords":"Pembrolizumab; Gastro-; Medicine; Internal medicine; Adenocarcinoma; Gastroenterology; Oncology; Cancer; Immunotherapy; Reflux; Disease","score_opus":0.07346060626970793,"score_gpt":0.3594422757535952,"score_spread":0.28598166948388726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3042132061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99027586,0.004914972,0.00023586465,0.0008851266,0.0003563998,0.0006295767,0.00056432304,0.00009554336,0.0020424274],"genre_scores_gemma":[0.98648584,0.003587814,0.0008177532,0.0016200009,0.00026916768,0.00079503725,0.0017979636,0.000027563214,0.004598836],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99973303,0.0001061108,0.00001067898,0.000058669673,0.000021092199,0.0000703932],"domain_scores_gemma":[0.99971527,0.000044146676,0.00004917015,0.000020298457,0.0000151194145,0.00015595632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011647413,0.0016150352,0.0017974329,0.00028314194,0.00028587258,0.0010157063,0.0006852716,0.0012637934,0.0038694956],"category_scores_gemma":[0.0007114025,0.00050185714,0.0017187881,0.00029396918,0.00064851384,0.001096272,0.00034213768,0.0031836305,0.00090978947],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8558791,0.013802646,0.0033224712,0.0014249599,0.00340712,0.00024761521,0.00022133601,0.0027958169,0.012740227,0.0003528631,0.006214049,0.099591784],"study_design_scores_gemma":[0.86365664,0.118499,0.010378219,0.0000739282,0.00091119745,0.00022506493,0.00007641975,0.0015026102,0.0011115584,0.0003129165,0.0032178522,0.00003458768],"about_ca_topic_score_codex":0.0013434873,"about_ca_topic_score_gemma":0.005053739,"teacher_disagreement_score":0.0038694956,"about_ca_system_score_codex":0.0009783286,"about_ca_system_score_gemma":0.00083606923,"threshold_uncertainty_score":0.012944758},"labels":[],"label_agreement":null},{"id":"W3044038392","doi":"10.1016/s1470-2045(20)30397-1","title":"Disruption of cancer care in Canada during COVID-19","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Coronavirus disease 2019 (COVID-19); Pandemic; Anxiety; Cancer; 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Medicine; Psychology; Psychiatry; Virology; Internal medicine; Disease","score_opus":0.12518384551824777,"score_gpt":0.45260582988743936,"score_spread":0.32742198436919157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3044038392","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2395901,0.01013475,0.000765696,0.6391566,0.0086810915,0.0006132512,0.018092839,0.00031704907,0.08264865],"genre_scores_gemma":[0.7635414,0.00695184,0.0010076731,0.18620834,0.0018649352,0.00032046254,0.0068893456,0.00029125236,0.032924768],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.97871083,0.0010376689,0.00065069256,0.00052755704,0.0053478815,0.013725409],"domain_scores_gemma":[0.9578569,0.0015967141,0.0030631323,0.00070051133,0.0077427328,0.029040076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060449173,0.00050535036,0.0008811418,0.0020292124,0.013092954,0.011981182,0.003542145,0.007953574,0.012862439],"category_scores_gemma":[0.022176147,0.0010618899,0.0019267804,0.005770294,0.0053596194,0.0027180535,0.011100751,0.013694217,0.0010546669],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0010894362,0.0004987553,0.18271,0.00087923324,0.0006197197,0.0020244487,0.012438735,0.0034528307,0.0009357542,0.048198186,0.68954223,0.057610653],"study_design_scores_gemma":[0.00015668217,0.00024136875,0.48252094,0.0011026614,0.00011038823,0.0003221668,0.022878317,0.0009769978,0.00042257376,0.0032174217,0.4877742,0.00027628828],"about_ca_topic_score_codex":0.98885417,"about_ca_topic_score_gemma":0.99306303,"teacher_disagreement_score":0.76237607,"about_ca_system_score_codex":0.23762392,"about_ca_system_score_gemma":0.36596477,"threshold_uncertainty_score":0.8842482},"labels":[],"label_agreement":null},{"id":"W3047018002","doi":"10.1016/s1470-2045(20)30171-6","title":"First case of osteosarcoma in a dinosaur: a multimodal diagnosis","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Ontario Museum; Royal Tyrrell Museum; University Health Network; Trent University; McMaster University","funders":"","keywords":"Osteosarcoma; Malignancy; Incidence (geometry); Limiting; Medicine; Multimodal therapy; Biology; Oncology; Pathology; Internal medicine","score_opus":0.07224953716804378,"score_gpt":0.34430150348616584,"score_spread":0.27205196631812206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047018002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8986,0.011602515,0.008867412,0.024080724,0.0024001233,0.00071970193,0.002802799,0.00053740526,0.050389245],"genre_scores_gemma":[0.9753949,0.0033146013,0.005422432,0.005373775,0.0027751124,0.00007516019,0.00055659196,0.00015197552,0.0069354554],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9989435,0.000087821296,0.00010766433,0.00029275357,0.00018218055,0.00038610166],"domain_scores_gemma":[0.9980958,0.00052793964,0.0002710948,0.00026361624,0.00015255294,0.0006890591],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047077078,0.0034287714,0.0021534467,0.0055445745,0.004971976,0.0021656035,0.0031926197,0.017951803,0.0058298954],"category_scores_gemma":[0.0044712042,0.002291522,0.0036223826,0.0027259146,0.0034463087,0.0028104447,0.0044909464,0.0052491073,0.0027370707],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046412817,0.00002443231,0.0022599255,0.00003601778,0.000007663203,0.9957073,0.00012748326,0.00008078167,0.0004332267,0.00013537172,0.00029589568,0.0008454874],"study_design_scores_gemma":[0.000011859535,0.00009607328,0.0038645342,0.000039746243,0.000023719038,0.993887,0.00026215691,0.00018328363,0.00033347856,0.00040582012,0.0008680454,0.000024212472],"about_ca_topic_score_codex":0.006860876,"about_ca_topic_score_gemma":0.0104864435,"teacher_disagreement_score":0.017951803,"about_ca_system_score_codex":0.0032673234,"about_ca_system_score_gemma":0.0014816555,"threshold_uncertainty_score":0.023706138},"labels":[],"label_agreement":null},{"id":"W3047025380","doi":"10.1016/s1470-2045(20)30219-9","title":"Hereditary diffuse gastric cancer: updated clinical practice guidelines","year":2020,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":480,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"University of California Davis School of Medicine; Instituto Superior Técnico; Beijing Genomics Institute; Fundação para a Ciência e a Tecnologia; Health Research Council of New Zealand; David Geffen School of Medicine, University of California, Los Angeles; National Institute for Health and Care Research; National Cancer Institute; Medical Research Council; DeGregorio Family Foundation; University of Otago; Roche","keywords":"Medicine; CDH1; Cancer; Genetic testing; Genetic counseling; Cancer syndrome; Germline mutation; Surgical oncology; Breast cancer; Gastrectomy; Oncology; Internal medicine; Mutation; Genetics; Gene; Biology","score_opus":0.305222821832052,"score_gpt":0.5367221859876632,"score_spread":0.23149936415561118,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047025380","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006565854,0.99377835,0.00017947557,0.0031693191,0.001389558,0.00002835067,0.00025787286,0.000027255215,0.0011041875],"genre_scores_gemma":[0.0005576684,0.99335504,0.000817608,0.003390908,0.0006941642,0.000056575962,0.00036403132,0.00000632495,0.00075766805],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988373,0.0003048747,0.0003062922,0.0001225936,0.0003452748,0.000083721265],"domain_scores_gemma":[0.99651825,0.001622809,0.000785643,0.000063864914,0.00081320637,0.00019620125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002615149,0.0012886316,0.0030807587,0.004888258,0.00032051085,0.0017050698,0.0021410915,0.0029691516,0.008646034],"category_scores_gemma":[0.0059514134,0.0005255252,0.0025597857,0.004372671,0.00050853594,0.0015008092,0.00145032,0.00276678,0.002619305],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020821321,0.00005362868,0.00040539366,0.06609845,0.00061215536,0.00016829217,0.00006215805,0.0005037172,0.0003612578,0.0022033432,0.2469605,0.6823629],"study_design_scores_gemma":[0.00035593333,0.00010478251,0.0018596577,0.082671136,0.0021870981,0.0005860513,0.00007821338,0.00018822149,0.00011593678,0.0022433249,0.90956026,0.000049404312],"about_ca_topic_score_codex":0.0067345803,"about_ca_topic_score_gemma":0.01524308,"teacher_disagreement_score":0.008646034,"about_ca_system_score_codex":0.0021847342,"about_ca_system_score_gemma":0.00427805,"threshold_uncertainty_score":0.02892387},"labels":[],"label_agreement":null},{"id":"W3048697601","doi":"10.1016/s1470-2045(20)30428-9","title":"Final results of the UK Age trial on breast cancer screening age","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Public Health Ontario; University of Toronto","funders":"","keywords":"Breast cancer; Medicine; Cancer; Oncology; Gerontology; Demography; Internal medicine; Sociology","score_opus":0.2598885890687011,"score_gpt":0.4076897206584964,"score_spread":0.1478011315897953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3048697601","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14947361,0.62988496,0.0046161655,0.07286365,0.053636394,0.012823744,0.038250886,0.0007353566,0.037715264],"genre_scores_gemma":[0.7248484,0.08849019,0.009727156,0.07709343,0.015458338,0.023493262,0.0188551,0.00057652406,0.04145769],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.97560805,0.019345473,0.0017218728,0.0008545393,0.0016185977,0.00085145904],"domain_scores_gemma":[0.98226166,0.008493795,0.004020589,0.0018500715,0.0020259193,0.0013479698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020479184,0.0011435639,0.0039110044,0.0006108071,0.00058400695,0.0024681403,0.0007655899,0.0044505107,0.014774221],"category_scores_gemma":[0.055156667,0.00048036795,0.0059054815,0.0007538337,0.0008300605,0.0028802606,0.0014973341,0.0038419121,0.0020440298],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.741742,0.00056781986,0.0021568346,0.024410766,0.016065184,0.00043047598,0.0003559461,0.00058209355,0.0011413076,0.0034147552,0.11550225,0.09363059],"study_design_scores_gemma":[0.81018275,0.023063608,0.01598001,0.017201476,0.026550416,0.00038998658,0.00027043998,0.00047412436,0.0010363511,0.00512669,0.099470176,0.0002539754],"about_ca_topic_score_codex":0.0018924241,"about_ca_topic_score_gemma":0.0045736795,"teacher_disagreement_score":0.020479184,"about_ca_system_score_codex":0.0013289883,"about_ca_system_score_gemma":0.001622909,"threshold_uncertainty_score":0.10830557},"labels":[],"label_agreement":null},{"id":"W3081315565","doi":"10.1016/s1470-2045(20)30447-2","title":"Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":321,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; AstraZeneca; Invitae; PharmaMar; Eisai; Pfizer","keywords":"Veliparib; Carboplatin; Oncology; Medicine; Placebo; Breast cancer; Internal medicine; BRCA mutation; Paclitaxel; Cancer; Chemotherapy; Biology; Genetics; Alternative medicine; Poly ADP ribose polymerase; Cisplatin; Pathology","score_opus":0.07829391178294297,"score_gpt":0.3971052690556947,"score_spread":0.3188113572727517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081315565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9618255,0.01512365,0.0014941925,0.002056065,0.0014902406,0.007901863,0.0038637759,0.00047456383,0.0057701757],"genre_scores_gemma":[0.969234,0.007888721,0.0021345546,0.0027496885,0.0006033727,0.007032774,0.002678137,0.000081961574,0.007596899],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994254,0.00026083193,0.000028712107,0.00012514972,0.00004056028,0.00011938362],"domain_scores_gemma":[0.99938416,0.00018032659,0.00013684799,0.00005780456,0.000034932447,0.00020594375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016545226,0.0019734954,0.0031971328,0.00043996584,0.0005126193,0.0014878056,0.0011837893,0.0023115668,0.009383349],"category_scores_gemma":[0.0015977891,0.00079006766,0.0025281082,0.0005803425,0.0012587779,0.0012274507,0.00048170367,0.0043141986,0.0016819502],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.985104,0.0020004744,0.00015656425,0.00061340065,0.0008735593,0.000028179535,0.000030228019,0.00025395758,0.0013582374,0.00011996816,0.0010249859,0.008436336],"study_design_scores_gemma":[0.9863434,0.012199371,0.0004156991,0.000023983526,0.00021415911,0.000018630943,0.000009815364,0.00013621262,0.00010742963,0.000106795684,0.00041541748,0.000009117639],"about_ca_topic_score_codex":0.0016588,"about_ca_topic_score_gemma":0.003452639,"teacher_disagreement_score":0.009383349,"about_ca_system_score_codex":0.0010133543,"about_ca_system_score_gemma":0.0011004017,"threshold_uncertainty_score":0.03139043},"labels":[],"label_agreement":null},{"id":"W3081850846","doi":"10.1016/s1470-2045(20)30481-2","title":"Vision 2020: looking back and thinking forward on The Lancet Oncology Commissions","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Pfizer Canada; Merck KGaA; Roche; Pfizer","keywords":"Psychology; Medical education; Medicine; Medical physics","score_opus":0.061231728302472505,"score_gpt":0.41921254910311156,"score_spread":0.3579808208006391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081850846","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014599638,0.02724583,0.0004121052,0.8965939,0.0672133,0.000015610745,0.0002529843,0.00009247397,0.008027838],"genre_scores_gemma":[0.011703881,0.030528953,0.0026273604,0.8769462,0.055972982,0.000103287224,0.00057318725,0.0002673707,0.021276664],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9659077,0.011499614,0.0016340048,0.0016073361,0.012925395,0.006425949],"domain_scores_gemma":[0.8921012,0.031247469,0.005892881,0.002215177,0.021977296,0.046565916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.041005254,0.0021648493,0.0032346514,0.0032341657,0.0050710794,0.02213225,0.0045513995,0.04559414,0.036735836],"category_scores_gemma":[0.11728644,0.0009439304,0.0024750694,0.0030378886,0.010479816,0.021425007,0.009264306,0.036309533,0.018359559],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008296378,0.00003784391,0.00010059001,0.00024380178,0.000026169275,0.000059308222,0.00011320516,0.000120825716,0.000058554455,0.037756205,0.94453967,0.016861008],"study_design_scores_gemma":[0.00008510274,0.000036231668,0.00022887156,0.0007158501,0.000020523144,0.000060657356,0.00042598633,0.00009701138,0.00006110617,0.050693016,0.94751936,0.000056311794],"about_ca_topic_score_codex":0.015696295,"about_ca_topic_score_gemma":0.023208315,"teacher_disagreement_score":0.04559414,"about_ca_system_score_codex":0.016980812,"about_ca_system_score_gemma":0.07005291,"threshold_uncertainty_score":0.2168591},"labels":[],"label_agreement":null},{"id":"W3082650529","doi":"10.1016/s1470-2045(20)30320-x","title":"Development of paediatric non-stage prognosticator guidelines for population-based cancer registries and updates to the 2014 Toronto Paediatric Cancer Stage Guidelines","year":2020,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Pediatric Oncology Group; Princess Margaret Cancer Centre; Hospital for Sick Children","funders":"Hospital for Sick Children; Great Ormond Street Hospital Charity; National Institute for Health and Care Research; World Health Organization","keywords":"Medicine; Stage (stratigraphy); Cancer; Delphi method; Incidence (geometry); Population; Family medicine; Environmental health; Internal medicine; Computer science","score_opus":0.20102718359173113,"score_gpt":0.477977122137466,"score_spread":0.2769499385457349,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3082650529","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0031567921,0.82010114,0.02719858,0.0778841,0.012043432,0.0027125918,0.029518055,0.0011169313,0.026268335],"genre_scores_gemma":[0.019328367,0.76449597,0.12758842,0.0227434,0.0024563444,0.004833802,0.047565673,0.0004859781,0.010501974],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98865753,0.0034678637,0.0038194153,0.00065854663,0.0028712254,0.0005254269],"domain_scores_gemma":[0.9599695,0.0110528525,0.006638229,0.0008455952,0.019949881,0.0015438872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02662811,0.0010278608,0.0032817584,0.007280908,0.0007141716,0.002894263,0.0044326247,0.0026012582,0.0057563535],"category_scores_gemma":[0.05875116,0.0010604489,0.004648083,0.007234048,0.00083747413,0.002720394,0.0029148187,0.0051838276,0.002306131],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011197019,0.000061079336,0.0060901004,0.02646315,0.0005420174,0.00013191224,0.0005256172,0.001253397,0.0002933738,0.011065822,0.40918273,0.5442788],"study_design_scores_gemma":[0.00021729215,0.000074294,0.016108453,0.08636146,0.0012602698,0.00035650271,0.00039570505,0.0007146297,0.0004337595,0.0032279277,0.89074206,0.00010761585],"about_ca_topic_score_codex":0.096968636,"about_ca_topic_score_gemma":0.14724289,"teacher_disagreement_score":0.096968636,"about_ca_system_score_codex":0.009072344,"about_ca_system_score_gemma":0.049307127,"threshold_uncertainty_score":0.19280845},"labels":[],"label_agreement":null},{"id":"W3082899459","doi":"10.1016/s1470-2045(20)30443-5","title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":327,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"F. Hoffmann-La Roche; AbbVie","keywords":"Obinutuzumab; Chlorambucil; Venetoclax; Medicine; Internal medicine; Oncology; Chronic lymphocytic leukemia; Fludarabine; Open label; Clinical trial; Chemotherapy; Leukemia; Cyclophosphamide","score_opus":0.22414891033952375,"score_gpt":0.4279868705273332,"score_spread":0.20383796018780945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3082899459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842519,0.010400426,0.00046704093,0.0006932714,0.00064183725,0.000953879,0.0008021313,0.00010674215,0.0016827341],"genre_scores_gemma":[0.98778206,0.0040917653,0.00097641494,0.00088072364,0.00035300798,0.0010794984,0.001079184,0.000029802624,0.00372745],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99936086,0.000347679,0.000023639528,0.00009422802,0.000038106467,0.00013552539],"domain_scores_gemma":[0.9989544,0.00037604084,0.00022403922,0.00007618161,0.000042743544,0.0003266386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00148085,0.0015325191,0.0026628852,0.00038665844,0.00041527796,0.001413886,0.0009794747,0.0015583236,0.0054093907],"category_scores_gemma":[0.0019879444,0.00045347936,0.0022626035,0.0004651858,0.0011175371,0.0012047763,0.0004278537,0.0035058449,0.0009871573],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9727518,0.0023076457,0.0004513965,0.00054097775,0.0009708174,0.000039215218,0.000065446555,0.00034612275,0.0016155922,0.000119804965,0.00071764766,0.020073486],"study_design_scores_gemma":[0.9533328,0.043032784,0.0017725019,0.000058476915,0.00044922714,0.00004312171,0.000032299875,0.00024980662,0.00022105734,0.00019034903,0.00060298864,0.000014555971],"about_ca_topic_score_codex":0.0018194952,"about_ca_topic_score_gemma":0.004128269,"teacher_disagreement_score":0.0054093907,"about_ca_system_score_codex":0.0010289826,"about_ca_system_score_gemma":0.00094699906,"threshold_uncertainty_score":0.018096209},"labels":[],"label_agreement":null},{"id":"W3083986479","doi":"10.1016/s1470-2045(20)30445-9","title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2492,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Response Evaluation Criteria in Solid Tumors; Oncology; Cohort; Mesothelioma; Biomarker; Clinical endpoint; Prospective cohort study; Cancer; Progressive disease; Disease; Immunotherapy; Pathology; Clinical trial","score_opus":0.03122114611269687,"score_gpt":0.3549706413578277,"score_spread":0.3237494952451308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083986479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980667,0.0008749082,0.00010601469,0.000060188446,0.0000131171155,0.00002589774,0.00063668046,0.0000056976655,0.00021085065],"genre_scores_gemma":[0.99831957,0.0002194005,0.00014025866,0.00007901016,0.000032780972,0.000038254693,0.0009819688,0.0000043259142,0.00018442597],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9992494,0.00033950584,0.00004875937,0.0002002903,0.0000804466,0.00008168501],"domain_scores_gemma":[0.99792564,0.0005268918,0.00092838705,0.00026513287,0.00011976224,0.00023410682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020446621,0.0005779573,0.00088049506,0.00029995845,0.0002637473,0.0009462599,0.0004744206,0.0007805817,0.0010385326],"category_scores_gemma":[0.002396993,0.0003890384,0.0012084956,0.00054140156,0.00032742004,0.0009004441,0.00054839504,0.0011146065,0.00020968808],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1576905,0.0012843711,0.7985094,0.00039731784,0.008238673,0.00015577557,0.00016108563,0.0012270367,0.0085618505,0.0001818771,0.001443428,0.022148706],"study_design_scores_gemma":[0.0077413516,0.010457868,0.97495914,0.00004000811,0.0031516587,0.00029584215,0.000098756034,0.0012074533,0.00073444314,0.00030598458,0.00096990616,0.00003763095],"about_ca_topic_score_codex":0.0004088657,"about_ca_topic_score_gemma":0.0006477624,"teacher_disagreement_score":0.0020446621,"about_ca_system_score_codex":0.00033028336,"about_ca_system_score_gemma":0.00026024572,"threshold_uncertainty_score":0.010813355},"labels":[],"label_agreement":null},{"id":"W3086258129","doi":"10.1016/s1470-2045(20)30446-0","title":"Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":482,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Institut Claudius Regaud; Radboud Universitair Medisch Centrum; Universitair Medisch Centrum Groningen; European Organisation for Research and Treatment of Cancer; Leids Universitair Medisch Centrum; Royal Marsden NHS Foundation Trust; European Commission; Herlev Hospital; Radboud Universiteit; Universiteit Leiden","keywords":"Medicine; Radiation therapy; Clinical endpoint; Surgery; Randomized controlled trial; Sarcoma","score_opus":0.12377641344454836,"score_gpt":0.3730701604643574,"score_spread":0.24929374701980905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3086258129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9792768,0.0086575365,0.0010456032,0.0017673494,0.0014572369,0.00285152,0.0017258682,0.0001991069,0.0030190405],"genre_scores_gemma":[0.98196435,0.003964754,0.0016933479,0.0018696272,0.0005348039,0.003013326,0.001346832,0.000044314234,0.0055686063],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993864,0.0003635553,0.00002839317,0.00010120426,0.00003256799,0.00008796452],"domain_scores_gemma":[0.99922144,0.0002834878,0.00017939114,0.00005555985,0.00003064382,0.00022944827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015533756,0.0022473573,0.0028015638,0.00041235192,0.00038299797,0.0011192567,0.00086994754,0.0019948103,0.010633452],"category_scores_gemma":[0.0017530217,0.0007041741,0.0032468415,0.00046228088,0.0013100116,0.0012957101,0.0005833366,0.0040280446,0.0016002975],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9829259,0.002183113,0.0002750297,0.0007318426,0.0010532138,0.000019729092,0.000045925357,0.00038829373,0.0009159158,0.00011589362,0.000846809,0.010498393],"study_design_scores_gemma":[0.9488545,0.04839016,0.0010028194,0.000055496603,0.0005161388,0.000024687984,0.000031850122,0.000292193,0.00011896035,0.00023848054,0.00045837785,0.000016343567],"about_ca_topic_score_codex":0.0015509349,"about_ca_topic_score_gemma":0.0041331025,"teacher_disagreement_score":0.010633452,"about_ca_system_score_codex":0.00085225806,"about_ca_system_score_gemma":0.0009355445,"threshold_uncertainty_score":0.03557241},"labels":[],"label_agreement":null},{"id":"W3087466624","doi":"10.1016/s1470-2045(20)30541-6","title":"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":498,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; McMaster University; Université Laval; Hamilton Health Sciences; Juravinski Cancer Centre","funders":"Foundation Medicine; EMD Serono; Pharmacyclics; Genentech; AstraZeneca; EUSA Pharma; Astellas Pharma; Eisai; INOVIO Pharmaceuticals; AstraZeneca España; Pfizer; Incyte; Ipsen; Clovis Oncology; Les Laboratories Pierre Fabre; Endocyte; Sanofi; Exelixis; GlaxoSmithKline; Celldex Therapeutics; Amgen; Celgene; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Durvalumab; Medicine; Tremelimumab; Chemotherapy; Metastatic Urothelial Carcinoma; Oncology; Open label; Internal medicine; Urology; Carcinoma; Randomized controlled trial; Urothelial carcinoma; Cancer; Immunotherapy; Bladder cancer","score_opus":0.09417910979039026,"score_gpt":0.3763797989152469,"score_spread":0.28220068912485663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087466624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99159396,0.0032444098,0.00025256432,0.00089809846,0.00043153088,0.0010147429,0.0006576888,0.000056478246,0.0018504858],"genre_scores_gemma":[0.9883909,0.0022001974,0.00079232117,0.0009934204,0.00024477538,0.0013878477,0.0009740965,0.000021259122,0.0049952655],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994072,0.0003637758,0.00001878439,0.000090632944,0.000031509153,0.00008811429],"domain_scores_gemma":[0.99925834,0.00023403324,0.0001327772,0.00004810468,0.000028756493,0.0002979978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015032857,0.0015631588,0.0025618623,0.00029606323,0.00033820732,0.0010316628,0.0010131008,0.001281164,0.006124247],"category_scores_gemma":[0.0013943086,0.00047225735,0.0015723282,0.00033684794,0.00107963,0.0011964018,0.0004974237,0.003295342,0.0008755295],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97165626,0.0048883716,0.0006650267,0.0005408808,0.0011300554,0.000056237335,0.000081339436,0.00053066056,0.0022978962,0.0001725518,0.0011141399,0.016866714],"study_design_scores_gemma":[0.9250899,0.07020089,0.0023098257,0.000038096612,0.00041867665,0.0000582049,0.000045701287,0.00049194484,0.00031426558,0.0002236947,0.0007916984,0.000016943779],"about_ca_topic_score_codex":0.0018433549,"about_ca_topic_score_gemma":0.0061384584,"teacher_disagreement_score":0.006124247,"about_ca_system_score_codex":0.0012729409,"about_ca_system_score_gemma":0.0010612352,"threshold_uncertainty_score":0.020487666},"labels":[],"label_agreement":null},{"id":"W3087697977","doi":"10.1016/s1470-2045(20)30494-0","title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":525,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Bristol-Myers Squibb","keywords":"Ipilimumab; Medicine; Nivolumab; Clinical endpoint; Internal medicine; Population; Clinical trial; Adjuvant; Stage (stratigraphy); Randomized controlled trial; Surgery; Phases of clinical research; Adverse effect; Melanoma; Cancer; Oncology; Immunotherapy","score_opus":0.11363129802389245,"score_gpt":0.3789429370514308,"score_spread":0.26531163902753835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087697977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99047405,0.0052099517,0.000414926,0.0004551739,0.00048574296,0.0008627071,0.0007038947,0.000103407525,0.0012900463],"genre_scores_gemma":[0.98878443,0.0027420155,0.0010765134,0.0008067394,0.0003634307,0.0013001544,0.0012076742,0.00003598771,0.0036831808],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99952424,0.00023379811,0.000022008704,0.000094964096,0.00003536772,0.00008955251],"domain_scores_gemma":[0.99929297,0.00022639954,0.00014775054,0.00006425858,0.00003635603,0.00023225414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016556177,0.0015662571,0.0026725268,0.00030384265,0.00032737106,0.0010473606,0.0009469119,0.001477412,0.0043531735],"category_scores_gemma":[0.0015672022,0.0005872174,0.0022637749,0.00028379486,0.0009097054,0.0010730273,0.0004190808,0.002991394,0.0009709154],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.975957,0.0027590902,0.0005229366,0.00057107833,0.00096083834,0.000027080774,0.000048691545,0.00039423775,0.0023852102,0.00006584587,0.00081633066,0.01549161],"study_design_scores_gemma":[0.94823915,0.047392882,0.0022492653,0.000045346256,0.00058330206,0.00003271549,0.000023719971,0.0004100803,0.0003519651,0.00013828068,0.0005159918,0.000017241595],"about_ca_topic_score_codex":0.0013423989,"about_ca_topic_score_gemma":0.0027862885,"teacher_disagreement_score":0.0043531735,"about_ca_system_score_codex":0.0007943745,"about_ca_system_score_gemma":0.0008331866,"threshold_uncertainty_score":0.014562786},"labels":[],"label_agreement":null},{"id":"W3089740894","doi":"10.1016/s1470-2045(20)30158-3","title":"Oncology training in Latin America: are we ready for 2040?","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Public Health Policies and Epidemiology","field":"Business, Management and Accounting","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Latin Americans; Life expectancy; Population; Social determinants of health; Poverty; Health equity; Economic growth; Political science; Medicine; Development economics; Environmental health; Health care; Economics","score_opus":0.32319437441143173,"score_gpt":0.41527400723762065,"score_spread":0.09207963282618892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089740894","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011705202,0.038031977,0.00007075862,0.9542614,0.0039166277,0.0000050314693,0.00027057788,0.000019615352,0.002253551],"genre_scores_gemma":[0.07034346,0.13125743,0.0013546275,0.76865125,0.01917732,0.00013308448,0.0012366832,0.000120486744,0.007725638],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954804,0.0014192311,0.00024772715,0.0003027319,0.0005004701,0.002049422],"domain_scores_gemma":[0.9721748,0.0062534576,0.002658163,0.0005888723,0.004574756,0.013749973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010932712,0.0008662422,0.0010542134,0.0014831454,0.0024021068,0.0078051244,0.0019796998,0.010586709,0.029167833],"category_scores_gemma":[0.02339898,0.00046643996,0.0012754829,0.002806992,0.0044489563,0.01052777,0.0065381248,0.014856368,0.0038524948],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004552833,0.0003232222,0.020828012,0.0034753524,0.00021563131,0.00030068378,0.0012271478,0.0003491231,0.000521754,0.026069012,0.72522116,0.22101359],"study_design_scores_gemma":[0.0003302615,0.00023403263,0.04113674,0.011618899,0.00024184097,0.0002301838,0.01443891,0.00022058711,0.0002498412,0.02461663,0.9065579,0.00012408795],"about_ca_topic_score_codex":0.061407942,"about_ca_topic_score_gemma":0.092391476,"teacher_disagreement_score":0.061407942,"about_ca_system_score_codex":0.014979796,"about_ca_system_score_gemma":0.050204474,"threshold_uncertainty_score":0.12210107},"labels":[],"label_agreement":null},{"id":"W3092409743","doi":"10.1016/s1470-2045(20)30451-4","title":"Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":406,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Princess Margaret Cancer Centre; Hospital for Sick Children","funders":"University of Colorado Denver","keywords":"Epithelioid sarcoma; SMARCB1; Medicine; Sarcoma; Dermatology; Oncology; Internal medicine; Pathology; Chemistry; Gene","score_opus":0.08187789777292803,"score_gpt":0.41122938910292295,"score_spread":0.3293514913299949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092409743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98167086,0.009411106,0.0011795219,0.0015371304,0.00036711208,0.00097629067,0.0015099016,0.000112025664,0.0032360952],"genre_scores_gemma":[0.9810994,0.0075494433,0.001771546,0.0017639159,0.00015263009,0.0011874704,0.002576558,0.000059554874,0.003839443],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999726,0.000083297615,0.00001167151,0.000042509135,0.00003859999,0.00009789411],"domain_scores_gemma":[0.99962056,0.000076788994,0.00008006471,0.000041539122,0.000030418216,0.00015063936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012515432,0.0010251972,0.0016843483,0.0002883251,0.00021197225,0.0012040233,0.0005398096,0.0009130712,0.0038242328],"category_scores_gemma":[0.0006562709,0.00039108263,0.0015623374,0.00037671512,0.00065484946,0.0010149572,0.00030141388,0.0030291395,0.0008109485],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5432179,0.03567513,0.010659706,0.002535548,0.0050078565,0.00036539495,0.00046732693,0.0049103447,0.060920764,0.002146804,0.01514565,0.31894752],"study_design_scores_gemma":[0.6087587,0.32700205,0.024065392,0.00026365859,0.002970703,0.0010561089,0.0003954147,0.0033829776,0.0073094484,0.002000298,0.022690903,0.000104354345],"about_ca_topic_score_codex":0.00083348044,"about_ca_topic_score_gemma":0.002998061,"teacher_disagreement_score":0.0038242328,"about_ca_system_score_codex":0.00093449146,"about_ca_system_score_gemma":0.0009418507,"threshold_uncertainty_score":0.012793362},"labels":[],"label_agreement":null},{"id":"W3092484545","doi":"10.1016/s1470-2045(20)30441-1","title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":587,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"Cilag; Takeda Pharmaceutical Company; AbbVie; National Cancer Institute; Merck Sharp and Dohme; Pharmacyclics; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer; Roche","keywords":"Open label; Medicine; Follicular lymphoma; Refractory (planetary science); Oncology; Internal medicine; Phases of clinical research; Follicular phase; Clinical trial; Lymphoma","score_opus":0.1386246272526778,"score_gpt":0.38730405804533874,"score_spread":0.24867943079266094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092484545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887822,0.0055395737,0.00048641715,0.000948155,0.0003351832,0.0010571206,0.00088516896,0.0001281742,0.0018379991],"genre_scores_gemma":[0.9901788,0.0026726145,0.0010379092,0.0010748999,0.00018876501,0.0012388536,0.0010519212,0.000023584164,0.002532599],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99972624,0.00013071904,0.000009944632,0.00004585708,0.000020632953,0.000066658824],"domain_scores_gemma":[0.9995522,0.00012035277,0.00008678992,0.0000377996,0.000023417897,0.00017943511],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092824816,0.0011028454,0.0018477988,0.00025770182,0.0002470472,0.00090249046,0.00062349765,0.0011518279,0.0047453707],"category_scores_gemma":[0.0009283344,0.00032711896,0.0013003672,0.0002659076,0.0007359479,0.0010261304,0.00028686668,0.002684715,0.00089266663],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9134678,0.007973909,0.001916254,0.0012373031,0.0019388754,0.00014678361,0.0001638636,0.00090341497,0.009034409,0.00037428745,0.0034184025,0.05942475],"study_design_scores_gemma":[0.93897253,0.054343827,0.003246079,0.000041333955,0.0004216168,0.00014124144,0.000055800603,0.00054278784,0.00040556662,0.0002745099,0.0015376678,0.000016993537],"about_ca_topic_score_codex":0.0006407153,"about_ca_topic_score_gemma":0.0019433496,"teacher_disagreement_score":0.0047453707,"about_ca_system_score_codex":0.0005808901,"about_ca_system_score_gemma":0.00064293516,"threshold_uncertainty_score":0.015874803},"labels":[],"label_agreement":null},{"id":"W3093673980","doi":"10.1016/s1470-2045(20)30592-1","title":"How current assay approval policies are leading to unintended imprecision medicine","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Biomedical Ethics and Regulation","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Ontario Institute for Cancer Research","funders":"Breast Cancer Society of Canada; World Health Organization; Merck; AstraZeneca Australia; Bayer; Pfizer","keywords":"Reimbursement; Food and drug administration; Drug; Medicine; Drug approval; Clinical trial; Pharmacology; Clinical research; Health care; Internal medicine; Political science","score_opus":0.204421744804693,"score_gpt":0.42393240281780725,"score_spread":0.21951065801311426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093673980","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0097478945,0.011897124,0.02636619,0.8818441,0.0043036416,0.000055502325,0.00018363753,0.00022440126,0.06537749],"genre_scores_gemma":[0.4188559,0.0072827446,0.015486108,0.53892785,0.008680924,0.00023984218,0.00014050548,0.00038563705,0.010000471],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.81770766,0.102977835,0.008104316,0.0143245915,0.047881674,0.009003847],"domain_scores_gemma":[0.43068677,0.46747246,0.02528875,0.028029812,0.041174818,0.0073474534],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.1902911,0.0005635179,0.0013820055,0.0029903299,0.0044059805,0.025538819,0.0045283306,0.027875807,0.008080316],"category_scores_gemma":[0.41094938,0.0015357184,0.002010258,0.0019183551,0.03315677,0.014046659,0.0060359593,0.032697257,0.0023594361],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024398991,0.00009588392,0.005942728,0.00030267745,0.0002911276,0.00051697216,0.0030006936,0.002276481,0.00047147044,0.842101,0.08691478,0.05784218],"study_design_scores_gemma":[0.00010300375,0.000059092457,0.0022946068,0.0011733881,0.00018179015,0.00052439584,0.0009041443,0.0016360256,0.0011899786,0.84558916,0.1462065,0.00013796642],"about_ca_topic_score_codex":0.009185839,"about_ca_topic_score_gemma":0.0077568246,"teacher_disagreement_score":0.8097089,"about_ca_system_score_codex":0.010665967,"about_ca_system_score_gemma":0.023968989,"threshold_uncertainty_score":0.9985152},"labels":[],"label_agreement":null},{"id":"W3093923068","doi":"10.1016/s1470-2045(20)30436-8","title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":745,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre Hospitalier de l’Université de Montréal","funders":"Merck Sharp and Dohme","keywords":"Axitinib; Medicine; Sunitinib; Renal cell carcinoma; Pembrolizumab; Interim analysis; Internal medicine; Clinical endpoint; Oncology; Population; Kidney cancer; Clinical trial; Cancer; Immunotherapy","score_opus":0.1632971678821501,"score_gpt":0.3918027228166789,"score_spread":0.2285055549345288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093923068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9783593,0.00876496,0.00083692145,0.001238563,0.0010309746,0.0027690674,0.0026975144,0.00023744637,0.004065208],"genre_scores_gemma":[0.9803389,0.0040212097,0.0016408426,0.0018147298,0.00064882357,0.0025190641,0.0028885044,0.00006182494,0.006066147],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99891484,0.0005787715,0.00004633615,0.00019415558,0.000069018344,0.0001968523],"domain_scores_gemma":[0.9986933,0.0003857687,0.00025802938,0.00011564323,0.00007442509,0.0004729628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031315323,0.0022858037,0.004239344,0.0005607781,0.0006006578,0.0018337109,0.0011539909,0.0021618106,0.0100435605],"category_scores_gemma":[0.0024301081,0.0008584244,0.00387186,0.00055296277,0.0013163735,0.0023150514,0.00062970666,0.0053895116,0.0019280298],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98098814,0.002824141,0.0002705517,0.000498054,0.0011276645,0.000025754784,0.000048571408,0.00045964718,0.0011791023,0.00007121005,0.0008602381,0.011646854],"study_design_scores_gemma":[0.9532052,0.04358189,0.0014082615,0.000038875485,0.00050197623,0.000033563454,0.000024360437,0.00031309162,0.00019879443,0.00016842592,0.00050967286,0.000015866295],"about_ca_topic_score_codex":0.0017110435,"about_ca_topic_score_gemma":0.0043964004,"teacher_disagreement_score":0.0100435605,"about_ca_system_score_codex":0.0012841142,"about_ca_system_score_gemma":0.0012913931,"threshold_uncertainty_score":0.03359908},"labels":[],"label_agreement":null},{"id":"W3095373064","doi":"10.1016/s1470-2045(20)30629-x","title":"Recommendations for breast cancer screening – Author's reply","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Public Health Ontario","funders":"","keywords":"Breast cancer; Overdiagnosis; Medicine; Cancer; Family medicine; Breast cancer screening; International agency; Mammography; Gerontology; Gynecology; Internal medicine","score_opus":0.29433173746817676,"score_gpt":0.446158495410637,"score_spread":0.15182675794246026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095373064","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004220886,0.00059881393,0.000024310573,0.96925855,0.029432312,0.0000049743935,0.00003857032,0.000009189245,0.0005909783],"genre_scores_gemma":[0.00033072144,0.00024967638,0.00004073267,0.97846246,0.018979229,0.00001894442,0.00001890403,0.000008934674,0.001890368],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98945135,0.0029156331,0.0014726641,0.0013565064,0.0029637867,0.0018400982],"domain_scores_gemma":[0.9470867,0.03178391,0.0033598372,0.0012969858,0.008562308,0.007910314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010007904,0.0015103567,0.0027409028,0.002084357,0.0071280734,0.009288631,0.004079496,0.17504524,0.017723503],"category_scores_gemma":[0.07917151,0.0021609426,0.0031148633,0.0014929958,0.006316501,0.0075407047,0.005867104,0.10774849,0.015022211],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019648487,0.00000828589,0.00014217377,0.000034215613,0.000011254709,0.00017841771,0.00007141178,0.00002167491,0.00003815765,0.0011024552,0.9968112,0.0015612069],"study_design_scores_gemma":[0.00015841665,0.00003615383,0.0007879357,0.00058266806,0.000060278657,0.00046866675,0.00052409904,0.00018335933,0.00012067516,0.0071184975,0.98986113,0.00009825784],"about_ca_topic_score_codex":0.014331358,"about_ca_topic_score_gemma":0.01827185,"teacher_disagreement_score":0.17504524,"about_ca_system_score_codex":0.0072873114,"about_ca_system_score_gemma":0.013463664,"threshold_uncertainty_score":0.059291005},"labels":[],"label_agreement":null},{"id":"W3095605271","doi":"10.1016/s1470-2045(20)30587-8","title":"BELLINI: a renaissance for an era of precision therapy in multiple myeloma","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Genentech; Takeda Pharmaceuticals U.S.A.; Janssen Biotech; Celgene","keywords":"Venetoclax; Bortezomib; Multiple myeloma; Dexamethasone; Context (archaeology); Medicine; Oncology; Internal medicine; Cancer research; Chromosomal translocation; Biology; Leukemia; Chronic lymphocytic leukemia; Genetics; Gene","score_opus":0.1744093802438907,"score_gpt":0.4059269157998305,"score_spread":0.2315175355559398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095605271","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000060165192,0.0028983573,0.000045271674,0.97475207,0.020965165,0.0000031398615,0.000012887853,0.00000874054,0.0012541924],"genre_scores_gemma":[0.0017594767,0.0017840035,0.0001195523,0.94016844,0.05077473,0.000021082622,0.000010077461,0.000022065864,0.00534048],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9901202,0.0036685874,0.000634823,0.00097407773,0.0032271533,0.0013752887],"domain_scores_gemma":[0.9816218,0.010885071,0.0009694709,0.00054530293,0.002450642,0.0035277668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009059865,0.0014146746,0.002337102,0.0011111092,0.00747926,0.009077318,0.0026204786,0.09056232,0.010405235],"category_scores_gemma":[0.044062577,0.0007987665,0.0015776551,0.0010642979,0.0086014345,0.01107123,0.004667926,0.07839992,0.006556949],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005861554,0.00002124269,0.00009816817,0.00006630119,0.000014662244,0.00048722062,0.00014266965,0.000033512446,0.00008397441,0.0078084655,0.9856209,0.00556424],"study_design_scores_gemma":[0.00013088826,0.000038551567,0.00023471461,0.00028407676,0.00002058108,0.00052278396,0.00030978635,0.00018679719,0.00010126653,0.022545101,0.9755795,0.000045960827],"about_ca_topic_score_codex":0.007816928,"about_ca_topic_score_gemma":0.0125617,"teacher_disagreement_score":0.09056232,"about_ca_system_score_codex":0.009138305,"about_ca_system_score_gemma":0.008761189,"threshold_uncertainty_score":0.06630331},"labels":[],"label_agreement":null},{"id":"W3096044474","doi":"10.1016/s1470-2045(20)30475-7","title":"Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":124,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; Bristol-Myers Squibb Canada; AbbVie; Genentech; AstraZeneca; National Cancer Institute; National Institutes of Health; Pfizer; Amgen","keywords":"Biomarker; Medicine; Lung cancer; Oncology; Internal medicine; Clinical trial; Cancer","score_opus":0.06882650635968865,"score_gpt":0.39472622814967956,"score_spread":0.32589972178999094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096044474","genre_codex":"commentary","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07642598,0.0515633,0.1001539,0.31222442,0.014352155,0.17457873,0.05112993,0.002635088,0.21693651],"genre_scores_gemma":[0.22694063,0.05053269,0.19863409,0.16303101,0.008540279,0.21629757,0.051127978,0.0016013387,0.08329438],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99593866,0.002377928,0.00032813777,0.0003073856,0.00057529204,0.00047252155],"domain_scores_gemma":[0.9923254,0.0022798593,0.0011519354,0.0006836858,0.0012284793,0.0023305516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015188998,0.000671258,0.0010313351,0.0006271155,0.0009622309,0.002885077,0.0017794593,0.0030942701,0.014962721],"category_scores_gemma":[0.0130354455,0.00045994535,0.0024234047,0.0005123109,0.0006887216,0.0019639025,0.0042277295,0.005252121,0.0041903844],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013200269,0.0016031697,0.0037448104,0.0045255246,0.00073672837,0.0002498187,0.00046804437,0.0058536436,0.008248154,0.028043242,0.34910426,0.5842223],"study_design_scores_gemma":[0.017970324,0.01028319,0.015020191,0.005841549,0.0009768018,0.0004208194,0.00028225008,0.0045174877,0.007804022,0.0321925,0.9045594,0.0001313584],"about_ca_topic_score_codex":0.0015968067,"about_ca_topic_score_gemma":0.0053835358,"teacher_disagreement_score":0.015188998,"about_ca_system_score_codex":0.004336426,"about_ca_system_score_gemma":0.014241626,"threshold_uncertainty_score":0.08032805},"labels":[],"label_agreement":null},{"id":"W3096200050","doi":"10.1016/s1470-2045(20)30543-x","title":"Recommendations for breast cancer screening","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"British Columbia Centre of Excellence for Women's Health; University of British Columbia; Ontario Institute for Cancer Research; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Mammography; Guideline; Observational study; Family medicine; Breast screening; Randomized controlled trial; Cancer; Gynecology; Internal medicine; Pathology","score_opus":0.29484071213160107,"score_gpt":0.4416033240936061,"score_spread":0.14676261196200502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096200050","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005118517,0.0013026837,0.0000889439,0.9544629,0.03906804,0.000025161939,0.000102977574,0.000035279303,0.004862911],"genre_scores_gemma":[0.00028811774,0.00046025348,0.00017452356,0.9740892,0.017576395,0.00006403396,0.000064203145,0.000017675948,0.007265581],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9750404,0.0071322406,0.0032447716,0.0020057352,0.008112446,0.0044644047],"domain_scores_gemma":[0.9282262,0.03086242,0.0038869043,0.0024849265,0.014091748,0.020447789],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017024342,0.002396413,0.0031093927,0.004044311,0.009623412,0.011347636,0.006394383,0.22573996,0.05244366],"category_scores_gemma":[0.110474676,0.0027272666,0.005430046,0.0022556055,0.00859652,0.011238074,0.01033849,0.112110406,0.040005825],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026377946,0.000027737466,0.0000917171,0.000065033004,0.000009109899,0.00015374656,0.000052459163,0.000037690046,0.000072035866,0.0030173971,0.9919425,0.004504069],"study_design_scores_gemma":[0.0001868227,0.00004210658,0.0006799749,0.0008930888,0.000045643454,0.00029207728,0.0002184487,0.00015948368,0.000084935884,0.012288813,0.9850445,0.000064191896],"about_ca_topic_score_codex":0.037252277,"about_ca_topic_score_gemma":0.054461222,"teacher_disagreement_score":0.22573996,"about_ca_system_score_codex":0.012137607,"about_ca_system_score_gemma":0.037495848,"threshold_uncertainty_score":0.1754415},"labels":[],"label_agreement":null},{"id":"W3097553720","doi":"10.1016/s1470-2045(20)30490-3","title":"Mammography screening for breast cancer—the UK Age trial","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto; Women's College Hospital","funders":"","keywords":"Medicine; Mammography; Breast cancer; Cancer; Breast cancer screening; Gynecology; Randomized controlled trial; Obstetrics; Demography; Internal medicine","score_opus":0.2247315705978011,"score_gpt":0.41328785790321887,"score_spread":0.18855628730541776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097553720","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019741122,0.06749515,0.00022003612,0.8149612,0.045757625,0.00025193248,0.0075903814,0.000102049635,0.043880645],"genre_scores_gemma":[0.113639176,0.019250778,0.00078873883,0.78636,0.04231457,0.0010744863,0.0022092573,0.000087237895,0.034275677],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9947029,0.0037240484,0.0003900607,0.00022746593,0.0005366451,0.00041890732],"domain_scores_gemma":[0.9871164,0.00827511,0.0016484573,0.00044685593,0.0006481741,0.0018650133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050858124,0.00065939146,0.001681322,0.0005290182,0.0008810036,0.0019060177,0.00079205143,0.014152453,0.012084367],"category_scores_gemma":[0.029554522,0.0004921028,0.00090466434,0.0007175027,0.0008252551,0.002270933,0.001275761,0.0068113697,0.0031196466],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045574877,0.00030603848,0.0038983328,0.0010814068,0.00040432735,0.00052656914,0.00009601574,0.00027291366,0.00039230142,0.0028034209,0.86925364,0.07539013],"study_design_scores_gemma":[0.15854785,0.006130436,0.051900674,0.008900917,0.0036580889,0.0017499177,0.00069671776,0.0025819095,0.001334904,0.019353328,0.7448019,0.00034346263],"about_ca_topic_score_codex":0.007597193,"about_ca_topic_score_gemma":0.019528646,"teacher_disagreement_score":0.014152453,"about_ca_system_score_codex":0.0022364045,"about_ca_system_score_gemma":0.0027875328,"threshold_uncertainty_score":0.040426254},"labels":[],"label_agreement":null},{"id":"W3099458684","doi":"10.1016/s1470-2045(20)30605-7","title":"Oncology nursing workforce: challenges, solutions, and future strategies","year":2020,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Healthcare professionals’ stress and burnout","field":"Health Professions","cited_by":155,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Workforce; Nursing; Medicine; Oncology nursing; Nurse education; Occupational health nursing; Workforce planning; Nursing shortage; Health policy; Political science; Public health","score_opus":0.38564723688076513,"score_gpt":0.5618801644795668,"score_spread":0.17623292759880166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3099458684","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000072502444,0.983295,0.000101389276,0.014697113,0.0013582273,0.0000069975677,0.000028819544,0.000008108548,0.00043179773],"genre_scores_gemma":[0.0011998605,0.99204457,0.00033557965,0.004552257,0.0014419404,0.00002689084,0.000035222227,0.0000036244621,0.00036006473],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977221,0.00081765954,0.00028775673,0.00023809733,0.0006238367,0.00031057952],"domain_scores_gemma":[0.98350346,0.011088566,0.0011632264,0.00016308652,0.0027839441,0.0012976407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00878431,0.001153887,0.0030286382,0.003272001,0.0012223981,0.0050626155,0.0024108754,0.0054301126,0.011993714],"category_scores_gemma":[0.014330678,0.00061376544,0.0016070175,0.0038324362,0.0017843649,0.0064150905,0.003538012,0.006437907,0.0027075754],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013361426,0.0001207407,0.0005796714,0.049381148,0.0002862587,0.00012933736,0.00037071135,0.00033265166,0.00015691908,0.011621768,0.10140162,0.8354856],"study_design_scores_gemma":[0.00008732991,0.00018388359,0.0025620242,0.1465284,0.00063716044,0.0004467357,0.0028881796,0.0003438446,0.000104656865,0.02044353,0.82568055,0.0000937007],"about_ca_topic_score_codex":0.00875133,"about_ca_topic_score_gemma":0.030494519,"teacher_disagreement_score":0.011993714,"about_ca_system_score_codex":0.0043673455,"about_ca_system_score_gemma":0.020869268,"threshold_uncertainty_score":0.046456397},"labels":[],"label_agreement":null},{"id":"W3103760605","doi":"10.1016/s1470-2045(20)30612-4","title":"Essential oncology nursing care along the cancer continuum","year":2020,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Oncology nursing; Nursing; Promotion (chess); Medicine; Oncology; Pillar; Internal medicine; Nurse education; Political science","score_opus":0.32283938954102565,"score_gpt":0.5639838032665098,"score_spread":0.24114441372548412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3103760605","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002137456,0.99696463,0.000036087793,0.0013062477,0.00069612573,0.000004817335,0.00000738119,0.0000027994256,0.00096039294],"genre_scores_gemma":[0.0003554791,0.99736124,0.0001262066,0.0013623264,0.00041669694,0.000010485624,0.000013120062,0.0000011892137,0.0003533127],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987953,0.00044085592,0.00014192004,0.00008468171,0.0004260609,0.000111185225],"domain_scores_gemma":[0.99583673,0.0027961119,0.00043300833,0.000051957257,0.0005693468,0.00031279033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028791819,0.0010499696,0.0021901953,0.0024893472,0.0006440329,0.0027214484,0.0013567319,0.0027877423,0.0095887985],"category_scores_gemma":[0.0058483635,0.00042664018,0.00095361855,0.003112732,0.0010385935,0.0027190542,0.0024578504,0.0046851947,0.0019424168],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006787646,0.000049690934,0.000114033886,0.045485474,0.00012987532,0.00007411982,0.00012330298,0.00018119524,0.0001500403,0.008089496,0.061300047,0.88423485],"study_design_scores_gemma":[0.000052436302,0.00006899455,0.00077154656,0.08957177,0.00019663642,0.00036339843,0.00026236934,0.000064664906,0.0000512787,0.0058378526,0.9027382,0.000020855592],"about_ca_topic_score_codex":0.004338804,"about_ca_topic_score_gemma":0.014362247,"teacher_disagreement_score":0.0095887985,"about_ca_system_score_codex":0.0033300694,"about_ca_system_score_gemma":0.007646221,"threshold_uncertainty_score":0.03207773},"labels":[],"label_agreement":null},{"id":"W3108852904","doi":"10.1016/s1470-2045(20)30561-1","title":"Drug repurposing in oncology","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Computational Drug Discovery Methods","field":"Computer Science","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Astellas Pharma; Merck Sharp and Dohme; EMD Serono; Ipsen; Pfizer","keywords":"Drug repositioning; Repurposing; Medicine; Drug; Alternative medicine; Scopus; Pharmacology; Oncology; MEDLINE; Internal medicine; Pathology; Political science","score_opus":0.08677252661125053,"score_gpt":0.37699662881572,"score_spread":0.2902241022044695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3108852904","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000112615155,0.0018218925,0.00015282744,0.981307,0.013092211,0.0000146990715,0.000055860623,0.000020801137,0.0034220398],"genre_scores_gemma":[0.0017692349,0.0014424886,0.0002585092,0.9610422,0.027085712,0.000048588,0.000035963134,0.00002276492,0.008294535],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98966414,0.0039423066,0.0007868913,0.0008814723,0.003472527,0.0012525823],"domain_scores_gemma":[0.9539387,0.03319905,0.001460192,0.0010904429,0.0040875413,0.0062241456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010043806,0.0012568976,0.0019780085,0.001426904,0.0072441367,0.0086644655,0.0026379519,0.107873686,0.013139474],"category_scores_gemma":[0.061852966,0.001397778,0.0022656873,0.0013631586,0.007444355,0.006309627,0.0043238467,0.05938367,0.009953856],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003306884,0.000019427585,0.0001324757,0.000033966007,0.000011918972,0.00015005295,0.00004233674,0.00009938972,0.000060475173,0.006224783,0.9856871,0.0075050564],"study_design_scores_gemma":[0.0002232808,0.000080588485,0.0005347843,0.0004285902,0.000033933986,0.0003088483,0.00014819296,0.0017576521,0.0002007475,0.056491625,0.9397253,0.00006649131],"about_ca_topic_score_codex":0.015508561,"about_ca_topic_score_gemma":0.03086146,"teacher_disagreement_score":0.107873686,"about_ca_system_score_codex":0.008769397,"about_ca_system_score_gemma":0.0119974995,"threshold_uncertainty_score":0.06362671},"labels":[],"label_agreement":null},{"id":"W3110361823","doi":"10.1016/s1470-2045(20)30586-6","title":"Nadofaragene firadenovec: a new gold standard for BCG-unresponsive bladder cancer?","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Cystectomy; Bladder cancer; Medicine; Cancer; Gold standard (test); Disease; Urology; Internal medicine; Oncology; Surgery","score_opus":0.09688751176217797,"score_gpt":0.37808595999089734,"score_spread":0.28119844822871937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3110361823","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003926891,0.008116255,0.0001856468,0.96930605,0.019002207,0.000012510185,0.00010241524,0.000037489866,0.0028448731],"genre_scores_gemma":[0.0050065992,0.00459411,0.00044613157,0.93902045,0.042107757,0.00004910858,0.00012143021,0.000035998233,0.008618254],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966133,0.0010602671,0.00039454253,0.00032660674,0.0010467377,0.0005584757],"domain_scores_gemma":[0.9940818,0.0029719244,0.00064268423,0.00022725997,0.0007182414,0.0013581481],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051068636,0.00092521514,0.002008699,0.0008265191,0.0018048966,0.0032918106,0.001810585,0.047541536,0.009255946],"category_scores_gemma":[0.01651067,0.0007202118,0.0018083362,0.0006150684,0.0031569595,0.0047152643,0.0018751125,0.03190893,0.008743024],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004732567,0.000089485984,0.0005619291,0.00021760001,0.000044555913,0.00087669515,0.000081963524,0.00017539665,0.0006712832,0.008305198,0.92732954,0.061173093],"study_design_scores_gemma":[0.0005568232,0.0003278306,0.0008106317,0.00050299865,0.000051592135,0.0007773141,0.00012843174,0.00041214257,0.00030855834,0.017388899,0.97866976,0.00006504453],"about_ca_topic_score_codex":0.00317873,"about_ca_topic_score_gemma":0.008850119,"teacher_disagreement_score":0.047541536,"about_ca_system_score_codex":0.003458626,"about_ca_system_score_gemma":0.0042685443,"threshold_uncertainty_score":0.030964196},"labels":[],"label_agreement":null},{"id":"W3117371653","doi":"10.1016/s1470-2045(20)30633-1","title":"Should stereotactic ablative body radiotherapy be the standard of care in oligometastatic cancer?","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"SABR volatility model; Medicine; Ablative case; Radiosurgery; Radiation therapy; Observational study; Oncology; Internal medicine","score_opus":0.08530910389744431,"score_gpt":0.3918557738200811,"score_spread":0.3065466699226368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3117371653","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017619778,0.00120901,0.000044875465,0.9873871,0.009066044,0.000004248454,0.00003585213,0.0000082735905,0.0020683024],"genre_scores_gemma":[0.002295236,0.0012748053,0.00015709958,0.9670396,0.0248675,0.000021306785,0.000039275677,0.000015638781,0.004289581],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951539,0.0013676587,0.0005105939,0.00039276993,0.001618259,0.0009567904],"domain_scores_gemma":[0.9882605,0.0054779476,0.00087972544,0.00027284477,0.0018375225,0.0032715765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053219674,0.00073307427,0.0016106311,0.0009388707,0.0035854366,0.0044266903,0.0019327216,0.07917922,0.009788164],"category_scores_gemma":[0.027726723,0.00076382235,0.0014348187,0.0010293924,0.004245399,0.0057312734,0.002238495,0.04963924,0.008319251],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016841773,0.00005071949,0.00092268013,0.00010670626,0.000026811385,0.00095724664,0.0001057102,0.0001264727,0.00026796214,0.006958491,0.9722883,0.018020427],"study_design_scores_gemma":[0.0002688485,0.00012479171,0.0015518285,0.00053566473,0.000040898216,0.0014645063,0.00039242767,0.00046421893,0.00018706195,0.022147207,0.9727349,0.00008769039],"about_ca_topic_score_codex":0.013658443,"about_ca_topic_score_gemma":0.03079383,"teacher_disagreement_score":0.07917922,"about_ca_system_score_codex":0.0063664503,"about_ca_system_score_gemma":0.010181049,"threshold_uncertainty_score":0.04619199},"labels":[],"label_agreement":null},{"id":"W3118656197","doi":"10.1016/s1470-2045(20)30606-9","title":"Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Princess Margaret Hospital Foundation","keywords":"Medicine; Extrapleural Pneumonectomy; Mesothelioma; Perioperative; Radiation therapy; Clinical endpoint; Surgery; Pneumonectomy; Cumulative incidence; Randomized controlled trial; Internal medicine; Lung; Pathology","score_opus":0.10286350707183199,"score_gpt":0.35235488199664755,"score_spread":0.24949137492481555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3118656197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97006905,0.018469283,0.0010172785,0.0021050097,0.000758256,0.0014449283,0.002962466,0.00016533057,0.0030084352],"genre_scores_gemma":[0.97409487,0.009722636,0.0020094374,0.0028065701,0.0004550079,0.0017952808,0.004765435,0.000067115594,0.0042837346],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99954563,0.00021805114,0.000025029038,0.000083565974,0.000038691087,0.000088970446],"domain_scores_gemma":[0.9991748,0.00023643753,0.00021454772,0.000082077684,0.000056356646,0.0002358864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017987731,0.0012893731,0.0022881634,0.00025367053,0.00030823608,0.001355048,0.0006220615,0.001222015,0.0043151407],"category_scores_gemma":[0.0016653936,0.00036904815,0.0035682907,0.00032492276,0.0008268763,0.0010710347,0.0004152352,0.0030229995,0.0010318044],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8413711,0.0065722084,0.005348118,0.0035195055,0.008798302,0.00016357772,0.00024968805,0.0026056827,0.0101034725,0.00049757527,0.009589077,0.11118166],"study_design_scores_gemma":[0.8603241,0.115832835,0.012554079,0.00022520409,0.0036271943,0.00023592587,0.000118243566,0.0006544094,0.00092643435,0.0009207904,0.004530574,0.000050273597],"about_ca_topic_score_codex":0.00062503596,"about_ca_topic_score_gemma":0.002282184,"teacher_disagreement_score":0.0043151407,"about_ca_system_score_codex":0.00061377924,"about_ca_system_score_gemma":0.00077111984,"threshold_uncertainty_score":0.014435589},"labels":[],"label_agreement":null},{"id":"W3120241209","doi":"10.1016/s1470-2045(20)30642-2","title":"Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":255,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Pfizer","keywords":"Palbociclib; Interim analysis; Medicine; Interim; Adjuvant; Oncology; Breast cancer; Internal medicine; Cancer; Endocrine system; Adjuvant therapy; Gynecology; Clinical trial; Metastatic breast cancer; History; Hormone","score_opus":0.08323415090640111,"score_gpt":0.4366332390939129,"score_spread":0.35339908818751176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120241209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9593751,0.015289469,0.0031158421,0.0020422377,0.0012898435,0.00570979,0.0069188755,0.00047622854,0.0057826242],"genre_scores_gemma":[0.971832,0.0037212488,0.0045038834,0.0023707761,0.0005168662,0.006047471,0.006262518,0.0001387614,0.004606488],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997189,0.0017897615,0.00012145136,0.00028919242,0.00022499595,0.0003855421],"domain_scores_gemma":[0.9968052,0.001189527,0.00069413317,0.00045539,0.00017768749,0.0006781837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069461367,0.0023569874,0.00435596,0.000560916,0.0006220289,0.0022999013,0.001409381,0.0018298886,0.0071826736],"category_scores_gemma":[0.0049764058,0.0008946105,0.0050040293,0.00074128906,0.0013693327,0.0021696412,0.00092971924,0.005336387,0.0015144835],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9794663,0.0014976532,0.0006981238,0.00043879068,0.002378645,0.00003278148,0.000040676936,0.0005810591,0.0010276084,0.00012340034,0.0012593325,0.012455621],"study_design_scores_gemma":[0.94465166,0.04722232,0.0037938652,0.000054769243,0.001742291,0.00006177147,0.00003404506,0.00050963595,0.000288589,0.00039979172,0.0012099689,0.000031200892],"about_ca_topic_score_codex":0.0011088633,"about_ca_topic_score_gemma":0.0030070622,"teacher_disagreement_score":0.0071826736,"about_ca_system_score_codex":0.001336322,"about_ca_system_score_gemma":0.00220274,"threshold_uncertainty_score":0.036735117},"labels":[],"label_agreement":null},{"id":"W3122379226","doi":"10.1016/s1470-2045(20)30675-6","title":"Global demand for cancer surgery and an estimate of the optimal surgical and anaesthesia workforce between 2018 and 2040: a population-based modelling study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":131,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"University of New South Wales; UK Research and Innovation; World Health Organization","keywords":"Workforce; Cancer surgery; Population; Medicine; Cancer; Operations management; Business; Economics; Environmental health; Economic growth; Internal medicine","score_opus":0.07665875296806546,"score_gpt":0.4412849846689496,"score_spread":0.36462623170088415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3122379226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.974515,0.0006086546,0.003819062,0.0024525484,0.00006142513,0.000032220265,0.016164621,0.000059531932,0.002286857],"genre_scores_gemma":[0.9888827,0.0003142794,0.001015888,0.00020278926,0.000024981342,0.00006702827,0.008016143,0.000024460014,0.0014517761],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9995702,0.00016227036,0.000026563526,0.00009281073,0.00003125945,0.00011696894],"domain_scores_gemma":[0.99819857,0.0009601782,0.00031817844,0.00013441249,0.00019155678,0.00019713145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015468061,0.00057848496,0.00076047133,0.00075264566,0.00027836385,0.0012714275,0.0014702982,0.001972451,0.0041269385],"category_scores_gemma":[0.0039721434,0.00090881303,0.0027937577,0.0016758667,0.0005470385,0.0016038587,0.0009870285,0.0022754094,0.0008339162],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010218265,0.0004514546,0.36744866,0.00023318836,0.0017464618,0.0007347117,0.00069976895,0.60086304,0.00038368008,0.0073661334,0.011830413,0.0072207907],"study_design_scores_gemma":[0.00040432933,0.00042276562,0.27894384,0.00025582162,0.0008408592,0.0005432478,0.0028857782,0.6946739,0.00035001067,0.008581869,0.011918619,0.00017901993],"about_ca_topic_score_codex":0.10719621,"about_ca_topic_score_gemma":0.06315666,"teacher_disagreement_score":0.10719621,"about_ca_system_score_codex":0.0026574312,"about_ca_system_score_gemma":0.0014174263,"threshold_uncertainty_score":0.21314454},"labels":[],"label_agreement":null},{"id":"W3126453280","doi":"10.1016/s1470-2045(21)00017-6","title":"SARS-CoV-2 vaccination and phase 1 cancer clinical trials","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"SARS-CoV-2 and COVID-19 Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy; National Center for Advancing Translational Sciences; University of Texas MD Anderson Cancer Center; National Institutes of Health; National Cancer Institute; National Institute for Health and Care Research","keywords":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Vaccination; Clinical trial; Cancer; Coronavirus disease 2019 (COVID-19); Virology; 2019-20 coronavirus outbreak; Medicine; Cancer vaccine; Phase (matter); Internal medicine; Immunotherapy; Outbreak; Disease; Infectious disease (medical specialty); Physics","score_opus":0.4146818085413431,"score_gpt":0.59758254373599,"score_spread":0.18290073519464684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3126453280","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34812164,0.5041858,0.0031127012,0.077305436,0.012164714,0.0047545703,0.010932015,0.0004545825,0.03896864],"genre_scores_gemma":[0.8116568,0.12089875,0.00525955,0.03101348,0.0049624518,0.0039186054,0.009420277,0.00014426066,0.012725842],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99523795,0.0035767825,0.00019790929,0.0002556232,0.00029422017,0.00043750557],"domain_scores_gemma":[0.99397224,0.0025534546,0.0015087833,0.00033577188,0.0004437044,0.0011860174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009936831,0.00076055137,0.0017088238,0.00044435434,0.00031087862,0.0017034676,0.0006465415,0.0022381383,0.0077827233],"category_scores_gemma":[0.010394693,0.00040900955,0.0023193571,0.0007295443,0.00062331173,0.0012982188,0.0006811331,0.003232609,0.0010544434],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34684852,0.004966729,0.0075170803,0.007843775,0.0059743756,0.00019019764,0.00023437427,0.0041481024,0.007816654,0.0042212987,0.08001296,0.530226],"study_design_scores_gemma":[0.40549675,0.2608465,0.045916315,0.0052541997,0.004933278,0.00054870214,0.00027371195,0.0025801978,0.0043781926,0.009682661,0.25992757,0.00016191599],"about_ca_topic_score_codex":0.0007678864,"about_ca_topic_score_gemma":0.00267785,"teacher_disagreement_score":0.009936831,"about_ca_system_score_codex":0.001607876,"about_ca_system_score_gemma":0.0024409867,"threshold_uncertainty_score":0.052551568},"labels":[],"label_agreement":null},{"id":"W3127104364","doi":"10.1016/s1470-2045(20)30582-9","title":"Fertility preservation for male patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group","year":2021,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Reproductive Biology and Fertility","field":"Medicine","cited_by":200,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children","funders":"Medical Research Council; European Commission; University of Leeds; UK Research and Innovation; Memorial Sloan-Kettering Cancer Center","keywords":"Fertility; Guideline; Medicine; Fertility preservation; Grading (engineering); Harmonization; Family medicine; Cancer; Psychological intervention; Young adult; Gerontology; Pediatrics; Gynecology; Population; Environmental health; Nursing; Pathology; Internal medicine","score_opus":0.03741093181337938,"score_gpt":0.34715840043879465,"score_spread":0.30974746862541525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3127104364","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015029314,0.99276924,0.0003034824,0.004663833,0.000584774,0.000075174634,0.00041310737,0.000019172026,0.0010209822],"genre_scores_gemma":[0.0011155566,0.99218917,0.0015691533,0.0038994236,0.00019003874,0.00010582394,0.0004709532,0.000006176687,0.00045374176],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989557,0.0003016107,0.00028364334,0.00009459608,0.00029687435,0.00006749203],"domain_scores_gemma":[0.9983284,0.0008780108,0.0002824468,0.000026707565,0.0004078086,0.000076610566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034381154,0.0007844174,0.0025181558,0.0018363197,0.0003813679,0.0011913714,0.0021193991,0.0017991833,0.0033578195],"category_scores_gemma":[0.004839304,0.00039986096,0.0027146072,0.0014774399,0.00045566758,0.0009541538,0.0009156718,0.00341244,0.0008866556],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025982468,0.0000762864,0.00058272865,0.06972262,0.0007488995,0.00011577869,0.00010751246,0.0009633776,0.0006172888,0.0046403636,0.114740126,0.80742514],"study_design_scores_gemma":[0.00043281922,0.00018054344,0.0029377344,0.11811277,0.0023510559,0.00061589264,0.00014207579,0.0003131998,0.00032197442,0.0036748303,0.8708592,0.00005782315],"about_ca_topic_score_codex":0.013297391,"about_ca_topic_score_gemma":0.03157902,"teacher_disagreement_score":0.013297391,"about_ca_system_score_codex":0.0019245938,"about_ca_system_score_gemma":0.0062425816,"threshold_uncertainty_score":0.026439965},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"split"},{"id":"W3134103265","doi":"10.1016/s1470-2045(20)30756-7","title":"Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group","year":2021,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":268,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Hotel Dieu Hospital","funders":"Janssen Pharmaceuticals; Merck Sharp and Dohme; Genesis Pharma; Genentech; National Natural Science Foundation of China; Takeda Pharmaceutical Company; AbbVie; Sanofi; Roche; Novartis; GlaxoSmithKline; Celgene; Bayer; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Multiple myeloma; Refractory (planetary science); Medicine; Clinical trial; Internal medicine; Oncology; Clinical Practice; Family medicine","score_opus":0.17899591068222734,"score_gpt":0.42305126285013306,"score_spread":0.24405535216790572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134103265","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000033168384,0.99158984,0.00011415292,0.0057942844,0.0017410103,0.000035748802,0.00016273014,0.000013821788,0.00051535014],"genre_scores_gemma":[0.00031754002,0.99219924,0.00058526767,0.005494996,0.0007064915,0.00006387414,0.00017167156,0.000004930248,0.00045604608],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99865144,0.00034729467,0.000345163,0.00015211952,0.00039433927,0.00010979864],"domain_scores_gemma":[0.9966487,0.001452524,0.00068695855,0.00005002143,0.00091067783,0.00025111716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053171534,0.001515419,0.004267758,0.004064594,0.00044245058,0.0026554642,0.0028092526,0.004085834,0.005372482],"category_scores_gemma":[0.005816826,0.0006025508,0.003492223,0.003671412,0.0007965606,0.0023656962,0.0016276729,0.0063250368,0.0028417937],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049945305,0.00012946063,0.00023563048,0.06137076,0.00069293333,0.00011290789,0.000079487225,0.0005395732,0.0005545349,0.0039929296,0.26662475,0.6651676],"study_design_scores_gemma":[0.0005369191,0.00018767496,0.0011377967,0.068000644,0.0016486763,0.00022908158,0.00008507992,0.00015406526,0.00015800966,0.0032367588,0.9245782,0.000047119986],"about_ca_topic_score_codex":0.009503485,"about_ca_topic_score_gemma":0.018621566,"teacher_disagreement_score":0.009503485,"about_ca_system_score_codex":0.0034486332,"about_ca_system_score_gemma":0.009274736,"threshold_uncertainty_score":0.0281201},"labels":[],"label_agreement":null},{"id":"W3135376158","doi":"10.1016/s1470-2045(21)00006-1","title":"Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":227,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Zhongshan Hospital","keywords":"Medicine; Chemotherapy; Ovarian cancer; Internal medicine; Open label; Oncology; Randomized controlled trial; Surgery; Cancer","score_opus":0.061897894713462485,"score_gpt":0.393795617724443,"score_spread":0.3318977230109805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135376158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98700494,0.005060573,0.0005590813,0.0010355219,0.0009806575,0.002389577,0.0009966341,0.0001287815,0.0018442059],"genre_scores_gemma":[0.9872508,0.0025669166,0.001265608,0.0011998562,0.0005583882,0.002843965,0.001069439,0.000033413307,0.0032115148],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993575,0.00033307937,0.000029782408,0.000121787576,0.000039729857,0.000118191514],"domain_scores_gemma":[0.99878484,0.000408788,0.00025711933,0.000095462514,0.000054483913,0.00039934774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016746585,0.001985232,0.003569761,0.00048359364,0.0004218889,0.0010577498,0.0009802525,0.0019533834,0.010031804],"category_scores_gemma":[0.0020014464,0.0005909827,0.0032671418,0.00043015156,0.0014939657,0.0011530882,0.0006444231,0.0040366165,0.0010766304],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9865768,0.0023536333,0.00021295021,0.0004961084,0.0006575995,0.000016353475,0.0000342669,0.0003028856,0.00067605026,0.00008313412,0.00060929125,0.007980909],"study_design_scores_gemma":[0.957054,0.041114353,0.0007842536,0.000034065786,0.00025159042,0.00001957277,0.000016480384,0.00023556311,0.00011461941,0.00014034052,0.00022592265,0.000009150147],"about_ca_topic_score_codex":0.0017851848,"about_ca_topic_score_gemma":0.0036992235,"teacher_disagreement_score":0.010031804,"about_ca_system_score_codex":0.0011284928,"about_ca_system_score_gemma":0.0013034559,"threshold_uncertainty_score":0.03355968},"labels":[],"label_agreement":null},{"id":"W3135662544","doi":"10.1016/s1470-2045(21)00019-x","title":"Pembrolizumab monotherapy in metastatic triple-negative breast cancer","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Pembrolizumab; Triple-negative breast cancer; Metastatic breast cancer; Oncology; Breast cancer; Internal medicine; Cancer; Immunotherapy","score_opus":0.05430835432453917,"score_gpt":0.3755661800372451,"score_spread":0.32125782571270595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135662544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.48282203,0.43859568,0.0009080244,0.032981664,0.0024564154,0.00015899935,0.0010068321,0.00019482475,0.04087551],"genre_scores_gemma":[0.89358664,0.09214947,0.0010573423,0.0040818793,0.0010379648,0.00013076277,0.0007133787,0.000021219721,0.0072213383],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9999093,0.00003276942,0.000007333621,0.000011658941,0.000016787932,0.000022082433],"domain_scores_gemma":[0.99983597,0.00006810242,0.000028272756,0.000007535825,0.000019831223,0.00004033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039065394,0.00017910924,0.0005649396,0.00020296761,0.00017592749,0.00044160534,0.00016213174,0.0003398625,0.0022829985],"category_scores_gemma":[0.0007506866,0.00009409007,0.00023438464,0.00022730588,0.000107124804,0.0003660064,0.00012993526,0.00086407905,0.0005751566],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0121693835,0.00032509377,0.0062014596,0.0015905825,0.00052681216,0.0005058871,0.0000788123,0.0012152949,0.016196424,0.0011107593,0.039551936,0.9205275],"study_design_scores_gemma":[0.02509222,0.031455606,0.2273232,0.0043600686,0.0040116375,0.013298415,0.0007325654,0.010610341,0.03063269,0.010837482,0.64148116,0.00016458602],"about_ca_topic_score_codex":0.0006704432,"about_ca_topic_score_gemma":0.0026593641,"teacher_disagreement_score":0.0022829985,"about_ca_system_score_codex":0.00059129763,"about_ca_system_score_gemma":0.00037002505,"threshold_uncertainty_score":0.007637441},"labels":[],"label_agreement":null},{"id":"W3137610925","doi":"10.1016/s1470-2045(21)00005-x","title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":258,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Princess Margaret Cancer Centre","funders":"Merck","keywords":"Brentuximab vedotin; Pembrolizumab; Medicine; Interim analysis; Oncology; Internal medicine; Interim; Refractory (planetary science); Open label; Lymphoma; Hodgkin lymphoma; Clinical trial; Cancer; Immunotherapy; Materials science","score_opus":0.15786344631065277,"score_gpt":0.45622588838626277,"score_spread":0.29836244207561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137610925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98892885,0.004728906,0.0008013291,0.0006114053,0.0004405001,0.0011946072,0.0011994046,0.00013175189,0.0019631982],"genre_scores_gemma":[0.9908943,0.0016245549,0.0015032982,0.0009718023,0.0002528113,0.0012165399,0.0012148722,0.000037120633,0.0022847364],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9986745,0.00081761007,0.000053132346,0.00014886676,0.0000696646,0.00023624838],"domain_scores_gemma":[0.99830973,0.0007239273,0.00029108694,0.00017572384,0.00007341534,0.00042612109],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004080823,0.0016739004,0.0032810753,0.00042198284,0.00049569656,0.0016781667,0.0011359839,0.001618525,0.005713834],"category_scores_gemma":[0.0026745764,0.0007966677,0.002722519,0.00039063144,0.0013166914,0.0020675736,0.0005787378,0.0043156017,0.0012210261],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98282653,0.0018092568,0.00036074445,0.00027155058,0.0009948631,0.000026703698,0.000041380565,0.00056243147,0.0012005657,0.000081446145,0.0004827073,0.011341888],"study_design_scores_gemma":[0.91782695,0.076201156,0.0029929492,0.00004526773,0.0009963618,0.000050200848,0.00004033328,0.0005995665,0.0004385711,0.00026557996,0.0005191419,0.00002400568],"about_ca_topic_score_codex":0.00095705583,"about_ca_topic_score_gemma":0.0019012999,"teacher_disagreement_score":0.005713834,"about_ca_system_score_codex":0.0009737032,"about_ca_system_score_gemma":0.001010517,"threshold_uncertainty_score":0.02158171},"labels":[],"label_agreement":null},{"id":"W3141372695","doi":"10.1016/s1470-2045(21)00034-6","title":"Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":349,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Fulvestrant; Medicine; Aromatase inhibitor; Internal medicine; Oncology; Breast cancer; Cancer; Cohort; Regimen; Clinical endpoint; Clinical trial; Estrogen receptor; Aromatase","score_opus":0.05096464552649327,"score_gpt":0.3993410276253444,"score_spread":0.34837638209885113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3141372695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949609,0.0030717144,0.00019133574,0.00017178497,0.00010986482,0.00030499062,0.00048780657,0.000021868937,0.00067971897],"genre_scores_gemma":[0.9937158,0.0022618168,0.00045665298,0.00046032324,0.00020931615,0.00032212172,0.001367775,0.00001643003,0.0011898432],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999175,0.00040452767,0.00004176815,0.0001270418,0.000068391964,0.0001832059],"domain_scores_gemma":[0.9989355,0.00035465066,0.0002003741,0.00014501555,0.000065112894,0.00029930827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002448632,0.0013130247,0.0025922477,0.00048604087,0.00036792594,0.0013041707,0.00069198816,0.0011689807,0.0025149803],"category_scores_gemma":[0.0016656687,0.0004332487,0.002304659,0.0005312184,0.0009815631,0.0012615445,0.00031729002,0.0022298745,0.0006026875],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9341796,0.010583824,0.0054366384,0.0005030094,0.0025255617,0.00010654988,0.00012676216,0.00078549783,0.0074497927,0.00012183275,0.0007600661,0.03742071],"study_design_scores_gemma":[0.6140949,0.35423866,0.024310283,0.00005858281,0.0024590981,0.0002134414,0.00013224458,0.00064266945,0.0017069328,0.00024401776,0.0018513099,0.00004779493],"about_ca_topic_score_codex":0.0014991538,"about_ca_topic_score_gemma":0.0031099573,"teacher_disagreement_score":0.0025922477,"about_ca_system_score_codex":0.0011171901,"about_ca_system_score_gemma":0.00081508205,"threshold_uncertainty_score":0.012949765},"labels":[],"label_agreement":null},{"id":"W3142845014","doi":"10.1016/s1470-2045(20)30753-1","title":"MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":628,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Elekta; Medizinische Universität Wien; Aarhus Universitetshospital; Varian Medical Systems","keywords":"Brachytherapy; Medicine; Cervical cancer; Prospective cohort study; Cohort; Radiology; Medical physics; Radiation therapy; Oncology; Cancer; Internal medicine","score_opus":0.04642688280566548,"score_gpt":0.3808476131739682,"score_spread":0.3344207303683027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3142845014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969405,0.0008060148,0.00023125327,0.0000926997,0.000023373132,0.0000758341,0.0014299222,0.0000087399585,0.00039154035],"genre_scores_gemma":[0.99654466,0.00042320474,0.00037288002,0.00016335481,0.000035790745,0.00011031425,0.0017461334,0.000026564443,0.00057712576],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986462,0.00038610311,0.00008189841,0.00050942675,0.00012901286,0.0002472712],"domain_scores_gemma":[0.99702126,0.00048263415,0.00089998345,0.0008677069,0.00025286374,0.00047548208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019422347,0.0010732465,0.0010421571,0.00044247461,0.0008979389,0.0016844599,0.0013154623,0.001447284,0.003065605],"category_scores_gemma":[0.003706184,0.0012959784,0.002003357,0.0013805729,0.000598373,0.0008502489,0.0012064534,0.001888299,0.00070273847],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015071514,0.0007770164,0.9684945,0.00020982034,0.0036555247,0.00067091075,0.00092747365,0.00022205111,0.0036536877,0.00017886449,0.0016909487,0.0044478206],"study_design_scores_gemma":[0.001314257,0.0024147576,0.9913947,0.000055689463,0.0018294507,0.0006572576,0.0007333585,0.000225971,0.00020907812,0.00007166514,0.0010360439,0.000057824658],"about_ca_topic_score_codex":0.010358171,"about_ca_topic_score_gemma":0.010647968,"teacher_disagreement_score":0.010358171,"about_ca_system_score_codex":0.0007226022,"about_ca_system_score_gemma":0.00084890256,"threshold_uncertainty_score":0.020595789},"labels":[],"label_agreement":null},{"id":"W3145416765","doi":"10.1016/s1470-2045(21)00033-4","title":"Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renin-Angiotensin System Studies","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"NIHR Oxford Biomedical Research Centre; Oxford Martin School, University of Oxford; Medical Research Council; National Institute for Health and Care Research; Department of Health and Social Care; British Heart Foundation; Cancer Research UK","keywords":"Meta-analysis; Medicine; Cancer; Clinical trial; Internal medicine; Oncology","score_opus":0.5616213605570728,"score_gpt":0.4741281292402311,"score_spread":0.08749323131684167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3145416765","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.020532053,0.96027744,0.011675874,0.0009849273,0.0008775109,0.0019107205,0.0025676878,0.00022923823,0.00094471674],"genre_scores_gemma":[0.6340656,0.31972957,0.029679196,0.002471222,0.0007998677,0.008623003,0.003400433,0.0002329432,0.0009982459],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.95765865,0.03114846,0.00565112,0.0025714936,0.002352739,0.00061755115],"domain_scores_gemma":[0.9487415,0.041116696,0.0049284683,0.0028956148,0.0019003269,0.0004174466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.046379007,0.0035046942,0.020847721,0.0078967605,0.00069922593,0.0042352118,0.003239558,0.0029006964,0.0040641963],"category_scores_gemma":[0.08038864,0.0019566389,0.06480128,0.007943955,0.0008605628,0.002426502,0.002390763,0.0029585273,0.00046884734],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026985868,0.000022906035,0.0034697726,0.04479534,0.9441001,0.00007788754,0.000041986572,0.0007803974,0.00010168268,0.00011416748,0.0004330859,0.0033640838],"study_design_scores_gemma":[0.0010780998,0.00015338071,0.0017423496,0.0033873874,0.99188846,0.000060674152,0.00001772856,0.0005010679,0.000066227934,0.0003961237,0.00068657595,0.000021835674],"about_ca_topic_score_codex":0.004128832,"about_ca_topic_score_gemma":0.0058362414,"teacher_disagreement_score":0.046379007,"about_ca_system_score_codex":0.0023159645,"about_ca_system_score_gemma":0.0023914317,"threshold_uncertainty_score":0.2452786},"labels":[],"label_agreement":null},{"id":"W3149244744","doi":"10.1016/s1470-2045(18)30599-0","title":"Exercise as part of routine cancer care","year":2018,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; William Osler Health System; Toronto Rehabilitation Institute; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Context (archaeology); Position statement; Cancer; Alternative medicine; Health care; Family medicine; Clinical Oncology; Regimen; Internal medicine; Pathology","score_opus":0.051085282648173205,"score_gpt":0.3596898286255354,"score_spread":0.3086045459773622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3149244744","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005955816,0.0007950894,0.000038693393,0.98411995,0.010901539,0.000010102394,0.00004135812,0.000012698459,0.0034850303],"genre_scores_gemma":[0.005320986,0.001249313,0.00014632041,0.95776165,0.028442813,0.000060811595,0.000046975205,0.00002170224,0.006949448],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953852,0.0016365309,0.00056869554,0.00040666375,0.0012343008,0.0007684975],"domain_scores_gemma":[0.9876935,0.005704015,0.0009827793,0.00041206123,0.0014398434,0.0037677928],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002903514,0.00055205176,0.001151524,0.0006006978,0.004736412,0.0032009296,0.0012677738,0.043352965,0.008679625],"category_scores_gemma":[0.032464523,0.00062558276,0.0010708863,0.000906517,0.002768366,0.0031444675,0.002545294,0.04640607,0.004681913],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007019165,0.00009749191,0.0027543514,0.000119178534,0.000024270244,0.001448634,0.00030150832,0.000043943295,0.00013229252,0.0020712763,0.96692467,0.02601217],"study_design_scores_gemma":[0.00027483722,0.00021059545,0.00601935,0.0011126277,0.00006163093,0.0020932355,0.0012610091,0.00028488916,0.00020924612,0.007934044,0.980473,0.00006548871],"about_ca_topic_score_codex":0.010761771,"about_ca_topic_score_gemma":0.02914743,"teacher_disagreement_score":0.043352965,"about_ca_system_score_codex":0.00473754,"about_ca_system_score_gemma":0.0068044085,"threshold_uncertainty_score":0.034373403},"labels":[],"label_agreement":null},{"id":"W3149822024","doi":"10.1016/s1470-2045(21)00085-1","title":"Elucidating the association between antihypertensive drugs and cancer: a need for real-world studies","year":2021,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Hormonal Regulation and Hypertension","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Observational study; Thiazide; Calcium channel; Angiotensin Receptor Blockers; Calcium channel blocker; Antihypertensive drug; Meta-analysis; Cancer; Pharmacology; Internal medicine; Angiotensin-converting enzyme; Oncology; Calcium; Diuretic; Blood pressure","score_opus":0.1367906492051603,"score_gpt":0.3990965004591731,"score_spread":0.26230585125401285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3149822024","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016517073,0.006726698,0.00014123652,0.9799473,0.012514521,0.000006389113,0.00006515472,0.000011609242,0.00042189588],"genre_scores_gemma":[0.0020879898,0.007312656,0.00074876944,0.8999591,0.08891507,0.00003495963,0.00006390349,0.000015824871,0.0008616328],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98591703,0.0061711813,0.0024332704,0.0012867932,0.0035492973,0.0006424811],"domain_scores_gemma":[0.8538956,0.115727395,0.005780623,0.0032249934,0.013489493,0.007881961],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020283008,0.0012476031,0.005838322,0.0016369403,0.0037546076,0.006458629,0.004196565,0.05347459,0.006343861],"category_scores_gemma":[0.08212214,0.0012355155,0.0029519896,0.0019156219,0.007508459,0.011269335,0.003230761,0.060608514,0.006067326],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038765793,0.0001732882,0.0034987107,0.0008342026,0.00030430462,0.0019411643,0.0003043348,0.00015167674,0.000492369,0.007987225,0.92196345,0.061961636],"study_design_scores_gemma":[0.0007364685,0.00030080482,0.0051044435,0.0023888652,0.00039044858,0.0025893347,0.001726466,0.00060938747,0.00034086787,0.07317377,0.9124079,0.00023121604],"about_ca_topic_score_codex":0.005992281,"about_ca_topic_score_gemma":0.012118839,"teacher_disagreement_score":0.05347459,"about_ca_system_score_codex":0.004735931,"about_ca_system_score_gemma":0.007179414,"threshold_uncertainty_score":0.107268095},"labels":[],"label_agreement":null},{"id":"W3152750473","doi":"10.1016/s1470-2045(21)00081-4","title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Pharmacyclics; Novartis Pharma; EMD Serono; Meso Scale Diagnostics; Les Laboratories Pierre Fabre; Johnson and Johnson; Genentech; Eisai; SkylineDx; Array BioPharma; Ipsen; Syndax Pharmaceuticals; Pfizer; Incyte; Sun Pharma; Regeneron Pharmaceuticals; Sanofi; AstraZeneca; EUSA Pharma; Roche; Novartis; GlaxoSmithKline; Amgen; Qbiotics; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Clinical endpoint; Hazard ratio; Placebo; Internal medicine; Quality of life (healthcare); Population; Clinical trial; Adverse effect; Oncology; Melanoma; Randomized controlled trial; Surgery; Cancer; Confidence interval; Pathology; Immunotherapy; Alternative medicine","score_opus":0.16983074091665748,"score_gpt":0.43179126405716817,"score_spread":0.26196052314051066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3152750473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849888,0.007903379,0.0007239895,0.00067013473,0.0007353367,0.002199112,0.0009274982,0.00014040772,0.0017114292],"genre_scores_gemma":[0.9870706,0.0033484416,0.001274442,0.0010349436,0.00043794114,0.0024210273,0.000862762,0.000027157928,0.0035226748],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99934846,0.00034154754,0.000038556685,0.00012815156,0.0000388539,0.000104410174],"domain_scores_gemma":[0.9993668,0.00019619154,0.00016212552,0.000050649876,0.00003175261,0.00019241244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019011109,0.0018410236,0.0034625959,0.00046097834,0.00041389352,0.001045603,0.0009370374,0.0018201354,0.00575931],"category_scores_gemma":[0.0014301016,0.00067303464,0.0023877895,0.000401105,0.001233648,0.0012160543,0.0004672701,0.003115768,0.0011714017],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98644537,0.0023821555,0.00018172526,0.00046223088,0.00060516136,0.000015377962,0.000025113733,0.00018845183,0.0015597718,0.00004434349,0.00032140155,0.007768951],"study_design_scores_gemma":[0.95978683,0.038164828,0.00094300165,0.00003055044,0.00034299472,0.000013280768,0.000012228155,0.0002078397,0.00018887743,0.00008584572,0.00021368884,0.000009976476],"about_ca_topic_score_codex":0.001242963,"about_ca_topic_score_gemma":0.002338985,"teacher_disagreement_score":0.00575931,"about_ca_system_score_codex":0.00082981295,"about_ca_system_score_gemma":0.0008036922,"threshold_uncertainty_score":0.019266784},"labels":[],"label_agreement":null},{"id":"W3153228158","doi":"10.1016/s1470-2045(21)00065-6","title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":389,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Merck","keywords":"Medicine; Pembrolizumab; Hazard ratio; Internal medicine; Placebo; Clinical endpoint; Population; Oncology; Clinical trial; Melanoma; Surgery; Cancer; Confidence interval; Pathology; Immunotherapy","score_opus":0.10081132649555286,"score_gpt":0.3732081519797956,"score_spread":0.27239682548424277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3153228158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829895,0.009104853,0.00079217716,0.000775776,0.000872957,0.0021348628,0.00096670486,0.00016525015,0.0021978945],"genre_scores_gemma":[0.98429614,0.004257961,0.0013020014,0.0011638742,0.00050367863,0.0023117075,0.00089892984,0.000033558612,0.005232055],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994553,0.0002824578,0.000032464577,0.00010707076,0.000032231725,0.00009049919],"domain_scores_gemma":[0.99938726,0.00018668533,0.00015169755,0.000046835725,0.000029828376,0.00019770474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017654762,0.0017706782,0.0032461071,0.00042289248,0.00038219773,0.0009978594,0.0009527426,0.0016701078,0.0061757164],"category_scores_gemma":[0.0013956199,0.0006761228,0.0020979114,0.0003772565,0.0011377643,0.0011548871,0.00042398277,0.0031269377,0.0011980439],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98392016,0.0024065487,0.00017104301,0.0005272874,0.0006235327,0.000017233937,0.000029622108,0.00019602325,0.0019094453,0.000052429405,0.00046018334,0.009686537],"study_design_scores_gemma":[0.96199465,0.03581842,0.0010012493,0.000032572214,0.00036602846,0.000014142028,0.000013192257,0.00019953492,0.00019042731,0.000093460476,0.00026633023,0.000009908909],"about_ca_topic_score_codex":0.0014824322,"about_ca_topic_score_gemma":0.0030141724,"teacher_disagreement_score":0.0061757164,"about_ca_system_score_codex":0.00082233653,"about_ca_system_score_gemma":0.0008435167,"threshold_uncertainty_score":0.020659864},"labels":[],"label_agreement":null},{"id":"W3155089045","doi":"10.1016/s1470-2045(21)00098-x","title":"Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; AstraZeneca","keywords":"Medicine; BRCA mutation; Internal medicine; Ovarian cancer; Clinical endpoint; Oncology; Olaparib; Placebo; Quality of life (healthcare); Cancer; Response Evaluation Criteria in Solid Tumors; Progression-free survival; Clinical trial; Progressive disease; Chemotherapy; Pathology","score_opus":0.02288432002918147,"score_gpt":0.3707904252599238,"score_spread":0.34790610523074234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3155089045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99489695,0.002407919,0.00016882367,0.0003230935,0.00018993615,0.0005306845,0.0008156418,0.00002420672,0.00064270967],"genre_scores_gemma":[0.99498135,0.0009555386,0.00042178313,0.00044575718,0.00028757146,0.00092499,0.0010624084,0.00000854211,0.00091217353],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99889416,0.00060264743,0.00006229352,0.00022889978,0.00006729769,0.00014478111],"domain_scores_gemma":[0.99781895,0.0007243052,0.0006335407,0.00017132224,0.00008210432,0.0005698392],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021075145,0.0019567888,0.0031334844,0.00035458963,0.0004377849,0.0012404172,0.0010086448,0.0021934928,0.00471725],"category_scores_gemma":[0.0025444091,0.00067293044,0.0041277027,0.0005101633,0.0013304726,0.0012643508,0.0007068406,0.003987075,0.0005649081],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.986937,0.001993325,0.0022555096,0.00025887365,0.0013963855,0.000018652967,0.000043765536,0.00029680945,0.00051297474,0.000042423744,0.00023042755,0.0060137575],"study_design_scores_gemma":[0.8962571,0.08562639,0.01494534,0.0000489042,0.0015940082,0.000039764713,0.000047890346,0.00055847876,0.00023484092,0.00022922589,0.00038011174,0.0000380092],"about_ca_topic_score_codex":0.0016355282,"about_ca_topic_score_gemma":0.0023501506,"teacher_disagreement_score":0.00471725,"about_ca_system_score_codex":0.0011283138,"about_ca_system_score_gemma":0.0009238216,"threshold_uncertainty_score":0.015780807},"labels":[],"label_agreement":null},{"id":"W3155753566","doi":"10.1016/s1470-2045(21)00076-0","title":"Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Institut National Du Cancer; ECOG-ACRIN Cancer Research Group; Ministère des Affaires Sociales, de la Santé et des Droits des Femmes; NRG Oncology; Fondation ARC pour la Recherche sur le Cancer; American College of Radiology Imaging Network","keywords":"Radiation therapy; Head and neck cancer; Head and neck; Meta-analysis; Medicine; Oncology; Medical physics; Radiology; Internal medicine; Surgery","score_opus":0.17483215799017698,"score_gpt":0.4213770556082601,"score_spread":0.24654489761808313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3155753566","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24236757,0.73080444,0.011453522,0.0022963213,0.0021757975,0.00042367505,0.007901555,0.00040936918,0.0021677553],"genre_scores_gemma":[0.96555525,0.025509948,0.0036261256,0.001490177,0.00045376547,0.0003575729,0.0015675809,0.00018097046,0.0012586088],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.97385377,0.019638803,0.0019471222,0.0026445477,0.0010606572,0.00085511716],"domain_scores_gemma":[0.9692599,0.020918762,0.0036105148,0.004582596,0.0010489501,0.00057935267],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.019938909,0.0030525604,0.008363665,0.0018494962,0.0006835294,0.0027756868,0.002770643,0.0028249156,0.004831861],"category_scores_gemma":[0.038001698,0.0023854622,0.047187705,0.0031600762,0.00076374883,0.0017418641,0.002236282,0.0041725165,0.0006331336],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00675446,0.00002393706,0.017046489,0.0051070526,0.966924,0.00008095308,0.00004619193,0.0009439222,0.0001915238,0.00012998136,0.0006213857,0.0021302057],"study_design_scores_gemma":[0.0020111117,0.0003124665,0.011922473,0.0005843899,0.9828897,0.00008985289,0.00004345486,0.0006162711,0.00008727256,0.00038404285,0.0010266847,0.000032278105],"about_ca_topic_score_codex":0.013659701,"about_ca_topic_score_gemma":0.021969775,"teacher_disagreement_score":0.99163634,"about_ca_system_score_codex":0.0015945763,"about_ca_system_score_gemma":0.0015268887,"threshold_uncertainty_score":0.105448246},"labels":[],"label_agreement":null},{"id":"W3156638008","doi":"10.1016/s1470-2045(20)30688-4","title":"Surveillance for subsequent neoplasms of the CNS for childhood, adolescent, and young adult cancer survivors: a systematic review and recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group","year":2021,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster Children's Hospital","funders":"Brain Tumour Charity; CHILDREN with CANCER UK; Academy of Medical Sciences","keywords":"Medicine; Guideline; Psychological intervention; Cancer; Survivorship curve; Harmonization; Quality of life (healthcare); Health care; Family medicine; Intensive care medicine; Pathology; Psychiatry; Nursing; Internal medicine","score_opus":0.035375236342508255,"score_gpt":0.3573884212546502,"score_spread":0.3220131849121419,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3156638008","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00033511835,0.9982705,0.0001611802,0.0003319191,0.000121779776,0.00012924604,0.00046963943,0.0000060488733,0.00017451285],"genre_scores_gemma":[0.0037523916,0.99462974,0.0005424745,0.00056044577,0.00004196796,0.00014279212,0.00024757307,0.0000027268745,0.00007981287],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9980167,0.0005501039,0.0008054311,0.00018870119,0.00036139405,0.000077527715],"domain_scores_gemma":[0.9951101,0.0032051136,0.00097412453,0.00007231125,0.00055164885,0.000086680375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004305545,0.0009681461,0.005229814,0.0032883077,0.0003121884,0.0011872646,0.0013832874,0.0012189919,0.0023763743],"category_scores_gemma":[0.014362051,0.00053627405,0.008215752,0.0032340672,0.0004090031,0.0011475054,0.00095765473,0.0013233343,0.00028064224],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031801857,0.000020927106,0.0014015028,0.8067662,0.016500114,0.000067296634,0.00012065778,0.0003089779,0.00026455993,0.0005192276,0.0069328616,0.16677967],"study_design_scores_gemma":[0.0006184715,0.00020469537,0.007316892,0.8113217,0.1200454,0.00027177436,0.0002054791,0.0001446777,0.00030325705,0.0009131037,0.05859218,0.00006241547],"about_ca_topic_score_codex":0.021586431,"about_ca_topic_score_gemma":0.06306892,"teacher_disagreement_score":0.021586431,"about_ca_system_score_codex":0.002205093,"about_ca_system_score_gemma":0.007468765,"threshold_uncertainty_score":0.042921543},"labels":[],"label_agreement":null},{"id":"W3157621523","doi":"10.1016/s1470-2045(21)00244-8","title":"Cancer and COVID-19 vaccines: a complex global picture","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Guy's and St Thomas' NHS Foundation Trust; Menzies Centre for Australian Studies, King's College London, University of London; Science and Technology Facilities Council; Economic and Social Research Council; Homi Bhabha National Institute; Faculty of Medicine, American University of Beirut; Tata Memorial Centre; Queen's University; Hacettepe Üniversitesi; Universiti Malaya; National Institute for Health and Care Research; American University of Beirut; Cancer Research Institute; Pfizer; University of Warwick; King's College London","keywords":"Medicine; Cancer; Pandemic; Vaccination; Coronavirus disease 2019 (COVID-19); Population; Disadvantaged; Family medicine; Global health; Public health; Disease; Environmental health; Internal medicine; Economic growth; Virology; Pathology; Infectious disease (medical specialty)","score_opus":0.19691557538566312,"score_gpt":0.501693777433073,"score_spread":0.30477820204740985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157621523","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005134086,0.31482694,0.00084350817,0.65749186,0.0075829923,0.000020083484,0.0014514884,0.00006734112,0.012581668],"genre_scores_gemma":[0.12444212,0.6038028,0.0024662393,0.23737603,0.02505605,0.000088711866,0.0015499069,0.00019103558,0.0050271493],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958962,0.001229496,0.00028920034,0.00045051647,0.0012842058,0.00085034803],"domain_scores_gemma":[0.9862748,0.0077832574,0.0016805336,0.00039386135,0.0017825767,0.0020849695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009003182,0.0010547267,0.0018267732,0.002939373,0.0013379788,0.007905148,0.0012842042,0.007434838,0.020657107],"category_scores_gemma":[0.015181032,0.0006695074,0.0015652596,0.0045777108,0.0031787222,0.01458096,0.0063509797,0.008295171,0.0024679617],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007453825,0.00018289787,0.015635608,0.004626138,0.0008663567,0.00049145543,0.0009785542,0.0028781106,0.001206008,0.12954947,0.52331585,0.3195241],"study_design_scores_gemma":[0.0001248421,0.0002446981,0.022588873,0.006590971,0.0004047591,0.00047764764,0.004141396,0.00073500676,0.00041036357,0.1285217,0.83556455,0.00019513723],"about_ca_topic_score_codex":0.009716026,"about_ca_topic_score_gemma":0.01592581,"teacher_disagreement_score":0.020657107,"about_ca_system_score_codex":0.0057676956,"about_ca_system_score_gemma":0.00718431,"threshold_uncertainty_score":0.06910485},"labels":[],"label_agreement":null},{"id":"W3158782098","doi":"10.1016/s1470-2045(21)00009-7","title":"Diffuse intrinsic pontine glioma: a clinic in Mexico, social media, and unpublishable data","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Glioma; Brainstem; Medicine; Radiation therapy; Overall survival; Clinical trial; Pons; Oncology; Surgery; Internal medicine; Cancer research","score_opus":0.10263357418394638,"score_gpt":0.3697019884024751,"score_spread":0.2670684142185287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158782098","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95604223,0.0027722942,0.00027042467,0.02360131,0.00016771525,0.000047057292,0.0035660397,0.000048788235,0.013484149],"genre_scores_gemma":[0.9883889,0.003203499,0.0005186584,0.001619905,0.00029355258,0.000031117404,0.0012334386,0.000028988296,0.0046820403],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.9998036,0.000030234394,0.000015387735,0.000037574275,0.000034041877,0.00007916166],"domain_scores_gemma":[0.9990908,0.00019311678,0.00032060113,0.000030062176,0.00012401718,0.0002414266],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00023617792,0.00015593092,0.0001780902,0.00083814113,0.0018671225,0.0009083672,0.00034108997,0.00076193333,0.0060234275],"category_scores_gemma":[0.0011233719,0.00014328692,0.00012251512,0.0019846067,0.0004899227,0.00088037556,0.0006129234,0.00065167894,0.00040166843],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024854564,0.00021683087,0.84499896,0.00028816983,0.00005355947,0.077048585,0.005886645,0.00011978866,0.0025309334,0.0013186559,0.029053444,0.03823584],"study_design_scores_gemma":[0.000036376863,0.0001604652,0.881697,0.00030993225,0.00009873415,0.047729895,0.02876725,0.00029773277,0.00053132826,0.000890301,0.03942307,0.0000579431],"about_ca_topic_score_codex":0.07948965,"about_ca_topic_score_gemma":0.120836176,"teacher_disagreement_score":0.99976385,"about_ca_system_score_codex":0.0013826162,"about_ca_system_score_gemma":0.0023639807,"threshold_uncertainty_score":0.15805393},"labels":[],"label_agreement":null},{"id":"W3161800158","doi":"10.1016/s1470-2045(21)00090-5","title":"Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":327,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Vifor Pharma; European Organisation for Research and Treatment of Cancer; National Cancer Institute; Medac; KWF Kankerbestrijding; Daiichi-Sankyo; Brain Tumour Charity; NRG Oncology; Atara Biotherapeutics; AstraZeneca; American College of Radiology; Novocure; Douglas Pharmaceuticals; Merck Sharp and Dohme; Cancer Australia; National Health and Medical Research Council; Cancer Research UK; Medical Research Council; Celgene","keywords":"Temozolomide; Medicine; Internal medicine; Oncology; Interim analysis; Radiation therapy; Glioma; Dacarbazine; Clinical trial; Chemotherapy; Cancer research","score_opus":0.10069948046989596,"score_gpt":0.4439617932321269,"score_spread":0.34326231276223096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3161800158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99046725,0.002126405,0.000672289,0.0003897268,0.0003009547,0.0020053708,0.0017366494,0.00011013909,0.0021912018],"genre_scores_gemma":[0.98332095,0.0017964921,0.0018408285,0.00088562025,0.00023348733,0.003675139,0.003440454,0.00007217914,0.0047347494],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9989625,0.0005556519,0.000039357696,0.000155995,0.00006553729,0.00022098744],"domain_scores_gemma":[0.99879944,0.00032775142,0.00019818405,0.00015490285,0.00006235656,0.00045741297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002926899,0.001833634,0.0031831674,0.00052590383,0.00042960473,0.0013149068,0.00095144636,0.0016369942,0.0058418023],"category_scores_gemma":[0.001722882,0.000744152,0.002233337,0.00052890147,0.0013669365,0.0015674132,0.00048593892,0.003552418,0.0011736903],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97331965,0.0062844837,0.0008222242,0.00026400478,0.00077848893,0.00003446091,0.00007478594,0.00070703984,0.0025169598,0.00012551156,0.0008837408,0.0141887115],"study_design_scores_gemma":[0.8302129,0.16240384,0.00410538,0.000027557968,0.0006149011,0.000057674944,0.00004770194,0.0005272744,0.0006095553,0.00028856398,0.0010828876,0.000021771391],"about_ca_topic_score_codex":0.0022750858,"about_ca_topic_score_gemma":0.007102973,"teacher_disagreement_score":0.0058418023,"about_ca_system_score_codex":0.001449515,"about_ca_system_score_gemma":0.0021557831,"threshold_uncertainty_score":0.019542754},"labels":[],"label_agreement":null},{"id":"W3164197656","doi":"10.1016/s1470-2045(21)00152-2","title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":648,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Sunnybrook Health Science Centre","funders":"Janssen Pharmaceuticals; Merck Sharp and Dohme; British Microcirculation Society; Novartis; Sanofi; Merck; GlaxoSmithKline; Eli Lilly and Company; AstraZeneca; Bayer; Ipsen; Clovis Oncology; Roche; Astellas Pharma US; LEO Pharma Research Foundation; Pfizer","keywords":"Medicine; Pembrolizumab; Carboplatin; Gemcitabine; Chemotherapy; Oncology; Internal medicine; Metastatic Urothelial Carcinoma; Urothelial carcinoma; Population; Cisplatin; Cancer; Immunotherapy; Bladder cancer","score_opus":0.10115703839334929,"score_gpt":0.4104142656501243,"score_spread":0.309257227256775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164197656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96860784,0.011985543,0.0013415525,0.0021585338,0.0017758782,0.006199923,0.003327472,0.0003096708,0.004293576],"genre_scores_gemma":[0.97191525,0.006288302,0.0026701563,0.002274441,0.00066959125,0.0058359415,0.0023538421,0.00006896683,0.007923599],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991696,0.00043824143,0.000037266083,0.00016662474,0.000045347086,0.0001429295],"domain_scores_gemma":[0.99898773,0.0003302756,0.0001949141,0.000074128366,0.00004719711,0.0003657432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024809523,0.0025099767,0.0041620308,0.000577786,0.0005655047,0.0015654713,0.0013626971,0.0026990243,0.011792721],"category_scores_gemma":[0.0022174192,0.00094004464,0.0035826392,0.0005782025,0.0015436375,0.0019710371,0.0006453112,0.0054567046,0.002023682],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98306215,0.003347754,0.00014521816,0.0006942588,0.0007557115,0.000019869905,0.00004086585,0.00032975795,0.0011895619,0.00010611203,0.00083851593,0.009470177],"study_design_scores_gemma":[0.96501523,0.033267215,0.00047355125,0.000034018467,0.00032220158,0.000019279696,0.000014437401,0.00021306647,0.00012881531,0.0001431394,0.00035735537,0.000011675306],"about_ca_topic_score_codex":0.0017108952,"about_ca_topic_score_gemma":0.0033899688,"teacher_disagreement_score":0.011792721,"about_ca_system_score_codex":0.0013216818,"about_ca_system_score_gemma":0.001377877,"threshold_uncertainty_score":0.039450586},"labels":[],"label_agreement":null},{"id":"W3164781831","doi":"10.1016/s1470-2045(21)00147-9","title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":533,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Janssen Pharmaceuticals; Pfizer Japan; Genentech; Bavarian Nordic; Merck Sharp and Dohme; Ono Pharmaceutical; European Association of Urology; Bayer Fund; Mirati Therapeutics; Clovis Oncology; Sanofi; GlaxoSmithKline; Merck; Genzyme; Genomic Health; Chugai Pharmaceutical; Roche; Astellas Pharma US; Pfizer; Heron Therapeutics; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim","keywords":"Medicine; Pembrolizumab; Cystoscopy; Bladder cancer; Cystectomy; Cancer; Internal medicine; Clinical endpoint; Surgery; Progressive disease; Urology; Oncology; Clinical trial; Immunotherapy; Disease; Urinary system","score_opus":0.11916421107182466,"score_gpt":0.43648497625447374,"score_spread":0.31732076518264907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164781831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988684,0.0054141344,0.0006050118,0.00056319404,0.0002473076,0.0015789911,0.0009604404,0.00009785996,0.0018490889],"genre_scores_gemma":[0.982862,0.005849948,0.0018968867,0.0017709972,0.00029495178,0.0018196737,0.0021524176,0.000035267472,0.0033179228],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99964476,0.0001639549,0.000014699856,0.000060656665,0.000031956926,0.00008406435],"domain_scores_gemma":[0.99954623,0.00009818466,0.000084785235,0.00003178404,0.000031775067,0.00020712813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017786337,0.001430724,0.0023160041,0.00041519248,0.00035831844,0.0010782388,0.00081555673,0.0013946786,0.0034637954],"category_scores_gemma":[0.00081084226,0.00052574114,0.0016805416,0.00040327522,0.0008461967,0.0012600686,0.00032863783,0.0029859405,0.0009391243],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8424449,0.035174806,0.0019822163,0.0018753282,0.002474389,0.00017744402,0.00020599499,0.001551956,0.017562494,0.00031451936,0.0034759797,0.092759974],"study_design_scores_gemma":[0.77563506,0.21430403,0.005560243,0.000070884846,0.0007301702,0.00013409555,0.00005466065,0.00075025455,0.0009752059,0.00017754274,0.0015788599,0.00002892416],"about_ca_topic_score_codex":0.00089892425,"about_ca_topic_score_gemma":0.0025070678,"teacher_disagreement_score":0.0034637954,"about_ca_system_score_codex":0.0007554578,"about_ca_system_score_gemma":0.0011443824,"threshold_uncertainty_score":0.01158756},"labels":[],"label_agreement":null},{"id":"W3165241302","doi":"10.1016/s1470-2045(21)00151-0","title":"Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":373,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Genentech; F. Hoffmann-La Roche","keywords":"Medicine; Sorafenib; Bevacizumab; Atezolizumab; Internal medicine; Oncology; Hepatocellular carcinoma; Quality of life (healthcare); Response Evaluation Criteria in Solid Tumors; Clinical trial; Progression-free survival; Performance status; Cancer; Clinical endpoint; Phases of clinical research; Surgery; Chemotherapy; Pembrolizumab; Immunotherapy","score_opus":0.1298463038578968,"score_gpt":0.3448993800596667,"score_spread":0.2150530762017699,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165241302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98884493,0.0059319227,0.0004875122,0.00089925755,0.0004630692,0.00085061474,0.0010124774,0.00007443357,0.0014358246],"genre_scores_gemma":[0.9920697,0.0019637041,0.0007318628,0.0008282813,0.0003603901,0.0011777624,0.0013489836,0.000018780594,0.0015005497],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9992059,0.00043608772,0.000047465914,0.00013456441,0.00004683147,0.0001293205],"domain_scores_gemma":[0.99874485,0.0003825109,0.00037779534,0.00010153418,0.00006291601,0.00033039122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019424686,0.0017820785,0.0026550703,0.00031169355,0.00031113715,0.0013453049,0.00075133215,0.0016132186,0.0049651135],"category_scores_gemma":[0.0023351782,0.0006286911,0.0036451537,0.00036597345,0.0010563431,0.0013259768,0.00058362907,0.0036470296,0.0008978957],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97678703,0.0023121976,0.0013493851,0.000612547,0.0024613333,0.000032356143,0.000053310054,0.00052503287,0.0011355953,0.00010629284,0.00081817224,0.013806757],"study_design_scores_gemma":[0.93838185,0.054439567,0.003958068,0.000056356643,0.0013982287,0.000053275537,0.000036748817,0.0005331836,0.0002660276,0.00026651288,0.00058242114,0.000027812253],"about_ca_topic_score_codex":0.0008564305,"about_ca_topic_score_gemma":0.0017193593,"teacher_disagreement_score":0.0049651135,"about_ca_system_score_codex":0.0009416564,"about_ca_system_score_gemma":0.00066857267,"threshold_uncertainty_score":0.016610026},"labels":[],"label_agreement":null},{"id":"W3165702866","doi":"10.1016/s1470-2045(21)00240-0","title":"Impact of COVID-19 on cancer care in India: a cohort study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":164,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Cancer Society; Cancer Research UK","keywords":"Coronavirus disease 2019 (COVID-19); Cohort; 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Medicine; Cohort study; Cancer; Environmental health; Virology; Geography; Internal medicine; Outbreak; Disease; Infectious disease (medical specialty)","score_opus":0.11952425641143329,"score_gpt":0.5232355036656434,"score_spread":0.40371124725421015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165702866","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984121,0.0018071973,0.00010774039,0.0021460834,0.00012586653,0.00005120922,0.007292249,0.000014091791,0.0043345713],"genre_scores_gemma":[0.9962851,0.0007859177,0.000088127665,0.00043260446,0.000049519887,0.000026232507,0.0015702121,0.0000106860225,0.00075157644],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980938,0.00031766391,0.00019097379,0.00021930446,0.00024833015,0.000929925],"domain_scores_gemma":[0.99440295,0.00062641746,0.0023386145,0.0006308219,0.000725448,0.0012757819],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011928515,0.00025548073,0.000393846,0.00081206014,0.0011457289,0.0020184384,0.0010207376,0.00080487167,0.0051341425],"category_scores_gemma":[0.0055816453,0.00045493717,0.0009692947,0.0044066496,0.0006154399,0.0008621826,0.0025790452,0.0030714176,0.00068246515],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018988356,0.00008590361,0.994007,0.000076781595,0.00020294318,0.00013798142,0.00046639214,0.000049766906,0.000063898806,0.00031192575,0.002071121,0.0023363873],"study_design_scores_gemma":[0.000012908097,0.00010102259,0.99521685,0.00008736534,0.00018909825,0.00020029943,0.001946453,0.000079612546,0.000047442623,0.0000887883,0.0020069736,0.00002301095],"about_ca_topic_score_codex":0.105380654,"about_ca_topic_score_gemma":0.11022209,"teacher_disagreement_score":0.105380654,"about_ca_system_score_codex":0.0019428447,"about_ca_system_score_gemma":0.0034979014,"threshold_uncertainty_score":0.20953453},"labels":[],"label_agreement":null},{"id":"W3165727183","doi":"10.1016/s1470-2045(21)00290-4","title":"Pembrolizumab for relapsed or refractory Hodgkin lymphoma – Author's reply","year":2021,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck","keywords":"Brentuximab vedotin; Pembrolizumab; Medicine; Oncology; Context (archaeology); Internal medicine; Clinical endpoint; Refractory (planetary science); Population; Lymphoma; Hodgkin lymphoma; Randomized controlled trial; Cancer; Immunotherapy","score_opus":0.10220128046909066,"score_gpt":0.3670396438270521,"score_spread":0.26483836335796146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165727183","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021522235,0.002020784,0.000030620653,0.96565276,0.030485013,0.000006366412,0.00004052749,0.000009012635,0.0015397106],"genre_scores_gemma":[0.002535572,0.0010096029,0.000059817306,0.94869983,0.042978402,0.00002157814,0.000027536893,0.0000127003495,0.004655015],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99764544,0.0007739581,0.00026373588,0.0002999489,0.0005823091,0.00043460974],"domain_scores_gemma":[0.9926363,0.0046616923,0.0005017587,0.00018451754,0.00091672345,0.0010990573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027954981,0.0007421004,0.0015456532,0.0008178973,0.0032333618,0.0038772705,0.0016267387,0.06224779,0.006589104],"category_scores_gemma":[0.016852656,0.0007943775,0.0010865595,0.00066711643,0.0026656573,0.0027454984,0.0018103343,0.038900055,0.0045732195],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006379623,0.00001382832,0.00028721767,0.000049045855,0.00002042824,0.0008436879,0.00008076152,0.000037955295,0.00010479123,0.0014710249,0.99300694,0.004020508],"study_design_scores_gemma":[0.00026136494,0.00007068826,0.0011321588,0.000367972,0.00006903338,0.0015639764,0.00031651292,0.00025901114,0.00018945705,0.006046934,0.9896673,0.000055658],"about_ca_topic_score_codex":0.0040378207,"about_ca_topic_score_gemma":0.0063192523,"teacher_disagreement_score":0.06224779,"about_ca_system_score_codex":0.0039834804,"about_ca_system_score_gemma":0.003102163,"threshold_uncertainty_score":0.028902352},"labels":[],"label_agreement":null},{"id":"W3166415013","doi":"10.1016/s1470-2045(21)00189-3","title":"Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Health and Medical Research Council; Centre Léon Bérard; Universiti Sultan Zainal Abidin; National Institutes of Health; Ramsay Santé; Assistance publique-Hôpitaux de Paris; University of Colorado School of Medicine, Anschutz Medical Campus; Olav Thon Stiftelsen; Novo Nordisk Fonden; Instrumentariumin Tiedesäätiö; Universidad Pública de Navarra; Centro de Investigación Biomédica en Red de Cáncer; University of Cape Town; Aalborg Universitetshospital; Deutsche Krebshilfe; University of Texas MD Anderson Cancer Center; Leids Universitair Medisch Centrum; Emil Aaltosen Säätiö; City of Hope; Jane ja Aatos Erkon Säätiö; Universiti Sains Malaysia; Peter MacCallum Cancer Centre; Intelligent Manufacturing Research Center; Syöpäsäätiö; Financiadora de Estudos e Projetos; Novo Nordisk; Associazione Italiana per la Ricerca sul Cancro; Aalborg Universitet; Rigshospitalet; Kræftens Bekæmpelse; University of Melbourne; University of New South Wales; National Medical Research Council; Universiteit Leiden; Cancer Council NSW; National Cancer Centre of Singapore; Universiteit van Amsterdam; Universitair Medisch Centrum Groningen; Newcastle University; Health and Care Research Wales; KWF Kankerbestrijding; Cancer Research UK; Canadian Institutes of Health Research; Sigrid Juséliuksen Säätiö; University of Southampton; Amsterdam University Medical Centers; Institut National de la Santé et de la Recherche Médicale; Cancer Council Tasmania; Cedars-Sinai Medical Center; Swedish Cancer Foundation; University Hospitals of Leicester NHS Trust; Parc Geneteg Cymru; Svenska Läkaresällskapet; Gentofte Hospital; Deutsche Forschungsgemeinschaft; Medical Research Council; Nordea-fonden; National Institute for Health and Care Research; Odense Universitetshospital; Nebraska Department of Health and Human Services; Comprehensive Cancer Center, City of Hope; Kreftforeningen; South African Medical Research Council; Deutsches Krebsforschungszentrum; Academy of Finland; Suomen Lääketieteen Säätiö; University of Washington; Helsingin Yliopisto; Royal Adelaide Hospital; NIHR Maudsley Biomedical Research Centre; Rijksuniversiteit Groningen; U.S. Department of Health and Human Services; Creighton University; Instituto de Salud Carlos III; Ohio State University","keywords":"Colorectal cancer; Retrospective cohort study; Variation (astronomy); Lynch syndrome; Medicine; Cohort; Oncology; Cancer; Internal medicine; Demography; DNA mismatch repair; Sociology","score_opus":0.018034424145528947,"score_gpt":0.31292801673736964,"score_spread":0.29489359259184067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166415013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986399,0.0002197002,0.00019953231,0.000018369818,0.000004531879,0.000028960974,0.0007108627,0.000005611788,0.00017257941],"genre_scores_gemma":[0.99877685,0.00017234271,0.00022087664,0.00002515352,0.0000049200107,0.000031242176,0.00066566793,0.0000038222047,0.000099135956],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986198,0.00030898774,0.00013719188,0.0005528746,0.00019391932,0.00018726333],"domain_scores_gemma":[0.99779737,0.00037397668,0.00074109656,0.00049553666,0.00026541724,0.00032674137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014313175,0.0004649371,0.0005712735,0.0014064312,0.0010758963,0.0007078575,0.0005190193,0.0005993342,0.0012583487],"category_scores_gemma":[0.0028628048,0.00075830036,0.00079323765,0.0020054432,0.00042871755,0.00053820485,0.00070503395,0.00066306605,0.0002616165],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010465915,0.000030166737,0.99833435,0.000009029657,0.00011244801,0.00033538707,0.00016209662,0.00004489009,0.00022889087,0.000018054865,0.00009290635,0.00052699534],"study_design_scores_gemma":[0.000018294068,0.00019419049,0.9975758,0.000012662906,0.000102478945,0.0012390799,0.0003228008,0.00014438858,0.00006198076,0.000018049424,0.00029997007,0.000010395403],"about_ca_topic_score_codex":0.023698004,"about_ca_topic_score_gemma":0.019151382,"teacher_disagreement_score":0.023698004,"about_ca_system_score_codex":0.00061838713,"about_ca_system_score_gemma":0.00071476604,"threshold_uncertainty_score":0.047120154},"labels":[],"label_agreement":null},{"id":"W3167396950","doi":"10.1016/s1470-2045(21)00196-0","title":"Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":404,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; University of Alberta; BC Cancer Agency; Toronto Western Hospital; University of Manitoba; University of Toronto; McMaster University; Queen's University; Princess Margaret Cancer Centre; University of Calgary; Centre Hospitalier de l’Université de Montréal; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Health and Medical Research Council; Canadian Cancer Society","keywords":"Medicine; Radiation therapy; External beam radiotherapy; Stereotactic radiotherapy; Radiosurgery; Randomized controlled trial; Radiology; Surgery; Brachytherapy","score_opus":0.06422644521205337,"score_gpt":0.40031675943005973,"score_spread":0.3360903142180064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167396950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800234,0.008816249,0.0012512908,0.001158933,0.0012158761,0.003838252,0.0010843746,0.00017207129,0.0024397406],"genre_scores_gemma":[0.9821147,0.004639795,0.0019326517,0.0014946616,0.0007140743,0.004045163,0.00088472234,0.00004092532,0.004133447],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991861,0.00044401866,0.00004296191,0.00014317087,0.00006653373,0.00011708993],"domain_scores_gemma":[0.999158,0.00032704123,0.00020058488,0.00006486199,0.000047794765,0.00020169264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018242456,0.002354253,0.003739756,0.0005207952,0.0004639454,0.001122044,0.00125399,0.0022432064,0.008479965],"category_scores_gemma":[0.0022055032,0.0006874301,0.0028735143,0.0006943528,0.0016523539,0.0012671389,0.0005154497,0.003838231,0.0011935072],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9833815,0.0028100836,0.00019784101,0.00073010393,0.0010070655,0.000024291188,0.000057028272,0.00036266271,0.0014628805,0.00010439397,0.00062007864,0.009242009],"study_design_scores_gemma":[0.97080976,0.027589802,0.0005607539,0.000027711721,0.000294937,0.000017174612,0.00001628226,0.00022095576,0.00008988682,0.0001483059,0.00021520097,0.000009061156],"about_ca_topic_score_codex":0.0018719655,"about_ca_topic_score_gemma":0.0036830711,"teacher_disagreement_score":0.008479965,"about_ca_system_score_codex":0.0010092133,"about_ca_system_score_gemma":0.001202473,"threshold_uncertainty_score":0.028368294},"labels":[],"label_agreement":null},{"id":"W3169849224","doi":"10.1016/s1470-2045(21)00216-3","title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":405,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Eisai; Array BioPharma; Clovis Oncology; Roche; Mersana Therapeutics; Novartis; Merck KGaA; Merck; GlaxoSmithKline; Bristol-Myers Squibb; AstraZeneca; Pfizer","keywords":"Javelin; Ovarian cancer; Avelumab; Medicine; Refractory (planetary science); Chemotherapy; Open label; Oncology; Internal medicine; Cancer; Clinical trial; Immunotherapy; Nivolumab","score_opus":0.09341405805658175,"score_gpt":0.40025337878758066,"score_spread":0.3068393207309989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169849224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891243,0.0044856304,0.0006453345,0.0006115057,0.00047974385,0.0013785936,0.00096044486,0.00013722364,0.0021772997],"genre_scores_gemma":[0.98645234,0.0036234995,0.0013819595,0.0008578201,0.00032505472,0.0016447989,0.0009307336,0.000043611042,0.004740279],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99963677,0.00019298586,0.000017420018,0.00006127322,0.00002515377,0.00006646174],"domain_scores_gemma":[0.9993243,0.00025963766,0.00012576314,0.00005105353,0.000025551155,0.00021372268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012020178,0.0012373326,0.0025522693,0.00041328027,0.0002899703,0.0009954689,0.0007260093,0.0013426291,0.0063275457],"category_scores_gemma":[0.0013874558,0.00058830704,0.0016740862,0.00043067572,0.0010368777,0.001186102,0.00034105143,0.0028561226,0.0010142917],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9666677,0.0064301034,0.0004006393,0.0005937877,0.00077547133,0.000025376783,0.00005506372,0.00044176407,0.0027909102,0.0001429562,0.000866207,0.020810107],"study_design_scores_gemma":[0.9243148,0.072360195,0.0013765563,0.00002799371,0.00034978308,0.000030259644,0.000025462055,0.0004399921,0.00030225393,0.00017865904,0.0005768172,0.000017198972],"about_ca_topic_score_codex":0.00086523534,"about_ca_topic_score_gemma":0.0022067954,"teacher_disagreement_score":0.0063275457,"about_ca_system_score_codex":0.0005917924,"about_ca_system_score_gemma":0.0006481335,"threshold_uncertainty_score":0.021167755},"labels":[],"label_agreement":null},{"id":"W3173587834","doi":"10.1016/s1470-2045(21)00271-0","title":"Biomedicine and the soul of medicine: optimising the balance","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Biomedicine; Scopus; Psychological intervention; Health care; Medicine; Palliative care; Alternative medicine; Commission; Family medicine; Soul; Investment (military); Gerontology; Political science; MEDLINE; Nursing; Law; Pathology; Philosophy; Theology","score_opus":0.2011820643592713,"score_gpt":0.4728571802905071,"score_spread":0.27167511593123583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173587834","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008484241,0.112163834,0.002903995,0.85068834,0.010307602,0.000019005945,0.000035462024,0.00004984073,0.02298352],"genre_scores_gemma":[0.18517715,0.18384418,0.0087522855,0.53997177,0.06836534,0.00028599854,0.0000869717,0.00035928743,0.013156992],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.96677333,0.020320324,0.0013125268,0.0019016886,0.0068407473,0.0028512669],"domain_scores_gemma":[0.89108205,0.07717616,0.005007009,0.0041553807,0.0062061124,0.016373241],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.052369203,0.0016622333,0.0038640187,0.004196053,0.0077771354,0.031062696,0.003696562,0.031032396,0.01675257],"category_scores_gemma":[0.055837214,0.0010777977,0.0012897195,0.0027915651,0.074197985,0.050076287,0.025445357,0.029745061,0.004485311],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019584356,0.0001350686,0.0005392886,0.0020496696,0.0002439552,0.00020564275,0.0063449806,0.0008100844,0.0005820683,0.78122985,0.13973863,0.06792485],"study_design_scores_gemma":[0.00007470464,0.00007305927,0.00034016324,0.0018135795,0.000032149066,0.00014444024,0.0034113787,0.00020079453,0.00010614785,0.7176121,0.2761269,0.0000647683],"about_ca_topic_score_codex":0.0027645547,"about_ca_topic_score_gemma":0.0046456615,"teacher_disagreement_score":0.052369203,"about_ca_system_score_codex":0.012297154,"about_ca_system_score_gemma":0.0307676,"threshold_uncertainty_score":0.27695817},"labels":[],"label_agreement":null},{"id":"W3176933341","doi":"10.1016/s1470-2045(21)00077-2","title":"The International Collaboration for Research methods Development in Oncology (CReDO) workshops: shaping the future of global oncology research","year":2021,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Queen's University","funders":"Medical Research Council; National Institutes of Health; Cancer Research UK; World Health Organization","keywords":"Context (archaeology); Oncology; Medicine; Internal medicine; Observational study; Developing country; Capacity building; Clinical trial; Global health; Clinical research; Medical education; Political science; Public health; Nursing; Economic growth","score_opus":0.46434565745183876,"score_gpt":0.6903995163852735,"score_spread":0.22605385893343477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176933341","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008783286,0.9159552,0.0022635548,0.06876678,0.010056963,0.00010330151,0.0001262306,0.00006842883,0.0025716736],"genre_scores_gemma":[0.002989434,0.94536227,0.010928348,0.032224547,0.005580872,0.0004494801,0.0003206777,0.000077983415,0.0020665086],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9607004,0.025479682,0.0031900397,0.0012573657,0.0077345646,0.0016379438],"domain_scores_gemma":[0.7964474,0.1500675,0.0075766826,0.0068625347,0.028317599,0.010728219],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.1337749,0.0016622704,0.0036722647,0.0053669857,0.0014008438,0.007014595,0.00380173,0.010048787,0.008196263],"category_scores_gemma":[0.10677516,0.0007671239,0.002775696,0.005490639,0.0052432744,0.009044099,0.009909977,0.017316202,0.0027679761],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017457991,0.00009118073,0.0002895988,0.019166393,0.0002762399,0.00008677142,0.0006052076,0.00028768735,0.00038977366,0.05750541,0.19727282,0.7238543],"study_design_scores_gemma":[0.00010533445,0.00008353623,0.0006004086,0.032869466,0.00017596969,0.00016431128,0.00034351047,0.000085392625,0.00023391056,0.03406352,0.93122655,0.00004813603],"about_ca_topic_score_codex":0.0050695734,"about_ca_topic_score_gemma":0.006260438,"teacher_disagreement_score":0.8662251,"about_ca_system_score_codex":0.0064705703,"about_ca_system_score_gemma":0.05181565,"threshold_uncertainty_score":0.7074778},"labels":[],"label_agreement":null},{"id":"W3183035192","doi":"10.1016/s1470-2045(21)00279-5","title":"Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Alcohol Consumption and Health Effects","field":"Medicine","cited_by":664,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health; Public Health Ontario; University of Toronto","funders":"Centre International de Recherche sur le Cancer; World Health Organization","keywords":"Alcohol consumption; Environmental health; Alcohol; Attributable risk; Cancer; Consumption (sociology); Medicine; Population; Biology; Internal medicine","score_opus":0.16253989338880298,"score_gpt":0.482128908830147,"score_spread":0.319589015441344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3183035192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95665586,0.006507548,0.00053266424,0.00111941,0.00013093503,0.00007202804,0.032593124,0.000030031451,0.0023585428],"genre_scores_gemma":[0.9831533,0.0031424675,0.0002378753,0.00053550233,0.00014718648,0.00008523432,0.011873961,0.000009751844,0.00081480417],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996388,0.000088469445,0.000043264976,0.00008966464,0.00006387152,0.00007594276],"domain_scores_gemma":[0.9993056,0.00007547226,0.00027473966,0.00005782455,0.000146292,0.0001400487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007869581,0.0004481712,0.00056462386,0.0009811537,0.00022835268,0.0008194099,0.000469205,0.0009893973,0.0014374171],"category_scores_gemma":[0.0016142934,0.00044769255,0.0022894724,0.0030475566,0.0002221133,0.0010020068,0.00072640553,0.001100924,0.0005321717],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082035415,0.000098327044,0.9900832,0.00017006541,0.0017707562,0.00011029343,0.00012869152,0.00020958859,0.00021766222,0.00008124527,0.002735757,0.0035740747],"study_design_scores_gemma":[0.000038827347,0.00009807934,0.997823,0.000032945994,0.00058129185,0.00008197251,0.00019280864,0.00013818787,0.000019817682,0.000056936427,0.0009259423,0.000010226595],"about_ca_topic_score_codex":0.025157772,"about_ca_topic_score_gemma":0.029686904,"teacher_disagreement_score":0.025157772,"about_ca_system_score_codex":0.0007894908,"about_ca_system_score_gemma":0.0006030805,"threshold_uncertainty_score":0.05002266},"labels":[],"label_agreement":null},{"id":"W3188131079","doi":"10.1016/s1470-2045(21)00342-9","title":"Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":284,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck KGaA; Array BioPharma; Russian Academy of Sciences; Pfizer","keywords":"Avelumab; Javelin; Medicine; Chemotherapy; Ovarian cancer; Epithelial ovarian cancer; Oncology; Internal medicine; Open label; Cancer; Immunotherapy; Clinical trial; Pembrolizumab","score_opus":0.05096597704849702,"score_gpt":0.3713370121621499,"score_spread":0.3203710351136529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3188131079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98850083,0.0051220465,0.0005256934,0.00084242236,0.00059446006,0.0014107582,0.0007768166,0.00010706501,0.0021199388],"genre_scores_gemma":[0.9886857,0.0027774037,0.0010373151,0.00084852934,0.00030569907,0.0015465061,0.00080755557,0.000026017098,0.003965171],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995826,0.00022850576,0.00001882966,0.000078542485,0.000022368837,0.0000691464],"domain_scores_gemma":[0.99922645,0.00029772552,0.00014888257,0.00005546341,0.000024827963,0.00024672097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00124766,0.00132477,0.0024522592,0.00040355502,0.0003072655,0.0009937487,0.0007476716,0.0015662586,0.0070553687],"category_scores_gemma":[0.0015078901,0.00054963084,0.0018383353,0.00042229102,0.0012284361,0.0012226636,0.00038766142,0.0030454856,0.00095778756],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97551256,0.003830418,0.0004226328,0.00052287994,0.0007140061,0.000029530054,0.0000582869,0.00042331207,0.00207026,0.00013847541,0.000716584,0.015561],"study_design_scores_gemma":[0.94087964,0.05625111,0.0012876497,0.000030327748,0.0002708636,0.0000307462,0.000023633806,0.00034846357,0.00021353942,0.00016748262,0.00048392295,0.0000125896195],"about_ca_topic_score_codex":0.0010303633,"about_ca_topic_score_gemma":0.0025479333,"teacher_disagreement_score":0.0070553687,"about_ca_system_score_codex":0.0007456246,"about_ca_system_score_gemma":0.0007010868,"threshold_uncertainty_score":0.023602545},"labels":[],"label_agreement":null},{"id":"W3190141894","doi":"10.1016/s1470-2045(21)00376-4","title":"Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":277,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Centre for Mathematical Cognition, Loughborough University; Pfizer UK; Pfizer","keywords":"Medicine; Prostate cancer; Enzalutamide; Oncology; Internal medicine; PARP inhibitor; Clinical endpoint; Docetaxel; Cancer; Clinical trial; Poly ADP ribose polymerase; Androgen receptor; Biology","score_opus":0.17274289492622194,"score_gpt":0.47870194846347636,"score_spread":0.3059590535372544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3190141894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97476166,0.01238145,0.000890435,0.002219369,0.00062220596,0.001670914,0.0025147605,0.00033228303,0.0046068723],"genre_scores_gemma":[0.978501,0.007569927,0.0013680953,0.002308051,0.0003460192,0.0012191159,0.0029139016,0.000056149915,0.00571776],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997402,0.00009697892,0.000009163108,0.00005320436,0.000025973097,0.0000744196],"domain_scores_gemma":[0.9996424,0.00008139785,0.000067141285,0.000020372589,0.000021523017,0.0001671659],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010878288,0.0017325544,0.0019761191,0.0003620288,0.0002938658,0.0010538313,0.00068023306,0.0012367471,0.006373036],"category_scores_gemma":[0.00086135603,0.00043017167,0.0016931753,0.00034996067,0.0007474099,0.0009271023,0.00029858178,0.0030769184,0.0010584999],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78803134,0.016738405,0.002351904,0.0026699703,0.0039176857,0.00033418022,0.0002255095,0.0033496595,0.01872494,0.0009811637,0.01283339,0.14984185],"study_design_scores_gemma":[0.8514835,0.1351338,0.003720338,0.000117027725,0.0010521783,0.00036566582,0.00008184622,0.0016077447,0.0015508003,0.00062930264,0.004204581,0.00005313345],"about_ca_topic_score_codex":0.00117166,"about_ca_topic_score_gemma":0.004608686,"teacher_disagreement_score":0.006373036,"about_ca_system_score_codex":0.00087375636,"about_ca_system_score_gemma":0.00096567173,"threshold_uncertainty_score":0.021319985},"labels":[],"label_agreement":null},{"id":"W3192912903","doi":"10.1016/s1470-2045(21)00405-8","title":"Pathological complete response as a surrogate endpoint after neoadjuvant therapy for lung cancer","year":2021,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Neoadjuvant therapy; Lung cancer; Surrogate endpoint; Clinical endpoint; Oncology; Occult; Pathological; Internal medicine; Cancer; Systemic therapy; Clinical trial; Pathology; Breast cancer; Alternative medicine","score_opus":0.08392382717632799,"score_gpt":0.3971788207734106,"score_spread":0.31325499359708264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3192912903","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010053251,0.0030261616,0.00017170983,0.9748138,0.017213222,0.000017961183,0.00017575217,0.000015802887,0.0035602562],"genre_scores_gemma":[0.013460794,0.0020119257,0.00035347152,0.92192435,0.057905048,0.00011672522,0.0001357878,0.00003423638,0.0040575517],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9887242,0.006457345,0.0013770834,0.00057132513,0.002013357,0.00085665804],"domain_scores_gemma":[0.9604388,0.029963747,0.0023920299,0.000756364,0.003263519,0.0031856112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011888644,0.00056001,0.0020050576,0.0008528775,0.0019243355,0.0044015376,0.0012753638,0.025790077,0.003009409],"category_scores_gemma":[0.061606273,0.0006017487,0.0012037886,0.0013085352,0.00258288,0.0023907574,0.0014564528,0.033250913,0.0036312307],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010516327,0.00007750807,0.0044433633,0.00016484859,0.000056886598,0.00096704817,0.00015050675,0.00022360837,0.0003833916,0.005599096,0.9474074,0.03947458],"study_design_scores_gemma":[0.0013572645,0.0008408204,0.011238321,0.0012651645,0.00021997732,0.0031715983,0.0006035106,0.002873837,0.0010575005,0.04051896,0.9366716,0.00018142739],"about_ca_topic_score_codex":0.0038388511,"about_ca_topic_score_gemma":0.009217467,"teacher_disagreement_score":0.025790077,"about_ca_system_score_codex":0.0060862326,"about_ca_system_score_gemma":0.00565118,"threshold_uncertainty_score":0.0628739},"labels":[],"label_agreement":null},{"id":"W3196277563","doi":"10.1016/s1470-2045(21)00454-x","title":"Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":134,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute; National Institutes of Health; American Lebanese Syrian Associated Charities","keywords":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Cohort; Medicine; Coronavirus disease 2019 (COVID-19); Cancer; 2019-20 coronavirus outbreak; Cohort study; Sars virus; Pediatrics; Virology; Internal medicine; Disease; Outbreak; Infectious disease (medical specialty)","score_opus":0.05648938914656233,"score_gpt":0.42930313649031693,"score_spread":0.3728137473437546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3196277563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938088,0.00030950006,0.000092468006,0.0001569134,0.00003398984,0.000035157696,0.004973789,0.0000060272796,0.000583202],"genre_scores_gemma":[0.9960865,0.00025799058,0.00010003854,0.00010115949,0.000027625412,0.00004582597,0.0030172546,0.000009042095,0.00035451222],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990483,0.00018193784,0.00007805998,0.0002470829,0.00010842848,0.00033627154],"domain_scores_gemma":[0.99775785,0.00012977073,0.00083371776,0.0003617054,0.00030692766,0.0006101326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010401257,0.00059421454,0.00055230124,0.0007364773,0.0008717124,0.0014117615,0.0007512455,0.0010307173,0.0020618918],"category_scores_gemma":[0.0026547292,0.0007164393,0.0013004192,0.0023135648,0.0003848438,0.00095541606,0.0014827888,0.0020256129,0.000441814],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000104395134,0.000029912444,0.99864143,0.000009215346,0.00013422764,0.000047999027,0.00010434357,0.00002103969,0.00007046477,0.000023925117,0.00048787627,0.00032528213],"study_design_scores_gemma":[0.000012407781,0.00007223979,0.9989316,0.000013222091,0.000071562725,0.00011454837,0.0003675063,0.000038654158,0.0000152572175,0.000015060925,0.00034154538,0.000006424334],"about_ca_topic_score_codex":0.049333062,"about_ca_topic_score_gemma":0.05912641,"teacher_disagreement_score":0.049333062,"about_ca_system_score_codex":0.0009904022,"about_ca_system_score_gemma":0.0012627527,"threshold_uncertainty_score":0.09809184},"labels":[],"label_agreement":null},{"id":"W3197518149","doi":"10.1016/s1470-2045(21)00351-x","title":"Radiotherapy resources in Africa: an International Atomic Energy Agency update and analysis of projected needs","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Ottawa","funders":"National Cancer Institute","keywords":"Medicine; Radiation therapy; Brachytherapy; Context (archaeology); External beam radiotherapy; Medical physics; Agency (philosophy); Surgery","score_opus":0.03151376347589045,"score_gpt":0.37579721727884663,"score_spread":0.34428345380295616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197518149","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20099634,0.48461756,0.0056750593,0.11627924,0.0045693894,0.00035236267,0.1403332,0.00040305298,0.046773873],"genre_scores_gemma":[0.52176327,0.42642486,0.011744812,0.0052620154,0.0010293162,0.0005373096,0.02678112,0.00015318574,0.006304061],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9993401,0.00020095827,0.00009217279,0.00004783841,0.00018123341,0.00013768865],"domain_scores_gemma":[0.99674666,0.0012048999,0.00072621496,0.00007049693,0.0010090966,0.00024259186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002366886,0.00086992804,0.00047117012,0.003563362,0.0004279787,0.001572314,0.00065716996,0.0008483112,0.0037121926],"category_scores_gemma":[0.008143999,0.00032953796,0.00072001247,0.013986348,0.00034332,0.0029125856,0.001405652,0.0009486999,0.0005463655],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062042335,0.00011890117,0.14312044,0.011360554,0.0006530005,0.00065065996,0.0034185895,0.006503433,0.0008043786,0.006155615,0.25571507,0.5708789],"study_design_scores_gemma":[0.00007506882,0.00015991819,0.2318106,0.011575065,0.00072262203,0.00097297627,0.012216789,0.001955734,0.0016090537,0.0042985734,0.7345018,0.00010175182],"about_ca_topic_score_codex":0.0480088,"about_ca_topic_score_gemma":0.07255975,"teacher_disagreement_score":0.0480088,"about_ca_system_score_codex":0.0029928375,"about_ca_system_score_gemma":0.0071193753,"threshold_uncertainty_score":0.09545869},"labels":[],"label_agreement":null},{"id":"W3197866453","doi":"10.1016/s1470-2045(21)00459-9","title":"Stereotactic body radiotherapy for painful spinal metastases – Authors' reply","year":2021,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Princess Margaret Cancer Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"Varian Medical Systems; Elekta; AstraZeneca","keywords":"Medicine; Clinical endpoint; Radiation therapy; Stereotactic radiotherapy; Radiosurgery; Randomized controlled trial; Surgery","score_opus":0.09006943901398826,"score_gpt":0.38638569052977406,"score_spread":0.2963162515157858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197866453","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020662848,0.0017649708,0.000038819457,0.9702067,0.026528226,0.0000065055715,0.000046668585,0.000011294778,0.0011901114],"genre_scores_gemma":[0.002639995,0.0012204804,0.00008086743,0.95150846,0.040624622,0.000026971768,0.000029333192,0.000017244933,0.003852047],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967392,0.00107537,0.00036832615,0.00036715865,0.0009588732,0.00049098145],"domain_scores_gemma":[0.991824,0.005120661,0.0006735017,0.00018193749,0.0012317229,0.0009682492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029800367,0.0007879707,0.0017735889,0.0010748969,0.0031136244,0.0036246977,0.0017418077,0.061394196,0.0061581936],"category_scores_gemma":[0.023381462,0.0009359019,0.0012971096,0.00092501903,0.002960269,0.0032796895,0.0018717401,0.0408773,0.004394255],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006577256,0.000018371433,0.000407103,0.000066811896,0.000024646064,0.0013122004,0.0001296956,0.000058034617,0.0000988275,0.001280783,0.992535,0.0040028193],"study_design_scores_gemma":[0.00019955472,0.00008175609,0.001329569,0.00039930094,0.00007199457,0.0025425593,0.00055859913,0.00030990873,0.00021629939,0.006990105,0.9871859,0.00011449709],"about_ca_topic_score_codex":0.004994359,"about_ca_topic_score_gemma":0.008954942,"teacher_disagreement_score":0.061394196,"about_ca_system_score_codex":0.003739733,"about_ca_system_score_gemma":0.0032581666,"threshold_uncertainty_score":0.027133763},"labels":[],"label_agreement":null},{"id":"W3198462265","doi":"10.1016/s1470-2045(21)00374-0","title":"Transforming Canada's role in global cancer control","year":2021,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Global Health and Surgery","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Hospital for Sick Children; Canadian Partnership Against Cancer; Queen's University; University of Toronto; Centre for Global Health Research; St. Michael's Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Framing (construction); Political science; Corporate governance; Equity (law); Global governance; Global health; Public relations; Work (physics); Economic growth; Politics; Health equity; Public administration; Health care; Engineering; Management; Economics; Law","score_opus":0.053711964667115544,"score_gpt":0.41256117152722743,"score_spread":0.3588492068601119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198462265","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000439957,0.97613585,0.000050654096,0.017318472,0.002489406,0.0000065925765,0.00006508657,0.000013735891,0.003876151],"genre_scores_gemma":[0.001802254,0.98516375,0.00014390257,0.009852919,0.0009585461,0.000009054135,0.00005123787,0.00000829554,0.0020100058],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99706763,0.00049790036,0.00014478358,0.00013454346,0.0014966214,0.0006585881],"domain_scores_gemma":[0.9936905,0.0016558655,0.0004467559,0.00009858219,0.0030597588,0.0010486022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004771559,0.0016060736,0.0020274913,0.004304482,0.0019178148,0.0049765497,0.002241701,0.0050434466,0.013747802],"category_scores_gemma":[0.009229005,0.00042004316,0.0009005033,0.00936242,0.004233286,0.003456745,0.0028927443,0.006065246,0.0022018661],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009213725,0.00003381352,0.00027077182,0.014567662,0.00019281154,0.00015264332,0.00031546675,0.0004793167,0.0001976708,0.037429336,0.450881,0.49538746],"study_design_scores_gemma":[0.000027179427,0.000013481778,0.00045442334,0.0070652673,0.00007581024,0.00005323072,0.00019540395,0.000037732665,0.00003890137,0.0028916297,0.9891322,0.000014706566],"about_ca_topic_score_codex":0.74156183,"about_ca_topic_score_gemma":0.8317884,"teacher_disagreement_score":0.9584143,"about_ca_system_score_codex":0.041585706,"about_ca_system_score_gemma":0.13558847,"threshold_uncertainty_score":0.5199203},"labels":[],"label_agreement":null},{"id":"W3200107890","doi":"10.1016/s1470-2045(21)00457-5","title":"Surgery versus SABR for early-stage lung cancer—time to call it a draw?","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Health Sciences Centre","funders":"Varian Medical Systems; AstraZeneca","keywords":"SABR volatility model; Medicine; Lung cancer; Radiation therapy; Randomized controlled trial; Ablative case; Stage (stratigraphy); Confounding; Surgery; Oncology; Internal medicine","score_opus":0.07140197774656591,"score_gpt":0.4020876706559696,"score_spread":0.3306856929094037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200107890","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0051583326,0.34467077,0.0011445477,0.58470696,0.04996182,0.00011862133,0.00068321195,0.000114636925,0.013441045],"genre_scores_gemma":[0.09445213,0.16572846,0.0033571532,0.5964995,0.12973449,0.0002831559,0.00067226734,0.00036843677,0.008904541],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99214655,0.00397355,0.0010483416,0.00078683463,0.0012817287,0.00076294667],"domain_scores_gemma":[0.95401204,0.03185836,0.0041096825,0.001028496,0.0036171484,0.005374194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017671114,0.0012789463,0.0061888443,0.0011978921,0.0015793421,0.009787554,0.0033126874,0.011382665,0.027016534],"category_scores_gemma":[0.06126377,0.00089212286,0.0046613556,0.0021529703,0.003274106,0.014822203,0.0030500873,0.024234194,0.0077152587],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033121713,0.0008058798,0.004497122,0.0116863595,0.00484681,0.00042251445,0.0007208033,0.001455564,0.001162142,0.032527734,0.3150348,0.59371847],"study_design_scores_gemma":[0.028676966,0.008899853,0.014821705,0.04466297,0.012939457,0.0006970355,0.006519831,0.0025018605,0.0009582064,0.17533556,0.70316243,0.0008242604],"about_ca_topic_score_codex":0.007561337,"about_ca_topic_score_gemma":0.02534741,"teacher_disagreement_score":0.027016534,"about_ca_system_score_codex":0.004912179,"about_ca_system_score_gemma":0.005639697,"threshold_uncertainty_score":0.0934549},"labels":[],"label_agreement":null},{"id":"W3200608261","doi":"10.1016/s1470-2045(21)00463-0","title":"Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":171,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Queen's University; World Health Organization","keywords":"Medicine; Snowball sampling; Essential medicines; Access to medicines; Cross-sectional study; Family medicine; Developing country; Descriptive statistics; Public health; Alternative medicine; Global health; Cancer; Environmental health; Nursing; Economic growth; Pathology","score_opus":0.23093750127483378,"score_gpt":0.4812587039765077,"score_spread":0.2503212027016739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200608261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962347,0.00018663942,0.00008761339,0.00011182949,0.0000039455717,0.00008190395,0.0021699064,0.000005161803,0.001118402],"genre_scores_gemma":[0.9976737,0.00031758778,0.00021090334,0.00024980915,0.0000062626227,0.000101470076,0.0012568826,0.000003299283,0.00018004166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984738,0.0005421697,0.00027510384,0.00023287316,0.00021035448,0.00026569725],"domain_scores_gemma":[0.99544406,0.0010172882,0.0022062499,0.00024469907,0.00043669445,0.0006510707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002534082,0.00027208612,0.00041666528,0.0013160205,0.00050489965,0.0008301103,0.0003985184,0.00073496957,0.0021535442],"category_scores_gemma":[0.0046078395,0.00056780013,0.00039588526,0.002710518,0.00046844236,0.0011800892,0.0010550302,0.0007596478,0.0005599137],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000052515417,0.00009878442,0.9962788,0.000049827162,0.000025542886,0.000071202456,0.0011982212,0.000041820178,0.00014492133,0.000017871525,0.00044800315,0.0015724852],"study_design_scores_gemma":[0.000009480385,0.00015349909,0.9957373,0.000034099576,0.000014139238,0.00013906635,0.0032124908,0.000094990166,0.000053633725,0.000006492136,0.0005392433,0.000005516145],"about_ca_topic_score_codex":0.010081232,"about_ca_topic_score_gemma":0.009394783,"teacher_disagreement_score":0.010081232,"about_ca_system_score_codex":0.00048355767,"about_ca_system_score_gemma":0.000551632,"threshold_uncertainty_score":0.020045102},"labels":[],"label_agreement":null},{"id":"W3200717490","doi":"10.1016/s1470-2045(21)00428-9","title":"Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":175,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Janssen Research and Development","keywords":"Daratumumab; Medicine; Autologous stem-cell transplantation; Multiple myeloma; Thalidomide; Bortezomib; Internal medicine; Interim analysis; Clinical endpoint; Oncology; Dexamethasone; Progression-free survival; Surgery; Randomized controlled trial; Chemotherapy","score_opus":0.09038015065881295,"score_gpt":0.36434493194217504,"score_spread":0.2739647812833621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200717490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98600304,0.008416796,0.00036715562,0.0008345766,0.00077501894,0.0013010597,0.0007362339,0.00009162745,0.0014744942],"genre_scores_gemma":[0.99012494,0.0034920329,0.0007744067,0.0009849492,0.0004871785,0.0011675615,0.00096357544,0.000016353652,0.0019888657],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994081,0.0002662578,0.000036643367,0.00013389035,0.000034037857,0.000121011886],"domain_scores_gemma":[0.99906546,0.00028361523,0.00021772161,0.00007940063,0.000039690152,0.00031418866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001768234,0.0016779429,0.0033451954,0.00036749057,0.0005252866,0.0012993575,0.00093267515,0.0018313254,0.0052726036],"category_scores_gemma":[0.0014423089,0.00059886393,0.0031754375,0.0004600133,0.0014014503,0.0014064889,0.00050541945,0.004397444,0.0008907591],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98356044,0.0019720315,0.000616152,0.00040399257,0.0010021877,0.00002706313,0.000049748192,0.00022149234,0.00093678274,0.000068561494,0.00041500598,0.010726505],"study_design_scores_gemma":[0.9545319,0.04203885,0.0019362239,0.000036413177,0.0005468051,0.000033488013,0.000019314508,0.00018426841,0.00015762726,0.00012304282,0.0003810964,0.000010971007],"about_ca_topic_score_codex":0.0021187025,"about_ca_topic_score_gemma":0.0042259675,"teacher_disagreement_score":0.0052726036,"about_ca_system_score_codex":0.0011004872,"about_ca_system_score_gemma":0.0011254096,"threshold_uncertainty_score":0.017638624},"labels":[],"label_agreement":null},{"id":"W3201013983","doi":"10.1016/s1470-2045(21)00375-2","title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":561,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont; McMaster University","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Clinical endpoint; Internal medicine; Refractory (planetary science); Cytokine release syndrome; Oncology; Hematopoietic stem cell transplantation; Chimeric antigen receptor; Cohort; Transplantation; Clinical trial; Immunotherapy; Cancer; Biology","score_opus":0.14921257768924856,"score_gpt":0.4590593045005727,"score_spread":0.30984672681132414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201013983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978138,0.0010289988,0.00009132609,0.000118724274,0.00004101679,0.00016980959,0.00028683516,0.000021448599,0.00042802436],"genre_scores_gemma":[0.9940514,0.0011226771,0.00040109231,0.0005440929,0.00015168026,0.00061434606,0.0012514188,0.0000220552,0.0018412982],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99957126,0.0001631793,0.000020067233,0.00007013123,0.000047047386,0.0001283362],"domain_scores_gemma":[0.9992084,0.00013305322,0.00017466265,0.00008073412,0.00004612611,0.00035710132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013848171,0.0011032027,0.0018989632,0.00034493802,0.0003494171,0.0013178437,0.0006822866,0.0013528649,0.0017738094],"category_scores_gemma":[0.000795852,0.00032904383,0.0015334273,0.0003285827,0.000790326,0.00092915783,0.00041069466,0.0021833002,0.00064690824],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84206504,0.04095067,0.013788629,0.00069241435,0.0026373859,0.0002062283,0.00027331992,0.0015467146,0.017409569,0.00019763452,0.0022364096,0.077996105],"study_design_scores_gemma":[0.4275003,0.51585174,0.048363853,0.00006888903,0.0017295072,0.0002402611,0.00016438348,0.0012623658,0.0018452351,0.00029057654,0.002617574,0.00006529762],"about_ca_topic_score_codex":0.00062019465,"about_ca_topic_score_gemma":0.001300397,"teacher_disagreement_score":0.0018989632,"about_ca_system_score_codex":0.0006552793,"about_ca_system_score_gemma":0.000744865,"threshold_uncertainty_score":0.0073236823},"labels":[],"label_agreement":null},{"id":"W3201981182","doi":"10.1016/s1470-2045(21)00402-2","title":"Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development; National Cancer Institute","keywords":"Abiraterone acetate; Prednisone; Prostate cancer; Medicine; Placebo; Androgen deprivation therapy; Internal medicine; Oncology; Urology; Cancer; Pathology","score_opus":0.10851012393174991,"score_gpt":0.41889350831075456,"score_spread":0.31038338437900465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201981182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885343,0.0049276403,0.00056940864,0.00053233793,0.0007169356,0.0023757352,0.0006648059,0.00015218827,0.001526642],"genre_scores_gemma":[0.98892236,0.0030849758,0.0011498835,0.00065726787,0.0006486206,0.0020696265,0.00049326476,0.000032530428,0.0029414985],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99916613,0.0004543292,0.00005853684,0.0001394061,0.000071796734,0.00010987975],"domain_scores_gemma":[0.99840313,0.000531636,0.0003119383,0.00011852721,0.000082416766,0.00055241864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019488058,0.0020861023,0.0038082174,0.0007788404,0.0005834489,0.0013338285,0.0013385166,0.0022003455,0.005864248],"category_scores_gemma":[0.002315386,0.0009559327,0.002266139,0.0007594096,0.0019305934,0.0013603956,0.0005205721,0.0036053616,0.0011104002],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9891698,0.0035296697,0.00012430557,0.00028502362,0.00045458382,0.0000143979405,0.000030798143,0.000119632234,0.001318716,0.000036049973,0.00017051885,0.004746615],"study_design_scores_gemma":[0.9358589,0.062421173,0.0007306935,0.000016299477,0.00030627882,0.000017048405,0.000018269193,0.00016023341,0.00020079286,0.00008324367,0.00017467559,0.000012429669],"about_ca_topic_score_codex":0.0019372154,"about_ca_topic_score_gemma":0.0032963098,"teacher_disagreement_score":0.005864248,"about_ca_system_score_codex":0.0007485189,"about_ca_system_score_gemma":0.0012712695,"threshold_uncertainty_score":0.019617915},"labels":[],"label_agreement":null},{"id":"W3204184651","doi":"10.1016/s1470-2045(21)00344-2","title":"Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension","year":2021,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Women's College Hospital","funders":"Medical Research Council; Health and Care Research Wales; Blood Cancer UK; Prostate Cancer UK; Public Health Agency; Chief Scientist Office; Breast Cancer Now; Department of Health and Social Care; Cancer Research UK; Tenovus; National Institute for Health and Care Research; National Cancer Research Institute","keywords":"Path (computing); Extension (predicate logic); Clinical trial; Pathology; Content (measure theory); Computer science; Medicine; Mathematics; Computer network; Mathematical analysis; Programming language","score_opus":0.9511569958424636,"score_gpt":0.7335990082767821,"score_spread":0.21755798756568145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204184651","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010403929,0.5014508,0.32793388,0.113024846,0.018276744,0.0090988,0.0061082123,0.0028456175,0.020220716],"genre_scores_gemma":[0.015969012,0.21896927,0.6281229,0.08221936,0.0071942494,0.03249868,0.004645466,0.0012999657,0.009081123],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.84771603,0.110347286,0.025300063,0.00321774,0.012291122,0.0011277414],"domain_scores_gemma":[0.5989094,0.3459122,0.016042562,0.013988887,0.022612248,0.0025347264],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.15463921,0.00213934,0.0051748054,0.005924416,0.0013056402,0.006295976,0.007179342,0.012782501,0.010903278],"category_scores_gemma":[0.27195734,0.0029821992,0.009863143,0.005668414,0.0070443004,0.005001264,0.006088353,0.025239965,0.007874728],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087684015,0.0001529038,0.00049910985,0.046139874,0.0015295325,0.00024573045,0.001058596,0.0028153623,0.00045834694,0.15757951,0.2937842,0.49485996],"study_design_scores_gemma":[0.0031032157,0.00037899628,0.0024575114,0.12348102,0.0031481215,0.0011140318,0.00024408726,0.0048406385,0.0010535418,0.22525738,0.6346628,0.00025862805],"about_ca_topic_score_codex":0.004606709,"about_ca_topic_score_gemma":0.00510303,"teacher_disagreement_score":0.84536076,"about_ca_system_score_codex":0.005969172,"about_ca_system_score_gemma":0.025667036,"threshold_uncertainty_score":0.8178201},"labels":[],"label_agreement":null},{"id":"W3205063602","doi":"10.1016/s1470-2045(21)00494-0","title":"Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":191,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institutes of Health; National Cancer Institute; Medical Research Council; National Institute for Health and Care Research; Bristol-Myers Squibb","keywords":"Azacitidine; Medicine; IDH2; Internal medicine; Myeloid leukaemia; Population; Clinical endpoint; Myeloid leukemia; Oncology; Myeloid; Clinical trial; Surgery; IDH1; Mutant; Biology","score_opus":0.04659093949864618,"score_gpt":0.34979027695407056,"score_spread":0.3031993374554244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3205063602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98730356,0.006350046,0.00033754265,0.0010192326,0.00059574784,0.0008169428,0.000995614,0.00011151353,0.0024697243],"genre_scores_gemma":[0.9865367,0.0038383948,0.00086202106,0.0012304364,0.0004044745,0.0008649774,0.0016595945,0.0000249998,0.0045784605],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99972516,0.00012840064,0.000012904913,0.000059938866,0.000019442607,0.000054201606],"domain_scores_gemma":[0.99961025,0.00009330346,0.000075064505,0.00002504964,0.000017142933,0.00017923038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093059754,0.0017138256,0.0024184608,0.0003038015,0.0002255849,0.0011392273,0.0007466492,0.0012371747,0.005603321],"category_scores_gemma":[0.0009645696,0.0004794878,0.0015062067,0.00030579523,0.0007347413,0.0010034416,0.00038292038,0.0030487361,0.0009485829],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95114326,0.004189512,0.0010810759,0.0007230324,0.0014918384,0.00008276956,0.000096978336,0.0010083964,0.004770638,0.00026781173,0.0020248108,0.03311982],"study_design_scores_gemma":[0.93092394,0.062402055,0.0031091399,0.000044316457,0.00059616973,0.00009521887,0.000048839123,0.00066725735,0.00045185955,0.00031702686,0.001326501,0.00001757347],"about_ca_topic_score_codex":0.0010322448,"about_ca_topic_score_gemma":0.0037141384,"teacher_disagreement_score":0.005603321,"about_ca_system_score_codex":0.0008664911,"about_ca_system_score_gemma":0.00066334417,"threshold_uncertainty_score":0.018744946},"labels":[],"label_agreement":null},{"id":"W3205592551","doi":"10.1016/s1470-2045(21)00519-2","title":"Addressing breast cancer mortality in low-income and middle-income countries: if you can't measure it, it doesn't exist","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Breast cancer; Cancer; Population; Mortality rate; Demography; Public health; Incidence (geometry); Gerontology; Internal medicine; Environmental health; Pathology","score_opus":0.18371567891885437,"score_gpt":0.4131564228314922,"score_spread":0.2294407439126378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3205592551","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024188636,0.07532506,0.00074483146,0.8987538,0.016349666,0.00003785603,0.0008191885,0.00009073468,0.0054599363],"genre_scores_gemma":[0.111964904,0.18275405,0.007454833,0.6537496,0.03766265,0.00048395828,0.0010775459,0.00020491361,0.0046476326],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9834663,0.006964797,0.0016792382,0.0011415215,0.005348632,0.0013994372],"domain_scores_gemma":[0.94956034,0.024303861,0.006621233,0.0021860492,0.010380065,0.0069483765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02772443,0.0026542824,0.003793679,0.0026507769,0.0024395322,0.007474108,0.0028963676,0.009735815,0.008379859],"category_scores_gemma":[0.088968806,0.0009790937,0.00287798,0.0030776528,0.0055472413,0.01320555,0.007414021,0.01677461,0.0032235181],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044508724,0.0004430202,0.04533275,0.012163603,0.0038695915,0.00022877111,0.0020946052,0.00087415904,0.0005830576,0.015405573,0.60785276,0.31070706],"study_design_scores_gemma":[0.001228389,0.0018439054,0.115832515,0.060809698,0.0072074113,0.00056363345,0.015518891,0.0014534655,0.0014135151,0.097140126,0.69630164,0.00068690913],"about_ca_topic_score_codex":0.019020485,"about_ca_topic_score_gemma":0.0320095,"teacher_disagreement_score":0.02772443,"about_ca_system_score_codex":0.003991996,"about_ca_system_score_gemma":0.015688628,"threshold_uncertainty_score":0.14662254},"labels":[],"label_agreement":null},{"id":"W3206192616","doi":"10.1016/s1470-2045(21)00466-6","title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":363,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Alberta; University of Calgary","funders":"Janssen Research and Development; Strong","keywords":"Lenalidomide; Daratumumab; Dexamethasone; Medicine; Multiple myeloma; Open label; Oncology; Internal medicine; Clinical trial","score_opus":0.1690328158794252,"score_gpt":0.4209981267549274,"score_spread":0.2519653108755022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206192616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98022425,0.01321002,0.00040651753,0.0012062069,0.00088355475,0.001395012,0.001035356,0.00009469323,0.0015445302],"genre_scores_gemma":[0.9859029,0.005120836,0.0011858915,0.001420163,0.0006784432,0.001814517,0.0011402464,0.00002757518,0.0027094374],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99913883,0.00047412352,0.00004952779,0.00015453564,0.000053163236,0.00012984319],"domain_scores_gemma":[0.99822944,0.0007116284,0.00038487132,0.00010641499,0.0000669768,0.000500686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024308318,0.0021422573,0.003841593,0.00042157932,0.00053656293,0.0015778533,0.0011363843,0.0019912045,0.005030712],"category_scores_gemma":[0.0024616248,0.00068472704,0.004107087,0.0005003905,0.0015053686,0.001602548,0.0007003566,0.004887861,0.0009817249],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98551404,0.0021527922,0.00037412398,0.0004081751,0.0011673532,0.000023274535,0.000042341253,0.00024218645,0.0008245286,0.000058437116,0.00042845326,0.008764372],"study_design_scores_gemma":[0.9618001,0.03535942,0.0013018794,0.000040562645,0.0006203493,0.000034325578,0.000025201512,0.00017029405,0.00013036194,0.00016025848,0.00034545487,0.0000117811],"about_ca_topic_score_codex":0.0014049929,"about_ca_topic_score_gemma":0.0030802637,"teacher_disagreement_score":0.005030712,"about_ca_system_score_codex":0.0012363754,"about_ca_system_score_gemma":0.0011037008,"threshold_uncertainty_score":0.016829431},"labels":[],"label_agreement":null},{"id":"W3207368269","doi":"10.1016/s1470-2045(21)00522-2","title":"A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Cancer Institute; NIHR Cambridge Biomedical Research Centre; NIHR Oxford Biomedical Research Centre; European Regional Development Fund; Instituto de Salud Carlos III; Fundação para a Ciência e a Tecnologia; Cancer Council South Australia; Manchester Biomedical Research Centre; Cancer Council Tasmania; National Institutes of Health; Royal Marsden NHS Foundation Trust; Cancer Australia; Prostate Cancer Foundation of Australia; Generalitat de Catalunya; Centro de Investigación Biomédica en Red de Cáncer; Fundación Científica Asociación Española Contra el Cáncer; National Institute for Health and Care Research; Institut Català de la Salut; NorthShore University HealthSystem; Ministerio de Economía y Competitividad; Victorian Cancer Agency; Albert Einstein Cancer Center; Prostate Cancer Foundation; Memorial Sloan-Kettering Cancer Center; Cancer Council Victoria; Cancerfonden; Cancer Research UK","keywords":"Prospective cohort study; Prostate cancer; Gene; Cancer; Oncology; Medicine; Internal medicine; Prostate; Genetics; Biology","score_opus":0.06378057788104297,"score_gpt":0.39783938470088165,"score_spread":0.3340588068198387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3207368269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974062,0.0003158244,0.00020338292,0.000043590397,0.000007697788,0.00013973012,0.0010011618,0.000012363092,0.00086996006],"genre_scores_gemma":[0.9972851,0.00023061161,0.00030227643,0.00007117751,0.000027879998,0.00010989275,0.0016722305,0.000007823363,0.00029295514],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986279,0.00046873552,0.00007073771,0.00031045618,0.00031014666,0.0002120625],"domain_scores_gemma":[0.99615544,0.0006264252,0.0009996574,0.00036453677,0.0006542269,0.0011997549],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026244323,0.0012532455,0.0005998445,0.0019370229,0.00091265986,0.00095662335,0.00068704534,0.00057860767,0.0017232987],"category_scores_gemma":[0.005043052,0.0006428429,0.00088417873,0.0028083404,0.00055087486,0.0008265852,0.001243558,0.00091182225,0.00039341033],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088996376,0.00027633927,0.9959645,0.00002531416,0.00007114762,0.00010934179,0.00030266025,0.000057484383,0.00016503176,0.000018630279,0.00012991099,0.0019896599],"study_design_scores_gemma":[0.00013737616,0.0010912089,0.99774075,0.000013858419,0.00014964452,0.00019915504,0.00023015328,0.0001141535,0.00007169615,0.000013855631,0.00022749252,0.000010680124],"about_ca_topic_score_codex":0.015877368,"about_ca_topic_score_gemma":0.0111072445,"teacher_disagreement_score":0.015877368,"about_ca_system_score_codex":0.0005366842,"about_ca_system_score_gemma":0.00070919987,"threshold_uncertainty_score":0.031569898},"labels":[],"label_agreement":null},{"id":"W3208204329","doi":"10.1016/s1470-2045(21)00531-3","title":"Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":371,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; AstraZeneca","keywords":"Olaparib; Ovarian cancer; Mutation; BRCA mutation; Clinical trial; Cancer","score_opus":0.04020537618833177,"score_gpt":0.3627496910676291,"score_spread":0.32254431487929736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208204329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98426014,0.00923807,0.00065545936,0.0007589425,0.00045290941,0.0013533871,0.0014209655,0.00014439812,0.0017157927],"genre_scores_gemma":[0.98860055,0.0033665616,0.0007999042,0.0011413483,0.00037647935,0.0013804534,0.0019894638,0.000026107564,0.002319107],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99929214,0.0003454009,0.00003654573,0.00014557785,0.000050886276,0.00012943495],"domain_scores_gemma":[0.9987789,0.0003199797,0.00030472726,0.00013311785,0.000059334416,0.0004040481],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020662074,0.0016460153,0.0037016405,0.00042101627,0.0004827471,0.0012989157,0.0010414271,0.0020049957,0.00463624],"category_scores_gemma":[0.0017438632,0.00062947563,0.002743182,0.00047859323,0.0012405047,0.001489094,0.00047477664,0.003347686,0.0009892314],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98262006,0.001748991,0.00076242344,0.00030569176,0.00095593126,0.000031832315,0.0000334848,0.0002491619,0.0012295758,0.000044329317,0.00048798005,0.011530362],"study_design_scores_gemma":[0.9501166,0.04422098,0.0037009057,0.000034542387,0.00059104164,0.00004738449,0.000021811014,0.0003339581,0.00021949013,0.00016136043,0.00053444994,0.000017498436],"about_ca_topic_score_codex":0.0010004181,"about_ca_topic_score_gemma":0.0019189315,"teacher_disagreement_score":0.00463624,"about_ca_system_score_codex":0.0008135705,"about_ca_system_score_gemma":0.0008681882,"threshold_uncertainty_score":0.015509725},"labels":[],"label_agreement":null},{"id":"W3208718719","doi":"10.1016/s1470-2045(21)00521-0","title":"A growing vulvar mass in a post-menopausal woman","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer and Skin Lesions","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"Myriad Genetics; Purdue Pharma; Roche; Merck; Novartis; Pfizer; Eli Lilly and Company","keywords":"Immunohistochemistry; Vulva; Pathology; Medicine; Cervix; Progesterone receptor; Biopsy; Context (archaeology); Vulvar Carcinoma; Breast cancer; Estrogen receptor; Internal medicine; Cancer; Biology","score_opus":0.04048159202572352,"score_gpt":0.3517853224503171,"score_spread":0.3113037304245936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208718719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91030097,0.014440765,0.00070999475,0.033633173,0.002118697,0.000276757,0.0007313792,0.00019396853,0.037594333],"genre_scores_gemma":[0.9800346,0.006833546,0.0005091035,0.005431093,0.0022227897,0.00001789795,0.00013841674,0.00003241821,0.004780157],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99968123,0.000028021765,0.000024115783,0.000060648697,0.00006136495,0.00014463648],"domain_scores_gemma":[0.9988727,0.00032247658,0.00022531587,0.00004275848,0.000064881315,0.00047189],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024839156,0.00091754907,0.0006844257,0.0021154496,0.002153375,0.0015790617,0.00086196203,0.006229142,0.0064516957],"category_scores_gemma":[0.00325749,0.0009145745,0.00079395337,0.0011269356,0.0011877725,0.0014206208,0.001008735,0.0037402413,0.0014442337],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011601142,0.00008097813,0.023082914,0.000048421854,0.000009517994,0.9714765,0.00032514182,0.00004008311,0.0006595287,0.00016013149,0.0013331177,0.0026676534],"study_design_scores_gemma":[0.000024997953,0.00027692082,0.039390102,0.00012457813,0.00004574899,0.9551265,0.0019320119,0.00023270576,0.0001909412,0.00039875667,0.0022319201,0.000024799609],"about_ca_topic_score_codex":0.005756744,"about_ca_topic_score_gemma":0.009219648,"teacher_disagreement_score":0.0064516957,"about_ca_system_score_codex":0.0011090746,"about_ca_system_score_gemma":0.00092841976,"threshold_uncertainty_score":0.02158308},"labels":[],"label_agreement":null},{"id":"W3212751896","doi":"10.1016/s1470-2045(21)00536-2","title":"Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Novartis Pharmaceuticals Corporation","keywords":"Ceritinib; Anaplastic large-cell lymphoma; Lymphoma; Phases of clinical research; Phase (matter)","score_opus":0.04317782784484444,"score_gpt":0.3491828933605973,"score_spread":0.3060050655157529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212751896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913896,0.0053734644,0.00046542432,0.00038377594,0.000086543776,0.0005599035,0.0007225485,0.00008326612,0.0009355793],"genre_scores_gemma":[0.99146664,0.0039290395,0.001285348,0.00052685745,0.000090606634,0.0005686846,0.0013631787,0.000043398348,0.0007261943],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99930596,0.00033128378,0.000035577217,0.00012442042,0.00008157776,0.000121070625],"domain_scores_gemma":[0.99893504,0.00024660767,0.00032465527,0.000101632286,0.00006750241,0.00032454755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016490661,0.0012391408,0.002948661,0.00028391017,0.0003118398,0.0009757125,0.00067729654,0.0009993303,0.0019128105],"category_scores_gemma":[0.0014758362,0.0004413501,0.0019278887,0.0004407869,0.0009441206,0.0010435336,0.00035404257,0.0031525104,0.00050557556],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6819583,0.02222417,0.029797366,0.0028349787,0.00624055,0.0011818203,0.0007790238,0.009025298,0.029116327,0.00073299796,0.009213862,0.20689523],"study_design_scores_gemma":[0.6137454,0.29354474,0.06933601,0.00015571598,0.0027458258,0.0025531354,0.0002302996,0.00252592,0.004315977,0.0004089599,0.010330693,0.00010732405],"about_ca_topic_score_codex":0.0014343037,"about_ca_topic_score_gemma":0.0036011094,"teacher_disagreement_score":0.002948661,"about_ca_system_score_codex":0.0015911243,"about_ca_system_score_gemma":0.001956112,"threshold_uncertainty_score":0.011544526},"labels":[],"label_agreement":null},{"id":"W3217142409","doi":"10.1016/s1470-2045(21)00602-1","title":"Global cancer research in the post-pandemic world","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Science and Technology Facilities Council; Economic and Social Research Council; Merck Sharp and Dohme; National Institute for Health and Care Research; Bristol-Myers Squibb; UK Research and Innovation; Janssen Pharmaceuticals; AstraZeneca; Bayer; Astellas Pharma US","keywords":"Pandemic; Cancer; Coronavirus disease 2019 (COVID-19); Political science; Medicine; Disease; Pathology; Internal medicine","score_opus":0.4143096540076404,"score_gpt":0.5965710100512617,"score_spread":0.18226135604362126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217142409","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015489735,0.08234181,0.0002434242,0.8826876,0.015560574,0.000021483185,0.0009573261,0.000060522267,0.016578281],"genre_scores_gemma":[0.07364467,0.29727432,0.0019555483,0.5511196,0.056281995,0.00016678212,0.00209366,0.0002200949,0.01724327],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98923874,0.0050829747,0.0005835704,0.00063870504,0.0024383469,0.0020176258],"domain_scores_gemma":[0.9499675,0.018431772,0.0038826177,0.0022704373,0.009173935,0.016273731],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018581863,0.0010219758,0.0015608498,0.0033138522,0.0025001871,0.012359268,0.001749762,0.011405289,0.039436113],"category_scores_gemma":[0.038885966,0.00055203255,0.0015966023,0.005527543,0.0061356314,0.011630823,0.0093755955,0.010730479,0.0062494623],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030423133,0.00014526548,0.006715235,0.0030486393,0.0002708316,0.00025372254,0.0012227647,0.00044908782,0.00073859474,0.08403519,0.76259255,0.14022394],"study_design_scores_gemma":[0.00007052016,0.00010828132,0.004764049,0.0025016714,0.00007840025,0.00013108514,0.0031999869,0.00006618958,0.00029419348,0.046303097,0.9424303,0.00005223768],"about_ca_topic_score_codex":0.010186558,"about_ca_topic_score_gemma":0.019492116,"teacher_disagreement_score":0.039436113,"about_ca_system_score_codex":0.010167882,"about_ca_system_score_gemma":0.029513951,"threshold_uncertainty_score":0.1319269},"labels":[],"label_agreement":null},{"id":"W3217494531","doi":"10.1016/s1470-2045(21)00578-7","title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":353,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"National Cancer Institute; Loxo Oncology; PharmaMar; Innovent Biologics; Incyte; Sanofi; Andrew Sabin Family Foundation; National Institutes of Health; Helsinn; GlaxoSmithKline; University of Texas MD Anderson Cancer Center; Pfizer; Novartis Pharmaceuticals Corporation; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Dabrafenib; Trametinib; Glioma; Glioblastoma; Temozolomide; Clinical trial","score_opus":0.06301962313348018,"score_gpt":0.34848886777246735,"score_spread":0.28546924463898715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217494531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98578066,0.008612377,0.00030072936,0.0012107126,0.00037179043,0.00064369116,0.0013175083,0.0001140837,0.0016484001],"genre_scores_gemma":[0.9866034,0.0050516683,0.0010073065,0.001216473,0.00025179237,0.00068465876,0.0024427213,0.000031195792,0.002710711],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99959844,0.00016499602,0.000021247753,0.00008264325,0.000027473174,0.000105190265],"domain_scores_gemma":[0.99957913,0.00007239521,0.00010195408,0.000029868035,0.00003035639,0.00018625628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012953134,0.0018546599,0.0025666666,0.00034635232,0.00029865184,0.001257937,0.0007702502,0.0011582777,0.0036014034],"category_scores_gemma":[0.0010326372,0.00047982336,0.002073719,0.00045878429,0.00066294067,0.0013956452,0.00039250284,0.0031146011,0.0009196071],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9235789,0.0044513443,0.0025767942,0.0013205535,0.0028118205,0.00011055276,0.00012948035,0.0012387281,0.004689025,0.00031437617,0.004301597,0.05447677],"study_design_scores_gemma":[0.9159372,0.07291633,0.0055914205,0.0000678432,0.0010694953,0.0002486908,0.00008935596,0.00093440455,0.00049011194,0.00043436236,0.0021790098,0.000041777857],"about_ca_topic_score_codex":0.0016707934,"about_ca_topic_score_gemma":0.005610406,"teacher_disagreement_score":0.0036014034,"about_ca_system_score_codex":0.0010718084,"about_ca_system_score_gemma":0.0009922005,"threshold_uncertainty_score":0.012047887},"labels":[],"label_agreement":null},{"id":"W4200028620","doi":"10.1016/s1470-2045(21)00589-1","title":"Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":437,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; Ontario Institute for Cancer Research","funders":"National Institute of General Medical Sciences; Cancer Prevention and Research Institute of Texas; Genentech; National Institutes of Health; Instituto de Investigación Sanitaria Gregorio Marañón; Bristol-Myers Squibb; Max-Planck-Gesellschaft; Eisai; National Institute for Health and Care Research; University of California, San Francisco; Cancer Research UK; Puma Biotechnology; Syndax Pharmaceuticals; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; PharmaMar; Celgene; Intas Pharmaceuticals; Eli Lilly and Company; AstraZeneca; European Regional Development Fund; Breast Cancer Research Foundation; Instituto de Salud Carlos III; Amgen; Pfizer","keywords":"Pooled analysis; Chemotherapy; Breast cancer; Cancer; Survival analysis; Meta-analysis","score_opus":0.012837194240986978,"score_gpt":0.3124301090058624,"score_spread":0.2995929147648754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200028620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9353107,0.04626769,0.0049786232,0.00024165597,0.00018105375,0.0003647047,0.0118777435,0.00011851928,0.0006593116],"genre_scores_gemma":[0.9898078,0.0023994031,0.0012752573,0.00015395007,0.00008958845,0.00037319752,0.0056793788,0.000033457865,0.00018805725],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9853806,0.007152481,0.0028706917,0.0026938198,0.0013072315,0.00059519487],"domain_scores_gemma":[0.981962,0.0060619903,0.0061661587,0.0038518794,0.0014904141,0.0004675595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.021275857,0.0014040967,0.0047201966,0.0031243463,0.00045418105,0.0020579533,0.0011906798,0.0012634649,0.001191718],"category_scores_gemma":[0.022363838,0.00095351035,0.012927084,0.0043754494,0.00051158475,0.00085307617,0.0020658555,0.0006344435,0.0002844957],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015355597,0.000115227136,0.7311625,0.0034405296,0.23234281,0.00024586642,0.00034962702,0.0025158492,0.001013286,0.00010153256,0.0014889868,0.011868213],"study_design_scores_gemma":[0.0016652527,0.0017101101,0.8110499,0.00048486673,0.17959487,0.0004265049,0.00023557614,0.0018040395,0.0005403305,0.0002591713,0.002118542,0.00011073468],"about_ca_topic_score_codex":0.004100165,"about_ca_topic_score_gemma":0.0048928573,"teacher_disagreement_score":0.021275857,"about_ca_system_score_codex":0.0009332982,"about_ca_system_score_gemma":0.0011617052,"threshold_uncertainty_score":0.11251885},"labels":[],"label_agreement":null},{"id":"W4200116461","doi":"10.1016/s1470-2045(21)00590-8","title":"USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":161,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Alberta; Centre for Advancing Health Outcomes; Foothills Medical Centre; Brock University; BC Cancer Agency; Simon Fraser University; Vancouver Coastal Health; University of Calgary","funders":"National Health and Medical Research Council; National Cancer Institute; Cancer Research UK; BC Cancer Foundation; Medical Research Council; Terry Fox Research Institute; Alberta Cancer Foundation; Roy Castle Lung Cancer Foundation","keywords":"Lung cancer; Interim analysis; Lung cancer screening; Prospective cohort study; Interim; Cancer; Cohort study; Cohort","score_opus":0.07810916812081006,"score_gpt":0.4749829657438349,"score_spread":0.3968737976230249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200116461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98836887,0.0021983676,0.0015012547,0.00035612402,0.00032205158,0.0015213169,0.0039875275,0.000068562,0.0016758867],"genre_scores_gemma":[0.9872972,0.00036355385,0.0012903622,0.0005140912,0.00023135515,0.0026686566,0.006116689,0.000026949889,0.0014911842],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9937236,0.0039081685,0.00034658134,0.00065077026,0.0004887477,0.00088205794],"domain_scores_gemma":[0.9858521,0.004780353,0.0036610176,0.0033903713,0.0009209192,0.001395096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019599842,0.0014391643,0.0029010412,0.00041064393,0.0006219661,0.001761868,0.0011517956,0.0017778617,0.0041235373],"category_scores_gemma":[0.017957874,0.0007273607,0.005354756,0.0005908388,0.00055016286,0.0012625812,0.0010093013,0.0024693322,0.00065501773],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92860293,0.003358023,0.04771021,0.0002606577,0.0067946264,0.00009373329,0.000084312545,0.001195942,0.0004246325,0.00019666247,0.0028227097,0.008455524],"study_design_scores_gemma":[0.4452917,0.18417285,0.31776834,0.00030529496,0.03278013,0.0003749236,0.00029416196,0.011544028,0.0017797444,0.0016131363,0.0038525609,0.0002230928],"about_ca_topic_score_codex":0.0020935514,"about_ca_topic_score_gemma":0.0021675022,"teacher_disagreement_score":0.019599842,"about_ca_system_score_codex":0.00079588045,"about_ca_system_score_gemma":0.0019527707,"threshold_uncertainty_score":0.1036551},"labels":[],"label_agreement":null},{"id":"W4200186760","doi":"10.1016/s1470-2045(21)00719-1","title":"Radiographic progression-free survival in the ACIS trial for prostate cancer","year":2021,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prednisone; Abiraterone acetate; Placebo; Clinical endpoint; Prostate cancer; Internal medicine; Enzalutamide; Oncology; Progression-free survival; Surgery; Randomized controlled trial; Cancer; Androgen deprivation therapy; Pathology; Chemotherapy","score_opus":0.11843179758308021,"score_gpt":0.4310193453638538,"score_spread":0.3125875477807736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200186760","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0039824597,0.008781449,0.00010607001,0.9526236,0.020046895,0.000044114124,0.0008387737,0.000044000386,0.013532746],"genre_scores_gemma":[0.0400884,0.003885114,0.0002722208,0.88283324,0.05701883,0.00021841473,0.0005849939,0.000056699846,0.015042079],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99474573,0.0031075382,0.00036183896,0.00029070766,0.0009018273,0.00059240934],"domain_scores_gemma":[0.9887262,0.0076671364,0.0007417058,0.00027446623,0.00073020736,0.0018603478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007003361,0.00054090744,0.0021690745,0.00046035813,0.0015718492,0.0021633273,0.0012816777,0.019239252,0.008640983],"category_scores_gemma":[0.023718797,0.0004909952,0.0012256718,0.00073541724,0.0013044004,0.0020916257,0.0008642544,0.01650319,0.0036677194],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007245108,0.00016381519,0.0026721752,0.00025824053,0.00013399757,0.0006461788,0.000097419135,0.00027302516,0.00035075535,0.0037767089,0.9337195,0.050662994],"study_design_scores_gemma":[0.015883608,0.0027016904,0.020809311,0.0012478194,0.0006466359,0.0017065482,0.00044171253,0.0026308384,0.0010358173,0.02884089,0.9238729,0.00018220287],"about_ca_topic_score_codex":0.005694224,"about_ca_topic_score_gemma":0.014793822,"teacher_disagreement_score":0.019239252,"about_ca_system_score_codex":0.0033095556,"about_ca_system_score_gemma":0.0037182572,"threshold_uncertainty_score":0.03703779},"labels":[],"label_agreement":null},{"id":"W4200333351","doi":"10.1016/s1470-2045(25)00522-4","title":"Correction to Lancet Oncol 2024; 25: 1038–52","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Grail; Program for Creating STart-ups from Advanced Research and Technology; UCLH Biomedical Research Centre; Novartis; Merck Sharp and Dohme; American Association for Cancer Research; Servier; Basilea Pharmaceutica; Medical Research Council; Celgene; Johnson and Johnson; AstraZeneca; Genentech; Ipsen; Vifor Pharma; PharmaMar; Deutsche Krebshilfe; Bayer; Astellas Pharma; MedImmune; Daiichi-Sankyo; National Institutes of Health; CRUK Lung Cancer Centre of Excellence; Rosetrees Trust; Cancer Research UK; Janssen Pharmaceuticals; Breast Cancer Research Foundation; Canadian Cancer Society; Center for Cancer Research; National Institute for Health and Care Research; Clovis Oncology; Astex Pharmaceuticals; Harvard University; Entertainment Industry Foundation; AbbVie; National Cancer Institute; Gilead Sciences; Pfizer; Baxter International; Merck; GlaxoSmithKline; Boehringer Ingelheim; Amgen; American Society of Clinical Oncology; Bristol-Myers Squibb; Deutsche Forschungsgemeinschaft; Roche; Astellas Pharma US","keywords":"Medicine; Family medicine","score_opus":0.04504243712373093,"score_gpt":0.37463845798410506,"score_spread":0.3295960208603741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200333351","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00001768233,0.0017396203,0.00014050829,0.06718129,0.9286129,0.00001405456,0.00045041487,0.00013576177,0.0017077709],"genre_scores_gemma":[0.0019423516,0.007356091,0.0007934462,0.22354892,0.6803234,0.00021809556,0.00097445166,0.0005543391,0.084288895],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99162525,0.0016028212,0.0010047283,0.0010851882,0.003476922,0.0012051101],"domain_scores_gemma":[0.9557072,0.014348086,0.0031003365,0.0028507458,0.019268492,0.004725123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007938043,0.0033918056,0.003824943,0.004474504,0.0031525898,0.008085573,0.0042863027,0.019624412,0.1045188],"category_scores_gemma":[0.08315608,0.0017820946,0.0035748375,0.0025317085,0.0030926496,0.0030715275,0.0033103344,0.026189612,0.070311286],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016373546,0.000002010838,0.000013645389,0.00007287073,0.000009299173,0.000028912233,0.000005001728,0.000011932451,0.000008900793,0.00020746449,0.9977724,0.001851081],"study_design_scores_gemma":[0.00009915014,0.000013936382,0.00019742767,0.00038238076,0.000045857818,0.00009977115,0.000020459793,0.00006692647,0.00004856669,0.0009526546,0.99805045,0.000022411],"about_ca_topic_score_codex":0.012719305,"about_ca_topic_score_gemma":0.017743528,"teacher_disagreement_score":0.1045188,"about_ca_system_score_codex":0.005857034,"about_ca_system_score_gemma":0.00867239,"threshold_uncertainty_score":0.3496502},"labels":[],"label_agreement":null},{"id":"W4200359149","doi":"10.1016/s1470-2045(21)00581-7","title":"The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":278,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"EIT Health; Fogarty International Center; National Cancer Institute; National Human Genome Research Institute; Guy's and St Thomas' NHS Foundation Trust; Instituto de Salud Carlos III; Sydney Medical School; Fundação para a Ciência e a Tecnologia; National Health and Medical Research Council; Medical Research Council; School of Public Health and Family Medicine, University of Cape Town; College of Science and Engineering, University of Minnesota; University of Florida Health; University of Oklahoma Health Sciences Center; College of Engineering, Michigan State University; University of Veterinary and Animal Sciences; Directorate for Biological Sciences; Debre Markos University; George Institute for Global Health; King Faisal University; Université de Versailles Saint-Quentin-en-Yvelines; Madda Walabu University; King Saud bin Abdulaziz University for Health Science; Alfaisal University; Laboratório Associado para a Química Verde; RUDN University; Universitas Padjadjaran; Jahrom University of Medical Sciences; University at Buffalo; Samara University; Imam Abdulrahman Bin Faisal University; Razi Vaccine and Serum Research Institute; Lorestan University of Medical Sciences; Kwame Nkrumah University of Science and Technology; Peking Union Medical College; University of Toronto; Imperial College London; Syöpäsäätiö; Universidade Federal do Rio Grande do Sul; University of Colombo; Novo Nordisk Fonden; Walailak University; University of Calcutta; The Wellcome Trust DBT India Alliance; Shenzhen University; NSW Ministry of Health; Università degli Studi di Milano; Pomorski Uniwersytet Medyczny W Szczecinie; Universitas Airlangga; Yasuj University of Medical Sciences; Tarbiat Modares University; Department of Biotechnology, Ministry of Science and Technology, India; University of Sulaimani; University of California, Los Angeles; China Medical University; Cairo University; Secretaría Nacional de Ciencia, Tecnología e Innovación; Universidade do Porto; University of Tsukuba; University of Dhaka; Universitatea Sapientia; Universitat de Barcelona; Fasa University of Medical Sciences; University of South Carolina; Qazvin University of Medical Sciences; Chinese Center for Disease Control and Prevention; Oulun Yliopisto; Hokkaido University; Università di Bologna; Universitatea de Medicină şi Farmacie \"Carol Davila\" Bucureşti; Shahid Beheshti University of Medical Sciences; Zanjan University of Medical Sciences; University of Gondar; United Arab Emirates University; Kermanshah University of Medical Sciences; Autoritatea Natională pentru Cercetare Stiintifică; Wolkite University; Universiti Sultan Zainal Abidin; Menofia University; Göteborgs Universitet; Shahrekord University of Medical Sciences; Liverpool University Hospitals NHS Foundation Trust; Centro de Investigación Biomédica en Red de Salud Mental; Monash University; Università degli Studi del Piemonte Orientale; Universidade de São Paulo; Bloomberg Philanthropies; Department of Social Services, Australian Government; Jawaharlal Institute Of Postgraduate Medical Education and Research; Universitetet i Oslo; Tartu Ülikool; Danmarks Tekniske Universitet; Birjand University of Medical Sciences; Universitetet i Bergen; Mazandaran University of Medical Sciences; Shahrekord University; Haramaya University; Tanta University; Hamadan University of Medical Sciences; Semmelweis Egyetem; Universiti Kebangsaan Malaysia; University of Waterloo; Kuwait University; Tabriz University of Medical Sciences; Addis Ababa University; Sultan Qaboos University; Seoul National University Hospital; Qatar University; Babol University of Medical Sciences; Shahroud University of Medical Sciences; National Center for Advancing Translational Sciences; Päivikki ja Sakari Sohlbergin Säätiö; Indian Council of Medical Research; Mahidol University; King Abdulaziz University; Karolinska Institutet; Università degli Studi di Genova; Universidade Federal de Santa Catarina; Eastern Virginia Medical School; Isfahan University of Medical Sciences; Universitas Ahmad Dahlan; Islamic Azad University; Seoul National University; Gachon University; Ajou University; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior; Alborz University of Medical Sciences; Universidad Nacional de Colombia; Nankai University; Flinders University; Debre Tabor University; Universiteit Utrecht; Curtin University of Technology; University of South Australia; Instituto Politécnico do Porto; University of Science and Technology of China; University of Pennsylvania; Tsinghua University; National Taiwan Normal University; National and Kapodistrian University of Athens; Tehran University of Medical Sciences and Health Services; South Eastern Sydney Local Health District; McGovern Medical School; University of Technology Sydney; Charles Sturt University; University of Leicester; Deutsche Forschungsgemeinschaft; Amity University; Ministério da Ciência, Tecnologia e Ensino Superior; Sigrid Juséliuksen Säätiö; Queensland University of Technology; London South Bank University; University of Oxford; King's College London; University of Queensland; National Institute for Health and Care Research; American Lebanese Syrian Associated Charities; Uniwersytet Jagielloński Collegium Medicum; Shaheed Benazir Bhutto University; Sanjay Gandhi Postgraduate Institute of Medical Sciences; Technische Universität München; Arabian Gulf University; Tulane University; Neyshabur University of Medical Sciences; Kashan University of Medical Sciences; Macquarie University; Jordan University of Science and Technology; Hamad Bin Khalifa University; Shanghai Jiao Tong University; Kasturba Medical College, Manipal; Krishna Institute Of Medical Sciences Deemed To Be University; Samsung; Applied Molecular Biosciences Unit; Public Health Foundation of India; Australian Catholic University; University of Cape Town; Khalifa University of Science, Technology and Research; University of Ottawa; National Authority for Scientific Research and Innovation; Aksum University; James Cook University; Trường Đại học Duy Tân; Social Science Research Council; Ohio State University; Johns Hopkins University; Wellcome Trust; Institució Catalana de Recerca i Estudis Avançats; Universidade Federal de Juiz de Fora; Bill and Melinda Gates Foundation; Iran University of Medical Sciences; Student Research Committee, Tabriz University of Medical Sciences; La Trobe University; Deakin University; Uniwersytet Łódzki; Helsingin Yliopisto; Tufts Medical Center; Universidade de Lisboa; Ottawa Hospital Research Institute; Xiamen University; Jazan University; Universiti Brunei Darussalam; University of Rochester; Chinese University of Hong Kong; Florida Department of Health; Georgetown University; National Center of Neurology and Psychiatry; University of Agriculture, Faisalabad; Alexander von Humboldt-Stiftung; University of Southern California; University of Oklahoma; University of Zanjan; Florida International University; Jimma University; Zahedan University of Medical Sciences; Harvard University; Deutsches Krebsforschungszentrum; Conselho Nacional de Desenvolvimento Científico e Tecnológico; Univerzita Karlova v Praze; Michigan State University; Taipei Medical University; U.S. President’s Emergency Plan for AIDS Relief; Cleveland Clinic; Università di Catania; Eesti Teadusagentuur; Wayne State University; National Institutes of Health; Banaras Hindu University; Case Western Reserve University; Hamad Medical Corporation; University of Tabriz; European Commission; Yasouj University; Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute; Jackson State University; United Nations Population Fund; Rush University; Centre Hospitalier Universitaire Vaudois; New Mexico State University; Nazarbayev University; Wuhan University; Alberta Health Services; St. Baldrick's Foundation","keywords":"Burden of disease; Disease; Medicine; Cancer; Disease burden; Gerontology; Internal medicine","score_opus":0.03307815963245642,"score_gpt":0.3786533053267764,"score_spread":0.34557514569431996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200359149","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015698718,0.8763377,0.0022983013,0.0029903904,0.0008248622,0.0008598861,0.099188104,0.0001395488,0.0016624137],"genre_scores_gemma":[0.25309172,0.661972,0.007542557,0.003986871,0.0008844703,0.0046759145,0.066928,0.00013391291,0.0007845367],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99352235,0.00246584,0.001601114,0.00072201114,0.0013896605,0.00029906674],"domain_scores_gemma":[0.9898274,0.0038087794,0.002837772,0.00050454546,0.0026672692,0.00035411885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0109887095,0.001130872,0.004008547,0.0100050755,0.00042897818,0.0012285244,0.00086815224,0.0009588033,0.002058436],"category_scores_gemma":[0.0242616,0.0007265654,0.011697292,0.014843861,0.000435587,0.0009710366,0.0017997357,0.0012454814,0.00035527497],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018585151,0.00004693497,0.2651529,0.31584245,0.14403248,0.00037801656,0.00089795067,0.003318969,0.00045440832,0.0031819483,0.105761826,0.15907365],"study_design_scores_gemma":[0.0011367326,0.00036602555,0.4412441,0.21845222,0.20167033,0.00089513586,0.00088544533,0.0028745653,0.00043035555,0.0023572368,0.1294194,0.00026853036],"about_ca_topic_score_codex":0.06283882,"about_ca_topic_score_gemma":0.09964148,"teacher_disagreement_score":0.06283882,"about_ca_system_score_codex":0.002981387,"about_ca_system_score_gemma":0.008368356,"threshold_uncertainty_score":0.12494612},"labels":[],"label_agreement":null},{"id":"W4200605608","doi":"10.1016/s1470-2045(21)00406-x","title":"Should brachytherapy be added to external beam radiotherapy for prostate cancer?","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Brachytherapy; External beam radiotherapy; Prostate cancer; External beam radiation; Radiation therapy; Medicine; Beam (structure); Radiology; Medical physics; Oncology; Cancer; Internal medicine; Physics; Optics","score_opus":0.09168546390392768,"score_gpt":0.41024865960250145,"score_spread":0.3185631956985738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200605608","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007288296,0.28987893,0.0013050146,0.6178511,0.05566421,0.000038294624,0.0006179432,0.00017183703,0.02718438],"genre_scores_gemma":[0.11076282,0.18584886,0.006638443,0.5076218,0.1740253,0.000118716,0.0007180682,0.00032161994,0.013944358],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9941837,0.001814496,0.0008458365,0.00062360516,0.0020508117,0.00048154293],"domain_scores_gemma":[0.9763998,0.015258696,0.0025187633,0.0012192588,0.003066364,0.001537104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009062691,0.00075173355,0.0026036582,0.0013605484,0.0011235848,0.0039073355,0.002211276,0.0097506335,0.016931525],"category_scores_gemma":[0.04803894,0.0009906646,0.0029332554,0.0019101114,0.0034812815,0.005532475,0.0014684853,0.012691086,0.0049212915],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0076198843,0.0005585584,0.0072872234,0.005566401,0.0014685519,0.0018127108,0.00042869127,0.0015984534,0.0035113832,0.027739564,0.30942002,0.6329886],"study_design_scores_gemma":[0.001860885,0.002101089,0.021491364,0.005865497,0.002068511,0.0043320917,0.000706513,0.00060422387,0.0016280473,0.039126195,0.91992193,0.0002936084],"about_ca_topic_score_codex":0.005203251,"about_ca_topic_score_gemma":0.0144983465,"teacher_disagreement_score":0.016931525,"about_ca_system_score_codex":0.0024235004,"about_ca_system_score_gemma":0.006050266,"threshold_uncertainty_score":0.05664164},"labels":[],"label_agreement":null},{"id":"W4205245374","doi":"10.1016/s1470-2045(21)00641-0","title":"Prioritising access to cancer drugs","year":2021,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cancer; Family medicine; Resource (disambiguation); Low and middle income countries; Limited resources; Developing country; Internal medicine; Economic growth; Risk analysis (engineering)","score_opus":0.12116397908599112,"score_gpt":0.3447051492846027,"score_spread":0.22354117019861158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205245374","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020657238,0.0009786735,0.000050881736,0.99055475,0.005477632,0.0000077188215,0.00006713738,0.000007894885,0.002648716],"genre_scores_gemma":[0.0038634958,0.0010702399,0.00016945263,0.966085,0.021964181,0.00003456683,0.000041982523,0.000022361186,0.006748715],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99115187,0.0038405603,0.00075565174,0.0005882028,0.0020959992,0.0015677633],"domain_scores_gemma":[0.95457983,0.03069311,0.0021393073,0.0008714475,0.004387439,0.0073288335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012151451,0.00067611027,0.0018468465,0.0013581171,0.003449143,0.009138854,0.002235496,0.083698675,0.020310314],"category_scores_gemma":[0.07312594,0.0010737067,0.0015530518,0.0016902318,0.0047218613,0.008697038,0.0042926692,0.050154474,0.007372016],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008385343,0.000038778486,0.0005923293,0.0000710786,0.000021938844,0.00029735093,0.000077519,0.00014698376,0.000133147,0.011584911,0.9761267,0.010825508],"study_design_scores_gemma":[0.00030471612,0.00006779782,0.0014134443,0.0003517969,0.00003573123,0.00038929094,0.00037477093,0.0011417862,0.00020407359,0.04608563,0.9495583,0.000072596384],"about_ca_topic_score_codex":0.021373484,"about_ca_topic_score_gemma":0.047069374,"teacher_disagreement_score":0.083698675,"about_ca_system_score_codex":0.008921126,"about_ca_system_score_gemma":0.015809685,"threshold_uncertainty_score":0.067944765},"labels":[],"label_agreement":null},{"id":"W4205284185","doi":"10.1016/s1470-2045(21)00705-1","title":"Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":181,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Centre Hospitalier Universitaire de Sherbrooke","funders":"Jonsson Comprehensive Cancer Center; American Society for Radiation Oncology; Prostate Cancer Foundation","keywords":"Prostate cancer; Duration (music); Androgen deprivation therapy; Radiation therapy; Prostate; Androgen; Patient data","score_opus":0.2618211436098287,"score_gpt":0.3853407944443986,"score_spread":0.1235196508345699,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205284185","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23374595,0.73629826,0.011999105,0.0019028193,0.0028246883,0.00045739269,0.009562019,0.0006327237,0.0025770098],"genre_scores_gemma":[0.9608826,0.02835334,0.003457701,0.0020567165,0.0005624957,0.00040342432,0.002149779,0.00026987886,0.001864053],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9844832,0.009675532,0.0017172823,0.0025651935,0.000785079,0.0007736125],"domain_scores_gemma":[0.9749919,0.016611842,0.0032761698,0.00363976,0.00084446004,0.00063582935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01568134,0.0036848567,0.010104376,0.0019473453,0.00074897095,0.0037055642,0.0031388511,0.0032002223,0.006929743],"category_scores_gemma":[0.03473592,0.002881222,0.07517935,0.003051088,0.0010472923,0.0020920746,0.0025315543,0.0046343305,0.0009132061],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075355717,0.000021367016,0.011955091,0.006140666,0.97120976,0.00008878878,0.00003876188,0.000576378,0.00021522828,0.00009017212,0.0005149267,0.0016132011],"study_design_scores_gemma":[0.0017550756,0.0003365679,0.007869853,0.00047134867,0.98788387,0.00010801721,0.000032671247,0.00034826208,0.00006696593,0.00026035905,0.0008358824,0.000031062293],"about_ca_topic_score_codex":0.010289908,"about_ca_topic_score_gemma":0.01760137,"teacher_disagreement_score":0.01568134,"about_ca_system_score_codex":0.0017153869,"about_ca_system_score_gemma":0.0015482235,"threshold_uncertainty_score":0.082931876},"labels":[],"label_agreement":null},{"id":"W4205524306","doi":"10.1016/s1470-2045(21)00723-3","title":"Radiographic progression-free survival in the ACIS trial for prostate cancer – Authors' reply","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Pharmaceuticals; Astellas Pharma Canada; Bayer; AstraZeneca; Bristol-Myers Squibb","keywords":"Prednisone; Prostate cancer; Abiraterone acetate; Enzalutamide; Placebo; Clinical endpoint; Acis","score_opus":0.1013740712609857,"score_gpt":0.44420525823761475,"score_spread":0.34283118697662907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205524306","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006684648,0.0041655125,0.0000710622,0.9436586,0.050461423,0.000013151215,0.00037676512,0.000022759654,0.000562252],"genre_scores_gemma":[0.0072713033,0.00273961,0.00014964976,0.8994572,0.08758629,0.0000920305,0.00019518957,0.00003821708,0.0024704565],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.995436,0.0019810495,0.00073462457,0.00064067333,0.0008028142,0.00040480698],"domain_scores_gemma":[0.96852666,0.024274798,0.0015463207,0.00083716447,0.0031832946,0.0016317815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009076147,0.0007579232,0.0027381333,0.0008667528,0.0012801284,0.0026508283,0.0025012088,0.019364191,0.0059423367],"category_scores_gemma":[0.047237597,0.000798027,0.0018513377,0.0010157595,0.002387977,0.0032903387,0.0016608745,0.03567627,0.0027657237],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009830487,0.000044453835,0.0010431584,0.00028875133,0.00019841065,0.00024341447,0.000109516564,0.00014402889,0.00010865881,0.0012470953,0.98649895,0.009090601],"study_design_scores_gemma":[0.00454944,0.0005978554,0.009051784,0.0012916838,0.0009745808,0.0011354747,0.00085140875,0.00081445853,0.0010101066,0.012903695,0.9663758,0.0004436417],"about_ca_topic_score_codex":0.0034822458,"about_ca_topic_score_gemma":0.0045557227,"teacher_disagreement_score":0.019364191,"about_ca_system_score_codex":0.0018641221,"about_ca_system_score_gemma":0.0030187014,"threshold_uncertainty_score":0.04799986},"labels":[],"label_agreement":null},{"id":"W4210332821","doi":"10.1016/s1470-2045(21)00757-9","title":"Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":186,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of British Columbia","funders":"Janssen Biotech; Daiichi Sankyo Europe; National Cancer Institute; Pharmacyclics; Stand Up To Cancer; Janssen Research and Development; EMD Serono; Genentech; Ipsen; Astellas Pharma; Daiichi-Sankyo; Seagen; Pfizer; Incyte; National Institutes of Health; Menarini Silicon Biosystems; Eli Lilly and Company; U.S. Department of Defense; Sanofi; Exelixis; Flatiron Health; Advanced Accelerator Applications; Endocyte; Prostate Cancer Foundation; Bristol-Myers Squibb; AstraZeneca; American Association for Cancer Research; Amgen","keywords":"Prostate cancer; DNA repair; Gene; DNA; DNA Damage Repair; Phase (matter); Cancer","score_opus":0.08052415143704984,"score_gpt":0.39797207989690686,"score_spread":0.31744792845985703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210332821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98241377,0.008894555,0.00077931624,0.0015250756,0.00052184775,0.0012555923,0.0014200723,0.00018822798,0.003001586],"genre_scores_gemma":[0.9854579,0.0049802735,0.0014493656,0.0017589368,0.0002907153,0.0010064268,0.0018625841,0.00004186426,0.0031519057],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99950945,0.0002609412,0.00001539081,0.00009078756,0.00003615118,0.00008738918],"domain_scores_gemma":[0.9995685,0.00010220017,0.000076138786,0.000037309128,0.000022630556,0.0001932141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014418227,0.0018067937,0.0021226015,0.00032409362,0.00030482828,0.0013048309,0.0007455748,0.0013278162,0.0037864195],"category_scores_gemma":[0.0011792571,0.00053366966,0.002011747,0.0004624435,0.0010507277,0.0011120914,0.0004371858,0.003728747,0.00087114325],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88472944,0.009054312,0.002374056,0.0012124935,0.0025093963,0.00017494,0.00016223078,0.0022379041,0.009555012,0.00041746857,0.0038388376,0.08373396],"study_design_scores_gemma":[0.9086898,0.08259355,0.003757072,0.0000501167,0.00052134006,0.0002237871,0.000052747135,0.00091705547,0.0005727515,0.00047116444,0.0021120466,0.000038609105],"about_ca_topic_score_codex":0.0007362738,"about_ca_topic_score_gemma":0.0021064237,"teacher_disagreement_score":0.0037864195,"about_ca_system_score_codex":0.0007584925,"about_ca_system_score_gemma":0.000917365,"threshold_uncertainty_score":0.0126668215},"labels":[],"label_agreement":null},{"id":"W4210538987","doi":"10.1016/s1470-2045(21)00709-9","title":"Global consequences of the US FDA's accelerated approval of cancer drugs","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Mandate; Food and drug administration; Cancer drugs; Compassionate Use; Drug approval; Clinical trial; Scopus; Alternative medicine; Drug","score_opus":0.06840567706329904,"score_gpt":0.3097890429960882,"score_spread":0.2413833659327892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210538987","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.107504375,0.03813426,0.0030289085,0.73284465,0.00589501,0.00004696914,0.004846706,0.00019599858,0.10750308],"genre_scores_gemma":[0.88439626,0.027311977,0.0014470797,0.06959027,0.0047486145,0.00004067444,0.0009738002,0.00014234068,0.011348984],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99751127,0.00092391693,0.000106567364,0.00022388546,0.00081615866,0.00041811637],"domain_scores_gemma":[0.9918498,0.003023984,0.0020121832,0.00036644915,0.0019707074,0.00077696703],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004659312,0.00043648,0.0005024074,0.0016478577,0.0006383893,0.0039967685,0.00039702325,0.0036377818,0.008786888],"category_scores_gemma":[0.0133498525,0.00027808503,0.000875915,0.0020476778,0.0020803409,0.0021755488,0.0016960875,0.005123265,0.0008918271],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023742747,0.00024360635,0.042065393,0.0007209786,0.0006399913,0.0016498179,0.00049581134,0.02478711,0.0026485156,0.3454225,0.3689899,0.20996206],"study_design_scores_gemma":[0.0004151278,0.0005201688,0.21860509,0.0008467928,0.0004567127,0.0011193278,0.001593093,0.008460559,0.0021716394,0.16166653,0.60388947,0.00025548763],"about_ca_topic_score_codex":0.017734222,"about_ca_topic_score_gemma":0.020610249,"teacher_disagreement_score":0.9953407,"about_ca_system_score_codex":0.00539889,"about_ca_system_score_gemma":0.0030814542,"threshold_uncertainty_score":0.039171815},"labels":[],"label_agreement":null},{"id":"W4213247158","doi":"10.1016/s1470-2045(22)00017-1","title":"Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Merck Sharp and Dohme; National Institute for Health and Care Research; Merck; AstraZeneca","keywords":"Prostate cancer; Homologous recombination; Olaparib; Drug; Quality of life (healthcare); Hormonal therapy; Gene","score_opus":0.20043690397895775,"score_gpt":0.42880753078566086,"score_spread":0.22837062680670311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213247158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934521,0.0034313418,0.000252242,0.0004457211,0.00028617212,0.00060311,0.00048039804,0.000037211837,0.0010118376],"genre_scores_gemma":[0.9954781,0.0012838613,0.00054352207,0.0004110933,0.0002986008,0.00065052847,0.00037257705,0.000008086284,0.00095360033],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994506,0.00030453055,0.000023389182,0.00009156684,0.000034416185,0.00009548335],"domain_scores_gemma":[0.99912685,0.0003768168,0.00017688514,0.00005415739,0.000029503666,0.00023582672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012133822,0.001464725,0.0024408926,0.00031508884,0.00034639327,0.0011216828,0.0007303036,0.00145339,0.0057747443],"category_scores_gemma":[0.0015310118,0.0005623587,0.00248271,0.00036540325,0.0012476797,0.0010120465,0.00046352192,0.003341722,0.0005164108],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9808646,0.0038493196,0.0007355813,0.0003686436,0.0007830241,0.00002066124,0.000039624116,0.00045759388,0.0009920353,0.000072524075,0.0002716329,0.0115447715],"study_design_scores_gemma":[0.91186947,0.08398251,0.0024436482,0.000029253444,0.0004950214,0.000030696316,0.00003610806,0.00046052795,0.00019791446,0.00018690813,0.00025011884,0.000017834465],"about_ca_topic_score_codex":0.0011553377,"about_ca_topic_score_gemma":0.0023870743,"teacher_disagreement_score":0.0057747443,"about_ca_system_score_codex":0.00075663906,"about_ca_system_score_gemma":0.00076440925,"threshold_uncertainty_score":0.019318402},"labels":[],"label_agreement":null},{"id":"W4214517876","doi":"10.1016/s1470-2045(22)00058-4","title":"Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nasopharyngeal carcinoma; Chemoradiotherapy; Radiation therapy; Clinical endpoint; Surgery; Internal medicine; Head and neck cancer; Stage (stratigraphy); Randomized controlled trial; Oncology","score_opus":0.059944473757817786,"score_gpt":0.36151814264806353,"score_spread":0.3015736688902457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214517876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800521,0.009414723,0.0011141399,0.0011865337,0.0014988204,0.0028591019,0.0011369608,0.00013811408,0.0025995367],"genre_scores_gemma":[0.9822941,0.004086232,0.0017538365,0.0016559905,0.0006716154,0.003463445,0.000997817,0.00004374494,0.0050332313],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991818,0.00046818933,0.000038918322,0.00014138775,0.000044825818,0.0001248871],"domain_scores_gemma":[0.9989256,0.0004715524,0.00019490533,0.00009954752,0.000043591113,0.00026477687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019583325,0.0027299188,0.0039858157,0.0003556184,0.0005196143,0.0013374615,0.0013240359,0.0023093412,0.0093101],"category_scores_gemma":[0.002298675,0.0007780745,0.0038457245,0.00047816918,0.001622498,0.0013661823,0.0005488142,0.0043762866,0.0011459095],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98839045,0.0018884594,0.00018418145,0.00059254316,0.0008183017,0.000023467059,0.00004318962,0.00030416934,0.0008774433,0.00009004186,0.00050108146,0.00628669],"study_design_scores_gemma":[0.9719748,0.02614147,0.0005989149,0.00003703303,0.00037716853,0.00002149438,0.000023994131,0.0002377919,0.00011041848,0.00020760328,0.00025694794,0.000012312604],"about_ca_topic_score_codex":0.0019655928,"about_ca_topic_score_gemma":0.00464416,"teacher_disagreement_score":0.0093101,"about_ca_system_score_codex":0.0011381264,"about_ca_system_score_gemma":0.00128636,"threshold_uncertainty_score":0.031145394},"labels":[],"label_agreement":null},{"id":"W4214704026","doi":"10.1016/s1470-2045(22)00015-8","title":"Progression-free survival: it is time for a new name","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Clinical endpoint; Progression-free survival; Clinical trial; Quality of life (healthcare); Guideline; Internal medicine; Disease; Oncology; Cancer; Overall survival; Pathology; Nursing","score_opus":0.08270184093113529,"score_gpt":0.32196041692389227,"score_spread":0.23925857599275696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214704026","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021917792,0.30024347,0.0035617147,0.6518121,0.038183462,0.000014405051,0.0006092814,0.00007684911,0.0033068757],"genre_scores_gemma":[0.14164507,0.32292652,0.004899397,0.28560522,0.2358135,0.000111592424,0.00074624957,0.00043180617,0.0078207115],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99283314,0.003026936,0.0007970287,0.0010473508,0.001748758,0.0005467512],"domain_scores_gemma":[0.92385185,0.05196608,0.0064031365,0.0039622006,0.007863804,0.0059528556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.034126937,0.0010852049,0.0043818103,0.0020198557,0.0013844689,0.009303682,0.0024780333,0.008796666,0.010301604],"category_scores_gemma":[0.087360024,0.00059111847,0.001494905,0.0032783337,0.011304472,0.030918196,0.003320199,0.021824745,0.0025155174],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019272348,0.0001764253,0.004277003,0.00373619,0.0008458801,0.00018279243,0.0005498218,0.0028350193,0.00046954097,0.26009387,0.41029212,0.31461406],"study_design_scores_gemma":[0.00035237125,0.0003903546,0.0056392546,0.003991709,0.00039949652,0.00031915493,0.0011570475,0.001997921,0.00021227564,0.61524576,0.37003168,0.00026296594],"about_ca_topic_score_codex":0.0038309854,"about_ca_topic_score_gemma":0.004158927,"teacher_disagreement_score":0.034126937,"about_ca_system_score_codex":0.0056557017,"about_ca_system_score_gemma":0.004258463,"threshold_uncertainty_score":0.18048263},"labels":[],"label_agreement":null},{"id":"W4220668260","doi":"10.1016/s1470-2045(22)00088-2","title":"Consequences of US FDA approval decisions in high-income countries","year":2022,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Food and drug administration; Drug approval; Cancer drugs; Nomination; Expanded access; Drug; Pharmacology; Political science; Law; Oncology","score_opus":0.06043877707711726,"score_gpt":0.28660405973931713,"score_spread":0.22616528266219987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220668260","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004719472,0.0022772513,0.00008322823,0.9752274,0.0033130574,0.000011875839,0.00027938635,0.000009840534,0.01407846],"genre_scores_gemma":[0.06969615,0.0026115999,0.00017756067,0.9101127,0.008781889,0.000042501564,0.00012066349,0.000031407028,0.008425558],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.988986,0.0054757698,0.00084232393,0.0006275723,0.0018925514,0.0021757316],"domain_scores_gemma":[0.9512693,0.03633818,0.0038779296,0.0008115913,0.004183932,0.0035190785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015965503,0.00037383658,0.0009721151,0.0011787658,0.0033299795,0.008074184,0.0011897808,0.042457554,0.008534956],"category_scores_gemma":[0.07665683,0.00057749916,0.001592424,0.0022763123,0.003702168,0.0029116606,0.0022357907,0.01721552,0.0019441221],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008425314,0.00009081709,0.00814399,0.000113618946,0.00012674747,0.0029818914,0.0003932058,0.001049311,0.00029338352,0.04883632,0.9208238,0.016304348],"study_design_scores_gemma":[0.0009216947,0.00022086059,0.026152743,0.0008488952,0.00028671548,0.0017427952,0.0026592645,0.0027330564,0.0012521845,0.066697255,0.896192,0.00029261783],"about_ca_topic_score_codex":0.030154936,"about_ca_topic_score_gemma":0.043854535,"teacher_disagreement_score":0.042457554,"about_ca_system_score_codex":0.008564329,"about_ca_system_score_gemma":0.007864602,"threshold_uncertainty_score":0.08443469},"labels":[],"label_agreement":null},{"id":"W4220672160","doi":"10.1016/s1470-2045(22)00122-x","title":"Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":143,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Clovis Oncology","keywords":"Ovarian cancer; Chemotherapy; Mutation; Cancer; Phases of clinical research; Poly ADP ribose polymerase; Clinical trial","score_opus":0.07535907588749029,"score_gpt":0.4198910124240871,"score_spread":0.3445319365365968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220672160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97216606,0.014983958,0.00094379555,0.0017097935,0.001310368,0.0020324555,0.0014880231,0.00031246673,0.005052928],"genre_scores_gemma":[0.98476183,0.004451014,0.0012912976,0.0014850743,0.0004837427,0.0014646546,0.0014265893,0.000040471426,0.0045953062],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993654,0.00036957918,0.000025411091,0.00010457637,0.000035610872,0.00009952678],"domain_scores_gemma":[0.99916816,0.00032269533,0.00014418676,0.000067950445,0.000040765855,0.00025627483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015722383,0.0016296493,0.0030238274,0.0004441079,0.0003122804,0.0010725628,0.0011415363,0.0017346687,0.0085806325],"category_scores_gemma":[0.0019023826,0.0005939917,0.0022437228,0.000488608,0.0011997935,0.001281098,0.00044221577,0.004355559,0.0012906644],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96942186,0.0027576252,0.00042456805,0.0007289898,0.001246409,0.000035533616,0.000044341177,0.00055556424,0.0013534991,0.00017508115,0.0012162003,0.022040354],"study_design_scores_gemma":[0.9443165,0.051537264,0.0013711108,0.000054621676,0.0005421708,0.00005392974,0.000028092063,0.00062000303,0.00024307307,0.0002805853,0.00093339843,0.00001935108],"about_ca_topic_score_codex":0.0010379252,"about_ca_topic_score_gemma":0.0023669244,"teacher_disagreement_score":0.0085806325,"about_ca_system_score_codex":0.0008244857,"about_ca_system_score_gemma":0.00069992157,"threshold_uncertainty_score":0.02870506},"labels":[],"label_agreement":null},{"id":"W4220833376","doi":"10.1016/s1470-2045(22)00123-1","title":"Prioritising locations for radiotherapy equipment in Brazil: a cross-sectional, population-based study and development of a LINAC shortage index","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Kingston General Hospital; Queen's University","funders":"","keywords":"Economic shortage; Index (typography); Linear particle accelerator; Radiation therapy","score_opus":0.05928119540905707,"score_gpt":0.4586169276786404,"score_spread":0.3993357322695833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220833376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997493,0.00028210555,0.00031667622,0.00022593615,0.0000069955418,0.000054047232,0.0007445786,0.000005423261,0.0008710814],"genre_scores_gemma":[0.9990472,0.00014946982,0.00038153265,0.000044788165,0.0000025243476,0.000028157923,0.0002324436,0.0000032655337,0.00011059782],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990715,0.00027146385,0.00014517379,0.0001763436,0.00019124658,0.00014424736],"domain_scores_gemma":[0.9963875,0.0007907924,0.0018997841,0.00017785882,0.0004704875,0.00027370892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018665654,0.00029222245,0.00041505456,0.0011096615,0.00050416414,0.00077251426,0.0010093523,0.0005732359,0.001284658],"category_scores_gemma":[0.008183257,0.0006068141,0.0006686931,0.002112222,0.00042214093,0.000855815,0.0011275461,0.0006220028,0.00015654946],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012949874,0.00003513457,0.9966446,0.000041763058,0.00004398821,0.00003447288,0.0011867069,0.00004582516,0.0001435302,0.00007947132,0.00013568343,0.0015959144],"study_design_scores_gemma":[0.0000037265233,0.0000745966,0.99471974,0.000066525,0.000042752006,0.00013035537,0.0036551554,0.0004803638,0.000057258727,0.00007071905,0.0006900061,0.0000088338],"about_ca_topic_score_codex":0.0768531,"about_ca_topic_score_gemma":0.10974875,"teacher_disagreement_score":0.0768531,"about_ca_system_score_codex":0.0015020866,"about_ca_system_score_gemma":0.0019313351,"threshold_uncertainty_score":0.15281153},"labels":[],"label_agreement":null},{"id":"W4223605782","doi":"10.1016/s1470-2045(22)00127-9","title":"Risk factors and prognostic implications of diagnosis of cancer within 30 days after an emergency hospital admission (emergency presentation): an International Cancer Benchmarking Partnership (ICBP) population-based study","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":131,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Nova Scotia; Alberta Bible College; Government of New Brunswick; Canadian Partnership Against Cancer; Health PEI; Saskatchewan Cancer Agency; St. John’s Health Sciences Centre; CancerCare Manitoba; Alberta Health Services; Cancer Care Ontario","funders":"Cancer Council Victoria; Partenariat Canadien Contre Le Cancer; Public Health England; Public Health Agency; Cancer Society of New Zealand; Cancer Institute NSW; University College London; Cancer Research UK; Public Health Wales; Alberta Health Services","keywords":"Cancer; General partnership; Cancer registry; Norwegian; Benchmarking; Public health; Agency (philosophy); Danish","score_opus":0.10803121393096099,"score_gpt":0.4328404661690418,"score_spread":0.3248092522380808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223605782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915047,0.00524738,0.0007293538,0.0002571144,0.000025988023,0.000040100997,0.0018076289,0.000009293326,0.00037838993],"genre_scores_gemma":[0.99825543,0.0005677709,0.00024139135,0.00006611738,0.000016752621,0.000029204219,0.00079301995,0.000003216911,0.000027129528],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953335,0.0026690841,0.00040279623,0.0008713838,0.00038710737,0.0003360336],"domain_scores_gemma":[0.9905901,0.0032184846,0.0036696284,0.0011480292,0.0008044078,0.00056942576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0062031113,0.0004977332,0.0008055788,0.0020363329,0.000448977,0.0011886673,0.0010841964,0.0006868892,0.00068985345],"category_scores_gemma":[0.012654996,0.0005554606,0.0024355485,0.0041899486,0.0006570212,0.0007583878,0.001874643,0.0009271023,0.00008342576],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015205602,0.000023890658,0.9951197,0.00011064146,0.0017694143,0.00004424584,0.00012523888,0.0003448955,0.000025369944,0.00004341182,0.00026522277,0.001975902],"study_design_scores_gemma":[0.000040047224,0.00012315797,0.99527055,0.00012572891,0.0016588733,0.00019638531,0.000512882,0.0014809001,0.000036197805,0.00012722274,0.0004112381,0.000016848031],"about_ca_topic_score_codex":0.02353335,"about_ca_topic_score_gemma":0.020275472,"teacher_disagreement_score":0.02353335,"about_ca_system_score_codex":0.001018401,"about_ca_system_score_gemma":0.0008735249,"threshold_uncertainty_score":0.046792746},"labels":[],"label_agreement":null},{"id":"W4223627834","doi":"10.1016/s1470-2045(22)00223-6","title":"Long-term versus short-term androgen deprivation combined with EBRT for unfavourable prostate cancer","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia, Okanagan Campus","funders":"","keywords":"Prostate cancer; Androgen; Androgen deprivation therapy; Radiation therapy; Androgen suppression; Prostate; Randomized controlled trial","score_opus":0.08354481682497854,"score_gpt":0.3878135536795813,"score_spread":0.30426873685460276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223627834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8553867,0.12864116,0.00062534906,0.0041958475,0.0019577781,0.00019927043,0.00073899614,0.000052152074,0.008202698],"genre_scores_gemma":[0.9836512,0.012275498,0.00034774686,0.0009447918,0.00075079233,0.000055451816,0.00031200264,0.000011268922,0.0016512817],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995074,0.00025594753,0.000043601656,0.000057619978,0.000055963745,0.00007938456],"domain_scores_gemma":[0.99887425,0.00064951373,0.00011937902,0.000064814245,0.000032776174,0.00025921175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012025022,0.00035965728,0.0012323551,0.00023768602,0.00018793822,0.00075240945,0.0005471339,0.0007478544,0.005372433],"category_scores_gemma":[0.0022264025,0.00016718372,0.0015435279,0.0002805007,0.0005570188,0.0007746443,0.00038052083,0.0015529128,0.0004568188],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.63379323,0.0029459842,0.005719101,0.003540039,0.0047292146,0.00013978525,0.0001497089,0.0033338293,0.0052409526,0.0007717684,0.0026284454,0.33700788],"study_design_scores_gemma":[0.21420193,0.5029397,0.21979032,0.0025046328,0.0136528695,0.0013568813,0.0008228991,0.0045673014,0.004390752,0.006465819,0.029049303,0.00025761226],"about_ca_topic_score_codex":0.0014165046,"about_ca_topic_score_gemma":0.0054606157,"teacher_disagreement_score":0.005372433,"about_ca_system_score_codex":0.0007206066,"about_ca_system_score_gemma":0.0006522307,"threshold_uncertainty_score":0.017972589},"labels":[],"label_agreement":null},{"id":"W4224982972","doi":"10.1016/s1470-2045(22)00212-1","title":"Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Cancer Institute; Chugai Pharmaceutical; MSD Australia; EMD Serono; Genentech; Takeda Pharmaceuticals U.S.A.; Merck Sharp and Dohme; Astellas Pharma; Eisai; Pfizer; Incyte; Ipsen; Exelixis; Kissei; Bayer Fund; Sanofi; GlaxoSmithKline; Merck; Memorial Sloan-Kettering Cancer Center; Bristol-Myers Squibb; Eli Lilly and Company; EUSA Pharma; AstraZeneca; Amgen; Alexion Pharmaceuticals; Astellas Pharma US","keywords":"Pembrolizumab; Lenvatinib; Sunitinib; Renal cell carcinoma; Everolimus; Kidney cancer; Phases of clinical research; Carcinoma","score_opus":0.08879883769833696,"score_gpt":0.36365213383543105,"score_spread":0.2748532961370941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224982972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947477,0.0032217603,0.00012276079,0.0003000101,0.00017779622,0.00041216376,0.0004113244,0.000016186454,0.00059030694],"genre_scores_gemma":[0.99626416,0.001138852,0.0003126859,0.0004034342,0.00019038499,0.0005297591,0.0005378612,0.0000053301123,0.0006175001],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991844,0.00042752372,0.000048744438,0.00015125524,0.000065500855,0.00012258992],"domain_scores_gemma":[0.99900275,0.0002871394,0.00028172584,0.000052910396,0.000052428048,0.00032299565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014046377,0.0012240573,0.002907585,0.00033775042,0.00041090418,0.0010250601,0.0007617239,0.0014704682,0.0035886508],"category_scores_gemma":[0.0014137641,0.00060025114,0.0035805902,0.0005092157,0.0009705705,0.0010256476,0.00050621305,0.003133526,0.00043110558],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97899044,0.0044241585,0.0024993622,0.00042875443,0.002100858,0.000023343442,0.000043696844,0.00041482618,0.0012160485,0.000041715986,0.00034243223,0.009474326],"study_design_scores_gemma":[0.8788199,0.10517237,0.013080172,0.000037851674,0.0015555451,0.000035078894,0.000040792354,0.00044330856,0.0002626257,0.00013216547,0.0003970733,0.000023082326],"about_ca_topic_score_codex":0.0017841078,"about_ca_topic_score_gemma":0.0034158097,"teacher_disagreement_score":0.0035886508,"about_ca_system_score_codex":0.0012570459,"about_ca_system_score_gemma":0.00096035836,"threshold_uncertainty_score":0.01200521},"labels":[],"label_agreement":null},{"id":"W4224983146","doi":"10.1016/s1470-2045(22)00155-3","title":"Sodium thiosulfate for prevention of cisplatin-induced hearing loss: updated survival from ACCL0431","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute","keywords":"Cohort; Chemotherapy; Quality of life (healthcare); Hearing loss; Childhood cancer; Cisplatin; Cancer; Scopus","score_opus":0.16263474852385781,"score_gpt":0.4396365639109289,"score_spread":0.27700181538707114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224983146","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01742578,0.8825631,0.0017331393,0.02204904,0.006220533,0.0005872726,0.048532493,0.0002645618,0.020624053],"genre_scores_gemma":[0.09742951,0.7687113,0.0040592733,0.033203408,0.012799939,0.0011564967,0.06913887,0.00028541373,0.013215716],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9974401,0.00060949574,0.0005679952,0.00019644438,0.00095710915,0.00022891843],"domain_scores_gemma":[0.9920007,0.002268321,0.0024769332,0.0004158363,0.0022412403,0.00059699273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050274218,0.00090458937,0.0030551082,0.0028440957,0.0003073924,0.001723667,0.0010071204,0.0016030334,0.007373214],"category_scores_gemma":[0.009670495,0.00044202586,0.0035691455,0.004847744,0.00026865772,0.0012202831,0.00093405036,0.002211322,0.0019493771],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010920401,0.0002822672,0.008360649,0.016184196,0.0064645903,0.00016029475,0.00008351189,0.0013310419,0.0008357233,0.0007341744,0.28450018,0.670143],"study_design_scores_gemma":[0.012503417,0.005114517,0.13549049,0.025695827,0.033765804,0.0008749773,0.0001540796,0.00075704453,0.0014545086,0.0019796593,0.78198963,0.00021995552],"about_ca_topic_score_codex":0.011747534,"about_ca_topic_score_gemma":0.027611613,"teacher_disagreement_score":0.011747534,"about_ca_system_score_codex":0.0020868082,"about_ca_system_score_gemma":0.0033915865,"threshold_uncertainty_score":0.026587903},"labels":[],"label_agreement":null},{"id":"W4224990434","doi":"10.1016/s1470-2045(22)00063-8","title":"Imaging response assessment for CNS germ cell tumours: consensus recommendations from the European Society for Paediatric Oncology Brain Tumour Group and North American Children's Oncology Group","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Cancer Research UK","keywords":"Germ cell; Germ cell tumors; Disease; Clinical trial; Consensus conference; Homogeneous","score_opus":0.02919742736994963,"score_gpt":0.3310829031241969,"score_spread":0.3018854757542473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224990434","genre_codex":"review","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0059675286,0.6028368,0.028832532,0.31773314,0.0143718235,0.0028047774,0.0031072136,0.0008335382,0.023512576],"genre_scores_gemma":[0.08416808,0.52271575,0.24053182,0.10994643,0.012758547,0.007960571,0.012174041,0.0006854988,0.009059335],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.97974044,0.006542618,0.0069151414,0.0012192717,0.0045857294,0.0009968359],"domain_scores_gemma":[0.92674637,0.029546678,0.0077043697,0.0013478601,0.031432044,0.0032227044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.051250223,0.0018046577,0.004819021,0.0054701827,0.0018642924,0.0045018727,0.008470933,0.007852534,0.0026999267],"category_scores_gemma":[0.07432882,0.0009634156,0.008047221,0.00384535,0.0021852136,0.0035361769,0.003926248,0.01114186,0.0023730078],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007754522,0.00030650487,0.0077513386,0.024520643,0.0017970477,0.000484122,0.0010686106,0.0029747274,0.0019360466,0.0056420965,0.28267467,0.67006874],"study_design_scores_gemma":[0.0019639696,0.0008096168,0.035389125,0.12118716,0.005987475,0.003106787,0.0026818714,0.0040780245,0.0028704419,0.016576678,0.8049311,0.00041768208],"about_ca_topic_score_codex":0.019375246,"about_ca_topic_score_gemma":0.02796883,"teacher_disagreement_score":0.051250223,"about_ca_system_score_codex":0.006387068,"about_ca_system_score_gemma":0.017489964,"threshold_uncertainty_score":0.27104032},"labels":[],"label_agreement":null},{"id":"W4229439346","doi":"10.1016/s1470-2045(21)00720-8","title":"Cancer in sub-Saharan Africa: a Lancet Oncology Commission","year":2022,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":361,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Queen's University","funders":"Uganda Cancer Institute; National Cancer Institute; Medical Research Council; Dana-Farber Cancer Institute; World Health Organization","keywords":"Psychological intervention; Medicine; Workforce; Psychosocial; Cancer; Pandemic; Cancer prevention; Family medicine; Business; Environmental health; Economic growth; Nursing; Coronavirus disease 2019 (COVID-19); Disease; Internal medicine","score_opus":0.3942694405909314,"score_gpt":0.49235835738087214,"score_spread":0.09808891678994075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229439346","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000031630763,0.9867488,0.000016692435,0.0087627005,0.0037778192,0.000008150309,0.000035052417,0.0000043781633,0.0006148888],"genre_scores_gemma":[0.00075297884,0.9896387,0.00009810525,0.0065933946,0.0018421472,0.000019076972,0.000034953326,0.000003870159,0.0010168443],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988556,0.0003237026,0.00015802326,0.00009628626,0.0003728666,0.0001935488],"domain_scores_gemma":[0.9965969,0.0014624839,0.000550348,0.00006512943,0.00082726066,0.0004979392],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046045035,0.0015198773,0.0023193802,0.0034438123,0.0007217997,0.0030879944,0.0010691901,0.0037825922,0.0072527733],"category_scores_gemma":[0.0076690055,0.0006814263,0.0010249726,0.005321566,0.00084952445,0.0035001389,0.002570269,0.0051464764,0.0014425651],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016063267,0.000034766166,0.00020942959,0.028685475,0.00022111568,0.00016907978,0.00021694183,0.00018598404,0.00024757595,0.005849316,0.43780956,0.5262101],"study_design_scores_gemma":[0.00007100405,0.000037122813,0.00049207464,0.018536113,0.0002193435,0.00013685357,0.00012048261,0.000020651969,0.000040221104,0.0013568024,0.97895753,0.000011757109],"about_ca_topic_score_codex":0.011242503,"about_ca_topic_score_gemma":0.022885116,"teacher_disagreement_score":0.011242503,"about_ca_system_score_codex":0.0045338753,"about_ca_system_score_gemma":0.015477912,"threshold_uncertainty_score":0.032895684},"labels":[],"label_agreement":null},{"id":"W4233447779","doi":"10.1016/s1470-2045(20)30173-x","title":"Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group","year":2020,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":142,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Dalhousie University","funders":"National Cancer Institute; F. Hoffmann-La Roche","keywords":"Medicine; Glioma; Oncology; Medical physics; Internal medicine; Intensive care medicine","score_opus":0.09733537766704278,"score_gpt":0.41390526653161064,"score_spread":0.3165698888645678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233447779","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020245383,0.9923671,0.0005834334,0.0049475506,0.0005671886,0.00018293441,0.00032825043,0.0000342393,0.0007868313],"genre_scores_gemma":[0.0032228427,0.9862351,0.004466618,0.004163882,0.00033734136,0.00048910966,0.0006573417,0.000021289543,0.00040649244],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99493647,0.0021033206,0.0014237465,0.00037010704,0.00095327786,0.00021316308],"domain_scores_gemma":[0.9844801,0.010089331,0.0024986386,0.00021692614,0.002274836,0.00044003205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018498402,0.0012412043,0.006034432,0.0033571112,0.00038665917,0.002550096,0.0032250814,0.0027569865,0.003475183],"category_scores_gemma":[0.021418585,0.000630378,0.006547259,0.0028107374,0.0007363268,0.001888787,0.0018608484,0.0054620276,0.0013481483],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005804525,0.00007309297,0.00065279275,0.08809466,0.0015185777,0.0000655053,0.00012994753,0.000715162,0.00037784566,0.0020100856,0.037283476,0.8684983],"study_design_scores_gemma":[0.0016029328,0.0006727269,0.005845162,0.3252676,0.010401323,0.00069383765,0.0002575245,0.00094141066,0.0007799018,0.005642616,0.64776707,0.00012795573],"about_ca_topic_score_codex":0.0066841235,"about_ca_topic_score_gemma":0.012898684,"teacher_disagreement_score":0.018498402,"about_ca_system_score_codex":0.00438747,"about_ca_system_score_gemma":0.008620938,"threshold_uncertainty_score":0.09783012},"labels":[],"label_agreement":null},{"id":"W4236289131","doi":"10.1016/s1470-2045(21)00073-5","title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":416,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck; AstraZeneca","keywords":"Olaparib; Medicine; BRCA mutation; Internal medicine; Clinical endpoint; Ovarian cancer; Oncology; Placebo; Progression-free survival; PARP inhibitor; Randomized controlled trial; Cancer; Chemotherapy; Pathology","score_opus":0.05218418572592092,"score_gpt":0.3670435714528127,"score_spread":0.31485938572689176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236289131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97495306,0.017586345,0.00080513203,0.0008432092,0.00054533937,0.0017588122,0.0012533695,0.00021450651,0.0020401336],"genre_scores_gemma":[0.98710424,0.005775774,0.0011936935,0.0009277305,0.00031615718,0.0011585174,0.0011358263,0.000033110984,0.0023549118],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994628,0.00030213036,0.000037825463,0.000098256445,0.000035411507,0.000063713305],"domain_scores_gemma":[0.99917525,0.00031249854,0.00016543544,0.00006999048,0.000041658248,0.00023509217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014061341,0.0012918672,0.003287844,0.00041746756,0.00032432855,0.0010959343,0.00089027727,0.0015503879,0.0046667634],"category_scores_gemma":[0.0016026618,0.00059181044,0.0018250151,0.0004768669,0.0009539338,0.0013036806,0.00035331128,0.0028106077,0.0008294868],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9733479,0.001581118,0.0004424025,0.00077465957,0.00090770074,0.000041135838,0.000048885246,0.00025842272,0.002182692,0.00006914138,0.0005837756,0.019762218],"study_design_scores_gemma":[0.9626267,0.03402028,0.0015382764,0.00004324348,0.00038884615,0.000050258226,0.000021307113,0.0003236893,0.00027412534,0.0001240438,0.00057149923,0.000017631162],"about_ca_topic_score_codex":0.0006049051,"about_ca_topic_score_gemma":0.001442006,"teacher_disagreement_score":0.0046667634,"about_ca_system_score_codex":0.00051894464,"about_ca_system_score_gemma":0.00068373134,"threshold_uncertainty_score":0.015611947},"labels":[],"label_agreement":null},{"id":"W4252148737","doi":"10.1016/s1470-2045(15)70040-9","title":"Recalibrating emergency care in the UK","year":2015,"lang":"en","type":"editorial","venue":"The Lancet Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Hotline; Medicine; Accident and emergency; Quarter (Canadian coin); Population; Service (business); Medical emergency; Mental health; Population ageing; Health care; Family medicine; Psychiatry; Environmental health; Business","score_opus":0.2223935450351709,"score_gpt":0.5011679446326861,"score_spread":0.2787743995975152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252148737","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000027068543,0.018644648,0.00005463086,0.10505358,0.8753865,0.000014427746,0.000028134273,0.000022016267,0.0007690422],"genre_scores_gemma":[0.0007086801,0.0144861955,0.0000884715,0.086031325,0.89514905,0.000026613152,0.000019923056,0.000041991847,0.0034478004],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9705311,0.009215257,0.0057727937,0.0020695883,0.01036664,0.002044602],"domain_scores_gemma":[0.86616266,0.08246937,0.0075476244,0.002536035,0.029014388,0.012269998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03011965,0.00407613,0.005320602,0.006210382,0.0050228275,0.01816568,0.0054940977,0.041655794,0.013256],"category_scores_gemma":[0.12814915,0.002117352,0.0040634554,0.0033648629,0.007155004,0.010750294,0.0053927917,0.046878543,0.0060420013],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050767398,0.00001037119,0.000027434296,0.00075438386,0.000044559016,0.00009506658,0.000098842,0.000025559531,0.000025856332,0.00064016343,0.9922983,0.0059287027],"study_design_scores_gemma":[0.00014931097,0.000051342493,0.00038880346,0.0040255436,0.00018092613,0.00017634993,0.0003431509,0.00008221723,0.00007416962,0.0015911422,0.9928848,0.000052175295],"about_ca_topic_score_codex":0.011039925,"about_ca_topic_score_gemma":0.026143804,"teacher_disagreement_score":0.041655794,"about_ca_system_score_codex":0.011961064,"about_ca_system_score_gemma":0.015118534,"threshold_uncertainty_score":0.15928978},"labels":[],"label_agreement":null},{"id":"W4281654705","doi":"10.1016/s1470-2045(22)00188-7","title":"The future of precise cancer chronotherapeutics","year":2022,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Circadian rhythm and melatonin","field":"Neuroscience","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Oncology; Internal medicine; Scopus; Clinical trial; Chemotherapy; Systematic review; Intensive care medicine; MEDLINE","score_opus":0.059506148423246655,"score_gpt":0.33308729468559883,"score_spread":0.2735811462623522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281654705","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012588201,0.032367475,0.00019597168,0.9287733,0.036650997,0.0000049621913,0.00002893362,0.00002955464,0.00182295],"genre_scores_gemma":[0.004945386,0.027542684,0.0004879679,0.745928,0.21625486,0.000038207352,0.000031719654,0.000027012158,0.004744145],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99730194,0.00088958495,0.00024322659,0.00032008023,0.00093929784,0.00030581793],"domain_scores_gemma":[0.98825103,0.0075842743,0.0007218792,0.00035966307,0.00163834,0.0014446535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004373109,0.0009635092,0.0021753034,0.00082254584,0.002316033,0.0040780995,0.0018587329,0.03437249,0.00847429],"category_scores_gemma":[0.016072502,0.00055349356,0.0015313377,0.0005948832,0.0057639508,0.007271942,0.002518023,0.040309742,0.0048803617],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002025466,0.000058372436,0.00021775781,0.0003980094,0.000050248444,0.00088104996,0.00010642364,0.000162969,0.00031754933,0.012578445,0.93898314,0.046043497],"study_design_scores_gemma":[0.0001677668,0.000081539365,0.00028378566,0.00035785197,0.0000323567,0.0006171404,0.0002027005,0.0002896645,0.00009354135,0.03214124,0.9656934,0.000039000348],"about_ca_topic_score_codex":0.0025440983,"about_ca_topic_score_gemma":0.006524088,"teacher_disagreement_score":0.03437249,"about_ca_system_score_codex":0.0039326064,"about_ca_system_score_gemma":0.0039546653,"threshold_uncertainty_score":0.02853322},"labels":[],"label_agreement":null},{"id":"W4281893891","doi":"10.1016/s1470-2045(22)00271-6","title":"Stereotactic radiosurgery versus whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer: a systematic review and meta-analysis","year":2022,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"Canadian Institutes of Health Research; American Association of Neurological Surgeons; University of Toronto; AstraZeneca; Congress of Neurological Surgeons; Pfizer","keywords":"Medicine; Radiosurgery; Meta-analysis; Oncology; Hazard ratio; Radiation therapy; Internal medicine; Lung cancer; Confidence interval","score_opus":0.1196381221426109,"score_gpt":0.4222014629856351,"score_spread":0.3025633408430242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281893891","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00885896,0.9891145,0.00050851674,0.00017326053,0.00025845747,0.00021030649,0.00059015,0.00003701076,0.00024882177],"genre_scores_gemma":[0.3652165,0.62798446,0.0023950555,0.0017683711,0.00037048868,0.00064940366,0.00077951414,0.00007684663,0.00075927144],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9941397,0.0027755671,0.0015292986,0.00078232825,0.00050221395,0.00027092232],"domain_scores_gemma":[0.99230367,0.005134172,0.0016939649,0.00029909267,0.0004217923,0.00014724673],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0071356203,0.0027281567,0.015419681,0.0030893043,0.0005095772,0.0026195156,0.0020708574,0.0025757859,0.0051044757],"category_scores_gemma":[0.018342594,0.001829084,0.038748406,0.004527813,0.0007814346,0.0015695302,0.0017441225,0.0027254687,0.00048340604],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031987329,0.000025068228,0.0030370997,0.18927148,0.79671234,0.00008561669,0.00008196369,0.00038555762,0.00020847468,0.000087896646,0.0005089494,0.0063968278],"study_design_scores_gemma":[0.0011546264,0.00015490614,0.0021353625,0.0069518625,0.9884417,0.00004731675,0.000039463015,0.000098699085,0.000046903013,0.000105899366,0.0008046843,0.000018636281],"about_ca_topic_score_codex":0.012931271,"about_ca_topic_score_gemma":0.037917353,"teacher_disagreement_score":0.98458034,"about_ca_system_score_codex":0.0028918544,"about_ca_system_score_gemma":0.0026395344,"threshold_uncertainty_score":0.03773719},"labels":[],"label_agreement":null},{"id":"W4283205267","doi":"10.1016/s1470-2045(22)00367-9","title":"Ethical considerations for the modification of routine human papillomavirus immunisation schedules","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Health Centre","funders":"","keywords":"Medicine; Population; Immunization; Advisory committee; Vaccination; Human papillomavirus; Regimen; Family medicine; Environmental health; Management; Internal medicine; Immunology","score_opus":0.2937722778644988,"score_gpt":0.4851582535778768,"score_spread":0.191385975713378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283205267","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01630941,0.0037319867,0.031476736,0.8867219,0.013952699,0.0014806967,0.0001660567,0.00021546116,0.045945104],"genre_scores_gemma":[0.23608242,0.00210244,0.07022595,0.65641326,0.013424366,0.003347011,0.0001494141,0.00026053513,0.017994625],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.71982676,0.20584911,0.016857509,0.0068915132,0.042818233,0.007756798],"domain_scores_gemma":[0.50126684,0.38521275,0.022134842,0.047890626,0.030078629,0.01341635],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.2352181,0.00055910257,0.0011061181,0.0012432608,0.0039336807,0.008149297,0.0049266233,0.031814203,0.0051238043],"category_scores_gemma":[0.4282832,0.0010548879,0.0020184424,0.0011737003,0.011909482,0.005198817,0.0037597173,0.0322701,0.0016408048],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015646509,0.000936178,0.0073067425,0.00092013896,0.00030810008,0.002413056,0.020129792,0.00422434,0.005064849,0.46536887,0.32434377,0.16741952],"study_design_scores_gemma":[0.0008826206,0.0010266781,0.012213675,0.0032855675,0.00020883698,0.0033090964,0.006101936,0.0063936273,0.002836902,0.21012838,0.7532429,0.0003696889],"about_ca_topic_score_codex":0.0056531364,"about_ca_topic_score_gemma":0.009481377,"teacher_disagreement_score":0.2352181,"about_ca_system_score_codex":0.0057952832,"about_ca_system_score_gemma":0.02606071,"threshold_uncertainty_score":0.94311225},"labels":[],"label_agreement":null},{"id":"W4283640661","doi":"10.1016/s1470-2045(22)00126-7","title":"Systemic considerations for the surgical treatment of spinal metastatic disease: a scoping literature review","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University Health Network; Health Sciences Centre; Vancouver General Hospital; University of British Columbia; McGill University; Montreal General Hospital; University of Saskatchewan; Université de Montréal; Université de Sherbrooke; University of Toronto; Dalhousie University","funders":"National Cancer Institute","keywords":"Medicine; Disease; Internal medicine; CINAHL; MEDLINE; Intensive care medicine; Psychological intervention","score_opus":0.1290347138779802,"score_gpt":0.42085890712436425,"score_spread":0.29182419324638403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283640661","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000118136566,0.9984339,0.00005645025,0.0008370924,0.00012345247,0.000009216612,0.000021481033,0.000002117786,0.0003982177],"genre_scores_gemma":[0.0016495162,0.9972631,0.00018536398,0.00063840166,0.00016352482,0.000014674402,0.000030012105,0.0000017696462,0.000053669522],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9974884,0.0006714267,0.00089675793,0.00021948623,0.0006261973,0.00009780271],"domain_scores_gemma":[0.9758931,0.019067569,0.0032222008,0.00015379679,0.0014142696,0.00024914264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004945268,0.0008880291,0.0025294106,0.008040559,0.00083464,0.003359952,0.0014994879,0.0024723632,0.00363437],"category_scores_gemma":[0.025297731,0.00060120417,0.002138142,0.009753645,0.0015307151,0.0023114835,0.0013636026,0.002382881,0.00052271836],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001729658,0.000065546126,0.002001799,0.34397903,0.0018790952,0.00072787685,0.0006189872,0.00070659234,0.00044449282,0.0044263075,0.031958673,0.61301863],"study_design_scores_gemma":[0.000059803417,0.00007743455,0.0034153934,0.7911017,0.005050964,0.0019063966,0.0007362898,0.00017524711,0.00016649872,0.002272159,0.19498155,0.000056659897],"about_ca_topic_score_codex":0.00909526,"about_ca_topic_score_gemma":0.020967124,"teacher_disagreement_score":0.00909526,"about_ca_system_score_codex":0.0027562014,"about_ca_system_score_gemma":0.008795302,"threshold_uncertainty_score":0.026153386},"labels":[],"label_agreement":null},{"id":"W4283644627","doi":"10.1016/s1470-2045(22)00160-7","title":"2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","year":2022,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":448,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McGill University Health Centre","funders":"National Institutes of Health; LEO Pharma; Servier; Astellas Pharma; Nippon Shinyaku; Société Académique de Genève; Incyte; International Society on Thrombosis and Haemostasis; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; CSL Behring; Alnylam Pharmaceuticals; Daiichi-Sankyo; Teva Pharmaceutical Industries; Daiichi Sankyo Europe; Sanofi; Amgen; National Heart, Lung, and Blood Institute; Pfizer; Celgene","keywords":"Medicine; Thrombosis; Rivaroxaban; Cancer; Venous thrombosis; Intensive care medicine; Apixaban; Internal medicine; Surgery; Warfarin; Atrial fibrillation","score_opus":0.27625489733849357,"score_gpt":0.5170136550109575,"score_spread":0.24075875767246396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283644627","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000112868154,0.98322177,0.00061733305,0.0054057078,0.002189673,0.0003096774,0.0016060611,0.00006202023,0.006474924],"genre_scores_gemma":[0.000700741,0.9880823,0.0024418551,0.0037714585,0.00063738483,0.00032856668,0.0017202573,0.000016385911,0.0023011423],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99820983,0.00043589153,0.00054825115,0.00011435234,0.0005840059,0.00010770095],"domain_scores_gemma":[0.9959182,0.0016030485,0.001007585,0.00007378933,0.0012215639,0.00017582459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028788026,0.0013259636,0.002585552,0.0058435695,0.0004522292,0.0015441865,0.0021698042,0.0028785411,0.012482262],"category_scores_gemma":[0.007294531,0.0005416914,0.002656141,0.0054151043,0.0005072926,0.0009852232,0.0010761397,0.0026201834,0.005711258],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016468519,0.000092530085,0.00024098481,0.06865116,0.00037637688,0.00011799268,0.000070875554,0.00032408047,0.0005491703,0.0027287907,0.25456905,0.6721143],"study_design_scores_gemma":[0.00026220558,0.000087859036,0.0016047364,0.09097215,0.0010302259,0.00036731327,0.0000547124,0.00012358389,0.00015352143,0.0018010724,0.9035085,0.00003420309],"about_ca_topic_score_codex":0.011646812,"about_ca_topic_score_gemma":0.016786685,"teacher_disagreement_score":0.012482262,"about_ca_system_score_codex":0.0020616592,"about_ca_system_score_gemma":0.010051386,"threshold_uncertainty_score":0.041757286},"labels":[],"label_agreement":null},{"id":"W4283771201","doi":"10.1016/s1470-2045(22)00343-6","title":"Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations – Authors' reply","year":2022,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Trabectedin; Topotecan; Oncology; Medicine; Ovarian cancer; Internal medicine; Regimen; Olaparib; BRCA mutation; Chemotherapy; Cancer; Pathology; Sarcoma; Biology","score_opus":0.06730842307923487,"score_gpt":0.3634795755095666,"score_spread":0.29617115243033176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283771201","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027262102,0.0017126993,0.00003029027,0.9765911,0.020143222,0.0000061892024,0.00005240057,0.00001184572,0.0011795617],"genre_scores_gemma":[0.0028468235,0.0009842002,0.000057959365,0.9596846,0.03291566,0.00002398033,0.000036705493,0.000014818584,0.003435176],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99715036,0.00090903847,0.00031126893,0.00035004015,0.00073125045,0.000548017],"domain_scores_gemma":[0.9921457,0.004826753,0.0006273597,0.00021435699,0.0009118825,0.0012739127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026144215,0.00074952573,0.0017140083,0.0009075912,0.00301088,0.0036871992,0.0017692695,0.073285975,0.007048798],"category_scores_gemma":[0.02041866,0.00091947615,0.0013095739,0.0007682431,0.0027976062,0.0030077526,0.0020503073,0.043648507,0.005165724],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000077506666,0.000018001405,0.0005723235,0.0000559558,0.00002877552,0.0015474585,0.00011168275,0.000067393376,0.00012697336,0.0015478365,0.9911772,0.0046689687],"study_design_scores_gemma":[0.00029619192,0.00011773018,0.0013226124,0.0004154886,0.00007507476,0.0025970414,0.00046873084,0.00040584485,0.00027530166,0.0074530244,0.98647225,0.0001007112],"about_ca_topic_score_codex":0.004254979,"about_ca_topic_score_gemma":0.005912204,"teacher_disagreement_score":0.073285975,"about_ca_system_score_codex":0.00355096,"about_ca_system_score_gemma":0.003060552,"threshold_uncertainty_score":0.025764167},"labels":[],"label_agreement":null},{"id":"W4284987950","doi":"10.1016/s1470-2045(22)00335-7","title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":436,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre; Jewish General Hospital; University of British Columbia; Spinal Cord Injury BC","funders":"Genentech; F. Hoffmann-La Roche","keywords":"Medicine; Follicular lymphoma; Refractory (planetary science); Internal medicine; Clinical endpoint; Progressive disease; CD20; Follicular phase; Lymphoma; Oncology; Rituximab; Phases of clinical research; Gastroenterology; Chemotherapy; Clinical trial; Biology","score_opus":0.04388713937975811,"score_gpt":0.36045103446850474,"score_spread":0.3165638950887466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4284987950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967098,0.0019445018,0.00018219807,0.00015621084,0.000043126114,0.00024603694,0.00022806121,0.000025898047,0.0004640493],"genre_scores_gemma":[0.996846,0.0008206821,0.00032490457,0.0003508392,0.000100561505,0.00035252335,0.00052972964,0.000011406882,0.00066327763],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994055,0.00027585414,0.000027777054,0.00010233924,0.00006612322,0.00012239155],"domain_scores_gemma":[0.99936646,0.00012456116,0.00014728786,0.00007073354,0.000037716534,0.00025325923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017414503,0.001374853,0.002215523,0.00038116472,0.0003289322,0.0010534057,0.00068206165,0.0013185737,0.0012798693],"category_scores_gemma":[0.001053321,0.0005213505,0.0014562322,0.00036405603,0.0009343183,0.0009476592,0.0002826699,0.0022287206,0.00043594066],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83275163,0.017551301,0.01241836,0.000722836,0.0024643827,0.00020683219,0.0002940323,0.0020585367,0.039742485,0.00018186014,0.0016915251,0.08991622],"study_design_scores_gemma":[0.56335264,0.39055857,0.037382726,0.000041480107,0.00138873,0.00033536225,0.0000819516,0.0016507044,0.0028550597,0.00022091372,0.0020768922,0.00005507403],"about_ca_topic_score_codex":0.0007775979,"about_ca_topic_score_gemma":0.0013358429,"teacher_disagreement_score":0.002215523,"about_ca_system_score_codex":0.0010862786,"about_ca_system_score_gemma":0.00083550886,"threshold_uncertainty_score":0.009209812},"labels":[],"label_agreement":null},{"id":"W4285045571","doi":"10.1016/s1470-2045(22)00334-5","title":"Comparative effectiveness and risk of preterm birth of local treatments for cervical intraepithelial neoplasia and stage IA1 cervical cancer: a systematic review and network meta-analysis","year":2022,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Research for Patient Benefit Programme; Horizon 2020 Framework Programme; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; European Commission; National Institute for Health and Care Research; Department of Health and Social Care; Institut National Du Cancer; Cancer Research UK; National Science Foundation","keywords":"Medicine; Cryotherapy; Colposcopy; Cervical intraepithelial neoplasia; Meta-analysis; Obstetrics; Randomized controlled trial; Odds ratio; Cervical cancer; Gynecology; Relative risk; Intraepithelial neoplasia; Cancer; Surgery; Internal medicine; Confidence interval","score_opus":0.1973763679235681,"score_gpt":0.4676421479563756,"score_spread":0.2702657800328075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285045571","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0054749087,0.9920481,0.0007035377,0.00019185682,0.00017722344,0.00039206594,0.0006761238,0.000028177186,0.00030797126],"genre_scores_gemma":[0.25377935,0.73675877,0.0037077318,0.0010981038,0.00039340457,0.0024798207,0.0013049735,0.00005852441,0.00041931568],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9768047,0.013258013,0.005343649,0.0019803443,0.0021111243,0.00050218665],"domain_scores_gemma":[0.9530727,0.037147455,0.0060331505,0.0012209396,0.002144545,0.00038108544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.023821231,0.0029436592,0.024192521,0.008914973,0.00064665114,0.0041434546,0.002629047,0.002755499,0.0033965365],"category_scores_gemma":[0.07058369,0.0016744448,0.04832806,0.008669947,0.0009940777,0.002238083,0.0021796103,0.0024950278,0.0002890316],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016243801,0.000016344611,0.0026146339,0.2782389,0.71040976,0.00007012511,0.000059015176,0.0004574574,0.000081447695,0.00013339147,0.00031748266,0.00597692],"study_design_scores_gemma":[0.00050152576,0.00013696204,0.002162993,0.019674446,0.97622,0.00005920632,0.00003294206,0.00019317579,0.00006799649,0.00021164457,0.00071978854,0.000019234607],"about_ca_topic_score_codex":0.008381484,"about_ca_topic_score_gemma":0.01296008,"teacher_disagreement_score":0.024192521,"about_ca_system_score_codex":0.00364847,"about_ca_system_score_gemma":0.0033991102,"threshold_uncertainty_score":0.12598026},"labels":[],"label_agreement":null},{"id":"W4287730147","doi":"10.1016/s1470-2045(22)00139-5","title":"Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup","year":2022,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":142,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University of British Columbia","funders":"Daiichi Sankyo Europe; National Cancer Institute; Chugai Pharmaceutical; Genentech; National Institutes of Health; Mereo BioPharma; Medac; PharmaMar; Eisai; Seagen; Verastem Oncology; Pfizer; NuCana; Incyte; National Medical Research Council; Karyopharm Therapeutics; Kissei; National Institute for Health and Care Research; Clovis Oncology; Nippon Shinyaku; AstraZeneca; Novocure; Mersana Therapeutics; Amgen; Deciphera Pharmaceuticals; Medical Research Council; Teva Pharmaceutical Industries; Fuji Pharma; GlaxoSmithKline; European Commission; PTC Therapeutics; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Consensus conference; Concordance; Ovarian cancer; Medicine; Clinical trial; Deliberation; Gynecologic cancer; Family medicine; Clinical research; MEDLINE; Gynecology; Cancer; Oncology; Internal medicine; Political science","score_opus":0.5870445998710079,"score_gpt":0.5953735657196614,"score_spread":0.008328965848653502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4287730147","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000072268645,0.9727482,0.0005117784,0.020133091,0.0046837027,0.00021940352,0.00035848405,0.000033311124,0.001239822],"genre_scores_gemma":[0.0009370441,0.9797507,0.00278341,0.013202593,0.0018322015,0.00037095379,0.0004447501,0.00002193679,0.00065639196],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9830898,0.005225309,0.0048617227,0.0014216622,0.004468182,0.00093324867],"domain_scores_gemma":[0.94001657,0.036978927,0.006572005,0.0010148087,0.01229547,0.0031222962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.049955994,0.002561011,0.008926347,0.0118972175,0.001450093,0.007434676,0.0069034067,0.010391163,0.0057796626],"category_scores_gemma":[0.05624937,0.0014813662,0.0073470194,0.011421724,0.002147885,0.0051138992,0.0058354833,0.011902027,0.0030006089],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006771314,0.000102088234,0.0005625388,0.18575016,0.0022948934,0.00015322484,0.00033652148,0.0006029684,0.00058131665,0.006799298,0.23250511,0.5696348],"study_design_scores_gemma":[0.0007806054,0.00014359865,0.001778344,0.26521152,0.005371476,0.00020696792,0.00026198576,0.00019838358,0.00022830458,0.007005849,0.7187268,0.00008605002],"about_ca_topic_score_codex":0.013431453,"about_ca_topic_score_gemma":0.023066469,"teacher_disagreement_score":0.049955994,"about_ca_system_score_codex":0.008828125,"about_ca_system_score_gemma":0.03741724,"threshold_uncertainty_score":0.26419568},"labels":[],"label_agreement":null},{"id":"W4293708362","doi":"10.1016/s1470-2045(22)00371-0","title":"CNS prophylaxis for diffuse large B-cell lymphoma","year":2022,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Manchester Biomedical Research Centre; National Institute for Health and Care Research","keywords":"Leptomeninges; Medicine; Intensive care medicine; Lymphoma; Parenchyma; Complication; Pathology; Surgery; Central nervous system; Internal medicine","score_opus":0.12355826958781037,"score_gpt":0.3982815940841744,"score_spread":0.27472332449636405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293708362","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003333115,0.99926513,0.000021191037,0.00014071468,0.00017293467,0.0000029522905,0.000013481652,0.0000028242534,0.00034735288],"genre_scores_gemma":[0.000758318,0.99815637,0.00007933413,0.00048564965,0.00022073688,0.0000067688184,0.000022953453,0.0000012690488,0.00026854675],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99972945,0.00006968168,0.000057208927,0.00004342367,0.00007275759,0.000027416547],"domain_scores_gemma":[0.9992879,0.00041377256,0.00016797727,0.00001381769,0.00008099782,0.00003557922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076655974,0.00080881856,0.0021405006,0.0017094283,0.00019247802,0.0009219548,0.0008071316,0.001202489,0.006812759],"category_scores_gemma":[0.0017243293,0.000280945,0.00086125184,0.0016988945,0.00036117647,0.0007928855,0.00055507873,0.002060145,0.0014346861],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025933233,0.000040246563,0.00011186137,0.050277315,0.00035683505,0.000094154515,0.000024716921,0.00023743241,0.00048209587,0.0011572212,0.040809628,0.9061491],"study_design_scores_gemma":[0.00058546924,0.0004484237,0.0021309664,0.053554308,0.002665689,0.0013596765,0.000066631765,0.00016379452,0.0003355401,0.001607347,0.9370439,0.00003819778],"about_ca_topic_score_codex":0.0020762892,"about_ca_topic_score_gemma":0.0057095797,"teacher_disagreement_score":0.006812759,"about_ca_system_score_codex":0.00080881355,"about_ca_system_score_gemma":0.0011680557,"threshold_uncertainty_score":0.022790909},"labels":[],"label_agreement":null},{"id":"W4295838570","doi":"10.1016/s1470-2045(22)00517-4","title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":303,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Cancer Research UK","keywords":"Medicine; Prostate cancer; Radiation therapy; Toxicity; Dose fractionation; Randomized controlled trial; Androgen deprivation therapy; Urology; Prostate; External beam radiotherapy; Internal medicine; Cancer; Surgery","score_opus":0.08975264517769489,"score_gpt":0.42285274172221715,"score_spread":0.3331000965445223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295838570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9779808,0.0076633766,0.0012244727,0.0009337818,0.00063877343,0.0064524347,0.0020695233,0.00015886004,0.0028779942],"genre_scores_gemma":[0.9682152,0.0048413337,0.0028018942,0.0023772817,0.0011567683,0.01318741,0.0030613581,0.00008399172,0.004274771],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960167,0.0029170392,0.00018442057,0.00036098517,0.00025526903,0.0002656487],"domain_scores_gemma":[0.99575895,0.0014663503,0.0013093852,0.0004188914,0.00025468608,0.00079166377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008260403,0.0025710235,0.0037502705,0.000598969,0.00055316655,0.0016833545,0.0015722825,0.0028395755,0.008806604],"category_scores_gemma":[0.0067709987,0.00073959655,0.004492147,0.00074874255,0.0016043741,0.001776263,0.0008318028,0.0035767525,0.0011739072],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9872557,0.0043012155,0.00023239513,0.00053312024,0.00093261694,0.000021099859,0.000039542396,0.0002935596,0.0009628185,0.00006946647,0.00051725825,0.0048411987],"study_design_scores_gemma":[0.9469233,0.05094463,0.00084917876,0.00003246538,0.0004442128,0.000018032093,0.000010417123,0.0002169127,0.00012575094,0.00013874656,0.00028525526,0.000011106242],"about_ca_topic_score_codex":0.0007265651,"about_ca_topic_score_gemma":0.0013171422,"teacher_disagreement_score":0.008806604,"about_ca_system_score_codex":0.0011280752,"about_ca_system_score_gemma":0.001627274,"threshold_uncertainty_score":0.043685675},"labels":[],"label_agreement":null},{"id":"W4307906450","doi":"10.1016/s1470-2045(22)00629-5","title":"Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma","year":2022,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Renal cell carcinoma; Adjuvant therapy; Oncology; Adjuvant; Internal medicine; Immunotherapy; Cancer","score_opus":0.06916348275263576,"score_gpt":0.317035747058509,"score_spread":0.24787226430587325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307906450","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001507905,0.0024953138,0.000055683147,0.9796989,0.015552646,0.0000069830553,0.000026484491,0.000011203623,0.0020019226],"genre_scores_gemma":[0.002441381,0.0013193444,0.00019328936,0.93566924,0.056706175,0.000031465454,0.000027268345,0.000021995691,0.0035899482],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9916932,0.0033231308,0.0012544228,0.0007858059,0.001886707,0.0010567402],"domain_scores_gemma":[0.97541094,0.016198255,0.0014405185,0.0007486158,0.0026542712,0.0035474235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0092980275,0.0009514613,0.002732058,0.0009679925,0.0047721867,0.0074398997,0.002497255,0.11151937,0.008372096],"category_scores_gemma":[0.045164734,0.0011381898,0.0023827518,0.0007762622,0.0063226456,0.0065055666,0.0027626744,0.07749323,0.0063765426],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000175352,0.000040176095,0.00031784104,0.00013462435,0.000033401564,0.0014406905,0.000121640245,0.00012379371,0.00033767152,0.0069315303,0.97700447,0.013338894],"study_design_scores_gemma":[0.0004219196,0.00009658319,0.00080117444,0.0008691903,0.00008477844,0.0016603904,0.00023888891,0.00052614784,0.00023906051,0.018186554,0.9767903,0.00008492629],"about_ca_topic_score_codex":0.0064543253,"about_ca_topic_score_gemma":0.012484254,"teacher_disagreement_score":0.11151937,"about_ca_system_score_codex":0.00852864,"about_ca_system_score_gemma":0.008372615,"threshold_uncertainty_score":0.061879873},"labels":[],"label_agreement":null},{"id":"W4308327197","doi":"10.1016/s1470-2045(22)00642-8","title":"Intra-individual comparison of 18F-sodium fluoride PET–CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Medical Imaging Techniques and Applications","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; McGill University; Centre Hospitalier de l’Université de Montréal; Western University; St Joseph's Health Care; University Health Network; University of British Columbia; Centre Hospitalier Universitaire de Sherbrooke; Montreal Heart Institute; Université de Montréal; Jewish General Hospital; London Health Sciences Centre; McMaster University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Prostate cancer; Breast cancer; Bone scintigraphy; Radiology; Bone metastasis; Cancer; Population; Nuclear medicine; Prospective cohort study; Oncology; Internal medicine","score_opus":0.031131532751266087,"score_gpt":0.36561772162705974,"score_spread":0.3344861888757937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308327197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993582,0.0024493877,0.00055852777,0.0004412021,0.00030047985,0.00086506055,0.0006016582,0.00012441882,0.0010772072],"genre_scores_gemma":[0.991667,0.0012111625,0.0013187139,0.0007135052,0.00037702097,0.001424497,0.0014100733,0.00006627164,0.0018118083],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99776936,0.0011976971,0.00006790406,0.00053485716,0.00013488645,0.00029530856],"domain_scores_gemma":[0.99754167,0.0006792872,0.00056268636,0.00034277624,0.00013130505,0.00074230914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004066851,0.0037346021,0.0058948705,0.0005723763,0.000756128,0.0019576112,0.0015010365,0.003856424,0.0060685533],"category_scores_gemma":[0.0031662425,0.0016942291,0.003743844,0.0007773997,0.0024438007,0.0020048842,0.0008560422,0.005141191,0.0016327315],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9884062,0.0027014303,0.0008969606,0.000071594804,0.0011695268,0.000014003318,0.000035180943,0.00037475093,0.001303867,0.00003300984,0.00022796959,0.004765537],"study_design_scores_gemma":[0.8565272,0.13233423,0.007718116,0.000018803617,0.0013287789,0.000058378384,0.000040670348,0.00080139557,0.00045722717,0.00018003685,0.00048026544,0.00005492867],"about_ca_topic_score_codex":0.0025069902,"about_ca_topic_score_gemma":0.0036717064,"teacher_disagreement_score":0.0060685533,"about_ca_system_score_codex":0.0019322452,"about_ca_system_score_gemma":0.0016580368,"threshold_uncertainty_score":0.02150786},"labels":[],"label_agreement":null},{"id":"W4309412449","doi":"10.1016/s1470-2045(22)00656-8","title":"5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney)","year":2022,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":133,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; University of Ottawa; Ottawa Hospital; Cancer Care Ontario; McMaster University; Sunnybrook Health Science Centre; McGill University Health Centre; Juravinski Cancer Centre","funders":"Cancer Council Tasmania","keywords":"SABR volatility model; Medicine; Renal cell carcinoma; Radiosurgery; Cyberknife; Radiation therapy; Clinical endpoint; Discontinuation; Urology; Internal medicine; Surgery; Clinical trial","score_opus":0.20941639527428876,"score_gpt":0.3794208878707568,"score_spread":0.17000449259646802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309412449","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018952262,0.9764083,0.0008657764,0.00035597157,0.00031907012,0.00008333124,0.002344582,0.000059414368,0.0006111882],"genre_scores_gemma":[0.51077205,0.47950673,0.0018533987,0.0019879895,0.000417003,0.00025498515,0.0038069515,0.00013100274,0.0012697675],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9972053,0.0014001976,0.00048321288,0.0004842857,0.00025259636,0.0001743476],"domain_scores_gemma":[0.99694437,0.001977272,0.0005334398,0.00019694329,0.00024818187,0.00009982152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004368691,0.0018692726,0.008164913,0.0016394297,0.00026803272,0.0014570882,0.0012823011,0.0012201825,0.0035995662],"category_scores_gemma":[0.008709376,0.0009067354,0.031389285,0.0025444236,0.00030725115,0.0008661106,0.0011316205,0.002286885,0.0004713646],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006378537,0.000026538624,0.006909078,0.077166304,0.89011914,0.00010329441,0.000066143235,0.001101808,0.00040047753,0.00015171106,0.002272318,0.0153047],"study_design_scores_gemma":[0.0013923146,0.00023229608,0.008078022,0.0031221688,0.9836872,0.000078294834,0.000032626038,0.00020623281,0.00009464827,0.00026279278,0.002783819,0.000029612975],"about_ca_topic_score_codex":0.009982868,"about_ca_topic_score_gemma":0.023618227,"teacher_disagreement_score":0.009982868,"about_ca_system_score_codex":0.0013497055,"about_ca_system_score_gemma":0.0011907666,"threshold_uncertainty_score":0.023104131},"labels":[],"label_agreement":null},{"id":"W4309412600","doi":"10.1016/s1470-2045(22)00621-0","title":"Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":182,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada); Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Oncology; Internal medicine; Trastuzumab; Adverse effect; Bispecific antibody; Metastatic breast cancer; Response Evaluation Criteria in Solid Tumors; Clinical trial; Phases of clinical research; Cancer; Monoclonal antibody; Antibody; Breast cancer; Immunology","score_opus":0.2538568129815828,"score_gpt":0.5097609920992456,"score_spread":0.25590417911766283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309412600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806637,0.009637418,0.0011195455,0.0010757409,0.00023911383,0.0013540605,0.001484361,0.00016968086,0.004256353],"genre_scores_gemma":[0.9705173,0.012767815,0.0034198433,0.0018778822,0.00012892672,0.0011823222,0.0030845483,0.00009019991,0.0069312253],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99972004,0.000097770375,0.000011069263,0.000038591217,0.00004499649,0.00008745253],"domain_scores_gemma":[0.99977905,0.000036841175,0.000048644448,0.000022566908,0.00001657908,0.00009637969],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013287865,0.0011082048,0.0015031542,0.0004513504,0.00028286374,0.00093304255,0.00077071873,0.0008464645,0.0027225346],"category_scores_gemma":[0.0005228534,0.0005115482,0.0011655039,0.00047317432,0.0006548289,0.00085570005,0.00028956888,0.0032978612,0.0006489129],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34653217,0.05756346,0.0073034316,0.002536609,0.003319026,0.0004017234,0.0006457659,0.010982722,0.11058601,0.0018805867,0.01842643,0.43982205],"study_design_scores_gemma":[0.65752846,0.277361,0.02091561,0.00014483921,0.0019954385,0.0008720714,0.0001584245,0.0041914596,0.014883153,0.00087340345,0.02096942,0.00010679906],"about_ca_topic_score_codex":0.0020169772,"about_ca_topic_score_gemma":0.0071771224,"teacher_disagreement_score":0.0027225346,"about_ca_system_score_codex":0.0010539668,"about_ca_system_score_gemma":0.001147301,"threshold_uncertainty_score":0.009107769},"labels":[],"label_agreement":null},{"id":"W4310121368","doi":"10.1016/s1470-2045(22)00505-8","title":"International recommendations for plasma Epstein-Barr virus DNA measurement in nasopharyngeal carcinoma in resource-constrained settings: lessons from the COVID-19 pandemic","year":2022,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; University of Hong Kong","keywords":"Nasopharyngeal carcinoma; Medicine; Pandemic; Context (archaeology); Otorhinolaryngology; Intensive care medicine; Personal protective equipment; Health care; Medical emergency; Internal medicine; Radiation therapy; Disease; Surgery; Coronavirus disease 2019 (COVID-19); Infectious disease (medical specialty); Political science","score_opus":0.4414952550388219,"score_gpt":0.4936516964643402,"score_spread":0.052156441425518285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310121368","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006478793,0.98596674,0.00035251825,0.010570764,0.0015273534,0.00003401017,0.00024791405,0.000019369596,0.001216606],"genre_scores_gemma":[0.0011307575,0.9895483,0.001544724,0.0061708693,0.0006842484,0.00008672833,0.0002989873,0.000009580621,0.00052576786],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974341,0.0009846747,0.00058459095,0.00021399184,0.00060897146,0.00017356695],"domain_scores_gemma":[0.9908687,0.004748946,0.0009766077,0.00017479654,0.0028713392,0.0003595524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009786472,0.0012864169,0.0035135846,0.0022923683,0.00036500534,0.0023171678,0.003404194,0.0042564967,0.006458228],"category_scores_gemma":[0.019814866,0.00057655375,0.0032918777,0.0022689202,0.0010342421,0.002620157,0.0016144786,0.005973891,0.0024584187],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024105459,0.00007232493,0.0004545901,0.044394597,0.00058730453,0.00012654983,0.00012480382,0.000723101,0.00035364975,0.008303811,0.14656195,0.79805624],"study_design_scores_gemma":[0.00022788007,0.000122299,0.001678283,0.089124255,0.0011259167,0.00025716156,0.0001892256,0.00020700374,0.00024404682,0.0063896812,0.9003715,0.00006283315],"about_ca_topic_score_codex":0.013092967,"about_ca_topic_score_gemma":0.0144941285,"teacher_disagreement_score":0.013092967,"about_ca_system_score_codex":0.0028214266,"about_ca_system_score_gemma":0.010675255,"threshold_uncertainty_score":0.05175644},"labels":[],"label_agreement":null},{"id":"W4310121745","doi":"10.1016/s1470-2045(22)00689-1","title":"Essential anticancer medicines for children: defining what matters most for Europe","year":2022,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; SickKids Foundation","funders":"","keywords":"Medicine; Pharmacology; Traditional medicine","score_opus":0.04701082017788962,"score_gpt":0.36283187796006755,"score_spread":0.31582105778217795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310121745","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002418031,0.0053973044,0.000035682224,0.9868466,0.006098201,0.0000029415662,0.000031397212,0.000004433258,0.0013416108],"genre_scores_gemma":[0.0038764225,0.0052896068,0.00019264707,0.9716466,0.016422067,0.000018476532,0.000031719464,0.000017717319,0.0025047525],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99257565,0.0025801242,0.0011059887,0.00055710436,0.0017916003,0.0013896418],"domain_scores_gemma":[0.9723593,0.015495465,0.0021938682,0.00045273398,0.003042885,0.006455675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008635964,0.00072675,0.0021895408,0.0008815511,0.003427548,0.0063029192,0.0015090931,0.047501132,0.0063274526],"category_scores_gemma":[0.031665888,0.0006871681,0.0016034929,0.0011865784,0.005066686,0.0068378686,0.0035643496,0.042343903,0.00218186],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001045099,0.00006919973,0.001813365,0.00031885164,0.00007435674,0.0012291619,0.00044413676,0.00010602396,0.00035086914,0.014321407,0.9501155,0.031052656],"study_design_scores_gemma":[0.00018271887,0.00008228876,0.0024242552,0.0015053778,0.0000821408,0.0012652512,0.0011832123,0.00017402548,0.00024175749,0.017641956,0.9751339,0.00008302643],"about_ca_topic_score_codex":0.011907663,"about_ca_topic_score_gemma":0.02051932,"teacher_disagreement_score":0.047501132,"about_ca_system_score_codex":0.0075294212,"about_ca_system_score_gemma":0.016617956,"threshold_uncertainty_score":0.05463004},"labels":[],"label_agreement":null},{"id":"W4310554573","doi":"10.1016/s1470-2045(22)00687-8","title":"Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":104,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche; Roche","keywords":"Medicine; Vemurafenib; Atezolizumab; Interim analysis; Placebo; Internal medicine; Tolerability; Oncology; Adverse effect; Surgery; Randomized controlled trial; Metastatic melanoma; Pembrolizumab; Cancer; Immunotherapy; Pathology","score_opus":0.017250538822363423,"score_gpt":0.2996574736859282,"score_spread":0.2824069348635648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310554573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99141484,0.0031694453,0.00053117156,0.00065380847,0.0002893747,0.0004904216,0.0020292432,0.00009760702,0.0013241738],"genre_scores_gemma":[0.98725224,0.0015294278,0.0009812092,0.0010888431,0.00025691738,0.0009666019,0.0049534137,0.000058395206,0.0029129658],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9989215,0.00048342795,0.000041178086,0.00018269016,0.00008228022,0.000288897],"domain_scores_gemma":[0.9988275,0.00024241352,0.000230533,0.00014028534,0.00007099923,0.00048826457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041050334,0.0020926103,0.0040409495,0.0004045912,0.00037409095,0.0018446196,0.0011756249,0.0017568677,0.00327141],"category_scores_gemma":[0.0016331488,0.0007734328,0.005019004,0.00037990863,0.0009149283,0.0016404134,0.00065030874,0.004613081,0.0009403778],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9626947,0.003310014,0.002225103,0.00034312168,0.0023754167,0.000048659105,0.000060738155,0.0016203122,0.0041108234,0.000090468086,0.0019171777,0.021203427],"study_design_scores_gemma":[0.7764504,0.19416119,0.02168575,0.0000600119,0.0029804872,0.00015906781,0.00005256892,0.0011899639,0.001351712,0.00028249956,0.0015701953,0.000056067285],"about_ca_topic_score_codex":0.0012207424,"about_ca_topic_score_gemma":0.0031529253,"teacher_disagreement_score":0.0041050334,"about_ca_system_score_codex":0.001532682,"about_ca_system_score_gemma":0.0013921658,"threshold_uncertainty_score":0.02170974},"labels":[],"label_agreement":null},{"id":"W4313452563","doi":"10.1016/s1470-2045(22)00704-5","title":"Cancer survival in Africa, central and south America, and Asia (SURVCAN-3): a population-based benchmarking study in 32 countries","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Red Cross Society","funders":"Tata Memorial Centre; Centre International de Recherche sur le Cancer; World Health Organization","keywords":"Cancer registry; Population; Medicine; Benchmarking; Cancer; Demography; Environmental health; Internal medicine; Business","score_opus":0.14522996187102502,"score_gpt":0.3965041995073788,"score_spread":0.2512742376363538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313452563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99215287,0.00041688888,0.0001888724,0.0001245243,0.000008162248,0.000024077484,0.0064170673,0.000008997879,0.0006585093],"genre_scores_gemma":[0.9947478,0.00025010286,0.00015330708,0.00003802339,0.000004221281,0.00003838533,0.004677339,0.0000062668905,0.00008455382],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99791604,0.0008933559,0.00023395369,0.00035201304,0.0002481323,0.00035645417],"domain_scores_gemma":[0.9967595,0.0006314967,0.0011354014,0.00034519247,0.0006631397,0.0004653388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029510201,0.00060849276,0.00065153517,0.0026087414,0.00058367086,0.001203897,0.001110661,0.0009241143,0.0006456745],"category_scores_gemma":[0.0052154013,0.00027544267,0.0009396094,0.007228605,0.0005990843,0.0012984347,0.0018072942,0.00076580443,0.00017198971],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025902496,0.00007630136,0.99223584,0.00006741544,0.0003213029,0.00014806406,0.0006453322,0.0007149645,0.00011234434,0.00016481345,0.0011237247,0.0041308412],"study_design_scores_gemma":[0.000019246156,0.00009167547,0.9971992,0.000033425946,0.00008590713,0.00021654116,0.0012724178,0.0003493529,0.000052197563,0.000051103492,0.0006160274,0.000012900006],"about_ca_topic_score_codex":0.059951104,"about_ca_topic_score_gemma":0.058700286,"teacher_disagreement_score":0.059951104,"about_ca_system_score_codex":0.002163312,"about_ca_system_score_gemma":0.0013183829,"threshold_uncertainty_score":0.11920428},"labels":[],"label_agreement":null},{"id":"W4318541421","doi":"10.1016/s1470-2045(22)00639-8","title":"Pharmaceutical industry relationships with oncologists in sub-Saharan Africa","year":2023,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Pharmaceutical industry and healthcare","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Queen's University","funders":"","keywords":"Context (archaeology); Pharmaceutical industry; Pharmaceutical policy; Business; Developing country; Health care; Low and middle income countries; TRIPS architecture; Economic growth; Health policy; Medicine; Geography; Economics","score_opus":0.8608037434120723,"score_gpt":0.6449379706512048,"score_spread":0.2158657727608675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318541421","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009177935,0.99881566,0.000008958163,0.0005817156,0.00009517467,0.0000014863596,0.0000054786624,7.0091846e-7,0.00039917752],"genre_scores_gemma":[0.0011239884,0.99824286,0.0000307287,0.0003230829,0.00009949504,0.0000024445437,0.0000042571637,3.3272894e-7,0.00017271575],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99959165,0.00015468572,0.000051014125,0.00003623942,0.00008809257,0.00007833891],"domain_scores_gemma":[0.99809307,0.001145405,0.00048489508,0.000013812202,0.00014609387,0.00011674297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013560472,0.0005289178,0.0007437277,0.0018816896,0.00034498321,0.00150895,0.00042292592,0.0012908316,0.0064539853],"category_scores_gemma":[0.0025434787,0.00021798004,0.00043578303,0.0044077276,0.0005172219,0.0009653787,0.0010209038,0.0012035685,0.0005734955],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012221494,0.000056436405,0.0007003645,0.03693749,0.00024062507,0.00027668008,0.00022617854,0.00020069137,0.00032566758,0.003330507,0.02628092,0.93130213],"study_design_scores_gemma":[0.000110468354,0.00016940202,0.006160508,0.05090291,0.00066225097,0.0010759382,0.00084362546,0.000064717555,0.00030783436,0.0017864354,0.93789154,0.000024430637],"about_ca_topic_score_codex":0.0037031637,"about_ca_topic_score_gemma":0.015273838,"teacher_disagreement_score":0.0064539853,"about_ca_system_score_codex":0.0011385222,"about_ca_system_score_gemma":0.0037929583,"threshold_uncertainty_score":0.02159077},"labels":[],"label_agreement":null},{"id":"W4318913053","doi":"10.1016/s1470-2045(23)00017-7","title":"18F-NaF PET–CT versus 99mTc SPECT in bone metastasis assessment – Authors' reply","year":2023,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Medical Imaging Techniques and Applications","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Nuclear medicine; Bone metastasis; Positron Emission Tomography-Computed Tomography; Radiology; Metastasis; Positron emission tomography; Internal medicine; Cancer","score_opus":0.14383366091233843,"score_gpt":0.45062370371638627,"score_spread":0.30679004280404787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318913053","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020652718,0.001725912,0.000058297017,0.9736249,0.023534512,0.0000066861417,0.000043654036,0.000011999161,0.00078759127],"genre_scores_gemma":[0.0020820256,0.00071226736,0.000102034595,0.9614149,0.033781894,0.000023287059,0.000020654163,0.000015498477,0.0018475268],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954466,0.001543468,0.00059686246,0.0006880867,0.0010757796,0.0006491058],"domain_scores_gemma":[0.9808959,0.012821421,0.0012784955,0.0004390319,0.0028605822,0.0017045062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004658014,0.0008666179,0.0021470515,0.0010646451,0.0035049922,0.004863389,0.002201268,0.092649825,0.0061122486],"category_scores_gemma":[0.034155305,0.0012405147,0.0015283478,0.00092274573,0.003936441,0.0035947945,0.002478552,0.058231693,0.0060631344],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000107887085,0.000016119946,0.00065568887,0.00006788914,0.000034650348,0.0014080284,0.00015749813,0.00006450655,0.00015549941,0.0017022463,0.9903536,0.0052763945],"study_design_scores_gemma":[0.0002699898,0.00009257456,0.0014877932,0.00057057553,0.00012268992,0.002419738,0.0007238323,0.00046744465,0.00043069548,0.010196089,0.9830634,0.0001550214],"about_ca_topic_score_codex":0.006032284,"about_ca_topic_score_gemma":0.008538036,"teacher_disagreement_score":0.092649825,"about_ca_system_score_codex":0.0049170945,"about_ca_system_score_gemma":0.0040923646,"threshold_uncertainty_score":0.03567624},"labels":[],"label_agreement":null},{"id":"W4318919835","doi":"10.1016/s1470-2045(23)00007-4","title":"Accelerating cancer omics and precision oncology in health care and research: a Lancet Oncology Commission","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"Cancer Research UK; World Health Organization","keywords":"Precision oncology; Omics; Clinical Oncology; Medicine; Cancer; Oncology; Precision medicine; Molecular oncology; Bioinformatics; Internal medicine; Computational biology; Biology; Pathology","score_opus":0.16406786068415202,"score_gpt":0.4647747784755713,"score_spread":0.3007069177914193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318919835","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010716484,0.07108471,0.0009332306,0.8595546,0.06593469,0.000024498046,0.00010226042,0.00008097145,0.0021779768],"genre_scores_gemma":[0.006139297,0.07315616,0.0042518047,0.80231375,0.10737314,0.00016389407,0.000160628,0.0001937828,0.0062476383],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9530451,0.016537536,0.0031210645,0.0047967676,0.018284133,0.0042153765],"domain_scores_gemma":[0.75470185,0.140475,0.0064857593,0.010046662,0.03754115,0.050749477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.11317648,0.0036788567,0.006688377,0.0035594718,0.004762056,0.019289004,0.005566181,0.065115675,0.011486023],"category_scores_gemma":[0.15829597,0.002243565,0.0039600707,0.0038011144,0.01845915,0.029488327,0.013773424,0.06977109,0.005793412],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001203169,0.0000674784,0.00014575572,0.0003635543,0.000114070506,0.00010265225,0.00020798514,0.00022729764,0.00014533335,0.031930923,0.9379491,0.028625485],"study_design_scores_gemma":[0.00040180056,0.00011024822,0.00034049217,0.0017554371,0.0001270819,0.00014144895,0.0003027664,0.00032048632,0.000118498436,0.100489885,0.8957658,0.00012603548],"about_ca_topic_score_codex":0.012651296,"about_ca_topic_score_gemma":0.014151561,"teacher_disagreement_score":0.11317648,"about_ca_system_score_codex":0.015048721,"about_ca_system_score_gemma":0.05099553,"threshold_uncertainty_score":0.5985416},"labels":[],"label_agreement":null},{"id":"W4318930461","doi":"10.1016/s1470-2045(23)00009-8","title":"Essential medicines for childhood cancer in Europe","year":2023,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Dalhousie University","funders":"","keywords":"Childhood cancer; Cancer; Medicine; Traditional medicine; Internal medicine","score_opus":0.06319597506726028,"score_gpt":0.31275034460307777,"score_spread":0.2495543695358175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318930461","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009260852,0.013035419,0.00010492694,0.96267486,0.017914116,0.000010411243,0.00026837,0.000015345156,0.0050505525],"genre_scores_gemma":[0.014761736,0.0092625655,0.0002991791,0.92544395,0.040809236,0.00005351988,0.0001571945,0.000034860645,0.009177793],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99511224,0.0018509205,0.00057945674,0.00028045478,0.0013431719,0.0008336692],"domain_scores_gemma":[0.98476714,0.009522232,0.001362575,0.00032183877,0.0016511533,0.0023750511],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007862161,0.000539816,0.0014831737,0.0009480787,0.0015637112,0.003709908,0.0012228267,0.030179244,0.005442387],"category_scores_gemma":[0.027756255,0.00046327896,0.00155541,0.000921633,0.0020984914,0.0028903985,0.0022574165,0.018892847,0.001188284],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001947896,0.00005257566,0.0013193277,0.00023634027,0.000087536275,0.00076295214,0.00007684709,0.00036103535,0.00018488076,0.020996468,0.9537909,0.021936271],"study_design_scores_gemma":[0.00034300337,0.00008416987,0.0053057387,0.0010344409,0.00011194433,0.0007068875,0.00021915315,0.0008155343,0.00033160642,0.021459186,0.96952325,0.00006505793],"about_ca_topic_score_codex":0.022254996,"about_ca_topic_score_gemma":0.043955036,"teacher_disagreement_score":0.030179244,"about_ca_system_score_codex":0.0068339193,"about_ca_system_score_gemma":0.0101072425,"threshold_uncertainty_score":0.049583852},"labels":[],"label_agreement":null},{"id":"W4320483165","doi":"10.1016/s1470-2045(23)00013-x","title":"Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":281,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"European Regional Development Fund; Universität zu Köln; Cancerföreningen i Stockholm; GlaxoSmithKline; Public Health Agency; University of Birmingham; Stockholms Läns Landsting; Generalitat de Catalunya; National Institute for Health and Care Research; Seagen; ZonMw; Medical Research Council; Swedish Cancer Foundation; Cancer Research UK; AstraZeneca","keywords":"EPIC; Multinational corporation; Medicine; Oncology; Internal medicine; Business; Art","score_opus":0.13685457644282537,"score_gpt":0.42511547419756246,"score_spread":0.28826089775473707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320483165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7671294,0.1830105,0.0032405518,0.00081275555,0.00010715933,0.005275141,0.03931826,0.00006412185,0.001042022],"genre_scores_gemma":[0.9515632,0.01308209,0.01083011,0.000657741,0.00008805959,0.006887104,0.016708568,0.000040238414,0.00014288264],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9493307,0.02803355,0.014463156,0.0039857025,0.0033918673,0.0007949822],"domain_scores_gemma":[0.89984465,0.055253737,0.029743224,0.0092612095,0.0046512363,0.0012460032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.045759887,0.0010800605,0.004011099,0.011964812,0.0007298357,0.0019906093,0.002106598,0.0011644452,0.0014571457],"category_scores_gemma":[0.083777055,0.000836486,0.008575179,0.014510158,0.00088922516,0.000951595,0.0039534597,0.00063231465,0.00018947317],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01705838,0.00038974843,0.6606578,0.09943995,0.16783926,0.0017289773,0.002313119,0.0017100136,0.0020531653,0.0004465966,0.0031879055,0.04317512],"study_design_scores_gemma":[0.004286004,0.0033592184,0.74935365,0.015740935,0.20821519,0.0029558977,0.0018074926,0.0016043978,0.0010653519,0.0004343463,0.01094529,0.00023218947],"about_ca_topic_score_codex":0.0054774326,"about_ca_topic_score_gemma":0.012158349,"teacher_disagreement_score":0.045759887,"about_ca_system_score_codex":0.002090571,"about_ca_system_score_gemma":0.004636203,"threshold_uncertainty_score":0.24200428},"labels":[],"label_agreement":null},{"id":"W4320715991","doi":"10.1016/s1470-2045(23)00070-0","title":"Access to new drugs in paediatric oncology: can we learn from the ongoing ONC201 saga?","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Oncology; Internal medicine; Psychology","score_opus":0.08568365502871851,"score_gpt":0.3743098064957676,"score_spread":0.2886261514670491,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320715991","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005109403,0.07603542,0.0005243165,0.9043982,0.012036897,0.000012583625,0.00059786835,0.00011748713,0.005766274],"genre_scores_gemma":[0.020859048,0.18091963,0.0028151376,0.7216192,0.06475916,0.000120161894,0.0011441215,0.00030172465,0.007461955],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9891906,0.003159647,0.0011016121,0.00096812844,0.0032488124,0.0023311623],"domain_scores_gemma":[0.9076704,0.051335644,0.0069584204,0.002031227,0.012264088,0.019740207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.025700985,0.0010453111,0.0028045988,0.0021363522,0.0018430831,0.013545357,0.0033266877,0.023918979,0.037781745],"category_scores_gemma":[0.071718074,0.00081231364,0.002542146,0.0026832435,0.0059508574,0.022923673,0.008289901,0.024275418,0.0097708665],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034855146,0.00012733704,0.0011222146,0.0018271554,0.00013771857,0.0002624937,0.00019600581,0.00067118934,0.00026019075,0.027958917,0.79024225,0.17684592],"study_design_scores_gemma":[0.00016782845,0.00014343715,0.001277285,0.0024995496,0.0000961141,0.0001972673,0.00037170722,0.00029219294,0.0001454243,0.029884476,0.9648542,0.00007054655],"about_ca_topic_score_codex":0.010920684,"about_ca_topic_score_gemma":0.023692679,"teacher_disagreement_score":0.037781745,"about_ca_system_score_codex":0.010087791,"about_ca_system_score_gemma":0.02208011,"threshold_uncertainty_score":0.13592142},"labels":[],"label_agreement":null},{"id":"W4320716080","doi":"10.1016/s1470-2045(23)00012-8","title":"Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the International Late Effects of Childhood Cancer Guideline Harmonization Group","year":2023,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":136,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Guideline; Asymptomatic; Cardiomyopathy; Pediatrics; Cancer; Intensive care medicine; Internal medicine; Heart failure; Pathology","score_opus":0.04101758170435237,"score_gpt":0.36528840107140564,"score_spread":0.32427081936705326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320716080","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00060490274,0.9807467,0.0016076282,0.004486589,0.0015165948,0.0024759392,0.0066303127,0.00008984562,0.001841512],"genre_scores_gemma":[0.0054406244,0.9757932,0.0056965398,0.0058444794,0.00036665087,0.002620527,0.0029861997,0.000032138032,0.001219601],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9920541,0.0023190356,0.0035603454,0.00050037185,0.0013364104,0.00022972951],"domain_scores_gemma":[0.98646134,0.0067388825,0.0033801508,0.00034471683,0.002831892,0.00024289943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012143045,0.0015438705,0.00712241,0.007024247,0.0005771632,0.0021814115,0.0029899862,0.002325676,0.008013809],"category_scores_gemma":[0.038407374,0.001127472,0.012741104,0.004356558,0.00070895895,0.0021031199,0.0019984553,0.0023600054,0.0013499144],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043168914,0.000030518357,0.0008819346,0.79916835,0.014631206,0.000093077375,0.00017240219,0.0003630681,0.00040274512,0.0010745141,0.03425208,0.14849839],"study_design_scores_gemma":[0.0011900146,0.00012707812,0.004467369,0.79873705,0.0773262,0.00017794486,0.000103787985,0.00013121308,0.00022812541,0.0015327282,0.115896754,0.00008169005],"about_ca_topic_score_codex":0.02087421,"about_ca_topic_score_gemma":0.052008312,"teacher_disagreement_score":0.02087421,"about_ca_system_score_codex":0.0034124027,"about_ca_system_score_gemma":0.014944881,"threshold_uncertainty_score":0.064219356},"labels":[],"label_agreement":null},{"id":"W4322422761","doi":"10.1016/s1470-2045(22)00742-2","title":"Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop","year":2023,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institutes of Health; National Cancer Institute; Canadian Institute of Steel Construction","keywords":"Medical physics; Medicine; Clinical trial; Magnetic resonance imaging; Cancer; Immunotherapy; Steering committee; Radiology; Pathology; Internal medicine; Engineering","score_opus":0.3285918679246932,"score_gpt":0.5010001650143106,"score_spread":0.17240829708961736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322422761","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000109683875,0.9732572,0.00062452076,0.01889509,0.0052813627,0.000130895,0.00030170707,0.000033445376,0.0013660894],"genre_scores_gemma":[0.0009262122,0.9761294,0.0014635558,0.016789507,0.0022701086,0.00022465439,0.0004145122,0.000024825165,0.0017572346],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973687,0.00097202836,0.00040095308,0.00021957734,0.0007927149,0.00024612824],"domain_scores_gemma":[0.9872705,0.006141163,0.0009838097,0.00022958007,0.004529093,0.0008459204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020277621,0.0020322546,0.0032786885,0.00254329,0.00044501515,0.0038531595,0.0026773673,0.004656036,0.0043166345],"category_scores_gemma":[0.01642636,0.00072026846,0.0033737526,0.0027079182,0.00076968817,0.0037451766,0.0028179649,0.008895327,0.0028019352],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047025015,0.00007930192,0.00017866396,0.024456395,0.00059262983,0.00007547121,0.00008996382,0.00049354555,0.0007068463,0.0061277496,0.354833,0.61189616],"study_design_scores_gemma":[0.00033020932,0.00014356674,0.0006633484,0.033559207,0.00095589424,0.0001328254,0.000060035138,0.00014530921,0.00032275234,0.0028312367,0.96080923,0.00004627852],"about_ca_topic_score_codex":0.0066229743,"about_ca_topic_score_gemma":0.013775275,"teacher_disagreement_score":0.020277621,"about_ca_system_score_codex":0.003932554,"about_ca_system_score_gemma":0.014435466,"threshold_uncertainty_score":0.107239604},"labels":[],"label_agreement":null},{"id":"W4322422773","doi":"10.1016/s1470-2045(23)00049-9","title":"Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":163,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; University of Alberta","funders":"","keywords":"Lenvatinib; Medicine; Sunitinib; Renal cell carcinoma; Pembrolizumab; Everolimus; Internal medicine; Oncology; Clinical endpoint; Kidney cancer; Cancer; Clinical trial; Immunotherapy","score_opus":0.11808466686181321,"score_gpt":0.3742417348262079,"score_spread":0.25615706796439464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322422773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853932,0.008845246,0.00040449263,0.00080298947,0.0006025457,0.00085937715,0.001192953,0.00008908025,0.0018101687],"genre_scores_gemma":[0.9911725,0.0027686323,0.0006381772,0.001027228,0.00034893057,0.0007250665,0.0012140628,0.00002371411,0.0020817225],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99895906,0.0005893877,0.000053067968,0.000144092,0.00007256174,0.00018182429],"domain_scores_gemma":[0.99847573,0.0004869565,0.0003553834,0.000118783995,0.00007234123,0.00049074093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025208488,0.0016254591,0.004031423,0.00044058525,0.0004580906,0.0016339623,0.0009897999,0.0018835436,0.0048790397],"category_scores_gemma":[0.0022249382,0.00072678144,0.004014251,0.00052029104,0.0009822545,0.0020815716,0.0005256936,0.004643684,0.0008896523],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97959167,0.002108353,0.00067773764,0.00045542093,0.0016411047,0.00003121672,0.00004729745,0.00048670796,0.0010865484,0.000051482104,0.0006686269,0.013153866],"study_design_scores_gemma":[0.9209279,0.06889055,0.0066863885,0.00006901239,0.0014138125,0.00006194963,0.000045500707,0.0005908015,0.0002809594,0.00023055833,0.0007740618,0.000028553015],"about_ca_topic_score_codex":0.0018175808,"about_ca_topic_score_gemma":0.005215129,"teacher_disagreement_score":0.0048790397,"about_ca_system_score_codex":0.0014415646,"about_ca_system_score_gemma":0.0011889056,"threshold_uncertainty_score":0.016321957},"labels":[],"label_agreement":null},{"id":"W4323033688","doi":"10.1016/s1470-2045(23)00052-9","title":"Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec; Centre Hospitalier de l’Université de Montréal","funders":"Pfizer Canada; European Society for Medical Oncology; Merck Sharp and Dohme; Eisai; Bayer HealthCare; Seagen; Incyte; Ipsen; Clovis Oncology; PharmaMar; Ipsen Biopharmaceuticals; AstraZeneca Canada; Gilead Sciences; Mersana Therapeutics; Bristol-Myers Squibb; AstraZeneca; Takeda Oncology; Amgen; Pfizer; GlaxoSmithKline","keywords":"Medicine; Bevacizumab; Pembrolizumab; Carboplatin; Chemotherapy; Placebo; Clinical endpoint; Internal medicine; Cervical cancer; Oncology; Cancer; Surgery; Clinical trial; Cisplatin; Immunotherapy; Pathology","score_opus":0.21000950227401172,"score_gpt":0.45566592571097175,"score_spread":0.24565642343696004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323033688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9715409,0.013951462,0.0010461307,0.0010847736,0.001457975,0.005328671,0.0016187715,0.00024105652,0.0037301595],"genre_scores_gemma":[0.9818747,0.004565287,0.0016058007,0.0012330338,0.0005440289,0.0052445503,0.0009874087,0.000028615981,0.0039165597],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993204,0.00032545734,0.00003977918,0.00015641803,0.000045918317,0.00011211704],"domain_scores_gemma":[0.9993868,0.00022344044,0.00014526422,0.000043687625,0.000036788315,0.00016402345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001753772,0.0020014436,0.0036721549,0.00055706926,0.00053114985,0.0011728688,0.0009997102,0.0022644082,0.008738752],"category_scores_gemma":[0.0018545416,0.00080328825,0.0026109596,0.00049031375,0.001442789,0.0012633048,0.0004918707,0.0038162756,0.0013388443],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9866022,0.002265243,0.00013484221,0.00077355537,0.00069641334,0.000015728843,0.000026517744,0.00014384027,0.0012305169,0.00006647957,0.00041600328,0.0076287827],"study_design_scores_gemma":[0.9721947,0.02633532,0.0005120533,0.000034435598,0.00030611723,0.000011511535,0.000010132179,0.00013900407,0.00013541666,0.00007589987,0.00023795641,0.000007614801],"about_ca_topic_score_codex":0.0015528455,"about_ca_topic_score_gemma":0.0027275833,"teacher_disagreement_score":0.008738752,"about_ca_system_score_codex":0.0009156744,"about_ca_system_score_gemma":0.0008880109,"threshold_uncertainty_score":0.029234052},"labels":[],"label_agreement":null},{"id":"W4361026261","doi":"10.1016/s1470-2045(23)00067-0","title":"Multinational Association of Supportive Care in Cancer (MASCC) clinical practice guidelines for the prevention and management of acute radiation dermatitis: international Delphi consensus-based recommendations","year":2023,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Effects of Radiation Exposure","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Toronto; McMaster University","funders":"National Cancer Institute; University of Rochester","keywords":"Multinational corporation; Medicine; Delphi method; Delphi; Clinical Practice; Family medicine; Intensive care medicine; Medical physics; Political science","score_opus":0.21632425902884972,"score_gpt":0.5777859755552123,"score_spread":0.36146171652636255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361026261","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015606284,0.8994743,0.012992809,0.05885602,0.0046729282,0.0074120373,0.0021957718,0.00021494494,0.012620504],"genre_scores_gemma":[0.012439291,0.8791809,0.082122125,0.011291462,0.0007423718,0.008413903,0.0031159976,0.00007788441,0.002616091],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9696742,0.01299423,0.009749553,0.0008528027,0.0059642405,0.0007650287],"domain_scores_gemma":[0.94103765,0.03174538,0.006971888,0.00095566706,0.017692426,0.0015969445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.060407918,0.0017702465,0.005376397,0.010178579,0.0017996578,0.0036363907,0.005266375,0.004257681,0.005141372],"category_scores_gemma":[0.07906028,0.0011624314,0.007859209,0.007831409,0.001456346,0.0030020988,0.0043150056,0.0053909277,0.0017590524],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025747807,0.00025863512,0.0016557707,0.16329397,0.0016679511,0.00020752299,0.0014323639,0.00094227697,0.00073055126,0.0051235817,0.1074656,0.71696424],"study_design_scores_gemma":[0.00055655633,0.0002450011,0.0073904106,0.5192965,0.005194862,0.0006330025,0.0016428749,0.00080089405,0.0005962351,0.008394507,0.455073,0.00017620105],"about_ca_topic_score_codex":0.017482515,"about_ca_topic_score_gemma":0.023195893,"teacher_disagreement_score":0.060407918,"about_ca_system_score_codex":0.006392117,"about_ca_system_score_gemma":0.036333926,"threshold_uncertainty_score":0.31947142},"labels":[],"label_agreement":null},{"id":"W4361026527","doi":"10.1016/s1470-2045(23)00063-3","title":"Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":188,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Alberta; Ottawa Hospital; Queen's University; Kingston Health Sciences Centre; University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Docetaxel; Enzalutamide; Clinical endpoint; Prostate cancer; Internal medicine; Antiandrogen; Population; Flutamide; Oncology; Interim analysis; Bicalutamide; Testosterone (patch); Urology; Randomized controlled trial; Cancer; Androgen receptor","score_opus":0.20026769745623704,"score_gpt":0.4825725563967049,"score_spread":0.28230485894046786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361026527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9743251,0.013074572,0.0010332899,0.0014918733,0.001206941,0.0023264727,0.0020041023,0.00031242182,0.0042252573],"genre_scores_gemma":[0.9798641,0.0057539213,0.002017633,0.0015352682,0.00056909845,0.0022458388,0.0018011965,0.000059566286,0.0061534042],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994948,0.00027026763,0.000023918903,0.000090035486,0.000037704398,0.00008325897],"domain_scores_gemma":[0.999252,0.00025300257,0.00014427576,0.00005343083,0.000034438763,0.0002628754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015151981,0.002194305,0.003081658,0.0004471272,0.00039479046,0.0011222567,0.0010611487,0.0017063512,0.009970038],"category_scores_gemma":[0.0015920921,0.00065331225,0.0029444136,0.0005429157,0.0013792588,0.00131128,0.00044852315,0.003865328,0.0011563115],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9823576,0.0022416455,0.00022910522,0.00061605027,0.0010517595,0.000026599198,0.000036609774,0.00039519332,0.000985397,0.00012868417,0.0009120363,0.011019249],"study_design_scores_gemma":[0.9680862,0.02962668,0.0007408383,0.000035304947,0.00041070912,0.000031813215,0.00001791083,0.00027209742,0.00012305609,0.00017138857,0.00046959505,0.000014378092],"about_ca_topic_score_codex":0.0019908585,"about_ca_topic_score_gemma":0.0049301987,"teacher_disagreement_score":0.009970038,"about_ca_system_score_codex":0.0009664821,"about_ca_system_score_gemma":0.0011459603,"threshold_uncertainty_score":0.03335309},"labels":[],"label_agreement":null},{"id":"W4361026857","doi":"10.1016/s1470-2045(23)00005-0","title":"Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference","year":2023,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute of Neurological Disorders and Stroke; Foundation Medicine; Genentech; National Institutes of Health; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Servier; Astellas Pharma; Eisai; Ben and Catherine Ivy Foundation; Puma Biotechnology; Boston Pharmaceuticals; Voyager Therapeutics; BeiGene; Deciphera Pharmaceuticals; Agios Pharmaceuticals; Ipsen; Five Prime Therapeutics; Sanofi; GW Pharmaceuticals; Karyopharm Therapeutics; GlaxoSmithKline; AstraZeneca; Novocure; Celldex Therapeutics; Pfizer; Celgene; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Clinical trial; Drug development; Clinical Oncology; Oncology; Internal medicine; Drug; Cancer; Pharmacology","score_opus":0.6506715989117712,"score_gpt":0.5827464133019178,"score_spread":0.06792518560985339,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361026857","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028062635,0.9926528,0.00055540574,0.0037316035,0.000891358,0.00024121423,0.00041566583,0.00003651298,0.0011949498],"genre_scores_gemma":[0.0037155766,0.984823,0.0031184864,0.005877425,0.0007400279,0.00048006847,0.00044823668,0.00003823282,0.0007589729],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.989141,0.006068217,0.0016716189,0.00081007456,0.0019243647,0.0003848063],"domain_scores_gemma":[0.93483245,0.050902367,0.0050349636,0.0009370566,0.00679597,0.0014970859],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.055718165,0.0015805328,0.007486574,0.0030735824,0.0003799528,0.0060574994,0.002869226,0.0037944736,0.0073926845],"category_scores_gemma":[0.051242866,0.0009995055,0.0053392053,0.0044943606,0.0012177832,0.0039900076,0.0017385134,0.005901245,0.0018421095],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004158604,0.00018894525,0.00040729129,0.09030449,0.0027469846,0.000066788874,0.00011656343,0.0011629302,0.0008231897,0.0070895134,0.0770856,0.8158491],"study_design_scores_gemma":[0.007692809,0.002032164,0.00360916,0.115039505,0.012193188,0.00034526628,0.00013584393,0.00094655715,0.000862139,0.009892409,0.84712046,0.00013047273],"about_ca_topic_score_codex":0.0030068292,"about_ca_topic_score_gemma":0.008795435,"teacher_disagreement_score":0.055718165,"about_ca_system_score_codex":0.005243884,"about_ca_system_score_gemma":0.011268481,"threshold_uncertainty_score":0.2946694},"labels":[],"label_agreement":null},{"id":"W4362576010","doi":"10.1016/s1470-2045(23)00072-4","title":"Access to essential cancer medicines for children: a comparative mixed-methods analysis of availability, price, and health-system determinants in east Africa","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Western University; Institute for Clinical Evaluative Sciences; SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Tanzania; Medicine; Essential medicines; Referral; Health care; Family medicine; Public health; Environmental health; Socioeconomics; Economic growth; Nursing","score_opus":0.2611706477913128,"score_gpt":0.49857130540933786,"score_spread":0.23740065761802503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362576010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99515957,0.0025414757,0.0008067916,0.00024775832,0.000015693686,0.00007366713,0.00091109617,0.000004472009,0.00023949707],"genre_scores_gemma":[0.99768627,0.000819571,0.0008145886,0.000074375006,0.000014116257,0.00011410842,0.00034019112,0.00000531648,0.00013158057],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98297775,0.013938662,0.0005481103,0.0005621233,0.00036434745,0.0016089651],"domain_scores_gemma":[0.95778733,0.03524672,0.0045324806,0.0011089582,0.000710922,0.00061367045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013668009,0.0010754429,0.0017817037,0.0018751052,0.00085084746,0.0016519255,0.0017371617,0.001388196,0.0036727986],"category_scores_gemma":[0.030390752,0.00095109874,0.0041393605,0.003852978,0.0010733006,0.0022004563,0.0020346437,0.0017185427,0.00020463584],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006331779,0.001721696,0.9333126,0.002601799,0.022546554,0.0009645644,0.0039004888,0.0047970354,0.00038385764,0.0024657596,0.0011693913,0.0198045],"study_design_scores_gemma":[0.0009982531,0.0036775097,0.9413909,0.0012665936,0.016063452,0.00071923767,0.016954903,0.014679969,0.0007937468,0.0013339543,0.0019731268,0.00014828668],"about_ca_topic_score_codex":0.08134358,"about_ca_topic_score_gemma":0.057052705,"teacher_disagreement_score":0.08134358,"about_ca_system_score_codex":0.0023220044,"about_ca_system_score_gemma":0.0019405022,"threshold_uncertainty_score":0.16174024},"labels":[],"label_agreement":null},{"id":"W4366085279","doi":"10.1016/s1470-2045(23)00147-x","title":"Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":190,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; University of Sydney; National Health and Medical Research Council; Hospira","keywords":"Medicine; Chemoradiotherapy; Carboplatin; Cervical cancer; Oncology; Internal medicine; Clinical endpoint; Radiation therapy; Brachytherapy; Surgery; Chemotherapy; Cancer; Randomized controlled trial; Cisplatin","score_opus":0.13857106524791302,"score_gpt":0.47322040351547234,"score_spread":0.3346493382675593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366085279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97350603,0.010022534,0.0010380339,0.0013597792,0.0019172446,0.006063538,0.0016437958,0.0001928952,0.0042561516],"genre_scores_gemma":[0.97982156,0.0046018725,0.0019086277,0.0017410568,0.00077311584,0.00472925,0.0010912622,0.00004626398,0.0052870507],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99929285,0.00041577002,0.000034393695,0.00011319431,0.000034853816,0.00010877281],"domain_scores_gemma":[0.9987764,0.0005068345,0.00022706678,0.00010291215,0.00005171122,0.00033512144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019861837,0.0020686572,0.0038361277,0.0004991464,0.0005506048,0.0013349488,0.0011725125,0.0026755852,0.01194022],"category_scores_gemma":[0.0023454262,0.0007270094,0.0029715227,0.000612165,0.0015359422,0.0015475501,0.00058308424,0.004068472,0.0014636299],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98677117,0.0032419174,0.00014545291,0.00049855816,0.0005556546,0.000015685007,0.00003660571,0.00016477337,0.00070540747,0.00006975254,0.00040643345,0.007388417],"study_design_scores_gemma":[0.9557734,0.042037703,0.00062565034,0.000062058854,0.00047810114,0.000019982632,0.000023179484,0.00019277161,0.00017006844,0.00018219442,0.00042296012,0.000011914675],"about_ca_topic_score_codex":0.001742963,"about_ca_topic_score_gemma":0.003184213,"teacher_disagreement_score":0.01194022,"about_ca_system_score_codex":0.0010852184,"about_ca_system_score_gemma":0.0011319277,"threshold_uncertainty_score":0.039943993},"labels":[],"label_agreement":null},{"id":"W4367670225","doi":"10.1016/s1470-2045(23)00026-8","title":"The rise of immuno-oncology in China: a challenge to western dominance?","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Institute for Health and Care Research","keywords":"China; Population; Government (linguistics); Political science; Christian ministry; Library science; Scopus; Action plan; Economic growth; Geography; Medicine; Traditional medicine; Demography; Public administration; Management; MEDLINE; Sociology; Environmental health; Law","score_opus":0.04492027790961976,"score_gpt":0.3693331403452687,"score_spread":0.32441286243564893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367670225","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.036037352,0.034795985,0.0005518634,0.90453315,0.005045501,0.000020076659,0.00044362483,0.000058883666,0.018513585],"genre_scores_gemma":[0.5360851,0.081892185,0.0017193308,0.33527675,0.018362932,0.00009189294,0.00052691484,0.00009976892,0.025945058],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985056,0.0002841798,0.000076879034,0.00014565735,0.0003404085,0.0006472503],"domain_scores_gemma":[0.99650204,0.0005147667,0.00039461625,0.00016255776,0.00076163537,0.0016644476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033978021,0.00044691612,0.00083529763,0.0010838525,0.0031017591,0.0042731455,0.00082836807,0.002999341,0.01386252],"category_scores_gemma":[0.003623551,0.00019179286,0.0004931744,0.0027945705,0.0048043416,0.004038672,0.0030915004,0.005201568,0.0013741644],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007143087,0.0003096432,0.093623355,0.001930308,0.0003112358,0.0017625093,0.013751643,0.0006280356,0.002975625,0.1989537,0.4012517,0.283788],"study_design_scores_gemma":[0.00020900393,0.00030176176,0.15820876,0.00150776,0.00014759184,0.0005283774,0.0154528385,0.0007217463,0.0007011087,0.0640334,0.75802845,0.00015917217],"about_ca_topic_score_codex":0.09435137,"about_ca_topic_score_gemma":0.11546653,"teacher_disagreement_score":0.09435137,"about_ca_system_score_codex":0.0077851983,"about_ca_system_score_gemma":0.019338593,"threshold_uncertainty_score":0.18760437},"labels":[],"label_agreement":null},{"id":"W4367673953","doi":"10.1016/s1470-2045(23)00165-1","title":"Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University","funders":"","keywords":"Medicine; Breast cancer; Adjuvant; Oncology; Internal medicine; Adjuvant therapy; Clinical trial; Population; Randomized controlled trial; Cancer; Disease; Family medicine","score_opus":0.1417651738107499,"score_gpt":0.42229626471409526,"score_spread":0.2805310909033454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367673953","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0048097693,0.9692815,0.0004434793,0.012125606,0.0034913367,0.00038742955,0.0029195063,0.00005783252,0.006483549],"genre_scores_gemma":[0.05920446,0.90521556,0.0009355529,0.02651542,0.0029022167,0.0003579882,0.0021088126,0.00007378266,0.0026862947],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99669707,0.0016057885,0.0007490941,0.00027886676,0.0005495369,0.00011969651],"domain_scores_gemma":[0.9863556,0.009442765,0.0026066133,0.00030607005,0.001015479,0.00027355133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064047617,0.0008392148,0.004542072,0.0013255702,0.00031074588,0.0016724581,0.0015785333,0.0018370285,0.0093649505],"category_scores_gemma":[0.021767186,0.00049297704,0.005032751,0.0018589062,0.0007125081,0.0011511807,0.0006229933,0.0029861024,0.0015029465],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041437373,0.00011442655,0.0014677164,0.5085766,0.037912544,0.00024759248,0.00020985195,0.00052931765,0.0019410381,0.0018633485,0.0855383,0.320162],"study_design_scores_gemma":[0.062163644,0.0061450563,0.015102626,0.2599791,0.23118782,0.0008379067,0.00030332097,0.0003196722,0.0014544834,0.0039217793,0.4184036,0.00018095013],"about_ca_topic_score_codex":0.0036912216,"about_ca_topic_score_gemma":0.013049279,"teacher_disagreement_score":0.0093649505,"about_ca_system_score_codex":0.0023584801,"about_ca_system_score_gemma":0.0027208289,"threshold_uncertainty_score":0.03387201},"labels":[],"label_agreement":null},{"id":"W4376126456","doi":"10.1016/s1470-2045(23)00154-7","title":"Cumulative burden of late, major surgical intervention in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study (CCSS) cohort","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; National Institutes of Health; American Lebanese Syrian Associated Charities; St. Jude Children's Research Hospital","keywords":"Medicine; Psychological intervention; Cancer; Pediatrics; Cohort; Retrospective cohort study; Cohort study; Surgery; Internal medicine; Psychiatry","score_opus":0.05240440087832999,"score_gpt":0.39572720666030364,"score_spread":0.34332280578197366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376126456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872162,0.0010434221,0.00008730124,0.00030704433,0.000029565652,0.000008562758,0.010670911,0.0000084310095,0.0006285656],"genre_scores_gemma":[0.99179184,0.001002168,0.000058757563,0.000071622024,0.000027396065,0.00001420407,0.006595762,0.0000050741605,0.00043322777],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997385,0.000039180493,0.000026210186,0.00007197714,0.000045482557,0.00007852051],"domain_scores_gemma":[0.9990202,0.000075420634,0.0004245853,0.000098299155,0.00012456148,0.00025686002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049757713,0.00025830028,0.00038384722,0.0007028355,0.00039763536,0.00070876436,0.00040645065,0.000382851,0.0012420943],"category_scores_gemma":[0.001668201,0.00028179216,0.00074053917,0.0017081943,0.00017045879,0.00050696975,0.00089933584,0.00074143347,0.00014825095],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007107672,0.000012964712,0.99749446,0.000012351598,0.00017527954,0.000046666264,0.00009255884,0.00006724936,0.00008807508,0.000037658665,0.00072801503,0.0011738429],"study_design_scores_gemma":[0.0000034312995,0.000020113299,0.9993704,0.0000064066057,0.000047776943,0.00006770865,0.00016423332,0.00003440929,0.000014075869,0.000013178251,0.00025506745,0.000003201881],"about_ca_topic_score_codex":0.07168426,"about_ca_topic_score_gemma":0.09174487,"teacher_disagreement_score":0.07168426,"about_ca_system_score_codex":0.0006201412,"about_ca_system_score_gemma":0.00088187924,"threshold_uncertainty_score":0.14253402},"labels":[],"label_agreement":null},{"id":"W4376126708","doi":"10.1016/s1470-2045(23)00166-3","title":"Long-term surgical consequences of childhood cancer","year":2023,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Survivorship curve; Cancer; Psychological intervention; Radiation therapy; Childhood cancer; Disease; Cancer survivorship; Harm; Intervention (counseling); Pediatrics; Gerontology; Surgery; Psychiatry; Psychology; Internal medicine","score_opus":0.09706267654190277,"score_gpt":0.40192848258817643,"score_spread":0.30486580604627367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376126708","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002007041,0.0038130297,0.000022757471,0.9809394,0.009153051,0.000004632252,0.00009619991,0.0000053081135,0.0039586574],"genre_scores_gemma":[0.028833551,0.0073840683,0.00009997934,0.9040587,0.046712194,0.00005124222,0.00014098111,0.000024711626,0.012694564],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99827456,0.0006354862,0.0001748996,0.000098719946,0.00044572144,0.00037057122],"domain_scores_gemma":[0.99326456,0.0036031196,0.00060499844,0.00012572765,0.00063863926,0.0017628537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002043108,0.00033976225,0.00077139685,0.000360977,0.002581049,0.002092462,0.00080385874,0.020523455,0.0066233817],"category_scores_gemma":[0.016112335,0.00035126827,0.0008604271,0.00063903973,0.0019620669,0.00196294,0.001565844,0.019951195,0.0017921772],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010997944,0.0000572002,0.006897388,0.00015053037,0.000040364597,0.0037037162,0.00051868457,0.00010045268,0.00023162436,0.005995221,0.95706123,0.025133748],"study_design_scores_gemma":[0.00023125792,0.00020924515,0.024037391,0.0015710825,0.00011147137,0.006586135,0.0032352244,0.00037729015,0.0002625411,0.0107812835,0.95249647,0.00010043705],"about_ca_topic_score_codex":0.016657969,"about_ca_topic_score_gemma":0.04905001,"teacher_disagreement_score":0.020523455,"about_ca_system_score_codex":0.0035885742,"about_ca_system_score_gemma":0.005292501,"threshold_uncertainty_score":0.033122063},"labels":[],"label_agreement":null},{"id":"W4376272229","doi":"10.1016/s1470-2045(23)00170-5","title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":245,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Sinai Health System; University of Toronto; University Health Network; Mount Sinai Hospital","funders":"","keywords":"Cystectomy; Medicine; Propensity score matching; Bladder cancer; Urology; Retrospective cohort study; Stage (stratigraphy); Clinical endpoint; Surgery; Cancer; Internal medicine; Randomized controlled trial","score_opus":0.1688769722248086,"score_gpt":0.3886908834160771,"score_spread":0.2198139111912685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376272229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939091,0.0015726764,0.002890776,0.000119465556,0.000110488625,0.00012560782,0.0007124337,0.000019805006,0.00053956243],"genre_scores_gemma":[0.9978124,0.00022715396,0.0007532431,0.00008493638,0.000044309327,0.00006537773,0.0005974992,0.00001668135,0.00039827012],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99618125,0.0017400843,0.0004051611,0.0008915992,0.0003109827,0.0004708919],"domain_scores_gemma":[0.99396557,0.0023565681,0.0020988095,0.0009603118,0.0003208581,0.0002979515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049727876,0.0007858322,0.0016306815,0.0007250089,0.00042192466,0.0012022508,0.0015095875,0.0009693672,0.003146757],"category_scores_gemma":[0.011161863,0.00065163174,0.0060598883,0.0012308898,0.00046890162,0.0011894669,0.0012879776,0.001252913,0.00033014422],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15309373,0.0010184173,0.70940244,0.0009513348,0.069221266,0.00045658034,0.00039762622,0.009523219,0.0020026746,0.0015006686,0.0044643306,0.047967777],"study_design_scores_gemma":[0.012138856,0.013766504,0.8598783,0.0002065118,0.052076194,0.00090350705,0.00090675836,0.05048086,0.0010807426,0.0048044017,0.0035109704,0.00024639175],"about_ca_topic_score_codex":0.004043124,"about_ca_topic_score_gemma":0.005370184,"teacher_disagreement_score":0.0049727876,"about_ca_system_score_codex":0.0009282875,"about_ca_system_score_gemma":0.000809231,"threshold_uncertainty_score":0.02629894},"labels":[],"label_agreement":null},{"id":"W4378800385","doi":"10.1016/s1470-2045(23)00158-4","title":"Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; BC Cancer Agency","funders":"National Cancer Institute; Medical Research Council; Advanced Accelerator Applications; Astellas Pharma; Clovis Oncology; AstraZeneca; National Institute for Health and Care Research; Novartis; Pfizer","keywords":"Medicine; Prostate cancer; Glutamate carboxypeptidase II; Radioligand; Quality of life (healthcare); Oncology; Internal medicine; Lutetium; Cancer; Nursing; Receptor","score_opus":0.09987168394441787,"score_gpt":0.45554696749601414,"score_spread":0.3556752835515963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378800385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99312663,0.0034835713,0.0002794599,0.00040028323,0.00025243583,0.00094139524,0.00044880007,0.000060480226,0.0010069815],"genre_scores_gemma":[0.99462247,0.0011775942,0.0007138468,0.0004549346,0.00025521888,0.0011253078,0.0005844234,0.000014858823,0.0010512447],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9990048,0.0005505919,0.00004860177,0.00015980347,0.000073926305,0.00016234245],"domain_scores_gemma":[0.99908733,0.00027538787,0.0002517602,0.00006506146,0.000051743402,0.0002687944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017615745,0.0017793517,0.0033293306,0.00047139812,0.00040529203,0.00123945,0.0011272781,0.002032393,0.005097707],"category_scores_gemma":[0.0017041733,0.0006623022,0.0031991408,0.0005925823,0.0016405088,0.0011718476,0.00056806725,0.0038034332,0.0007452804],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98361635,0.003175191,0.0005111989,0.00044513732,0.0011970642,0.000014846998,0.000038068316,0.00039577516,0.0013130663,0.00008270384,0.00036141332,0.008849165],"study_design_scores_gemma":[0.91847605,0.07771826,0.0020304048,0.000028452729,0.00071435637,0.000021719869,0.000021348067,0.00038732428,0.0002549269,0.00012561322,0.00020284153,0.00001876642],"about_ca_topic_score_codex":0.0020104016,"about_ca_topic_score_gemma":0.002901284,"teacher_disagreement_score":0.005097707,"about_ca_system_score_codex":0.0014745487,"about_ca_system_score_gemma":0.0011327524,"threshold_uncertainty_score":0.017053545},"labels":[],"label_agreement":null},{"id":"W4378803683","doi":"10.1016/s1470-2045(23)00183-3","title":"Global application of National Comprehensive Cancer Network resource-stratified guidelines for systemic treatment of colon cancer: a population-based, customisable model for cost, demand, and procurement","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Institute for Health and Care Research","keywords":"Medicine; Cancer registry; Procurement; Cancer; Population; Intensive care medicine; Business; Environmental health; Internal medicine","score_opus":0.21920006142761905,"score_gpt":0.39798021093759656,"score_spread":0.1787801495099775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378803683","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3854068,0.0027613444,0.48271847,0.02263513,0.0006156984,0.0011451317,0.03008782,0.001188636,0.073440984],"genre_scores_gemma":[0.93310773,0.00081635173,0.035982016,0.0011922079,0.00014914457,0.00059344433,0.0038029107,0.00019949929,0.024156746],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99726045,0.0018635317,0.00007145684,0.0003375925,0.00017139611,0.0002955861],"domain_scores_gemma":[0.99426115,0.0040808767,0.00059869845,0.00026879887,0.00054108375,0.00024941974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005364848,0.0009909695,0.0016769799,0.0013217415,0.0004997806,0.002916664,0.0027328713,0.0034947412,0.010607708],"category_scores_gemma":[0.01646233,0.0013396192,0.0020801765,0.0029554807,0.0012986895,0.001949507,0.0013317683,0.002856045,0.0014408126],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007176815,0.000050022936,0.0036952943,0.000028718252,0.00010098235,0.000097812095,0.00006009873,0.97309506,0.000043012642,0.014754692,0.0032721607,0.0047303373],"study_design_scores_gemma":[0.000110627014,0.00010112291,0.004271367,0.00005052576,0.00012764422,0.00012431464,0.00009714699,0.9698224,0.000057009915,0.021774624,0.0034246636,0.000038628623],"about_ca_topic_score_codex":0.09506031,"about_ca_topic_score_gemma":0.07066385,"teacher_disagreement_score":0.09506031,"about_ca_system_score_codex":0.005531234,"about_ca_system_score_gemma":0.0038326348,"threshold_uncertainty_score":0.18901402},"labels":[],"label_agreement":null},{"id":"W4378803794","doi":"10.1016/s1470-2045(23)00175-4","title":"Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Canadian Institutes of Health Research","keywords":"Cross-sectional study; Environmental health; Cancer; Medicine; Geography; Traditional medicine; Pathology; Internal medicine","score_opus":0.4824217619720488,"score_gpt":0.6009260566361347,"score_spread":0.11850429466408596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378803794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844806,0.0025748473,0.0003248917,0.00093135296,0.000030833213,0.000046665362,0.009794941,0.000010425903,0.0018053611],"genre_scores_gemma":[0.9913623,0.001306277,0.00036821663,0.0002831725,0.000025053036,0.0000768878,0.0061854217,0.0000087110375,0.0003839517],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99688715,0.0011708906,0.00058998377,0.00036682357,0.00047911075,0.0005059376],"domain_scores_gemma":[0.9863138,0.0037827822,0.007081909,0.0007774718,0.0012813412,0.0007626254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042776684,0.00045294667,0.0008172881,0.00226278,0.00032356262,0.0015398052,0.00072733336,0.00082501024,0.0013080724],"category_scores_gemma":[0.012386917,0.0003522347,0.0022106352,0.009364237,0.00059193256,0.0010202049,0.0019405392,0.001472709,0.00023400951],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000111034315,0.00003729413,0.9957345,0.00008401701,0.00056589465,0.000035693945,0.00017819916,0.00019647386,0.000035844863,0.00011709836,0.0004987841,0.002405183],"study_design_scores_gemma":[0.000008881298,0.000038806236,0.99871004,0.000046716363,0.00016855841,0.000035025463,0.00033478648,0.00011944536,0.000021804248,0.00002592442,0.00048453864,0.000005356463],"about_ca_topic_score_codex":0.08100549,"about_ca_topic_score_gemma":0.049746606,"teacher_disagreement_score":0.08100549,"about_ca_system_score_codex":0.0020537025,"about_ca_system_score_gemma":0.0019042587,"threshold_uncertainty_score":0.16106796},"labels":[],"label_agreement":null},{"id":"W4379114671","doi":"10.1016/s1470-2045(23)00242-5","title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":247,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Medicine; Internal medicine; Cohort; Tolerability; Biliary tract cancer; Clinical endpoint; Oncology; Cancer; Response Evaluation Criteria in Solid Tumors; Biliary tract; Gastroenterology; Immunohistochemistry; Gemcitabine; Phases of clinical research; Clinical trial; Adverse effect","score_opus":0.16486487869779953,"score_gpt":0.43504478601068974,"score_spread":0.2701799073128902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379114671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799454,0.011295877,0.0006029727,0.0009364348,0.00032954174,0.001701371,0.00236382,0.000115991774,0.0027085335],"genre_scores_gemma":[0.973598,0.011807411,0.0016473386,0.001703484,0.00022902462,0.0016526801,0.0036089832,0.00007771213,0.0056754267],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994313,0.0002748969,0.000024372115,0.00008108876,0.000056284574,0.00013202659],"domain_scores_gemma":[0.9993536,0.000121833444,0.00018062175,0.000069033056,0.000041678642,0.00023322199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00220089,0.0018719728,0.002539643,0.00048479752,0.0004023995,0.001372372,0.0009618574,0.0014515913,0.005028884],"category_scores_gemma":[0.0012331946,0.00083057676,0.0024262331,0.00068950147,0.00091060996,0.001127479,0.00040808905,0.0033803405,0.0010716685],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90383124,0.011514404,0.004069702,0.0020325566,0.0051108385,0.000131502,0.00020446422,0.0016392501,0.0091653345,0.00035185018,0.0041830107,0.05776585],"study_design_scores_gemma":[0.9198495,0.06511051,0.008964467,0.00006903342,0.002284335,0.00012772683,0.00007377613,0.00044005405,0.00058740156,0.00020249012,0.00225592,0.000034725894],"about_ca_topic_score_codex":0.0022683502,"about_ca_topic_score_gemma":0.008144056,"teacher_disagreement_score":0.005028884,"about_ca_system_score_codex":0.0010775062,"about_ca_system_score_gemma":0.0012539547,"threshold_uncertainty_score":0.016823232},"labels":[],"label_agreement":null},{"id":"W4379801164","doi":"10.1016/s1470-2045(23)00279-6","title":"Canada to put health warnings on individual cigarettes","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Public Health Policies and Epidemiology","field":"Business, Management and Accounting","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Agency (philosophy); Tobacco control; Business; Health protection; Labelling; Advertising; Health claims on food labels; Control (management); Political science; Environmental health; Public health; Medicine; Psychology; Economics; Management; Sociology; Criminology","score_opus":0.09609168010326435,"score_gpt":0.35750838632823806,"score_spread":0.2614167062249737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379801164","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005024166,0.005682229,0.0005647787,0.85557777,0.02146768,0.00018505589,0.0026796877,0.00020677166,0.10861191],"genre_scores_gemma":[0.055819344,0.0052842116,0.0018692983,0.71897054,0.004029923,0.00013135879,0.0009918816,0.00014379744,0.21275967],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99313265,0.00075717457,0.0002604834,0.00035656252,0.0034722192,0.0020210547],"domain_scores_gemma":[0.9718409,0.0051838798,0.0009784127,0.0007971271,0.012513732,0.008686065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005695693,0.00061194977,0.00068569556,0.002041449,0.0069017396,0.005851941,0.0022930065,0.019570505,0.028250398],"category_scores_gemma":[0.035727005,0.0006859184,0.0016312865,0.0018584251,0.0029701355,0.0019243466,0.0018856728,0.021594094,0.003663484],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007616858,0.000056010645,0.0017433908,0.00009475068,0.000040830924,0.00008632933,0.00018524728,0.00018034529,0.0001510084,0.023954593,0.9560045,0.017426778],"study_design_scores_gemma":[0.00022727014,0.000052129606,0.0067221113,0.00046541326,0.00010601792,0.000057525234,0.0004987464,0.0003752025,0.0005374072,0.007879056,0.9829905,0.00008869388],"about_ca_topic_score_codex":0.9752069,"about_ca_topic_score_gemma":0.9828668,"teacher_disagreement_score":0.040193155,"about_ca_system_score_codex":0.040193155,"about_ca_system_score_gemma":0.22872809,"threshold_uncertainty_score":0.29162312},"labels":[],"label_agreement":null},{"id":"W4382933931","doi":"10.1016/s1470-2045(23)00212-7","title":"Endoscopic surveillance in hereditary diffuse gastric cancer","year":2023,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Montreal General Hospital","funders":"","keywords":"Medicine; Gastrectomy; Cancer; Signet ring cell carcinoma; Cohort; Surgery; Prospective cohort study; Internal medicine; CDH1; General surgery; Gastroenterology; Adenocarcinoma","score_opus":0.06145302085543939,"score_gpt":0.3409045621487638,"score_spread":0.2794515412933244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382933931","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018908004,0.0036175838,0.000062023086,0.97946733,0.010772864,0.000006192093,0.0000622443,0.000017454053,0.0041035167],"genre_scores_gemma":[0.03170035,0.0042915293,0.00030710702,0.86865085,0.08747683,0.000035520698,0.00012792923,0.00003475473,0.0073750787],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9985108,0.0005139213,0.00019499708,0.00013426231,0.00032793806,0.00031815932],"domain_scores_gemma":[0.9944036,0.0026074077,0.0005833803,0.00016068574,0.00073162443,0.0015133198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016830692,0.00042400218,0.0008898243,0.0008649703,0.001881625,0.0017433463,0.0008901911,0.029519694,0.00436395],"category_scores_gemma":[0.014876592,0.0004567404,0.0008995317,0.00084189227,0.0017936187,0.0017400078,0.0012756604,0.017450323,0.0021161414],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014489506,0.00006227172,0.009517742,0.000115553245,0.00003689794,0.00977667,0.00016639335,0.00013576097,0.000425595,0.0028786284,0.9499471,0.026792461],"study_design_scores_gemma":[0.0010483611,0.00051964866,0.03798199,0.0027183006,0.00025990538,0.049610466,0.0016500383,0.003371427,0.0010231456,0.024208007,0.8774415,0.00016716719],"about_ca_topic_score_codex":0.009023178,"about_ca_topic_score_gemma":0.015739163,"teacher_disagreement_score":0.029519694,"about_ca_system_score_codex":0.003676107,"about_ca_system_score_gemma":0.0025369907,"threshold_uncertainty_score":0.026672125},"labels":[],"label_agreement":null},{"id":"W4383982112","doi":"10.1016/s1470-2045(23)00276-0","title":"Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":149,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"Merck Sharp and Dohme; National Cancer Institute; Eisai","keywords":"Lenvatinib; Pembrolizumab; Medicine; Renal cell carcinoma; Internal medicine; Clinical endpoint; Population; Oncology; Adverse effect; Phases of clinical research; Cancer; Clinical trial; Immunotherapy","score_opus":0.09302847659005466,"score_gpt":0.3660065527882697,"score_spread":0.27297807619821507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383982112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9771236,0.010955972,0.0007813377,0.0017669315,0.0007608303,0.0023102167,0.0019803552,0.00022795497,0.0040928177],"genre_scores_gemma":[0.9775688,0.006788195,0.0018583405,0.002497628,0.0003991183,0.0020073436,0.0026638573,0.000052136988,0.0061645578],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99952495,0.00021588251,0.000016826301,0.000100025325,0.000036702106,0.000105681254],"domain_scores_gemma":[0.9994153,0.0001272739,0.00010692545,0.000048522616,0.000033909473,0.0002680996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018699006,0.001804145,0.0028274497,0.00036107574,0.000374494,0.0013337123,0.0008666522,0.0015066018,0.005962691],"category_scores_gemma":[0.0012365121,0.0005573892,0.0020695757,0.00041907444,0.0008384167,0.0014355903,0.00044767992,0.0046934467,0.001394672],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90258026,0.011423105,0.0009864209,0.0015383295,0.002242878,0.000088883266,0.00012684723,0.0014993182,0.0057444684,0.0003366959,0.004978302,0.068454616],"study_design_scores_gemma":[0.92936474,0.06537043,0.0021839882,0.000047152465,0.0004876702,0.00008529223,0.00003057403,0.00053083384,0.00036866523,0.00025191822,0.0012620279,0.000016626554],"about_ca_topic_score_codex":0.0011556641,"about_ca_topic_score_gemma":0.0031522047,"teacher_disagreement_score":0.005962691,"about_ca_system_score_codex":0.0010792053,"about_ca_system_score_gemma":0.0012541363,"threshold_uncertainty_score":0.01994723},"labels":[],"label_agreement":null},{"id":"W4384463924","doi":"10.1016/s1470-2045(23)00319-4","title":"Common Sense Oncology: outcomes that matter","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph; Princess Margaret Cancer Centre; Kingston Health Sciences Centre; Hospital for Sick Children; Queen's University","funders":"National Institute for Health and Care Research","keywords":"Medicine; Quality of life (healthcare); Intensive care medicine; Internal medicine; Oncology; Nursing","score_opus":0.3533455849318626,"score_gpt":0.514592108476374,"score_spread":0.16124652354451147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384463924","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.033322547,0.071155645,0.0014106834,0.85344005,0.0076552695,0.00007377874,0.002072724,0.000051699313,0.030817617],"genre_scores_gemma":[0.85214067,0.029958803,0.0011023958,0.101658106,0.008971714,0.00019602587,0.0016503311,0.0002344825,0.0040874765],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.97576004,0.013167779,0.0019617605,0.0016734942,0.0044164453,0.0030205357],"domain_scores_gemma":[0.89385563,0.046926558,0.020364303,0.002716609,0.013425183,0.022711685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020930786,0.0004557019,0.0014716863,0.0022070736,0.0024476186,0.009515216,0.0018824027,0.0035229216,0.021232206],"category_scores_gemma":[0.15864585,0.00030150844,0.001088654,0.00548014,0.005553018,0.015418044,0.0059024203,0.006760533,0.0018530445],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000915064,0.00032363812,0.13564971,0.004724434,0.001114882,0.00043465706,0.005431934,0.0006461451,0.000121438556,0.1395166,0.387233,0.32388863],"study_design_scores_gemma":[0.00039169565,0.0006145896,0.17975411,0.022247424,0.00087408244,0.001601215,0.03925961,0.00077682105,0.0002697268,0.5151049,0.23873626,0.00036960538],"about_ca_topic_score_codex":0.0063333735,"about_ca_topic_score_gemma":0.0103771575,"teacher_disagreement_score":0.021232206,"about_ca_system_score_codex":0.007703822,"about_ca_system_score_gemma":0.009250831,"threshold_uncertainty_score":0.11069387},"labels":[],"label_agreement":null},{"id":"W4385297096","doi":"10.1016/s1470-2045(23)00318-2","title":"Treatment-related mortality in children with cancer in low-income and middle-income countries: a systematic review and meta-analysis","year":2023,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stollery Children's Hospital","funders":"National Cancer Institute; American Lebanese Syrian Associated Charities","keywords":"Medicine; Meta-analysis; Cancer; MEDLINE; Mortality rate; Demography; Internal medicine","score_opus":0.1147548615962682,"score_gpt":0.42185105843413184,"score_spread":0.30709619683786366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385297096","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0050427406,0.99375397,0.00024307703,0.00010290026,0.00012616311,0.00007368932,0.00052391645,0.000016451986,0.00011713804],"genre_scores_gemma":[0.19351459,0.8024902,0.0013799771,0.0009591829,0.00022532846,0.0003263451,0.0007939773,0.000034259854,0.00027616645],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9943271,0.0019567262,0.0020300378,0.0008062452,0.0005824882,0.00029747607],"domain_scores_gemma":[0.9915131,0.005788393,0.0016392792,0.00035016675,0.0005450368,0.00016404789],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0062985835,0.0024122659,0.01678829,0.005183358,0.00052619085,0.0028262858,0.0018396105,0.0021391485,0.003491692],"category_scores_gemma":[0.01796122,0.0018369945,0.03996158,0.0072197816,0.0006702298,0.0017222598,0.0021517363,0.0025105462,0.00032795334],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012260317,0.00002248933,0.007993743,0.25884926,0.72092396,0.00010818366,0.000086604465,0.00032862183,0.00015338592,0.00008809228,0.00069803465,0.009521596],"study_design_scores_gemma":[0.00039923043,0.00009717893,0.006353137,0.015296107,0.97625935,0.00008137154,0.00006615572,0.00008504679,0.000056063447,0.000107171305,0.0011719367,0.000027271286],"about_ca_topic_score_codex":0.012732367,"about_ca_topic_score_gemma":0.033595636,"teacher_disagreement_score":0.01678829,"about_ca_system_score_codex":0.0021802648,"about_ca_system_score_gemma":0.0028662265,"threshold_uncertainty_score":0.033310533},"labels":[],"label_agreement":null},{"id":"W4385443610","doi":"10.1016/s1470-2045(23)00346-7","title":"Establishing a Lancet Oncology Commission on the humanitarian crisis of cancer","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Health and Conflict Studies","field":"Health Professions","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Scopus; Political science; Commission; Biomedicine; Cancer; Medicine; Legislation; Humanitarian crisis; MEDLINE; Law; Internal medicine","score_opus":0.3632203274188722,"score_gpt":0.550406581883935,"score_spread":0.18718625446506276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385443610","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006024448,0.003929745,0.00029619623,0.9581137,0.027506243,0.00003437731,0.000023445411,0.000013738975,0.009480169],"genre_scores_gemma":[0.04301777,0.005073699,0.0014987052,0.899602,0.022050388,0.00020658417,0.00007778859,0.0001275681,0.028345332],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9339551,0.03465446,0.0025763735,0.0022168562,0.014244643,0.012352467],"domain_scores_gemma":[0.7549037,0.13038917,0.010325189,0.0074435603,0.028192483,0.068746015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.09885399,0.0009865969,0.0019091316,0.0022179119,0.019329822,0.028047726,0.0038671202,0.0641626,0.014029102],"category_scores_gemma":[0.18571068,0.001161349,0.0013598287,0.003010478,0.028893316,0.02280812,0.02681088,0.07135707,0.0028719997],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000062789455,0.000061318744,0.00049089064,0.0002710316,0.000025910584,0.00024867745,0.004976481,0.000102786464,0.00017684902,0.15032429,0.8293271,0.013931913],"study_design_scores_gemma":[0.000059720227,0.000034450903,0.00038222494,0.00072862796,0.000011671357,0.000077593824,0.0067371875,0.000055194374,0.00013645049,0.03059937,0.9611303,0.00004720129],"about_ca_topic_score_codex":0.021218391,"about_ca_topic_score_gemma":0.03466715,"teacher_disagreement_score":0.09885399,"about_ca_system_score_codex":0.01728533,"about_ca_system_score_gemma":0.12676185,"threshold_uncertainty_score":0.52279615},"labels":[],"label_agreement":null},{"id":"W4385448612","doi":"10.1016/s1470-2045(23)00284-x","title":"Radiotherapy resources in Brazil (RT2030): a comprehensive analysis and projections for 2030","year":2023,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; Queen's University","funders":"","keywords":"Radiation therapy; Medicine; Workload; Action plan; Scarcity; Population; Health care; Economic growth; Environmental health; Surgery; Management","score_opus":0.1447072455974648,"score_gpt":0.5253753254294113,"score_spread":0.3806680798319465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385448612","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0089704385,0.9463308,0.0014647944,0.012283742,0.000525749,0.00008008687,0.02310904,0.000094020455,0.0071413848],"genre_scores_gemma":[0.0676845,0.9201152,0.002517473,0.0014908038,0.00019914916,0.00013219188,0.0067013022,0.000026465063,0.0011329914],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99939656,0.00013349151,0.00007380741,0.000049878283,0.00023989961,0.00010629128],"domain_scores_gemma":[0.9990545,0.00024870053,0.00028984234,0.000020199424,0.00027864348,0.00010808669],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015108053,0.0010156711,0.0010741916,0.003205436,0.00023998896,0.0011762141,0.0008991118,0.000611491,0.0039486913],"category_scores_gemma":[0.0032930437,0.000375813,0.0024610197,0.0073280837,0.0002935606,0.0010610779,0.0013273711,0.0010332365,0.0006178731],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049449614,0.00007692366,0.028085029,0.061310835,0.002922274,0.00057209673,0.00047017715,0.011091236,0.0011917608,0.02772983,0.09558809,0.7704673],"study_design_scores_gemma":[0.00011227261,0.00021914554,0.12217946,0.05035195,0.0038111254,0.0014814263,0.0011648454,0.004239908,0.0008724618,0.009203164,0.8062546,0.00010958192],"about_ca_topic_score_codex":0.13479528,"about_ca_topic_score_gemma":0.22574764,"teacher_disagreement_score":0.13479528,"about_ca_system_score_codex":0.0061774785,"about_ca_system_score_gemma":0.015009578,"threshold_uncertainty_score":0.26802135},"labels":[],"label_agreement":null},{"id":"W4385471203","doi":"10.1016/s1470-2045(23)00322-4","title":"Radical cystectomy vs trimodality therapy for muscle-invasive bladder cancer: further extensive evaluation needed – Authors' reply","year":2023,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; University of Toronto; University Health Network; Mount Sinai Hospital","funders":"","keywords":"Cystectomy; Bladder cancer; Medicine; Urology; Oncology; General surgery; Cancer; Internal medicine","score_opus":0.12795852453085177,"score_gpt":0.4080312789043165,"score_spread":0.28007275437346474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385471203","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013740551,0.0010649139,0.00003133586,0.9802874,0.017813284,0.0000045857387,0.00005369743,0.0000073297156,0.0006001042],"genre_scores_gemma":[0.0014293625,0.0006746809,0.000059133825,0.96931356,0.026939582,0.000018782648,0.0000259408,0.000010844778,0.0015281045],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99562114,0.0016480228,0.00059623824,0.0005525389,0.0009733504,0.00060868484],"domain_scores_gemma":[0.97936475,0.014867357,0.0009983518,0.0004068403,0.0025963401,0.0017663415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005480124,0.0006602989,0.0020312394,0.00082595577,0.0034193338,0.004056599,0.002281713,0.06574391,0.007108097],"category_scores_gemma":[0.0323879,0.00086046726,0.0016741228,0.0009649498,0.0034884082,0.0042814454,0.0023084548,0.057465006,0.0055309036],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008060371,0.000016901275,0.00035446853,0.00005961858,0.000027076812,0.00033552534,0.00009987899,0.000044336,0.000074087766,0.0014230252,0.9927135,0.0047710426],"study_design_scores_gemma":[0.0003484149,0.00011254863,0.0015558521,0.0005837568,0.00010860464,0.00088311656,0.0008014643,0.00033218093,0.00024696914,0.013227448,0.9816405,0.00015904961],"about_ca_topic_score_codex":0.006839368,"about_ca_topic_score_gemma":0.0120275,"teacher_disagreement_score":0.06574391,"about_ca_system_score_codex":0.0040077036,"about_ca_system_score_gemma":0.0056432546,"threshold_uncertainty_score":0.029078007},"labels":[],"label_agreement":null},{"id":"W4385471264","doi":"10.1016/s1470-2045(23)00287-5","title":"Metastatic seminoma masquerading as sarcoidosis","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; University of British Columbia","funders":"","keywords":"Sarcoidosis; Seminoma; Medicine; Dermatology; Internal medicine; Chemotherapy","score_opus":0.08985608337436563,"score_gpt":0.39786402364675794,"score_spread":0.3080079402723923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385471264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.35997832,0.35858497,0.003119562,0.12510851,0.017865336,0.00013718221,0.0013104738,0.00044795725,0.13344763],"genre_scores_gemma":[0.883816,0.05720863,0.0012820518,0.013236785,0.03396938,0.000013822527,0.00043026387,0.00004937016,0.009993722],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9997944,0.000044262775,0.000016795624,0.000035145178,0.000051609793,0.000057715068],"domain_scores_gemma":[0.99919635,0.00036143427,0.00014384773,0.00004855762,0.00007926849,0.00017059811],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002961324,0.00029337424,0.0007763703,0.00074562564,0.0005158313,0.0008574341,0.00024255755,0.001981719,0.0058407723],"category_scores_gemma":[0.0017169219,0.00021597206,0.0003607126,0.00075896434,0.0006584093,0.0006018549,0.00030047508,0.0016272446,0.0011977479],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001449769,0.00017786316,0.09704785,0.002023613,0.00040641843,0.5525721,0.00035626322,0.00088386727,0.021350965,0.015908167,0.12556478,0.18225837],"study_design_scores_gemma":[0.0003735535,0.00037089505,0.044109594,0.00062962895,0.00023514584,0.8569605,0.00040999486,0.0009780603,0.0024246573,0.007869668,0.08560249,0.000035842517],"about_ca_topic_score_codex":0.0008819002,"about_ca_topic_score_gemma":0.0025948207,"teacher_disagreement_score":0.0058407723,"about_ca_system_score_codex":0.00048397036,"about_ca_system_score_gemma":0.00046304148,"threshold_uncertainty_score":0.019539356},"labels":[],"label_agreement":null},{"id":"W4386241120","doi":"10.1016/s1470-2045(23)00386-8","title":"Precision medicine for children with cancer","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Precision medicine; Cancer Medicine; Medicine; Cancer; Medical physics; Internal medicine; Pathology","score_opus":0.030050324620537326,"score_gpt":0.3426169021118465,"score_spread":0.31256657749130917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386241120","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015103709,0.4121802,0.004229524,0.5409907,0.0137274815,0.000024235771,0.0009597394,0.00028845362,0.026089348],"genre_scores_gemma":[0.0974245,0.57837605,0.01609555,0.23403038,0.054918658,0.00017147076,0.0013157488,0.00020439918,0.017463244],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975545,0.0010586458,0.00014074976,0.00028347163,0.0007336952,0.00022886481],"domain_scores_gemma":[0.9851509,0.009818618,0.0013440556,0.0010683464,0.0013204484,0.0012976072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055934726,0.0006711505,0.0010301674,0.001306636,0.00094548037,0.0023787653,0.0008076467,0.0037495506,0.0137327975],"category_scores_gemma":[0.022829758,0.00030183085,0.00088361185,0.0009857016,0.0024848012,0.0029738646,0.0029281334,0.007658964,0.0024050327],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012095227,0.000037846206,0.0037500153,0.0013433017,0.00021324998,0.00035956813,0.00036117772,0.00041119987,0.00057690387,0.09987951,0.579769,0.31317723],"study_design_scores_gemma":[0.000097206284,0.00009717736,0.003919095,0.002042985,0.0001526929,0.0011227876,0.00027743037,0.00015577223,0.0005616045,0.110348456,0.88119084,0.00003407728],"about_ca_topic_score_codex":0.0031917195,"about_ca_topic_score_gemma":0.0037057367,"teacher_disagreement_score":0.0137327975,"about_ca_system_score_codex":0.0030947041,"about_ca_system_score_gemma":0.00465021,"threshold_uncertainty_score":0.045940757},"labels":[],"label_agreement":null},{"id":"W4386241167","doi":"10.1016/s1470-2045(23)00384-4","title":"Incorporating absolute effects to enrich interpretation of findings from meta-analyses","year":2023,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact; McMaster University","funders":"","keywords":"Nasopharyngeal carcinoma; Meta-analysis; Radiation therapy; Oncology; Medicine; Chemotherapy; Chemoradiotherapy; Internal medicine; Adjuvant chemotherapy; Carcinoma; Cancer","score_opus":0.2207518665985026,"score_gpt":0.4411331526312673,"score_spread":0.2203812860327647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386241167","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00083108986,0.026452782,0.008070428,0.91135645,0.048763596,0.00012164988,0.0010982251,0.0002200546,0.0030857862],"genre_scores_gemma":[0.014943104,0.0056014475,0.01313978,0.87883246,0.08498905,0.00032516677,0.00016637148,0.00025479327,0.0017477527],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.6782483,0.25815913,0.029825281,0.008862773,0.023152944,0.0017515571],"domain_scores_gemma":[0.17047171,0.7798988,0.011751741,0.017065693,0.018258465,0.0025535387],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.24050082,0.0022710855,0.00852321,0.005567659,0.0024710805,0.011481697,0.0076767537,0.036595676,0.0072263572],"category_scores_gemma":[0.7007897,0.0030812144,0.009107106,0.005545468,0.006547864,0.012478953,0.0059497776,0.04198813,0.004605625],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002397058,0.000088670604,0.0053328415,0.006116813,0.01515389,0.00203351,0.0010735438,0.0010961043,0.0005894314,0.01681246,0.8285387,0.120766915],"study_design_scores_gemma":[0.007697519,0.00065813493,0.0076657473,0.015951185,0.021958603,0.0038342117,0.00087708613,0.0075302073,0.001903821,0.36694533,0.5639992,0.000979026],"about_ca_topic_score_codex":0.004604464,"about_ca_topic_score_gemma":0.0096825035,"teacher_disagreement_score":0.7594992,"about_ca_system_score_codex":0.0043204357,"about_ca_system_score_gemma":0.006831735,"threshold_uncertainty_score":0.9365977},"labels":[],"label_agreement":null},{"id":"W4386243714","doi":"10.1016/s1470-2045(23)00344-3","title":"Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Microbial Inactivation Methods","field":"Biochemistry, Genetics and Molecular Biology","cited_by":101,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"National Institutes of Health; Novocure","keywords":"Systemic therapy; Medicine; Lung cancer; Oncology; Cancer therapy; Cancer; Internal medicine; Breast cancer","score_opus":0.07348996886503766,"score_gpt":0.4277260181715512,"score_spread":0.35423604930651353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386243714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925835,0.0033641935,0.0004288383,0.00037327968,0.0003689428,0.00093492784,0.0003971382,0.0000783143,0.0014708037],"genre_scores_gemma":[0.99093986,0.0024646732,0.0008997612,0.00054216554,0.0003217903,0.0010258446,0.0005836867,0.000028884035,0.0031933854],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99951196,0.0002376435,0.000017543542,0.000092135204,0.000036622474,0.00010414371],"domain_scores_gemma":[0.99937016,0.00021507176,0.00012493352,0.000056156106,0.000028720022,0.00020499894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014822425,0.0013010355,0.0031050413,0.0005412997,0.00032342938,0.001234524,0.0007533568,0.0015152682,0.005742455],"category_scores_gemma":[0.0009969115,0.00052673084,0.0021614558,0.00047242033,0.001324818,0.0012398332,0.0004142474,0.003149091,0.00082759437],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9449683,0.014390511,0.0006636797,0.0005288165,0.0007241937,0.000029348155,0.00006214735,0.00081317633,0.0048601846,0.00014671727,0.00087858347,0.031934306],"study_design_scores_gemma":[0.5636612,0.42810434,0.0040421467,0.00006186782,0.0006108709,0.000057770023,0.000059337675,0.00091772666,0.001282428,0.00032131036,0.000855202,0.000025751315],"about_ca_topic_score_codex":0.0010277476,"about_ca_topic_score_gemma":0.0028402428,"teacher_disagreement_score":0.005742455,"about_ca_system_score_codex":0.000982122,"about_ca_system_score_gemma":0.0008696976,"threshold_uncertainty_score":0.019210458},"labels":[],"label_agreement":null},{"id":"W4386243741","doi":"10.1016/s1470-2045(23)00268-1","title":"Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Genentech; F. Hoffmann-La Roche; Roche; Amgen","keywords":"Anastrozole; Medicine; Palbociclib; Breast cancer; Internal medicine; Oncology; Clinical endpoint; Cancer; Gynecology; Regimen; Phases of clinical research; Tamoxifen; Clinical trial; Metastatic breast cancer","score_opus":0.07426775205635529,"score_gpt":0.41728094600258087,"score_spread":0.3430131939462256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386243741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880035,0.0022780546,0.00036231714,0.0003875517,0.00032940824,0.0060491064,0.0010040503,0.00009346755,0.0014924674],"genre_scores_gemma":[0.9762146,0.0027518158,0.002378757,0.00093118876,0.0006755378,0.011756767,0.0014172553,0.00003462491,0.0038395515],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99887735,0.00062205415,0.000066956694,0.0001812186,0.00010126999,0.00015118885],"domain_scores_gemma":[0.99859434,0.00035859094,0.00030827848,0.00013762068,0.00007568325,0.0005254065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030457147,0.0019299733,0.0038214962,0.0008487368,0.00048169863,0.001110224,0.0013743732,0.001764547,0.0068524205],"category_scores_gemma":[0.0017968247,0.0012688634,0.0014657805,0.00069924287,0.0016857842,0.0013849891,0.0006095463,0.0028782727,0.0014272669],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96320057,0.02005138,0.0005982051,0.00048439737,0.00029822413,0.000031415868,0.00004696834,0.0002619561,0.0046942146,0.00006039465,0.00039417087,0.009878214],"study_design_scores_gemma":[0.8103378,0.18749295,0.0010365084,0.000017473014,0.00014457185,0.000023991599,0.000014168413,0.00012684344,0.00033655905,0.00004461499,0.0004141571,0.000010322123],"about_ca_topic_score_codex":0.0013415068,"about_ca_topic_score_gemma":0.0032437195,"teacher_disagreement_score":0.0068524205,"about_ca_system_score_codex":0.001106741,"about_ca_system_score_gemma":0.0023907484,"threshold_uncertainty_score":0.022923648},"labels":[],"label_agreement":null},{"id":"W4386263948","doi":"10.1016/s1470-2045(23)00320-0","title":"Financial hardship in families of children or adolescents with cancer: a systematic literature review","year":2023,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University","funders":"National Cancer Institute; World Health Organization","keywords":"Psychosocial; Psychological intervention; Childhood cancer; Finance; Public economics; Psychology; Economics; Cancer; Medicine; Psychiatry","score_opus":0.1008015807198064,"score_gpt":0.4195214927809506,"score_spread":0.3187199120611442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386263948","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017296161,0.9974045,0.000023481938,0.00021440815,0.00006997633,0.000046719546,0.00040207568,0.0000019060963,0.00010727132],"genre_scores_gemma":[0.024058968,0.9749165,0.00017921795,0.0004605809,0.00004601895,0.0001175636,0.000161794,0.0000017737611,0.000057466827],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9973851,0.0007959763,0.00094855035,0.00026697258,0.0004257266,0.00017763801],"domain_scores_gemma":[0.98573536,0.009799418,0.0034346087,0.00013773066,0.00057201536,0.00032077287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035471471,0.0010436559,0.0047155507,0.0071554985,0.0005082299,0.0021231207,0.00094683573,0.0017162298,0.0050494997],"category_scores_gemma":[0.022083959,0.0008979984,0.006370485,0.0097793685,0.0006471528,0.0018095288,0.0020190764,0.0014708681,0.00017574591],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021495213,0.000038333044,0.009317565,0.91067874,0.022872487,0.00023064228,0.0005170374,0.00014428904,0.0000761015,0.00027820427,0.0038849856,0.05174668],"study_design_scores_gemma":[0.00029958508,0.00016610252,0.031534795,0.8436104,0.10251033,0.0006791806,0.0013835537,0.00006540355,0.00006394815,0.00032686561,0.019288672,0.000071194685],"about_ca_topic_score_codex":0.023367992,"about_ca_topic_score_gemma":0.08590479,"teacher_disagreement_score":0.023367992,"about_ca_system_score_codex":0.0032968489,"about_ca_system_score_gemma":0.008937785,"threshold_uncertainty_score":0.046463966},"labels":[],"label_agreement":null},{"id":"W4386631299","doi":"10.1016/s1470-2045(23)00382-0","title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":288,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Merck Sharp and Dohme; Genentech; EMD Serono; Bavarian Nordic; Astellas Pharma; Sanofi; Exelixis; Advanced Accelerator Applications; Endocyte; Janssen Pharmaceuticals; Invitae; Gilead Sciences; Merck; Amgen; Pfizer; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Ipsen; BeiGene; Constellation Pharmaceuticals","keywords":"Abiraterone; Prostate cancer; Medicine; Placebo; Olaparib; Urology; Abiraterone acetate; Internal medicine; Oncology; Double blind; Androgen deprivation therapy; Cancer; Androgen receptor; Poly ADP ribose polymerase","score_opus":0.313893449351758,"score_gpt":0.459480059444977,"score_spread":0.145586610093219,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386631299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97621346,0.010911421,0.001361222,0.0013834278,0.0013251081,0.0029322617,0.0019193891,0.00045843166,0.0034953223],"genre_scores_gemma":[0.9823423,0.0045656106,0.0018015086,0.0012795837,0.00073934044,0.0025681586,0.0012795225,0.0000699616,0.005353998],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99919134,0.00047718137,0.000047202586,0.00012375554,0.000052518368,0.00010801875],"domain_scores_gemma":[0.9984567,0.00066096144,0.00030002283,0.00012768274,0.00006884808,0.00038575035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002159244,0.0023611384,0.0033319043,0.0006105903,0.0005144275,0.0015972401,0.0011132827,0.0018633885,0.007873175],"category_scores_gemma":[0.002771212,0.0007547368,0.00278788,0.0005263145,0.0015075288,0.0016022369,0.0005491653,0.0037465007,0.001431625],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9884332,0.0010537781,0.00010518042,0.00040202014,0.00053829415,0.000016866592,0.000032077234,0.00023854346,0.0007605168,0.00006017259,0.00035526368,0.008004147],"study_design_scores_gemma":[0.97580045,0.022689015,0.00039222874,0.000027405007,0.00026219653,0.00001945305,0.000015088971,0.00019736894,0.00015931971,0.00017061972,0.0002535817,0.000013133989],"about_ca_topic_score_codex":0.0011938865,"about_ca_topic_score_gemma":0.0025414168,"teacher_disagreement_score":0.007873175,"about_ca_system_score_codex":0.00082192535,"about_ca_system_score_gemma":0.0012473238,"threshold_uncertainty_score":0.026338398},"labels":[],"label_agreement":null},{"id":"W4387246665","doi":"10.1016/s1470-2045(23)00464-3","title":"Common Sense Oncology: including everyone – Authors' reply","year":2023,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Internal medicine; Oncology; Medicine; Geriatric oncology; Cancer","score_opus":0.1723274002211334,"score_gpt":0.4288289530329309,"score_spread":0.2565015528117975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387246665","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009569268,0.0004709959,0.00001506867,0.978227,0.020681169,0.0000043517625,0.000016082608,0.0000069301236,0.0004827452],"genre_scores_gemma":[0.0009928296,0.00026798577,0.000030437672,0.9786033,0.017951936,0.00001976854,0.000010435028,0.000011417491,0.0021118352],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.990464,0.002302345,0.0010163069,0.0012648782,0.002935399,0.0020171122],"domain_scores_gemma":[0.9613897,0.020481449,0.0029701565,0.0009047846,0.005453184,0.008800724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0073271818,0.0010759599,0.0025611378,0.0011772616,0.009945115,0.00928879,0.0034097363,0.11881457,0.012451764],"category_scores_gemma":[0.057429906,0.001737954,0.002146939,0.0012821002,0.0073691313,0.0067927884,0.0068531926,0.106219254,0.0064269877],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015310417,0.000009522061,0.00026478778,0.00003905866,0.000014360261,0.00038482956,0.00027623048,0.000025029267,0.00004525939,0.0014003487,0.99558383,0.0019415143],"study_design_scores_gemma":[0.00012880164,0.0000631839,0.0011801104,0.0005825881,0.00006878893,0.0013162923,0.0023082106,0.00018598909,0.00015920663,0.007759137,0.98610824,0.00013954497],"about_ca_topic_score_codex":0.0090965275,"about_ca_topic_score_gemma":0.015499994,"teacher_disagreement_score":0.11881457,"about_ca_system_score_codex":0.0085796425,"about_ca_system_score_gemma":0.013502499,"threshold_uncertainty_score":0.06224996},"labels":[],"label_agreement":null},{"id":"W4387246862","doi":"10.1016/s1470-2045(23)00387-x","title":"Dysphagia-optimised intensity-modulated radiotherapy versus standard radiotherapy in patients with pharyngeal cancer","year":2023,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Dysphagia; Radiation therapy; Medicine; Swallowing; Head and neck cancer; Radiology; Pharynx; Intensity (physics); Surgery; Optics","score_opus":0.05071362834495731,"score_gpt":0.35270245032102643,"score_spread":0.30198882197606913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387246862","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07882631,0.07820412,0.00027845273,0.7910579,0.023236057,0.00020137698,0.0010473178,0.000045062792,0.027103404],"genre_scores_gemma":[0.39623138,0.032041777,0.0012355986,0.52311337,0.034847315,0.00050627225,0.00063135015,0.00007719899,0.011315735],"study_design_codex":"not_applicable","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9985789,0.00088434166,0.00016843858,0.00010006836,0.00013557312,0.00013264934],"domain_scores_gemma":[0.99550503,0.0032296632,0.00040226002,0.00011247011,0.00019911282,0.00055139797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028532096,0.0002761937,0.0011674428,0.00030861335,0.00058976136,0.001121559,0.00075989106,0.0059333043,0.007452121],"category_scores_gemma":[0.014555188,0.00025102758,0.0013191666,0.000813841,0.00070569577,0.0011390386,0.00060811534,0.0042607305,0.0011583782],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08948936,0.0011241377,0.019318216,0.0046633417,0.0020386393,0.0029537817,0.0006417081,0.00322857,0.0023157673,0.0041397586,0.4514641,0.41862255],"study_design_scores_gemma":[0.096059136,0.032984033,0.13331929,0.008281548,0.008368518,0.0058051287,0.0023676613,0.00543322,0.0030425647,0.03489271,0.66910815,0.00033804792],"about_ca_topic_score_codex":0.0054253866,"about_ca_topic_score_gemma":0.018294489,"teacher_disagreement_score":0.007452121,"about_ca_system_score_codex":0.0038981263,"about_ca_system_score_gemma":0.0021951632,"threshold_uncertainty_score":0.02828306},"labels":[],"label_agreement":null},{"id":"W4387610595","doi":"10.1016/s1470-2045(23)00473-4","title":"Immunotherapy in renal cell carcinoma","year":2023,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Nivolumab; Ipilimumab; Medicine; Renal cell carcinoma; Oncology; Internal medicine; Immunotherapy; Sunitinib; Kidney cancer; Cancer","score_opus":0.06913184320899503,"score_gpt":0.32171012868270427,"score_spread":0.25257828547370925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387610595","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021324703,0.004175075,0.000053649244,0.9657953,0.02420334,0.0000122262645,0.000031361775,0.00001291888,0.005502948],"genre_scores_gemma":[0.0027347421,0.0021197593,0.000075593765,0.93572885,0.048969276,0.000027831762,0.000023935389,0.000017897517,0.010302144],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99558276,0.0013839476,0.00038643408,0.00041818127,0.0014152464,0.00081338064],"domain_scores_gemma":[0.99137115,0.004842856,0.00057254557,0.00024322051,0.00087953015,0.002090645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004669635,0.00096154126,0.0017403216,0.0011144143,0.0063981223,0.00659123,0.0018505544,0.090650626,0.010299513],"category_scores_gemma":[0.023859292,0.00093968824,0.0017076936,0.00096066674,0.004074317,0.0043187416,0.0032918216,0.054098018,0.0063815806],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000049667546,0.000022195463,0.00027029272,0.00005137354,0.000016248385,0.0008356522,0.00007506939,0.00008007435,0.00011402263,0.005003454,0.9852632,0.008218787],"study_design_scores_gemma":[0.00017908751,0.00006858042,0.0007796638,0.00044363024,0.000039625986,0.0011455399,0.00017845396,0.00046347955,0.00018608946,0.0136632165,0.9828042,0.000048480953],"about_ca_topic_score_codex":0.011608813,"about_ca_topic_score_gemma":0.024772001,"teacher_disagreement_score":0.090650626,"about_ca_system_score_codex":0.0075898306,"about_ca_system_score_gemma":0.007835522,"threshold_uncertainty_score":0.055068314},"labels":[],"label_agreement":null},{"id":"W4388226965","doi":"10.1016/s1470-2045(23)00521-1","title":"Investing in gender equality and equitable access improves outcomes","year":2023,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Commission; Medicine; Cancer; Workforce; Global health; Scopus; Health care; Family medicine; MEDLINE; Political science; Nursing; Public health; Internal medicine; Law","score_opus":0.22837828759137463,"score_gpt":0.5009419345273847,"score_spread":0.27256364693601004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388226965","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011616462,0.0006228444,0.000035025376,0.9909979,0.006771449,0.000002318371,0.000016162034,0.0000052523155,0.0014329458],"genre_scores_gemma":[0.0027985568,0.0009839273,0.000080823265,0.96530795,0.026754182,0.000018683491,0.000014386754,0.00001761601,0.004023823],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99136484,0.0028184068,0.0006713128,0.000721239,0.002580597,0.0018436523],"domain_scores_gemma":[0.96271515,0.024455996,0.001770811,0.0008234274,0.0031821993,0.007052373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0103438245,0.00085956993,0.0017093916,0.00082691293,0.006152689,0.0076656425,0.0018495136,0.0932395,0.018385801],"category_scores_gemma":[0.070429556,0.0008492473,0.0015088639,0.0010469228,0.007713853,0.0075755096,0.005479007,0.06862229,0.008049505],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004735114,0.000028459126,0.0004546496,0.00006920764,0.00002340234,0.00037989137,0.00021985921,0.000066975044,0.00009962004,0.013334042,0.97413015,0.011146441],"study_design_scores_gemma":[0.00022669412,0.00007551597,0.0009321261,0.00056178676,0.000050995794,0.0007608303,0.000754704,0.00031573666,0.00022344298,0.0583572,0.9376845,0.000056395165],"about_ca_topic_score_codex":0.009649616,"about_ca_topic_score_gemma":0.017779667,"teacher_disagreement_score":0.0932395,"about_ca_system_score_codex":0.007407367,"about_ca_system_score_gemma":0.013946901,"threshold_uncertainty_score":0.06150663},"labels":[],"label_agreement":null},{"id":"W4388227008","doi":"10.1016/s1470-2045(23)00484-9","title":"Cancer surgery: orchestrating cancer control by strengthening health systems","year":2023,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Commission; Global health; Cancer; Medicine; Scopus; Cancer surgery; Health care; Family medicine; Political science; MEDLINE; Nursing; Law; Public health; Internal medicine","score_opus":0.08129784435503122,"score_gpt":0.441601480565986,"score_spread":0.3603036362109548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388227008","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007363081,0.0010096612,0.000064991174,0.98787296,0.010161294,0.0000033491058,0.000012806933,0.00000995682,0.00079127477],"genre_scores_gemma":[0.0018755576,0.0011407152,0.00018620696,0.9652243,0.028178187,0.000025234764,0.000011903858,0.000017450062,0.0033404357],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9903729,0.0033027588,0.00064276234,0.0009999344,0.0028590872,0.0018226126],"domain_scores_gemma":[0.97122663,0.016460454,0.001563704,0.0008011561,0.00312034,0.0068276348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010519826,0.001367867,0.0017480113,0.0007657629,0.0055859135,0.0085783815,0.0028128335,0.086563945,0.013666654],"category_scores_gemma":[0.042012315,0.0010178641,0.0016810114,0.001052568,0.009032355,0.012566025,0.00634015,0.068578325,0.008572925],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043935146,0.000029523144,0.00022942982,0.000098713426,0.000022127635,0.00024161843,0.00018065052,0.000071893046,0.00016442082,0.0073612407,0.9820134,0.009543049],"study_design_scores_gemma":[0.00016365635,0.00006231126,0.0005785744,0.00026479064,0.000029907276,0.00031910103,0.0007227471,0.00034211628,0.00019936578,0.033074174,0.96417314,0.000070120666],"about_ca_topic_score_codex":0.00985858,"about_ca_topic_score_gemma":0.018460779,"teacher_disagreement_score":0.086563945,"about_ca_system_score_codex":0.007467949,"about_ca_system_score_gemma":0.015599705,"threshold_uncertainty_score":0.055634856},"labels":[],"label_agreement":null},{"id":"W4388657015","doi":"10.1016/s1470-2045(23)00510-7","title":"Development and validation of age-specific risk prediction models for primary ovarian insufficiency in long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study and St Jude Lifetime Cohort","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Reproductive Biology and Fertility","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Alberta","funders":"National Cancer Institute; Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Canadian Cancer Society; Canadian Centre for Applied Research in Cancer Control","keywords":"Childhood cancer; Medicine; Cancer; Ovarian cancer; Term (time); Pediatrics; Oncology; Internal medicine","score_opus":0.04398770063291266,"score_gpt":0.3167914911038883,"score_spread":0.2728037904709757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388657015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98799384,0.00052035984,0.0063116187,0.00033264683,0.00007446638,0.00010116181,0.003918078,0.000099416655,0.0006483936],"genre_scores_gemma":[0.98862374,0.00024256727,0.004978038,0.000054883578,0.000030195974,0.000089277564,0.0054360814,0.00003101836,0.0005141392],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763954,0.0011684465,0.00020811673,0.00041712815,0.00038920797,0.00017753527],"domain_scores_gemma":[0.9876023,0.0071061864,0.001283832,0.0015726974,0.0019842887,0.00045067046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014495669,0.0010156285,0.0007637678,0.0012226659,0.0005560038,0.0017725982,0.0015816649,0.0008730898,0.00079529296],"category_scores_gemma":[0.021479536,0.0005576161,0.0017944956,0.0009795281,0.00029280977,0.0008143236,0.0013077921,0.0016229887,0.0004214154],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003989631,0.00016595458,0.9834042,0.000021020189,0.00065245095,0.000040517934,0.00015050752,0.0034980483,0.00019292052,0.00014448089,0.0011151688,0.0102157835],"study_design_scores_gemma":[0.00016471605,0.0004045098,0.91297996,0.00006482398,0.0011564774,0.00023777067,0.00055199914,0.08077429,0.00089009217,0.00086683827,0.0018568716,0.00005160309],"about_ca_topic_score_codex":0.022583233,"about_ca_topic_score_gemma":0.023396883,"teacher_disagreement_score":0.022583233,"about_ca_system_score_codex":0.00092250446,"about_ca_system_score_gemma":0.0018808589,"threshold_uncertainty_score":0.07666135},"labels":[],"label_agreement":null},{"id":"W4389606368","doi":"10.1016/s1470-2045(23)00540-5","title":"Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"National Health and Medical Research Council; F. Hoffmann-La Roche; Roche","keywords":"Metastatic Urothelial Carcinoma; Atezolizumab; Medicine; Chemotherapy; Placebo; Oncology; Internal medicine; Urothelial carcinoma; Carcinoma; Urology; Cancer; Bladder cancer; Immunotherapy; Pathology; Pembrolizumab","score_opus":0.0867280660593854,"score_gpt":0.389108017368519,"score_spread":0.30237995130913364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389606368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98772836,0.007406757,0.00057813467,0.0005645551,0.0004937624,0.0010076517,0.00091519306,0.00010850876,0.0011971325],"genre_scores_gemma":[0.98950493,0.003557025,0.0010223121,0.00079245766,0.0003737956,0.0011732375,0.0010519532,0.00004346268,0.002480807],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.999119,0.0005821043,0.000040294737,0.00011118606,0.000043727552,0.000103696715],"domain_scores_gemma":[0.99882954,0.0004952296,0.00026066648,0.000095215386,0.000045478362,0.00027394047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002447834,0.0015585263,0.0038839744,0.00045612545,0.00027563944,0.0009772088,0.0010051314,0.0016454888,0.003883353],"category_scores_gemma":[0.0018786597,0.00055296964,0.0040344414,0.000478786,0.0011538211,0.0010808819,0.00051705656,0.0035237167,0.00056121044],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97847086,0.002370902,0.00036946137,0.0006056208,0.0011560139,0.00001774415,0.000040509804,0.00045412875,0.0016869358,0.000057867903,0.00040349332,0.014366426],"study_design_scores_gemma":[0.87767124,0.11685152,0.0028443336,0.0000503334,0.0012418907,0.00002694551,0.0000286659,0.00043021882,0.00032967154,0.0001269243,0.00037907725,0.000019072675],"about_ca_topic_score_codex":0.0010916668,"about_ca_topic_score_gemma":0.0022819855,"teacher_disagreement_score":0.0038839744,"about_ca_system_score_codex":0.0008049407,"about_ca_system_score_gemma":0.00079083827,"threshold_uncertainty_score":0.01299113},"labels":[],"label_agreement":null},{"id":"W4389608093","doi":"10.1016/s1470-2045(23)00539-9","title":"Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"National Health and Medical Research Council; F. Hoffmann-La Roche; Roche","keywords":"Atezolizumab; Metastatic Urothelial Carcinoma; Medicine; Placebo; Internal medicine; Oncology; Chemotherapy; Cancer; Bladder cancer; Pembrolizumab; Immunotherapy; Urothelial carcinoma; Pathology","score_opus":0.09030359634918199,"score_gpt":0.3988979223683898,"score_spread":0.3085943260192078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389608093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98911333,0.006192375,0.000561239,0.0005428115,0.00035595408,0.0009815665,0.0010547573,0.000082150014,0.0011158064],"genre_scores_gemma":[0.99026954,0.003238754,0.000940089,0.0008658061,0.00030155273,0.0010645099,0.001468406,0.000042709395,0.0018087851],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988538,0.0007689408,0.000046875277,0.00013233807,0.000056888868,0.00014108318],"domain_scores_gemma":[0.9986511,0.0005309389,0.000295138,0.00012521994,0.000052475007,0.00034513604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031022115,0.0015950934,0.0040322575,0.00045789976,0.0002824046,0.0011386452,0.0010315051,0.0016391496,0.0039554113],"category_scores_gemma":[0.001988091,0.0005847834,0.004560413,0.0005504429,0.0012671031,0.0011940058,0.0005973977,0.0038066853,0.0005822945],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97668856,0.00235711,0.0006127163,0.0006629347,0.0016831679,0.000027158927,0.00005213308,0.00064121024,0.0021013974,0.000073829695,0.0005270866,0.01457278],"study_design_scores_gemma":[0.8800161,0.11270452,0.0041332734,0.000055539607,0.0016306704,0.000036356607,0.000036134177,0.00043897124,0.00029269452,0.00015644204,0.00047377913,0.000025588512],"about_ca_topic_score_codex":0.001122855,"about_ca_topic_score_gemma":0.002690268,"teacher_disagreement_score":0.0040322575,"about_ca_system_score_codex":0.00090334826,"about_ca_system_score_gemma":0.000902699,"threshold_uncertainty_score":0.016406238},"labels":[],"label_agreement":null},{"id":"W4390490764","doi":"10.1016/s1470-2045(23)00513-2","title":"Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS)","year":2024,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Cancer Council Tasmania; Cancer Council Victoria","keywords":"Medicine; Radiosurgery; Guideline; Renal cell carcinoma; Stereotactic biopsy; Radiology; Radiation therapy; Biopsy; Oncology; Pathology","score_opus":0.08282780186880907,"score_gpt":0.38686672395237626,"score_spread":0.3040389220835672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390490764","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003067377,0.9951709,0.00048788832,0.0015175474,0.0004133482,0.0005160527,0.0010500096,0.000036360452,0.00050118193],"genre_scores_gemma":[0.0036957522,0.9908455,0.002014901,0.0017466415,0.00012197546,0.0006112576,0.0005745455,0.000014643849,0.00037479744],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9952495,0.0013924388,0.001952984,0.00038054693,0.0008826578,0.00014173539],"domain_scores_gemma":[0.9886623,0.0059801745,0.003373539,0.00020361523,0.0015498379,0.00023046699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008356415,0.0014013362,0.0067054317,0.0074781105,0.0005248384,0.0020597363,0.0021053455,0.0020829728,0.004746668],"category_scores_gemma":[0.023175057,0.00090782123,0.0075019235,0.0068886494,0.0006392115,0.0019288706,0.0015669508,0.0015800701,0.00082770566],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026017101,0.000019777075,0.000628173,0.8607075,0.013157982,0.000084592284,0.00014164421,0.00027411038,0.0003678038,0.0006633361,0.022704713,0.10099018],"study_design_scores_gemma":[0.00089003274,0.00018016668,0.003816723,0.7957759,0.090650484,0.00036836078,0.0001315592,0.00022194382,0.00032422086,0.001326324,0.10623159,0.00008263009],"about_ca_topic_score_codex":0.017000554,"about_ca_topic_score_gemma":0.050841838,"teacher_disagreement_score":0.017000554,"about_ca_system_score_codex":0.004037023,"about_ca_system_score_gemma":0.011831092,"threshold_uncertainty_score":0.044193447},"labels":[],"label_agreement":null},{"id":"W4391329053","doi":"10.1016/s1470-2045(24)00027-5","title":"Primary ovarian insufficiency prediction in adult survivors of childhood cancer: model concerns – Authors' reply","year":2024,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; Natural Sciences and Engineering Research Council of Canada; National Institutes of Health","keywords":"Childhood cancer; Ovarian cancer; Medicine; Cancer; Primary (astronomy); Oncology; Internal medicine; Physics","score_opus":0.04994628448906693,"score_gpt":0.3439204968099209,"score_spread":0.29397421232085397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391329053","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00040010223,0.0007215686,0.00007677707,0.98796624,0.010209425,0.000006881658,0.00028692355,0.000011527674,0.00032054333],"genre_scores_gemma":[0.009274435,0.001308927,0.00039210555,0.9516642,0.03541944,0.00012663339,0.00026139844,0.000036215944,0.0015166191],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949509,0.0028653948,0.0006665996,0.0005340398,0.00065879896,0.00032435337],"domain_scores_gemma":[0.9245796,0.062051784,0.0017291013,0.0013402476,0.0072120195,0.0030872782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01096812,0.0007669079,0.0023182924,0.00088805286,0.001976534,0.0028662768,0.0022126355,0.01994275,0.006763627],"category_scores_gemma":[0.09626279,0.00087353744,0.0017936929,0.0011622305,0.0018935303,0.002859471,0.0019983887,0.030230226,0.0034897067],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013576636,0.000033977314,0.005651422,0.0001258212,0.000100965575,0.00022676562,0.00017376794,0.0003233404,0.000028821738,0.00084873085,0.98255056,0.009800078],"study_design_scores_gemma":[0.0020873875,0.0004571981,0.018304728,0.0031183898,0.00095036055,0.0022532383,0.0031619393,0.009571666,0.00055396155,0.0426279,0.91628367,0.00062963687],"about_ca_topic_score_codex":0.016305016,"about_ca_topic_score_gemma":0.021338072,"teacher_disagreement_score":0.01994275,"about_ca_system_score_codex":0.0029572053,"about_ca_system_score_gemma":0.0055600503,"threshold_uncertainty_score":0.05800563},"labels":[],"label_agreement":null},{"id":"W4391329144","doi":"10.1016/s1470-2045(24)00010-x","title":"World Oncology Forum amplifies its appeal in global fight against cancer","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Public Health Policies and Epidemiology","field":"Business, Management and Accounting","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"World Health Organization","keywords":"Appeal; Political science; Psychological intervention; Medicine; Public relations; Law; Nursing","score_opus":0.08117751442663694,"score_gpt":0.39772835630743103,"score_spread":0.3165508418807941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391329144","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020557818,0.0029321907,0.00033236292,0.89601225,0.09393448,0.00000810876,0.00006248822,0.00004169371,0.0064709247],"genre_scores_gemma":[0.011471411,0.0026380937,0.0006546934,0.7928462,0.1711007,0.00005552976,0.00007054705,0.00017258541,0.020990126],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9796576,0.0051389276,0.0009769965,0.0014176029,0.009721532,0.0030872861],"domain_scores_gemma":[0.859527,0.10145748,0.0058712154,0.004790667,0.0128329545,0.015520768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03561382,0.0022882845,0.0019546694,0.0036387001,0.0072992593,0.021291973,0.0035112165,0.07896626,0.01723784],"category_scores_gemma":[0.12569323,0.001100569,0.002213342,0.0035196287,0.014580775,0.013846293,0.011621212,0.064486355,0.006102887],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030631614,0.000017845041,0.00017179265,0.00008070779,0.0000142921745,0.00011285524,0.00021552086,0.00007630046,0.000058660138,0.030375434,0.9588202,0.010025682],"study_design_scores_gemma":[0.0000424699,0.000025181833,0.00061642745,0.00036673,0.000023781162,0.00007257713,0.00033686945,0.00015559782,0.000096197036,0.017621424,0.98060054,0.000042217915],"about_ca_topic_score_codex":0.0075599994,"about_ca_topic_score_gemma":0.017127514,"teacher_disagreement_score":0.07896626,"about_ca_system_score_codex":0.005589445,"about_ca_system_score_gemma":0.009341785,"threshold_uncertainty_score":0.18834615},"labels":[],"label_agreement":null},{"id":"W4391329149","doi":"10.1016/s1470-2045(24)00002-0","title":"Accelerating progress on EU cancer control","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Global Health Research; University of Toronto","funders":"","keywords":"Cancer; Colorectal cancer; Prostate cancer; Lung cancer; Medicine; Breast cancer; Survivorship curve; Obesity; Cancer incidence; Incidence (geometry); Cause of death; Demography; Environmental health; Gerontology; Oncology; Internal medicine","score_opus":0.21879301528132017,"score_gpt":0.4667224805174229,"score_spread":0.2479294652361027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391329149","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002711018,0.13288201,0.0024069585,0.7600289,0.05333025,0.000034983917,0.0005726003,0.00028050155,0.04775274],"genre_scores_gemma":[0.19136384,0.1347213,0.010772149,0.56825805,0.043564655,0.000366975,0.0023760817,0.0004510064,0.04812596],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98926485,0.0047309236,0.00067000004,0.0008118861,0.0022125242,0.0023098506],"domain_scores_gemma":[0.98449564,0.0057523223,0.0012832315,0.0014003362,0.0022665216,0.0048019867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.021178335,0.0012958365,0.0020463248,0.0024481602,0.0017774242,0.007567054,0.0015416075,0.010498464,0.031261906],"category_scores_gemma":[0.03784873,0.0003994611,0.0017568592,0.0020747269,0.004157803,0.008807662,0.010494087,0.00989406,0.0049494556],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034790457,0.00021050016,0.0026036703,0.002474303,0.00024277765,0.00021081597,0.0012650888,0.0006938431,0.00061366893,0.20447797,0.5083884,0.2784711],"study_design_scores_gemma":[0.00011206068,0.00013754863,0.0042170295,0.0021823263,0.00006925686,0.0001053882,0.0013058966,0.00020190419,0.00024426842,0.042307425,0.949088,0.000028899092],"about_ca_topic_score_codex":0.0074132914,"about_ca_topic_score_gemma":0.0042900224,"teacher_disagreement_score":0.031261906,"about_ca_system_score_codex":0.005146626,"about_ca_system_score_gemma":0.019471841,"threshold_uncertainty_score":0.11200309},"labels":[],"label_agreement":null},{"id":"W4391329238","doi":"10.1016/s1470-2045(23)00516-8","title":"Treatment of metastatic pancreatic cancer: 25 years of innovation with little progress for patients","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Pancreatic cancer; Medicine; Cancer; Colorectal cancer; Lung cancer; Cause of death; Oncology; Clinical trial; Internal medicine; Overall survival; Disease","score_opus":0.08304822614337355,"score_gpt":0.42812021737297457,"score_spread":0.345071991229601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391329238","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00086477876,0.7100881,0.0016934904,0.26403895,0.020004302,0.00002583521,0.00018877978,0.0001758561,0.0029199524],"genre_scores_gemma":[0.028084379,0.7065323,0.006171894,0.17873605,0.07531159,0.00012700321,0.00069671264,0.00018792119,0.0041520707],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9838217,0.0066004214,0.0016929369,0.0014227559,0.0042084386,0.0022538193],"domain_scores_gemma":[0.9302208,0.043305054,0.0038199814,0.003312909,0.011156315,0.008185076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.047409113,0.002397276,0.005055794,0.0024051506,0.001871898,0.013799439,0.0048637507,0.014705541,0.0147658065],"category_scores_gemma":[0.059051555,0.00079166394,0.0040534483,0.0021997415,0.0093645295,0.020083994,0.0058610304,0.018092265,0.006176428],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022606992,0.0005497238,0.0012841551,0.009403774,0.0008856293,0.0004697331,0.0006092024,0.0016686488,0.0014075963,0.039842777,0.36323237,0.57838565],"study_design_scores_gemma":[0.0011467525,0.0015643178,0.002288972,0.014774663,0.0008369518,0.0006502386,0.0016376846,0.00079374947,0.0006365579,0.08309189,0.89232737,0.0002508371],"about_ca_topic_score_codex":0.003527474,"about_ca_topic_score_gemma":0.0053280797,"teacher_disagreement_score":0.047409113,"about_ca_system_score_codex":0.0059164516,"about_ca_system_score_gemma":0.013500824,"threshold_uncertainty_score":0.2507264},"labels":[],"label_agreement":null},{"id":"W4391329318","doi":"10.1016/s1470-2045(23)00568-5","title":"Quality indicators for evaluating cancer care in low-income and middle-income country settings: a multinational modified Delphi study","year":2024,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Delphi Technique in Research","field":"Social Sciences","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Medical Research Council; National Institute for Health and Care Research; World Health Organization","keywords":"Delphi method; Medicine; Quality (philosophy); Delphi; Inclusion (mineral); Health care; Business; Family medicine; Medical physics; Psychology; Computer science; Political science","score_opus":0.37051550147705,"score_gpt":0.6088117163114214,"score_spread":0.2382962148343714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391329318","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.031411055,0.9592204,0.0027887174,0.0020124083,0.00014456305,0.0027564648,0.0004322052,0.000013864921,0.0012203004],"genre_scores_gemma":[0.31993493,0.6465695,0.022264827,0.0013526734,0.00007190009,0.008595619,0.00092014956,0.000023064697,0.0002672939],"study_design_codex":"design_other","study_design_gemma":"qualitative","domain_scores_codex":[0.9314891,0.04722927,0.009700216,0.0014906267,0.008907419,0.0011833421],"domain_scores_gemma":[0.9040694,0.07501403,0.008737831,0.0017553273,0.009440396,0.0009829863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.12164005,0.0011552563,0.004529498,0.0069989255,0.00082853535,0.0034079235,0.0021392552,0.0013084917,0.0013968459],"category_scores_gemma":[0.12102183,0.0008110977,0.00562718,0.012286856,0.0012690205,0.003357443,0.0045834747,0.0022853415,0.00009726119],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013764277,0.00037367488,0.019821107,0.27131304,0.0115813585,0.000071903974,0.00658318,0.0010261592,0.00031357942,0.0042701964,0.0032941771,0.6799752],"study_design_scores_gemma":[0.0030319095,0.0045816367,0.19671091,0.6505352,0.04749104,0.0007651428,0.026503466,0.004467469,0.0014909008,0.0049340194,0.05893795,0.00055036537],"about_ca_topic_score_codex":0.011518215,"about_ca_topic_score_gemma":0.018301846,"teacher_disagreement_score":0.12164005,"about_ca_system_score_codex":0.008658913,"about_ca_system_score_gemma":0.018551739,"threshold_uncertainty_score":0.6433017},"labels":[],"label_agreement":null},{"id":"W4392179988","doi":"10.1016/s1470-2045(24)00032-9","title":"Use of radiotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study","year":2024,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Cancer Foundation; Government of New Brunswick; Cancer Care Nova Scotia; Health PEI; Saskatchewan Cancer Agency; St. John’s Health Sciences Centre; CancerCare Manitoba; Alberta Health Services; Cancer Care Ontario","funders":"Medical Research Council; NSW Ministry of Health; Saskatchewan Cancer Agency; Public Health Agency; Cancer Council Victoria; Partenariat Canadien Contre Le Cancer; Cancer Society of New Zealand; Ministry of Health, British Columbia; Cancer Institute NSW; Public Health England; Department of Health, State Government of Victoria; Alberta Health Services; Public Health Wales; Cancer Care Ontario; Cancer Research UK","keywords":"Medicine; Cancer registry; Pancreatic cancer; Colorectal cancer; Population; Cancer; Radiation therapy; Ovarian cancer; Internal medicine; Environmental health","score_opus":0.0853141961814186,"score_gpt":0.453001454189658,"score_spread":0.36768725800823937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392179988","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97093946,0.019192101,0.0011054481,0.00037455396,0.00007258848,0.00013094155,0.0070774932,0.000016207203,0.0010912952],"genre_scores_gemma":[0.9957209,0.0016976276,0.00031750707,0.00015370164,0.000025858959,0.000083222876,0.0019234485,0.0000063907946,0.00007132932],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994183,0.002538575,0.00087709766,0.0011934047,0.000873994,0.00033394567],"domain_scores_gemma":[0.99222636,0.0024786196,0.002959071,0.0009667465,0.0010696398,0.00029956724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006917855,0.00040942285,0.0010264067,0.0014213205,0.00044807568,0.0011818497,0.0010413161,0.0006673211,0.00074072793],"category_scores_gemma":[0.013358517,0.00049676176,0.0032252439,0.0043574474,0.00048350997,0.0006256045,0.000934735,0.00084993424,0.000105242136],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005520995,0.00004560761,0.9859958,0.00052915944,0.0078023234,0.000068452726,0.00020104031,0.00036780332,0.00007203612,0.00008371324,0.0006586193,0.003623434],"study_design_scores_gemma":[0.0001570127,0.0002362772,0.98991853,0.00036287177,0.0065911473,0.0002588623,0.0003748786,0.0006766277,0.00007337544,0.00014133738,0.0011805764,0.000028498556],"about_ca_topic_score_codex":0.050616026,"about_ca_topic_score_gemma":0.059300307,"teacher_disagreement_score":0.050616026,"about_ca_system_score_codex":0.0016275923,"about_ca_system_score_gemma":0.0014653926,"threshold_uncertainty_score":0.1006428},"labels":[],"label_agreement":null},{"id":"W4392180000","doi":"10.1016/s1470-2045(24)00021-4","title":"Data sharing in cancer research: perceived risks and the consequences of not sharing","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Pancreas Centre (Canada)","funders":"Cancer Research UK","keywords":"Data sharing; Component (thermodynamics); Uniqueness; Data science; Computer science; Research data; Open data; Internet privacy; Psychology; World Wide Web; Medicine; Data curation; Social psychology; Alternative medicine","score_opus":0.9394535900401945,"score_gpt":0.7188992211455324,"score_spread":0.22055436889466207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392180000","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":"methods","domain_gemma":"reproducibility","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"reproducibility","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09784828,0.012731996,0.037978888,0.8100595,0.0020767294,0.0003680815,0.00021674299,0.00007743939,0.038642425],"genre_scores_gemma":[0.92666346,0.0041845315,0.012271097,0.052308194,0.0020343766,0.0004940208,0.00010093958,0.00009235692,0.0018509367],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"qualitative","domain_scores_codex":[0.2934665,0.6293374,0.022786392,0.007016273,0.0415513,0.0058421064],"domain_scores_gemma":[0.11314197,0.74040157,0.060833827,0.045786206,0.024403,0.015433425],"candidate_categories":["metaresearch","open_science"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.4867934,0.00052992,0.0013928635,0.00261517,0.010692527,0.015286582,0.00413086,0.014060085,0.005344769],"category_scores_gemma":[0.685216,0.0012824984,0.0019505426,0.003747731,0.035775226,0.02519167,0.01755164,0.018309709,0.0008735961],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010402054,0.0005243963,0.08904256,0.0031250399,0.0017405032,0.0029378152,0.1680818,0.0026539457,0.001074833,0.45787945,0.043462217,0.22843733],"study_design_scores_gemma":[0.00027899165,0.0005025241,0.01619784,0.007328714,0.00047592464,0.0057403552,0.08366689,0.003374204,0.0010836585,0.78776944,0.093218446,0.00036296737],"about_ca_topic_score_codex":0.0039909757,"about_ca_topic_score_gemma":0.0038221932,"teacher_disagreement_score":0.99586916,"about_ca_system_score_codex":0.0076533193,"about_ca_system_score_gemma":0.028595923,"threshold_uncertainty_score":0.63287514},"labels":[],"label_agreement":null},{"id":"W4392180666","doi":"10.1016/s1470-2045(24)00031-7","title":"Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study","year":2024,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Cancer Foundation; Cancer Care Nova Scotia; Health PEI; Saskatchewan Cancer Agency; St. John’s Health Sciences Centre; CancerCare Manitoba; Alberta Health Services; Cancer Care Ontario","funders":"Medical Research Council; NSW Ministry of Health; Saskatchewan Cancer Agency; Public Health Agency; Cancer Council Victoria; Partenariat Canadien Contre Le Cancer; Cancer Society of New Zealand; Cancer Institute NSW; Public Health England; Department of Health, State Government of Victoria; Alberta Health Services; Public Health Wales; Cancer Care Ontario; Cancer Research UK","keywords":"Medicine; Cancer registry; Colorectal cancer; Pancreatic cancer; Internal medicine; Cancer; Population; Oncology","score_opus":0.11423523467180223,"score_gpt":0.4378918221408296,"score_spread":0.32365658746902737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392180666","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97711176,0.015076777,0.0010162566,0.00030272175,0.00006497641,0.00012754832,0.0053435224,0.000013996577,0.0009424149],"genre_scores_gemma":[0.99643826,0.001392307,0.00033232442,0.00013709703,0.000024580822,0.00007326632,0.0015320044,0.0000056070407,0.00006462636],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943879,0.0025689877,0.0007926227,0.0011299294,0.0008056077,0.0003148945],"domain_scores_gemma":[0.99280703,0.0023515744,0.0025973662,0.00094671664,0.000996578,0.00030083963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0067322073,0.00045118007,0.0010390739,0.0013442643,0.00045731987,0.0012173685,0.0009856644,0.00062642636,0.00076529954],"category_scores_gemma":[0.011421742,0.0005311906,0.0033177433,0.0041851127,0.00049373275,0.0005600973,0.00087940635,0.0008687671,0.000107664186],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006311834,0.000054812677,0.9851457,0.00045834607,0.009205196,0.000080036785,0.00020078059,0.00029238404,0.00008448153,0.00007725014,0.00061594445,0.0031538382],"study_design_scores_gemma":[0.00020908685,0.00024895853,0.9876452,0.00034358754,0.008767123,0.00027864755,0.00038144365,0.00075389404,0.00007025453,0.00014479127,0.0011278066,0.00002911754],"about_ca_topic_score_codex":0.048795316,"about_ca_topic_score_gemma":0.057888955,"teacher_disagreement_score":0.048795316,"about_ca_system_score_codex":0.0013887455,"about_ca_system_score_gemma":0.0014490912,"threshold_uncertainty_score":0.09702259},"labels":[],"label_agreement":null},{"id":"W4392180709","doi":"10.1016/s1470-2045(24)00016-0","title":"Surrogate endpoints in clinical trials of p16-positive squamous cell carcinoma of the oropharynx: an individual patient data meta-analysis","year":2024,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; National Institutes of Health; National Comprehensive Cancer Network; Georgia Research Alliance; NRG Oncology; Regeneron Pharmaceuticals; Castle Biosciences; Varian Medical Systems; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; Society for Immunotherapy of Cancer; University of Michigan","keywords":"Medicine; Clinical endpoint; Oncology; Radiation therapy; Internal medicine; Clinical trial; Cancer; Progression-free survival; Chemotherapy; Incidence (geometry); Stage (stratigraphy); Metastasis; Head and neck cancer; Surgery","score_opus":0.6678367344596181,"score_gpt":0.564782398172578,"score_spread":0.10305433628704008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392180709","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004792268,0.992132,0.0017112446,0.00022757343,0.00029515367,0.00014734529,0.00034690578,0.00003580992,0.00031169146],"genre_scores_gemma":[0.31367955,0.67681426,0.0044455356,0.0018442791,0.00048068175,0.00075069006,0.00105027,0.00010146888,0.0008332347],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9825251,0.01330874,0.002120615,0.0009867956,0.0007772379,0.0002814816],"domain_scores_gemma":[0.97638863,0.019824017,0.0021280053,0.0008475732,0.00058951235,0.0002221488],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.021465087,0.0027673682,0.01612141,0.0016918306,0.0002851942,0.0028439441,0.0018604527,0.0019843369,0.0039410954],"category_scores_gemma":[0.040026687,0.0013299095,0.034810502,0.002340373,0.00059950043,0.0017321167,0.0015177167,0.0041875774,0.00036173727],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011189077,0.000028143344,0.0014028613,0.12961763,0.833673,0.00007481003,0.000050706978,0.001354311,0.00023030215,0.00033285338,0.00087809836,0.021168243],"study_design_scores_gemma":[0.0055049057,0.00060957146,0.00229433,0.008953807,0.9777428,0.00008497238,0.00004061628,0.0005739532,0.00014021258,0.0010922923,0.002922684,0.000039825412],"about_ca_topic_score_codex":0.0024274809,"about_ca_topic_score_gemma":0.005965385,"teacher_disagreement_score":0.97853494,"about_ca_system_score_codex":0.001909747,"about_ca_system_score_gemma":0.0015835803,"threshold_uncertainty_score":0.11351961},"labels":[],"label_agreement":null},{"id":"W4392582468","doi":"10.1016/s1470-2045(24)00070-6","title":"Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Venetoclax; Open label; Medicine; Refractory (planetary science); Oncology; Internal medicine; Chronic lymphocytic leukemia; Clinical trial; Leukemia; Biology","score_opus":0.09800376265592863,"score_gpt":0.4116209237309606,"score_spread":0.31361716107503196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392582468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98769844,0.009414792,0.00020947694,0.0002308597,0.000063606414,0.0007713851,0.0005812659,0.000028277147,0.0010019246],"genre_scores_gemma":[0.99536705,0.0016310205,0.00041951475,0.00028079454,0.000108690314,0.00052663736,0.0011363442,0.000009697381,0.0005203404],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9985171,0.0010502924,0.000059409274,0.00015852388,0.0000932883,0.000121321544],"domain_scores_gemma":[0.9979493,0.00067285064,0.0005406489,0.00018232795,0.000108180575,0.000546692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042949016,0.00066443306,0.0016442413,0.0002815553,0.0002481932,0.0009964914,0.0006166465,0.0008111355,0.0016997617],"category_scores_gemma":[0.001944507,0.00025031797,0.0015372144,0.00040782848,0.00062989094,0.00050328544,0.00031767107,0.0019039024,0.00024683223],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91179144,0.0052519655,0.02001517,0.0013382974,0.0032538837,0.000113742404,0.00016747904,0.0013209912,0.007401304,0.00022913993,0.0017399003,0.04737669],"study_design_scores_gemma":[0.7265916,0.1980459,0.06596398,0.00018029676,0.0020926143,0.00047202827,0.000081260376,0.0014536271,0.0013701422,0.00026131573,0.0034407352,0.000046476485],"about_ca_topic_score_codex":0.0004948534,"about_ca_topic_score_gemma":0.0015387204,"teacher_disagreement_score":0.0042949016,"about_ca_system_score_codex":0.00066732406,"about_ca_system_score_gemma":0.00096760393,"threshold_uncertainty_score":0.0227139},"labels":[],"label_agreement":null},{"id":"W4393177013","doi":"10.1016/s1470-2045(24)00099-8","title":"The cost and value of cancer medicines in Ontario, Canada","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Value (mathematics); Granularity; Demography; Family medicine; Environmental health; Statistics; Computer science; Mathematics; Sociology","score_opus":0.04023127997809138,"score_gpt":0.28588100096810326,"score_spread":0.24564972099001187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393177013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.60227966,0.09006522,0.000885438,0.13662562,0.0011155054,0.0003710457,0.08286373,0.000120306955,0.08567355],"genre_scores_gemma":[0.95313543,0.02435189,0.00055682723,0.002122859,0.00020527416,0.000049937975,0.00440158,0.000032882945,0.015143326],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974546,0.00025148373,0.00018181016,0.00010714705,0.001261346,0.0007436047],"domain_scores_gemma":[0.9922065,0.0010712818,0.001521872,0.000114097405,0.0031496682,0.0019365387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012378661,0.00037091007,0.00072222215,0.00229496,0.002078277,0.00363446,0.0013230238,0.0013719356,0.0057236706],"category_scores_gemma":[0.010438405,0.00060946203,0.0010779898,0.0079274755,0.0012545915,0.00089368323,0.000929523,0.0017754862,0.00024124612],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031204692,0.00026914992,0.49130774,0.004550021,0.0021207898,0.002373887,0.0025002575,0.035410944,0.00077493896,0.063846074,0.26037565,0.13335018],"study_design_scores_gemma":[0.0006384566,0.00018993898,0.8457762,0.0016405971,0.0009106861,0.0007292899,0.003764903,0.015217452,0.0003591995,0.0051051793,0.12543121,0.00023693833],"about_ca_topic_score_codex":0.99862945,"about_ca_topic_score_gemma":0.99924976,"teacher_disagreement_score":0.2456389,"about_ca_system_score_codex":0.2456389,"about_ca_system_score_gemma":0.17914395,"threshold_uncertainty_score":0.87495196},"labels":[],"label_agreement":null},{"id":"W4393177464","doi":"10.1016/s1470-2045(24)00072-x","title":"Cost and value of cancer medicines in a single-payer public health system in Ontario, Canada: a cross-sectional study","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Cancer Care Ontario; Canadian Centre for Applied Research in Cancer Control; NOSM University; Thunder Bay Regional Health Sciences Centre","funders":"Canada Research Chairs; Government of Canada; Government of Ontario; Ontario Institute for Cancer Research","keywords":"Medicine; Formulary; Cancer; Health economics; Pembrolizumab; Family medicine; Health care; Public health; Internal medicine; Nursing","score_opus":0.14132470748780093,"score_gpt":0.3414761371791186,"score_spread":0.2001514296913177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393177464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98449624,0.0012986867,0.00012163143,0.0017139781,0.000022866401,0.000092662296,0.009928177,0.000012609711,0.002313054],"genre_scores_gemma":[0.9944296,0.00091368094,0.00016256177,0.00031922836,0.000015367594,0.000029749268,0.0025917082,0.0000073681103,0.0015308004],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978452,0.00019021561,0.0002050114,0.00022686113,0.0007194861,0.0008132535],"domain_scores_gemma":[0.99229854,0.00054608687,0.0026791608,0.00024241082,0.002391453,0.0018422438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010839336,0.00041450476,0.0008230057,0.0015932999,0.0029186057,0.0023007002,0.0024409078,0.0012325153,0.0030106509],"category_scores_gemma":[0.0052699507,0.00085378735,0.0015374112,0.009618047,0.0012220849,0.0011063889,0.0013541862,0.0016989802,0.0003321923],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000999556,0.00009036489,0.9944977,0.0000664432,0.00018533258,0.00008794524,0.00086211006,0.0002375133,0.00006476122,0.00020049323,0.0017058941,0.0019014932],"study_design_scores_gemma":[0.000013145423,0.000027356607,0.99758184,0.000038498216,0.00006210415,0.000035138677,0.0011650911,0.00032800657,0.000017218419,0.00002489114,0.0006921014,0.000014559943],"about_ca_topic_score_codex":0.99749076,"about_ca_topic_score_gemma":0.99822956,"teacher_disagreement_score":0.08113896,"about_ca_system_score_codex":0.08113896,"about_ca_system_score_gemma":0.057160206,"threshold_uncertainty_score":0.5887071},"labels":[],"label_agreement":null},{"id":"W4393177495","doi":"10.1016/s1470-2045(24)00136-0","title":"Venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Institute in Oncology and Hematology; University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Venetoclax; Medicine; Chronic lymphocytic leukemia; Lymphoma; Chemotherapy; Refractory (planetary science); Ibrutinib; Oncology; Internal medicine; Immunology; Leukemia; Biology","score_opus":0.03514648133347344,"score_gpt":0.3473009736240493,"score_spread":0.3121544922905759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393177495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7652459,0.20762357,0.00016667484,0.011881195,0.0009664014,0.0000698201,0.0007652367,0.00004813235,0.013233047],"genre_scores_gemma":[0.9667146,0.027940582,0.00014260216,0.0024045934,0.0010298706,0.000026225534,0.00050175854,0.0000063618263,0.0012334669],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9998086,0.00007128348,0.000014338122,0.000022414622,0.000029249853,0.00005419228],"domain_scores_gemma":[0.9991509,0.00038460948,0.00020306247,0.00002269461,0.000032560936,0.00020627736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004235223,0.00013200723,0.00057265273,0.0002603569,0.00026860522,0.0005653708,0.000204637,0.00058528385,0.0025971297],"category_scores_gemma":[0.0022998094,0.00009641312,0.00032341335,0.00057695864,0.00027883158,0.00031032218,0.00016147958,0.0013261631,0.00019443476],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02572587,0.0006542661,0.4546297,0.0021962717,0.000822634,0.0035185802,0.00057192694,0.0006258959,0.0035755034,0.0013443612,0.024828859,0.48150617],"study_design_scores_gemma":[0.0071252515,0.009188505,0.92870253,0.0014018555,0.0016285025,0.00922291,0.0010365987,0.00065193325,0.0006805624,0.0020290695,0.038276073,0.000056233643],"about_ca_topic_score_codex":0.003796082,"about_ca_topic_score_gemma":0.006928004,"teacher_disagreement_score":0.003796082,"about_ca_system_score_codex":0.0005236756,"about_ca_system_score_gemma":0.00063312997,"threshold_uncertainty_score":0.008688271},"labels":[],"label_agreement":null},{"id":"W4393183638","doi":"10.1016/s1470-2045(24)00026-3","title":"Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University of Toronto; Université Laval; Jewish General Hospital; Hospital for Sick Children; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine; Children's Hospital of Eastern Ontario; CancerCare Manitoba; Occupational Cancer Research Centre; University Health Network; Ottawa Hospital; Izaak Walton Killam Health Centre; Princess Margaret Cancer Centre; McGill University Health Centre; Sinai Health System","funders":"Garron Family Cancer Centre; Canadian Institutes of Health Research; Royal Marsden Cancer Charity; Stand Up To Cancer; St. Baldrick's Foundation; Ministerstvo Zdravotnictví Ceské Republiky; V Foundation for Cancer Research","keywords":"Medicine; Cancer; Cohort; Incidence (geometry); Pediatrics; Internal medicine","score_opus":0.08264978873133547,"score_gpt":0.4070467130719613,"score_spread":0.32439692434062584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393183638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932476,0.00065901625,0.0002533542,0.00043521775,0.000023984176,0.000018438826,0.0043034083,0.00001241973,0.0010465133],"genre_scores_gemma":[0.9967804,0.00023724821,0.00020414017,0.00012854348,0.000026857848,0.000026834192,0.0021502995,0.000016166267,0.00042959733],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987563,0.0003255222,0.00007449704,0.00048492537,0.00011555119,0.00024306451],"domain_scores_gemma":[0.9976909,0.00025910302,0.00065599004,0.0006523125,0.00024808504,0.00049356243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001315292,0.0005811127,0.0007072813,0.0007604325,0.0011014857,0.0013905732,0.0011722328,0.00092807267,0.0028284977],"category_scores_gemma":[0.0037594636,0.0005876057,0.0009329853,0.0026235376,0.0006309671,0.0007508329,0.0014348344,0.0014360264,0.00040538225],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004287783,0.000033026507,0.99523735,0.000014237098,0.0004287166,0.00029513647,0.00027923353,0.00007227259,0.0007420897,0.0001967004,0.0011225108,0.0011499104],"study_design_scores_gemma":[0.000037306538,0.00007393228,0.99764013,0.000015121956,0.00028086384,0.00058135047,0.0004320914,0.00010815005,0.00006451372,0.00012982513,0.0006200913,0.000016646847],"about_ca_topic_score_codex":0.022660492,"about_ca_topic_score_gemma":0.02187514,"teacher_disagreement_score":0.022660492,"about_ca_system_score_codex":0.0005800502,"about_ca_system_score_gemma":0.0008140916,"threshold_uncertainty_score":0.045057178},"labels":[],"label_agreement":null},{"id":"W4393301802","doi":"10.1016/s1470-2045(24)00100-1","title":"Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":210,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Merck Sharp and Dohme","keywords":"Medicine; Pembrolizumab; Chemoradiotherapy; Placebo; Regimen; Head and neck squamous-cell carcinoma; Clinical endpoint; Internal medicine; Radiation therapy; Oncology; Head and neck cancer; Clinical trial; Surgery; Cancer; Pathology","score_opus":0.0493403772247069,"score_gpt":0.3628449011368754,"score_spread":0.3135045239121685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393301802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9772938,0.009864717,0.000841198,0.0009889674,0.0014199694,0.004962569,0.0013965569,0.00018065782,0.0030515695],"genre_scores_gemma":[0.97897494,0.0052248496,0.001397617,0.0013531153,0.0006271545,0.00505535,0.0011078406,0.000034407483,0.006224725],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99936503,0.00030519787,0.00003776705,0.00014298758,0.000042625776,0.000106340245],"domain_scores_gemma":[0.99936634,0.00019987446,0.00013303454,0.000056635414,0.000042051037,0.0002020077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019474993,0.0022307055,0.004028751,0.0005307814,0.00059907115,0.0012745872,0.0012357539,0.0022480814,0.008720992],"category_scores_gemma":[0.0016451199,0.0010044341,0.0028539884,0.0005909005,0.0013557406,0.0015427427,0.00051603984,0.0037011413,0.0015464968],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98726827,0.002609881,0.00016112259,0.0006255006,0.00076580106,0.000020347565,0.000038841397,0.00020568488,0.0012781139,0.00006972494,0.00039847186,0.006558238],"study_design_scores_gemma":[0.9719768,0.026533633,0.00051710865,0.000025956813,0.00033133008,0.0000118694425,0.000015103816,0.00013956409,0.00012742273,0.000074779826,0.00023759951,0.000008706865],"about_ca_topic_score_codex":0.0021988708,"about_ca_topic_score_gemma":0.003916849,"teacher_disagreement_score":0.008720992,"about_ca_system_score_codex":0.0009926538,"about_ca_system_score_gemma":0.0012324584,"threshold_uncertainty_score":0.029174626},"labels":[],"label_agreement":null},{"id":"W4396213258","doi":"10.1016/s1470-2045(24)00023-8","title":"Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma—a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre; London Health Sciences Centre","funders":"Associazione Italiana per la Ricerca sul Cancro; Cancer Council Tasmania; Ministero della Salute; National Institute for Health and Care Research; Institute of Cancer Research; Cancer Research UK; Istituto Europeo di Oncologia; Royal Marsden NHS Foundation Trust","keywords":"Ablative case; Medicine; Radiation therapy; Renal cell carcinoma; Stereotactic radiotherapy; Medical physics; Oncology; Internal medicine; Radiosurgery","score_opus":0.04174781330594428,"score_gpt":0.33545671988045817,"score_spread":0.2937089065745139,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396213258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30668926,0.040199235,0.033821583,0.29363322,0.012063498,0.1092163,0.013094345,0.0001751987,0.19110736],"genre_scores_gemma":[0.667889,0.020007739,0.038660683,0.091927975,0.0017689499,0.16052805,0.0058719097,0.00021742865,0.013128199],"study_design_codex":"design_other","study_design_gemma":"qualitative","domain_scores_codex":[0.8105653,0.14890192,0.01811785,0.0031816424,0.012111046,0.0071223765],"domain_scores_gemma":[0.8689791,0.07120887,0.0068441774,0.0051366882,0.042152148,0.0056790086],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.21241578,0.00084522855,0.0013733853,0.0027557716,0.0044469736,0.0035688418,0.0021875591,0.0039546764,0.009450982],"category_scores_gemma":[0.15855682,0.00096545235,0.0026814397,0.0035113783,0.0038656914,0.0028438764,0.011266281,0.004601161,0.0018971981],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00713396,0.0010024768,0.05628166,0.029093014,0.0019714776,0.0013964731,0.13665533,0.0024787935,0.0036946528,0.047296807,0.29992744,0.4130679],"study_design_scores_gemma":[0.004604339,0.0014553842,0.091844164,0.056768086,0.0011071146,0.0012519251,0.13575408,0.0022734862,0.0018549303,0.031023744,0.67138445,0.00067836203],"about_ca_topic_score_codex":0.009692046,"about_ca_topic_score_gemma":0.012199332,"teacher_disagreement_score":0.21241578,"about_ca_system_score_codex":0.009688536,"about_ca_system_score_gemma":0.064291015,"threshold_uncertainty_score":0.9712316},"labels":[],"label_agreement":null},{"id":"W4396520760","doi":"10.1016/s1470-2045(24)00142-6","title":"Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trials","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Leids Universitair Medisch Centrum; KWF Kankerbestrijding; Erasmus Medisch Centrum; Universiteit Leiden","keywords":"Endometrial cancer; Medicine; Oncology; Internal medicine; Cancer; Gynecology; Causal inference; Risk factor; Clinical trial; Pathology","score_opus":0.10855857113639082,"score_gpt":0.4459417076580216,"score_spread":0.33738313652163077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396520760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9300337,0.06491003,0.0012785577,0.00078065123,0.0003251285,0.00028557034,0.001475733,0.000023053952,0.00088744966],"genre_scores_gemma":[0.9934789,0.003991196,0.0006884751,0.00037631087,0.00024292147,0.00018694375,0.0007332026,0.00001209812,0.00028999872],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9862104,0.010928529,0.001017772,0.000997903,0.00041136795,0.0004339979],"domain_scores_gemma":[0.9689344,0.021333039,0.0050275535,0.0035598085,0.000509558,0.0006356363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01746989,0.0011903334,0.0035029277,0.00057925633,0.0005001802,0.0016939653,0.0010486945,0.0021723858,0.0028134394],"category_scores_gemma":[0.03031416,0.0007240588,0.0083201835,0.0009294119,0.0010326318,0.0018777711,0.0017549319,0.002467944,0.00020523572],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6403203,0.00054102525,0.1516174,0.0054069418,0.15978672,0.00016372558,0.00027473186,0.0018357644,0.0010082325,0.0004724107,0.0012332652,0.03733956],"study_design_scores_gemma":[0.2825701,0.04075411,0.38178393,0.0023331037,0.26923501,0.000907861,0.00059290655,0.0042998437,0.0019284423,0.008490764,0.006754534,0.0003494068],"about_ca_topic_score_codex":0.00088215026,"about_ca_topic_score_gemma":0.0017941011,"teacher_disagreement_score":0.01746989,"about_ca_system_score_codex":0.0006161809,"about_ca_system_score_gemma":0.00075972127,"threshold_uncertainty_score":0.092390776},"labels":[],"label_agreement":null},{"id":"W4396827653","doi":"10.1016/s1470-2045(24)00178-5","title":"Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Foundation Medicine; Sanofi Genzyme; Chugai Pharmaceutical; University of Texas MD Anderson Cancer Center; EMD Serono; Silverback Therapeutics; Bavarian Nordic; Eli Lilly and Company; Ono Pharmaceutical; Astellas Pharma; Seagen; G1 Therapeutics; Genentech; UroGen Pharma; Pfizer; Incyte; Ipsen; Mirati Therapeutics; Amgen; Bladder Cancer Canada; Sanofi; Exelixis; Regeneron Pharmaceuticals; Boston Scientific Corporation; AstraZeneca; Invitae; National Cancer Institute; Gilead Sciences; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Carcinoma in situ; Cystectomy; Bladder cancer; Cohort; Internal medicine; Oncology; Carcinoma; Cancer; Urology; Immunotherapy","score_opus":0.05105573192091713,"score_gpt":0.3836772905862923,"score_spread":0.3326215586653752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396827653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98288375,0.007113093,0.00084499636,0.0014219133,0.0006005425,0.0021741593,0.0017510093,0.00019252517,0.0030179801],"genre_scores_gemma":[0.9801033,0.0050835833,0.0017167954,0.002230628,0.00033545893,0.0025588593,0.0027589889,0.000045965124,0.005166419],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996265,0.00016283232,0.00001462648,0.00007781431,0.000025703932,0.000092403076],"domain_scores_gemma":[0.9995338,0.00009999569,0.00008514533,0.00003388653,0.00002934694,0.00021786333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017700081,0.0018713162,0.002593186,0.00037451382,0.00040672542,0.0011935498,0.00090780866,0.0015671282,0.0053889896],"category_scores_gemma":[0.0010753296,0.00053986796,0.0019921693,0.00037273555,0.0009502483,0.0014968556,0.00038626333,0.003855975,0.001413126],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9174325,0.011411975,0.001187031,0.0016251551,0.0024504382,0.00013458825,0.00015291582,0.0013469033,0.0079307165,0.00034718643,0.004497842,0.051482793],"study_design_scores_gemma":[0.92065763,0.07407381,0.0022710257,0.0000546268,0.0005044,0.00008883818,0.000040719264,0.00052466633,0.00043723802,0.00023580363,0.0010926361,0.00001858647],"about_ca_topic_score_codex":0.0010424317,"about_ca_topic_score_gemma":0.002850983,"teacher_disagreement_score":0.0053889896,"about_ca_system_score_codex":0.0009506194,"about_ca_system_score_gemma":0.0011178971,"threshold_uncertainty_score":0.018027902},"labels":[],"label_agreement":null},{"id":"W4399068281","doi":"10.1016/s1470-2045(24)00038-x","title":"Addressing challenges in low-income and middle-income countries through novel radiotherapy research opportunities","year":2024,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Health and Medical Research Council; Medical Research Council; National Institutes of Health; Associazione Italiana per la Ricerca sul Cancro; Astellas Pharma; Cancer Institute NSW; European SocieTy for Radiotherapy and Oncology; National Cancer Institute; Accuray; Australian Government; Fondazione Istituto Europeo di Oncologia e Centro Cardiologico Monzino; Huntsman Cancer Institute","keywords":"Low and middle income countries; Low income; Business; Economic growth; Economics; Demographic economics; Developing country","score_opus":0.6226939617834713,"score_gpt":0.5649439755476936,"score_spread":0.05774998623577765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399068281","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024278562,0.9873352,0.00034004488,0.008317506,0.0007015206,0.000012239859,0.00004332187,0.000012791249,0.0029945935],"genre_scores_gemma":[0.0023476677,0.99401265,0.00054363627,0.0017745504,0.0005745896,0.000018354636,0.000046487945,0.0000049146893,0.0006771614],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99937314,0.0002745529,0.000051698167,0.000067941575,0.00014008835,0.00009258604],"domain_scores_gemma":[0.9982262,0.0011248162,0.00016096262,0.000052529223,0.00030026608,0.00013521539],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027808563,0.00052858744,0.0008851017,0.0016226642,0.00045812005,0.0022413363,0.00089604285,0.002021349,0.007631],"category_scores_gemma":[0.0036847042,0.00021048832,0.0008111483,0.0019652813,0.000948883,0.0026966853,0.0019057149,0.0024251726,0.0021658125],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006438216,0.000067356654,0.0005100716,0.021932146,0.00012281323,0.00033809175,0.0005008296,0.0006198432,0.00071933144,0.026727183,0.06750946,0.8808884],"study_design_scores_gemma":[0.000013358981,0.00007377583,0.0007104903,0.009356227,0.00006129908,0.0005659716,0.0005041935,0.00006887348,0.00023679224,0.007726036,0.980667,0.000015939979],"about_ca_topic_score_codex":0.002188571,"about_ca_topic_score_gemma":0.0045038215,"teacher_disagreement_score":0.007631,"about_ca_system_score_codex":0.0012478431,"about_ca_system_score_gemma":0.004759984,"threshold_uncertainty_score":0.025528252},"labels":[],"label_agreement":null},{"id":"W4399068337","doi":"10.1016/s1470-2045(24)00157-8","title":"The burden of cardiovascular disease and risk for subsequent major adverse cardiovascular events in survivors of childhood cancer: a prospective, longitudinal analysis from the St Jude Lifetime Cohort Study","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; National Institutes of Health; American Lebanese Syrian Associated Charities; St. Jude Children's Research Hospital","keywords":"Medicine; Adverse effect; Prospective cohort study; Cohort; Cancer; Cohort study; Common Terminology Criteria for Adverse Events; Internal medicine; Disease; Pediatrics","score_opus":0.017109048143422075,"score_gpt":0.2914682188470733,"score_spread":0.27435917070365123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399068337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958658,0.0005458809,0.00012978914,0.00020943163,0.000015035264,0.000007284112,0.002955178,0.000005099573,0.00026643934],"genre_scores_gemma":[0.99599224,0.00047666533,0.00015412639,0.000060995648,0.000021504738,0.000012755385,0.002820796,0.000005178413,0.0004558425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996712,0.00007989059,0.000031966705,0.000078847035,0.00005039535,0.00008768701],"domain_scores_gemma":[0.99849916,0.00014171096,0.0005330142,0.00031357305,0.00020192751,0.00031068298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009985061,0.0003178298,0.00035525026,0.0005972389,0.00059053564,0.00085088913,0.00048399827,0.00077314395,0.0010151786],"category_scores_gemma":[0.0019062826,0.00058372563,0.0009533637,0.0013497202,0.00021930087,0.0005425021,0.00080504693,0.0013632644,0.00019461653],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002694615,0.00003656993,0.99783534,0.0000067492983,0.00019407435,0.000048365673,0.00006931684,0.000093914925,0.00020578956,0.000037873226,0.00031018228,0.0008923406],"study_design_scores_gemma":[0.000011871413,0.00004345187,0.999286,0.0000051325555,0.00007904978,0.00005841877,0.000096373966,0.00012731012,0.000029531395,0.000018238796,0.00024012804,0.0000045218035],"about_ca_topic_score_codex":0.041775964,"about_ca_topic_score_gemma":0.055731505,"teacher_disagreement_score":0.041775964,"about_ca_system_score_codex":0.000637436,"about_ca_system_score_gemma":0.0008635819,"threshold_uncertainty_score":0.08306563},"labels":[],"label_agreement":null},{"id":"W4399379154","doi":"10.1016/s1470-2045(24)00330-9","title":"New Canadian draft breast screening guidelines issued","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Political science","score_opus":0.22824360181294895,"score_gpt":0.45115737359314967,"score_spread":0.22291377178020072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399379154","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014450363,0.019371731,0.0015473627,0.71644175,0.104946926,0.0010379945,0.02834227,0.00062370877,0.12624313],"genre_scores_gemma":[0.011750439,0.022341069,0.010473008,0.575137,0.017539725,0.0016211641,0.025949247,0.00061797816,0.33457044],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9744913,0.0021510771,0.0021074896,0.00090889796,0.015162196,0.005179001],"domain_scores_gemma":[0.88532203,0.011088202,0.0028843547,0.002292369,0.08582054,0.01259244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0181951,0.001582241,0.0017983476,0.0058231144,0.005368485,0.009134416,0.0067212256,0.028763417,0.024745675],"category_scores_gemma":[0.077113815,0.0018121644,0.004299308,0.007137803,0.0031466,0.002361145,0.0031257146,0.020262158,0.0082821],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019216372,0.0000129411255,0.0001939671,0.000100868914,0.000010300488,0.00003135708,0.00006111017,0.00004064267,0.000032281852,0.001550662,0.99337405,0.0045725256],"study_design_scores_gemma":[0.00009905867,0.000011533622,0.0043585342,0.00071596104,0.00006627476,0.000043472428,0.0001794164,0.00005538874,0.00008820751,0.0010837311,0.9932508,0.00004772099],"about_ca_topic_score_codex":0.94717765,"about_ca_topic_score_gemma":0.9694891,"teacher_disagreement_score":0.94185424,"about_ca_system_score_codex":0.058145747,"about_ca_system_score_gemma":0.30736944,"threshold_uncertainty_score":0.42187887},"labels":[],"label_agreement":null},{"id":"W4399564385","doi":"10.1016/s1470-2045(24)00220-1","title":"Artificial intelligence and radiologists in prostate cancer detection on MRI (PI-CAI): an international, paired, non-inferiority, confirmatory study","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":273,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"National Cancer Institute; HORIZON EUROPE Framework Programme; Genentech; Ipsen; Siemens Healthineers; European Association of Urology; Astellas Pharma; Nvidia; National Institutes of Health; Prostate Cancer UK; AstraZeneca; European Commission; Bayer Vital; Health~Holland; Amgen","keywords":"Prostate cancer; Medicine; Medical physics; Cancer detection; Prostate; Cancer; Psychology; Internal medicine","score_opus":0.09290539477408025,"score_gpt":0.40374125065297256,"score_spread":0.3108358558788923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399564385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99189305,0.0013335169,0.0034141485,0.00012355694,0.00011218982,0.00034261073,0.00031358068,0.000030976527,0.0024363662],"genre_scores_gemma":[0.997017,0.00008906078,0.0018573866,0.000114794464,0.00009859351,0.00014140079,0.00044258538,0.000021338534,0.000217911],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.97036135,0.019704612,0.0022010799,0.003975149,0.003083253,0.00067459786],"domain_scores_gemma":[0.8478715,0.085432045,0.023356112,0.025765887,0.013994162,0.0035803616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.04420017,0.0011136105,0.00057358795,0.0014594704,0.00058917626,0.0014514087,0.0009771814,0.001159142,0.002575396],"category_scores_gemma":[0.10013097,0.0005794261,0.0012206377,0.0010927535,0.0018430215,0.0016495803,0.0017330189,0.0013869267,0.00080735475],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03295428,0.0019762337,0.93086344,0.0005031724,0.0025134613,0.00031507338,0.0015868902,0.00077996287,0.0032140152,0.00051851664,0.0008836848,0.0238914],"study_design_scores_gemma":[0.0030837893,0.052326612,0.9211422,0.00015144686,0.0022302708,0.0036961487,0.00093149464,0.0036890635,0.0066188243,0.00079563376,0.0052181575,0.00011637199],"about_ca_topic_score_codex":0.0005112238,"about_ca_topic_score_gemma":0.00050627196,"teacher_disagreement_score":0.04420017,"about_ca_system_score_codex":0.00053327385,"about_ca_system_score_gemma":0.0007884221,"threshold_uncertainty_score":0.23375565},"labels":[],"label_agreement":null},{"id":"W4399703344","doi":"10.1016/s1470-2045(24)00282-1","title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Adaptive Biotechnologies; Celgene; National Cancer Institute; Yale University; Sanofi; Amgen; Pfizer; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Daratumumab; Medicine; Bortezomib; Multiple myeloma; Thalidomide; Internal medicine; Oncology; Regimen; Dexamethasone; Surgery","score_opus":0.0623832820278561,"score_gpt":0.36822774319097507,"score_spread":0.305844461163119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399703344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98438984,0.010010538,0.0003588198,0.0009708571,0.0008777611,0.0007669897,0.0010174232,0.00007000841,0.00153774],"genre_scores_gemma":[0.9899042,0.0035133003,0.0005714116,0.0010565564,0.0005113311,0.0008178712,0.0012619182,0.000023891522,0.0023394623],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99899644,0.00050582434,0.00005398635,0.00019739365,0.00005500548,0.00019132797],"domain_scores_gemma":[0.9985623,0.00041751596,0.00035696794,0.00015996455,0.000068235655,0.0004350589],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023499103,0.001734251,0.0039537526,0.00029030858,0.0006361318,0.0018356714,0.0010269157,0.0018511756,0.004750553],"category_scores_gemma":[0.0022882202,0.0006544646,0.004714584,0.0004916785,0.0015546425,0.001281731,0.0006343141,0.0049235174,0.0009077642],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9918257,0.00084091816,0.00048388544,0.0002545294,0.0016281349,0.000019782554,0.000023108727,0.00019467135,0.00065040455,0.000055370434,0.0004320491,0.0035915307],"study_design_scores_gemma":[0.9770718,0.017622128,0.002844005,0.000044081666,0.0015149903,0.000031008112,0.000022804323,0.00015711022,0.00015525539,0.00015730558,0.000365518,0.000013907789],"about_ca_topic_score_codex":0.0038711377,"about_ca_topic_score_gemma":0.0076320367,"teacher_disagreement_score":0.004750553,"about_ca_system_score_codex":0.0016547312,"about_ca_system_score_gemma":0.0016606956,"threshold_uncertainty_score":0.015892148},"labels":[],"label_agreement":null},{"id":"W4399933562","doi":"10.1016/s1470-2045(24)00261-4","title":"CNS activity of trastuzumab deruxtecan in HER2-expressing non-small-cell lung cancer","year":2024,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Montreal Neurological Institute and Hospital; McGill University","funders":"","keywords":"Trastuzumab; Lung cancer; Medicine; Internal medicine; Oncology; Cancer research; Cancer; Biology; Breast cancer","score_opus":0.04752182909479873,"score_gpt":0.3539609166558717,"score_spread":0.30643908756107296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399933562","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.035194024,0.017181272,0.00040166566,0.9095085,0.011395569,0.000053551335,0.00029970342,0.00006878056,0.025896976],"genre_scores_gemma":[0.2789788,0.015480847,0.00069351116,0.618866,0.054894228,0.00012320194,0.00034261952,0.00007655022,0.030544177],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994916,0.00015998764,0.00005380479,0.000039290764,0.0001345807,0.00012063827],"domain_scores_gemma":[0.99871516,0.00079765444,0.000118879805,0.000028877988,0.000118742595,0.00022065078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007589155,0.00036052646,0.000909994,0.00028559606,0.0009631559,0.0013927328,0.0006595404,0.010300112,0.0017147951],"category_scores_gemma":[0.00422943,0.00023986815,0.0005825854,0.00035372612,0.0007436479,0.0007519704,0.00044822713,0.006973147,0.0008535592],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002595014,0.00029404784,0.008171468,0.0005310411,0.0002218339,0.067846745,0.00038781058,0.0020885656,0.006769285,0.008064675,0.77978796,0.123241596],"study_design_scores_gemma":[0.0020004825,0.0022934703,0.017391128,0.0005815504,0.00042379604,0.04041902,0.0005674345,0.006840237,0.005268692,0.016087655,0.90802604,0.00010055953],"about_ca_topic_score_codex":0.00567617,"about_ca_topic_score_gemma":0.01335655,"teacher_disagreement_score":0.010300112,"about_ca_system_score_codex":0.0043974463,"about_ca_system_score_gemma":0.0015564732,"threshold_uncertainty_score":0.03190589},"labels":[],"label_agreement":null},{"id":"W4399933819","doi":"10.1016/s1470-2045(24)00067-6","title":"Assessment of endpoint definitions in curative-intent trials for mucosal head and neck squamous cell carcinomas: Head and Neck Cancer International Group consensus recommendations","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Clinical endpoint; Medicine; Head and neck cancer; Clinical trial; Head and neck; Basal cell; Head and neck squamous-cell carcinoma; Oncology; Surrogate endpoint; Cancer; Internal medicine; Surgery","score_opus":0.24070805503133097,"score_gpt":0.4635384935144048,"score_spread":0.22283043848307382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399933819","genre_codex":"review","genre_gemma":"methods","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008518646,0.4363525,0.22151004,0.22876135,0.035079867,0.03391443,0.010984912,0.0029690461,0.02190927],"genre_scores_gemma":[0.052595973,0.061950833,0.720192,0.08513375,0.007855912,0.05530011,0.011796518,0.0014769088,0.0036980088],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.5194709,0.317015,0.110671125,0.009408913,0.03869598,0.004738154],"domain_scores_gemma":[0.33102843,0.5122159,0.048920535,0.018063731,0.08177216,0.007999206],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.51448774,0.0057289917,0.02164763,0.009861116,0.0043060393,0.016643869,0.023835488,0.01548696,0.00549844],"category_scores_gemma":[0.5482163,0.005284794,0.03928893,0.0074016443,0.005610659,0.008738661,0.009756588,0.03814,0.0035814645],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007832,0.00077679165,0.011575879,0.16670817,0.035929978,0.00031101398,0.0045573823,0.0058899648,0.0018186411,0.031670157,0.24766159,0.48526853],"study_design_scores_gemma":[0.02034788,0.0031887938,0.02675647,0.4041133,0.058282338,0.0009700276,0.0025065832,0.014898835,0.0036880686,0.08353589,0.38041455,0.0012972588],"about_ca_topic_score_codex":0.010664262,"about_ca_topic_score_gemma":0.013566215,"teacher_disagreement_score":0.48551226,"about_ca_system_score_codex":0.014286586,"about_ca_system_score_gemma":0.03578467,"threshold_uncertainty_score":0.59872305},"labels":[],"label_agreement":null},{"id":"W4399933845","doi":"10.1016/s1470-2045(24)00255-9","title":"Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Princess Margaret Cancer Centre","funders":"National Institutes of Health; Children’s Oncology Group; National Cancer Institute; St. Baldrick's Foundation","keywords":"Medicine; Rhabdomyosarcoma; Temsirolimus; Chemotherapy; Oncology; Internal medicine; Pediatrics; Sarcoma; Discovery and development of mTOR inhibitors; Pathology","score_opus":0.021650026687221706,"score_gpt":0.3291325067953292,"score_spread":0.30748248010810747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399933845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98567444,0.0075525236,0.00038367556,0.0008872447,0.00044594452,0.0017673044,0.0011383272,0.0001254831,0.002025153],"genre_scores_gemma":[0.9822563,0.006126138,0.0016143356,0.0015921635,0.0003180316,0.0028397692,0.0020457678,0.000033131877,0.003174424],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996755,0.00015069578,0.000022419485,0.00006681716,0.00002459656,0.00006004734],"domain_scores_gemma":[0.99943024,0.00015843296,0.0001097722,0.00003156125,0.000025707024,0.00024423475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010995729,0.0012020367,0.0024069073,0.00040220522,0.00025672675,0.00075731426,0.00075238466,0.0014144805,0.006124432],"category_scores_gemma":[0.0010991079,0.00050233264,0.0022735407,0.00033901175,0.0007478174,0.00095805124,0.00043722874,0.004171395,0.0008431383],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.923791,0.0071334257,0.0018919597,0.0011804563,0.0020755772,0.00009772895,0.00017099702,0.0010771012,0.0034324042,0.00036428013,0.0027726784,0.056012306],"study_design_scores_gemma":[0.9019085,0.09045843,0.0039658016,0.000097219985,0.0006245987,0.000108168526,0.000059496466,0.0004916446,0.0005412831,0.00021655348,0.0015081287,0.000020226424],"about_ca_topic_score_codex":0.0011911495,"about_ca_topic_score_gemma":0.0041826195,"teacher_disagreement_score":0.006124432,"about_ca_system_score_codex":0.0006694793,"about_ca_system_score_gemma":0.0011329564,"threshold_uncertainty_score":0.020488262},"labels":[],"label_agreement":null},{"id":"W4399933883","doi":"10.1016/s1470-2045(24)00066-4","title":"Criteria for the diagnosis of extranodal extension detected on radiological imaging in head and neck cancer: Head and Neck Cancer International Group consensus recommendations","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Women's College Hospital","funders":"","keywords":"Medicine; Grading (engineering); Head and neck cancer; Terminology; Radiological weapon; Head and neck; Radiology; Medical physics; Radiation therapy; Delphi method; Cancer; Surgery; Internal medicine; Artificial intelligence","score_opus":0.1111209968390932,"score_gpt":0.43501093644447414,"score_spread":0.3238899396053809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399933883","genre_codex":"review","genre_gemma":"methods","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015855085,0.45041466,0.05209099,0.3608311,0.037889104,0.007047897,0.011498334,0.0011035631,0.06326932],"genre_scores_gemma":[0.12653016,0.284956,0.3894477,0.103742205,0.015206791,0.015410174,0.042542953,0.00080710696,0.021356912],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9736762,0.0069879163,0.008383724,0.0014721986,0.00777146,0.0017085196],"domain_scores_gemma":[0.91516966,0.022330662,0.008207369,0.0015039871,0.048353,0.004435328],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.05841857,0.0023224035,0.004860327,0.010621855,0.0030160146,0.004634126,0.0142598385,0.011741929,0.0036320174],"category_scores_gemma":[0.075031035,0.0016762239,0.008208552,0.006123681,0.0031247297,0.0032064205,0.004575699,0.0115535855,0.0030967512],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006480558,0.0005628455,0.042147573,0.024065431,0.0016019678,0.0008940906,0.0017916977,0.0029308067,0.0023378085,0.010679429,0.5480003,0.36434004],"study_design_scores_gemma":[0.0014202305,0.0006383335,0.087970816,0.12756984,0.0063218316,0.0049049733,0.0066810832,0.004915868,0.0030764374,0.023965979,0.7318852,0.000649505],"about_ca_topic_score_codex":0.05863202,"about_ca_topic_score_gemma":0.05154726,"teacher_disagreement_score":0.9415814,"about_ca_system_score_codex":0.009182767,"about_ca_system_score_gemma":0.025948316,"threshold_uncertainty_score":0.3089506},"labels":[],"label_agreement":null},{"id":"W4399933994","doi":"10.1016/s1470-2045(24)00143-8","title":"Standardised definitions and diagnostic criteria for extranodal extension detected on histopathological examination in head and neck cancer: Head and Neck Cancer International Group consensus recommendations","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"National Institute for Health and Care Research","keywords":"Medicine; Head and neck cancer; Histology; Histopathology; Head and neck; Pathology; Cancer; Radiology; Surgery; Internal medicine","score_opus":0.13001224407561246,"score_gpt":0.4175313374934358,"score_spread":0.28751909341782333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399933994","genre_codex":"review","genre_gemma":"methods","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023584468,0.41809556,0.14261377,0.27428284,0.051470112,0.018641682,0.025838803,0.0019640662,0.043508735],"genre_scores_gemma":[0.10023007,0.16711906,0.5569144,0.06996468,0.008814593,0.027681068,0.058216862,0.00093448994,0.010124845],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9366332,0.023228442,0.021900197,0.0029356165,0.012758658,0.0025439344],"domain_scores_gemma":[0.8433206,0.055631746,0.018139869,0.0055553117,0.07301972,0.0043327617],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.12251547,0.0023089072,0.0054854625,0.013251299,0.0024693569,0.005237639,0.016532827,0.00985918,0.0033871457],"category_scores_gemma":[0.14912161,0.002145838,0.011100725,0.007794626,0.003947523,0.0034439873,0.0060013626,0.013687675,0.0027592974],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009745003,0.0007666686,0.04553595,0.04280727,0.002334206,0.0005470498,0.0030891164,0.0036104773,0.0031749483,0.014782955,0.47802922,0.4043477],"study_design_scores_gemma":[0.002376275,0.0010107888,0.15180089,0.17704846,0.008418775,0.002952558,0.007881331,0.0059408685,0.0052473624,0.03320943,0.6031749,0.0009382686],"about_ca_topic_score_codex":0.039040618,"about_ca_topic_score_gemma":0.029946411,"teacher_disagreement_score":0.87748456,"about_ca_system_score_codex":0.010237203,"about_ca_system_score_gemma":0.028185751,"threshold_uncertainty_score":0.64793146},"labels":[],"label_agreement":null},{"id":"W4399993529","doi":"10.1016/s1470-2045(24)00211-0","title":"Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Saskatchewan","funders":"National Cancer Institute; EMD Serono; Ipsen; Eisai; National Institutes of Health; ECOG-ACRIN Cancer Research Group; Canadian Cancer Society; Sanofi; Exelixis; Dana-Farber/Harvard Cancer Center; Genentech; Coherus Biosciences; Bristol-Myers Squibb; Pfizer; Dana-Farber Cancer Institute; American College of Radiology Imaging Network; Veracyte","keywords":"Medicine; Nivolumab; Renal cell carcinoma; Nephrectomy; Clinical endpoint; Perioperative; Kidney cancer; Internal medicine; Surgery; Clinical trial; Urology; Cancer; Kidney; Immunotherapy","score_opus":0.09033592788829715,"score_gpt":0.3633928836903327,"score_spread":0.27305695580203554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399993529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817555,0.0121586,0.00078989274,0.00059752876,0.0008503076,0.001257345,0.0006756121,0.00007642703,0.0018388077],"genre_scores_gemma":[0.98959535,0.00396884,0.0012247333,0.0009354108,0.00044086826,0.0012398255,0.00061062386,0.000021843676,0.0019625085],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99929035,0.00043779306,0.00003752806,0.000095828706,0.000041574138,0.00009690127],"domain_scores_gemma":[0.9992742,0.00024799843,0.00018556554,0.00006560052,0.000042232827,0.00018436128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015937308,0.0013948579,0.0029301292,0.0002270477,0.00034771638,0.0010589517,0.00068472873,0.0011520814,0.0034324867],"category_scores_gemma":[0.0017613801,0.0004990408,0.00333138,0.00028578265,0.0010094417,0.0011917431,0.00044036988,0.0032311096,0.00062061305],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9746439,0.0019324293,0.0007372561,0.0011008355,0.0020074546,0.000021759626,0.000048594095,0.00045057441,0.0011006423,0.000102248785,0.0005926421,0.017261704],"study_design_scores_gemma":[0.91286504,0.07873135,0.004288068,0.00014116483,0.0016785249,0.000040291834,0.000056904326,0.0005084884,0.00032742397,0.00037832794,0.0009499248,0.000034476285],"about_ca_topic_score_codex":0.0011953379,"about_ca_topic_score_gemma":0.0035141122,"teacher_disagreement_score":0.0034324867,"about_ca_system_score_codex":0.00082228257,"about_ca_system_score_gemma":0.00094319636,"threshold_uncertainty_score":0.011482775},"labels":[],"label_agreement":null},{"id":"W4400178708","doi":"10.1016/s1470-2045(24)00327-9","title":"Cancer and premature mortality—pushing the frontiers of cancer care","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton","funders":"","keywords":"Cancer; Medicine; Internal medicine","score_opus":0.10116383091816032,"score_gpt":0.4354763752846711,"score_spread":0.33431254436651076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400178708","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012887418,0.13536024,0.0003425457,0.8517593,0.006452786,0.000008337497,0.00018863971,0.00002717597,0.0045722136],"genre_scores_gemma":[0.14009623,0.41143197,0.0016227822,0.34831202,0.09424524,0.000115772076,0.00032868722,0.00009929451,0.003748031],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9899671,0.0047219424,0.0005279629,0.00069370505,0.002560173,0.0015290962],"domain_scores_gemma":[0.9513631,0.030109588,0.0035303591,0.0017378097,0.005590329,0.0076687536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019917754,0.0008132632,0.003103554,0.0028564185,0.0027515811,0.011646894,0.0024667648,0.01407247,0.014213684],"category_scores_gemma":[0.04959274,0.0007682355,0.0016682396,0.0036898176,0.011965009,0.02344037,0.009843645,0.020993123,0.0023307288],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055668136,0.00021078503,0.014226253,0.0038600205,0.0005465679,0.00037644178,0.0024447236,0.0011378626,0.0004905916,0.2858514,0.4384844,0.25181428],"study_design_scores_gemma":[0.00026074352,0.00026656588,0.019850552,0.007149669,0.0002559588,0.00026990994,0.0077196285,0.0008786614,0.00020442995,0.5357279,0.4271962,0.00021974184],"about_ca_topic_score_codex":0.012115951,"about_ca_topic_score_gemma":0.021511232,"teacher_disagreement_score":0.019917754,"about_ca_system_score_codex":0.008027706,"about_ca_system_score_gemma":0.017101148,"threshold_uncertainty_score":0.10533643},"labels":[],"label_agreement":null},{"id":"W4400519828","doi":"10.1016/s1470-2045(24)00286-9","title":"Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Arnold Ventures","keywords":"Reimbursement; Medicine; Cancer drugs; Family medicine; Political science; Pharmacology; Drug; Law; Health care","score_opus":0.44982876337795014,"score_gpt":0.5326180964832753,"score_spread":0.08278933310532516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400519828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97031635,0.004293729,0.0002483661,0.00032726894,0.000030784027,0.0003383555,0.020346304,0.000014851315,0.004083955],"genre_scores_gemma":[0.9895544,0.0013989776,0.0003383057,0.0002634589,0.00005286412,0.0002424874,0.007650527,0.000014250632,0.00048474706],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98358476,0.0021932616,0.0032223305,0.0023033086,0.0066331015,0.0020631824],"domain_scores_gemma":[0.9312412,0.010436867,0.039974127,0.0017174368,0.013547236,0.0030831674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0072562383,0.00037930644,0.0009760946,0.009158794,0.001132488,0.0022109677,0.0009907901,0.0007145903,0.002921303],"category_scores_gemma":[0.027799198,0.0004683437,0.0012591765,0.014326226,0.0010853336,0.0012796036,0.001550286,0.0007954782,0.00042261425],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070015347,0.000040767718,0.9926763,0.00020068658,0.00027059292,0.00014969449,0.00030280816,0.000084442145,0.00007191276,0.00012464134,0.0014518757,0.0039260876],"study_design_scores_gemma":[0.000042002805,0.00020281624,0.9962134,0.00010659275,0.00021401611,0.00035859467,0.00065634673,0.00014376586,0.000106171006,0.000019635207,0.0019126243,0.000023982833],"about_ca_topic_score_codex":0.30235904,"about_ca_topic_score_gemma":0.33542392,"teacher_disagreement_score":0.69764096,"about_ca_system_score_codex":0.013116303,"about_ca_system_score_gemma":0.0097975135,"threshold_uncertainty_score":0.6011982},"labels":[],"label_agreement":null},{"id":"W4400673149","doi":"10.1016/s1470-2045(24)00223-7","title":"Celiac plexus radiosurgery for pain management in advanced cancer: a multicentre, single-arm, phase 2 trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Israel Cancer Association USA; Gateway for Cancer Research","keywords":"Medicine; Celiac plexus; Refractory (planetary science); Radiosurgery; Abdominal pain; Ablative case; Plexus; Radiation therapy; Pain management; Pancreatic cancer; Surgery; Cancer; Physical therapy; Internal medicine","score_opus":0.07550196199514499,"score_gpt":0.40167383514007693,"score_spread":0.32617187314493196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400673149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97214013,0.015662268,0.0012320362,0.0020649515,0.00091608684,0.0029794967,0.0019430008,0.00020094146,0.0028611107],"genre_scores_gemma":[0.97423303,0.009674418,0.0025119926,0.002389073,0.0005570461,0.0038646334,0.0017535681,0.00005331451,0.0049630087],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995414,0.00022213954,0.000020120424,0.000091072645,0.000035020534,0.00009026494],"domain_scores_gemma":[0.99933547,0.00019492208,0.00015275029,0.000053288528,0.00004740918,0.0002161417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014881457,0.0019559443,0.002543377,0.00033069833,0.00038819967,0.0011443245,0.0008212845,0.0014914242,0.0063588894],"category_scores_gemma":[0.0017294119,0.00048514447,0.0024382677,0.00047171858,0.00091290596,0.0008735433,0.00036911145,0.0033909997,0.0009484248],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9349288,0.008135076,0.000977164,0.002320659,0.0046121543,0.000092369795,0.00015608847,0.0010818194,0.0043538944,0.00025211193,0.004296345,0.038793635],"study_design_scores_gemma":[0.9508223,0.044427615,0.0018843693,0.00007661302,0.0009887372,0.000064868946,0.00003730411,0.0003252661,0.00017930544,0.00021611499,0.00095921167,0.000018179806],"about_ca_topic_score_codex":0.001724125,"about_ca_topic_score_gemma":0.0053216466,"teacher_disagreement_score":0.0063588894,"about_ca_system_score_codex":0.0010082019,"about_ca_system_score_gemma":0.001272641,"threshold_uncertainty_score":0.0212726},"labels":[],"label_agreement":null},{"id":"W4400673370","doi":"10.1016/s1470-2045(24)00285-7","title":"Alleviating retroperitoneal pain with celiac plexus radiosurgery","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Anesthesia and Pain Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Radiosurgery; Celiac plexus; Plexus; Radiology; Surgery; Radiation therapy","score_opus":0.040998421477938245,"score_gpt":0.3095564381240145,"score_spread":0.26855801664607626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400673370","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38445574,0.47187337,0.010793399,0.043324154,0.006647392,0.00024904194,0.00035132136,0.00060434116,0.08170122],"genre_scores_gemma":[0.827574,0.13864163,0.0056639365,0.009018802,0.01017728,0.000092117785,0.00013738974,0.000047215475,0.008647651],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.999821,0.000044360855,0.000011707224,0.000013235694,0.00006267958,0.00004700949],"domain_scores_gemma":[0.9997875,0.00009456457,0.000059546557,0.000015086601,0.000015262473,0.000028042174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036317733,0.00026536663,0.00049892353,0.00029986468,0.00015917927,0.0004582065,0.00032932282,0.00046596667,0.0050358362],"category_scores_gemma":[0.0010513238,0.0000860032,0.00055783516,0.00035768194,0.00056321564,0.0003272918,0.00034266696,0.0013289163,0.00062686444],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005642663,0.000769588,0.0037698327,0.003865156,0.00077099697,0.00223897,0.00022292277,0.001354398,0.023849923,0.004841914,0.016562674,0.9361109],"study_design_scores_gemma":[0.02365141,0.07221272,0.18503071,0.0067435685,0.00436962,0.051544555,0.0018994643,0.0045865094,0.04007438,0.026436435,0.58312106,0.00032962346],"about_ca_topic_score_codex":0.0005778948,"about_ca_topic_score_gemma":0.001732247,"teacher_disagreement_score":0.0050358362,"about_ca_system_score_codex":0.00033910127,"about_ca_system_score_gemma":0.00042231823,"threshold_uncertainty_score":0.016846597},"labels":[],"label_agreement":null},{"id":"W4401503118","doi":"10.1016/s1470-2045(24)00338-3","title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"MSD K.K.; Merck","keywords":"Pembrolizumab; Medicine; Quality of life (healthcare); Adjuvant; Internal medicine; Oncology; Placebo; Stage (stratigraphy); Melanoma; Clinical trial; Cancer; Surgery; Immunotherapy; Alternative medicine; Pathology; Nursing","score_opus":0.1603378670695152,"score_gpt":0.4411800088781165,"score_spread":0.2808421418086013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401503118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863934,0.0072511006,0.000659997,0.00061497546,0.0006574678,0.0019326836,0.00086889695,0.00012535925,0.0014962058],"genre_scores_gemma":[0.9876414,0.0031211942,0.0011650777,0.00104534,0.0004240201,0.0023410385,0.0008658234,0.00002579435,0.0033703288],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993351,0.00034609303,0.00004134403,0.00013004482,0.000039969294,0.00010735807],"domain_scores_gemma":[0.999353,0.0001889225,0.00017397071,0.000052036794,0.000033620974,0.00019853552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019457679,0.0017922531,0.0033735505,0.00043172267,0.00042863624,0.0010854247,0.000959044,0.0018281892,0.005275891],"category_scores_gemma":[0.001449426,0.00066296686,0.0024987415,0.00037965085,0.0012036803,0.0012445694,0.00048042886,0.0031603558,0.0011047759],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9860314,0.0025386317,0.00020995249,0.00047468182,0.0006918729,0.000017277509,0.000027423457,0.00019279243,0.0016112751,0.000042266183,0.0003306902,0.0078317085],"study_design_scores_gemma":[0.95631087,0.04136543,0.0011243491,0.000032541735,0.00040640432,0.000014709537,0.000013922434,0.00020900696,0.0002002254,0.000084510015,0.0002274284,0.000010569864],"about_ca_topic_score_codex":0.0012711599,"about_ca_topic_score_gemma":0.0024689832,"teacher_disagreement_score":0.005275891,"about_ca_system_score_codex":0.000850436,"about_ca_system_score_gemma":0.0008167696,"threshold_uncertainty_score":0.01764965},"labels":[],"label_agreement":null},{"id":"W4401899165","doi":"10.1016/s1470-2045(24)00192-x","title":"Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Robarts Clinical Trials; Canadian Cancer Society; Princess Margaret Cancer Centre","funders":"","keywords":"Endometrial cancer; Gynecologic cancer; Medicine; Oncology; Gynecology; Internal medicine; Cancer; Ovarian cancer","score_opus":0.3793100072915736,"score_gpt":0.5548710089520578,"score_spread":0.17556100166048416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401899165","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007036226,0.2900349,0.0056531304,0.6510786,0.041456014,0.001486445,0.0012304372,0.00021363885,0.008143178],"genre_scores_gemma":[0.019399296,0.3754878,0.096533135,0.45093322,0.04242004,0.005399733,0.0039582886,0.00051980396,0.0053486703],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.78296626,0.089143015,0.06167548,0.012261202,0.045920197,0.008033799],"domain_scores_gemma":[0.45612168,0.30945522,0.03747059,0.013355438,0.14707156,0.036525503],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.31630433,0.003929061,0.01063431,0.014956756,0.0064975065,0.018999532,0.019228201,0.039975416,0.0060724313],"category_scores_gemma":[0.34308562,0.00335262,0.013973057,0.0145950895,0.007798362,0.011056039,0.016971773,0.044131536,0.004407744],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015349761,0.00035591645,0.0031022395,0.05987427,0.0037646065,0.0003203268,0.0022013555,0.0013182001,0.0010597543,0.0161793,0.56459767,0.34569135],"study_design_scores_gemma":[0.0025211608,0.00037661372,0.0066342326,0.16069886,0.0058081145,0.00033191382,0.0021243154,0.0008328134,0.00071546366,0.02913334,0.7904982,0.0003249424],"about_ca_topic_score_codex":0.0236536,"about_ca_topic_score_gemma":0.032283865,"teacher_disagreement_score":0.31630433,"about_ca_system_score_codex":0.016773138,"about_ca_system_score_gemma":0.096028246,"threshold_uncertainty_score":0.8431185},"labels":[],"label_agreement":null},{"id":"W4402305047","doi":"10.1016/s1470-2045(24)00438-8","title":"Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Royal Victoria Regional Health Centre; Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre; Kingston General Hospital; Ottawa Hospital; McMaster University; Queen's University; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Dr. H. Bliss Murphy Cancer Centre; University of Ottawa","funders":"Canadian Cancer Society Research Institute; Canadian Cancer Society","keywords":"Medicine; Palliative care; Radiation therapy; Refractory (planetary science); Cancer; Palliative treatment; Internal medicine; Oncology; Nursing","score_opus":0.0600968270802309,"score_gpt":0.4230809140907763,"score_spread":0.3629840870105454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402305047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98312217,0.007221787,0.00082992186,0.00084522995,0.00064020173,0.0045988993,0.0008078273,0.0001018861,0.0018320252],"genre_scores_gemma":[0.98285633,0.004404324,0.0019159531,0.001413692,0.0005245932,0.005250765,0.00072217954,0.000026458589,0.0028857735],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993461,0.0003892095,0.000029727584,0.00008789892,0.000039938757,0.00010705416],"domain_scores_gemma":[0.9988726,0.00049678667,0.00022190475,0.000068340494,0.000050262635,0.00029001656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001623981,0.0013635085,0.003313835,0.00041908622,0.00047617304,0.00086875254,0.00092565914,0.0018975077,0.009381917],"category_scores_gemma":[0.0020239903,0.00054719235,0.0021902388,0.000518668,0.0013737503,0.0009237288,0.0004117843,0.0034034986,0.00082922843],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9779284,0.0063856654,0.00021973565,0.000992152,0.00070487795,0.000023547422,0.00005457794,0.0002819307,0.0013182947,0.00007898279,0.0004845359,0.011527427],"study_design_scores_gemma":[0.9347034,0.063781604,0.0007234215,0.00004099199,0.0002195961,0.000014174357,0.000019176734,0.00013448294,0.000079538964,0.000069779875,0.00020429118,0.000009526955],"about_ca_topic_score_codex":0.0018958136,"about_ca_topic_score_gemma":0.0043694065,"teacher_disagreement_score":0.009381917,"about_ca_system_score_codex":0.00077750714,"about_ca_system_score_gemma":0.0012086729,"threshold_uncertainty_score":0.03138566},"labels":[],"label_agreement":null},{"id":"W4402388619","doi":"10.1016/s1470-2045(24)00402-9","title":"[89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":127,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Health and Medical Research Council; Astellas Pharma; Ipsen; National Breast Cancer Foundation; Y-mAbs Therapeutics; Exelixis; Australian and New Zealand Society of Nuclear Medicine; Actinium Pharmaceuticals; Pfizer; Intuitive Surgical; Australian Cancer Research Foundation; Regeneron Pharmaceuticals; Veracyte; Verily Life Sciences; Society of Nuclear Medicine and Molecular Imaging; National Imaging Facility; Medical Research Council; Australian Nuclear Science and Technology Organisation; U.S. Department of Justice; Bristol-Myers Squibb; Progenics Pharmaceuticals","keywords":"Open label; Renal cell carcinoma; Medicine; Nuclear medicine; Oncology; Clinical trial; Internal medicine","score_opus":0.07505544025566038,"score_gpt":0.38647430477783923,"score_spread":0.3114188645221788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402388619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98816246,0.003259417,0.00097588584,0.00031481276,0.000120228426,0.005618367,0.00059889676,0.00008108836,0.00086885295],"genre_scores_gemma":[0.9873016,0.001973783,0.0028813276,0.00082264096,0.00016381628,0.004615487,0.0013205393,0.000035487676,0.00088530796],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983145,0.0009776695,0.00008143389,0.0002449195,0.00014320009,0.00023839029],"domain_scores_gemma":[0.9987764,0.00017949002,0.00037250615,0.00014245215,0.00012148574,0.00040769132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058542243,0.0019017527,0.0023304285,0.0005434438,0.00054327544,0.0014993058,0.0011230251,0.0019587453,0.0019820235],"category_scores_gemma":[0.0017057168,0.00078449363,0.0019062399,0.00071064325,0.0017171124,0.0011559217,0.0005846756,0.0024627564,0.0006510138],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9133104,0.021487642,0.0062013594,0.0007205413,0.0014051809,0.00017117872,0.00028555607,0.0016487511,0.025658593,0.00019703658,0.0009946148,0.02791917],"study_design_scores_gemma":[0.6525284,0.33086035,0.011069827,0.000033530516,0.0006901566,0.00020890901,0.000069977825,0.0008056085,0.0018358503,0.00015724469,0.0017047025,0.000035407582],"about_ca_topic_score_codex":0.0013854291,"about_ca_topic_score_gemma":0.0026022533,"teacher_disagreement_score":0.0058542243,"about_ca_system_score_codex":0.0012760037,"about_ca_system_score_gemma":0.002066894,"threshold_uncertainty_score":0.03096044},"labels":[],"label_agreement":null},{"id":"W4402966374","doi":"10.1016/s1470-2045(24)00494-7","title":"Radiotherapy gaps and new frontiers in the Commonwealth","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Health and Medical Research Council","keywords":"Commonwealth; Radiation therapy; Political science; Medicine; Law","score_opus":0.0443610369808377,"score_gpt":0.42053396302744417,"score_spread":0.37617292604660646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402966374","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007204436,0.10697353,0.0012037021,0.8405685,0.00904194,0.000015291034,0.00024944436,0.00007574019,0.034667347],"genre_scores_gemma":[0.43631774,0.17606643,0.0025643606,0.3109152,0.029753316,0.00017312652,0.0005763473,0.00028806156,0.043345414],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99211144,0.002545127,0.0003345867,0.0005566389,0.001373435,0.0030786744],"domain_scores_gemma":[0.97806096,0.008860493,0.0012490008,0.0011298362,0.0015141994,0.0091854995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012100129,0.00051702623,0.0013455496,0.0015709042,0.0049956082,0.008903087,0.0021097248,0.011198521,0.04097868],"category_scores_gemma":[0.020565754,0.00051041576,0.001182535,0.0023198174,0.012542214,0.022158215,0.016370468,0.013126126,0.003677487],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023699368,0.0001415559,0.0021807496,0.0011767575,0.000082980965,0.0006493413,0.004934869,0.0009856052,0.00039491622,0.5720396,0.2693626,0.147814],"study_design_scores_gemma":[0.000054281583,0.00010361853,0.0024799267,0.0013335809,0.000025026946,0.00040231174,0.0050161057,0.00019801749,0.00014166675,0.25059837,0.73958546,0.00006170822],"about_ca_topic_score_codex":0.01615905,"about_ca_topic_score_gemma":0.023352005,"teacher_disagreement_score":0.04097868,"about_ca_system_score_codex":0.012640329,"about_ca_system_score_gemma":0.03332455,"threshold_uncertainty_score":0.13708729},"labels":[],"label_agreement":null},{"id":"W4402966386","doi":"10.1016/s1470-2045(24)00407-8","title":"Radiotherapy and theranostics: a Lancet Oncology Commission","year":2024,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":120,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brantford Energy (Canada); Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Sidney Kimmel Comprehensive Cancer Center; National Institutes of Health; Australian and New Zealand Society of Nuclear Medicine; Universität Wien; European Association of Nuclear Medicine; Amgen; Johns Hopkins University; European SocieTy for Radiotherapy and Oncology; Deutsches Krebsforschungszentrum; University of Washington; Society of Nuclear Medicine and Molecular Imaging; American Society for Radiation Oncology","keywords":"Radiation oncology; Commission; Radiation therapy; Medical physics; Medicine; Oncology; Internal medicine; Business; Finance","score_opus":0.07294719185871013,"score_gpt":0.43710483675976836,"score_spread":0.36415764490105823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402966386","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000027128732,0.9517077,0.00008605426,0.023422595,0.02147323,0.000012723618,0.000053894277,0.000026148831,0.0031904092],"genre_scores_gemma":[0.00090894586,0.9179149,0.00029596308,0.04541967,0.026226666,0.000042525848,0.00013396388,0.000024426434,0.009032858],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99786276,0.00047783888,0.00016425713,0.00019788303,0.0010446609,0.00025265542],"domain_scores_gemma":[0.9944425,0.002222142,0.000522101,0.00013382973,0.0016303302,0.0010490366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004281151,0.0018504708,0.0030496349,0.0032173756,0.00091856235,0.004953097,0.0014801754,0.007468256,0.01306803],"category_scores_gemma":[0.0087474305,0.00067284703,0.0011310293,0.0035336558,0.0014740861,0.0051828637,0.0034008569,0.0102876015,0.007316726],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056875917,0.000026285255,0.000035874167,0.0029153524,0.000044537046,0.000052808817,0.000038604667,0.00011557474,0.0001443079,0.0042152195,0.8149215,0.1774332],"study_design_scores_gemma":[0.000033365537,0.000021789341,0.00007895969,0.0021179626,0.00003208619,0.000072934185,0.000022164853,0.000018698709,0.000014472078,0.0016739873,0.99590504,0.00000851977],"about_ca_topic_score_codex":0.0040555396,"about_ca_topic_score_gemma":0.009726326,"teacher_disagreement_score":0.01306803,"about_ca_system_score_codex":0.0049683517,"about_ca_system_score_gemma":0.010397206,"threshold_uncertainty_score":0.043716908},"labels":[],"label_agreement":null},{"id":"W4402966446","doi":"10.1016/s1470-2045(24)00493-5","title":"Radiotherapy and conflict: from disruption to expansion and hope","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Political science","score_opus":0.03505174327755152,"score_gpt":0.4141312736031108,"score_spread":0.3790795303255593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402966446","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0038317638,0.09037565,0.00092396996,0.85106117,0.0073691346,0.000009169203,0.00006220287,0.000023112636,0.046343837],"genre_scores_gemma":[0.52830946,0.12548974,0.0013325816,0.28649488,0.03755065,0.00011264324,0.00011669326,0.00018284918,0.020410426],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.990906,0.005402297,0.00026633992,0.00039756674,0.0016996148,0.0013281781],"domain_scores_gemma":[0.97382724,0.016306613,0.002447427,0.0012868212,0.0014071866,0.00472473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014133067,0.00049482676,0.0009869608,0.0013453413,0.0045628855,0.01174231,0.0015397444,0.01093609,0.0124361245],"category_scores_gemma":[0.035615582,0.00048512412,0.0005662936,0.0019888047,0.029630544,0.014439137,0.008800549,0.018420378,0.0017550563],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014185815,0.000064349246,0.0014835229,0.0003216407,0.000106474065,0.00040101638,0.008160077,0.0004904411,0.000101651276,0.711449,0.21255736,0.06472259],"study_design_scores_gemma":[0.00007378308,0.000040358795,0.0010100534,0.00076779805,0.000018728551,0.00042564847,0.007831312,0.00012053082,0.00005855014,0.6532819,0.336319,0.00005230637],"about_ca_topic_score_codex":0.0031243495,"about_ca_topic_score_gemma":0.005840174,"teacher_disagreement_score":0.014133067,"about_ca_system_score_codex":0.006481744,"about_ca_system_score_gemma":0.008909476,"threshold_uncertainty_score":0.07474369},"labels":[],"label_agreement":null},{"id":"W4403012542","doi":"10.1016/s1470-2045(24)00386-3","title":"Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial","year":2024,"lang":"nl","type":"article","venue":"The Lancet Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Agence Nationale de la Recherche","keywords":"Open label; Myeloid leukaemia; Medicine; Refractory (planetary science); Cohort; Internal medicine; Oncology; Clinical trial; Biology","score_opus":0.1475039105224535,"score_gpt":0.46556586142230166,"score_spread":0.3180619508998481,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403012542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876059,0.004385422,0.0004764597,0.0012328114,0.00030102997,0.0008606993,0.0025628468,0.00014580687,0.0024288902],"genre_scores_gemma":[0.98191375,0.004218557,0.0012886851,0.0015168812,0.00021983158,0.0012109188,0.0047098035,0.00004513157,0.004876409],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99970275,0.00013846681,0.000009224207,0.000052584146,0.000026519685,0.00007042431],"domain_scores_gemma":[0.9995383,0.00011268932,0.000113662645,0.000037043093,0.00002142116,0.00017686267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013021122,0.001324176,0.0015345936,0.00025667317,0.00027550597,0.0011799302,0.00075871556,0.00094750617,0.0057499795],"category_scores_gemma":[0.001152845,0.00036671976,0.0013876304,0.00031956687,0.000666655,0.00094130257,0.00038760487,0.0035945554,0.00102643],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86473244,0.009251941,0.0040162946,0.0014283134,0.0031998057,0.00017970272,0.00017654977,0.0021946812,0.009953473,0.00076350936,0.009983019,0.09412018],"study_design_scores_gemma":[0.92805064,0.05751688,0.0078388695,0.000057619345,0.0009636813,0.000230151,0.000066027016,0.0011187121,0.0007082243,0.000468916,0.0029500276,0.000030216115],"about_ca_topic_score_codex":0.0007599073,"about_ca_topic_score_gemma":0.0027719776,"teacher_disagreement_score":0.0057499795,"about_ca_system_score_codex":0.00094748504,"about_ca_system_score_gemma":0.0007841274,"threshold_uncertainty_score":0.019235551},"labels":[],"label_agreement":null},{"id":"W4403012546","doi":"10.1016/s1470-2045(24)00500-x","title":"IVLBCL mimicking VEXAS syndrome","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Otitis Media and Relapsing Polychondritis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Fraser Health; University of British Columbia","funders":"","keywords":"Computer science","score_opus":0.044992881539252794,"score_gpt":0.35747957550029386,"score_spread":0.31248669396104106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403012546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84063476,0.038109478,0.005738012,0.012989904,0.0021905436,0.00041753033,0.0009381942,0.0007716308,0.098209925],"genre_scores_gemma":[0.9867982,0.0038652893,0.0011028119,0.002275869,0.001813533,0.000026580188,0.000227418,0.000040810366,0.0038493478],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9995296,0.000075407006,0.000042336625,0.00006194003,0.000076140546,0.00021468573],"domain_scores_gemma":[0.9988495,0.0003719011,0.00037963438,0.00011695899,0.00007960195,0.00020237127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024920236,0.0014181465,0.00088694977,0.0020070253,0.00059676316,0.0013342064,0.0008481967,0.0043307124,0.004182502],"category_scores_gemma":[0.0022967553,0.00052495324,0.00077962084,0.0009998998,0.0011315191,0.0009793413,0.0010940039,0.0022313327,0.0012760554],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017035156,0.000028833889,0.010534012,0.00013982848,0.000029633193,0.97567534,0.000048473292,0.00013961966,0.003834923,0.0007934747,0.0024026479,0.006202857],"study_design_scores_gemma":[0.00008749805,0.00009900305,0.0095967995,0.00008429182,0.000039167167,0.98588043,0.000102662176,0.00039238634,0.0008567711,0.00072871835,0.0021186417,0.0000136702865],"about_ca_topic_score_codex":0.0016441161,"about_ca_topic_score_gemma":0.0012138926,"teacher_disagreement_score":0.0043307124,"about_ca_system_score_codex":0.0007584615,"about_ca_system_score_gemma":0.0004383593,"threshold_uncertainty_score":0.013991833},"labels":[],"label_agreement":null},{"id":"W4403012554","doi":"10.1016/s1470-2045(24)00492-3","title":"Precision medicine with MET exon 14: a partial success","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Exon; Precision medicine; Computational biology; Genetics; Psychology; Biology; Gene","score_opus":0.04578434813325103,"score_gpt":0.43022742791886226,"score_spread":0.3844430797856112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403012554","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027206664,0.5764048,0.0044159344,0.37884247,0.017449494,0.0000414652,0.0006278233,0.00040819708,0.01908919],"genre_scores_gemma":[0.100328274,0.4911662,0.018913347,0.30327016,0.060473006,0.00020766334,0.0013488262,0.00045079438,0.023841701],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942,0.002505057,0.00035549124,0.00081063586,0.0014159776,0.0007130025],"domain_scores_gemma":[0.96027577,0.031137072,0.0013057312,0.0014815485,0.0035920062,0.0022079702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018044876,0.0017831392,0.003576934,0.0018405829,0.0010135502,0.0046934984,0.0017340629,0.008848354,0.015970532],"category_scores_gemma":[0.029361464,0.0006256137,0.0025277368,0.00097528676,0.004455534,0.006005935,0.0035483441,0.011490566,0.00458791],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022123281,0.00025157517,0.0018289335,0.0038092483,0.0010544402,0.0006548901,0.00031269257,0.0018911742,0.0017501024,0.0912989,0.34335867,0.551577],"study_design_scores_gemma":[0.0011504522,0.001546658,0.002034504,0.0059560747,0.0007596646,0.0009627516,0.00028083878,0.001219216,0.0018104106,0.1139206,0.8701666,0.00019224243],"about_ca_topic_score_codex":0.00354617,"about_ca_topic_score_gemma":0.0050743427,"teacher_disagreement_score":0.018044876,"about_ca_system_score_codex":0.0036825272,"about_ca_system_score_gemma":0.005443706,"threshold_uncertainty_score":0.095431566},"labels":[],"label_agreement":null},{"id":"W4403012555","doi":"10.1016/s1470-2045(24)00218-3","title":"The tyranny of non-inferiority trials","year":2024,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Political science; Psychology","score_opus":0.9052723731323669,"score_gpt":0.7364709370930209,"score_spread":0.16880143603934594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403012555","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032439976,0.922037,0.016479103,0.053404883,0.0054704444,0.00012400713,0.00011922681,0.000072511604,0.0019685167],"genre_scores_gemma":[0.040619135,0.7907526,0.041809846,0.09522831,0.027361434,0.0015758922,0.00016810045,0.0003490065,0.0021355927],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.74198633,0.22072537,0.013579439,0.0040822066,0.01881931,0.00080734945],"domain_scores_gemma":[0.264051,0.7056937,0.012235705,0.00935206,0.0076183043,0.0010491925],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.23999728,0.0013975397,0.011631919,0.003449102,0.00081811287,0.0062009864,0.0036446238,0.006949743,0.005553192],"category_scores_gemma":[0.41772792,0.0014326655,0.004702504,0.0033531776,0.011844612,0.010151252,0.0036240816,0.019035703,0.0012701064],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017453409,0.00006105884,0.00041188765,0.06255312,0.0053182524,0.00010645632,0.00038045226,0.0022044478,0.00017814856,0.18796001,0.0688654,0.6702154],"study_design_scores_gemma":[0.0028517584,0.00062617194,0.0012469037,0.08170958,0.0040616114,0.00062398356,0.00016669708,0.0038416844,0.0003265673,0.61703825,0.28736722,0.00013945474],"about_ca_topic_score_codex":0.0015378549,"about_ca_topic_score_gemma":0.002372641,"teacher_disagreement_score":0.76000273,"about_ca_system_score_codex":0.005031564,"about_ca_system_score_gemma":0.009426725,"threshold_uncertainty_score":0.93721867},"labels":[],"label_agreement":null},{"id":"W4403012565","doi":"10.1016/s1470-2045(24)00190-6","title":"A brave new framework for glioma drug development","year":2024,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Medac; Daiichi Sankyo Europe; National Cancer Institute; Servier; Seagen; University of Oxford; Sanofi; Apollomics; Innovent Biologics; Pfizer; Incyte; AstraZeneca; Novocure; Advanced Accelerator Applications; Voyager Therapeutics; Regeneron Pharmaceuticals; National Institutes of Health; Sage Therapeutics; Australian Government; Varian Medical Systems; ViewRay; Les Laboratories Pierre Fabre; Congress of Neurological Surgeons; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Glioma; Drug development; Drug; Computer science; Medicine; Pharmacology; Cancer research","score_opus":0.15245442751984276,"score_gpt":0.44903900229466864,"score_spread":0.2965845747748259,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403012565","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004841937,0.9941618,0.00027051472,0.0028900467,0.0009932728,0.0000071055856,0.00004184433,0.000022491473,0.0015644958],"genre_scores_gemma":[0.00095897814,0.9929671,0.00051226816,0.0034397785,0.00076955993,0.000014934009,0.00006278147,0.0000067987103,0.0012677382],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992249,0.0002647451,0.00007338243,0.00008837254,0.00023924753,0.000109297376],"domain_scores_gemma":[0.99842715,0.0009598144,0.0001540365,0.000046452955,0.00029535222,0.000117267744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026733405,0.0014417616,0.0028601082,0.0025570225,0.0004904617,0.0029986596,0.0016227815,0.0032627487,0.011063866],"category_scores_gemma":[0.0026690303,0.00049089995,0.0011040458,0.0022525555,0.0016110529,0.004876461,0.0019782505,0.0058349106,0.0043848488],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002290699,0.000094063194,0.00009982054,0.020938752,0.00020791081,0.00020922518,0.000095178875,0.00086891383,0.0012478355,0.037881758,0.16960166,0.7685259],"study_design_scores_gemma":[0.000074028714,0.00010495676,0.00012506133,0.004608291,0.00010146423,0.00018945387,0.000043117157,0.00012343221,0.00010388822,0.009292342,0.9852182,0.000015768223],"about_ca_topic_score_codex":0.0025397893,"about_ca_topic_score_gemma":0.0063156416,"teacher_disagreement_score":0.011063866,"about_ca_system_score_codex":0.0022938978,"about_ca_system_score_gemma":0.0036654286,"threshold_uncertainty_score":0.03701234},"labels":[],"label_agreement":null},{"id":"W4403507296","doi":"10.1016/s1470-2045(24)00591-6","title":"Cancer control in the Commonwealth: a roadmap","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Commonwealth; Cancer; Control (management); Medicine; Business; Political science; Computer science; Internal medicine; Artificial intelligence; Law","score_opus":0.052443689666848196,"score_gpt":0.47208242276619383,"score_spread":0.41963873309934563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403507296","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025137074,0.13699093,0.0027163033,0.82256246,0.020841364,0.000115530216,0.0007871068,0.0003953193,0.013077257],"genre_scores_gemma":[0.12479684,0.43225116,0.011536478,0.35184455,0.04711073,0.0011288564,0.003602951,0.00032759894,0.027400948],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98895246,0.002292089,0.0007234746,0.0007677529,0.002517952,0.0047462396],"domain_scores_gemma":[0.95688796,0.010295218,0.001987707,0.0010037278,0.007853157,0.021972233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013246916,0.0025857044,0.0033295332,0.0047531873,0.0036483693,0.0107983975,0.003815065,0.022070095,0.042859513],"category_scores_gemma":[0.027135754,0.0010559506,0.0033154674,0.0031831963,0.008437114,0.017293295,0.015887726,0.015700547,0.005933558],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049447006,0.00084310916,0.0045139855,0.004464388,0.00026084526,0.00083418156,0.00084641506,0.0027292857,0.0007496408,0.06757829,0.6576404,0.25904483],"study_design_scores_gemma":[0.00047603602,0.0008081846,0.012834815,0.009216872,0.00025116696,0.00048695836,0.003365004,0.002118604,0.00028998937,0.08351824,0.8864114,0.00022276174],"about_ca_topic_score_codex":0.07312893,"about_ca_topic_score_gemma":0.06674257,"teacher_disagreement_score":0.07312893,"about_ca_system_score_codex":0.016491253,"about_ca_system_score_gemma":0.11274017,"threshold_uncertainty_score":0.14540654},"labels":[],"label_agreement":null},{"id":"W4403855182","doi":"10.1016/s1470-2045(24)00316-4","title":"Artificial Intelligence for Response Assessment in Neuro Oncology (AI-RANO), part 1: review of current advancements","year":2024,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"DOD Peer Reviewed Cancer Research Program; National Institute of Neurological Disorders and Stroke; National Cancer Institute; Centre For Medical Engineering, King’s College London; Engineering and Physical Sciences Research Council; Servier; Siemens Healthineers; Deutsche Forschungsgemeinschaft; National Institutes of Health; Novocure; National Center for Advancing Translational Sciences; Wellcome Trust; Stryker; University of Wisconsin-Madison; Medical Research Council; Musella Foundation For Brain Tumor Research and Information; U.S. Department of Veterans Affairs; U.S. Department of Defense","keywords":"Current (fluid); Medical physics; Computer science; Medicine; Neuroscience; Engineering; Psychology; Electrical engineering","score_opus":0.21247130692308325,"score_gpt":0.5590866697953906,"score_spread":0.3466153628723073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403855182","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000032162792,0.99915504,0.00010428997,0.0003353835,0.00011067095,0.0000057352586,0.00001077037,0.00000410654,0.00024183204],"genre_scores_gemma":[0.0003863779,0.99857104,0.00034643116,0.00032334973,0.00023783177,0.000009863852,0.000018764558,0.0000016269871,0.00010468386],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99941814,0.0001679298,0.00010963267,0.00008452202,0.00018697404,0.000032899083],"domain_scores_gemma":[0.9971595,0.0021564567,0.00022775996,0.00004162876,0.00033271627,0.000081916754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024915317,0.00088024384,0.002149876,0.002273004,0.00019955686,0.0015245127,0.0011482789,0.0015118899,0.0029570465],"category_scores_gemma":[0.0035822492,0.00034530787,0.0010811822,0.0025147207,0.0006679387,0.001603864,0.00091134245,0.002531611,0.0011386024],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008813542,0.000063159336,0.00018493942,0.026773194,0.00019531744,0.00004870188,0.000036991834,0.00036108136,0.00036705658,0.0027038162,0.019932402,0.9492452],"study_design_scores_gemma":[0.00017638071,0.00037747767,0.0028647783,0.040079147,0.0010135509,0.0011384428,0.0001199983,0.0007827366,0.0005693943,0.008320812,0.9444664,0.00009082574],"about_ca_topic_score_codex":0.001680772,"about_ca_topic_score_gemma":0.0027715613,"teacher_disagreement_score":0.0029570465,"about_ca_system_score_codex":0.0010282521,"about_ca_system_score_gemma":0.0019450363,"threshold_uncertainty_score":0.01317662},"labels":[],"label_agreement":null},{"id":"W4403855186","doi":"10.1016/s1470-2045(24)00315-2","title":"Artificial Intelligence for Response Assessment in Neuro Oncology (AI-RANO), part 2: recommendations for standardisation, validation, and good clinical practice","year":2024,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"Department of Radiology, Weill Cornell Medical College; DOD Peer Reviewed Cancer Research Program; National Institute of Neurological Disorders and Stroke; Servier; National Cancer Institute; Centre For Medical Engineering, King’s College London; European Research Council; Dana Foundation; Engineering and Physical Sciences Research Council; Perelman School of Medicine, University of Pennsylvania; National Institutes of Health; Siemens Healthineers; Deutsche Forschungsgemeinschaft; Novocure; U.S. Department of Defense; European Commission; University of Pennsylvania; Musella Foundation For Brain Tumor Research and Information; Stryker; Instituto Tecnológico de Costa Rica; University of Wisconsin-Madison; Medical Research Council; National Center for Advancing Translational Sciences; Wellcome Trust; U.S. Department of Veterans Affairs","keywords":"Medical physics; Clinical Practice; Artificial intelligence; Computer science; Psychology; Engineering; Medicine; Family medicine","score_opus":0.2640646117355813,"score_gpt":0.592935452089632,"score_spread":0.32887084035405073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403855186","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002949688,0.9757953,0.0051014186,0.014456452,0.0011932836,0.0006091968,0.00035139968,0.00012117359,0.0020768323],"genre_scores_gemma":[0.0048575695,0.9451748,0.039637197,0.006182672,0.0010747481,0.0017584732,0.00072138215,0.000060866503,0.0005322345],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.97788596,0.011325023,0.0048599923,0.0010139802,0.004540229,0.00037478685],"domain_scores_gemma":[0.91002345,0.07035177,0.005921787,0.0021655078,0.010604945,0.0009324839],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.070856296,0.0015560826,0.0069189453,0.005819088,0.0006038153,0.004858268,0.005152897,0.004283662,0.0031411885],"category_scores_gemma":[0.08504295,0.00097250915,0.004497088,0.0037780167,0.002939599,0.003063178,0.003099713,0.0069913673,0.002073113],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024738663,0.0001129232,0.0005590088,0.037900608,0.0006734999,0.00004363865,0.00017512319,0.0010364915,0.00030982104,0.010824537,0.034653965,0.91346294],"study_design_scores_gemma":[0.0009305846,0.0007088289,0.0077432944,0.22609071,0.0038759513,0.00070571445,0.0003587377,0.0032984614,0.0014442008,0.044044837,0.7105336,0.00026509847],"about_ca_topic_score_codex":0.005769917,"about_ca_topic_score_gemma":0.0057751024,"teacher_disagreement_score":0.9291437,"about_ca_system_score_codex":0.0052724583,"about_ca_system_score_gemma":0.015061144,"threshold_uncertainty_score":0.37472838},"labels":[],"label_agreement":null},{"id":"W4403912554","doi":"10.1016/s1470-2045(24)00503-5","title":"Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"T-cell and Retrovirus Studies","field":"Immunology and Microbiology","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"National Cancer Institute; Daiichi-Sankyo","keywords":"Open label; Refractory (planetary science); Medicine; Peripheral; Phases of clinical research; Lymphoma; Peripheral T-cell lymphoma; Internal medicine; T cell; Clinical trial; Materials science; Immunology","score_opus":0.05829991833264942,"score_gpt":0.3377466569531937,"score_spread":0.2794467386205443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403912554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946814,0.0022865757,0.0003288224,0.00030537232,0.00012467474,0.0007862448,0.00058931706,0.00006630872,0.00083138095],"genre_scores_gemma":[0.99085414,0.0024405455,0.0010975449,0.00080540765,0.00016418104,0.0011623902,0.0012812439,0.00002739505,0.0021671795],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99953794,0.0002391183,0.000017127068,0.00007039819,0.000035901125,0.00009958745],"domain_scores_gemma":[0.99940145,0.00015174803,0.000102647115,0.000054636635,0.000031341086,0.00025814516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016074138,0.0016517721,0.0022827368,0.0003864517,0.00034570543,0.0012170364,0.00084543234,0.0017276084,0.0027744186],"category_scores_gemma":[0.0009606911,0.00061400566,0.0017185524,0.00043005563,0.0009955638,0.0012615547,0.00028922732,0.002836093,0.00062881334],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88366675,0.019660296,0.002581909,0.00090422016,0.0018610794,0.00019828929,0.00022713197,0.0013746833,0.017929994,0.00021654861,0.0020147145,0.0693643],"study_design_scores_gemma":[0.71648705,0.2731183,0.0062919427,0.000038781167,0.00059007836,0.00019239483,0.00006394586,0.0006324995,0.0009559726,0.00017133179,0.0014218434,0.000035952264],"about_ca_topic_score_codex":0.0011622366,"about_ca_topic_score_gemma":0.0028076714,"teacher_disagreement_score":0.0027744186,"about_ca_system_score_codex":0.00096243166,"about_ca_system_score_gemma":0.0011113294,"threshold_uncertainty_score":0.009281337},"labels":[],"label_agreement":null},{"id":"W4404354036","doi":"10.1016/s1470-2045(24)00507-2","title":"Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"National Cancer Institute; NRG Oncology; National Center for Advancing Translational Sciences; AstraZeneca; U.S. Department of Veterans Affairs","keywords":"Cetuximab; Durvalumab; Medicine; Contraindication; Head and neck cancer; Cisplatin; Oncology; Radiation therapy; Internal medicine; Randomized controlled trial; Head and neck; Cancer; Surgery; Chemotherapy; Alternative medicine; Colorectal cancer; Nivolumab","score_opus":0.06597821994464595,"score_gpt":0.42670553737652556,"score_spread":0.3607273174318796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404354036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905207,0.0014739513,0.0005443584,0.0004197505,0.00032126857,0.005043524,0.00046033447,0.000068985006,0.0011470428],"genre_scores_gemma":[0.9868297,0.0012163118,0.0021413306,0.0007532076,0.00025729646,0.006144474,0.00059156324,0.000016419339,0.0020497087],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.999076,0.0006210681,0.000044960296,0.00011456624,0.000051852134,0.0000915074],"domain_scores_gemma":[0.9991738,0.00022776323,0.00019852113,0.00007519119,0.00004685114,0.00027786737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026775938,0.0012700593,0.002175851,0.00032793367,0.00033133707,0.0005959938,0.0010559799,0.0013208223,0.0043390556],"category_scores_gemma":[0.0018795559,0.00057518354,0.0014029124,0.00034295046,0.0010211904,0.00078466185,0.0004559283,0.0020209076,0.0006209674],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97320855,0.008244262,0.0007341256,0.00037268575,0.00043899208,0.000034830748,0.00005054334,0.0005350166,0.0028545405,0.000093056384,0.0005364881,0.012896883],"study_design_scores_gemma":[0.92880344,0.069041364,0.0009050221,0.000013603739,0.00020970784,0.000019588955,0.000008807106,0.00026707232,0.00026951762,0.00009541338,0.0003591033,0.0000073224896],"about_ca_topic_score_codex":0.0008245957,"about_ca_topic_score_gemma":0.0028972947,"teacher_disagreement_score":0.0043390556,"about_ca_system_score_codex":0.0009820075,"about_ca_system_score_gemma":0.0015112077,"threshold_uncertainty_score":0.014515638},"labels":[],"label_agreement":null},{"id":"W4404365234","doi":"10.1016/s1470-2045(24)00531-x","title":"Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Intraperitoneal and Appendiceal Malignancies","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Institut National Du Cancer; Unicancer; Ligue Contre le Cancer","keywords":"Hyperthermic intraperitoneal chemotherapy; Medicine; Ovarian cancer; Cytoreductive surgery; Chemotherapy; Intraperitoneal chemotherapy; Oncology; Internal medicine; Surgery; Cancer","score_opus":0.11247817903258171,"score_gpt":0.4409487727974481,"score_spread":0.32847059376486637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404365234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96623766,0.017705759,0.0020325324,0.0013120944,0.0011874179,0.005268545,0.002180253,0.00026393167,0.0038117575],"genre_scores_gemma":[0.9744906,0.008395559,0.002714359,0.0019304333,0.00048463055,0.005166076,0.0018348221,0.00005179054,0.004931726],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99943966,0.00032008425,0.000025742349,0.000090429014,0.00003216821,0.00009196491],"domain_scores_gemma":[0.99923444,0.00028728542,0.00016133985,0.0000758263,0.000037781854,0.00020347202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014124492,0.0013679574,0.0025890837,0.00027731303,0.00026115993,0.00094113796,0.0006457831,0.0012977398,0.0073565603],"category_scores_gemma":[0.001872395,0.0004053954,0.0024083205,0.00042324903,0.0010063181,0.00088223175,0.00045557032,0.0028387306,0.00091001496],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9678591,0.002363467,0.00040660342,0.0014656497,0.0017424402,0.00003191611,0.00005974531,0.00052704243,0.0017622188,0.00020639111,0.0014814809,0.022094011],"study_design_scores_gemma":[0.96363604,0.033617016,0.00083207845,0.000053708118,0.0005809315,0.000031725194,0.000020121075,0.00021959427,0.00015055877,0.00016097407,0.0006843587,0.000012865729],"about_ca_topic_score_codex":0.0011376733,"about_ca_topic_score_gemma":0.0027886755,"teacher_disagreement_score":0.0073565603,"about_ca_system_score_codex":0.0006199013,"about_ca_system_score_gemma":0.00088364724,"threshold_uncertainty_score":0.024610102},"labels":[],"label_agreement":null},{"id":"W4404404312","doi":"10.1016/s1470-2045(24)00523-0","title":"The current and future global burden of cancer among adolescents and young adults: a population-based study","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Alberta Health Services; Alberta Cancer Foundation; University of Calgary","funders":"","keywords":"Current (fluid); Cancer; Environmental health; Gerontology; Medicine; Demography; Psychology; Sociology; Engineering; Internal medicine","score_opus":0.024185013570832397,"score_gpt":0.37507290568126095,"score_spread":0.35088789211042853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404404312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996523,0.000653916,0.000070007365,0.00026055632,0.000015025184,0.00002079527,0.0018657009,0.0000021514898,0.00058891316],"genre_scores_gemma":[0.99757993,0.00071410474,0.00006757421,0.00015613057,0.000026549471,0.000030409028,0.0011701487,0.000002084859,0.00025310103],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996543,0.00009390666,0.000040039184,0.00007143067,0.00005535365,0.00008492268],"domain_scores_gemma":[0.9992737,0.00009648746,0.00024222824,0.000052419513,0.00010373928,0.00023145432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007381043,0.00023124128,0.00037536037,0.00083257555,0.00044236623,0.0010321563,0.00033963547,0.00068204314,0.0010442048],"category_scores_gemma":[0.0016670648,0.00034537798,0.00086987,0.0021144394,0.00028466745,0.0011645134,0.0007373622,0.000948963,0.00026944524],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037247613,0.000030692216,0.99850863,0.0000121781695,0.00007791713,0.000026367838,0.00022309342,0.000010379157,0.00005053742,0.000016589578,0.00017302374,0.00083332526],"study_design_scores_gemma":[0.0000048159736,0.00005563438,0.9987895,0.000011873472,0.000050340674,0.0000604027,0.00071062177,0.000019026465,0.000008498967,0.000012627173,0.0002741467,0.0000025937993],"about_ca_topic_score_codex":0.018941294,"about_ca_topic_score_gemma":0.031801473,"teacher_disagreement_score":0.018941294,"about_ca_system_score_codex":0.00055420486,"about_ca_system_score_gemma":0.0005915502,"threshold_uncertainty_score":0.03766209},"labels":[],"label_agreement":null},{"id":"W4404799289","doi":"10.1016/s1470-2045(24)00508-4","title":"Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"CRISPR; Refractory (planetary science); Open label; Medicine; Cancer research; Internal medicine; Adverse effect; Biology; Genetics; Gene","score_opus":0.0810241588147585,"score_gpt":0.3709479855397072,"score_spread":0.2899238267249487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404799289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99841666,0.00050305977,0.00024040975,0.000048841644,0.000015010628,0.00025245862,0.00015548067,0.00003250463,0.00033560512],"genre_scores_gemma":[0.9982387,0.00029361722,0.00032698066,0.00012444159,0.00002451389,0.00020103066,0.00031358513,0.000010477379,0.00046664156],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997831,0.00008293481,0.000012009546,0.000043179047,0.00003191883,0.00004680234],"domain_scores_gemma":[0.9997415,0.00003999783,0.00006807937,0.000025394169,0.000015310708,0.00010979141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007015831,0.0005579798,0.00086583867,0.00020245598,0.00023091478,0.0004906871,0.0003789087,0.0006074168,0.0013465323],"category_scores_gemma":[0.00027063186,0.0002435749,0.0006261909,0.00016515581,0.0005631399,0.00044565703,0.00017594075,0.0013287542,0.000319604],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29500127,0.0822172,0.0149738565,0.0007629247,0.0010892858,0.00043429717,0.0005862701,0.005896336,0.42528573,0.00029711716,0.0036318046,0.16982396],"study_design_scores_gemma":[0.074760415,0.8545927,0.023998048,0.00002297075,0.00043600204,0.00057604106,0.0000934763,0.0024654304,0.040359713,0.00014306138,0.0025128892,0.000039365743],"about_ca_topic_score_codex":0.0007200269,"about_ca_topic_score_gemma":0.0014967183,"teacher_disagreement_score":0.0013465323,"about_ca_system_score_codex":0.00054380676,"about_ca_system_score_gemma":0.00073187187,"threshold_uncertainty_score":0.0045045614},"labels":[],"label_agreement":null},{"id":"W4404909609","doi":"10.1016/s1470-2045(24)00557-6","title":"Balancing clinical benefit and social value: challenges in HTA assessments","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Gilead Sciences","keywords":"Medicine; Health technology; Reimbursement; Authorization; Judgement; Cancer drugs; Actuarial science; Family medicine; Intensive care medicine; Drug; Psychiatry; Health care; Business","score_opus":0.739947547352971,"score_gpt":0.5849100145302042,"score_spread":0.15503753282276678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404909609","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018722834,0.09577423,0.09212592,0.7465307,0.005179027,0.0005095435,0.0021168184,0.00014691656,0.03889398],"genre_scores_gemma":[0.7955453,0.034908146,0.07706432,0.0731259,0.015104316,0.0011447239,0.00072502834,0.0002526574,0.002129635],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.78536016,0.17824623,0.00933609,0.0039446796,0.02078606,0.0023266575],"domain_scores_gemma":[0.28730553,0.66843873,0.012107225,0.0076385136,0.020127047,0.0043828874],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.24311686,0.001721056,0.006434888,0.006556719,0.0026749058,0.017711619,0.0050825323,0.010024335,0.007907161],"category_scores_gemma":[0.5381979,0.0011451828,0.0019738306,0.008697893,0.012171616,0.023157904,0.008527031,0.015587343,0.0011231605],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009364476,0.00047651457,0.016449096,0.005016037,0.003450705,0.0002797128,0.0019443954,0.021314673,0.0002327668,0.5131024,0.07700343,0.3597939],"study_design_scores_gemma":[0.0001592182,0.00014432245,0.0039115143,0.0036012342,0.000310087,0.00009979197,0.0010371376,0.012244412,0.000107760476,0.96234715,0.015927123,0.00011013735],"about_ca_topic_score_codex":0.01141982,"about_ca_topic_score_gemma":0.013121525,"teacher_disagreement_score":0.24311686,"about_ca_system_score_codex":0.010420177,"about_ca_system_score_gemma":0.020761948,"threshold_uncertainty_score":0.93337166},"labels":[],"label_agreement":null},{"id":"W4404909842","doi":"10.1016/s1470-2045(24)00505-9","title":"Use of the ESMO-Magnitude of Clinical Benefit Scale to guide HTA recommendations on coverage and reimbursement for cancer medicines: a retrospective analysis","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Reimbursement; Health technology; Family medicine; Scale (ratio); Health care; Actuarial science; Economic growth; Business","score_opus":0.5671370179349159,"score_gpt":0.5705790316570364,"score_spread":0.003442013722120496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404909842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95982957,0.003269616,0.0021688286,0.00030065133,0.0000360276,0.0017189159,0.029689742,0.000049208116,0.0029374575],"genre_scores_gemma":[0.98838997,0.0007646813,0.002057998,0.00015468177,0.000030107984,0.0011003118,0.007251414,0.000020867446,0.00022994496],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9749698,0.0067286827,0.007888907,0.0028728792,0.0063046706,0.0012350846],"domain_scores_gemma":[0.881698,0.038079828,0.05739994,0.0077130604,0.0131476,0.0019615411],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.021844212,0.0005105559,0.0009812233,0.008211662,0.00075320783,0.0018351846,0.0010472244,0.0004366916,0.0018663183],"category_scores_gemma":[0.057786137,0.00068816816,0.0014085645,0.010054319,0.0011112738,0.00095598423,0.0016341491,0.0006733907,0.0003784342],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017249282,0.000021331436,0.99536777,0.000250931,0.00017214424,0.00009290179,0.00028750484,0.00013011043,0.000053840708,0.00009662138,0.00077394914,0.0025804148],"study_design_scores_gemma":[0.000026864996,0.00014591425,0.9939744,0.00032638808,0.00024739202,0.00042795882,0.00083418644,0.00095817784,0.00028719194,0.00007154619,0.0026694362,0.000030587973],"about_ca_topic_score_codex":0.04698392,"about_ca_topic_score_gemma":0.036923908,"teacher_disagreement_score":0.9781558,"about_ca_system_score_codex":0.0030437359,"about_ca_system_score_gemma":0.0048831273,"threshold_uncertainty_score":0.11552459},"labels":[],"label_agreement":null},{"id":"W4404910188","doi":"10.1016/s1470-2045(24)00673-9","title":"Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation; Novartis","keywords":"Fulvestrant; Medicine; Aromatase inhibitor; Internal medicine; Oncology; Breast cancer; Cancer; Cohort; Regimen; Letrozole; Clinical endpoint; Clinical trial; Aromatase; Estrogen receptor","score_opus":0.04917139460894078,"score_gpt":0.40713169796505505,"score_spread":0.3579603033561143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404910188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950352,0.0029857797,0.00019368724,0.00017095494,0.0001126208,0.00030727964,0.00048794047,0.00002263264,0.0006840197],"genre_scores_gemma":[0.9937384,0.0022055604,0.0004660321,0.0004613168,0.00021313838,0.0003292201,0.0013587384,0.000016736132,0.0012108126],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9991769,0.00040567567,0.000041260322,0.00012574866,0.000068035275,0.0001824043],"domain_scores_gemma":[0.9989303,0.00035713066,0.00020058909,0.00014560374,0.00006529412,0.0003011851],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024567926,0.0013252464,0.0026032955,0.0004937172,0.00037062468,0.0013051952,0.00070365885,0.0011820288,0.002534253],"category_scores_gemma":[0.0016850727,0.0004382594,0.0023104919,0.00053096283,0.0009989429,0.0012795116,0.00032071842,0.0022572167,0.00060676644],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9352004,0.010570111,0.0053426647,0.00049465126,0.0025260777,0.000108182,0.00012461936,0.00079010194,0.0073932153,0.00012104121,0.00076584716,0.036563095],"study_design_scores_gemma":[0.6185454,0.35080114,0.02340913,0.000057026286,0.0024154726,0.0002121266,0.00013045518,0.0006398916,0.0016782549,0.00024487294,0.0018191149,0.000047109832],"about_ca_topic_score_codex":0.0015132797,"about_ca_topic_score_gemma":0.0030908699,"teacher_disagreement_score":0.0026032955,"about_ca_system_score_codex":0.0011213062,"about_ca_system_score_gemma":0.00082340225,"threshold_uncertainty_score":0.012992978},"labels":[],"label_agreement":null},{"id":"W4404910194","doi":"10.1016/s1470-2045(24)00657-0","title":"Palliative radiotherapy for hepatic cancer pain – Authors' reply","year":2024,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Queen's University; University Health Network","funders":"Canadian Cancer Society","keywords":"Radiation therapy; Medicine; Palliative care; Cancer pain; Cancer; Psychology; Internal medicine; Psychotherapist; Nursing","score_opus":0.08584021821421386,"score_gpt":0.4076242109850543,"score_spread":0.32178399277084047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404910194","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017740874,0.0014254147,0.000037601632,0.9721644,0.024945145,0.0000062984673,0.00003773844,0.0000107031265,0.0011953805],"genre_scores_gemma":[0.0023094455,0.0008999995,0.000079192476,0.9566241,0.036044136,0.00002786888,0.00002282362,0.000018233646,0.0039741932],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99663997,0.0011121761,0.00039463607,0.00037191325,0.00095544517,0.000525818],"domain_scores_gemma":[0.99017894,0.0060594487,0.00077701604,0.00021818311,0.0014666439,0.0012996795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032732436,0.0007778224,0.0017905163,0.0009550214,0.0035308008,0.0042079184,0.0017083032,0.062147737,0.008405606],"category_scores_gemma":[0.02660298,0.0010183894,0.0014844743,0.0008853403,0.003426193,0.003531675,0.002449445,0.05076572,0.005676574],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060837614,0.000017014372,0.00040141647,0.00007235961,0.000024573752,0.00095249893,0.0001552706,0.00006501917,0.00009747985,0.00151137,0.9926958,0.003946472],"study_design_scores_gemma":[0.00016755739,0.000067164074,0.0010461021,0.00038317323,0.000052515108,0.0016421071,0.00055764883,0.00025256196,0.00016486214,0.006506935,0.9890565,0.00010276871],"about_ca_topic_score_codex":0.0041913968,"about_ca_topic_score_gemma":0.007887815,"teacher_disagreement_score":0.062147737,"about_ca_system_score_codex":0.0036939671,"about_ca_system_score_gemma":0.0034151832,"threshold_uncertainty_score":0.028119504},"labels":[],"label_agreement":null},{"id":"W4405267343","doi":"10.1016/s1470-2045(24)00600-4","title":"Colorectal cancer incidence trends in younger versus older adults: an analysis of population-based cancer registry data","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":263,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Institut National Du Cancer; Cancer Research UK; Centre International de Recherche sur le Cancer; World Health Organization; American Cancer Society","keywords":"Incidence (geometry); Medicine; Colorectal cancer; Cancer registry; Cancer incidence; Demography; Cancer; Young adult; Population; Gerontology; Internal medicine; Environmental health","score_opus":0.07133531787502449,"score_gpt":0.4129180765997136,"score_spread":0.3415827587246891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405267343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905556,0.0008051619,0.00043042333,0.000062961,0.000008007678,0.00003897738,0.007671015,0.000016840268,0.00041104705],"genre_scores_gemma":[0.9889915,0.0004968375,0.0007775192,0.00003205229,0.000017099723,0.00007722233,0.009508343,0.000007654364,0.00009177667],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99789596,0.00063172344,0.00045609789,0.0004486794,0.00041956722,0.00014801344],"domain_scores_gemma":[0.9945642,0.0012054321,0.0029086312,0.00048828073,0.00059493876,0.00023851388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00360108,0.0001554434,0.0004955997,0.0023746735,0.000168497,0.0005934974,0.00029351606,0.00021561653,0.00065661623],"category_scores_gemma":[0.0054315473,0.0001576607,0.00090522226,0.005211607,0.00017458196,0.0006518457,0.00063472404,0.00034873423,0.00022804266],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000064037966,0.00000828575,0.9975979,0.000042413343,0.00014733107,0.00002143155,0.00008555721,0.00008750698,0.00006106555,0.0000195326,0.00016009195,0.001704921],"study_design_scores_gemma":[0.0000045175757,0.000040771483,0.9988888,0.000013054597,0.000058288882,0.00007748239,0.000136197,0.0002614622,0.00003901049,0.000009965207,0.0004675341,0.0000029195767],"about_ca_topic_score_codex":0.009884283,"about_ca_topic_score_gemma":0.014502673,"teacher_disagreement_score":0.009884283,"about_ca_system_score_codex":0.0004821787,"about_ca_system_score_gemma":0.00063594844,"threshold_uncertainty_score":0.019653559},"labels":[],"label_agreement":null},{"id":"W4405436978","doi":"10.1016/s1470-2045(24)00640-5","title":"The landscape of primary mismatch repair deficient gliomas in children, adolescents, and young adults: a multi-cohort study","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Sunnybrook Health Science Centre; Sinai Health System; Princess Margaret Cancer Centre; University of Toronto; University Health Network; SickKids Foundation; Stollery Children's Hospital; Hospital for Sick Children","funders":"Stand Up To Cancer; Canadian Institutes of Health Research; American Lebanese Syrian Associated Charities; Children’s Oncology Group; V Foundation for Cancer Research; Department of Science and Technology, Ministry of Science and Technology, India; National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Cohort; Medicine; Gerontology; Psychology; Internal medicine","score_opus":0.01809468824186251,"score_gpt":0.2981594577119601,"score_spread":0.2800647694700976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405436978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99658406,0.00083735224,0.00012328685,0.00019313111,0.000015171782,0.0000098093815,0.0018739844,0.0000036250676,0.00035947622],"genre_scores_gemma":[0.9982224,0.0004905556,0.00009005862,0.000084439256,0.000011467326,0.000015306305,0.0008340511,0.000005991407,0.00024574925],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994624,0.00009499971,0.000043029235,0.00021326332,0.00005160914,0.00013467923],"domain_scores_gemma":[0.99898857,0.000097871365,0.00039450964,0.00012660278,0.0001395802,0.00025287076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005598406,0.0003065147,0.0004974491,0.0006085328,0.00073708885,0.0009920052,0.0005445892,0.00060511415,0.0015933908],"category_scores_gemma":[0.0018267261,0.000444984,0.00072366453,0.0014960885,0.0002448376,0.0008729745,0.00089463784,0.0009948626,0.00023841097],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009498142,0.000016743517,0.9978986,0.0000143923035,0.00020060448,0.000102441256,0.00024154682,0.000020406564,0.00021007938,0.00005604171,0.00031521192,0.000828886],"study_design_scores_gemma":[0.00000497916,0.0000508876,0.99848264,0.00001476487,0.00009534839,0.00026576218,0.00060643035,0.000041439125,0.000024314917,0.000039359693,0.00036811776,0.0000058798964],"about_ca_topic_score_codex":0.031069983,"about_ca_topic_score_gemma":0.036661256,"teacher_disagreement_score":0.031069983,"about_ca_system_score_codex":0.00053253805,"about_ca_system_score_gemma":0.0005604465,"threshold_uncertainty_score":0.061778307},"labels":[],"label_agreement":null},{"id":"W4405535660","doi":"10.1016/s1470-2045(24)00522-9","title":"Integrating cancer into crisis: a global vision for action from WHO and partners","year":2024,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"OpenAI; World Health Organization","keywords":"Action (physics); Cancer; Political science; Medicine","score_opus":0.6945686094663495,"score_gpt":0.6352259290948944,"score_spread":0.05934268037145507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405535660","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010371889,0.9151861,0.0006101749,0.079009205,0.0019655195,0.0000326436,0.000092847105,0.000024430652,0.0029753717],"genre_scores_gemma":[0.0038349808,0.97460526,0.0016219255,0.017392725,0.001363355,0.00012138737,0.00012837468,0.000017545142,0.00091444893],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99705315,0.0017538596,0.00024740875,0.00012890254,0.0005420363,0.0002746278],"domain_scores_gemma":[0.98789877,0.008784612,0.00073818385,0.00026371662,0.001485784,0.0008290353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012208977,0.0013121396,0.0018862841,0.0023239197,0.0008598206,0.005134842,0.0018176896,0.005857653,0.0075640576],"category_scores_gemma":[0.016680174,0.00039263105,0.0020267428,0.0032284064,0.0026030787,0.006579921,0.0038382208,0.007910584,0.0015989009],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000908963,0.00007395175,0.0003157365,0.02673463,0.00033493218,0.00014408317,0.00051154365,0.0012182117,0.0001499729,0.09787687,0.22404782,0.6485012],"study_design_scores_gemma":[0.00004980914,0.00008278315,0.0006162239,0.039793693,0.00016637886,0.000225478,0.0008870725,0.00018692853,0.00008068107,0.04283645,0.9150303,0.000044206965],"about_ca_topic_score_codex":0.006223651,"about_ca_topic_score_gemma":0.006651505,"teacher_disagreement_score":0.012208977,"about_ca_system_score_codex":0.005206406,"about_ca_system_score_gemma":0.020799575,"threshold_uncertainty_score":0.06456804},"labels":[],"label_agreement":null},{"id":"W4406069862","doi":"10.1016/s1470-2045(24)00717-4","title":"Non-inferiority trials: tyranny or good governance? – Authors' reply","year":2025,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Certainty; Clinical trial; Outcome (game theory); Imperfect; Corporate governance; Psychology; Actuarial science; Sample size determination; Medicine; Economics; Internal medicine; Epistemology; Statistics; Management; Philosophy; Mathematics","score_opus":0.6947687374654694,"score_gpt":0.6143013693445082,"score_spread":0.08046736812096122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406069862","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000056328725,0.0007217018,0.00007347288,0.98406625,0.014711845,0.000005725548,0.000038488022,0.0000127115545,0.00031353615],"genre_scores_gemma":[0.00074798154,0.00029687164,0.00016115361,0.9685697,0.029381314,0.000029263403,0.000012021662,0.000018565117,0.0007830019],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9701441,0.012764701,0.0048497,0.0039359895,0.0062642517,0.002041248],"domain_scores_gemma":[0.8373163,0.122806616,0.008310319,0.0046556555,0.017764648,0.009146497],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.038558446,0.0011662412,0.0047800266,0.0020086314,0.005504305,0.010070364,0.0042651123,0.1160971,0.0080684535],"category_scores_gemma":[0.18801785,0.001985115,0.0024657885,0.0023321928,0.0123090735,0.009626267,0.004298957,0.09946641,0.0067891637],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007767446,0.00001631543,0.00025408066,0.00010196725,0.00006126627,0.0002489345,0.00017477354,0.00003940865,0.00005476564,0.0039331983,0.99126464,0.0037730117],"study_design_scores_gemma":[0.0006418109,0.00007827291,0.0012315543,0.0013189338,0.00021353153,0.00091208884,0.0006960359,0.00066329935,0.00026468502,0.0513564,0.942322,0.00030140614],"about_ca_topic_score_codex":0.0055991085,"about_ca_topic_score_gemma":0.008568261,"teacher_disagreement_score":0.9614416,"about_ca_system_score_codex":0.0070639797,"about_ca_system_score_gemma":0.010540558,"threshold_uncertainty_score":0.20391893},"labels":[],"label_agreement":null},{"id":"W4406579979","doi":"10.1016/s1470-2045(24)00678-8","title":"Global linear accelerator requirements and personalised country recommendations: a cross-sectional, population-based study","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Queen's University","funders":"National Cancer Institute; Prostate Cancer Fight Foundation","keywords":"Cross-sectional study; Population; Medicine; Environmental health","score_opus":0.07674652482535393,"score_gpt":0.49724009395603236,"score_spread":0.4204935691306784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406579979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974113,0.00029202423,0.00007900743,0.0000963963,0.000006167366,0.000019628018,0.0013001116,0.000003904754,0.00079138455],"genre_scores_gemma":[0.9987142,0.00015090879,0.00008743456,0.00007537546,0.000006058093,0.000015976208,0.00056333357,0.000004770495,0.00038193143],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99935716,0.0001968576,0.000093158305,0.00013870887,0.000118758544,0.000095303934],"domain_scores_gemma":[0.99673176,0.0007275194,0.0016393403,0.00025449958,0.00029119028,0.00035559392],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010620645,0.00023493459,0.00040607885,0.0005760525,0.00045588418,0.0010727752,0.0006045653,0.0009909897,0.0043610423],"category_scores_gemma":[0.004950623,0.00071685686,0.00076926436,0.0017304099,0.000322502,0.0011634125,0.0005746024,0.0011771057,0.0008397859],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010159217,0.0000849364,0.9981515,0.000020138987,0.00012031211,0.000024144483,0.00024802992,0.000046003075,0.000055698612,0.000017243556,0.0002208295,0.0009096153],"study_design_scores_gemma":[0.0000099655945,0.00015899974,0.9987656,0.000011783397,0.00006709935,0.00008169554,0.0005316284,0.00008359079,0.000016774871,0.000018141938,0.0002484364,0.000006283819],"about_ca_topic_score_codex":0.012201877,"about_ca_topic_score_gemma":0.011857087,"teacher_disagreement_score":0.012201877,"about_ca_system_score_codex":0.00056761666,"about_ca_system_score_gemma":0.00042883423,"threshold_uncertainty_score":0.024261713},"labels":[],"label_agreement":null},{"id":"W4406973835","doi":"10.1016/s1470-2045(24)00720-4","title":"The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trials","year":2025,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; University of Ottawa; Hamilton Health Sciences; Princess Margaret Cancer Centre; University of Toronto","funders":"Parker Institute for Cancer Immunotherapy; Office of Economic Adjustment; National Institutes of Health; Prostate Cancer Foundation; NRG Oncology; National Institute for Health and Care Research; Swim Across America; National Cancer Institute; Accuray; Institute for Mental Health Research; Cilag; Astellas Pharma; Varian Medical Systems; National Institute on Handicapped Research; Cancer Research Institute; AstraZeneca; Bristol-Myers Squibb; Cancer Research UK; Boston Scientific Corporation; Department of Health and Social Care; Royal Marsden NHS Foundation Trust; Pfizer; National Comprehensive Cancer Network; U.S. Department of Defense","keywords":"Meta-analysis; Medicine; Radiation therapy; Prostate cancer; Acute toxicity; Oncology; Internal medicine; Toxicity; Patient data; Database; Cancer; Computer science","score_opus":0.2174150352659144,"score_gpt":0.4680060619734827,"score_spread":0.2505910267075683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406973835","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08768738,0.89302033,0.009279218,0.0010228015,0.0005959008,0.0020784093,0.004833557,0.00023045829,0.0012517958],"genre_scores_gemma":[0.87608695,0.10095394,0.011590867,0.0019681982,0.00027226552,0.0044711796,0.0037364094,0.00016223642,0.0007579012],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.95291686,0.034069005,0.007146061,0.0031330108,0.0021092666,0.00062586635],"domain_scores_gemma":[0.9536963,0.034969084,0.006323525,0.0031740265,0.0013520935,0.00048489182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.041938473,0.0027632471,0.01565707,0.0038937535,0.000664177,0.003851635,0.002382849,0.0023122623,0.0030446071],"category_scores_gemma":[0.06719119,0.0016324081,0.05625882,0.005335859,0.0009432124,0.0018656079,0.0020446894,0.002632807,0.0003676351],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0082422225,0.00002541485,0.0059277765,0.030478483,0.94992346,0.000084502746,0.00004690529,0.0011874784,0.00022332769,0.00011038676,0.00035087013,0.0033990997],"study_design_scores_gemma":[0.002650686,0.00034969673,0.0036938295,0.0017792843,0.9897682,0.00008022223,0.000021941662,0.00040221642,0.0001281604,0.00033925814,0.0007624385,0.000024068435],"about_ca_topic_score_codex":0.0029379379,"about_ca_topic_score_gemma":0.0050277174,"teacher_disagreement_score":0.041938473,"about_ca_system_score_codex":0.0021047245,"about_ca_system_score_gemma":0.001915694,"threshold_uncertainty_score":0.22179449},"labels":[],"label_agreement":null},{"id":"W4407095407","doi":"10.1016/s1470-2045(24)00682-x","title":"Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"Janssen Alzheimer Immunotherapy Research And Development; Janssen Research and Development","keywords":"Ibrutinib; Venetoclax; Mantle cell lymphoma; Medicine; Placebo; Refractory (planetary science); Internal medicine; Oncology; Double blind; Phases of clinical research; Lymphoma; Clinical trial; Leukemia; Pathology; Chronic lymphocytic leukemia","score_opus":0.06933435470979207,"score_gpt":0.41336113665975854,"score_spread":0.3440267819499665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407095407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819474,0.010973884,0.00067184505,0.00054257794,0.00073860504,0.0017590844,0.0008806602,0.00019191705,0.0022939309],"genre_scores_gemma":[0.98432,0.005835246,0.0013937836,0.0012003919,0.00056515,0.002021671,0.00093354797,0.000038943133,0.0036913524],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995627,0.00021300036,0.000019103381,0.00007417938,0.00003460799,0.000096502474],"domain_scores_gemma":[0.99948514,0.0001423158,0.00010208516,0.00004502158,0.000025412559,0.00020001836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001491434,0.0017755978,0.0032307336,0.00049158407,0.00042244204,0.0011927697,0.0010003705,0.0016535927,0.005817516],"category_scores_gemma":[0.0011354743,0.0006595046,0.0018223693,0.0004557734,0.0011130706,0.0009901172,0.00038431003,0.0029750424,0.0010669281],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9712659,0.005340309,0.00030468687,0.0009212582,0.00096557796,0.000036773898,0.000051642153,0.00027760395,0.0034170267,0.00012544659,0.0007701152,0.016523734],"study_design_scores_gemma":[0.9499043,0.047714032,0.0010955848,0.00003220106,0.00032226776,0.000023627581,0.000019192938,0.000170696,0.00019356064,0.00008070162,0.0004315665,0.000012193062],"about_ca_topic_score_codex":0.0011345715,"about_ca_topic_score_gemma":0.0024794033,"teacher_disagreement_score":0.005817516,"about_ca_system_score_codex":0.00064208644,"about_ca_system_score_gemma":0.0007687829,"threshold_uncertainty_score":0.019461513},"labels":[],"label_agreement":null},{"id":"W4407095785","doi":"10.1016/s1470-2045(24)00451-0","title":"Common Sense Oncology principles for the design, analysis, and reporting of phase 3 randomised clinical trials","year":2025,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Queen's University; McMaster University; Kingston Health Sciences Centre; Cancer Care South East","funders":"","keywords":"Medicine; Clinical trial; Oncology; Internal medicine; Clinical Oncology; Medical physics; Cancer","score_opus":0.953424582561647,"score_gpt":0.7698343604004043,"score_spread":0.18359022216124266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407095785","genre_codex":"methods","genre_gemma":"methods","domain_codex":"methods","domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":"methods","domain_consensus":"methods","prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032139377,0.016284944,0.9600589,0.015184674,0.0023703717,0.0031612462,0.0005070515,0.0005404744,0.0015709378],"genre_scores_gemma":[0.014149451,0.012350466,0.93821347,0.008022565,0.003187509,0.022732604,0.00033193597,0.0003139998,0.0006979234],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.3334928,0.60091287,0.035949975,0.0074146725,0.02079964,0.0014300589],"domain_scores_gemma":[0.16788295,0.76258534,0.021736471,0.031626716,0.014268907,0.0018996265],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.45706585,0.004419033,0.013292957,0.011096392,0.0029366896,0.014190111,0.00836859,0.011471468,0.0070880037],"category_scores_gemma":[0.6342097,0.00573908,0.01180182,0.009701291,0.022282809,0.0069230814,0.0082908645,0.0360614,0.003553824],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016110992,0.00019775143,0.00070811773,0.02372886,0.006391673,0.00038700318,0.0035864806,0.010408613,0.0006896347,0.65173966,0.0470355,0.25351563],"study_design_scores_gemma":[0.0021518169,0.00063276,0.00067234307,0.014561107,0.0018206908,0.000751963,0.00026012017,0.011813529,0.0010771774,0.8884902,0.07752518,0.00024313177],"about_ca_topic_score_codex":0.002297242,"about_ca_topic_score_gemma":0.0021961075,"teacher_disagreement_score":0.5429342,"about_ca_system_score_codex":0.0065429313,"about_ca_system_score_gemma":0.024929285,"threshold_uncertainty_score":0.66953444},"labels":[],"label_agreement":null},{"id":"W4407095946","doi":"10.1016/s1470-2045(24)00674-0","title":"Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Clovis Oncology","keywords":"Oncology; Ovarian cancer; Medicine; Open label; Internal medicine; Chemotherapy; BRCA mutation; Cancer; Randomized controlled trial","score_opus":0.17658309875335135,"score_gpt":0.48424069930187097,"score_spread":0.30765760054851965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407095946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9584879,0.026083456,0.0013685614,0.002316852,0.0014988881,0.0023716658,0.0022885175,0.0003469061,0.0052372795],"genre_scores_gemma":[0.9751561,0.008849065,0.002065954,0.0023764363,0.0005815657,0.002143989,0.002045842,0.00006696469,0.0067140316],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99923825,0.0004647232,0.000030275334,0.00010513151,0.000044663593,0.00011694126],"domain_scores_gemma":[0.99905366,0.0004101081,0.00017909575,0.000075318356,0.000044686312,0.00023713979],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018081676,0.0016021874,0.002972362,0.00038687873,0.00030577395,0.0011150892,0.0010535106,0.0017893116,0.0071695973],"category_scores_gemma":[0.0021950053,0.00055633724,0.0028308937,0.00044433953,0.0010669286,0.0012117922,0.0004181614,0.004620349,0.0011898108],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9626512,0.0024195309,0.00039077224,0.00090683013,0.0018173499,0.00004256399,0.00005027839,0.0006165171,0.0016531094,0.00016518007,0.0013246201,0.027962074],"study_design_scores_gemma":[0.95423585,0.041554313,0.0013069332,0.00006752665,0.00074208475,0.000045993827,0.000026247162,0.00042251736,0.00025717058,0.00027959456,0.0010425207,0.000019114621],"about_ca_topic_score_codex":0.0013018157,"about_ca_topic_score_gemma":0.0033345781,"teacher_disagreement_score":0.0071695973,"about_ca_system_score_codex":0.00084649347,"about_ca_system_score_gemma":0.0007846708,"threshold_uncertainty_score":0.02398473},"labels":[],"label_agreement":null},{"id":"W4407096049","doi":"10.1016/s1470-2045(24)00681-8","title":"Transforming oncology care in Latin America: artificial intelligence-driven solutions to bridge workforce gaps","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Kingston Health Sciences Centre","funders":"National Cancer Institute","keywords":"Workforce; Bridge (graph theory); Latin Americans; Political science; Engineering; Medicine; Internal medicine","score_opus":0.08298119047212708,"score_gpt":0.44054293724503873,"score_spread":0.35756174677291164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407096049","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0041188635,0.015884226,0.0042194906,0.95072466,0.0023096725,0.00003796015,0.0001502625,0.00008215736,0.02247261],"genre_scores_gemma":[0.5105004,0.108866476,0.036385782,0.31945664,0.008578403,0.00047141704,0.0009204582,0.00035584834,0.014464686],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.994177,0.0033671095,0.00021669967,0.00033613105,0.00061340677,0.001289632],"domain_scores_gemma":[0.97108036,0.014410884,0.0022683982,0.0013168122,0.003653754,0.0072698095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017030742,0.00080050307,0.00075201725,0.0016454206,0.0030266317,0.010018635,0.0022479724,0.0058411015,0.015458319],"category_scores_gemma":[0.030367916,0.00034022026,0.0009918994,0.0019412921,0.005873076,0.008122949,0.01079933,0.010026342,0.0020582206],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023093319,0.0006002552,0.021298092,0.003932101,0.0003184645,0.00056028244,0.011050167,0.008071704,0.0013761591,0.29429144,0.29970104,0.35856935],"study_design_scores_gemma":[0.00015924845,0.00020133126,0.009206719,0.0070220204,0.00009241713,0.0002368051,0.0332302,0.00523777,0.000491161,0.41180027,0.53219813,0.00012392775],"about_ca_topic_score_codex":0.025899401,"about_ca_topic_score_gemma":0.04413701,"teacher_disagreement_score":0.025899401,"about_ca_system_score_codex":0.010717383,"about_ca_system_score_gemma":0.049847197,"threshold_uncertainty_score":0.09006828},"labels":[],"label_agreement":null},{"id":"W4407164384","doi":"10.1016/s1470-2045(24)00731-9","title":"Comparative efficacy and safety of ablative therapies in the management of primary localised renal cell carcinoma: a systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Western University; McMaster University; London Health Sciences Centre","funders":"","keywords":"Ablative case; Renal cell carcinoma; Meta-analysis; Medicine; Systematic review; Oncology; Internal medicine; Intensive care medicine; MEDLINE; Radiation therapy; Chemistry","score_opus":0.14908601705857505,"score_gpt":0.38820661703559206,"score_spread":0.239120599977017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407164384","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0054851435,0.9934089,0.00031414352,0.00009971237,0.00012600436,0.00010930643,0.00025362236,0.000012023679,0.00019105733],"genre_scores_gemma":[0.168728,0.827954,0.0011518721,0.0008022673,0.0002428155,0.0002989288,0.000466734,0.000020811034,0.00033454545],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99563736,0.0020302825,0.0011905862,0.0005058638,0.0004748017,0.00016119442],"domain_scores_gemma":[0.98997974,0.0076892325,0.001519243,0.00024529442,0.00044208067,0.00012451502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0065749926,0.0019591462,0.014696072,0.002658508,0.00041877353,0.0024028874,0.001665844,0.0020571132,0.003662344],"category_scores_gemma":[0.018131867,0.0009607198,0.02433353,0.003592138,0.0007305709,0.0014146112,0.0011963978,0.0022145608,0.000307349],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005974262,0.000049755967,0.0023447769,0.349315,0.6227213,0.0000925517,0.00008594905,0.0005602206,0.00034872795,0.00015600258,0.0005612631,0.017790118],"study_design_scores_gemma":[0.0014912693,0.00034054124,0.0032274192,0.015278653,0.977653,0.000066971355,0.00005525061,0.00013704227,0.000107296364,0.00022159655,0.0013915704,0.000029313953],"about_ca_topic_score_codex":0.0052732765,"about_ca_topic_score_gemma":0.013473072,"teacher_disagreement_score":0.014696072,"about_ca_system_score_codex":0.0018249456,"about_ca_system_score_gemma":0.0017203358,"threshold_uncertainty_score":0.034772277},"labels":[],"label_agreement":null},{"id":"W4407989366","doi":"10.1016/s1470-2045(25)00017-8","title":"Cancer incidence and mortality estimates in 2022 in southeast Asia: a comparative analysis","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; Queen's University","funders":"National Institutes of Health; Institut National Du Cancer; World Health Organization; National Heart, Lung, and Blood Institute; Prostate Cancer Foundation","keywords":"Incidence (geometry); Cancer incidence; Cancer; Southeast asia; Demography; Geography; Medicine; History; Internal medicine; Ancient history; Sociology; Mathematics","score_opus":0.13537473392206062,"score_gpt":0.4686896833084056,"score_spread":0.333314949386345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407989366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9003001,0.03199014,0.00075695344,0.0010397714,0.00015804733,0.000047642876,0.060275164,0.00005096984,0.0053811963],"genre_scores_gemma":[0.9705601,0.0075514517,0.00041020443,0.00017469212,0.00006311086,0.000053262385,0.020515515,0.000017923307,0.00065378513],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987643,0.00041502493,0.00023898265,0.00016886603,0.00023641072,0.00017644902],"domain_scores_gemma":[0.9973454,0.0006299089,0.0008252995,0.00018719833,0.0008581429,0.00015398087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033001818,0.0004925926,0.0007353069,0.004371668,0.00020807644,0.0009442865,0.00065748225,0.00050561223,0.0016260635],"category_scores_gemma":[0.004295171,0.00025867144,0.0028517013,0.010316442,0.00020236644,0.00087386003,0.00081737764,0.0006125275,0.0003801769],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011632794,0.000058338457,0.9678252,0.00084144174,0.0038239255,0.00021931456,0.0005204088,0.0012345325,0.0001816944,0.00043959753,0.004014173,0.019678159],"study_design_scores_gemma":[0.000022790975,0.00009772431,0.9951407,0.000118515796,0.0009686774,0.0001762596,0.00070623355,0.00032093306,0.000084594154,0.00005692668,0.0022915094,0.000015242863],"about_ca_topic_score_codex":0.07417056,"about_ca_topic_score_gemma":0.06544281,"teacher_disagreement_score":0.07417056,"about_ca_system_score_codex":0.0019203831,"about_ca_system_score_gemma":0.001286086,"threshold_uncertainty_score":0.14747769},"labels":[],"label_agreement":null},{"id":"W4408110957","doi":"10.1016/s1470-2045(24)00648-x","title":"Dose optimisation to improve access to effective cancer medicines","year":2025,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"European Commission; Irish Aid; Ministère de l'Europe et des Affaires Étrangères; World Health Organization","keywords":"Access to medicines; Medical physics; Medicine; Computer science; Pathology","score_opus":0.10286992273043866,"score_gpt":0.4117046879583415,"score_spread":0.3088347652279028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408110957","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005101949,0.9944863,0.00075128913,0.0023458807,0.00020411874,0.00001541809,0.00012808519,0.00000878389,0.0015499057],"genre_scores_gemma":[0.019426854,0.97659177,0.0012452974,0.0012858614,0.0004870215,0.000037725935,0.00012008822,0.000010053531,0.0007953195],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987851,0.00072990236,0.00009617686,0.00007199633,0.00025272957,0.00006403425],"domain_scores_gemma":[0.9957274,0.0034766262,0.0005040076,0.00006067864,0.00018653992,0.000044723198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023919095,0.0006469887,0.0018320201,0.0012005263,0.00009656549,0.0011510338,0.00094399956,0.0014418701,0.013073849],"category_scores_gemma":[0.008738653,0.00022705484,0.0016446272,0.0018056589,0.00047792765,0.0011774517,0.0005862058,0.0022627735,0.0008350688],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005405746,0.00013582704,0.0005388149,0.030727332,0.0016748351,0.00007722647,0.000028780303,0.008849724,0.00027967454,0.04003591,0.021490524,0.89562076],"study_design_scores_gemma":[0.0019573036,0.00081053504,0.00842932,0.05657586,0.004620329,0.0012915728,0.00014827137,0.007257352,0.00089044234,0.11217991,0.8057334,0.000105724735],"about_ca_topic_score_codex":0.0031325165,"about_ca_topic_score_gemma":0.004997796,"teacher_disagreement_score":0.013073849,"about_ca_system_score_codex":0.0019448004,"about_ca_system_score_gemma":0.0017789241,"threshold_uncertainty_score":0.0437364},"labels":[],"label_agreement":null},{"id":"W4408110958","doi":"10.1016/s1470-2045(24)00730-7","title":"ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"Associazione Italiana per la Ricerca sul Cancro; Ministero della Salute; Istituto Europeo di Oncologia; Fondazione AIRC per la ricerca sul cancro ETS","keywords":"Prostate cancer; Open label; Medicine; Oncology; Randomized controlled trial; Internal medicine; Clinical trial; Urology; Cancer","score_opus":0.17892813163927979,"score_gpt":0.5022070697166905,"score_spread":0.3232789380774107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408110958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9772016,0.0056256745,0.0011376569,0.001145289,0.0016424512,0.0069727697,0.0023704565,0.00021651191,0.0036876595],"genre_scores_gemma":[0.97165215,0.004721745,0.0027930518,0.0015413235,0.0012676134,0.008241799,0.0022375141,0.000065273765,0.0074794823],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9990307,0.00054127374,0.000046190846,0.00017943593,0.000057644695,0.00014476155],"domain_scores_gemma":[0.99887437,0.00040710362,0.00019967913,0.000087177796,0.000059725873,0.0003718438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023568233,0.0035002802,0.003953993,0.00087348704,0.0005683805,0.0015755533,0.0012484696,0.002692791,0.014077646],"category_scores_gemma":[0.0022641348,0.00097157236,0.0036364358,0.0007127482,0.0022708424,0.0017893278,0.0007191731,0.004848851,0.0021460883],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9838368,0.0054970924,0.00015755782,0.0005041936,0.0005861463,0.000018039655,0.00004202634,0.00029590508,0.0010438156,0.00011490166,0.00050675287,0.007396702],"study_design_scores_gemma":[0.9339186,0.064456604,0.00037954087,0.000027115817,0.00024903138,0.000017357632,0.000018145887,0.00021193226,0.0001424766,0.00018153217,0.0003852785,0.000012346636],"about_ca_topic_score_codex":0.0015005821,"about_ca_topic_score_gemma":0.002759363,"teacher_disagreement_score":0.014077646,"about_ca_system_score_codex":0.0010140751,"about_ca_system_score_gemma":0.0013522195,"threshold_uncertainty_score":0.047094405},"labels":[],"label_agreement":null},{"id":"W4408511515","doi":"10.1016/s1470-2045(25)00034-8","title":"Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortium","year":2025,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Juravinski Cancer Centre; University of Toronto; Hamilton Health Sciences; Princess Margaret Cancer Centre; McMaster University","funders":"Institute for Mental Health Research; National Institutes of Health; Rising Tide Foundation; NIH Blueprint for Neuroscience Research; Astellas Pharma; U.S. Department of Defense; Sanofi; ViewRay; Accuray; Department of Health and Social Care; Cancer Research Institute; Royal Marsden NHS Foundation Trust; National Institute for Health and Care Research; Swim Across America; Varian Medical Systems; Cancer Research UK; Prostate Cancer Foundation; National Institute on Handicapped Research","keywords":"Prostate cancer; Medicine; Lernaean Hydra; Meta-analysis; Radiation therapy; Oncology; Cancer; Internal medicine; Biology","score_opus":0.46397613657863224,"score_gpt":0.5250809240926702,"score_spread":0.06110478751403792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408511515","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014341279,0.98078215,0.0019379319,0.0004960464,0.0004281284,0.00033982194,0.0010499089,0.000102271435,0.00052261923],"genre_scores_gemma":[0.4256863,0.55886537,0.0076580904,0.0025690168,0.0005172764,0.0010638519,0.002005029,0.00022887986,0.0014061929],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9872945,0.009225121,0.0015769014,0.0009234327,0.00063303334,0.00034695255],"domain_scores_gemma":[0.987568,0.009420451,0.0016957264,0.00070637785,0.0003892581,0.00022020671],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014906923,0.0026830914,0.014056349,0.0021215917,0.00039022794,0.002558099,0.001825168,0.0018542381,0.0060419096],"category_scores_gemma":[0.028686156,0.0012869133,0.03457269,0.0026186074,0.00062392565,0.0016469331,0.001983839,0.0033550619,0.0004879852],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016266331,0.000030559047,0.0017163282,0.11002097,0.8491533,0.00008118199,0.00008691426,0.0007437164,0.00035048835,0.0002866753,0.0012512665,0.020012293],"study_design_scores_gemma":[0.008734559,0.00045282478,0.0027658232,0.0067224256,0.97744614,0.00008505733,0.000040003782,0.00023624265,0.00011008171,0.0006511355,0.002715234,0.00004040113],"about_ca_topic_score_codex":0.005756853,"about_ca_topic_score_gemma":0.014464463,"teacher_disagreement_score":0.014906923,"about_ca_system_score_codex":0.0018753507,"about_ca_system_score_gemma":0.0020823712,"threshold_uncertainty_score":0.07883632},"labels":[],"label_agreement":null},{"id":"W4408887789","doi":"10.1016/s1470-2045(25)00082-8","title":"Low-dose CT for lung cancer screening in a high-risk population (SUMMIT): a prospective, longitudinal cohort study","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Grail; Medical Research Council; W. Garfield Weston Foundation; CRUK Lung Cancer Centre of Excellence; Longfonds; National Institute for Health and Care Research; Cancer Research UK; Garfield Weston Foundation; HORIZON EUROPE Framework Programme; Rosetrees Trust; American Association for Cancer Research; UK Research and Innovation; Johnson and Johnson","keywords":"Summit; Lung cancer; Medicine; Prospective cohort study; Cohort; Oncology; Population; Demography; Environmental health; Internal medicine; Geography; Cartography; Sociology","score_opus":0.025799135640048675,"score_gpt":0.3853799313955376,"score_spread":0.35958079575548896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408887789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938955,0.00038975562,0.0002512344,0.00022941873,0.00002897549,0.0002265075,0.0041368273,0.000012691829,0.0008290154],"genre_scores_gemma":[0.99138993,0.00035570798,0.00059896195,0.00033185916,0.00006569455,0.00051022344,0.00537154,0.000013249386,0.0013628289],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866354,0.00036574865,0.00014138517,0.00029857832,0.00028220718,0.00024860035],"domain_scores_gemma":[0.9968636,0.00032260292,0.0009875821,0.0006612329,0.00054853375,0.0006164341],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003358913,0.00049023714,0.00044405367,0.0007634887,0.0017200476,0.001408751,0.001017934,0.0011853024,0.0026806057],"category_scores_gemma":[0.004697117,0.00086080347,0.0010982805,0.0011844509,0.00045781425,0.0011323042,0.0015014147,0.0017379167,0.0011222947],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000801823,0.0003539844,0.9959949,0.000042353553,0.00021725975,0.00014964846,0.00028143614,0.000028860368,0.00024724516,0.000047398327,0.0008371023,0.0009980965],"study_design_scores_gemma":[0.00013466773,0.00090326153,0.9966551,0.0000661848,0.00021574093,0.0003818893,0.00040251316,0.00021084964,0.00007904109,0.000038861243,0.00089191995,0.000019932677],"about_ca_topic_score_codex":0.018176552,"about_ca_topic_score_gemma":0.026151339,"teacher_disagreement_score":0.018176552,"about_ca_system_score_codex":0.00080675294,"about_ca_system_score_gemma":0.0012169245,"threshold_uncertainty_score":0.036141515},"labels":[],"label_agreement":null},{"id":"W4409097319","doi":"10.1016/s1470-2045(25)00021-x","title":"Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"ImmunoGen; AbbVie","keywords":"Open label; Medicine; Oncology; Folate receptor; Chemotherapy; Internal medicine; Ovarian cancer; Randomized controlled trial; Cancer; Cancer cell","score_opus":0.08608806022690466,"score_gpt":0.41194481523072124,"score_spread":0.3258567550038166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409097319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881725,0.0063526887,0.00031395725,0.00094957725,0.0004135903,0.00080236996,0.0014887619,0.000045385772,0.0014611552],"genre_scores_gemma":[0.9910617,0.0021472469,0.0006000785,0.00087769993,0.00029719752,0.001005109,0.001980415,0.00001872653,0.0020117296],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9990656,0.0005652423,0.00005320914,0.00014084739,0.00006774516,0.00010739751],"domain_scores_gemma":[0.9983134,0.000588479,0.0004944628,0.00010619289,0.00009398681,0.00040340077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018534642,0.0015866924,0.002486532,0.0002773225,0.0003630143,0.0010783051,0.0006657975,0.0017702171,0.005423079],"category_scores_gemma":[0.0029320412,0.00046952823,0.003152966,0.00033365167,0.00087996334,0.0009485549,0.00050091016,0.0035891968,0.0006902477],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9842838,0.0015489253,0.0012550933,0.0005954473,0.0029408957,0.00003533921,0.000044977147,0.00037731626,0.0010759612,0.0000762648,0.00066810334,0.0070978706],"study_design_scores_gemma":[0.9358869,0.052828297,0.006576615,0.000067634704,0.0026752893,0.00006187485,0.000048466285,0.00044196038,0.00033468727,0.00025245384,0.00079714105,0.000028772283],"about_ca_topic_score_codex":0.00096257834,"about_ca_topic_score_gemma":0.0022634463,"teacher_disagreement_score":0.005423079,"about_ca_system_score_codex":0.0009165752,"about_ca_system_score_gemma":0.00067970395,"threshold_uncertainty_score":0.018141985},"labels":[],"label_agreement":null},{"id":"W4409097322","doi":"10.1016/s1470-2045(25)00031-2","title":"First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Astellas Pharma US; Pfizer","keywords":"Enzalutamide; Prostate cancer; Placebo; Medicine; Homologous recombination; Oncology; Internal medicine; Cancer research; Gene; Cancer; Biology; Genetics; Pathology; Androgen receptor","score_opus":0.07915377553234595,"score_gpt":0.38702915174321567,"score_spread":0.3078753762108697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409097322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97923636,0.014387795,0.00044257613,0.0009899212,0.0007241775,0.00061075186,0.0013327566,0.00015250845,0.002123152],"genre_scores_gemma":[0.9907259,0.0036937452,0.00044707747,0.00094429613,0.0003884356,0.0004345301,0.0011453016,0.000021271377,0.0021993977],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.999496,0.00027711078,0.000027171403,0.00008358845,0.000031247473,0.00008487336],"domain_scores_gemma":[0.9993394,0.00020884605,0.00017814043,0.000042347463,0.000035183468,0.00019611281],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001433685,0.0018478956,0.0030398937,0.00040946092,0.00026237962,0.000983151,0.0009005063,0.0014476825,0.0057736267],"category_scores_gemma":[0.0015309048,0.0005265265,0.0028396042,0.00034259737,0.0009548768,0.0011048417,0.000401651,0.002889569,0.00068640953],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9867632,0.0010783192,0.00042864154,0.0005825376,0.001781941,0.000025409201,0.000027036249,0.0003806455,0.00097196776,0.00006205845,0.0006067261,0.007291466],"study_design_scores_gemma":[0.94991434,0.043070998,0.0033825864,0.00006183709,0.001842747,0.000048815433,0.000044834236,0.00049728027,0.00033381555,0.00019840589,0.0005793685,0.00002499381],"about_ca_topic_score_codex":0.0014988768,"about_ca_topic_score_gemma":0.003920845,"teacher_disagreement_score":0.0057736267,"about_ca_system_score_codex":0.00085677864,"about_ca_system_score_gemma":0.0006347595,"threshold_uncertainty_score":0.019314706},"labels":[],"label_agreement":null},{"id":"W4409103399","doi":"10.1016/s1470-2045(25)00030-0","title":"First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Astellas Pharma US; Pfizer","keywords":"Enzalutamide; Medicine; Placebo; Prostate cancer; Internal medicine; Clinical trial; Double blind; Oncology; First line; Urology; Cancer; Androgen receptor; Pathology","score_opus":0.12787455261069358,"score_gpt":0.4242313951586915,"score_spread":0.29635684254799793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409103399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9756443,0.0138374055,0.0008045112,0.0013218095,0.0012118436,0.00140277,0.002533399,0.00024952844,0.0029945485],"genre_scores_gemma":[0.985967,0.00418921,0.00085799757,0.0013215297,0.00072428357,0.0011827642,0.0020172533,0.00004209235,0.003697917],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99923444,0.00043200754,0.0000396821,0.00012470348,0.000051363524,0.00011790081],"domain_scores_gemma":[0.9990127,0.0003231098,0.00024028044,0.00007670177,0.000056425695,0.00029072934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019745172,0.0025896574,0.00391954,0.0005223675,0.00036552764,0.0011659747,0.001128932,0.001846682,0.007890047],"category_scores_gemma":[0.0020616571,0.00067108945,0.003639381,0.00038611345,0.0012234137,0.0013699634,0.0005358068,0.0038891954,0.0009906018],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9914881,0.0010394183,0.00018318211,0.00043259806,0.0012880332,0.000015627978,0.000018701563,0.00024026605,0.0007382271,0.000048180635,0.00047467425,0.0040329094],"study_design_scores_gemma":[0.97445077,0.022393798,0.0011931518,0.00003172448,0.0009914115,0.000023785136,0.000018117398,0.00026374153,0.00018545741,0.00011907618,0.00031361595,0.000015260846],"about_ca_topic_score_codex":0.0015730829,"about_ca_topic_score_gemma":0.0036853394,"teacher_disagreement_score":0.007890047,"about_ca_system_score_codex":0.0009889831,"about_ca_system_score_gemma":0.00080074865,"threshold_uncertainty_score":0.026394844},"labels":[],"label_agreement":null},{"id":"W4409417639","doi":"10.1016/s1470-2045(25)00150-0","title":"Using patient-reported outcomes and health-related quality of life data in regulatory decisions on cancer treatment: highlights from an EMA-EORTC workshop","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada; Queen's University","funders":"PTC Therapeutics; Pfizer; Merck KGaA; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Quality of life (healthcare); Cancer; Medicine; Quality (philosophy); Gerontology; Internal medicine; Nursing","score_opus":0.7337403083292157,"score_gpt":0.5605171469390939,"score_spread":0.17322316139012173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409417639","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008322159,0.1374355,0.021251034,0.81237787,0.00882433,0.00019290262,0.0043911864,0.000100218,0.0071048266],"genre_scores_gemma":[0.27634364,0.29939175,0.11669667,0.2517842,0.04292236,0.0012449465,0.007298434,0.00059303,0.0037249557],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.8749612,0.09880915,0.0075157634,0.0036489267,0.013230304,0.001834653],"domain_scores_gemma":[0.37350765,0.55299383,0.01384312,0.011712196,0.04401058,0.003932668],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.26122525,0.0015397435,0.003220509,0.004100899,0.00071753794,0.017203946,0.004843207,0.010291904,0.0026080888],"category_scores_gemma":[0.35412443,0.0012210923,0.0043105786,0.009025988,0.00528054,0.017324269,0.005840387,0.019047469,0.00087992265],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011977827,0.0006017407,0.051910006,0.004268281,0.0027616767,0.00019734478,0.0016478123,0.010364972,0.0005394288,0.09478376,0.2616129,0.5701144],"study_design_scores_gemma":[0.00074757106,0.00051496876,0.0681681,0.033268962,0.0011571333,0.000430181,0.003956901,0.028653102,0.0015697012,0.34545022,0.5151219,0.0009612675],"about_ca_topic_score_codex":0.024188202,"about_ca_topic_score_gemma":0.03243256,"teacher_disagreement_score":0.7387748,"about_ca_system_score_codex":0.009058089,"about_ca_system_score_gemma":0.010434318,"threshold_uncertainty_score":0.9110408},"labels":[],"label_agreement":null},{"id":"W4409417679","doi":"10.1016/s1470-2045(25)00151-2","title":"Use of patient-reported outcomes to inform symptom and functional outcomes in cancer drug regulatory decisions: challenges and future directions","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Drug; Cancer drugs; Cancer; Regulatory science; Medicine; Psychology; Risk analysis (engineering); Pharmacology; Internal medicine","score_opus":0.37081789683269756,"score_gpt":0.44724596277178247,"score_spread":0.07642806593908491,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409417679","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.060903847,0.29368106,0.04513678,0.5538189,0.0065783854,0.000385828,0.013640204,0.00028504437,0.025569862],"genre_scores_gemma":[0.7507014,0.13254237,0.04968501,0.049153272,0.009661579,0.000810529,0.005103978,0.00018585069,0.0021560434],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.88175493,0.09998763,0.0056199455,0.00301849,0.0083545465,0.0012644269],"domain_scores_gemma":[0.41022003,0.50928843,0.033472233,0.0141130285,0.029516136,0.003390137],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.16217406,0.0014299687,0.0043852106,0.0044444324,0.0005559975,0.011187497,0.0033082222,0.005610635,0.00447437],"category_scores_gemma":[0.3296826,0.00079484895,0.0030669225,0.009735194,0.0042904946,0.012093656,0.003916596,0.009344933,0.0010185989],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001546659,0.000966612,0.20841672,0.0069203367,0.0053329337,0.00015409382,0.0011617617,0.016557299,0.00024110997,0.07227169,0.06059082,0.6258399],"study_design_scores_gemma":[0.0010183407,0.0018873595,0.19104098,0.029963326,0.0033401442,0.00052605633,0.003851945,0.077141665,0.001255107,0.52187175,0.16707982,0.0010234646],"about_ca_topic_score_codex":0.0119011635,"about_ca_topic_score_gemma":0.01254241,"teacher_disagreement_score":0.83782595,"about_ca_system_score_codex":0.0046087103,"about_ca_system_score_gemma":0.006918942,"threshold_uncertainty_score":0.85766864},"labels":[],"label_agreement":null},{"id":"W4409986468","doi":"10.1016/s1470-2045(25)00212-8","title":"Meta-analysis on SBRT and ablation for localised RCC – Authors' reply","year":2025,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Advanced X-ray and CT Imaging","field":"Engineering","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ablation; Medicine; Internal medicine","score_opus":0.09482312639389179,"score_gpt":0.33581998624526954,"score_spread":0.24099685985137775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409986468","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024411334,0.0044373763,0.000092903334,0.94895035,0.04523616,0.000018500463,0.00041008176,0.000018633797,0.00059189036],"genre_scores_gemma":[0.0022777426,0.001655781,0.00015070528,0.9333852,0.060565464,0.00008122501,0.0000937655,0.000027123187,0.0017629915],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9886811,0.005896223,0.0018177576,0.0011208379,0.001832301,0.0006518558],"domain_scores_gemma":[0.9088623,0.0743205,0.00480844,0.0019634669,0.007217948,0.0028274101],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015764253,0.0009848736,0.0037787328,0.0015403808,0.0019977316,0.003498714,0.002225906,0.03206642,0.008342221],"category_scores_gemma":[0.10547714,0.0011380641,0.0030534067,0.001648428,0.0021608307,0.0025991276,0.0021129297,0.024173673,0.0047447872],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025136885,0.000010251805,0.0006718364,0.00042885848,0.00028947202,0.00024389218,0.00007299251,0.0000691887,0.0000503287,0.00048703625,0.99203205,0.005392753],"study_design_scores_gemma":[0.002971187,0.00026128785,0.0038119992,0.0034364644,0.0025294812,0.0012646489,0.0004960791,0.0008085606,0.00047530243,0.015216589,0.9684863,0.00024213227],"about_ca_topic_score_codex":0.006076013,"about_ca_topic_score_gemma":0.011190397,"teacher_disagreement_score":0.03206642,"about_ca_system_score_codex":0.0033873548,"about_ca_system_score_gemma":0.005264372,"threshold_uncertainty_score":0.08337033},"labels":[],"label_agreement":null},{"id":"W4410015461","doi":"10.1016/s1470-2045(25)00128-7","title":"Incidence and prevalence of antimicrobial resistance in outpatients with cancer: a multicentre, retrospective, cohort study","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Retrospective cohort study; Medicine; Incidence (geometry); Antimicrobial; Cohort; Cancer; Cancer incidence; Cohort study; Internal medicine; Microbiology; Biology","score_opus":0.015814742378796924,"score_gpt":0.33387405134784404,"score_spread":0.3180593089690471,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410015461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991026,0.00022122002,0.000060803082,0.000029649622,0.000006675388,0.000009163886,0.00044000498,0.0000028427055,0.00012704724],"genre_scores_gemma":[0.99925596,0.00014533581,0.00007775668,0.00003767487,0.000010247436,0.000009828104,0.00037847855,0.0000031618329,0.00008156045],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985637,0.00034328518,0.000163587,0.0004953434,0.00017404281,0.00026005312],"domain_scores_gemma":[0.99728,0.0003471407,0.0011933538,0.00042558313,0.00027671378,0.00047712144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010528027,0.00052409084,0.00074601546,0.00092818716,0.0006589674,0.0013791103,0.0008692718,0.0011258856,0.0014069002],"category_scores_gemma":[0.00313362,0.0010042053,0.0012922316,0.0019777252,0.0005624978,0.0012238427,0.00090345496,0.0012093327,0.00031896876],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021360787,0.00004720317,0.9988979,0.00000981053,0.00015538241,0.000058932943,0.00009390427,0.000015008815,0.0001676541,0.000008728104,0.00007940935,0.00025232436],"study_design_scores_gemma":[0.000016794935,0.00017279161,0.99895084,0.0000072716766,0.00007527513,0.0002907887,0.00030081524,0.00008211918,0.000023006889,0.000010424544,0.000063525506,0.0000064673713],"about_ca_topic_score_codex":0.01453439,"about_ca_topic_score_gemma":0.013565588,"teacher_disagreement_score":0.01453439,"about_ca_system_score_codex":0.0006939423,"about_ca_system_score_gemma":0.00053437974,"threshold_uncertainty_score":0.02889955},"labels":[],"label_agreement":null},{"id":"W4410015550","doi":"10.1016/s1470-2045(25)00020-8","title":"International consensus on laryngeal preservation strategies in laryngeal and hypopharyngeal cancer","year":2025,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Rehabilitation Institute","funders":"","keywords":"Hypopharyngeal cancer; Larynx; Medicine; Cancer; General surgery; Surgery; Internal medicine","score_opus":0.13223500994658555,"score_gpt":0.45350917649095857,"score_spread":0.321274166544373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410015550","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000035194473,0.9975198,0.000044851793,0.0013047955,0.0005094771,0.000009732831,0.000063529864,0.000002568458,0.0005100376],"genre_scores_gemma":[0.0006317039,0.99709463,0.0001970391,0.0015292098,0.00020710698,0.000023101908,0.000063246946,0.0000023295836,0.00025171877],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99850863,0.00044996562,0.00044326994,0.00016542223,0.0003219449,0.00011074797],"domain_scores_gemma":[0.9958176,0.0028445462,0.00048609692,0.00007336719,0.00065191777,0.00012645598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060949987,0.000870389,0.0035723285,0.0038108914,0.00038897872,0.0022846796,0.0018080429,0.0026940464,0.00773317],"category_scores_gemma":[0.00889986,0.00044695186,0.0030858743,0.004371745,0.000837888,0.0017717842,0.0016844141,0.0026864428,0.0015618689],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003076556,0.000036188703,0.00028446384,0.18281113,0.0013121226,0.00012196508,0.00016466109,0.00033751887,0.00038467845,0.0039945943,0.06930033,0.74094474],"study_design_scores_gemma":[0.00025180614,0.00012520017,0.0014660602,0.21483842,0.005108413,0.0003208583,0.00019720245,0.000057123158,0.00021583111,0.002795947,0.77458835,0.000034806308],"about_ca_topic_score_codex":0.005745181,"about_ca_topic_score_gemma":0.01150066,"teacher_disagreement_score":0.00773317,"about_ca_system_score_codex":0.0023089536,"about_ca_system_score_gemma":0.008423876,"threshold_uncertainty_score":0.032233775},"labels":[],"label_agreement":null},{"id":"W4410015558","doi":"10.1016/s1470-2045(25)00079-8","title":"Antimicrobial resistance in patients with haematological malignancies: a scoping review","year":2025,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Kingston Health Sciences Centre; Princess Margaret Cancer Centre; Occupational Cancer Research Centre; Queen's University; Cancer Care Ontario; University of Toronto; Ontario Institute for Cancer Research","funders":"Princess Margaret Cancer Foundation","keywords":"Antimicrobial; Medicine; Antibiotic resistance; Intensive care medicine; Oncology; Internal medicine; Biology; Microbiology; Antibiotics","score_opus":0.06813807971903882,"score_gpt":0.40276218604490405,"score_spread":0.33462410632586526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410015558","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006922139,0.99960595,0.000019891755,0.00011278693,0.000054498552,0.000008083354,0.000033314296,0.0000016271377,0.000094646],"genre_scores_gemma":[0.0007615074,0.9988644,0.00007483132,0.00019117139,0.000035386256,0.000011784867,0.00002453349,8.197327e-7,0.00003564744],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9981184,0.00044765905,0.00070998824,0.00022161247,0.00039262706,0.0001097009],"domain_scores_gemma":[0.99318975,0.0047436203,0.0014234337,0.00007470766,0.00045942797,0.000109007735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034645773,0.0012028401,0.004805249,0.006306701,0.00038197916,0.002726451,0.00136886,0.00245079,0.004376762],"category_scores_gemma":[0.009768578,0.0007373193,0.0036547745,0.0074701337,0.00067970715,0.0019980813,0.001677982,0.0017269572,0.00043554668],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001770375,0.000043341195,0.0007834762,0.65816736,0.0031659768,0.00015022642,0.00023834793,0.00026033114,0.00035116466,0.00084539247,0.011810067,0.32400733],"study_design_scores_gemma":[0.00012961375,0.0001406952,0.0034453669,0.83461463,0.016374797,0.00067675026,0.0003677524,0.00011019549,0.00017723873,0.0007331717,0.14317884,0.000050972274],"about_ca_topic_score_codex":0.0058590914,"about_ca_topic_score_gemma":0.01451481,"teacher_disagreement_score":0.006306701,"about_ca_system_score_codex":0.0016227793,"about_ca_system_score_gemma":0.0048538577,"threshold_uncertainty_score":0.018322647},"labels":[],"label_agreement":null},{"id":"W4410080762","doi":"10.1016/s1470-2045(25)00140-8","title":"Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Ottawa Hospital; Jewish General Hospital","funders":"Jazz Pharmaceuticals; Pfizer","keywords":"Fulvestrant; Palbociclib; Metastatic breast cancer; Medicine; Oncology; Internal medicine; Cancer; Breast cancer; Hormone receptor; Gynecology; Estrogen receptor","score_opus":0.02242860463022142,"score_gpt":0.3244790213498309,"score_spread":0.3020504167196095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410080762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99198675,0.004837388,0.00022898425,0.00040150827,0.000149413,0.0004796426,0.00069386093,0.000052015723,0.00117049],"genre_scores_gemma":[0.990119,0.00410135,0.0006884631,0.00076127646,0.00016880421,0.0005050585,0.0016942384,0.00002705905,0.0019347436],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995765,0.00019288277,0.000022057073,0.00006417036,0.000048133214,0.00009622811],"domain_scores_gemma":[0.9995245,0.0000887209,0.00012336463,0.00004553396,0.000021660884,0.00019632674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015898085,0.0013675953,0.0025769142,0.00047070798,0.00028264942,0.0011591845,0.00083472754,0.0008807203,0.0024388884],"category_scores_gemma":[0.00095656817,0.00060557853,0.0019419639,0.00061233685,0.00077820796,0.0012080203,0.00037332342,0.0026194684,0.00074544805],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88250154,0.012598614,0.006660733,0.0009098163,0.0039290045,0.00012473472,0.00015267245,0.0021514946,0.012333762,0.00016843178,0.002181694,0.07628757],"study_design_scores_gemma":[0.80143,0.15853316,0.032722972,0.000059293903,0.0021497228,0.00021779968,0.00009988957,0.001075675,0.0010542476,0.00024203048,0.0023706483,0.00004461054],"about_ca_topic_score_codex":0.0015521861,"about_ca_topic_score_gemma":0.005843345,"teacher_disagreement_score":0.0025769142,"about_ca_system_score_codex":0.0011028606,"about_ca_system_score_gemma":0.0010646253,"threshold_uncertainty_score":0.008407772},"labels":[],"label_agreement":null},{"id":"W4410202982","doi":"10.1016/s1470-2045(25)00152-4","title":"Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"Cancer Council Queensland; National Health and Medical Research Council; National Institutes of Health; Arts South Australia; Associazione Italiana per la Ricerca sul Cancro; Korea Health Industry Development Institute; European Society for Medical Oncology; Ministry of Health and Welfare; Cancer Australia; Peter MacCallum Cancer Centre; National Breast Cancer Foundation; Fondazione AIRC per la ricerca sul cancro ETS; Susan G. Komen; Breast Cancer Research Foundation","keywords":"Medicine; Breast cancer; Oncology; Cohort; Cancer; Cohort study; Gynecology; Internal medicine; Obstetrics","score_opus":0.012886156496256743,"score_gpt":0.32309992416142397,"score_spread":0.31021376766516723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410202982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99713,0.00077534217,0.000110337365,0.00017502892,0.000027294349,0.000008082056,0.0011561933,0.0000063257785,0.00061150524],"genre_scores_gemma":[0.9979494,0.000534614,0.00011446259,0.0000857232,0.000024815206,0.0000120412105,0.0007393549,0.0000064114715,0.00053302513],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99958056,0.00007811602,0.00003423628,0.0001341938,0.000041916534,0.00013098725],"domain_scores_gemma":[0.9982363,0.00023909153,0.00065753114,0.00025674736,0.00015641845,0.00045395058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086018234,0.00047126488,0.00051203725,0.0005799452,0.0006569605,0.001035912,0.00068906334,0.0011313306,0.0023918117],"category_scores_gemma":[0.0022959602,0.00068909285,0.0013785188,0.0013835311,0.00034613642,0.00065106223,0.00062157644,0.0020022038,0.00030644724],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042825894,0.00006999036,0.99722785,0.000013931139,0.0003827985,0.00012007635,0.00014913561,0.000042889737,0.00030309905,0.000036403657,0.00025291689,0.000972567],"study_design_scores_gemma":[0.000021852991,0.00011425028,0.99899524,0.000009179186,0.00019525211,0.00016268807,0.00018619222,0.00007319378,0.000030142033,0.000025932242,0.00017784555,0.000008345989],"about_ca_topic_score_codex":0.025627617,"about_ca_topic_score_gemma":0.026090138,"teacher_disagreement_score":0.025627617,"about_ca_system_score_codex":0.00040304233,"about_ca_system_score_gemma":0.00051128055,"threshold_uncertainty_score":0.050956905},"labels":[],"label_agreement":null},{"id":"W4410795851","doi":"10.1016/s1470-2045(25)00157-3","title":"Contributions of cancer treatment and genetic predisposition to risk of subsequent neoplasms in long-term survivors of childhood cancer: a report from the St Jude Lifetime Cohort and the Childhood Cancer Survivor Study","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; National Institutes of Health; Gaming Technologies Association; American Lebanese Syrian Associated Charities","keywords":"Childhood cancer; Cancer; Medicine; Cohort; Term (time); Genetic predisposition; Pediatrics; Oncology; Internal medicine; Disease","score_opus":0.015195685274299956,"score_gpt":0.34656154873407635,"score_spread":0.3313658634597764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410795851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975769,0.0009785983,0.000053516334,0.00020447034,0.000015107765,0.0000034684126,0.0006608326,0.0000023863593,0.00050469534],"genre_scores_gemma":[0.9989672,0.00036330504,0.00002711914,0.000034312354,0.000012759356,0.000003393083,0.0003238027,0.0000019638444,0.0002661583],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996259,0.000121179975,0.000032900247,0.00006495012,0.00006250381,0.000092480426],"domain_scores_gemma":[0.9984664,0.00032418466,0.00056277204,0.00017011813,0.00012972648,0.0003468762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005563452,0.00021266458,0.00026371813,0.0005527454,0.00043502304,0.0006715395,0.00038287637,0.00054076046,0.0013198899],"category_scores_gemma":[0.0022124113,0.0002841845,0.0007208486,0.00116982,0.00028717698,0.00026993867,0.00048732167,0.0007233284,0.000098683166],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007785856,0.000014418975,0.9989254,0.0000036184656,0.00009447059,0.000039515133,0.000059722373,0.000024745632,0.000115417104,0.00001869552,0.00006258338,0.00056345854],"study_design_scores_gemma":[0.0000031515974,0.000021234782,0.9995858,0.0000027088731,0.000049675135,0.00005515784,0.00010864398,0.000025267746,0.00002993251,0.000012141126,0.00010407059,0.0000022314205],"about_ca_topic_score_codex":0.032741483,"about_ca_topic_score_gemma":0.037054133,"teacher_disagreement_score":0.032741483,"about_ca_system_score_codex":0.0004529499,"about_ca_system_score_gemma":0.000615664,"threshold_uncertainty_score":0.0651018},"labels":[],"label_agreement":null},{"id":"W4410799892","doi":"10.1016/s1470-2045(25)00026-9","title":"Impact of suboptimal cancer care in the Commonwealth: a scoping review and call to action","year":2025,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University; University Health Network; University of Toronto; Sault Area Hospital","funders":"","keywords":"Call to action; Commonwealth; Action (physics); Cancer; Medicine; Business; Psychology; Political science; Marketing; Law; Internal medicine","score_opus":0.15009217086490642,"score_gpt":0.6038674467284837,"score_spread":0.45377527586357724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410799892","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000049518723,0.995462,0.000028813996,0.0038487609,0.00047218055,0.000004966905,0.000036985486,0.0000029407404,0.00009381717],"genre_scores_gemma":[0.00089197373,0.99595547,0.00014329137,0.002543644,0.00036292756,0.000014075813,0.000034711455,0.0000020130192,0.000051920706],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.993863,0.0018465301,0.0014949037,0.00051285094,0.0018581433,0.00042460675],"domain_scores_gemma":[0.96199954,0.027324231,0.0049833436,0.00045046656,0.0043417355,0.00090061093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016363857,0.0015740133,0.0070712576,0.0067232857,0.00086663966,0.0067963824,0.0029018342,0.006749486,0.0047312984],"category_scores_gemma":[0.03556194,0.0009889252,0.0047438466,0.010569432,0.0022948661,0.0071319523,0.003909849,0.0051890113,0.00061010366],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019541259,0.000064962434,0.0019948836,0.32850286,0.0038739915,0.00029845748,0.00070989557,0.0007709556,0.00024571127,0.007551728,0.11236838,0.54342276],"study_design_scores_gemma":[0.000092262344,0.00008400006,0.004920166,0.6656426,0.0054257815,0.00043567535,0.0016430477,0.00025202817,0.00008218804,0.0062170895,0.31509757,0.00010748915],"about_ca_topic_score_codex":0.033448648,"about_ca_topic_score_gemma":0.08091363,"teacher_disagreement_score":0.033448648,"about_ca_system_score_codex":0.009772777,"about_ca_system_score_gemma":0.032661427,"threshold_uncertainty_score":0.086541414},"labels":[],"label_agreement":null},{"id":"W4410799942","doi":"10.1016/s1470-2045(25)00158-5","title":"Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; Astellas Pharma; Seagen; Pfizer","keywords":"Pembrolizumab; Urothelial cancer; Medicine; Open label; Oncology; Internal medicine; Chemotherapy; Phases of clinical research; Cancer; Clinical trial; Immunotherapy; Bladder cancer","score_opus":0.054222734857564785,"score_gpt":0.40464735792672296,"score_spread":0.35042462306915817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410799942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99274135,0.004808374,0.00019450538,0.00031274307,0.0002336169,0.00044660553,0.00037886333,0.00003235897,0.0008516043],"genre_scores_gemma":[0.9943315,0.002331151,0.0004295388,0.00047189626,0.0001653934,0.00048784862,0.0005240862,0.00001025996,0.0012483685],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994235,0.00033221662,0.00002598637,0.00008317757,0.000039428618,0.00009569616],"domain_scores_gemma":[0.9992489,0.00026647368,0.00017859155,0.000044265253,0.000031318945,0.00023037942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013687811,0.001006928,0.0024874925,0.00030439702,0.00026867285,0.0009244538,0.0007161266,0.0011140471,0.0031741157],"category_scores_gemma":[0.0013066455,0.00042969626,0.0019396594,0.00034334956,0.0008095109,0.0010775842,0.00035115192,0.0027290545,0.00048010473],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96732837,0.0048621767,0.0008453089,0.0006580316,0.0012773531,0.000034089313,0.00006344431,0.00063006807,0.0023440016,0.00009577165,0.0004962003,0.02136513],"study_design_scores_gemma":[0.83671296,0.15383518,0.0060451804,0.00008850167,0.0010305292,0.000054095184,0.00006864833,0.0007415357,0.00049348944,0.00020471089,0.0007016013,0.000023519568],"about_ca_topic_score_codex":0.0012472359,"about_ca_topic_score_gemma":0.0031555283,"teacher_disagreement_score":0.0031741157,"about_ca_system_score_codex":0.0007712521,"about_ca_system_score_gemma":0.0007401158,"threshold_uncertainty_score":0.010618508},"labels":[],"label_agreement":null},{"id":"W4410800041","doi":"10.1016/s1470-2045(25)00039-7","title":"National cancer control plans in Latin America and the Caribbean: challenges and future directions","year":2025,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Cancer Institute","keywords":"Latin Americans; Caribbean region; Political science; Cancer; Regional science; Geography; Medicine","score_opus":0.14339810513901127,"score_gpt":0.43006023449725245,"score_spread":0.2866621293582412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410800041","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004699744,0.99105525,0.00005066861,0.00780177,0.00044205054,0.0000044286408,0.000058260288,0.000008218215,0.00053240295],"genre_scores_gemma":[0.0008473545,0.9956584,0.00025170928,0.002604841,0.00035473926,0.000015520964,0.000049201866,0.0000029360547,0.00021529138],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988707,0.00040612006,0.00013470555,0.00009719137,0.00031504393,0.00017622461],"domain_scores_gemma":[0.9953885,0.00254406,0.00052175607,0.00005410759,0.0011028177,0.0003886875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057945354,0.0009846672,0.002941628,0.0027086122,0.0006047353,0.0032385187,0.0019286603,0.0028113278,0.008925178],"category_scores_gemma":[0.008637732,0.00043886752,0.0014195152,0.0047969557,0.0012047756,0.0036804492,0.0021663434,0.0042381105,0.0010000675],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000100107274,0.000052904627,0.0005778587,0.032260325,0.00023963905,0.00008554516,0.00023746098,0.00052704755,0.00016688628,0.016209494,0.089125365,0.86041737],"study_design_scores_gemma":[0.0000735622,0.00008103719,0.002328179,0.067488275,0.0005328196,0.00019039285,0.0009946726,0.0002546135,0.00006889098,0.008281278,0.9196663,0.00004001518],"about_ca_topic_score_codex":0.044182807,"about_ca_topic_score_gemma":0.079776414,"teacher_disagreement_score":0.044182807,"about_ca_system_score_codex":0.00551103,"about_ca_system_score_gemma":0.020676449,"threshold_uncertainty_score":0.087851286},"labels":[],"label_agreement":null},{"id":"W4410952304","doi":"10.1016/s1470-2045(25)00287-6","title":"Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Jazz Pharmaceuticals","keywords":"Oxaliplatin; Medicine; Capecitabine; Regimen; Internal medicine; Tolerability; Chemotherapy; Gastroenterology; Dosing; Oncology; Adenocarcinoma; Adverse effect; Cancer; Colorectal cancer","score_opus":0.04556820725942549,"score_gpt":0.3980022265406252,"score_spread":0.3524340192811997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410952304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880052,0.007970619,0.00029375,0.00052912073,0.000259607,0.0007457594,0.00092438044,0.000060447164,0.0012111319],"genre_scores_gemma":[0.9853897,0.0071869814,0.0011297121,0.0009956533,0.00023399707,0.000682368,0.0017536832,0.000037656275,0.0025902994],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995709,0.00022223679,0.000021690377,0.00006662902,0.0000382009,0.000080238446],"domain_scores_gemma":[0.9993974,0.00012776173,0.00016254555,0.000050816467,0.000035675508,0.00022595188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016558092,0.001362673,0.0031128828,0.00048370034,0.00030299192,0.0011591895,0.0008026505,0.0010545091,0.0028889054],"category_scores_gemma":[0.0011777562,0.0006814081,0.0023465212,0.00055439933,0.00073593116,0.0010194499,0.00033366823,0.0028720691,0.000652768],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8922676,0.014198796,0.004135979,0.0017408438,0.004135097,0.00009852435,0.00017607,0.0018128221,0.009438254,0.00012835792,0.0021943203,0.06967343],"study_design_scores_gemma":[0.8242712,0.15219952,0.017215025,0.000084872336,0.0024995187,0.00013594961,0.00008446425,0.00081506785,0.0007835426,0.00016130289,0.0017078747,0.000041682008],"about_ca_topic_score_codex":0.0015994285,"about_ca_topic_score_gemma":0.00604533,"teacher_disagreement_score":0.0031128828,"about_ca_system_score_codex":0.0009210615,"about_ca_system_score_gemma":0.0009534614,"threshold_uncertainty_score":0.009664416},"labels":[],"label_agreement":null},{"id":"W4411197793","doi":"10.1016/s1470-2045(25)00194-9","title":"Partial-breast radiotherapy after breast conservation surgery for women with early breast cancer (UK IMPORT LOW): 10-year outcomes from a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Health Service Corps; Department of Health and Social Care; National Institute for Health and Care Research; Royal Marsden NHS Foundation Trust; Health and Care Research Wales; Institute of Cancer Research; Cancer Research UK; NIHR Cambridge Biomedical Research Centre; National Institute on Handicapped Research","keywords":"Medicine; Breast cancer; Open label; Breast-conserving surgery; Randomized controlled trial; Radiation therapy; Oncology; Surgery; Cancer; Internal medicine; Mastectomy","score_opus":0.023654093187701838,"score_gpt":0.33913521222369725,"score_spread":0.3154811190359954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411197793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98134434,0.0107837245,0.00065823126,0.0010410357,0.00037590897,0.0022754797,0.0012884495,0.000084693056,0.002148181],"genre_scores_gemma":[0.9860991,0.0034260142,0.0012003159,0.0017091715,0.00031393318,0.003627965,0.0016461939,0.000022132057,0.001955134],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99807274,0.0014696476,0.00010612498,0.00013808002,0.000082029626,0.00013139925],"domain_scores_gemma":[0.99746835,0.0008493605,0.00089638936,0.00024996838,0.00015531905,0.00038056457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037346093,0.000868842,0.0023099938,0.00032000616,0.00035704128,0.0010460084,0.0007445272,0.0012652954,0.005394035],"category_scores_gemma":[0.0048313905,0.00038845974,0.0018005866,0.0004122961,0.00096229784,0.0009653346,0.00066624716,0.0017929715,0.0005924648],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97675055,0.0030187974,0.0011709732,0.0012831173,0.00096692296,0.00003632667,0.000058024947,0.00029214547,0.0011438902,0.00006439642,0.001024785,0.014190128],"study_design_scores_gemma":[0.9166812,0.076229624,0.004416214,0.000141455,0.0011666674,0.000048906622,0.000030954583,0.0002579358,0.00020028322,0.00014622546,0.0006639367,0.000016586882],"about_ca_topic_score_codex":0.00094295957,"about_ca_topic_score_gemma":0.002229152,"teacher_disagreement_score":0.005394035,"about_ca_system_score_codex":0.00090806565,"about_ca_system_score_gemma":0.0007992515,"threshold_uncertainty_score":0.019750714},"labels":[],"label_agreement":null},{"id":"W4411225252","doi":"10.1016/s1470-2045(25)00205-0","title":"Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Health Service Corps; Auckland Medical Research Foundation; National Institute for Health and Care Research; Institute of Cancer Research; Cancer Research UK; Royal Marsden Cancer Charity; Accuray; Royal Marsden NHS Foundation Trust","keywords":"Prostate cancer; Medicine; Radiation therapy; Toxicity; Oncology; Prostate; Internal medicine; Cancer","score_opus":0.09065600622373889,"score_gpt":0.42525760184701067,"score_spread":0.3346015956232718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411225252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98791015,0.0054117413,0.00089821045,0.00058288855,0.00043958076,0.0014759139,0.00093322224,0.00016406708,0.0021841265],"genre_scores_gemma":[0.98687035,0.003077158,0.0017771508,0.0011677184,0.00041876934,0.0018814972,0.0012955657,0.00006332947,0.0034484118],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99912995,0.00051115424,0.000038247428,0.00014311873,0.00006835921,0.00010923041],"domain_scores_gemma":[0.99882406,0.0004227159,0.0002938376,0.00013135304,0.00005043843,0.00027752595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022394953,0.0018893454,0.0029101644,0.0003817056,0.00038892793,0.0012878021,0.0011700495,0.0019454549,0.0062871245],"category_scores_gemma":[0.002191614,0.00048705348,0.0035507795,0.0005802623,0.001373991,0.0010939117,0.00048190667,0.003825748,0.0008157747],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97210807,0.003354884,0.0003560105,0.00057131256,0.0014990474,0.000032873428,0.000058102705,0.0008335021,0.0025305836,0.000195304,0.0008738552,0.017586526],"study_design_scores_gemma":[0.9436755,0.05259402,0.0015314113,0.000028116052,0.0006044241,0.00003740559,0.000016951175,0.00044158893,0.00031855347,0.00028361214,0.00045053475,0.000017842734],"about_ca_topic_score_codex":0.0010023558,"about_ca_topic_score_gemma":0.0018420911,"teacher_disagreement_score":0.0062871245,"about_ca_system_score_codex":0.0008563705,"about_ca_system_score_gemma":0.0012053209,"threshold_uncertainty_score":0.021032512},"labels":[],"label_agreement":null},{"id":"W4411260753","doi":"10.1016/s1470-2045(25)00209-8","title":"Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Exelixis","keywords":"Atezolizumab; Cabozantinib; Medicine; Oncology; Prostate cancer; Prostate; Internal medicine; Cancer; Immunotherapy; Pembrolizumab","score_opus":0.3279042008534256,"score_gpt":0.5471206174015985,"score_spread":0.21921641654817287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411260753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9711033,0.015795989,0.0009261697,0.0015202623,0.000817179,0.0017458657,0.0035937896,0.00027692184,0.004220487],"genre_scores_gemma":[0.98423785,0.004308586,0.0012801177,0.0014259962,0.00043468515,0.0012725592,0.0027261449,0.00005303228,0.0042610806],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9992015,0.00044417518,0.000041561958,0.00012741669,0.00006072687,0.00012457979],"domain_scores_gemma":[0.99880004,0.0004217038,0.00022461255,0.0001175493,0.00008742748,0.0003487707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018888831,0.0016536391,0.0025981402,0.0003101149,0.00039861264,0.0015018479,0.00092612754,0.0015634454,0.009521199],"category_scores_gemma":[0.0021912197,0.00054330286,0.0032768738,0.00048872444,0.0008505369,0.0013306101,0.00037262953,0.003293792,0.0015286105],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9736322,0.0016602792,0.0006558142,0.000911666,0.002865249,0.000044830977,0.000072402574,0.00040056,0.0018037679,0.00014191764,0.0020985163,0.015712697],"study_design_scores_gemma":[0.966359,0.028817995,0.0019325998,0.000042607815,0.0011622723,0.00005668181,0.00003933482,0.000230036,0.00019393284,0.00018861152,0.00095886283,0.000018130404],"about_ca_topic_score_codex":0.0019924166,"about_ca_topic_score_gemma":0.0066395616,"teacher_disagreement_score":0.009521199,"about_ca_system_score_codex":0.0009372815,"about_ca_system_score_gemma":0.0011259967,"threshold_uncertainty_score":0.03185153},"labels":[],"label_agreement":null},{"id":"W4411847959","doi":"10.1016/s1470-2045(25)00237-2","title":"SANO trial: innovations, risks, and unanswered questions","year":2025,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Psychology","score_opus":0.14373754334454894,"score_gpt":0.4464597041298731,"score_spread":0.3027221607853242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411847959","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009938283,0.003135559,0.000045237106,0.9894537,0.0062469104,0.0000041356466,0.00005730604,0.0000073738956,0.00095036783],"genre_scores_gemma":[0.0023720188,0.002096976,0.00023527497,0.94481444,0.048921905,0.000047745158,0.00004192352,0.00002178021,0.0014479901],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9721807,0.015867576,0.0023670737,0.0018944168,0.0061534187,0.0015367606],"domain_scores_gemma":[0.8638012,0.11000266,0.0052266996,0.002320107,0.008903112,0.0097461855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.036439966,0.001048296,0.0029097383,0.0011060286,0.00368614,0.007953808,0.0037862344,0.068458326,0.010050508],"category_scores_gemma":[0.13655283,0.00081526814,0.0021673786,0.0016247659,0.00806927,0.00828847,0.0028240425,0.056455426,0.008262247],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049306167,0.000038449758,0.000491317,0.00017286598,0.000065142485,0.00033711767,0.000086143125,0.00009036896,0.00009753265,0.012815774,0.963247,0.022065196],"study_design_scores_gemma":[0.0020939405,0.00019052865,0.0012026725,0.001668885,0.00018217896,0.0008131467,0.00045400613,0.00090854504,0.00028299485,0.10495077,0.8870951,0.00015718848],"about_ca_topic_score_codex":0.004318184,"about_ca_topic_score_gemma":0.0075714663,"teacher_disagreement_score":0.068458326,"about_ca_system_score_codex":0.00711223,"about_ca_system_score_gemma":0.011563735,"threshold_uncertainty_score":0.19271529},"labels":[],"label_agreement":null},{"id":"W4411848010","doi":"10.1016/s1470-2045(25)00211-6","title":"Hormone therapy use and young-onset breast cancer: a pooled analysis of prospective cohorts included in the Premenopausal Breast Cancer Collaborative Group","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; Ontario Institute for Cancer Research","funders":"National Center for Chronic Disease Prevention and Health Promotion; National Health Service Corps; National Institute of Environmental Health Sciences; National Cancer Institute; Centers for Disease Control and Prevention; Breast Cancer Now; California Department of Public Health; Instituto Nacional del Cáncer; Breast Cancer Research Foundation; Avon Foundation for Women; Foundation for the National Institutes of Health; American Cancer Society; U.S. Department of Health and Human Services; National Institutes of Health; Institute of Cancer Research","keywords":"Breast cancer; Medicine; Cancer; Oncology; Prospective cohort study; Internal medicine; Gynecology; Hormone therapy; Obstetrics","score_opus":0.014502982720521989,"score_gpt":0.31586021876895537,"score_spread":0.3013572360484334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411848010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9344558,0.056025878,0.0016260124,0.00023208268,0.0002940674,0.00008402488,0.0063917586,0.00007713359,0.0008131756],"genre_scores_gemma":[0.99070156,0.004822711,0.0004997617,0.00012540801,0.00012726182,0.00007517463,0.0030959316,0.00003045811,0.0005216593],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99523336,0.0023637656,0.00053029135,0.0011188678,0.00035409376,0.00039948747],"domain_scores_gemma":[0.99412763,0.0016531298,0.0015646146,0.0017285777,0.00051717414,0.00040892864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006013321,0.0014043434,0.0035302911,0.0018131238,0.00071257266,0.0019472889,0.0012085071,0.0015167465,0.0012523081],"category_scores_gemma":[0.006369078,0.0013807195,0.009993024,0.0038236135,0.00039905804,0.0007707337,0.0013222094,0.00091404223,0.00020045067],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011822902,0.00006889236,0.8549545,0.00064828934,0.12392738,0.00028746287,0.00016686022,0.00054888893,0.0014416592,0.00013194632,0.0013534562,0.0046478454],"study_design_scores_gemma":[0.0010028834,0.00055710867,0.9242941,0.0001271901,0.071482696,0.00026140403,0.00028178605,0.00047320352,0.0002522746,0.00014637271,0.0010729269,0.00004809651],"about_ca_topic_score_codex":0.023776047,"about_ca_topic_score_gemma":0.027013695,"teacher_disagreement_score":0.023776047,"about_ca_system_score_codex":0.00056701264,"about_ca_system_score_gemma":0.0008128947,"threshold_uncertainty_score":0.047275305},"labels":[],"label_agreement":null},{"id":"W4412006675","doi":"10.1016/s1470-2045(25)00222-0","title":"Oral contraceptive use and risk of liver cancer: a population-based study, systematic review, and meta-analysis","year":2025,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Reproductive Health and Contraception","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Canadian Institutes of Health Research; National Institutes of Health; Cancer Research UK; NHS Health Scotland","keywords":"Meta-analysis; Medicine; Cancer; Gynecology; Obstetrics; Internal medicine","score_opus":0.18014328231167145,"score_gpt":0.4543361045288443,"score_spread":0.2741928222171729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412006675","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0031667794,0.99522746,0.0003625869,0.00012081257,0.00008738377,0.00034361464,0.0005205858,0.00001876957,0.00015198882],"genre_scores_gemma":[0.08061244,0.9143955,0.0019377496,0.0005019711,0.0001787283,0.0014448477,0.0007069873,0.000017137956,0.00020466867],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99228305,0.003265415,0.0024013224,0.0007898876,0.00097080733,0.00028956402],"domain_scores_gemma":[0.9837037,0.0116636455,0.002611053,0.0004610365,0.0013560286,0.00020445674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010608864,0.0022679241,0.017825056,0.009421361,0.0006784254,0.0029117854,0.0018642233,0.0018148376,0.0032672149],"category_scores_gemma":[0.027712733,0.0012740185,0.026840808,0.011728169,0.0007214466,0.001505077,0.0012366882,0.0013488323,0.00025214753],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011579959,0.000034849047,0.0050922334,0.58306664,0.39362046,0.00015951855,0.000093528884,0.00047041418,0.00016243175,0.00012879739,0.00088973314,0.0151234595],"study_design_scores_gemma":[0.00050988223,0.00019708676,0.0049521676,0.053352054,0.9381057,0.0001777719,0.00005881296,0.00018697923,0.00010294725,0.00022301039,0.0021031592,0.000030467127],"about_ca_topic_score_codex":0.008333646,"about_ca_topic_score_gemma":0.018167863,"teacher_disagreement_score":0.017825056,"about_ca_system_score_codex":0.0029505854,"about_ca_system_score_gemma":0.0051622675,"threshold_uncertainty_score":0.056105733},"labels":[],"label_agreement":null},{"id":"W4412391704","doi":"10.1016/s1470-2045(25)00281-5","title":"Derivation and validation of the AJCC9V pathological stage classification for HPV-positive oropharyngeal carcinoma: a multicentre registry analysis","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cohort; Oncology; Internal medicine; Lymph node; Pathological; Proportional hazards model; Hazard ratio; Stage (stratigraphy); Cancer; Cancer registry; Cancer staging; Confidence interval","score_opus":0.06605659301961105,"score_gpt":0.3736456508279245,"score_spread":0.30758905780831347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412391704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98431087,0.0008614462,0.0042687994,0.00017032961,0.00010633723,0.00037432706,0.0076207905,0.00003919887,0.0022479414],"genre_scores_gemma":[0.98757243,0.00021707897,0.0028234443,0.000085369415,0.000042484673,0.00037662446,0.008476023,0.000075938035,0.0003305586],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9713679,0.016203826,0.003444072,0.0042231246,0.0031519171,0.0016090045],"domain_scores_gemma":[0.951262,0.011484228,0.0114188,0.017646046,0.007109364,0.0010795261],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.029739253,0.00080206833,0.0012952085,0.0022434935,0.0010910284,0.003088056,0.0020989818,0.0009987402,0.0025175763],"category_scores_gemma":[0.048808213,0.001041766,0.0027985694,0.004448445,0.00090458686,0.0019409965,0.0034605248,0.0012097671,0.001178653],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010920679,0.000106658146,0.9872569,0.00015848354,0.0013644315,0.00011387718,0.0007526172,0.0003219363,0.00081861945,0.00041292564,0.0016654548,0.005936154],"study_design_scores_gemma":[0.00023196937,0.00043295493,0.9907721,0.00013547362,0.0017051166,0.0003984547,0.0006351314,0.0011592713,0.00049668446,0.00020366073,0.0037886908,0.00004055532],"about_ca_topic_score_codex":0.007855005,"about_ca_topic_score_gemma":0.012052399,"teacher_disagreement_score":0.029739253,"about_ca_system_score_codex":0.0010108777,"about_ca_system_score_gemma":0.0024953696,"threshold_uncertainty_score":0.15727806},"labels":[],"label_agreement":null},{"id":"W4412461073","doi":"10.1016/s1470-2045(25)00330-4","title":"Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"GlaxoSmithKline","keywords":"Bortezomib; Dexamethasone; Multiple myeloma; Medicine; Refractory (planetary science); Open label; Oncology; Internal medicine; Lenalidomide; Clinical trial; Materials science","score_opus":0.06159927844167269,"score_gpt":0.3929654672770072,"score_spread":0.33136618883533453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412461073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9491863,0.03978373,0.0008590591,0.0020837376,0.0010309692,0.0010848957,0.0019134902,0.00019488092,0.0038628934],"genre_scores_gemma":[0.9762797,0.012767868,0.001879845,0.0022160055,0.0004510006,0.0010852123,0.002638418,0.000048504706,0.002633501],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99900216,0.0006045276,0.000052958625,0.00012442932,0.00008792383,0.00012799674],"domain_scores_gemma":[0.9991203,0.00029691166,0.00021909185,0.00006760894,0.00005429506,0.00024179503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028364868,0.0011595257,0.0031048758,0.00043748182,0.0002715538,0.0012518902,0.0009660522,0.0010578764,0.0033971097],"category_scores_gemma":[0.0016537658,0.0004749156,0.0032688393,0.00042751792,0.0010737763,0.001690425,0.0006460004,0.0039133104,0.0007687155],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9181183,0.002173001,0.001473483,0.0018027917,0.0051489267,0.000044724595,0.00010383975,0.0011979829,0.0025114596,0.0003670088,0.0027698365,0.06428865],"study_design_scores_gemma":[0.93524075,0.05339593,0.0042788144,0.00016881291,0.0021650617,0.00012663365,0.00007677035,0.0006911131,0.00041268603,0.00059772166,0.0028097264,0.000035961097],"about_ca_topic_score_codex":0.0011397928,"about_ca_topic_score_gemma":0.0037509403,"teacher_disagreement_score":0.0033971097,"about_ca_system_score_codex":0.0012259071,"about_ca_system_score_gemma":0.0010451818,"threshold_uncertainty_score":0.015000939},"labels":[],"label_agreement":null},{"id":"W4412855756","doi":"10.1016/s1470-2045(25)00364-x","title":"Cancer clinical trials should capture tobacco smoking status","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Cancer Care Ontario","funders":"World Health Organization","keywords":"Cancer; Medicine; Clinical trial; Tobacco use; Environmental health; Oncology; Internal medicine","score_opus":0.247731422496764,"score_gpt":0.5755754296091893,"score_spread":0.3278440071124253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412855756","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.038755257,0.14476414,0.047359724,0.6130555,0.054567896,0.0045014587,0.015781209,0.0007375639,0.08047725],"genre_scores_gemma":[0.45454353,0.03410756,0.043608475,0.40173092,0.035270654,0.008235555,0.0098769935,0.00041543404,0.012210978],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.7779934,0.18128785,0.021405991,0.0060442314,0.010426906,0.002841633],"domain_scores_gemma":[0.4428383,0.43851116,0.048246708,0.03446457,0.02630768,0.009631604],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.1900846,0.0019373667,0.005508738,0.0022913893,0.001431612,0.008113308,0.0023889316,0.009390523,0.009575132],"category_scores_gemma":[0.4853257,0.0019360329,0.0035347657,0.004069581,0.0028422042,0.01175145,0.0044528292,0.00950889,0.0047761584],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029497983,0.0010649749,0.0908595,0.02094031,0.024682846,0.00038705792,0.0011879045,0.006820918,0.001383008,0.050520528,0.29925933,0.47339562],"study_design_scores_gemma":[0.023807473,0.0061360677,0.06680429,0.024042992,0.020665096,0.00064763974,0.00072261423,0.009433684,0.0022004216,0.33137724,0.5136675,0.00049493957],"about_ca_topic_score_codex":0.0026737347,"about_ca_topic_score_gemma":0.00515532,"teacher_disagreement_score":0.8099154,"about_ca_system_score_codex":0.003241445,"about_ca_system_score_gemma":0.009068765,"threshold_uncertainty_score":0.9987699},"labels":[],"label_agreement":null},{"id":"W4413439141","doi":"10.1016/s1470-2045(25)00519-4","title":"Australia invests in cancer research grants led by First Nations communities","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Global Health and Surgery","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science; Cancer; Geography; Economic growth; Regional science; Medicine; Economics; Internal medicine","score_opus":0.2703629004057976,"score_gpt":0.5305050538835938,"score_spread":0.26014215347779623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413439141","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.032841314,0.01646542,0.0020660048,0.6991172,0.08884262,0.00054289436,0.002423435,0.00075345533,0.15694761],"genre_scores_gemma":[0.18256104,0.010260332,0.0066981325,0.12475545,0.0072847637,0.00030986016,0.0017609217,0.0003302608,0.6660392],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9926508,0.0018725139,0.00028572517,0.0004290521,0.0025345115,0.0022274305],"domain_scores_gemma":[0.9566349,0.0038392043,0.0015924925,0.0013326007,0.0086282035,0.027972631],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009051777,0.0006900191,0.0008498285,0.0014457563,0.0020847893,0.0035476426,0.00097010954,0.005972707,0.032953598],"category_scores_gemma":[0.026731184,0.00060697,0.0008898269,0.0010502422,0.0014781302,0.0025327466,0.005743321,0.006341361,0.007039649],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056468527,0.0004289895,0.007853955,0.00042649364,0.00015804301,0.00053042773,0.00045261258,0.00040394336,0.0014250824,0.025147874,0.8718482,0.090759724],"study_design_scores_gemma":[0.000263074,0.00036408924,0.014744617,0.00021010144,0.000063318716,0.00036031037,0.00046200925,0.0005198402,0.0005445183,0.0022676915,0.9801705,0.000029817027],"about_ca_topic_score_codex":0.033073723,"about_ca_topic_score_gemma":0.08440348,"teacher_disagreement_score":0.033073723,"about_ca_system_score_codex":0.0067149317,"about_ca_system_score_gemma":0.047894277,"threshold_uncertainty_score":0.11024076},"labels":[],"label_agreement":null},{"id":"W4413935657","doi":"10.1016/s1470-2045(25)00422-x","title":"The effect of TERT promoter mutation on predicting meningioma outcomes: a multi-institutional cohort analysis","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Meningioma and schwannoma management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Department of Pathology, University of Utah; National Institute of Neurological Disorders and Stroke; National Institutes of Health; National Cancer Institute; Friedberg Charitable Foundation; Deutsche Forschungsgemeinschaft; Gray Family Foundation; Division of Cancer Epidemiology and Genetics, National Cancer Institute; Cancer Prevention and Research Institute of Texas","keywords":"Cohort; Meningioma; Internal medicine; Mutation; Medicine; Oncology; Cancer research; Genetics; Biology; Surgery; Gene","score_opus":0.02548517251654213,"score_gpt":0.35857804164688917,"score_spread":0.333092869130347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413935657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976222,0.00046848768,0.00031307037,0.00013158983,0.000043382835,0.0000091217125,0.0011123182,0.000012783536,0.00028702553],"genre_scores_gemma":[0.9983954,0.00015337668,0.0001928727,0.000054312357,0.000031134605,0.000009877648,0.00090033765,0.000017123977,0.00024555545],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99788266,0.00054401247,0.00018307104,0.00074125256,0.00018331966,0.00046562887],"domain_scores_gemma":[0.99512404,0.000969911,0.001419428,0.0013815947,0.00041557042,0.0006895129],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027778193,0.00076628436,0.0008197684,0.0008952884,0.0010482066,0.0018679847,0.0012256023,0.00089680904,0.0021671073],"category_scores_gemma":[0.0061910884,0.0008334777,0.0034465462,0.0016713851,0.00058627117,0.001250572,0.0015258503,0.0017863698,0.0004477544],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010725344,0.00005144864,0.9936659,0.000017079421,0.0021329646,0.00016384668,0.000108555476,0.0001324859,0.0005457901,0.000047444057,0.00044808676,0.0016138604],"study_design_scores_gemma":[0.00008666662,0.00037925865,0.995235,0.000019021796,0.001735809,0.0005083451,0.0003891533,0.0006554946,0.00022046185,0.00015341317,0.0005833014,0.000034101362],"about_ca_topic_score_codex":0.008754211,"about_ca_topic_score_gemma":0.014869229,"teacher_disagreement_score":0.008754211,"about_ca_system_score_codex":0.0006333074,"about_ca_system_score_gemma":0.00090331206,"threshold_uncertainty_score":0.017406523},"labels":[],"label_agreement":null},{"id":"W4413939355","doi":"10.1016/s1470-2045(25)00326-2","title":"Primary target volume delineation for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas","year":2025,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Guangzhou Municipal Health and Family Planning Commission; Chinese Society of Clinical Oncology; Sun Yat-sen University Cancer Center; Overseas Expertise Introduction Project for Discipline Innovation; National Medical Research Council; National Natural Science Foundation of China; Higher Education Discipline Innovation Project; American Society for Radiation Oncology; Canadian Cancer Society; GOH Foundation; National Cancer Centre of Singapore","keywords":"Contouring; Nasopharyngeal carcinoma; Atlas (anatomy); Medicine; Radiation therapy; Medical physics; Radiology; Computer science; Anatomy; Computer graphics (images)","score_opus":0.10156185675425393,"score_gpt":0.41643085071343705,"score_spread":0.3148689939591831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413939355","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011608912,0.9981927,0.00039302738,0.00033799445,0.00015301218,0.000044426903,0.00026773923,0.000014011243,0.000481026],"genre_scores_gemma":[0.001940424,0.99355924,0.0027872536,0.0005667344,0.000073678246,0.00010949368,0.0005598388,0.000024591984,0.00037865833],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985071,0.00043762833,0.0004399829,0.00016662656,0.00039316108,0.000055486784],"domain_scores_gemma":[0.99845445,0.0008103175,0.0003499632,0.00004230294,0.00030879697,0.00003421601],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004573923,0.0011458548,0.0035852066,0.004108667,0.00029238494,0.0012246858,0.002829825,0.0009196676,0.004370778],"category_scores_gemma":[0.005187235,0.00061748043,0.003644714,0.004341246,0.00063473557,0.00090448896,0.0010352401,0.0020229241,0.001380811],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022016527,0.000022982631,0.00039290084,0.091469556,0.00074590166,0.00003278934,0.00008849475,0.0014342368,0.00047303253,0.002604159,0.03613327,0.86638254],"study_design_scores_gemma":[0.0004484324,0.0003215595,0.0075368676,0.12747286,0.0052909274,0.0011183772,0.00016544416,0.0010246856,0.0010233466,0.0045437287,0.8509388,0.00011497947],"about_ca_topic_score_codex":0.018714769,"about_ca_topic_score_gemma":0.02876194,"teacher_disagreement_score":0.018714769,"about_ca_system_score_codex":0.0033318647,"about_ca_system_score_gemma":0.0054214355,"threshold_uncertainty_score":0.037211657},"labels":[],"label_agreement":null},{"id":"W4413942740","doi":"10.1016/s1470-2045(25)00267-0","title":"Analysis of TERT association with clinical outcome in meningiomas: a multi-institutional cohort study","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Meningioma and schwannoma management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Toronto; SickKids Foundation; Hospital for Sick Children; Princess Margaret Cancer Centre","funders":"Canadian Institutes of Health Research; University Health Network Foundation; National Cancer Institute; National Institutes of Health; Foundation for the National Institutes of Health; Brain Tumour Charity; V Foundation for Cancer Research","keywords":"Cohort; Outcome (game theory); Association (psychology); Medicine; Internal medicine; Cohort study; Psychology; Economics; Psychotherapist","score_opus":0.09450548751622428,"score_gpt":0.4393346326823405,"score_spread":0.34482914516611624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413942740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985813,0.00024403266,0.00014376976,0.000051644987,0.000012638612,0.0000058705314,0.0008103571,0.0000056005733,0.00014492127],"genre_scores_gemma":[0.9986872,0.00014616034,0.00013335123,0.0000318546,0.000015944466,0.000009233839,0.0007749529,0.000008656952,0.00019266394],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989304,0.00024812098,0.00012270891,0.0003652604,0.0000975522,0.00023599609],"domain_scores_gemma":[0.996802,0.0003900687,0.0012413316,0.0008296295,0.00025464472,0.00048241505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011829681,0.00049305434,0.0006220031,0.0010381681,0.0007980528,0.0012914587,0.0008090251,0.0007091854,0.001967974],"category_scores_gemma":[0.0030875863,0.00064069027,0.0016940588,0.0022497976,0.00041935238,0.00071369024,0.001020217,0.0011725929,0.00042387482],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00072770036,0.000040680985,0.99599695,0.00001389954,0.00088903244,0.00020766175,0.0000846684,0.000055084376,0.00089902926,0.000036309175,0.0002205084,0.0008284892],"study_design_scores_gemma":[0.000041534877,0.00020938225,0.99765944,0.000008702083,0.00046270352,0.00055458327,0.00028561984,0.00018731212,0.00017107087,0.00006116712,0.0003429861,0.000015454914],"about_ca_topic_score_codex":0.0055394997,"about_ca_topic_score_gemma":0.006206272,"teacher_disagreement_score":0.0055394997,"about_ca_system_score_codex":0.00046552691,"about_ca_system_score_gemma":0.000569391,"threshold_uncertainty_score":0.011014521},"labels":[],"label_agreement":null},{"id":"W4414005916","doi":"10.1016/s1470-2045(25)00379-1","title":"Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre; Université de Sherbrooke","funders":"National Health and Medical Research Council; Cancer Australia; Cancer Research UK; Canadian Cancer Society Research Institute; KWF Kankerbestrijding; Agenzia Italiana del Farmaco, Ministero della Salute; National Cancer Research Institute; Australia New Zealand Gynaecological Oncology Group","keywords":"Medicine; Post-hoc analysis; Chemoradiotherapy; Oncology; Post hoc; Endometrial cancer; Internal medicine; Adjuvant; Radiation therapy; Clinical trial; Adjuvant radiotherapy; Randomized controlled trial; Cancer","score_opus":0.04016505597897605,"score_gpt":0.3997591718153088,"score_spread":0.3595941158363327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414005916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827654,0.008877545,0.00092172116,0.0007127687,0.00042096613,0.0033545068,0.0013494755,0.00006084624,0.001536813],"genre_scores_gemma":[0.9890353,0.0023405417,0.0012592921,0.00073403056,0.0002953209,0.0035130428,0.0013238786,0.00001920835,0.0014794096],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99682176,0.0024064707,0.00020628775,0.00022855934,0.00013264836,0.00020427133],"domain_scores_gemma":[0.9953832,0.0022945744,0.0012732182,0.00038917843,0.00016794886,0.0004918996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007892388,0.001379419,0.0027014113,0.00030587922,0.00026769866,0.0010562848,0.00081319606,0.0013713503,0.0051529873],"category_scores_gemma":[0.00697045,0.00040391294,0.00522095,0.00047141852,0.00095163804,0.0010023897,0.0006335552,0.0027925237,0.00052340835],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98818785,0.000980634,0.0011465653,0.0006975087,0.0027222019,0.000027541235,0.000027283006,0.00045599803,0.0004047074,0.00004458811,0.00034688367,0.004958236],"study_design_scores_gemma":[0.9213071,0.066688724,0.005178036,0.00012667426,0.0046950104,0.000055725704,0.000030492241,0.0006672818,0.00037609777,0.0002934325,0.0005592775,0.000022101096],"about_ca_topic_score_codex":0.0006066091,"about_ca_topic_score_gemma":0.0014139282,"teacher_disagreement_score":0.007892388,"about_ca_system_score_codex":0.00077833293,"about_ca_system_score_gemma":0.0010581773,"threshold_uncertainty_score":0.041739404},"labels":[],"label_agreement":null},{"id":"W4414035458","doi":"10.1016/s1470-2045(25)00333-x","title":"Broadening our view of power in clinician–patient relationships in oncology","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Ethics in medical practice","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Cancer Care Ontario; University of British Columbia","funders":"","keywords":"Power (physics); Medicine; Oncology; Medical physics; Internal medicine; Physics","score_opus":0.3067056193040064,"score_gpt":0.599955963446697,"score_spread":0.2932503441426906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414035458","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011502613,0.016560214,0.010086433,0.88597745,0.0036961145,0.00003409784,0.000016143833,0.00002909875,0.07209779],"genre_scores_gemma":[0.7641253,0.008254916,0.004190602,0.20821552,0.0075180624,0.00017616284,0.00001593428,0.00012663726,0.0073768515],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.8745306,0.100565776,0.0025172164,0.0041958387,0.011000823,0.007189847],"domain_scores_gemma":[0.6496519,0.30483404,0.009088,0.006582525,0.009266343,0.020577148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.09773035,0.00070688105,0.0015305256,0.0037149608,0.019826788,0.033451725,0.005268596,0.02987326,0.008803117],"category_scores_gemma":[0.1301729,0.0012930164,0.001131717,0.0026770576,0.18266712,0.03900219,0.023515644,0.051895875,0.0012120238],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041234714,0.000053897787,0.00066294055,0.00028613096,0.000035092602,0.00034047625,0.10129081,0.0002545103,0.00014748635,0.86343086,0.017341139,0.016115388],"study_design_scores_gemma":[0.000059018806,0.00005287098,0.0006235718,0.00092707213,0.000016604605,0.0005076613,0.04689746,0.00024159823,0.00013574216,0.810331,0.14015353,0.000053942207],"about_ca_topic_score_codex":0.00653155,"about_ca_topic_score_gemma":0.008360331,"teacher_disagreement_score":0.09773035,"about_ca_system_score_codex":0.015894305,"about_ca_system_score_gemma":0.035399675,"threshold_uncertainty_score":0.5168537},"labels":[],"label_agreement":null},{"id":"W4414035513","doi":"10.1016/s1470-2045(25)00467-x","title":"Clarifying the consensus on laryngeal preservation strategies – Authors' reply","year":2025,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Tracheal and airway disorders","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Rehabilitation Institute","funders":"","keywords":"Medicine; Intensive care medicine","score_opus":0.09091201991477084,"score_gpt":0.36808724687035965,"score_spread":0.2771752269555888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414035513","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007588765,0.0007323167,0.000032610056,0.97733355,0.021413583,0.000002997587,0.00002252418,0.000005447323,0.00038115168],"genre_scores_gemma":[0.001140536,0.0003853956,0.000057851998,0.9707506,0.026886476,0.000014210935,0.000011743498,0.000011037468,0.0007422983],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9825639,0.0066404385,0.0025041746,0.0021975026,0.0040021366,0.002091895],"domain_scores_gemma":[0.9187943,0.055515107,0.0049687047,0.0015462907,0.01258862,0.0065870606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017686423,0.0008799684,0.003031933,0.0016363062,0.006637229,0.009386665,0.0037494956,0.11749032,0.008380897],"category_scores_gemma":[0.10825462,0.0015157791,0.0020107555,0.0014174499,0.0086779585,0.008345291,0.005083878,0.09074786,0.0070710364],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003751615,0.000009568465,0.00026313536,0.00007798855,0.000024480627,0.0004076849,0.00033927898,0.000031675692,0.000055786637,0.0024487996,0.99389017,0.0024139173],"study_design_scores_gemma":[0.00021912562,0.000045602566,0.00082632503,0.0009290135,0.00008572249,0.0010614853,0.0017657871,0.00023404905,0.00022957336,0.018700244,0.9757195,0.00018350531],"about_ca_topic_score_codex":0.006466022,"about_ca_topic_score_gemma":0.007862931,"teacher_disagreement_score":0.11749032,"about_ca_system_score_codex":0.0074123754,"about_ca_system_score_gemma":0.010112438,"threshold_uncertainty_score":0.0935359},"labels":[],"label_agreement":null},{"id":"W4414035571","doi":"10.1016/s1470-2045(25)00327-4","title":"Target volume delineation of the neck for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas","year":2025,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Guangzhou Municipal Health and Family Planning Commission; Chinese Society of Clinical Oncology; Sun Yat-sen University Cancer Center; Overseas Expertise Introduction Project for Discipline Innovation; National Medical Research Council; National Natural Science Foundation of China; Higher Education Discipline Innovation Project; American Society for Radiation Oncology; Canadian Cancer Society; GOH Foundation; National Cancer Centre of Singapore","keywords":"Contouring; Nasopharyngeal carcinoma; Medicine; Atlas (anatomy); Radiation therapy; Nuclear medicine; Medical physics; Radiology; Anatomy; Computer science; Computer graphics (images)","score_opus":0.09640573677932696,"score_gpt":0.41333095173065165,"score_spread":0.3169252149513247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414035571","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015145718,0.99774665,0.00056399155,0.00036044378,0.00017921573,0.000050736835,0.00029614088,0.000015061032,0.00063621806],"genre_scores_gemma":[0.0025143884,0.9919003,0.003700149,0.00057476043,0.00008745327,0.00012228232,0.0006281117,0.000025493737,0.00044713495],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986154,0.00042518094,0.00038976932,0.0001399541,0.00038105488,0.00004870321],"domain_scores_gemma":[0.9986706,0.0007262115,0.0002789229,0.000036464528,0.00026066028,0.000027197788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004041053,0.0011206863,0.0032614137,0.003848272,0.0002531472,0.0011032389,0.0030350608,0.00089455594,0.003633552],"category_scores_gemma":[0.00516034,0.0005338564,0.0031504969,0.003994556,0.00062895875,0.00082414836,0.0009235338,0.0017988441,0.0011482429],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021685996,0.000020539672,0.00040880888,0.08327699,0.00076198037,0.00003647004,0.000084873456,0.0017642624,0.00046996344,0.00322525,0.035600238,0.87413377],"study_design_scores_gemma":[0.00047576713,0.0003173348,0.008290162,0.12809393,0.005779468,0.0013169593,0.00017005645,0.0013893164,0.0011221927,0.005782771,0.84713185,0.00013024251],"about_ca_topic_score_codex":0.023751138,"about_ca_topic_score_gemma":0.033074584,"teacher_disagreement_score":0.023751138,"about_ca_system_score_codex":0.0029048934,"about_ca_system_score_gemma":0.0054049543,"threshold_uncertainty_score":0.047225773},"labels":[],"label_agreement":null},{"id":"W4414035684","doi":"10.1016/s1470-2045(25)00288-8","title":"Importance of responder criteria for reporting health-related quality-of-life data in clinical trials for advanced cancer: recommendations of Common Sense Oncology and the European Organisation for Research and Treatment of Cancer","year":2025,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Queen's University; Princess Margaret Cancer Centre","funders":"European Organisation for Research and Treatment of Cancer","keywords":"Medicine; Clinical trial; Quality of life (healthcare); Cancer; Oncology; Clinical Oncology; Cancer treatment; Internal medicine; Medical physics; Nursing","score_opus":0.8211171485551215,"score_gpt":0.7051988091568826,"score_spread":0.11591833939823892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414035684","genre_codex":"review","genre_gemma":"review","domain_codex":"methods","domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001895857,0.85230595,0.037369505,0.06765235,0.01748926,0.0135992365,0.004140143,0.00041003016,0.00513769],"genre_scores_gemma":[0.06882608,0.3934904,0.34707746,0.107677005,0.012728016,0.057790264,0.008326368,0.00073264894,0.003351806],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.32521853,0.47287065,0.145479,0.00918479,0.045040607,0.002206515],"domain_scores_gemma":[0.1875737,0.6895727,0.047984656,0.01740977,0.055002403,0.0024566934],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.5767993,0.0032631536,0.026127337,0.0076810517,0.0023610664,0.014162255,0.010388398,0.012011514,0.004955845],"category_scores_gemma":[0.6871996,0.0026036373,0.022906292,0.00806645,0.005622097,0.009256567,0.0060638757,0.017367573,0.0015824806],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004273361,0.0002030834,0.0057374374,0.30954918,0.02640405,0.0001594283,0.0022385283,0.00095894217,0.00077948254,0.016098773,0.10867251,0.5249252],"study_design_scores_gemma":[0.007602553,0.0012413744,0.020965448,0.55372113,0.043572582,0.0007549715,0.0015817783,0.0054916055,0.0018474944,0.03573265,0.32665598,0.00083242485],"about_ca_topic_score_codex":0.0046584825,"about_ca_topic_score_gemma":0.008648028,"teacher_disagreement_score":0.42320073,"about_ca_system_score_codex":0.008421972,"about_ca_system_score_gemma":0.019194625,"threshold_uncertainty_score":0.5218819},"labels":[],"label_agreement":null},{"id":"W4414035710","doi":"10.1016/s1470-2045(25)00351-1","title":"Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Nova Scotia Cancer Centre; Dalhousie University; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; McMaster University; Juravinski Cancer Centre; Trillium Health Centre; London Health Sciences Centre; CancerCare Manitoba; University Health Network; Princess Margaret Cancer Centre; Credit Valley Hospital; Centre hospitalier universitaire de Québec; Université du Québec en Outaouais; Université de Montréal; McGill University Health Centre; McGill University; Hôpital Charles-Le Moyne; Centre Hospitalier de l’Université de Montréal; Jewish General Hospital","funders":"Jewish General Hospital; Astellas Pharma Canada","keywords":"Medicine; Prostate cancer; Systemic therapy; Open label; Oncology; Randomized controlled trial; Internal medicine; Castration; Clinical trial; Cancer; Hormone","score_opus":0.0798744365701188,"score_gpt":0.42850142216545367,"score_spread":0.3486269855953349,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414035710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834119,0.0056443913,0.00045420183,0.0012291298,0.00061203126,0.0030164472,0.002154126,0.00016775973,0.0033100771],"genre_scores_gemma":[0.9843419,0.0038439725,0.0012773528,0.0011371602,0.0003054985,0.0014364055,0.0017935686,0.000033192286,0.0058310423],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99945897,0.00018417183,0.000014727024,0.00011763953,0.00006786736,0.00015649416],"domain_scores_gemma":[0.99930155,0.000115379335,0.0001005241,0.000028794757,0.000058305908,0.00039541983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010644632,0.001935098,0.0026435794,0.0005021548,0.00064507604,0.0010357309,0.0012559347,0.0016200251,0.0089613],"category_scores_gemma":[0.0011508174,0.000539903,0.0018916082,0.0006704802,0.0016883219,0.00074227405,0.0005056088,0.0036894544,0.0008829268],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96056134,0.0059267553,0.00073216687,0.0007640738,0.001035098,0.0000412389,0.00011140706,0.0007801349,0.0017214328,0.00017994865,0.0022479012,0.025898505],"study_design_scores_gemma":[0.9154631,0.07785655,0.004339614,0.000058454396,0.0004707189,0.00003724616,0.000060437815,0.0005407171,0.00022284554,0.00014896505,0.00077826256,0.000023113307],"about_ca_topic_score_codex":0.089477286,"about_ca_topic_score_gemma":0.22990766,"teacher_disagreement_score":0.9105227,"about_ca_system_score_codex":0.0043308563,"about_ca_system_score_gemma":0.0057290457,"threshold_uncertainty_score":0.17791295},"labels":[],"label_agreement":null},{"id":"W4414711510","doi":"10.1016/s1470-2045(25)00360-2","title":"Digital health and artificial intelligence innovations for oncology in sub-Saharan Africa","year":2025,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Artificial Intelligence in Healthcare and Education","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Neurological Institute and Hospital; McGill University; Queen's University","funders":"","keywords":"Digital health; mHealth; Workforce; eHealth; Health care; Global health; Health policy","score_opus":0.47746124249957994,"score_gpt":0.5504750179637085,"score_spread":0.07301377546412852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414711510","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003354562,0.99930847,0.000014517173,0.00030758267,0.000073085575,0.0000014382026,0.0000052086134,9.744302e-7,0.00025524752],"genre_scores_gemma":[0.0005109665,0.9990393,0.000046858684,0.00021386272,0.00007285117,0.0000021435665,0.0000053093913,4.8188383e-7,0.00010829027],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996432,0.000118371165,0.00005460505,0.00003983361,0.0000930389,0.000050914106],"domain_scores_gemma":[0.9976749,0.0018224244,0.00022114463,0.000023996654,0.00018358446,0.000073982534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016711545,0.0006925714,0.0015285711,0.0024986286,0.00030983944,0.00188198,0.00067474623,0.0016168731,0.0066443095],"category_scores_gemma":[0.003328606,0.00025683423,0.0007038846,0.003971647,0.0007943708,0.0020160128,0.0011650743,0.0020520242,0.0007904157],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000067545116,0.000034602494,0.00015412309,0.050410163,0.00016481326,0.000121589546,0.00012782557,0.00031202057,0.0002919342,0.009966284,0.019782752,0.91856635],"study_design_scores_gemma":[0.000063163876,0.00011290697,0.0018702985,0.062149465,0.00048641217,0.0006245375,0.00032272542,0.00013455944,0.00024455096,0.0068006185,0.9271635,0.000027227035],"about_ca_topic_score_codex":0.0050313133,"about_ca_topic_score_gemma":0.010645975,"teacher_disagreement_score":0.0066443095,"about_ca_system_score_codex":0.0017268832,"about_ca_system_score_gemma":0.0036981443,"threshold_uncertainty_score":0.022227407},"labels":[],"label_agreement":null},{"id":"W4414711646","doi":"10.1016/s1470-2045(25)00554-6","title":"AJCC9V classification for HPV-positive oropharyngeal carcinoma – Authors' reply","year":2025,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Carcinoma; Epidermoid carcinoma; MEDLINE; Cancer","score_opus":0.09648121623464327,"score_gpt":0.3844868367144086,"score_spread":0.2880056204797653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414711646","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028684942,0.0009944417,0.00003184527,0.95433974,0.043419678,0.000008871476,0.00015929255,0.000010445689,0.0007487872],"genre_scores_gemma":[0.002195209,0.0005719006,0.000075671676,0.94612634,0.04803933,0.000038625363,0.00009948819,0.000015490652,0.0028379604],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99573165,0.0012403808,0.00074954773,0.00057699153,0.0009647652,0.0007366063],"domain_scores_gemma":[0.98386025,0.009242846,0.0013326819,0.00049669005,0.0029308028,0.0021366063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00470814,0.0007954502,0.0019575758,0.001773449,0.0035784948,0.0035801101,0.0018837971,0.04817208,0.007952995],"category_scores_gemma":[0.033028796,0.0011665124,0.0013941488,0.0014628586,0.0029106154,0.003433317,0.0025031287,0.03638982,0.007390002],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000048682432,0.000011507184,0.001058904,0.00004952241,0.000016777509,0.00038821978,0.00009451053,0.00002273693,0.00006209239,0.00051706046,0.99469334,0.0030366704],"study_design_scores_gemma":[0.00032291407,0.00010406019,0.0050845095,0.00080894644,0.00013794271,0.0018180461,0.0011170501,0.00033946286,0.00031985162,0.007139652,0.98264474,0.00016287497],"about_ca_topic_score_codex":0.00869317,"about_ca_topic_score_gemma":0.012784746,"teacher_disagreement_score":0.04817208,"about_ca_system_score_codex":0.004017858,"about_ca_system_score_gemma":0.004673639,"threshold_uncertainty_score":0.029151738},"labels":[],"label_agreement":null},{"id":"W4415023189","doi":"10.1016/s1470-2045(25)00400-0","title":"Clinical potential of whole-genome data linked to mortality statistics in patients with breast cancer in the UK: a retrospective analysis","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Cancer Research UK Cambridge Institute, University of Cambridge; Medical Research Council; Fru Berta Kamprads Stiftelse; Lunds Universitet; Cancerfonden; Vetenskapsrådet; Sunway University; Cancer Research UK; National Institute for Health and Care Research; Heart of England NHS Foundation Trust; Dr. Josef Steiner Krebsstiftung; Department of Health and Social Care; Mats Paulssons Stiftelse; Wellcome Trust; NIHR Cambridge Biomedical Research Centre; Breast Cancer Research Foundation","keywords":"Breast cancer; Linked data; Cancer; Population; Retrospective cohort study; Epidemiology","score_opus":0.025687368576819285,"score_gpt":0.3671962507591854,"score_spread":0.3415088821823661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415023189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933289,0.0010564686,0.00033275154,0.000083974766,0.000007445384,0.000021572572,0.004771246,0.000008706363,0.00038885273],"genre_scores_gemma":[0.9939283,0.0004314805,0.00026743012,0.00006741584,0.000009130217,0.000034896682,0.0051269857,0.00000718388,0.00012714813],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996393,0.0009294859,0.0007124285,0.00097493205,0.00070220913,0.00028787678],"domain_scores_gemma":[0.9881684,0.002595604,0.005377001,0.002119509,0.0012283318,0.0005111798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023548119,0.0003669768,0.0006317277,0.0024574802,0.00040616983,0.001175869,0.0006261175,0.0005436158,0.0011063978],"category_scores_gemma":[0.013213978,0.00049612083,0.000657884,0.0048687686,0.0005676026,0.00055454066,0.0017095496,0.00050658936,0.00031515164],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000098387834,0.000004491909,0.99785054,0.000039052684,0.00011823261,0.00017396048,0.00012017573,0.0000789062,0.0002035071,0.000020169582,0.00019536066,0.0010973471],"study_design_scores_gemma":[0.000005787393,0.00003831749,0.9980938,0.000028529857,0.00007850857,0.0006791455,0.00013276673,0.00019894414,0.000102912854,0.000020912541,0.0006131214,0.0000073594556],"about_ca_topic_score_codex":0.010864439,"about_ca_topic_score_gemma":0.009234395,"teacher_disagreement_score":0.010864439,"about_ca_system_score_codex":0.00075430435,"about_ca_system_score_gemma":0.0005634036,"threshold_uncertainty_score":0.021602392},"labels":[],"label_agreement":null},{"id":"W4415255286","doi":"10.1016/s1470-2045(25)00606-0","title":"Overall survival assessment in cancer drug trials: a luxury or a necessity?","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Overall survival; Drug; Cancer drugs; Cancer; Survival analysis; Cancer survival","score_opus":0.06787061010744802,"score_gpt":0.42730788821816773,"score_spread":0.3594372781107197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415255286","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027681252,0.29066107,0.016029287,0.65076834,0.033671282,0.0002278325,0.0011952224,0.00041708708,0.0042618574],"genre_scores_gemma":[0.100912064,0.16461693,0.07085554,0.50455177,0.15090476,0.0015965413,0.0021369522,0.00088241306,0.0035429667],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.75144285,0.17969118,0.028514732,0.008782131,0.028136233,0.0034329025],"domain_scores_gemma":[0.39106154,0.4501835,0.03601813,0.03064792,0.073002875,0.019085933],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.38746178,0.0033988084,0.029153395,0.005038642,0.0027355223,0.016488492,0.011428436,0.015708655,0.011471934],"category_scores_gemma":[0.47720277,0.0021775516,0.008562543,0.0072221262,0.012984214,0.03590551,0.009773778,0.028018557,0.005293221],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005882799,0.00044495674,0.010306537,0.015513271,0.008609164,0.00026057663,0.001152998,0.0022374906,0.0007909602,0.037005365,0.43048462,0.48731118],"study_design_scores_gemma":[0.007028965,0.0054096757,0.028872976,0.050826494,0.008160296,0.0011037211,0.0040006014,0.009771856,0.0006928886,0.40372828,0.4789804,0.0014238],"about_ca_topic_score_codex":0.0067612696,"about_ca_topic_score_gemma":0.012433055,"teacher_disagreement_score":0.38746178,"about_ca_system_score_codex":0.008357644,"about_ca_system_score_gemma":0.014755147,"threshold_uncertainty_score":0.7553687},"labels":[],"label_agreement":null},{"id":"W4415255311","doi":"10.1016/s1470-2045(25)00619-9","title":"British Columbia's proposed law to combat deceptive practices promoting vaping products","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Sexuality, Behavior, and Technology","field":"Psychology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Legislation; Deception; Government (linguistics); Liability; Punitive damages","score_opus":0.08475969968865377,"score_gpt":0.4157463258595791,"score_spread":0.33098662617092534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415255311","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.027811272,0.008132751,0.0044212085,0.49715295,0.016482543,0.0009921271,0.0023136034,0.00075403304,0.44193953],"genre_scores_gemma":[0.10953649,0.00304941,0.0056082765,0.41740263,0.0017316561,0.0006118432,0.00044677933,0.00012662272,0.46148625],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98403233,0.0015541122,0.00080365274,0.0010696701,0.008960364,0.0035797765],"domain_scores_gemma":[0.9792835,0.0084772175,0.0008126364,0.0007952991,0.008015334,0.0026159924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007745324,0.0008476934,0.00077402487,0.0031426104,0.009840708,0.009276126,0.0042577377,0.04648685,0.01098053],"category_scores_gemma":[0.03347198,0.0011218031,0.0014912417,0.0015875144,0.0050795963,0.0019718262,0.002863166,0.022827512,0.0024812345],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018406547,0.0004993482,0.006732264,0.00038142252,0.000089053414,0.0012659596,0.001723323,0.0014103533,0.002431141,0.14042632,0.7914023,0.053454444],"study_design_scores_gemma":[0.00030903032,0.00020221679,0.0145789925,0.0011198849,0.00023438418,0.00039727305,0.0010237264,0.0015508337,0.0019991542,0.012153836,0.96616024,0.00027046338],"about_ca_topic_score_codex":0.83812904,"about_ca_topic_score_gemma":0.9114597,"teacher_disagreement_score":0.16187096,"about_ca_system_score_codex":0.02816485,"about_ca_system_score_gemma":0.111091465,"threshold_uncertainty_score":0.32564843},"labels":[],"label_agreement":null},{"id":"W4415601999","doi":"10.1016/s1470-2045(25)00561-3","title":"Systemic therapy for brain metastases: a changing landscape","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Systemic therapy; Disease; Action (physics); MEDLINE; Systemic risk","score_opus":0.04806460891737202,"score_gpt":0.37635903967958295,"score_spread":0.32829443076221093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415601999","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005927813,0.7648819,0.00071698433,0.2233599,0.005904016,0.000007748842,0.00010246011,0.00004232219,0.004391976],"genre_scores_gemma":[0.013678511,0.8547082,0.0014812758,0.09249569,0.035533268,0.000032622178,0.00013994765,0.00008781216,0.001842676],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99543285,0.0014761256,0.0006386064,0.00061421207,0.0014250677,0.00041314345],"domain_scores_gemma":[0.97512203,0.015608053,0.0019309466,0.0004585948,0.004853321,0.0020271358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014937154,0.00092523015,0.0030487014,0.0026066839,0.001227881,0.007647582,0.0021611587,0.008256794,0.008700426],"category_scores_gemma":[0.020225104,0.00047982336,0.001410059,0.003302113,0.005607039,0.011048747,0.0023820058,0.012229865,0.0025109393],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005848159,0.00015134213,0.0010159869,0.0056179953,0.0001824826,0.00031073176,0.00025917316,0.0013570769,0.0010201423,0.060587425,0.25181636,0.6770964],"study_design_scores_gemma":[0.00032045302,0.0005109705,0.0022153833,0.0072377273,0.00019225909,0.0009666937,0.0006981378,0.00070310966,0.0003465089,0.056153275,0.93055415,0.00010130162],"about_ca_topic_score_codex":0.0035690386,"about_ca_topic_score_gemma":0.011656384,"teacher_disagreement_score":0.014937154,"about_ca_system_score_codex":0.0066602565,"about_ca_system_score_gemma":0.006870064,"threshold_uncertainty_score":0.07899612},"labels":[],"label_agreement":null},{"id":"W4415678781","doi":"10.1016/s1470-2045(25)00472-3","title":"Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network","funders":"Servier","keywords":"Phase (matter); Glioma; Clinical trial; Phases of clinical research; Glioblastoma","score_opus":0.05830452800028042,"score_gpt":0.3686986930068263,"score_spread":0.3103941650065459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415678781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97661954,0.014389882,0.00059743057,0.0011191701,0.00067989714,0.0015095093,0.0016486159,0.00016802238,0.0032680146],"genre_scores_gemma":[0.9846757,0.006013019,0.00091322116,0.0012135481,0.00032446586,0.0016867209,0.0018340622,0.000032517506,0.0033067097],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99966383,0.000172127,0.000016069687,0.00005156488,0.000025887728,0.00007048755],"domain_scores_gemma":[0.999491,0.00016868924,0.00010014639,0.000034042238,0.000035036304,0.00017100322],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013031265,0.0014453222,0.0023955714,0.00036426733,0.00029854762,0.0010441248,0.00063166686,0.0013810161,0.0047754827],"category_scores_gemma":[0.0012376999,0.00040060538,0.0020121203,0.0003768512,0.0008929436,0.00092451106,0.00032193214,0.00332797,0.00076826947],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96576226,0.0024932178,0.00051576394,0.0016371525,0.0017854924,0.00005873821,0.0000714124,0.00051104376,0.004724878,0.0002556591,0.0020357845,0.020148568],"study_design_scores_gemma":[0.9337806,0.06045431,0.0019178275,0.00008308289,0.0009229002,0.00007818601,0.000044176944,0.00037028786,0.00075043,0.00032658613,0.0012499272,0.000021737866],"about_ca_topic_score_codex":0.00082796835,"about_ca_topic_score_gemma":0.0029180313,"teacher_disagreement_score":0.0047754827,"about_ca_system_score_codex":0.0008349388,"about_ca_system_score_gemma":0.0008473703,"threshold_uncertainty_score":0.015975595},"labels":[],"label_agreement":null},{"id":"W4415829162","doi":"10.1016/s1470-2045(25)00530-3","title":"The human crisis in cancer: a Lancet Oncology Commission","year":2025,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Canadian Institutes of Health Research; Princess Margaret Cancer Foundation; World Health Organization","keywords":"Commission; Existentialism; Compassion; Incentive; Blame; Ideology","score_opus":0.17682488692619072,"score_gpt":0.4226891298372398,"score_spread":0.24586424291104905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415829162","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000051819625,0.87583643,0.000058014255,0.10232377,0.020382913,0.00000894555,0.000093843686,0.000012842377,0.0012314316],"genre_scores_gemma":[0.0024148999,0.88696104,0.00026925962,0.08459706,0.021843871,0.000038121052,0.00013807064,0.000024396752,0.0037132269],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975485,0.00081754307,0.0001806709,0.00018754187,0.0009886782,0.00027711605],"domain_scores_gemma":[0.9883663,0.005831055,0.00088580645,0.0002772113,0.0029025879,0.0017370966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008329876,0.0011168965,0.002452399,0.002373317,0.0009060718,0.0042602834,0.0014008183,0.008392679,0.0073784436],"category_scores_gemma":[0.020346723,0.0005933447,0.0010899735,0.003958482,0.0018160752,0.0055437675,0.002872651,0.011782573,0.00265674],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007883721,0.000022937751,0.000090256115,0.0028046048,0.00006490373,0.000058180325,0.000054254957,0.00013456769,0.00005902613,0.008370512,0.872989,0.115273],"study_design_scores_gemma":[0.00005066921,0.000021386339,0.00032468847,0.0047151153,0.00004968861,0.000060781134,0.00006936481,0.00003287745,0.00001808309,0.0044376673,0.9902035,0.000016078555],"about_ca_topic_score_codex":0.00984602,"about_ca_topic_score_gemma":0.0210019,"teacher_disagreement_score":0.00984602,"about_ca_system_score_codex":0.006478011,"about_ca_system_score_gemma":0.016494919,"threshold_uncertainty_score":0.04700148},"labels":[],"label_agreement":null},{"id":"W4416589081","doi":"10.1016/s1470-2045(25)00543-1","title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Jiangsu Hengrui Medicine","keywords":"Hepatocellular carcinoma; Sorafenib; Overall survival; Phases of clinical research; Phase (matter); Clinical trial; Carcinoma","score_opus":0.25364071666358595,"score_gpt":0.43083491518274847,"score_spread":0.17719419851916252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416589081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830754,0.008705404,0.0007988554,0.0009995695,0.0006287131,0.001439044,0.0018118918,0.00020181281,0.002339233],"genre_scores_gemma":[0.98843,0.0032752627,0.00147325,0.0010526809,0.0003934926,0.0011351483,0.0019516321,0.000043548454,0.0022450562],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988702,0.00067830516,0.000055265096,0.00014943065,0.00007295341,0.00017381056],"domain_scores_gemma":[0.9984908,0.0005405163,0.00032613942,0.00014566742,0.000084677544,0.00041225212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031936439,0.0017472843,0.0033137626,0.00047300837,0.00038961243,0.001369527,0.0008152665,0.0014348569,0.004983447],"category_scores_gemma":[0.0026700445,0.0007083876,0.0044826316,0.0005673054,0.0014663816,0.0015203166,0.00045659373,0.003655556,0.0010368777],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97763205,0.001789979,0.000620377,0.00054941257,0.0016724273,0.000025615615,0.000046659177,0.0006053688,0.0010710611,0.00009777353,0.0009853062,0.014904079],"study_design_scores_gemma":[0.9484435,0.046625495,0.0024000604,0.000047531714,0.0009827347,0.00004484609,0.000032581356,0.00047206075,0.0002255447,0.00021291694,0.0004920654,0.000020587053],"about_ca_topic_score_codex":0.0018660778,"about_ca_topic_score_gemma":0.004427842,"teacher_disagreement_score":0.004983447,"about_ca_system_score_codex":0.0014173067,"about_ca_system_score_gemma":0.0013453497,"threshold_uncertainty_score":0.01688981},"labels":[],"label_agreement":null},{"id":"W4416589103","doi":"10.1016/s1470-2045(25)00492-9","title":"Microbubble-enhanced transcranial focused ultrasound with temozolomide for patients with high-grade glioma (BT008NA): a multicentre, open-label, phase 1/2 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Ultrasound and Hyperthermia Applications","field":"Engineering","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Institute of Neurological Disorders and Stroke; National Institutes of Health; University of Maryland; School of Medicine, University of Maryland; National Center for Advancing Translational Sciences; Institute for Clinical and Translational Research, University of Maryland, Baltimore; Johns Hopkins University","keywords":"Temozolomide; Glioma; Focused ultrasound; Glioblastoma; Ultrasound; Phase (matter); Clinical trial","score_opus":0.025370552062386205,"score_gpt":0.3028433950160666,"score_spread":0.2774728429536804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416589103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842387,0.005958475,0.00066460395,0.00085848325,0.00022452291,0.0043887133,0.0015883486,0.00012963136,0.0019484718],"genre_scores_gemma":[0.98215526,0.0034311751,0.0020488158,0.0012791033,0.00031013132,0.005883466,0.0019734188,0.000032259737,0.002886296],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995586,0.0002183205,0.000024922843,0.00008208793,0.00004583746,0.000070138965],"domain_scores_gemma":[0.9995715,0.00006533617,0.00012453206,0.000031243155,0.000041147076,0.00016624249],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017439058,0.0011577377,0.0012041378,0.00028793997,0.00033745723,0.00075756037,0.0006576571,0.0011991337,0.0037757508],"category_scores_gemma":[0.0010990221,0.00035747516,0.0009631082,0.00035763724,0.00070154906,0.00074929505,0.0003143705,0.00166195,0.000740343],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8539589,0.027149329,0.0029676156,0.0016991314,0.0012760988,0.00012787631,0.00023510118,0.00085285236,0.017062236,0.00027622335,0.005523893,0.08887084],"study_design_scores_gemma":[0.8139861,0.17477179,0.0059238737,0.00006710036,0.00048536257,0.00012716469,0.00004119254,0.00053404167,0.0011744007,0.00019093722,0.002674327,0.00002364487],"about_ca_topic_score_codex":0.0011985084,"about_ca_topic_score_gemma":0.0038436481,"teacher_disagreement_score":0.0037757508,"about_ca_system_score_codex":0.0009875944,"about_ca_system_score_gemma":0.0016941096,"threshold_uncertainty_score":0.012631118},"labels":[],"label_agreement":null},{"id":"W4416589127","doi":"10.1016/s1470-2045(25)00520-0","title":"SISAQOL-IMI consensus-based guidelines to design, analyse, interpret, and present patient-reported outcomes in cancer clinical trials","year":2025,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada; University Health Network; Queen's University","funders":"Health Canada; Horizon 2020 Framework Programme; U.S. Food and Drug Administration; National Cancer Institute; National Institutes of Health; European Medicines Agency; European Society for Medical Oncology; European Commission; Innovative Health Initiative; European Federation of Pharmaceutical Industries and Associations; American Society of Clinical Oncology","keywords":"Clinical trial; Quality (philosophy); Selection (genetic algorithm); Quality of life (healthcare); Cancer; Alternative medicine; MEDLINE","score_opus":0.5470586733715724,"score_gpt":0.6086951238402815,"score_spread":0.061636450468709025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416589127","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016399692,0.4072585,0.30638793,0.06891436,0.015041066,0.13346225,0.03628376,0.0065040067,0.02450816],"genre_scores_gemma":[0.010356799,0.12737447,0.6844833,0.015127527,0.0024950886,0.13345917,0.019200496,0.0013817198,0.0061214915],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.6882297,0.1781635,0.10007804,0.0068826107,0.02400114,0.0026449838],"domain_scores_gemma":[0.53295904,0.30912524,0.04427489,0.019619351,0.088121615,0.005899836],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.26230726,0.004829238,0.021343281,0.018849216,0.0034023297,0.014474914,0.020334017,0.012849357,0.019632164],"category_scores_gemma":[0.34918883,0.004553781,0.03500227,0.015666686,0.0047096326,0.004735953,0.011011816,0.020489573,0.013537039],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018635956,0.00033974458,0.0013712066,0.379072,0.023535885,0.00034141992,0.0021323347,0.0033512823,0.0013550324,0.019443678,0.19014144,0.3770524],"study_design_scores_gemma":[0.006434253,0.0005886829,0.0047949427,0.48070765,0.032356232,0.0005457101,0.000857383,0.003950723,0.0022358154,0.046761133,0.4201898,0.0005776999],"about_ca_topic_score_codex":0.010056194,"about_ca_topic_score_gemma":0.015587847,"teacher_disagreement_score":0.7376927,"about_ca_system_score_codex":0.009771771,"about_ca_system_score_gemma":0.05627399,"threshold_uncertainty_score":0.9097065},"labels":[],"label_agreement":null},{"id":"W7116858522","doi":"10.1016/s1470-2045(25)00566-2","title":"Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Bristol-Myers Squibb","keywords":"Docetaxel; Prostate cancer; Placebo; Nivolumab; Androgen receptor; Enzalutamide; Clinical trial; Phases of clinical research","score_opus":0.10426939970091895,"score_gpt":0.42134323272015745,"score_spread":0.3170738330192385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116858522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824829,0.006446936,0.0007646415,0.0006845161,0.0014302724,0.004331634,0.0010890261,0.00021938601,0.0025506213],"genre_scores_gemma":[0.98300683,0.0032876867,0.0015162813,0.0010352064,0.0005958823,0.003389693,0.00093873154,0.000045678058,0.006184014],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993088,0.00035944622,0.00003651088,0.00014086317,0.00004388033,0.00011062625],"domain_scores_gemma":[0.9992077,0.00027337467,0.000141362,0.00006127496,0.000048416765,0.0002680117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017256415,0.0022478567,0.0036125376,0.0005106586,0.00056430185,0.0012900776,0.0013323721,0.002209914,0.008322403],"category_scores_gemma":[0.0018793904,0.0010057689,0.0027044048,0.00043735298,0.0015829742,0.0012990012,0.00048322475,0.0038467883,0.0014526948],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9890209,0.0024060286,0.00011655457,0.00038019053,0.00052185863,0.000012092192,0.000028717435,0.00020211108,0.0006862926,0.00006682827,0.0003881708,0.006170269],"study_design_scores_gemma":[0.967389,0.031243661,0.0004177127,0.00002168142,0.00023910608,0.000010207996,0.00001366782,0.00023694802,0.00011417393,0.000098024466,0.00020545741,0.000010481041],"about_ca_topic_score_codex":0.0024855104,"about_ca_topic_score_gemma":0.0051618023,"teacher_disagreement_score":0.008322403,"about_ca_system_score_codex":0.0010582907,"about_ca_system_score_gemma":0.0012298796,"threshold_uncertainty_score":0.02784115},"labels":[],"label_agreement":null},{"id":"W7116870583","doi":"10.1016/s1470-2045(25)00614-x","title":"Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Health and Medical Research Council; Brain Tumour Charity; Cancer Research UK; Cancer Australia; American College of Radiology; KWF Kankerbestrijding; NRG Oncology; European Organisation for Research and Treatment of Cancer; MSD","keywords":"Temozolomide; Adjuvant; Glioblastoma; Clinical trial; Phases of clinical research; Anaplastic astrocytoma","score_opus":0.21907793404736797,"score_gpt":0.49292166654188846,"score_spread":0.2738437324945205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116870583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99123937,0.003754547,0.0004112804,0.0003815586,0.00027409894,0.0011255813,0.0009343681,0.00006470966,0.0018144067],"genre_scores_gemma":[0.98997444,0.0025726706,0.0009395203,0.0004465844,0.0001725632,0.001304192,0.0015846938,0.000029757402,0.0029756255],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99933076,0.00035901886,0.000027688126,0.00012758165,0.000046428795,0.000108592234],"domain_scores_gemma":[0.9991098,0.00024907629,0.00016456548,0.00008422691,0.000041671174,0.00035055596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016904547,0.0014675083,0.0027090723,0.00036639548,0.0003465908,0.0010815313,0.000847504,0.001244343,0.005027338],"category_scores_gemma":[0.0015448682,0.00057844614,0.0018451175,0.00046633082,0.0012931075,0.0012624508,0.00045932495,0.0031490808,0.00086302747],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9728981,0.003809551,0.0009001393,0.0005399008,0.0011198506,0.000034024495,0.00008843792,0.00073497574,0.002465535,0.00015703835,0.00084227935,0.016410062],"study_design_scores_gemma":[0.8839354,0.10893462,0.0037864977,0.000049400947,0.0008214805,0.00006418793,0.000056869038,0.00057142513,0.00045586866,0.00030620248,0.0009972863,0.000020787578],"about_ca_topic_score_codex":0.0030770923,"about_ca_topic_score_gemma":0.010887827,"teacher_disagreement_score":0.005027338,"about_ca_system_score_codex":0.0013335325,"about_ca_system_score_gemma":0.001631789,"threshold_uncertainty_score":0.016818047},"labels":[],"label_agreement":null},{"id":"W7116980363","doi":"10.1016/s1470-2045(25)00598-4","title":"Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy (OPBC-07/microNAC): an international, retrospective cohort study","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"National Cancer Institute; National Institutes of Health","keywords":"Retrospective cohort study; Chemotherapy; Dissection (medical); Breast cancer; Cancer; Lymph node; Axillary Dissection; Cohort study","score_opus":0.008727459523990287,"score_gpt":0.2993103599565483,"score_spread":0.290582900432558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116980363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99899215,0.0001817079,0.000035340432,0.00001043935,0.0000029922192,0.0000147128185,0.0006048293,0.0000011992488,0.00015656152],"genre_scores_gemma":[0.99872285,0.00011847351,0.00005710153,0.000020701167,0.0000073515125,0.000023026549,0.0009904824,0.0000018360264,0.00005804037],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99945587,0.00009503824,0.000066814144,0.00019863663,0.000081089194,0.00010246941],"domain_scores_gemma":[0.9986595,0.0001564385,0.0007064991,0.00016339499,0.00010338809,0.00021089643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008779128,0.00032506062,0.00047875888,0.0008212008,0.00038916362,0.0006292684,0.00046643123,0.00038171728,0.00075980887],"category_scores_gemma":[0.0015346126,0.00037108606,0.00063420134,0.0012980452,0.00033817586,0.00049177743,0.00056951423,0.00051777787,0.00018626802],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021186206,0.000019273019,0.9991436,0.0000060495754,0.000052653715,0.000057135665,0.000033943637,0.000022134422,0.00008963903,0.0000059802933,0.000045045832,0.00031274327],"study_design_scores_gemma":[0.000029012588,0.00020324782,0.9986809,0.000007817446,0.00008200536,0.0004442449,0.00015262184,0.000106959844,0.000053912972,0.000010784126,0.00022317363,0.0000052673945],"about_ca_topic_score_codex":0.0054455884,"about_ca_topic_score_gemma":0.0067408225,"teacher_disagreement_score":0.0054455884,"about_ca_system_score_codex":0.00052659353,"about_ca_system_score_gemma":0.00049039087,"threshold_uncertainty_score":0.01082778},"labels":[],"label_agreement":null},{"id":"W7117077043","doi":"10.1016/s1470-2045(25)00535-2","title":"International consensus recommendations and alignment of terminology for the histopathological diagnosis of extranodal extension in head and neck squamous cell carcinoma: an HN-CLEAR initiative","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre; Dalhousie University","funders":"National Health and Medical Research Council","keywords":"Terminology; Head and neck; Concordance; Head and neck cancer; Squamous cell cancer; MEDLINE","score_opus":0.10401294649971668,"score_gpt":0.3851906460608598,"score_spread":0.28117769956114314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117077043","genre_codex":"commentary","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015501677,0.15411565,0.14535029,0.5274173,0.09271969,0.01017683,0.00990942,0.0013277988,0.04348139],"genre_scores_gemma":[0.071621194,0.08179182,0.675737,0.10526639,0.011236315,0.015524676,0.024785519,0.001428005,0.012609086],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.8586188,0.06079925,0.04139448,0.005222602,0.029215774,0.004749115],"domain_scores_gemma":[0.6725585,0.090950936,0.028590914,0.014642732,0.18122064,0.0120363915],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.23780501,0.0018425997,0.004443426,0.014584332,0.0041668755,0.00973593,0.015612076,0.01131106,0.003307804],"category_scores_gemma":[0.22816405,0.0019895467,0.009777212,0.011838,0.006293295,0.005801074,0.0099898735,0.02146728,0.0027700355],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070195476,0.00063315197,0.015663855,0.019033482,0.0012908289,0.000625374,0.009578575,0.002893373,0.0045534647,0.054582726,0.49837542,0.39206776],"study_design_scores_gemma":[0.0006342017,0.0005186823,0.035967242,0.0716269,0.0020363203,0.0011727767,0.009484125,0.0029267413,0.0034725927,0.043669008,0.8279526,0.0005388558],"about_ca_topic_score_codex":0.044404563,"about_ca_topic_score_gemma":0.030660408,"teacher_disagreement_score":0.23780501,"about_ca_system_score_codex":0.015780177,"about_ca_system_score_gemma":0.075495355,"threshold_uncertainty_score":0.9399221},"labels":[],"label_agreement":null}]}